

Improved Survival with Ipilimumab in Patients with M

New England Journal of Medicine

363, 711-723

DOI: [10.1056/nejmoa1003466](https://doi.org/10.1056/nejmoa1003466)

Citation Report

#	ARTICLE	IF	CITATIONS
1	ecancermedalscience. Ecancermedalscience, 2014, 8, 441.	0.6	30
2	Calcium-Induced Contraction of the Rhizoplast of a Quadriflagellate Green Alga. Science, 1978, 202, 975-977.	6.0	185
3	Plasma Fibrinogen Levels and the Clinical Course of Acute Myocardial Infarction. Angiology, 1983, 34, 693-698.	0.8	22
4	CANCER VACCINES. Hematology/Oncology Clinics of North America, 2001, 15, 741-773.	0.9	25
5	Placebo-Controlled Phase III Trial of Immunologic Therapy with Sipuleucel-T (APC8015) in Patients with Metastatic, Asymptomatic Hormone Refractory Prostate Cancer. Journal of Clinical Oncology, 2006, 24, 3089-3094.	0.8	1,004
6	Immune Stimulatory Features of Classical Chemotherapy. , 2007, , 235-256.		3
7	Combining immunotherapy and radiation therapy for small cell lung cancer and thymic tumors. Translational Lung Cancer Research, 2007, 6, 186-195.	1.3	13
8	Mini-review of conventional and hypofractionated radiation therapy combined with immunotherapy for non-small cell lung cancer. Translational Lung Cancer Research, 2007, 6, 220-229.	1.3	10
9	Immunotherapy and radiation therapy for malignant pleural mesothelioma. Translational Lung Cancer Research, 2007, 6, 212-219.	1.3	31
10	Special topics in immunotherapy and radiation therapy: reirradiation and palliation. Translational Lung Cancer Research, 2007, 6, 119-130.	1.3	11
11	Galectin-9 Increases Tim-3+ Dendritic Cells and CD8+ T Cells and Enhances Antitumor Immunity via Galectin-9-Tim-3 Interactions. Journal of Immunology, 2008, 181, 7660-7669.	0.4	181
12	What Is Cancer?. , 2009, , 323-327.		0
13	Melanoma and Immunosuppression. Dermatology, 2009, 218, 88-88.	0.9	11
14	Paving the way to the cure of melanoma. Melanoma Research, 2010, 20, 441-442.	0.6	2
15	Advances in Treatment of Metastatic Melanoma: Ipilimumab. Journal of the Dermatology Nurses' Association, 2010, 2, 262-264.	0.1	0
16	Current status of immunological therapies for prostate cancer. Current Opinion in Urology, 2010, 20, 241-246.	0.9	45
17	Immune Regulatory Antibodies. Cancer Journal (Sudbury, Mass), 2010, 16, 311-317.	1.0	27
18	Narrative Review: BRAF Opens the Door for Therapeutic Advances in Melanoma. Annals of Internal Medicine, 2010, 153, 587.	2.0	34

#	ARTICLE	IF	CITATIONS
19	Melanoma Immunotherapy. Mount Sinai Journal of Medicine, 2010, 77, 620-642.	1.9	13
20	Head and Neck Squamous Cell Carcinoma: New Translational Therapies. Mount Sinai Journal of Medicine, 2010, 77, 684-699.	1.9	40
21	Genetically modified dendritic cells in cancer immunotherapy: a better tomorrow?. Expert Opinion on Biological Therapy, 2010, 10, 1539-1553.	1.4	19
24	Designing Vaccines Based on Biology of Human Dendritic Cell Subsets. Immunity, 2010, 33, 464-478.	6.6	290
26	Targeting the Immune System as a Therapeutic Strategy for Patients with Breast Cancer. Current Breast Cancer Reports, 2010, 2, 214-221.	0.5	0
27	Renal cell carcinoma: ten years of significant advances. Targeted Oncology, 2010, 5, 73-74.	1.7	4
28	Anti-CTLA-4 Antibody Therapy: Immune Monitoring During Clinical Development of a Novel Immunotherapy. Seminars in Oncology, 2010, 37, 473-484.	0.8	208
29	Update on Immunologic Therapy With Anti-CTLA-4 Antibodies in Melanoma: Identification of Clinical and Biological Response Patterns, Immune-Related Adverse Events, and Their Management. Seminars in Oncology, 2010, 37, 485-498.	0.8	153
30	Ipilimumab: Unleashing the Power of the Immune System Through CTLA-4 Blockade. Seminars in Oncology, 2010, 37, 440-449.	0.8	65
31	The Emerging Toxicity Profiles of Anti-CTLA-4 Antibodies Across Clinical Indications. Seminars in Oncology, 2010, 37, 499-507.	0.8	224
32	Clinical Experiences With Anti-CD137 and Anti-PD1 Therapeutic Antibodies. Seminars in Oncology, 2010, 37, 508-516.	0.8	256
33	Anti-CTLA-4 Antibody Adjuvant Therapy in Melanoma. Seminars in Oncology, 2010, 37, 455-459.	0.8	37
34	Brain Metastasis in Melanoma: Clinical Activity of CTLA-4 Antibody Therapy. Seminars in Oncology, 2010, 37, 468-472.	0.8	33
35	Development of Ipilimumab: Contribution to a New Paradigm for Cancer Immunotherapy. Seminars in Oncology, 2010, 37, 533-546.	0.8	218
36	BRAF Inhibitor Unveils Its Potential against Advanced Melanoma. Cancer Cell, 2010, 18, 301-302.	7.7	15
38	Development trends for human monoclonal antibody therapeutics. Nature Reviews Drug Discovery, 2010, 9, 767-774.	21.5	873
39	Prostate cancer as a model for tumour immunotherapy. Nature Reviews Immunology, 2010, 10, 580-593.	10.6	314
40	Desirable cell death during anticancer chemotherapy. Annals of the New York Academy of Sciences, 2010, 1209, 99-108.	1.8	70

#	ARTICLE	IF	CITATIONS
41	Expansion and Characterization of Human Melanoma Tumor-Infiltrating Lymphocytes (TILs). PLoS ONE, 2010, 5, e13940.	1.1	46
42	Bevacizumab plus Fotemustine as First-line Treatment in Metastatic Melanoma Patients: Clinical Activity and Modulation of Angiogenesis and Lymphangiogenesis Factors. Clinical Cancer Research, 2010, 16, 5862-5872.	3.2	56
43	Overview of Cellular Immunotherapy for Patients with Glioblastoma. Clinical and Developmental Immunology, 2010, 2010, 1-18.	3.3	76
44	Focus on Adoptive T Cell Transfer Trials in Melanoma. Clinical and Developmental Immunology, 2010, 2010, 1-11.	3.3	34
45	Clinical Cancer Advances 2010: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. Journal of Clinical Oncology, 2010, 28, 5327-5347.	0.8	54
46	The Oncogenic BRAF Kinase Inhibitor PLX4032/RG7204 Does Not Affect the Viability or Function of Human Lymphocytes across a Wide Range of Concentrations. Clinical Cancer Research, 2010, 16, 6040-6048.	3.2	142
47	Releasing the Brake on the Immune System: Ipilimumab in Melanoma and Other Tumors. Cancer Biotherapy and Radiopharmaceuticals, 2010, 25, 601-613.	0.7	125
48	Cancer immunotherapy: In vivo imaging of adoptively transferred T cells in an immunocompetent host. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 13977-13978.	3.3	2
49	Simultaneous Blockade of Multiple Immune System Inhibitory Checkpoints Enhances Antitumor Activity Mediated by Interleukin-15 in a Murine Metastatic Colon Carcinoma Model. Clinical Cancer Research, 2010, 16, 6019-6028.	3.2	178
50	CD8+ Enriched "Young" Tumor Infiltrating Lymphocytes Can Mediate Regression of Metastatic Melanoma. Clinical Cancer Research, 2010, 16, 6122-6131.	3.2	269
51	Melanoma "An Unlikely Poster Child for Personalized Cancer Therapy. New England Journal of Medicine, 2010, 363, 876-878.	13.9	70
52	Cabazitaxel/Ipilimumab. Hospital Pharmacy, 2010, 45, 828-835.	0.4	2
53	T regulatory cells in cancer: recent advances and therapeutic potential. Expert Opinion on Biological Therapy, 2010, 10, 1573-1586.	1.4	94
54	Paying "Particle" Attention to Novel Melanoma Treatment Strategies. Journal of Investigative Dermatology, 2010, 130, 2699-2701.	0.3	10
55	Immunotherapy of Brain Cancers: The Past, the Present, and Future Directions. Clinical and Developmental Immunology, 2010, 2010, 1-19.	3.3	9
56	In situ photoimmunotherapy: A new hope for cutaneous melanoma patients. Cancer Biology and Therapy, 2010, 10, 1088-1090.	1.5	5
57	Diarrhea from Ipilimumab in Melanoma. New England Journal of Medicine, 2010, 363, 2262-2263.	13.9	0
58	Taking the Guesswork Out of Uveal Melanoma. New England Journal of Medicine, 2010, 363, 2256-2257.	13.9	8

#	ARTICLE	IF	CITATIONS
59	TroVax, a recombinant modified vaccinia Ankara virus encoding 5T4: Lessons learned and future development. <i>Hum Vaccin</i> , 2010, 6, 784-791.	2.4	31
61	A new understanding in the epidemiology of melanoma. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 1811-1823.	1.1	264
62	Ipilimumab: attenuation of an inhibitory immune checkpoint improves survival in metastatic melanoma. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 1697-1701.	1.1	28
63	Treating Cancer by Targeting the Immune System. <i>New England Journal of Medicine</i> , 2010, 363, 779-781.	13.9	48
64	Modern immunotherapy for the treatment of prostate cancer. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2010, 7, 37-42.	0.5	1
65	Multicenter phase II study of matured dendritic cells pulsed with melanoma cell line lysates in patients with advanced melanoma. <i>Journal of Translational Medicine</i> , 2010, 8, 89.	1.8	33
66	The Current and Emerging Role of Immunotherapy in Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2010, 8, 10-16.	0.9	10
67	Pathways to Melanoma. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2010, 29, 210-217.	1.6	25
68	New Therapeutic Options in the Medical Management of Advanced Melanoma. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2010, 29, 249-257.	1.6	14
69	PLX4032, a potent inhibitor of the Bâ€Raf V600E oncogene, selectively inhibits V600Eâ€positive melanomas. <i>Pigment Cell and Melanoma Research</i> , 2010, 23, 820-827.	1.5	142
70	Ipilimumab improves survival in previously treated metastatic melanoma. <i>Community Oncology</i> , 2010, 7, 395-396.	0.2	0
71	A milestone, yes, but many questions remain unanswered. <i>Community Oncology</i> , 2010, 7, 398.	0.2	0
72	New drugs for aggressive B-cell and T-cell lymphomas. <i>Lancet Oncology</i> , The, 2010, 11, 1074-1085.	5.1	53
73	Functional and Clinical Relevance of Chondroitin Sulfate Proteoglycan 4. <i>Advances in Cancer Research</i> , 2010, 109, 73-121.	1.9	93
75	Improved Endpoints for Cancer Immunotherapy Trials. <i>Journal of the National Cancer Institute</i> , 2010, 102, 1388-1397.	3.0	495
76	Rituximab-based chemotherapy may raise the risk of HBV* reactivation. <i>Reactions Weekly</i> , 2010, &NA;, 6.	0.0	0
77	Immunotherapy for Prostate Cancer: Recent Advances, Lessons Learned, and Areas for Further Research. <i>Clinical Cancer Research</i> , 2011, 17, 3884-3891.	3.2	110
78	Melanoma vaccines: developments over the past 10 years. <i>Expert Review of Vaccines</i> , 2011, 10, 853-873.	2.0	27

#	ARTICLE	IF	CITATIONS
79	Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma. Expert Opinion on Pharmacotherapy, 2011, 12, 2695-2706.	0.9	32
80	Integrated NY-ESO-1 antibody and CD8 ⁺ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 16723-16728.	3.3	310
81	Antigen-specific versus Antigen-nonspecific Immunotherapeutic Approaches for Human Melanoma: The Need for Integration for Optimal Efficacy?. International Reviews of Immunology, 2011, 30, 238-293.	1.5	5
82	Systematic Review of Medical Treatment in Melanoma: Current Status and Future Prospects. Oncologist, 2011, 16, 5-24.	1.9	472
83	Prophylactic cancer vaccination by targeting functional non-self. Annals of Medicine, 2011, 43, 356-365.	1.5	12
84	Gene Therapy for Lung Neoplasms. Clinics in Chest Medicine, 2011, 32, 865-885.	0.8	21
85	The Dermis as a Portal for Dendritic Cell-Targeted Immunotherapy of Cutaneous Melanoma. Current Topics in Microbiology and Immunology, 2011, 351, 181-220.	0.7	15
86	Thunder and Lightning: Immunotherapy and Oncolytic Viruses Collide. Molecular Therapy, 2011, 19, 1008-1016.	3.7	201
87	Immunotherapy for Metastatic Solid Cancers. Advances in Surgery, 2011, 45, 341-360.	0.6	71
88	Targeted Therapy for Melanoma: A Primer. Surgical Oncology Clinics of North America, 2011, 20, 165-180.	0.6	25
89	Surgical Approach to Primary Cutaneous Melanoma. Surgical Oncology Clinics of North America, 2011, 20, 39-56.	0.6	12
90	Immunotherapy of Melanoma: An Update. Surgical Oncology Clinics of North America, 2011, 20, 145-163.	0.6	7
91	Nuclear Medicine in Early-Stage Melanoma: Sentinel Node Biopsyâ€”FDG-PET/CT. PET Clinics, 2011, 6, 9-25.	1.5	6
93	Allogeneic stem cell transplantation for renal cell carcinoma. Expert Review of Anticancer Therapy, 2011, 11, 901-911.	1.1	13
94	Ipilimumab: A Novel Treatment for Metastatic Melanoma. Annals of Pharmacotherapy, 2011, 45, 510-519.	0.9	49
95	Recent advances in immunotherapy for the treatment of prostate cancer. Expert Opinion on Biological Therapy, 2011, 11, 997-1009.	1.4	20
96	Vaccines and Vaccine Adjuvants as Biological Response Modifiers. Infectious Disease Clinics of North America, 2011, 25, 755-772.	1.9	7
97	Antibody-based therapeutics to watch in 2011. MAbs, 2011, 3, 76-99.	2.6	207

#	ARTICLE	IF	CITATIONS
99	Immunologic functions as prognostic indicators in melanoma. <i>Molecular Oncology</i> , 2011, 5, 183-189.	2.1	22
100	Biological challenges of BRAF inhibitor therapy. <i>Molecular Oncology</i> , 2011, 5, 116-123.	2.1	30
101	The dual role of the X-linked FoxP3 gene in human cancers. <i>Molecular Oncology</i> , 2011, 5, 156-163.	2.1	21
102	Melanoma â€” The pieces of the puzzle finally start coming together!. <i>Molecular Oncology</i> , 2011, 5, 113-115.	2.1	2
103	Novel Immunotherapeutic Agents and Small Molecule Antagonists of Signalling Kinases for the Treatment of Metastatic Melanoma. <i>Drugs</i> , 2011, 71, 1233-1250.	4.9	20
104	Ipilimumab. <i>Drugs</i> , 2011, 71, 1093-1104.	4.9	161
105	Hemophilia A Induced by Ipilimumab. <i>New England Journal of Medicine</i> , 2011, 365, 1747-1748.	13.9	93
106	Defining the critical hurdles in cancer immunotherapy. <i>Journal of Translational Medicine</i> , 2011, 9, 214.	1.8	139
107	Fotemustine for the treatment of melanoma. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 2891-2904.	0.9	24
108	Hiding the road signs that lead to tumor immunity. <i>Journal of Experimental Medicine</i> , 2011, 208, 1937-1940.	4.2	16
109	Cancer Immunotherapy. <i>Surgical Oncology Clinics of North America</i> , 2011, 20, 531-554.	0.6	3
110	gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma. <i>New England Journal of Medicine</i> , 2011, 364, 2119-2127.	13.9	809
111	Cancer Immunotherapy. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2011, 26, 1-64.	0.7	120
112	BRAF targeted therapy changes the treatment paradigm in melanoma. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 426-433.	12.5	229
113	Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma. <i>New England Journal of Medicine</i> , 2011, 364, 2517-2526.	13.9	4,074
114	Cancer immunotherapy comes of age. <i>Nature</i> , 2011, 480, 480-489.	13.7	3,115
115	A methodological framework to enhance the clinical success of cancer immunotherapy. <i>Nature Biotechnology</i> , 2011, 29, 867-870.	9.4	57
116	Vemurafenib. <i>Nature Reviews Drug Discovery</i> , 2011, 10, 811-812.	21.5	135

#	ARTICLE	IF	CITATIONS
118	Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. <i>Nature Medicine</i> , 2011, 17, 1094-1100.	15.2	476
119	Colorectal cancer vaccines in clinical trials. <i>Expert Review of Vaccines</i> , 2011, 10, 899-921.	2.0	23
120	Brain cancer immunoediting: novel examples provided by immunotherapy of malignant gliomas. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 1759-1774.	1.1	24
121	The immunological era in melanoma treatment: new challenges for heat shock protein-based vaccine in the advanced disease. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 1395-1407.	1.4	8
122	Development of Novel Targeted Agents in the Treatment of Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2011, 10, 266-278.	1.0	6
123	Current and future adjuvant immunotherapies for melanoma: Blockade of cytotoxic T-lymphocyte antigen-4 as a novel approach. <i>Cancer Treatment Reviews</i> , 2011, 37, 133-142.	3.4	9
124	Current Surgical Treatment in Melanoma. <i>Current Problems in Cancer</i> , 2011, 35, 173-184.	1.0	5
125	Melanoma Brain Metastases: Is It Time to Reassess the Bias?. <i>Current Problems in Cancer</i> , 2011, 35, 200-210.	1.0	33
126	Molecular Alternations in Uveal Melanoma. <i>Current Problems in Cancer</i> , 2011, 35, 211-224.	1.0	9
127	Mutant onco-proteins as drug targets: successes, failures, and future prospects. <i>Current Opinion in Genetics and Development</i> , 2011, 21, 29-33.	1.5	10
128	Targeted immunotherapy for acute myeloid leukemia. <i>Best Practice and Research in Clinical Haematology</i> , 2011, 24, 533-540.	0.7	7
129	New drugs in melanoma: It's a whole new world. <i>European Journal of Cancer</i> , 2011, 47, 2150-2157.	1.3	168
130	Differential PAX3 functions in normal skin melanocytes and melanoma cells. <i>Biochemical and Biophysical Research Communications</i> , 2011, 411, 832-837.	1.0	34
132	Profile of ipilimumab and its role in the treatment of metastatic melanoma. <i>Drug Design, Development and Therapy</i> , 2011, 5, 489.	2.0	23
133	Active and Passive Immunotherapy for Lymphoma: Proving Principles and Improving Results. <i>Journal of Clinical Oncology</i> , 2011, 29, 1864-1875.	0.8	42
134	Principles and Current Strategies for Targeting Autophagy for Cancer Treatment. <i>Clinical Cancer Research</i> , 2011, 17, 654-666.	3.2	789
135	Breast cancer vaccines: ongoing National Cancer Institute-registered clinical trials. <i>Expert Review of Vaccines</i> , 2011, 10, 755-774.	2.0	14
136	Immunotherapy for the treatment of prostate cancer. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 551-561.	12.5	86

#	ARTICLE	IF	CITATIONS
137	Inhibitory Fc γ 3 Receptor Engagement Drives Adjuvant and Anti-Tumor Activities of Agonistic CD40 Antibodies. <i>Science</i> , 2011, 333, 1030-1034.	6.0	313
138	Immunotherapy for Prostate Cancer: Biology and Therapeutic Approaches. <i>Journal of Clinical Oncology</i> , 2011, 29, 3677-3685.	0.8	41
139	Immune parameters affecting the efficacy of chemotherapeutic regimens. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 151-160.	12.5	592
140	Long-term survivors after immunotherapy for metastatic melanoma. <i>Immunology Letters</i> , 2011, 139, 117-118.	1.1	3
141	Targeting immune effector cells to promote antibody-induced cytotoxicity in cancer immunotherapy. <i>Trends in Immunology</i> , 2011, 32, 510-516.	2.9	52
142	Melanoma survival in the United States, 1992 to 2005. <i>Journal of the American Academy of Dermatology</i> , 2011, 65, S78.e1-S78.e10.	0.6	160
143	Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2011, 14, 206-218.	2.0	25
144	Cancer immunotherapy “revisited”. <i>Nature Reviews Drug Discovery</i> , 2011, 10, 591-600.	21.5	346
145	Immunotherapy in prostate cancer: Emerging strategies against a formidable foe. <i>Vaccine</i> , 2011, 29, 6485-6497.	1.7	20
146	Treatment implications of the emerging molecular classification system for melanoma. <i>Lancet Oncology</i> , The, 2011, 12, 913-922.	5.1	82
147	Adjuvant interferon: recommit or move on?. <i>Lancet Oncology</i> , The, 2011, 12, 112-113.	5.1	3
148	Delivering affordable cancer care in high-income countries. <i>Lancet Oncology</i> , The, 2011, 12, 933-980.	5.1	571
149	Striking a balance between idealism and fatalism. <i>Lancet Oncology</i> , The, 2011, 12, 923-924.	5.1	5
150	Harmonization of Immune Biomarker Assays for Clinical Studies. <i>Science Translational Medicine</i> , 2011, 3, 108ps44.	5.8	87
151	Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation. <i>New England Journal of Medicine</i> , 2011, 364, 2507-2516.	13.9	6,976
152	Therapy for metastatic melanoma: an overview and update. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 725-737.	1.1	55
153	Immune reactions in benign and malignant melanocytic lesions: lessons for immunotherapy. <i>Pigment Cell and Melanoma Research</i> , 2011, 24, 334-344.	1.5	45
154	Unwelcome guests: macrophages promote UV-induced melanoma. <i>Pigment Cell and Melanoma Research</i> , 2011, 24, 265-267.	1.5	0

#	ARTICLE	IF	CITATIONS
155	Progress in the management of metastatic melanoma. <i>Community Oncology</i> , 2011, 8, 17-19.	0.2	0
156	An unusual presentation of metastatic melanoma. <i>Community Oncology</i> , 2011, 8, 445-446.	0.2	1
157	Translating p53 into the clinic. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 25-37.	12.5	343
158	Cell transfer immunotherapy for metastatic solid cancer—what clinicians need to know. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 577-585.	12.5	285
159	Immunotherapy for Advanced Melanoma. <i>Clinical Journal of Oncology Nursing</i> , 2011, 15, E58-E65.	0.3	2
160	Impact of Tumour Volume on the Potential Efficacy of Therapeutic Vaccines. <i>Current Oncology</i> , 2011, 18, 150-157.	0.9	90
161	Melanoma Immunomodulation: A War of Attrition. , 2011, , .		0
162	A Bromophosphonate Analogue of Lysophosphatidic Acid Surpasses Dacarbazine in Reducing Cell Proliferation and Viability of MeWo Melanoma Cells. , 2011, , .		1
163	Promising Experimental Therapies for Metastatic Melanoma. , 2011, , .		0
164	Adjuvant Treatment of Melanoma. , 0, , .		0
165	Current Insight Into the Metastatic Process and Melanoma Cell Dissemination. , 0, , .		0
166	Chemocentric Chemoimmunotherapy: A New Concept in Melanoma Immunotherapy. , 0, , .		0
167	Melanoma During Pregnancy. , 2011, , .		1
168	Pulse Power Ablation of Melanoma with Nanosecond Pulsed Electric Fields. , 0, , .		5
170	Future of radiation therapy for malignant melanoma in an era of newer, more effective biological agents. <i>OncoTargets and Therapy</i> , 2011, 4, 137.	1.0	46
171	An update on TroVax® for the treatment of progressive castration-resistant prostate cancer. <i>OncoTargets and Therapy</i> , 2011, 4, 33.	1.0	2
173	Cytotoxic T Lymphocytes and Vaccine Development 2011. <i>Journal of Biomedicine and Biotechnology</i> , 2011, 2011, 1-1.	3.0	1
174	Immune-Based Therapies for Sarcoma. <i>Sarcoma</i> , 2011, 2011, 1-7.	0.7	29

#	ARTICLE	IF	CITATIONS
175	The ultimate goal of curative anti-cancer therapies: inducing an adaptive anti-tumor immune response. <i>Frontiers in Immunology</i> , 2011, 2, 66.	2.2	9
176	Born to be Alive: A Role for the BCL-2 Family in Melanoma Tumor Cell Survival, Apoptosis, and Treatment. <i>Frontiers in Oncology</i> , 2011, 1, .	1.3	42
177	The Novel Gamma Secretase Inhibitor RO4929097 Reduces the Tumor Initiating Potential of Melanoma. <i>PLoS ONE</i> , 2011, 6, e25264.	1.1	60
178	Role of Immunotherapy for Renal Cell Cancer in 2011. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, 1011-1018.	2.3	22
179	Immunotherapy for melanoma. <i>Current Opinion in Oncology</i> , 2011, 23, 163-169.	1.1	35
180	Beyond Cancer Vaccines. <i>Cancer Journal (Sudbury, Mass)</i> , 2011, 17, 372-378.	1.0	26
181	Multiple Vaccinations. <i>Cancer Journal (Sudbury, Mass)</i> , 2011, 17, 379-396.	1.0	13
182	Immunotherapy for glioma. <i>Current Opinion in Neurology</i> , 2011, 24, 641-647.	1.8	29
183	P017. Results of "classical"™ second line with cytotoxic chemotherapies in metastatic melanoma. <i>Melanoma Research</i> , 2011, 21, e25-e26.	0.6	0
184	Autoimmunity and treatment outcome in melanoma. <i>Current Opinion in Oncology</i> , 2011, 23, 170-176.	1.1	48
185	Isolated limb perfusion for melanoma in-transit metastases: developments in recent years and the role of tumor necrosis factor alpha. <i>Current Opinion in Oncology</i> , 2011, 23, 183-188.	1.1	28
187	Therapeutic Vaccination With an Autologous mRNA Electroporated Dendritic Cell Vaccine in Patients With Advanced Melanoma. <i>Journal of Immunotherapy</i> , 2011, 34, 448-456.	1.2	124
188	Restoration of tumor equilibrium after immunotherapy for advanced melanoma. <i>Melanoma Research</i> , 2011, 21, 152-159.	0.6	11
189	Update on Prostate Cancer Vaccines. <i>Cancer Journal (Sudbury, Mass)</i> , 2011, 17, 294-299.	1.0	19
190	P013. Wnt-1 reduces VEGF-C expression and lymph-angiogenesis in a melanoma mouse model. <i>Melanoma Research</i> , 2011, 21, e23-e24.	0.6	0
191	P014. Orbital myositis associated with ipilimumab. <i>Melanoma Research</i> , 2011, 21, e24.	0.6	4
192	Immunotherapy for head and neck cancer. <i>Anti-Cancer Drugs</i> , 2011, 22, 674-681.	0.7	22
193	Industry Update: The latest developments in therapeutic delivery. <i>Therapeutic Delivery</i> , 2011, 2, 695-710.	1.2	1

#	ARTICLE	IF	CITATIONS
194	P001. What's the best therapy for treating resected stage III melanoma patients?. Melanoma Research, 2011, 21, e17.	0.6	0
195	Complete regression of subcutaneous and cutaneous metastatic melanoma with high-dose intralesional interleukin 2 in combination with topical imiquimod and retinoid cream. Melanoma Research, 2011, 21, 235-243.	0.6	35
196	Augmented Lymphocyte Expansion from Solid Tumors With Engineered Cells for Costimulatory Enhancement. Journal of Immunotherapy, 2011, 34, 651-661.	1.2	19
197	Review. Melanoma Research, 2011, 21, 257-266.	0.6	78
198	High-dose interleukin-2 in patients with metastatic melanoma whose disease progressed after biochemotherapy. Melanoma Research, 2011, 21, 370-375.	0.6	2
199	Molecular Markers of Response to Treatment for Melanoma. Cancer Journal (Sudbury, Mass), 2011, 17, 127-133.	1.0	19
200	Therapeutic Cancer Vaccine Development. Cancer Journal (Sudbury, Mass), 2011, 17, 276.	1.0	4
201	P015. Different dosing schedules positively influence the effect of the EGF-receptor inhibitor erlotinib in combination with chemotherapy on malignant melanoma. Melanoma Research, 2011, 21, e24-e25.	0.6	1
202	Assessment of Copy Number Status of Chromosomes 6 and 11 by FISH Provides Independent Prognostic Information in Primary Melanoma. American Journal of Surgical Pathology, 2011, 35, 1146-1150.	2.1	60
203	Melanoma Vaccines. Cancer Journal (Sudbury, Mass), 2011, 17, 277-282.	1.0	10
204	Dose-Dependent Effect of Anti-CTLA-4 on Survival in Sepsis. Shock, 2011, 36, 38-44.	1.0	112
205	IFN-Conditioned Dendritic Cells for the Therapy of Melanoma. Journal of Immunotherapy, 2011, 34, 607-609.	1.2	1
207	New Perspectives in Glioma Immunotherapy. Current Pharmaceutical Design, 2011, 17, 2439-2467.	0.9	23
208	Case of the Month. JAAPA: Official Journal of the American Academy of Physician Assistants, 2011, 24, 68.	0.1	3
209	BRAF-targeted therapy for metastatic melanoma: rationale, clinical activity and safety. Clinical Investigation, 2011, 1, 1127-1139.	0.0	6
210	Autoimmunity associated with immunotherapy of cancer. Blood, 2011, 118, 499-509.	0.6	163
211	Targeted cancer therapy: dendritic cell metabolism. Therapeutic Delivery, 2011, 2, 133-136.	1.2	0
212	Immunotherapy for Non-small Cell Lung Cancer: Novel Approaches to Improve Patient Outcome. Journal of Thoracic Oncology, 2011, 6, 1763-1773.	0.5	70

#	ARTICLE	IF	CITATIONS
216	Exploring immune therapy for renal cancer. International Journal of Urology, 2011, 18, 412-421.	0.5	0
217	Roles of the immune system in skin cancer. British Journal of Dermatology, 2011, 165, 953-965.	1.4	151
218	GMCSF-Interleukin fusion cytokines induce novel immune effectors that can serve as biopharmaceuticals for treatment of autoimmunity and cancer. Journal of Internal Medicine, 2011, 269, 74-84.	2.7	17
219	Dendritic cells and immunity against cancer. Journal of Internal Medicine, 2011, 269, 64-73.	2.7	143
220	A Decade of Melanomas: Identification of Factors Associated with Delayed Detection in an Academic Group Practice. Dermatologic Surgery, 2011, 37, 1620-1630.	0.4	13
221	Update on monoclonal antibodies for the treatment of cancer. Asia-Pacific Journal of Clinical Oncology, 2011, 7, 20-25.	0.7	0
222	Therapeutic cancer vaccines: are we there yet?. Immunological Reviews, 2011, 239, 27-44.	2.8	249
223	Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication. Immunological Reviews, 2011, 241, 104-118.	2.8	229
224	Intrinsic and extrinsic control of peripheral T cell tolerance by costimulatory molecules of the CD28/B7 family. Immunological Reviews, 2011, 241, 180-205.	2.8	330
225	Science gone translational: the OX40 agonist story. Immunological Reviews, 2011, 244, 218-231.	2.8	130
226	Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanoma. JDDG - Journal of the German Society of Dermatology, 2011, 9, 277-286.	0.4	87
227	Behandlung und Nebenwirkungsmanagement des metastasierten Melanoms mit CTLA-4-Antikörpern. JDDG - Journal of the German Society of Dermatology, 2011, 9, 277-286.	0.4	33
228	Timeline: a decade of advances in immunotherapy. Nature Medicine, 2011, 17, 296-296.	15.2	4
229	Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nature Reviews Cancer, 2011, 11, 805-812.	12.8	554
230	Upcoming market catalysts in Q1 2011. Nature Reviews Drug Discovery, 2011, 10, 10-10.	21.5	1
232	Ipilimumab. Nature Reviews Drug Discovery, 2011, 10, 411-412.	21.5	135
233	Whole recombinant yeast vaccine induces antitumor immunity and improves survival in a genetically engineered mouse model of melanoma. Gene Therapy, 2011, 18, 827-834.	2.3	23
234	Melanoma stem cells: not rare, but well done. Laboratory Investigation, 2011, 91, 647-664.	1.7	70

#	ARTICLE	IF	CITATIONS
235	Interferon- β links ultraviolet radiation to melanomagenesis in mice. <i>Nature</i> , 2011, 469, 548-553.	13.7	264
236	Antibodies in oncology. <i>New Biotechnology</i> , 2011, 28, 518-529.	2.4	62
237	In vivo 6-thioguanine-resistant T cells from melanoma patients have public TCR and share TCR beta amino acid sequences with melanoma-reactive T cells. <i>Journal of Immunological Methods</i> , 2011, 365, 76-86.	0.6	6
238	Morphological changes in early melanoma development: Influence of nutrients, growth inhibitors and cell-adhesion mechanisms. <i>Journal of Theoretical Biology</i> , 2011, 290, 46-59.	0.8	28
239	Cancer Immunotherapy: Sipuleucel β and Beyond. <i>Pharmacotherapy</i> , 2011, 31, 813-828.	1.2	79
240	4-Methylcatechol-induced oxidative stress induces intrinsic apoptotic pathway in metastatic melanoma cells. <i>Biochemical Pharmacology</i> , 2011, 81, 1211-1218.	2.0	20
241	β -Catenin Signaling Controls Metastasis in Braf-Activated Pten-Deficient Melanomas. <i>Cancer Cell</i> , 2011, 20, 741-754.	7.7	317
242	Natural Innate and Adaptive Immunity to Cancer. <i>Annual Review of Immunology</i> , 2011, 29, 235-271.	9.5	1,691
243	Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy. <i>Clinical Cancer Research</i> , 2011, 17, 4550-4557.	3.2	1,823
244	Targeting inhibitor of apoptosis proteins in combination with dacarbazine or TRAIL in melanoma cells. <i>Cancer Biology and Therapy</i> , 2011, 12, 47-58.	1.5	21
245	Cancer Immunotherapy Comes of Age. <i>Journal of Clinical Oncology</i> , 2011, 29, 4828-4836.	0.8	411
246	Targeting Regulatory T Cells in Cancer. <i>Cancer Research</i> , 2011, 71, 6915-6920.	0.4	172
247	Cancer immunology—analysis of host and tumor factors for personalized medicine. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 711-719.	12.5	251
248	Current status and future applications of cellular therapies for cancer. <i>Immunotherapy</i> , 2011, 3, 507-516.	1.0	26
249	Novel therapies in melanoma. <i>Immunotherapy</i> , 2011, 3, 1461-1469.	1.0	18
250	Vemurafenib (PLX4032): An Orally Available Inhibitor of Mutated BRAF for the Treatment of Metastatic Melanoma. <i>Annals of Pharmacotherapy</i> , 2011, 45, 1399-1405.	0.9	44
251	Establishment of Antitumor Memory in Humans Using in Vitro "Educated" CD8 ⁺ T Cells. <i>Science Translational Medicine</i> , 2011, 3, 80ra34.	5.8	94
252	Cancer Immunoeediting: Integrating Immunity's Roles in Cancer Suppression and Promotion. <i>Science</i> , 2011, 331, 1565-1570.	6.0	4,987

#	ARTICLE	IF	CITATIONS
253	Development of bavituximab, a vascular targeting agent with immune-modulating properties, for lung cancer treatment. <i>Immunotherapy</i> , 2011, 3, 933-944.	1.0	48
254	Vaccine-based clinical trials in ovarian cancer. <i>Expert Review of Vaccines</i> , 2011, 10, 775-784.	2.0	13
255	Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2011, 17, 6958-6962.	3.2	438
256	Ipilimumab: showing survival benefit in metastatic melanoma. <i>Future Oncology</i> , 2011, 7, 1255-1264.	1.1	6
257	Immunomodulating antibodies and drugs for the treatment of hematological malignancies. <i>Cancer and Metastasis Reviews</i> , 2011, 30, 97-109.	2.7	17
261	¹⁸ F-FDG PET/CT imaging of an anti-CTLA-4 antibody-associated autoimmune pancolitis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 1390-1391.	3.3	15
262	Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 15-22.	2.0	65
263	Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy). <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 467-477.	2.0	79
264	Immunologic biomarkers as correlates of clinical response to cancer immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 433-442.	2.0	111
265	Ten years of progress in vaccination against cancer: the need to counteract cancer evasion by dual targeting in future therapies. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 1127-1135.	2.0	26
266	CTLA-4 blockade increases antigen-specific CD8+ T cells in prevaccinated patients with melanoma: three cases. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 1137-1146.	2.0	82
267	Tumor-infiltrating lymphocytes: apparently good for melanoma patients. But why?. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 1153-1160.	2.0	57
268	DNA fusion vaccines enter the clinic. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 1147-1151.	2.0	21
269	Combination of targeted therapy and immunotherapy in melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 1359-1371.	2.0	40
270	Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 1509-1527.	2.0	50
271	Phase II clinical trial evaluating docetaxel, vinorelbine and GM-CSF in stage IV melanoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 1081-1087.	1.1	8
272	Immunomodulatory effects of cyclophosphamide and implementations for vaccine design. <i>Seminars in Immunopathology</i> , 2011, 33, 369-383.	2.8	265
273	Prognostic significance of autoimmunity during treatment of melanoma with interferon. <i>Seminars in Immunopathology</i> , 2011, 33, 385-391.	2.8	143

#	ARTICLE	IF	CITATIONS
274	Polyclonal immune responses to antigens associated with cancer signaling pathways and new strategies to enhance cancer vaccines. <i>Immunologic Research</i> , 2011, 49, 235-247.	1.3	11
275	Continuous systemic corticosteroids do not affect the ongoing regression of metastatic melanoma for more than two years following ipilimumab therapy. <i>Medical Oncology</i> , 2011, 28, 1140-1144.	1.2	91
276	A new era in the treatment of melanoma: from biology to clinical practice. <i>Clinical and Translational Oncology</i> , 2011, 13, 787-792.	1.2	9
278	The mechanisms of cancer immunoescape and development of overcoming strategies. <i>International Journal of Hematology</i> , 2011, 93, 294-300.	0.7	106
279	Antibody therapy for Adult T-cell leukemia lymphoma. <i>International Journal of Hematology</i> , 2011, 94, 443-452.	0.7	42
280	Immunosuppressive Tumor Microenvironment in Cervical Cancer Patients. <i>Cancer Microenvironment</i> , 2011, 4, 361-375.	3.1	105
281	Novel Targeted Therapies and Vaccination Strategies for Mesothelioma. <i>Current Treatment Options in Oncology</i> , 2011, 12, 149-162.	1.3	15
282	Treatment of Advanced Melanoma with Immunological Checkpoint Block. <i>Current Oncology Reports</i> , 2011, 13, 430-432.	1.8	2
283	The "SWOT" of BRAF Inhibition in Melanoma: RAF Inhibitors, MEK Inhibitors or Both?. <i>Current Oncology Reports</i> , 2011, 13, 479-487.	1.8	33
284	Low back pain as the presenting sign in a patient with primary extradural melanoma of the thoracic spine - A metastatic disease 17 Years after complete surgical resection. <i>World Journal of Surgical Oncology</i> , 2011, 9, 150.	0.8	7
285	Combination therapy: the next opportunity and challenge of medicine. <i>Journal of Translational Medicine</i> , 2011, 9, 115.	1.8	71
286	Cytotoxic T lymphocyte responses against melanocytes and melanoma. <i>Journal of Translational Medicine</i> , 2011, 9, 122.	1.8	7
287	Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application. <i>Journal of Translational Medicine</i> , 2011, 9, 196.	1.8	64
288	A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. <i>Journal of Translational Medicine</i> , 2011, 9, 204.	1.8	500
290	A new era: melanoma genetics and therapeutics. <i>Journal of Pathology</i> , 2011, 223, 242-251.	2.1	107
292	Current and planned multicenter trials for patients with primary or metastatic melanoma. <i>Journal of Surgical Oncology</i> , 2011, 104, 430-437.	0.8	5
293	Rationale for complete metastasectomy in patients with stage IV metastatic melanoma. <i>Journal of Surgical Oncology</i> , 2011, 104, 420-424.	0.8	47
294	Systemic treatment of metastatic melanoma: New approaches. <i>Journal of Surgical Oncology</i> , 2011, 104, 425-429.	0.8	11

#	ARTICLE	IF	CITATIONS
295	Enhancement of anti-tumor immunity through local modulation of CTLA-4 and GITR by dendritic cells. <i>European Journal of Immunology</i> , 2011, 41, 3553-3563.	1.6	67
296	Cancer immunotherapy: Progress and challenges in the clinical setting. <i>European Journal of Immunology</i> , 2011, 41, 1510-1515.	1.6	24
297	A phase 2 study of tasisulam sodium (LY573636 sodium) as second-line treatment for patients with unresectable or metastatic melanoma. <i>Cancer</i> , 2011, 117, 4732-4739.	2.0	19
298	Cancer Immunotherapy Trials Network launches effort to generate new research. <i>Cancer</i> , 2011, 117, 3287-3288.	2.0	0
299	Synergistic effects of CTLA-4 blockade with tremelimumab and elimination of regulatory T lymphocytes <i>in vitro</i> and <i>in vivo</i> . <i>International Journal of Cancer</i> , 2011, 129, 374-386.	2.3	16
300	Cytotoxic immunotherapy strategies for cancer: Mechanisms and clinical development. <i>Journal of Cellular Biochemistry</i> , 2011, 112, 1969-1977.	1.2	64
301	Long-term outcome of isolated limb perfusion with tumour necrosis factor- α for patients with melanoma in-transit metastases. <i>British Journal of Surgery</i> , 2011, 98, 1573-1580.	0.1	51
302	The Evolving Role of Radiation Therapy in the Management of Malignant Melanoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 645-654.	0.4	58
303	Immunological Effects of Low-dose Cyclophosphamide in Cancer Patients Treated With Oncolytic Adenovirus. <i>Molecular Therapy</i> , 2011, 19, 1737-1746.	3.7	141
304	Potential targets for pancreatic cancer immunotherapeutics. <i>Immunotherapy</i> , 2011, 3, 517-537.	1.0	57
305	Do human lymphocyte antigens play a role in the clinical antimelanoma activity of ipilimumab?. <i>Immunotherapy</i> , 2011, 3, 595-599.	1.0	1
306	Norcantharidin induces melanoma cell apoptosis through activation of TR3 dependent pathway. <i>Cancer Biology and Therapy</i> , 2011, 12, 1005-1014.	1.5	22
307	Radiologic Manifestations of Immune-Related Adverse Events in Patients With Metastatic Melanoma Undergoing Anti-CTLA-4 Antibody Therapy. <i>American Journal of Roentgenology</i> , 2011, 197, W992-W1000.	1.0	231
308	Anti-angiogenesis immunotherapy. <i>Hum Vaccin</i> , 2011, 7, 976-981.	2.4	17
309	The unfolding treatment landscape for men with castration-resistant prostate cancer. <i>Clinical Investigation</i> , 2011, 1, 1533-1544.	0.0	2
310	Therapeutic cancer vaccine fulfills the promise of immunotherapy in prostate cancer. <i>Immunotherapy</i> , 2011, 3, 27-31.	1.0	12
311	Research Highlights. <i>Immunotherapy</i> , 2011, 3, 927-930.	1.0	3
312	Immunotherapy of Uveal Melanoma. <i>Developments in Ophthalmology</i> , 2012, 49, 137-149.	0.1	8

#	ARTICLE	IF	CITATIONS
313	Immunotherapy coming of age: What will it take to make it standard of care for glioblastoma?. <i>Neuro-Oncology</i> , 2011, 13, 3-13.	0.6	97
314	Sipuleucel-T: harbinger of a new age of therapeutics for prostate cancer. <i>Expert Review of Vaccines</i> , 2011, 10, 141-150.	2.0	23
315	Proving the principle: dendritic cell-based vaccines in urogenital cancers. <i>Expert Review of Vaccines</i> , 2011, 10, 1355-1357.	2.0	0
316	Using monoclonal antibodies to stimulate antitumor cellular immunity. <i>Expert Review of Vaccines</i> , 2011, 10, 1093-1106.	2.0	14
317	Radiologic Aspects of Immune-Related Tumor Response Criteria and Patterns of Immune-Related Adverse Events in Patients Undergoing Ipilimumab Therapy. <i>American Journal of Roentgenology</i> , 2011, 197, W241-W246.	1.0	62
319	Small-molecule protein kinase inhibitors and their effects on the immune system: implications for cancer treatment. <i>Immunotherapy</i> , 2011, 3, 213-227.	1.0	53
320	Ipilimumab plus Dacarbazine in Melanoma. <i>New England Journal of Medicine</i> , 2011, 365, 1256-1258.	13.9	12
321	Therapeutic options in cutaneous melanoma: latest developments. <i>Therapeutic Advances in Medical Oncology</i> , 2011, 3, 245-251.	1.4	8
322	Resistance to Chemotherapy and Molecularly Targeted Therapies: Rationale for Combination Therapy in Malignant Melanoma. <i>Current Molecular Medicine</i> , 2011, 11, 553-563.	0.6	37
323	Improved outcomes for patients with metastatic melanoma. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 513-515.	12.5	20
324	Immunologic therapy targeting metastatic melanoma: Allovectin-7 [®] . <i>Immunotherapy</i> , 2011, 3, 17-21.	1.0	16
325	Cancer Vaccines: Personalizing Health Interventions. <i>Current Pharmacogenomics and Personalized Medicine</i> , 2011, 9, 208-228.	0.2	1
326	Editorial. <i>Journal of Neurosurgery</i> , 2011, 115, 245-247.	0.9	4
327	Immune microenvironments in solid tumors: new targets for therapy. <i>Genes and Development</i> , 2011, 25, 2559-2572.	2.7	277
328	Should High-Dose Interleukin-2 Still be the Preferred Treatment for Patients with Metastatic Renal Cell Cancer?. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2011, 26, 273-277.	0.7	8
330	Preclinical and clinical activity of the topoisomerase I inhibitor, karenitecin, in melanoma. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 1565-1574.	1.9	32
331	Expression of the embryological morphogen Nodal in stage III/IV melanoma. <i>Melanoma Research</i> , 2011, 21, 491-501.	0.6	11
332	Safety and clinical activity of ipilimumab in melanoma patients with brain metastases. <i>Melanoma Research</i> , 2011, 21, 530-534.	0.6	111

#	ARTICLE	IF	CITATIONS
333	BRAF Inhibitors and Melanoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2011, 17, 505-511.	1.0	28
334	Dendritic cell-based vaccine in advanced melanoma. <i>Melanoma Research</i> , 2011, 21, 524-529.	0.6	36
335	T-Cell Receptor Gene Therapy: Critical Parameters for Clinical Success. <i>Journal of Investigative Dermatology</i> , 2011, 131, 1806-1816.	0.3	38
336	A Pilot Study of MUC-1/CEA/TRICOM Poxviral-Based Vaccine in Patients with Metastatic Breast and Ovarian Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 7164-7173.	3.2	111
337	Unique Functional Status of Natural Killer Cells in Metastatic Stage IV Melanoma Patients and Its Modulation by Chemotherapy. <i>Clinical Cancer Research</i> , 2011, 17, 2628-2637.	3.2	52
338	Latest developments in the treatment of melanoma: â€“a penicillin moment for cancerâ€™?. <i>Journal of the Royal Society of Medicine</i> , 2011, 104, 269-272.	1.1	4
339	Multicenter, Phase II Study of Axitinib, a Selective Second-Generation Inhibitor of Vascular Endothelial Growth Factor Receptors 1, 2, and 3, in Patients with Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2011, 17, 7462-7469.	3.2	100
340	KIT as a Therapeutic Target in Metastatic Melanoma. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 2327.	3.8	755
341	Prospects for TIM3-Targeted Antitumor Immunotherapy. <i>Cancer Research</i> , 2011, 71, 6567-6571.	0.4	111
342	Novel Therapies for Metastatic Castrate-Resistant Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1665-1675.	3.0	120
343	T-Cell Activation and Maturation at Tumor Site Associated With Objective Response to Ipilimumab in Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2011, 29, e783-e788.	0.8	8
344	Targeting BRAF in Advanced Melanoma: A First Step toward Manageable Disease. <i>Clinical Cancer Research</i> , 2011, 17, 1658-1663.	3.2	65
345	Anti-CTLA-4 antibody-induced Guillainâ€“BarrÃ© syndrome in a melanoma patient. <i>Annals of Oncology</i> , 2011, 22, 991-993.	0.6	167
346	Melanoma update: diagnostic and prognostic factors that can effectively shape and personalize management. <i>Biomarkers in Medicine</i> , 2011, 5, 333-360.	0.6	6
347	The Akt signaling pathway. <i>Cancer Biology and Therapy</i> , 2011, 12, 1032-1049.	1.5	77
348	Immune Recruitment and Therapeutic Synergy: Keys to Optimizing Oncolytic Viral Therapy?. <i>Clinical Cancer Research</i> , 2011, 17, 4214-4224.	3.2	35
349	CTLA4 Blockade Induces Frequent Tumor Infiltration by Activated Lymphocytes Regardless of Clinical Responses in Humans. <i>Clinical Cancer Research</i> , 2011, 17, 4101-4109.	3.2	142
350	Interleukin-7 Inhibits Tumor-Induced CD27â€“CD28â€“ Suppressor T Cells: Implications for Cancer Immunotherapy. <i>Clinical Cancer Research</i> , 2011, 17, 4975-4986.	3.2	29

#	ARTICLE	IF	CITATIONS
351	Towards new therapeutic approaches for malignant melanoma. <i>Expert Reviews in Molecular Medicine</i> , 2011, 13, e33.	1.6	38
352	Prostate Cancer Immunotherapy: Figure 1.. <i>Clinical Cancer Research</i> , 2011, 17, 5233-5238.	3.2	57
353	Case Report: Response to Ipilimumab in a Patient With HIV With Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2011, 29, e792-e794.	0.8	33
355	Immunological and Clinical Effects of Vaccines Targeting p53-Overexpressing Malignancies. <i>Journal of Biomedicine and Biotechnology</i> , 2011, 2011, 1-11.	3.0	31
356	Immune Modulation by Chemotherapy or Immunotherapy to Enhance Cancer Vaccines. <i>Cancers</i> , 2011, 3, 3114-3142.	1.7	64
357	Treatment of Locally Advanced Melanoma by Isolated Limb Infusion with Cytotoxic Drugs. <i>Journal of Skin Cancer</i> , 2011, 2011, 1-7.	0.5	13
358	BRAF in Melanoma: Pathogenesis, Diagnosis, Inhibition, and Resistance. <i>Journal of Skin Cancer</i> , 2011, 2011, 1-8.	0.5	46
359	Immune Microenvironment in Colorectal Cancer: A New Hallmark to Change Old Paradigms. <i>Clinical and Developmental Immunology</i> , 2011, 2011, 1-9.	3.3	24
360	The Immune Response to Tumors as a Tool toward Immunotherapy. <i>Clinical and Developmental Immunology</i> , 2011, 2011, 1-12.	3.3	40
361	Management Options in Advanced Prostate Cancer: What is the Role for Sipuleucel-T?. <i>Clinical Medicine Insights: Oncology</i> , 2011, 5, CMO.S5977.	0.6	2
362	Randomized Multicenter Trial of the Effects of Melanoma-Associated Helper Peptides and Cyclophosphamide on the Immunogenicity of a Multi-peptide Melanoma Vaccine. <i>Journal of Clinical Oncology</i> , 2011, 29, 2924-2932.	0.8	102
363	Randomized Trial of Autologous Cellular Immunotherapy with Sipuleucel-T in Androgen-Dependent Prostate Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 4558-4567.	3.2	128
364	Getting Personal with Melanoma. <i>Clinical Cancer Research</i> , 2011, 17, 4189-4191.	3.2	2
365	Debulking surgery in advanced melanoma. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 1703-1712.	1.1	9
366	Single dose of anti-CTLA-4 enhances CD8 ⁺ T-cell memory formation, function, and maintenance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 266-271.	3.3	151
367	Interaction with Fcγ3RIIB Is Critical for the Agonistic Activity of Anti-CD40 Monoclonal Antibody. <i>Journal of Immunology</i> , 2011, 187, 1754-1763.	0.4	202
368	Monitoring the Systemic Human Memory B Cell Compartment of Melanoma Patients for Anti-Tumor IgG Antibodies. <i>PLoS ONE</i> , 2011, 6, e19330.	1.1	72
369	Thyroid Dysfunction from Antineoplastic Agents. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1572-1587.	3.0	143

#	ARTICLE	IF	CITATIONS
370	Liver Metastases from Melanoma: Hepatic Intra-Arterial Chemotherapy. A Retrospective Study. <i>Journal of Chemotherapy</i> , 2011, 23, 300-305.	0.7	14
371	Chemotherapy in Metastatic Melanoma – Still Useful or Out of Date?. <i>Onkologie</i> , 2011, 34, 159-160.	1.1	2
372	Outcomes of Patients with Metastatic Melanoma Treated with Molecularly Targeted Agents in Phase I Clinical Trials. <i>Oncology</i> , 2011, 81, 135-140.	0.9	6
373	Enrollment in Clinical Trials Correlates with Improved Survival in Metastatic Melanoma. <i>Oncology</i> , 2011, 81, 403-409.	0.9	3
374	Tumor-infiltrating T cells – ready for prime time in melanoma?. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 449-450.	12.5	0
375	New considerations in the design of clinical trials for the treatment of acute leukemia. <i>Clinical Investigation</i> , 2011, 1, 509-517.	0.0	7
376	Comment on –Conventional B2 B Cell Depletion Ameliorates whereas Its Adoptive Transfer Aggravates Atherosclerosis–. <i>Journal of Immunology</i> , 2011, 186, 4.1-4.	0.4	8
377	Response to Comment on –Conventional B2 B Cell Depletion Ameliorates whereas Its Adoptive Transfer Aggravates Atherosclerosis–. <i>Journal of Immunology</i> , 2011, 186, 4.2-5.	0.4	0
378	Recent Developments in Cancer Vaccines. <i>Journal of Immunology</i> , 2011, 186, 1325-1331.	0.4	168
379	Resolution of Severe Ipilimumab-Induced Hepatitis After Antithymocyte Globulin Therapy. <i>Journal of Clinical Oncology</i> , 2011, 29, e237-e240.	0.8	148
380	Cytotoxic T-Lymphocyte –Associated Antigen-4. <i>Clinical Cancer Research</i> , 2011, 17, 4622-4628.	3.2	100
381	Early identification of antigen-specific immune responses in vivo by [¹⁸ F]-labeled 3- ² -fluoro-3- ² -deoxy-thymidine ([¹⁸ F]FLT) PET imaging. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 18396-18399.	3.3	65
382	The ICOS/ICOSL Pathway Is Required for Optimal Antitumor Responses Mediated by Anti –CTLA-4 Therapy. <i>Cancer Research</i> , 2011, 71, 5445-5454.	0.4	203
383	Comment on –Regulatory T Cells Protect from Local and Systemic Bone Destruction in Arthritis–. <i>Journal of Immunology</i> , 2011, 186, 3.1-3.	0.4	0
384	Response to Comment on –Regulatory T Cells Protect from Local and Systemic Bone Destruction in Arthritis–. <i>Journal of Immunology</i> , 2011, 186, 3.2-4.	0.4	0
385	Augmentation of tumor-specific immunity by upregulation of apoptotic melanoma cell calreticulin expression. <i>Cancer Biology and Therapy</i> , 2011, 11, 581-583.	1.5	2
386	Translating Scientific Advancement into Clinical Benefit for Castration-Resistant Prostate Cancer Patients. <i>Clinical Cancer Research</i> , 2011, 17, 3867-3875.	3.2	53
387	Controversies in clinical cancer dormancy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 12396-12400.	3.3	231

#	ARTICLE	IF	CITATIONS
388	Epitope-based vaccines for cancer. , 2011, , 140-149.		0
389	Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies. <i>British Journal of Cancer</i> , 2011, 105, 353-359.	2.9	48
390	Metastatic melanoma in the older patient: immunologic insights and treatment outcomes. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2011, 11, 185-193.	0.7	17
391	Treatment of mesothelioma with gene-modified PA1STK cells and ganciclovir: a phase I study. <i>Cancer Gene Therapy</i> , 2011, 18, 906-912.	2.2	12
392	A randomised, phase II study of intetumumab, an anti- α v-integrin mAb, alone and with dacarbazine in stage IV melanoma. <i>British Journal of Cancer</i> , 2011, 105, 346-352.	2.9	108
393	Inhibition of DNA repair with MGMT pseudosubstrates: phase I study of lomeguatrib in combination with dacarbazine in patients with advanced melanoma and other solid tumours. <i>British Journal of Cancer</i> , 2011, 105, 773-777.	2.9	34
394	Identification of <i>BRAF</i> mutations in eruptive melanocytic nevi: new insights into melanomagenesis?. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 711-714.	1.1	17
395	From clinical trials to clinical practice: therapeutic cancer vaccines for the treatment of prostate cancer. <i>Expert Review of Vaccines</i> , 2011, 10, 743-753.	2.0	20
396	Do we need novel radiologic response criteria for brain tumor immunotherapy?. <i>Expert Review of Neurotherapeutics</i> , 2011, 11, 619-622.	1.4	22
397	Direct Effects of Type I Interferons on Cells of the Immune System. <i>Clinical Cancer Research</i> , 2011, 17, 2619-2627.	3.2	390
398	Extended Dose Ipilimumab with a Peptide Vaccine: Immune Correlates Associated with Clinical Benefit in Patients with Resected High-Risk Stage IIIc/IV Melanoma. <i>Clinical Cancer Research</i> , 2011, 17, 896-906.	3.2	185
399	TNM Staging in Colorectal Cancer: T Is for T Cell and M Is for Memory. <i>Journal of Clinical Oncology</i> , 2011, 29, 601-603.	0.8	87
400	Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy. <i>European Journal of Endocrinology</i> , 2011, 164, 303-307.	1.9	157
401	Immune Suppression in Tumors as a Surmountable Obstacle to Clinical Efficacy of Cancer Vaccines. <i>Cancers</i> , 2011, 3, 2904-2954.	1.7	12
402	Recent Advance in Antigen-Specific Immunotherapy for Acute Myeloid Leukemia. <i>Clinical and Developmental Immunology</i> , 2011, 2011, 1-7.	3.3	12
403	The Consequence of Immune Suppressive Cells in the Use of Therapeutic Cancer Vaccines and Their Importance in Immune Monitoring. <i>Journal of Biomedicine and Biotechnology</i> , 2011, 2011, 1-8.	3.0	8
404	Management of Melanoma Brain Metastases in the Era of Targeted Therapy. <i>Journal of Skin Cancer</i> , 2011, 2011, 1-6.	0.5	12
405	Atypical Clinical Response Patterns to Ipilimumab. <i>Clinical Journal of Oncology Nursing</i> , 2011, 15, 393-403.	0.3	17

#	ARTICLE	IF	CITATIONS
406	Forty Years of Translational Cancer Research. <i>Cancer Discovery</i> , 2011, 1, 383-390.	7.7	17
407	Phase I Trial of ALT-801, an Interleukin-2/T-Cell Receptor Fusion Protein Targeting p53 (aa264â€“272)/HLA-A*0201 Complex, in Patients with Advanced Malignancies. <i>Clinical Cancer Research</i> , 2011, 17, 7765-7775.	3.2	49
408	Adjuvant Therapy: Melanoma. <i>Journal of Skin Cancer</i> , 2011, 2011, 1-19.	0.5	13
409	Emerging Cancer Vaccines: The Promise of Genetic Vectors. <i>Cancers</i> , 2011, 3, 3687-3713.	1.7	16
410	Tumor Evasion from T Cell Surveillance. <i>Journal of Biomedicine and Biotechnology</i> , 2011, 2011, 1-19.	3.0	139
412	Pulling RANK: Are Some Melanoma Cells More Malignant than Others?. <i>Journal of Investigative Dermatology</i> , 2011, 131, 814-816.	0.3	0
413	Breaking Immunological Tolerance to Melanocyte Differentiation Antigens by Hypopigmenting Agents: A New Means for Melanoma Immunotherapy?. <i>Journal of Investigative Dermatology</i> , 2011, 131, 1185-1187.	0.3	3
414	Salvage surgery for a giant melanoma on the back. <i>Rare Tumors</i> , 2011, 3, 90-91.	0.3	8
415	Ipilimumab: Melanoma and beyond. <i>Journal of Pharmacy and Bioallied Sciences</i> , 2011, 3, 546.	0.2	4
416	MECHANISMS IN ENDOCRINOLOGY: Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review. <i>European Journal of Endocrinology</i> , 2012, 167, 1-5.	1.9	120
417	Drug targets and predictive biomarkers in the management of metastatic melanoma. <i>Pharmacogenomics and Personalized Medicine</i> , 2012, 5, 139.	0.4	3
418	Therapeutic Cancer Vaccines in Prostate Cancer: The Quest for Intermediate Markers of Response. <i>Cancers</i> , 2012, 4, 1229-1246.	1.7	3
419	Imaging features of bowel toxicities in the setting of molecular targeted therapies in cancer patients. <i>British Journal of Radiology</i> , 2012, 85, 1420-1426.	1.0	36
420	Identity, Potency, <i>In Vivo</i> Viability, and Scaling Up Production of Lentiviral Vector-Induced Dendritic Cells for Melanoma Immunotherapy. <i>Human Gene Therapy Methods</i> , 2012, 23, 38-55.	2.1	18
421	An intra-patient placebo-controlled phase I trial to evaluate the safety and tolerability of intradermal IMM-101 in melanoma. <i>Annals of Oncology</i> , 2012, 23, 1314-1319.	0.6	45
422	Towards Curative Cancer Immunotherapy: Overcoming Posttherapy Tumor Escape. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-12.	3.3	39
423	Tracking and Treating Malignant Melanoma Metastases. <i>Dermatology Research and Practice</i> , 2012, 2012, 1-2.	0.3	1
424	Targeting Multiple-Myeloma-Induced Immune Dysfunction to Improve Immunotherapy Outcomes. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-13.	3.3	36

#	ARTICLE	IF	CITATIONS
425	Role of Immune Escape Mechanisms in Hodgkin's Lymphoma Development and Progression: A Whole New World with Therapeutic Implications. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-24.	3.3	28
426	Novel Anti-Melanoma Immunotherapies: Disarming Tumor Escape Mechanisms. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-9.	3.3	24
427	Shedding Light on Melanocyte Pathobiology In Vivo : Figure 1.. <i>Cancer Research</i> , 2012, 72, 1591-1595.	0.4	19
428	BRAF Inhibitors for the Treatment of Metastatic Melanoma: Clinical Trials and Mechanisms of Resistance. <i>Clinical Cancer Research</i> , 2012, 18, 33-39.	3.2	120
429	Vaccination therapy for non-small-cell lung cancer: review of agents in phase III development. <i>Annals of Oncology</i> , 2012, 23, 1387-1393.	0.6	52
430	Pulmonary Sarcoid-Like Granulomatosis Induced by Ipilimumab. <i>Journal of Clinical Oncology</i> , 2012, 30, e156-e159.	0.8	177
431	The cancer antigenome. <i>EMBO Journal</i> , 2012, 32, 194-203.	3.5	208
432	Mining Gene Expression Signature for the Detection of Pre-Malignant Melanocytes and Early Melanomas with Risk for Metastasis. <i>PLoS ONE</i> , 2012, 7, e44800.	1.1	20
433	Kinesin Family Member 20A is a Novel Melanoma-associated Antigen. <i>Acta Dermato-Venereologica</i> , 2012, 92, 593-597.	0.6	35
434	How Does Ionizing Irradiation Contribute to the Induction of Anti-Tumor Immunity?. <i>Frontiers in Oncology</i> , 2012, 2, 75.	1.3	71
435	Immunotherapy: Shifting the Balance of Cell-Mediated Immunity and Suppression in Human Prostate Cancer. <i>Cancers</i> , 2012, 4, 1333-1348.	1.7	4
436	Systematic Review and Network Meta-Analysis of Overall Survival Comparing 3 mg/kg Ipilimumab With Alternative Therapies in the Management of Pretreated Patients With Unresectable Stage III or IV Melanoma. <i>Oncologist</i> , 2012, 17, 1376-1385.	1.9	23
437	Monoclonal antibody-induced ErbB3 receptor internalization and degradation inhibits growth and migration of human melanoma cells. <i>Cell Cycle</i> , 2012, 11, 1455-1467.	1.3	29
438	Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2012, 23, vii86-vii91.	0.6	336
439	Role of T lymphocytes in tumor response to radiotherapy. <i>Frontiers in Oncology</i> , 2012, 2, 95.	1.3	137
440	Immune Response to Sipuleucel-T in Prostate Cancer. <i>Cancers</i> , 2012, 4, 420-441.	1.7	12
441	Toward Maximizing Immunotherapy in Metastatic Castration-Resistant Prostate Cancer – Rationale for Combinatorial Approaches Using Chemotherapy. <i>Frontiers in Oncology</i> , 2012, 2, 43.	1.3	9
442	Targeting Costimulatory Molecules to Improve Antitumor Immunity. <i>Journal of Biomedicine and Biotechnology</i> , 2012, 2012, 1-17.	3.0	71

#	ARTICLE	IF	CITATIONS
443	Regulatory T Cells in Radiotherapeutic Responses. <i>Frontiers in Oncology</i> , 2012, 2, 90.	1.3	71
444	Vaccination with mRNA-Electroporated Dendritic Cells Induces Robust Tumor Antigen-Specific CD4+ and CD8+ T Cells Responses in Stage III and IV Melanoma Patients. <i>Clinical Cancer Research</i> , 2012, 18, 5460-5470.	3.2	86
445	Melanoma Vaccines and Modulation of the Immune System in the Clinical Setting: Building from New Realities. <i>Frontiers in Immunology</i> , 2012, 3, 103.	2.2	5
446	Bevacizumab-Induced Alterations in Vascular Permeability and Drug Delivery: A Novel Approach to Augment Regional Chemotherapy for In-Transit Melanoma. <i>Clinical Cancer Research</i> , 2012, 18, 3328-3339.	3.2	51
447	Targeted Therapy for Brain Metastases. <i>Advances in Pharmacology</i> , 2012, 65, 109-142.	1.2	11
448	Ipilimumab-Induced Sarcoidosis in a Patient With Metastatic Melanoma Undergoing Complete Remission. <i>Journal of Clinical Oncology</i> , 2012, 30, e7-e10.	0.8	119
450	Concomitant Targeting of Tumor Cells and Induction of T-cell Response Synergizes to Effectively Inhibit Trastuzumab-Resistant Breast Cancer. <i>Cancer Research</i> , 2012, 72, 4417-4428.	0.4	42
451	Ipilimumab-induced thrombocytopenia in a patient with metastatic melanoma. <i>Journal of Oncology Pharmacy Practice</i> , 2012, 18, 287-292.	0.5	47
452	An <i>In Vivo</i> Immunotherapy Screen of Costimulatory Molecules Identifies Fc-OX40L as a Potent Reagent for the Treatment of Established Murine Gliomas. <i>Clinical Cancer Research</i> , 2012, 18, 4657-4668.	3.2	33
453	TIL therapy broadens the tumor-reactive CD8 ⁺ T cell compartment in melanoma patients. <i>Oncolmmunology</i> , 2012, 1, 409-418.	2.1	171
454	CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2012, 18, 2039-2047.	3.2	459
455	Human dendritic cells adenovirally-engineered to express three defined tumor antigens promote broad adaptive and innate immunity. <i>Oncolmmunology</i> , 2012, 1, 287-357.	2.1	24
456	Myeloma-Specific Multiple Peptides Able to Generate Cytotoxic T Lymphocytes: A Potential Therapeutic Application in Multiple Myeloma and Other Plasma Cell Disorders. <i>Clinical Cancer Research</i> , 2012, 18, 4850-4860.	3.2	66
457	BRAF Inhibitor Vemurafenib Improves the Antitumor Activity of Adoptive Cell Immunotherapy. <i>Cancer Research</i> , 2012, 72, 3928-3937.	0.4	210
458	Combined PI3K/mTOR and MEK Inhibition Provides Broad Antitumor Activity in Faithful Murine Cancer Models. <i>Clinical Cancer Research</i> , 2012, 18, 5290-5303.	3.2	118
459	A brief history of melanoma. <i>Melanoma Research</i> , 2012, 22, 114-122.	0.6	111
460	Serum interleukin-6 as a prognostic biomarker in patients with metastatic melanoma. <i>Melanoma Research</i> , 2012, 22, 287-293.	0.6	48
461	Combining immunological and androgen-directed approaches. <i>Current Opinion in Oncology</i> , 2012, 24, 258-265.	1.1	23

#	ARTICLE	IF	CITATIONS
462	A rare case of primary rhabdoid melanoma of the urinary bladder treated with ipilimumab, an anti-CTLA 4 monoclonal antibody. <i>Melanoma Research</i> , 2012, 22, 320-325.	0.6	11
463	Melanoma in the brain. <i>Melanoma Research</i> , 2012, 22, 177-183.	0.6	43
464	Hypophysitis Induced by Monoclonal Antibodies to Cytotoxic T Lymphocyte Antigen 4: Challenges from a New Cause of a Rare Disease. <i>Oncologist</i> , 2012, 17, 525-535.	1.9	73
465	Molecular Testing in Melanoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2012, 18, 117-123.	1.0	22
466	Community acquired respiratory and gastrointestinal viral infections. <i>Current Opinion in Infectious Diseases</i> , 2012, 25, 423-430.	1.3	47
467	Special Issue on Melanoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2012, 18, 115-116.	1.0	1
468	Treatment of Melanoma Brain Metastases. <i>Cancer Journal (Sudbury, Mass)</i> , 2012, 18, 208-212.	1.0	43
469	Current status of immunological approaches for the treatment of prostate cancer. <i>Current Opinion in Urology</i> , 2012, 22, 197-202.	0.9	14
470	Therapeutic Cancer Vaccines. <i>American Journal of Therapeutics</i> , 2012, 19, e172-e181.	0.5	24
471	Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor. <i>Melanoma Research</i> , 2012, 22, 466-472.	0.6	112
472	T-cell Inhibitors. <i>Dermatitis</i> , 2012, 23, 195-202.	0.8	6
473	Modulating T-cell costimulation as new immunosuppressive concept in organ transplantation. <i>Current Opinion in Organ Transplantation</i> , 2012, Publish Ahead of Print, 368-75.	0.8	12
474	Trends of cutaneous melanoma in The Netherlands: increasing incidence rates among all Breslow thickness categories and rising mortality rates since 1989. <i>Annals of Oncology</i> , 2012, 23, 524-530.	0.6	109
475	Adjuvant Therapy for Melanoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2012, 18, 192-202.	1.0	47
476	Therapeutic Implications of KIT in Melanoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2012, 18, 137-141.	1.0	51
477	Atypical Melanocytic Proliferations and New Primary Melanomas in Patients With Advanced Melanoma Undergoing Selective BRAF Inhibition. <i>Journal of Clinical Oncology</i> , 2012, 30, 2375-2383.	0.8	216
478	Advances in the treatment of melanoma. <i>Clinical Medicine</i> , 2012, 12, 168-171.	0.8	12
479	The Vitamin E Analogue Î±-TEA Stimulates Tumor Autophagy and Enhances Antigen Cross-Presentation. <i>Cancer Research</i> , 2012, 72, 3535-3545.	0.4	77

#	ARTICLE	IF	CITATIONS
480	Safety and Efficacy of Combination Immunotherapy With Interferon Alfa-2b and Tremelimumab in Patients With Stage IV Melanoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 322-328.	0.8	131
481	Chemotherapy for Brain Tumors. , 2012, , 94-104.		0
482	A Live-Attenuated <i>Listeria</i> Vaccine (ANZ-100) and a Live-Attenuated <i>Listeria</i> Vaccine Expressing Mesothelin (CRS-207) for Advanced Cancers: Phase I Studies of Safety and Immune Induction. <i>Clinical Cancer Research</i> , 2012, 18, 858-868.	3.2	304
483	Selenium-containing histone deacetylase inhibitors for melanoma management. <i>Cancer Biology and Therapy</i> , 2012, 13, 756-765.	1.5	51
484	A Changing Landscape in Castration-Resistant Prostate Cancer Treatment. <i>Frontiers in Endocrinology</i> , 2012, 3, 85.	1.5	13
485	New therapies in the treatment of melanoma. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 1643-1659.	1.9	9
486	Induction of tumoricidal function in CD4+ T cells is associated with concomitant memory and terminally differentiated phenotype. <i>Journal of Experimental Medicine</i> , 2012, 209, 2113-2126.	4.2	130
487	Method to Our Madness or Madness in Our Methods? Pitfalls in Trial Methodology. <i>Journal of Clinical Oncology</i> , 2012, 30, 2025-2027.	0.8	4
488	Paclitaxel Enhances Therapeutic Efficacy of the F8-IL2 Immunocytokine to EDA-Fibronectinâ€“Positive Metastatic Human Melanoma Xenografts. <i>Cancer Research</i> , 2012, 72, 1814-1824.	0.4	86
489	Phase 1 Study of Stereotactic Body Radiotherapy and Interleukin-2â€“Tumor and Immunological Responses. <i>Science Translational Medicine</i> , 2012, 4, 137ra74.	5.8	272
490	Pneumatosis Intestinalis and Bowel Perforation Associated With Molecular Targeted Therapy: An Emerging Problem and the Role of Radiologists in Its Management. <i>American Journal of Roentgenology</i> , 2012, 199, 1259-1265.	1.0	92
491	Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2012, 18, 1386-1394.	3.2	589
492	The potential for BRAF V600 inhibitors in advanced cutaneous melanoma: rationale and latest evidence. <i>Therapeutic Advances in Medical Oncology</i> , 2012, 4, 61-73.	1.4	26
493	Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape. <i>Science Translational Medicine</i> , 2012, 4, 127ra37.	5.8	1,837
496	How can chemoimmunotherapy best be used for the treatment of colon cancer?. <i>Immunotherapy</i> , 2012, 4, 1787-1790.	1.0	3
497	Combinatorial Immunotherapy. <i>Oncolmmunology</i> , 2012, 1, 1172-1174.	2.1	16
498	EGFR inhibitors, MHC expression and immune responses : Can EGFR inhibitors be used as immune response modifiers?. <i>Oncolmmunology</i> , 2012, 1, 71-74.	2.1	25
501	Monoclonal Antibodies as Cancer Therapeutics. <i>Recent Patents on Biotechnology</i> , 2012, 6, 45-56.	0.4	6

#	ARTICLE	IF	CITATIONS
503	Cancer vaccines and immunotherapeutics. <i>Human Vaccines and Immunotherapeutics</i> , 2012, 8, 1360-1363.	1.4	14
504	Selumetinib (AZD6244; ARRY-142886) in the treatment of metastatic melanoma. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 531-539.	1.9	22
505	AACR Cancer Progress Report 2012. <i>Clinical Cancer Research</i> , 2012, 18, S1-S100.	3.2	28
506	Targeting CD20 in Melanoma Patients at High Risk of Disease Recurrence. <i>Molecular Therapy</i> , 2012, 20, 1056-1062.	3.7	69
507	A neoadjuvant biochemotherapy approach to stage III melanoma: analysis of surgical outcomes. <i>Immunotherapy</i> , 2012, 4, 679-686.	1.0	9
508	Activation of Abl Family Kinases in Solid Tumors. <i>Genes and Cancer</i> , 2012, 3, 414-425.	0.6	41
509	The liver, liver metastasis and liver cancer: a special case for immunotherapy with cytokines and immunostimulatory monoclonal antibodies. <i>Immunotherapy</i> , 2012, 4, 1081-1085.	1.0	6
510	Recent advances in the application of antibodies as therapeutics. <i>Future Medicinal Chemistry</i> , 2012, 4, 73-86.	1.1	10
511	Immunotherapy synergizes with chemotherapy targeting pancreatic cancer. <i>Immunotherapy</i> , 2012, 4, 5-7.	1.0	11
512	Boosting antibody-dependant cellular cytotoxicity against tumor cells with a CD137 stimulatory antibody. <i>Oncolmunology</i> , 2012, 1, 957-958.	2.1	26
513	Application of Monoclonal Antibodies as Cancer Therapy in Solid Tumors. <i>Current Clinical Pharmacology</i> , 2012, 7, 137-145.	0.2	36
514	Combined targeted therapy and immunotherapy in the treatment of advanced melanoma. <i>Oncolmunology</i> , 2012, 1, 997-999.	2.1	27
515	Immunotherapy in ovarian cancer. <i>Human Vaccines and Immunotherapeutics</i> , 2012, 8, 1179-1191.	1.4	48
516	Virotherapy, gene transfer and immunostimulatory monoclonal antibodies. <i>Oncolmunology</i> , 2012, 1, 1344-1354.	2.1	8
517	Radiation and immunotherapy. <i>Oncolmunology</i> , 2012, 1, 1645-1647.	2.1	11
518	Intratumoral Heterogeneity as a Therapy Resistance Mechanism. <i>Advances in Pharmacology</i> , 2012, 65, 335-359.	1.2	76
519	TroVax vaccine therapy for renal cell carcinoma. <i>Immunotherapy</i> , 2012, 4, 27-42.	1.0	14
520	Is there a role for cytokine-induced killer cells in cancer immunotherapy?. <i>Immunotherapy</i> , 2012, 4, 867-869.	1.0	4

#	ARTICLE	IF	CITATIONS
521	Editorial: Stage IV melanoma. <i>Journal of Neurosurgery</i> , 2012, 117, 225-226.	0.9	1
522	Vemurafenib Sensitivity Skin Reaction after Ipilimumab. <i>New England Journal of Medicine</i> , 2012, 366, 866-868.	13.9	82
523	Myriocin, a serine palmitoyltransferase inhibitor, suppresses tumor growth in a murine melanoma model by inhibiting de novo sphingolipid synthesis. <i>Cancer Biology and Therapy</i> , 2012, 13, 92-100.	1.5	41
524	MART-1- and gp100-Expressing and -Non-Expressing Melanoma Cells Are Equally Proliferative in Tumors and Clonogenic In Vitro. <i>Journal of Investigative Dermatology</i> , 2012, 132, 365-374.	0.3	20
525	HLA-A*0201 + Plasmacytoid Dendritic Cells Provide a Cell-Based Immunotherapy for Melanoma Patients. <i>Journal of Investigative Dermatology</i> , 2012, 132, 2395-2406.	0.3	37
526	Narrowing the knowledge gaps for melanoma. <i>Upsala Journal of Medical Sciences</i> , 2012, 117, 237-243.	0.4	15
527	Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. <i>Journal of Neurosurgery</i> , 2012, 117, 227-233.	0.9	296
530	Fluorescein-guided confocal laser endomicroscopy for the detection of ipilimumab-induced colitis. <i>Endoscopy</i> , 2012, 44, E78-E79.	1.0	5
532	A vaccine in renal cell carcinoma: are we nearing reality?. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 1503-1505.	1.1	3
533	A pilot study of paclitaxel combined with gemcitabine followed by interleukin-2 and granulocyte macrophage colony-stimulating factor for patients with metastatic melanoma. <i>Cancer Biology and Therapy</i> , 2012, 13, 1443-1448.	1.5	3
534	Sipuleucel-T for the treatment of metastatic prostate cancer. <i>Human Vaccines and Immunotherapeutics</i> , 2012, 8, 509-519.	1.4	16
535	Blood cells and their use in active immunotherapy of prostate cancer. <i>Human Vaccines and Immunotherapeutics</i> , 2012, 8, 528-533.	1.4	4
536	Challenges in the development of an autologous heat shock protein based anti-tumor vaccine. <i>Human Vaccines and Immunotherapeutics</i> , 2012, 8, 1152-1155.	1.4	15
537	Immunotherapy of hepatocellular carcinoma. <i>Oncolmmunology</i> , 2012, 1, 48-55.	2.1	146
538	Survivin the battle against immunosuppression. <i>Oncolmmunology</i> , 2012, 1, 240-241.	2.1	4
539	Combination of vaccine and immune checkpoint inhibitor is safe with encouraging clinical activity. <i>Oncolmmunology</i> , 2012, 1, 1167-1168.	2.1	19
540	What new immunotherapeutic techniques are currently being investigated for the treatment of melanoma?. <i>Immunotherapy</i> , 2012, 4, 749-751.	1.0	3
541	Enhancing anti-melanoma immunity by electrochemotherapy and in vivo dendritic-cell activation. <i>Oncolmmunology</i> , 2012, 1, 1655-1657.	2.1	38

#	ARTICLE	IF	CITATIONS
542	Advancing the field of cancer immunotherapy. <i>Oncolmmunology</i> , 2012, 1, 1457-1459.	2.1	11
543	Adoptive Transfer of Cytotoxic T Lymphocytes Targeting Two Different Antigens Limits Antigen Loss and Tumor Escape. <i>Human Gene Therapy</i> , 2012, 23, 1054-1064.	1.4	34
544	Mutated Ras-Transfected, EBV-Transformed Lymphoblastoid Cell Lines as a Model Tumor Vaccine for Boosting T-Cell Responses Against Pancreatic Cancer: A Pilot Trial. <i>Human Gene Therapy</i> , 2012, 23, 1224-1236.	1.4	17
545	Stereotactic body radiotherapy treatment of extracranial metastases. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 654-665.	12.5	40
546	Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 2497-2502.	3.3	498
547	Cancer vaccines: is prevention better than cure?. <i>Future Oncology</i> , 2012, 8, 899-901.	1.1	1
548	Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanoma. <i>Oncolmmunology</i> , 2012, 1, 609-617.	2.1	67
550	Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4. <i>Gene Therapy</i> , 2012, 19, 988-998.	2.3	132
551	Mechanisms of action underlying the immunotherapeutic activity of Allovectin in advanced melanoma. <i>Cancer Gene Therapy</i> , 2012, 19, 811-817.	2.2	16
552	Melanoma's hidden act. <i>Science-Business EXchange</i> , 2012, 5, 1100-1100.	0.0	1
553	Advances in Cancer Stem Cell Biology. , 2012, , .		3
554	Quantitative monitoring of mouse lung tumors by magnetic resonance imaging. <i>Nature Protocols</i> , 2012, 7, 128-142.	5.5	44
555	Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape. <i>Cancer Research</i> , 2012, 72, 917-927.	0.4	1,311
556	Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma. <i>British Journal of Cancer</i> , 2012, 106, 85-91.	2.9	38
557	Aurora B Is Regulated by the Mitogen-activated Protein Kinase/Extracellular Signal-regulated Kinase (MAPK/ERK) Signaling Pathway and Is a Valuable Potential Target in Melanoma Cells. <i>Journal of Biological Chemistry</i> , 2012, 287, 29887-29898.	1.6	70
559	Defucosylated Anti-CCR4 Monoclonal Antibody (KW-0761) for Relapsed Adult T-Cell Leukemia-Lymphoma: A Multicenter Phase II Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 837-842.	0.8	581
560	Anti-“Cytotoxic T-Cell Lymphocyte Antigen-4” Induced Regression of Spinal Cord Metastases in Association With Renal Failure, Atypical Pneumonia, Vision Loss, and Hearing Loss. <i>Journal of Clinical Oncology</i> , 2012, 30, e356-e357.	0.8	41
561	Posterior Reversible Encephalopathy Syndrome During Ipilimumab Therapy for Malignant Melanoma. <i>Journal of Clinical Oncology</i> , 2012, 30, e76-e78.	0.8	118

#	ARTICLE	IF	CITATIONS
562	Model T Muscle CARs Can Treat Brain Tumors. <i>Clinical Cancer Research</i> , 2012, 18, 5834-5836.	3.2	2
563	BEAM: A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 34-41.	0.8	172
564	Advances in Ovarian Cancer Management. , 2012, , .		1
565	Prevention and treatment of bone metastases. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 76-78.	12.5	72
566	Immunotherapeutic applications of IL-15. <i>Immunotherapy</i> , 2012, 4, 957-969.	1.0	31
567	The TIGIT/CD226 Axis Regulates Human T Cell Function. <i>Journal of Immunology</i> , 2012, 188, 3869-3875.	0.4	393
568	BRAF(V600) Inhibitor GSK2118436 Targeted Inhibition of Mutant BRAF in Cancer Patients Does Not Impair Overall Immune Competency. <i>Clinical Cancer Research</i> , 2012, 18, 2326-2335.	3.2	109
569	Ipilimumab: its potential in non-small cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2012, 4, 43-50.	1.4	65
570	Major Response to Everolimus in Melanoma With Acquired Imatinib Resistance. <i>Journal of Clinical Oncology</i> , 2012, 30, e37-e40.	0.8	23
571	Potent Induction of Tumor Immunity by Combining Tumor Cryoablation with Anti-CTLA-4 Therapy. <i>Cancer Research</i> , 2012, 72, 430-439.	0.4	248
572	Augmentation of Therapeutic Responses in Melanoma by Inhibition of IRAK-1,-4. <i>Cancer Research</i> , 2012, 72, 6209-6216.	0.4	64
573	New Challenges in Endpoints for Drug Development in Advanced Melanoma. <i>Clinical Cancer Research</i> , 2012, 18, 336-341.	3.2	72
574	Rehabilitation for Oncogene Addiction: Role of Immunity in Cellular Sobriety. <i>Clinical Cancer Research</i> , 2012, 18, 1192-1194.	3.2	6
575	Combination of vaccine plus ipilimumab—safety and toxicity. <i>Nature Reviews Urology</i> , 2012, 9, 302-303.	1.9	5
576	Severe colitis while responding to ipilimumab in metastatic melanoma. <i>Acta Oncologica</i> , 2012, 51, 805-807.	0.8	8
577	Functional T Cells Targeting NY-ESO-1 or Melan-A Are Predictive for Survival of Patients With Distant Melanoma Metastasis. <i>Journal of Clinical Oncology</i> , 2012, 30, 1835-1841.	0.8	112
578	Melanoma as a model tumour for immuno-oncology. <i>Annals of Oncology</i> , 2012, 23, viii10-viii14.	0.6	92
579	The confluence of radiotherapy and immunotherapy. <i>Frontiers in Oncology</i> , 2012, 2, 143.	1.3	56

#	ARTICLE	IF	CITATIONS
580	Current and Potential Uses of Immunocytokines as Cancer Immunotherapy. <i>Antibodies</i> , 2012, 1, 149-171.	1.2	36
581	Novel Treatments for Metastatic Cutaneous Melanoma and the Management of Emergent Toxicities. <i>Clinical Medicine Insights: Oncology</i> , 2012, 6, CMO.S5855.	0.6	47
582	Ipilimumab Pharmacotherapy in Patients with Metastatic Melanoma. <i>Clinical Medicine Insights: Oncology</i> , 2012, 6, CMO.S7245.	0.6	6
583	Ipilimumab, a Promising Immunotherapy with Increased Overall Survival in Metastatic Melanoma?. <i>Dermatology Research and Practice</i> , 2012, 2012, 1-4.	0.3	7
584	Lessons from Cancer Immunoediting in Cutaneous Melanoma. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-14.	3.3	18
585	Biomarkers as Key Contributors in Treating Malignant Melanoma Metastases. <i>Dermatology Research and Practice</i> , 2012, 2012, 1-14.	0.3	17
586	Nanobiotechnological Nanocapsules Containing Polyhemoglobin-Tyrosinase: Effects on Murine B16F10 Melanoma Cell Proliferation and Attachment. <i>Journal of Skin Cancer</i> , 2012, 2012, 1-9.	0.5	17
587	New Roads Open Up for Implementing Immunotherapy in Mesothelioma. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-13.	3.3	21
588	Strategies for Enhancing Vaccine-Induced CTL Antitumor Immune Responses. <i>Journal of Biomedicine and Biotechnology</i> , 2012, 2012, 1-9.	3.0	13
589	Lung Cancer: A Classic Example of Tumor Escape and Progression While Providing Opportunities for Immunological Intervention. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-21.	3.3	47
590	Trial Watch. <i>Onc Immunology</i> , 2012, 1, 306-315.	2.1	70
591	Targeted therapy in brain metastasis. <i>Current Opinion in Oncology</i> , 2012, 24, 679-686.	1.1	64
592	Ipilimumab in advanced melanoma. <i>Melanoma Research</i> , 2012, 22, 263-270.	0.6	47
593	Patient Responses to Ipilimumab, a Novel Immunopotentiator for Metastatic Melanoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2012, 35, 606-611.	0.6	69
594	Update on the diagnosis and management of hypophysitis. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2012, 19, 314-321.	1.2	42
595	Surgery for Distant Melanoma Metastasis. <i>Cancer Journal (Sudbury, Mass)</i> , 2012, 18, 176-184.	1.0	81
596	Polysaccharide-K augments docetaxel-induced tumor suppression and antitumor immune response in an immunocompetent murine model of human prostate cancer. <i>International Journal of Oncology</i> , 2012, 40, 905-913.	1.4	23
597	Genetic modification of human T lymphocytes for the treatment of hematologic malignancies. <i>Haematologica</i> , 2012, 97, 1622-1631.	1.7	12

#	ARTICLE	IF	CITATIONS
598	CTLA-4 blockade synergizes with cryoablation to mediate tumor rejection. <i>Oncolmmunology</i> , 2012, 1, 544-546.	2.1	32
599	Immunomodulation via Chemotherapy and Targeted Therapy: A New Paradigm in Breast Cancer Therapy?. <i>Breast Care</i> , 2012, 7, 267-272.	0.8	12
601	Immunotherapeutic Approaches to Hepatocellular Carcinoma Treatment. <i>Liver Cancer</i> , 2012, 1, 226-237.	4.2	50
602	Personalized Tumor Response Assessment in the Era of Molecular Medicine: Cancer-Specific and Therapy-Specific Response Criteria to Complement Pitfalls of RECIST. <i>American Journal of Roentgenology</i> , 2012, 198, 737-745.	1.0	169
603	Lymphopenia combined with low TCR diversity (divpenia) predicts poor overall survival in metastatic breast cancer patients. <i>Oncolmmunology</i> , 2012, 1, 432-440.	2.1	102
604	Therapeutic Additions and Possible Deletions in Oncology in 2011. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 91, 15-17.	2.3	8
605	Improvements and continued challenges in the early detection of skin cancers. <i>Expert Review of Dermatology</i> , 2012, 7, 459-471.	0.3	2
606	Systemic Therapy for Metastatic Melanoma in 2012: Dawn of a New Era. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 403-412.	2.3	22
607	Targeting Spatiotemporal Expression of CD137 on Tumor-infiltrating Cytotoxic T Lymphocytes as a Novel Strategy for Agonistic Antibody Therapy. <i>Journal of Immunotherapy</i> , 2012, 35, 460-472.	1.2	12
608	Immunologic Effects of an Orally Available BRAFV600E Inhibitor in BRAF Wild-type Murine Models. <i>Journal of Immunotherapy</i> , 2012, 35, 473-477.	1.2	6
609	Efficacy of Adoptive Cell Transfer of Tumor-infiltrating Lymphocytes After Lymphopenia Induction for Metastatic Melanoma. <i>Journal of Immunotherapy</i> , 2012, 35, 615-620.	1.2	150
610	Brain metastasis. <i>Current Opinion in Neurology</i> , 2012, 25, 786-794.	1.8	20
611	DNA Vaccines for Prostate Cancer. <i>Current Cancer Therapy Reviews</i> , 2012, 8, 245-253.	0.2	8
612	Carcinoembryonic Antigen (CEA)-Based Cancer Vaccines: Recent Patents and Antitumor Effects from Experimental Models to Clinical Trials. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2012, 7, 265-296.	0.8	45
613	Correlation of NRAS Mutations With Clinical Response to High-dose IL-2 in Patients With Advanced Melanoma. <i>Journal of Immunotherapy</i> , 2012, 35, 66-72.	1.2	111
614	Circumventing Melanoma Chemoresistance by Targeting DNA Repair. <i>Current Medicinal Chemistry</i> , 2012, 19, 3893-3899.	1.2	8
616	Characterization of T-cell Receptors Directed Against HLA-A*01-restricted and C*07-restricted Epitopes of MAGE-A3 and MAGE-A12. <i>Journal of Immunotherapy</i> , 2012, 35, 680-688.	1.2	7
617	Prostate Cancer Immunotherapy: An Evolving Field. <i>Current Cancer Therapy Reviews</i> , 2012, 8, 274-282.	0.2	0

#	ARTICLE	IF	CITATIONS
618	Ocular melanoma. <i>Current Opinion in Oncology</i> , 2012, 24, 162-169.	1.1	21
619	Antigen-specific Immunotherapy in Ovarian Cancer and p53 as Tumor Antigen. <i>Current Pharmaceutical Design</i> , 2012, 18, 3804-3811.	0.9	12
620	Melphalan in Regional Chemotherapy for Locally Recurrent Metastatic Melanoma. <i>Current Topics in Medicinal Chemistry</i> , 2012, 12, 53-60.	1.0	19
621	Tumor-specific CD4+ Melanoma Tumor-infiltrating Lymphocytes. <i>Journal of Immunotherapy</i> , 2012, 35, 400-408.	1.2	88
622	Lymphocyte Composition and Distribution in Inflammatory, Well-differentiated Retroperitoneal Liposarcoma. <i>American Journal of Surgical Pathology</i> , 2012, 36, 941-944.	2.1	21
623	Approaches Used in Immunotherapy for Prostate Cancer. <i>Current Cancer Therapy Reviews</i> , 2012, 8, 238-244.	0.2	0
624	The Vaccine-site Microenvironment Induced by Injection of Incomplete Freund's Adjuvant, With or Without Melanoma Peptides. <i>Journal of Immunotherapy</i> , 2012, 35, 78-88.	1.2	31
625	Ipilimumab in Treatment-naïve and Previously Treated Patients with Metastatic Melanoma. <i>Journal of Immunotherapy</i> , 2012, 35, 73-77.	1.2	25
626	Assessment of Prognostic Circulating Tumor Cells in a Phase III Trial of Adjuvant Immunotherapy After Complete Resection of Stage IV Melanoma. <i>Annals of Surgery</i> , 2012, 255, 357-362.	2.1	83
627	Ipilimumab Increases Activated T Cells and Enhances Humoral Immunity in Patients With Advanced Melanoma. <i>Journal of Immunotherapy</i> , 2012, 35, 89-97.	1.2	115
628	Safety and Immunogenicity of Vaccination With MART-1 (26â€“35, 27L), gp100 (209â€“217, 210M), and Tyrosinase (368â€“376, 370D) In Adjuvant With PF-3512676 and GM-CSF In Metastatic Melanoma. <i>Journal of Immunotherapy</i> , 2012, 35, 359-366.	1.2	53
629	Sequential Immunotherapy by Vaccination With GM-CSFâ€“expressing Glioma Cells and CTLA-4 Blockade Effectively Treats Established Murine Intracranial Tumors. <i>Journal of Immunotherapy</i> , 2012, 35, 385-389.	1.2	108
630	Differing Patterns of Circulating Regulatory T Cells and Myeloid-derived Suppressor Cells in Metastatic Melanoma Patients Receiving Anti-CTLA4 Antibody and Interferon-Î± or TLR-9 Agonist and GM-CSF With Peptide Vaccination. <i>Journal of Immunotherapy</i> , 2012, 35, 702-710.	1.2	63
631	Cancer Immunoediting in Malignant Glioma. <i>Neurosurgery</i> , 2012, 71, 201-223.	0.6	79
633	Combined Intralesional Bacille Calmette-GuÃ©rin (BCG) and Topical Imiquimod for In-transit Melanoma. <i>Journal of Immunotherapy</i> , 2012, 35, 716-720.	1.2	75
634	Tumor Stem Cell Antigens as Consolidative Active Specific Immunotherapy. <i>Journal of Immunotherapy</i> , 2012, 35, 641-649.	1.2	72
635	Characterizing the Clinical Benefit of Ipilimumab in Patients Who Progressed on High-dose IL-2. <i>Journal of Immunotherapy</i> , 2012, 35, 711-715.	1.2	24
636	Strategies for Optimizing the Clinical Impact of Immunotherapeutic Agents Such as Sipuleucel-T in Prostate Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 1505-1512.	2.3	11

#	ARTICLE	IF	CITATIONS
637	Characterization of Lymphomas Developing in Immunodeficient Mice Implanted With Primary Human Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1101-1108.	0.5	44
638	Mucosal Melanoma: A Clinically and Biologically Unique Disease Entity. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 345-356.	2.3	117
643	Melanoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 366-400.	2.3	63
644	Long-term Survival in Metastatic Malignant Melanoma: Ipilimumab Followed by Vemurafenib in a Patient with Brain Metastasis. <i>Internal Medicine</i> , 2012, 51, 2819-2823.	0.3	13
647	Personalized therapy for metastatic melanoma: could timing be everything?. <i>Future Oncology</i> , 2012, 8, 1401-1406.	1.1	10
648	A therapeutic renaissance: emergence of novel targeted agents for metastatic melanoma. <i>Clinical Investigation</i> , 2012, 2, 883-893.	0.0	1
649	Interventional immunotherapy in breast cancer. <i>Breast Cancer Management</i> , 2012, 1, 257-260.	0.2	0
650	Dendritic cell-based immunotherapy in mesothelioma. <i>Immunotherapy</i> , 2012, 4, 1011-1022.	1.0	10
651	Predictive value of the MGMT promoter methylation status in metastatic melanoma patients receiving first-line temozolomide plus bevacizumab in the trial SAKK 50/07. <i>Oncology Reports</i> , 2012, 28, 654-658.	1.2	29
652	Immunotherapy and cancer – making the past prologue. <i>Clinical Investigation</i> , 2012, 2, 873-881.	0.0	0
653	A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. <i>Blood</i> , 2012, 120, 4324-4333.	0.6	217
655	Metastatic melanoma can be cured: advances in immunotherapy and targeted approaches. <i>Clinical Investigation</i> , 2012, 2, 957-959.	0.0	0
656	Immunogenic cell death and DAMPs in cancer therapy. <i>Nature Reviews Cancer</i> , 2012, 12, 860-875.	12.8	1,984
657	Association Between Circulating Tumor Cells and Prognosis in Patients With Stage III Melanoma With Sentinel Lymph Node Metastasis in a Phase III International Multicenter Trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 3819-3826.	0.8	77
658	Therapeutic Antibodies Against Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2012, 26, 447-481.	0.9	71
659	Metastatic melanoma: the new era of targeted therapy. <i>Expert Opinion on Therapeutic Targets</i> , 2012, 16, S61-S70.	1.5	21
660	Autophagy inhibition in cancer therapy: metabolic considerations for antitumor immunity. <i>Immunological Reviews</i> , 2012, 249, 176-194.	2.8	87
661	Lycorine hydrochloride inhibits metastatic melanoma cell-dominant vasculogenic mimicry. <i>Pigment Cell and Melanoma Research</i> , 2012, 25, 630-638.	1.5	52

#	ARTICLE	IF	CITATIONS
662	Mechanisms of intrinsic and acquired resistance to kinase-targeted therapies. <i>Pigment Cell and Melanoma Research</i> , 2012, 25, 819-831.	1.5	43
663	Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 1791-1804.	2.0	103
664	Immunology beats cancer: a blueprint for successful translation. <i>Nature Immunology</i> , 2012, 13, 1129-1132.	7.0	148
665	Intracerebral CpG Immunotherapy with Carbon Nanotubes Abrogates Growth of Subcutaneous Melanomas in Mice. <i>Clinical Cancer Research</i> , 2012, 18, 5628-5638.	3.2	52
666	Tax is a potential molecular target for immunotherapy of adult T-cell leukemia/lymphoma. <i>Cancer Science</i> , 2012, 103, 1764-1773.	1.7	23
667	Advances in the management of melanoma: targeted therapy, immunotherapy and future directions. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 1437-1448.	1.1	24
668	Regulatory T Cells Move in When Gliomas Say "Hello". <i>Clinical Cancer Research</i> , 2012, 18, 6086-6088.	3.2	11
669	Advances in bispecific biotherapeutics for the treatment of cancer. <i>Biochemical Pharmacology</i> , 2012, 84, 1105-1112.	2.0	72
670	Immunotherapy for melanoma. <i>Expert Review of Dermatology</i> , 2012, 7, 51-68.	0.3	0
671	Improving the Clinical Efficacy of Cancer Vaccines by Targeting Immune Suppression in Human Tumors. <i>ACS Symposium Series</i> , 2012, , 267-288.	0.5	0
672	Survival in BRAF V600E Mutant Advanced Melanoma Treated with Vemurafenib. <i>New England Journal of Medicine</i> , 2012, 366, 707-714.	13.9	1,955
673	Ipilimumab: A novel immunostimulatory monoclonal antibody for the treatment of cancer. <i>Pharmacological Research</i> , 2012, 65, 9-22.	3.1	119
674	Immunomodulating antibodies in the treatment of metastatic melanoma: The experience with anti-CTLA-4, anti-CD137, and anti-PD1. <i>Journal of Immunotoxicology</i> , 2012, 9, 241-247.	0.9	81
675	Convergent Multi-miRNA Targeting of ApoE Drives LRP1/LRP8-Dependent Melanoma Metastasis and Angiogenesis. <i>Cell</i> , 2012, 151, 1068-1082.	13.5	334
676	Immune Response Is an Important Aspect of the Antitumor Effect Produced by a CD40L-Encoding Oncolytic Adenovirus. <i>Cancer Research</i> , 2012, 72, 2327-2338.	0.4	144
677	Oncolytic Adenoviruses for Cancer Immunotherapy. <i>Advances in Cancer Research</i> , 2012, 115, 265-318.	1.9	61
678	Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions. <i>Future Microbiology</i> , 2012, 7, 347-367.	1.0	185
679	Reviewing the somatic genetics of melanoma: from current to future analytical approaches. <i>Pigment Cell and Melanoma Research</i> , 2012, 25, 144-154.	1.5	46

#	ARTICLE	IF	CITATIONS
680	Systematic classification of melanoma cells by phenotype-specific gene expression mapping. <i>Pigment Cell and Melanoma Research</i> , 2012, 25, 343-353.	1.5	155
681	Immunotherapy of Cancer. , 2012, , 391-414.		17
682	Pathologic Changes in Ipilimumab-Related Hepatitis in Patients with Metastatic Melanoma. <i>Digestive Diseases and Sciences</i> , 2012, 57, 2233-2240.	1.1	131
683	Severe meningo-radiculo-nevritis associated with ipilimumab. <i>Investigational New Drugs</i> , 2012, 30, 2407-2410.	1.2	64
684	6 Communication in Genetics and Genomics. <i>European Journal of Oncology Nursing</i> , 2012, 16, S2-S3.	0.9	0
685	7 New Developments in the Systemic Treatment of Melanoma. <i>European Journal of Oncology Nursing</i> , 2012, 16, S3.	0.9	0
686	8 Impact and Management of Malignant Wounds. <i>European Journal of Oncology Nursing</i> , 2012, 16, S3-S4.	0.9	0
687	Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy?. <i>Lancet Oncology</i> , The, 2012, 13, e32-e42.	5.1	219
688	Melanoma molecular classes and prognosis in the postgenomic era. <i>Lancet Oncology</i> , The, 2012, 13, e205-e211.	5.1	29
689	A tale of two tumours and a plea for progress. <i>Lancet Oncology</i> , The, 2012, 13, 124-125.	5.1	2
690	Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. <i>Lancet Oncology</i> , The, 2012, 13, 501-508.	5.1	333
691	Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. <i>Lancet Oncology</i> , The, 2012, 13, 509-517.	5.1	390
692	Intensifying tumour immunity through combination therapy. <i>Lancet Oncology</i> , The, 2012, 13, 440-442.	5.1	3
693	Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2012, 13, 459-465.	5.1	995
694	Treatment of brain metastases in patients with melanoma. <i>Lancet Oncology</i> , The, 2012, 13, 434-435.	5.1	11
695	Finally, a substantial role for radiotherapy in melanoma. <i>Lancet Oncology</i> , The, 2012, 13, 561-562.	5.1	1
696	Ipilimumab in patients with melanoma and brain metastases. <i>Lancet Oncology</i> , The, 2012, 13, e277.	5.1	6
697	Ipilimumab in patients with melanoma and brain metastases – Authors' reply. <i>Lancet Oncology</i> , The, 2012, 13, e277-e278.	5.1	3

#	ARTICLE	IF	CITATIONS
698	Current management of prostate cancer: dilemmas and trials. <i>British Journal of Radiology</i> , 2012, 85, S28-S40.	1.0	4
699	Whole Genome and Exome Sequencing of Melanoma. <i>Advances in Pharmacology</i> , 2012, 65, 399-435.	1.2	10
702	Evaluation of CTLA-4 expression and relevance as a novel prognostic factor in patients with non-small cell lung cancer. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 1463-1472.	2.0	110
703	Re-purposing cancer therapeutics for breast cancer immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 1299-1305.	2.0	8
704	DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8+ T-cell responses and increases PSA doubling time. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 2161-2170.	2.0	89
705	Phase II trial of hu14.18-IL2 for patients with metastatic melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 2261-2271.	2.0	64
706	The expression, function, and clinical relevance of B7 family members in cancer. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 1327-1341.	2.0	72
707	Clinical and radiological response of leptomeningeal melanoma after whole brain radiotherapy and ipilimumab. <i>Journal of Neurology</i> , 2012, 259, 1976-1978.	1.8	59
708	Ethical issues in cutaneous melanoma. <i>Clinics in Dermatology</i> , 2012, 30, 501-510.	0.8	4
709	Ipilimumab (Yervoy) and the TGN1412 catastrophe. <i>Immunobiology</i> , 2012, 217, 583-589.	0.8	32
710	Recurrent and Metastatic Malignant Melanoma of the Penis. <i>Journal of Urology</i> , 2012, 187, 1438-1439.	0.2	3
711	Integration of immunotherapy into the management of advanced prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2012, 30, S41-S47.	0.8	11
712	Therapeutic Cancer Vaccines: Current Status and Moving Forward. <i>Journal of the National Cancer Institute</i> , 2012, 104, 599-613.	3.0	239
715	Immunotherapies in Dermatologic Disorders. <i>Medical Clinics of North America</i> , 2012, 96, 565-582.	1.1	7
716	Sarcomas and the Immune System: Implications for Therapeutic Strategies. <i>Surgical Oncology Clinics of North America</i> , 2012, 21, 341-355.	0.6	5
718	The Effect of Metastatic Site and Decade of Diagnosis on the Individual Burden of Metastatic Melanoma: Contemporary Estimates of Average Years of Life Lost. <i>Cancer Investigation</i> , 2012, 30, 637-641.	0.6	6
719	Patterns of Response in Patients with Pretreated Metastatic Melanoma who Received Ipilimumab 3 mg/kg in a European Expanded Access Program: Five Illustrative Case Reports. <i>Cancer Investigation</i> , 2012, 30, 712-720.	0.6	10
720	Ipilimumab (MDX-010) in the treatment of non-small cell lung cancer. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 939-948.	1.4	19

#	ARTICLE	IF	CITATIONS
721	Emerging immunotherapies for renal cell carcinoma. <i>Annals of Oncology</i> , 2012, 23, viii35-viii40.	0.6	80
722	Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non-Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 2046-2054.	0.8	931
723	Melanoma brain metastasis: overview of current management and emerging targeted therapies. <i>Expert Review of Neurotherapeutics</i> , 2012, 12, 1207-1215.	1.4	69
724	Immune alterations and emerging immunotherapeutic approaches in lung cancer. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 923-937.	1.4	42
726	Metastasectomy for Distant Metastatic Melanoma: Analysis of Data from the First Multicenter Selective Lymphadenectomy Trial (MSLT-I). <i>Annals of Surgical Oncology</i> , 2012, 19, 2547-2555.	0.7	155
727	Race and the Molecular Origins of Breast Cancer in Chinese Women. <i>Annals of Surgical Oncology</i> , 2012, 19, 4085-4093.	0.7	4
728	Immunotherapy of breast cancer. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 479-490.	1.4	31
729	Immunotherapy earns its spot in the ranks of cancer therapy. <i>Journal of Experimental Medicine</i> , 2012, 209, 201-209.	4.2	118
730	Melanoma: New Insights and New Therapies. <i>Journal of Investigative Dermatology</i> , 2012, 132, 854-863.	0.3	136
731	A Systemic Complete Response of Metastatic Melanoma to Local Radiation and Immunotherapy. <i>Translational Oncology</i> , 2012, 5, 404-407.	1.7	220
732	IFN- γ in the Treatment of Melanoma. <i>Journal of Immunology</i> , 2012, 189, 3789-3793.	0.4	112
733	Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab. <i>Journal of Clinical Oncology</i> , 2012, 30, 2691-2697.	0.8	1,272
734	Sorafenib in melanoma. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 557-568.	1.9	48
735	Dividing and conquering: controlling advanced melanoma by targeting oncogene-defined subsets. <i>Clinical and Experimental Metastasis</i> , 2012, 29, 841-846.	1.7	14
736	Lymphatics, lymph nodes and the immune system: barriers and gateways for cancer spread. <i>Clinical and Experimental Metastasis</i> , 2012, 29, 729-736.	1.7	39
737	c-Abl and Arg are activated in human primary melanomas, promote melanoma cell invasion via distinct pathways, and drive metastatic progression. <i>Oncogene</i> , 2012, 31, 1804-1816.	2.6	55
738	Robust tumor immunity to melanoma mediated by interleukin-9-producing T cells. <i>Nature Medicine</i> , 2012, 18, 1248-1253.	15.2	368
739	PD-1 blockade: promoting endogenous anti-tumor immunity. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 1279-1282.	1.1	13

#	ARTICLE	IF	CITATIONS
740	Immune response in melanoma: an in-depth analysis of the primary tumor and corresponding sentinel lymph node. <i>Modern Pathology</i> , 2012, 25, 1000-1010.	2.9	61
741	Malignant Melanoma: Advances in Diagnosis, Prognosis, and Treatment. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2012, 31, 45-49.	1.6	7
742	Interleukin-15 biology and its therapeutic implications in cancer. <i>Trends in Pharmacological Sciences</i> , 2012, 33, 35-41.	4.0	301
743	Saponin-based adjuvants create a highly effective anti-tumor vaccine when combined with in situ tumor destruction. <i>Vaccine</i> , 2012, 30, 737-744.	1.7	31
744	Immunotherapy Trials for Glioblastoma Multiforme: Promise and Pitfalls. <i>World Neurosurgery</i> , 2012, 77, 636-638.	0.7	3
745	Peto's paradox and cancer: a response to Caulin and Maley. <i>Trends in Ecology and Evolution</i> , 2012, 27, 254-255.	4.2	4
746	NF- κ B as potential target in the treatment of melanoma. <i>Journal of Translational Medicine</i> , 2012, 10, 53.	1.8	118
747	Adjuvant vaccination with melanoma antigen-pulsed dendritic cells in stage III melanoma patients. <i>Medical Oncology</i> , 2012, 29, 2966-2977.	1.2	18
748	Immunotherapy for metastatic colorectal cancer: Present status and new options. <i>Scandinavian Journal of Gastroenterology</i> , 2012, 47, 315-324.	0.6	22
749	Eruptive Squamous Cell Carcinomas Associated with BRAF-Inhibitor Therapy in a Patient with Metastatic Melanoma. <i>Dermatologic Surgery</i> , 2012, 38, 1086-1090.	0.4	2
750	What future opportunities may immuno-oncology provide for improving the treatment of patients with lung cancer?. <i>Annals of Oncology</i> , 2012, 23, viii28-viii34.	0.6	44
751	Combination immunotherapy approaches. <i>Annals of Oncology</i> , 2012, 23, viii41-viii46.	0.6	129
752	Can immuno-oncology offer a truly pan-tumour approach to therapy?. <i>Annals of Oncology</i> , 2012, 23, viii53-viii57.	0.6	12
753	Evolution of end points for cancer immunotherapy trials. <i>Annals of Oncology</i> , 2012, 23, viii47-viii52.	0.6	92
754	How recent advances in immunotherapy are changing the standard of care for patients with metastatic melanoma. <i>Annals of Oncology</i> , 2012, 23, viii15-viii21.	0.6	49
755	Ocular Toxicity of Targeted Therapies. <i>Journal of Clinical Oncology</i> , 2012, 30, 3277-3286.	0.8	117
756	How Cancer Patients Value Hope And The Implications For Cost-Effectiveness Assessments Of High-Cost Cancer Therapies. <i>Health Affairs</i> , 2012, 31, 676-682.	2.5	99
757	Induced and natural regulatory T cells in human cancer. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 1383-1397.	1.4	105

#	ARTICLE	IF	CITATIONS
758	Cancer vaccines: should we be targeting patients with less aggressive disease?. Expert Review of Vaccines, 2012, 11, 721-731.	2.0	26
759	RAF265 Inhibits the Growth of Advanced Human Melanoma Tumors. Clinical Cancer Research, 2012, 18, 2184-2198.	3.2	61
760	Spectrum of central nervous system abnormalities in neurocutaneous melanocytosis. Developmental Medicine and Child Neurology, 2012, 54, 563-568.	1.1	84
761	The secret ally: immunostimulation by anticancer drugs. Nature Reviews Drug Discovery, 2012, 11, 215-233.	21.5	591
762	Personalized peptide vaccination: A novel immunotherapeutic approach for advanced cancer. Human Vaccines and Immunotherapeutics, 2012, 8, 1309-1313.	1.4	26
763	Progress in the management of patients with uveal melanoma. The 2012 Ashton Lecture. Eye, 2012, 26, 1157-1172.	1.1	129
764	Clinical Significance of Tumor-Associated Inflammatory Cells in Metastatic Neuroblastoma. Journal of Clinical Oncology, 2012, 30, 3525-3532.	0.8	236
765	Long-term survival of high-risk melanoma patients immunized with a Hyper-IL-6-modified allogeneic whole-cell vaccine after complete resection. Expert Opinion on Investigational Drugs, 2012, 21, 773-783.	1.9	22
766	A new paradigm tumor for drug development. Nature Reviews Clinical Oncology, 2012, 9, 74-76.	12.5	29
767	When Progressive Disease Does Not Mean Treatment Failure: Reconsidering the Criteria for Progression. Journal of the National Cancer Institute, 2012, 104, 1534-1541.	3.0	118
768	The Antitumor Immunity of Ipilimumab: (T-cell) Memories to Last a Lifetime?. Clinical Cancer Research, 2012, 18, 1821-1823.	3.2	27
769	Mutated <i>BCR-ABL</i> Generates Immunogenic T-cell Epitopes in CML Patients. Clinical Cancer Research, 2012, 18, 5761-5772.	3.2	57
770	Tumor profiling using protein biomarker panels in malignant melanoma: application of tissue microarrays and beyond. Expert Review of Proteomics, 2012, 9, 415-423.	1.3	9
771	Nuevas dianas terapéuticas en el melanoma. Actas Dermo-sifiligráficas, 2012, 103, 579-590.	0.2	12
772	Response to ipilimumab (Yervoy) and the TGN1412 catastrophe. Immunobiology, 2012, 217, 590-592.	0.8	10
773	Surfing the waves of the tide model of T cell co-stimulation. Immunologia (Barcelona, Spain: 1987), 2012, 31, 31-33.	0.1	0
774	Cannabinoid receptor 2: an innovative multi-targeted approach in the treatment of breast cancer and related skeletal metastasis. Journal of Pain, 2012, 13, S66.	0.7	1
775	Genetic Variation in Donor CTLA-4 Regulatory Region is a Strong Predictor of Outcome after Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 2012, 18, 1069-1075.	2.0	18

#	ARTICLE	IF	CITATIONS
776	Down-regulation of the PTTG1 proto-oncogene contributes to the melanoma suppressive effects of the cyclin-dependent kinase inhibitor PHA-848125. <i>Biochemical Pharmacology</i> , 2012, 84, 598-611.	2.0	26
777	Uveal melanoma. <i>Cancer Treatment Reviews</i> , 2012, 38, 549-553.	3.4	120
778	Novel Therapeutic Approaches for Small Cell Lung Cancer: The Future has Arrived. <i>Current Problems in Cancer</i> , 2012, 36, 156-173.	1.0	6
779	Tim-3, a negative regulator of anti-tumor immunity. <i>Current Opinion in Immunology</i> , 2012, 24, 213-216.	2.4	175
780	Indoleamine 2,3-dioxygenase, a new prognostic marker in sentinel lymph nodes of melanoma patients. <i>European Journal of Cancer</i> , 2012, 48, 2004-2011.	1.3	92
781	The European Medicines Agency review of ipilimumab (Yervoy) for the treatment of advanced (unresectable or metastatic) melanoma in adults who have received prior therapy: Summary of the scientific assessment of the Committee for Medicinal Products for Human Use. <i>European Journal of Cancer</i> , 2012, 48, 237-242.	1.3	54
782	Economic impact of healthcare resource utilisation patterns among patients diagnosed with advanced melanoma in the United Kingdom, Italy, and France: Results from a retrospective, longitudinal survey (MELODY study). <i>European Journal of Cancer</i> , 2012, 48, 2175-2182.	1.3	39
783	Radiation necrosis of the brain in melanoma patients successfully treated with ipilimumab, three case studies. <i>European Journal of Cancer</i> , 2012, 48, 3045-3051.	1.3	51
784	Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline "Update 2012. <i>European Journal of Cancer</i> , 2012, 48, 2375-2390.	1.3	407
785	The current status of S-100B as a biomarker in melanoma. <i>European Journal of Surgical Oncology</i> , 2012, 38, 281-285.	0.5	43
786	Malignant melanoma arising in mature cystic teratoma of the ovary. <i>Gynecologic Oncology Case Reports</i> , 2012, 2, 14-15.	0.9	7
788	Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients. <i>Journal of Translational Medicine</i> , 2012, 10, 169.	1.8	134
789	Pulmonary nodules in patients with melanoma "assume nothing. <i>Annals of Oncology</i> , 2012, 23, 545-546.	0.6	0
790	Nano-particle vaccination combined with TLR7 and 9 ligands triggers memory and effector CD8 ⁺ T cell responses in melanoma patients. <i>European Journal of Immunology</i> , 2012, 42, 3049-3061.	1.6	173
791	Autoimmunity-mediated antitumor immunity: Tumor as an immunoprivileged self. <i>European Journal of Immunology</i> , 2012, 42, 2584-2596.	1.6	26
792	HEDGEHOG-GLI Signaling Drives Self-Renewal and Tumorigenicity of Human Melanoma-Initiating Cells. <i>Stem Cells</i> , 2012, 30, 1808-1818.	1.4	134
793	Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment. <i>Health and Quality of Life Outcomes</i> , 2012, 10, 66.	1.0	55
794	Minimally invasive liver resection to obtain tumor-infiltrating lymphocytes for adoptive cell therapy in patients with metastatic melanoma. <i>World Journal of Surgical Oncology</i> , 2012, 10, 113.	0.8	10

#	ARTICLE	IF	CITATIONS
795	Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use. <i>Journal of Translational Medicine</i> , 2012, 10, 107.	1.8	112
797	Biomarkers on melanoma patient T Cells associated with ipilimumab treatment. <i>Journal of Translational Medicine</i> , 2012, 10, 146.	1.8	101
798	Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion. <i>Journal of Translational Medicine</i> , 2012, 10, 236.	1.8	36
799	Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104). <i>Journal of Translational Medicine</i> , 2012, 10, 246.	1.8	74
800	Toward integrative cancer immunotherapy: targeting the tumor microenvironment. <i>Journal of Translational Medicine</i> , 2012, 10, 70.	1.8	53
802	The role of BRAF V600 mutation in melanoma. <i>Journal of Translational Medicine</i> , 2012, 10, 85.	1.8	563
803	Arginine deprivation therapy for malignant melanoma. <i>Clinical Pharmacology: Advances and Applications</i> , 2013, 5, 11.	0.8	23
804	The immuno-oncology framework. <i>Oncolmmunology</i> , 2012, 1, 334-339.	2.1	40
805	Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities. <i>British Journal of Dermatology</i> , 2012, 167, 987-994.	1.4	102
806	Landmarks in non-hormonal pharmacological therapies for castration-resistant prostate cancer. <i>BJU International</i> , 2012, 110, 14-22.	1.3	8
807	Unique antineoplastic profile of Saquinavir-NO, a novel NO-derivative of the protease inhibitor Saquinavir, on the in vitro and in vivo tumor formation of A375 human melanoma cells. <i>Oncology Reports</i> , 2012, 28, 682-688.	1.2	18
808	Melanoma: Epidemiology, Diagnosis, Treatment, and Outcomes. <i>Dermatologic Clinics</i> , 2012, 30, 113-124.	1.0	58
809	Drug development and clinical trials—the path to an approved cancer drug. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 215-222.	12.5	107
810	To Market, To Market—2011. <i>Annual Reports in Medicinal Chemistry</i> , 2012, 47, 499-569.	0.5	23
811	New therapeutical strategies in the treatment of metastatic disease. <i>Dermatologic Therapy</i> , 2012, 25, 452-457.	0.8	11
812	Thymosin α 1 in melanoma: from the clinical trial setting to the daily practice and beyond. <i>Annals of the New York Academy of Sciences</i> , 2012, 1270, 8-12.	1.8	14
813	Vemurafenib. <i>Drugs</i> , 2012, 72, 2207-2222.	4.9	89
814	Vemurafenib and BRAF Inhibition: A New Class of Treatment for Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2012, 18, 9-14.	3.2	59

#	ARTICLE	IF	CITATIONS
815	Targeted inhibition of BRAF kinase: opportunities and challenges for therapeutics in melanoma. Bioscience Reports, 2012, 32, 25-33.	1.1	17
816	Trial watch. Oncolmmunology, 2012, 1, 1111-1134.	2.1	152
817	Selecting antigens for cancer vaccines. Nature Biotechnology, 2012, 30, 328-329.	9.4	9
818	Ipilimumab for advanced metastatic melanoma. Expert Opinion on Biological Therapy, 2012, 12, 981-982.	1.4	4
819	Ipilimumab in the treatment of melanoma. Expert Opinion on Biological Therapy, 2012, 12, 773-782.	1.4	22
820	Ipilimumab. BioDrugs, 2012, 26, 185-193.	2.2	5
821	Targeted Therapies for Metastatic Melanoma. Dermatologic Clinics, 2012, 30, 517-524.	1.0	5
822	Ipilimumab in melanoma. Expert Review of Anticancer Therapy, 2012, 12, 1511-1521.	1.1	6
823	Prostate cancer vaccines: moving therapeutic vaccination forward in the post-Provengeâ„¢ era. Expert Review of Vaccines, 2012, 11, 287-302.	2.0	7
824	Biology of Human Papillomavirus Infection and Immune Therapy for HPV-Related Head and Neck Cancers. Otolaryngologic Clinics of North America, 2012, 45, 807-822.	0.5	48
825	Therapy of Human Papillomavirus-Related Disease. Vaccine, 2012, 30, F71-F82.	1.7	144
826	A new era for the management of metastatic melanoma. Expert Review of Dermatology, 2012, 7, 27-35.	0.3	1
827	BRIM-1, -2 and -3 trials: improved survival with vemurafenib in metastatic melanoma patients with a BRAF^{V600E} mutation. Future Oncology, 2012, 8, 499-507.	1.1	69
828	Immunotherapy for Castration-Resistant Prostate Cancer. Urologic Clinics of North America, 2012, 39, 465-481.	0.8	11
829	Melanoma of the Skin. , 2012, , 385-416.		7
830	Modeling and predicting clinical efficacy for drugs targeting the tumor milieu. Nature Biotechnology, 2012, 30, 648-657.	9.4	95
831	Enterocolitis in a Patient Being Treated With Ipilimumab for Metastatic Melanoma. Gastroenterology, 2012, 143, 298-505.	0.6	5
832	A Woman With a Rare Cause of Hemoperitoneum. Gastroenterology, 2012, 143, 299-506.	0.6	0

#	ARTICLE	IF	CITATIONS
833	Dead on Arrival: Understanding the Failure of CTLA4-Immunoglobulin Therapy in Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2012, 143, 13-17.	0.6	20
834	Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. <i>Lancet Oncology</i> , The, 2012, 13, 782-789.	5.1	479
835	Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. <i>Lancet Oncology</i> , The, 2012, 13, 879-886.	5.1	273
836	Ipilimumab with fotemustine in metastatic melanoma. <i>Lancet Oncology</i> , The, 2012, 13, 851-852.	5.1	3
837	New Therapeutic Targets in Melanoma. <i>Actas Dermo-sifiligráficas</i> , 2012, 103, 579-590.	0.2	11
838	Vemurafenib's companion assay refines use of the targeted therapy. <i>Community Oncology</i> , 2012, 9, 83-84.	0.2	0
839	Maintenance therapy in solid tumors. <i>Community Oncology</i> , 2012, 9, 247-258.	0.2	0
840	Best practices in integrating novel agents in melanoma. <i>Community Oncology</i> , 2012, 9, S44-S46.	0.2	0
841	Vaccines in non-small cell lung cancer: Rationale, combination strategies and update on clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 83, 432-443.	2.0	28
842	The Ends Justify the Mean: Outcome Measures for Estimating the Value of New Cancer Therapies. <i>Health Outcomes Research in Medicine</i> , 2012, 3, e25-e36.	0.6	39
843	Treatment patterns and outcomes among patients diagnosed with unresectable stage III or IV melanoma in Europe: A retrospective, longitudinal survey (MELODY study). <i>European Journal of Cancer</i> , 2012, 48, 3205-3214.	1.3	24
844	Targeting the MAGE A3 antigen in pancreatic cancer. <i>Surgery</i> , 2012, 152, S13-S18.	1.0	18
845	Node positive melanoma – A positive note?. <i>Journal of the Royal College of Surgeons of Edinburgh</i> , 2012, 10, 63-64.	0.8	2
846	Interesting possibilities to improve the safety and efficacy of ipilimumab (Yervoy). <i>Pharmacological Research</i> , 2012, 66, 192-197.	3.1	14
847	Cutting Edge in Medical Management of Cutaneous Oncology. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2012, 31, 140-149.	1.6	7
848	The High Cost of Cancer Drugs and What We Can Do About It. <i>Mayo Clinic Proceedings</i> , 2012, 87, 935-943.	1.4	189
849	Cancer immunotherapy. <i>Molecular Oncology</i> , 2012, 6, 242-250.	2.1	71
851	Vemurafenib for the treatment of melanoma. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 2533-2543.	0.9	28

#	ARTICLE	IF	CITATIONS
852	Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma. <i>New England Journal of Medicine</i> , 2012, 366, 925-931.	13.9	1,836
853	Identification of Prostate-Specific G-Protein Coupled Receptor as a Tumor Antigen Recognized by CD8+ T Cells for Cancer Immunotherapy. <i>PLoS ONE</i> , 2012, 7, e45756.	1.1	13
854	Driving transcriptional regulators in melanoma metastasis. <i>Cancer and Metastasis Reviews</i> , 2012, 31, 621-632.	2.7	38
855	Systems Biology of Vaccination in the Elderly. <i>Current Topics in Microbiology and Immunology</i> , 2012, 363, 117-142.	0.7	28
856	Enhancing Cancer Immunotherapy by Intracellular Delivery of Cell-Penetrating Peptides and Stimulation of Pattern-Recognition Receptor Signaling. <i>Advances in Immunology</i> , 2012, 114, 151-176.	1.1	30
857	Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 1597-1611.	1.1	144
858	Poxviral vectors for cancer immunotherapy. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 463-478.	1.4	35
859	Adoptive Immunotherapy of Advanced Melanoma. <i>Current Treatment Options in Oncology</i> , 2012, 13, 340-353.	1.3	13
860	The Spectrum of Vaccine Therapies for Patients With Glioblastoma Multiforme. <i>Current Treatment Options in Oncology</i> , 2012, 13, 437-450.	1.3	20
861	Active Immunotherapy: Current State of the Art in Vaccine Approaches for NHL. <i>Current Oncology Reports</i> , 2012, 14, 433-440.	1.8	8
862	Tumor-Infiltrating Lymphocytes in Melanoma. <i>Current Oncology Reports</i> , 2012, 14, 468-474.	1.8	82
863	Recognizing and reversing the immunosuppressive tumor microenvironment of head and neck cancer. <i>Immunologic Research</i> , 2012, 54, 266-274.	1.3	58
864	Targeting BRAF in an Inducible Murine Model of Melanoma. <i>American Journal of Pathology</i> , 2012, 181, 785-794.	1.9	58
865	Progression of cutaneous melanoma: implications for treatment. <i>Clinical and Experimental Metastasis</i> , 2012, 29, 775-796.	1.7	32
867	ISCOMATRIX vaccines mediate CD8 ⁺ T cell cross-priming by a MyD88-dependent signaling pathway. <i>Immunology and Cell Biology</i> , 2012, 90, 540-552.	1.0	92
868	Outlining novel scenarios for improved therapeutic cancer vaccines: the PANVAC paradigm. <i>Expert Review of Vaccines</i> , 2012, 11, 275-277.	2.0	9
871	Activity of Imatinib Mesylate in Metastatic Anorectal Melanoma: A Case Report. <i>Journal of Gastrointestinal Cancer</i> , 2012, 43, 145-147.	0.6	0
872	Ipilimumab: A Guide to Its Use in Advanced Melanoma. <i>American Journal of Clinical Dermatology</i> , 2012, 13, 349-354.	3.3	1

#	ARTICLE	IF	CITATIONS
873	Identification of Human Regulatory T Cells in the Setting of T-Cell Activation and Anti-CTLA-4 Immunotherapy on the Basis of Expression of Latency-Associated Peptide. <i>Cancer Discovery</i> , 2012, 2, 122-130.	7.7	25
874	Central Nervous System Metastasis, the Biological Basis and Clinical Considerations. <i>Cancer Metastasis - Biology and Treatment</i> , 2012, , .	0.1	9
875	From genes to drugs: targeted strategies for melanoma. <i>Nature Reviews Cancer</i> , 2012, 12, 349-361.	12.8	323
876	Natural Killer (NK)- and T-Cell Engaging Antibody-Derived Therapeutics. <i>Antibodies</i> , 2012, 1, 88-123.	1.2	5
877	Should High-Dose Interleukin-2 Still Be the Preferred Treatment for Patients with Metastatic Melanoma?. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2012, 27, 337-343.	0.7	21
878	The immune contexture in human tumours: impact on clinical outcome. <i>Nature Reviews Cancer</i> , 2012, 12, 298-306.	12.8	3,873
880	Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer. <i>New England Journal of Medicine</i> , 2012, 366, 2443-2454.	13.9	10,727
881	An update on pegylated IFN- β for the adjuvant treatment of melanoma. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 1449-1459.	1.1	8
882	Adenovirus-Based Immunotherapy of Cancer: Promises to Keep. <i>Advances in Cancer Research</i> , 2012, 115, 147-220.	1.9	16
883	Dendritic cell-based tumor vaccinations in epithelial ovarian cancer: a systematic review. <i>Immunotherapy</i> , 2012, 4, 995-1009.	1.0	7
884	Combination immunotherapy with prostate GVAX and ipilimumab: safety and toxicity. <i>Immunotherapy</i> , 2012, 4, 577-580.	1.0	15
885	Combination strategies to enhance antitumor ADCC. <i>Immunotherapy</i> , 2012, 4, 511-527.	1.0	87
887	Dabrafenib and its potential for the treatment of metastatic melanoma. <i>Drug Design, Development and Therapy</i> , 2012, 6, 391.	2.0	102
888	Rare Tumors In Children and Adolescents. <i>Pediatric Oncology</i> , 2012, , .	0.5	8
889	Neoplastic leptomeningitis presenting in a melanoma patient treated with dabrafenib (a V600EBRAF Tj ETQq0 0 0 rBT /Overlock 10 Tf	0.4	24
890	Cell Cycle Gene Networks Are Associated with Melanoma Prognosis. <i>PLoS ONE</i> , 2012, 7, e34247.	1.1	32
891	Repertoire Enhancement with Adoptively Transferred Female Lymphocytes Controls the Growth of Pre-Implanted Murine Prostate Cancer. <i>PLoS ONE</i> , 2012, 7, e35222.	1.1	5
892	Dacarbazine and the Agonistic TRAIL Receptor-2 Antibody Lexatumumab Induce Synergistic Anticancer Effects in Melanoma. <i>PLoS ONE</i> , 2012, 7, e45492.	1.1	14

#	ARTICLE	IF	CITATIONS
893	Gene Expression Profile of Peripheral Blood Lymphocytes from Renal Cell Carcinoma Patients Treated with IL-2, Interferon- γ and Dendritic Cell Vaccine. <i>PLoS ONE</i> , 2012, 7, e50221.	1.1	17
894	Effect of vaccination with N-glycolyl GM3/VSSP vaccine by subcutaneous injection in patients with advanced cutaneous melanoma. <i>Cancer Management and Research</i> , 2012, 4, 341.	0.9	21
895	Metastatic Melanoma: A Regional Review and Future Directions. <i>Tumori</i> , 2012, 98, 575-580.	0.6	14
896	Adjuvant Therapy for Resected Stage III Melanoma Patients: High-Dose Interferon-Alpha versus Ipilimumab Combined with Kinases Inhibitors. <i>Tumori</i> , 2012, 98, 185-190.	0.6	8
897	Targeting the Cellular Signaling: BRAF Inhibition and Beyond for the Treatment of Metastatic Malignant Melanoma. <i>Dermatology Research and Practice</i> , 2012, 2012, 1-9.	0.3	12
898	Trends in Personalized Therapies in Oncology: The (Venture) Capitalist's Perspective. <i>Journal of Personalized Medicine</i> , 2012, 2, 15-34.	1.1	10
899	Targeting the Immune System to Fight Cancer Using Chemical Receptor Homing Vectors Carrying Polyinosine/Cytosine (PolyIC). <i>Frontiers in Oncology</i> , 2012, 2, 4.	1.3	12
900	Dermatological. <i>Medical Radiology</i> , 2012, , 229-251.	0.0	0
901	Cutaneous Side Effects of New Antitumor Drugs. <i>Deutsches A&#x0308;rztblatt International</i> , 2012, 109, 133-40.	0.6	40
902	Combining active immunotherapy with immune checkpoint blockade for the treatment of advanced prostate cancer. <i>Asian Journal of Andrology</i> , 2012, 14, 520-521.	0.8	10
903	Ten Years of Progress in Melanoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 932-935.	2.3	3
904	Thyroid Function Abnormalities in Patients Receiving Anticancer Agents. , 0, , .		4
905	Early Recurrence in Sentinel Lymph Node Positive Stage III Melanoma Patients. <i>American Surgeon</i> , 2012, 78, 808-813.	0.4	4
907	Melanoma and Nonmelanoma Skin Cancers. , 2012, , 1329-1334.		1
908	Practical Management of Immune-Related Adverse Events from Immune Checkpoint Protein Antibodies for the Oncologist. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2012, , 174-177.	1.8	47
909	Ipilimumab: report and comment about the MDX010-020 clinical trial. <i>Expert Review of Dermatology</i> , 2012, 7, 507-512.	0.3	0
910	The Economic Crisis and Cancer Chemotherapy: The Role of the Oncologist. <i>Tumori</i> , 2012, 98, 532-533.	0.6	3
911	Targeting Immune Checkpoints. <i>Cancer Journal (Sudbury, Mass)</i> , 2012, 18, 153-159.	1.0	41

#	ARTICLE	IF	CITATIONS
912	The monoclonal antibody to cytotoxic T lymphocyte antigen 4, ipilimumab, in the treatment of melanoma. <i>Cancer Management and Research</i> , 2012, 4, 1.	0.9	44
913	Drug treatment for melanoma: progress, but who pays?. <i>Medical Journal of Australia</i> , 2012, 197, 198-199.	0.8	13
914	Combinatorial treatment with carboxyamidotriazole- orotate and temozolomide in sc-implanted human LOX IMVI melanoma xenografts. <i>Journal of Solid Tumors</i> , 2012, 2, .	0.1	5
915	Association of Ipilimumab Therapy for Advanced Melanoma with Secondary Adrenal Insufficiency: A Case Series. <i>Endocrine Practice</i> , 2012, 18, 351-355.	1.1	55
916	Managing Immune-Related Adverse Events to Ipilimumab: A Nurse's Guide. <i>Clinical Journal of Oncology Nursing</i> , 2012, 16, E69-E75.	0.3	21
917	Regulation of Tumor Angiogenesis by the Immune System. <i>Current Angiogenesis</i> , 2012, 1, 88-97.	0.1	2
918	Monoclonal antibodies and Fc fragments for treating solid tumors. <i>Biologics: Targets and Therapy</i> , 2012, 6, 13.	3.0	4
919	Recent Advances in Immunotherapy of Lung Cancer. <i>Journal of Lung Cancer</i> , 2012, 11, 1.	0.2	1
920	What is new in the treatment of advanced melanoma? State of the art. <i>Wspolczesna Onkologia</i> , 2012, 5, 363-370.	0.7	8
921	Targeted agents for the treatment of metastatic melanoma. <i>OncoTargets and Therapy</i> , 2012, 5, 31.	1.0	13
922	Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma. <i>Cancer Management and Research</i> , 2012, 4, 243.	0.9	50
923	Characteristics and management of immune-related adverse effects associated with ipilimumab, a new immunotherapy for metastatic melanoma. <i>Cancer Management and Research</i> , 2012, 4, 299.	0.9	64
924	Complete clinical responses to cancer therapy caused by multiple divergent approaches: a repeating theme lost in translation. <i>Cancer Management and Research</i> , 2012, 4, 137.	0.9	26
925	Current management and novel agents for malignant melanoma. <i>Journal of Hematology and Oncology</i> , 2012, 5, 3.	6.9	39
926	Combining immunotherapy and targeted therapies in cancer treatment. <i>Nature Reviews Cancer</i> , 2012, 12, 237-251.	12.8	1,261
927	Cancer immunotherapy via dendritic cells. <i>Nature Reviews Cancer</i> , 2012, 12, 265-277.	12.8	1,738
928	The blockade of immune checkpoints in cancer immunotherapy. <i>Nature Reviews Cancer</i> , 2012, 12, 252-264.	12.8	10,874
929	Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 5797-5802.	3.3	173

#	ARTICLE	IF	CITATIONS
930	Novel Therapies for Metastatic Renal Cell Carcinoma: Efforts to Expand beyond the VEGF/mTOR Signaling Paradigm. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 526-537.	1.9	39
931	20 Years Experience of TNF-Based Isolated Limb Perfusion for In-Transit Melanoma Metastases: TNF Dose Matters. <i>Annals of Surgical Oncology</i> , 2012, 19, 627-635.	0.7	61
932	Inhibiting Systemic Autophagy during Interleukin 2 Immunotherapy Promotes Long-term Tumor Regression. <i>Cancer Research</i> , 2012, 72, 2791-2801.	0.4	133
933	Cellular teamwork in antibacterial innate immunity. <i>Nature Immunology</i> , 2012, 13, 115-117.	7.0	10
934	Cancer Genomics: Technology, Discovery, and Translation. <i>Journal of Clinical Oncology</i> , 2012, 30, 647-660.	0.8	173
935	Use of S-100B to Evaluate Therapy Effects during Bevacizumab Induction Treatment in AJCC Stage III Melanoma. <i>Annals of Surgical Oncology</i> , 2012, 19, 620-626.	0.7	18
936	Genetic cancer vaccines: current status and perspectives. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 1043-1058.	1.4	62
937	Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer. <i>New England Journal of Medicine</i> , 2012, 366, 2455-2465.	13.9	6,820
938	Clinical scale rapid expansion of lymphocytes for adoptive cell transfer therapy in the WAVE® bioreactor. <i>Journal of Translational Medicine</i> , 2012, 10, 69.	1.8	84
939	Combinatorial drug therapy for cancer in the post-genomic era. <i>Nature Biotechnology</i> , 2012, 30, 679-692.	9.4	883
940	Advances in cutaneous melanoma. <i>Clinical and Translational Oncology</i> , 2012, 14, 325-332.	1.2	6
941	Tumor control versus adverse events with targeted anticancer therapies. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 98-109.	12.5	90
942	The role of antigen-specific and non-specific immunotherapy in the treatment of cancer. <i>Journal of Immunotoxicology</i> , 2012, 9, 248-258.	0.9	34
943	Function but not phenotype of melanoma peptide-specific CD8 ⁺ T cells correlate with survival in a multiepitope peptide vaccine trial (ECOG 1696). <i>International Journal of Cancer</i> , 2012, 131, 874-884.	2.3	37
944	Active-specific immunotherapy of human cancers with the heat shock protein Gp96" revisited. <i>International Journal of Cancer</i> , 2012, 130, 2219-2231.	2.3	51
945	State of the Science: An Update on Renal Cell Carcinoma. <i>Molecular Cancer Research</i> , 2012, 10, 859-880.	1.5	142
946	The determinants of tumour immunogenicity. <i>Nature Reviews Cancer</i> , 2012, 12, 307-313.	12.8	343
947	Raising the Bar: The Curative Potential of Human Cancer Immunotherapy. <i>Science Translational Medicine</i> , 2012, 4, 127ps8.	5.8	218

#	ARTICLE	IF	CITATIONS
948	Cellular Constituents of Immune Escape within the Tumor Microenvironment. <i>Cancer Research</i> , 2012, 72, 3125-3130.	0.4	308
949	Engineering Nano- and Microparticles to Tune Immunity. <i>Advanced Materials</i> , 2012, 24, 3724-3746.	11.1	334
950	Multivalent Porous Silicon Nanoparticles Enhance the Immune Activation Potency of Agonistic CD40 Antibody. <i>Advanced Materials</i> , 2012, 24, 3981-3987.	11.1	93
951	Electrochemotherapy for disseminated superficial metastases from malignant melanoma. <i>British Journal of Surgery</i> , 2012, 99, 821-830.	0.1	89
952	<i>NRAS</i> mutation status is an independent prognostic factor in metastatic melanoma. <i>Cancer</i> , 2012, 118, 4014-4023.	2.0	589
953	Antibody therapy of cancer. <i>Nature Reviews Cancer</i> , 2012, 12, 278-287.	12.8	1,861
954	Unmasking the immune recognition of prostate cancer with CTLA4 blockade. <i>Nature Reviews Cancer</i> , 2012, 12, 289-297.	12.8	54
955	Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma. <i>New England Journal of Medicine</i> , 2012, 367, 107-114.	13.9	1,976
956	A new therapeutic strategy for malaria: targeting T cell exhaustion. <i>Nature Immunology</i> , 2012, 13, 113-115.	7.0	22
957	Mucosal Melanoma: Pathogenesis, Clinical Behavior, and Management. <i>Current Oncology Reports</i> , 2012, 14, 441-448.	1.8	138
958	Molecular testing in malignant melanoma. <i>Diagnostic Cytopathology</i> , 2012, 40, 503-510.	0.5	27
959	Two Hundred Years of Cancer Research. <i>New England Journal of Medicine</i> , 2012, 366, 2207-2214.	13.9	228
960	Recent Advances in Therapeutic Cancer Vaccines. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2012, 27, 2-5.	0.7	11
961	Tumor Immunotherapy Directed at PD-1. <i>New England Journal of Medicine</i> , 2012, 366, 2517-2519.	13.9	597
962	Integrating New Therapies in the Treatment of Advanced Melanoma. <i>Current Treatment Options in Oncology</i> , 2012, 13, 327-339.	1.3	8
963	Targeting Metastatic Melanoma. <i>Annual Review of Medicine</i> , 2012, 63, 171-183.	5.0	57
964	Melanoma Vaccines. , 2012, , 207-232.		0
965	Targeting embryonic signaling pathways in cancer therapy. <i>Expert Opinion on Therapeutic Targets</i> , 2012, 16, 131-145.	1.5	36

#	ARTICLE	IF	CITATIONS
966	Cancer immunotherapy: a paradigm shift for prostate cancer treatment. <i>Nature Reviews Urology</i> , 2012, 9, 376-385.	1.9	31
967	Advocating Sentinel Node Biopsy in the Management of Cutaneous Melanoma. <i>Current Dermatology Reports</i> , 2012, 1, 76-81.	1.1	0
968	Topical treatment of cutaneous metastases of malignant melanoma using combined imiquimod and 5-fluorouracil. <i>Investigational New Drugs</i> , 2012, 30, 1641-1645.	1.2	52
969	Role of PD-1 in HIV Pathogenesis and as Target for Therapy. <i>Current HIV/AIDS Reports</i> , 2012, 9, 81-90.	1.1	127
970	The Etiology of Paraneoplastic Autoimmunity. <i>Clinical Reviews in Allergy and Immunology</i> , 2012, 42, 135-144.	2.9	85
971	Invagination intestinale sur m�tastase d�un m�lanome cutan�. <i>Journal Africain D'Hepato-Gastroenterologie</i> , 2012, 6, 144-147.	0.0	0
972	Immunity to the melanoma inhibitor of apoptosis protein (ML-IAP; livin) in patients with malignant melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 655-665.	2.0	21
973	An immune-active tumor microenvironment favors clinical response to ipilimumab. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 1019-1031.	2.0	703
974	Intravenous and intradermal TriMix-dendritic cell therapy results in a broad T-cell response and durable tumor response in a chemorefractory stage IV-M1c melanoma patient. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 1033-1043.	2.0	63
975	Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 1137-1147.	2.0	85
976	Prostate cancer, tumor immunity and a renewed sense of optimism in immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 453-468.	2.0	22
977	Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 733-737.	2.0	84
978	Harmonization of the intracellular cytokine staining assay. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 967-978.	2.0	47
979	Upcoming strategies for the treatment of metastatic melanoma. <i>Archives of Dermatological Research</i> , 2012, 304, 177-184.	1.1	44
980	Possibility of immunotherapy for biliary tract cancer: how do we prove efficacy? Introduction to a current ongoing phase I and randomized phase II study to evaluate the efficacy and safety of adding Wilms tumor 1 peptide vaccine to gemcitabine and cisplatin for the treatment of advanced biliary tract cancer (WT�BT trial). <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2012, 19, 314-318.	1.4	12
981	Quantified Visual Scoring of Metastatic Melanoma Patient Treatment Response Using Computed Tomography: Improving on the Current Standard. <i>Journal of Digital Imaging</i> , 2012, 25, 258-265.	1.6	1
982	Genetic engineering with T cell receptors. <i>Advanced Drug Delivery Reviews</i> , 2012, 64, 756-762.	6.6	24
983	Belatacept: from rational design to clinical application. <i>Transplant International</i> , 2012, 25, 139-150.	0.8	66

#	ARTICLE	IF	CITATIONS
984	The illusion of scientific objectivity and the death of the investigator. <i>European Journal of Clinical Investigation</i> , 2012, 42, 213-215.	1.7	6
985	Experimental mouse tumour models: what can be learnt about human cancer immunology?. <i>Nature Reviews Immunology</i> , 2012, 12, 61-66.	10.6	105
986	Marginating Dendritic Cells of the Tumor Microenvironment Cross-Present Tumor Antigens and Stably Engage Tumor-Specific T Cells. <i>Cancer Cell</i> , 2012, 21, 402-417.	7.7	288
987	The Future of Cancer Treatment: Will It Include Immunotherapy?. <i>Cancer Cell</i> , 2012, 22, 7-8.	7.7	9
988	Tumor associated antigen specific T-cell populations identified in ex vivo expanded TIL cultures. <i>Cellular Immunology</i> , 2012, 273, 1-9.	1.4	23
989	Development of Novel Immune Interventions for Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2012, 10, 84-92.	0.9	17
991	Vemurafenib in Patients With BRAF V600E Mutationâ€“Positive Advanced Melanoma. <i>Clinical Therapeutics</i> , 2012, 34, 1474-1486.	1.1	80
992	Adjuvant Interferon Therapy for Patients at High Risk for Recurrent Melanoma: An Updated Systematic Review. <i>Clinical Oncology</i> , 2012, 24, 410-412.	0.6	3
993	The Role of Sipuleucel-T in Therapy for Castration-Resistant Prostate Cancer: A Critical Analysis of the Literature. <i>European Urology</i> , 2012, 61, 639-647.	0.9	28
995	Genetics and epigenetics of cutaneous malignant melanoma: A concert out of tune. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2012, 1826, 89-102.	3.3	46
996	Synapse-directed delivery of immunomodulators using T-cell-conjugated nanoparticles. <i>Biomaterials</i> , 2012, 33, 5776-5787.	5.7	168
997	Advances in the Treatment of Metastatic Melanoma: Adoptive T-Cell Therapy. <i>Seminars in Oncology</i> , 2012, 39, 215-226.	0.8	34
998	Advances in the Treatment of Metastatic Melanoma: New Immunomodulatory Agents. <i>Seminars in Oncology</i> , 2012, 39, 192-203.	0.8	12
999	Sipuleucel-T for the Treatment of Advanced Prostate Cancer. <i>Seminars in Oncology</i> , 2012, 39, 245-252.	0.8	22
1000	Whole Cell Vaccinesâ€“Past Progress and Future Strategies. <i>Seminars in Oncology</i> , 2012, 39, 276-286.	0.8	143
1001	Clinical Evaluation of TRICOM Vector Therapeutic Cancer Vaccines. <i>Seminars in Oncology</i> , 2012, 39, 296-304.	0.8	75
1002	Vaccines for Melanoma and Renal Cell Carcinoma. <i>Seminars in Oncology</i> , 2012, 39, 263-275.	0.8	29
1003	Current advances and perspectives in the treatment of advanced melanoma. <i>JDDG - Journal of the German Society of Dermatology</i> , 2012, 10, 319-325.	0.4	15

#	ARTICLE	IF	CITATIONS
1004	Aktuelle Fortschritte und Ausblicke in der Therapie des metastasierten Melanoms. JDDG - Journal of the German Society of Dermatology, 2012, 10, 319-325.	0.4	13
1005	Side effects of systemic oncological therapies in dermatology. JDDG - Journal of the German Society of Dermatology, 2012, 10, 475-486.	0.4	20
1007	Proteasome inhibition and ROS generation by 4-aminobiphenylcatechol induces melanoma cell death. Pigment Cell and Melanoma Research, 2012, 25, 354-369.	1.5	32
1008	The B7 Homologues and their Receptors in Hematologic Malignancies. European Journal of Haematology, 2012, 88, 465-475.	1.1	17
1009	Monoclonal antibodies for the treatment of cancer. Seminars in Cancer Biology, 2012, 22, 3-13.	4.3	141
1010	Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression. Seminars in Cancer Biology, 2012, 22, 275-281.	4.3	468
1011	Principles of cancer treatment by immunotherapy. Surgery, 2012, 30, 198-202.	0.1	1
1013	Prognostic importance of tumour-infiltrating memory T cells in oesophageal squamous cell carcinoma. Clinical and Experimental Immunology, 2012, 168, 186-191.	1.1	43
1014	Immunotherapy of cancer in 2012. Ca-A Cancer Journal for Clinicians, 2012, 62, 309-335.	157.7	379
1015	Translatability scoring in drug development: eight case studies. Journal of Translational Medicine, 2012, 10, 39.	1.8	37
1016	Therapy for metastatic melanoma: the past, present, and future. BMC Medicine, 2012, 10, 23.	2.3	179
1017	Large granular lymphocytosis with severe neutropenia following ipilimumab therapy for metastatic melanoma. Experimental Hematology and Oncology, 2012, 1, 3.	2.0	18
1018	Immunotherapy for metastatic melanoma. Journal of Cellular Biochemistry, 2012, 113, 725-734.	1.2	14
1019	Surgical resection for bulky or recurrent axillary metastatic melanoma. Journal of Surgical Oncology, 2012, 105, 21-25.	0.8	8
1020	Hyponatremia associated with Ipilimumab-induced hypophysitis. Medical Oncology, 2012, 29, 374-377.	1.2	63
1022	Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy. Cancer Immunology, Immunotherapy, 2012, 61, 41-48.	2.0	118
1023	Role of CD44 in lymphokine-activated killer cell-mediated killing of melanoma. Cancer Immunology, Immunotherapy, 2012, 61, 323-334.	2.0	3
1024	Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccines. Cancer Immunology, Immunotherapy, 2012, 61, 109-117.	2.0	34

#	ARTICLE	IF	CITATIONS
1025	Muscle CARs and TcRs: turbo-charged technologies for the (T cell) masses. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 127-135.	2.0	20
1026	A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial. <i>Investigational New Drugs</i> , 2012, 30, 741-748.	1.2	52
1027	Current and Emerging Treatment Options for Castration-Resistant Prostate Cancer: A Focus on Immunotherapy. <i>Journal of Clinical Immunology</i> , 2012, 32, 25-35.	2.0	25
1028	Brain metastases: pathobiology and emerging targeted therapies. <i>Acta Neuropathologica</i> , 2012, 123, 205-222.	3.9	163
1029	Metastatic melanoma: spontaneous occurrence of auto antibodies is a good prognosis factor in a prospective cohort. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, 92-96.	1.3	28
1030	Lymphocytic Colitis Secondary to Ipilimumab Treatment. <i>Inflammatory Bowel Diseases</i> , 2013, 19, E15-E16.	0.9	27
1031	Drug-Induced Inflammatory Bowel Disease and IBD-Like Conditions. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 445-456.	0.9	50
1032	³¹ P and ¹ H MRS of DB α 1 melanoma xenografts: lonidamine selectively decreases tumor intracellular pH and energy status and sensitizes tumors to melphalan. <i>NMR in Biomedicine</i> , 2013, 26, 98-105.	1.6	35
1033	Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma. <i>Investigational New Drugs</i> , 2013, 31, 425-434.	1.2	123
1034	MicroRNAs in the pathogenesis of malignant melanoma. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, 142-150.	1.3	28
1035	Activation of an early feedback survival loop involving phospho-ErbB3 is a general response of melanoma cells to RAF/MEK inhibition and is abrogated by anti-ErbB3 antibodies. <i>Journal of Translational Medicine</i> , 2013, 11, 180.	1.8	61
1036	The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF- α production. <i>Journal of Translational Medicine</i> , 2013, 11, 108.	1.8	136
1037	Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer. <i>Journal of Translational Medicine</i> , 2013, 11, 89.	1.8	84
1038	Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events. <i>Journal of Translational Medicine</i> , 2013, 11, 75.	1.8	142
1039	Shedding LIGHT (TNFSF14) on the tumor microenvironment of colorectal cancer liver metastases. <i>Journal of Translational Medicine</i> , 2013, 11, 70.	1.8	28
1040	Do BRAF inhibitors select for populations with different disease progression kinetics?. <i>Journal of Translational Medicine</i> , 2013, 11, 61.	1.8	25
1041	The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment. <i>Journal of Translational Medicine</i> , 2013, 11, 54.	1.8	104
1042	Phase III randomized study of ftemustine and dacarbazine versus dacarbazine with or without interferon- α in advanced malignant melanoma. <i>Journal of Translational Medicine</i> , 2013, 11, 38.	1.8	21

#	ARTICLE	IF	CITATIONS
1043	Systemic treatment for hereditary cancers: a 2012 update. <i>Hereditary Cancer in Clinical Practice</i> , 2013, 11, 2.	0.6	7
1044	Recent advances revolutionize treatment of metastatic prostate cancer. <i>Future Oncology</i> , 2013, 9, 1133-1144.	1.1	18
1045	Targeting the immune system for management of NSCLC: the revival?. <i>Current Respiratory Care Reports</i> , 2013, 2, 22-39.	0.6	1
1046	The Cutaneous Side Effects of Selective BRAF Inhibitors and Anti-CTLA4 Agents: the Growing Role of the Dermatologist in the Management of Patients with Metastatic Melanoma. <i>Current Dermatology Reports</i> , 2013, 2, 84-100.	1.1	6
1047	In vivo imaging of therapy-induced anti-cancer immune responses in humans. <i>Cellular and Molecular Life Sciences</i> , 2013, 70, 2237-2257.	2.4	21
1048	Circulating Melanoma Cells as a Predictive Biomarker. <i>Journal of Investigative Dermatology</i> , 2013, 133, 1460-1462.	0.3	21
1049	Systems level immune response analysis and personalized medicine. <i>Expert Review of Clinical Immunology</i> , 2013, 9, 307-317.	1.3	8
1050	IMA901: a peptide vaccine in renal cell carcinoma. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 1329-1336.	1.9	12
1051	Therapeutic Cancer Vaccines. <i>Advances in Cancer Research</i> , 2013, 119, 421-475.	1.9	450
1052	Current strategies in immunotherapy for acute myeloid leukemia. <i>Immunotherapy</i> , 2013, 5, 63-78.	1.0	20
1053	Targeting the acute myeloid leukemic stem cell compartment by enhancing tumor cell-based vaccines. <i>Immunotherapy</i> , 2013, 5, 859-868.	1.0	8
1054	Targeted chemotherapy of metastatic melanoma: the impact of tumor cell heterogeneity. <i>Expert Review of Dermatology</i> , 2013, 8, 131-134.	0.3	1
1055	The Immune Microenvironment of Human Tumors: General Significance and Clinical Impact. <i>Cancer Microenvironment</i> , 2013, 6, 117-122.	3.1	119
1056	Personalized peptide vaccination: a new approach for advanced cancer as therapeutic cancer vaccine. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 919-929.	2.0	80
1057	Cracking the code of human T-cell immunity. <i>Nature Biotechnology</i> , 2013, 31, 609-610.	9.4	8
1058	MicroRNA Cancer Regulation. <i>Advances in Experimental Medicine and Biology</i> , 2013, , .	0.8	17
1059	Case 21-2013. <i>New England Journal of Medicine</i> , 2013, 369, 173-183.	13.9	30
1060	Nivolumab plus Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2013, 369, 122-133.	13.9	3,776

#	ARTICLE	IF	CITATIONS
1061	The use of systemic therapies for the treatment of brain metastases in metastatic melanoma: Opportunities and unanswered questions. <i>Cancer Treatment Reviews</i> , 2013, 39, 833-838.	3.4	21
1062	Resistance to Immunotherapeutic Antibodies in Cancer. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2013, , .	0.1	2
1063	An EGFRvIII-targeted bispecific T-cell engager overcomes limitations of the standard of care for glioblastoma. <i>Expert Review of Clinical Pharmacology</i> , 2013, 6, 375-386.	1.3	20
1064	Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013, 9, 893-899.	1.5	64
1065	Molecular changes induced by the curcumin analogue D6 in human melanoma cells. <i>Molecular Cancer</i> , 2013, 12, 37.	7.9	21
1066	Antibody, T-cell and dendritic cell immunotherapy for malignant brain tumors. <i>Future Oncology</i> , 2013, 9, 977-990.	1.1	21
1067	Impact of Genetic Targets on Cancer Therapy. <i>Advances in Experimental Medicine and Biology</i> , 2013, 779, v-vi.	0.8	1
1068	Is combination therapy the next step to overcome resistance and reduce toxicities in melanoma?. <i>Cancer Treatment Reviews</i> , 2013, 39, 305-312.	3.4	13
1069	New Targets in Non-Small Cell Lung Cancer. <i>Current Oncology Reports</i> , 2013, 15, 411-423.	1.8	12
1070	Novel Immunotherapies in GU Malignancies. <i>Current Oncology Reports</i> , 2013, 15, 224-231.	1.8	5
1071	Programmed Death 1 Pathway inhibition in Metastatic Renal Cell Cancer and Prostate Cancer. <i>Current Oncology Reports</i> , 2013, 15, 98-104.	1.8	41
1072	Presence of antigen-specific somatic allelic mutations and splice variants do not predict for immunological response to genetic vaccination. , 2013, 1, 2.		2
1073	Genetic Vaccines against Cancer. , 2013, , 223-239.		1
1075	Metastatic Melanoma to the Brain: Surgery and Radiation Is Still the Standard of Care. <i>Current Treatment Options in Oncology</i> , 2013, 14, 264-279.	1.3	19
1076	Effector CD4 and CD8 T Cells and Their Role in the Tumor Microenvironment. <i>Cancer Microenvironment</i> , 2013, 6, 123-133.	3.1	263
1077	Blockade of the negative co-stimulatory molecules PD-1 and CTLA-4 improves survival in primary and secondary fungal sepsis. <i>Critical Care</i> , 2013, 17, R85.	2.5	205
1078	S-100B: A Stronger Prognostic Biomarker than LDH in Stage III Bâ€C Melanoma. <i>Annals of Surgical Oncology</i> , 2013, 20, 2772-2779.	0.7	40
1079	Phase I trial of bortezomib and dacarbazine in melanoma and soft tissue sarcoma. <i>Investigational New Drugs</i> , 2013, 31, 937-942.	1.2	11

#	ARTICLE	IF	CITATIONS
1080	Ipilimumab associated hepatitis: imaging and clinicopathologic findings. <i>Investigational New Drugs</i> , 2013, 31, 1071-1077.	1.2	211
1081	Adjuvant hypofractionated intensity modulated radiation therapy after resection of regional lymph node metastases in patients with cutaneous malignant melanoma of the head and neck. <i>Practical Radiation Oncology</i> , 2013, 3, e71-e77.	1.1	6
1082	Oncology Meets Immunology: The Cancer-Immunity Cycle. <i>Immunity</i> , 2013, 39, 1-10.	6.6	4,815
1083	Trametinib (GSK1120212) in the treatment of melanoma. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 619-627.	0.9	39
1084	Melanoma genotypes and phenotypes get personal. <i>Laboratory Investigation</i> , 2013, 93, 858-867.	1.7	23
1085	Drug of the year: Programmed Death-1 receptor/Programmed Death-1 Ligand-1 receptor monoclonal antibodies. <i>European Journal of Cancer</i> , 2013, 49, 2968-2971.	1.3	84
1086	Stem Cells and Cancer Stem Cells, Volume 9. , 2013, , .		0
1088	Synergy between chemotherapeutic agents and CTLA-4 blockade in preclinical tumor models. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 1533-1545.	2.0	78
1089	Intratumoral treatment of smaller mouse neuroblastoma tumors with a recombinant protein consisting of IL-2 linked to the Hu14.18 antibody increases intratumoral CD8+ T and NK cells and improves survival. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 1303-1313.	2.0	44
1090	Therapy model for advanced intracerebral B16 mouse melanoma using radiation therapy combined with immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 1187-1197.	2.0	9
1091	Fc γ RIIIb controls the potency of agonistic anti-TNFR mAbs. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 941-948.	2.0	41
1092	Harnessing the antigenic fingerprint of each individual cancer for immunotherapy of human cancer: genomics shows a new way and its challenges. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 967-974.	2.0	24
1093	Combined blockade of TIM-3 and TIM-4 augments cancer vaccine efficacy against established melanomas. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 629-637.	2.0	46
1094	Inhibition of both BRAF and MEK in BRAFV600E mutant melanoma restores compromised dendritic cell (DC) function while having differential direct effects on DC properties. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 811-822.	2.0	97
1095	Inhibitor of apoptosis protein (IAP) antagonists demonstrate divergent immunomodulatory properties in human immune subsets with implications for combination therapy. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 321-335.	2.0	31
1096	A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentialiation. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 1191-1199.	1.1	164
1097	Oblimersen in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma: a phase I trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 183-191.	1.1	40
1098	Vemurafenib reverses immunosuppression by myeloid derived suppressor cells. <i>International Journal of Cancer</i> , 2013, 133, 1653-1663.	2.3	107

#	ARTICLE	IF	CITATIONS
1099	Biomarker Utility of Circulating Tumor Cells in Metastatic Cutaneous Melanoma. <i>Journal of Investigative Dermatology</i> , 2013, 133, 1582-1590.	0.3	122
1102	The repertoire of human tumor-associated epitopes – identification and selection of antigens and their application in clinical trials. <i>Current Opinion in Immunology</i> , 2013, 25, 277-283.	2.4	39
1104	Emerging phytochemicals for prevention of melanoma invasion. <i>Cancer Letters</i> , 2013, 335, 251-258.	3.2	22
1105	Deciphering and Reversing Tumor Immune Suppression. <i>Immunity</i> , 2013, 39, 61-73.	6.6	496
1106	B7 family checkpoint regulators in immune regulation and disease. <i>Trends in Immunology</i> , 2013, 34, 556-563.	2.9	263
1107	New therapeutic options in systemic treatment of advanced cutaneous melanoma. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 181-190.	1.9	12
1108	Current Applications of Molecular Genetic Technologies to the Diagnosis and Treatment of Cutaneous Melanocytic Neoplasms. <i>Clinics in Laboratory Medicine</i> , 2013, 33, 881-890.	0.7	1
1110	Nuclear hormone receptor functions in keratinocyte and melanocyte homeostasis, epidermal carcinogenesis and melanomagenesis. <i>FEBS Letters</i> , 2013, 587, 529-541.	1.3	19
1111	The risk of rash associated with ipilimumab in patients with cancer: A systematic review of the literature and meta-analysis. <i>Journal of the American Academy of Dermatology</i> , 2013, 69, e121-e128.	0.6	126
1112	Prospects of combinatorial synthetic peptide vaccine-based immunotherapy against cancer. <i>Seminars in Immunology</i> , 2013, 25, 182-190.	2.7	44
1113	Gene Electrotransfer of Plasmid Antiangiogenic Metargidin Peptide (AMEP) in Disseminated Melanoma: Safety and Efficacy Results of a Phase I First-in-Man Study. <i>Human Gene Therapy Clinical Development</i> , 2013, 24, 99-107.	3.2	64
1115	Individualising treatment choices in a crowded treatment algorithm. <i>European Journal of Cancer, Supplement</i> , 2013, 11, 160-168.	2.2	2
1116	Molecular Pathways: Coexpression of Immune Checkpoint Molecules: Signaling Pathways and Implications for Cancer Immunotherapy. <i>Clinical Cancer Research</i> , 2013, 19, 4917-4924.	3.2	244
1117	Dual Blockade of PD-1 and CTLA-4 Combined with Tumor Vaccine Effectively Restores T-Cell Rejection Function in Tumors. <i>Cancer Research</i> , 2013, 73, 3591-3603.	0.4	604
1118	Humoral immune responses to CTL epitope peptides from tumor-associated antigens are widely detectable in humans: A new biomarker for overall survival of patients with malignant diseases. <i>Developmental and Comparative Immunology</i> , 2013, 41, 68-76.	1.0	14
1119	Clinical significance of the frequency of regulatory T cells in regional lymph node lymphocytes as a prognostic factor for non-small-cell lung cancer. <i>Lung Cancer</i> , 2013, 81, 475-479.	0.9	31
1120	Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 20212-20217.	3.3	1,482
1121	Management of Primary Cutaneous and Metastatic Melanoma. <i>Seminars in Oncology Nursing</i> , 2013, 29, 195-205.	0.7	14

#	ARTICLE	IF	CITATIONS
1122	Is cancer gene therapy an empty suit?. <i>Lancet Oncology</i> , The, 2013, 14, e447-e456.	5.1	48
1123	Depletion of regulatory T cells by targeting folate receptor 4 enhances the potency of a GM-CSF-secreting tumor cell immunotherapy. <i>Clinical Immunology</i> , 2013, 148, 287-298.	1.4	17
1124	Immune Stimulatory Features of Classical Chemotherapy. , 2013, , 395-414.		2
1125	Influence of tumour micro-environment heterogeneity on therapeutic response. <i>Nature</i> , 2013, 501, 346-354.	13.7	2,093
1126	Systematic review and meta-analysis of liver resection for metastatic melanoma. <i>British Journal of Surgery</i> , 2013, 100, 1138-1147.	0.1	36
1127	Turning Tumors into Vaccines: Co-opting the Innate Immune System. <i>Immunity</i> , 2013, 39, 27-37.	6.6	93
1128	An Update on Criteria for Assessing Tumor Response to Treatment. <i>Current Problems in Diagnostic Radiology</i> , 2013, 42, 209-219.	0.6	1
1129	Regulatory T Cell Infiltration Predicts Outcome Following Resection of Colorectal Cancer Liver Metastases. <i>Annals of Surgical Oncology</i> , 2013, 20, 946-955.	0.7	141
1130	Nanotechnology in Dermatology. , 2013, , .		8
1131	Immunotherapy for advanced melanoma: Fulfilling the promise. <i>Cancer Treatment Reviews</i> , 2013, 39, 879-885.	3.4	44
1133	Promising systemic immunotherapies in head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2013, 49, 1089-1096.	0.8	101
1134	Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 4199-4206.	0.8	433
1135	Cancer Genome Landscapes. <i>Science</i> , 2013, 339, 1546-1558.	6.0	6,507
1136	Diagnosis and Treatment of <i>KIT</i> -Mutant Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 3176-3181.	0.8	33
1137	Oncolytic and Immunotherapeutic Vaccinia Induces Antibody-Mediated Complement-Dependent Cancer Cell Lysis in Humans. <i>Science Translational Medicine</i> , 2013, 5, 185ra63.	5.8	87
1138	Microenvironmental regulation of tumor progression and metastasis. <i>Nature Medicine</i> , 2013, 19, 1423-1437.	15.2	5,730
1139	Large-scale Analysis of <i>PDGFRA</i> Mutations in Melanomas and Evaluation of Their Sensitivity to Tyrosine Kinase Inhibitors Imatinib and Crenolanib. <i>Clinical Cancer Research</i> , 2013, 19, 6935-6942.	3.2	43
1140	UV Radiation and the Skin. <i>International Journal of Molecular Sciences</i> , 2013, 14, 12222-12248.	1.8	1,295

#	ARTICLE	IF	CITATIONS
1141	Advances in therapy for melanoma brain metastases. <i>Clinics in Dermatology</i> , 2013, 31, 264-281.	0.8	36
1142	Challenging resistance mechanisms to therapies for metastatic melanoma. <i>Trends in Pharmacological Sciences</i> , 2013, 34, 656-666.	4.0	90
1143	A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma. <i>Investigational New Drugs</i> , 2013, 31, 707-713.	1.2	86
1144	Tumor metastasis: moving new biological insights into the clinic. <i>Nature Medicine</i> , 2013, 19, 1450-1464.	15.2	685
1145	A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments. <i>Carcinogenesis</i> , 2013, 34, 725-738.	1.3	86
1146	Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effect <i>in vivo</i> . <i>Clinical and Experimental Immunology</i> , 2013, 172, 500-506.	1.1	222
1147	Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. <i>Nature Reviews Immunology</i> , 2013, 13, 862-874.	10.6	1,819
1148	Ependymomas: development of immunotherapeutic strategies. <i>Expert Review of Neurotherapeutics</i> , 2013, 13, 1089-1098.	1.4	8
1149	Harnessing the Immune System for the Treatment of Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 1021-1028.	0.8	144
1150	Immune-Checkpoint Blockade and Active Immunotherapy for Glioma. <i>Cancers</i> , 2013, 5, 1379-1412.	1.7	33
1151	Restoring Antitumor Immunity via PD-1 Blockade After Autologous Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 4268-4270.	0.8	12
1152	The Small GTPase ARF6 Stimulates β -Catenin Transcriptional Activity During WNT5A-Mediated Melanoma Invasion and Metastasis. <i>Science Signaling</i> , 2013, 6, ra14.	1.6	122
1153	The Novel SMAC Mimetic Birinapant Exhibits Potent Activity against Human Melanoma Cells. <i>Clinical Cancer Research</i> , 2013, 19, 1784-1794.	3.2	98
1154	Severe Cutaneous and Neurologic Toxicity in Melanoma Patients during Vemurafenib Administration Following Anti-PD-1 Therapy. <i>Cancer Immunology Research</i> , 2013, 1, 373-377.	1.6	100
1155	Major Cancer Regressions in Mesothelioma After Treatment with an Anti-Mesothelin Immunotoxin and Immune Suppression. <i>Science Translational Medicine</i> , 2013, 5, 208ra147.	5.8	198
1156	Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8 ⁺ T Cells. <i>Science Translational Medicine</i> , 2013, 5, 200ra116.	5.8	1,447
1157	A potential role for resveratrol as a radiation sensitizer for melanoma treatment. <i>Journal of Surgical Research</i> , 2013, 183, 645-653.	0.8	50
1159	Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 616-622.	0.8	720

#	ARTICLE	IF	CITATIONS
1160	Immunotherapeutic strategies for the treatment of renal cell carcinoma: where are we now?. Expert Review of Anticancer Therapy, 2013, 13, 1399-1408.	1.1	10
1161	Antibody Therapeutics in Cancer. Science, 2013, 341, 1192-1198.	6.0	474
1162	CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients. Clinical Cancer Research, 2013, 19, 5300-5309.	3.2	596
1163	Tumor-Infiltrating Lymphocytes in Glioblastoma Are Associated with Specific Genomic Alterations and Related to Transcriptional Class. Clinical Cancer Research, 2013, 19, 4951-4960.	3.2	182
1164	Statistical issues and challenges in immuno-oncology. , 2013, 1, 18.		133
1165	Myeloid-derived suppressor cells are associated with disease progression and decreased overall survival in advanced-stage melanoma patients. Cancer Immunology, Immunotherapy, 2013, 62, 1711-1722.	2.0	113
1166	Rational combinations of immunotherapeutics that target discrete pathways. , 2013, 1, 16.		62
1167	Clinical impact of 18F-FDG PET-CT in recurrent stage III/IV melanoma: a tertiary centre Specialist Skin Cancer Multidisciplinary Team (SSMDT) experience. Insights Into Imaging, 2013, 4, 701-709.	1.6	10
1168	Immune evasion in acute myeloid leukemia: current concepts and future directions. , 2013, 1, .		85
1170	Concurrent whole brain radiotherapy and bortezomib for brain metastasis. Radiation Oncology, 2013, 8, 204.	1.2	14
1171	Primer on tumor immunology and cancer immunotherapy. , 2013, 1, 12.		63
1172	Autoimmune diseases and hypersensitivities improve the prognosis in ER-negative breast cancer. SpringerPlus, 2013, 2, 357.	1.2	4
1173	Immunological Insights from Patients Undergoing Surgery on Ipilimumab for Metastatic Melanoma. Annals of Surgical Oncology, 2013, 20, 3106-3111.	0.7	47
1174	Immunotherapy for the Management of Advanced Melanoma: The Next Steps. American Journal of Clinical Dermatology, 2013, 14, 261-272.	3.3	15
1175	Stage IV Melanoma: Completely Resectable Patients are Scarce. Annals of Surgical Oncology, 2013, 20, 2352-2356.	0.7	19
1176	Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10Âmg/kg within an expanded access programme. Cancer Immunology, Immunotherapy, 2013, 62, 1021-1028.	2.0	121
1177	How Often do Level III Nodes Bear Melanoma Metastases and does it Affect Patient Outcomes?. Annals of Surgical Oncology, 2013, 20, 2056-2064.	0.7	16
1180	Cancer immunotherapy: are we there yet?. Experimental Hematology and Oncology, 2013, 2, 33.	2.0	22

#	ARTICLE	IF	CITATIONS
1181	Severe pan-uveitis in a patient treated with vemurafenib for metastatic melanoma. <i>BMC Cancer</i> , 2013, 13, 561.	1.1	27
1182	Mek inhibition results in marked antitumor activity against metastatic melanoma patient-derived melanospheres and in melanosphere-generated xenografts. <i>Journal of Experimental and Clinical Cancer Research</i> , 2013, 32, 91.	3.5	18
1183	Targeting MAPK pathway in melanoma therapy. <i>Cancer and Metastasis Reviews</i> , 2013, 32, 567-584.	2.7	72
1184	Neoadjuvant treatment of melanoma: case reports and review. <i>Experimental Hematology and Oncology</i> , 2013, 2, 30.	2.0	7
1185	Peripheral blood mononuclear cells of patients with breast cancer can be reprogrammed to enhance anti-HER-2/neu reactivity and overcome myeloid-derived suppressor cells. <i>Breast Cancer Research and Treatment</i> , 2013, 142, 45-57.	1.1	20
1186	Innate and adaptive immune cells in the tumor microenvironment. <i>Nature Immunology</i> , 2013, 14, 1014-1022.	7.0	3,109
1187	Current management of melanoma. <i>Current Problems in Surgery</i> , 2013, 50, 351-382.	0.6	36
1188	Advances in the development of cancer immunotherapies. <i>Trends in Immunology</i> , 2013, 34, 90-98.	2.9	37
1189	Integration of cancer genomics with treatment selection. <i>Cancer</i> , 2013, 119, 3914-3928.	2.0	15
1190	Immunotherapy and the concept of a clinical cure. <i>European Journal of Cancer</i> , 2013, 49, 2965-2967.	1.3	41
1191	Checkpoint Modulation in Melanoma: An Update on Ipilimumab and Future Directions. <i>Current Oncology Reports</i> , 2013, 15, 500-508.	1.8	20
1192	Cancer Immunotherapy. <i>Surgical Oncology Clinics of North America</i> , 2013, 22, 765-783.	0.6	27
1193	Biology of brain metastases and novel targeted therapies: Time to translate the research. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2013, 1835, 61-75.	3.3	37
1194	Tumour cell lysate-loaded dendritic cell vaccine induces biochemical and memory immune response in castration-resistant prostate cancer patients. <i>British Journal of Cancer</i> , 2013, 109, 1488-1497.	2.9	55
1195	From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer. <i>Current Opinion in Immunology</i> , 2013, 25, 261-267.	2.4	444
1196	Lung cancer: potential targets for immunotherapy. <i>Lancet Respiratory Medicine</i> , 2013, 1, 551-563.	5.2	69
1197	Progress and potential of immune checkpoint blockade for treating advanced renal cell carcinoma. <i>Immunotherapy</i> , 2013, 5, 607-619.	1.0	3
1198	Recent advances in melanoma systemic therapy. BRAF inhibitors, CTLA4 antibodies and beyond. <i>European Journal of Cancer</i> , 2013, 49, 3229-3241.	1.3	40

#	ARTICLE	IF	CITATIONS
1199	A DNA vaccine against cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) prevents tumor growth. <i>Biochemical and Biophysical Research Communications</i> , 2013, 440, 222-228.	1.0	15
1200	Revisiting Immune-Based Therapies for Aggressive Follicular Cell-Derived Thyroid Cancers. <i>Thyroid</i> , 2013, 23, 529-542.	2.4	15
1201	Ipilimumab in pretreated metastatic uveal melanoma patients. Results of the Dutch Working group on Immunotherapy of Oncology (WIN-O). <i>Acta Oncologica</i> , 2013, 52, 1786-1788.	0.8	67
1202	Interferon alpha for the adjuvant treatment of cutaneous melanoma. <i>The Cochrane Library</i> , 2015, 2015, CD008955.	1.5	110
1203	The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 588-598.	12.5	177
1204	The Continuum of Cancer Immunosurveillance: Prognostic, Predictive, and Mechanistic Signatures. <i>Immunity</i> , 2013, 39, 11-26.	6.6	700
1205	Photodynamic therapy plus regulatory T-cell depletion produces immunity against a mouse tumour that expresses a self-antigen. <i>British Journal of Cancer</i> , 2013, 109, 2167-2174.	2.9	46
1206	Current and future systemic treatments for renal cell carcinoma. <i>Seminars in Cancer Biology</i> , 2013, 23, 38-45.	4.3	100
1207	Immune Escape. , 2013, , 149-164.		1
1208	Comprehensive Immunomonitoring to Guide the Development of Immunotherapeutic Products for Cancer. , 2013, , 241-258.		1
1209	Antibodies to Stimulate Host Immunity. , 2013, , 287-307.		2
1210	Elevated CD3+ and CD8+ tumor-infiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor microenvironment and at the systemic level. <i>Journal of Neuroimmunology</i> , 2013, 264, 71-83.	1.1	330
1211	The potential role of sunitinib targeting melanomas. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 1473-1483.	1.9	15
1212	Modulation of Immune System Inhibitory Checkpoints in Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2013, 9, 391-397.	1.0	9
1213	Optimal Management of Metastatic Melanoma: Current Strategies and Future Directions. <i>American Journal of Clinical Dermatology</i> , 2013, 14, 179-194.	3.3	89
1214	T-cell tolerance in cancer. <i>Immunotherapy</i> , 2013, 5, 513-531.	1.0	46
1215	Ipilimumab Administration in Patients With Advanced Melanoma and Hepatitis B and C. <i>Journal of Clinical Oncology</i> , 2013, 31, e370-e372.	0.8	23
1216	Stat3-Targeted Therapies Overcome the Acquired Resistance to Vemurafenib in Melanomas. <i>Journal of Investigative Dermatology</i> , 2013, 133, 2041-2049.	0.3	95

#	ARTICLE	IF	CITATIONS
1217	The Ludwig Institute for Cancer Research Melbourne Melanoma Cell Line Panel. <i>Pigment Cell and Melanoma Research</i> , 2013, 26, 597-600.	1.5	49
1218	Review article: antitumoural immunity in colorectal cancer – current and potential future implications in clinical practice. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 38, 3-15.	1.9	10
1219	Melanomas of unknown primary have a mutation profile consistent with cutaneous sun-exposed melanoma. <i>Pigment Cell and Melanoma Research</i> , 2013, 26, 852-860.	1.5	48
1220	Expression of gastrin-releasing peptide receptor in patients with cutaneous malignant melanoma. <i>Clinical and Experimental Dermatology</i> , 2013, 38, n/a-n/a.	0.6	5
1221	Pathologic and gene expression features of metastatic melanomas to the brain. <i>Cancer</i> , 2013, 119, 2737-2746.	2.0	42
1222	Response to a costly revolution for a subgroup of patients with metastatic melanoma. <i>British Journal of Dermatology</i> , 2013, 168, 470-471.	1.4	0
1223	Design and evaluation of radiolabeled tracers for tumor imaging. <i>Biotechnology and Applied Biochemistry</i> , 2013, 60, 365-383.	1.4	15
1224	Thyroid Dysfunction as an Unintended Side Effect of Anticancer Drugs. <i>Thyroid</i> , 2013, 23, 1345-1366.	2.4	93
1226	Current and future directions for Phase II trials in high-grade glioma. <i>Expert Review of Neurotherapeutics</i> , 2013, 13, 369-387.	1.4	4
1227	GTR Pathway Activation Abrogates Tumor Immune Suppression through Loss of Regulatory T-cell Lineage Stability. <i>Cancer Immunology Research</i> , 2013, 1, 320-331.	1.6	135
1228	Applications of systems biology in cancer immunotherapy: from target discovery to biomarkers of clinical outcome. <i>Expert Review of Clinical Pharmacology</i> , 2013, 6, 387-401.	1.3	17
1229	Vaccine Injection Site Matters: Qualitative and Quantitative Defects in CD8 T Cells Primed as a Function of Proximity to the Tumor in a Murine Glioma Model. <i>Journal of Immunology</i> , 2013, 190, 613-620.	0.4	50
1230	Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors. <i>Cancer Discovery</i> , 2013, 3, 1355-1363.	7.7	1,073
1231	Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. <i>Annals of Oncology</i> , 2013, 24, 75-83.	0.6	567
1232	Immune classification of colorectal cancer patients: impressive but how complete?. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 517-526.	1.4	18
1233	Neutralizing Tumor-Promoting Chronic Inflammation: A Magic Bullet?. <i>Science</i> , 2013, 339, 286-291.	6.0	943
1234	Oncolytic virus therapy for cancer: the first wave of translational clinical trials. <i>Translational Research</i> , 2013, 161, 355-364.	2.2	87
1235	Harnessing the Power of the Immune System to Target Cancer. <i>Annual Review of Medicine</i> , 2013, 64, 71-90.	5.0	126

#	ARTICLE	IF	CITATIONS
1236	Monoclonal antibodies in lung cancer. Expert Opinion on Biological Therapy, 2013, 13, 209-226.	1.4	17
1237	Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end?. Nature Reviews Clinical Oncology, 2013, 10, 14-26.	12.5	281
1238	Impact of Genetic Markers on Treatment of Non-small Cell Lung Cancer. Advances in Experimental Medicine and Biology, 2013, 779, 145-164.	0.8	7
1240	Evidence for a Role of the PD-1:PD-L1 Pathway in Immune Resistance of HPV-Associated Head and Neck Squamous Cell Carcinoma. Cancer Research, 2013, 73, 1733-1741.	0.4	678
1241	BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma. Clinical Cancer Research, 2013, 19, 1225-1231.	3.2	832
1242	Targeting Oncogenic Drivers and the Immune System in Melanoma. Journal of Clinical Oncology, 2013, 31, 499-506.	0.8	98
1243	Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody. Clinical Cancer Research, 2013, 19, 462-468.	3.2	485
1244	Therapeutic cancer vaccines. , 2013, , 1018-1031.		2
1245	The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition. Clinical Cancer Research, 2013, 19, 598-609.	3.2	410
1246	Novel Immunotherapeutic Strategies in Development for Renal Cell Carcinoma. European Urology, 2013, 63, 881-889.	0.9	39
1247	Radiofrequency Ablation in Cancer Therapy: Tuning in to in situ Tumor Vaccines. , 2013, , 39-59.		6
1248	Immune Co-signaling to Treat Cancer. , 2013, , 211-280.		1
1249	Microenvironment and tumor progression of melanoma: New therapeutic perspectives. Journal of Immunotoxicology, 2013, 10, 235-252.	0.9	37
1250	FDG PET scans as evaluation of clinical response to dendritic cell vaccination in patients with malignant melanoma. Cancer Immunology, Immunotherapy, 2013, 62, 17-25.	2.0	12
1251	Molecular Pathways: Mitogen-Activated Protein Kinase Pathway Mutations and Drug Resistance. Clinical Cancer Research, 2013, 19, 2301-2309.	3.2	77
1252	Chemoimmunotherapy: reengineering tumor immunity. Cancer Immunology, Immunotherapy, 2013, 62, 203-216.	2.0	215
1253	Surgery and the management of cutaneous melanoma. British Journal of Surgery, 2013, 100, 313-315.	0.1	2
1254	Î²-Blocker use and all-cause mortality of melanoma patients: Results from a population-based Dutch cohort study. European Journal of Cancer, 2013, 49, 3863-3871.	1.3	49

#	ARTICLE	IF	CITATIONS
1255	Immunotherapy of melanoma. <i>European Journal of Cancer, Supplement</i> , 2013, 11, 97-105.	2.2	53
1256	Patients with metastatic breast cancer leading to CD4+ T cell lymphopaenia have poor outcome. <i>European Journal of Cancer</i> , 2013, 49, 1673-1682.	1.3	42
1257	Brand name versus generic drugs: The ethical quandary in caring for our sophisticated patients while trying to reduce health-care costs: Facts and controversies. <i>Clinics in Dermatology</i> , 2013, 31, 772-776.	0.8	2
1258	Effect of Î²-Blockers and Other Antihypertensive Drugs On the Risk of Melanoma Recurrence and Death. <i>Mayo Clinic Proceedings</i> , 2013, 88, 1196-1203.	1.4	66
1259	Facing the dawn of immunotherapy for hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2013, 59, 9-10.	1.8	15
1260	JAAD Grand Rounds quiz â—. <i>Journal of the American Academy of Dermatology</i> , 2013, 69, 845-847.	0.6	0
1261	Inhibition of autophagy with chloroquine is effective inÂmelanoma. <i>Journal of Surgical Research</i> , 2013, 184, 274-281.	0.8	53
1263	Targeting BRAF in melanoma: Biological and clinical challenges. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 87, 239-255.	2.0	41
1265	Strategies to reverse melanoma-induced T-cell dysfunction. <i>Clinics in Dermatology</i> , 2013, 31, 251-256.	0.8	8
1266	Pruritus in patients treated with targeted cancer therapies: Systematic review and meta-analysis. <i>Journal of the American Academy of Dermatology</i> , 2013, 69, 708-720.	0.6	94
1267	Cancer immunotherapy: accomplishments to date and future promise. <i>Therapeutic Delivery</i> , 2013, 4, 1307-1320.	1.2	106
1268	Tumor-Infiltrating Lymphocyte Grade in Primary Melanomas Is Independently Associated With Melanoma-Specific Survival in the Population-Based Genes, Environment and Melanoma Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 4252-4259.	0.8	232
1269	Melanomaâ€associated leukoderma â€ immunology in black and white?. <i>Pigment Cell and Melanoma Research</i> , 2013, 26, 796-804.	1.5	38
1270	Preconditioning thermal therapy: Flipping the switch on IL-6 for anti-tumour immunity. <i>International Journal of Hyperthermia</i> , 2013, 29, 464-473.	1.1	37
1271	Ipilimumab, Vemurafenib, Dabrafenib, and Trametinib: Synergistic Competitors in the Clinical Management of BRAF Mutant Malignant Melanoma. <i>Oncologist</i> , 2013, 18, 717-725.	1.9	72
1272	BRD4 Sustains Melanoma Proliferation and Represents a New Target for Epigenetic Therapy. <i>Cancer Research</i> , 2013, 73, 6264-6276.	0.4	196
1273	Image-guided Thermal Ablation of Tumor Increases the Plasma Level of Interleukin-6 and Interleukin-10: Is Plasma Level of Interleukin-6 a Surrogate for Immunogenic Cell Death?. <i>Journal of Vascular and Interventional Radiology</i> , 2013, 24, 1112-1113.	0.2	2
1274	Mitochondria: gatekeepers of response to chemotherapy. <i>Trends in Cell Biology</i> , 2013, 23, 612-619.	3.6	140

#	ARTICLE	IF	CITATIONS
1276	Low level of education is associated with later stage at diagnosis and reduced survival in cutaneous malignant melanoma: A nationwide population-based study in Sweden. <i>European Journal of Cancer</i> , 2013, 49, 2705-2716.	1.3	55
1277	Targeting versus tinkering: Explaining why the clinic is frustrated with molecular mapping of disease mechanisms. <i>Medical Hypotheses</i> , 2013, 81, 553-556.	0.8	2
1278	Current advances in immunotherapy for pancreatic cancer. <i>Current Problems in Cancer</i> , 2013, 37, 273-279.	1.0	13
1279	Tumor B7-H1 and B7-H3 Expression in Squamous Cell Carcinoma of the Lung. <i>Clinical Lung Cancer</i> , 2013, 14, 157-163.	1.1	176
1280	The role of radiotherapy in the overall treatment of melanoma. <i>Clinics in Dermatology</i> , 2013, 31, 282-289.	0.8	10
1281	Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2013, 14, 1104-1111.	5.1	326
1282	Adjuvant interferon alfa in malignant melanoma: An interdisciplinary and multinational expert review. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 85, 149-161.	2.0	33
1284	Mission impossible: How HPV-associated head and neck cancers escape a primed immune response. <i>Oral Oncology</i> , 2013, 49, 723-725.	0.8	7
1286	Translational Research in Melanoma. <i>Surgical Oncology Clinics of North America</i> , 2013, 22, 785-804.	0.6	0
1288	Modeling cancer immunotherapy: Assessing the effects of lymphocytes on cancer cell growth and motility. <i>Physica A: Statistical Mechanics and Its Applications</i> , 2013, 392, 2415-2425.	1.2	6
1289	Chemotherapy in the management of advanced cutaneous malignant melanoma. <i>Clinics in Dermatology</i> , 2013, 31, 290-297.	0.8	80
1291	MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. <i>Lancet Oncology</i> , The, 2013, 14, 249-256.	5.1	587
1292	Metastatic melanoma in the older patient: Special considerations. <i>Clinics in Dermatology</i> , 2013, 31, 311-316.	0.8	9
1293	Immunotherapeutic strategies for relapse control in acute myeloid leukemia. <i>Blood Reviews</i> , 2013, 27, 209-216.	2.8	71
1294	CD33+/p-STAT1+ double-positive cell as a prognostic factor for stage IIIa gastric cancer. <i>Medical Oncology</i> , 2013, 30, 442.	1.2	25
1295	T-helper-1-cell cytokines drive cancer into senescence. <i>Nature</i> , 2013, 494, 361-365.	13.7	601
1296	Next-generation peptide vaccines for advanced cancer. <i>Cancer Science</i> , 2013, 104, 15-21.	1.7	108
1297	The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. <i>Immunology</i> , 2013, 138, 105-115.	2.0	643

#	ARTICLE	IF	CITATIONS
1298	Suppression, subversion and escape: the role of regulatory T cells in cancer progression. <i>Clinical and Experimental Immunology</i> , 2012, 171, 36-45.	1.1	188
1299	Prostate cancer vaccines. <i>Expert Review of Vaccines</i> , 2013, 12, 253-262.	2.0	12
1300	Melanoma Prognostics and Personalized Therapeutics at a Crossroad. <i>Journal of Investigative Dermatology</i> , 2013, 133, 292-295.	0.3	1
1301	Proposed mechanisms of action for prostate cancer vaccines. <i>Nature Reviews Urology</i> , 2013, 10, 149-160.	1.9	15
1302	Natural Human Plasmacytoid Dendritic Cells Induce Antigen-Specific T-Cell Responses in Melanoma Patients. <i>Cancer Research</i> , 2013, 73, 1063-1075.	0.4	295
1303	Agonist Antibodies to TNFR Molecules That Costimulate T and NK Cells. <i>Clinical Cancer Research</i> , 2013, 19, 1044-1053.	3.2	154
1304	Agonistic CD40 Antibodies and Cancer Therapy. <i>Clinical Cancer Research</i> , 2013, 19, 1035-1043.	3.2	352
1305	Interaction of tumor cells with the immune system: implications for dendritic cell therapy and cancer progression. <i>Drug Discovery Today</i> , 2013, 18, 35-42.	3.2	7
1306	Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance?. <i>Nature Reviews Cancer</i> , 2013, 13, 365-376.	12.8	242
1307	Using macrophage activation to augment immunotherapy of established tumours. <i>British Journal of Cancer</i> , 2013, 108, 1288-1297.	2.9	57
1308	Endocrine Side Effects Induced by Immune Checkpoint Inhibitors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 1361-1375.	1.8	358
1309	Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. <i>Current Opinion in Immunology</i> , 2013, 25, 268-276.	2.4	352
1310	Human cancer regression antigens. <i>Current Opinion in Immunology</i> , 2013, 25, 284-290.	2.4	38
1311	Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 847-861.	1.4	110
1312	<i>BRAF</i> mutation testing algorithm for vemurafenib treatment in melanoma: recommendations from an expert panel. <i>British Journal of Dermatology</i> , 2013, 168, 700-707.	1.4	36
1313	Vaccines against advanced melanoma. <i>Clinics in Dermatology</i> , 2013, 31, 179-190.	0.8	20
1314	Immunotherapy for Renal Cell Carcinoma. , 2013, , 279-301.		0
1315	Cancer stem cell antigen-based vaccines: the preferred strategy for active specific immunotherapy of metastatic melanoma?. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 643-656.	1.4	27

#	ARTICLE	IF	CITATIONS
1316	Coinhibitory molecules in cancer biology and therapy. <i>Cytokine and Growth Factor Reviews</i> , 2013, 24, 147-161.	3.2	26
1317	Relapse or Eradication of Cancer Is Predicted by Peptide-Major Histocompatibility Complex Affinity. <i>Cancer Cell</i> , 2013, 23, 516-526.	7.7	131
1318	The metastasis-promoting roles of tumor-associated immune cells. <i>Journal of Molecular Medicine</i> , 2013, 91, 411-429.	1.7	305
1319	At the Bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. <i>Journal of Leukocyte Biology</i> , 2013, 94, 25-39.	1.5	317
1320	The soluble isoform of CTLA-4 as a regulator of T-cell responses. <i>European Journal of Immunology</i> , 2013, 43, 1274-1285.	1.6	96
1321	Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 260-268.	4.6	1,138
1322	18F-labelled fluorodeoxyglucose-positron emission tomography (FDG-PET) heterogeneity of response is prognostic in dabrafenib treated BRAF mutant metastatic melanoma. <i>European Journal of Cancer</i> , 2013, 49, 395-402.	1.3	42
1323	Melanoma immunotherapy: historical precedents, recent successes and future prospects. <i>Immunotherapy</i> , 2013, 5, 169-182.	1.0	27
1324	Developing melanoma therapeutics: overview and update. <i>Wiley Interdisciplinary Reviews: Systems Biology and Medicine</i> , 2013, 5, 257-271.	6.6	13
1325	Phase I/II RAF kinase inhibitors in cancer therapy. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 739-749.	1.9	11
1326	Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma. <i>New England Journal of Medicine</i> , 2013, 369, 134-144.	13.9	3,128
1327	Pharmacotherapy of metastatic melanoma: Emerging trends and opportunities for a cure. , 2013, 139, 405-411.		12
1328	Dacarbazine in Melanoma: From a Chemotherapeutic Drug to an Immunomodulating Agent. <i>Journal of Investigative Dermatology</i> , 2013, 133, 289-292.	0.3	32
1329	Cancer Gene Therapy with Small Oligonucleotides. , 0, , .		1
1330	Combining Vaccines with Therapies that Render Tumor Cells more Susceptible to Immune Mediated Killing. , 2013, , 621-642.		0
1331	CTLA-4 blockade and the renaissance of cancer immunotherapy. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2013, 1836, 187-196.	3.3	42
1332	Immune checkpoint blockade immunotherapy to activate anti-tumour T-cell immunity. <i>British Journal of Haematology</i> , 2013, 162, 313-325.	1.2	102
1333	At the Bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. <i>Journal of Leukocyte Biology</i> , 2013, 94, 41-53.	1.5	305

#	ARTICLE	IF	CITATIONS
1334	Cancer immunotherapies, their safety and toxicity. <i>Expert Opinion on Drug Safety</i> , 2013, 12, 631-645.	1.0	123
1335	Novel Targets in the Treatment of Advanced Melanoma: New First-Line Treatment Options. <i>Annals of Pharmacotherapy</i> , 2013, 47, 519-526.	0.9	16
1336	Enhancement of antitumor immunity by combining anti-cytotoxic T lymphocyte antigen-4 antibodies and cryotreated tumor lysate-pulsed dendritic cells in murine osteosarcoma. <i>Oncology Reports</i> , 2013, 29, 1001-1006.	1.2	36
1337	T cell profiling reveals high CD4+CTLA-4+ T cell frequency as dominant predictor for survival after Prostate GVAX/ipilimumab treatment. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 245-256.	2.0	79
1338	Vemurafenib in melanoma. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 513-522.	1.1	9
1339	Novel antibodies targeting immune regulatory checkpoints for cancer therapy. <i>British Journal of Clinical Pharmacology</i> , 2013, 76, 233-247.	1.1	38
1340	Basic principles of tumor-associated regulatory T cell biology. <i>Trends in Immunology</i> , 2013, 34, 33-40.	2.9	91
1341	Therapeutic Improvement of a Stroma-Targeted CRAd by Incorporating Motives Responsive to the Melanoma Microenvironment. <i>Journal of Investigative Dermatology</i> , 2013, 133, 2576-2584.	0.3	15
1342	Adjuvant immunotherapy of melanoma and development of new approaches using the neoadjuvant approach. <i>Clinics in Dermatology</i> , 2013, 31, 237-250.	0.8	40
1343	Monoclonal antibodies in oncology therapeutics: present and future indications. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 269-282.	1.4	22
1344	Emerging and Mechanism-Based Therapies for Recurrent or Metastatic Merkel Cell Carcinoma. <i>Current Treatment Options in Oncology</i> , 2013, 14, 249-263.	1.3	54
1345	Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. <i>Annals of the New York Academy of Sciences</i> , 2013, 1291, 1-13.	1.8	270
1346	MicroRNAs in Melanoma Biology. <i>Advances in Experimental Medicine and Biology</i> , 2013, 774, 103-120.	0.8	60
1347	Which drug, and when, for patients with BRAF-mutant melanoma?. <i>Lancet Oncology</i> , The, 2013, 14, e60-e69.	5.1	164
1348	Perspectives on Immunotherapy in Prostate Cancer and Solid Tumors: Where Is the Future?. <i>Seminars in Oncology</i> , 2013, 40, 347-360.	0.8	13
1349	Immunomodulatory therapy for melanoma: Ipilimumab and beyond. <i>Clinics in Dermatology</i> , 2013, 31, 191-199.	0.8	57
1350	Metronomic chemotherapy for cancer treatment: a decade of clinical studies. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 13-33.	1.1	81
1351	Genome-based cancer therapeutics: targets, kinase drug resistance and future strategies for precision oncology. <i>Current Opinion in Pharmacology</i> , 2013, 13, 486-496.	1.7	55

#	ARTICLE	IF	CITATIONS
1352	The Tumor Immunoenvironment. , 2013, , .		4
1353	B7-H5 costimulates human T cells via CD28H. Nature Communications, 2013, 4, 2043.	5.8	148
1354	Dendritic cell immunotherapy. Annals of the New York Academy of Sciences, 2013, 1284, 31-45.	1.8	45
1355	Cellular immunotherapy for plasma cell myeloma. Bone Marrow Transplantation, 2013, 48, 1377-1386.	1.3	8
1356	Dendritic cells in cancer immunotherapy: vaccines and combination immunotherapies. Expert Review of Vaccines, 2013, 12, 285-295.	2.0	55
1357	Human dendritic cells subsets as targets and vectors for therapy. Annals of the New York Academy of Sciences, 2013, 1284, 24-30.	1.8	38
1358	Targeted cancer immunotherapy. Current Opinion in Pharmacology, 2013, 13, 504-510.	1.7	30
1359	The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy. Current Opinion in Immunology, 2013, 25, 230-237.	2.4	138
1360	Cancer Stem Cell Antigens from Autologous Tumor Cell Lines in Patient-Specific Active Immunotherapy for Metastatic Cancer. , 2013, , 271-284.		1
1361	Tumour heterogeneity and immune-modulation. Current Opinion in Pharmacology, 2013, 13, 497-503.	1.7	37
1362	Combination Molecularly Targeted Drug Therapy in Metastatic Melanoma: Progress to Date. Drugs, 2013, 73, 767-777.	4.9	11
1363	Management options for metastatic melanoma in the era of novel therapies: A primer for the practicing dermatologist. Journal of the American Academy of Dermatology, 2013, 68, 13.e1-13.e13.	0.6	11
1364	Malignant melanoma in 63 dogs (2001â€“2011): the effect of carboplatin chemotherapy on survival. New Zealand Veterinary Journal, 2013, 61, 25-31.	0.4	61
1365	Cellular Players in Breast Cancer Bone Metastases. Clinical Reviews in Bone and Mineral Metabolism, 2013, 11, 122-132.	1.3	1
1366	Systems biology analysis of immune signaling in peripheral blood mononuclear cells (PBMC) of melanoma patients receiving ipilimumab; basis for clinical response biomarker identification. , 2013, 1, .		1
1367	Low Total Lymphocyte Count Is Associated with Poor Survival in Patients with Resected Pancreatic Adenocarcinoma Receiving a GM-CSF Secreting Pancreatic Tumor Vaccine. Annals of Surgical Oncology, 2013, 20, 725-730.	0.7	31
1368	Ipilimumab and Its Toxicities: A Multidisciplinary Approach. Oncologist, 2013, 18, 733-743.	1.9	288
1369	The density and type of <sc>MECA</sc>-positive high endothelial venules correlate with lymphocytic infiltration and tumour regression in primary cutaneous melanoma. Histopathology, 2013, 63, 852-861.	1.6	41

#	ARTICLE	IF	CITATIONS
1370	Molecularly targeted therapies for melanoma. <i>International Journal of Dermatology</i> , 2013, 52, 523-530.	0.5	13
1371	Hepatocellular Carcinoma from an Immunologic Perspective. <i>Clinical Cancer Research</i> , 2013, 19, 6678-6685.	3.2	89
1374	Characterization of Distinct Immunophenotypes across Pediatric Brain Tumor Types. <i>Journal of Immunology</i> , 2013, 191, 4880-4888.	0.4	182
1375	Structure-Based Design of Altered MHC Class II "Restricted Peptide Ligands with Heterogeneous Immunogenicity. <i>Journal of Immunology</i> , 2013, 191, 5097-5106.	0.4	18
1376	Clinical trials in cellular immunotherapy for brain/CNS tumors. <i>Expert Review of Neurotherapeutics</i> , 2013, 13, 405-424.	1.4	18
1377	Preclinical vaccines against mammary carcinoma. <i>Expert Review of Vaccines</i> , 2013, 12, 1449-1463.	2.0	11
1378	A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. <i>Journal of Hepatology</i> , 2013, 59, 81-88.	1.8	816
1379	Long-term follow-up of 163 consecutive patients treated with isolated limb perfusion for in-transit metastases of malignant melanoma. <i>International Journal of Hyperthermia</i> , 2013, 29, 551-557.	1.1	42
1380	Oncolytic vaccines. <i>Expert Review of Vaccines</i> , 2013, 12, 1155-1172.	2.0	38
1381	Clinical Development of Immunostimulatory Monoclonal Antibodies and Opportunities for Combination. <i>Clinical Cancer Research</i> , 2013, 19, 997-1008.	3.2	161
1382	Immune Checkpoint Inhibitors: Making Immunotherapy a Reality for the Treatment of Lung Cancer. <i>Cancer Immunology Research</i> , 2013, 1, 85-91.	1.6	161
1383	Ipilimumab in prostate cancer. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 303-313.	1.4	7
1384	Systemic treatment in the management of head and neck cutaneous malignancies. <i>Operative Techniques in Otolaryngology - Head and Neck Surgery</i> , 2013, 24, 63-68.	0.1	1
1385	OX40 Is a Potent Immune-Stimulating Target in Late-Stage Cancer Patients. <i>Cancer Research</i> , 2013, 73, 7189-7198.	0.4	410
1386	Inhibition of Angiogenesis for the Treatment of Metastatic Melanoma. <i>Current Oncology Reports</i> , 2013, 15, 492-499.	1.8	5
1387	Melanoma Brain Metastases: an Unmet Challenge in the Era of Active Therapy. <i>Current Oncology Reports</i> , 2013, 15, 483-491.	1.8	32
1388	MEK Inhibition in the Treatment of Advanced Melanoma. <i>Current Oncology Reports</i> , 2013, 15, 473-482.	1.8	21
1389	Rationale for and Review of Neoadjuvant Therapy Prior to Radical Prostatectomy for Patients with High-Risk Prostate Cancer. <i>Drugs</i> , 2013, 73, 1417-1430.	4.9	39

#	ARTICLE	IF	CITATIONS
1390	The Intersection of Immune-Directed and Molecularly Targeted Therapy in Advanced Melanoma: Where We Have Been, Are, and Will Be. <i>Clinical Cancer Research</i> , 2013, 19, 5283-5291.	3.2	54
1391	Emerging BRAF inhibitors for melanoma. <i>Expert Opinion on Emerging Drugs</i> , 2013, 18, 431-443.	1.0	5
1392	Safety, Efficacy, and Biomarkers of Nivolumab With Vaccine in Ipilimumab-Refractory or -Naive Melanoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 4311-4318.	0.8	515
1393	Late divergence of survival curves in cancer immunotherapy trials: interpretation and implications. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 1547-1551.	2.0	20
1395	Neurological immune-related adverse events of ipilimumab. <i>Practical Neurology</i> , 2013, 13, 278-280.	0.5	120
1396	NRAS mutant melanoma: biological behavior and future strategies for therapeutic management. <i>Oncogene</i> , 2013, 32, 3009-3018.	2.6	127
1397	A randomized phase 2 study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma. <i>Cancer</i> , 2013, 119, 586-592.	2.0	81
1398	Clinical responses to selumetinib (AZD6244;ARRY142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma. <i>Cancer</i> , 2013, 119, 799-805.	2.0	63
1399	MAP kinase signaling and inhibition in melanoma. <i>Oncogene</i> , 2013, 32, 2373-2379.	2.6	127
1400	Influence of human immune cells on cancer: studies at the University of Colorado. <i>Immunologic Research</i> , 2013, 55, 22-33.	1.3	13
1401	Anti-CTLA-4 and BRAF inhibition in patients with metastatic melanoma and brain metastases. <i>Expert Review of Dermatology</i> , 2013, 8, 479-487.	0.3	4
1402	Systemic Administration of a Novel Immune-Stimulatory Pseudovirus Suppresses Lung Metastatic Melanoma by Regionally Enhancing IFN- γ Production. <i>Clinical Cancer Research</i> , 2013, 19, 668-679.	3.2	21
1403	The Clinical Viewpoint: Definitions, Limitations of RECIST, Practical Considerations of Measurement. <i>Clinical Cancer Research</i> , 2013, 19, 2629-2636.	3.2	110
1404	Koch Institute Symposium on Cancer Immunology and Immunotherapy. <i>Cancer Immunology Research</i> , 2013, 1, 217-222.	1.6	1
1405	Immunotherapeutic strategies including transplantation: eradication of disease. <i>Hematology American Society of Hematology Education Program</i> , 2013, 2013, 151-157.	0.9	13
1406	AACR Cancer Progress Report 2013. <i>Clinical Cancer Research</i> , 2013, 19, S1-S98.	3.2	55
1407	Inflammation in uveal melanoma. <i>Eye</i> , 2013, 27, 217-223.	1.1	67
1408	An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma. <i>Expert Review of Vaccines</i> , 2013, 12, 597-615.	2.0	60

#	ARTICLE	IF	CITATIONS
1410	A new role for NF κ B in immunosurveillance and its implications for cancer immunotherapy. <i>OncolImmunology</i> , 2013, 2, e25963.	2.1	3
1411	Vaccine-based immunotherapy for glioblastoma. <i>CNS Oncology</i> , 2013, 2, 331-349.	1.2	11
1412	Getting Personal with Neoantigen-Based Therapeutic Cancer Vaccines. <i>Cancer Immunology Research</i> , 2013, 1, 11-15.	1.6	167
1413	Differentiated thyroid carcinomas and their B7H1 shield. <i>Future Oncology</i> , 2013, 9, 1417-1419.	1.1	13
1414	Targeting epigenetic mechanisms for clinical translation: enhancing the efficacy of tumor immunotherapies. <i>Immunotherapy</i> , 2013, 5, 1243-1254.	1.0	4
1415	Striving for synergy: how to improve cancer immunotherapy through multiple agonist costimulation. <i>Immunotherapy</i> , 2013, 5, 1271-1273.	1.0	1
1416	Rethinking cancer vaccines to avoid T-cell traps. <i>Immunotherapy</i> , 2013, 5, 665-668.	1.0	0
1417	Mobilizing and evaluating anticancer T cells: pitfalls and solutions. <i>Expert Review of Vaccines</i> , 2013, 12, 1325-1340.	2.0	5
1418	Immune aspects of the breast tumor microenvironment. <i>Breast Cancer Management</i> , 2013, 2, 231-244.	0.2	11
1420	Ipilimumab-Associated Colitis: CT Findings. <i>American Journal of Roentgenology</i> , 2013, 200, W468-W474.	1.0	137
1421	Increased Frequency of ICOS ⁺ CD4 T Cells as a Pharmacodynamic Biomarker for Anti-CTLA-4 Therapy. <i>Cancer Immunology Research</i> , 2013, 1, 229-234.	1.6	178
1422	Colorectal Cancer: Basic and Translational Research. <i>Gastrointestinal Tumors</i> , 2013, 1, 18-24.	0.3	0
1423	Immunotherapeutic strategies to target prognostic and predictive markers of cancer. <i>Biomarkers in Medicine</i> , 2013, 7, 23-35.	0.6	9
1424	Immunotherapy treatments for small-cell lung cancer: past, present and future. <i>Lung Cancer Management</i> , 2013, 2, 517-525.	1.5	1
1426	B7-H3 Associated with Tumor Progression and Epigenetic Regulatory Activity in Cutaneous Melanoma. <i>Journal of Investigative Dermatology</i> , 2013, 133, 2050-2058.	0.3	121
1427	Hypoxia Contributes to Melanoma Heterogeneity by Triggering HIF1 α -Dependent Phenotype Switching. <i>Journal of Investigative Dermatology</i> , 2013, 133, 2436-2443.	0.3	127
1428	Revisiting the role of systemic therapies in patients with metastatic melanoma to the CNS. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 559-567.	1.1	6
1429	Pathophysiological Characteristics of Melanoma In-Transit Metastasis in a Lymphedema Mouse Model. <i>Journal of Investigative Dermatology</i> , 2013, 133, 537-544.	0.3	13

#	ARTICLE	IF	CITATIONS
1430	New Therapeutic Targets and Drugs for the Treatment of Chronic Hepatitis B. <i>Seminars in Liver Disease</i> , 2013, 33, 130-137.	1.8	21
1431	Targeting Brain Metastases in Patients with Melanoma. <i>BioMed Research International</i> , 2013, 2013, 1-6.	0.9	4
1432	Virosome Presents Multimodel Cancer Therapy without Viral Replication. <i>BioMed Research International</i> , 2013, 2013, 1-9.	0.9	22
1433	Monitoring Regulatory Immune Responses in Tumor Immunotherapy Clinical Trials. <i>Frontiers in Oncology</i> , 2013, 3, 109.	1.3	18
1434	In vivo Modeling and Molecular Characterization: A Path Toward Targeted Therapy of Melanoma Brain Metastasis. <i>Frontiers in Oncology</i> , 2013, 3, 127.	1.3	9
1435	Immunoediting and Antigen Loss: Overcoming the Achilles Heel of Immunotherapy with Antigen Non-Specific Therapies. <i>Frontiers in Oncology</i> , 2013, 3, 197.	1.3	36
1436	Home Sweet Home: The Tumor Microenvironment as a Haven for Regulatory T Cells. <i>Frontiers in Immunology</i> , 2013, 4, 197.	2.2	70
1437	A Patient with HIV Treated with Ipilimumab and Stereotactic Radiosurgery for Melanoma Metastases to the Brain. <i>Case Reports in Oncological Medicine</i> , 2013, 2013, 1-4.	0.2	12
1438	Dendritic Cell-Based Immunotherapy for Myeloid Leukemias. <i>Frontiers in Immunology</i> , 2013, 4, 496.	2.2	37
1439	An evolutionary perspective on anti-tumor immunity. <i>Frontiers in Oncology</i> , 2012, 2, 202.	1.3	15
1440	The Tumor Microenvironment: A Pitch for Multiple Players. <i>Frontiers in Oncology</i> , 2013, 3, 90.	1.3	121
1441	Novel Systemic Therapies in Advanced Liposarcoma: A Review of Recent Clinical Trial Results. <i>Cancers</i> , 2013, 5, 529-549.	1.7	43
1442	Biologics in Dermatology. <i>Pharmaceuticals</i> , 2013, 6, 557-578.	1.7	9
1443	Natural and Induced T Regulatory Cells in Cancer. <i>Frontiers in Immunology</i> , 2013, 4, 190.	2.2	202
1444	Urgent treatment of patients with metastatic melanoma using braf inhibitors in the absence of braf mutation status. <i>Annals of Oncology</i> , 2013, 24, 1712-1713.	0.6	2
1445	Sarcoidosis complicating anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody biotherapy. <i>European Respiratory Journal</i> , 2013, 41, 246-247.	3.1	54
1446	Improvement of Cancer Immunotherapy by Combining Molecular Targeted Therapy. <i>Frontiers in Oncology</i> , 2013, 3, 136.	1.3	22
1447	Dacarbazine-Mediated Upregulation of NKG2D Ligands on Tumor Cells Activates NK and CD8 T Cells and Restrains Melanoma Growth. <i>Journal of Investigative Dermatology</i> , 2013, 133, 499-508.	0.3	75

#	ARTICLE	IF	CITATIONS
1448	Hypophysitis Caused by Ipilimumab in Cancer Patients: Hormone Replacement or Immunosuppressive Therapy. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2013, 121, 581-587.	0.6	45
1449	Targeting of the Tumor Necrosis Factor Receptor Superfamily for Cancer Immunotherapy. <i>ISRN Oncology</i> , 2013, 2013, 1-25.	2.1	65
1450	Improving Drug Uptake and Penetration into Tumors: Current and Forthcoming Opportunities. <i>Frontiers in Oncology</i> , 2013, 3, 161.	1.3	6
1451	Impact of MAPK Pathway Activation in BRAFV600 Melanoma on T Cell and Dendritic Cell Function. <i>Frontiers in Immunology</i> , 2013, 4, 346.	2.2	36
1452	The Role of the Immune Response in Merkel Cell Carcinoma. <i>Cancers</i> , 2013, 5, 234-254.	1.7	33
1453	Ipilimumab for advanced melanoma: A pharmacologic perspective. <i>Journal of Oncology Pharmacy Practice</i> , 2013, 19, 195-201.	0.5	16
1454	TIM-3 Does Not Act as a Receptor for Galectin-9. <i>PLoS Pathogens</i> , 2013, 9, e1003253.	2.1	81
1455	Adjuvant Treatment of Melanoma. <i>ISRN Dermatology</i> , 2013, 2013, 1-17.	1.9	8
1456	Identification of Pre- and Post-Treatment Markers, Clinical, and Laboratory Parameters Associated with Outcome in Renal Cancer Patients Treated with MVA-5T4. <i>Frontiers in Oncology</i> , 2013, 3, 185.	1.3	7
1457	Immune Toxicities and Long Remission Duration after Ipilimumab Therapy for Metastatic Melanoma: Two Illustrative Cases. <i>Current Oncology</i> , 2013, 20, 165-169.	0.9	33
1458	Selection of Immunostimulant AS15 for Active Immunization With MAGE-A3 Protein: Results of a Randomized Phase II Study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 2413-2420.	0.8	188
1459	Vemurafenib and ipilimumab: New agents for metastatic melanoma. <i>American Journal of Health-System Pharmacy</i> , 2013, 70, 1205-1210.	0.5	16
1460	Single Cell Functional Proteomics for Assessing Immune Response in Cancer Therapy: Technology, Methods, and Applications. <i>Frontiers in Oncology</i> , 2013, 3, 133.	1.3	33
1461	Paradigm Shift in Metastatic Malignant Melanoma. <i>UHOD - Uluslararası Hematoloji-Onkoloji Dergisi</i> , 2013, 23, 3-9.	0.1	1
1462	Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival. <i>Annals of Oncology</i> , 2013, 24, 1697-1703.	0.6	280
1463	The Immunocytokine L19â€“IL2 Eradicates Cancer When Used in Combination with CTLA-4 Blockade or with L19-TNF. <i>Journal of Investigative Dermatology</i> , 2013, 133, 751-758.	0.3	86
1464	T-Cell Costimulatory Blockade in Organ Transplantation. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2013, 3, a015537-a015537.	2.9	17
1465	Intratumoral IL-12 combined with CTLA-4 blockade elicits T cellâ€“mediated glioma rejection. <i>Journal of Experimental Medicine</i> , 2013, 210, 2803-2811.	4.2	177

#	ARTICLE	IF	CITATIONS
1466	Immunomodulatory Monoclonal Antibodies Combined with Peptide Vaccination Provide Potent Immunotherapy in an Aggressive Murine Neuroblastoma Model. <i>Clinical Cancer Research</i> , 2013, 19, 3545-3555.	3.2	38
1467	Phase II Randomized Trial Comparing High-Dose IFN- γ ±2b with Temozolomide Plus Cisplatin as Systemic Adjuvant Therapy for Resected Mucosal Melanoma. <i>Clinical Cancer Research</i> , 2013, 19, 4488-4498.	3.2	158
1468	Activating Fc γ 3 receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. <i>Journal of Experimental Medicine</i> , 2013, 210, 1685-1693.	4.2	400
1469	Clonal expansion of renal cell carcinoma-infiltrating T lymphocytes. <i>Oncolmmunology</i> , 2013, 2, e26014.	2.1	20
1470	Pathology and genetics of uveal melanoma. <i>Pathology</i> , 2013, 45, 18-27.	0.3	31
1471	C-kit-mutated melanomas. <i>Current Opinion in Oncology</i> , 2013, 25, 160-165.	1.1	15
1472	Evaluation of Ipilimumab in Combination With Allogeneic Pancreatic Tumor Cells Transfected With a GM-CSF Gene in Previously Treated Pancreatic Cancer. <i>Journal of Immunotherapy</i> , 2013, 36, 382-389.	1.2	460
1473	Comparison of Glioma-associated Antigen Peptide-loaded Versus Autologous Tumor Lysate-loaded Dendritic Cell Vaccination in Malignant Glioma Patients. <i>Journal of Immunotherapy</i> , 2013, 36, 152-157.	1.2	111
1474	Immune Checkpoint Inhibitors as Novel Targets for Renal Cell Carcinoma Therapeutics. <i>Cancer Journal (Sudbury, Mass)</i> , 2013, 19, 348-352.	1.0	17
1475	Single-Center Experience With Ipilimumab in an Expanded Access Program for Patients With Pretreated Advanced Melanoma. <i>Journal of Immunotherapy</i> , 2013, 36, 215-222.	1.2	78
1476	Parthenolide enhances dacarbazine activity against melanoma cells. <i>Anti-Cancer Drugs</i> , 2013, 24, 835-845.	0.7	23
1477	A Pan-Inhibitor of DASH Family Enzymes Induces Immune-mediated Regression of Murine Sarcoma and Is a Potent Adjuvant to Dendritic Cell Vaccination and Adoptive T-cell Therapy. <i>Journal of Immunotherapy</i> , 2013, 36, 400-411.	1.2	12
1478	Ipilimumab-induced acute severe colitis treated by infliximab. <i>Melanoma Research</i> , 2013, 23, 227-230.	0.6	117
1480	Elevated rates of transaminitis during ipilimumab therapy for metastatic melanoma. <i>Melanoma Research</i> , 2013, 23, 47-54.	0.6	54
1481	High expression of glycolytic and pigment proteins is associated with worse clinical outcome in stage III melanoma. <i>Melanoma Research</i> , 2013, 23, 452-460.	0.6	24
1482	Update on the role of ipilimumab in melanoma and first data on new combination therapies. <i>Current Opinion in Oncology</i> , 2013, 25, 166-172.	1.1	27
1483	Demystifying Immunotherapy in Prostate Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2013, 19, 50-58.	1.0	20
1484	Ipilimumab activity in advanced uveal melanoma. <i>Melanoma Research</i> , 2013, 23, 79-81.	0.6	52

#	ARTICLE	IF	CITATIONS
1485	Immunotherapeutics for breast cancer. <i>Current Opinion in Oncology</i> , 2013, 25, 602-608.	1.1	27
1486	Indicators of the standard of care for melanoma. <i>Melanoma Research</i> , 2013, 23, 283-289.	0.6	9
1487	Immunotherapy of sarcomas. <i>Current Opinion in Oncology</i> , 2013, 25, 390-397.	1.1	4
1488	Esophageal carcinoma. <i>Current Opinion in Oncology</i> , 2013, 25, 417-424.	1.1	10
1489	Sensitive detection of melanoma metastasis using circulating microRNA expression profiles. <i>Melanoma Research</i> , 2013, 23, 366-372.	0.6	57
1490	CD40 Therapy and Surgery. <i>Journal of Immunotherapy</i> , 2013, 36, 359-361.	1.2	5
1491	PD-1 and CTLA-4-Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses. <i>Science Translational Medicine</i> , 2013, 5, 215ra172.	5.8	565
1492	The burden of metastatic melanoma. <i>Melanoma Research</i> , 2013, 23, 159-166.	0.6	17
1493	New developments in biomarkers for melanoma. <i>Current Opinion in Oncology</i> , 2013, 25, 145-151.	1.1	20
1494	Cancer vaccines. <i>Oncolmunology</i> , 2013, 2, e23403.	2.1	62
1495	Sweet's syndrome in a patient with metastatic melanoma after ipilimumab therapy. <i>Melanoma Research</i> , 2013, 23, 498-501.	0.6	75
1496	BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes. <i>Oncolmunology</i> , 2013, 2, e26615.	2.1	97
1497	Ipilimumab-Induced Hepatitis C Viral Suppression. <i>Journal of Clinical Oncology</i> , 2013, 31, e307-e308.	0.8	21
1498	Is Tremelimumab Beneficial in Advanced Melanoma?. <i>Journal of Clinical Oncology</i> , 2013, 31, 2835-2836.	0.8	10
1499	Final Results of Phase III SYMMETRY Study: Randomized, Double-Blind Trial of Elesclomol Plus Paclitaxel Versus Paclitaxel Alone As Treatment for Chemotherapy-Naive Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 1211-1218.	0.8	182
1500	Conjunctival Melanomas Harbor <i>BRAF</i> and <i>NRAS</i> Mutations and Copy Number Changes Similar to Cutaneous and Mucosal Melanomas. <i>Clinical Cancer Research</i> , 2013, 19, 3143-3152.	3.2	187
1501	Is there a future for adoptive cell transfer in melanoma patients?. <i>Oncolmunology</i> , 2013, 2, e26098.	2.1	7
1502	Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma: Intent-to-Treat Analysis and Efficacy after Failure to Prior Immunotherapies. <i>Clinical Cancer Research</i> , 2013, 19, 4792-4800.	3.2	330

#	ARTICLE	IF	CITATIONS
1503	Long-term survival and outcome of patients originally given <i>Mycobacterium vaccae</i> for metastatic malignant melanoma. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 2427-2433.	1.4	12
1504	Recent developments in the treatment of renal cell carcinoma. <i>Therapeutic Advances in Urology</i> , 2013, 5, 338-353.	0.9	64
1505	Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials. <i>Annals of Oncology</i> , 2013, 24, 2174-2180.	0.6	150
1506	An Abscopal Response to Radiation and Ipilimumab in a Patient with Metastatic Non-Small Cell Lung Cancer. <i>Cancer Immunology Research</i> , 2013, 1, 365-372.	1.6	599
1507	Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer. <i>Annals of Oncology</i> , 2013, 24, 1170-1179.	0.6	80
1508	Cancer Drugs in the United States: <i>Justum Pretium</i> "The Just Price. <i>Journal of Clinical Oncology</i> , 2013, 31, 3600-3604.	0.8	276
1509	Severe acute respiratory distress syndrome due to ipilimumab. <i>European Respiratory Journal</i> , 2013, 42, 866-868.	3.1	12
1510	Molecular Profiling of Immunotherapeutic Resistance. , 2013, , 373-394.		2
1511	What Lies Within: Novel Strategies in Immunotherapy for Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2013, 18, 1203-1213.	1.9	35
1512	Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma: a phase I/II study and pharmacokinetic analysis. <i>Annals of Oncology</i> , 2013, 24, 1112-1119.	0.6	62
1513	Reply to P.J. Leary et al. <i>Journal of Clinical Oncology</i> , 2013, 31, 2834-2835.	0.8	0
1514	Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy. <i>Journal of Experimental Medicine</i> , 2013, 210, 2435-2466.	4.2	251
1515	Tumor-Specific T-cell Help Is Associated with Improved Survival in Melanoma. <i>Clinical Cancer Research</i> , 2013, 19, 4021-4023.	3.2	13
1516	Efficacy and Safety of Retreatment with Ipilimumab in Patients with Pretreated Advanced Melanoma Who Progressed after Initially Achieving Disease Control. <i>Clinical Cancer Research</i> , 2013, 19, 2232-2239.	3.2	145
1517	Ipilimumab Treatment Results in an Early Decrease in the Frequency of Circulating Granulocytic Myeloid-Derived Suppressor Cells as well as Their Arginase1 Production. <i>Cancer Immunology Research</i> , 2013, 1, 158-162.	1.6	112
1518	Molecular Insights for Optimizing T Cell Receptor Specificity Against Cancer. <i>Frontiers in Immunology</i> , 2013, 4, 154.	2.2	35
1519	Melanoma: Treatments and Resistance. , 0, , .		0
1520	Enhancement of Tumor-Reactive Cytotoxic CD4+ T-cell Responses after Ipilimumab Treatment in Four Advanced Melanoma Patients. <i>Cancer Immunology Research</i> , 2013, 1, 235-244.	1.6	109

#	ARTICLE	IF	CITATIONS
1521	Melanoma: More Answers, More Questions. <i>Oncologist</i> , 2013, 18, 658-660.	1.9	0
1522	Ipilimumab-Induced Pneumonitis: A Case Report. <i>Journal of Pharmacy Technology</i> , 2013, 29, 94-98.	0.5	4
1523	ENDOCRINE SIDE-EFFECTS OF ANTI-CANCER DRUGS: mAbs and pituitary dysfunction: clinical evidence and pathogenic hypotheses. <i>European Journal of Endocrinology</i> , 2013, 169, R153-R164.	1.9	102
1524	Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm. <i>Therapeutic Advances in Medical Oncology</i> , 2013, 5, 105-118.	1.4	45
1525	“License to Kill” Reflects Joint Action of CD4 and CD8 T Cells. <i>Clinical Cancer Research</i> , 2013, 19, 4295-4296.	3.2	24
1526	Multifocal bilateral choroidal neovascularization in a patient on ipilimumab for metastatic melanoma. <i>Cutaneous and Ocular Toxicology</i> , 2013, 32, 341-343.	0.5	39
1527	Transnuclear TRP1-Specific CD8 T Cells with High or Low Affinity TCRs Show Equivalent Antitumor Activity. <i>Cancer Immunology Research</i> , 2013, 1, 99-111.	1.6	45
1528	Lysophosphatidic Acid Inhibits CD8 T-cell Activation and Control of Tumor Progression. <i>Cancer Immunology Research</i> , 2013, 1, 245-255.	1.6	71
1529	Controlled Local Delivery of CTLA-4 Blocking Antibody Induces CD8+ T-Cell-Dependent Tumor Eradication and Decreases Risk of Toxic Side Effects. <i>Clinical Cancer Research</i> , 2013, 19, 5381-5389.	3.2	172
1530	Blockade of TGF- β 2 Signaling Greatly Enhances the Efficacy of TCR Gene Therapy of Cancer. <i>Journal of Immunology</i> , 2013, 191, 3232-3239.	0.4	40
1531	Use of Oligonucleotide Aptamer Ligands to Modulate the Function of Immune Receptors. <i>Clinical Cancer Research</i> , 2013, 19, 1054-1062.	3.2	68
1532	Developing a Common Language for Tumor Response to Immunotherapy: Immune-Related Response Criteria Using Unidimensional Measurements. <i>Clinical Cancer Research</i> , 2013, 19, 3936-3943.	3.2	438
1533	Concurrent Radiotherapy and Ipilimumab Immunotherapy for Patients with Melanoma. <i>Cancer Immunology Research</i> , 2013, 1, 92-98.	1.6	133
1534	Novel cancer therapies: treatments driven by tumour biology. <i>Postgraduate Medical Journal</i> , 2013, 89, 652-658.	0.9	16
1536	Treatment Efficacy and Immune Stimulation by AdCD40L Gene Therapy of Spontaneous Canine Malignant Melanoma. <i>Journal of Immunotherapy</i> , 2013, 36, 350-358.	1.2	56
1537	Asymptomatic brain metastases in patients with cutaneous metastatic malignant melanoma. <i>Melanoma Research</i> , 2013, 23, 21-26.	0.6	11
1538	Hepatic resection for metastatic melanoma in The Netherlands. <i>Melanoma Research</i> , 2013, 23, 27-32.	0.6	11
1539	Comments and controversies. <i>Melanoma Research</i> , 2013, 23, 181-184.	0.6	3

#	ARTICLE	IF	CITATIONS
1540	Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery. <i>Melanoma Research</i> , 2013, 23, 191-195.	0.6	166
1541	Similar efficacy for phase I trials in comparison with DTIC for advanced malignant melanoma. <i>Melanoma Research</i> , 2013, 23, 152-158.	0.6	2
1542	Treatment of metastatic uveal melanoma with intravenous fotemustine. <i>Melanoma Research</i> , 2013, 23, 196-198.	0.6	30
1543	Isolated Malignant Melanoma Metastasis to the Pancreas. <i>Plastic and Reconstructive Surgery - Global Open</i> , 2013, 1, e74.	0.3	10
1544	Dendritic Cells, Inflammation, and Breast Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2013, 19, 511-516.	1.0	42
1545	Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. <i>Journal of Experimental Medicine</i> , 2013, 210, 1695-1710.	4.2	1,203
1546	Melanoma patients in a phase I clinic: molecular aberrations, targeted therapy and outcomes. <i>Annals of Oncology</i> , 2013, 24, 2158-2165.	0.6	14
1547	Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma. <i>Annals of Oncology</i> , 2013, 24, 2911-2915.	0.6	119
1548	Survivin promotion of melanoma metastasis requires upregulation of $\alpha 5$ integrin. <i>Carcinogenesis</i> , 2013, 34, 2137-2144.	1.3	36
1549	Dabrafenib for treatment of BRAF-mutant melanoma. <i>Pharmacogenomics and Personalized Medicine</i> , 2013, 7, 21.	0.4	14
1550	Immunosuppressive Microenvironment in Neuroblastoma. <i>Frontiers in Oncology</i> , 2013, 3, 167.	1.3	61
1551	TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor Milieu. <i>Frontiers in Immunology</i> , 2013, 4, 363.	2.2	70
1552	Statins Reduce Melanoma Development and Metastasis through MICA Overexpression. <i>Frontiers in Immunology</i> , 2013, 4, 62.	2.2	40
1553	Melanoma Biomolecules: Independently Identified but Functionally Intertwined. <i>Frontiers in Oncology</i> , 2013, 3, 252.	1.3	35
1554	Hedgehog Pathway Blockade Inhibits Melanoma Cell Growth in Vitro and in Vivo. <i>Pharmaceuticals</i> , 2013, 6, 1429-1450.	1.7	40
1555	Isolated pancreatic metastasis from malignant melanoma: Is pancreatectomy worthwhile?. <i>Journal of Surgical Technique and Case Report</i> , 2013, 5, 82.	0.2	7
1556	Safety and Efficacy of Cabazitaxel in the Docetaxel-Treated Patients with Hormone-Refractory Prostate Cancer. <i>Clinical Medicine Insights: Oncology</i> , 2013, 7, CMO.S7256.	0.6	18
1557	Evolving Pharmacotherapies for the Treatment of Metastatic Melanoma. <i>Clinical Medicine Insights: Oncology</i> , 2013, 7, CMO.S9565.	0.6	8

#	ARTICLE	IF	CITATIONS
1558	Immunotherapy in advanced cutaneous melanoma patients. <i>Przegląd Menopauzalny</i> , 2013, 5, 429-433.	0.6	0
1559	Role of T Cell Receptor Affinity in the Efficacy and Specificity of Adoptive T Cell Therapies. <i>Frontiers in Immunology</i> , 2013, 4, 244.	2.2	79
1560	Reply to K.S. Wilson et al. <i>Journal of Clinical Oncology</i> , 2013, 31, 2836-2837.	0.8	6
1561	Emerging treatments in management of prostate cancer: biomarker validation and endpoints for immunotherapy clinical trial design. <i>ImmunoTargets and Therapy</i> , 2013, 3, 1.	2.7	4
1562	Immunotherapy in the management of melanoma: current status. <i>ImmunoTargets and Therapy</i> , 2013, 2, 1.	2.7	3
1563	A Pilot Study of Anti-CTLA4 Antibody Ipilimumab in Patients with Synovial Sarcoma. <i>Sarcoma</i> , 2013, 2013, 1-8.	0.7	151
1564	Ipilimumab: A First-in-Class T-Cell Potentiator for Metastatic Melanoma. <i>Journal of Skin Cancer</i> , 2013, 2013, 1-8.	0.5	15
1565	Modulation of Tumor Immunity by Soluble and Membrane-Bound Molecules at the Immunological Synapse. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-19.	3.3	12
1566	Melanoma: From Melanocyte to Genetic Alterations and Clinical Options. <i>Scientifica</i> , 2013, 2013, 1-22.	0.6	80
1567	Latest Approved Therapies for Metastatic Melanoma: What Comes Next?. <i>Journal of Skin Cancer</i> , 2013, 2013, 1-10.	0.5	26
1568	Melanoma-Targeted Chemothermotherapy and <i>In Situ</i> Peptide Immunotherapy through HSP Production by Using Melanogenesis Substrate, NPrCAP, and Magnetite Nanoparticles. <i>Journal of Skin Cancer</i> , 2013, 2013, 1-12.	0.5	13
1569	Tumor Inhibition by DepoVax-Based Cancer Vaccine Is Accompanied by Reduced Regulatory/Suppressor Cell Proliferation and Tumor Infiltration. <i>ISRN Oncology</i> , 2013, 2013, 1-13.	2.1	14
1570	Safety and Efficacy of 188-Rhenium-Labeled Antibody to Melanin in Patients with Metastatic Melanoma. <i>Journal of Skin Cancer</i> , 2013, 2013, 1-8.	0.5	37
1571	Immune-Mediated Adverse Events Associated with Ipilimumab CTLA-4 Blockade Therapy: The Underlying Mechanisms and Clinical Management. <i>Scientifica</i> , 2013, 2013, 1-19.	0.6	186
1572	Gene Therapy for Advanced Melanoma: Selective Targeting and Therapeutic Nucleic Acids. <i>Journal of Drug Delivery</i> , 2013, 2013, 1-15.	2.5	18
1573	Exposure-Response Relationships of the Efficacy and Safety of Ipilimumab in Patients with Advanced Melanoma. <i>Clinical Cancer Research</i> , 2013, 19, 3977-3986.	3.2	153
1574	Conditional Deletion of PTEN in Peripheral T Cells Augments TCR-Mediated Activation but Does Not Abrogate CD28 Dependency or Prevent Energy Induction. <i>Journal of Immunology</i> , 2013, 191, 1677-1685.	0.4	12
1575	Impaired Function of CTLA-4 in the Lungs of Patients with Chronic Beryllium Disease Contributes to Persistent Inflammation. <i>Journal of Immunology</i> , 2013, 191, 1648-1656.	0.4	13

#	ARTICLE	IF	CITATIONS
1576	Betting on improved cancer immunotherapy by doubling down on CD134 and CD137 co-stimulation. <i>Onc Immunology</i> , 2013, 2, e22837.	2.1	24
1577	Identification of new prognostic biomarkers for Stage III metastatic melanoma patients. <i>Onc Immunology</i> , 2013, 2, e25564.	2.1	6
1578	Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20). <i>Annals of Oncology</i> , 2013, 24, 2694-2698.	0.6	169
1579	Systemic treatment of metastatic uveal melanoma: review of literature and future perspectives. <i>Cancer Medicine</i> , 2013, 2, 674-686.	1.3	95
1580	Treatment of BRAF-Mutant Melanoma: The Role of Vemurafenib and Other Therapies. <i>Clinical Pharmacology and Therapeutics</i> , 2013, 95, 24-31.	2.3	75
1581	Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab. <i>Cancer</i> , 2013, 119, 1675-1682.	2.0	394
1582	A Novel Treatment Approach for Extensive, Eruptive, Cutaneous Squamous Cell Carcinomas in a Patient Receiving BRAF Inhibitor Therapy for Metastatic Melanoma. <i>Dermatologic Surgery</i> , 2013, 39, 341-344.	0.4	10
1583	Immunosuppression in inflammatory melanoma: can it be resisted by adoptively transferred T cells?. <i>Pigment Cell and Melanoma Research</i> , 2013, 26, 167-175.	1.5	9
1584	Multifocal radiculoneuropathy during ipilimumab treatment of melanoma. <i>Muscle and Nerve</i> , 2013, 48, 440-444.	1.0	65
1585	Pruritus to anticancer agents targeting the EGFR, BRAF, and CTLA-4. <i>Dermatologic Therapy</i> , 2013, 26, 135-148.	0.8	43
1586	Ongoing adaptive immune responses in the microenvironment of melanoma metastases. <i>Annals of the New York Academy of Sciences</i> , 2013, 1284, 62-65.	1.8	3
1587	Recent advances in cutaneous melanoma: towards a molecular model and targeted treatment. <i>Australasian Journal of Dermatology</i> , 2013, 54, 163-172.	0.4	13
1588	Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive Melanoma. <i>Journal of Clinical Oncology</i> , 2013, 31, e439-e442.	0.8	746
1589	Pharmacokinetics, Clinical Indications, and Resistance Mechanisms in Molecular Targeted Therapies in Cancer. <i>Pharmacological Reviews</i> , 2013, 65, 1351-1395.	7.1	33
1590	Recent advances and developments in the antitumor effect of the HVJ envelope vector on malignant melanoma: from the bench to clinical application. <i>Cancer Gene Therapy</i> , 2013, 20, 599-605.	2.2	18
1591	Ultra-deep T cell receptor sequencing reveals the complexity and intratumour heterogeneity of T cell clones in renal cell carcinomas. <i>Journal of Pathology</i> , 2013, 231, 424-432.	2.1	93
1592	A costly revolution for a subgroup of patients with metastatic melanoma. <i>British Journal of Dermatology</i> , 2013, 168, 467-470.	1.4	3
1593	Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. <i>Annals of Oncology</i> , 2013, 24, 1813-1821.	0.6	481

#	ARTICLE	IF	CITATIONS
1594	Surgical Management of the Patient with Metastatic Melanoma to the Heart. <i>Journal of Cardiac Surgery</i> , 2013, 28, 124-128.	0.3	7
1595	Ipilimumab induces simultaneous regression of melanocytic naevi and melanoma metastases. <i>Clinical and Experimental Dermatology</i> , 2013, 38, 276-279.	0.6	19
1596	Is there a role for immune checkpoint blockade with ipilimumab in prostate cancer?. <i>Cancer Medicine</i> , 2013, 2, 243-252.	1.3	13
1597	Ipilimumab and radiation therapy for melanoma brain metastases. <i>Cancer Medicine</i> , 2013, 2, 899-906.	1.3	256
1598	Clinical activity of ipilimumab for metastatic uveal melanoma. <i>Cancer</i> , 2013, 119, 3687-3695.	2.0	171
1599	Increased PD-1 expression on CD4+ and CD8+ T cells is involved in immune evasion in gastric cancer. <i>Journal of Surgical Oncology</i> , 2013, 107, 517-522.	0.8	75
1600	PD-1 as a potential target in cancer therapy. <i>Cancer Medicine</i> , 2013, 2, 662-673.	1.3	369
1601	A pharmacologic perspective on newly emerging T cell manipulation technologies. <i>British Journal of Clinical Pharmacology</i> , 2013, 76, 173-187.	1.1	5
1602	Antitumor T cell responses in bladder cancer are directed against a limited set of antigens and are modulated by regulatory T cells and routine treatment approaches. <i>International Journal of Cancer</i> , 2013, 133, 2145-2156.	2.3	28
1603	IgG4 antibodies and cancer-associated inflammation. <i>Oncolmmunology</i> , 2013, 2, e24889.	2.1	28
1604	Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy. <i>Oncolmmunology</i> , 2013, 2, e25961.	2.1	162
1605	High frequency of T cells specific for cryptic epitopes in melanoma patients. <i>Oncolmmunology</i> , 2013, 2, e25374.	2.1	21
1606	The CD226/CD155 Interaction Regulates the Proinflammatory (Th1/Th17)/Anti-Inflammatory (Th2) Balance in Humans. <i>Journal of Immunology</i> , 2013, 191, 3673-3680.	0.4	89
1607	Agonist Anti-Human CD27 Monoclonal Antibody Induces T Cell Activation and Tumor Immunity in Human CD27 Transgenic Mice. <i>Journal of Immunology</i> , 2013, 191, 4174-4183.	0.4	90
1608	Exploiting the stress response to radiation to sensitize poorly immunogenic tumors to anti-CTLA-4 treatment. <i>Oncolmmunology</i> , 2013, 2, e23127.	2.1	34
1609	High immunosuppressive burden in advanced hepatocellular carcinoma patients. <i>Oncolmmunology</i> , 2013, 2, e24679.	2.1	14
1610	Epigenetic regulation of <i>REG1A</i> and chemosensitivity of cutaneous melanoma. <i>Epigenetics</i> , 2013, 8, 1043-1052.	1.3	14
1611	High-affinity peptide-based anticancer vaccination to overcome resistance to immunostimulatory antibodies. <i>Oncolmmunology</i> , 2013, 2, e26704.	2.1	3

#	ARTICLE	IF	CITATIONS
1612	Vesicular Stomatitis Virus Variants Selectively Infect and Kill Human Melanomas but Not Normal Melanocytes. <i>Journal of Virology</i> , 2013, 87, 6644-6659.	1.5	25
1613	Dacarbazine mediates antimelanoma effects via NK cells. <i>Oncolmmunology</i> , 2013, 2, e23714.	2.1	15
1614	A Phase II, Randomized, Double-blind, Placebo-controlled Multicenter Trial of Endostar in Patients With Metastatic Melanoma. <i>Molecular Therapy</i> , 2013, 21, 1456-1463.	3.7	88
1615	Association of CTLA-4 Polymorphisms with Improved Overall Survival in Melanoma Patients Treated with CTLA-4 Blockade: A Pilot Study. <i>Cancer Investigation</i> , 2013, 31, 336-345.	0.6	55
1616	Adaptive immune resistance in HPV-associated head and neck squamous cell carcinoma. <i>Oncolmmunology</i> , 2013, 2, e24065.	2.1	15
1617	Vemurafenib enhances MHC induction in <i>BRAF</i> ^{V600E} homozygous melanoma cells. <i>Oncolmmunology</i> , 2013, 2, e22890.	2.1	127
1618	Therapeutic vaccines. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 219-221.	1.4	42
1619	Treatment patterns and outcomes in patients with advanced melanoma in France. <i>Current Medical Research and Opinion</i> , 2013, 29, 1297-1305.	0.9	10
1620	Tremelimumab: a review of development to date in solid tumors. <i>Immunotherapy</i> , 2013, 5, 215-229.	1.0	55
1621	Approaches to improve tumor accumulation and interactions between monoclonal antibodies and immune cells. <i>MABs</i> , 2013, 5, 34-46.	2.6	46
1622	T-cell modulatory properties of CD5 and its role in antitumor immune responses. <i>Oncolmmunology</i> , 2013, 2, e22841.	2.1	37
1623	Cancer vaccines: 21st century approaches to harnessing an ancient modality to fight cancer. <i>Expert Review of Vaccines</i> , 2013, 12, 1115-1118.	2.0	7
1624	Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma. <i>Oncolmmunology</i> , 2013, 2, e24320.	2.1	40
1625	The immunomodulatory effects of bevacizumab on systemic immunity in patients with metastatic melanoma. <i>Oncolmmunology</i> , 2013, 2, e24436.	2.1	37
1626	Prostate cancer vaccines. <i>Oncolmmunology</i> , 2013, 2, e24523.	2.1	34
1627	Unique pulmonary antigen presentation may call for an alternative approach toward lung cancer immunotherapy. <i>Oncolmmunology</i> , 2013, 2, e23563.	2.1	5
1629	Ipilimumab in 2nd line treatment of patients with advanced melanoma: a cost-effectiveness analysis. <i>Journal of Medical Economics</i> , 2013, 16, 202-212.	1.0	44
1630	The delicate balance of melanoma immunotherapy. <i>Clinical and Translational Immunology</i> , 2013, 2, e5.	1.7	22

#	ARTICLE	IF	CITATIONS
1631	Genomic Medicine Frontier in Human Solid Tumors: Prospects and Challenges. <i>Journal of Clinical Oncology</i> , 2013, 31, 1874-1884.	0.8	101
1632	Induction of high-titer IgG antibodies against multiple leukemia-associated antigens in CML patients with clinical responses to K562/GVAX immunotherapy. <i>Blood Cancer Journal</i> , 2013, 3, e145-e145.	2.8	21
1633	Q-TWiST analysis comparing ipilimumab/dacarbazine vs placebo/dacarbazine for patients with stage III/IV melanoma. <i>British Journal of Cancer</i> , 2013, 109, 8-13.	2.9	24
1634	Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer. <i>British Journal of Cancer</i> , 2013, 108, 1560-1565.	2.9	139
1635	Optimal conditions required for influenza A infection-enhanced cross-priming of CD8 + T cells specific to cell-associated antigens. <i>Immunology and Cell Biology</i> , 2013, 91, 576-582.	1.0	2
1636	Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells. <i>Clinical Cancer Research</i> , 2013, 19, 5636-5646.	3.2	598
1637	Immune alterations in malignant melanoma and current immunotherapy concepts. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 1413-1427.	1.4	19
1638	Adoptive T-cell transfer in melanoma. <i>Immunotherapy</i> , 2013, 5, 79-90.	1.0	21
1639	Fc γ receptors enable anticancer action of proapoptotic and immune-modulatory antibodies. <i>Journal of Experimental Medicine</i> , 2013, 210, 1647-1651.	4.2	34
1640	Targeting CD73 Enhances the Antitumor Activity of Anti-PD-1 and Anti-CTLA-4 mAbs. <i>Clinical Cancer Research</i> , 2013, 19, 5626-5635.	3.2	381
1641	Ipilimumab for Patients With Advanced Mucosal Melanoma. <i>Oncologist</i> , 2013, 18, 726-732.	1.9	140
1642	Phase III Trial of Carboplatin and Paclitaxel With or Without Sorafenib in Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 373-379.	0.8	199
1643	HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 9879-9884.	3.3	160
1644	Vaccine therapy for pancreatic cancer. <i>Oncolimmunology</i> , 2013, 2, e26662.	2.1	50
1645	Biomarkers for Immunostimulatory Monoclonal Antibodies in Combination Strategies for Melanoma and Other Tumor Types. <i>Clinical Cancer Research</i> , 2013, 19, 1009-1020.	3.2	134
1646	Molecular profiling of tumor-specific T _H 1 cells activated in vivo. <i>Oncolimmunology</i> , 2013, 2, e24383.	2.1	13
1647	Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells. <i>Cancer Immunology Research</i> , 2013, 1, 32-42.	1.6	726
1648	Targeting castration-resistant prostate cancer with monoclonal antibodies and constructs. <i>Immunotherapy</i> , 2013, 5, 1347-1355.	1.0	4

#	ARTICLE	IF	CITATIONS
1649	Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. <i>Journal of Experimental Medicine</i> , 2013, 210, 1389-1402.	4.2	562
1650	The immunological identity of tumor. <i>Oncolmmunology</i> , 2013, 2, e23794.	2.1	4
1651	Melanoma treatment: where are we now and whatâ€™s on the horizon?. <i>Clinical Practice (London,)</i> Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	0.1	0
1652	Melanoma-Associated Retinopathy Treated with Ipilimumab Therapy. <i>Dermatology</i> , 2013, 227, 146-149.	0.9	34
1653	PD-L1 gene expression in Japanese lung cancer patients. <i>Biomedical Reports</i> , 2013, 1, 93-96.	0.9	12
1654	Malignes Melanom S3-Leitlinie â€œDiagnostik, Therapie und Nachsorge des Melanomsâ€•JDDG - Journal of the German Society of Dermatology, 2013, 11, 1-126.	0.4	9
1655	Malignant Melanoma S3-Guideline â€œDiagnosis, Therapy and Follow-up of Melanomaâ€•JDDG - Journal of the German Society of Dermatology, 2013, 11, 1-116.	0.4	122
1656	Novel immunotherapeutic agents for castration-resistant prostate cancer: update from clinical trials. <i>Clinical Investigation</i> , 2013, 3, 651-663.	0.0	0
1657	The role of B7 family molecules in hematologic malignancy. <i>Blood</i> , 2013, 121, 734-744.	0.6	159
1658	A shot in the arm for radiotherapy. <i>Blood</i> , 2013, 121, 246-248.	0.6	0
1659	Immunologic responses to xenogeneic tyrosinase DNA vaccine administered by electroporation in patients with malignant melanoma. , 2013, 1, 20.		31
1660	Clinical impact of tumor-infiltrating CD45RO+ memory T cells on human gastric cancer. <i>Oncology Reports</i> , 2013, 29, 1756-1762.	1.2	44
1661	Advances in the treatment of late stage melanoma. <i>BMJ, The</i> , 2013, 346, f1265-f1265.	3.0	6
1663	Immunotherapy for Gastrointestinal Malignancies. <i>Cancer Control</i> , 2013, 20, 32-42.	0.7	36
1664	Sequencing Systemic Therapies in Metastatic Castration-Resistant Prostate Cancer. <i>Cancer Control</i> , 2013, 20, 181-187.	0.7	10
1665	Melanoma Mutagenesis and Aberrant Cell Signaling. <i>Cancer Control</i> , 2013, 20, 261-281.	0.7	29
1666	New Targeted Therapies in Melanoma. <i>Cancer Control</i> , 2013, 20, 282-288.	0.7	11
1667	Novel Treatments for Melanoma Brain Metastases. <i>Cancer Control</i> , 2013, 20, 298-306.	0.7	14

#	ARTICLE	IF	CITATIONS
1668	Building on Sipuleucel-T for Immunologic Treatment of Castration-Resistant Prostate Cancer. <i>Cancer Control</i> , 2013, 20, 7-16.	0.7	18
1669	Cancer immunotherapy. <i>Journal of Japan Society of Immunology & Allergology in Otolaryngology</i> , 2013, 31, 237-246.	0.0	0
1670	Immunotherapy Strategies in the Treatment of Breast Cancer. <i>Cancer Control</i> , 2013, 20, 17-21.	0.7	30
1671	Next-Generation Cancer Vaccine Approaches: Integrating Lessons Learned From Current Successes With Promising Biotechnologic Advances. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 766-772.	2.3	10
1672	Malignant melanoma rather than malignant cutaneous melanoma?. <i>European Journal of Gastroenterology and Hepatology</i> , 2013, 25, 503-506.	0.8	3
1673	Diagnostic and Therapeutic Approaches in Italian Hospitals: Adjuvant and Metastatic Therapy in Melanoma. <i>Dermatology</i> , 2013, 226, 22-27.	0.9	4
1674	Adoptive Cell Transfer for Patients with Metastatic Melanoma: The Potential and Promise of Cancer Immunotherapy. <i>Cancer Control</i> , 2013, 20, 289-297.	0.7	95
1675	Identifying <i>BRAF</i> and <i>KIT</i> mutations in melanoma. <i>Expert Review of Dermatology</i> , 2013, 8, 171-176.	0.3	1
1678	Rationale for Chemotherapy, Immunotherapy, and Checkpoint Blockade in SCLC: Beyond Traditional Treatment Approaches. <i>Journal of Thoracic Oncology</i> , 2013, 8, 587-598.	0.5	67
1679	Mutation analysis in malignant melanoma. <i>JDDG - Journal of the German Society of Dermatology</i> , 2013, 11, 2-10.	0.4	2
1680	What does the future hold for uveal melanoma, a historically untreatable disease?. <i>Clinical Investigation</i> , 2013, 3, 1097-1099.	0.0	0
1681	Current Advances in Therapy for Metastatic Melanoma. <i>Current Cancer Therapy Reviews</i> , 2013, 9, 8-23.	0.2	0
1682	Intratumoral Anti-CTLA-4 Therapy: Enhancing Efficacy While Avoiding Toxicity. <i>Clinical Cancer Research</i> , 2013, 19, 5261-5263.	3.2	48
1684	Ipilimumab in cancer patients. <i>Anti-Cancer Drugs</i> , 2013, 24, 324-326.	0.7	5
1685	S3 "Guideline "Diagnosis, therapy and follow-up of melanoma" short version. <i>JDDG - Journal of the German Society of Dermatology</i> , 2013, 11, 563-602.	0.4	63
1686	Mutationsanalysen im malignen Melanom. <i>JDDG - Journal of the German Society of Dermatology</i> , 2013, 11, 2-11.	0.4	11
1687	Effective Activity of Cytokine-Induced Killer Cells against Autologous Metastatic Melanoma Including Cells with Stemness Features. <i>Clinical Cancer Research</i> , 2013, 19, 4347-4358.	3.2	81
1688	Efficacy of chemotherapy in limited-disease small-cell lung cancer. <i>Lung Cancer Management</i> , 2013, 2, 483-492.	1.5	0

#	ARTICLE	IF	CITATIONS
1689	Managing Malignant Melanoma. <i>Plastic and Reconstructive Surgery</i> , 2013, 132, 446e-460e.	0.7	53
1690	Anal Versus Rectal Melanoma. <i>Diseases of the Colon and Rectum</i> , 2013, 56, 150-157.	0.7	57
1691	MERTK receptor tyrosine kinase is a therapeutic target in melanoma. <i>Journal of Clinical Investigation</i> , 2013, 123, 2257-2267.	3.9	124
1692	Evolutionary dynamics of cancer in response to targeted combination therapy. <i>ELife</i> , 2013, 2, e00747.	2.8	516
1693	Serum S100B Levels Correlate with Clinical Benefit in a Metastatic Melanoma Patient Treated by CTLA-4 Blockade: A Case Report. <i>Onkologie</i> , 2013, 36, 578-581.	1.1	5
1694	Clinical experience with ipilimumab 10Âmg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme. <i>Journal of Experimental and Clinical Cancer Research</i> , 2013, 32, 82.	3.5	23
1695	Sequential use of protein kinase inhibitors potentiates their toxicity to melanoma cells: A rationale to combine targeted drugs based on protein expression inhibition profiles. <i>International Journal of Oncology</i> , 2013, 43, 919-926.	1.4	6
1696	Melanoma, Version 2.2013. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 395-407.	2.3	134
1698	Dendritic Cell-Based Immunotherapy for Glioma: Multiple Regimens and Implications in Clinical Trials. <i>Neurologia Medico-Chirurgica</i> , 2013, 53, 741-754.	1.0	19
1699	Clinical significance of B7-H4 expression in matched non-small cell lung cancer brain metastases and primary tumors. <i>OncoTargets and Therapy</i> , 2013, 6, 869.	1.0	32
1700	Real-world impact of education: treating patients with ipilimumab in a community practice setting. <i>Cancer Management and Research</i> , 2013, 6, 5.	0.9	18
1701	Anti-cytotoxic T lymphocyte antigen-4 antibodies in melanoma. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2013, 6, 245.	0.8	14
1702	Targeting immunosuppression for cancer therapy. <i>Journal of Clinical Investigation</i> , 2013, 123, 2355-2357.	3.9	53
1703	TAPCells, the Chilean dendritic cell vaccine against melanoma and prostate cancer. <i>Biological Research</i> , 2013, 46, 431-440.	1.5	13
1704	<i>Ex Vivo</i> Derived Primary Melanoma Cells: Implications for Immunotherapeutic Vaccines. <i>Journal of Cancer</i> , 2013, 4, 371-382.	1.2	10
1705	Update on the challenges and recent advances in cancer immunotherapy. <i>ImmunoTargets and Therapy</i> , 2013, 2, 39.	2.7	8
1706	What Are the Molecules Involved in Regulatory T-Cells Induction by Dendritic Cells in Cancer?. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-10.	3.3	22
1707	Use of ipilimumab in the treatment of melanoma. <i>Clinical Pharmacology: Advances and Applications</i> , 2013, 5, 21.	0.8	15

#	ARTICLE	IF	CITATIONS
1708	Follow-up analysis of a randomized phase III immunotherapeutic clinical trial on melanoma. <i>Molecular and Clinical Oncology</i> , 2013, 1, 466-472.	0.4	13
1709	Engineering Anti-Tumor T Cell Immunity. <i>Advancements in Genetic Engineering</i> , 2013, 02, .	0.1	0
1710	Molecular targeted therapies in metastatic melanoma. <i>Pharmacogenomics and Personalized Medicine</i> , 2013, 6, 49.	0.4	24
1711	Oncolytic herpes viruses, chemotherapeutics, and other cancer drugs. <i>Oncolytic Virotherapy</i> , 2013, 2, 57.	6.0	6
1712	Mixed Response to Ipilimumab in a Melanoma Patient with Brain Metastases: Case Report and Review of the Literature. <i>Case Reports in Oncology</i> , 2013, 6, 229-235.	0.3	5
1713	Recombinant DNA Technology in Emerging Modalities for Melanoma Immunotherapy. , 2013, , .		0
1714	Improving the Effect of FDA-Mandated Drug Safety Alerts with Internet- Based Continuing Medical Education. <i>Current Drug Safety</i> , 2013, 8, 11-16.	0.3	10
1715	Melanoma "Epidemiology, Genetics and Risk Factors. , 2013, , .		2
1716	T cell immunoglobulin domain and mucin domain-3 as an emerging target for immunotherapy in cancer management. <i>ImmunoTargets and Therapy</i> , 2013, 2, 135.	2.7	5
1717	Inhibitory Effect of Melanoma Differentiation Associated Gene-7/Interleukin-24 on Invasion In Vitro of Human Melanoma Cancer Cells. <i>Journal of Korean Medical Science</i> , 2013, 28, 833.	1.1	9
1718	The role of natural killer cells in pulmonary immunosurveillance. <i>Frontiers in Bioscience - Scholar</i> , 2013, S5, 575-587.	0.8	21
1719	Treatment with Ipilimumab: A Case Report of Complete Response in a Metastatic Malignant Melanoma Patient. <i>Case Reports in Oncology</i> , 2013, 6, 285-288.	0.3	4
1720	Identification and Validation of Targets for Cancer Immunotherapy: From the Bench-to-Bedside. , 0, , .		0
1721	Ipilimumab in the Treatment of Metastatic Melanoma: A Summary of Recent Studies. <i>Tumori</i> , 2013, 99, e302-e305.	0.6	6
1723	Identification of Special AT-Rich Sequence Binding Protein 1 as a Novel Tumor Antigen Recognized by CD8+ T Cells: Implication for Cancer Immunotherapy. <i>PLoS ONE</i> , 2013, 8, e56730.	1.1	8
1724	Myeloablative Temozolomide Enhances CD8+ T-Cell Responses to Vaccine and Is Required for Efficacy against Brain Tumors in Mice. <i>PLoS ONE</i> , 2013, 8, e59082.	1.1	56
1725	Synergistic Effect of CTLA-4 Blockade and Cancer Chemotherapy in the Induction of Anti-Tumor Immunity. <i>PLoS ONE</i> , 2013, 8, e61895.	1.1	129
1726	Adoptive Cellular Immunotherapy in Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2013, 8, e62847.	1.1	21

#	ARTICLE	IF	CITATIONS
1727	An Enhanced Heterologous Virus-Like Particle for Human Papillomavirus Type 16 Tumour Immunotherapy. PLoS ONE, 2013, 8, e66866.	1.1	32
1728	Natural Killer T Cells in Advanced Melanoma Patients Treated with Tremelimumab. PLoS ONE, 2013, 8, e76829.	1.1	15
1729	Serum S100B, Lactate Dehydrogenase and Brain Metastasis Are Prognostic Factors in Patients with Distant Melanoma Metastasis and Systemic Therapy. PLoS ONE, 2013, 8, e81624.	1.1	54
1730	Efficacy and safety of ipilimumab therapy in patients with metastatic melanoma: a retrospective multicenter analysis. Wspolczesna Onkologia, 2013, 3, 257-262.	0.7	11
1731	Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Perspectives. , 2013, , .		2
1732	Advanced Urothelial Carcinoma: Overcoming Treatment Resistance through Novel Treatment Approaches. Frontiers in Pharmacology, 2013, 4, 3.	1.6	20
1733	Systemic cancer therapy: achievements and challenges that lie ahead. Frontiers in Pharmacology, 2013, 4, 57.	1.6	165
1734	Clinical Implications of Co-Inhibitory Molecule Expression in the Tumor Microenvironment for DC Vaccination: A Game of Stop and Go. Frontiers in Immunology, 2013, 4, 417.	2.2	62
1735	Dendritic Cell-Targeted Approaches to Modulate Immune Dysfunction in the Tumor Microenvironment. Frontiers in Immunology, 2013, 4, 436.	2.2	21
1736	Advances in Personalized Targeted Treatment of Metastatic Melanoma and Non-Invasive Tumor Monitoring. Frontiers in Oncology, 2013, 3, 54.	1.3	27
1737	Radioimmunotherapy Combined with Maintenance Anti-CD20 Antibody May Trigger Long-Term Protective T Cell Immunity in Follicular Lymphoma Patients. Clinical and Developmental Immunology, 2013, 2013, 1-8.	3.3	9
1738	Tumor-Associated Macrophages in Glioma: Friend or Foe?. Journal of Oncology, 2013, 2013, 1-11.	0.6	135
1739	New Insights into the Role of the Immune Microenvironment in Breast Carcinoma. Clinical and Developmental Immunology, 2013, 2013, 1-11.	3.3	50
1740	Current Trends in Glioblastoma Multiforme Treatment: Radiation Therapy and Immune Checkpoint Inhibitors. Brain Tumor Research and Treatment, 2013, 1, 2.	0.4	15
1742	Cancer testis antigen and immunotherapy. ImmunoTargets and Therapy, 2013, 2, 11.	2.7	43
1743	Targeted Agents for the Treatment of Melanoma: An Overview. , 0, , .		0
1744	Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. Journal of Clinical Investigation, 2013, 123, 2447-2463.	3.9	323
1745	BRAF mutations in human cancer: biologic and therapeutic implications. , 0, , 272-277.		0

#	ARTICLE	IF	CITATIONS
1746	Oncology drug discovery for biologics: antibody development strategies and considerations. , 0, , 836-842.		0
1747	Controversies in the Evaluation and Management of Atypical Melanocytic Proliferations in Children, Adolescents, and Young Adults. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 679-686.	2.3	28
1748	Management of Brain Metastasis in Melanoma Patients. , 0, , .		0
1749	Combination Therapies to Improve Delivery of Protective T Cells into the Melanoma Microenvironment. , 0, , .		0
1750	Current Therapies and New Pharmacologic Targets for Metastatic Melanoma. , 2013, , .		1
1751	Melanoma vaccines: trials and tribulations. <i>Vaccine (Auckland, N Z)</i> , 0, , 57.	1.7	12
1752	Targeted Therapies in Melanoma: Successes and Pitfalls. , 0, , .		1
1753	Treating Metastatic Melanoma in 2014: What Just Happened and What Is Next?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014, , 16-19.	1.8	1
1754	Frontline Approach to Metastatic <i>BRAF</i> -Mutant Melanoma Diagnosis, Molecular Evaluation, and Treatment Choice. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014, , e412-e421.	1.8	4
1755	Applications of coxsackievirus A21 in oncology. <i>Oncolytic Virotherapy</i> , 2014, 3, 47.	6.0	84
1756	New modalities of cancer treatment for NSCLC: focus on immunotherapy. <i>Cancer Management and Research</i> , 2014, 6, 63.	0.9	68
1757	Update on benefit of immunotherapy and targeted therapy in melanoma: the changing landscape. <i>Cancer Management and Research</i> , 2014, 6, 279.	0.9	23
1758	Benign Melanocytic Lesions and Melanoma. , 2014, , 1182-1192.		0
1759	Interferon- γ and celecoxib inhibit lung-tumor growth through modulating M2/M1 macrophage ratio in the tumor microenvironment. <i>Drug Design, Development and Therapy</i> , 2014, 8, 1527.	2.0	32
1760	Identifying differential expression genes and single nucleotide variations using RNA-seq in metastatic melanoma. <i>Genetics and Molecular Research</i> , 2014, 13, 8153-8162.	0.3	4
1761	Cross-sectional and longitudinal analysis of cancer vaccination trials registered on the US Clinical Trials Database demonstrates paucity of immunological trial endpoints and decline in registration since 2008. <i>Drug Design, Development and Therapy</i> , 2014, 8, 1539.	2.0	12
1762	Therapeutic cancer vaccines and combination immunotherapies involving vaccination. <i>ImmunoTargets and Therapy</i> , 2014, 3, 135.	2.7	9
1763	Focal Radiation Therapy Combined with 4-1BB Activation and CTLA-4 Blockade Yields Long-Term Survival and a Protective Antigen-Specific Memory Response in a Murine Glioma Model. <i>PLoS ONE</i> , 2014, 9, e101764.	1.1	206

#	ARTICLE	IF	CITATIONS
1764	Risk of Melanoma in People with HIV/AIDS in the Pre- and Post-HAART Eras: A Systematic Review and Meta-Analysis of Cohort Studies. PLoS ONE, 2014, 9, e95096.	1.1	55
1765	C/EBP β Is Dispensable for the Ontogeny of PD-1+ CD4+ Memory T Cells but Restricts Their Expansion in an Age-Dependent Manner. PLoS ONE, 2014, 9, e84728.	1.1	15
1766	A Natural Bacterial-Derived Product, the Metalloprotease Arazyme, Inhibits Metastatic Murine Melanoma by Inducing MMP-8 Cross-Reactive Antibodies. PLoS ONE, 2014, 9, e96141.	1.1	17
1767	Cost-Effectiveness of Treatment Strategies for BRAF-Mutated Metastatic Melanoma. PLoS ONE, 2014, 9, e107255.	1.1	35
1768	Clonal Architectures and Driver Mutations in Metastatic Melanomas. PLoS ONE, 2014, 9, e111153.	1.1	69
1769	Therapy Preferences in Melanoma Treatment - Willingness to Pay and Preference of Quality versus Length of Life of Patients, Physicians and Healthy Controls. PLoS ONE, 2014, 9, e111237.	1.1	28
1770	The Dual RAF/MEK Inhibitor CH5126766/RO5126766 May Be a Potential Therapy for RAS-Mutated Tumor Cells. PLoS ONE, 2014, 9, e113217.	1.1	38
1771	Ask ACCC's Community Resource Centers: Pancreatic Cancer. Oncology Issues, 2014, 29, 60-62.	0.0	0
1773	Tumour Immunogenicity, Antigen Presentation, and Immunological Barriers in Cancer Immunotherapy. New Journal of Science, 2014, 2014, 1-25.	1.0	75
1774	Ipilimumab in pretreated patients with unresectable or metastatic cutaneous, uveal and mucosal melanoma. Medical Journal of Australia, 2014, 201, 49-53.	0.8	52
1775	Current and Future Roles of Targeted Therapy and Immunotherapy in Advanced Melanoma. Journal of Managed Care Pharmacy, 2014, 20, 346-356.	2.2	57
1776	Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway. Pharmacogenomics and Personalized Medicine, 2014, 7, 357.	0.4	60
1778	New developments in the treatment of metastatic melanoma – role of dabrafenib–trametinib combination therapy. Drug, Healthcare and Patient Safety, 2014, 6, 77.	1.0	32
1779	Pathways and therapeutic targets in melanoma. Oncotarget, 2014, 5, 1701-1752.	0.8	202
1780	Attenuated Listeria monocytogenes: a powerful and versatile vector for the future of tumor immunotherapy. Frontiers in Cellular and Infection Microbiology, 2014, 4, 51.	1.8	112
1781	Role of HGFαMET Signaling in Primary and Acquired Resistance to Targeted Therapies in Cancer. Biomedicines, 2014, 2, 345-358.	1.4	30
1782	Malignant Melanoma. Healthcare (Switzerland), 2014, 2, 1-19.	1.0	39
1783	Paradigm Shift in Dendritic Cell-Based Immunotherapy: From in vitro Generated Monocyte-Derived DCs to Naturally Circulating DC Subsets. Frontiers in Immunology, 2014, 5, 165.	2.2	127

#	ARTICLE	IF	CITATIONS
1784	Cost-Effectiveness Evaluation of Oncological Drugs Newly Marketed in Italy. <i>Global & Regional Health Technology Assessment</i> , 2014, 1, GRHTA.5000182.	0.2	9
1785	A Phase I Study of High-Dose Calcitriol in Combination with Temozolomide for Patients with Metastatic Melanoma. <i>Journal of Personalized Medicine</i> , 2014, 4, 448-458.	1.1	5
1786	Therapeutic Vaccine Strategies against Human Papillomavirus. <i>Vaccines</i> , 2014, 2, 422-462.	2.1	55
1787	PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence. <i>OncoTargets and Therapy</i> , 2014, 7, 1349.	1.0	37
1788	Immunotherapy for Bladder Cancer: Changing the Landscape. <i>Cancer and Clinical Oncology</i> , 2014, 3, .	0.2	1
1789	Colorectal cancer and immunity: What we know and perspectives. <i>World Journal of Gastroenterology</i> , 2014, 20, 3738.	1.4	105
1790	An updated overview of HPV-associated head and neck carcinomas. <i>Oncotarget</i> , 2014, 5, 3956-3969.	0.8	107
1791	Optimum chemotherapy in the management of metastatic pancreatic cancer. <i>World Journal of Gastroenterology</i> , 2014, 20, 2352.	1.4	19
1792	Ipilimumab in the treatment of metastatic melanoma: management of adverse events. <i>OncoTargets and Therapy</i> , 2014, 7, 203.	1.0	87
1793	The Importance of a Biopsychosocial Approach in Melanoma Research Experiences from a Single-center Multidisciplinary Melanoma Working Group in Middle-Europe. <i>Acta Dermato-Venereologica</i> , 2014, 96, 51-4.	0.6	1
1794	The CD28-B7 Family in Anti-Tumor Immunity: Emerging Concepts in Cancer Immunotherapy. <i>Immune Network</i> , 2014, 14, 265.	1.6	78
1795	Classification of current anticancer immunotherapies. <i>Oncotarget</i> , 2014, 5, 12472-12508.	0.8	395
1796	PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors. <i>Journal of Clinical Investigation</i> , 2014, 124, 2246-2259.	3.9	892
1797	Managing Multi-center Flow Cytometry Data for Immune Monitoring. <i>Cancer Informatics</i> , 2014, 13s7, CIN.S16346.	0.9	9
1798	Tumor Immunology. <i>Juntendo Medical Journal</i> , 2014, 60, 358-361.	0.1	0
1799	Emerging options for the treatment of melanoma – focus on ipilimumab. <i>ImmunoTargets and Therapy</i> , 2014, 3, 67.	2.7	2
1800	Cutaneous melanoma: new advances in treatment. <i>Anais Brasileiros De Dermatologia</i> , 2014, 89, 301-310.	0.5	28
1802	Profile of selumetinib and its potential in the treatment of melanoma. <i>OncoTargets and Therapy</i> , 2014, 7, 1631.	1.0	15

#	ARTICLE	IF	CITATIONS
1803	Indoleamine 2,3-Dioxygenase as A Prognostic Factor in Patients with Non-Small Cell Lung Cancer. <i>Journal of Clinical & Cellular Immunology</i> , 2014, 05, .	1.5	1
1804	Visual Vignette. <i>Endocrine Practice</i> , 2014, 20, 760.	1.1	0
1806	EBV-driven LMP1 and IFN- γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy. <i>Oncotarget</i> , 2014, 5, 12189-12202.	0.8	324
1807	Systematic Review: Surgery for Patients with Metastatic Melanoma during Active Treatment with Ipilimumab. <i>American Surgeon</i> , 2014, 80, 805-810.	0.4	7
1808	An incidental finding of a nodal recurrence of cutaneous malignant melanoma after a 45-year disease-free period. <i>BMJ Case Reports</i> , 2014, 2014, bcr2014204289-bcr2014204289.	0.2	3
1809	Management of Vulvar and Vaginal Melanomas: Current and Future Strategies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014, , e277-e281.	1.8	45
1810	Victory and Defeat in the Induction of a Therapeutic Response through Vaccine Therapy for Human and Canine Brain Tumors: A Review of the State of the Art. <i>Critical Reviews in Immunology</i> , 2014, 34, 399-432.	1.0	13
1811	Precision Cancer Medicine: The Future Is Now, Only Better. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014, , 61-69.	1.8	38
1812	Trial watch. <i>Oncolmunology</i> , 2014, 3, e29030.	2.1	51
1813	Cellular and molecular immunology of lung cancer: therapeutic implications. <i>Expert Review of Clinical Immunology</i> , 2014, 10, 1711-1730.	1.3	10
1814	Differential CTLA-4 expression in human CD4+ versus CD8+ T cells is associated with increased NFAT1 and inhibition of CD4+ proliferation. <i>Genes and Immunity</i> , 2014, 15, 25-32.	2.2	99
1815	Opening the door to innovation. <i>MAbs</i> , 2014, 6, 812-819.	2.6	14
1816	Targeting the alternatively spliced soluble isoform of CTLA-4: prospects for immunotherapy?. <i>Immunotherapy</i> , 2014, 6, 1073-1084.	1.0	21
1817	Adding fuel to the fire: Immunogenic intensification. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 3306-3312.	1.4	4
1818	The Use of Anti-CD40 mAb in Cancer. <i>Current Topics in Microbiology and Immunology</i> , 2014, 405, 165-207.	0.7	21
1819	Trial Watch. <i>Oncolmunology</i> , 2014, 3, e29179.	2.1	76
1820	Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo. <i>Oncolmunology</i> , 2014, 3, e27614.	2.1	70
1821	Challenges for the implementation of high-throughput testing and liquid biopsies in personalized medicine cancer trials. <i>Personalized Medicine</i> , 2014, 11, 545-558.	0.8	8

#	ARTICLE	IF	CITATIONS
1822	Sustained Complete Response to CTLA-4 Blockade in a Patient with Metastatic, Castration-Resistant Prostate Cancer. <i>Cancer Immunology Research</i> , 2014, 2, 399-403.	1.6	38
1823	Pharmacotherapeutic Management of Metastatic, Castration-Resistant Prostate Cancer in the Elderly: Focus on Non-Chemotherapy Agents. <i>Drugs and Aging</i> , 2014, 31, 873-882.	1.3	13
1824	Interleukin-15 in the treatment of cancer. <i>Expert Review of Clinical Immunology</i> , 2014, 10, 1689-1701.	1.3	61
1825	AERIO news in brief. <i>Oncologie</i> , 2014, 16, 605-608.	0.2	0
1827	Intratumoral checkpoint subversion as a strategy for minimizing adverse effects. <i>Oncolmmunology</i> , 2014, 3, e27580.	2.1	2
1828	FDA Approval Summary: Vemurafenib for Treatment of Unresectable or Metastatic Melanoma with the BRAFV600E Mutation. <i>Clinical Cancer Research</i> , 2014, 20, 4994-5000.	3.2	164
1829	Subverting the adaptive immune resistance mechanism to improve clinical responses to immune checkpoint blockade therapy. <i>Oncolmmunology</i> , 2014, 3, e954868.	2.1	8
1830	PD-1 and PD-L1 antibodies for melanoma. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 3111-3116.	1.4	54
1831	Cancer immunotherapy drives implementation science in oncology. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 3107-3110.	1.4	8
1832	Biomarkers in melanoma: where are we now?. <i>Melanoma Management</i> , 2014, 1, 139-150.	0.1	1
1833	TroVax in colorectal cancer. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 3196-3200.	1.4	19
1834	Genetic and molecular targets in lymphoma: implications for prognosis and treatment. <i>Future Oncology</i> , 2014, 10, 2509-2528.	1.1	4
1835	Trametinib, a first-in-class oral MEK inhibitor mass balance study with limited enrollment of two male subjects with advanced cancers. <i>Xenobiotica</i> , 2014, 44, 352-368.	0.5	22
1836	Trial Watch. <i>Oncolmmunology</i> , 2014, 3, e27297.	2.1	99
1837	Economic evaluation of therapeutic cancer vaccines and immunotherapy: A systematic review. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 3415-3424.	1.4	39
1838	Non-BRAF-targeted therapy, immunotherapy, and combination therapy for melanoma. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 663-686.	1.4	17
1839	Immunoregulatory activity of adenosine and its role in human cancer progression. <i>Expert Review of Clinical Immunology</i> , 2014, 10, 897-914.	1.3	74
1840	Role of the MEK inhibitor trametinib in the treatment of metastatic melanoma. <i>Future Oncology</i> , 2014, 10, 1559-1570.	1.1	17

#	ARTICLE	IF	CITATIONS
1841	Co-blockade of immune checkpoints and adenosine A _{2A} receptor suppresses metastasis. <i>Oncolmmunology</i> , 2014, 3, e958952.	2.1	22
1842	Pancreatic cancer: Role of the immune system in cancer progression and vaccine-based immunotherapy. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 3354-3368.	1.4	85
1843	Vaccines versus immunotherapy: Overview of approaches in deciding between options. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 3369-3374.	1.4	11
1844	Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. <i>Cell Death and Differentiation</i> , 2014, 21, 15-25.	5.0	740
1845	Antigen-specific vaccines for cancer treatment. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 3332-3346.	1.4	124
1846	Spontaneous and therapeutic immune responses in hepatocellular carcinoma: implications for current and future immunotherapies. <i>Expert Review of Gastroenterology and Hepatology</i> , 2014, 8, 101-110.	1.4	9
1847	Disruption of CD8+ Treg Activity Results in Expansion of T Follicular Helper Cells and Enhanced Antitumor Immunity. <i>Cancer Immunology Research</i> , 2014, 2, 207-216.	1.6	38
1848	Combination of Alphavirus Replicon Particle-Based Vaccination with Immunomodulatory Antibodies: Therapeutic Activity in the B16 Melanoma Mouse Model and Immune Correlates. <i>Cancer Immunology Research</i> , 2014, 2, 448-458.	1.6	37
1849	Long-term tolerability of the BRAF inhibitor vemurafenib in patients with metastatic melanoma: current study data and real-life observations. <i>Memo - Magazine of European Medical Oncology</i> , 2014, 7, 181-186.	0.3	1
1850	Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome. , 2014, 2, 40.		50
1851	The role of immunotherapy in solid tumors: report from the Campania Society of Oncology Immunotherapy (SCITO) meeting, Naples 2014. <i>Journal of Translational Medicine</i> , 2014, 12, 291.	1.8	32
1852	Cancer, Inflammation, and Therapy: Effects on Cytochrome P450-Mediated Drug Metabolism and Implications for Novel Immunotherapeutic Agents. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 96, 449-457.	2.3	120
1853	Cutaneous T Cell Lymphoma Expresses Immunosuppressive CD80 (B7-1) Cell Surface Protein in a STAT5-Dependent Manner. <i>Journal of Immunology</i> , 2014, 192, 2913-2919.	0.4	27
1854	Engineered chimeric antigen receptor-expressing T cells for the treatment of pancreatic ductal adenocarcinoma. <i>Oncolmmunology</i> , 2014, 3, e28327.	2.1	10
1855	Potential roles of self-reactive T cells in autoimmunity: lessons from cancer immunology. <i>Immunologic Research</i> , 2014, 60, 156-164.	1.3	3
1856	Gene therapy for cancer: present status and future perspective. <i>Molecular and Cellular Therapies</i> , 2014, 2, 27.	0.2	185
1857	Is immune checkpoint modulation a potential therapeutic option in triple negative breast cancer?. <i>Breast Cancer Research</i> , 2014, 16, 457.	2.2	2
1858	Ipilimumab administration for advanced melanoma in patients with pre-existing Hepatitis B or C infection: a multicenter, retrospective case series. , 2014, 2, 33.		52

#	ARTICLE	IF	CITATIONS
1859	Melanoma expression of matrix metalloproteinase-23 is associated with blunted tumor immunity and poor responses to immunotherapy. <i>Journal of Translational Medicine</i> , 2014, 12, 342.	1.8	24
1860	Evaluation of response to immunotherapy: new challenges and opportunities for PET imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 2090-2092.	3.3	14
1861	Melanoma immunotherapy. <i>Cancer Biology and Therapy</i> , 2014, 15, 665-674.	1.5	73
1863	Challenges in the Management of <i>EGFR</i>-Mutated Non-Small Cell Lung Cancer Patients with Acquired Resistance to Tyrosine Kinase Inhibitors. <i>Oncology</i> , 2014, 87, 83-94.	0.9	4
1864	When unity makes strength. <i>Oncolmmunology</i> , 2014, 3, e28048.	2.1	3
1865	Altered Peptide Ligands Revisited: Vaccine Design through Chemically Modified HLA-A2“Restricted T Cell Epitopes. <i>Journal of Immunology</i> , 2014, 193, 4803-4813.	0.4	40
1866	Ipilimumab. <i>Cancer Biology and Therapy</i> , 2014, 15, 1299-1300.	1.5	5
1867	Immune checkpoint receptors in regulating immune reactivity in rheumatic disease. <i>Arthritis Research and Therapy</i> , 2014, 16, 469.	1.6	55
1868	High sensitivity of cancer exome-based CD8 T cell neo-antigen identification. <i>Oncolmmunology</i> , 2014, 3, e28836.	2.1	85
1869	Harnessing the immune system to provide long-term survival in patients with melanoma and other solid tumors. <i>Oncolmmunology</i> , 2014, 3, e27560.	2.1	38
1870	Successful Administration of Ipilimumab to Two Kidney Transplantation Patients With Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2014, 32, e69-e71.	0.8	137
1872	Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma. <i>Cancer Imaging</i> , 2014, 14, 30.	1.2	16
1873	The novel immunotherapeutic molecule T11TS modulates glioma-induced changes of key components of the immunological synapse in favor of T cell activation and glioma abrogation. <i>Journal of Neuro-Oncology</i> , 2014, 120, 19-31.	1.4	16
1874	Preclinical Evidence That PD1 Blockade Cooperates with Cancer Vaccine TEGVAX to Elicit Regression of Established Tumors. <i>Cancer Research</i> , 2014, 74, 4042-4052.	0.4	117
1875	Engineering better immunotherapies via RNA interference. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 3165-3174.	1.4	19
1876	Ipilimumab-Induced Hypophysitis: A Detailed Longitudinal Analysis in a Large Cohort of Patients With Metastatic Melanoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 4078-4085.	1.8	376
1877	Functional expression cloning identifies COX-2 as a suppressor of antigen-specific cancer immunity. <i>Cell Death and Disease</i> , 2014, 5, e1568-e1568.	2.7	42
1878	DC-HIL + CD14 + HLA-DR no/low Cells Are a Potential Blood Marker and Therapeutic Target for Melanoma. <i>Journal of Investigative Dermatology</i> , 2014, 134, 2839-2842.	0.3	11

#	ARTICLE	IF	CITATIONS
1879	Current advances in T-cell-based cancer immunotherapy. <i>Immunotherapy</i> , 2014, 6, 1265-1278.	1.0	119
1880	Successful treatment with Ipilimumab and Interleukin-2 in two patients with metastatic melanoma and systemic autoimmune disease. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 1341-1346.	2.0	55
1881	Successes and Limitations of Targeted Cancer Therapy in Melanoma. <i>Progress in Tumor Research</i> , 2014, 41, 78-88.	0.1	4
1882	Could targeting T-helper cells aid the development of effective cancer vaccines?. <i>Immunotherapy</i> , 2014, 6, 959-961.	1.0	1
1883	Sentinel lymph node biopsy in melanoma: controversies and current guidelines. <i>Future Oncology</i> , 2014, 10, 429-442.	1.1	14
1884	Reversal of Tumor Immune Inhibition Using a Chimeric Cytokine Receptor. <i>Molecular Therapy</i> , 2014, 22, 1211-1220.	3.7	145
1885	Evaluation of stromal HGF immunoreactivity as a biomarker for melanoma response to RAF inhibitors. <i>Modern Pathology</i> , 2014, 27, 1193-1202.	2.9	18
1886	Acid sphingomyelinase determines melanoma progression and metastatic behaviour via the microphthalmia-associated transcription factor signalling pathway. <i>Cell Death and Differentiation</i> , 2014, 21, 507-520.	5.0	37
1887	Effects of <i>BRAF</i> Mutations and <i>BRAF</i> Inhibition on Immune Responses to Melanoma. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 2769-2783.	1.9	73
1888	Fc γ 3 Receptor Dependency of Agonistic CD40 Antibody in Lymphoma Therapy Can Be Overcome through Antibody Multimerization. <i>Journal of Immunology</i> , 2014, 193, 1828-1835.	0.4	56
1889	Ovarian Cancer from an Immune Perspective. <i>Radiation Research</i> , 2014, 182, 239-251.	0.7	3
1890	Reducing TNF Receptor 2+ Regulatory T Cells via the Combined Action of Azacitidine and the HDAC Inhibitor, Panobinostat for Clinical Benefit in Acute Myeloid Leukemia Patients. <i>Clinical Cancer Research</i> , 2014, 20, 724-735.	3.2	76
1891	Sequential Treatment with Ipilimumab and BRAF Inhibitors in Patients With Metastatic Melanoma: Data From the Italian Cohort of the Ipilimumab Expanded Access Program. <i>Cancer Investigation</i> , 2014, 32, 144-149.	0.6	90
1892	Agonistic CD200R1 DNA Aptamers Are Potent Immunosuppressants That Prolong Allogeneic Skin Graft Survival. <i>Molecular Therapy - Nucleic Acids</i> , 2014, 3, e190.	2.3	17
1893	Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy. <i>British Journal of Cancer</i> , 2014, 110, 1721-1726.	2.9	53
1894	Current management options for liposarcoma and challenges for the future. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 297-306.	1.1	26
1895	Myeloid-Derived Suppressor Cells Predict Survival of Patients with Advanced Melanoma: Comparison with Regulatory T Cells and NY-ESO-1- or Melan-A-Specific T Cells. <i>Clinical Cancer Research</i> , 2014, 20, 1601-1609.	3.2	222
1896	The impact of the TIM gene family on tumor immunity and immunosuppression. <i>Cellular and Molecular Immunology</i> , 2014, 11, 41-48.	4.8	24

#	ARTICLE	IF	CITATIONS
1897	The immune escape in melanoma: role of the impaired dendritic cell function. <i>Expert Review of Clinical Immunology</i> , 2014, 10, 1395-1404.	1.3	56
1898	Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. <i>Oncolmmunology</i> , 2014, 3, e28780.	2.1	318
1899	Immune checkpoints. <i>Oncolmmunology</i> , 2014, 3, e28325.	2.1	32
1900	Overcoming tumor-mediated immunosuppression. <i>Immunotherapy</i> , 2014, 6, 973-988.	1.0	38
1901	Synergistic anti-tumor activity and inhibition of angiogenesis by cotargeting of oncogenic and death receptor pathways in human melanoma. <i>Cell Death and Disease</i> , 2014, 5, e1434-e1434.	2.7	20
1902	Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. <i>Genome Research</i> , 2014, 24, 743-750.	2.4	534
1903	Diverse Mechanisms Regulate the Surface Expression of Immunotherapeutic Target CTLA-4. <i>Frontiers in Immunology</i> , 2014, 5, 619.	2.2	52
1904	Advanced Pancreatic Cancer: Flourishing Novel Approaches in the Era of Biological Therapy. <i>Oncologist</i> , 2014, 19, 937-950.	1.9	9
1905	Metastatic melanoma: results of 'classical' second-line treatment with cytotoxic chemotherapies. <i>Journal of Dermatological Treatment</i> , 2014, 25, 396-400.	1.1	2
1906	A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer. <i>Annals of Oncology</i> , 2014, 25, 1750-1755.	0.6	164
1907	Autoimmunity as a Double Agent in Tumor Killing and Cancer Promotion. <i>Frontiers in Immunology</i> , 2014, 5, 116.	2.2	49
1908	Does the Immune System Naturally Protect Against Cancer?. <i>Frontiers in Immunology</i> , 2014, 5, 197.	2.2	183
1909	Cancer Stem Cell Immunology: Key to Understanding Tumorigenesis and Tumor Immune Escape?. <i>Frontiers in Immunology</i> , 2014, 5, 360.	2.2	147
1910	Control of the Immune Response by Pro-Angiogenic Factors. <i>Frontiers in Oncology</i> , 2014, 4, 70.	1.3	260
1911	Exploiting Synergy: Immune-Based Combinations in the Treatment of Prostate Cancer. <i>Frontiers in Oncology</i> , 2014, 4, 351.	1.3	15
1912	Experiences and Expectations for Glioma Immunotherapeutic Approaches. <i>Frontiers in Oncology</i> , 2014, 4, 355.	1.3	1
1913	The inducible caspase-9 suicide gene system as a "safety switch" to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells. <i>Frontiers in Pharmacology</i> , 2014, 5, 235.	1.6	280
1914	Systemic Therapy for Merkel Cell Carcinoma: What's on the Horizon?. <i>Cancers</i> , 2014, 6, 1180-1194.	1.7	14

#	ARTICLE	IF	CITATIONS
1915	Class II-associated invariant chain peptide as predictive immune marker in minimal residual disease in acute myeloid leukemia. <i>Oncolimmunology</i> , 2014, 3, e941737.	2.1	3
1916	Long Overall Survival After Dendritic Cell Vaccination in Metastatic Uveal Melanoma Patients. <i>American Journal of Ophthalmology</i> , 2014, 158, 939-947.e5.	1.7	53
1917	Is vaccine research still relevant for metastatic melanoma?. <i>Melanoma Management</i> , 2014, 1, 91-94.	0.1	5
1918	The financial burden of cancer care: do patients in the US know what to expect?. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2014, 14, 835-842.	0.7	20
1919	From Bench to Bedside: Immunotherapy for Prostate Cancer. <i>BioMed Research International</i> , 2014, 2014, 1-11.	0.9	18
1920	Regulation of CD4+NKG2D+ Th1 Cells in Patients with Metastatic Melanoma Treated with Sorafenib: Role of IL-15R α and NKG2D Triggering. <i>Cancer Research</i> , 2014, 74, 68-80.	0.4	43
1921	Comparison of Clinicopathologic Features and Survival of Histopathologically Amelanotic and Pigmented Melanomas. <i>JAMA Dermatology</i> , 2014, 150, 1306.	2.0	142
1922	Diagnostic Endosonography. , 2014, , .		1
1923	Immunotherapy for Gastrointestinal Malignancies. <i>Journal of Cancer Therapy</i> , 2014, 05, 622-646.	0.1	0
1924	Evolving Strategies for Cancer and Autoimmunity: Back to the Future. <i>Frontiers in Immunology</i> , 2014, 5, 154.	2.2	4
1925	Oncolytic Viruses as Anticancer Vaccines. <i>Frontiers in Oncology</i> , 2014, 4, 188.	1.3	65
1926	Influence of Interferon-Alpha Combined with Chemo (Radio) Therapy on Immunological Parameters in Pancreatic Adenocarcinoma. <i>International Journal of Molecular Sciences</i> , 2014, 15, 4104-4125.	1.8	16
1927	BRAF and beyond: Tailoring strategies for the individual melanoma patient. <i>Journal of Carcinogenesis</i> , 2014, 13, 1.	2.5	19
1928	Ipilimumab in Melanoma Patients with Brain Metastasis: A Retrospective Multicentre Evaluation of Thirty-eight Patients. <i>Acta Dermato-Venereologica</i> , 2014, 94, 45-49.	0.6	41
1929	Clinical Benefit from Ipilimumab Therapy in Melanoma Patients may be Associated with Serum CTLA4 Levels. <i>Frontiers in Oncology</i> , 2014, 4, 110.	1.3	51
1930	Cancer Microenvironments as Therapeutic Targets. , 2014, , 412-422.		0
1932	Melanoma stem cells and metastasis: mimicking hematopoietic cell trafficking?. <i>Laboratory Investigation</i> , 2014, 94, 13-30.	1.7	63
1933	Immune checkpoints in cancer clinical trials. <i>Chinese Journal of Cancer</i> , 2014, 33, 434-444.	4.9	96

#	ARTICLE	IF	CITATIONS
1934	Combinations of Immunotherapy and Radiation in Cancer Therapy. <i>Frontiers in Oncology</i> , 2014, 4, 325.	1.3	205
1935	Myeloid-Derived Suppressor Cells in Sepsis. <i>BioMed Research International</i> , 2014, 2014, 1-8.	0.9	21
1936	CD4 ⁺ T Lymphocytes as a First Line of Immune Defense: Old and New Ways of Antigen Recognition and Implications for Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2014, 5, 575.	2.2	57
1937	New-Onset Mediastinal and Central Nervous System Sarcoidosis in a Patient with Metastatic Melanoma Undergoing CTLA4 Monoclonal Antibody Treatment. <i>Oncology Research and Treatment</i> , 2014, 37, 351-353.	0.8	78
1938	Immunotherapeutic and oncolytic viral therapeutic strategies in pancreatic cancer. <i>Future Oncology</i> , 2014, 10, 1255-1275.	1.1	5
1939	Treating advanced melanoma: current insights and opportunities. <i>Cancer Management and Research</i> , 2014, 6, 349.	0.9	33
1940	Immunotherapy for Prostate Cancer: Lessons from Responses to Tumor-Associated Antigens. <i>Frontiers in Immunology</i> , 2014, 5, 191.	2.2	71
1941	RepSox Slows Decay of CD34+ Acute Myeloid Leukemia Cells and Decreases T Cell Immunoglobulin Mucin-3 Expression. <i>Stem Cells Translational Medicine</i> , 2014, 3, 836-848.	1.6	7
1942	Whole-Cell Vaccines. , 2014, , 1-14.		0
1943	Combining chemotherapy and checkpoint blockade in thoracic cancer: how to proceed?. <i>Lung Cancer Management</i> , 2014, 3, 443-457.	1.5	8
1944	Dendritic cell vaccination for glioblastoma multiforme: Clinical experience and future directions. , 2014, , .		0
1945	Interferon alpha for the adjuvant treatment of melanoma: review of international literature and practical recommendations from an expert panel on the use of interferon. <i>Journal of Chemotherapy</i> , 2014, 26, 193-201.	0.7	17
1946	High-risk cutaneous melanoma follow-up: time for more intensive surveillance?. <i>Melanoma Management</i> , 2014, 1, 7-10.	0.1	1
1948	New treatments for metastatic melanoma. <i>Cmaj</i> , 2014, 186, 754-760.	0.9	9
1949	Targeting CD8 ⁺ T-cell tolerance for cancer immunotherapy. <i>Immunotherapy</i> , 2014, 6, 833-852.	1.0	41
1951	Systemic treatments for metastatic cutaneous melanoma. <i>The Cochrane Library</i> , 2014, , .	1.5	12
1952	Sipuleucel-T and immunotherapy in the treatment of prostate cancer. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 709-719.	1.4	8
1955	Evidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanoma. <i>Oncolmmunology</i> , 2014, 3, e954956.	2.1	19

#	ARTICLE	IF	CITATIONS
1956	Duality of the Immune Response in Cancer: Lessons Learned from Skin. <i>Journal of Investigative Dermatology</i> , 2014, 134, E23-E28.	0.3	23
1958	Does vaccine-primed pancreatic cancer offer better candidates for immune-based therapies?. <i>Immunotherapy</i> , 2014, 6, 1017-1020.	1.0	10
1959	Mogamulizumab and the treatment of CCR4-positive T-cell lymphomas. <i>Immunotherapy</i> , 2014, 6, 1187-1206.	1.0	33
1960	Budget impact analysis of a novel gene expression assay for the diagnosis of malignant melanoma. <i>Journal of Medical Economics</i> , 2014, 17, 782-791.	1.0	12
1961	Targeting CD28 to prevent transplant rejection. <i>Expert Opinion on Therapeutic Targets</i> , 2014, 18, 225-242.	1.5	8
1962	How detection of epigenetic alterations of blood-borne DNA could improve melanoma diagnosis. <i>Expert Review of Molecular Diagnostics</i> , 2014, 14, 639-642.	1.5	3
1963	Tumor-infiltrating T-cells: important players in clinical outcome of advanced melanoma patients. <i>OncImmunology</i> , 2014, 3, e954862.	2.1	4
1964	PROSTVACÂ® targeted immunotherapy candidate for prostate cancer. <i>Immunotherapy</i> , 2014, 6, 235-247.	1.0	7
1965	Breakthrough therapies in melanoma. <i>Future Oncology</i> , 2014, 10, 781-784.	1.1	0
1966	Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma. <i>Cancer Treatment Reviews</i> , 2014, 40, 1056-1064.	3.4	178
1968	New Approaches in Immunotherapy for the Treatment of Lung Cancer. <i>Current Topics in Microbiology and Immunology</i> , 2014, 405, 1-31.	0.7	9
1969	High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial. <i>Leukemia</i> , 2014, 28, 2367-2375.	3.3	281
1970	Tumoral Immune Suppression by Macrophages Expressing Fibroblast Activation Protein-Î± and Heme Oxygenase-1. <i>Cancer Immunology Research</i> , 2014, 2, 121-126.	1.6	127
1971	Trafficking of T Cells into Tumors. <i>Cancer Research</i> , 2014, 74, 7168-7174.	0.4	313
1972	Galectin-1 and Immune Suppression during Radiotherapy. <i>Clinical Cancer Research</i> , 2014, 20, 6230-6232.	3.2	8
1973	Therapeutic cancer vaccines: a long and winding road to success. <i>Expert Review of Vaccines</i> , 2014, 13, 131-144.	2.0	12
1974	Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma. <i>Nature Communications</i> , 2014, 5, 5712.	5.8	503
1975	Computational Algorithm-Driven Evaluation of Monocytic Myeloid-Derived Suppressor Cell Frequency for Prediction of Clinical Outcomes. <i>Cancer Immunology Research</i> , 2014, 2, 812-821.	1.6	122

#	ARTICLE	IF	CITATIONS
1976	Motor function and survival following radiotherapy alone for metastatic epidural spinal cord compression in melanoma patients. <i>Journal of Dermatology</i> , 2014, 41, 1082-1086.	0.6	3
1977	Dilemmas in the compassionate supply of investigational cancer drugs. <i>Internal Medicine Journal</i> , 2014, 44, 841-845.	0.5	19
1978	Differential regulation of aggressive features in melanoma cells by members of the miR-17-92 complex. <i>Open Biology</i> , 2014, 4, 140030.	1.5	11
1979	Immunotherapy and lung cancer: current developments and novel targeted therapies. <i>Immunotherapy</i> , 2014, 6, 1221-1235.	1.0	44
1981	Rapid Evolution of Combination Therapy in Melanoma. <i>New England Journal of Medicine</i> , 2014, 371, 1929-1930.	13.9	10
1982	Moving Receptor Redirected Adoptive Cell Therapy Toward Fine Tuning of Antitumor Responses. <i>International Reviews of Immunology</i> , 2014, 33, 402-416.	1.5	12
1983	Clinical Utility of a Blood-Based BRAFV600E Mutation Assay in Melanoma. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 3210-3218.	1.9	21
1984	Immunotherapy in pediatric malignancies: current status and future perspectives. <i>Future Oncology</i> , 2014, 10, 1659-1678.	1.1	11
1985	Factors associated with response, survival, and limb salvage in patients undergoing isolated limb infusion. <i>Journal of Surgical Oncology</i> , 2014, 109, 405-409.	0.8	23
1986	Immunotherapy and Radiation Therapy: Considerations for Successfully Combining Radiation into the Paradigm of Immuno-Oncology Drug Development. <i>Radiation Research</i> , 2014, 182, 252-257.	0.7	15
1987	Transient MEK inhibitor-associated retinopathy in metastatic melanoma. <i>Annals of Oncology</i> , 2014, 25, 1437-1441.	0.6	117
1988	Re-adapting T cells for cancer therapy: from mouse models to clinical trials. <i>Immunological Reviews</i> , 2014, 257, 145-164.	2.8	67
1989	Programmed Cell Death 1 (PD-1) and Its Ligand (PD-L1) in Common Cancers and Their Correlation with Molecular Cancer Type. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 2965-2970.	1.1	432
1990	Microsphere priming facilitates induction of potent therapeutic T cell immune responses against autochthonous liver cancers. <i>European Journal of Immunology</i> , 2014, 44, 1213-1224.	1.6	17
1991	Advances in Tumor Immunology and Immunotherapy. , 2014, , .		2
1992	Metastatic melanoma to the upper aerodigestive tract. <i>Laryngoscope</i> , 2014, 124, 1143-1149.	1.1	17
1993	Phase III placebo-controlled double-blind randomized trial of radiotherapy for stage IIB-IVA cervical cancer with or without immunomodulator Z-100: a JGOG study. <i>Annals of Oncology</i> , 2014, 25, 1011-1017.	0.6	22
1994	Nano-Oncologicals. <i>Advances in Delivery Science and Technology</i> , 2014, , .	0.4	7

#	ARTICLE	IF	CITATIONS
1995	Enhancement of T cell recruitment and infiltration into tumours. <i>Clinical and Experimental Immunology</i> , 2014, 178, 1-8.	1.1	118
1996	Somatic Mutations and Immunotherapy Outcome with CTLA-4 Blockade in Melanoma. <i>New England Journal of Medicine</i> , 2014, 371, 2230-2232.	13.9	43
1997	<sc>TCR</sc> repertoires of intratumoral T cell subsets. <i>Immunological Reviews</i> , 2014, 257, 72-82.	2.8	59
1998	Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma. <i>New England Journal of Medicine</i> , 2014, 371, 2189-2199.	13.9	3,753
1999	Ipilimumab in a patient with known Crohn's disease: To give or not to give?. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 1742.	0.6	14
2000	Therapeutic targets in subependymoma. <i>Journal of Neuroimmunology</i> , 2014, 277, 168-175.	1.1	21
2001	Malignant melanoma of the lacrimal sac: a case report. <i>International Journal of Dermatology</i> , 2014, 53, 243-245.	0.5	7
2002	Population pharmacokinetic and pharmacodynamic analysis of tremelimumab in patients with metastatic melanoma. <i>Journal of Clinical Pharmacology</i> , 2014, 54, 1108-1116.	1.0	35
2003	Isolated limb perfusion for in-transit melanoma metastases: Melphalan or TNF- α melphalan perfusion?. <i>Journal of Surgical Oncology</i> , 2014, 109, 338-347.	0.8	26
2004	<sc>CTLA</sc>-4 (<sc>CD</sc>152) enhances the <sc>T</sc>c17 differentiation program. <i>European Journal of Immunology</i> , 2014, 44, 2139-2152.	1.6	10
2005	Mucosal Melanoma of the Head and Neck: A Systematic Review of the Literature. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 1108-1118.	0.4	97
2006	High expression of FOXP3 in primary melanoma is associated with tumour progression. <i>British Journal of Dermatology</i> , 2014, 170, 103-109.	1.4	54
2007	The use of endogenous T cells for adoptive transfer. <i>Immunological Reviews</i> , 2014, 257, 250-263.	2.8	61
2008	Cancer inflammation and inflammatory biomarkers: can neutrophil, lymphocyte, and platelet counts represent the complexity of the immune system?. <i>Transplant International</i> , 2014, 27, 28-31.	0.8	13
2009	Isolated limb infusion with melphalan and actinomycin D for melanoma: A systematic review. <i>Journal of Surgical Oncology</i> , 2014, 109, 348-351.	0.8	52
2010	Universes Collide: Combining Immunotherapy with Targeted Therapy for Cancer. <i>Cancer Discovery</i> , 2014, 4, 1377-1386.	7.7	76
2011	FoxP3 and indoleamine 2,3-dioxygenase immunoreactivity in sentinel nodes from melanoma patients. <i>American Journal of Otolaryngology - Head and Neck Medicine and Surgery</i> , 2014, 35, 689-694.	0.6	11
2012	Comparison of melanoma guidelines in the U.S.A., Canada, Europe, Australia and New Zealand: a critical appraisal and comprehensive review. <i>British Journal of Dermatology</i> , 2014, 170, 20-30.	1.4	61

#	ARTICLE	IF	CITATIONS
2013	Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. <i>Nature</i> , 2014, 515, 563-567.	13.7	4,342
2014	Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. <i>Nature</i> , 2014, 515, 577-581.	13.7	1,705
2015	High-Dose IL2 in Metastatic Melanoma: Better Survival in Patients Immunized with Antigens from Autologous Tumor Cell Lines. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2014, 29, 53-57.	0.7	14
2016	Î³ T cells for cancer immunotherapy. <i>Oncolmmunology</i> , 2014, 3, e27572.	2.1	158
2017	Podoplanin expression in cancer-associated fibroblasts predicts aggressive behavior in melanoma. <i>Journal of Cutaneous Pathology</i> , 2014, 41, 561-567.	0.7	38
2018	Human cell-based artificial antigen-presenting cells for cancer immunotherapy. <i>Immunological Reviews</i> , 2014, 257, 191-209.	2.8	96
2019	Immunotherapy following relapse of acute leukaemia after T cell-replete allogeneic peripheral blood progenitor cell transplantation: importance of new onset chronic graft-versus-host disease. <i>International Journal of Laboratory Hematology</i> , 2014, 36, 197-204.	0.7	4
2020	Current management and future perspectives of metastatic renal cell carcinoma. <i>International Journal of Urology</i> , 2014, 21, 847-855.	0.5	27
2021	The immunogenicity of breast cancer's molecular subtypes matter. <i>Annals of Oncology</i> , 2014, 25, 1453-1455.	0.6	29
2022	Efficacy of a general practitioner training campaign for early detection of melanoma in France. <i>British Journal of Dermatology</i> , 2014, 170, 123-129.	1.4	25
2023	Management of metastatic kidney cancer in the era of personalized medicine. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2014, 51, 85-97.	2.7	6
2024	Animal models of vitiligo: Matching the model to the question. <i>Dermatologica Sinica</i> , 2014, 32, 240-247.	0.2	24
2025	Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies. <i>Annals of Oncology</i> , 2014, 25, 2277-2284.	0.6	119
2026	Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 11774-11779.	3.3	578
2027	Clinical Impact of Checkpoint Inhibitors as Novel Cancer Therapies. <i>Drugs</i> , 2014, 74, 1993-2013.	4.9	96
2028	Intralesional immunotherapy for melanoma. <i>Journal of Surgical Oncology</i> , 2014, 109, 320-326.	0.8	54
2029	Integrating novel therapeutic monoclonal antibodies into the management of head and neck cancer. <i>Cancer</i> , 2014, 120, 624-632.	2.0	51
2030	PD-1 Blockade in Renal Cell Carcinoma: To Equilibrium and Beyond. <i>Cancer Immunology Research</i> , 2014, 2, 1132-1141.	1.6	42

#	ARTICLE	IF	CITATIONS
2031	(R)Evolutionary Therapy: The Potential of Immunotherapy to Fulfill the Promise of Personalized Cancer Treatment. <i>Journal of the National Cancer Institute</i> , 2014, 107, dju347-dju347.	3.0	4
2033	A phase I clinical trial combining dendritic cell vaccination with adoptive T cell transfer in patients with stage IV melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 1061-1071.	2.0	68
2034	Major therapeutic developments and current challenges in advanced melanoma. <i>British Journal of Dermatology</i> , 2014, 170, 36-44.	1.4	20
2035	Fast neutron radiotherapy for primary mucosal melanomas of the head and neck. <i>Head and Neck</i> , 2014, 36, 1162-1167.	0.9	21
2036	Early Administration of Infliximab for Severe Ipilimumab-Related Diarrhea in a Critically Ill Patient. <i>Annals of Pharmacotherapy</i> , 2014, 48, 806-810.	0.9	55
2037	Investigating the positive relationship between tumor-infiltrating lymphocytes and trastuzumab therapy. <i>Immunotherapy</i> , 2014, 6, 803-805.	1.0	6
2038	Evolving role of tumor antigens for future melanoma therapies. <i>Future Oncology</i> , 2014, 10, 1457-1468.	1.1	15
2039	Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy. <i>Science Translational Medicine</i> , 2014, 6, 226ra32.	5.8	590
2040	Proteomic Profile and In Silico Analysis in Metastatic Melanoma with and without BRAF Mutation. <i>PLoS ONE</i> , 2014, 9, e112025.	1.1	15
2041	Ipilimumab Plus Sargramostim vs Ipilimumab Alone for Treatment of Metastatic Melanoma. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 1744.	3.8	312
2042	Molecular Determinants of Head and Neck Cancer. , 2014, , .		2
2044	Bisphosphonamidate Clodronate Prodrug Exhibits Selective Cytotoxic Activity against Melanoma Cell Lines. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 297-306.	1.9	11
2045	Anti-CTLA-4 therapy broadens the melanoma-reactive CD8 ⁺ T cell response. <i>Science Translational Medicine</i> , 2014, 6, 254ra128.	5.8	325
2046	Reversal of natural killer cell exhaustion by TIM-3 blockade. <i>Oncotarget</i> , 2014, 3, e946365.	2.1	76
2047	Blood mRNA Expression Profiling Predicts Survival in Patients Treated with Tremelimumab. <i>Clinical Cancer Research</i> , 2014, 20, 3310-3318.	3.2	29
2048	Germline CDKN2A mutations in Brazilian patients of hereditary cutaneous melanoma. <i>Familial Cancer</i> , 2014, 13, 645-649.	0.9	18
2049	Melanoma 2014: an update. <i>Memo - Magazine of European Medical Oncology</i> , 2014, 7, 249-251.	0.3	0
2050	Cell-Cell Communication in the Tumor Microenvironment, Carcinogenesis, and Anticancer Treatment. <i>Cellular Physiology and Biochemistry</i> , 2014, 34, 213-243.	1.1	170

#	ARTICLE	IF	CITATIONS
2051	Role of immunotherapy in the treatment of advanced non-small-cell lung cancer. <i>Future Oncology</i> , 2014, 10, 79-90.	1.1	23
2052	Sequencing therapy in advanced prostate cancer: focus on sipuleucel-T. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 51-61.	1.1	1
2053	Partial hepatectomy for primary hepatic melanoma: a report of two cases and review of the literature. <i>World Journal of Surgical Oncology</i> , 2014, 12, 362.	0.8	7
2054	Ipilimumab augments antitumor activity of bispecific antibody-armed T cells. <i>Journal of Translational Medicine</i> , 2014, 12, 191.	1.8	23
2055	Melanoma: the role of surgery in the era of new therapies. <i>Journal of Translational Medicine</i> , 2014, 12, 195.	1.8	4
2056	Vaccination with autologous dendritic cells loaded with autologous tumor lysate or homogenate combined with immunomodulating radiotherapy and/or preleukapheresis IFN- γ in patients with metastatic melanoma: a randomised "proof-of-principle" phase II study. <i>Journal of Translational Medicine</i> , 2014, 12, 209.	1.8	26
2057	Patient-reported utilities in advanced or metastatic melanoma, including analysis of utilities by time to death. <i>Health and Quality of Life Outcomes</i> , 2014, 12, 140.	1.0	38
2058	Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine. <i>Journal of Translational Medicine</i> , 2014, 12, 294.	1.8	144
2059	Strategies for modern biomarker and drug development in oncology. <i>Journal of Hematology and Oncology</i> , 2014, 7, 70.	6.9	98
2060	Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab. , 2014, 2, 31.		92
2061	Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade. , 2014, 2, 42.		186
2062	Potential for immunotherapy in soft tissue sarcoma. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 3117-3124.	1.4	26
2063	Local tumour ablative therapies: Opportunities for maximising immune engagement and activation. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1846, 510-523.	3.3	21
2064	Aspirin and Other NSAIDs as Chemoprevention Agents in Melanoma. <i>Cancer Prevention Research</i> , 2014, 7, 557-564.	0.7	30
2065	Regression of Metastatic Merkel Cell Carcinoma Following Transfer of Polyomavirus-Specific T Cells and Therapies Capable of Reinducing HLA Class-I. <i>Cancer Immunology Research</i> , 2014, 2, 27-36.	1.6	89
2066	Melanoma brain metastasis globally reconfigures chemokine and cytokine profiles in patient cerebrospinal fluid. <i>Melanoma Research</i> , 2014, 24, 120-130.	0.6	30
2067	The role of systemic therapies in the management of melanoma brain metastases. <i>Current Opinion in Oncology</i> , 2014, 26, 222-229.	1.1	19
2068	Cutaneous Melanoma Metastatic to the Orbit. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2014, 30, 233-237.	0.4	19

#	ARTICLE	IF	CITATIONS
2069	Where to start with systemic melanoma therapy?. <i>Melanoma Management</i> , 2014, 1, 15-18.	0.1	0
2070	New developments in the treatment of squamous cell lung cancer. <i>Current Opinion in Oncology</i> , 2014, 26, 152-158.	1.1	20
2071	Therapeutic monoclonal antibodies in human breast milk. <i>Melanoma Research</i> , 2014, 24, 177-180.	0.6	9
2072	Does metastasectomy improve survival in skeletal melanoma?. <i>Melanoma Research</i> , 2014, 24, 354-359.	0.6	20
2073	A Single-Arm, Open-Label, Expanded Access Study of Vemurafenib in Patients With Metastatic Melanoma in the United States. <i>Cancer Journal (Sudbury, Mass)</i> , 2014, 20, 18-24.	1.0	43
2074	The treatment of melanoma brain metastases before the advent of targeted therapies. <i>Melanoma Research</i> , 2014, 24, 61-67.	0.6	22
2075	CAR T Cells for Solid Tumors. <i>Cancer Journal (Sudbury, Mass)</i> , 2014, 20, 151-155.	1.0	170
2076	Implementing combinatorial immunotherapeutic regimens against cancer. <i>Oncolmmunology</i> , 2014, 3, e27588.	2.1	13
2077	Improved Survival with T Cell Clonotype Stability After Anti-CTLA-4 Treatment in Cancer Patients. <i>Science Translational Medicine</i> , 2014, 6, 238ra70.	5.8	348
2078	Gynecologic Cancer InterGroup (GFIG) Consensus Review for Vulvovaginal Melanomas. <i>International Journal of Gynecological Cancer</i> , 2014, 24, S117-S122.	1.2	67
2079	Prevalence and heterogeneity of circulating tumour cells in metastatic cutaneous melanoma. <i>Melanoma Research</i> , 2014, 24, 40-46.	0.6	67
2080	Effectiveness and Tolerability of Ipilimumab. <i>Journal of Immunotherapy</i> , 2014, 37, 374-381.	1.2	23
2081	Vaccination therapy for non-small-cell lung cancer. <i>Current Opinion in Oncology</i> , 2014, 26, 165-170.	1.1	40
2082	The perspective of immunotherapy. <i>Current Opinion in Oncology</i> , 2014, 26, 204-214.	1.1	64
2083	B7-H1 Expression in Malignant Pleural Mesothelioma is Associated with Sarcomatoid Histology and Poor Prognosis. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1036-1040.	0.5	208
2084	Pigmentation in the sentinel node correlates with increased sentinel node tumor burden in melanoma patients. <i>Melanoma Research</i> , 2014, 24, 261-266.	0.6	6
2085	Inducible Expression of B7-H1 (PD-L1) and Its Selective Role in Tumor Site Immune Modulation. <i>Cancer Journal (Sudbury, Mass)</i> , 2014, 20, 256-261.	1.0	131
2086	Incorporating Immune-Checkpoint Inhibitors into Systemic Therapy of NSCLC. <i>Journal of Thoracic Oncology</i> , 2014, 9, 144-153.	0.5	83

#	ARTICLE	IF	CITATIONS
2087	Current Systemic Therapies for Melanoma. <i>Dermatologic Surgery</i> , 2014, 40, 948-963.	0.4	29
2088	A Phase I Trial of Bortezomib and Interferon- α -2b in Metastatic Melanoma. <i>Journal of Immunotherapy</i> , 2014, 37, 55-62.	1.2	14
2089	Immunotherapy for ovarian cancer. <i>Current Opinion in Oncology</i> , 2014, 26, 492-500.	1.1	36
2090	Prognostic Factors for Overall Survival After Radiosurgery for Brain Metastases From Melanoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2014, 37, 580-584.	0.6	18
2091	Management of melanomas of the gynaecological tract. <i>Current Opinion in Oncology</i> , 2014, 26, 508-513.	1.1	19
2092	Ipilimumab-Induced Immunomediated Adverse Events. <i>Clinical Nuclear Medicine</i> , 2014, 39, 472-474.	0.7	14
2093	Biomarkers in Early-Stage Non-Small-Cell Lung Cancer: Current Concepts and Future Directions. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1609-1617.	0.5	54
2094	Hepatic resection for metastatic melanoma. <i>Melanoma Research</i> , 2014, 24, 1-10.	0.6	11
2095	Perspectives for immunotherapy in glioblastoma treatment. <i>Current Opinion in Oncology</i> , 2014, 26, 608-614.	1.1	26
2097	Ipilimumab for advanced melanoma. <i>Melanoma Research</i> , 2014, 24, 577-583.	0.6	38
2098	Harnessing the immune system for cancer therapy. <i>Current Opinion in Oncology</i> , 2014, 26, 600-607.	1.1	25
2099	Subverting the B7-H1/PD-1 Pathway in Advanced Melanoma and Kidney Cancer. <i>Cancer Journal (Sudbury, Mass)</i> 2014; 17(10):1417-1424.	0.784314	17
2100	Dose rounding of ipilimumab in adult metastatic melanoma patients results in significant cost savings. <i>Journal of Oncology Pharmacy Practice</i> , 2014, 20, 47-50.	0.5	20
2101	Management of conjunctival malignant melanoma: a review and update. <i>Expert Review of Ophthalmology</i> , 2014, 9, 185-204.	0.3	116
2103	Dendritic Cell Cancer Vaccines: From the Bench to the Bedside. <i>Rambam Maimonides Medical Journal</i> , 2014, 5, e0024.	0.4	11
2104	Therapeutic Cancer Vaccines. <i>Advances in Cancer Research</i> , 2014, 121, 67-124.	1.9	68
2105	Cancer Immunotherapy via Dendritic Cells. <i>Journal of Immunotherapy</i> , 2014, 37, 75-89.		11
2106	The Immune Microenvironment: A Major Player in Human Cancers. <i>International Archives of Allergy and Immunology</i> , 2014, 164, 13-26.	0.9	63

#	ARTICLE	IF	CITATIONS
2107	Priming the pancreatic cancer tumor microenvironment for checkpoint-inhibitor immunotherapy. <i>Oncolimmunology</i> , 2014, 3, e962401.	2.1	37
2108	Tumor antigen-targeting monoclonal antibody-based immunotherapy: Orchestrating combined strategies for the development of long-term antitumor immunity. <i>Oncolimmunology</i> , 2014, 3, e955684.	2.1	44
2109	Malignancies in HIV/AIDS. <i>Aids</i> , 2014, 28, 453-465.	1.0	197
2110	WNT5A-mediated β -catenin-independent signalling is a novel regulator of cancer cell metabolism. <i>Carcinogenesis</i> , 2014, 35, 784-794.	1.3	42
2111	Genetic Evolution of T-cell Resistance in the Course of Melanoma Progression. <i>Clinical Cancer Research</i> , 2014, 20, 6593-6604.	3.2	145
2112	Vemurafenib in Brafv600 Mutated Metastatic Melanoma (Mm): a Subanalysis of the Italian Population of a Global Safety Study. <i>Annals of Oncology</i> , 2014, 25, iv384.	0.6	4
2113	Targeted therapies for cutaneous T-cell lymphomas. <i>Expert Review of Hematology</i> , 2014, 7, 481-493.	1.0	6
2114	Breaking through the central tolerance ceiling to unleash anticancer immune responses. <i>Oncolimmunology</i> , 2014, 3, e950169.	2.1	5
2115	Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy. <i>Science Translational Medicine</i> , 2014, 6, 237ra67.	5.8	579
2116	Drug-Associated Polymyalgia Rheumatica/Giant Cell Arteritis Occurring in Two Patients After Treatment With Ipilimumab, an Antagonist of CTLA-4. <i>Arthritis and Rheumatology</i> , 2014, 66, 768-769.	2.9	167
2118	IMA901 for metastatic renal cell carcinoma in the context of new approaches to immunotherapy. <i>Future Oncology</i> , 2014, 10, 937-948.	1.1	10
2119	Moving from histological subtyping to molecular characterization: new treatment opportunities in advanced non-small-cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 1495-1513.	1.1	8
2120	Poxvirus-Based Strategies for Combined Vaccine and Tumor Microenvironment Manipulation. , 2014, , 241-257.		0
2121	Genetically Modified Dendritic Cell Vaccines for Solid Tumors. , 2014, , 273-282.		0
2122	Adoptive TIL Transfer in the Adjuvant Setting for Melanoma: Long-Term Patient Survival. <i>Journal of Immunology Research</i> , 2014, 2014, 1-10.	0.9	25
2123	Opportunistic Autoimmune Disorders Potentiated by Immune-Checkpoint Inhibitors Anti-CTLA-4 and Anti-PD-1. <i>Frontiers in Immunology</i> , 2014, 5, 206.	2.2	108
2124	Cancer chemotherapy agents target intratumoral dendritic cells to potentiate antitumor immunity. <i>Oncolimmunology</i> , 2014, 3, e954460.	2.1	19
2125	Novel immune checkpoint blocker approved for the treatment of advanced melanoma. <i>Oncolimmunology</i> , 2014, 3, e967147.	2.1	27

#	ARTICLE	IF	CITATIONS
2126	Novel dendritic cell-based vaccination in late stage melanoma. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 3132-3138.	1.4	10
2127	Immunotherapeutic implications of the immunophenotype of pediatric brain tumors. <i>OncolImmunology</i> , 2014, 3, e27256.	2.1	5
2128	Combined OX40 ligation plus CTLA-4 blockade. <i>OncolImmunology</i> , 2014, 3, e28245.	2.1	21
2129	Discovering cancer immunotherapy targets in vivo. <i>OncolImmunology</i> , 2014, 3, e28500.	2.1	2
2130	Armed Therapeutic Viruses – A Disruptive Therapy on the Horizon of Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2014, 5, 74.	2.2	39
2131	Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade. <i>Cancer Immunology Research</i> , 2014, 2, 643-654.	1.6	226
2132	Early Carcinogenesis Involves the Establishment of Immune Privilege via Intrinsic and Extrinsic Regulation of Indoleamine 2,3-dioxygenase-1: Translational Implications in Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2014, 5, 438.	2.2	12
2133	DILI and Drug Development: A Regulatory Perspective. <i>Seminars in Liver Disease</i> , 2014, 34, 215-226.	1.8	25
2134	Structure and Cancer Immunotherapy of the B7 Family Member B7x. <i>Cell Reports</i> , 2014, 9, 1089-1098.	2.9	58
2136	Current concepts in the diagnosis and management of cytokine release syndrome. <i>Blood</i> , 2014, 124, 188-195.	0.6	2,080
2137	Cancer Immunotherapy Using T _H 17 Cells: Dealing with Diversity. <i>Frontiers in Immunology</i> , 2014, 5, 601.	2.2	40
2138	Immunoguiding, the Final Frontier in the Immunotherapy of Cancer. , 2014, , 37-51.		0
2139	T Cell Costimulation Molecules CD80/86 Inhibit Osteoclast Differentiation by Inducing the IDO/Tryptophan Pathway. <i>Science Translational Medicine</i> , 2014, 6, 235ra60.	5.8	150
2140	Nasopharyngeal Carcinoma: Management Strategies. , 2014, , .		2
2141	Drug development: A chance of survival. <i>Nature</i> , 2014, 515, S118-S120.	13.7	8
2142	Characterization of S628N. <i>JAMA Dermatology</i> , 2014, 150, 1345.	2.0	6
2143	Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia. <i>Blood</i> , 2014, 124, 453-462.	0.6	286
2144	Late development of splenic sarcoidosis-like lesions in a patient with metastatic melanoma and long-lasting clinical response to ipilimumab. <i>OncolImmunology</i> , 2014, 3, e954506.	2.1	56

#	ARTICLE	IF	CITATIONS
2145	Evaluating biomarkers in melanoma. <i>Frontiers in Oncology</i> , 2014, 4, 383.	1.3	38
2146	Thyroid-Like Ophthalmopathy in a Euthyroid Patient Receiving Ipilimumab. <i>Orbit</i> , 2014, 33, 424-427.	0.5	72
2147	Combination Therapies for the Treatment of Advanced Melanoma: A Review of Current Evidence. <i>Biochemistry Research International</i> , 2014, 2014, 1-9.	1.5	18
2148	Radiation for Awakening the Dormant Immune System, a Promising Challenge to be Explored. <i>Frontiers in Immunology</i> , 2014, 5, 102.	2.2	35
2149	Adoptive Immunotherapy for Hematological Malignancies Using T Cells Gene-Modified to Express Tumor Antigen-Specific Receptors. <i>Pharmaceuticals</i> , 2014, 7, 1049-1068.	1.7	21
2150	Immune Checkpoint Blockade in Cancer Treatment: A Double-Edged Sword Cross-Targeting the Host as an "Innocent Bystander". <i>Toxins</i> , 2014, 6, 914-933.	1.5	62
2151	PD-1 gene promoter polymorphisms correlate with a poor prognosis in non-small cell lung cancer. <i>Molecular and Clinical Oncology</i> , 2014, 2, 1035-1042.	0.4	25
2152	Ipilimumab-induced colonic perforation. <i>Journal of Surgical Case Reports</i> , 2014, 2014, rju010-rju010.	0.2	25
2153	Adaptive Resistance to Immunotherapy Directed Against p53 Can be Overcome by Global Expression of Tumor-Antigens in Dendritic Cells. <i>Frontiers in Oncology</i> , 2014, 4, 270.	1.3	3
2154	Critical analysis of an oncolytic herpesvirus encoding granulocyte-macrophage colony stimulating factor for the treatment of malignant melanoma. <i>Oncolytic Virotherapy</i> , 2014, 3, 11.	6.0	19
2155	Therapeutic vaccines and cancer: focus on DPX-0907. <i>Biologics: Targets and Therapy</i> , 2014, 8, 27.	3.0	45
2156	Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy. , 2014, 2, 7.		105
2157	Ipilimumab in patients with melanoma and autoimmune disease. , 2014, 2, 35.		82
2158	T-cell Responses to Oncogenic Merkel Cell Polyomavirus Proteins Distinguish Patients with Merkel Cell Carcinoma from Healthy Donors. <i>Clinical Cancer Research</i> , 2014, 20, 1768-1778.	3.2	81
2159	TGF β 2 Inhibition Prior to Hypofractionated Radiation Enhances Efficacy in Preclinical Models. <i>Cancer Immunology Research</i> , 2014, 2, 1011-1022.	1.6	44
2160	Cytotoxic T Lymphocyte Antigen-4 Blockade Enhances Antitumor Immunity by Stimulating Melanoma-Specific T-cell Motility. <i>Cancer Immunology Research</i> , 2014, 2, 970-980.	1.6	68
2161	Late-Onset Paraplegia after Complete Response to Two Cycles of Ipilimumab for Metastatic Melanoma. <i>Oncology Research and Treatment</i> , 2014, 37, 757-760.	0.8	33
2162	The promise of combining radiation therapy and immunotherapy: morbidity and toxicity. <i>Future Oncology</i> , 2014, 10, 2319-2328.	1.1	8

#	ARTICLE	IF	CITATIONS
2163	Immunotherapy of hepatocellular carcinoma. <i>Hepatic Oncology</i> , 2014, 1, 433-446.	4.2	5
2164	Combination of cancer immunotherapy with clinically available drugs that can block immunosuppressive cells. <i>Immunological Investigations</i> , 2014, 43, 517-534.	1.0	10
2165	Ipilimumab-induced Autoimmune Pancytopenia in a Case of Metastatic Melanoma. <i>Journal of Immunotherapy</i> , 2014, 37, 348-350.	1.2	36
2166	State-of-the-Art Management of Renal Cell Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2014, 37, 498-505.	0.6	18
2167	Induction of Antigen-Specific Immunity with a Vaccine Targeting NY-ESO-1 to the Dendritic Cell Receptor DEC-205. <i>Science Translational Medicine</i> , 2014, 6, 232ra51.	5.8	315
2168	Cutaneous melanoma. <i>Lancet, The</i> , 2014, 383, 816-827.	6.3	465
2169	New drug targets in metastatic melanoma. <i>Journal of Pathology</i> , 2014, 232, 134-141.	2.1	50
2170	A personalized view on cancer immunotherapy. <i>Cancer Letters</i> , 2014, 352, 113-125.	3.2	63
2171	The current role and limitations of surrogate endpoints in advanced prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 28.e1-28.e9.	0.8	14
2172	Anti-tumor activity of human IgG1 anti-gp75 TA99 mAb against B16F10 melanoma in human FcγRI transgenic mice. <i>Immunology Letters</i> , 2014, 160, 151-157.	1.1	12
2173	Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials. <i>Lancet Oncology, The</i> , 2014, 15, 297-304.	5.1	55
2174	Melanotic and non-melanotic malignancies of the face and external ear – A review of current treatment concepts and future options. <i>Cancer Treatment Reviews</i> , 2014, 40, 819-837.	3.4	38
2175	Cutaneous melanoma: Medical specialists' opinions on follow-up and sentinel lymph node biopsy. <i>European Journal of Surgical Oncology</i> , 2014, 40, 1276-1283.	0.5	8
2176	Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes. <i>European Journal of Cancer</i> , 2014, 50, 1361-1369.	1.3	276
2177	A near miss for prostate cancer immunotherapy. <i>Lancet Oncology, The</i> , 2014, 15, 669-671.	5.1	5
2178	Risk of cutaneous malignant melanoma in patients with celiac disease: A population-based study. <i>Journal of the American Academy of Dermatology</i> , 2014, 71, 245-248.	0.6	13
2179	Cytotoxic T-Lymphocyte Antigen-4 Single Nucleotide Polymorphisms Are Not Associated with Outcomes after Unrelated Donor Transplantation: A Center for International Blood and Marrow Transplant Research Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 900-903.	2.0	10
2180	Immunological Basis of Melanoma-Associated Vitiligo-Like Depigmentation. <i>Actas Dermo-sifiliográficas</i> , 2014, 105, 122-127.	0.2	2

#	ARTICLE	IF	CITATIONS
2181	Severe adverse events from the treatment of advanced melanoma: a systematic review of severe side effects associated with ipilimumab, vemurafenib, interferon alfa-2b, dacarbazine and interleukin-2. <i>Journal of Dermatological Treatment</i> , 2014, 25, 401-408.	1.1	59
2182	Colorectal cancer defeating? Challenge accepted!. <i>Molecular Aspects of Medicine</i> , 2014, 39, 61-81.	2.7	17
2183	Intracranial Stereotactic Radiosurgery in High Risk Patients with Metastases from Radioresistant Primary Tumors. <i>Tumors of the Central Nervous System</i> , 2014, , 163-172.	0.1	0
2184	Tumors of the Central Nervous System, Volume 11. <i>Tumors of the Central Nervous System</i> , 2014, , .	0.1	0
2185	Metastatic Malignant Melanoma to the Colon: a Case Report and Review of the Literature. <i>Journal of Gastrointestinal Cancer</i> , 2014, 45, 221-224.	0.6	5
2186	Human CD14 ⁺ CTLA-4 ⁺ regulatory dendritic cells suppress T-cell response by cytotoxic T-lymphocyte antigen-4-dependent IL-10 and indoleamine-2,3-dioxygenase production in hepatocellular carcinoma. <i>Hepatology</i> , 2014, 59, 567-579.	3.6	178
2187	Comparison of acute toxicity and mortality after two different dosing regimens of high-dose interleukin-2 for patients with metastatic melanoma. <i>Targeted Oncology</i> , 2014, 9, 63-71.	1.7	46
2188	Targeted therapy in renal cell carcinoma: moving from molecular agents to specific immunotherapy. <i>World Journal of Urology</i> , 2014, 32, 31-38.	1.2	28
2189	Targeted Therapies in Brain Metastases. <i>Current Treatment Options in Neurology</i> , 2014, 16, 276.	0.7	42
2190	BRAF and MEK Gene Rearrangements in Melanoma: Implications for Targeted Therapy. <i>Molecular Diagnosis and Therapy</i> , 2014, 18, 285-91.	1.6	8
2191	Long-lasting complete response of metastatic melanoma to ipilimumab with analysis of the resident immune cells. <i>Medical Oncology</i> , 2014, 31, 813.	1.2	7
2192	Two immune faces of pancreatic adenocarcinoma: possible implication for immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 59-65.	2.0	61
2193	Patterns of Recurrence and Survival After Lymphadenectomy in Melanoma Patients: Clarifying the Effects of Timing of Surgery and Lymph Node Tumor Burden. <i>Annals of Surgical Oncology</i> , 2014, 21, 292-299.	0.7	28
2194	Emerging insights into resistance to BRAF inhibitors in melanoma. <i>Biochemical Pharmacology</i> , 2014, 87, 381-389.	2.0	70
2195	Systemic treatment of soft-tissue sarcoma—gold standard and novel therapies. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 187-202.	12.5	185
2196	Adoptive Immunotherapy for Cancer or Viruses. <i>Annual Review of Immunology</i> , 2014, 32, 189-225.	9.5	240
2197	New insights into cancer immunoediting and its three component phases—elimination, equilibrium and escape. <i>Current Opinion in Immunology</i> , 2014, 27, 16-25.	2.4	1,163
2198	Effectiveness of slow-release systems in CD40 agonistic antibody immunotherapy of cancer. <i>Vaccine</i> , 2014, 32, 1654-1660.	1.7	22

#	ARTICLE	IF	CITATIONS
2200	Decitabine facilitates immune recognition of sarcoma cells by upregulating CT antigens, MHC molecules, and ICAM-1. <i>Tumor Biology</i> , 2014, 35, 5753-5762.	0.8	44
2201	Immunology and Immunotherapy of Chronic Myeloid Leukemia. <i>Current Hematologic Malignancy Reports</i> , 2014, 9, 17-23.	1.2	24
2202	Ipilimumab, not just another anti-cancer therapy: hypophysitis as side effect illustrated by four case-reports. <i>Endocrine</i> , 2014, 47, 878-883.	1.1	37
2203	Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 247-257.	2.0	472
2204	Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 225-234.	2.0	86
2205	Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases. <i>Journal of Neuro-Oncology</i> , 2014, 118, 109-116.	1.4	103
2206	The GIST of Targeted Therapy for Malignant Melanoma. <i>Annals of Surgical Oncology</i> , 2014, 21, 2059-2067.	0.7	17
2207	A four-marker signature of TNF-RII, TGF- β , TIMP-1 and CRP is prognostic of worse survival in high-risk surgically resected melanoma. <i>Journal of Translational Medicine</i> , 2014, 12, 19.	1.8	42
2208	Failing to improve overall survival because post-protocol survival is long: fact, myth, excuse or improper study design?. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 521-524.	1.2	2
2210	Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody. <i>Science Translational Medicine</i> , 2014, 6, 230ra45.	5.8	526
2211	Targeting tumour-supportive cellular machineries in anticancer drug development. <i>Nature Reviews Drug Discovery</i> , 2014, 13, 179-196.	21.5	202
2212	Regulatory T cells in cancer immunotherapy. <i>Current Opinion in Immunology</i> , 2014, 27, 1-7.	2.4	612
2213	3D cell culture systems modeling tumor growth determinants in cancer target discovery. <i>Advanced Drug Delivery Reviews</i> , 2014, 69-70, 29-41.	6.6	369
2214	Immunotherapy for solid tumors—a review for surgeons. <i>Journal of Surgical Research</i> , 2014, 187, 525-535.	0.8	16
2215	Intratumoral Immunization: A New Paradigm for Cancer Therapy. <i>Clinical Cancer Research</i> , 2014, 20, 1747-1756.	3.2	191
2216	Targeted therapies in gastroesophageal cancer. <i>European Journal of Cancer</i> , 2014, 50, 1247-1258.	1.3	45
2217	Broad-Spectrum Therapeutic Suppression of Metastatic Melanoma through Nuclear Hormone Receptor Activation. <i>Cell</i> , 2014, 156, 986-1001.	13.5	149
2218	Orchestrating immune check-point blockade for cancer immunotherapy in combinations. <i>Current Opinion in Immunology</i> , 2014, 27, 89-97.	2.4	111

#	ARTICLE	IF	CITATIONS
2219	State of the science in cervical cancer: Where we are today and where we need to go. <i>Cancer</i> , 2014, 120, 2282-2288.	2.0	36
2220	Determining the optimal dose in the development of anticancer agents. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 272-281.	12.5	144
2221	The challenge of intratumour heterogeneity in precision medicine. <i>Journal of Internal Medicine</i> , 2014, 276, 41-51.	2.7	66
2222	Targeting tumor-stromal interactions in bone metastasis. , 2014, 141, 222-233.		115
2223	New agents for prostate cancer. <i>Annals of Oncology</i> , 2014, 25, 1700-1709.	0.6	51
2224	Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 5153-5158.	3.3	346
2225	Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. <i>Cancer</i> , 2014, 120, 1695-1701.	2.0	195
2226	Perioral Lesions and Dermatoses. <i>Dental Clinics of North America</i> , 2014, 58, 401-435.	0.8	8
2228	The scope of nanoparticle therapies for future metastatic melanoma treatment. <i>Lancet Oncology</i> , The, 2014, 15, e22-e32.	5.1	75
2229	CTLA4 Blockade Broadens the Peripheral T-Cell Receptor Repertoire. <i>Clinical Cancer Research</i> , 2014, 20, 2424-2432.	3.2	323
2230	Mouse tumour models to guide drug development and identify resistance mechanisms. <i>Journal of Pathology</i> , 2014, 232, 103-111.	2.1	28
2231	Spontaneous regression of metastatic melanoma - Clinical evidence of the abscopal effect. <i>European Journal of Surgical Oncology</i> , 2014, 40, 34-41.	0.5	64
2232	Anti-vascular endothelial growth factor receptor (VEGFR) 2 autoantibody identification in glioblastoma patient using single B cell-based antibody gene cloning. <i>Immunology Letters</i> , 2014, 159, 15-22.	1.1	6
2233	Targeting Multiple Key Signaling Pathways in Melanoma Using Leelamine. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 1679-1689.	1.9	44
2234	Tim-3: An Emerging Target in the Cancer Immunotherapy Landscape. <i>Cancer Immunology Research</i> , 2014, 2, 393-398.	1.6	278
2235	Advances in Understanding Autoimmune Pituitary Disease: Standardized Methods for Autoantibody Detection. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 1589-1592.	1.8	1
2236	Cancer vaccines: Trafficking of tumor-specific T cells to tumor after therapeutic vaccination. <i>International Journal of Biochemistry and Cell Biology</i> , 2014, 53, 46-50.	1.2	16
2237	Growth inhibitory effects of large subunit ribosomal proteins in melanoma. <i>Pigment Cell and Melanoma Research</i> , 2014, 27, 801-812.	1.5	20

#	ARTICLE	IF	CITATIONS
2238	Update: The Status of Clinical Trials With Kinase Inhibitors in Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 1543-1555.	1.8	30
2239	Not all monoclonals are created equal – Lessons from failed drug trials in Crohn's disease. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2014, 28, 437-449.	1.0	37
2240	Newer developments in the immunotherapy of malignant melanoma. <i>Journal of Oncology Pharmacy Practice</i> , 2014, 20, 3-10.	0.5	3
2241	Interaction of Immune and Cancer Cells. , 2014, , .		0
2242	Tumor-Infiltrating Lymphocytes and Their Significance in Melanoma Prognosis. <i>Methods in Molecular Biology</i> , 2014, 1102, 287-324.	0.4	78
2243	Adoptive T-cell therapy for hematological malignancies using T cells gene-modified to express tumor antigen-specific receptors. <i>International Journal of Hematology</i> , 2014, 99, 123-131.	0.7	12
2244	Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma. <i>Leukemia</i> , 2014, 28, 993-1000.	3.3	92
2245	Immune Modulation in Cancer with Antibodies. <i>Annual Review of Medicine</i> , 2014, 65, 185-202.	5.0	455
2246	Checkpoint blocking antibodies in cancer immunotherapy. <i>FEBS Letters</i> , 2014, 588, 368-376.	1.3	227
2247	Do inhibitory immune receptors play a role in the etiology of autoimmune disease?. <i>Clinical Immunology</i> , 2014, 150, 31-42.	1.4	23
2248	Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. <i>Nature Reviews Cancer</i> , 2014, 14, 135-146.	12.8	925
2249	Targeted therapy-induced diarrhea: A review of the literature. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 90, 165-179.	2.0	47
2250	Beyond Sipuleucel-T: Immune Approaches to Treating Prostate Cancer. <i>Current Treatment Options in Oncology</i> , 2014, 15, 115-126.	1.3	13
2251	Interference identifies immune modulators. <i>Nature</i> , 2014, 506, 39-40.	13.7	0
2252	Mitigating the toxic effects of anticancer immunotherapy. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 91-99.	12.5	189
2253	Tumor antigenicity revealed. <i>Trends in Immunology</i> , 2014, 35, 47-48.	2.9	10
2254	The immune system and response to HER2-targeted treatment in breast cancer. <i>Lancet Oncology</i> , The, 2014, 15, e58-e68.	5.1	244
2255	Tolerance and exhaustion: defining mechanisms of T cell dysfunction. <i>Trends in Immunology</i> , 2014, 35, 51-60.	2.9	513

#	ARTICLE	IF	CITATIONS
2256	Immunotherapy for prostate cancer: recent developments and future challenges. <i>Cancer and Metastasis Reviews</i> , 2014, 33, 641-655.	2.7	53
2257	In vivo discovery of immunotherapy targets in the tumour microenvironment. <i>Nature</i> , 2014, 506, 52-57.	13.7	197
2258	DC-based immunotherapy for hematological malignancies. <i>International Journal of Hematology</i> , 2014, 99, 117-122.	0.7	6
2259	CD8+ T Cell-Independent Tumor Regression Induced by Fc-OX40L and Therapeutic Vaccination in a Mouse Model of Glioma. <i>Journal of Immunology</i> , 2014, 192, 224-233.	0.4	21
2260	The immunoregulatory role of type I and type II NKT cells in cancer and other diseases. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 199-213.	2.0	71
2261	Advances in Adjuvant Therapy: Potential for Prognostic and Predictive Biomarkers. <i>Methods in Molecular Biology</i> , 2014, 1102, 45-69.	0.4	3
2262	Impaired and imbalanced cellular immunological status assessed in advanced cancer patients and restoration of the T cell immune status by adoptive T-cell immunotherapy. <i>International Immunopharmacology</i> , 2014, 18, 90-97.	1.7	29
2263	Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 24-37.	12.5	380
2264	Assaying for BRAF V600E in Tissue and Blood in Melanoma. <i>Methods in Molecular Biology</i> , 2014, 1102, 117-136.	0.4	5
2265	Induced regulatory T cells in inhibitory microenvironments created by cancer. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 1411-1425.	1.4	76
2266	Recognition of Tumors by the Innate Immune System and Natural Killer Cells. <i>Advances in Immunology</i> , 2014, 122, 91-128.	1.1	296
2267	Targeting melanocyte and melanoma stem cells by 8-hydroxy-2-dipropylaminotetralin. <i>Archives of Biochemistry and Biophysics</i> , 2014, 563, 71-78.	1.4	6
2268	How To Train Your Oncolytic Virus: the Immunological Sequel. <i>Molecular Therapy</i> , 2014, 22, 1881-1884.	3.7	6
2269	Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. <i>Blood</i> , 2014, 123, 678-686.	0.6	253
2270	Improved mouse models to assess tumour immunity and irAEs after combination cancer immunotherapies. <i>Clinical and Translational Immunology</i> , 2014, 3, e22.	1.7	64
2271	Targeting metastatic castration-resistant prostate cancer: mechanisms of progression and novel early therapeutic approaches. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 469-487.	1.9	19
2272	Immunotherapy and Radiation. <i>Seminars in Oncology</i> , 2014, 41, 702-713.	0.8	8
2273	Gastrointestinal Stromal Tumors. <i>Advances in Surgery</i> , 2014, 48, 165-183.	0.6	38

#	ARTICLE	IF	CITATIONS
2274	Sample size determination for the weighted log-rank test with the Fleming-Harrington class of weights in cancer vaccine studies. <i>Pharmaceutical Statistics</i> , 2014, 13, 128-135.	0.7	36
2276	The melanoma revolution: From UV carcinogenesis to a new era in therapeutics. <i>Science</i> , 2014, 346, 945-949.	6.0	328
2278	Model-based clinical pharmacology profiling of ipilimumab in patients with advanced melanoma. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 106-117.	1.1	83
2279	Trial Watch. <i>Oncolimmunology</i> , 2014, 3, e27878.	2.1	134
2280	A power surge for cancer immunotherapy. <i>Cancer Cytopathology</i> , 2014, 122, 1-2.	1.4	0
2281	Recent developments in the medical and surgical treatment of melanoma. <i>Ca-A Cancer Journal for Clinicians</i> , 2014, 64, 171-185.	157.7	56
2282	Treatment patterns, outcomes, and resource utilization of patients with metastatic melanoma in the U.K.: the MELODY study. <i>British Journal of Dermatology</i> , 2014, 170, 87-95.	1.4	11
2283	Current management of advanced melanoma: a transformed landscape. <i>ANZ Journal of Surgery</i> , 2014, 84, 612-617.	0.3	13
2284	Balance and Imbalance in the Immune System: Life on the Edge. <i>Immunity</i> , 2014, 41, 682-684.	6.6	33
2285	Isolated limb infusion as a model to test new agents to treat metastatic melanoma. <i>Journal of Surgical Oncology</i> , 2014, 109, 357-365.	0.8	9
2286	Anti-PD1 Following Ipilimumab for Mucosal Melanoma: Durable Tumor Response Associated with Severe Hypothyroidism and Rhabdomyolysis. <i>Cancer Immunology Research</i> , 2014, 2, 15-18.	1.6	95
2287	Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma. <i>New England Journal of Medicine</i> , 2014, 371, 1867-1876.	13.9	1,824
2288	Optimal Treatment for Metastatic Bladder Cancer. <i>Current Oncology Reports</i> , 2014, 16, 404.	1.8	32
2289	Induction of B _L -Specific Cytotoxic T Lymphocytes in Mice. <i>Scandinavian Journal of Immunology</i> , 2014, 80, 111-120.	1.3	2
2290	Immunotherapeutic Agents in Non-small-cell Lung Cancer Finally Coming to the Front Lines. <i>Current Oncology Reports</i> , 2014, 16, 400.	1.8	27
2291	Isolated hepatic perfusion for metastatic melanoma. <i>Journal of Surgical Oncology</i> , 2014, 109, 383-388.	0.8	9
2292	Southwest Oncology Group S0008: A Phase III Trial of High-Dose Interferon Alfa-2b Versus Cisplatin, Vinblastine, and Dacarbazine, Plus Interleukin-2 and Interferon in Patients With High-Risk Melanoma—An Intergroup Study of Cancer and Leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. <i>Journal of Clinical Oncology</i> , 2014, 32, 3771-3778.	0.8	99
2293	Insights into the Mechanism of Organ-Specific Cancer Metastasis. <i>Cancer Discovery</i> , 2014, 4, 1262-1264.	7.7	8

#	ARTICLE	IF	CITATIONS
2294	Antitumor Efficacy of a Bispecific Antibody That Targets HER2 and Activates T Cells. <i>Cancer Research</i> , 2014, 74, 5561-5571.	0.4	135
2295	Immune-based therapies for childhood cancer. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 693-703.	12.5	84
2296	Specificity Delivers: Therapeutic Role of Tumor Antigen-Specific Antibodies in Pancreatic Cancer. <i>Seminars in Oncology</i> , 2014, 41, 559-575.	0.8	3
2297	Real-Time Immune Monitoring to Guide Plasmid DNA Vaccination Schedule Targeting Prostatic Acid Phosphatase in Patients with Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 3692-3704.	3.2	41
2298	Designing effective vaccines for colorectal cancer. <i>Immunotherapy</i> , 2014, 6, 913-926.	1.0	3
2299	CTLA-4 and PD-L1 Checkpoint Blockade Enhances Oncolytic Measles Virus Therapy. <i>Molecular Therapy</i> , 2014, 22, 1949-1959.	3.7	249
2300	Current Perspectives on Immunotherapy. <i>Seminars in Oncology</i> , 2014, 41, S14-S29.	0.8	28
2301	Dual Blockade of PD-1 and CTLA-4 Combined with Tumor Vaccine Effectively Restores T-Cell Rejection Function in Tumors. <i>Cancer Research</i> , 2014, 74, 632-632.	0.4	14
2302	Fibroblasts Protect Melanoma Cells from the Cytotoxic Effects of Doxorubicin. <i>Tissue Engineering - Part A</i> , 2014, 20, 2412-2421.	1.6	40
2303	Immunotherapy for Brain Cancer: Recent Progress and Future Promise. <i>Clinical Cancer Research</i> , 2014, 20, 3651-3659.	3.2	92
2304	CD4 T Cells Require ICOS-Mediated PI3K Signaling to Increase T-Bet Expression in the Setting of Anti-CTLA-4 Therapy. <i>Cancer Immunology Research</i> , 2014, 2, 167-176.	1.6	39
2305	Successful engineering cancer immunotherapy. <i>European Journal of Immunology</i> , 2014, 44, 318-320.	1.6	2
2306	Controversies in the Management of Advanced Melanoma. <i>Annals of Pharmacotherapy</i> , 2014, 48, 1456-1468.	0.9	10
2307	Immunomodulation in cancer. <i>Current Opinion in Pharmacology</i> , 2014, 17, 17-21.	1.7	29
2308	Considerations for Combined Immune Checkpoint Modulation and Radiation Treatment. <i>Radiation Research</i> , 2014, 182, 230-238.	0.7	7
2309	The Optimal Partnership of Radiation and Immunotherapy: from Preclinical Studies to Clinical Translation. <i>Radiation Research</i> , 2014, 182, 170-181.	0.7	80
2310	Hallmarks of gastrointestinal neuroendocrine tumours: implications for treatment. <i>Endocrine-Related Cancer</i> , 2014, 21, R445-R460.	1.6	44
2311	New Strategies in Acute Myelogenous Leukemia: Leukemogenesis and Personalized Medicine. <i>Clinical Cancer Research</i> , 2014, 20, 6233-6241.	3.2	17

#	ARTICLE	IF	CITATIONS
2312	Immune approaches to the treatment of breast cancer, around the corner?. <i>Breast Cancer Research</i> , 2014, 16, 204.	2.2	38
2313	Metastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapy. <i>Oncogene</i> , 2014, 33, 5053-5064.	2.6	41
2314	Therapeutic vaccines as a promising treatment modality against prostate cancer: rationale and recent advances. <i>Therapeutic Advances in Vaccines</i> , 2014, 2, 137-148.	2.7	19
2315	Recent advances in the use of therapeutic cancer vaccines in genitourinary malignancies. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 1769-1781.	1.4	4
2316	Immunotherapy for Primary Brain Tumors: No Longer a Matter of Privilege. <i>Clinical Cancer Research</i> , 2014, 20, 5620-5629.	3.2	91
2317	Emerging immunotherapy strategies in breast cancer. <i>Immunotherapy</i> , 2014, 6, 195-209.	1.0	23
2318	Molecular Diagnostics for Dermatology. , 2014, , .		2
2319	Adenocarcinoma of Moll's gland with multiple metastases. <i>European Journal of Dermatology</i> , 2014, 24, 269-271.	0.3	1
2320	Neutrophilic disease of the skin and intestines after ipilimumab treatment for malignant melanoma â€“ simultaneous occurrence of pyoderma gangrenosum and colitis. <i>European Journal of Dermatology</i> , 2014, 24, 268-269.	0.3	23
2321	Nonstandard personalized medicine strategies for cancer may lead to improved patient outcomes. <i>Personalized Medicine</i> , 2014, 11, 705-719.	0.8	8
2322	Chimeric DNA Vaccines: An Effective Way to Overcome Immune Tolerance. <i>Current Topics in Microbiology and Immunology</i> , 2014, 405, 99-122.	0.7	10
2323	Long-term Complete Remission Following Radiosurgery and Immunotherapy in a Melanoma Patient with Brain Metastasis: Immunologic Correlates. <i>Cancer Immunology Research</i> , 2014, 2, 404-409.	1.6	10
2324	Design and development of therapies using chimeric antigen receptorâ€“expressing T cells. <i>Immunological Reviews</i> , 2014, 257, 107-126.	2.8	418
2325	The Curative Outcome of Radioimmunotherapy in a Mouse Breast Cancer Model Relies on mTOR Signaling. <i>Radiation Research</i> , 2014, 182, 219.	0.7	29
2326	Anaphylaxis caused by repetitive doses of a GITR agonist monoclonal antibody in mice. <i>Blood</i> , 2014, 123, 2172-2180.	0.6	23
2327	Antibody-based immunotherapy for ovarian cancer: where are we at?. <i>Annals of Oncology</i> , 2014, 25, 322-331.	0.6	38
2328	Immuno-oncology Combinations: A Review of Clinical Experience and Future Prospects. <i>Clinical Cancer Research</i> , 2014, 20, 6258-6268.	3.2	88
2329	The Path to Reactivation of Antitumor Immunity and Checkpoint Immunotherapy. <i>Cancer Immunology Research</i> , 2014, 2, 926-936.	1.6	23

#	ARTICLE	IF	CITATIONS
2331	Combining Radiation and Immunotherapy: A New Systemic Therapy for Solid Tumors?. <i>Cancer Immunology Research</i> , 2014, 2, 831-838.	1.6	270
2332	Immunotherapy advances for glioblastoma. <i>Neuro-Oncology</i> , 2014, 16, 1441-1458.	0.6	164
2333	Feasibility Study on Measuring Selected Proteins in Malignant Melanoma Tissue by SRM Quantification. <i>Journal of Proteome Research</i> , 2014, 13, 1315-1326.	1.8	9
2334	Stereotactic ablative body radiotherapy combined with immunotherapy: Present status and future perspectives. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2014, 18, 391-395.	0.6	23
2335	Antilymphocyte Globulin, Monoclonal Antibodies, and Fusion Proteins. , 2014, , 287-313.		1
2336	The Carcinoma-Associated Fibroblast Expressing Fibroblast Activation Protein and Escape from Immune Surveillance. <i>Cancer Immunology Research</i> , 2014, 2, 187-193.	1.6	223
2337	Primer on Immuno-Oncology and Immune Response. <i>Clinical Journal of Oncology Nursing</i> , 2014, 18, 311-317.	0.3	10
2338	Pituitary side effects of old and new drugs. <i>Journal of Endocrinological Investigation</i> , 2014, 37, 917-923.	1.8	18
2339	123I-BZA2 as a Melanin-Targeted Radiotracer for the Identification of Melanoma Metastases: Results and Perspectives of a Multicenter Phase III Clinical Trial. <i>Journal of Nuclear Medicine</i> , 2014, 55, 15-22.	2.8	38
2340	Antibody-Based Immunotherapy for Malignant Glioma. <i>Seminars in Oncology</i> , 2014, 41, 496-510.	0.8	11
2341	Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. <i>Lancet, The</i> , 2014, 384, 1109-1117.	6.3	1,588
2342	Acquired and intrinsic resistance in cancer immunotherapy. <i>Molecular Oncology</i> , 2014, 8, 1132-1139.	2.1	153
2343	Significance of interleukin-13 receptor alpha 2-targeted glioblastoma therapy. <i>Neuro-Oncology</i> , 2014, 16, 1304-1312.	0.6	131
2344	Immunotherapy: is a minor god yet in the pantheon of treatments for lung cancer?. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 1173-1187.	1.1	25
2345	Tracking Cellular and Immune Therapies in Cancer. <i>Advances in Cancer Research</i> , 2014, 124, 257-296.	1.9	25
2346	Immune modulation for cancer therapy. <i>British Journal of Cancer</i> , 2014, 111, 2214-2219.	2.9	128
2347	Ipilimumab in the treatment of advanced melanoma – a clinical update. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 1709-1718.	1.4	8
2348	Humanized Mice as a Model for Aberrant Responses in Human T Cell Immunotherapy. <i>Journal of Immunology</i> , 2014, 193, 587-596.	0.4	51

#	ARTICLE	IF	CITATIONS
2349	LSECTin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses. <i>Cancer Research</i> , 2014, 74, 3418-3428.	0.4	270
2350	T cell differentiation in chronic infection and cancer: functional adaptation or exhaustion?. <i>Nature Reviews Immunology</i> , 2014, 14, 768-774.	10.6	248
2351	Tumor-Reactive CD8+ T Cells in Metastatic Gastrointestinal Cancer Refractory to Chemotherapy. <i>Clinical Cancer Research</i> , 2014, 20, 331-343.	3.2	55
2352	Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma. <i>New England Journal of Medicine</i> , 2014, 371, 1877-1888.	13.9	1,572
2353	Optimal Management of Skin Cancer in Immunosuppressed Patients. <i>American Journal of Clinical Dermatology</i> , 2014, 15, 339-356.	3.3	38
2354	Achievements and challenges of adoptive T cell therapy with tumor-infiltrating or blood-derived lymphocytes for metastatic melanoma: what is needed to achieve standard of care?. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 1081-1091.	2.0	48
2355	No longer an untreatable disease: How targeted and immunotherapies have changed the management of melanoma patients. <i>Molecular Oncology</i> , 2014, 8, 1140-1158.	2.1	47
2356	Hostile, Hypoxiaâ€A2-Adenosinergic Tumor Biology as the Next Barrier to Overcome for Tumor Immunologists. <i>Cancer Immunology Research</i> , 2014, 2, 598-605.	1.6	180
2357	Adjuvant Interferon in Melanoma: Is Duration of Therapy Important?. <i>Journal of Clinical Oncology</i> , 2014, 32, 171-173.	0.8	6
2358	New Strategies in Lung Cancer: Translating Immunotherapy into Clinical Practice. <i>Clinical Cancer Research</i> , 2014, 20, 1067-1073.	3.2	52
2359	A Notch for Noncoding RNA in Melanoma. <i>New England Journal of Medicine</i> , 2014, 370, 1950-1951.	13.9	5
2360	Clinical cancer research: the past, present and the future. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 663-669.	12.5	29
2361	PTPN2 restrains CD8+ T cell responses after antigen cross-presentation for the maintenance of peripheral tolerance in mice. <i>Journal of Autoimmunity</i> , 2014, 53, 105-114.	3.0	39
2362	Management of Castration Resistant Prostate Cancer. <i>Current Clinical Urology</i> , 2014, , .	0.0	2
2363	American Society of Clinical Oncology Perspective: Raising the Bar for Clinical Trials by Defining Clinically Meaningful Outcomes. <i>Journal of Clinical Oncology</i> , 2014, 32, 1277-1280.	0.8	354
2364	Tumorâ€specific <sc>CD</sc>4⁺<sc>T</sc> cells maintain effector and memory tumorâ€specific <sc>CD</sc>8⁺<sc>T</sc> cells. <i>European Journal of Immunology</i> , 2014, 44, 69-79.	1.6	98
2365	A Novel Cancer Therapeutic Using Thrombospondin 1 in Dendritic Cells. <i>Molecular Therapy</i> , 2014, 22, 292-302.	3.7	35
2366	Heat-shock proteins-based immunotherapy for advanced melanoma in the era of target therapies and immunomodulating agents. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 955-967.	1.4	20

#	ARTICLE	IF	CITATIONS
2370	Radical Irradiation of Extracranial Oligometastases. <i>Journal of Clinical Oncology</i> , 2014, 32, 2902-2912.	0.8	82
2371	Management of melanoma. <i>British Medical Bulletin</i> , 2014, 111, 149-162.	2.7	61
2372	Targeting Cancer-Derived Adenosine:New Therapeutic Approaches. <i>Cancer Discovery</i> , 2014, 4, 879-888.	7.7	256
2373	Foxp3+ T Cells Inhibit Antitumor Immune Memory Modulated by mTOR Inhibition. <i>Cancer Research</i> , 2014, 74, 2217-2228.	0.4	32
2374	Targeted Therapy in Older Patients With Solid Tumors. <i>Journal of Clinical Oncology</i> , 2014, 32, 2635-2646.	0.8	36
2375	Systemic treatment for BRAF-mutant melanoma: where do we go next?. <i>Lancet Oncology</i> , The, 2014, 15, e371-e381.	5.1	130
2376	Myeloid-derived suppressor cell heterogeneity in human cancers. <i>Annals of the New York Academy of Sciences</i> , 2014, 1319, 47-65.	1.8	349
2377	Message in a bottle: decoding medication injury patterns in the gastrointestinal tract. <i>Journal of Clinical Pathology</i> , 2014, 67, 903-912.	1.0	17
2378	New Strategies in Advanced Cervical Cancer: From Angiogenesis Blockade to Immunotherapy. <i>Clinical Cancer Research</i> , 2014, 20, 5349-5358.	3.2	69
2379	Combined Targeting of Costimulatory (OX40) and Coinhibitory (CTLA-4) Pathways Elicits Potent Effector T Cells Capable of Driving Robust Antitumor Immunity. <i>Cancer Immunology Research</i> , 2014, 2, 142-153.	1.6	131
2380	Immune-based therapies in pancreatic and colorectal cancers and biomarkers of responsiveness. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 1219-1228.	1.1	1
2381	Melanocytic Lesions. , 2014, , .		2
2382	Crosstalk between dendritic cell subsets and implications for dendritic cell-based anticancer immunotherapy. <i>Expert Review of Clinical Immunology</i> , 2014, 10, 915-926.	1.3	22
2383	Molecular insights into the development of T cell-based immunotherapy for prostate cancer. <i>Expert Review of Clinical Immunology</i> , 2014, 10, 1547-1557.	1.3	7
2384	Stromal reengineering to treat pancreas cancer. <i>Carcinogenesis</i> , 2014, 35, 1451-1460.	1.3	108
2385	Entering the mainstream of cancer treatment. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 630-632.	12.5	150
2386	Serious haematological toxicity during and after ipilimumab treatment: a case series. <i>Journal of Medical Case Reports</i> , 2014, 8, 240.	0.4	50
2387	Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma. , 2014, 2, 11.		173

#	ARTICLE	IF	CITATIONS
2388	Optimizing immune-related tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab?. , 2014, 2, 17.		77
2389	Opportunistic infections in patients treated with immunotherapy for cancer. , 2014, 2, 19.		98
2390	Neoadjuvant anti-tumor vaccination prior to surgery enhances survival. Journal of Translational Medicine, 2014, 12, 245.	1.8	12
2391	Treatment of unresectable stage IV metastatic melanoma with aviscumine after anti-neoplastic treatment failure: a phase II, multi-centre study. , 2014, 2, 27.		7
2392	The role of Fc gamma receptors in the activity of immunomodulatory antibodies for cancer. , 2014, 2, .		110
2393	Phase I/II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients With Advanced Melanoma. Journal of Clinical Oncology, 2014, 32, 3659-3666.	0.8	72
2394	Shaping of an effective immune microenvironment to and by cancer cells. Cancer Immunology, Immunotherapy, 2014, 63, 991-997.	2.0	30
2395	Fc Receptors. Current Topics in Microbiology and Immunology, 2014, , .	0.7	11
2396	Nivolumab: Promising Survival Signal Coupled With Limited Toxicity Raises Expectations. Journal of Clinical Oncology, 2014, 32, 986-988.	0.8	50
2397	Going viral with cancer immunotherapy. Nature Reviews Cancer, 2014, 14, 559-567.	12.8	500
2398	Melanoma Vaccines. Surgical Clinics of North America, 2014, 94, 1017-1030.	0.5	36
2399	Indications and Options for Systemic Therapy in Melanoma. Surgical Clinics of North America, 2014, 94, 1049-1058.	0.5	12
2400	Surgical Treatment Options for Stage IV Melanoma. Surgical Clinics of North America, 2014, 94, 1075-1089.	0.5	10
2401	Drug therapies in dermatology. Clinical Medicine, 2014, 14, 47-53.	0.8	7
2403	The Alarmin HMG1L1 Contributes to Antitumor Immunity and Is a Potent Immunoadjuvant. Cancer Research, 2014, 74, 5989-5998.	0.4	56
2405	Myeloid-derived suppressor cells and their role in CTLA-4 blockade therapy. Cancer Immunology, Immunotherapy, 2014, 63, 977-983.	2.0	31
2406	Stromal Fibroblasts and the Immune Microenvironment: Partners in Mammary Gland Biology and Pathology?. Journal of Mammary Gland Biology and Neoplasia, 2014, 19, 169-182.	1.0	31
2407	Phenotypic alterations, clinical impact and therapeutic potential of regulatory T cells in cancer. Expert Opinion on Biological Therapy, 2014, 14, 931-945.	1.4	28

#	ARTICLE	IF	CITATIONS
2409	Human hepatocellular carcinoma-infiltrating CD4+CD69+Foxp3 ⁺ regulatory T cell suppresses T cell response via membrane-bound TGF- β 1. <i>Journal of Molecular Medicine</i> , 2014, 92, 539-550.	1.7	33
2410	Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies. <i>Journal of Molecular Medicine</i> , 2014, 92, 709-722.	1.7	75
2411	Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 449-58.	2.0	253
2412	Influence of natural killer cells and perforin-mediated cytotoxicity on the development of chemically induced lung cancer in A/J mice. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 571-580.	2.0	12
2413	Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 675-683.	2.0	230
2414	Optimized dendritic cell-based immunotherapy for melanoma: the TriMix-formula. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 959-967.	2.0	74
2415	Radiation-induced autophagy potentiates immunotherapy of cancer via up-regulation of mannose 6-phosphate receptor on tumor cells in mice. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 1009-1021.	2.0	40
2416	Electrochemotherapy for the management of melanoma skin metastasis: a review of the literature and possible combinations with immunotherapy. <i>Archives of Dermatological Research</i> , 2014, 306, 521-526.	1.1	31
2417	Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 1615-1624.	1.2	84
2419	Kidney injuries related to ipilimumab. <i>Investigational New Drugs</i> , 2014, 32, 769-773.	1.2	153
2420	Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme. <i>Journal of Experimental and Clinical Cancer Research</i> , 2014, 33, 30.	3.5	97
2421	Cytokine responsiveness of CD8 ⁺ T cells is a reproducible biomarker for the clinical efficacy of dendritic cell vaccination in glioblastoma patients. , 2014, 2, 10.		29
2422	Durable responses and reversible toxicity of high-dose interleukin-2 treatment of melanoma and renal cancer in a Community Hospital Biotherapy Program. , 2014, 2, 13.		82
2423	Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer. , 2014, 2, 14.		108
2424	Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8 ⁺ T cells directly within the tumor microenvironment. , 2014, 2, 3.		460
2425	Prolonged repeated vaccine immuno-chemotherapy induces long-term clinical responses and survival for advanced metastatic melanoma. , 2014, 2, 9.		14
2426	Immunotherapy Following Regional Chemotherapy Treatment of Advanced Extremity Melanoma. <i>Annals of Surgical Oncology</i> , 2014, 21, 2525-2531.	0.7	13
2427	Inflammatory Adverse Events are Associated with Disease-Free Survival after Vaccine Therapy among Patients with Melanoma. <i>Annals of Surgical Oncology</i> , 2014, 21, 3978-3984.	0.7	7

#	ARTICLE	IF	CITATIONS
2428	A Safety and Feasibility Study of an Allogeneic Colon Cancer Cell Vaccine Administered with a Granulocyte Macrophage Colony Stimulating Factor Producing Bystander Cell Line in Patients with Metastatic Colorectal Cancer. <i>Annals of Surgical Oncology</i> , 2014, 21, 3931-3937.	0.7	26
2429	Discovery of <i>N</i> -((4-([1,2,4]Triazolo[1,5- <i>a</i>]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1 <i>H</i> -imidazol-2-yl)methyl)-2-fluoroaniline (EW-7197): A Highly Potent, Selective, and Orally Bioavailable Inhibitor of TGF- β Type I Receptor Kinase as Cancer Immunotherapeutic/Antifibrotic Agent. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 4213-4238.	2.9	108
2430	Stem Cells in Cancer: Should We Believe or Not?. , 2014, , .		2
2431	Monoclonal antibodies as therapeutics in human malignancies. <i>Future Oncology</i> , 2014, 10, 609-636.	1.1	20
2432	Breast cancer immunotherapy: monoclonal antibodies and peptide-based vaccines. <i>Expert Review of Clinical Immunology</i> , 2014, 10, 927-961.	1.3	33
2433	Shaping the repertoire of tumor-infiltrating effector and regulatory T cells. <i>Immunological Reviews</i> , 2014, 259, 245-258.	2.8	70
2434	Metastatic melanoma to the liver: A contemporary and comprehensive review of surgical, systemic, and regional therapeutic options. <i>Cancer</i> , 2014, 120, 781-789.	2.0	79
2435	Immunotherapy for lung cancer: ongoing clinical trials. <i>Future Oncology</i> , 2014, 10, 91-105.	1.1	27
2436	Towards the introduction of the Immunoscore™ in the classification of malignant tumours. <i>Journal of Pathology</i> , 2014, 232, 199-209.	2.1	1,151
2437	Adoptive immunotherapy for cancer. <i>Immunological Reviews</i> , 2014, 257, 14-38.	2.8	119
2438	Whole genome gene copy number profiling of gastric cancer identifies <i>PAK1</i> and <i>KRAS</i> gene amplification as therapy targets. <i>Genes Chromosomes and Cancer</i> , 2014, 53, 883-894.	1.5	69
2439	Combining Targeted Therapy With Immunotherapy in <i>BRAF</i> -Mutant Melanoma: Promise and Challenges. <i>Journal of Clinical Oncology</i> , 2014, 32, 2248-2254.	0.8	184
2440	Efficient Induction of Antitumor Immunity by Synthetic Toll-like Receptor Ligand Peptide Conjugates. <i>Cancer Immunology Research</i> , 2014, 2, 756-764.	1.6	83
2441	The novel PI3 kinase inhibitor, BAY 806946, impairs melanoma growth <i>in vivo</i> and <i>in vitro</i> . <i>Experimental Dermatology</i> , 2014, 23, 579-584.	1.4	13
2442	Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy. <i>Clinical Cancer Research</i> , 2014, 20, 5064-5074.	3.2	2,050
2443	Phase I Expansion and Pharmacodynamic Study of the Oral MEK Inhibitor RO4987655 (CH4987655) in Selected Patients with Advanced Cancer with <i>RAS</i> / <i>RAF</i> Mutations. <i>Clinical Cancer Research</i> , 2014, 20, 4251-4261.	3.2	60
2444	Clinical Atlas of Skin Tumors. , 2014, , .		7
2445	Therapeutic vaccines for cancer: an overview of clinical trials. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 509-524.	12.5	636

#	ARTICLE	IF	CITATIONS
2446	Lymphoma Immune Reconstitution Inflammatory Syndrome in the Center for AIDS Research Network of Integrated Clinical Systems Cohort. <i>Clinical Infectious Diseases</i> , 2014, 59, 279-286.	2.9	35
2447	Antimetastatic Effects of Blocking PD-1 and the Adenosine A2A Receptor. <i>Cancer Research</i> , 2014, 74, 3652-3658.	0.4	217
2448	What Is the Role of Chemotherapy in the Treatment of Melanoma?. <i>Current Treatment Options in Oncology</i> , 2014, 15, 321-335.	1.3	20
2449	Managing The Skin Toxicities From New Melanoma Drugs. <i>Current Treatment Options in Oncology</i> , 2014, 15, 281-301.	1.3	17
2450	Microenvironmental Clues for Glioma Immunotherapy. <i>Current Neurology and Neuroscience Reports</i> , 2014, 14, 440.	2.0	51
2451	Tumor antigen discovery through translation of the cancer genome. <i>Immunologic Research</i> , 2014, 58, 292-299.	1.3	13
2452	Unmet needs in squamous cell carcinoma of the lung: potential role for immunotherapy. <i>Medical Oncology</i> , 2014, 31, 960.	1.2	19
2453	Psychological Changes in Melanoma Patients During Ipilimumab Treatment Compared to Low-Dose Interferon Alpha Therapy—A Follow-Up Study of First Experiences. <i>Pathology and Oncology Research</i> , 2014, 20, 939-944.	0.9	6
2455	Ipilimumab: a guide to its use in advanced melanoma in the EU. <i>Drugs and Therapy Perspectives</i> , 2014, 30, 124-129.	0.3	1
2456	Monitoring changes in circulating tumour cells as a prognostic indicator of overall survival and treatment response in patients with metastatic melanoma. <i>BMC Cancer</i> , 2014, 14, 423.	1.1	48
2457	Clinical experience with ipilimumab 3Âmg/kg: real-world efficacy and safety data from an expanded access programme cohort. <i>Journal of Translational Medicine</i> , 2014, 12, 116.	1.8	149
2458	Phage idiotype vaccination: first phase I/II clinical trial in patients with multiple myeloma. <i>Journal of Translational Medicine</i> , 2014, 12, 119.	1.8	24
2459	What have we learned from cancer immunotherapy in the last 3Âyears?. <i>Journal of Translational Medicine</i> , 2014, 12, 141.	1.8	28
2460	MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial. <i>Journal of Translational Medicine</i> , 2014, 12, 97.	1.8	69
2461	Systems biology analysis of immune signaling in peripheral blood mononuclear cells (PBMC) of melanoma patients receiving ipilimumab; basis for response biomarker identification. <i>Journal of Translational Medicine</i> , 2014, 12, O13.	1.8	1
2462	Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid derived suppressor cells as well as their arginase1 production. <i>Journal of Translational Medicine</i> , 2014, 12, O9.	1.8	1
2463	Overall survival of patients with chemotherapy-naïve advanced melanoma treated with ipilimumab 3 mg/kg in clinical trials. <i>Journal of Translational Medicine</i> , 2014, 12, P8.	1.8	1
2464	Proteomics analysis of melanoma metastases: association between S100A13 expression and chemotherapy resistance. <i>British Journal of Cancer</i> , 2014, 110, 2489-2495.	2.9	39

#	ARTICLE	IF	CITATIONS
2465	Dabrafenib and Trametinib, Alone and in Combination for <i>BRAF</i> -Mutant Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2014, 20, 2035-2043.	3.2	135
2466	Low-dose inhalation of interleukin-2 bio-chemotherapy for the treatment of pulmonary metastases in melanoma patients. <i>British Journal of Cancer</i> , 2014, 110, 1427-1432.	2.9	26
2467	Novel treatments for head and neck squamous cell carcinoma: preclinical identification and clinical investigation. <i>Future Oncology</i> , 2014, 10, 1065-1080.	1.1	8
2468	Tackling the cancer stem cells " what challenges do they pose?. <i>Nature Reviews Drug Discovery</i> , 2014, 13, 497-512.	21.5	831
2469	Modern Cancer Drug Discovery. , 2014, , 3-53.		8
2470	Immunologic and Clinical Effects of Targeting PD-1 in Lung Cancer. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 96, 214-223.	2.3	73
2471	Multicenter Phase II Study of Mogamulizumab (KW-0761), a Defucosylated Anti-CC Chemokine Receptor 4 Antibody, in Patients With Relapsed Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 1157-1163.	0.8	309
2472	Correlation of Somatic Mutations and Clinical Outcome in Melanoma Patients Treated with Carboplatin, Paclitaxel, and Sorafenib. <i>Clinical Cancer Research</i> , 2014, 20, 3328-3337.	3.2	33
2473	Melanoma: Diagnosis, Staging, and Treatment. Consensus group recommendations. <i>Advances in Therapy</i> , 2014, 31, 945-960.	1.3	35
2474	Melanoma: immune checkpoint blockade story gets better. <i>Lancet, The</i> , 2014, 384, 1078-1079.	6.3	10
2475	Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab. <i>Journal of Clinical Oncology</i> , 2014, 32, 1020-1030.	0.8	2,015
2476	Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. <i>Endocrine-Related Cancer</i> , 2014, 21, 371-381.	1.6	370
2477	VISTA Is a Novel Broad-Spectrum Negative Checkpoint Regulator for Cancer Immunotherapy. <i>Cancer Immunology Research</i> , 2014, 2, 510-517.	1.6	187
2478	Melanoma-derived <i>IL-1</i> converts vascular endothelium to a proinflammatory and procoagulatory phenotype via <i>NF-κB</i> activation. <i>Experimental Dermatology</i> , 2014, 23, 670-676.	1.4	23
2479	Cancer-related inflammation and treatment effectiveness. <i>Lancet Oncology, The</i> , 2014, 15, e493-e503.	5.1	1,525
2480	Tumor-Induced Immune Suppression. , 2014, , .		3
2481	Castration-resistant prostate cancer: latest evidence and therapeutic implications. <i>Therapeutic Advances in Medical Oncology</i> , 2014, 6, 167-179.	1.4	67
2482	Personalized treatments of cancer patients: A reality in daily practice, a costly dream or a shared vision of the future from the oncology community?. <i>Cancer Treatment Reviews</i> , 2014, 40, 1192-1198.	3.4	51

#	ARTICLE	IF	CITATIONS
2483	Immunological off-target effects of standard treatments in gastrointestinal cancers. <i>Annals of Oncology</i> , 2014, 25, 24-32.	0.6	51
2484	Cyclin-dependent kinases as therapeutic targets in melanoma. <i>Pigment Cell and Melanoma Research</i> , 2014, 27, 351-365.	1.5	21
2485	Fc Receptor-Dependent Mechanisms of Monoclonal Antibody Therapy of Cancer. <i>Current Topics in Microbiology and Immunology</i> , 2014, 382, 373-392.	0.7	65
2486	<i>In Vitro</i> Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and <i>In Vivo</i> Toxicology in Non-Human Primates. <i>Cancer Immunology Research</i> , 2014, 2, 846-856.	1.6	514
2487	Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma. <i>Cancer Immunology Research</i> , 2014, 2, 632-642.	1.6	512
2488	Breaking immune tolerance by targeting CD25+ regulatory T cells is essential for the anti-tumor effect of the CTLA-4 blockade in an HLA-DR transgenic mouse model of prostate cancer. <i>Prostate</i> , 2014, 74, 1423-1432.	1.2	16
2489	Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. <i>Lancet Oncology</i> , The, 2014, 15, 323-332.	5.1	890
2490	Value of positron emission tomography scan in stage III cutaneous melanoma: A systematic review and meta-analysis. <i>Surgical Oncology</i> , 2014, 23, 11-16.	0.8	49
2491	Angiogenesis and the Tumor Microenvironment: Vascular Endothelial Growth Factor and Beyond. <i>Seminars in Oncology</i> , 2014, 41, 235-251.	0.8	129
2492	Bases inmunológicas de la hipopigmentación vitiligoide asociada a melanoma. <i>Actas Dermo-sifiliográficas</i> , 2014, 105, 122-127.	0.2	3
2493	Commentary: Molecular testing in melanoma. <i>Journal of the American Academy of Dermatology</i> , 2014, 70, 863-870.	0.6	4
2494	Rôle de la TEP/TDM dans la prise en charge du mélanome. <i>Medecine Nucleaire</i> , 2014, 38, 216-220.	0.2	0
2495	Expression of cancer testis antigens CT10 (MAGE-C2) and GAGE in gastrointestinal stromal tumors. <i>European Journal of Surgical Oncology</i> , 2014, 40, 1307-1312.	0.5	11
2496	Acute phase response before treatment predicts radiation esophagitis in non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2014, 110, 493-498.	0.3	11
2497	Combinations of Radiation Therapy and Immunotherapy for Melanoma: A Review of Clinical Outcomes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 986-997.	0.4	142
2498	BRAF inhibitor (vemurafenib) concurrent with radiation therapy for metastatic melanoma producing severe skin and oral cavity reactions. <i>Practical Radiation Oncology</i> , 2014, 4, e213-e216.	1.1	6
2499	PFS as a surrogate for overall survival in metastatic melanoma. <i>Lancet Oncology</i> , The, 2014, 15, 246-248.	5.1	2
2500	Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study. <i>Lancet Oncology</i> , The, 2014, 15, 620-630.	5.1	96

#	ARTICLE	IF	CITATIONS
2501	166Ho and 90Y labeled 6D2 monoclonal antibody for targeted radiotherapy of melanoma: Comparison with 188Re radiolabel. <i>Nuclear Medicine and Biology</i> , 2014, 41, 276-281.	0.3	21
2502	A 20-Year Experience of Hepatic Resection for Melanoma: Is There an Expanding Role?. <i>Journal of the American College of Surgeons</i> , 2014, 219, 62-68.	0.2	41
2503	The State of the Art in Non-“Small Cell Lung Cancer Immunotherapy. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2014, 26, 26-35.	0.4	11
2504	Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study. <i>Lancet Oncology, The</i> , 2014, 15, 436-444.	5.1	242
2505	Cutaneous Melanoma in Children and Adolescents: The Italian Rare Tumors in Pediatric Age Project Experience. <i>Journal of Pediatrics</i> , 2014, 164, 376-382.e2.	0.9	47
2506	Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. <i>Lancet Oncology, The</i> , 2014, 15, 700-712.	5.1	1,280
2507	Microsurgery for the treatment of primary malignant intracranial melanoma: A surgical series and literature review. <i>European Journal of Surgical Oncology</i> , 2014, 40, 1062-1071.	0.5	18
2508	Estimating the cure proportion of malignant melanoma, an alternative approach to assess long term survival: A population-based study. <i>Cancer Epidemiology</i> , 2014, 38, 93-99.	0.8	20
2509	Control of minimal residual cancer by low dose ipilimumab activating autologous anti-tumor immunity. <i>Pharmacological Research</i> , 2014, 79, 9-12.	3.1	9
2510	Stem cells and targeted approaches to melanoma cure. <i>Molecular Aspects of Medicine</i> , 2014, 39, 33-49.	2.7	44
2511	Can calcium signaling be harnessed for cancer immunotherapy?. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2014, 1843, 2334-2340.	1.9	9
2512	Ipilimumab in patients with cancer and the management of dermatologic adverse events. <i>Journal of the American Academy of Dermatology</i> , 2014, 71, 161-169.	0.6	170
2513	Tumor Radiation Therapy Creates Therapeutic Vaccine Responses to the Colorectal Cancer Antigen GUCY2C. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 1188-1195.	0.4	29
2514	Targeting and depletion of circulating leukocytes and cancer cells by lipophilic antibody-modified erythrocytes. <i>Journal of Controlled Release</i> , 2014, 183, 146-153.	4.8	45
2515	Role of the immune system in pancreatic cancer progression and immune modulating treatment strategies. <i>Cancer Treatment Reviews</i> , 2014, 40, 513-522.	3.4	141
2516	Immunomodulatory Effects of Sex Hormones: Requirements for Pregnancy and Relevance in Melanoma. <i>Mayo Clinic Proceedings</i> , 2014, 89, 520-535.	1.4	53
2517	Vaccines and Melanoma. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 559-569.	0.9	20
2518	Impact of tumour microenvironment and Fc receptors on the activity of immunomodulatory antibodies. <i>Trends in Immunology</i> , 2014, 35, 290-298.	2.9	96

#	ARTICLE	IF	CITATIONS
2519	Immunosurveillance by Antiangiogenesis: Tumor Growth Arrest by T Cell-Derived Thrombospondin-1. <i>Cancer Research</i> , 2014, 74, 2171-2181.	0.4	17
2520	Reversal of NK-Cell Exhaustion in Advanced Melanoma by Tim-3 Blockade. <i>Cancer Immunology Research</i> , 2014, 2, 410-422.	1.6	322
2521	Immune checkpoint blockade in hepatocellular carcinoma: Current progress and future directions. <i>Hepatology</i> , 2014, 60, 1776-1782.	3.6	210
2522	Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy. <i>Journal of Experimental Medicine</i> , 2014, 211, 715-725.	4.2	242
2523	The interplay between the immune system and chemotherapy: emerging methods for optimizing therapy. <i>Expert Review of Clinical Immunology</i> , 2014, 10, 19-30.	1.3	48
2524	Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma. <i>Clinical Cancer Research</i> , 2014, 20, 3446-3457.	3.2	294
2525	A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 407-418.	2.0	82
2526	Vaccines for the 21st century. <i>EMBO Molecular Medicine</i> , 2014, 6, 708-720.	3.3	342
2527	Targeting the PD-1 pathway: a promising future for the treatment of melanoma. <i>Archives of Dermatological Research</i> , 2014, 306, 511-519.	1.1	63
2528	Regulatory T-cell homeostasis: steady-state maintenance and modulation during inflammation. <i>Immunological Reviews</i> , 2014, 259, 40-59.	2.8	177
2529	Prostate cancer vaccines in combination with additional treatment modalities. <i>Immunologic Research</i> , 2014, 59, 236-242.	1.3	15
2530	Cancer treatment and survivorship statistics, 2014. <i>Ca-A Cancer Journal for Clinicians</i> , 2014, 64, 252-271.	157.7	2,474
2531	Updates on immunotherapy in non-small cell lung cancer. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 411-418.	1.4	3
2532	Current Advances in Osteosarcoma. <i>Advances in Experimental Medicine and Biology</i> , 2014, , .	0.8	14
2533	Emerging therapeutic targets for synovial sarcoma. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 791-806.	1.1	11
2534	Study of Circulating MicroRNA-125b Levels in Serum Exosomes in Advanced Melanoma. <i>Archives of Pathology and Laboratory Medicine</i> , 2014, 138, 828-832.	1.2	117
2535	Advances in Therapy for Pediatric Sarcomas. <i>Current Oncology Reports</i> , 2014, 16, 395.	1.8	25
2536	Treatments for Noncutaneous Melanoma. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 507-521.	0.9	12

#	ARTICLE	IF	CITATIONS
2537	Precision Medicine in Oncology Standard of Care. <i>Seminars in Oncology Nursing</i> , 2014, 30, 100-108.	0.7	1
2538	Ipilimumab in non-small cell lung cancer and small-cell lung cancer: new knowledge on a new therapeutic strategy. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 1007-1017.	1.4	10
2539	Transient Ablation of Regulatory T cells Improves Antitumor Immunity in Colitis-Associated Colon Cancer. <i>Cancer Research</i> , 2014, 74, 4258-4269.	0.4	84
2540	Pretreatment Serum VEGF Is Associated with Clinical Response and Overall Survival in Advanced Melanoma Patients Treated with Ipilimumab. <i>Cancer Immunology Research</i> , 2014, 2, 127-132.	1.6	122
2541	A Review of Novel Therapies for Melanoma. <i>American Journal of Clinical Dermatology</i> , 2014, 15, 323-337.	3.3	55
2542	B Cells Regulate Macrophage Phenotype and Response to Chemotherapy in Squamous Carcinomas. <i>Cancer Cell</i> , 2014, 25, 809-821.	7.7	245
2543	Surgical Management of Melanoma. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 455-470.	0.9	14
2544	Melanoma Adjuvant Therapy. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 471-489.	0.9	13
2545	Activation of benign autoimmunity as both tumor and autoimmune disease immunotherapy: A comprehensive review. <i>Journal of Autoimmunity</i> , 2014, 54, 112-117.	3.0	42
2546	Understanding the Biology of Melanoma and Therapeutic Implications. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 437-453.	0.9	33
2547	Clinical use of dendritic cells for cancer therapy. <i>Lancet Oncology</i> , The, 2014, 15, e257-e267.	5.1	565
2548	State of Melanoma. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 415-435.	0.9	32
2549	Malignant melanoma of the gastro-intestinal tract: A case series. <i>International Journal of Surgery</i> , 2014, 12, 523-527.	1.1	24
2550	Systemic treatments for brain metastases from breast cancer, non-small cell lung cancer, melanoma and renal cell carcinoma: An overview of the literature. <i>Cancer Treatment Reviews</i> , 2014, 40, 951-959.	3.4	43
2551	Immune Checkpoint Blockade. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 585-600.	0.9	70
2552	Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma. <i>European Journal of Cancer</i> , 2014, 50, 121-127.	1.3	149
2553	Latest Advances in Chemotherapeutic, Targeted, and Immune Approaches in the Treatment of Metastatic Melanoma. <i>Mayo Clinic Proceedings</i> , 2014, 89, 504-519.	1.4	77
2554	Melanoma metastasis: new concepts and evolving paradigms. <i>Oncogene</i> , 2014, 33, 2413-2422.	2.6	120

#	ARTICLE	IF	CITATIONS
2555	Targeted therapy for melanoma: rational combinatorial approaches. <i>Oncogene</i> , 2014, 33, 1-9.	2.6	85
2556	The Use of Registries to Improve Cancer Treatment: A National Database for Patients Treated with Interleukin-2 (IL-2). <i>Journal of Personalized Medicine</i> , 2014, 4, 52-64.	1.1	12
2557	Management of a Patient With Advanced BRAF-Mutant Melanoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 315-319.	2.3	1
2558	Towards combinatorial targeted therapy in melanoma: From pre-clinical evidence to clinical application (Review). <i>International Journal of Oncology</i> , 2014, 45, 929-949.	1.4	34
2559	Patterns of long-term survival following Ipilimumab (Ipi): the Memorial Sloan Kettering Cancer Center 10-year metastatic melanoma (MM) experience. , 2014, 2, .		1
2560	Reversing gp100/IFA-induced impairment of anti-CTLA-4 checkpoint blockade therapy. , 2014, 2, .		1
2561	Systemic and Targeted Therapies for Early-Stage Lung Cancer. <i>Cancer Control</i> , 2014, 21, 21-31.	0.7	22
2562	PD-1 Pathway Inhibitors: Changing the Landscape of Cancer Immunotherapy. <i>Cancer Control</i> , 2014, 21, 231-237.	0.7	127
2563	Current Clinical Application of Genomic and Proteomic Profiling in Non-Small-Cell Lung Cancer. <i>Cancer Control</i> , 2014, 21, 32-39.	0.7	6
2564	Antibody therapies for melanoma: New and emerging opportunities to activate immunity (Review). <i>Oncology Reports</i> , 2014, 32, 875-886.	1.2	37
2565	A blood test to identify when melanoma metastasizes: a reality for melanoma management?. <i>Melanoma Management</i> , 2014, 1, 11-14.	0.1	0
2566	The role of chemotherapy in the modern management of melanoma. <i>Melanoma Management</i> , 2014, 1, 173-184.	0.1	8
2567	Advances in targeted therapy for melanoma: a focus on MEK inhibition. <i>Clinical Investigation</i> , 2014, 4, 903-913.	0.0	0
2569	Clinical electrochemotherapy for advanced superficial melanoma. , 2014, , 35-53.		2
2570	Potential of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer. <i>Molecular Therapy - Oncolytics</i> , 2014, 1, 14004.	2.0	33
2571	Management and orphan drug development for acute myeloid leukemia. <i>Expert Opinion on Orphan Drugs</i> , 2014, 2, 441-451.	0.5	0
2573	Melanoma of the gallbladder: appropriate surgical management and review of the literature. <i>Clinical Case Reports (discontinued)</i> , 2014, 2, 313-318.	0.2	20
2574	Medical application of magnetic materials for cancer therapy. <i>Drug Delivery System</i> , 2014, 29, 304-314.	0.0	1

#	ARTICLE	IF	CITATIONS
2576	Helper T-cell based immunotherapy combined with adjuvants in head and neck squamous cell carcinoma. <i>Journal of Japan Society of Immunology & Allergology in Otolaryngology</i> , 2014, 32, 185-190.	0.0	0
2577	Antimelanoma CTL recognizes peptides derived from an ORF transcribed from the antisense strand of the 3' untranslated region of TRIT1. <i>Molecular Therapy - Oncolytics</i> , 2014, 1, 14009.	2.0	2
2579	Cancer Immunology, Success Without Sequencing. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 443-445.	2.3	0
2580	BRAFV600E-Mutant Melanoma Presenting With Cardiac Involvement. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 611-615.	2.3	2
2581	Ipilimumab-Induced Hypophysitis and Uveitis in a Patient With Metastatic Melanoma and a History of Ipilimumab-Induced Skin Rash. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 1077-1081.	2.3	66
2582	Agents Make "Preferred List" in Metastatic Melanoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 785-787.	2.3	0
2583	Anti-CTLA4 Antibody Therapy Related Complications on FDG PET/CT. <i>Clinical Nuclear Medicine</i> , 2014, 39, e93-e96.	0.7	13
2584	Emerging targeted therapies for melanoma treatment (Review). <i>International Journal of Oncology</i> , 2014, 45, 516-524.	1.4	39
2585	Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. , 2014, 2, .		8
2586	Overcoming immune system evasion by personalized immunotherapy. <i>Personalized Medicine</i> , 2014, 11, 561-564.	0.8	1
2587	Management of "pan-negative" melanoma: current and emerging strategies. <i>Melanoma Management</i> , 2014, 1, 87-90.	0.1	0
2588	Is Surveillance Imaging Effective for Detecting Surgically Treatable Recurrences in Patients With Melanoma? A Comparative Analysis of Stage-Specific Surveillance Strategies. <i>Annals of Surgery</i> , 2014, 259, 1215-1222.	2.1	46
2589	Melanoma and nuclear medicine. <i>Melanoma Management</i> , 2014, 1, 57-74.	0.1	9
2590	Primary extramedullary spinal melanoma mimicking spinal meningioma: A case report and literature review. <i>Oncology Letters</i> , 2014, 8, 339-344.	0.8	14
2591	Combination therapies in advanced melanoma. <i>Melanoma Management</i> , 2014, 1, 47-56.	0.1	2
2592	How anti-PD1 treatments are changing the management of melanoma. <i>Melanoma Management</i> , 2014, 1, 165-172.	0.1	5
2593	Telomerase (GV1001) vaccination together with gemcitabine in advanced pancreatic cancer patients. <i>International Journal of Oncology</i> , 2014, 45, 1293-1303.	1.4	56
2594	Rethinking cancer immunotherapy: Using advanced cancer genetics in immune-mediated eradication of gastrointestinal cancers. <i>Hepatology</i> , 2014, 60, 2121-2124.	3.6	4

#	ARTICLE	IF	CITATIONS
2595	Multiple Metastatic Malignant Melanoma Presenting Intraluminal Gallbladder Bleeding. International Surgery, 2014, 99, 600-605.	0.0	12
2596	Adjuvant radiation for patients with melanoma. Lancet Oncology, The, 2015, 16, 1003-1004.	5.1	1
2597	Income-associated discrepancies in melanoma survival. Cancer Treatment Communications, 2015, 4, 143-147.	0.4	4
2598	Cutaneous melanoma and the new drugs. CirugÃa Y Cirujanos (English Edition), 2015, 83, 175-180.	0.0	1
2599	Predicting the outcome of melanoma: can we tell the future of a patient's melanoma?. Melanoma Management, 2015, 2, 217-224.	0.1	5
2600	Treatment possibilities of ipilimumab-induced thrombocytopenia--case study and literature review. Japanese Journal of Clinical Oncology, 2015, 45, 381-384.	0.6	28
2601	Targeting immune checkpoints in melanoma: an update. Melanoma Management, 2015, 2, 339-352.	0.1	2
2602	How should we use anti-CTLA-4 antibodies?. European Journal of Cancer, 2015, 51, 2686-2688.	1.3	6
2603	Nanomedicines Targeting the Tumor Microenvironment. Cancer Journal (Sudbury, Mass), 2015, 21, 314-321.	1.0	64
2604	Combination immunotherapy with \pm -CTLA-4 and \pm -PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma. , 2015, 3, 21.		157
2606	Pharmacist's role in optimizing therapy of the newer agents for the treatment of metastatic melanoma. Melanoma Management, 2015, 2, 75-82.	0.1	2
2607	Multidrug Efflux Pumps Attenuate the Effect of MGMT Inhibitors. Molecular Pharmaceutics, 2015, 12, 3924-3934.	2.3	18
2608	A novel design for randomized immuno-oncology clinical trials with potentially delayed treatment effects. Contemporary Clinical Trials Communications, 2015, 1, 28-31.	0.5	6
2609	2015 Guidance on cancer immunotherapy development in early-phase clinical studies. Cancer Science, 2015, 106, 1761-1771.	1.7	16
2610	Treatment of melanoma with a serotype 5/3 chimeric oncolytic adenovirus coding for GM-CSF: results <i>in vitro</i> , in rodents and in humans. International Journal of Cancer, 2015, 137, 1775-1783.	2.3	41
2611	Cost-effectiveness analysis of staging strategies in patients with regionally metastatic melanoma. Journal of Surgical Oncology, 2015, 111, 423-430.	0.8	13
2613	New clinical advances in immunotherapy for the treatment of solid tumours. Immunology, 2015, 145, 182-201.	2.0	35
2614	Pembrolizumab: a novel antiprogrammed death 1 (PD-1) monoclonal antibody for treatment of metastatic melanoma. Journal of Clinical Pharmacy and Therapeutics, 2015, 40, 504-507.	0.7	12

#	ARTICLE	IF	CITATIONS
2615	Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab. <i>Pigment Cell and Melanoma Research</i> , 2015, 28, 611-612.	1.5	125
2616	Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy. <i>Cancer Science</i> , 2015, 106, 945-950.	1.7	78
2617	Potential clinical application of interleukin-27 as an antitumor agent. <i>Cancer Science</i> , 2015, 106, 1103-1110.	1.7	49
2618	Identification of novel L-derived T helper epitope long peptides applicable for HLA-A*2⁺ cancer patients as cancer vaccine. <i>Cancer Science</i> , 2015, 106, 1493-1498.	1.7	5
2619	Clinical significance of tumor-infiltrating immune cells focusing on BTLA and Cblb in patients with gallbladder cancer. <i>Cancer Science</i> , 2015, 106, 1750-1760.	1.7	51
2620	Unmet clinical needs in the management of advanced melanoma: findings from a survey of oncologists. <i>European Journal of Cancer Care</i> , 2015, 24, 867-872.	0.7	6
2621	Patterns of practice in oncology: is progress reaching our practice?. <i>European Journal of Cancer Care</i> , 2015, 24, 768-770.	0.7	0
2622	Spanish Multidisciplinary Melanoma Group (GEM) guidelines for the management of patients with advanced melanoma. <i>European Journal of Dermatology</i> , 2015, 25, 392-403.	0.3	12
2623	Ectopic expression of B and T lymphocyte attenuator in gastric cancer: A potential independent prognostic factor in patients with gastric cancer. <i>Molecular Medicine Reports</i> , 2015, 11, 658-664.	1.1	18
2624	Suppression of established hepatocarcinoma in adjuvant only immunotherapy: alum triggers anti-tumor CD8+ T cell response. <i>Scientific Reports</i> , 2015, 5, 17695.	1.6	11
2626	Tests to assist in the diagnosis of cutaneous melanoma in adults: a generic protocol. <i>The Cochrane Library</i> , 0, , .	1.5	19
2627	Ipilimumab-Induced Hepatitis on 18F-FDG PET/CT in a Patient With Malignant Melanoma. <i>Clinical Nuclear Medicine</i> , 2015, 40, 258-259.	0.7	23
2628	Long-term Outcomes of Helper Peptide Vaccination for Metastatic Melanoma. <i>Annals of Surgery</i> , 2015, 262, 456-464.	2.1	26
2629	Glioma. <i>Nature Reviews Disease Primers</i> , 2015, 1, 15017.	18.1	718
2630	Competitive allele-specific TaqMan PCR (Cast-PCR) is a sensitive, specific and fast method for BRAF V600 mutation detection in Melanoma patients. <i>Scientific Reports</i> , 2015, 5, 18592.	1.6	27
2631	Non-Small-Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy. <i>Journal of Thoracic Oncology</i> , 2015, 10, 974-984.	0.5	127
2635	The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell-based immunotherapy. <i>Blood</i> , 2015, 126, 1203-1213.	0.6	103
2636	Expanding the peptidome for immunotherapy. <i>Blood</i> , 2015, 126, 1154-1156.	0.6	1

#	ARTICLE	IF	CITATIONS
2637	ç”2çŠřè...ç™CEä:æ,æ€Šé»’è%o²è...«ã«ã~3/4ã™ã,æ—°ã—ã,ã^tãæ”™çš,,è—r. Journal of Otolaryngology of Japan, 2015, 118, 1366-1367.		
2638	On the Verge: Immunotherapy for Colorectal Carcinoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 970-978.	2.3	9
2640	Licensed monoclonal antibodies and associated challenges. Human Antibodies, 2015, 23, 63-72.	0.6	10
2641	Network analysis of immunotherapy-induced regressing tumours identifies novel synergistic drug combinations. Scientific Reports, 2015, 5, 12298.	1.6	63
2642	Clostridium difficile infection may loom behind ipilimumab-induced auto-immune colitis. European Journal of Dermatology, 2015, 25, 344-344.	0.3	12
2643	Understanding Immune Checkpoint Inhibitors for Effective Patient Care. Clinical Journal of Oncology Nursing, 2015, 19, 709-717.	0.3	17
2644	The wound inflammatory response exacerbates growth of preneoplastic cells and progression to cancer. EMBO Journal, 2015, 34, 2219-2236.	3.5	210
2645	A Perspective of Immunotherapy for Breast Cancer: Lessons Learned and Forward Directions for All Cancers. Breast Cancer: Basic and Clinical Research, 2015, 9s2, BCBCR.S29425.	0.6	4
2646	Current State of Animal (Mouse) Modeling in Melanoma Research. Cancer Growth and Metastasis, 2015, 8s1, CGM.S21214.	3.5	74
2647	The 2014 San Antonio Breast Cancer Symposium: A successful lift-off for breast immunotherapy?. Npj Breast Cancer, 2015, 1, .	2.3	0
2648	CTLA-4 checkpoint blockade in breast cancer, a case in point report. , 2015, 3, .		0
2649	Novel melanoma therapy. Experimental Hematology and Oncology, 2015, 5, 23.	2.0	8
2650	Treatment Options Expanding for Advanced Melanoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 673-675.	2.3	1
2651	Ipilimumab in the real world. Melanoma Research, 2015, 25, 432-442.	0.6	50
2652	Integrating first-line treatment options into clinical practice. Melanoma Research, 2015, 25, 461-469.	0.6	25
2653	Emerging immunotherapies for bladder cancer. Current Opinion in Oncology, 2015, 27, 191-200.	1.1	24
2654	The Prognostic Role of the Preoperative Absolute Lymphocyte Count and Absolute Monocyte Count in Patients With Resected Advanced Melanoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2015, 38, 252-258.	0.6	26
2655	Whole Cell Therapeutic Vaccine Modified With Hyper-IL6 for Combinational Treatment of Nonresected Advanced Melanoma. Medicine (United States), 2015, 94, e853.	0.4	14

#	ARTICLE	IF	CITATIONS
2656	Lactate as a Predictor in Severe Pneumonia. <i>Acta Chirurgica Latviensis</i> , 2015, 15, 29-34.	0.2	0
2657	SEOM guidelines for the management of Malignant Melanoma 2015. <i>Clinical and Translational Oncology</i> , 2015, 17, 1030-1035.	1.2	11
2659	Radiation with immunotherapy: an emerging combination for cancer treatment. <i>Journal of Radiation Oncology</i> , 2015, 4, 331-338.	0.7	5
2661	Molecular alterations in signal pathways of melanoma and new personalized treatment strategies: Targeting of Notch. <i>Medicina (Lithuania)</i> , 2015, 51, 133-145.	0.8	12
2662	Combined dabrafenib and trametinib therapy in metastatic melanoma and organ transplantation: Case report and review of the literature. <i>JAAD Case Reports</i> , 2015, 1, S23-S25.	0.4	12
2663	Autoimmune endocrinopathies induced by immunomodulating antibodies in the treatment of cancer. <i>Medicina Clínica (English Edition)</i> , 2015, 145, 264-268.	0.1	1
2665	The role of combined radiation and immunotherapy in breast cancer treatment. <i>Journal of Radiation Oncology</i> , 2015, 4, 347-354.	0.7	5
2666	Nivolumab plus ipilimumab in the treatment of advanced melanoma. <i>Journal of Hematology and Oncology</i> , 2015, 8, 123.	6.9	42
2667	Evaluation of immune cell markers in tumor tissue treated with radioimmunotherapy in an immunocompetent rat colon carcinoma model. <i>EJNMMI Research</i> , 2015, 5, 47.	1.1	1
2668	NK cells and CD8+ T cells cooperate to improve therapeutic responses in melanoma treated with interleukin-2 (IL-2) and CTLA-4 blockade. , 2015, 3, 18.		51
2669	Enhancing the discovery and development of immunotherapies for cancer using quantitative and systems pharmacology: Interleukin-12 as a case study. , 2015, 3, 27.		17
2670	Phase II Trial of Nilotinib in Patients With Metastatic Malignant Melanoma Harboring <i>KIT</i> Gene Aberration: A Multicenter Trial of Korean Cancer Study Group (UN10-06). <i>Oncologist</i> , 2015, 20, 1312-1319.	1.9	70
2671	Ipilimumab and cranial radiation in metastatic melanoma patients: a case series and review. , 2015, 3, 50.		84
2672	Principles of immunology and its nuances in the central nervous system: Fig. 1.. <i>Neuro-Oncology</i> , 2015, 17, vii3-vii8.	0.6	28
2673	A single-center retrospective study on 659 re-excisions of melanoma and 769 sentinel node biopsies in 2008–2012. <i>European Journal of Plastic Surgery</i> , 2015, 38, 471-478.	0.3	2
2674	Silymarin inhibits melanoma cell growth both in vitro and in vivo by targeting cell cycle regulators, angiogenic biomarkers and induction of apoptosis. <i>Molecular Carcinogenesis</i> , 2015, 54, 1328-1339.	1.3	29
2675	Dacarbazine in combination with bevacizumab for the treatment of unresectable/metastatic melanoma. <i>Melanoma Research</i> , 2015, 25, 239-245.	0.6	23
2676	Navigating uncertainty: a valuable cost-effectiveness analysis in the rapidly changing field of metastatic melanoma treatment. <i>British Journal of Dermatology</i> , 2015, 173, 1365-1366.	1.4	4

#	ARTICLE	IF	CITATIONS
2677	Sigmoid diverticulosis - a risk factor for perforation of the sigmoid colon due to ipilimumab-associated enterocolitis?. JDDG - Journal of the German Society of Dermatology, 2015, 13, 575-577.	0.4	1
2678	Ipilimumab-induced hypophysitis in melanoma patients: an Australian case series. Internal Medicine Journal, 2015, 45, 1066-1073.	0.5	32
2679	Brain Tumor Clinical Trials. Neurosurgery, 2015, 62, 141-145.	0.6	0
2680	Ipilimumab for the treatment of melanoma. Melanoma Management, 2015, 2, 33-39.	0.1	2
2681	From personalized to patient-specific treatment of metastatic melanoma. Melanoma Management, 2015, 2, 193-197.	0.1	0
2682	Patient-derived heavy chain antibody targets cell surface HSP90 on breast tumors. BMC Cancer, 2015, 15, 614.	1.1	17
2683	Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma. Journal of Translational Medicine, 2015, 13, 351.	1.8	56
2685	Primary malignant mucosal melanoma of the upper lip: a case report and review of the literature. BMC Research Notes, 2015, 8, 499.	0.6	21
2686	MicroRNA expression profiling predicts clinical outcome of carboplatin/paclitaxel-based therapy in metastatic melanoma treated on the ECOG-ACRIN trial E2603. Clinical Epigenetics, 2015, 7, 58.	1.8	19
2687	A prospective evaluation of the role of Vascular Endothelial Growth Factor (VEGF) and the immune system in stage III/IV melanoma. SpringerPlus, 2015, 4, 186.	1.2	8
2688	Rapid complete response of metastatic melanoma in a patient undergoing ipilimumab immunotherapy in the setting of active ulcerative colitis. , 2015, 3, 19.		54
2689	Safety and efficacy of ipilimumab to treat advanced melanoma in the setting of liver transplantation. , 2015, 3, 22.		95
2690	Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study. , 2015, 3, 26.		206
2691	Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma. , 2015, 3, 23.		190
2692	Baseline circulating IL-17 predicts toxicity while TGF- β 1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma. , 2015, 3, 39.		302
2693	Increased CTLA-4+ T cells and an increased ratio of monocytes with loss of class II (CD14+HLA-DRlo/neg) found in aggressive pediatric sarcoma patients. , 2015, 3, 35.		45
2694	Acute skin reaction suggestive of pembrolizumab-induced radiosensitization. Melanoma Research, 2015, 25, 555-558.	0.6	35
2695	Inhibitory receptors as targets for cancer immunotherapy. European Journal of Immunology, 2015, 45, 1892-1905.	1.6	116

#	ARTICLE	IF	CITATIONS
2696	Neoadjuvant use of ipilimumab in locally advanced melanoma. <i>Journal of Surgical Oncology</i> , 2015, 112, 841-843.	0.8	11
2697	Treatment for metastatic melanoma: a new and evolving era. <i>International Journal of Clinical Practice</i> , 2015, 69, 273-280.	0.8	2
2698	Converting biology into clinical benefit: lessons learned from BRAF inhibitors. <i>Melanoma Management</i> , 2015, 2, 241-254.	0.1	10
2699	Immune Checkpoint Inhibitor Therapy Associated Hypophysitis. <i>Clinical Medicine Insights: Endocrinology and Diabetes</i> , 2015, 8, CMED.S22469.	1.0	38
2700	Ad-REIC Gene Therapy: Promising Results in a Patient with Metastatic CRPC following Chemotherapy. <i>Clinical Medicine Insights: Oncology</i> , 2015, 9, CMO.S23252.	0.6	27
2701	Efficacy and safety of bio-chemotherapy with dacarbazine plus interleukin-2 in patients with unresectable malignant melanoma. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2015, 11, 314-318.	0.7	4
2702	Sigmadivertikuloose - ein Risikofaktor für eine Sigmaperforation nach Ipilimumab-induzierter Enterokolitis?. <i>JDDG - Journal of the German Society of Dermatology</i> , 2015, 13, 575-577.	0.4	1
2703	Ultrasound-guided core needle biopsy of superficial lymph nodes. <i>Melanoma Research</i> , 2015, 25, 519-527.	0.6	19
2704	Role of Radiation Therapy as Immune Activator in the Era of Modern Immunotherapy for Metastatic Malignant Melanoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 119-125.	0.6	65
2705	Primary Cutaneous Small/Medium CD4+ T-Cell Lymphoma Occurring During Treatment With Vemurafenib for Advanced Melanoma. <i>American Journal of Dermatopathology</i> , 2015, 37, 440-443.	0.3	8
2706	Ipilimumab-associated Hepatitis. <i>American Journal of Surgical Pathology</i> , 2015, 39, 1075-1084.	2.1	181
2707	From Uniplex to Multiplex Molecular Profiling in Advanced Non-Small Cell Lung Carcinoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2015, 21, 413-424.	1.0	3
2708	Pembrolizumab in the management of metastatic melanoma. <i>Melanoma Management</i> , 2015, 2, 315-325.	0.1	4
2709	Phase 2 study of sunitinib in patients with metastatic mucosal or acral melanoma. <i>Cancer</i> , 2015, 121, 4007-4015.	2.0	56
2710	Morphomics predicts response to ipilimumab in patients with stage IV melanoma. <i>Journal of Surgical Oncology</i> , 2015, 112, 333-337.	0.8	14
2711	Report of ipilimumab in a heart transplant patient with metastatic melanoma on tacrolimus. <i>Melanoma Management</i> , 2015, 2, 311-314.	0.1	22
2712	Systemic therapy of metastatic melanoma. <i>JDDG - Journal of the German Society of Dermatology</i> , 2015, 13, 1223-1237.	0.4	12
2713	Checkpoint immunotherapy for cancer: superior survival, unaccustomed toxicities. <i>Internal Medicine Journal</i> , 2015, 45, 696-701.	0.5	28

#	ARTICLE	IF	CITATIONS
2714	Fc γ R requirements leading to successful immunotherapy. <i>Immunological Reviews</i> , 2015, 268, 104-122.	2.8	41
2715	Statistical Considerations in Clinical Trial Design of Immunotherapeutic Cancer Agents. <i>Journal of Immunotherapy</i> , 2015, 38, 259-266.	1.2	9
2716	A Case Report of Orbital Inflammatory Syndrome Secondary to Ipilimumab. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2015, 31, e68-e70.	0.4	30
2717	Liver resection and ablation for metastatic melanoma: A single center experience. <i>Journal of Surgical Oncology</i> , 2015, 111, 962-968.	0.8	19
2718	Administration of Ipilimumab to a Liver Transplant Recipient With Unresectable Metastatic Melanoma. <i>Journal of Immunotherapy</i> , 2015, 38, 211.	1.2	79
2719	Autoimmune Colitis and Subsequent CMV-induced Hepatitis After Treatment With Ipilimumab. <i>Journal of Immunotherapy</i> , 2015, 38, 212-215.	1.2	53
2720	Induction vemurafenib followed by consolidative radiation therapy for surgically incurable melanoma. <i>Melanoma Research</i> , 2015, 25, 246-251.	0.6	7
2721	A phase 2 study of tremelimumab in patients with advanced uveal melanoma. <i>Melanoma Research</i> , 2015, 25, 342-347.	0.6	79
2722	Repeated isolated limb perfusion in melanoma patients with recurrent in-transit metastases. <i>Melanoma Research</i> , 2015, 25, 427-431.	0.6	14
2723	Immunotherapy for Advanced Lung Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2015, 21, 383-391.	1.0	10
2724	Systemtherapie des metastasierten malignen Melanoms. <i>JDDG - Journal of the German Society of Dermatology</i> , 2015, 13, 1223-1238.	0.4	7
2725	Histological evaluation of a "residual" metastasis after ipilimumab therapy in a patient with advanced melanoma. <i>Journal of Dermatology</i> , 2015, 42, 927-928.	0.6	0
2726	Combined cytotoxic activity of an infectious, but non-replicative herpes simplex virus type 1 and plasmacytoid dendritic cells against tumour cells. <i>Immunology</i> , 2015, 146, 327-338.	2.0	14
2727	Vemurafenib Resistance Signature by Proteome Analysis Offers New Strategies and Rational Therapeutic Concepts. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 757-768.	1.9	27
2728	The end of the beginning: PD-1 inhibition as the new standard of care first-line immunotherapy in metastatic melanoma. <i>Melanoma Management</i> , 2015, 2, 305-309.	0.1	1
2729	Comparative healthcare costs in patients with metastatic melanoma in the USA. <i>Melanoma Research</i> , 2015, 25, 312-320.	0.6	22
2730	Chemotherapy-induced peripheral neurotoxicity. <i>Current Opinion in Neurology</i> , 2015, 28, 500-507.	1.8	115
2731	Tumor-targeted and immune-targeted monoclonal antibodies: Going from passive to active immunotherapy. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1317-1325.	0.8	13

#	ARTICLE	IF	CITATIONS
2733	Blocking of the PD-1/PD-L1 Interaction by a D-Peptide Antagonist for Cancer Immunotherapy. <i>Angewandte Chemie - International Edition</i> , 2015, 54, 11760-11764.	7.2	286
2734	Leukemic progenitor cells are susceptible to targeting by stimulated cytotoxic T cells against immunogenic leukemia-associated antigens. <i>International Journal of Cancer</i> , 2015, 137, 2083-2092.	2.3	19
2735	Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy. <i>Pharmacotherapy</i> , 2015, 35, 963-976.	1.2	183
2736	Systematic review: colitis associated with anti-CTLA-4 therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 406-417.	1.9	227
2737	Growth and hormonal profiling in children with congenital melanocytic naevi. <i>British Journal of Dermatology</i> , 2015, 173, 1366-1367.	1.4	0
2738	Will modern immunotherapies become the standard of care for advanced synchronous or metachronous cancers?. <i>Future Oncology</i> , 2015, 11, 3053-3055.	1.1	2
2739	Recent developments and future challenges in immune checkpoint inhibitory cancer treatment. <i>Current Opinion in Oncology</i> , 2015, 27, 482-488.	1.1	31
2740	The cost of ipilimumab toxicity. <i>Melanoma Research</i> , 2015, 25, 259-264.	0.6	22
2741	Ipilimumab-induced colitis in patients with metastatic melanoma. <i>Melanoma Research</i> , 2015, 25, 321-327.	0.6	44
2742	Emerging Immunotherapies in the Treatment of Non-small Cell Lung Cancer (NSCLC). <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 422-430.	0.6	64
2743	Ipilimumab Granulomatous Interstitial Nephritis. <i>American Journal of Therapeutics</i> , 2015, 22, e84-e87.	0.5	66
2744	Immunotherapies for bladder cancer. <i>Current Opinion in Urology</i> , 2015, 25, 586-596.	0.9	17
2745	Reversal of T-cell exhaustion as a strategy to improve immune control of HIV-1. <i>Aids</i> , 2015, 29, 1911-1915.	1.0	14
2746	Ipilimumab-Induced Adrenalitis. <i>Clinical Nuclear Medicine</i> , 2015, 40, e518-e519.	0.7	69
2747	Immunotherapy for glioblastoma. <i>Current Opinion in Neurology</i> , 2015, 28, 639-646.	1.8	25
2748	Management of melanoma. , 0, , 499-512.		0
2750	Targeted and Immunotherapeutic Approaches in Brain Metastases. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , 67-74.	1.8	16
2751	Emerging Role for Novel Immunotherapy Agents in Metastatic Renal Cell Carcinoma: From Bench to Bedside. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , e291-e297.	1.8	4

#	ARTICLE	IF	CITATIONS
2752	The Evolution of Therapies in Non-Small Cell Lung Cancer. <i>Cancers</i> , 2015, 7, 1815-1846.	1.7	107
2753	Verzagert auftretende Paraplegie nach Vollremission unter 2 Zyklen Ipilimumab bei metastasiertem Melanom. <i>Karger Kompass Dermatologie</i> , 2015, 3, 94-97.	0.0	0
2754	Regulation of Murine Ovarian Epithelial Carcinoma by Vaccination against the Cytoplasmic Domain of Anti-Mallerian Hormone Receptor II. <i>Journal of Immunology Research</i> , 2015, 2015, 1-13.	0.9	8
2755	Immune Checkpoint Inhibitors: New Drugs on the Horizon. <i>Journal of Leukemia (Los Angeles, Calif)</i> , 2015, s1, .	0.1	0
2756	Increased Treatment-Related Toxicity Subsequent to an Anti-PD-1 Agent. <i>Current Oncology</i> , 2015, 22, 320-322.	0.9	6
2757	Granuloma Annulare in the Setting of Ipilimumab Therapy. <i>Journal of Clinical & Experimental Dermatology Research</i> , 2015, 06, .	0.1	1
2758	Classification of clinical outcomes using high-throughput informatics: Part 1 – nonparametric method reviews. <i>Model Assisted Statistics and Applications</i> , 2015, 10, 3-23.	0.2	8
2759	Lang anhaltendes Ansprechen auf die Behandlung mit Ipilimumab: Ein Argument gegen die Erhaltungstherapie?. <i>Karger Kompass Onkologie</i> , 2015, 2, 72-75.	0.0	0
2760	Targeting PD-1/PD-L1 in lung cancer: current perspectives. <i>Lung Cancer: Targets and Therapy</i> , 2015, 6, 55.	1.3	10
2761	Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. <i>Oncotarget</i> , 2015, 6, 42008-42018.	0.8	278
2762	Ipilimumab was safe and effective in two patients with metastatic melanoma and end-stage renal disease. <i>Cancer Management and Research</i> , 2015, 7, 47.	0.9	29
2763	Long-term survival in advanced melanoma patients using repeated therapies: successive immunomodulation improving the odds?. <i>Cancer Management and Research</i> , 2015, 7, 93.	0.9	10
2764	Adoptive T Cell Immunotherapy For Cancer. <i>Rambam Maimonides Medical Journal</i> , 2015, 6, e0004.	0.4	187
2765	Tumor neoantigens: building a framework for personalized cancer immunotherapy. <i>Journal of Clinical Investigation</i> , 2015, 125, 3413-3421.	3.9	502
2766	Cancer stem cell plasticity and tumor hierarchy. <i>World Journal of Stem Cells</i> , 2015, 7, 27.	1.3	202
2767	Immunosuppressive Microenvironment in Head and Neck Cancer. , 2015, , .		1
2768	Nivolumab in the treatment of malignant melanoma: review of the literature. <i>OncoTargets and Therapy</i> , 2015, 8, 2045.	1.0	21
2769	Nonsurgical Management of Cervical Cancer: Locally Advanced, Recurrent, and Metastatic Disease, Survivorship, and Beyond. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , e299-e309.	1.8	21

#	ARTICLE	IF	CITATIONS
2770	Treating melanoma in adolescents and young adults: challenges and solutions. <i>Clinical Oncology in Adolescents and Young Adults</i> , 2015, , 75.	0.8	2
2771	The role of regulatory T cells in cancer immunology. <i>ImmunoTargets and Therapy</i> , 2015, 4, 159.	2.7	96
2772	Combined Therapy for Gastrointestinal Carcinomas: Exploiting Synergies Between Gene Therapy and Classical Chemo-Radiotherapy. <i>Current Gene Therapy</i> , 2015, 15, 151-160.	0.9	8
2773	The prognostic significance of indoleamine-2,3-dioxygenase and the receptors for transforming growth factor β^2 and interferon β^3 in metastatic lymph nodes in malignant melanoma. <i>Polish Journal of Pathology</i> , 2015, 4, 376-382.	0.1	14
2774	Novel therapeutic strategies in human malignancy: combining immunotherapy and oncolytic virotherapy. <i>Oncolytic Virotherapy</i> , 2015, 4, 75.	6.0	15
2775	Biomarkers of Response to Immune Modulatory Therapies in Cancer. <i>Journal of Clinical & Cellular Immunology</i> , 2015, 06, .	1.5	1
2776	New developments in the management of advanced melanoma – role of pembrolizumab. <i>OncoTargets and Therapy</i> , 2015, 8, 2535.	1.0	16
2777	Therapeutic cancer vaccines. <i>Journal of Clinical Investigation</i> , 2015, 125, 3401-3412.	3.9	640
2778	From dismal prognosis to rising star: melanoma leads the way with new generation cancer therapies. <i>Medical Journal of Australia</i> , 2015, 202, 115-116.	0.8	2
2779	Epidemiology, Clinical Presentation and Treatment of Uveal Melanoma. <i>Clinical Cancer Drugs</i> , 2015, 2, 29-37.	0.3	0
2780	Population-Based Estimates of Survival and Cost for Metastatic Melanoma. <i>Current Oncology</i> , 2015, 22, 326-332.	0.9	6
2781	New and Promising Strategies in the Management of Bladder Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , 105-112.	1.8	20
2782	Immunotherapeutic Approaches in Prostate Cancer: Combinations and Clinical Integration. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , e275-e283.	1.8	2
2783	Neoadjuvant Therapy for Melanoma: A Promising Therapeutic Approach and an Ideal Platform in Drug Development. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , e535-e542.	1.8	8
2784	Molecular Fundamentals and Rationale for Immunotherapy in Metastatic Melanoma Treatment. <i>Clinical Cancer Drugs</i> , 2015, 2, 4-15.	0.3	0
2785	Merkel Cell Carcinoma: Emerging Biology, Current Approaches, and Future Directions. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , e519-e526.	1.8	54
2786	Zielgerichtete Therapien gegen PD-1 bei malignen Erkrankungen des Lymphsystems: Biologischer Hintergrund, klinische Herausforderungen und Chancen. <i>Karger Kompass Onkologie</i> , 2015, 2, 8-14.	0.0	0
2787	Oncolytic Adenovirus: Strategies and Insights for Vector Design and Immuno-Oncolytic Applications. <i>Viruses</i> , 2015, 7, 6009-6042.	1.5	67

#	ARTICLE	IF	CITATIONS
2788	Evidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going?. <i>Viruses</i> , 2015, 7, 6291-6312.	1.5	48
2789	Integrating Immune Checkpoint Blockade with Anti-Neo/Mutated Antigens Reactivity to Increase the Clinical Outcome of Immunotherapy. <i>Vaccines</i> , 2015, 3, 420-428.	2.1	14
2790	The Promise of Preventive Cancer Vaccines. <i>Vaccines</i> , 2015, 3, 467-489.	2.1	38
2791	Dendritic Cell-Based Adjuvant Vaccination Targeting Wilms's Tumor 1 in Patients with Advanced Colorectal Cancer. <i>Vaccines</i> , 2015, 3, 1004-1018.	2.1	34
2792	Nanoparticle Drug Delivery Systems Designed to Improve Cancer Vaccines and Immunotherapy. <i>Vaccines</i> , 2015, 3, 662-685.	2.1	225
2793	Therapeutic Monoclonal Antibodies for Cancer: The Past, Present, and Future. <i>Juntendo Medical Journal</i> , 2015, 61, 601-607.	0.1	0
2794	Challenges in Antibody Development against Tn and Sialyl-Tn Antigens. <i>Biomolecules</i> , 2015, 5, 1783-1809.	1.8	60
2795	Melanoma in the Italian Population and Regional Environmental Influences: A National Retrospective Survey on 2001-2008 Hospitalization Records. <i>International Journal of Environmental Research and Public Health</i> , 2015, 12, 9102-9118.	1.2	7
2796	A Quantitative Systems Pharmacology Perspective on Cancer Immunology. <i>Processes</i> , 2015, 3, 235-256.	1.3	8
2797	Establishing the pig as a large animal model for vaccine development against human cancer. <i>Frontiers in Genetics</i> , 2015, 6, 286.	1.1	24
2798	Therapeutic Potential and Challenges of Natural Killer Cells in Treatment of Solid Tumors. <i>Frontiers in Immunology</i> , 2015, 6, 202.	2.2	130
2799	Rationale for a Multimodality Strategy to Enhance the Efficacy of Dendritic Cell-Based Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2015, 6, 271.	2.2	36
2800	Inhibitory Receptors Beyond T Cell Exhaustion. <i>Frontiers in Immunology</i> , 2015, 6, 310.	2.2	188
2801	Editorial: "Cancer Immunotherapy: Lights and Shadows". <i>Frontiers in Immunology</i> , 2015, 6, 350.	2.2	2
2802	Co-Stimulatory Blockade of the CD28/CD80-86/CTLA-4 Balance in Transplantation: Impact on Memory T Cells?. <i>Frontiers in Immunology</i> , 2015, 6, 411.	2.2	39
2803	Immune Reactivation by Cell-Free Fetal DNA in Healthy Pregnancies Re-Purposed to Target Tumors: Novel Checkpoint Inhibition in Cancer Therapeutics. <i>Frontiers in Immunology</i> , 2015, 6, 424.	2.2	12
2804	Exploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2015, 6, 516.	2.2	79
2805	Identifying Individual T Cell Receptors of Optimal Avidity for Tumor Antigens. <i>Frontiers in Immunology</i> , 2015, 6, 582.	2.2	73

#	ARTICLE	IF	CITATIONS
2806	Natural Killer Cell Immunomodulation: Targeting Activating, Inhibitory, and Co-stimulatory Receptor Signaling for Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2015, 6, 601.	2.2	140
2807	The Role of Chemokines in Shaping the Balance Between CD4+ T Cell Subsets and Its Therapeutic Implications in Autoimmune and Cancer Diseases. <i>Frontiers in Immunology</i> , 2015, 6, 609.	2.2	46
2808	Melanoma: From Incurable Beast to a Curable Bet. The Success of Immunotherapy. <i>Frontiers in Oncology</i> , 2015, 5, 152.	1.3	26
2809	Immunosuppressive Mechanisms of Malignant Gliomas: Parallels at Non-CNS Sites. <i>Frontiers in Oncology</i> , 2015, 5, 153.	1.3	129
2810	Immunotherapy of Childhood Sarcomas. <i>Frontiers in Oncology</i> , 2015, 5, 181.	1.3	54
2811	Resection Followed by Involved-Field Fractionated Radiotherapy in the Management of Single Brain Metastasis. <i>Frontiers in Oncology</i> , 2015, 5, 206.	1.3	13
2812	ANTI-TUMOR IMMUNE RESPONSES INDUCED BY RADIOTHERAPY: A REVIEW. <i>Fukushima Journal of Medical Sciences</i> , 2015, 61, 13-22.	0.1	20
2813	Review Hepatotoxicity of molecular targeted therapy. <i>Wspolczesna Onkologia</i> , 2015, 2, 87-92.	0.7	16
2814	Clinical applications of PD-1-based therapy: a focus on pembrolizumab (MK-3475) in the management of melanoma and other tumor types. <i>OncoTargets and Therapy</i> , 2015, 8, 929.	1.0	27
2815	Update on use of aldesleukin for treatment of high-risk metastatic melanoma. <i>ImmunoTargets and Therapy</i> , 2015, 4, 79.	2.7	21
2816	Immune Derangements in Patients with Myelofibrosis: The Role of Treg, Th17, and sIL2R β . <i>PLoS ONE</i> , 2015, 10, e0116723.	1.1	25
2817	Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal Melanoma. <i>PLoS ONE</i> , 2015, 10, e0118564.	1.1	197
2818	Blockade of PD-1/PD-L1 Promotes Adoptive T-Cell Immunotherapy in a Tolerogenic Environment. <i>PLoS ONE</i> , 2015, 10, e0119483.	1.1	35
2819	A Protein Deep Sequencing Evaluation of Metastatic Melanoma Tissues. <i>PLoS ONE</i> , 2015, 10, e0123661.	1.1	19
2820	Identification of DRG-1 As a Melanoma-Associated Antigen Recognized by CD4+ Th1 Cells. <i>PLoS ONE</i> , 2015, 10, e0124094.	1.1	9
2821	Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers. <i>PLoS ONE</i> , 2015, 10, e0130142.	1.1	390
2822	The Cooperative Landscape of Multinational Clinical Trials. <i>PLoS ONE</i> , 2015, 10, e0130930.	1.1	9
2823	Pro-Inflammatory Cytokines Predict Relapse-Free Survival after One Month of Interferon- β but Not Observation in Intermediate Risk Melanoma Patients. <i>PLoS ONE</i> , 2015, 10, e0132745.	1.1	9

#	ARTICLE	IF	CITATIONS
2824	Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?. PLoS ONE, 2015, 10, e0139438.	1.1	27
2825	Improving the safety of cell therapy with the TK-suicide gene. Frontiers in Pharmacology, 2015, 6, 95.	1.6	102
2826	MEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapy. Drug Design, Development and Therapy, 2016, 10, 43.	2.0	22
2827	Adjuvant Therapy of Uveal Melanoma: Current Status. Ocular Oncology and Pathology, 2015, 1, 54-62.	0.5	55
2828	Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and Immunotherapy. BioMed Research International, 2015, 2015, 1-16.	0.9	111
2829	Analysis of the Intratumoral Adaptive Immune Response in Well Differentiated and Dedifferentiated Retroperitoneal Liposarcoma. Sarcoma, 2015, 2015, 1-9.	0.7	48
2830	The Immune System in Hepatocellular Carcinoma and Potential New Immunotherapeutic Strategies. BioMed Research International, 2015, 2015, 1-12.	0.9	25
2831	Immunotherapy for Bone and Soft Tissue Sarcomas. BioMed Research International, 2015, 2015, 1-11.	0.9	16
2832	Dissecting the Potential Interplay of DEK Functions in Inflammation and Cancer. Journal of Oncology, 2015, 2015, 1-13.	0.6	32
2833	Immunotherapy of Ovarian Cancer: The Role of Checkpoint Inhibitors. Journal of Immunology Research, 2015, 2015, 1-7.	0.9	49
2834	Harnessing the Microbiome to Enhance Cancer Immunotherapy. Journal of Immunology Research, 2015, 2015, 1-12.	0.9	54
2835	Clinical Development of Immune Checkpoint Inhibitors. BioMed Research International, 2015, 2015, 1-12.	0.9	51
2836	Dendritic Cell-Based Immunotherapy Treatment for Glioblastoma Multiforme. BioMed Research International, 2015, 2015, 1-12.	0.9	29
2837	Which Metrics Are Appropriate to Describe the Value of New Cancer Therapies?. BioMed Research International, 2015, 2015, 1-9.	0.9	19
2838	Late Onset Ipilimumab-Induced Pericarditis and Pericardial Effusion: A Rare but Life Threatening Complication. Case Reports in Oncological Medicine, 2015, 2015, 1-5.	0.2	90
2839	Immunotherapy in Metastatic Renal Cell Carcinoma: A Comprehensive Review. BioMed Research International, 2015, 2015, 1-8.	0.9	43
2840	Immunotherapy in Tumors. Deutsches Ärztblatt International, 2015, 112, 809-15.	0.6	31
2841	Adverse Events of Monoclonal Antibodies Used for Cancer Therapy. BioMed Research International, 2015, 2015, 1-13.	0.9	59

#	ARTICLE	IF	CITATIONS
2842	Right Atrial Metastatic Melanoma with Unknown Primaries. Case Reports in Cardiology, 2015, 2015, 1-3.	0.1	5
2843	Increased NY-ESO-1 Expression and Reduced Infiltrating CD3+ T Cells in Cutaneous Melanoma. Journal of Immunology Research, 2015, 2015, 1-8.	0.9	14
2844	RNA-Based Vaccines in Cancer Immunotherapy. Journal of Immunology Research, 2015, 2015, 1-9.	0.9	169
2845	Human Tumor Antigens and Cancer Immunotherapy. BioMed Research International, 2015, 2015, 1-17.	0.9	173
2846	From mice to humans: developments in cancer immunoediting. Journal of Clinical Investigation, 2015, 125, 3338-3346.	3.9	271
2847	Patient-Specific Therapeutic Vaccines for Metastatic Melanoma. Oncology Issues, 2015, 30, 48-57.	0.0	3
2848	Surgery and Staging of Melanoma. , 2015, , .		0
2850	Monoclonal Antibodies for the Treatment of Cancer. , 2015, , 683-694.e3.		0
2851	Principles of Cancer Immunobiology and Immunotherapy of Solid Tumors. , 0, , .		4
2852	Recent Clinical Advances in the Treatment of Cutaneous Melanoma. Clinical Cancer Drugs, 2015, 2, 16-28.	0.3	0
2853	Managing Immune Checkpoint-Blocking Antibody Side Effects. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , 76-83.	1.8	344
2854	Oncogenic cancer/testis antigens: prime candidates for immunotherapy. Oncotarget, 2015, 6, 15772-15787.	0.8	265
2855	Curcumin combined with FAPÎ±c vaccine elicits effective antitumor response by targeting indolamine-2,3-dioxygenase and inhibiting EMT induced by TNF-Î± in melanoma. Oncotarget, 2015, 6, 25932-25942.	0.8	39
2856	Cancer and the Cellular Immune Response. , 2015, , 695-708.e2.		0
2857	Targeted massively parallel sequencing of angiosarcomas reveals frequent activation of the mitogen activated protein kinase pathway. Oncotarget, 2015, 6, 36041-36052.	0.8	103
2858	Clinically relevant genes and regulatory pathways associated with NRASQ61 mutations in melanoma through an integrative genomics approach. Oncotarget, 2015, 6, 2496-2508.	0.8	16
2859	Cancer Therapeutics. , 2015, , 635-650.e1.		0
2860	Cancer Neoantigens: A Promising Source of Immunogens for Cancer Immunotherapy. Journal of Clinical & Cellular Immunology, 2015, 06, .	1.5	17

#	ARTICLE	IF	CITATIONS
2861	Current Therapeutic Leads for the Treatment of Melanoma: Targeted Immunotherapy in the Post-genomic Era. <i>Current Molecular Pharmacology</i> , 2015, 7, 33-43.	0.7	3
2862	Psychological Stress and Immunological Modulations in Early-stage Melanoma Patients. <i>Acta Dermato-Venereologica</i> , 2015, 95, 691-695.	0.6	5
2863	Evolving Immunotherapy Strategies in Urothelial Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , e284-e290.	1.8	3
2864	Histone Modifications, Modifiers and Readers in Melanoma Resistance to Targeted and Immune Therapy. <i>Cancers</i> , 2015, 7, 1959-1982.	1.7	32
2865	Implications and benefits of the NICE appraisal of pembrolizumab. <i>British Journal of Health Care Management</i> , 2015, 21, 506-508.	0.1	0
2866	Can Redirected T Cells Outsmart Aggressive Melanoma? The Promise and Challenge of Adoptive Cell Therapy. , 0, , .		0
2867	Toxicities of New Drugs for Melanoma Treatment and their Management. , 0, , .		0
2868	Challenges of Patient Selection for Phase I Oncology Trials. , 0, , .		2
2869	Emerging Drug Combination Approaches in Melanoma Therapy. , 0, , .		1
2870	New Insights in Cutaneous Melanoma Immune-Therapy â€” Tackling Immune-Suppression and Specific Anti-Tumoral Response. , 0, , .		2
2871	Variations in genes involved in immune response checkpoints and association with outcomes in patients with resected colorectal liver metastases. <i>Pharmacogenomics Journal</i> , 2015, 15, 521-529.	0.9	13
2872	The Ipilimumab Lesson in Melanoma: Achieving Long-Term Survival. <i>Seminars in Oncology</i> , 2015, 42, 387-401.	0.8	24
2873	Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?. <i>Annals of Oncology</i> , 2015, 26, 1813-1823.	0.6	219
2874	Rational development and characterization of humanized anti-â€œEGFR variant III chimeric antigen receptor T cells for glioblastoma. <i>Science Translational Medicine</i> , 2015, 7, 275ra22.	5.8	369
2875	Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy. <i>Clinical Cancer Research</i> , 2015, 21, 3113-3120.	3.2	109
2876	Preexisting Levels of CD4 T Cells Expressing PD-1 Are Related to Overall Survival in Prostate Cancer Patients Treated with Ipilimumab. <i>Cancer Immunology Research</i> , 2015, 3, 1008-1016.	1.6	49
2877	T cell exclusion, immune privilege, and the tumor microenvironment. <i>Science</i> , 2015, 348, 74-80.	6.0	1,735
2878	Beyond CTLA-4: novel immunotherapy strategies for metastatic melanoma. <i>Future Oncology</i> , 2015, 11, 997-1009.	1.1	2

#	ARTICLE	IF	CITATIONS
2879	FcÎ³R dependent mechanisms of cytotoxic, agonistic, and neutralizing antibody activities. Trends in Immunology, 2015, 36, 325-336.	2.9	157
2880	Adoptive T-Cell Therapy: Optimizing Chemokine Receptor-Mediated Homing of T Cells in Cancer Immunotherapy. , 2015, , 263-282.		1
2881	Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. Journal of Clinical Oncology, 2015, 33, 2780-2788.	0.8	1,988
2882	Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients. British Journal of Cancer, 2015, 112, 1904-1910.	2.9	191
2883	Stereotactic Radiosurgery for Melanoma Brain Metastases in Patients Receiving Ipilimumab: Safety Profile and Efficacy of Combined Treatment. International Journal of Radiation Oncology Biology Physics, 2015, 92, 368-375.	0.4	334
2884	Current Status and Future Directions of the Immune Checkpoint Inhibitors Ipilimumab, Pembrolizumab, and Nivolumab in Oncology. Annals of Pharmacotherapy, 2015, 49, 907-937.	0.9	155
2885	Building better monoclonal antibody-based therapeutics. Nature Reviews Cancer, 2015, 15, 361-370.	12.8	558
2886	New approaches in vaccine-based immunotherapy for human papillomavirus-induced cancer. Current Opinion in Immunology, 2015, 35, 9-14.	2.4	12
2887	Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nature Reviews Clinical Oncology, 2015, 12, 408-424.	12.5	456
2888	Clinical Activity, Toxicity, Biomarkers, and Future Development of CTLA-4 Checkpoint Antagonists. Seminars in Oncology, 2015, 42, 573-586.	0.8	21
2889	MHC-I modulation due to changes in tumor cell metabolism regulates tumor sensitivity to CTL and NK cells. Oncoimmunology, 2015, 4, e985924.	2.1	48
2890	Targeted Therapies for Prostate Cancer. Cancer Investigation, 2015, 33, 276-285.	0.6	7
2891	<i>POLE</i> Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer. Clinical Cancer Research, 2015, 21, 3347-3355.	3.2	249
2892	Programmed death-1 checkpoint blockade in acute myeloid leukemia. Expert Opinion on Biological Therapy, 2015, 15, 1191-1203.	1.4	75
2893	Ipilimumab for Previously Untreated Unresectable Malignant Melanoma: A Critique of the Evidence. Pharmacoeconomics, 2015, 33, 1269-1279.	1.7	13
2894	Vaccines, Adjuvants, and Dendritic Cell Activatorsâ€”Current Status and Future Challenges. Seminars in Oncology, 2015, 42, 549-561.	0.8	37
2895	Blinded by the light: why the treatment of metastatic melanoma has created a new paradigm for the management of cancer. Therapeutic Advances in Medical Oncology, 2015, 7, 107-121.	1.4	8
2896	The role of active vaccination in cancer immunotherapy: lessons from clinical trials. Current Opinion in Immunology, 2015, 35, 15-22.	2.4	33

#	ARTICLE	IF	CITATIONS
2897	Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen. <i>Cancer Immunology Research</i> , 2015, 3, 345-355.	1.6	520
2898	Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. <i>New England Journal of Medicine</i> , 2015, 373, 23-34.	13.9	6,773
2899	Porous Silicon Microparticle Potentiates Anti-Tumor Immunity by Enhancing Cross-Presentation and Inducing Type I Interferon Response. <i>Cell Reports</i> , 2015, 11, 957-966.	2.9	90
2900	The path forward. <i>Vaccine</i> , 2015, 33, B60-B63.	1.7	14
2902	Expression profile and in vitro blockade of programmed death-1 in human papillomavirus-negative head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2015, 37, 1088-1095.	0.9	56
2904	Immunotherapies Targeting a Tumor-Associated Antigen, 5T4 Oncofetal Glycoprotein. , 2015, , 409-425.		3
2905	Development of Personalized Combination Cancer Immunotherapy Based on the Patients' Immune Status. , 2015, , 255-266.		2
2906	Costimulation in Lymphomas and Cancers. , 2015, , 185-254.		7
2907	T-Cell Costimulation and Its Applications in Diseases. , 2015, , 255-292.		12
2908	Development of a potent melanoma vaccine capable of stimulating CD8+ T-cells independently of dendritic cells in a mouse model. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 861-872.	2.0	5
2909	Survival patterns following brain metastases for patients with melanoma in the MAP-kinase inhibitor era. <i>Journal of Neuro-Oncology</i> , 2015, 123, 75-84.	1.4	8
2910	Renal Toxicities of Targeted Therapies. <i>Targeted Oncology</i> , 2015, 10, 487-499.	1.7	66
2911	Novel Immunologic Approaches in Lymphoma: Unleashing the Brakes on the Immune System. <i>Current Oncology Reports</i> , 2015, 17, 30.	1.8	9
2912	Immune modulation in advanced radiotherapies: Targeting out-of-field effects. <i>Cancer Letters</i> , 2015, 368, 246-251.	3.2	43
2913	Acquired Hypothyroidism as a Predictive Marker of Outcome in Patients With Metastatic Renal Cell Carcinoma Treated With Tyrosine Kinase Inhibitors: A Literature-Based Meta-Analysis. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 280-286.	0.9	21
2914	The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. <i>Clinical Therapeutics</i> , 2015, 37, 764-782.	1.1	469
2915	MGN1703, an immunomodulator and toll-like receptor 9 (TLR-9) agonist: From bench to bedside. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 94, 31-44.	2.0	66
2916	Optimal management of immune-related toxicities associated with checkpoint inhibitors in lung cancer. <i>Lung Cancer</i> , 2015, 88, 117-123.	0.9	49

#	ARTICLE	IF	CITATIONS
2917	Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. <i>Lancet</i> , The, 2015, 386, 444-451.	6.3	1,175
2918	Overexpression of pyruvate dehydrogenase kinase supports dichloroacetate as a candidate for cutaneous melanoma therapy. <i>Expert Opinion on Therapeutic Targets</i> , 2015, 19, 733-745.	1.5	22
2919	Pembrolizumab joins the anti-PD-1 armamentarium in the treatment of melanoma. <i>Future Oncology</i> , 2015, 11, 133-140.	1.1	9
2920	Vemurafenib for the treatment of BRAF mutant metastatic melanoma. <i>Future Oncology</i> , 2015, 11, 579-589.	1.1	16
2921	Immunotherapy for non-small-cell lung cancer: the past 10 years. <i>Future Oncology</i> , 2015, 11, 2681-2695.	1.1	6
2922	Immunization with amodiaquine-modified hepatic proteins prevents amodiaquine-induced liver injury. <i>Journal of Immunotoxicology</i> , 2015, 12, 361-367.	0.9	13
2923	Bridging infectious disease vaccines with cancer immunotherapy: a role for targeted RNA based immunotherapeutics. , 2015, 3, 13.		13
2924	Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2-Positive and Triple-Negative Primary Breast Cancers. <i>Journal of Clinical Oncology</i> , 2015, 33, 983-991.	0.8	863
2925	Overall Response Rate, Progression-Free Survival, and Overall Survival With Targeted and Standard Therapies in Advanced Non-Small-Cell Lung Cancer: US Food and Drug Administration Trial-Level and Patient-Level Analyses. <i>Journal of Clinical Oncology</i> , 2015, 33, 1008-1014.	0.8	179
2926	Cancer Immunotherapy: Imaging Assessment of Novel Treatment Response Patterns and Immune-related Adverse Events. <i>Radiographics</i> , 2015, 35, 424-437.	1.4	161
2927	Systemic High-Dose Corticosteroid Treatment Does Not Improve the Outcome of Ipilimumab-Related Hypophysitis: A Retrospective Cohort Study. <i>Clinical Cancer Research</i> , 2015, 21, 749-755.	3.2	223
2928	Immune Checkpoint Modulation for Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 2256-2262.	3.2	90
2929	Does It MEK a Difference? Understanding Immune Effects of Targeted Therapy. <i>Clinical Cancer Research</i> , 2015, 21, 3102-3104.	3.2	27
2930	Tumor-Associated and Disease-Associated Autoantibody Repertoires in Healthy Colostrum and Maternal and Newborn Cord Sera. <i>Journal of Immunology</i> , 2015, 194, 5272-5281.	0.4	23
2931	Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma. <i>JAMA Oncology</i> , 2015, 1, 359.	3.4	164
2932	Phase I/II study of adjuvant immunotherapy with sentinel lymph node T lymphocytes in patients with colorectal cancer. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 1083-1093.	2.0	44
2933	Single Institution Experience of Ipilimumab 3 mg/kg with Sargramostim (GM-CSF) in Metastatic Melanoma. <i>Cancer Immunology Research</i> , 2015, 3, 986-991.	1.6	21
2934	Radiotherapy combined with immune checkpoint blockade immunotherapy: Achievements and challenges. <i>Cancer Letters</i> , 2015, 365, 23-29.	3.2	84

#	ARTICLE	IF	CITATIONS
2935	Increased CCL17 serum levels are associated with improved survival in advanced melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 1075-1082.	2.0	16
2936	Drug-Associated Dermatomyositis Following Ipilimumab Therapy. <i>JAMA Dermatology</i> , 2015, 151, 195.	2.0	144
2937	Febrile Neutropenia in a Metastatic Melanoma Patient Treated with Ipilimumab - Case Report. <i>Oncology Research and Treatment</i> , 2015, 38, 105-108.	0.8	25
2938	PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes. <i>Annals of Oncology</i> , 2015, 26, 1488-1493.	0.6	234
2939	Transcriptional repression of IFN γ by ATF2 confers melanoma resistance to therapy. <i>Oncogene</i> , 2015, 34, 5739-5748.	2.6	23
2940	Rationale for targeting the ErbB family of receptors in patients with advanced squamous cell carcinoma of the lung. <i>Future Oncology</i> , 2015, 11, 2175-2191.	1.1	5
2941	Beyond adjuvants: Immunomodulation strategies to enhance T cell immunity. <i>Vaccine</i> , 2015, 33, B21-B28.	1.7	28
2942	Adolescent and young adult patients with cancer: a milieu of unique features. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 465-480.	12.5	99
2943	Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells. <i>Cancer Immunology Research</i> , 2015, 3, 1148-1157.	1.6	391
2944	The CASC15 Long Intergenic Noncoding RNA Locus Is Involved in Melanoma Progression and Phenotype Switching. <i>Journal of Investigative Dermatology</i> , 2015, 135, 2464-2474.	0.3	90
2945	Cancer and the Immune System: Basic Concepts and Targets for Intervention. <i>Seminars in Oncology</i> , 2015, 42, 523-538.	0.8	220
2946	CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic. <i>Frontiers in Oncology</i> , 2014, 4, 385.	1.3	175
2947	New Strategies in Melanoma: Entering the Era of Combinatorial Therapy. <i>Clinical Cancer Research</i> , 2015, 21, 2424-2435.	3.2	29
2948	Pitfalls in the Neuroimaging of Glioblastoma in the Era of Antiangiogenic and Immuno/Targeted Therapy - Detecting Illusive Disease, Defining Response. <i>Frontiers in Neurology</i> , 2015, 6, 33.	1.1	139
2949	DNA vaccines, electroporation and their applications in cancer treatment. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 1889-1900.	1.4	58
2950	Emerging clinical applications of selected biomarkers in melanoma. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2015, 8, 35.	0.8	18
2951	Parathyroid Hormone-Related Peptide-Linked Hypercalcemia in a Melanoma Patient Treated With Ipilimumab: Hormone Source and Clinical and Metabolic Correlates. <i>Seminars in Oncology</i> , 2015, 42, 909-914.	0.8	10
2953	Is chemotherapy still an option in the treatment of melanoma?. <i>Annals of Oncology</i> , 2015, 26, 2203-2204.	0.6	1

#	ARTICLE	IF	CITATIONS
2954	Targeting the immune system in head and neck cancer. <i>Current Opinion in Oncology</i> , 2015, 27, 157-158.	1.1	1
2955	Do inflammatory pathways drive melanomagenesis?. <i>Experimental Dermatology</i> , 2015, 24, 86-90.	1.4	28
2956	Survival of melanoma patients with brain metastases treated with ipilimumab and stereotactic radiosurgery. <i>Cancer Medicine</i> , 2015, 4, 1-6.	1.3	101
2957	Stimulating immune responses to fight cancer: Basic biology and mechanisms. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2015, 11, 9-15.	0.7	9
2958	Checkpoint blockade in lymphoma. <i>Hematology American Society of Hematology Education Program</i> , 2015, 2015, 69-73.	0.9	11
2959	Therapeutic interventions to disrupt the protein synthetic machinery in melanoma. <i>Pigment Cell and Melanoma Research</i> , 2015, 28, 501-519.	1.5	3
2960	Myasthenia Gravis Induced by Ipilimumab in Patients With Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2015, 33, e122-e124.	0.8	101
2961	Immunotherapy of Melanoma. <i>Progress in Tumor Research</i> , 2015, 42, 22-29.	0.1	14
2962	Immunotherapy of Breast Cancer. <i>Progress in Tumor Research</i> , 2015, 42, 30-43.	0.1	27
2963	CCR 20th Anniversary Commentary: Immune-Related Response Criteria—Capturing Clinical Activity in Immuno-Oncology. <i>Clinical Cancer Research</i> , 2015, 21, 4989-4991.	3.2	57
2964	Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2015, 26, v126-v132.	0.6	308
2965	Beating Cancer with a Gut Feeling. <i>Cell Host and Microbe</i> , 2015, 18, 646-648.	5.1	4
2966	Statistical Challenges in the Design of Late-Stage Cancer Immunotherapy Studies. <i>Cancer Immunology Research</i> , 2015, 3, 1292-1298.	1.6	38
2967	Osteonecrosis of the jaw a new complication related to Ipilimumab. <i>Oral Oncology</i> , 2015, 51, e100-e101.	0.8	38
2969	Immunotherapies in Early and Advanced Renal Cell Cancer. <i>Progress in Tumor Research</i> , 2015, 42, 1-10.	0.1	12
2970	Talimogene laherparepvec in the treatment of melanoma. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 1517-1530.	1.4	8
2971	Insights on Peptide Vaccines in Cancer Immunotherapy. <i>Cancer Drug Discovery and Development</i> , 2015, , 1-27.	0.2	2
2972	Toward the Identification of Genetic Determinants of Responsiveness to Cancer Immunotherapy. <i>Cancer Drug Discovery and Development</i> , 2015, , 99-127.	0.2	4

#	ARTICLE	IF	CITATIONS
2973	Therapeutic Antibodies in Cancer Therapy. , 2015, , 95-120.		1
2974	Prognostic score for patients with advanced melanoma treated with ipilimumab. <i>European Journal of Cancer</i> , 2015, 51, 2785-2791.	1.3	53
2975	Phase I Study of Pembrolizumab (MK-3475; Anti-“PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2015, 21, 4286-4293.	3.2	627
2976	Ipilimumab-Induced Encephalopathy with a Reversible Splenic Lesion. <i>Cancer Immunology Research</i> , 2015, 3, 598-601.	1.6	57
2977	Interleukin-6/STAT3 Pathway Signaling Drives an Inflammatory Phenotype in Group A Ependymoma. <i>Cancer Immunology Research</i> , 2015, 3, 1165-1174.	1.6	61
2979	Immunotherapy for Head and Neck Squamous Cell Carcinoma. <i>Hematology/Oncology Clinics of North America</i> , 2015, 29, 1033-1043.	0.9	30
2980	The potential complementary role of targeted alpha therapy in the management of metastatic melanoma. <i>Melanoma Management</i> , 2015, 2, 353-366.	0.1	1
2981	Erfolge und Grenzen zielgerichteter Krebstherapien beim Melanom. <i>Karger Kompass Dermatologie</i> , 2015, 3, 65-72.	0.0	0
2982	Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. <i>BMC Medicine</i> , 2015, 13, 211.	2.3	570
2983	Advances in the treatment of newly diagnosed glioblastoma. <i>BMC Medicine</i> , 2015, 13, 293.	2.3	36
2984	Current status of checkpoint inhibitors in lymphoma. <i>International Journal of Hematologic Oncology</i> , 2015, 4, 167-174.	0.7	0
2985	The Nuclear Orphan Receptor NR2F6 Is a Central Checkpoint for Cancer Immune Surveillance. <i>Cell Reports</i> , 2015, 12, 2072-2085.	2.9	47
2986	Current and Emerging Perspectives on Immunotherapy for Melanoma. <i>Seminars in Oncology</i> , 2015, 42, S3-S11.	0.8	19
2987	“Cell receptor gene therapy “ ready to go viral?. <i>Molecular Oncology</i> , 2015, 9, 2019-2042.	2.1	21
2988	Tumor immunology and cancer immunotherapy: summary of the 2014 SITC primer. , 2015, 3, .		12
2989	Intratumoral talimogene laherparepvec therapy in melanoma. <i>Melanoma Management</i> , 2015, 2, 297-300.	0.1	2
2990	Current Statistical Challenges in Oncology Clinical Trials in the Era of Targeted Therapy. <i>Statistics in Biopharmaceutical Research</i> , 2015, 7, 348-356.	0.6	5
2991	Serum Immunoregulatory Proteins as Predictors of Overall Survival of Metastatic Melanoma Patients Treated with Ipilimumab. <i>Cancer Research</i> , 2015, 75, 5084-5092.	0.4	46

#	ARTICLE	IF	CITATIONS
2992	Long-term survival as a treatment benchmark in melanoma: latest results and clinical implications. <i>Therapeutic Advances in Medical Oncology</i> , 2015, 7, 181-191.	1.4	20
2993	Docetaxel Alone or in Combination With a Therapeutic Cancer Vaccine (PANVAC) in Patients With Metastatic Breast Cancer. <i>JAMA Oncology</i> , 2015, 1, 1087.	3.4	80
2994	Phase II study of the immune-checkpoint inhibitor ipilimumab plus dacarbazine in Japanese patients with previously untreated, unresectable or metastatic melanoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 969-975.	1.1	38
2995	Depletion of B220 ⁺ NK1.1 ⁺ cells enhances the rejection of established melanoma by tumor-specific CD4 ⁺ T cells. <i>Oncolmunology</i> , 2015, 4, e1019196.	2.1	10
2996	Unusual pulmonary toxicity of ipilimumab treated by macrolides. <i>Acta Clinica Belgica</i> , 2015, 70, 442-444.	0.5	5
2997	Co-potentialion of antigen recognition: A mechanism to boost weak T cell responses and provide immunotherapy in vivo. <i>Science Advances</i> , 2015, 1, e1500415.	4.7	10
2998	Enhancing T Cell Performance Against Cancer in Combination Treatment Strategies. <i>Cancer Drug Discovery and Development</i> , 2015, , 245-258.	0.2	0
2999	Cytotoxic T lymphocyte-associated antigen 4 inhibition increases the antitumor activity of adoptive T-cell therapy when carried out with na ⁺ ve rather than differentiated T cells. <i>Oncology Reports</i> , 2015, 33, 2545-2552.	1.2	4
3000	Expression of immune checkpoint molecules of T cell immunoglobulin and mucin protein 3/galectin-9 for NK cell suppression in human gastrointestinal stromal tumors. <i>Oncology Reports</i> , 2015, 34, 2099-2105.	1.2	43
3001	Unusual pulmonary toxicity of ipilimumab treated by macrolides. <i>Acta Clinica Belgica</i> , 2015, 70, 442-444.	0.5	7
3002	The role of inflammation in progression of breast cancer: Friend or foe? (Review). <i>International Journal of Oncology</i> , 2015, 47, 797-805.	1.4	52
3003	A longitudinal study of CEACAM1 expression in melanoma disease progression. <i>Oncology Reports</i> , 2015, 33, 1314-1318.	1.2	11
3004	Sorafenib enhances the antitumor effects of anti-CTLA-4 antibody in a murine cancer model by inhibiting myeloid-derived suppressor cells. <i>Oncology Reports</i> , 2015, 33, 2947-2953.	1.2	21
3005	ERK/GSK3 ^β signaling is involved in atractylenolide I-induced apoptosis and cell cycle arrest in melanoma cells. <i>Oncology Reports</i> , 2015, 34, 1543-1548.	1.2	17
3006	Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer. <i>Current Breast Cancer Reports</i> , 2015, 7, 232-241.	0.5	0
3007	T Cell Fate in the Tumor Microenvironment. <i>Cancer Drug Discovery and Development</i> , 2015, , 53-74.	0.2	0
3008	Infliximab for IPILIMUMAB-Related Colitis Letter. <i>Clinical Cancer Research</i> , 2015, 21, 5642-5643.	3.2	47
3009	Long-Lasting Responses under Treatment with Ipilimumab: An Argument against Maintenance Therapy?. <i>Dermatology</i> , 2015, 230, 8-10.	0.9	11

#	ARTICLE	IF	CITATIONS
3011	Malignant melanoma in elderly patients: biological, surgical and medical issues. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 101-108.	1.1	27
3012	Drug design strategies for the treatment of prostate cancer. <i>Expert Opinion on Drug Discovery</i> , 2015, 10, 81-90.	2.5	9
3013	Successful Combined Intratumoral Immunotherapy of Established Murine Mesotheliomas Requires B-Cell Involvement. <i>Journal of Interferon and Cytokine Research</i> , 2015, 35, 100-107.	0.5	7
3014	Somatically mutated tumor antigens in the quest for a more efficacious patient-oriented immunotherapy of cancer. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 99-104.	2.0	32
3015	Regulation of cytotoxic T-Lymphocyte trafficking to tumors by chemoattractants: implications for immunotherapy. <i>Expert Review of Vaccines</i> , 2015, 14, 537-549.	2.0	14
3016	Beyond immune checkpoint blockade: New approaches to targeting host-tumor interactions in prostate cancer: Report from the 2014 Coffey-Holden prostate cancer Academy meeting. <i>Prostate</i> , 2015, 75, 337-347.	1.2	12
3017	Retinoic acid receptors: From molecular mechanisms to cancer therapy. <i>Molecular Aspects of Medicine</i> , 2015, 41, 1-115.	2.7	284
3018	Pancreatic Ductal Adenocarcinoma Treatment—The Past, Present, and Future. <i>Seminars in Oncology</i> , 2015, 42, 4-7.	0.8	1
3019	Checkpoint inhibitors in immunotherapy of ovarian cancer. <i>Tumor Biology</i> , 2015, 36, 33-39.	0.8	19
3020	Circulating Biomarkers in Malignant Melanoma. <i>Advances in Clinical Chemistry</i> , 2015, 69, 47-89.	1.8	34
3021	Clinical trial designs for rare diseases: Studies developed and discussed by the International Rare Cancers Initiative. <i>European Journal of Cancer</i> , 2015, 51, 271-281.	1.3	108
3022	Immune Checkpoint Inhibitors in Melanoma Provide the Cornerstones for Curative Therapies. <i>Seminars in Oncology</i> , 2015, 42, 429-435.	0.8	68
3023	Dabrafenib in combination with trametinib for the treatment of metastatic melanoma. <i>Expert Review of Clinical Pharmacology</i> , 2015, 8, 25-33.	1.3	8
3024	Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. <i>Oncolmmunology</i> , 2015, 4, e985940.	2.1	47
3025	Mucosal Melanoma: An Update. <i>Actas Dermo-sifiliográficas</i> , 2015, 106, 96-103.	0.2	2
3026	Raising the Bar for Antineoplastic Agents: How to Choose Threshold Values for Superiority Trials in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2015, 21, 1036-1043.	3.2	31
3027	Advances in targeted therapy for unresectable melanoma: New drugs and combinations. <i>Cancer Letters</i> , 2015, 359, 1-8.	3.2	42
3028	Trial Watch: Peptide-based anticancer vaccines. <i>Oncolmmunology</i> , 2015, 4, e974411.	2.1	97

#	ARTICLE	IF	CITATIONS
3029	Glioblastoma stem cells and stem cell-targeting immunotherapies. <i>Journal of Neuro-Oncology</i> , 2015, 123, 449-457.	1.4	25
3030	Mechanisms of and strategies for overcoming resistance to anti-vascular endothelial growth factor therapy in non-small cell lung cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2015, 1855, 193-201.	3.3	11
3031	Hypophysitis. <i>Endocrinology and Metabolism Clinics of North America</i> , 2015, 44, 143-149.	1.2	46
3032	Immune Checkpoint Blockade in Patients With Melanoma Metastatic to the Brain. <i>Seminars in Oncology</i> , 2015, 42, 459-465.	0.8	20
3033	PACMEL: A phase 1 dose escalation trial of trametinib (GSK1120212) in combination with paclitaxel. <i>European Journal of Cancer</i> , 2015, 51, 359-366.	1.3	21
3034	Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. <i>Lancet Oncology</i> , The, 2015, 16, 177-186.	5.1	240
3035	Immune Checkpoint Blockade and Interferon- γ in Melanoma. <i>Seminars in Oncology</i> , 2015, 42, 436-447.	0.8	34
3037	Immunotherapy for head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2015, 51, 299-304.	0.8	19
3038	Immunotherapy for the Treatment of Breast Cancer. <i>Current Oncology Reports</i> , 2015, 17, 5.	1.8	59
3039	Tim-3 fosters HCC development by enhancing TGF- β -mediated alternative activation of macrophages. <i>Gut</i> , 2015, 64, 1593-1604.	6.1	236
3041	CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations. <i>Cancer Medicine</i> , 2015, 4, 661-672.	1.3	100
3042	Conformation of the Human Immunoglobulin G2 Hinge Imparts Superagonistic Properties to Immunostimulatory Anticancer Antibodies. <i>Cancer Cell</i> , 2015, 27, 138-148.	7.7	135
3043	Targeting drivers of melanoma with synthetic small molecules and phytochemicals. <i>Cancer Letters</i> , 2015, 359, 20-35.	3.2	67
3044	Immunogenic peptide discovery in cancer genomes. <i>Current Opinion in Genetics and Development</i> , 2015, 30, 7-16.	1.5	63
3045	Mechanisms of tumor-induced T cell immune suppression and therapeutics to counter those effects. <i>Archives of Pharmacal Research</i> , 2015, 38, 1415-1433.	2.7	14
3046	Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. <i>Cell Research</i> , 2015, 25, 208-224.	5.7	143
3047	The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?. <i>Current Opinion in Immunology</i> , 2015, 33, 23-35.	2.4	298
3048	New perspectives on type I IFNs in cancer. <i>Cytokine and Growth Factor Reviews</i> , 2015, 26, 175-178.	3.2	50

#	ARTICLE	IF	CITATIONS
3049	Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study. <i>Annals of Oncology</i> , 2015, 26, 798-803.	0.6	118
3050	Image-derived biomarkers and multimodal imaging strategies for lung cancer management. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 634-643.	3.3	20
3051	Synthesis, radiolabeling and preliminary in vivo evaluation of multimodal radiotracers for PET imaging and targeted radionuclide therapy of pigmented melanoma. <i>European Journal of Medicinal Chemistry</i> , 2015, 92, 818-838.	2.6	7
3052	Increased expression of the regulatory T cell-associated marker CTLA-4 in bovine leukemia virus infection. <i>Veterinary Immunology and Immunopathology</i> , 2015, 163, 115-124.	0.5	20
3053	BRAF and MEK inhibition in melanoma. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 559-570.	1.0	67
3054	Cancer immunotherapy utilizing gene-modified T cells: From the bench to the clinic. <i>Molecular Immunology</i> , 2015, 67, 46-57.	1.0	100
3055	Immune Checkpoint Blockade in Cancer Therapy. <i>Journal of Clinical Oncology</i> , 2015, 33, 1974-1982.	0.8	2,220
3056	Targeted localized use of therapeutic antibodies: a review of non-systemic, topical and oral applications. <i>Critical Reviews in Biotechnology</i> , 2015, 36, 1-15.	5.1	28
3057	Ipilimumab-induced toxicities and the gastroenterologist. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 657-666.	1.4	74
3058	Recurrence of Melanoma Following T Cell Treatment: Continued Antigen Expression in a Tumor That Evades T Cell Recruitment. <i>Molecular Therapy</i> , 2015, 23, 396-406.	3.7	22
3059	Immune checkpoint modulation: Rational design of combination strategies. , 2015, 150, 23-32.		76
3060	Lichenoid Dermatitis in Three Patients with Metastatic Melanoma Treated with Anti-PD-1 Therapy. <i>Cancer Immunology Research</i> , 2015, 3, 18-22.	1.6	100
3061	Immunotherapy: An Evolving Paradigm in the Treatment of Advanced Cervical Cancer. <i>Clinical Therapeutics</i> , 2015, 37, 20-38.	1.1	46
3062	Lobaplatin arrests cell cycle progression, induces apoptosis and impairs migration and invasion in B16-F10 melanoma cell line in vitro. <i>Biomedicine and Pharmacotherapy</i> , 2015, 69, 402-408.	2.5	29
3063	Enhanced immunosuppression by therapy-exposed glioblastoma multiforme tumor cells. <i>International Journal of Cancer</i> , 2015, 136, 2566-2578.	2.3	38
3064	Blockade of CTLA-4 promotes the development of effector CD8+ T lymphocytes and the therapeutic effect of vaccination with an attenuated protozoan expressing NY-ESO-1. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 311-323.	2.0	14
3065	Anti-programmed death receptor 1 immunotherapy in melanoma: rationale, evidence and clinical potential. <i>Therapeutic Advances in Medical Oncology</i> , 2015, 7, 12-21.	1.4	22
3066	Exploring the potential of immuno-oncology-based treatment for patients with non-small cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 69-83.	1.1	13

#	ARTICLE	IF	CITATIONS
3067	Recent advances in targeted nanoparticles drug delivery to melanoma. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2015, 11, 769-794.	1.7	94
3068	Cutaneous adverse effects of targeted therapies. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 221-236.	0.6	150
3069	Advanced pancreatic adenocarcinoma: a review of current treatment strategies and developing therapies. <i>Therapeutic Advances in Medical Oncology</i> , 2015, 7, 68-84.	1.4	123
3070	Molecular Basis for Treating Cutaneous Melanoma. , 2015, , 591-600.e3.		0
3071	Neuroendocrine Causes of Amenorrhea—An Update. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 812-824.	1.8	106
3072	Immunotherapy of melanoma: Present options and future promises. <i>Cancer and Metastasis Reviews</i> , 2015, 34, 115-128.	2.7	59
3073	TRIB2 as a biomarker for diagnosis and progression of melanoma. <i>Carcinogenesis</i> , 2015, 36, 469-477.	1.3	31
3074	Monoclonal Antibodies for Cancer Immunotherapy. , 2015, , 293-328.		6
3075	Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation. <i>New England Journal of Medicine</i> , 2015, 372, 320-330.	13.9	4,795
3076	The potential role of immunotherapy to treat colorectal cancer. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 329-344.	1.9	27
3077	A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1—Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response. <i>Clinical Cancer Research</i> , 2015, 21, 1019-1027.	3.2	677
3078	Systemic treatment of advanced hepatocellular carcinoma: From disillusion to new horizons. <i>European Journal of Cancer</i> , 2015, 51, 327-339.	1.3	63
3079	Building immunity to cancer with radiation therapy. <i>Cancer Letters</i> , 2015, 368, 198-208.	3.2	69
3080	Combination Therapy with Anti—CTLA-4 and Anti—PD-1 Leads to Distinct Immunologic Changes In Vivo. <i>Journal of Immunology</i> , 2015, 194, 950-959.	0.4	362
3081	HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL). <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E166-75.	3.3	150
3082	Exchange protein directly activated by cAMP modulates regulatory T-cell-mediated immunosuppression. <i>Biochemical Journal</i> , 2015, 465, 295-303.	1.7	38
3083	Phase 2 Study of Intralesional PV-10 in Refractory Metastatic Melanoma. <i>Annals of Surgical Oncology</i> , 2015, 22, 2135-2142.	0.7	126
3084	Current challenges in designing GBM trials for immunotherapy. <i>Journal of Neuro-Oncology</i> , 2015, 123, 331-337.	1.4	34

#	ARTICLE	IF	CITATIONS
3085	Increased proportion of FoxP3+ regulatory T cells in tumor infiltrating lymphocytes is associated with tumor recurrence and reduced survival in patients with glioblastoma. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 419-427.	2.0	152
3087	ImmTACs for targeted cancer therapy: Why, what, how, and which. <i>Molecular Immunology</i> , 2015, 67, 67-74.	1.0	75
3088	Long-term Follow-up for Melanoma Patients. <i>Surgical Oncology Clinics of North America</i> , 2015, 24, 359-377.	0.6	32
3090	Impact of NRAS Mutations for Patients with Advanced Melanoma Treated with Immune Therapies. <i>Cancer Immunology Research</i> , 2015, 3, 288-295.	1.6	145
3091	Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma. , 2015, 3, 2.		93
3092	Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. <i>Lancet Oncology, The</i> , 2015, 16, 257-265.	5.1	1,269
3093	The Contemporary Role of Major Amputation in the Management of Advanced Limb Melanoma. <i>Annals of Surgical Oncology</i> , 2015, 22, 4067-4072.	0.7	14
3094	Requirement for Innate Immunity and CD90+ NK1.1 ^{hi} Lymphocytes to Treat Established Melanoma with Chemo-Immunotherapy. <i>Cancer Immunology Research</i> , 2015, 3, 296-304.	1.6	25
3095	A first-in-human phase I, dose-escalation, multicentre study of HSP990 administered orally in adult patients with advanced solid malignancies. <i>British Journal of Cancer</i> , 2015, 112, 650-659.	2.9	34
3096	Can oncology recapitulate paleontology? Lessons from species extinctions. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 273-285.	12.5	31
3097	PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 847-856.	1.9	1,787
3098	Paradigm shift in oncology: targeting the immune system rather than cancer cells. <i>Mutagenesis</i> , 2015, 30, 205-211.	1.0	46
3099	Diffuse thyroid 18F-FDG uptake after R-CHOP therapy predicts favorable outcome in patients with DLBCL. <i>Annals of Hematology</i> , 2015, 94, 995-1001.	0.8	2
3100	Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome. <i>Clinical Cancer Research</i> , 2015, 21, 3619-3630.	3.2	115
3101	Low immunogenicity in non-small cell lung cancer; do new developments and novel treatments have a role?. <i>Cancer and Metastasis Reviews</i> , 2015, 34, 129-144.	2.7	11
3103	Ipilimumab and whole brain radiation therapy for melanoma brain metastases. <i>Journal of Neuro-Oncology</i> , 2015, 121, 159-165.	1.4	53
3104	Biomarkers for glioma immunotherapy: the next generation. <i>Journal of Neuro-Oncology</i> , 2015, 123, 359-372.	1.4	23
3105	Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience. <i>Oncogene</i> , 2015, 34, 5411-5417.	2.6	48

#	ARTICLE	IF	CITATIONS
3106	Antigen targeting to dendritic cells combined with transient regulatory T cell inhibition results in long-term tumor regression. <i>Oncolmmunology</i> , 2015, 4, e970462.	2.1	30
3107	Translational Implications of Tumor Heterogeneity. <i>Clinical Cancer Research</i> , 2015, 21, 1258-1266.	3.2	424
3108	Vitiligo-Like Depigmentation in Patients With Stage III-IV Melanoma Receiving Immunotherapy and Its Association With Survival: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2015, 33, 773-781.	0.8	501
3109	Utility of chest X-ray and abdominal ultrasound for stage III cutaneous malignant melanoma. <i>European Journal of Plastic Surgery</i> , 2015, 38, 189-192.	0.3	1
3110	New drug toxicities in the onco-nephrology world. <i>Kidney International</i> , 2015, 87, 909-917.	2.6	70
3111	Phase I pilot study of Wilms tumor gene 1 peptide-pulsed dendritic cell vaccination combined with gemcitabine in pancreatic cancer. <i>Cancer Science</i> , 2015, 106, 397-406.	1.7	65
3112	Genetic Engineering of Oncolytic Viruses for Cancer Therapy. , 2015, , 261-279.		3
3113	Nivolumab in melanoma: latest evidence and clinical potential. <i>Therapeutic Advances in Medical Oncology</i> , 2015, 7, 97-106.	1.4	124
3114	The immune response in cancer: from immunology to pathology to immunotherapy. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2015, 467, 127-135.	1.4	51
3115	Elevated Cancer-Specific Mortality Among HIV-Infected Patients in the United States. <i>Journal of Clinical Oncology</i> , 2015, 33, 2376-2383.	0.8	266
3116	Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy. <i>Nature Immunology</i> , 2015, 16, 850-858.	7.0	244
3117	Severe relapse in a multiple sclerosis patient associated with ipilimumab treatment of melanoma. <i>Multiple Sclerosis Journal</i> , 2015, 21, 670-670.	1.4	86
3118	Evolving Concepts: Immunity in Oncology from Targets to Treatments. <i>Journal of Oncology</i> , 2015, 2015, 1-15.	0.6	23
3119	Natural killer cell dysfunction in hepatocellular carcinoma and NK cell-based immunotherapy. <i>Acta Pharmacologica Sinica</i> , 2015, 36, 1191-1199.	2.8	144
3120	Nivolumab: targeting PD-1 to bolster antitumor immunity. <i>Future Oncology</i> , 2015, 11, 1307-1326.	1.1	158
3121	A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1. <i>Cancer Research</i> , 2015, 75, 3800-3811.	0.4	201
3122	¹⁸ F-FDG PET/CT and Melanoma: Staging, Immune Modulation and Mutation-Targeted Therapy Assessment, and Prognosis. <i>American Journal of Roentgenology</i> , 2015, 205, 259-270.	1.0	57
3123	Melanoma and a Headache. <i>JAMA Oncology</i> , 2015, 1, 1167.	3.4	5

#	ARTICLE	IF	CITATIONS
3124	Combination cancer immunotherapy and new immunomodulatory targets. <i>Nature Reviews Drug Discovery</i> , 2015, 14, 561-584.	21.5	1,058
3126	Fifty shades of chronic colitis: non-infectious imposters of inflammatory bowel disease. <i>Diagnostic Histopathology</i> , 2015, 21, 276-282.	0.2	2
3127	The Evolution of T-cell Therapies for Solid Malignancies. <i>Clinical Cancer Research</i> , 2015, 21, 3384-3392.	3.2	71
3128	Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral Center. <i>Cancer Immunology Research</i> , 2015, 3, 464-469.	1.6	91
3129	ErbB3/ErbB2 Complexes as a Therapeutic Target in a Subset of Wild-type BRAF/NRAS Cutaneous Melanomas. <i>Cancer Research</i> , 2015, 75, 3554-3567.	0.4	18
3130	Immunotherapy of Metastatic Colorectal Cancer: Prevailing Challenges and New Perspectives. <i>Current Colorectal Cancer Reports</i> , 2015, 11, 125-140.	1.0	27
3131	A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors. <i>Annals of Oncology</i> , 2015, 26, 1824-1829.	0.6	184
3132	Melanoma: Advances in Targeted Therapy and Molecular Markers. <i>Annals of Surgical Oncology</i> , 2015, 22, 3451-3458.	0.7	15
3133	Immune Checkpoint Inhibition in Renal Cell Carcinoma. , 2015, , 259-279.		0
3134	The Prognostic and Predictive Value of Melanoma-related MicroRNAs Using Tissue and Serum: A MicroRNA Expression Analysis. <i>EBioMedicine</i> , 2015, 2, 671-680.	2.7	86
3135	Targeted Therapies in Melanoma: Translational Research at Its Finest. <i>Journal of Investigative Dermatology</i> , 2015, 135, 1929-1933.	0.3	12
3137	Personalised medicine: Development and external validation of a prognostic model for metastatic melanoma patients treated with ipilimumab. <i>European Journal of Cancer</i> , 2015, 51, 2086-2094.	1.3	45
3138	Evaluating immune responses after sipuleucel-T therapy. <i>Cancer Biology and Therapy</i> , 2015, 16, 1119-1121.	1.5	4
3139	Hematological Effects, Serum, and Pulmonary Cytokine Profiles in a Melanoma Mouse Model Treated with GK1. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2015, 30, 247-254.	0.7	5
3140	The combination of axitinib followed by paclitaxel/carboplatin yields extended survival in advanced BRAF wild-type melanoma: results of a clinical/correlative prospective phase II clinical trial. <i>British Journal of Cancer</i> , 2015, 112, 1326-1331.	2.9	30
3141	Therapeutic Advances and Treatment Options in Metastatic Melanoma. <i>JAMA Oncology</i> , 2015, 1, 380.	3.4	66
3142	Beyond conventional chemotherapy: Emerging molecular targeted and immunotherapy strategies in urothelial carcinoma. <i>Cancer Treatment Reviews</i> , 2015, 41, 699-706.	3.4	14
3143	Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2 ^Δ /IL2R ^Δ null Immunodeficient Mice. <i>Cancer Research</i> , 2015, 75, 3466-3478.	0.4	137

#	ARTICLE	IF	CITATIONS
3144	CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer. <i>Cancer Immunology Research</i> , 2015, 3, 1257-1268.	1.6	241
3145	Novel drugs in clinical development for hepatocellular carcinoma. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 1075-1082.	1.9	34
3146	Pembrolizumab for the treatment of melanoma. <i>Expert Review of Clinical Pharmacology</i> , 2015, 8, 515-527.	1.3	2
3147	Enhancing the efficacy of adoptive cellular therapy by targeting tumor-induced immunosuppression. <i>Immunotherapy</i> , 2015, 7, 499-512.	1.0	18
3148	Immune Regulation by Self-Recognition: Novel Possibilities for Anticancer Immunotherapy. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv154-djv154.	3.0	39
3149	Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. <i>OncoImmunology</i> , 2015, 4, e1008814.	2.1	102
3150	BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies. <i>OncoTargets and Therapy</i> , 2015, 8, 157.	1.0	134
3151	Adoptive T-cell therapy: a need for standard immune monitoring. <i>Immunotherapy</i> , 2015, 7, 513-533.	1.0	17
3152	In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment. <i>Vaccine</i> , 2015, 33, 7415-7422.	1.7	142
3153	Synthetic Nanoparticles for Vaccines and Immunotherapy. <i>Chemical Reviews</i> , 2015, 115, 11109-11146.	23.0	623
3154	New immunotherapies targeting the PD-1 pathway. <i>Trends in Pharmacological Sciences</i> , 2015, 36, 587-595.	4.0	158
3155	Inflammation and Lung Cancer. , 2015, , .		2
3157	Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 655-663.	2.0	21
3158	Challenges and future perspectives of T cell immunotherapy in cancer. <i>Immunology Letters</i> , 2015, 166, 117-133.	1.1	41
3159	The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. <i>Nature Reviews Cancer</i> , 2015, 15, 409-425.	12.8	1,474
3160	Combined immunotherapyâ€”a new standard in metastatic melanoma?. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 439-440.	12.5	8
3161	A miRNA-Based Signature Detected in Primary Melanoma Tissue Predicts Development of Brain Metastasis. <i>Clinical Cancer Research</i> , 2015, 21, 4903-4912.	3.2	73
3162	Successes and setbacks of early investigational drugs for melanoma. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 993-997.	1.9	4

#	ARTICLE	IF	CITATIONS
3163	Immunotherapy in Cancer: A Combat between Tumors and the Immune System; You Win Some, You Lose Some. <i>Frontiers in Immunology</i> , 2015, 6, 127.	2.2	51
3164	Modulation of Immune Cell Functions by the E3 Ligase Cbl-b. <i>Frontiers in Oncology</i> , 2015, 5, 58.	1.3	64
3165	Swinging for the Fences: Long-Term Survival With Ipilimumab in Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 1873-1877.	0.8	9
3166	Histone deacetylase inhibitors prevent activation-induced cell death and promote anti-tumor immunity. <i>Oncogene</i> , 2015, 34, 5960-5970.	2.6	67
3167	Milestone Survival: A Potential Intermediate Endpoint for Immune Checkpoint Inhibitors. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv156.	3.0	62
3168	Targeted Therapies for Melanoma. , 2015, , 1529-1541.		0
3169	Reorienting the immune system in the treatment of cancer by using anti-PD-1 and anti-PD-L1 antibodies. <i>Drug Discovery Today</i> , 2015, 20, 1127-1134.	3.2	27
3170	Treatment of Liver Cancer. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2015, 5, a021535.	2.9	241
3171	Efficacy and Safety of Nivolumab in Patients With <i>BRAF</i> V600 Mutant and <i>BRAF</i> Wild-Type Advanced Melanoma. <i>JAMA Oncology</i> , 2015, 1, 433.	3.4	201
3173	Changing Treatment Paradigms in Metastatic Breast Cancer. <i>JAMA Oncology</i> , 2015, 1, 528.	3.4	88
3174	Cancer Immunotherapy Confers a Global Benefit. , 2015, , 1-39.		0
3175	Lentivirus-induced "Smart" dendritic cells: Pharmacodynamics and GMP-compliant production for immunotherapy against TRP2-positive melanoma. <i>Gene Therapy</i> , 2015, 22, 707-720.	2.3	37
3176	Combined Immune Checkpoint Blockade. <i>Seminars in Oncology</i> , 2015, 42, 656-662.	0.8	12
3177	Chondroitin sulfate proteoglycan 4 as a target for chimeric antigen receptor-based T-cell immunotherapy of solid tumors. <i>Expert Opinion on Therapeutic Targets</i> , 2015, 19, 1339-1350.	1.5	22
3178	Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma. <i>Immunotherapy</i> , 2015, 7, 611-619.	1.0	141
3179	The Contained Self-Reactive Peripheral T Cell Repertoire: Size, Diversity, and Cellular Composition. <i>Journal of Immunology</i> , 2015, 195, 2067-2079.	0.4	30
3180	Evolving synergistic combinations of targeted immunotherapies to combat cancer. <i>Nature Reviews Cancer</i> , 2015, 15, 457-472.	12.8	576
3181	Trametinib in metastatic melanoma. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 749-760.	1.1	8

#	ARTICLE	IF	CITATIONS
3182	Cost-effectiveness of therapies for melanoma. Expert Review of Pharmacoeconomics and Outcomes Research, 2015, 15, 229-242.	0.7	9
3183	Clinical Management of Multiple Melanoma Brain Metastases. JAMA Oncology, 2015, 1, 668.	3.4	70
3184	Cancer Immunotherapy with Vaccines and Checkpoint Blockade. , 2015, , 709-738.e8.		0
3186	Rational Combination of Immunotherapies with Clinical Efficacy in Mice with Advanced Cancer. Cancer Immunology Research, 2015, 3, 1279-1288.	1.6	3
3187	Vaccination of multiple myeloma: Current strategies and future prospects. Critical Reviews in Oncology/Hematology, 2015, 96, 339-354.	2.0	20
3188	Engineered materials for cancer immunotherapy. Nano Today, 2015, 10, 511-531.	6.2	96
3189	Immune Targeting of Tumor Epithelial-Mesenchymal Transition via Brachyury-Based Vaccines. Advances in Cancer Research, 2015, 128, 69-93.	1.9	12
3190	Nivolumab in the treatment of advanced melanoma. Expert Opinion on Orphan Drugs, 2015, 3, 945-956.	0.5	0
3191	Costs, resource utilization, and treatment patterns for patients with metastatic melanoma in a commercially insured setting. Current Medical Research and Opinion, 2015, 31, 1561-1572.	0.9	26
3192	The immunecheckpoints in modern oncology: the next 15 years. Expert Opinion on Biological Therapy, 2015, 15, 917-921.	1.4	24
3193	Metastatic Melanoma - A Review of Current and Future Treatment Options. Acta Dermato-Venereologica, 2015, 95, 516-524.	0.6	186
3194	Concepts of immunotherapy for glioma. Journal of Neuro-Oncology, 2015, 123, 323-330.	1.4	12
3195	Cost Effectiveness of Sequencing 34 Cancer-Associated Genes as an Aid for Treatment Selection in Patients with Metastatic Melanoma. Molecular Diagnosis and Therapy, 2015, 19, 169-177.	1.6	28
3196	General Aspects of Cancer Chemotherapy. , 2015, , 1-22.		5
3197	Biological Therapy of Cancer. , 2015, , 561-593.		0
3198	The New Era of Cancer Immunotherapy. Advances in Cancer Research, 2015, 128, 1-68.	1.9	41
3199	Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system. Trends in Molecular Medicine, 2015, 21, 482-491.	3.5	146
3200	Cancer Immunotherapy: Past Progress and Future Directions. Seminars in Oncology, 2015, 42, 518-522.	0.8	17

#	ARTICLE	IF	CITATIONS
3201	Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy. <i>Seminars in Oncology</i> , 2015, 42, 601-616.	0.8	139
3202	PET/CT, MR, and PET/MR in Lymphoma and Melanoma. <i>Seminars in Nuclear Medicine</i> , 2015, 45, 322-331.	2.5	32
3203	Identifying genes that mediate anthracycline toxicity in immune cells. <i>Frontiers in Pharmacology</i> , 2015, 6, 62.	1.6	4
3204	Gaining momentum: New options and opportunities for the treatment of advanced melanoma. <i>Cancer Treatment Reviews</i> , 2015, 41, 660-670.	3.4	51
3205	In-situ tumor vaccination: Bringing the fight to the tumor. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 1901-1909.	1.4	60
3206	Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. <i>Lancet Oncology</i> , The, 2015, 16, 908-918.	5.1	1,419
3207	OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal. <i>Frontiers in Oncology</i> , 2015, 5, 34.	1.3	193
3208	The rise in metastasectomy across cancer types over the past decade. <i>Cancer</i> , 2015, 121, 747-757.	2.0	127
3209	The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment. <i>Oncologist</i> , 2015, 20, 812-822.	1.9	198
3210	Targeting the T-cell co-stimulatory CD27/CD70 pathway in cancer immunotherapy: rationale and potential. <i>Immunotherapy</i> , 2015, 7, 655-667.	1.0	135
3211	Epigenetic modulation with histone deacetylase inhibitors in combination with immunotherapy. <i>Epigenomics</i> , 2015, 7, 641-652.	1.0	46
3212	Viral Infection of Tumors Overcomes Resistance to PD-1-immunotherapy by Broadening Neoantigenome-directed T-cell Responses. <i>Molecular Therapy</i> , 2015, 23, 1630-1640.	3.7	165
3213	Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints. <i>Nature Communications</i> , 2015, 6, 7458.	5.8	383
3214	The pharmacology of second-generation chimeric antigen receptors. <i>Nature Reviews Drug Discovery</i> , 2015, 14, 499-509.	21.5	411
3215	Combining Immunotherapy with Oncogene-Targeted Therapy: A New Road for Melanoma Treatment. <i>Frontiers in Immunology</i> , 2015, 6, 46.	2.2	69
3216	Are Macrophages in Tumors Good Targets for Novel Therapeutic Approaches?. <i>Molecules and Cells</i> , 2015, 38, 95-104.	1.0	9
3217	Targeting the Innate Immune System as Immunotherapy for Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2015, 5, 83.	1.3	33
3218	Greater patient access to immuno-oncology therapies—what can. <i>Ecancermedicalscience</i> , 2015, 9, ed48.	0.6	1

#	ARTICLE	IF	CITATIONS
3219	Rapid Eradication of a Bulky Melanoma Mass with One Dose of Immunotherapy. <i>New England Journal of Medicine</i> , 2015, 372, 2073-2074.	13.9	57
3220	Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results. <i>Journal of Clinical Oncology</i> , 2015, 33, 14.		160
3221	Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 6140-6145.	3.3	498
3222	Serum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapy. <i>Oncotarget</i> , 2015, 4, e989771.	2.1	47
3223	Durable complete responses off all treatment in patients with metastatic malignant melanoma after sequential immunotherapy followed by a finite course of BRAF inhibitor therapy. <i>Cancer Biology and Therapy</i> , 2015, 16, 662-670.	1.5	27
3224	Adjuvant immunotherapy for cancer: the next step. <i>Lancet Oncology</i> , 2015, 16, 478-480.	5.1	10
3225	Second-Line Therapies in Metastatic Urothelial Carcinoma. <i>Hematology/Oncology Clinics of North America</i> , 2015, 29, 341-359.	0.9	11
3226	Cytotoxic T-Lymphocyte Antigen-4 Blockade in Melanoma. <i>Clinical Therapeutics</i> , 2015, 37, 755-763.	1.1	28
3227	Mechanisms of action of therapeutic antibodies for cancer. <i>Molecular Immunology</i> , 2015, 67, 28-45.	1.0	136
3228	Anti-PD-1-Targeted Therapies Focusing on Lymphatic Malignancies: Biological Rationale, Clinical Challenges and Opportunities. <i>Acta Haematologica</i> , 2015, 133, 129-135.	0.7	8
3229	Case-Control Estimation of the Impact of Oncolytic Adenovirus on the Survival of Patients With Refractory Solid Tumors. <i>Molecular Therapy</i> , 2015, 23, 321-329.	3.7	14
3230	Role of immunotherapy in lung cancer: Preliminary results of new vaccines and immune checkpoint inhibitors. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2015, 11, 2-8.	0.7	3
3231	Immunotherapy for urothelial cancer: from BCG to checkpoint inhibitors and beyond. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 509-523.	1.1	21
3232	Immuno-regulatory antibodies for the treatment of cancer. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 787-801.	1.4	40
3233	PD-L1 Inhibition With MPDL3280A for Solid Tumors. <i>Seminars in Oncology</i> , 2015, 42, 484-487.	0.8	46
3234	Treatment modality of malignant melanoma that metastasized to the mandible and multiple organs: A rare case report and the literature review. <i>Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology</i> , 2015, 27, 398-401.	0.2	1
3235	Galectin-8 predicts postoperative recurrence of patients with localized T1 clear cell renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 112.e1-112.e8.	0.8	5
3236	CTLA4 blockade in patients with malignant mesothelioma. <i>Lancet Respiratory Medicine</i> , 2015, 3, 261-263.	5.2	0

#	ARTICLE	IF	CITATIONS
3237	Toxicities of Immunotherapy for the Practitioner. <i>Journal of Clinical Oncology</i> , 2015, 33, 2092-2099.	0.8	521
3238	Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab. <i>Journal of Clinical Oncology</i> , 2015, 33, 2013-2020.	0.8	385
3239	PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitorâ€Treated Melanoma Patients. <i>Clinical Cancer Research</i> , 2015, 21, 3140-3148.	3.2	120
3240	The future of immune checkpoint therapy. <i>Science</i> , 2015, 348, 56-61.	6.0	3,735
3241	Neoantigens in cancer immunotherapy. <i>Science</i> , 2015, 348, 69-74.	6.0	3,809
3242	Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. <i>European Journal of Cancer</i> , 2015, 51, 833-840.	1.3	71
3244	Predictive value of early 18F-FDG PET/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 386-396.	3.3	130
3245	Fever and the use of paracetamol during IL-2-based immunotherapy in metastatic melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 349-355.	2.0	12
3246	Long-term clinical outcome of melanoma patients treated with messenger RNA-electroporated dendritic cell therapy following complete resection of metastases. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 381-388.	2.0	70
3247	Low-dose cyclophosphamide enhances antigen-specific CD4+ T cell responses to NY-ESO-1/ISCOMATRIXâ„ vaccine in patients with advanced melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 507-518.	2.0	31
3248	Broadening the repertoire of melanoma-associated T-cell epitopes. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 609-620.	2.0	8
3249	Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-T. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 817-829.	2.0	184
3250	Cytotoxic T lymphocyte antigen 4 expression in human breast cancer: implications for prognosis. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 853-860.	2.0	93
3251	Esophageal malignant melanoma: analysis of 134 cases collected by the Japan Esophageal Society. <i>Esophagus</i> , 2015, 12, 158-169.	1.0	18
3252	The role of checkpoints in the treatment of GBM. <i>Journal of Neuro-Oncology</i> , 2015, 123, 413-423.	1.4	15
3253	Re-defining response and treatment effects for neuro-oncology immunotherapy clinical trials. <i>Journal of Neuro-Oncology</i> , 2015, 123, 339-346.	1.4	10
3254	Treatment of NRAS-Mutant Melanoma. <i>Current Treatment Options in Oncology</i> , 2015, 16, 15.	1.3	110
3255	Immunotherapy in Upper GI Malignancies. <i>Current Treatment Options in Oncology</i> , 2015, 16, 20.	1.3	9

#	ARTICLE	IF	CITATIONS
3256	Identifying Appropriate Colorectal Cancer-Associated Antigens for the Clinical Trials. <i>Current Colorectal Cancer Reports</i> , 2015, 11, 29-36.	1.0	6
3257	Translational Considerations on the Outlook of Immunotherapy for Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2015, 11, 92-97.	1.0	6
3258	Immunotherapeutic Strategies for Colon Cancer: Monoclonal Antibody Therapy. <i>Current Colorectal Cancer Reports</i> , 2015, 11, 84-91.	1.0	1
3259	Immunotherapy in Prostate Cancer. <i>Current Urology Reports</i> , 2015, 16, 34.	1.0	8
3260	Immunotherapy for lung cancer: for whom the bell tolls?. <i>Tumor Biology</i> , 2015, 36, 1411-1422.	0.8	17
3262	Cancer therapy with Newcastle disease virus: rationale for new immunotherapeutic combinations. <i>Clinical Investigation</i> , 2015, 5, 75-87.	0.0	1
3263	Pembrolizumab versus Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2015, 372, 2521-2532.	13.9	4,838
3264	Safety and Survival With GVAX Pancreas Prime and <i>Listeria Monocytogenes</i> Expressing Mesothelin (CRS-207) Boost Vaccines for Metastatic Pancreatic Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 1325-1333.	0.8	490
3265	Monoclonal antibodies against GARP/TGF- β 1 complexes inhibit the immunosuppressive activity of human regulatory T cells in vivo. <i>Science Translational Medicine</i> , 2015, 7, 284ra56.	5.8	130
3266	The Emerging Understanding of Myeloid Cells as Partners and Targets in Tumor Rejection. <i>Cancer Immunology Research</i> , 2015, 3, 313-319.	1.6	53
3267	Melanoma Treatments: Advances and Mechanisms. <i>Journal of Cellular Physiology</i> , 2015, 230, 2626-2633.	2.0	40
3268	Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma. <i>New England Journal of Medicine</i> , 2015, 372, 2006-2017.	13.9	2,489
3269	Ipilimumab and immune-mediated adverse events: a case report of anti-CTLA4 induced ileitis. <i>BMC Cancer</i> , 2015, 15, 87.	1.1	33
3270	A functional in vitro model of heterotypic interactions reveals a role for interferon-positive carcinoma associated fibroblasts in breast cancer. <i>BMC Cancer</i> , 2015, 15, 130.	1.1	16
3271	Cancer stem cells in basic science and in translational oncology: can we translate into clinical application?. <i>Journal of Hematology and Oncology</i> , 2015, 8, 16.	6.9	80
3272	Clinical characteristics and treatment-related biomarkers associated with response to high-dose interleukin-2 in metastatic melanoma and renal cell carcinoma: retrospective analysis of an academic community hospital's experience. <i>SpringerPlus</i> , 2015, 4, 118.	1.2	4
3273	Apical ballooning and cardiomyopathy in a melanoma patient treated with ipilimumab: a case of takotsubo-like syndrome. , 2015, 3, 4.		122
3274	Immune therapy of metastatic melanoma developing after allogeneic bone marrow transplant. , 2015, 3, 10.		11

#	ARTICLE	IF	CITATIONS
3275	Single-center study under a French Temporary Authorization for Use (TAU) protocol for ipilimumab in metastatic melanoma: negative impact of baseline corticosteroids. <i>European Journal of Dermatology</i> , 2015, 25, 36-44.	0.3	35
3276	The Role of Anti-PD-1/PD-L1 Agents in Melanoma: Progress to Date. <i>Drugs</i> , 2015, 75, 563-575.	4.9	18
3277	Ganglion sentinelle et m�lanome. <i>Medecine Nucleaire</i> , 2015, 39, 339-347.	0.2	0
3278	A combined approach of human leukocyte antigen ligandomics and immunogenicity analysis to improve peptide-based cancer immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 1295-1303.	2.0	10
3279	Addressing the unmet need in lung cancer: The potential of immuno-oncology. <i>Cancer Treatment Reviews</i> , 2015, 41, 465-475.	3.4	30
3280	Immune checkpoint blockade in hematologic malignancies. <i>Blood</i> , 2015, 125, 3393-3400.	0.6	208
3281	Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma. <i>Cancer Immunology Research</i> , 2015, 3, 399-411.	1.6	387
3282	Alternative Treatments For Melanoma: Targeting BCL-2 Family Members to De-Bulk and Kill Cancer Stem Cells. <i>Journal of Investigative Dermatology</i> , 2015, 135, 2155-2161.	0.3	38
3283	Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect. <i>Cell</i> , 2015, 161, 1035-1045.	13.5	228
3284	FGL2 as a Multimodality Regulator of Tumor-Mediated Immune Suppression and Therapeutic Target in Gliomas. <i>Journal of the National Cancer Institute</i> , 2015, 107, .	3.0	80
3285	Classifying Cancers Based on T-cell Infiltration and PD-L1. <i>Cancer Research</i> , 2015, 75, 2139-2145.	0.4	1,167
3286	Targeting Nodal in Conjunction with Dacarbazine Induces Synergistic Anticancer Effects in Metastatic Melanoma. <i>Molecular Cancer Research</i> , 2015, 13, 670-680.	1.5	22
3287	Regulatory T cells and potential immunotherapeutic targets in lung cancer. <i>Cancer and Metastasis Reviews</i> , 2015, 34, 277-290.	2.7	27
3288	Treating recurrent glioblastoma: an update. <i>CNS Oncology</i> , 2015, 4, 91-104.	1.2	57
3289	Immunotherapeutic Approaches to Sarcoma. <i>Current Treatment Options in Oncology</i> , 2015, 16, 26.	1.3	48
3290	Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. , 2015, 3, 11.		274
3291	Beyond the Vascular Endothelial Growth Factor Axis: Update on Role of Imaging in Nonantiangiogenic Molecular Targeted Therapies in Oncology. <i>American Journal of Roentgenology</i> , 2015, 204, 919-932.	1.0	10
3292	Mutational landscape determines sensitivity to PD-1 blockade in non�small cell lung cancer. <i>Science</i> , 2015, 348, 124-128.	6.0	6,756

#	ARTICLE	IF	CITATIONS
3293	Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in <i>BRAF</i> ^{V600E} melanoma. <i>Science Translational Medicine</i> , 2015, 7, 279ra41.	5.8	470
3294	An infrared spectral signature of human lymphocyte subpopulations from peripheral blood. <i>Analyst</i> , 2015, 140, 2257-2265.	1.7	13
3295	Current and Emerging Immunotherapies for Castration-resistant Prostate Cancer. <i>Urology</i> , 2015, 85, 976-986.	0.5	13
3296	First-in-Human Dose Study of the Novel Transforming Growth Factor- β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma. <i>Clinical Cancer Research</i> , 2015, 21, 553-560.	3.2	199
3298	Adoptive cellular therapy: A race to the finish line. <i>Science Translational Medicine</i> , 2015, 7, 280ps7.	5.8	320
3299	Immunotherapy for Acute Myeloid Leukemia. <i>Seminars in Hematology</i> , 2015, 52, 207-214.	1.8	44
3300	Awakening the immune system with radiation: Optimal dose and fractionation. <i>Cancer Letters</i> , 2015, 368, 185-190.	3.2	91
3301	TLR5 Ligand- α Secreting T Cells Reshape the Tumor Microenvironment and Enhance Antitumor Activity. <i>Cancer Research</i> , 2015, 75, 1959-1971.	0.4	33
3302	How Treatment Monitoring Is Influencing Treatment Decisions in Glioblastomas. <i>Current Treatment Options in Neurology</i> , 2015, 17, 343.	0.7	13
3303	The prognostic significance of stable disease following high-dose interleukin-2 (IL-2) treatment in patients with metastatic melanoma and renal cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 459-465.	2.0	34
3304	Cytomegalovirus-Based Vaccine Expressing a Modified Tumor Antigen Induces Potent Tumor-Specific CD8 ⁺ T-cell Response and Protects Mice from Melanoma. <i>Cancer Immunology Research</i> , 2015, 3, 536-546.	1.6	51
3305	A Stressful Microenvironment: Opposing Effects of the Endoplasmic Reticulum Stress Response in the Suppression and Enhancement of Adaptive Tumor Immunity. <i>International Reviews of Immunology</i> , 2015, 34, 104-122.	1.5	16
3306	Antitumor Granuloma Formation by CD4 ⁺ T Cells in a Patient With Rapidly Progressive Melanoma Experiencing Spiking Fevers, Neuropathy, and Other Immune-Related Toxicity After Treatment With Ipilimumab. <i>Journal of Clinical Oncology</i> , 2015, 33, e32-e35.	0.8	21
3308	On being less tolerant: Enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation. <i>Science Translational Medicine</i> , 2015, 7, 280sr1.	5.8	134
3309	The interplay of effector and regulatory T cells in cancer. <i>Current Opinion in Immunology</i> , 2015, 33, 101-111.	2.4	114
3310	Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. <i>Nature</i> , 2015, 520, 373-377.	13.7	1,955
3311	Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites. <i>Clinical Cancer Research</i> , 2015, 21, 3052-3060.	3.2	198
3312	Curing Mice with Large Tumors by Locally Delivering Combinations of Immunomodulatory Antibodies. <i>Clinical Cancer Research</i> , 2015, 21, 1127-1138.	3.2	52

#	ARTICLE	IF	CITATIONS
3313	Inflammation and Immunity in Cancer. , 2015, , .		1
3314	Haematological malignancies: at the forefront of immunotherapeutic innovation. Nature Reviews Cancer, 2015, 15, 201-215.	12.8	63
3315	Update on Immunotherapy in Melanoma. Surgical Oncology Clinics of North America, 2015, 24, 337-346.	0.6	11
3316	Role for Radiation Therapy in Melanoma. Surgical Oncology Clinics of North America, 2015, 24, 323-335.	0.6	13
3317	Metastasectomy for Stage IV Melanoma. Surgical Oncology Clinics of North America, 2015, 24, 279-298.	0.6	23
3318	Current Staging and Prognostic Factors in Melanoma. Surgical Oncology Clinics of North America, 2015, 24, 215-227.	0.6	51
3319	Elevating the Horizon: Emerging Molecular and Genomic Targets in the Treatment of Advanced Urothelial Carcinoma. Clinical Genitourinary Cancer, 2015, 13, 410-420.	0.9	17
3320	Immunological mechanisms of the antitumor effects of supplemental oxygenation. Science Translational Medicine, 2015, 7, 277ra30.	5.8	458
3321	Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy. Molecular Immunology, 2015, 67, 4-17.	1.0	180
3322	Generation of TCR-Engineered T Cells and Their Use To Control the Performance of T Cell Assays. Journal of Immunology, 2015, 194, 6177-6189.	0.4	9
3323	Melanoma-intrinsic β -catenin signalling prevents anti-tumour immunity. Nature, 2015, 523, 231-235.	13.7	2,130
3324	Expression, Clinical Significance, and Receptor Identification of the Newest B7 Family Member HHLA2 Protein. Clinical Cancer Research, 2015, 21, 2359-2366.	3.2	125
3325	T-cell exhaustion in chronic hepatitis B infection: current knowledge and clinical significance. Cell Death and Disease, 2015, 6, e1694-e1694.	2.7	276
3326	IL2 Inducible T-cell Kinase, a Novel Therapeutic Target in Melanoma. Clinical Cancer Research, 2015, 21, 2167-2176.	3.2	16
3327	American Society of Clinical Oncology Policy Statement Update: The Critical Role of Phase I Trials in Cancer Research and Treatment. Journal of Clinical Oncology, 2015, 33, 278-284.	0.8	102
3328	Ipilimumab-induced hypophysitis: review of the literature. Journal of Endocrinological Investigation, 2015, 38, 1159-1166.	1.8	56
3329	Pembrolizumab for Treatment of Patients with Advanced or Unresectable Melanoma. Clinical Cancer Research, 2015, 21, 2892-2897.	3.2	31
3330	Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care. Journal of Visualized Experiments, 2015, , .	0.2	17

#	ARTICLE	IF	CITATIONS
3331	The Expanding Role of Therapeutic Antibodies. <i>International Reviews of Immunology</i> , 2015, 34, 202-264.	1.5	22
3332	Translational value of mouse models in oncology drug development. <i>Nature Medicine</i> , 2015, 21, 431-439.	15.2	242
3333	Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma. <i>Cancer Treatment Reviews</i> , 2015, 41, 519-526.	3.4	63
3334	Safety of pembrolizumab for the treatment of melanoma. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 957-964.	1.0	27
3335	Treg(s) in Cancer: Friends or Foe?. <i>Journal of Cellular Physiology</i> , 2015, 230, 2598-2605.	2.0	105
3336	Management of metastatic pancreatic cancer: Current treatment options and potential new therapeutic targets. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 95, 318-336.	2.0	18
3337	Evaluation of ⁶⁸ Ga- and ¹⁷⁷ Lu-DOTA-PEG ₄ -LLP2A for VLA-4-Targeted PET Imaging and Treatment of Metastatic Melanoma. <i>Molecular Pharmaceutics</i> , 2015, 12, 1929-1938.	2.3	39
3338	B7-H4 Expression by Nonhematopoietic Cells in the Tumor Microenvironment Promotes Antitumor Immunity. <i>Cancer Immunology Research</i> , 2015, 3, 184-195.	1.6	36
3339	Identification and Characterization of MEDI4736, an Antagonistic Anti- α PD-L1 Monoclonal Antibody. <i>Cancer Immunology Research</i> , 2015, 3, 1052-1062.	1.6	314
3340	Cellular therapy in Tuberculosis. <i>International Journal of Infectious Diseases</i> , 2015, 32, 32-38.	1.5	26
3341	Melanoma. <i>Nature Reviews Disease Primers</i> , 2015, 1, 15003.	18.1	417
3342	Vaccine-Induced Tumor Necrosis Factor-Producing T Cells Synergize with Cisplatin to Promote Tumor Cell Death. <i>Clinical Cancer Research</i> , 2015, 21, 781-794.	3.2	81
3343	BRAF and MEK Inhibition Variably Affect GD2-specific Chimeric Antigen Receptor (CAR) T-Cell Function In Vitro. <i>Journal of Immunotherapy</i> , 2015, 38, 12-23.	1.2	32
3344	Molecularly Targeted Therapies in Non-Small-Cell Lung Cancer Annual Update 2014. <i>Journal of Thoracic Oncology</i> , 2015, 10, S1-S63.	0.5	119
3345	Combination of 4-1BB Agonist and PD-1 Antagonist Promotes Antitumor Effector/Memory CD8 T Cells in a Poorly Immunogenic Tumor Model. <i>Cancer Immunology Research</i> , 2015, 3, 149-160.	1.6	239
3346	PD-1/PD-L1 Blockade Together With Vaccine Therapy Facilitates Effector T-Cell Infiltration Into Pancreatic Tumors. <i>Journal of Immunotherapy</i> , 2015, 38, 1-11.	1.2	333
3347	Objective responses can be obtained by CTLA-4 inhibition in metastatic melanoma after BRAF inhibitor failure. <i>Melanoma Research</i> , 2015, 25, 68-74.	0.6	11
3348	Vogt-Koyanagi-Harada-like Syndrome After CTLA-4 Inhibition With Ipilimumab for Metastatic Melanoma. <i>Journal of Immunotherapy</i> , 2015, 38, 80-84.	1.2	79

#	ARTICLE	IF	CITATIONS
3349	Immune checkpoint inhibitors in advanced nonsmall cell lung cancer. <i>Current Opinion in Oncology</i> , 2015, 27, 108-117.	1.1	26
3350	Peripheral Neuropathy Associated With Ipilimumab. <i>Journal of Immunotherapy</i> , 2015, 38, 77-79.	1.2	53
3351	CTLA-4 Blockade Plus Adoptive T-Cell Transfer Promotes Optimal Melanoma Immunity in Mice. <i>Journal of Immunotherapy</i> , 2015, 38, 54-61.	1.2	31
3352	Surgical management of metastatic melanoma in the era of targeted systemic therapies. <i>Melanoma Research</i> , 2015, 25, 1-8.	0.6	5
3353	Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 1889-1894.	0.8	1,809
3354	Genetics and immunotherapy: using the genetic landscape of gliomas to inform management strategies. <i>Journal of Neuro-Oncology</i> , 2015, 123, 373-383.	1.4	14
3355	Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC Tj ETQq0 0 0 rgBT /Overlock 10 Tf	5.1	1,093
3356	MicroRNA control of protein expression noise. <i>Science</i> , 2015, 348, 128-132.	6.0	337
3357	Immune checkpoint inhibition in lymphoid disease. <i>British Journal of Haematology</i> , 2015, 170, 291-304.	1.2	20
3358	Phase II Study of Nab-Paclitaxel and Bevacizumab as First-line Therapy for Patients with Unresectable Stage III and IV Melanoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 61-67.	0.6	36
3359	Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 1191-1196.	0.8	445
3360	BRAF V600 mutations and pathological features in Japanese melanoma patients. <i>Melanoma Research</i> , 2015, 25, 9-14.	0.6	43
3361	Immunologic Checkpoint Blockade in Lung Cancer. <i>Seminars in Oncology</i> , 2015, 42, 402-417.	0.8	23
3362	Clinical deployment of antibodies for treatment of melanoma. <i>Molecular Immunology</i> , 2015, 67, 18-27.	1.0	11
3363	Anti-€PD-1 Therapy in Melanoma. <i>Seminars in Oncology</i> , 2015, 42, 466-473.	0.8	41
3364	Immune-priming of the Tumor Microenvironment by Radiotherapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 90-97.	0.6	79
3365	Metabolic disorders associated with the use of targeted cancer therapies. <i>Current Opinion in Oncology</i> , 2015, 27, 258-266.	1.1	3
3366	Treatment Algorithms in Stage IV Melanoma. <i>American Journal of Therapeutics</i> , 2015, 22, 61-67.	0.5	9

#	ARTICLE	IF	CITATIONS
3367	Targeting ALDH1 to decrease tumorigenicity, growth and metastasis of human melanoma. <i>Melanoma Research</i> , 2015, 25, 138-148.	0.6	53
3368	Side Effects and Toxicities of Targeted Therapies in Stage IV Melanoma. <i>American Journal of Therapeutics</i> , 2015, 22, 44-53.	0.5	11
3369	Uveal Melanoma. <i>International Ophthalmology Clinics</i> , 2015, 55, 45-51.	0.3	9
3370	Immune evasion in cancer: Mechanistic basis and therapeutic strategies. <i>Seminars in Cancer Biology</i> , 2015, 35, S185-S198.	4.3	1,122
3371	CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 677-688.	2.0	75
3372	A prospective phase II trial of EGCG in treatment of acute radiation-induced esophagitis for stage III lung cancer. <i>Radiotherapy and Oncology</i> , 2015, 114, 351-356.	0.3	63
3373	Anti-programmed cell death protein-1/ligand-1 therapy in different cancers. <i>British Journal of Cancer</i> , 2015, 112, 1421-1427.	2.9	215
3374	Unsanctifying the sanctuary: challenges and opportunities with brain metastases. <i>Neuro-Oncology</i> , 2015, 17, 639-651.	0.6	62
3375	New Targeted Therapies for Brain Metastases from Breast and Lung Cancer and Melanoma. , 2015, , 105-112.		1
3376	Toxicity Patterns With Immunomodulating Antibodies and Their Combinations. <i>Seminars in Oncology</i> , 2015, 42, 423-428.	0.8	55
3377	Immunologic Correlates in the Course of Treatment With Immunomodulating Antibodies. <i>Seminars in Oncology</i> , 2015, 42, 448-458.	0.8	22
3378	Cancer immunotherapy and immune-related response assessment: The role of radiologists in the new arena of cancer treatment. <i>European Journal of Radiology</i> , 2015, 84, 1259-1268.	1.2	105
3379	Immune-mediated mechanisms influencing the efficacy of anticancer therapies. <i>Trends in Immunology</i> , 2015, 36, 198-216.	2.9	121
3380	Epigenetics Meets Immune Checkpoints. <i>Seminars in Oncology</i> , 2015, 42, 506-513.	0.8	32
3381	Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy. <i>Cancer Cell</i> , 2015, 27, 450-461.	7.7	3,266
3382	Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential. <i>Cell</i> , 2015, 161, 205-214.	13.5	1,872
3383	A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy. <i>Computational and Structural Biotechnology Journal</i> , 2015, 13, 265-272.	1.9	188
3384	Ipilimumab in the treatment of prostate cancer. <i>Future Oncology</i> , 2015, 11, 27-37.	1.1	10

#	ARTICLE	IF	CITATIONS
3385	Trametinib in the treatment of melanoma. Expert Opinion on Biological Therapy, 2015, 15, 735-747.	1.4	23
3386	Principles of cancer treatment by immunotherapy. Surgery, 2015, 33, 117-121.	0.1	0
3387	When are signal transduction targeted therapies acting as immunotherapy?. Cancer Biology and Therapy, 2015, 16, 645-647.	1.5	1
3388	Oncolytic Virus Immunotherapy for Melanoma. Current Treatment Options in Oncology, 2015, 16, 326.	1.3	40
3389	Targeting the immune system to treat lung cancer: rationale and clinical experience. Therapeutic Advances in Respiratory Disease, 2015, 9, 105-120.	1.0	13
3390	Beyond consolidation: auto-SCT and immunotherapy for plasma cell myeloma. Bone Marrow Transplantation, 2015, 50, 770-780.	1.3	9
3391	Trial Watch: Therapeutic vaccines in metastatic renal cell carcinoma. OncoImmunology, 2015, 4, e1001236.	2.1	22
3392	Effects of hyperglycemia on lonidamine-induced acidification and deenergization of human melanoma xenografts and sensitization to melphalan. NMR in Biomedicine, 2015, 28, 395-403.	1.6	15
3393	TGF β 2 Is a Master Regulator of Radiation Therapy-Induced Antitumor Immunity. Cancer Research, 2015, 75, 2232-2242.	0.4	429
3394	Cancer Vaccines: Can They Improve Survival?. Cancer Biotherapy and Radiopharmaceuticals, 2015, 30, 147-151.	0.7	6
3395	The progress of immunotherapy for glioblastoma. Human Vaccines and Immunotherapeutics, 2015, 11, 2654-2658.	1.4	7
3397	Risk of elevated transaminases in cancer patients treated with immune checkpoint inhibitors: a meta-analysis. Expert Opinion on Drug Safety, 2015, 14, 1507-1518.	1.0	44
3398	The role of immunotherapy in oncology. Future Oncology, 2015, 11, 2861-2864.	1.1	0
3399	Biomaterial Strategies for Immunomodulation. Annual Review of Biomedical Engineering, 2015, 17, 317-349.	5.7	132
3400	The Lasker Awards at 70. JAMA - Journal of the American Medical Association, 2015, 314, 1117.	3.8	1
3401	Targeting Glutamatergic Signaling and the PI3 Kinase Pathway to Halt Melanoma Progression. Translational Oncology, 2015, 8, 1-9.	1.7	23
3402	Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. Lancet Oncology, The, 2015, 16, e498-e509.	5.1	660
3403	Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. New England Journal of Medicine, 2015, 373, 1627-1639.	13.9	7,973

#	ARTICLE	IF	CITATIONS
3404	Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases. <i>Modern Pathology</i> , 2015, 28, 1535-1544.	2.9	76
3405	Biomarkers in Pharmaceutical Research. <i>Clinical Chemistry</i> , 2015, 61, 1343-1353.	1.5	48
3406	A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma. <i>Annals of Oncology</i> , 2015, 26, 2267-2274.	0.6	67
3407	Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. <i>Annals of Oncology</i> , 2015, 26, 2375-2391.	0.6	1,136
3408	Predictive biomarkers in precision medicine and drug development against lung cancer. <i>Chinese Journal of Cancer</i> , 2015, 34, 295-309.	4.9	34
3409	Risk Factors for Melanoma Among Survivors of Non-Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 3096-3104.	0.8	26
3410	Nivolumab in combination with ipilimumab for the treatment of melanoma. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 1135-1141.	1.1	22
3411	Anti-PD-1 therapies—a new first-line option in advanced melanoma. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 625-626.	12.5	38
3412	Interleukin-2, Ipilimumab, and Anti-PD-1: clinical management and the evolving role of immunotherapy for the treatment of patients with metastatic melanoma. <i>Cancer Biology and Therapy</i> , 2021, 22, 513-526.	1.5	24
3413	PD-L1 Expression in Melanocytic Lesions Does Not Correlate with the BRAF V600E Mutation. <i>Cancer Immunology Research</i> , 2015, 3, 110-115.	1.6	45
3414	Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors. <i>Cancer Immunology Research</i> , 2015, 3, 1344-1355.	1.6	285
3415	CD8 + T cell response to adenovirus vaccination and subsequent suppression of tumor growth: modeling, simulation and analysis. <i>BMC Systems Biology</i> , 2015, 9, 27.	3.0	16
3416	Rationale for combining immunotherapy with chemotherapy. <i>Immunotherapy</i> , 2015, 7, 309-316.	1.0	41
3418	Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanoma. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 96, 385-398.	2.0	51
3419	Clinical Activity of Ipilimumab in Acral Melanoma: A Retrospective Review. <i>Oncologist</i> , 2015, 20, 648-652.	1.9	38
3420	Immunothérapie anticancer : les molécules immunomodulatrices en développement clinique. <i>Oncologie</i> , 2015, 17, 379-389.	0.2	0
3421	Predictors of clinical response to immunotherapy with or without radiotherapy. <i>Journal of Radiation Oncology</i> , 2015, 4, 339-345.	0.7	17
3422	Safety of Infusing Ipilimumab Over 30 Minutes. <i>Journal of Clinical Oncology</i> , 2015, 33, 3454-3458.	0.8	24

#	ARTICLE	IF	CITATIONS
3425	The Rapid Emergence of Novel Therapeutics in Advanced Malignant Melanoma. <i>Dermatology and Therapy</i> , 2015, 5, 151-169.	1.4	19
3426	Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma. <i>Annals of Oncology</i> , 2015, 26, 2173-2179.	0.6	74
3427	Immune checkpoints and immunotherapy for colorectal cancer. <i>Gastroenterology Report</i> , 2015, 3, gov053.	0.6	80
3428	Immunosuppressive mechanisms in glioblastoma: Fig. 1.. <i>Neuro-Oncology</i> , 2015, 17, vii9-vii14.	0.6	275
3429	Immunomodulation: checkpoint blockade etc.: Fig. 1.. <i>Neuro-Oncology</i> , 2015, 17, vii26-vii31.	0.6	26
3430	Multifunctional receptor-targeting antibodies for cancer therapy. <i>Lancet Oncology</i> , The, 2015, 16, e543-e554.	5.1	36
3431	Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. <i>Lancet Oncology</i> , The, 2015, 16, e534-e542.	5.1	582
3432	Cancer immunotherapy via nucleic acid aptamers. <i>International Immunopharmacology</i> , 2015, 29, 926-936.	1.7	44
3433	The Microbiome and Cancer: Is the "Oncobiome"™ Mirage Real?. <i>Trends in Cancer</i> , 2015, 1, 24-35.	3.8	73
3434	Subacute CNS Demyelination after Treatment with Nivolumab for Melanoma. <i>Cancer Immunology Research</i> , 2015, 3, 1299-1302.	1.6	68
3435	Combined inhibition of the cell cycle related proteins Wee1 and Chk1/2 induces synergistic anti-cancer effect in melanoma. <i>BMC Cancer</i> , 2015, 15, 462.	1.1	43
3436	Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 997-1004.	1.1	58
3437	Cancer immunotherapy: Strategies for personalization and combinatorial approaches. <i>Molecular Oncology</i> , 2015, 9, 2043-2053.	2.1	87
3438	Checkpoint blockade in combination with cancer vaccines. <i>Vaccine</i> , 2015, 33, 7377-7385.	1.7	33
3439	Several immune escape patterns in non-Hodgkin's lymphomas. <i>Oncolimmunology</i> , 2015, 4, e1026530.	2.1	82
3440	Anti-TNF agents in patients with inflammatory bowel disease and malignant melanoma" challenges in management. <i>International Journal of Colorectal Disease</i> , 2015, 30, 1595-1602.	1.0	5
3441	Optimizing systemic therapy for metastatic renal cell carcinoma beyond the first-line setting. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 538-545.	0.8	14
3442	Targeted next-generation sequencing reveals high frequency of mutations in epigenetic regulators across treatment-naïve patient melanomas. <i>Clinical Epigenetics</i> , 2015, 7, 59.	1.8	49

#	ARTICLE	IF	CITATIONS
3443	Immune-checkpoint blockade: the springboard for immuno-combination therapy. <i>Gene Therapy</i> , 2015, 22, 849-850.	2.3	3
3444	Assessing a novel immuno-oncology-based combination therapy: Ipilimumab plus electrochemotherapy. <i>OncolImmunology</i> , 2015, 4, e1008842.	2.1	72
3445	Immunotherapy for neuro-oncology: the critical rationale for combinatorial therapy. <i>Neuro-Oncology</i> , 2015, 17, vii32-vii40.	0.6	21
3446	Commensal <i>Bifidobacterium</i> promotes antitumor immunity and facilitates anti-PD-L1 efficacy. <i>Science</i> , 2015, 350, 1084-1089.	6.0	2,782
3447	Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. <i>Science</i> , 2015, 350, 1079-1084.	6.0	2,539
3448	Ocular Toxicity in Metastatic Melanoma Patients Treated With Mitogen-Activated Protein Kinase Inhibitors: A Case Series. <i>American Journal of Ophthalmology</i> , 2015, 160, 959-967.e1.	1.7	38
3450	Practical Approaches to Immunotherapy in the Clinic. <i>Seminars in Oncology</i> , 2015, 42, S20-S27.	0.8	10
3451	Brain metastasis from melanoma: the prognostic value of varying sites of extracranial disease. <i>Journal of Neuro-Oncology</i> , 2015, 125, 411-418.	1.4	14
3452	Post-transplantation malignancies: here today, gone tomorrow?. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 705-717.	12.5	53
3453	Understanding the Rationale for Immunotherapy in Non-Small Cell Lung Cancer. <i>Seminars in Oncology</i> , 2015, 42, S3-S10.	0.8	96
3454	ER stress-induced autophagy in melanoma. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2015, 42, 811-816.	0.9	21
3457	Immunogenicity of somatic mutations in human gastrointestinal cancers. <i>Science</i> , 2015, 350, 1387-1390.	6.0	639
3458	Extracellular Vesicles Present in Human Ovarian Tumor Microenvironments Induce a Phosphatidylserine-Dependent Arrest in the T-cell Signaling Cascade. <i>Cancer Immunology Research</i> , 2015, 3, 1269-1278.	1.6	84
3459	Chemotherapy: A Viable Partner for Cancer Immunotherapy?. <i>JAMA Oncology</i> , 2015, 1, 1095.	3.4	1
3460	Tumor-infiltrating lymphocytes for the treatment of metastatic cancer. <i>Molecular Oncology</i> , 2015, 9, 1918-1935.	2.1	104
3461	Multiple Structural and Epigenetic Defects in the Human Leukocyte Antigen Class I Antigen Presentation Pathway in a Recurrent Metastatic Melanoma Following Immunotherapy. <i>Journal of Biological Chemistry</i> , 2015, 290, 26562-26575.	1.6	59
3462	Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy. <i>Clinical Cancer Research</i> , 2015, 21, 5427-5433.	3.2	254
3463	Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab. <i>Cancer Immunology Research</i> , 2015, 3, 1185-1192.	1.6	227

#	ARTICLE	IF	CITATIONS
3464	Pilot Trial of Selecting Molecularly Guided Therapy for Patients with Non-V600 BRAF-Mutant Metastatic Melanoma: Experience of the SU2C/MRA Melanoma Dream Team. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1962-1971.	1.9	25
3465	Vemurafenib in BRAFV600 mutated metastatic melanoma: a subanalysis of the Italian population of a global safety study. <i>Future Oncology</i> , 2015, 11, 1355-1362.	1.1	6
3466	Nanocarriers for delivery of siRNA and co-delivery of siRNA and other therapeutic agents. <i>Nanomedicine</i> , 2015, 10, 2199-2228.	1.7	52
3467	Prospects of immune checkpoint modulators in the treatment of glioblastoma. <i>Nature Reviews Neurology</i> , 2015, 11, 504-514.	4.9	307
3468	Vemurafenib-Induced Radiation Recall Dermatitis: Case Report and Review of the Literature. <i>Dermatology</i> , 2015, 230, 1-4.	0.9	23
3469	Melanoma-Derived Wnt5a Promotes Local Dendritic-Cell Expression of IDO and Immunotolerance: Opportunities for Pharmacologic Enhancement of Immunotherapy. <i>Cancer Immunology Research</i> , 2015, 3, 1082-1095.	1.6	147
3470	An overview of early investigational therapies for chemoresistant ovarian cancer. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 1163-1183.	1.9	15
3471	Diffuse melanosis cutis in the setting of BRAF ^{V600E} mutant melanoma and treatment with targeted therapies. <i>Australasian Journal of Dermatology</i> , 2015, 56, 128-130.	0.4	5
3472	Role of the cystathionine β -lyase/hydrogen sulfide pathway in human melanoma progression. <i>Pigment Cell and Melanoma Research</i> , 2015, 28, 61-72.	1.5	110
3473	Dendritic Cells as Pharmacological Tools for Cancer Immunotherapy. <i>Pharmacological Reviews</i> , 2015, 67, 731-753.	7.1	129
3474	Combinatorial immunotherapy with checkpoint blockers solves the problem of metastatic melanoma—An exclamation sign with a question mark. <i>Oncolmmunology</i> , 2015, 4, e1058037.	2.1	27
3475	Anti-PD-1 and PD-L1 therapy for bladder cancer: what is on the horizon?. <i>Future Oncology</i> , 2015, 11, 2299-2306.	1.1	20
3476	Immunological landscape and immunotherapy of hepatocellular carcinoma. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2015, 12, 681-700.	8.2	478
3477	Targeting the undruggable: immunotherapy meets personalized oncology in the genomic era. <i>Annals of Oncology</i> , 2015, 26, 2367-2374.	0.6	40
3478	Intratumoral injection of IFN-alpha dendritic cells after dacarbazine activates anti-tumor immunity: results from a phase I trial in advanced melanoma. <i>Journal of Translational Medicine</i> , 2015, 13, 139.	1.8	36
3479	Early recognition of ipilimumab-related autoimmune hypophysitis in patients with metastatic melanoma: Case studies and recommendations for management. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2015, 11, 190-194.	0.7	3
3480	Immunological evaluation of peptide vaccination for cancer patients with the HLA A*26 allele. <i>Cancer Science</i> , 2015, 106, 1257-1263.	1.7	7
3481	Colitis mimicking graft-versus-host disease during treatment with the anti-CCR4 monoclonal antibody, mogamulizumab. <i>International Journal of Hematology</i> , 2015, 102, 493-497.	0.7	12

#	ARTICLE	IF	CITATIONS
3482	Evolving treatment options for melanoma brain metastases. <i>Lancet Oncology</i> , The, 2015, 16, e486-e497.	5.1	74
3483	Decreased Plasma Ascorbate Levels in Stage IV Melanoma Patients. <i>Metabolism and Nutrition in Oncology</i> , 2015, 01, e2-e6.	0.2	10
3484	Targeting immune checkpoints: New opportunity for mesothelioma treatment?. <i>Cancer Treatment Reviews</i> , 2015, 41, 914-924.	3.4	41
3485	Antitumor activity of epigenetic immunomodulation combined with CTLA-4 blockade in syngeneic mouse models. <i>Oncimmunology</i> , 2015, 4, e1019978.	2.1	61
3486	Ablation of B7-H3 but Not B7-H4 Results in Highly Increased Tumor Burden in a Murine Model of Spontaneous Prostate Cancer. <i>Cancer Immunology Research</i> , 2015, 3, 849-854.	1.6	32
3487	Late administration of murine CTLA-4 blockade prolongs CD8-mediated anti-tumor effects following stimulatory cancer immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 1541-1552.	2.0	9
3488	Analogue peptides for the immunotherapy of human acute myeloid leukemia. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 1357-1367.	2.0	11
3490	An Update on the Role of Immunotherapy and Vaccine Strategies for Primary Brain Tumors. <i>Current Treatment Options in Oncology</i> , 2015, 16, 54.	1.3	44
3492	Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer. <i>Seminars in Oncology</i> , 2015, 42, S11-S18.	0.8	55
3494	Elevated IgG4 in patient circulation is associated with the risk of disease progression in melanoma. <i>Oncimmunology</i> , 2015, 4, e1032492.	2.1	53
3495	Adoptive T-Cell Immunotherapy. <i>Current Topics in Microbiology and Immunology</i> , 2015, 391, 427-454.	0.7	48
3496	Pharmacotherapeutic options for treating brain metastases in non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2601-2613.	0.9	22
3497	Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 1757-1771.	1.4	54
3498	Novel Therapies for Metastatic Melanoma: An Update on Their Use in Older Patients. <i>Drugs and Aging</i> , 2015, 32, 821-834.	1.3	12
3499	A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). <i>Annals of Oncology</i> , 2015, 26, 1547-1573.	0.6	635
3500	Translating Pembrolizumab to Clinical Practice: Speak Immunology and Learn Fast!. <i>Clinical Cancer Research</i> , 2015, 21, 4251-4253.	3.2	1
3501	Alphavirus-based vaccines in melanoma: rationale and potential improvements in immunotherapeutic combinations. <i>Immunotherapy</i> , 2015, 7, 981-997.	1.0	5
3502	ImmunogÃ©nitÃ© de la chimiothÃ©rapie. <i>Oncologie</i> , 2015, 17, 345-353.	0.2	0

#	ARTICLE	IF	CITATIONS
3503	Immune Response to Cancer Therapy: Mounting an Effective Antitumor Response and Mechanisms of Resistance. <i>Trends in Cancer</i> , 2015, 1, 66-75.	3.8	101
3504	Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT). <i>BMC Cancer</i> , 2015, 15, 467.	1.1	45
3505	Update on Mucin-1 immunotherapy in cancer: a clinical perspective. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 1773-1787.	1.4	36
3506	Nanomedicine and cancer immunotherapy â€œtargeting immunosuppressive cells. <i>Journal of Drug Targeting</i> , 2015, 23, 656-671.	2.1	32
3507	Role of the Medical Oncologist in the Management of Skin Cancer. <i>Current Dermatology Reports</i> , 2015, 4, 205-212.	1.1	0
3508	HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade. <i>Cancer Immunology Research</i> , 2015, 3, 1375-1385.	1.6	342
3510	Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab. <i>Clinical Cancer Research</i> , 2015, 21, 5453-5459.	3.2	304
3511	Current position of TNF-Î± in melanomagenesis. <i>Tumor Biology</i> , 2015, 36, 6589-6602.	0.8	13
3512	Intratumoral oncolytic adenoviral treatment modulates the glioma microenvironment and facilitates systemic tumor-antigen-specific T cell therapy. <i>Oncolmmunology</i> , 2015, 4, e1022302.	2.1	23
3513	Lung cancer: Biology and treatment options. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2015, 1856, 189-210.	3.3	526
3514	Gauging the Long-Term Benefits of Ipilimumab in Melanoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 1865-1866.	0.8	41
3515	Strategies for combining immunotherapy with radiation for anticancer therapy. <i>Immunotherapy</i> , 2015, 7, 967-980.	1.0	83
3516	Axitinib increases the infiltration of immune cells and reduces the suppressive capacity of monocytic MDSCs in an intracranial mouse melanoma model. <i>Oncolmmunology</i> , 2015, 4, e998107.	2.1	65
3517	A Phase I Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma. <i>Oncologist</i> , 2015, 20, 617-618.	1.9	9
3518	Regulatory T Cells in Tumor-Associated Tertiary Lymphoid Structures Suppress Anti-tumor T Cell Responses. <i>Immunity</i> , 2015, 43, 579-590.	6.6	360
3519	Ipilimumab-induced Ocular and Orbital Inflammationâ€”A Case Series and Review of the Literature. <i>Ocular Immunology and Inflammation</i> , 2016, 24, 1-7.	1.0	79
3520	Prognostic Significance of Cutaneous Adverse Events Associated With Pembrolizumab Therapy. <i>JAMA Oncology</i> , 2015, 1, 1340.	3.4	63
3521	Immune-mediated adverse events of anticytotoxic T lymphocyteâ€œassociated antigen 4 antibody therapy in metastatic melanoma. <i>Translational Research</i> , 2015, 166, 412-424.	2.2	65

#	ARTICLE	IF	CITATIONS
3522	Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center. <i>Journal of Clinical Oncology</i> , 2015, 33, 3193-3198.	0.8	892
3523	Adoptive transfer of tumor-infiltrating lymphocytes for melanoma: new players, old game. <i>Immunotherapy</i> , 2015, 7, 477-479.	1.0	4
3524	Mucosal melanoma of the head and neck: recurrence characteristics and survival outcomes. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2015, 120, 575-580.	0.2	19
3525	Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137, OX40, GITR, CD27, CD28, and ICOS. <i>Seminars in Oncology</i> , 2015, 42, 640-655.	0.8	179
3526	To BRCA or Not to PALB. <i>Journal of Clinical Oncology</i> , 2015, 33, 2581-2582.	0.8	1
3527	The future of immunotherapy in the treatment of lung cancer. <i>Lung Cancer Management</i> , 2015, 4, 57-73.	1.5	2
3528	Integrating Immunotherapies in Prostate Cancer. <i>Current Oncology Reports</i> , 2015, 17, 45.	1.8	3
3529	Shifting paradigms in the treatment of chronic lymphocytic leukemia. <i>Future Oncology</i> , 2015, 11, 641-657.	1.1	3
3530	Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis. <i>Future Oncology</i> , 2015, 11, 2471-2484.	1.1	70
3531	Are Cancer Outcomes Worse in the Presence of HIV Infection?. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1165-1166.	1.1	4
3532	Drug therapies for metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , 2015, 11, 2395-2403.	1.1	1
3533	Adoptive cell therapy for sarcoma. <i>Immunotherapy</i> , 2015, 7, 21-35.	1.0	12
3534	Cancer stem cells and the tumor microenvironment: interplay in tumor heterogeneity. <i>Connective Tissue Research</i> , 2015, 56, 414-425.	1.1	123
3535	Characterization of the <i>in vivo</i> immune network of IDO, tryptophan metabolism, PD-L1, and CTLA-4 in circulating immune cells in melanoma. <i>Onc Immunology</i> , 2015, 4, e982382.	2.1	95
3536	Checkpoint modulation - A new way to direct the immune system against renal cell carcinoma. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 1201-1208.	1.4	11
3537	Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses. <i>Cell</i> , 2015, 162, 974-986.	13.5	1,408
3538	Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. <i>Cell</i> , 2015, 162, 1229-1241.	13.5	2,158
3539	Are BiTEs the "missing link" in cancer therapy?. <i>Onc Immunology</i> , 2015, 4, e1008339.	2.1	59

#	ARTICLE	IF	CITATIONS
3540	PD-L1 and CD8+PD1+ lymphocytes exist as targets in the pediatric tumor microenvironment for immunomodulatory therapy. <i>Oncolmmunology</i> , 2015, 4, e1029701.	2.1	53
3541	Immunology and Immunotherapy of Head and Neck Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 3293-3304.	0.8	566
3542	Immune checkpoint inhibitors in melanoma. <i>Melanoma Management</i> , 2015, 2, 267-284.	0.1	6
3543	The prognostic impact of specific CD4 T-cell responses is critically dependent on the target antigen in melanoma. <i>Oncolmmunology</i> , 2015, 4, e955683.	2.1	4
3544	Immune Checkpoint Inhibitors. <i>Progress in Tumor Research</i> , 2015, 42, 55-66.	0.1	151
3545	Immunopharmacogenomics. , 2015, , .		3
3546	Releasing the Brakes on Cancer Immunotherapy. <i>Cell</i> , 2015, 162, 1186-1190.	13.5	111
3547	An HPV-E6/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression. <i>Cancer Gene Therapy</i> , 2015, 22, 454-462.	2.2	62
3548	Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. <i>Science</i> , 2015, 350, 207-211.	6.0	2,275
3549	GITR agonist enhances vaccination responses in lung cancer. <i>Oncolmmunology</i> , 2015, 4, e992237.	2.1	15
3550	Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab. <i>European Journal of Cancer</i> , 2015, 51, 2689-2697.	1.3	69
3551	Sensitive Multiplexed Quantitative Analysis of Autoantibodies to Cancer Antigens with Chemically Cationized Full-Length and Water-Soluble Denatured Proteins. <i>Bioconjugate Chemistry</i> , 2015, 26, 2076-2084.	1.8	9
3552	Deletion of CTLA-4 on regulatory T cells during adulthood leads to resistance to autoimmunity. <i>Journal of Experimental Medicine</i> , 2015, 212, 1603-1621.	4.2	183
3553	Two heads better than one? Ipilimumab immunotherapy and radiation therapy for melanoma brain metastases. <i>Neuro-Oncology</i> , 2015, 17, 1312-1321.	0.6	57
3554	Anti-PD1 and anti-PD-L1 in the treatment of metastatic melanoma. <i>Melanoma Management</i> , 2015, 2, 41-50.	0.1	7
3555	Emerging immune checkpoints for cancer therapy. <i>Acta OncolÃ³gica</i> , 2015, 54, 1706-1713.	0.8	40
3556	The kynurenine to tryptophan ratio as a prognostic tool for glioblastoma patients enrolling in immunotherapy. <i>Journal of Clinical Neuroscience</i> , 2015, 22, 1964-1968.	0.8	61
3557	Emerging strategies for cancer immunoprevention. <i>Oncogene</i> , 2015, 34, 6029-6039.	2.6	39

#	ARTICLE	IF	CITATIONS
3558	A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab. <i>Oncolmmunology</i> , 2015, 4, e1046028.	2.1	191
3559	Immunotherapy for Multiple Myeloma, Past, Present, and Future: Monoclonal Antibodies, Vaccines, and Cellular Therapies. <i>Current Hematologic Malignancy Reports</i> , 2015, 10, 395-404.	1.2	13
3560	Multiplying therapies and reducing toxicity in metastatic melanoma. <i>Cancer Biology and Therapy</i> , 2015, 16, 1014-1018.	1.5	9
3561	Cancer gene therapy with T cell receptors and chimeric antigen receptors. <i>Current Opinion in Pharmacology</i> , 2015, 24, 113-118.	1.7	30
3562	Immunosuppression for ipilimumab-related toxicity can cause <i>pneumocystis</i> pneumonia but spare antitumor immune control. <i>Oncolmmunology</i> , 2015, 4, e1040218.	2.1	39
3563	Regramming myeloid responses to improve cancer immunotherapy. <i>Oncolmmunology</i> , 2015, 4, e974399.	2.1	9
3564	Trial watch: Naked and vectored DNA-based anticancer vaccines. <i>Oncolmmunology</i> , 2015, 4, e1026531.	2.1	26
3565	Antibody-based immunotherapy of solid cancers: progress and possibilities. <i>Immunotherapy</i> , 2015, 7, 923-939.	1.0	24
3566	Enhancing Cancer Immunotherapy Via Activation of Innate Immunity. <i>Seminars in Oncology</i> , 2015, 42, 562-572.	0.8	30
3567	Clinical Evaluation of ErbB-Targeted CAR T-Cells, Following Intracavity Delivery in Patients with ErbB-Expressing Solid Tumors. <i>Methods in Molecular Biology</i> , 2015, 1317, 365-382.	0.4	32
3568	Breast cancer and immunology: biomarker and therapeutic developments. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 1215-1222.	1.1	9
3569	Critical issues in cancer vaccine trial design. <i>Vaccine</i> , 2015, 33, 7386-7392.	1.7	10
3570	What is the future for cancer clinical trials?. <i>Future Oncology</i> , 2015, 11, 5-7.	1.1	0
3573	Strategies for Improving Vaccines to Elicit T Cells to Treat Cancer. <i>Cancer Drug Discovery and Development</i> , 2015, , 29-52.	0.2	1
3574	Ipilimumab and craniotomy in patients with melanoma and brain metastases: a case series. <i>Neurosurgical Focus</i> , 2015, 38, E5.	1.0	20
3575	Author's view: radiation and immunotherapy as systemic therapy for solid tumors. <i>Oncolmmunology</i> , 2015, 4, e986402.	2.1	9
3577	Turning Radiotherapy into an Effective Systemic Anti-cancer Treatment in Combination with Immunotherapy. <i>Clinical Oncology</i> , 2015, 27, 696-699.	0.6	11
3579	Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1 derived oncolytic immunotherapy. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 1389-1403.	1.1	102

#	ARTICLE	IF	CITATIONS
3580	Adjuvant HER2/neu peptide cancer vaccines in breast cancer. <i>Immunotherapy</i> , 2015, 7, 1159-1168.	1.0	31
3581	GITR engagement in combination with CTLA-4 blockade completely abrogates immunosuppression mediated by human liver tumor-derived regulatory T cells <i>ex vivo</i> . <i>Oncolmunology</i> , 2015, 4, e1051297.	2.1	45
3582	Corticosteroid use in neuro-oncology: an update. <i>Neuro-Oncology Practice</i> , 2015, 2, 6-12.	1.0	51
3583	Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1. <i>Immunotherapy</i> , 2015, 7, 1169-1186.	1.0	45
3584	<i>Innovative Medicine</i> , 2015, , .		17
3585	Malaria parasites target the hepatocyte receptor EphA2 for successful host infection. <i>Science</i> , 2015, 350, 1089-1092.	6.0	119
3586	Targeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinoma. <i>Therapeutic Advances in Urology</i> , 2015, 7, 365-377.	0.9	103
3587	Overview of current immunotherapeutic strategies for glioma. <i>Immunotherapy</i> , 2015, 7, 1073-1104.	1.0	40
3588	Developing an Immunotherapy Strategy for the Effective Treatment of Oral, Head and Neck Squamous Cell Carcinoma. <i>Journal of Oral and Maxillofacial Surgery</i> , 2015, 73, S107-S115.	0.5	6
3589	<i>In situ</i> vaccination: Cancer immunotherapy both personalized and off-the-shelf. <i>Molecular Oncology</i> , 2015, 9, 1966-1981.	2.1	139
3590	STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 15408-15413.	3.3	404
3591	Risk of gastrointestinal complications in cancer patients treated with immune checkpoint inhibitors: a meta-analysis. <i>Immunotherapy</i> , 2015, 7, 1213-1227.	1.0	77
3592	Hypophysitis in 2014. <i>Annales D'Endocrinologie</i> , 2015, 76, 585-594.	0.6	12
3593	Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy. <i>Molecular Oncology</i> , 2015, 9, 1936-1965.	2.1	64
3594	CAR T cell immunotherapy: The path from the byroad to the freeway?. <i>Molecular Oncology</i> , 2015, 9, 1994-2018.	2.1	43
3595	Immunology: Another shot at cancer. <i>Nature</i> , 2015, 527, S105-S107.	13.7	7
3596	Tremelimumab for the treatment of malignant mesothelioma. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 1819-1829.	1.4	23
3597	Microenvironmental regulation of therapeutic response in cancer. <i>Trends in Cell Biology</i> , 2015, 25, 198-213.	3.6	604

#	ARTICLE	IF	CITATIONS
3598	Systemic Therapy of Brain Metastases. <i>Current Neurology and Neuroscience Reports</i> , 2015, 15, 518.	2.0	46
3599	Sequencing the functional antibody repertoire—diagnostic and therapeutic discovery. <i>Nature Reviews Rheumatology</i> , 2015, 11, 171-182.	3.5	158
3600	New therapeutic options for advanced non-resectable malignant melanoma. <i>Advances in Medical Sciences</i> , 2015, 60, 83-88.	0.9	40
3601	BRAF Targets in Melanoma. <i>Cancer Drug Discovery and Development</i> , 2015, , .	0.2	2
3603	Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy. <i>Journal of Oncology Pharmacy Practice</i> , 2015, 21, 451-467.	0.5	90
3604	Molecular Determinants of Radiation Response in Non—Small Cell Lung Cancer. <i>Seminars in Radiation Oncology</i> , 2015, 25, 67-77.	1.0	8
3606	Novel immunotherapies for hematologic malignancies. <i>Immunological Reviews</i> , 2015, 263, 90-105.	2.8	44
3607	Cancer Immunotherapy and Breaking Immune Tolerance: New Approaches to an Old Challenge. <i>Cancer Research</i> , 2015, 75, 5-10.	0.4	261
3608	Immunotherapy for Malignant Gliomas. <i>Cancer Treatment and Research</i> , 2015, 163, 143-158.	0.2	11
3609	PD-1/SHP-2 Inhibits Tc1/Th1 Phenotypic Responses and the Activation of T Cells in the Tumor Microenvironment. <i>Cancer Research</i> , 2015, 75, 508-518.	0.4	184
3610	Increased Levels of β -catenin, LEF-1, and HPA-1 Correlate with Poor Prognosis for Acral Melanoma with Negative <i>BRAF</i> and <i>NRAS</i> Mutation in <i>BRAF</i> Exons 11 and 15 and <i>NRAS</i> Exons 1 and 2. <i>DNA and Cell Biology</i> , 2015, 34, 69-77.	0.9	20
3611	Rationale for combined blockade of PD-1 and CTLA-4 in advanced head and neck squamous cell cancer — Review of current data. <i>Oral Oncology</i> , 2015, 51, 12-15.	0.8	50
3612	Combination of Radiotherapy and Immune Checkpoint Inhibitors. <i>Seminars in Radiation Oncology</i> , 2015, 25, 28-33.	1.0	121
3613	The development of immunomodulatory monoclonal antibodies as a new therapeutic modality for cancer: The Bristol-Myers Squibb experience. , 2015, 148, 132-153.		50
3614	Oral health in oncology: impact of immunotherapy. <i>Supportive Care in Cancer</i> , 2015, 23, 1-3.	1.0	39
3615	Persistence of CTL Clones Targeting Melanocyte Differentiation Antigens Was Insufficient to Mediate Significant Melanoma Regression in Humans. <i>Clinical Cancer Research</i> , 2015, 21, 534-543.	3.2	47
3616	Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib. <i>New England Journal of Medicine</i> , 2015, 372, 30-39.	13.9	2,240
3617	Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma. <i>European Journal of Endocrinology</i> , 2015, 172, 195-204.	1.9	232

#	ARTICLE	IF	CITATIONS
3618	Nanoparticle-Based Immunotherapy for Cancer. <i>ACS Nano</i> , 2015, 9, 16-30.	7.3	391
3619	Kupferâ€type immunological synapses in vivo : Raison Dâ€™Ãatre of SMAC. <i>Immunology and Cell Biology</i> , 2015, 93, 51-56.	1.0	5
3620	Subunit Vaccine Delivery. <i>Advances in Delivery Science and Technology</i> , 2015, , .	0.4	9
3623	Advances in the understanding of cancer immunotherapy. <i>BJU International</i> , 2015, 116, 321-329.	1.3	28
3624	Skin cancer and new treatment perspectives: A review. <i>Cancer Letters</i> , 2015, 357, 8-42.	3.2	272
3625	Tumor infiltrating lymphocytes (TIL) and prognosis in oral cavity squamous carcinoma: A preliminary study. <i>Oral Oncology</i> , 2015, 51, 90-95.	0.8	135
3626	Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies. <i>International Immunology</i> , 2015, 27, 39-46.	1.8	286
3627	Armed antibodies for cancer treatment: a promising tool in a changing era. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 113-121.	2.0	28
3628	ActualizaciÃ³n en melanoma mucoso. <i>Actas Dermo-sifiliogrÃ¡ficas</i> , 2015, 106, 96-103.	0.2	12
3629	Targeting myeloid cells using nanoparticles to improve cancer immunotherapy. <i>Advanced Drug Delivery Reviews</i> , 2015, 91, 38-51.	6.6	55
3630	Monoclonal antibodies for the treatment of non-haematological tumours: update of an expanding scenario. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 45-59.	1.4	8
3631	Novel Points of Attack for Targeted Cancer Therapy. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2015, 116, 9-18.	1.2	61
3632	Comparison of gene expression patterns across 12 tumor types identifies a cancer supercluster characterized by TP53 mutations and cell cycle defects. <i>Oncogene</i> , 2015, 34, 2732-2740.	2.6	46
3633	Therapeutic use of anti-CTLA-4 antibodies. <i>International Immunology</i> , 2015, 27, 3-10.	1.8	96
3634	Vaginal Amelanotic Nodular Malignant Melanoma in A Middle-Aged Female: A Rare Case Report and Review of Literature. <i>Journal of Obstetrics and Gynecology of India</i> , 2015, 65, 199-201.	0.3	2
3635	Immunotherapy in Melanoma. <i>Journal of Pharmacy Practice</i> , 2015, 28, 193-203.	0.5	8
3636	mRNA-based dendritic cell vaccines. <i>Expert Review of Vaccines</i> , 2015, 14, 161-176.	2.0	121
3637	Neoadjuvant therapy for localized prostate cancer: Examining mechanism of action and efficacy within the tumor. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 182-192.	0.8	26

#	ARTICLE	IF	CITATIONS
3638	Bulky scalp melanoma with metastasis responding completely to ipilimumab. BMJ Case Reports, 2016, 2016, bcr2016216204.	0.2	1
3639	Systemic sarcoidosis first manifesting in a tattoo in the setting of immune checkpoint inhibition. BMJ Case Reports, 2016, 2016, bcr2016216217.	0.2	28
3640	Safety and efficacy of pembrolizumab in a patient with advanced melanoma on haemodialysis. BMJ Case Reports, 2016, 2016, bcr2016216426.	0.2	20
3641	Challenges in the use of immunotherapy in metastatic melanoma. BMJ Case Reports, 2016, 2016, bcr2016216681.	0.2	1
3642	Vedolizumab: a novel treatment for ipilimumab-induced colitis. BMJ Case Reports, 2016, 2016, bcr2016216641.	0.2	39
3643	Economic Evaluation of Ipilimumab in First Line Treatment of Advanced Melanoma in Italy. Global & Regional Health Technology Assessment, 2016, 3, GRHTA.5000230.	0.2	1
3644	Nivolumab in treating advanced melanoma. British Journal of Health Care Management, 2016, 22, 294-296.	0.1	0
3645	Primary Melanoma of the Oral Mucosa: A Case Report and Review of Literature. Journal of Clinical Case Reports, 2016, 06, .	0.0	0
3646	Healthcare Analytics: From Data to Knowledge to Healthcare Improvement. , 2016, , .		12
3647	Translational Medicine Case Studies and Reports. , 2016, , 135-156.		0
3648	The steady progress of targeted therapies, promising advances for lung cancer. Ecancermedalscience, 2016, 10, 638.	0.6	6
3649	Expression of PD-1 on CD4+ T cells in peripheral blood associates with poor clinical outcome in non-small cell lung cancer. Oncotarget, 2016, 7, 56233-56240.	0.8	48
3652	Immunotherapy Targeting the PD-1 Signaling Pathway. Japanese Journal of Lung Cancer, 2016, 56, 61-65.	0.0	0
3653	Dabrafenib: a new opportunity for the treatment of BRAF V600-positive melanoma. OncoTargets and Therapy, 2016, 9, 2725.	1.0	18
3654	Immuno-oncology combinations: raising the tail of the survival curve. Cancer Biology and Medicine, 2016, 13, 171-193.	1.4	98
3655	Cancer Vaccines: Bench to Bedside. International Journal of Translational Science, 2016, 2016, 33-60.	0.2	5
3656	Regulatory T Cells in Tumor Immunity. , 2016, , 451-459.		2
3657	Tumor-targeted costimulation by using bi-specific aptamers. Cancer Cell & Microenvironment, 2016, 3, e1333.	0.8	1

#	ARTICLE	IF	CITATIONS
3658	Targeted therapies in gastric cancer and future perspectives. World Journal of Gastroenterology, 2016, 22, 471.	1.4	35
3659	Immune Checkpoint Blockade Therapy: Merits and Demerits. Journal of Clinical & Experimental Dermatology Research, 2016, 7, .	0.1	0
3660	Burden of Illness for Metastatic Melanoma in Canada, 2011â€“2013. Current Oncology, 2016, 23, 563-570.	0.9	16
3661	Immune checkpoint inhibition in patients with brain metastases. Annals of Translational Medicine, 2016, 4, S9-S9.	0.7	29
3662	Tremelimumab: research and clinical development. OncoTargets and Therapy, 2016, 9, 1767.	1.0	51
3663	Status of and prospects for cancer vaccines against hepatocellular carcinoma in clinical trials. BioScience Trends, 2016, 10, 85-91.	1.1	35
3664	CD8 T Cellâ€“Independent Antitumor Response and Its Potential for Treatment of Malignant Gliomas. Cancers, 2016, 8, 71.	1.7	8
3665	Dermal Delivery of Constructs Encoding Cre Recombinase to Induce Skin Tumors in PtenLoxP/LoxP;BrafCA/+ Mice. International Journal of Molecular Sciences, 2016, 17, 2149.	1.8	2
3666	An update on Dendritic Cell-Based Cancer Immunotherapy. Immunome Research, 2016, 12, .	0.1	1
3667	Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the Phase III OPTiM trial. OncoTargets and Therapy, 2016, Volume 9, 7081-7093.	1.0	83
3668	Congenital Immunodeficiency Diseases. , 2016, , 45-81.		0
3669	Immune Check Point Inhibitors Combination in Melanoma: Worth the Toxicity?. Reviews on Recent Clinical Trials, 2016, 11, 81-86.	0.4	12
3670	nab-Paclitaxel as a potential partner with checkpoint inhibitors in solid tumors. OncoTargets and Therapy, 2017, Volume 10, 101-112.	1.0	60
3671	NK Cells in Antitumor Immunity. , 2016, , 487-492.		0
3672	Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma. Journal of Hepatocellular Carcinoma, 2016, Volume 3, 31-36.	1.8	32
3673	The Pathophysiological Impact of HLA Class Ia and HLA-G Expression and Regulatory T Cells in Malignant Melanoma: A Review. Journal of Immunology Research, 2016, 2016, 1-11.	0.9	20
3674	The Emerging Epigenetic Landscape in Melanoma. , 0, , .		0
3675	Therapeutic approaches in myelofibrosis and myelodysplastic/myeloproliferative overlap syndromes. OncoTargets and Therapy, 2016, 9, 2273.	1.0	5

#	ARTICLE	IF	CITATIONS
3676	Dendritic cell immunotherapy versus bevacizumab plus irinotecan in recurrent malignant glioma patients: a survival gain analysis. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 6669-6677.	1.0	8
3678	Immunobiology of Tumors and Advances in Immunotherapy. <i>Journal of Clinical & Cellular Immunology</i> , 2016, 07, .	1.5	0
3679	Immunotherapy for Glioblastoma. <i>Journal of Clinical & Cellular Immunology</i> , 2016, 7, .	1.5	0
3680	Immunological battlefield in gastric cancer and role of immunotherapies. <i>World Journal of Gastroenterology</i> , 2016, 22, 6373.	1.4	33
3681	A phase I study of intratumoral ipilimumab and interleukin-2 in patients with advanced melanoma. <i>Oncotarget</i> , 2016, 7, 64390-64399.	0.8	60
3682	Immunotherapy and Checkpoint Inhibitors in Recurrent and Metastatic Head and Neck Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, , e277-e282.	1.8	2
3683	Management of Melanoma Therapy-Associated Toxicities. , 2016, , 299-319.		1
3684	Optimal Selection of Targeted Therapies for Melanoma Patients. , 2016, , 169-183.		0
3685	Current State of Immune-Based Therapies for Glioblastoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, e132-e139.	1.8	13
3686	The head and neck cancer immune landscape and its immunotherapeutic implications. <i>JCI Insight</i> , 2016, 1, e89829.	2.3	569
3687	Surgical Management and Adjuvant Therapy for High-Risk and Metastatic Melanoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, e505-e514.	1.8	10
3688	The Evolution of Triple-Negative Breast Cancer: From Biology to Novel Therapeutics. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, 34-42.	1.8	85
3689	Immune Checkpoint Inhibitors in Brain Metastases: From Biology to Treatment. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, e116-e122.	1.8	65
3690	Immunotherapy for Soft Tissue Sarcoma: Tomorrow Is Only a Day Away. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, 281-290.	1.8	11
3691	Immunotherapy in urothelial carcinoma: fade or future standard?. <i>Translational Andrology and Urology</i> , 2016, 5, 662-667.	0.6	2
3693	Brain Metastases from Melanoma. , 2016, , 65-83.		0
3694	Molecularly targeted therapy for advanced hepatocellular carcinoma - a drug development crisis?. <i>World Journal of Gastrointestinal Oncology</i> , 2016, 8, 173.	0.8	28
3695	Cocktails for cancer with a measure of immunotherapy. <i>Nature</i> , 2016, 532, 162-164.	13.7	53

#	ARTICLE	IF	CITATIONS
3697	Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer. <i>JCI Insight</i> , 2016, 1, e87415.	2.3	125
3698	NUEVAS TERAPIAS SISTÉMICAS PARA EL TRATAMIENTO DEL MELANOMA. <i>Revista Chilena De Cirugia</i> , 2016, 68, 81-86.	0.1	1
3699	Dendritic cell-based vaccine for pancreatic cancer in Japan. <i>World Journal of Gastrointestinal Pharmacology and Therapeutics</i> , 2016, 7, 133.	0.6	22
3700	Clinical pharmacologic aspects of immune checkpoint inhibitors in cancer therapy. <i>Translational and Clinical Pharmacology</i> , 2016, 24, 7.	0.3	3
3701	Reduction of Nodular Growth Pattern of Metastatic Uveal Melanoma after Radioembolization of Hepatic Metastases. <i>Ocular Oncology and Pathology</i> , 2016, 2, 160-165.	0.5	8
3702	Aptamers: A Feasible Technology in Cancer Immunotherapy. <i>Journal of Immunology Research</i> , 2016, 2016, 1-12.	0.9	26
3703	Treatment of Ipilimumab Induced Graves' Disease in a Patient with Metastatic Melanoma. <i>Case Reports in Endocrinology</i> , 2016, 2016, 1-4.	0.2	44
3704	Molecular Diagnostics for Precision Medicine in Colorectal Cancer: Current Status and Future Perspective. <i>BioMed Research International</i> , 2016, 2016, 1-12.	0.9	19
3705	Hallmarks of glioblastoma: a systematic review. <i>ESMO Open</i> , 2016, 1, e000144.	2.0	122
3706	Immune Checkpoint Modulators: An Emerging Antiglioma Armamentarium. <i>Journal of Immunology Research</i> , 2016, 2016, 1-14.	0.9	36
3707	A Rare Thyroid Metastasis from Uveal Melanoma and Response to Immunotherapy Agents. <i>Case Reports in Oncological Medicine</i> , 2016, 2016, 1-5.	0.2	9
3708	PD-L1 Expression Is Associated with Tumor FOXP3 ⁺ Regulatory T-Cell Infiltration of Breast Cancer and Poor Prognosis of Patient. <i>Journal of Cancer</i> , 2016, 7, 784-793.	1.2	125
3709	Challenges and Opportunities of Nanoparticle-Based Theranostics in Skin Cancer. , 2016, , 177-188.		4
3710	Targeted Nanoparticles for Drug Delivery to Melanoma. , 2016, , 203-215.		3
3711	How the Lab is Changing Our View of Colorectal Cancer. <i>Tumori</i> , 2016, 102, 541-547.	0.6	15
3712	Enhanced Anti-Tumor Efficacy through a Combination of Integrin $\alpha_6\beta_4$ -Targeted Photodynamic Therapy and Immune Checkpoint Inhibition. <i>Theranostics</i> , 2016, 6, 627-637.	4.6	92
3713	Toxicity management of immunotherapy for patients with metastatic melanoma. <i>Annals of Translational Medicine</i> , 2016, 4, 272-272.	0.7	92
3715	Immunotherapy for human papillomavirus-associated disease and cervical cancer: review of clinical and translational research. <i>Journal of Gynecologic Oncology</i> , 2016, 27, e51.	1.0	99

#	ARTICLE	IF	CITATIONS
3716	Epstein-Barr virus-positive gastric cancer: a distinct molecular subtype of the disease?. Revista Da Sociedade Brasileira De Medicina Tropical, 2016, 49, 150-157.	0.4	25
3717	Molecular targets in urothelial cancer: detection, treatment, and animal models of bladder cancer. Drug Design, Development and Therapy, 2016, Volume 10, 3305-3322.	2.0	26
3718	Immunotherapy against cancer: A comprehensive review. Journal of Cancer Research and Experimental Oncology, 2016, 8, 15-25.	0.1	8
3719	Inflammation and Cancer. , 2016, , 406-415.		10
3720	An update on clinical oncology for the non-oncologist. Einstein (Sao Paulo, Brazil), 2016, 14, 294-299.	0.3	2
3721	Clinical utility of nivolumab in the treatment of advanced melanoma. Therapeutics and Clinical Risk Management, 2016, 12, 313.	0.9	16
3722	High-Grade Glioma Management and Response Assessmentâ€”Recent Advances and Current Challenges. Current Oncology, 2016, 23, 383-391.	0.9	33
3723	The emerging role of immunotherapy in colorectal cancer. Annals of Translational Medicine, 2016, 4, 305-305.	0.7	63
3724	Overcoming Hypoxia-Mediated Tumor Progression: Combinatorial Approaches Targeting pH Regulation, Angiogenesis and Immune Dysfunction. Frontiers in Cell and Developmental Biology, 2016, 4, 27.	1.8	107
3725	Exploring Reovirus Plasticity for Improving Its Use as Oncolytic Virus. Viruses, 2016, 8, 4.	1.5	29
3726	Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade. Viruses, 2016, 8, 9.	1.5	79
3727	Direct Delivery of Antigens to Dendritic Cells via Antibodies Specific for Endocytic Receptors as a Promising Strategy for Future Therapies. Vaccines, 2016, 4, 8.	2.1	68
3728	Monitoring of the Immune Dysfunction in Cancer Patients. Vaccines, 2016, 4, 29.	2.1	15
3729	Is There Still Room for Cancer Vaccines at the Era of Checkpoint Inhibitors. Vaccines, 2016, 4, 37.	2.1	63
3730	Tumor Microenvironment Metabolism: A New Checkpoint for Anti-Tumor Immunity. Vaccines, 2016, 4, 46.	2.1	87
3731	Non-small cell lung cancer: current treatment and future advances. Translational Lung Cancer Research, 2016, 5, 288-300.	1.3	1,256
3732	Harnessing the immune system to improve cancer therapy. Annals of Translational Medicine, 2016, 4, 261-261.	0.7	225
3733	Thermal Ablative Therapies and Immune Checkpoint Modulation: Can Locoregional Approaches Effect a Systemic Response?. Gastroenterology Research and Practice, 2016, 2016, 1-11.	0.7	79

#	ARTICLE	IF	CITATIONS
3734	Improving the efficiency of image guided brachytherapy in cervical cancer. <i>Journal of Contemporary Brachytherapy</i> , 2016, 6, 557-565.	0.4	15
3735	Inducing and Administering Tregs to Treat Human Disease. <i>Frontiers in Immunology</i> , 2015, 6, 654.	2.2	40
3736	Exploiting the Immunogenic Potential of Cancer Cells for Improved Dendritic Cell Vaccines. <i>Frontiers in Immunology</i> , 2015, 6, 663.	2.2	74
3737	T Cells and Cancer: How Metabolism Shapes Immunity. <i>Frontiers in Immunology</i> , 2016, 7, 20.	2.2	77
3738	Structure and Function of HLA-A*02-Restricted Hantaan Virus Cytotoxic T-Cell Epitope That Mediates Effective Protective Responses in HLA-A2.1/Kb Transgenic Mice. <i>Frontiers in Immunology</i> , 2016, 7, 298.	2.2	11
3739	The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation. <i>Frontiers in Immunology</i> , 2016, 7, 550.	2.2	409
3740	The Role of the Tumor Vasculature in the Host Immune Response: Implications for Therapeutic Strategies Targeting the Tumor Microenvironment. <i>Frontiers in Immunology</i> , 2016, 7, 621.	2.2	132
3741	Focus on Nivolumab in NSCLC. <i>Frontiers in Medicine</i> , 2016, 3, 67.	1.2	7
3742	Quercetin as an Emerging Anti-Melanoma Agent: A Four-Focus Area Therapeutic Development Strategy. <i>Frontiers in Nutrition</i> , 2016, 3, 48.	1.6	41
3743	Systemic Immunotherapy for the Treatment of Brain Metastases. <i>Frontiers in Oncology</i> , 2016, 6, 49.	1.3	66
3744	Translational Research to Improve the Efficacy of Carbon Ion Radiotherapy: Experience of Gunma University. <i>Frontiers in Oncology</i> , 2016, 6, 139.	1.3	20
3745	Challenges of Using High-Dose Fractionation Radiotherapy in Combination Therapy. <i>Frontiers in Oncology</i> , 2016, 6, 165.	1.3	9
3746	Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy. <i>Frontiers in Oncology</i> , 2016, 6, 233.	1.3	148
3747	Cancer Immunosurveillance: Immunoediting. , 2016, , 396-405.		3
3748	Humanized Mice in Translational Immunology. , 2016, , 285-326.		11
3749	Taking up Cancer Immunotherapy Challenges: Bispecific Antibodies, the Path Forward?. <i>Antibodies</i> , 2016, 5, 1.	1.2	34
3750	Updates in Therapy for Advanced Melanoma. <i>Cancers</i> , 2016, 8, 17.	1.7	37
3751	Targeted Therapy in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (LA-R/M HNSCC). <i>Cancers</i> , 2016, 8, 27.	1.7	42

#	ARTICLE	IF	CITATIONS
3752	Advancing Clostridia to Clinical Trial: Past Lessons and Recent Progress. <i>Cancers</i> , 2016, 8, 63.	1.7	28
3753	A Perspective of Immunotherapy for Prostate Cancer. <i>Cancers</i> , 2016, 8, 64.	1.7	28
3754	Novel Immunotherapeutic Approaches for Head and Neck Squamous Cell Carcinoma. <i>Cancers</i> , 2016, 8, 87.	1.7	30
3755	Advances in Cancer Immunotherapy in Solid Tumors. <i>Cancers</i> , 2016, 8, 106.	1.7	131
3756	Retrospective Study of Metastatic Melanoma and Renal Cell Carcinoma to the Brain with Multivariate Analysis of Prognostic Pre-Treatment Clinical Factors. <i>International Journal of Molecular Sciences</i> , 2016, 17, 400.	1.8	9
3757	Bone Metastasis from Renal Cell Carcinoma. <i>International Journal of Molecular Sciences</i> , 2016, 17, 987.	1.8	63
3758	A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1151.	1.8	134
3759	Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer?. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1169.	1.8	53
3760	Classification of 27 Tumor-Associated Antigens by Histochemical Analysis of 36 Freshly Resected Lung Cancer Tissues. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1862.	1.8	3
3761	Impact of aging on host immune response and survival in melanoma: an analysis of 3 patient cohorts. <i>Journal of Translational Medicine</i> , 2016, 14, 299.	1.8	26
3762	Immune checkpoint inhibitors and response analysis: a tough challenge. A case report. <i>BMC Research Notes</i> , 2016, 9, 349.	0.6	9
3763	Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitorsâ€”an autopsy study. , 2016, 4, 13.		162
3765	Immune response-associated gene analysis of 1,000 cancer patients using whole-exome sequencing and gene expression profilingâ€”Project HOPEâ€” . <i>Biomedical Research</i> , 2016, 37, 233-242.	0.3	12
3766	Stability, Prognostic Factors and Survival of Spinal Bone Metastases in Malignant Melanoma Patients after Palliative Radiotherapy. <i>Tumori</i> , 2016, 102, 156-161.	0.6	27
3767	Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports. <i>PLoS ONE</i> , 2016, 11, e0160221.	1.1	373
3768	PD-1/CTLA-4 Blockade Inhibits Epstein-Barr Virus-Induced Lymphoma Growth in a Cord Blood Humanized-Mouse Model. <i>PLoS Pathogens</i> , 2016, 12, e1005642.	2.1	87
3770	Does Radiotherapy for the Primary Tumor Benefit Prostate Cancer Patients with Distant Metastasis at Initial Diagnosis?. <i>PLoS ONE</i> , 2016, 11, e0147191.	1.1	50
3771	Evaluation of Costimulatory Molecules in Peripheral Blood Lymphocytes of Canine Patients with Histiocytic Sarcoma. <i>PLoS ONE</i> , 2016, 11, e0150030.	1.1	25

#	ARTICLE	IF	CITATIONS
3772	Glycosylation Status of CD43 Protein Is Associated with Resistance of Leukemia Cells to CTL-Mediated Cytolysis. PLoS ONE, 2016, 11, e0152326.	1.1	6
3773	PD-L1 and Tumor Infiltrating Lymphocytes as Prognostic Markers in Resected NSCLC. PLoS ONE, 2016, 11, e0153954.	1.1	73
3774	Comparison of the Lonidamine Potentiated Effect of Nitrogen Mustard Alkylating Agents on the Systemic Treatment of DB-1 Human Melanoma Xenografts in Mice. PLoS ONE, 2016, 11, e0157125.	1.1	8
3775	Incidence and risk of hepatic toxicities with PD-1 inhibitors in cancer patients: a meta-analysis. Drug Design, Development and Therapy, 2016, Volume 10, 3153-3161.	2.0	29
3776	Gadolinium-Based Nanoparticles and Radiation Therapy for Multiple Brain Melanoma Metastases: Proof of Concept before Phase I Trial. Theranostics, 2016, 6, 418-427.	4.6	134
3777	Comparative safety of BRAF and MEK inhibitors (vemurafenib, dabrafenib and trametinib) in first-line therapy for BRAF-mutated metastatic melanoma. Molecular and Clinical Oncology, 2016, 5, 458-462.	0.4	23
3778	Aptamers: A New Technological Platform in Cancer Immunotherapy. Pharmaceuticals, 2016, 9, 64.	1.7	25
3779	Clinical significance of B7-H6 protein expression in astrocytoma. OncoTargets and Therapy, 2016, 9, 3291.	1.0	12
3780	Inhibiting Immune Checkpoints for the Treatment of Bladder Cancer. Bladder Cancer, 2016, 2, 15-25.	0.2	29
3781	Cutaneous melanoma " guidelines for diagnostics and therapy in 2016. Przegląd Dermatologiczny, 2016, 1, 1-18.	0.0	0
3782	The efficacy and safety of nivolumab in the treatment of advanced melanoma: a meta-analysis of clinical trials. OncoTargets and Therapy, 2016, 9, 1571.	1.0	7
3783	The role of pembrolizumab in the treatment of advanced non-small cell lung cancer. Annals of Translational Medicine, 2016, 4, 215-215.	0.7	13
3784	Immune checkpoint blockade therapy for bladder cancer treatment. Investigative and Clinical Urology, 2016, 57, S98.	1.0	26
3786	War-winning weapons. Nature Immunology, 2016, 17, S18-S18.	7.0	0
3787	Immunotherapy for gliomas. , 0, , 91-120.		0
3788	Icaritin, a novel FASN inhibitor, exerts anti-melanoma activities through IGF-1R/STAT3 signaling. Oncotarget, 2016, 7, 51251-51269.	0.8	31
3789	Suspected autoimmune myocarditis and cardiac conduction abnormalities with nivolumab therapy for non-small cell lung cancer. BMJ Case Reports, 2016, 2016, bcr2016216228.	0.2	61
3790	The challenge of developmental therapeutics for adrenocortical carcinoma. Oncotarget, 2016, 7, 46734-46749.	0.8	17

#	ARTICLE	IF	CITATIONS
3791	Prognostic Factors for Survival in Melanoma Patients with Brain Metastases. , 2016, , 267-297.		11
3792	Current and emerging therapies in unresectable and recurrent gastric cancer. World Journal of Gastroenterology, 2016, 22, 4812.	1.4	45
3793	The State of Immune Checkpoint Inhibition in Urothelial Carcinoma. Cancer Journal (Sudbury, Mass), 2016, 22, 96-100.	1.0	5
3794	Immune Checkpoint Inhibitors in the Treatment of Gynecologic Malignancies. Cancer Journal (Sudbury,) Tj ETQq1 1,0,784314 rgBT /Ove 1.0 175	1.0	175
3795	Immune Checkpoint Therapy in Head and Neck Cancers. Cancer Journal (Sudbury, Mass), 2016, 22, 108-116.	1.0	12
3796	Immune Checkpoint Therapy in Melanoma. Cancer Journal (Sudbury, Mass), 2016, 22, 73-80.	1.0	10
3797	Pretreatment Neutrophil to Lymphocyte Ratio Independently Predicts Disease-specific Survival in Resectable Gastroesophageal Junction and Gastric Adenocarcinoma. Annals of Surgery, 2016, 263, 292-297.	2.1	124
3798	Treatment of melanoma brain metastases. Current Opinion in Oncology, 2016, 28, 159-165.	1.1	11
3799	Checkpoint inhibitors and gastrointestinal immune-related adverse events. Current Opinion in Oncology, 2016, 28, 264-268.	1.1	35
3800	Successful Anti-PD-1 Antibody Treatment in a Metastatic Melanoma Patient With Known Severe Autoimmune Disease. Journal of Immunotherapy, 2016, 39, 188-190.	1.2	36
3801	Immune-related Adverse Events of Dendritic Cell Vaccination Correlate With Immunologic and Clinical Outcome in Stage III and IV Melanoma Patients. Journal of Immunotherapy, 2016, 39, 241-248.	1.2	26
3802	Neuropilin-2 promotes melanoma growth and progression in vivo. Melanoma Research, 2016, 26, 321-328.	0.6	23
3803	Type I-polarized BRAF-pulsed dendritic cells induce antigen-specific CD8+ T cells that impact BRAF-mutant murine melanoma. Melanoma Research, 2016, 26, 1-11.	0.6	13
3804	Treatment of in-transit and metastatic melanoma in two patients treated with ipilimumab and topical imiquimod. Melanoma Research, 2016, 26, 409-412.	0.6	20
3805	Safety of immune checkpoint inhibitors in Chinese patients with melanoma. Melanoma Research, 2016, 26, 284-289.	0.6	21
3806	Residual inflammation and viral reservoirs. Current Opinion in HIV and AIDS, 2016, 11, 234-241.	1.5	107
3807	Managing Cutaneous Side Effects From Targeted Molecular Inhibitors for Melanoma and Nonmelanoma Skin Cancer. Dermatologic Surgery, 2016, 42, S40-S48.	0.4	8
3808	The combination of bleomycin with suicide or interferon- β gene transfer is able to efficiently eliminate human melanoma tumor initiating cells. Biomedicine and Pharmacotherapy, 2016, 83, 290-301.	2.5	10

#	ARTICLE	IF	CITATIONS
3809	Proportions of blood-borne VÎ1+ and VÎ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab. <i>European Journal of Cancer</i> , 2016, 64, 116-126.	1.3	54
3810	Comprehensive molecular profiling of the B7 family of immune-regulatory ligands in breast cancer. <i>OncImmunology</i> , 2016, 5, e1207841.	2.1	33
3811	Pembrolizumab (Keytruda). <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 2777-2789.	1.4	237
3812	Immune checkpoint blockade in human cancer therapy: lung cancer and hematologic malignancies. <i>Immunotherapy</i> , 2016, 8, 809-819.	1.0	44
3813	Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges. <i>Immunotherapy</i> , 2016, 8, 821-837.	1.0	139
3814	Rationale for immune-based therapies in Merkel polyomavirus-positive and -negative Merkel cell carcinomas. <i>Immunotherapy</i> , 2016, 8, 907-921.	1.0	20
3816	Recognizing melanoma. <i>Nurse Practitioner</i> , 2016, 41, 24-29.	0.2	0
3817	Genetically Engineered Mouse Models of Pancreatic Cancer: The KPC Model (<i>LSLâ€Kras^{G12D/+};LSLâ€Trp53^{R172H/+};Pdxâ€1â€Cre</i>), Its Variants, and Their Application in Immunoâ€oncology Drug Discovery. <i>Current Protocols in Pharmacology</i> , 2016, 73, 14.39.1-14.39.20.	4.0	141
3818	The role of mitogen-activated protein targeting in melanoma beyond BRAFV600. <i>Current Opinion in Oncology</i> , 2016, 28, 185-191.	1.1	17
3819	The use of pembrolizumab for the treatment of metastatic uveal melanoma. <i>Melanoma Research</i> , 2016, 26, 300-303.	0.6	90
3820	Patient-derived tumor xenograft strategies for informed management of patients with metastatic melanoma. <i>Melanoma Research</i> , 2016, 26, 245-253.	0.6	0
3821	Immune Checkpoint Therapy and the Search for Predictive Biomarkers. <i>Cancer Journal (Sudbury, Mass)</i> Tj ETQq1 1 0.784314 rgBT /Over	1.0	38
3822	Managing Adverse Events With Immune Checkpoint Agents. <i>Cancer Journal (Sudbury, Mass)</i> , 2016, 22, 121-129.	1.0	42
3823	Mutational Landscape and Sensitivity to Immune Checkpoint Blockers. <i>Clinical Cancer Research</i> , 2016, 22, 4309-4321.	3.2	182
3824	Prolonged Benefit from Ipilimumab Correlates with Improved Outcomes from Subsequent Pembrolizumab. <i>Cancer Immunology Research</i> , 2016, 4, 569-573.	1.6	20
3825	Locally Advanced Unresectable Vaginal Melanoma. <i>Journal of Lower Genital Tract Disease</i> , 2016, 20, e4-e5.	0.9	4
3826	Cancer Vaccines. <i>Advances in Anatomic Pathology</i> , 2016, 23, 180-191.	2.4	22
3827	Immune Checkpoint Therapy in Renal Cell Carcinoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2016, 22, 92-95.	1.0	35

#	ARTICLE	IF	CITATIONS
3828	Targeted Therapies Combined With Immune Checkpoint Therapy. <i>Cancer Journal (Sudbury, Mass)</i> , 2016, 22, 138-146.	1.0	36
3829	New-onset toxicity with programmed death-1 inhibitor rechallenge. <i>Melanoma Research</i> , 2016, 26, 316-318.	0.6	3
3830	Immunotherapy advances in uro-genital malignancies. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 105, 52-64.	2.0	19
3831	Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline â€œ Update 2016. <i>European Journal of Cancer</i> , 2016, 63, 201-217.	1.3	330
3832	Immunohistochemical analysis of lichenoid reactions in patients treated with antiâ€PDâ€L1 and antiâ€PDâ€L1 therapy. <i>Journal of Cutaneous Pathology</i> , 2016, 43, 339-346.	0.7	101
3833	Irradiation and immunotherapy: From concept to the clinic. <i>Cancer</i> , 2016, 122, 1659-1671.	2.0	73
3834	CRISPRâ€Cas9 systems: versatile cancer modelling platforms and promising therapeutic strategies. <i>International Journal of Cancer</i> , 2016, 138, 1328-1336.	2.3	26
3835	Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab. <i>Muscle and Nerve</i> , 2016, 54, 157-161.	1.0	87
3836	Update on immune therapy in melanoma. <i>Expert Opinion on Orphan Drugs</i> , 2016, 4, 799-808.	0.5	0
3837	Effectiveness, toxicity, and economic evaluation of ipilimumab for the treatment of patients with metastatic melanoma in the Spanish outpatient setting. <i>Anti-Cancer Drugs</i> , 2016, 27, 679-684.	0.7	7
3838	Immune-mediated respiratory adverse events of checkpoint inhibitors. <i>Current Opinion in Oncology</i> , 2016, 28, 269-277.	1.1	39
3839	Rare side-effects of checkpoint inhibitors. <i>Current Opinion in Oncology</i> , 2016, 28, 295-305.	1.1	7
3840	End-of-life care for hospitalized patients with metastatic melanoma in France: a nationwide, register-based study. <i>British Journal of Dermatology</i> , 2016, 175, 583-592.	1.4	19
3841	Development of chronic lymphocytic leukaemia during ipilimumab therapy in a patient with metastatic melanoma. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 1626-1627.	1.3	3
3842	Weighing up the pros and cons of immune checkpoint inhibitors in the treatment of melanoma. <i>Immunotherapy</i> , 2016, 8, 677-679.	1.0	7
3843	The case for immuneâ€based approaches in biliary tract carcinoma. <i>Hepatology</i> , 2016, 64, 1785-1791.	3.6	25
3844	Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors. <i>JAMA Oncology</i> , 2016, 2, 1346.	3.4	667
3845	A New Class of Bifunctional Major Histocompatibility Class I Antibody Fusion Molecules to Redirect CD8 T Cells. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2130-2142.	1.9	15

#	ARTICLE	IF	CITATIONS
3846	Comment on the American Society of Clinical Oncology Value Statement. <i>Journal of Clinical Oncology</i> , 2016, 34, 2937-2938.	0.8	3
3848	Immunomodulation Within a Single Tumor Site to Induce Systemic Antitumor Immunity: In Situ Vaccination for Cancer. , 2016, , 129-162.		1
3849	Novel Targets and Their Assessment for Cancer Treatment. , 2016, , 163-180.		0
3850	Severe agranulocytosis in a patient with metastatic non-small-cell lung cancer treated with nivolumab. <i>Lung Cancer</i> , 2016, 99, 123-126.	0.9	46
3851	B7-H4 expression indicates poor prognosis of oral squamous cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 1035-1045.	2.0	58
3852	Immune checkpoint inhibitors side effects and management. <i>Immunotherapy</i> , 2016, 8, 799-807.	1.0	62
3853	Programmed death ligand-1 expression is associated with poor disease free survival in salivary gland carcinomas. <i>Journal of Surgical Oncology</i> , 2016, 114, 36-43.	0.8	87
3854	Prognostic markers and tumour growth kinetics in melanoma patients progressing on vemurafenib. <i>Melanoma Research</i> , 2016, 26, 138-144.	0.6	12
3855	How to Diagnose and Treat IBD Mimics in the Refractory IBD Patient Who Does Not Have IBD. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 1262-1274.	0.9	40
3856	Immune Checkpoint Therapies in Prostate Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2016, 22, 117-120.	1.0	46
3857	The current status of checkpoint inhibitors in metastatic bladder cancer. <i>Clinical and Experimental Metastasis</i> , 2016, 33, 629-635.	1.7	11
3858	Safety, immune and clinical responses in metastatic melanoma patients vaccinated with a long peptide derived from indoleamine 2,3-dioxygenase in combination with ipilimumab. <i>Cytotherapy</i> , 2016, 18, 1043-1055.	0.3	45
3859	Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer. <i>British Journal of Cancer</i> , 2016, 115, 252-260.	2.9	66
3860	Nivolumab-induced chronic inflammatory demyelinating polyradiculoneuropathy mimicking rapid-onset Guillain-Barré syndrome: a case report. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 875-878.	0.6	70
3861	Immunotherapy for genitourinary cancer. <i>Anti-Cancer Drugs</i> , 2016, 27, 585-599.	0.7	4
3862	Ocular and orbital side-effects of checkpoint inhibitors: a review article. <i>Current Opinion in Oncology</i> , 2016, 28, 288-294.	1.1	117
3863	Uveal melanoma: From diagnosis to treatment and the science in between. <i>Cancer</i> , 2016, 122, 2299-2312.	2.0	272
3864	Immune-Related Adverse Events From Immune Checkpoint Inhibitors. <i>Clinical Pharmacology and Therapeutics</i> , 2016, 100, 242-251.	2.3	84

#	ARTICLE	IF	CITATIONS
3865	Pan-cancer analysis of copy number changes in programmed death ligand 1 (PD-L1, CD274) associations with gene expression, mutational load, and survival. <i>Genes Chromosomes and Cancer</i> , 2016, 55, 626-639.	1.5	80
3866	Melanoma therapy: Check the checkpoints. <i>Journal of Dermatology</i> , 2016, 43, 121-124.	0.6	13
3867	Evolving systemic targeted therapy strategies in uveal melanoma and implications for ophthalmic management: a review. <i>Clinical and Experimental Ophthalmology</i> , 2016, 44, 509-519.	1.3	18
3868	Immunotherapy for uveal melanoma. <i>Melanoma Management</i> , 2016, 3, 125-135.	0.1	3
3869	Immunomodulatory antibodies for the treatment of lymphoma: Report on the CALYM Workshop. <i>Oncolimmunology</i> , 2016, 5, e1186323.	2.1	2
3870	NCCN Guidelines Insights: Melanoma, Version 3.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 945-958.	2.3	76
3871	The promise of immunotherapy in head and neck squamous cell carcinoma: combinatorial immunotherapy approaches. <i>ESMO Open</i> , 2016, 1, e000122.	2.0	55
3872	The positioning of palliative care in acute care: A multiperspective qualitative study in the context of metastatic melanoma. <i>Palliative and Supportive Care</i> , 2016, 14, 259-268.	0.6	10
3874	Explaining the Paucity of Intratumoral T Cells: A Construction Out of Known Entities. <i>Cold Spring Harbor Symposia on Quantitative Biology</i> , 2016, 81, 219-226.	2.0	6
3875	Major Changes in Systemic Therapy for Advanced Melanoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 638-640.	2.3	8
3876	Immunotherapy for breast cancer: past, present, and future. <i>Cancer and Metastasis Reviews</i> , 2016, 35, 525-546.	2.7	49
3877	AACR Cancer Progress Report 2016. <i>Clinical Cancer Research</i> , 2016, 22, S1-S137.	3.2	29
3878	Can T cells be too exhausted to fight back?. <i>Science</i> , 2016, 354, 1104-1105.	6.0	12
3879	Filling the Tank: Keeping Antitumor T Cells Metabolically Fit for the Long Haul. <i>Cancer Immunology Research</i> , 2016, 4, 1001-1006.	1.6	22
3880	Validation of biomarkers to predict response to immunotherapy in cancer: Volume I pre-analytical and analytical validation. , 2016, 4, 76.		155
3881	The role of immune checkpoint inhibition in the treatment of ovarian cancer. <i>Gynecologic Oncology Research and Practice</i> , 2016, 3, 11.	3.6	118
3882	Responses to immune checkpoint inhibitors in nonagenarians. <i>Oncolimmunology</i> , 2016, 5, e1234572.	2.1	24
3883	Survival of Lung Adenocarcinoma Patients Predicted from Expression of PD-L1, Galectin-9, and XAGE1 (GAGED2a) on Tumor Cells and Tumor-Infiltrating T Cells. <i>Cancer Immunology Research</i> , 2016, 4, 1049-1060.	1.6	34

#	ARTICLE	IF	CITATIONS
3885	Predictive biomarkers for checkpoint inhibitor-based immunotherapy. <i>Lancet Oncology</i> , The, 2016, 17, e542-e551.	5.1	1,274
3886	Cancer Immunotherapy for Gliomas: Overview and Future Directions. <i>Neurologia Medico-Chirurgica</i> , 2016, 56, 355-360.	1.0	5
3887	Evaluation of efficacy and safety of different pembrolizumab dose/schedules in treatment of non-small-cell lung cancer and melanoma: a systematic review. <i>Immunotherapy</i> , 2016, 8, 1383-1391.	1.0	16
3892	Major Contributions towards Finding a Cure for Cancer through Chemotherapy: A Historical Review. <i>Tumori</i> , 2016, 102, 6-17.	0.6	20
3893	Sarcoidosis in the setting of combination ipilimumab and nivolumab immunotherapy: a case report & review of the literature. , 2016, 4, 94.		91
3894	Electrochemotherapy with bleomycin is effective in BRAF mutated melanoma cells and interacts with BRAF inhibitors. <i>Radiology and Oncology</i> , 2016, 50, 274-279.	0.6	24
3895	Cancer immunotherapy trials: leading a paradigm shift in drug development. , 2016, 4, 42.		35
3896	Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma. , 2016, 4, 44.		54
3897	Administration and Handling of Talimogene Laherparepvec: An Intralesional Oncolytic Immunotherapy for Melanoma. <i>Oncology Nursing Forum</i> , 2016, 43, 219-226.	0.5	18
3898	T cell co-stimulatory factors. <i>Rheumatology</i> , 2016, 56, kew276.	0.9	3
3899	Canine cancer immunotherapy studies: linking mouse and human. , 2016, 4, 97.		86
3900	Biochemistry of Oxidative Stress. , 2016, , .		5
3902	hvTRA, a novel TRAIL receptor agonist, induces apoptosis and sustained growth retardation in melanoma. <i>Cell Death Discovery</i> , 2016, 2, 16081.	2.0	11
3903	Overview and management of toxicities of immune checkpoint-blocking drugs. <i>Forum of Clinical Oncology</i> , 2016, 7, 28-37.	0.1	1
3904	A New VISTA on combination therapy for negative checkpoint regulator blockade. , 2016, 4, 86.		36
3905	Unstable B7-H4 cell surface expression and T-cell redirection as a means of cancer therapy. <i>Oncology Reports</i> , 2016, 36, 2625-2632.	1.2	4
3906	Tumor-derived exosomes regulate expression of immune function-related genes in human T cell subsets. <i>Scientific Reports</i> , 2016, 6, 20254.	1.6	260
3907	A Cost-Effectiveness Analysis of Nivolumab Compared with Ipilimumab for the Treatment of BRAF Wild-Type Advanced Melanoma in Australia. <i>Value in Health</i> , 2016, 19, 1009-1015.	0.1	24

#	ARTICLE	IF	CITATIONS
3908	Pathological characterization of nivolumab-related liver injury in a patient with glioblastoma. <i>Immunotherapy</i> , 2016, 8, 1363-1369.	1.0	34
3909	Dermatologic adverse events of checkpoint inhibitors: what an oncologist should know. <i>Immunotherapy</i> , 2016, 8, 1437-1446.	1.0	25
3910	Immune checkpoint inhibitors renal side effects and management. <i>Immunotherapy</i> , 2016, 8, 1417-1425.	1.0	13
3911	Effect of an immunomodulatory regimen for cancer prevention: A case report. <i>Molecular and Clinical Oncology</i> , 2016, 5, 540-544.	0.4	0
3912	Bullous pemphigoid-like reaction in a patient with metastatic melanoma receiving pembrolizumab and previously treated with ipilimumab. <i>Australasian Journal of Dermatology</i> , 2016, 57, 333-335.	0.4	19
3913	Reprogramming the immunological microenvironment through radiation and targeting Axl. <i>Nature Communications</i> , 2016, 7, 13898.	5.8	150
3914	Myasthenic crisis and polymyositis induced by one dose of nivolumab. <i>Cancer Science</i> , 2016, 107, 1055-1058.	1.7	176
3915	Renal effects of immune checkpoint inhibitors. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, gfw382.	0.4	67
3916	Anti-PD-1 Antibody Treatment and the Development of Acute Pulmonary Tuberculosis. <i>Journal of Thoracic Oncology</i> , 2016, 11, 2048-2050.	0.5	43
3917	Current status and future prospects of peptide-based cancer vaccines. <i>Immunotherapy</i> , 2016, 8, 1321-1333.	1.0	9
3918	Adoptive immunotherapy for the treatment of glioblastoma: progress and possibilities. <i>Immunotherapy</i> , 2016, 8, 1393-1404.	1.0	8
3919	Advancements in unresectable melanoma: a multidisciplinary perspective. <i>Melanoma Management</i> , 2016, 3, 171-175.	0.1	0
3920	Outcomes and toxicity of stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab. <i>Melanoma Management</i> , 2016, 3, 177-186.	0.1	10
3921	Advances in the development of intralesional therapies for melanoma. <i>Melanoma Management</i> , 2016, 3, 259-266.	0.1	5
3922	The cutting edge of metastatic melanoma therapy. <i>Melanoma Management</i> , 2016, 3, 217-229.	0.1	1
3923	A review of drugs in development for the personalized treatment of head and neck squamous cell carcinoma. <i>Expert Review of Precision Medicine and Drug Development</i> , 2016, 1, 379-385.	0.4	5
3925	PD-L1 polymorphism can predict clinical outcomes of non-small cell lung cancer patients treated with first-line paclitaxel-cisplatin chemotherapy. <i>Scientific Reports</i> , 2016, 6, 25952.	1.6	36
3926	Prognostic factors for melanoma brain metastases treated with stereotactic radiosurgery. <i>Journal of Neurosurgery</i> , 2016, 125, 31-39.	0.9	13

#	ARTICLE	IF	CITATIONS
3927	Immunotherapy in genitourinary malignancies. <i>Current Opinion in Urology</i> , 2016, 26, 501-507.	0.9	6
3928	Targeting the host immune system: PD-1 and PD-L1 antibodies and breast cancer. <i>Current Opinion in Supportive and Palliative Care</i> , 2016, 10, 336-342.	0.5	9
3929	Pembrolizumab-triggered Uveitis: An Additional Surrogate Marker for Responders in Melanoma Immunotherapy?. <i>Journal of Immunotherapy</i> , 2016, 39, 379-382.	1.2	45
3930	A phase I study of TPI 287 in combination with temozolomide for patients with metastatic melanoma. <i>Melanoma Research</i> , 2016, 26, 604-608.	0.6	17
3931	Radiotherapy to Control Limited Melanoma Progression Following Ipilimumab. <i>Journal of Immunotherapy</i> , 2016, 39, 373-378.	1.2	19
3932	Challenges in the Delivery of Therapies to Melanoma Brain Metastases. <i>Current Pharmacology Reports</i> , 2016, 2, 309-325.	1.5	18
3933	Bi-cytopenia possibly induced by anti-PD-1 antibody for primary malignant melanoma of the esophagus. <i>Medicine (United States)</i> , 2016, 95, e4283.	0.4	35
3934	Immune Therapy for Prostate Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2016, 22, 334-341.	1.0	16
3935	Neurologic complications of immune checkpoint inhibitors. <i>Current Opinion in Neurology</i> , 2016, 29, 806-812.	1.8	179
3936	Analysis of the Abscopal Effect With Anti-PD1 Therapy in Patients With Metastatic Solid Tumors. <i>Journal of Immunotherapy</i> , 2016, 39, 367-372.	1.2	84
3937	An In Vitro Model That Predicts the Therapeutic Efficacy of Immunomodulatory Antibodies. <i>Journal of Immunotherapy</i> , 2016, 39, 298-305.	1.2	4
3938	A multidisciplinary approach to toxicity management of modern immune checkpoint inhibitors in cancer therapy. <i>Melanoma Research</i> , 2016, 26, 469-480.	0.6	30
3939	Third-generation CD28/4-1BB chimeric antigen receptor T cells for chemotherapy relapsed or refractory acute lymphoblastic leukaemia: a non-randomised, open-label phase I trial protocol. <i>BMJ Open</i> , 2016, 6, e013904.	0.8	63
3940	Immune-related endocrine disorders in novel immune checkpoint inhibition therapy. <i>Genes and Diseases</i> , 2016, 3, 252-256.	1.5	17
3941	The rationale for including immune checkpoint inhibition into multimodal primary treatment concepts of head and neck cancer. <i>Cancers of the Head & Neck</i> , 2016, 1, 8.	6.2	22
3943	Immune contexture and histological response after neoadjuvant chemotherapy predict clinical outcome of lung cancer patients. <i>Oncolmunology</i> , 2016, 5, e1255394.	2.1	62
3944	Renal Allograft Failure After Ipilimumab Therapy for Metastatic Melanoma: A Case Report and Review of the Literature. <i>Transplantation Proceedings</i> , 2016, 48, 3137-3141.	0.3	49
3945	Glycosylation of MUC1 influences the binding of a therapeutic antibody by altering the conformational equilibrium of the antigen. <i>Glycobiology</i> , 2017, 27, 677-687.	1.3	45

#	ARTICLE	IF	CITATIONS
3946	Molecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab-based immunotherapy in metastatic patients. <i>Journal of Translational Medicine</i> , 2016, 14, 232.	1.8	27
3947	A prospective population-based study, aiming to support decision-making in a follow-up programme for patients with cutaneous malignant melanoma, based on patterns of recurrence. <i>European Journal of Dermatology</i> , 2016, 26, 586-591.	0.3	4
3948	De-Risking Immunotherapy: Report of a Consensus Workshop of the Cancer Immunotherapy Consortium of the Cancer Research Institute. <i>Cancer Immunology Research</i> , 2016, 4, 279-288.	1.6	29
3949	Immunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients. <i>British Journal of Cancer</i> , 2016, 114, 872-880.	2.9	41
3951	Combination dabrafenib and trametinib in the management of advanced melanoma with BRAFV600 mutations. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1031-1038.	0.9	28
3952	Immune checkpoint inhibitors in lung cancer: past, present and future. <i>Future Oncology</i> , 2016, 12, 1151-1163.	1.1	26
3953	Antitumor vaccination of prostate cancer patients elicits PD-1/PD-L1 regulated antigen-specific immune responses. <i>Oncolmmunology</i> , 2016, 5, e1165377.	2.1	42
3954	Immunotherapy for genitourinary malignancies in the here and now!. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 169-170.	0.8	0
3955	Epigenetic modification augments the immunogenicity of human leukocyte antigen G serving as a tumor antigen for T cell-based immunotherapy. <i>Oncolmmunology</i> , 2016, 5, e1169356.	2.1	34
3956	GM-CSF and ipilimumab therapy in metastatic melanoma: Clinical outcomes and immunologic responses. <i>Oncolmmunology</i> , 2016, 5, e1101204.	2.1	26
3957	Considerations for the combination of anticancer vaccines and immune checkpoint inhibitors. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 895-901.	1.4	20
3958	Ipilimumab and Bevacizumab in Glioblastoma. <i>Clinical Oncology</i> , 2016, 28, 622-626.	0.6	64
3959	Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer. <i>Oral Oncology</i> , 2016, 58, 59-70.	0.8	115
3960	Drug-induced hepatotoxicity in cancer patients - implication for treatment. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 1219-1238.	1.0	52
3961	Can immunostimulatory agents enhance the abscopal effect of radiotherapy?. <i>European Journal of Cancer</i> , 2016, 62, 36-45.	1.3	105
3962	Adjuvant treatment for stage III melanoma in the era of targeted medicine and immunotherapy. <i>Melanoma Management</i> , 2016, 3, 137-147.	0.1	1
3963	New Pharmaceutical Agents in Oncology. <i>Physician Assistant Clinics</i> , 2016, 1, 435-463.	0.1	0
3964	Headache in a patient with renal cell carcinoma.. <i>European Journal of Internal Medicine</i> , 2016, 32, e3-e4.	1.0	1

#	ARTICLE	IF	CITATIONS
3965	Programmed death-1 immune checkpoint blockade in the treatment of hematological malignancies. <i>Annals of Medicine</i> , 2016, 48, 428-439.	1.5	32
3966	Emerging immunotherapies for glioblastoma. <i>Expert Opinion on Emerging Drugs</i> , 2016, 21, 133-145.	1.0	34
3967	Are there, or shall we discover, biomarkers to guide PD-1 inhibition?. <i>Immunotherapy</i> , 2016, 8, 681-686.	1.0	1
3968	Therapeutic Antibodies in Cancer Therapy. <i>Advances in Experimental Medicine and Biology</i> , 2016, 917, 95-120.	0.8	36
3969	Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?. <i>Drugs</i> , 2016, 76, 925-945.	4.9	123
3970	Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?. <i>European Journal of Cancer</i> , 2016, 62, 76-85.	1.3	178
3971	Severe acute colitis induced by ipilimumab. <i>Gastroenterology Y Hepatology (English Edition)</i> , 2016, 39, 277-279.	0.0	0
3972	Immunomodulatory effects of radiotherapy: Magical effects of the healing beam?. <i>Journal of Thoracic Oncology</i> , 2016, 11, S10-S11.	0.5	0
3973	Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 2389-2397.	0.8	293
3974	Novel immunotherapies for the treatment of melanoma. <i>Immunotherapy</i> , 2016, 8, 613-632.	1.0	5
3975	CSF-1R-Dependent Lethal Hepatotoxicity When Agonistic CD40 Antibody Is Given before but Not after Chemotherapy. <i>Journal of Immunology</i> , 2016, 197, 179-187.	0.4	48
3976	Targeting cellular and molecular drivers of head and neck squamous cell carcinoma: current options and emerging perspectives. <i>Cancer and Metastasis Reviews</i> , 2016, 35, 413-426.	2.7	44
3977	Lymph nodes and the melanoma surgeon: re-defining a long-term relationship. <i>Melanoma Management</i> , 2016, 3, 73-82.	0.1	0
3978	Hepatocellular Carcinoma Regression After Cessation of Immunosuppressive Therapy. <i>Journal of Clinical Oncology</i> , 2016, 34, e90-e92.	0.8	31
3979	The present status and future prospects of peptide-based cancer vaccines. <i>International Immunology</i> , 2016, 28, 319-328.	1.8	104
3980	What Is New in Melanoma Genetics and Treatment?. <i>Dermatology</i> , 2016, 232, 259-264.	0.9	25
3981	Influences of BRAF Inhibitors on the Immune Microenvironment and the Rationale for Combined Molecular and Immune Targeted Therapy. <i>Current Oncology Reports</i> , 2016, 18, 42.	1.8	54
3982	Modelling Comparative Efficacy of Drugs with Different Survival Profiles: Ipilimumab, Vemurafenib and Dacarbazine in Advanced Melanoma. <i>BioDrugs</i> , 2016, 30, 307-319.	2.2	7

#	ARTICLE	IF	CITATIONS
3983	Malignant melanomaâ€”The cradle of anti-neoplastic immunotherapy. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 106, 25-54.	2.0	33
3984	Head and neck melanoma (excluding ocular melanoma): United Kingdom National Multidisciplinary Guidelines. <i>Journal of Laryngology and Otology</i> , 2016, 130, S133-S141.	0.4	21
3985	Concomitant targeting of programmed death-1 (PD-1) and CD137 improves the efficacy of radiotherapy in a mouse model of human BRAFV600-mutant melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 753-763.	2.0	32
3986	Urothelial Cancer: Inflammatory Mediators and Implications for Immunotherapy. <i>BioDrugs</i> , 2016, 30, 263-273.	2.2	22
3987	Improving patient outcomes to targeted therapies in melanoma. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 633-641.	1.1	6
3988	Ipilimumab-Induced Granulomatous Disease Occurring Simultaneously With Disease Progression in a Patient With Metastatic Melanoma. <i>American Journal of Therapeutics</i> , 2016, 23, e1068-e1071.	0.5	21
3989	Clinical Significance of Circulating CD33+CD11b+HLA-DR ⁺ Myeloid Cells in Patients with Stage IV Melanoma Treated with Ipilimumab. <i>Clinical Cancer Research</i> , 2016, 22, 5661-5672.	3.2	170
3991	Nivolumab: A Review in Advanced Nonsquamous Non-Small Cell Lung Cancer. <i>Drugs</i> , 2016, 76, 969-978.	4.9	34
3992	Targeting T Cell Co-receptors for Cancer Therapy. <i>Immunity</i> , 2016, 44, 1069-1078.	6.6	418
3993	Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation. <i>Immunity</i> , 2016, 44, 989-1004.	6.6	1,538
3994	Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family. <i>Immunity</i> , 2016, 44, 955-972.	6.6	462
3995	Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 674-690.	12.5	1,938
3996	Combinatorial Cancer Immunotherapies. <i>Advances in Immunology</i> , 2016, 130, 251-277.	1.1	107
3997	Molecular Drivers of the Nonâ€”T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer. <i>Cancer Immunology Research</i> , 2016, 4, 563-568.	1.6	293
3998	Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors. <i>Immunotherapy</i> , 2016, 8, 705-719.	1.0	61
3999	System Engineering Approach to Planning Anticancer Therapies. , 2016, , .		19
4000	Therapy Optimization in Population Dynamics Models. , 2016, , 55-83.		0
4001	Combined immunotherapy and radiation for treatment of mucosal melanomas of the lower genital tract. <i>Gynecologic Oncology Reports</i> , 2016, 16, 42-46.	0.3	40

#	ARTICLE	IF	CITATIONS
4002	Targeting K-Ras cancers. <i>Journal of Thoracic Oncology</i> , 2016, 11, S9-S10.	0.5	0
4003	The Role of the Immune System and Immunoregulatory Mechanisms Relevant to Melanoma. , 2016, , 31-65.		0
4004	Ovarian cancer and the immune system – The role of targeted therapies. <i>Gynecologic Oncology</i> , 2016, 142, 349-356.	0.6	54
4005	Molecular Pathways: Targeting DNA Repair Pathway Defects Enriched in Metastasis. <i>Clinical Cancer Research</i> , 2016, 22, 3132-3137.	3.2	28
4006	Endocrinological side-effects of immune checkpoint inhibitors. <i>Current Opinion in Oncology</i> , 2016, 28, 278-287.	1.1	115
4007	The Role of Surgical Pathology in Guiding Cancer Immunotherapy. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2016, 11, 313-341.	9.6	15
4008	Burden of Nonsynonymous Mutations among TCGA Cancers and Candidate Immune Checkpoint Inhibitor Responses. <i>Cancer Research</i> , 2016, 76, 3767-3772.	0.4	124
4009	Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy. <i>Clinical Cancer Research</i> , 2016, 22, 3425-3431.	3.2	368
4010	PD-1 and PD-L1 inhibitors in melanoma treatment: past success, present application and future challenges. <i>Immunotherapy</i> , 2016, 8, 733-746.	1.0	28
4011	Phase I study to evaluate toxicity and feasibility of intratumoral injection of Î±-gal glycolipids in patients with advanced melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 897-907.	2.0	11
4012	Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer. <i>Trends in Immunology</i> , 2016, 37, 462-476.	2.9	232
4013	Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure). <i>Annals of Oncology</i> , 2016, 27, 1492-1504.	0.6	460
4014	The promising alliance of anti-cancer electrochemotherapy with immunotherapy. <i>Cancer and Metastasis Reviews</i> , 2016, 35, 165-177.	2.7	98
4015	The fourth modality: immunotherapy for head and neck cancer hits pay dirt. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2016, 121, 575-577.	0.2	6
4016	CIS is a potent checkpoint in NK cell-mediated tumor immunity. <i>Nature Immunology</i> , 2016, 17, 816-824.	7.0	289
4017	Pembrolizumab for the treatment of advanced melanoma. <i>Expert Opinion on Orphan Drugs</i> , 2016, 4, 867-873.	0.5	10
4018	Predictive and Prognostic Clinical Variables in Cancer Patients Treated With Adenoviral Oncolytic Immunotherapy. <i>Molecular Therapy</i> , 2016, 24, 1323-1332.	3.7	28
4019	Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma. <i>Oncolmmunology</i> , 2016, 5, e1052212.	2.1	83

#	ARTICLE	IF	CITATIONS
4020	Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. <i>Science</i> , 2016, 352, 189-196.	6.0	3,421
4021	Antibody-Mediated Phosphatidylserine Blockade Enhances the Antitumor Responses to CTLA-4 and PD-1 Antibodies in Melanoma. <i>Cancer Immunology Research</i> , 2016, 4, 531-540.	1.6	20
4022	Infiltration of lymphocyte subpopulations into cancer microtissues as a tool for the exploration of immunomodulatory agents and biomarkers. <i>Immunobiology</i> , 2016, 221, 604-617.	0.8	7
4023	Les anticorps monoclonaux dirigés contre les checkpoints immunologiques: de nouvelles approches de l'immunothérapie en oncologie. <i>Revue D'Oncologie Hématologie Pédiatrique</i> , 2016, 4, 5-12.	0.1	4
4024	Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1. <i>Cancer Immunology Research</i> , 2016, 4, 383-389.	1.6	247
4025	Systemic therapy for metastatic bladder cancer in 2016 and beyond. <i>Future Oncology</i> , 2016, 12, 1179-1192.	1.1	5
4026	ICOS Expression as Immunologic Marker in Immune Activating Monoclonal Antibodies. <i>Methods in Molecular Biology</i> , 2016, 1393, 133-139.	0.4	2
4027	Improving therapeutic activity of anti-CD20 antibody therapy through immunomodulation in lymphoid malignancies. <i>Leukemia and Lymphoma</i> , 2016, 57, 1269-1280.	0.6	4
4028	Immunological correlates of treatment and response in stage IV malignant melanoma patients treated with Ipilimumab. <i>OncoImmunology</i> , 2016, 5, e1100788.	2.1	73
4029	Novel immunotherapeutic approaches to the treatment of urothelial carcinoma. <i>Therapeutic Advances in Urology</i> , 2016, 8, 203-214.	0.9	9
4030	Severe Hyponatremia and Immune Nephritis Following an Initial Infusion of Nivolumab. <i>Targeted Oncology</i> , 2016, 11, 553-556.	1.7	32
4031	Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy. <i>Annals of Oncology</i> , 2016, 27, 1482-1492.	0.6	765
4032	A New Look at Toxicity in the Era of Precision Oncology: Imaging Findings, Their Relationship With Tumor Response, and Effect on Metastasectomy. <i>American Journal of Roentgenology</i> , 2016, 207, 4-14.	1.0	19
4033	Ipilimumab-induced colitis: A new challenge for gastroenterologists. <i>Gastroenterology & Hepatology (English Edition)</i> , 2016, 39, 233-238.	0.0	1
4034	Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. <i>Nature Reviews Cancer</i> , 2016, 16, 275-287.	12.8	2,133
4035	Immune checkpoint inhibitors in gynecologic cancers with lessons learned from non-gynecologic cancers. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 989-1004.	1.4	10
4036	The role of neoantigens in response to immune checkpoint blockade. <i>International Immunology</i> , 2016, 28, 411-419.	1.8	148
4037	Peptide-Based Cancer Vaccine Strategies and Clinical Results. <i>Methods in Molecular Biology</i> , 2016, 1403, 797-817.	0.4	18

#	ARTICLE	IF	CITATIONS
4038	The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition. <i>Clinical Cancer Research</i> , 2016, 22, 1865-1874.	3.2	700
4039	Emerging Opportunities and Challenges in Cancer Immunotherapy. <i>Clinical Cancer Research</i> , 2016, 22, 1845-1855.	3.2	242
4040	Editorial overview: Special section: New concepts in antibody therapeutics: What's in store for antibody therapy?. <i>Current Opinion in Immunology</i> , 2016, 40, vii-xiii.	2.4	20
4041	Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. <i>European Journal of Cancer</i> , 2016, 60, 190-209.	1.3	546
4042	Cost-Effectiveness of Surgery, Stereotactic Body Radiation Therapy, and Systemic Therapy for Pulmonary Oligometastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 663-672.	0.4	29
4043	Targeted Radionuclide Therapy of Melanoma. <i>Seminars in Nuclear Medicine</i> , 2016, 46, 250-259.	2.5	30
4044	Embracing rejection: Immunologic trends in brain metastasis. <i>Oncolmmunology</i> , 2016, 5, e1172153.	2.1	33
4045	Oncogenic roles and drug target of CXCR4/CXCL12 axis in lung cancer and cancer stem cell. <i>Tumor Biology</i> , 2016, 37, 8515-8528.	0.8	47
4046	Prenylated chalcones and flavonoids for the prevention and treatment of cancer. <i>Nutrition</i> , 2016, 32, 1171-1178.	1.1	149
4047	Programming the immune checkpoint to treat hematologic malignancies. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 755-770.	1.9	11
4048	The Efficacy and Safety of Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors for Advanced Melanoma. <i>Medicine (United States)</i> , 2016, 95, e3134.	0.4	13
4049	Advances in immunotherapy for melanoma. <i>BMC Medicine</i> , 2016, 14, 20.	2.3	111
4050	Advances in systemic delivery of anti-cancer agents for the treatment of metastatic cancer. <i>Expert Opinion on Drug Delivery</i> , 2016, 13, 999-1013.	2.4	6
4051	Proteomic Monitoring of B Cell Immunity. <i>Methods in Molecular Biology</i> , 2016, 1403, 131-152.	0.4	3
4052	Harnessing the immune system for the treatment of melanoma: current status and future prospects. <i>Expert Review of Clinical Immunology</i> , 2016, 12, 879-893.	1.3	8
4053	Minimal C-terminal modification boosts peptide self-assembling ability for necroptosis of cancer cells. <i>Chemical Communications</i> , 2016, 52, 6332-6335.	2.2	30
4054	Pharmacotherapies for the treatment of glioblastoma â€“ current evidence and perspectives. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1259-1270.	0.9	24
4055	Overexpression of Cytotoxic T-Lymphocyteâ€“Associated Antigen-4 Prevents Atherosclerosis in Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 1141-1151.	1.1	71

#	ARTICLE	IF	CITATIONS
4056	Nivolumab-induced thyroid dysfunction. Japanese Journal of Clinical Oncology, 2016, 46, 575-579.	0.6	44
4057	Low density of FOXP3-positive T cells in normal colonic mucosa is related to the presence of beta2-microglobulin mutations in Lynch syndrome-associated colorectal cancer. OncoImmunology, 2016, 5, e1075692.	2.1	28
4058	Regulatory T Cell Modulation by CBP/EP300 Bromodomain Inhibition. Journal of Biological Chemistry, 2016, 291, 13014-13027.	1.6	58
4059	Immune checkpoint inhibition in ovarian cancer. International Immunology, 2016, 28, 339-348.	1.8	122
4060	Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E2383-92.	3.3	185
4061	Cancer cell-derived IL-1 $\hat{\pm}$ induces CCL22 and the recruitment of regulatory T cells. OncoImmunology, 2016, 5, e1175794.	2.1	70
4062	Emerging targeted therapies for melanoma. Expert Opinion on Emerging Drugs, 2016, 21, 195-207.	1.0	22
4063	Future Medicine 2: Cancer Vaccines. , 2016, , 249-284.		0
4064	Cancer immunotherapy: the beginning of the end of cancer?. BMC Medicine, 2016, 14, 73.	2.3	908
4065	Talimogene Laherparepvec for the Treatment of Advanced Melanoma. Clinical Cancer Research, 2016, 22, 3127-3131.	3.2	80
4066	Cost and economic burden of adverse events associated with metastatic melanoma treatments in five countries. Journal of Medical Economics, 2016, 19, 900-912.	1.0	30
4067	Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy. British Journal of Cancer, 2016, 114, 1084-1089.	2.9	113
4068	Real-world efficacy, toxicity and clinical management of ipilimumab treatment in metastatic melanoma. Oncology Letters, 2016, 11, 1581-1585.	0.8	34
4069	Targeting Glycans for Immunotherapy of Human Cancers. , 2016, , 197-219.		0
4070	Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nature Reviews Clinical Oncology, 2016, 13, 473-486.	12.5	831
4071	Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers. Human Vaccines and Immunotherapeutics, 2016, 12, 2219-2231.	1.4	49
4072	Acquired Resistance to Clinical Cancer Therapy: A Twist in Physiological Signaling. Physiological Reviews, 2016, 96, 805-829.	13.1	49
4073	A network meta-analysis of the risk of immune-related renal toxicity in cancer patients treated with immune checkpoint inhibitors. Immunotherapy, 2016, 8, 665-674.	1.0	39

#	ARTICLE	IF	CITATIONS
4074	Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors. <i>Immunotherapy</i> , 2016, 8, 583-600.	1.0	71
4075	The safety and efficacy of nivolumab for the treatment of advanced renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 577-584.	1.1	12
4076	Recent developments in the use of immunotherapy in non-small cell lung cancer. <i>Expert Review of Respiratory Medicine</i> , 2016, 10, 781-798.	1.0	29
4077	HLA ligandomics identifies histone deacetylase 1 as target for ovarian cancer immunotherapy. <i>Oncolmmunology</i> , 2016, 5, e1065369.	2.1	18
4078	Primary mucosal melanoma of the oral cavity: current therapy and future directions. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2016, 122, 17-27.	0.2	27
4079	Personalized Oncology Meets Immunology: The Path toward Precision Immunotherapy. <i>Cancer Discovery</i> , 2016, 6, 703-713.	7.7	92
4080	Tumor control with PD-1 inhibition in a patient with concurrent metastatic melanoma and renal cell carcinoma. , 2016, 4, 26.		10
4083	Roles of regulatory T cells in cancer immunity. <i>International Immunology</i> , 2016, 28, 401-409.	1.8	412
4084	Heterologous Vaccination and Checkpoint Blockade Synergize To Induce Antileukemia Immunity. <i>Journal of Immunology</i> , 2016, 196, 4793-4804.	0.4	10
4085	Linking the Price of Cancer Drug Treatments to Their Clinical Value. <i>Clinical Drug Investigation</i> , 2016, 36, 579-589.	1.1	5
4086	Current Challenges in Cancer Treatment. <i>Clinical Therapeutics</i> , 2016, 38, 1551-1566.	1.1	549
4087	Targeting Carcinoembryonic Antigen with DNA Vaccination: On-Target Adverse Events Link with Immunologic and Clinical Outcomes. <i>Clinical Cancer Research</i> , 2016, 22, 4827-4836.	3.2	24
4088	The future of immunotherapy for sarcoma. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 1049-1057.	1.4	21
4089	TG4010: a vaccine with a therapeutic role in cancer. <i>Immunotherapy</i> , 2016, 8, 511-519.	1.0	14
4090	The integration of radiation therapy and immunotherapy in melanoma management. <i>Journal of Radiation Oncology</i> , 2016, 5, 131-142.	0.7	2
4091	Zebrafish Melanoma. <i>Advances in Experimental Medicine and Biology</i> , 2016, 916, 439-450.	0.8	10
4092	Intraocular Inflammation Associated with New Therapies for Cutaneous Melanoma – Case Series and Review. <i>Klinische Monatsblätter Fur Augenheilkunde</i> , 2016, 233, 540-544.	0.3	43
4093	The emerging role of immunotherapy in gastric and esophageal adenocarcinoma. <i>Future Oncology</i> , 2016, 12, 1833-1846.	1.1	16

#	ARTICLE	IF	CITATIONS
4094	Genetics of Melanoma. , 2016, , .		3
4095	Timing of CSF-1/CSF-1R signaling blockade is critical to improving responses to CTLA-4 based immunotherapy. <i>Oncolmmunology</i> , 2016, 5, e1151595.	2.1	57
4096	Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab. <i>Clinical Cancer Research</i> , 2016, 22, 4848-4858.	3.2	146
4097	Role of Immunity in Pathogenesis and Treatment of Hepatocellular Carcinoma. <i>Digestive Diseases</i> , 2016, 34, 429-437.	0.8	21
4098	Biology and treatment of BRAF mutant metastatic melanoma. <i>Melanoma Management</i> , 2016, 3, 33-45.	0.1	28
4099	Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. <i>Blood</i> , 2016, 128, 384-394.	0.6	697
4100	CHAI and LATAIE: new genetic diseases of CTLA-4 checkpoint insufficiency. <i>Blood</i> , 2016, 128, 1037-1042.	0.6	124
4101	Perspectives for immunotherapy in endocrine cancer. <i>Endocrine-Related Cancer</i> , 2016, 23, R469-R484.	1.6	12
4102	Autoimmune meningoencephalitis in a melanoma patient treated with ipilimumab. <i>Immunotherapy</i> , 2016, 8, 1163-1167.	1.0	9
4103	Ipilimumab plus nivolumab for advanced melanoma. <i>Lancet Oncology</i> , The, 2016, 17, 1471-1472.	5.1	20
4104	Ipilimumab after progression on anti-PD-1 treatment in advanced melanoma. <i>Future Oncology</i> , 2016, 12, 2683-2688.	1.1	17
4105	Clinical significance of [18F]-fluoro-deoxy-glucose positron emission tomography/computed tomography in patients with primary malignant melanoma of the esophagus: report of three cases. <i>Esophagus</i> , 2016, 13, 311-316.	1.0	1
4106	Melanomas prevent endothelial cell death under restrictive culture conditions by signaling through AKT and p38 MAPK/ ERK-1/2 cascades. <i>Oncolmmunology</i> , 2016, 5, e1219826.	2.1	9
4107	Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance. <i>Nature Genetics</i> , 2016, 48, 1131-1141.	9.4	332
4108	Genetic predisposition to melanoma. <i>Seminars in Oncology</i> , 2016, 43, 591-597.	0.8	39
4109	Phenotypic and functional testing of circulating regulatory T cells in advanced melanoma patients treated with neoadjuvant ipilimumab. , 2016, 4, 38.		22
4110	Systemic treatment for advanced hepatocellular carcinoma: the search of new agents to join sorafenib in the effective therapeutic armamentarium. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1923-1936.	0.9	15
4112	Reevaluating stereotactic radiosurgery for glioblastoma: new potential for targeted dose-escalation. <i>Journal of Neuro-Oncology</i> , 2016, 130, 397-411.	1.4	11

#	ARTICLE	IF	CITATIONS
4113	CTLA4 blockade elicits paraneoplastic neurological disease in a mouse model. <i>Brain</i> , 2016, 139, 2923-2934.	3.7	93
4114	Microbiotaâ€™ myeloid cell crosstalk beyond the gut. <i>Journal of Leukocyte Biology</i> , 2016, 100, 865-879.	1.5	76
4115	Cutaneous sarcoidosis in a melanoma patient under Ipilimumab therapy. <i>Dermatologic Therapy</i> , 2016, 29, 306-308.	0.8	26
4116	Immune phenotypes of prostate cancer cells: Evidence of epithelial immune cell-like transition?. <i>Asian Journal of Urology</i> , 2016, 3, 195-202.	0.5	12
4117	CD200R, a co-inhibitory receptor on immune cells, predicts the prognosis of human hepatocellular carcinoma. <i>Immunology Letters</i> , 2016, 178, 105-113.	1.1	10
4118	Isolated asymptomatic masseter muscle metastasis as first sign of metastatic disease in a patient with known melanoma. <i>JPRAS Open</i> , 2016, 10, 1-4.	0.4	1
4119	Biomarkers in Melanoma: Lessons from Translational Medicine. <i>Trends in Cancer</i> , 2016, 2, 305-312.	3.8	11
4121	Novel immunotherapy approaches for metastatic urothelial and renal cell carcinoma. <i>Asian Journal of Urology</i> , 2016, 3, 268-277.	0.5	4
4122	T cell exhaustion and immune-mediated diseaseâ€™the potential for therapeutic exhaustion. <i>Current Opinion in Immunology</i> , 2016, 43, 74-80.	2.4	66
4123	Inmunoterapia del melanoma. <i>Piel</i> , 2016, 31, 649-656.	0.0	0
4124	Recurrent SERPINB3 and SERPINB4 mutations in patients who respond to anti-CTLA4 immunotherapy. <i>Nature Genetics</i> , 2016, 48, 1327-1329.	9.4	115
4125	A case report of Groverâ€™s disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1. , 2016, 4, 55.		50
4126	Adjuvants for peptide-based cancer vaccines. , 2016, 4, 56.		126
4128	Suppression of inducible CD4 regulatory cells by MHC class I-restricted human tumor epitope specific TCR engineered multifunctional CD4 T cells. <i>Human Immunology</i> , 2016, 77, 905-911.	1.2	1
4129	Immunotherapy of Melanoma. <i>Oncology Research and Treatment</i> , 2016, 39, 369-376.	0.8	14
4130	The full blood count as a biomarker of outcome and toxicity in ipilimumabâ€™treated cutaneous metastatic melanoma. <i>Cancer Medicine</i> , 2016, 5, 2792-2799.	1.3	72
4132	Identification of Small Novel Coding Sequences, a Proteogenomics Endeavor. <i>Advances in Experimental Medicine and Biology</i> , 2016, 926, 49-64.	0.8	14
4133	Plasma Cell Dyscrasias. <i>Cancer Treatment and Research</i> , 2016, , .	0.2	3

#	ARTICLE	IF	CITATIONS
4134	The genomic landscape of breast cancer and its interaction with host immunity. <i>Breast</i> , 2016, 29, 241-250.	0.9	194
4135	Role of the Immune Response in Disease Progression and Therapy in Multiple Myeloma. <i>Cancer Treatment and Research</i> , 2016, 169, 207-225.	0.2	20
4136	Immunotherapy in breast cancer: An overview of modern checkpoint blockade strategies and vaccines. <i>Current Problems in Cancer</i> , 2016, 40, 151-162.	1.0	18
4137	Developing immunotherapy strategies in the treatment of prostate cancer. <i>Asian Journal of Urology</i> , 2016, 3, 278-285.	0.5	11
4138	Relevance of serum biomarkers associated with melanoma during follow-up of anti-CTLA-4 immunotherapy. <i>International Immunopharmacology</i> , 2016, 40, 466-473.	1.7	25
4139	Coming-of-Age of Antibodies in Cancer Therapeutics. <i>Trends in Pharmacological Sciences</i> , 2016, 37, 1009-1028.	4.0	89
4141	Immunotherapy for Lung Cancer: No Longer an Abstract Concept. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2016, 37, 771-782.	0.8	12
4142	LAG-3 confers poor prognosis and its blockade reshapes antitumor response in head and neck squamous cell carcinoma. <i>OncImmunology</i> , 2016, 5, e1239005.	2.1	108
4143	Patterns of response to anti-PD-1 treatment: an exploratory comparison of four radiological response criteria and associations with overall survival in metastatic melanoma patients. <i>British Journal of Cancer</i> , 2016, 115, 1186-1192.	2.9	50
4144	Approaches for targeting cancer stem cells drug resistance. <i>Expert Opinion on Drug Discovery</i> , 2016, 11, 1201-1212.	2.5	38
4145	Checkpoint-Inhibitoren in der Immuntherapie: Ein Meilenstein in der Behandlung des malignen Melanoms. <i>JDDG - Journal of the German Society of Dermatology</i> , 2016, 14, 685-697.	0.4	6
4146	Genomic Approaches to Understanding Response and Resistance to Immunotherapy. <i>Clinical Cancer Research</i> , 2016, 22, 5642-5650.	3.2	134
4147	Costimulatory and coinhibitory immune checkpoint receptors in head and neck cancer: unleashing immune responses through therapeutic combinations. <i>Cancers of the Head & Neck</i> , 2016, 1, 12.	6.2	17
4148	Immune checkpoint inhibitors: a new class of anticancer drug. <i>The Prescriber</i> , 2016, 27, 23-28.	0.1	1
4149	Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series. <i>British Journal of Cancer</i> , 2016, 115, 1280-1284.	2.9	36
4150	Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 11919-11924.	3.3	197
4151	Adult Cancers in Adolescents and Young Adults. <i>Progress in Tumor Research</i> , 2016, 43, 64-73.	0.1	3
4152	Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 1533-1544.	2.0	89

#	ARTICLE	IF	CITATIONS
4153	Pediatric melanoma. <i>Seminars in Pediatric Surgery</i> , 2016, 25, 290-298.	0.5	25
4154	Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. <i>New England Journal of Medicine</i> , 2016, 375, 1845-1855.	13.9	1,140
4155	The future of melanoma therapy: developing new drugs and improving the use of old ones. <i>Future Oncology</i> , 2016, 12, 2531-2534.	1.1	7
4156	Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 4102-4109.	0.8	528
4157	Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy. <i>Cancer Discovery</i> , 2016, 6, 1090-1105.	7.7	217
4158	Genomic insights into head and neck cancer. <i>Cancers of the Head & Neck</i> , 2016, 1, .	6.2	65
4159	Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy. <i>Journal of Clinical Oncology</i> , 2016, 4, 53.		278
4160	Melanoma: Kids are not just little people. <i>Clinics in Dermatology</i> , 2016, 34, 742-748.	0.8	12
4161	Rapid and objective CT scan prognostic scoring identifies metastatic patients with long-term clinical benefit on anti-PD-1/L1 therapy. <i>European Journal of Cancer</i> , 2016, 65, 33-42.	1.3	58
4162	Antibody Therapy Targeting CD47 and CD271 Effectively Suppresses Melanoma Metastasis in Patient-Derived Xenografts. <i>Cell Reports</i> , 2016, 16, 1701-1716.	2.9	56
4163	Olaratumab – really a breakthrough for soft-tissue sarcomas?. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 534-536.	12.5	8
4164	Circulating Tumor DNA as an Early Indicator of Response to T-cell Transfer Immunotherapy in Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2016, 22, 5480-5486.	3.2	84
4165	Genomics- and Transcriptomics-Based Patient Selection for Cancer Treatment With Immune Checkpoint Inhibitors. <i>JAMA Oncology</i> , 2016, 2, 1490.	3.4	68
4166	CD4+FOXP3+ T regulatory cells decrease and CD3+CD8+ T cells recruitment in TILs from melanoma metastases after electrochemotherapy. <i>Clinical and Experimental Metastasis</i> , 2016, 33, 787-798.	1.7	29
4167	Metastatic melanoma and immunotherapy. <i>Clinical Immunology</i> , 2016, 172, 105-110.	1.4	43
4168	Emerging biological therapies for the treatment of myelodysplastic syndromes. <i>Expert Opinion on Emerging Drugs</i> , 2016, 21, 283-300.	1.0	15
4170	Cancer treatment and survivorship statistics, 2016. <i>CA: A Cancer Journal for Clinicians</i> , 2016, 66, 271-289.	157.7	4,123
4171	Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma. <i>Head and Neck</i> , 2016, 38, 1752-1758.	0.9	49

#	ARTICLE	IF	CITATIONS
4172	Treatment outcome of PD-1 immune checkpoint inhibitor in Asian metastatic melanoma patients: correlative analysis with PD-L1 immunohistochemistry. <i>Investigational New Drugs</i> , 2016, 34, 677-684.	1.2	30
4173	Neurologic Complications of Oncologic Therapy. , 2016, , 125-142.		1
4174	The Spectrum of Serious Infections Among Patients Receiving Immune Checkpoint Blockade for the Treatment of Melanoma. <i>Clinical Infectious Diseases</i> , 2016, 63, 1490-1493.	2.9	226
4175	The Future of Immunotherapy in the Treatment of Small Cell Lung Cancer. <i>Oncologist</i> , 2016, 21, 910-921.	1.9	58
4176	The Role of Molecular Diagnostics in the Management of Patients with Gliomas. <i>Current Treatment Options in Oncology</i> , 2016, 17, 51.	1.3	32
4177	Inflammation and cancer: tissue regeneration gone awry. <i>Current Opinion in Cell Biology</i> , 2016, 43, 55-61.	2.6	110
4178	The Future of Precision Medicine in Oncology. <i>Clinics in Laboratory Medicine</i> , 2016, 36, 557-573.	0.7	39
4179	Glioblastoma multiforme targeted therapy: The Chlorotoxin story. <i>Journal of Clinical Neuroscience</i> , 2016, 33, 52-58.	0.8	59
4180	Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents. <i>Oncologist</i> , 2016, 21, 1230-1240.	1.9	212
4181	Mechanisms of immune evasion and current status of checkpoint inhibitors in non-small cell lung cancer. <i>Cancer Medicine</i> , 2016, 5, 2567-2578.	1.3	56
4182	Real-world treatment practice in patients with advanced melanoma in the era before ipilimumab: results from the <sc>IMAGE</sc> study. <i>Cancer Medicine</i> , 2016, 5, 1436-1443.	1.3	14
4183	Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta-analysis of anti-CTLA-4 and anti-PD-1 agents trials. <i>Cancer Medicine</i> , 2016, 5, 1481-1491.	1.3	86
4184	Inflammation and Metastasis. , 2016, , .		4
4185	Purity of transferred CD8 ⁺ T cells is crucial for safety and efficacy of combinatorial tumor immunotherapy in the absence of SHP-1. <i>Immunology and Cell Biology</i> , 2016, 94, 802-808.	1.0	18
4186	Still waters run deep: latent cytokine activity in nonlesional psoriasis skin. <i>British Journal of Dermatology</i> , 2016, 174, 19-20.	1.4	0
4187	Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti-cancer antibodies: IUPHAR Review 18. <i>British Journal of Pharmacology</i> , 2016, 173, 1407-1424.	2.7	56
4188	Therapeutic implications of melanoma heterogeneity. <i>Experimental Dermatology</i> , 2016, 25, 497-500.	1.4	28
4189	The immune system and cancer evasion strategies: therapeutic concepts. <i>Journal of Internal Medicine</i> , 2016, 279, 541-562.	2.7	212

#	ARTICLE	IF	CITATIONS
4190	PD-1 Pathway Inhibitors: Immunotherapy Agents for Restoring Antitumor Immune Responses. <i>Pharmacotherapy</i> , 2016, 36, 317-334.	1.2	82
4191	Checkpoint Inhibitors in Kidney Transplant Recipients and the Potential Risk of Rejection. <i>American Journal of Transplantation</i> , 2016, 16, 1332-1333.	2.6	110
4192	Letter: cytomegalovirus colitis in a patient treated with ipilimumab for metastatic melanoma. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 174-175.	1.9	5
4193	High neutrophil to lymphocyte ratio measured before starting ipilimumab treatment is associated with reduced overall survival in patients with melanoma. <i>British Journal of Dermatology</i> , 2016, 174, 146-151.	1.4	132
4194	Prognostic and predictive biomarkers for the benefit of immunotherapy in patients with metastatic melanoma. <i>British Journal of Dermatology</i> , 2016, 174, 20-20.	1.4	0
4195	Importance of immunopharmacogenomics in cancer treatment: Patient selection and monitoring for immune checkpoint antibodies. <i>Cancer Science</i> , 2016, 107, 107-115.	1.7	28
4197	Biomarkers in melanoma. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2016, 76, S104-S112.	0.6	8
4198	Fine-Tuning Cancer Immunotherapy: Optimizing the Gut Microbiome. <i>Cancer Research</i> , 2016, 76, 4602-4607.	0.4	92
4199	Fractal and multifractal analysis of PET/CT images of metastatic melanoma before and after treatment with ipilimumab. <i>EJNMMI Research</i> , 2016, 6, 61.	1.1	29
4200	Evolving Immunotherapy Approaches for Renal Cell Carcinoma. <i>Current Oncology Reports</i> , 2016, 18, 57.	1.8	24
4201	A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling. <i>Clinical Cancer Research</i> , 2016, 22, 5729-5737.	3.2	175
4202	VEGF Neutralization Plus CTLA-4 Blockade Alters Soluble and Cellular Factors Associated with Enhancing Lymphocyte Infiltration and Humoral Recognition in Melanoma. <i>Cancer Immunology Research</i> , 2016, 4, 858-868.	1.6	73
4203	Combination or single-agent ipilimumab as immunotherapy of advanced melanoma: a critical review. <i>Melanoma Management</i> , 2016, 3, 231-243.	0.1	4
4204	Rare phenotypes in the understanding of autoimmunity. <i>Immunology and Cell Biology</i> , 2016, 94, 943-948.	1.0	2
4205	Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. , 2016, 4, 50.		413
4206	Trends in melanoma in the elderly in Denmark, 1980-2012. <i>Acta Oncologica</i> , 2016, 55, 52-58.	0.8	6
4208	Ipilimumab-related hypophysitis may precede severe CNS immune attack. <i>Annals of Oncology</i> , 2016, 27, 1975-1976.	0.6	6
4209	Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT). <i>Annals of Oncology</i> , 2016, 27, 1947.	0.6	21

#	ARTICLE	IF	CITATIONS
4210	Tolerability of immune checkpoint inhibition cancer therapy in a cardiac transplant patient. <i>Annals of Oncology</i> , 2016, 27, 2304-2305.	0.6	19
4211	Tumor Mutational Load and Immune Parameters across Metastatic Renal Cell Carcinoma Risk Groups. <i>Cancer Immunology Research</i> , 2016, 4, 820-822.	1.6	63
4212	Epithelial-to-mesenchymal plasticity of cancer stem cells: therapeutic targets in hepatocellular carcinoma. <i>Journal of Hematology and Oncology</i> , 2016, 9, 74.	6.9	146
4213	Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody. , 2016, 4, 36.		90
4214	Deep Sequencing of T-cell Receptor DNA as a Biomarker of Clonally Expanded TILs in Breast Cancer after Immunotherapy. <i>Cancer Immunology Research</i> , 2016, 4, 835-844.	1.6	138
4215	Methods to Evaluate the Antitumor Activity of Immune Checkpoint Inhibitors in Preclinical Studies. <i>Methods in Molecular Biology</i> , 2016, 1458, 159-177.	0.4	7
4216	Current Progress in Immunotherapy for the Treatment of Biliary Cancers. <i>Journal of Gastrointestinal Cancer</i> , 2016, 47, 351-357.	0.6	8
4217	A Prospective Clinical Trial Combining Radiation Therapy With Systemic Immunotherapy in Metastatic Melanoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 578-588.	0.4	190
4218	New insights in melanoma biomarkers: long-noncoding RNAs. <i>Melanoma Management</i> , 2016, 3, 195-205.	0.1	0
4219	Chorioretinal Lesions in a Case of Melanoma-Associated Retinopathy Treated With Pembrolizumab. <i>JAMA Ophthalmology</i> , 2016, 134, 1184.	1.4	43
4220	State of the science on prevention and screening to reduce melanoma incidence and mortality: The time is now. <i>Ca-A Cancer Journal for Clinicians</i> , 2016, 66, 460-480.	157.7	140
4221	Crosstalk in skin: melanocytes, keratinocytes, stem cells, and melanoma. <i>Journal of Cell Communication and Signaling</i> , 2016, 10, 191-196.	1.8	49
4222	Stereotactic ablative radiotherapy and immunotherapy combinations: turning the future into systemic therapy?. <i>British Journal of Radiology</i> , 2016, 89, 20160472.	1.0	32
4223	Enhanced expression of PD-L1 in oral squamous cell carcinoma-derived CD11b + Gr-1 + cells and its contribution to immunosuppressive activity. <i>Oral Oncology</i> , 2016, 59, 20-29.	0.8	23
4224	Cancer Immunotherapy by Checkpoint Blockade. , 2016, , 561-580.		2
4225	Sequencing of New and Old Therapies for Metastatic Melanoma. <i>Current Treatment Options in Oncology</i> , 2016, 17, 52.	1.3	7
4226	Use of LDH and autoimmune side effects to predict response to ipilimumab treatment. <i>Immunotherapy</i> , 2016, 8, 1033-1044.	1.0	47
4227	Immune modulation by hypofractionated stereotactic radiation therapy: Therapeutic implications. <i>Radiotherapy and Oncology</i> , 2016, 120, 185-194.	0.3	99

#	ARTICLE	IF	CITATIONS
4228	Analysis of the Expression and Single-Nucleotide Variant Frequencies of the Butyrophilin-like 2 Gene in Patients With Uveal Melanoma. <i>JAMA Ophthalmology</i> , 2016, 134, 1125.	1.4	7
4229	Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. <i>Cancer</i> , 2016, 122, 3344-3353.	2.0	288
4230	PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course. <i>Clinical Cancer Research</i> , 2016, 22, 6051-6060.	3.2	393
4231	Immunotherapy in Lung Cancer. <i>Cancer Treatment and Research</i> , 2016, 170, 203-223.	0.2	8
4232	Regulation of myeloid cells by activated T cells determines the efficacy of PD-1 blockade. <i>OncImmunology</i> , 2016, 5, e1232222.	2.1	48
4233	Emerging role of immunotherapy in urothelial carcinoma-Advanced disease. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 538-547.	0.8	41
4234	Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy. , 2016, 4, 72.		156
4235	Direct identification of clinically relevant neopeptides presented on native human melanoma tissue by mass spectrometry. <i>Nature Communications</i> , 2016, 7, 13404.	5.8	613
4236	Combinational Immunotherapy with Allo-DRIbble Vaccines and Anti-OX40 Co-Stimulation Leads to Generation of Cross-Reactive Effector T Cells and Tumor Regression. <i>Scientific Reports</i> , 2016, 6, 37558.	1.6	28
4237	Regeneration of CD8 ⁺ T Cells from T-cell-Derived iPSC Imparts Potent Tumor Antigen-Specific Cytotoxicity. <i>Cancer Research</i> , 2016, 76, 6839-6850.	0.4	93
4238	Validation of biomarkers to predict response to immunotherapy in cancer: Volume II - clinical validation and regulatory considerations. , 2016, 4, 77.		87
4239	Robust Ki67 detection in human blood by flow cytometry for clinical studies. <i>Bioanalysis</i> , 2016, 8, 2399-2413.	0.6	11
4240	Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: Where do we stand? A literature review. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 108, 164-174.	2.0	134
4241	Transcriptional Landscape of Human Tissue Lymphocytes Unveils Uniqueness of Tumor-Infiltrating T Regulatory Cells. <i>Immunity</i> , 2016, 45, 1135-1147.	6.6	510
4242	Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. <i>Nature Communications</i> , 2016, 7, 12632.	5.8	648
4243	Does clinical trial participation improve outcomes in patients with ovarian cancer?. <i>ESMO Open</i> , 2016, 1, e000057.	2.0	9
4247	Nivolumab-induced hypophysitis in a patient with advanced malignant melanoma. <i>Endocrine Journal</i> , 2016, 63, 905-912.	0.7	98
4248	Molecular Pathways: Targeting CD96 and TIGIT for Cancer Immunotherapy. <i>Clinical Cancer Research</i> , 2016, 22, 5183-5188.	3.2	171

#	ARTICLE	IF	CITATIONS
4249	Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1558-1568.	5.1	827
4250	Principles of Chemotherapy. , 2016, , 171-185.e2.		0
4251	Vaccination with trifunctional nanoparticles that address CD8+dendritic cells inhibits growth of established melanoma. <i>Nanomedicine</i> , 2016, 11, 2647-2662.	1.7	19
4252	Immunological effects of the anti-programmed death-1 antibody on human peripheral blood mononuclear cells. <i>International Journal of Oncology</i> , 2016, 49, 1099-1107.	1.4	17
4253	Immunotherapy for prostate cancer: False promises or true hope?. <i>Cancer</i> , 2016, 122, 3598-3607.	2.0	22
4254	Current management and future directions in metastatic pancreatic adenocarcinoma. <i>Cancer</i> , 2016, 122, 3765-3775.	2.0	18
4255	Cutaneous Complications of Targeted Melanoma Therapy. <i>Current Treatment Options in Oncology</i> , 2016, 17, 57.	1.3	62
4256	Clinical Prognostic Markers in Stage IIIB Melanoma. <i>Annals of Surgical Oncology</i> , 2016, 23, 4195-4202.	0.7	4
4257	Loss of IFN- γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy. <i>Cell</i> , 2016, 167, 397-404.e9.	13.5	1,009
4258	Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient. <i>European Journal of Cancer</i> , 2016, 67, 66-72.	1.3	90
4259	Cytoreductive surgery for head and neck squamous cell carcinoma in the new age of immunotherapy. <i>Oral Oncology</i> , 2016, 61, 166-176.	0.8	11
4260	Intralesional and systemic immunotherapy for metastatic melanoma. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 1491-1499.	1.4	15
4261	Melanoma central nervous system metastases: current approaches, challenges, and opportunities. <i>Pigment Cell and Melanoma Research</i> , 2016, 29, 627-642.	1.5	102
4262	Complete response to nivolumab monotherapy in a treatment-naive, BRAF wild-type patient with advanced mucosal melanoma and elevated lactate dehydrogenase: a case report from a phase III trial. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 1395-1400.	2.0	18
4263	Sneaky side effects and ineffectiveness of an immunotherapy with ipilimumab in a case of metastatic melanoma. <i>Dermato-Endocrinology</i> , 2016, 8, e1199307.	1.9	4
4264	Expression and prognostic impact of immune modulatory molecule PD-L1 in meningioma. <i>Journal of Neuro-Oncology</i> , 2016, 130, 543-552.	1.4	90
4265	Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 3740-3748.	0.8	438
4266	PD-L1 expression is associated with advanced non-small cell lung cancer. <i>Oncology Letters</i> , 2016, 12, 921-927.	0.8	18

#	ARTICLE	IF	CITATIONS
4267	Advances in immunotherapy for melanoma management. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 2501-2511.	1.4	15
4268	Immunotherapy and Novel Combinations in Oncology: Current Landscape, Challenges, and Opportunities. <i>Clinical and Translational Science</i> , 2016, 9, 89-104.	1.5	144
4269	Serum-derived exosomes from mice with highly metastatic breast cancer transfer increased metastatic capacity to a poorly metastatic tumor. <i>Cancer Medicine</i> , 2016, 5, 325-336.	1.3	22
4270	Local Tumor Treatment in Combination with Systemic Ipilimumab Immunotherapy Prolongs Overall Survival in Patients with Advanced Malignant Melanoma. <i>Cancer Immunology Research</i> , 2016, 4, 744-754.	1.6	131
4271	Autoimmune-like drug-induced liver injury: a review and update for the clinician. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 1291-1301.	1.5	24
4272	Emerging biomarkers as predictors to anti-PD1/PD-L1 therapies in advanced melanoma. <i>Immunotherapy</i> , 2016, 8, 775-784.	1.0	24
4273	Group sequential monitoring based on the weighted log-rank test statistic with the Fleming-Harrington class of weights in cancer vaccine studies. <i>Pharmaceutical Statistics</i> , 2016, 15, 412-419.	0.7	21
4274	Personalized Immunotherapy Targeting the Cancer Mutanome. , 2016, , 426-433.		1
4275	Checkpoint inhibitors for renal cell carcinoma: current landscape and future directions. <i>Immunotherapy</i> , 2016, 8, 785-798.	1.0	7
4276	Cellular immunotherapy for malignant gliomas. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 1265-1275.	1.4	37
4277	Peptide vaccination therapy: Towards the next generation. <i>Pathology International</i> , 2016, 66, 547-553.	0.6	16
4278	Immune checkpoint inhibitors: a milestone in the treatment of melanoma. <i>JDDG - Journal of the German Society of Dermatology</i> , 2016, 14, 685-695.	0.4	15
4279	Therapeutic Vaccination against A Modified Minimal Survivin Epitope Induces Functional CD4 T Cells That Recognize Survivin-Expressing Cells. <i>Scandinavian Journal of Immunology</i> , 2016, 84, 191-193.	1.3	7
4280	Molecular Pathways: Immune Checkpoint Antibodies and their Toxicities. <i>Clinical Cancer Research</i> , 2016, 22, 4550-4555.	3.2	73
4281	Ipilimumab in melanoma. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 811-826.	1.1	26
4282	Identification of a Natural Killer Cell Receptor Allele That Prolongs Survival of Cytomegalovirus-Positive Glioblastoma Patients. <i>Cancer Research</i> , 2016, 76, 5326-5336.	0.4	26
4284	Recent advances and future of immunotherapy for glioblastoma. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 1245-1264.	1.4	57
4285	Management of side effects of immune checkpoint blockade by anti-CTLA4 and anti-PD1 antibodies in metastatic melanoma. <i>JDDG - Journal of the German Society of Dermatology</i> , 2016, 14, 662-681.	0.4	63

#	ARTICLE	IF	CITATIONS
4286	Nebenwirkungsmanagement bei Immun-Checkpoint-Blockade durch CTLA-4- und PD-1-Antikörper beim metastasierten Melanom. JDDG - Journal of the German Society of Dermatology, 2016, 14, 662-683.	0.4	47
4287	Optimal design and endpoint of clinical trials using immune checkpoint blocking agents. Expert Review of Anticancer Therapy, 2016, 16, 1217-1218.	1.1	2
4288	Sample Size and Power of Survival Trials in Group Sequential Design With Delayed Treatment Effect. Statistics in Biopharmaceutical Research, 2016, 8, 268-275.	0.6	7
4289	Anti-GITR therapy promotes immunity against malignant glioma in a murine model. Cancer Immunology, Immunotherapy, 2016, 65, 1555-1567.	2.0	33
4290	Adoptive immunotherapy for hematological malignancies: Current status and new insights in chimeric antigen receptor T cells. Blood Cells, Molecules, and Diseases, 2016, 62, 49-63.	0.6	34
4291	Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors. BioDrugs, 2016, 30, 571-584.	2.2	93
4292	Talimogene laherparepvec: overview, combination therapy and current practices. Melanoma Management, 2016, 3, 267-272.	0.1	8
4293	One microenvironment does not fit all: heterogeneity beyond cancer cells. Cancer and Metastasis Reviews, 2016, 35, 601-629.	2.7	58
4294	Cytotoxic T Cells in PD-L1-Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors. Cancer Immunology Research, 2016, 4, 1038-1048.	1.6	62
4295	Emerging Strategies for Developing Next-Generation Protein Therapeutics for Cancer Treatment. Trends in Pharmacological Sciences, 2016, 37, 993-1008.	4.0	156
4296	The Treatment of Melanoma Brain Metastases. Current Oncology Reports, 2016, 18, 73.	1.8	16
4297	Combination approaches in NSCLC involving immune checkpoint inhibitors. Lung Cancer Management, 2016, 5, 163-171.	1.5	1
4298	A phase I trial of panobinostat (LBH589) in patients with metastatic melanoma. Cancer Medicine, 2016, 5, 3041-3050.	1.3	51
4299	Emerging role of immunotherapy in urothelial carcinoma: Immunobiology/biomarkers. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 556-565.	0.8	23
4300	PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Science Translational Medicine, 2016, 8, 328rv4.	5.8	1,844
4301	Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses. Nature Medicine, 2016, 22, 1402-1410.	15.2	437
4305	Adenovirus vector carrying REIC/DKK-3 gene: neoadjuvant intraprostatic injection for high-risk localized prostate cancer undergoing radical prostatectomy. Cancer Gene Therapy, 2016, 23, 400-409.	2.2	28
4306	Interdependent IL-7 and IFN- γ signalling in T-cell controls tumour eradication by combined CTLA-4+PD-1 therapy. Nature Communications, 2016, 7, 12335.	5.8	93

#	ARTICLE	IF	CITATIONS
4307	Talimogene laherparepvec (T-Vec) for the treatment of melanoma and other cancers. <i>Seminars in Oncology</i> , 2016, 43, 638-646.	0.8	45
4308	Network Meta-analysis of Progression-Free Survival and Overall Survival in First-Line Treatment of BRAF Mutation-Positive Metastatic Melanoma. <i>Oncology and Therapy</i> , 2016, 4, 239-256.	1.0	8
4309	Adjuvant ipilimumab in stage III melanoma: New landscape, new questions. <i>European Journal of Cancer</i> , 2016, 69, 39-42.	1.3	15
4310	Clinical implication of tumor-associated and immunological parameters in melanoma patients treated with ipilimumab. <i>Oncolmmunology</i> , 2016, 5, e1249559.	2.1	51
4311	Fine needle aspirate flow cytometric phenotyping characterizes immunosuppressive nature of the mesothelioma microenvironment. <i>Scientific Reports</i> , 2016, 6, 31745.	1.6	22
4312	Immune response and long-term clinical outcome in advanced melanoma patients vaccinated with tumor-mRNA-transfected dendritic cells. <i>Oncolmmunology</i> , 2016, 5, e1232237.	2.1	38
4313	The tumor microenvironment disarms CD8 ⁺ T lymphocyte function via a miR-26a-EZH2 axis. <i>Oncolmmunology</i> , 2016, 5, e1245267.	2.1	15
4314	Recent Development in Methodology for Gene Network Problems and Inferences. , 2016, , 1-29.		0
4315	Brain Metastases From Melanoma: Therapy at the Crossroads. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 713-716.	0.4	4
4316	In Silico Aptamer Docking Studies: From a Retrospective Validation to a Prospective Case Study/TIM3 Aptamers Binding. <i>Molecular Therapy - Nucleic Acids</i> , 2016, 5, e376.	2.3	40
4317	Drug Combinations as the New Standard for Melanoma Treatment. <i>Current Treatment Options in Oncology</i> , 2016, 17, 61.	1.3	16
4318	Immune checkpoint inhibitors for cancer treatment. <i>Archives of Pharmacal Research</i> , 2016, 39, 1577-1587.	2.7	43
4319	Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy. <i>Nature Communications</i> , 2016, 7, 13354.	5.8	224
4320	The Development of Systemic Therapies for Esophageal and Gastric Cancers. , 2016, , 153-170.		0
4321	Systemic Therapy for Metastatic Colorectal Cancer. , 2016, , 275-338.		0
4322	Approaches to modernize the combination drug development paradigm. <i>Genome Medicine</i> , 2016, 8, 115.	3.6	64
4323	Immunoglobulin Glycosylation Effects in Allergy and Immunity. <i>Current Allergy and Asthma Reports</i> , 2016, 16, 79.	2.4	34
4324	Fulminant Myocarditis with Combination Immune Checkpoint Blockade. <i>New England Journal of Medicine</i> , 2016, 375, 1749-1755.	13.9	1,668

#	ARTICLE	IF	CITATIONS
4325	Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway. <i>New England Journal of Medicine</i> , 2016, 375, 1767-1778.	13.9	1,025
4327	Imaging Biomarkers in Immunotherapy. <i>Biomarkers in Cancer</i> , 2016, 8s2, BIC.S31805.	3.6	31
4328	Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer. <i>Bladder Cancer</i> , 2016, 2, 165-202.	0.2	30
4331	Large molecular systems landscape uncovers T cell trapping in human skin cancer. <i>Scientific Reports</i> , 2016, 6, 19012.	1.6	12
4332	Appendiceal Enlargement During Immunotherapy Treatment for Melanoma. <i>Clinical Skin Cancer</i> , 2016, 1, 106-109.	0.1	2
4334	Injection of Syngeneic Murine Melanoma Cells to Determine Their Metastatic Potential in the Lungs. <i>Journal of Visualized Experiments</i> , 2016, , .	0.2	9
4336	Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge", Napoli, December 5th 2015. , 2016, 4, .		0
4337	Acute visual loss after ipilimumab treatment for metastatic melanoma. , 2016, 4, 66.		59
4338	It's TIME for a biomarker-driven approach to cancer immunotherapy. , 2016, 4, 43.		6
4339	Grover's-like drug eruption in a patient with metastatic melanoma under ipilimumab therapy. , 2016, 4, 47.		27
4340	A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma. , 2016, 4, 52.		37
4341	Daunting but Worthy Goal. <i>Transplantation</i> , 2016, 100, 2569-2583.	0.5	16
4342	31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one. , 2016, 4, .		11
4343	A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma. , 2016, 4, 85.		18
4344	Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy. , 2016, 4, 89.		81
4345	Galectin-9 modulates immunity by promoting Th2/M2 differentiation and impacts survival in patients with metastatic melanoma. <i>Melanoma Research</i> , 2016, 26, 429-441.	0.6	53
4346	Current Status of Immunotherapy Treatments for Pancreatic Cancer. <i>Journal of Clinical Gastroenterology</i> , 2016, 50, 836-848.	1.1	11
4348	A case report of using nivolumab for a malignant melanoma patient with rheumatoid arthritis. <i>International Cancer Conference Journal</i> , 2016, 5, 192-196.	0.2	6

#	ARTICLE	IF	CITATIONS
4349	Cancer Research in the 21st Century. <i>Annals of Surgery</i> , 2016, 264, 555-565.	2.1	0
4350	An Association Between Glatiramer Acetate and Malignant Melanoma. <i>Journal of Immunotherapy</i> , 2016, 39, 276-278.	1.2	6
4351	Immunotherapy for prostate cancer. <i>Current Opinion in Urology</i> , 2016, 26, 529-534.	0.9	8
4352	Innovation in Bladder Cancer Immunotherapy. <i>Journal of Immunotherapy</i> , 2016, 39, 291-297.	1.2	4
4353	Competing risks survival of older patients with metastatic cutaneous melanoma: a SEER population-based study. <i>Melanoma Research</i> , 2016, 26, 505-512.	0.6	8
4354	Effects of commonly used chronic medications on the outcomes of ipilimumab therapy in patients with metastatic melanoma. <i>Melanoma Research</i> , 2016, 26, 609-615.	0.6	41
4355	Early analysis of surrogate endpoints for metastatic melanoma in immune checkpoint inhibitor trials. <i>Medicine (United States)</i> , 2016, 95, e3997.	0.4	12
4356	Stereotactic Ablative Radiation Therapy Combined With Immunotherapy for Solid Tumors. <i>Cancer Journal (Sudbury, Mass)</i> , 2016, 22, 257-266.	1.0	38
4357	From the Guest Editor. <i>Cancer Journal (Sudbury, Mass)</i> , 2016, 22, 245-246.	1.0	0
4358	Expression and clinical significance of MAGE and NY-ESO-1 cancer-testis antigens in adenoid cystic carcinoma of the head and neck. <i>Head and Neck</i> , 2016, 38, 1008-1016.	0.9	14
4359	Phenotypic characterization and prognostic impact of circulating β 1 and β 2 T cells in metastatic malignant melanoma. <i>International Journal of Cancer</i> , 2016, 138, 698-704.	2.3	24
4360	Initial experience with combined BRAF and MEK inhibition with stereotactic radiosurgery for BRAF mutant melanoma brain metastases. <i>Melanoma Research</i> , 2016, 26, 382-386.	0.6	31
4361	Radiological imaging in all stage III melanoma: current practice in the U.K.. <i>British Journal of Dermatology</i> , 2016, 175, 426-428.	1.4	0
4362	Foreign body reaction triggered by cytotoxic T lymphocyte-associated protein 4 blockade 25 years after dermal filler injection. <i>British Journal of Dermatology</i> , 2016, 175, 1351-1353.	1.4	17
4363	Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review. <i>Clinical Endocrinology</i> , 2016, 85, 331-339.	1.2	177
4364	A single-institution study examining cutaneous and non-cutaneous melanomas treated with nivolumab. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, e227-e229.	1.3	0
4365	The role of CTLA-4 and PD-1 in anti-tumor immune response and their potential efficacy against osteosarcoma. <i>International Immunopharmacology</i> , 2016, 38, 81-89.	1.7	44
4366	Checkpoint inhibition in meningiomas. <i>Immunotherapy</i> , 2016, 8, 721-731.	1.0	22

#	ARTICLE	IF	CITATIONS
4367	Progress in Cancer Immunotherapy. <i>Advances in Experimental Medicine and Biology</i> , 2016, , .	0.8	6
4369	Harnessing the immune system in acute myeloid leukaemia. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 103, 62-77.	2.0	90
4370	Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. <i>Kidney International</i> , 2016, 90, 638-647.	2.6	524
4371	Preclinical exploration of combining plasmacytoid and myeloid dendritic cell vaccination with BRAF inhibition. <i>Journal of Translational Medicine</i> , 2016, 14, 88.	1.8	10
4372	Case report: mismatch repair proficiency and microsatellite stability in gastric cancer may not predict programmed death-1 blockade resistance. <i>Journal of Hematology and Oncology</i> , 2016, 9, 29.	6.9	21
4373	The 2nd meeting of the Campania Society of Oncology Immunotherapy (SCITO): focus on hepatocellular carcinoma, kidney and bladder cancer. , 2016, 4, .		18
4374	Treatment of elderly patients with melanoma. <i>Memo - Magazine of European Medical Oncology</i> , 2016, 9, 13-16.	0.3	0
4376	Talimogene laherparepvec in advanced melanoma. <i>Expert Opinion on Orphan Drugs</i> , 2016, 4, 781-788.	0.5	0
4377	Assessment of Brain Tumor Response: RANO and Its Offspring. <i>Current Treatment Options in Oncology</i> , 2016, 17, 35.	1.3	65
4378	Immunotherapy of Brain Cancer. <i>Oncology Research and Treatment</i> , 2016, 39, 326-334.	0.8	14
4379	Cancer therapy-related complications in the bowel and mesentery: an imaging perspective. <i>Abdominal Radiology</i> , 2016, 41, 2031-2047.	1.0	12
4380	Antitumor Efficacy of Radiation plus Immunotherapy Depends upon Dendritic Cell Activation of Effector CD8+ T Cells. <i>Cancer Immunology Research</i> , 2016, 4, 621-630.	1.6	50
4381	Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma. <i>CKJ: Clinical Kidney Journal</i> , 2016, 9, 411-417.	1.4	98
4382	Neurologic Immune-Related Adverse Events in Oncology Care. <i>JAMA Neurology</i> , 2016, 73, 907.	4.5	4
4383	Ipilimumab administered to metastatic melanoma patients who progressed after dendritic cell vaccination. <i>Oncolimmunology</i> , 2016, 5, e1201625.	2.1	21
4384	Radicality of initial surgery for primary malignant melanoma of the vagina. <i>Melanoma Research</i> , 2016, 26, 173-180.	0.6	4
4385	Economic sustainability of anti-PD-1 agents nivolumab and pembrolizumab in cancer patients: Recent insights and future challenges. <i>Cancer Treatment Reviews</i> , 2016, 48, 20-24.	3.4	118
4386	Analysis of PD-L1, T-cell infiltrate and HLA expression in chondrosarcoma indicates potential for response to immunotherapy specifically in the dedifferentiated subtype. <i>Modern Pathology</i> , 2016, 29, 1028-1037.	2.9	84

#	ARTICLE	IF	CITATIONS
4387	Immune Profiling of Adenoid Cystic Carcinoma: PD-L2 Expression and Associations with Tumor-Infiltrating Lymphocytes. <i>Cancer Immunology Research</i> , 2016, 4, 679-687.	1.6	81
4388	Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events. <i>Oncologist</i> , 2016, 21, 804-816.	1.9	208
4389	Emerging immune therapy of metastatic melanoma in the older patient: does age really matter?. <i>Melanoma Management</i> , 2016, 3, 9-12.	0.1	2
4390	Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors. <i>Immunity</i> , 2016, 44, 1255-1269.	6.6	797
4391	A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 Testing. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1846-1855.	0.5	80
4392	Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma. <i>Nature Reviews Urology</i> , 2016, 13, 420-431.	1.9	78
4393	Gaining ground on a cure through synergy: combining checkpoint inhibitors with cancer vaccines. <i>Expert Review of Clinical Immunology</i> , 2016, 12, 1347-1357.	1.3	24
4394	Treatment-associated Fatigue in Cancer Patients Treated with Immune Checkpoint Inhibitors; a Systematic Review and Meta-analysis. <i>Clinical Oncology</i> , 2016, 28, e127-e138.	0.6	35
4395	Radiotherapy and immune checkpoints inhibitors for advanced melanoma. <i>Radiotherapy and Oncology</i> , 2016, 120, 1-12.	0.3	44
4396	Combining immune checkpoint inhibitors for advanced melanoma: the key to optimizing treatment outcomes?. <i>Journal of Comparative Effectiveness Research</i> , 2016, 5, 329-333.	0.6	0
4397	Unintended Immunological Consequences of Biologic Therapy. <i>Current Allergy and Asthma Reports</i> , 2016, 16, 46.	2.4	18
4398	Mouse Models of Tumor Immunotherapy. <i>Advances in Immunology</i> , 2016, 130, 1-24.	1.1	30
4399	The development of immunotherapy in older adults: New treatments, new toxicities?. <i>Journal of Geriatric Oncology</i> , 2016, 7, 325-333.	0.5	93
4400	Molecular characterisation of cutaneous melanoma: creating a framework for targeted and immune therapies. <i>British Journal of Cancer</i> , 2016, 115, 145-155.	2.9	50
4401	Progression-free survival landmark analysis: a critical endpoint in melanoma clinical trials. <i>Lancet Oncology</i> , The, 2016, 17, 1037-1039.	5.1	26
4402	Inducing enhanced immunogenic cell death with nanocarrier-based drug delivery systems for pancreatic cancer therapy. <i>Biomaterials</i> , 2016, 102, 187-197.	5.7	208
4403	Ipilimumab in anti-PD1 refractory metastatic melanoma. <i>Melanoma Research</i> , 2016, 26, 153-156.	0.6	18
4404	Gamma-interferon-inducible lysosomal thiol reductase is upregulated in human melanoma. <i>Melanoma Research</i> , 2016, 26, 125-137.	0.6	18

#	ARTICLE	IF	CITATIONS
4405	Molecular targeted therapy in gynaecologic malignancies: primer for radiologists. <i>British Journal of Radiology</i> , 2016, 89, 20160086.	1.0	2
4406	Immune checkpoint inhibitors as first-line and salvage therapy for advanced non-small-cell lung cancer. <i>Future Oncology</i> , 2016, 12, 1805-1822.	1.1	6
4408	Combinatorial approach to cancer immunotherapy: strength in numbers. <i>Journal of Leukocyte Biology</i> , 2016, 100, 275-290.	1.5	90
4409	Combined IL-21-primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patient. <i>Journal of Experimental Medicine</i> , 2016, 213, 1133-1139.	4.2	78
4410	Immunotherapy in glioblastoma: emerging options in precision medicine. <i>CNS Oncology</i> , 2016, 5, 175-186.	1.2	11
4411	New Strategies for Multimodality Therapy in Treating Locally Advanced Cervix Cancer. <i>Seminars in Radiation Oncology</i> , 2016, 26, 344-348.	1.0	21
4412	Scientific Advances Shaping the Future Roles of Oncology Nurses. <i>Seminars in Oncology Nursing</i> , 2016, 32, 87-98.	0.7	13
4413	Frequent CTLA4-CD28 gene fusion in diverse types of T-cell lymphoma. <i>Haematologica</i> , 2016, 101, 757-763.	1.7	75
4415	Targeting the microenvironment of pancreatic cancer: overcoming treatment barriers and improving local immune responses. <i>Clinical and Translational Oncology</i> , 2016, 18, 653-659.	1.2	8
4416	Exudative Polymorphous Vitelliform Retinopathy: Importance of Early Recognition of the Condition in Patients with Metastatic Melanoma. <i>Ophthalmology and Therapy</i> , 2016, 5, 121-127.	1.0	6
4417	Immunotherapy for Head and Neck Squamous Cell Carcinoma. <i>Current Oral Health Reports</i> , 2016, 3, 74-81.	0.5	6
4418	Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 976-983.	5.1	846
4419	Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 883-895.	5.1	1,091
4420	Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 943-955.	5.1	293
4421	Past approaches and future directions for targeting tumor hypoxia in squamous cell carcinomas of the head and neck. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 103, 86-98.	2.0	18
4422	Head and neck cancer immunology and immunotherapeutics: Basic concepts to clinical translational approaches. <i>Oral Oncology</i> , 2016, 58, 49-51.	0.8	0
4423	Adoption of ipilimumab in the United States: a Medicare study. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2016, 16, 439-440.	0.7	0
4424	Checkpoint Inhibitors and Their Application in Breast Cancer. <i>Breast Care</i> , 2016, 11, 108-115.	0.8	45

#	ARTICLE	IF	CITATIONS
4425	Genomic determinants of cancer immunotherapy. <i>Current Opinion in Immunology</i> , 2016, 41, 32-38.	2.4	27
4427	Safety and Efficacy of Radiation Therapy in Advanced Melanoma Patients Treated With Ipilimumab. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 72-77.	0.4	64
4428	Drug costs and benefits of medical treatments in high-unmet need solid tumours in the Nordic countries. <i>Journal of Cancer Policy</i> , 2016, 7, 12-22.	0.6	4
4429	Quantitative CD3 PET Imaging Predicts Tumor Growth Response to Anti-CTLA-4 Therapy. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1607-1611.	2.8	105
4430	Adoptive Cellular Therapy (ACT) for Cancer Treatment. <i>Advances in Experimental Medicine and Biology</i> , 2016, 909, 169-239.	0.8	14
4431	Big Data and machine learning in radiation oncology: State of the art and future prospects. <i>Cancer Letters</i> , 2016, 382, 110-117.	3.2	240
4432	Melanoma Lesions Independently Acquire T-cell Resistance during Metastatic Latency. <i>Cancer Research</i> , 2016, 76, 4347-4358.	0.4	63
4433	Personalized immunotherapy in colorectal cancer. <i>Expert Review of Precision Medicine and Drug Development</i> , 2016, 1, 267-277.	0.4	2
4434	Clinical Response and Regional Toxicity Following Isolated Limb Infusion Compared with Isolated Limb Perfusion for In-Transit Melanoma. <i>Annals of Surgical Oncology</i> , 2016, 23, 2330-2335.	0.7	49
4435	Coley's Lessons Remembered. <i>Integrative Cancer Therapies</i> , 2016, 15, 502-511.	0.8	36
4436	Ipilimumab-induced colitis: experience from a tertiary referral center. <i>Therapeutic Advances in Gastroenterology</i> , 2016, 9, 457-462.	1.4	31
4437	Predicting analysis times in randomized clinical trials with cancer immunotherapy. <i>BMC Medical Research Methodology</i> , 2016, 16, 12.	1.4	17
4438	The occurrence of non-melanoma malignant skin lesions and non-cutaneous squamous-cell carcinoma among metastatic melanoma patients: an observational cohort study in Denmark. <i>BMC Cancer</i> , 2016, 16, 295.	1.1	2
4439	Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors. <i>Journal of Translational Medicine</i> , 2016, 14, 95.	1.8	117
4440	BRAF V600 mutations in Langerhans cell histiocytosis with a simple and unique assay. <i>Diagnostic Pathology</i> , 2016, 11, 39.	0.9	12
4441	Mismatch in epitope specificities between IFN γ inflamed and uninfamed conditions leads to escape from T lymphocyte killing in melanoma. , 2016, 4, 10.		35
4442	Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study. , 2016, 4, 12.		79
4443	Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials. , 2016, 4, 15.		67

#	ARTICLE	IF	CITATIONS
4444	From bench to bedside a comprehensive review of pancreatic cancer immunotherapy. , 2016, 4, 14.		101
4445	T-Cell Therapy Using Interleukin-21-Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression. <i>Journal of Clinical Oncology</i> , 2016, 34, 3787-3795.	0.8	98
4446	Immune Checkpoint Inhibitors in Older Adults. <i>Current Oncology Reports</i> , 2016, 18, 47.	1.8	49
4447	Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. <i>Cancer Discovery</i> , 2016, 6, 827-837.	7.7	785
4448	Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 2619-2626.	0.8	449
4449	Generation and Regeneration of T Cells. , 2016, , 31-56.		0
4450	mRNA-based dendritic cell immunization improves survival in ret transgenic mouse melanoma model. <i>Oncolimmunology</i> , 2016, 5, e1160183.	2.1	4
4451	Checkpoint Blockade - a New Treatment Paradigm in Renal Cell Carcinoma. <i>Oncology Research and Treatment</i> , 2016, 39, 353-358.	0.8	6
4452	Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First Metastasis. <i>Oncologist</i> , 2016, 21, 848-854.	1.9	154
4453	Enhancing the Efficacy of Checkpoint Blockade Through Combination Therapies. , 2016, , 1-39.		0
4454	Immune checkpoint blockade with concurrent electrochemotherapy in advanced melanoma: a retrospective multicenter analysis. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 951-959.	2.0	62
4455	Similar lymphocytic infiltration pattern in primary breast cancer and their corresponding distant metastases. <i>Oncolimmunology</i> , 2016, 5, e1153208.	2.1	36
4456	A plant-expressed conjugate vaccine breaks CD4 ⁺ tolerance and induces potent immunity against metastatic Her2 ⁺ breast cancer. <i>Oncolimmunology</i> , 2016, 5, e1166323.	2.1	36
4457	CTLA-4 polymorphisms and haplotype correlate with survival in ALL after allogeneic stem cell transplantation from related HLA-haplotype-mismatched donor. <i>Journal of Translational Medicine</i> , 2016, 14, 100.	1.8	14
4459	Biologics and Their Interactions with Radiation. , 2016, , 80-92.e4.		0
4460	Genetic screens to study the immune system in cancer. <i>Current Opinion in Immunology</i> , 2016, 41, 55-61.	2.4	15
4461	Success and Failures of Combined Modalities in Glioblastoma Multiforme: Old Problems and New Directions. <i>Seminars in Radiation Oncology</i> , 2016, 26, 281-298.	1.0	23
4462	SCIB2, an antibody DNA vaccine encoding NY-ESO-1 epitopes, induces potent antitumor immunity which is further enhanced by checkpoint blockade. <i>Oncolimmunology</i> , 2016, 5, e1169353.	2.1	33

#	ARTICLE	IF	CITATIONS
4463	Mind the gap: What is driving the survival disparity between the sexes in bladder cancer?. <i>Cancer</i> , 2016, 122, 1966-1970.	2.0	7
4464	A Phase 1 Dose Escalation Study of ASP2409, a Selective T Cell Costimulation Inhibitor, in Stable Rheumatoid Arthritis Patients on Methotrexate Therapy. <i>Clinical Pharmacology in Drug Development</i> , 2016, 5, 259-268.	0.8	3
4465	Immune Checkpoint inhibitors: An introduction to the next generation cancer immunotherapy. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 157-169.	1.0	102
4466	Severe rash associated with vemurafenib administration following nivolumab therapy. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, e84-e86.	1.3	12
4467	Citrullinated Vimentin Presented on MHC-II in Tumor Cells Is a Target for CD4+ T-Cell Mediated Antitumor Immunity. <i>Cancer Research</i> , 2016, 76, 548-560.	0.4	75
4468	Ipilimumab Combined with Nivolumab: A Standard of Care for the Treatment of Advanced Melanoma?. <i>Clinical Cancer Research</i> , 2016, 22, 3992-3998.	3.2	48
4469	Rare Genitourinary Tumors. , 2016, , .		0
4470	Contemporary and potential future molecular diagnosis of melanoma. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 975-985.	1.5	3
4471	Primary mucosal melanoma of the head and neck in Denmark, 1982-2012: Demographic and clinical aspects. A retrospective DAHANCA study. <i>Acta Oncologica</i> , 2016, 55, 1001-1008.	0.8	31
4472	Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1511-1521.	0.5	95
4474	Neoantigen heterogeneity: a key driver of immune response and sensitivity to immune checkpoint blockade?. <i>Immunotherapy</i> , 2016, 8, 763-766.	1.0	10
4475	Proteomics approaches to understanding mitogen-activated protein kinase inhibitor resistance in melanoma. <i>Current Opinion in Oncology</i> , 2016, 28, 172-179.	1.1	10
4476	Outcomes of mucosal melanoma of the head and neck. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2016, 60, 268-273.	0.9	5
4477	Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer. <i>Gastric Cancer</i> , 2016, 19, 42-52.	2.7	230
4478	Ipilimumab-induced necrotic myelopathy in a patient with metastatic melanoma: A case report and review of literature. <i>Journal of Oncology Pharmacy Practice</i> , 2016, 22, 537-542.	0.5	36
4479	Metastatic melanoma of the gallbladder: report of two cases and a review of the literature. <i>Clinical and Experimental Medicine</i> , 2016, 16, 295-300.	1.9	25
4481	Ipilimumab may increase the severity of cutaneous toxicity related to radiotherapy. <i>Journal of Oncology Pharmacy Practice</i> , 2016, 22, 533-536.	0.5	5
4482	Novel technologies and emerging biomarkers for personalized cancer immunotherapy. , 2016, 4, 3.		183

#	ARTICLE	IF	CITATIONS
4483	Unknown primary tumors: is there a future therapeutic role for immune checkpoint inhibitors?. <i>Future Oncology</i> , 2016, 12, 429-431.	1.1	3
4484	Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma. <i>British Journal of Cancer</i> , 2016, 114, 256-261.	2.9	256
4485	Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab. <i>Annals of Oncology</i> , 2016, 27, 732-738.	0.6	321
4486	Single Nucleotide Polymorphisms in CBLB, a Regulator of T-Cell Response, Predict Radiation Pneumonitis and Outcomes After Definitive Radiotherapy for Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2016, 17, 253-262.e5.	1.1	16
4487	Immune-related adverse events with immune checkpoint blockade: a comprehensive review. <i>European Journal of Cancer</i> , 2016, 54, 139-148.	1.3	1,687
4488	Immunotherapy for advanced melanoma: future directions. <i>Immunotherapy</i> , 2016, 8, 199-209.	1.0	19
4489	Doubling the blockade for melanoma immunotherapy. <i>Oncolimmunology</i> , 2016, 5, e1106127.	2.1	9
4490	Treatment of Melanoma CNS Metastases. <i>Cancer Treatment and Research</i> , 2016, 167, 263-279.	0.2	6
4491	IL-6 down-regulates HLA class II expression and IL-12 production of human dendritic cells to impair activation of antigen-specific CD4+ T cells. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 193-204.	2.0	83
4492	Potential biomarker for checkpoint blockade immunotherapy and treatment strategy. <i>Tumor Biology</i> , 2016, 37, 4251-4261.	0.8	78
4493	Liquid biopsy utility for the surveillance of cutaneous malignant melanoma patients. <i>Molecular Oncology</i> , 2016, 10, 450-463.	2.1	79
4494	Immunotherapy with checkpoint inhibitors for lung cancer: novel agents, biomarkers and paradigms. <i>Future Oncology</i> , 2016, 12, 551-564.	1.1	8
4495	Clinical trials exploring the benefit of immunotherapy and radiation in cancer treatment: A review of the past and a look into the future. <i>Current Problems in Cancer</i> , 2016, 40, 38-67.	1.0	9
4496	Immune-checkpoint blockade – durable cancer control. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 77-78.	12.5	71
4497	Current status of immunotherapy. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 191-203.	0.6	52
4498	Nanotechnology-based strategies for combating toxicity and resistance in melanoma therapy. <i>Biotechnology Advances</i> , 2016, 34, 565-577.	6.0	39
4499	Recurrence and Survival Outcomes After Percutaneous Thermal Ablation of Oligometastatic Melanoma. <i>Mayo Clinic Proceedings</i> , 2016, 91, 288-296.	1.4	17
4500	Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study. <i>Oncolimmunology</i> , 2016, 5, e1071007.	2.1	21

#	ARTICLE	IF	CITATIONS
4501	CAR T Cells Targeting Podoplanin Reduce Orthotopic Glioblastomas in Mouse Brains. <i>Cancer Immunology Research</i> , 2016, 4, 259-268.	1.6	90
4502	Synergistic COX2 Induction by IFN γ and TNF α Self-Limits Type-1 Immunity in the Human Tumor Microenvironment. <i>Cancer Immunology Research</i> , 2016, 4, 303-311.	1.6	53
4503	Clinical, Endoscopic, and Histologic Characteristics of Ipilimumab-Associated Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 836-842.	2.4	116
4504	Combination immune checkpoint blockade with ipilimumab and nivolumab in the management of advanced melanoma. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 389-396.	1.4	35
4505	Neutralization of Tumor Acidity Improves Antitumor Responses to Immunotherapy. <i>Cancer Research</i> , 2016, 76, 1381-1390.	0.4	451
4506	Assessment of costimulation and coinhibition in a triple parameter T cell reporter line: Simultaneous measurement of NF- κ B, NFAT and AP-1. <i>Journal of Immunological Methods</i> , 2016, 430, 10-20.	0.6	140
4507	Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 395-401.	0.6	274
4508	Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab. <i>Clinical Cancer Research</i> , 2016, 22, 2908-2918.	3.2	459
4509	Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy. <i>Cancer Discovery</i> , 2016, 6, 446-459.	7.7	198
4510	Risk of endocrine complications in cancer patients treated with immune check point inhibitors: a meta-analysis. <i>Future Oncology</i> , 2016, 12, 413-425.	1.1	115
4511	Pembrolizumab for the treatment of non-small cell lung cancer. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 397-406.	1.4	56
4513	Innovative perspectives of immunotherapy in head and neck cancer. From relevant scientific rationale to effective clinical practice. <i>Cancer Treatment Reviews</i> , 2016, 43, 113-123.	3.4	9
4514	T-Cell Immunoglobulin and ITIM Domain (TIGIT) Associates with CD8+ T-Cell Exhaustion and Poor Clinical Outcome in AML Patients. <i>Clinical Cancer Research</i> , 2016, 22, 3057-3066.	3.2	217
4515	Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E319-27.	3.3	71
4516	Epigenetic Therapeutics: A New Weapon in the War Against Cancer. <i>Annual Review of Medicine</i> , 2016, 67, 73-89.	5.0	285
4517	Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy. <i>Pathology</i> , 2016, 48, 177-187.	0.3	210
4518	Improved efficacy of mitoxantrone in patients with castration-resistant prostate cancer after vaccination with GM-CSF-transduced allogeneic prostate cancer cells. <i>Oncolimmunology</i> , 2016, 5, e1105431.	2.1	11
4519	Re-examining the Nature and Function of Self-Reactive T cells. <i>Trends in Immunology</i> , 2016, 37, 114-125.	2.9	68

#	ARTICLE	IF	CITATIONS
4520	Essential role of HDAC6 in the regulation of PD-L1 in melanoma. <i>Molecular Oncology</i> , 2016, 10, 735-750.	2.1	125
4521	Immune Therapy. <i>Advances in Experimental Medicine and Biology</i> , 2016, 893, 59-90.	0.8	1
4522	Delivery of cancer therapeutics to extracellular and intracellular targets: Determinants, barriers, challenges and opportunities. <i>Advanced Drug Delivery Reviews</i> , 2016, 97, 280-301.	6.6	130
4523	Doublet BRAF/MEK inhibition versus single-agent BRAF inhibition in the management of BRAF-mutant advanced melanoma, biological rationale and meta-analysis of published data. <i>Clinical and Translational Oncology</i> , 2016, 18, 848-858.	1.2	21
4524	Regulatory T cells in the immunotherapy of melanoma. <i>Tumor Biology</i> , 2016, 37, 77-85.	0.8	17
4525	The Future of Molecular Analysis in Melanoma: Diagnostics to Direct Molecularly Targeted Therapy. <i>American Journal of Clinical Dermatology</i> , 2016, 17, 1-10.	3.3	8
4526	Tumor microenvironment (TME)-driven immune suppression in B cell malignancy. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2016, 1863, 471-482.	1.9	89
4527	Combination Anti-CTLA-4 and Anti-RANKL in Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2016, 34, e104-e106.	0.8	65
4530	Clinical relevance of host immunity in breast cancer: from TILs to the clinic. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 228-241.	12.5	679
4531	MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints. <i>Neuro-Oncology</i> , 2016, 18, 639-648.	0.6	161
4532	New toxicity profile for novel immunotherapy agents: focus on immune-checkpoint inhibitors. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 57-75.	1.5	46
4533	Single versus combination immunotherapy drug treatment in melanoma. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 433-441.	1.4	16
4534	Novel therapeutic targets in advanced urothelial carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 98, 106-115.	2.0	45
4535	Metastatic spread in patients with non-small cell lung cancer is associated with a reduced density of tumor-infiltrating T cells. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 1-11.	2.0	34
4536	Integrating radiation therapy with emerging systemic therapies: Lessons from a patient with cerebral radionecrosis, spinal cord myelopathy, and radiation pneumonitis. <i>Practical Radiation Oncology</i> , 2016, 6, 110-113.	1.1	3
4537	Treatment Algorithms Based on Tumor Molecular Profiling: The Essence of Precision Medicine Trials. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv362.	3.0	71
4538	Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders. <i>JAMA Oncology</i> , 2016, 2, 234.	3.4	534
4539	Checkpoint Blockade for the Treatment of Advanced Melanoma. <i>Cancer Treatment and Research</i> , 2016, 167, 231-250.	0.2	36

#	ARTICLE	IF	CITATIONS
4540	Prognostic and predictive biomarkers in melanoma: an update. <i>Expert Review of Molecular Diagnostics</i> , 2016, 16, 223-237.	1.5	23
4541	Circulating Tumor Cells, DNA, and mRNA: Potential for Clinical Utility in Patients With Melanoma. <i>Oncologist</i> , 2016, 21, 84-94.	1.9	20
4542	Chemotherapy for Melanoma. <i>Cancer Treatment and Research</i> , 2016, 167, 209-229.	0.2	112
4543	Current and future directions in the treatment and prevention of drug-induced liver injury: a systematic review. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 517-536.	1.4	82
4544	Adjuvant Therapy of Melanoma. <i>Cancer Treatment and Research</i> , 2016, 167, 181-208.	0.2	17
4545	Immune checkpoints programmed death 1 ligand 1 and cytotoxic T lymphocyte associated molecule 4 in gastric adenocarcinoma. <i>Oncoimmunology</i> , 2016, 5, e1100789.	2.1	45
4546	Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability. <i>Immunity</i> , 2016, 44, 698-711.	6.6	814
4547	CNS demyelination and enhanced myelin-reactive responses after ipilimumab treatment. <i>Neurology</i> , 2016, 86, 1553-1556.	1.5	65
4548	Autologous melanoma cell vaccine using monocyte-derived dendritic cells (NBS20/eltrapuldencel-T). <i>Future Oncology</i> , 2016, 12, 751-762.	1.1	18
4549	Monocyte and interferon based therapy for the treatment of ovarian cancer. <i>Cytokine and Growth Factor Reviews</i> , 2016, 29, 109-115.	3.2	27
4550	Ipilimumab reshapes T cell memory subsets in melanoma patients with clinical response. <i>Oncoimmunology</i> , 2016, 5, 1136045.	2.1	22
4551	Overcoming drug resistance to receptor tyrosine kinase inhibitors: Learning from lung cancer. , 2016, 161, 97-110.		60
4552	Immunotherapy-Associated Hemolytic Anemia with Pure Red-Cell Aplasia. <i>New England Journal of Medicine</i> , 2016, 374, 1096-1097.	13.9	75
4553	CTLA-4 and PD-1 Pathways. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2016, 39, 98-106.	0.6	1,644
4554	Antigen Selection for Enhanced Affinity T-Cell Receptor-Based Cancer Therapies. <i>Journal of Biomolecular Screening</i> , 2016, 21, 769-785.	2.6	12
4555	Glioblastoma. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2016, 134, 381-397.	1.0	289
4556	Targeted immunotherapy for pediatric solid tumors. <i>Oncoimmunology</i> , 2016, 5, e1087637.	2.1	9
4557	CD4 + CD25 + regulatory T cells in tumor immunity. <i>International Immunopharmacology</i> , 2016, 34, 244-249.	1.7	102

#	ARTICLE	IF	CITATIONS
4558	Dendritic Cell-Secreted Cytotoxic T-Lymphocyte-Associated Protein-4 Regulates the T-cell Response by Downmodulating Bystander Surface B7. <i>Stem Cells and Development</i> , 2016, 25, 774-787.	1.1	42
4559	How Cancers Escape Immune Destruction and Mechanisms of Action for the New Significantly Active Immune Therapies: Helping Nonimmunologists Decipher Recent Advances. <i>Oncologist</i> , 2016, 21, 233-243.	1.9	71
4560	Combining Epigenetic and Immunotherapy to Combat Cancer. <i>Cancer Research</i> , 2016, 76, 1683-1689.	0.4	251
4561	Blocking Indolamine-2,3-Dioxygenase Rebound Immune Suppression Boosts Antitumor Effects of Radio-Immunotherapy in Murine Models and Spontaneous Canine Malignancies. <i>Clinical Cancer Research</i> , 2016, 22, 4328-4340.	3.2	94
4562	Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant Setting. <i>Oncologist</i> , 2016, 21, 283-291.	1.9	45
4563	Enhanced local and systemic anti-melanoma CD8+ T cell responses after memory T cell-based adoptive immunotherapy in mice. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 601-611.	2.0	13
4564	Indirect Treatment Comparison of Talimogene Laherparepvec Compared with Ipilimumab and Vemurafenib for the Treatment of Patients with Metastatic Melanoma. <i>Advances in Therapy</i> , 2016, 33, 643-657.	1.3	10
4565	Principles of immunotherapy. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2016, 134, 163-181.	1.0	12
4566	Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment. <i>International Immunology</i> , 2016, 28, 383-391.	1.8	223
4567	Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine. <i>Gynecologic Oncology</i> , 2016, 141, 86-94.	0.6	26
4568	Targeting metastasis. <i>Nature Reviews Cancer</i> , 2016, 16, 201-218.	12.8	1,111
4569	Immunotherapy approaches to treat adult acute lymphoblastic leukemia. <i>Expert Review of Hematology</i> , 2016, 9, 563-577.	1.0	10
4570	2015 and human cancer: back to overall survival. <i>Future Oncology</i> , 2016, 12, 1751-1754.	1.1	0
4571	New Translational Research in the Medical Management of Orbital Melanoma. <i>Seminars in Ophthalmology</i> , 2016, 31, 53-58.	0.8	4
4572	Is there a relation between type of primary melanoma treatment and the development of intralymphatic metastasis? A review of the literature. <i>Cancer Treatment Reviews</i> , 2016, 45, 120-128.	3.4	8
4573	Immune checkpoint blockade in lymphoid malignancies. <i>FEBS Journal</i> , 2016, 283, 2233-2244.	2.2	18
4574	Recognizing melanoma. <i>Nurse Practitioner</i> , 2016, 41, 29-30.	0.2	4
4575	Immuntherapie des Melanoms: Wirksamkeit und Wirkungsmechanismen. <i>JDDG - Journal of the German Society of Dermatology</i> , 2016, 14, 28-37.	0.4	4

#	ARTICLE	IF	CITATIONS
4576	Immunotherapy of melanoma: efficacy and mode of action. JDDG - Journal of the German Society of Dermatology, 2016, 14, 28-36.	0.4	16
4577	Checkpoint inhibitors in Hodgkin's lymphoma. European Journal of Haematology, 2016, 96, 335-343.	1.1	14
4578	Treg subsets in inflammatory bowel disease and colorectal carcinoma: Characteristics, role, and therapeutic targets. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 1393-1404.	1.4	28
4579	The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer. Advances in Immunology, 2016, 130, 25-74.	1.1	181
4580	Targeting inhibition of Foxp3 by a CD28 2 nd -Fluoro oligonucleotide aptamer conjugated to P60-peptide enhances active cancer immunotherapy. Biomaterials, 2016, 91, 73-80.	5.7	43
4581	In situ vaccination for the treatment of cancer. Immunotherapy, 2016, 8, 315-330.	1.0	71
4582	Combination Therapies for Melanoma: A New Standard of Care?. American Journal of Clinical Dermatology, 2016, 17, 99-105.	3.3	23
4583	Enhancement of CD3AK cell proliferation and killing ability by Î±-Thujone. International Immunopharmacology, 2016, 30, 57-61.	1.7	13
4584	Novel therapies for advanced squamous cell carcinoma of the lung. Future Oncology, 2016, 12, 659-667.	1.1	11
4585	Malignant pleural mesothelioma: an update on diagnosis and treatment options. Therapeutic Advances in Respiratory Disease, 2016, 10, 275-288.	1.0	45
4586	NRAS mutant melanoma: an overview for the clinician for melanoma management. Melanoma Management, 2016, 3, 47-59.	0.1	12
4587	Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too?. Expert Opinion on Biological Therapy, 2016, 16, 655-674.	1.4	21
4588	Immune checkpoint therapy for non-small-cell lung cancer: an update. Immunotherapy, 2016, 8, 279-298.	1.0	56
4589	Current treatment options of brain metastases and outcomes in patients with malignant melanoma. Reports of Practical Oncology and Radiotherapy, 2016, 21, 271-277.	0.3	15
4590	Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2?. Seminars in Immunology, 2016, 28, 73-80.	2.7	56
4591	Personalized chemotherapy of lung cancer: What the radiologist should know. Diagnostic and Interventional Imaging, 2016, 97, 287-296.	1.8	9
4592	Angiogenesis in melanoma: an update with a focus on current targeted therapies. Journal of Clinical Pathology, 2016, 69, 472-483.	1.0	55
4594	Immunotherapy for Gastric Cancer: A Focus on Immune Checkpoints. Targeted Oncology, 2016, 11, 469-477.	1.7	34

#	ARTICLE	IF	CITATIONS
4595	Glycogen Synthase Kinase 3 Inactivation Drives T-bet-Mediated Downregulation of Co-receptor PD-1 to Enhance CD8+ Cytolytic T Cell Responses. <i>Immunity</i> , 2016, 44, 274-286.	6.6	144
4596	Preparation and Evaluation of Radiolabeled Antibody Recruiting Small Molecules That Target Prostate-Specific Membrane Antigen for Combined Radiotherapy and Immunotherapy. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 2660-2673.	2.9	21
4597	A phase I/IIa clinical trial in stage IV melanoma of an autologous tumorâ€“dendritic cell fusion (dendritoma) vaccine with low dose interleukin-2. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 383-392.	2.0	28
4598	Anti-TNF-refractory colitis after checkpoint inhibitor therapy: Possible role of CMV-mediated immunopathogenesis. <i>Oncolmmunology</i> , 2016, 5, e1128611.	2.1	64
4599	Clinical activity and safety of Pembrolizumab in Ipilimumab pre-treated patients with uveal melanoma. <i>Oncolmmunology</i> , 2016, 5, e1143997.	2.1	74
4600	Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: Effectiveness and toxicity management. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 1092-1101.	1.4	37
4601	Therapeutic vaccines for prostate cancer: recent advances and future directions. <i>Expert Review of Vaccines</i> , 2016, 15, 907-914.	2.0	5
4602	Recent progress on third generation covalent EGFR inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 1861-1868.	1.0	87
4603	The immune mechanisms of abscopal effect in radiation therapy. <i>Current Problems in Cancer</i> , 2016, 40, 10-24.	1.0	131
4604	Prioritization schema for immunotherapy clinical trials in glioblastoma. <i>Oncolmmunology</i> , 2016, 5, e1145332.	2.1	13
4605	The use of ipilimumab in patients with rheumatoid arthritis and metastatic melanoma. <i>Annals of Oncology</i> , 2016, 27, 1174-1177.	0.6	53
4606	Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. <i>Oncolmmunology</i> , 2016, 5, e1136044.	2.1	55
4607	Pan-Cancer Immunogenomic Perspective on the Tumor Microenvironment Based on PD-L1 and CD8 T-Cell Infiltration. <i>Clinical Cancer Research</i> , 2016, 22, 2261-2270.	3.2	217
4608	Immune Suppression and Response to Ipilimumab: Assessing Risk-to-Benefit Ratio. <i>Journal of Clinical Oncology</i> , 2016, 34, 1017-1018.	0.8	5
4609	Management of toxicities of immune checkpoint inhibitors. <i>Cancer Treatment Reviews</i> , 2016, 44, 51-60.	3.4	706
4610	Ongoing Response in BRAF V600E-Mutant Melanoma After Cessation of Intermittent Vemurafenib Therapy: A Case Report. <i>Targeted Oncology</i> , 2016, 11, 557-563.	1.7	16
4611	Interleukin-35 Limits Anti-Tumor Immunity. <i>Immunity</i> , 2016, 44, 316-329.	6.6	230
4612	Nivolumab in Nonsquamous Nonâ€“Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2016, 374, 492-494.	13.9	48

#	ARTICLE	IF	CITATIONS
4613	Molecular characteristics and potential therapeutic targets in Merkel cell carcinoma. <i>Journal of Clinical Pathology</i> , 2016, 69, 382-390.	1.0	19
4614	The Role of the Immune System in Ovarian Cancer and Implications on Therapy. <i>Expert Review of Clinical Immunology</i> , 2016, 12, 681-695.	1.3	5
4615	Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. <i>Nature Communications</i> , 2016, 7, 10391.	5.8	784
4616	Expanding the antimalarial toolkit: Targeting host-parasite interactions. <i>Journal of Experimental Medicine</i> , 2016, 213, 143-153.	4.2	22
4619	Clinical use of ipilimumab for metastatic melanoma in Spain: towards a more consistent approach. <i>Clinical and Translational Oncology</i> , 2016, 18, 1044-1050.	1.2	0
4620	Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination. <i>OncoImmunology</i> , 2016, 5, e1057673.	2.1	67
4621	Immunotherapy Combined or Sequenced With Targeted Therapy in the Treatment of Solid Tumors: Current Perspectives. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv414.	3.0	81
4622	Pembrolizumab and nivolumab: PD-1 inhibitors for advanced melanoma. <i>American Journal of Health-System Pharmacy</i> , 2016, 73, 193-201.	0.5	75
4623	The Role of Tumor-Infiltrating Lymphocytes in Development, Progression, and Prognosis of Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, 789-800.	0.5	401
4624	Immunotherapy and Oncogenic Pathways: The PTEN Connection. <i>Cancer Discovery</i> , 2016, 6, 128-129.	7.7	17
4625	Glycosignals in Cancer: Mechanisms of Malignant Phenotypes. , 2016, , .		0
4626	Merkel Cell Carcinoma: Current Issues Regarding Diagnosis, Management, and Emerging Treatment Strategies. <i>American Journal of Clinical Dermatology</i> , 2016, 17, 49-62.	3.3	26
4627	CTLA4 blockade reduces immature myeloid cells in head and neck squamous cell carcinoma. <i>OncoImmunology</i> , 2016, 5, e1151594.	2.1	59
4628	The management of immune-related adverse events associated with immune checkpoint blockade. <i>Expert Review of Quality of Life in Cancer Care</i> , 2016, 1, 89-97.	0.6	15
4629	Reprint of: Fast Cars and No Brakes: Autologous Stem Cell Transplantation as a Platform for Novel Immunotherapies. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S9-S14.	2.0	0
4630	The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis. <i>Science Translational Medicine</i> , 2016, 8, 327ra26.	5.8	360
4631	Targeted therapies in gastric cancer treatment: where we are and where we are going. <i>Investigational New Drugs</i> , 2016, 34, 378-393.	1.2	16
4632	Ipilimumab-Induced Gastrointestinal Toxicities: A Management Algorithm. <i>Digestive Diseases and Sciences</i> , 2016, 61, 2132-2139.	1.1	17

#	ARTICLE	IF	CITATIONS
4633	Have lessons from past failures brought us closer to the success of immunotherapy in metastatic pancreatic cancer?. <i>Oncolmunology</i> , 2016, 5, e1112942.	2.1	19
4634	Coinhibitory Pathways in Immunotherapy for Cancer. <i>Annual Review of Immunology</i> , 2016, 34, 539-573.	9.5	718
4635	An increased number of PD-1+ and Tim-3+ CD8+ T cells is involved in immune evasion in gastric cancer. <i>Surgery Today</i> , 2016, 46, 1341-1347.	0.7	34
4636	Immunotherapy of Cancer. , 2016, , .		3
4637	The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 273-290.	12.5	909
4638	Cutting Edge: Engineering Active IKK $\hat{2}$ in T Cells Drives Tumor Rejection. <i>Journal of Immunology</i> , 2016, 196, 2933-2938.	0.4	18
4639	Overview of Current Cancer Immunotherapy. , 2016, , 3-17.		0
4640	Peptide Vaccine. , 2016, , 135-142.		0
4641	Personalized Peptide Vaccine. , 2016, , 143-158.		0
4642	WT1 Peptide Vaccine for the Treatment of Malignancies: Its Development, Recent Progress, and Future Perspectives. , 2016, , 159-185.		1
4643	Anti-CTLA-4 Ab. , 2016, , 263-282.		2
4644	NKT Cell-Based Immunotherapy. , 2016, , 75-86.		0
4645	Immune checkpoint pathways: perspectives on myeloid malignancies. <i>Leukemia and Lymphoma</i> , 2016, 57, 995-1001.	0.6	4
4646	Regulatory T Cells. , 2016, , 309-322.		0
4647	Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma. <i>Neuro-Oncology</i> , 2016, 18, 1137-1145.	0.6	126
4648	Personalized Cancer Immunotherapy: Immune Biomarkers and Combination Immunotherapy. , 2016, , 349-358.		0
4649	Development of brain metastases in patients with metastatic melanoma while receiving ipilimumab. <i>Journal of Neuro-Oncology</i> , 2016, 126, 355-360.	1.4	19
4650	Targeting Oral Cancer. , 2016, , .		0

#	ARTICLE	IF	CITATIONS
4651	Vaccination with Irradiated Autologous Tumor Cells Mixed with Irradiated GM-K562 Cells Stimulates Antitumor Immunity and T Lymphocyte Activation in Patients with Recurrent Malignant Glioma. <i>Clinical Cancer Research</i> , 2016, 22, 2885-2896.	3.2	45
4652	Stability of ipilimumab in its original vial after opening allows its use for at least 4 weeks and facilitates pooling of residues. <i>European Journal of Cancer</i> , 2016, 58, 8-16.	1.3	23
4653	Evolving molecularly targeted therapies for advanced-stage thyroid cancers. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 403-416.	12.5	80
4654	Cutaneous manifestations of nontargeted and targeted chemotherapies. <i>Seminars in Oncology</i> , 2016, 43, 419-425.	0.8	23
4655	Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 1330-1338.	0.8	259
4656	MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade. <i>Immunity</i> , 2016, 44, 609-621.	6.6	566
4657	A catalogue of treatment and technologies for malignant pleural mesothelioma. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 455-463.	1.1	12
4658	Targeted agents and combinations in ovarian cancer: where are we now?. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 441-454.	1.1	12
4659	Immunotherapy in Head and Neck Cancers. , 2016, , 211-224.		0
4660	Myeloid-derived suppressor cells in patients with myeloproliferative neoplasm. <i>Leukemia Research</i> , 2016, 43, 39-43.	0.4	47
4661	T cells targeting NY-ESO-1 demonstrate efficacy against disseminated neuroblastoma. <i>Oncolmmunology</i> , 2016, 5, e1040216.	2.1	37
4662	Activation of cytomegalovirus-specific CD8 ⁺ T-cell response by antibody-mediated peptide-major histocompatibility class I complexes. <i>Oncolmmunology</i> , 2016, 5, e1052930.	2.1	0
4663	Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. <i>Journal of Clinical Oncology</i> , 2016, 34, 1510-1517.	0.8	627
4664	A high number of IgG4-positive cells in gastric cancer tissue is associated with tumor progression and poor prognosis. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 468, 549-557.	1.4	22
4665	Meta-analysis of regression of advanced solid tumors in patients receiving placebo or no anti-cancer therapy in prospective trials. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 98, 122-136.	2.0	24
4666	Prospect and progress of personalized peptide vaccinations for advanced cancers. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 689-698.	1.4	14
4667	Dermal Drug Delivery for Cutaneous Malignancies: Literature at a Glance. <i>Journal of Pharmaceutical Innovation</i> , 2016, 11, 1-33.	1.1	6
4668	Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2016, 22, 1364-1370.	3.2	251

#	ARTICLE	IF	CITATIONS
4669	Emerging immunotherapy for the treatment of esophageal cancer. Expert Opinion on Investigational Drugs, 2016, 25, 667-677.	1.9	32
4670	Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors. EBioMedicine, 2016, 6, 50-58.	2.7	113
4672	Development of immuno-oncology drugs “ from CTLA4 to PD1 to the next generations. Nature Reviews Drug Discovery, 2016, 15, 235-247.	21.5	503
4673	Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis. Therapeutic Advances in Respiratory Disease, 2016, 10, 183-193.	1.0	112
4674	Express approval of immune checkpoint inhibitors: a conflict between science and finance. Future Oncology, 2016, 12, 1215-1217.	1.1	0
4675	Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells. Cancer Immunology, Immunotherapy, 2016, 65, 537-549.	2.0	22
4676	Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors. Science China Life Sciences, 2016, 59, 340-348.	2.3	70
4677	Advances in Therapeutic Cancer Vaccines. Advances in Immunology, 2016, 130, 191-249.	1.1	88
4679	Survival of patients with metastatic melanoma and brain metastases in the era of MAP-kinase inhibitors and immunologic checkpoint blockade antibodies: A systematic review. Cancer Treatment Reviews, 2016, 45, 38-45.	3.4	71
4680	Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients: a guide and update for pathologists. Pathology, 2016, 48, 194-202.	0.3	19
4681	Ocular toxicities of MEK inhibitors and other targeted therapies. Annals of Oncology, 2016, 27, 998-1005.	0.6	72
4682	Selumetinib for the treatment of melanoma. Expert Opinion on Orphan Drugs, 2016, 4, 223-231.	0.5	1
4683	Prevailing over T cell exhaustion: New developments in the immunotherapy of pancreatic cancer. Cancer Letters, 2016, 381, 259-268.	3.2	30
4684	Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: A systematic review and meta-analysis. Cancer Treatment Reviews, 2016, 45, 30-37.	3.4	242
4685	Restoring anti-tumor functions of T cells via nanoparticle-mediated immune checkpoint modulation. Journal of Controlled Release, 2016, 231, 17-28.	4.8	171
4686	Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy. Clinical Cancer Research, 2016, 22, 1048-1054.	3.2	226
4687	Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential. Therapeutic Advances in Medical Oncology, 2016, 8, 4-31.	1.4	40
4689	Long-lasting multifunctional CD8 ⁺ T cell responses in end-stage melanoma patients can be induced by dendritic cell vaccination. OncoImmunology, 2016, 5, e1067745.	2.1	55

#	ARTICLE	IF	CITATIONS
4690	Radiotherapy with BRAF inhibitor therapy for melanoma: progress and possibilities. <i>Future Oncology</i> , 2016, 12, 95-106.	1.1	15
4691	OX40 signaling in head and neck squamous cell carcinoma: Overcoming immunosuppression in the tumor microenvironment. <i>Oral Oncology</i> , 2016, 52, 1-10.	0.8	56
4692	Endocrinopathies induced by immune-checkpoint inhibitors in advanced non-small cell lung cancer. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 419-428.	1.3	25
4693	Predictors of tumor-infiltrating lymphocyte efficacy in melanoma. <i>Immunotherapy</i> , 2016, 8, 35-43.	1.0	21
4694	Isolated recto-sigmoid colitis: a new imaging pattern of ipilimumab-associated colitis. <i>Abdominal Radiology</i> , 2016, 41, 207-214.	1.0	36
4695	New Strategies in Bladder Cancer: A Second Coming for Immunotherapy. <i>Clinical Cancer Research</i> , 2016, 22, 793-801.	3.2	60
4696	Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies. <i>Clinical Cancer Research</i> , 2016, 22, 1592-1602.	3.2	108
4697	Biomaterials and emerging anticancer therapeutics: engineering the microenvironment. <i>Nature Reviews Cancer</i> , 2016, 16, 56-66.	12.8	341
4698	Survival of patients with advanced metastatic melanoma: The impact of novel therapies. <i>European Journal of Cancer</i> , 2016, 53, 125-134.	1.3	137
4699	Molecular Targeted Therapy Approaches for BRAF Wild-Type Melanoma. <i>Current Oncology Reports</i> , 2016, 18, 6.	1.8	26
4700	Vaccines Combined with Immune Checkpoint Antibodies Promote Cytotoxic T-cell Activity and Tumor Eradication. <i>Cancer Immunology Research</i> , 2016, 4, 95-100.	1.6	124
4702	Connecting the Dots: Therapy-Induced Senescence and a Tumor-Suppressive Immune Microenvironment. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv406.	3.0	61
4703	PD-L1-specific T cells. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 797-804.	2.0	20
4704	Melanoma: the intersection of molecular targeted therapy and immune checkpoint inhibition. <i>Current Opinion in Immunology</i> , 2016, 39, 30-38.	2.4	23
4705	The rapidly evolving therapies for advanced melanoma—Towards immunotherapy, molecular targeted therapy, and beyond. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 99, 91-99.	2.0	87
4706	Prospects for gene-engineered T cell immunotherapy for solid cancers. <i>Nature Medicine</i> , 2016, 22, 26-36.	15.2	296
4707	The Role of Anti-Drug Antibodies in the Pharmacokinetics, Disposition, Target Engagement, and Efficacy of a GITR Agonist Monoclonal Antibody in Mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2016, 356, 574-586.	1.3	15
4708	Immunotherapy against Metastatic Melanoma with Human iPS Cell-Derived Myeloid Cell Lines Producing Type I Interferons. <i>Cancer Immunology Research</i> , 2016, 4, 248-258.	1.6	20

#	ARTICLE	IF	CITATIONS
4709	Combining antibody-drug conjugates and immune-mediated cancer therapy: What to expect?. <i>Biochemical Pharmacology</i> , 2016, 102, 1-6.	2.0	119
4710	Cancer immunology and canine malignant melanoma: A comparative review. <i>Veterinary Immunology and Immunopathology</i> , 2016, 169, 15-26.	0.5	62
4711	Current progress in immunotherapy for pancreatic cancer. <i>Cancer Letters</i> , 2016, 381, 244-251.	3.2	149
4712	The pleiotropic role of exchange protein directly activated by cAMP 1 (EPAC1) in cancer: implications for therapeutic intervention. <i>Acta Biochimica Et Biophysica Sinica</i> , 2016, 48, 75-81.	0.9	30
4713	Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy. <i>Therapeutic Advances in Medical Oncology</i> , 2016, 8, 48-56.	1.4	240
4714	ReACT Phase II trial: a critical evaluation of the use of rindopepimut plus bevacizumab to treat EGFRvIII-positive recurrent glioblastoma (retracted). <i>CNS Oncology</i> , 2016, 5, 11-26.	1.2	21
4715	Melanoma Brain Metastasis Pseudoprogression after Pembrolizumab Treatment. <i>Cancer Immunology Research</i> , 2016, 4, 179-182.	1.6	115
4716	Prospects for the use of ipilimumab in treating advanced prostate cancer. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 421-432.	1.4	5
4717	Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy. <i>Annals of Oncology</i> , 2016, 27, 434-441.	0.6	213
4718	Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells. <i>Clinical Cancer Research</i> , 2016, 22, 2155-2166.	3.2	211
4719	Expression of inhibitory receptors on intratumoral T cells modulates the activity of a T cell-bispecific antibody targeting folate receptor. <i>Oncolmmunology</i> , 2016, 5, e1062969.	2.1	27
4720	Highly efficient homology-driven genome editing in human T cells by combining zinc-finger nuclease mRNA and AAV6 donor delivery. <i>Nucleic Acids Research</i> , 2016, 44, e30-e30.	6.5	109
4721	Immunosuppressive cells in tumor immune escape and metastasis. <i>Journal of Molecular Medicine</i> , 2016, 94, 509-522.	1.7	270
4722	TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 212-223.	5.1	158
4723	Stemming the Rising Incidence of Melanoma: Calling Prevention to Action. <i>Journal of the National Cancer Institute</i> , 2016, 108, .	3.0	61
4724	Emerging Systemic and Targeted Therapies. , 2016, , 159-168.		1
4725	Identification of an Immunogenic Subset of Metastatic Uveal Melanoma. <i>Clinical Cancer Research</i> , 2016, 22, 2237-2249.	3.2	71
4726	Influence of 18F-FDG PET/CT on therapy management in patients with stage III/IV malignant melanoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 482-488.	3.3	37

#	ARTICLE	IF	CITATIONS
4728	Reprogramming away from the exhausted T cell state. <i>Seminars in Immunology</i> , 2016, 28, 35-44.	2.7	25
4729	Reprogramming the tumor microenvironment to enhance adoptive cellular therapy. <i>Seminars in Immunology</i> , 2016, 28, 64-72.	2.7	52
4730	An Open-Label, Randomized Phase II Trial of Personalized Peptide Vaccination in Patients with Bladder Cancer that Progressed after Platinum-Based Chemotherapy. <i>Clinical Cancer Research</i> , 2016, 22, 54-60.	3.2	44
4731	Targeted Therapy for Melanoma. <i>Cancer Treatment and Research</i> , 2016, 167, 251-262.	0.2	75
4732	Mucosal Melanoma: Epidemiology, Biology and Treatment. <i>Cancer Treatment and Research</i> , 2016, 167, 295-320.	0.2	89
4733	Results of a Randomized Controlled Multicenter Phase III Trial of Percutaneous Hepatic Perfusion Compared with Best Available Care for Patients with Melanoma Liver Metastases. <i>Annals of Surgical Oncology</i> , 2016, 23, 1309-1319.	0.7	117
4734	MIF Is Necessary for Late-Stage Melanoma Patient MDSC Immune Suppression and Differentiation. <i>Cancer Immunology Research</i> , 2016, 4, 101-112.	1.6	73
4735	Identification of melanoma cells and lymphocyte subpopulations in lymph node metastases by FTIR imaging histopathology. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2016, 1862, 202-212.	1.8	28
4736	Immunotherapy and targeted therapy for cervical cancer: an update. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 83-98.	1.1	89
4737	Super natural killer cells that target metastases in the tumor draining lymph nodes. <i>Biomaterials</i> , 2016, 77, 66-76.	5.7	67
4738	Beginning of a novel frontier: T-cell-directed immune manipulation in lymphomas. <i>Expert Review of Hematology</i> , 2016, 9, 123-135.	1.0	2
4739	Anti-PD-1/PD-L1 Therapy as a Promising Option for Non-Small Cell Lung Cancer: a Single arm Meta-Analysis. <i>Pathology and Oncology Research</i> , 2016, 22, 331-339.	0.9	13
4740	Combination cancer immunotherapies tailored to the tumour microenvironment. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 143-158.	12.5	753
4741	Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies. <i>Annals of Oncology</i> , 2016, 27, 214-224.	0.6	86
4742	Novel Treatments in Development for Melanoma. <i>Cancer Treatment and Research</i> , 2016, 167, 371-416.	0.2	15
4743	Immunologic approaches to cancer prevention—current status, challenges, and future perspectives. <i>Seminars in Oncology</i> , 2016, 43, 161-172.	0.8	35
4744	Clinical Cases in Skin of Color. , 2016, , .		0
4745	The intersection of cancer, cancer stem cells, and the immune system: therapeutic opportunities. <i>Neuro-Oncology</i> , 2016, 18, 153-159.	0.6	86

#	ARTICLE	IF	CITATIONS
4746	Immunotherapy for cancer in the central nervous system: Current and future directions. <i>Oncolmmunology</i> , 2016, 5, e1082027.	2.1	72
4747	Combination viroimmunotherapy with checkpoint inhibition to treat glioma, based on location-specific tumor profiling. <i>Neuro-Oncology</i> , 2016, 18, 518-527.	0.6	57
4748	Differential Immune Microenvironments and Response to Immune Checkpoint Blockade among Molecular Subtypes of Murine Medulloblastoma. <i>Clinical Cancer Research</i> , 2016, 22, 582-595.	3.2	88
4749	Immune checkpoint inhibitors: a new frontier in bladder cancer. <i>World Journal of Urology</i> , 2016, 34, 49-55.	1.2	15
4750	Immunotherapy for non-small cell lung cancer: current concepts and clinical trials. <i>European Journal of Cardio-thoracic Surgery</i> , 2016, 49, 1324-1333.	0.6	33
4751	Vaccination with LAG-3Ig (IMP321) and Peptides Induces Specific CD4 and CD8 T-Cell Responses in Metastatic Melanoma Patients—Report of a Phase I/IIa Clinical Trial. <i>Clinical Cancer Research</i> , 2016, 22, 1330-1340.	3.2	74
4752	Fast Cars and No Brakes: Autologous Stem Cell Transplantation as a Platform for Novel Immunotherapies. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 17-22.	2.0	16
4753	Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 86-88.	0.6	129
4754	Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes. <i>Clinical Cancer Research</i> , 2016, 22, 886-894.	3.2	705
4755	Systemic Tolerance Mediated by Melanoma Brain Tumors Is Reversible by Radiotherapy and Vaccination. <i>Clinical Cancer Research</i> , 2016, 22, 1161-1172.	3.2	57
4756	PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 470-478.	3.2	168
4757	Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer. <i>Clinical Breast Cancer</i> , 2016, 16, 51-58.	1.1	71
4758	NF- κ B2 induces senescence bypass in melanoma via a direct transcriptional activation of EZH2. <i>Oncogene</i> , 2016, 35, 2735-2745.	2.6	49
4759	Immune checkpoints aberrations and gastric cancer; assessment of prognostic value and evaluation of therapeutic potentials. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 97, 65-71.	2.0	30
4761	Tumor-intrinsic oncogene pathways mediating immune avoidance. <i>Oncolmmunology</i> , 2016, 5, e1086862.	2.1	120
4762	Melanoma Cells Control Antimelanoma CTL Responses via Interaction between TIGIT and CD155 in the Effector Phase. <i>Journal of Investigative Dermatology</i> , 2016, 136, 255-263.	0.3	160
4763	Cancer immunotherapy in veterinary medicine: Current options and new developments. <i>Veterinary Journal</i> , 2016, 207, 20-28.	0.6	44
4764	“Hit the primary”: A paradigm shift in the treatment of metastatic prostate cancer?. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 97, 231-237.	2.0	18

#	ARTICLE	IF	CITATIONS
4765	A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition. <i>Clinical Cancer Research</i> , 2016, 22, 609-620.	3.2	388
4766	Cancer of Unknown Primary. , 2016, , .		7
4767	Sensitivity of plasma BRAF ^{mutant} and NRAS ^{mutant} cell-free DNA assays to detect metastatic melanoma in patients with low RECIST scores and non-RECIST disease progression. <i>Molecular Oncology</i> , 2016, 10, 157-165.	2.1	63
4768	From T cell "exhaustion" to anti-cancer immunity. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2016, 1865, 49-57.	3.3	18
4769	Personalized approaches to active immunotherapy in cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2016, 1865, 72-82.	3.3	41
4770	Therapeutic efficacy of PD-L1 blockade in a breast cancer model is enhanced by cellular vaccines expressing B7-1 and glycolipid-anchored IL-12. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 421-430.	1.4	18
4771	Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism. <i>Leukemia</i> , 2016, 30, 484-491.	3.3	201
4772	Studying cancer metastasis: Existing models, challenges and future perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 97, 107-117.	2.0	36
4773	TIGIT negatively regulates inflammation by altering macrophage phenotype. <i>Immunobiology</i> , 2016, 221, 48-55.	0.8	46
4774	More than a scaffold: Stromal modulation of tumor immunity. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2016, 1865, 3-13.	3.3	32
4775	Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights. <i>Pituitary</i> , 2016, 19, 82-92.	1.6	259
4776	Biomarkers for immunotherapy in genitourinary malignancies. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 205-213.	0.8	14
4777	Severe acute colitis induced by ipilimumab. <i>Gastroenterology & Hepatology</i> , 2016, 39, 277-279.	0.2	1
4778	Lectin microarray technology identifies specific lectins related to lymph node metastasis of advanced gastric cancer. <i>Gastric Cancer</i> , 2016, 19, 531-542.	2.7	33
4779	Biology of Lung Cancer. , 2016, , 912-926.e6.		1
4780	Integrating chemoradiation and molecularly targeted therapy. <i>Advanced Drug Delivery Reviews</i> , 2017, 109, 74-83.	6.6	22
4781	Enhancing the clinical coverage and anticancer efficacy of immune checkpoint blockade through manipulation of the gut microbiota. <i>Oncolmmunology</i> , 2017, 6, e1132137.	2.1	45
4782	Economic burden of toxicities associated with treating metastatic melanoma in eight countries. <i>European Journal of Health Economics</i> , 2017, 18, 49-58.	1.4	37

#	ARTICLE	IF	CITATIONS
4783	Advances in personalized cancer immunotherapy. <i>Breast Cancer</i> , 2017, 24, 16-24.	1.3	75
4784	Response of metastatic mucosal melanoma to immunotherapy: It can get worse before it gets better. <i>Journal of Oncology Pharmacy Practice</i> , 2017, 23, 215-219.	0.5	22
4785	Tricking the balance: NK cells in anti-cancer immunity. <i>Immunobiology</i> , 2017, 222, 11-20.	0.8	163
4786	Differences in Funding Sources of Phase III Oncology Clinical Trials by Treatment Modality and Cancer Type. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017, 40, 312-317.	0.6	9
4787	CTLA-4 Limits Anti-CD20-Mediated Tumor Regression. <i>Clinical Cancer Research</i> , 2017, 23, 193-203.	3.2	35
4788	Extracellular purines, purinergic receptors and tumor growth. <i>Oncogene</i> , 2017, 36, 293-303.	2.6	428
4789	Accounting for Cured Patients in Cost-Effectiveness Analysis. <i>Value in Health</i> , 2017, 20, 705-709.	0.1	58
4790	Radiotherapy utilization in <scp>BRAF</scp> mutation-†tested metastatic melanoma in the targeted therapy era. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017, 13, e117-e123.	0.7	2
4791	Translational aspects in targeting the stromal tumour microenvironment: From bench to bedside. <i>European Journal of Molecular and Clinical Medicine</i> , 2017, 3, 9.	0.5	18
4792	A second chance for telomerase reverse transcriptase in anticancer immunotherapy. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 115-128.	12.5	95
4793	Altered expression of major immune regulatory molecules in peripheral blood immune cells associated with breast cancer. <i>Breast Cancer</i> , 2017, 24, 111-120.	1.3	21
4794	Sequential treatment with immunotherapy and BRAF inhibitors in BRAF-mutant advanced melanoma. <i>Clinical and Translational Oncology</i> , 2017, 19, 119-124.	1.2	23
4795	Liver transplantation for hepatobiliary malignancies: a new era of †Transplant Oncology† has begun. <i>Surgery Today</i> , 2017, 47, 403-415.	0.7	48
4796	Late-onset pericardial tamponade, bilateral pleural effusions and recurrent immune monoarthritis induced by ipilimumab use for metastatic melanoma. <i>Journal of Oncology Pharmacy Practice</i> , 2017, 23, 231-234.	0.5	48
4798	Principles of Kinase Inhibitor Therapy for Solid Tumors. <i>Annals of Surgery</i> , 2017, 265, 311-319.	2.1	10
4799	Pulmonary sarcoid-like granulomatosis induced by nivolumab. <i>British Journal of Dermatology</i> , 2017, 176, 1060-1063.	1.4	106
4800	Ipilimumab and Stereotactic Radiosurgery Versus Stereotactic Radiosurgery Alone for Newly Diagnosed Melanoma Brain Metastases. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017, 40, 444-450.	0.6	155
4801	Selective Internal Yttrium-90 Radioembolization Therapy (90Y-SIRT) Versus Best Supportive Care in Patients With Unresectable Metastatic Melanoma to the Liver Refractory to Systemic Therapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017, 40, 27-34.	0.6	43

#	ARTICLE	IF	CITATIONS
4802	Elements of cancer immunity and the cancer's immune set point. <i>Nature</i> , 2017, 541, 321-330.	13.7	3,558
4803	PD-L1, Galectin-9 and CD8 ⁺ tumor-infiltrating lymphocytes are associated with survival in hepatocellular carcinoma. <i>OncImmunology</i> , 2017, 6, e1273309.	2.1	117
4804	Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	263
4805	Acute management of autoimmune toxicity in cancer patients on immunotherapy: Common toxicities and the approach for the emergency physician. <i>EMA - Emergency Medicine Australasia</i> , 2017, 29, 245-251.	0.5	25
4806	Inflammatory bowel disease and cancer response due to anti-CTLA-4: is it in the flora?. <i>Seminars in Immunopathology</i> , 2017, 39, 327-331.	2.8	22
4807	Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma. <i>British Journal of Cancer</i> , 2017, 116, 432-440.	2.9	59
4808	Cancer immunotherapy's immune checkpoint blockade and associated endocrinopathies. <i>Nature Reviews Endocrinology</i> , 2017, 13, 195-207.	4.3	515
4809	The differentiation and plasticity of Tc17 cells are regulated by CTLA-4-mediated effects on STATs. <i>OncImmunology</i> , 2017, 6, e1273300.	2.1	24
4810	Patterns of use of systemic therapies among patients with metastatic melanoma: a retrospective claims database analysis in the United States. <i>Journal of Dermatological Treatment</i> , 2017, 28, 549-553.	1.1	6
4811	Combination Treatment of Patients with BRAF-Mutant Melanoma: A New Standard of Care. <i>BioDrugs</i> , 2017, 31, 51-61.	2.2	46
4812	The effect of timing of stereotactic radiosurgery treatment of melanoma brain metastases treated with ipilimumab. <i>Journal of Neurosurgery</i> , 2017, 127, 1007-1014.	0.9	77
4813	Immunomodulatory Activity of VEGF in Cancer. <i>International Review of Cell and Molecular Biology</i> , 2017, 330, 295-342.	1.6	153
4814	Renal complications of immune checkpoint blockade. <i>Current Problems in Cancer</i> , 2017, 41, 100-110.	1.0	81
4815	Immune Checkpoint Inhibitors in Lung Cancer – An Unheralded Opportunity?. <i>Clinical Oncology</i> , 2017, 29, 207-217.	0.6	6
4816	Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature. <i>European Journal of Cancer</i> , 2017, 73, 1-8.	1.3	397
4817	Immunosuppressive Myeloid Cells's Blockade in the Glioma Microenvironment Enhances the Efficacy of Immune-Stimulatory Gene Therapy. <i>Molecular Therapy</i> , 2017, 25, 232-248.	3.7	130
4818	PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 305-312.	1.4	42
4819	Therapeutic Cancer Vaccines. , 2017, , 47-78.		2

#	ARTICLE	IF	CITATIONS
4820	Management of Prostate Cancer. , 2017, , .		5
4821	The development of dendritic cell vaccine-based immunotherapies for glioblastoma. <i>Seminars in Immunopathology</i> , 2017, 39, 225-239.	2.8	42
4822	Combined blockade of Tim-3 and MEK inhibitor enhances the efficacy against melanoma. <i>Biochemical and Biophysical Research Communications</i> , 2017, 484, 378-384.	1.0	21
4823	Pharmacological therapies for Liposarcoma. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 361-377.	1.3	17
4824	Epigenetics in cancer stem cells. <i>Molecular Cancer</i> , 2017, 16, 29.	7.9	296
4825	Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 393-403.	5.1	91
4826	Immune checkpoint inhibitors and targeted therapies for metastatic melanoma: A network meta-analysis. <i>Cancer Treatment Reviews</i> , 2017, 54, 34-42.	3.4	46
4827	Experimental animal modeling for immuno-oncology. , 2017, 173, 34-46.		44
4828	Immunotherapeutic strategies for the treatment of renal cell carcinoma: Where will we go?. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 357-368.	1.1	11
4829	Clinical Dosing Regimen of Selinexor Maintains Normal Immune Homeostasis and T-cell Effector Function in Mice: Implications for Combination with Immunotherapy. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 428-439.	1.9	25
4830	Novel immune check point inhibiting antibodies in cancer therapyâ€”Opportunities and challenges. <i>Drug Resistance Updates</i> , 2017, 30, 39-47.	6.5	98
4831	The impact of body composition parameters on ipilimumab toxicity and survival in patients with metastatic melanoma. <i>British Journal of Cancer</i> , 2017, 116, 310-317.	2.9	141
4832	T cell exhaustion: from pathophysiological basics to tumor immunotherapy. <i>Cell Communication and Signaling</i> , 2017, 15, 1.	2.7	154
4833	Pembrolizumab for advanced melanoma: experience from the Spanish Expanded Access Program. <i>Clinical and Translational Oncology</i> , 2017, 19, 761-768.	1.2	12
4834	Identification of inhibitors of myeloid-derived suppressor cells activity through phenotypic chemical screening. <i>Oncolmmunology</i> , 2017, 6, e1258503.	2.1	12
4835	Review: Immuneâ€”Related Adverse Events With Use of Checkpoint Inhibitors for Immunotherapy of Cancer. <i>Arthritis and Rheumatology</i> , 2017, 69, 687-699.	2.9	101
4836	Glioblastoma. , 2017, , 265-288.		11
4837	Is there still a role for cytotoxic chemotherapy after targeted therapy and immunotherapy in metastatic melanoma? A case report and literature review. <i>Chinese Journal of Cancer</i> , 2017, 36, 10.	4.9	38

#	ARTICLE	IF	CITATIONS
4838	An Immunogram for the Cancer-Immunity Cycle: Towards Personalized Immunotherapy of Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 791-803.	0.5	127
4839	Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition. <i>Oncogene</i> , 2017, 36, 3334-3345.	2.6	83
4840	Curing tumor-bearing mice by shifting a Th2 to a Th1 anti-tumor response. <i>Human Antibodies</i> , 2017, 25, 147-153.	0.6	4
4841	Gastrointestinal and Hepatic Complications of Immune Checkpoint Inhibitors. <i>Current Gastroenterology Reports</i> , 2017, 19, 3.	1.1	141
4842	<sc>PD</sc> expression by canine T cells and functional effects of <sc>PD</sc> blockade. <i>Veterinary and Comparative Oncology</i> , 2017, 15, 1487-1502.	0.8	51
4843	PD-1, PD-L1 (B7-H1) and Tumor-Site Immune Modulation Therapy: The Historical Perspective. <i>Journal of Hematology and Oncology</i> , 2017, 10, 34.	6.9	82
4844	Tumor Microenvironment for Melanoma Cells. , 2017, , 357-368.		1
4845	Medication-associated gastrointestinal tract injury. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 470, 245-266.	1.4	22
4847	Sunrise in melanoma management: Time to focus on melanoma burden in Asia. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017, 13, 423-427.	0.7	23
4848	Cardiovascular Toxicities Associated with Cancer Immunotherapies. <i>Current Cardiology Reports</i> , 2017, 19, 21.	1.3	126
4850	Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 387-394.	1.1	128
4851	PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors. <i>Clinical Cancer Research</i> , 2017, 23, 4270-4279.	3.2	117
4852	State of the art in anti-cancer mAbs. <i>Journal of Biomedical Science</i> , 2017, 24, 15.	2.6	64
4853	The biology of uveal melanoma. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 109-140.	2.7	160
4854	The majority of patients with metastatic melanoma are not represented in pivotal phase III immunotherapy trials. <i>European Journal of Cancer</i> , 2017, 74, 89-95.	1.3	77
4855	Severe bullous pemphigoid associated with pembrolizumab therapy for metastatic melanoma with complete regression. <i>Clinical and Experimental Dermatology</i> , 2017, 42, 309-312.	0.6	49
4856	Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers Part 1: GI carcinomas. , 2017, 174, 145-172.		22
4857	Nanomedicine as a potent strategy in melanoma tumor microenvironment. <i>Pharmacological Research</i> , 2017, 126, 31-53.	3.1	25

#	ARTICLE	IF	CITATIONS
4858	Targeting neoantigens to augment antitumour immunity. <i>Nature Reviews Cancer</i> , 2017, 17, 209-222.	12.8	724
4859	Next-Generation Sequencing to Guide Treatment of Advanced Melanoma. <i>American Journal of Clinical Dermatology</i> , 2017, 18, 303-310.	3.3	12
4860	Novel Therapies for Advanced Cervical Cancer. , 2017, , 263-299.		2
4861	Isolated Limb Perfusion for Melanoma is Safe and Effective in Elderly Patients. <i>Annals of Surgical Oncology</i> , 2017, 24, 1997-2005.	0.7	29
4862	The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy. <i>Endocrine-Related Cancer</i> , 2017, 24, R123-R144.	1.6	64
4864	NLRC5/CITA: A Key Player in Cancer Immune Surveillance. <i>Trends in Cancer</i> , 2017, 3, 28-38.	3.8	59
4865	T cell neoepitope discovery in colorectal cancer by high throughput profiling of somatic mutations in expressed genes. <i>Gut</i> , 2017, 66, 454-463.	6.1	48
4866	Crosstalk signaling in targeted melanoma therapy. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 23-33.	2.7	15
4867	Theranostic of biopharmaceuticals. , 2017, 175, 67-74.		5
4868	Cost-Effectiveness Analysis of a Skin Awareness Intervention for Early Detection of Skin Cancer Targeting Men Older Than 50 Years. <i>Value in Health</i> , 2017, 20, 593-601.	0.1	16
4869	Meta-analysis of randomized controlled trials for the incidence and risk of fatal adverse events in cancer patients treated with ipilimumab. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 423-428.	1.0	8
4870	Immune biomarkers for prognosis and prediction of responses to immune checkpoint blockade in cutaneous melanoma. <i>Oncolmmunology</i> , 2017, 6, e1299303.	2.1	20
4871	Standard of care in immunotherapy trials: Challenges and considerations. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 2164-2178.	1.4	4
4872	Mechanisms of Drug Resistance in Melanoma. <i>Handbook of Experimental Pharmacology</i> , 2017, 249, 91-108.	0.9	63
4873	Precision medicine driven by cancer systems biology. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 91-108.	2.7	38
4874	Towards a better cancer precision medicine: Systems biology meets immunotherapy. <i>Current Opinion in Systems Biology</i> , 2017, 2, 67-73.	1.3	7
4875	Checkpoint inhibitors in the treatment of brain metastases of non-small-cell lung cancer and melanoma. <i>Future Oncology</i> , 2017, 13, 1097-1103.	1.1	1
4876	Can binimetinib, encorafenib and masitinib be more efficacious than currently available mutation-based targeted therapies for melanoma treatment?. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 487-495.	0.9	7

#	ARTICLE	IF	CITATIONS
4877	Radiosurgery/stereotactic radiotherapy in combination with immunotherapy and targeted agents for melanoma brain metastases. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 347-356.	1.1	18
4878	The role of radiation in treating glioblastoma: here to stay. <i>Journal of Neuro-Oncology</i> , 2017, 134, 479-485.	1.4	26
4879	Structure-guided development of a high-affinity human Programmed Cell Death-1: Implications for tumor immunotherapy. <i>EBioMedicine</i> , 2017, 17, 30-44.	2.7	52
4880	COX-2 expression positively correlates with PD-L1 expression in human melanoma cells. <i>Journal of Translational Medicine</i> , 2017, 15, 46.	1.8	85
4881	Anti-CTLA-4 therapy for malignant mesothelioma. <i>Immunotherapy</i> , 2017, 9, 273-280.	1.0	19
4882	Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 683-695.	2.0	53
4883	Immune modulation by dendritic-cell-based cancer vaccines. <i>Journal of Biosciences</i> , 2017, 42, 161-173.	0.5	15
4884	Survival of patients with melanoma brain metastasis treated with stereotactic radiosurgery and active systemic drug therapies. <i>European Journal of Cancer</i> , 2017, 75, 169-178.	1.3	96
4885	Correlations of EGF G1380A, bFGF C754G and VEGF T460C polymorphisms with malignant melanoma susceptibility and prognosis: A case-control study. <i>Gene</i> , 2017, 617, 44-53.	1.0	6
4886	Checkpoint-based immunotherapy for autoimmune diseases – Opportunities and challenges. <i>Journal of Autoimmunity</i> , 2017, 79, 1-3.	3.0	25
4888	Tracking the fate and origin of clinically relevant adoptively transferred CD8 ⁺ T cells in vivo. <i>Science Immunology</i> , 2017, 2, .	5.6	68
4889	Combination immunotherapy: a road map. , 2017, 5, 16.		325
4890	Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients. <i>Cancer Immunology Research</i> , 2017, 5, 312-318.	1.6	354
4891	iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. <i>Lancet Oncology</i> , The, 2017, 18, e143-e152.	5.1	1,612
4892	DNA vaccines for prostate cancer. , 2017, 174, 27-42.		36
4893	PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression. <i>Clinical Cancer Research</i> , 2017, 23, 3711-3720.	3.2	710
4894	Immune Checkpoint Inhibition in Hepatocellular Carcinoma: Basics and Ongoing Clinical Trials. <i>Oncology</i> , 2017, 92, 50-62.	0.9	180
4895	Routine Computer Tomography Imaging for the Detection of Recurrences in High-Risk Melanoma Patients. <i>Annals of Surgical Oncology</i> , 2017, 24, 947-951.	0.7	26

#	ARTICLE	IF	CITATIONS
4896	Genetically engineered mouse models in oncology research and cancer medicine. <i>EMBO Molecular Medicine</i> , 2017, 9, 137-153.	3.3	356
4897	Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. <i>Cell</i> , 2017, 168, 707-723.	13.5	3,483
4898	AURKA Overexpression Is Driven by FOXM1 and MAPK/ERK Activation in Melanoma Cells Harboring BRAF or NRAS Mutations: Impact on Melanoma Prognosis and Therapy. <i>Journal of Investigative Dermatology</i> , 2017, 137, 1297-1310.	0.3	40
4899	Nivolumab for Squamous-Cell Cancer of Head and Neck. <i>New England Journal of Medicine</i> , 2017, 376, 595-596.	13.9	31
4900	Interplay between Immune Checkpoint Proteins and Cellular Metabolism. <i>Cancer Research</i> , 2017, 77, 1245-1249.	0.4	82
4901	The Role of Surgery for Melanoma in an Era of Effective Systemic Therapy. <i>Current Oncology Reports</i> , 2017, 19, 17.	1.8	30
4902	Biologic response modifiers: Indications, implications, and insights. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 1445-1456.	1.5	25
4903	Preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma. <i>Oncot Immunology</i> , 2017, 6, e1295903.	2.1	64
4904	Targeting TGF- β Signaling for Therapeutic Gain. <i>Cold Spring Harbor Perspectives in Biology</i> , 2017, 9, a022301.	2.3	153
4905	Checkpoint Blockade in Lung Cancer and Mesothelioma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 274-282.	2.5	59
4906	In vitro long-term treatment with MAPK inhibitors induces melanoma cells with resistance plasticity to inhibitors while retaining sensitivity to CD8 T cells. <i>Oncology Reports</i> , 2017, 37, 1367-1378.	1.2	5
4907	Development of Novel ImmunoPET Tracers to Image Human PD-1 Checkpoint Expression on Tumor-Infiltrating Lymphocytes in a Humanized Mouse Model. <i>Molecular Imaging and Biology</i> , 2017, 19, 903-914.	1.3	91
4908	Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial. <i>Lancet Oncology</i> , The, 2017, 18, 464-472.	5.1	139
4909	Tim-3 and its role in regulating anti-tumor immunity. <i>Immunological Reviews</i> , 2017, 276, 97-111.	2.8	599
4910	TAM receptor tyrosine kinases as emerging targets of innate immune checkpoint blockade for cancer therapy. <i>Immunological Reviews</i> , 2017, 276, 165-177.	2.8	125
4911	The CD47-SIRP α signaling axis as an innate immune checkpoint in cancer. <i>Immunological Reviews</i> , 2017, 276, 145-164.	2.8	410
4912	Introduction to checkpoint inhibitors and cancer immunotherapy. <i>Immunological Reviews</i> , 2017, 276, 5-8.	2.8	151
4913	The Role of Immune Checkpoint Inhibition in the Treatment of Brain Tumors. <i>Neurotherapeutics</i> , 2017, 14, 1049-1065.	2.1	20

#	ARTICLE	IF	CITATIONS
4914	<sc>LAG</sc>3 (<sc>CD</sc>223) as a cancer immunotherapy target. Immunological Reviews, 2017, 276, 80-96.	2.8	664
4915	The third group of the B7<sc>CD</sc>28 immune checkpoint family: <sc>HLA</sc>2, <sc>TMIGD</sc>2, B7x, and B7<sc>H3. Immunological Reviews, 2017, 276, 26-39.	2.8	185
4916	Co<sc>inhibitory blockade while preserving tolerance: checkpoint inhibitors for glioblastoma. Immunological Reviews, 2017, 276, 9-25.	2.8	13
4917	Stage IV advanced diffuse large B-cell lymphoma in human immunodeficiency virus infection with achieving cure by using highly active antiretroviral therapy alone: a case report. International Journal of STD and AIDS, 2017, 28, 932-936.	0.5	4
4918	Hypermutated Colorectal Cancer and Neoantigen Load. , 2017, , 187-215.		3
4919	INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology. ACS Medicinal Chemistry Letters, 2017, 8, 486-491.	1.3	235
4920	B cells and the humoral response in melanoma: The overlooked players of the tumor microenvironment. Oncoimmunology, 2017, 6, e1294296.	2.1	51
4921	Immunotherapy in pancreatic cancer treatment: a new frontier. Therapeutic Advances in Gastroenterology, 2017, 10, 168-194.	1.4	73
4922	Risk of hepatotoxicity in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta<sc>analysis of published data. International Journal of Cancer, 2017, 141, 1018-1028.	2.3	116
4923	The proportion of circulating CD45RO + CD8 + memory T cells is correlated with clinical response in melanoma patients treated with ipilimumab. European Journal of Cancer, 2017, 75, 268-279.	1.3	62
4924	The Current Status of Immunotherapies in Esophagogastric Cancer. Surgical Oncology Clinics of North America, 2017, 26, 277-292.	0.6	4
4925	The clinical evidence for targeting human myeloid-derived suppressor cells in cancer patients. Journal of Leukocyte Biology, 2017, 102, 381-391.	1.5	50
4926	Combining forces: the promise and peril of synergistic immune checkpoint blockade and targeted therapy in metastatic melanoma. Cancer and Metastasis Reviews, 2017, 36, 43-50.	2.7	23
4927	The expanding role of immunotherapy. Cancer Treatment Reviews, 2017, 54, 74-86.	3.4	100
4928	NK-Cell Recruitment Is Necessary for Eradication of Peritoneal Carcinomatosis with an IL12-Expressing Maraba Virus Cellular Vaccine. Cancer Immunology Research, 2017, 5, 211-221.	1.6	57
4929	Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2017, 98, 344-351.	0.4	143
4930	Avelumab: combining immune checkpoint inhibition and antibody-dependent cytotoxicity. Expert Opinion on Biological Therapy, 2017, 17, 515-523.	1.4	60
4931	Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients. European Journal of Cancer, 2017, 73, 61-70.	1.3	88

#	ARTICLE	IF	CITATIONS
4932	Histopathological aspects of cutaneous erythematousâ€papular eruptions induced by immune checkpoint inhibitors for the treatment of metastatic melanoma. <i>International Journal of Dermatology</i> , 2017, 56, 527-533.	0.5	30
4933	A multiâ€institutional comparison of outcomes of immunosuppressed and immunocompetent patients treated with surgery and radiation therapy for cutaneous squamous cell carcinoma of the head and neck. <i>Cancer</i> , 2017, 123, 2054-2060.	2.0	115
4934	Mucosal melanoma of the head and neck. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 112, 136-152.	2.0	125
4935	Interferon-Î±-inducible Dendritic Cells Matured with OK-432 Exhibit TRAIL and Fas Ligand Pathway-mediated Killer Activity. <i>Scientific Reports</i> , 2017, 7, 42145.	1.6	12
4936	Bladder cancer immunotherapy: swinging for the fences. <i>Future Oncology</i> , 2017, 13, 773-775.	1.1	0
4937	Radiotherapy in the age of cancer immunology: Current concepts and future developments. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 112, 1-10.	2.0	19
4938	Immune checkpoints and their inhibition in cancer and infectious diseases. <i>European Journal of Immunology</i> , 2017, 47, 765-779.	1.6	418
4939	Genetic evolution of uveal melanoma guides the development of an inflammatory microenvironment. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 903-912.	2.0	92
4940	Neutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab Treatment. <i>EBioMedicine</i> , 2017, 18, 56-61.	2.7	83
4941	The Prognostic Value of BRAF , C-KIT , and NRAS Mutations in Melanoma Patients With Brain Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 1069-1077.	0.4	58
4942	Diagnostic Comparison of CT Scans and Colonoscopy for Immune-Related Colitis in Ipilimumab-Treated Advanced Melanoma Patients. <i>Cancer Immunology Research</i> , 2017, 5, 286-291.	1.6	49
4944	Patient perspectives on ipilimumab across the melanoma treatment trajectory. <i>Supportive Care in Cancer</i> , 2017, 25, 2155-2167.	1.0	14
4945	Impact of BRAF kinase inhibitors on the miRNomes and transcriptomes of melanoma cells. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2017, 1861, 2980-2992.	1.1	25
4946	Interleukin-15 and cisplatin co-encapsulated thermosensitive polypeptide hydrogels for combined immuno-chemotherapy. <i>Journal of Controlled Release</i> , 2017, 255, 81-93.	4.8	99
4947	Chemotherapy and Transplantation: The Role of Immunosuppression in Malignancy and a Review of Antineoplastic Agents in Solid Organ Transplant Recipients. <i>American Journal of Transplantation</i> , 2017, 17, 1974-1991.	2.6	65
4948	Survival Deficit for HIV-Infected Lymphoma Patients in the National Cancer Database. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 289-290.	1.1	2
4949	End points and statistical considerations in immuno-oncology trials: impact on multiple myeloma. <i>Future Oncology</i> , 2017, 13, 1181-1193.	1.1	25
4950	Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab. <i>Endocrine</i> , 2017, 58, 535-541.	1.1	33

#	ARTICLE	IF	CITATIONS
4954	Ipilimumab in real-world clinical practice: efficacy and safety data from a multicenter observational study. <i>Journal of Chemotherapy</i> , 2017, 29, 245-251.	0.7	6
4955	Immune Checkpoint Inhibitors for Brain Metastases. <i>Current Oncology Reports</i> , 2017, 19, 38.	1.8	18
4956	Metastatic Melanoma: Treatment and Survival in the US after the Introduction of Ipilimumab and Vemurafenib. <i>Oncology Research and Treatment</i> , 2017, 40, 174-183.	0.8	14
4957	Programmed Death Ligand-1 (PD-L1) Expression in the Programmed Death Receptor-1 (PD-1)/PD-L1 Blockade: A Key Player Against Various Cancers. <i>Archives of Pathology and Laboratory Medicine</i> , 2017, 141, 851-861.	1.2	82
4958	CTLA-4. , 2017, , 157-170.		0
4959	Genomic Instability in Cancer: Teetering on the Limit of Tolerance. <i>Cancer Research</i> , 2017, 77, 2179-2185.	0.4	182
4960	Nanotechnology based therapeutic modality to boost anti-tumor immunity and collapse tumor defense. <i>Journal of Controlled Release</i> , 2017, 256, 26-45.	4.8	41
4961	Repolarizing macrophages improves breast cancer therapy. <i>Cell Research</i> , 2017, 27, 963-964.	5.7	40
4962	Pneumotoxicity associated with immune checkpoint inhibitor therapies. <i>Current Opinion in Pulmonary Medicine</i> , 2017, 23, 305-316.	1.2	18
4963	Tremelimumab-Induced Graves Hyperthyroidism. <i>European Thyroid Journal</i> , 2017, 6, 167-170.	1.2	42
4964	Expression of Programmed Cell Death Protein 1 by Tumor-Infiltrating Lymphocytes and Tumor Cells is Associated with Advanced Tumor Stage in Patients with Esophageal Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2017, 24, 2698-2706.	0.7	24
4965	Dendritic cell based vaccination strategy: an evolving paradigm. <i>Journal of Neuro-Oncology</i> , 2017, 133, 223-235.	1.4	39
4966	Management of skin adverse events associated with immune checkpoint inhibitors in patients with melanoma. <i>Journal of the American Association of Nurse Practitioners</i> , 2017, 29, 294-303.	0.5	11
4967	Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity. <i>RMD Open</i> , 2017, 3, e000412.	1.8	161
4968	Can local radiotherapy and IL-12 synergise to overcome the immunosuppressive tumor microenvironment and allow "in situ tumor vaccination"? <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 833-840.	2.0	21
4969	Regulatory T cells as suppressors of anti-tumor immunity: Role of metabolism. <i>Cytokine and Growth Factor Reviews</i> , 2017, 35, 15-25.	3.2	33
4970	Dendritic Cell Strategies for Eliciting Mutation-Derived Tumor Antigen Responses in Patients. <i>Cancer Journal (Sudbury, Mass)</i> , 2017, 23, 131-137.	1.0	10
4971	Laser immunotherapy for advanced solid tumors. <i>Proceedings of SPIE</i> , 2017, , .	0.8	0

#	ARTICLE	IF	CITATIONS
4972	History and current state of immunotherapy in glioma and brain metastasis. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 347-368.	1.4	59
4973	New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management. <i>Critical Care</i> , 2017, 21, 89.	2.5	340
4974	Clinical prognostic markers in stage IIIC melanoma. <i>Journal of Surgical Oncology</i> , 2017, 116, 244-251.	0.8	7
4975	Engineering of a self-adjuvanted iTEP-delivered CTL vaccine. <i>Acta Pharmacologica Sinica</i> , 2017, 38, 914-923.	2.8	7
4976	Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic. <i>Annals of Oncology</i> , 2017, 28, 1388-1398.	0.6	70
4977	PET/CT surveillance detects asymptomatic recurrences in stage IIIB and IIIC melanoma patients: a prospective cohort study. <i>Melanoma Research</i> , 2017, 27, 251-257.	0.6	16
4978	Cancer Genomics and Important Oncologic Mutations: A Contemporary Guide for Body Imagers. <i>Radiology</i> , 2017, 283, 314-340.	3.6	19
4979	Treatment of advanced melanoma with laser immunotherapy and ipilimumab. <i>Journal of Biophotonics</i> , 2017, 10, 618-622.	1.1	25
4980	Adjuvant Therapy for Melanoma. <i>Current Oncology Reports</i> , 2017, 19, 36.	1.8	26
4981	Histopathologic Features of Colitis Due to Immunotherapy With Anti-PD-1 Antibodies. <i>American Journal of Surgical Pathology</i> , 2017, 41, 643-654.	2.1	146
4982	Absence of miR-182 Augments Cardiac Allograft Survival. <i>Transplantation</i> , 2017, 101, 524-530.	0.5	15
4983	Elevated T cell activation score is associated with improved survival of breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 164, 689-696.	1.1	49
4984	Vaccine-based immunotherapeutic approaches to gliomas and beyond. <i>Nature Reviews Neurology</i> , 2017, 13, 363-374.	4.9	125
4985	Immune Checkpoint Inhibitors for Treatment of Metastatic Melanoma of the Orbit and Ocular Adnexa. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2017, 33, e82-e85.	0.4	41
4986	Mechanisms of Immune Tolerance in Leukemia and Lymphoma. <i>Trends in Immunology</i> , 2017, 38, 513-525.	2.9	86
4987	Immunotherapy is different: Implications for vaccine clinical trial design. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 2179-2184.	1.4	1
4988	Epigenetics and immunotherapy: The current state of play. <i>Molecular Immunology</i> , 2017, 87, 227-239.	1.0	167
4990	Checkpoint inhibition and melanoma: Considerations in treating the older adult. <i>Journal of Geriatric Oncology</i> , 2017, 8, 237-241.	0.5	27

#	ARTICLE	IF	CITATIONS
4991	Focus on cutaneous and uveal melanoma specificities. <i>Genes and Development</i> , 2017, 31, 724-743.	2.7	75
4992	Combined Anti-VEGF and Anti-CTLA-4 Therapy Elicits Humoral Immunity to Galectin-1 Which Is Associated with Favorable Clinical Outcomes. <i>Cancer Immunology Research</i> , 2017, 5, 446-454.	1.6	56
4993	Emerging therapies for breast cancer. <i>Journal of Hematology and Oncology</i> , 2017, 10, 98.	6.9	60
4994	Antiangiogenics and immunotherapies in cervical cancer: an update and future's view. <i>Medical Oncology</i> , 2017, 34, 115.	1.2	14
4996	Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy. <i>Cancer Cell</i> , 2017, 31, 711-723.e4.	7.7	1,011
4997	Heterogeneity of Tumor and Immune Cell PD-L1 Expression and Lymphocyte Counts in Surgical NSCLC Samples. <i>Clinical Lung Cancer</i> , 2017, 18, 682-691.e5.	1.1	74
4998	Melanoma antigens and related immunological markers. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 115, 36-49.	2.0	54
4999	Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E4223-E4232.	3.3	121
5000	Novel agents in mantle cell lymphoma. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 491-506.	1.1	7
5001	Immunotherapy in advanced melanoma: a network meta-analysis. <i>Immunotherapy</i> , 2017, 9, 471-479.	1.0	9
5002	The swinging pendulum of cancer immunotherapy personalization. <i>Personalized Medicine</i> , 2017, 14, 259-270.	0.8	3
5003	Checkpoint inhibitors in hematological malignancies. <i>Journal of Hematology and Oncology</i> , 2017, 10, 103.	6.9	106
5004	Current status of chimeric antigen receptor engineered T cell-based and immune checkpoint blockade-based cancer immunotherapies. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 1113-1121.	2.0	29
5005	The Potential of Cellular- and Viral-Based Immunotherapies for Malignant Glioma—Dendritic Cell Vaccines, Adoptive Cell Transfer, and Oncolytic Viruses. <i>Current Neurology and Neuroscience Reports</i> , 2017, 17, 50.	2.0	10
5006	Personalized T cell-mediated cancer immunotherapy: progress and challenges. <i>Current Opinion in Biotechnology</i> , 2017, 48, 142-152.	3.3	78
5007	RECISTing the Temptation to Prematurely Stop Nivolumab. <i>European Urology</i> , 2017, 72, 377-378.	0.9	0
5008	Checkpoint inhibitor-associated drug reaction with eosinophilia and systemic symptom syndrome. <i>Melanoma Research</i> , 2017, 27, 271-273.	0.6	40
5009	Immunobiology and Immune Based Therapies of Melanoma. , 2017, , 871-890.		0

#	ARTICLE	IF	CITATIONS
5010	Improving Antibody-Based Cancer Therapeutics Through Glycan Engineering. <i>BioDrugs</i> , 2017, 31, 151-166.	2.2	58
5011	Biologics in patients with skin diseases. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 1423-1430.	1.5	28
5012	Cellular immunotherapies for cancer. <i>Oncolmunology</i> , 2017, 6, e1306619.	2.1	17
5013	Treating Hepatobiliary Cancer: The Immunologic Approach. <i>Digestive Diseases</i> , 2017, 35, 390-396.	0.8	7
5014	RegulatorTrail: a web service for the identification of key transcriptional regulators. <i>Nucleic Acids Research</i> , 2017, 45, W146-W153.	6.5	21
5015	Does adjuvant ipilimumab have little adverse effect on quality of life?. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 395-396.	12.5	5
5016	The use of immunotherapy in the treatment of melanoma. <i>Journal of Hematology and Oncology</i> , 2017, 10, 88.	6.9	89
5017	The Immunobiology of Cancer: From Tumor Escape to Cancer Immunoediting Towards Immunotherapy in Gynecologic Oncology. , 2017, , 193-204.		3
5018	MITF suppression by CH5552074 inhibits cell growth in melanoma cells. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 1187-1193.	1.1	10
5019	Noscapinoids bearing silver nanocrystals augmented drug delivery, cytotoxicity, apoptosis and cellular uptake in B16F1, mouse melanoma skin cancer cells. <i>Biomedicine and Pharmacotherapy</i> , 2017, 90, 906-913.	2.5	15
5020	Genome variation across cancers scales with tissue stiffness – An invasion-mutation mechanism and implications for immune cell infiltration. <i>Current Opinion in Systems Biology</i> , 2017, 2, 103-114.	1.3	50
5021	Murinization and H Chain Isotype Matching of the Anti-GITR Antibody DTA-1 Reduces Immunogenicity-Mediated Anaphylaxis in C57BL/6 Mice. <i>Journal of Immunology</i> , 2017, 198, 4502-4512.	0.4	3
5022	Tumor-targeted IL-12 combined with local irradiation leads to systemic tumor control via abscopal effects <i>in vivo</i> . <i>Oncolmunology</i> , 2017, 6, e1323161.	2.1	39
5023	Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma. <i>Cancer Discovery</i> , 2017, 7, 832-851.	7.7	49
5024	Is minimal residual disease a convincing tool to determine the treatment duration of immune checkpoint inhibitors?. <i>Future Oncology</i> , 2017, 13, 381-383.	1.1	4
5025	The Immune Response to Implanted Materials and Devices. , 2017, , .		17
5026	Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. <i>Lancet Oncology</i> , The, 2017, 18, 31-41.	5.1	845
5027	Gene expression profiling of anti-CTLA4-treated metastatic melanoma in patients with treatment-induced autoimmunity. <i>Laboratory Investigation</i> , 2017, 97, 207-216.	1.7	13

#	ARTICLE	IF	CITATIONS
5028	Low baseline levels of <sc>NK</sc> cells may predict a positive response to ipilimumab in melanoma therapy. <i>Experimental Dermatology</i> , 2017, 26, 622-629.	1.4	19
5029	<sc>DEK</sc> oncogene is overexpressed during melanoma progression. <i>Pigment Cell and Melanoma Research</i> , 2017, 30, 194-202.	1.5	19
5030	High cytotoxic T-lymphocyte-associated antigen 4 and phospho-Akt expression in tumor samples predicts poor clinical outcomes in ipilimumab-treated melanoma patients. <i>Melanoma Research</i> , 2017, 27, 24-31.	0.6	15
5031	Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumab. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1977-1984.	1.2	14
5032	Administration of a vasoactive intestinal peptide antagonist enhances the autologous anti-leukemia T cell response in murine models of acute leukemia. <i>OncolImmunology</i> , 2017, 6, e1304336.	2.1	11
5033	Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape. <i>European Journal of Cancer</i> , 2017, 81, 116-129.	1.3	443
5034	Asiaâ€™Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. <i>Hepatology International</i> , 2017, 11, 317-370.	1.9	1,537
5035	Combinatorial immunotherapy and nanoparticle mediated hyperthermia. <i>Advanced Drug Delivery Reviews</i> , 2017, 114, 175-183.	6.6	91
5036	PD-L1 Expression in Pancreatic Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw304.	3.0	43
5037	Anti-programmed cell death protein 1 tolerance and efficacy after ipilimumab immunotherapy: observational study of 39 patients. <i>Melanoma Research</i> , 2017, 27, 110-115.	0.6	10
5038	A phase II study of ipilimumab plus temozolomide in patients with metastatic melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 1359-1366.	2.0	29
5039	CD8 T Cells. , 2017, , 131-142.		0
5040	Immunotherapy for the Treatment of Uveal Melanoma: Current Status and Emerging Therapies. <i>Current Oncology Reports</i> , 2017, 19, 45.	1.8	70
5041	Novel Opportunities to Use Radiation Therapy with Immune Checkpoint Inhibitors for Melanoma Management. <i>Surgical Oncology Clinics of North America</i> , 2017, 26, 515-529.	0.6	16
5042	Antibody-mediated neutralization of soluble MIC significantly enhances CTLA4 blockade therapy. <i>Science Advances</i> , 2017, 3, e1602133.	4.7	27
5043	Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis. <i>Oncologist</i> , 2017, 22, 709-718.	1.9	221
5044	Imaging Studies in Immunotherapy. , 2017, , 149-179.		1
5045	Pulmonary Toxicities from Checkpoint Immunotherapy for Malignancy. <i>Clinics in Chest Medicine</i> , 2017, 38, 223-232.	0.8	36

#	ARTICLE	IF	CITATIONS
5046	Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions. <i>Cancer Treatment Reviews</i> , 2017, 57, 36-49.	3.4	257
5047	Immune surveillance in melanoma: From immune attack to melanoma escape and even counterattack. <i>Cancer Biology and Therapy</i> , 2017, 18, 451-469.	1.5	35
5049	The Promise and the Hype of "Personalised Medicine"™. <i>New Bioethics</i> , 2017, 23, 13-20.	0.5	41
5050	Therapeutic Vaccine of Gastric Cancer. , 2017, , 131-147.		0
5051	Immunogenomics: using genomics to personalize cancer immunotherapy. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 471, 209-219.	1.4	7
5052	nRGD modified lycobetaine and octreotide combination delivery system to overcome multiple barriers and enhance anti-glioma efficacy. <i>Colloids and Surfaces B: Biointerfaces</i> , 2017, 156, 330-339.	2.5	9
5053	Hallmarks of response to immune checkpoint blockade. <i>British Journal of Cancer</i> , 2017, 117, 1-7.	2.9	194
5055	Fc Gamma R. , 2017, , 209-228.		0
5056	Peptide Vaccine: Overview. , 2017, , 427-439.		1
5057	Whole-Cell Vaccines. , 2017, , 561-574.		0
5058	gp100. , 2017, , 261-266.		1
5059	Interleukin-2. , 2017, , 323-334.		0
5060	Glucocorticoid-Induced TNF Receptor (GITR). , 2017, , 243-250.		0
5061	Immune Checkpoint Blockade and Gastric Cancer. , 2017, , 115-130.		2
5062	Advancing Immunotherapy in Metastatic Breast Cancer. <i>Current Treatment Options in Oncology</i> , 2017, 18, 35.	1.3	13
5063	Delivering safer immunotherapies for cancer. <i>Advanced Drug Delivery Reviews</i> , 2017, 114, 79-101.	6.6	233
5064	Combinatorial drug delivery approaches for immunomodulation. <i>Advanced Drug Delivery Reviews</i> , 2017, 114, 161-174.	6.6	42
5065	Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 2770-2780.	1.8	210

#	ARTICLE	IF	CITATIONS
5066	Overcoming the resistance of pancreatic cancer to immune checkpoint inhibitors. <i>Journal of Surgical Oncology</i> , 2017, 116, 55-62.	0.8	46
5067	Intratumoral injection of IFN- γ induces chemokine production in melanoma and augments the therapeutic efficacy of anti-PD-L1 mAb. <i>Biochemical and Biophysical Research Communications</i> , 2017, 490, 521-527.	1.0	15
5068	Immuno-oncologic Approaches: CAR-T Cells and Checkpoint Inhibitors. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 471-478.	0.2	34
5069	S3â€œLeitlinie Diagnostik, Therapie und Nachsorge des Melanoms â€œ Update 2015/2016, Kurzversion 2.0. <i>JDDG - Journal of the German Society of Dermatology</i> , 2017, 15, e1-e41.	0.4	29
5070	DNA Damage and Repair Biomarkers of Immunotherapy Response. <i>Cancer Discovery</i> , 2017, 7, 675-693.	7.7	519
5071	Immunotherapy: The Wave of the Future in Bladder Cancer?. <i>Clinical Genitourinary Cancer</i> , 2017, 15, S3-S17.	0.9	8
5072	Clinical development of immunotherapy for prostate cancer. <i>International Journal of Urology</i> , 2017, 24, 675-680.	0.5	6
5073	Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management. <i>Cancer Treatment Reviews</i> , 2017, 58, 70-76.	3.4	228
5074	Geographic region: Does it matter in cutaneous melanoma of the head and neck?. <i>Laryngoscope</i> , 2017, 127, 2763-2769.	1.1	2
5075	CD45RA ⁺ Foxp3 ^{high} regulatory T cells have a negative impact on the clinical outcome of head and neck squamous cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 1275-1285.	2.0	35
5076	Immune Checkpoint Inhibitor-Induced Colitis: Diagnosis and Management. <i>Targeted Oncology</i> , 2017, 12, 301-308.	1.7	66
5077	Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies. <i>Cancer Treatment Reviews</i> , 2017, 58, 22-33.	3.4	76
5079	Tumor cells PD-L1 expression as a favorable prognosis factor in nasopharyngeal carcinoma patients with pre-existing intratumor-infiltrating lymphocytes. <i>Oncolmmunology</i> , 2017, 6, e1312240.	2.1	68
5080	Combined immune checkpoint blockade as a therapeutic strategy for <i>BRCA1</i> -mutated breast cancer. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	227
5081	Cancer immunotherapy by targeting immune checkpoints: mechanism of T cell dysfunction in cancer immunity and new therapeutic targets. <i>Journal of Biomedical Science</i> , 2017, 24, 35.	2.6	88
5082	Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1747-1750.	0.5	200
5083	Immune Checkpoint Inhibitor Therapy: What Line of Therapy and How to Choose?. <i>Current Treatment Options in Oncology</i> , 2017, 18, 33.	1.3	13
5084	Usefulness of 11 C-methionine-PET for predicting the efficacy of carbon ion radiation therapy for head and neck mucosal malignant melanoma. <i>International Journal of Oral and Maxillofacial Surgery</i> , 2017, 46, 1220-1228.	0.7	7

#	ARTICLE	IF	CITATIONS
5085	Immunotherapeutic properties of chemotherapy. <i>Current Opinion in Pharmacology</i> , 2017, 35, 83-88.	1.7	30
5086	Myeloid-derived suppressor cellsâ€™ a new therapeutic target to overcome resistance to cancer immunotherapy. <i>Journal of Leukocyte Biology</i> , 2017, 102, 727-740.	1.5	88
5087	Ubiquitination in melanoma pathogenesis and treatment. <i>Cancer Medicine</i> , 2017, 6, 1362-1377.	1.3	24
5088	Interaction of molecular alterations with immune response in melanoma. <i>Cancer</i> , 2017, 123, 2130-2142.	2.0	24
5089	Breast Cancer and Transplantation. <i>American Journal of Transplantation</i> , 2017, 17, 2243-2253.	2.6	21
5090	Combining radiotherapy with immunotherapy: the past, the present and the future. <i>British Journal of Radiology</i> , 2017, 90, 20170157.	1.0	99
5091	Regional immunotherapy for liver and peritoneal metastases. <i>Journal of Surgical Oncology</i> , 2017, 116, 46-54.	0.8	6
5092	Immunological Characteristics of Colitis Associated with Anti-CTLA-4 Antibody Therapy. <i>Cancer Investigation</i> , 2017, 35, 443-455.	0.6	67
5093	Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study. <i>Thyroid</i> , 2017, 27, 894-901.	2.4	123
5094	Reprogramming the oncogenic response: SET protein as a potential therapeutic target in cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2017, 21, 685-694.	1.5	22
5095	An Introduction to Immunotherapy in the Treatment of Brain Tumors. , 2017, , 1-10.		0
5096	Checkpoint Blockade Immunotherapy for Glioblastoma. , 2017, , 261-300.		2
5097	Long-lived pancreatic ductal adenocarcinoma slice cultures enable precise study of the immune microenvironment. <i>Oncolmmunology</i> , 2017, 6, e1333210.	2.1	55
5098	Cytokine biomarkers to predict antitumor responses to nivolumab suggested in a phase 2 study for advanced melanoma. <i>Cancer Science</i> , 2017, 108, 1022-1031.	1.7	100
5100	Emerging growth factor receptor antagonists for the treatment of advanced melanoma. <i>Expert Opinion on Emerging Drugs</i> , 2017, 22, 165-174.	1.0	1
5101	Primary malignant melanoma of esophagus following chemoradiotherapy for esophageal squamous cell carcinoma: report of a case. <i>Clinical Journal of Gastroenterology</i> , 2017, 10, 336-341.	0.4	8
5102	Molecularly targeted agents in oculoplastic surgery. <i>Current Opinion in Ophthalmology</i> , 2017, 28, 485-492.	1.3	9
5103	Problems of Cancer Treatment. Part I. Theory of Treatment Based on Known Mechanisms of Anticancer Immunological Responses. <i>Advances in Cell Biology</i> , 2017, 5, 72-95.	1.5	0

#	ARTICLE	IF	CITATIONS
5104	Understanding the checkpoint blockade in lung cancer immunotherapy. <i>Drug Discovery Today</i> , 2017, 22, 1266-1273.	3.2	48
5105	Pharmacophore Identification and Scaffold Exploration to Discover Novel, Potent, and Chemically Stable Inhibitors of Acid Ceramidase in Melanoma Cells. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 5800-5815.	2.9	15
5106	Epigenetic modulation in cancer immunotherapy. <i>Current Opinion in Pharmacology</i> , 2017, 35, 48-56.	1.7	50
5107	Survival of melanoma patients treated with novel drugs: retrospective analysis of real-world data. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 2087-2094.	1.2	13
5108	Checkpoint inhibitors in advanced melanoma: effect on the field of immunotherapy. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 647-655.	1.1	14
5109	Intraepithelial Melanoma in the Stomach After Treatment With Immune Checkpoint Blockade Therapy. <i>American Journal of Dermatopathology</i> , 2017, 39, e116-e118.	0.3	5
5110	Pembrolizumab in cervical cancer: latest evidence and clinical usefulness. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 431-439.	1.4	73
5111	Zerumbone inhibits melanoma cell proliferation and migration by altering mitochondrial functions. <i>Oncology Letters</i> , 2017, 13, 2397-2402.	0.8	25
5112	Polymerase proofreading domain mutations: New opportunities for immunotherapy in hypermutated colorectal cancer beyond MMR deficiency. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 113, 242-248.	2.0	68
5113	Targeted Therapies for Melanoma Brain Metastases. <i>Current Treatment Options in Neurology</i> , 2017, 19, 13.	0.7	28
5114	Targeted agents and immunotherapies: optimizing outcomes in melanoma. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 463-482.	12.5	945
5115	Update on cholangiocarcinoma: potential impact of genomic studies on clinical management. <i>Zeitschrift Fur Gastroenterologie</i> , 2017, 55, 575-581.	0.2	25
5116	Promising immunotherapies for esophageal cancer. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 723-733.	1.4	25
5117	Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. <i>Annals of Oncology</i> , 2017, 28, 1368-1379.	0.6	908
5118	Next-Generation Sequencing Reveals Pathway Activations and New Routes to Targeted Therapies in Cutaneous Metastatic Melanoma. <i>American Journal of Dermatopathology</i> , 2017, 39, 1-13.	0.3	10
5119	Immunomodulation for glioblastoma. <i>Current Opinion in Neurology</i> , 2017, 30, 361-369.	1.8	21
5120	Association of Surgical Treatment, Systemic Therapy, and Survival in Patients With Abdominal Visceral Melanoma Metastases, 1965-2014. <i>JAMA Surgery</i> , 2017, 152, 672.	2.2	57
5122	Research progress in advanced melanoma. <i>Cancer Letters</i> , 2017, 397, 120-126.	3.2	34

#	ARTICLE	IF	CITATIONS
5123	Surveillance strategies in the follow-up of melanoma patients: too much or not enough?. <i>Journal of Surgical Research</i> , 2017, 214, 32-37.	0.8	31
5124	Peri-SRS Administration of Immune Checkpoint Therapy for Melanoma Metastatic to the Brain: Investigating Efficacy and the Effects of Relative Treatment Timing on Lesion Response. <i>World Neurosurgery</i> , 2017, 100, 632-640.e4.	0.7	48
5125	Unexpected recalcitrant course of drug-induced erythema multiforme-like eruption and interstitial pneumonia sequentially occurring after nivolumab therapy. <i>Journal of Dermatology</i> , 2017, 44, 818-821.	0.6	16
5126	Targeting Immunotherapy to the Tumor Microenvironment. <i>Journal of Cellular Biochemistry</i> , 2017, 118, 3049-3054.	1.2	54
5127	Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML. <i>Advances in Experimental Medicine and Biology</i> , 2017, 995, 73-95.	0.8	31
5128	Immunotherapy in NSCLC: A Promising and Revolutionary Weapon. <i>Advances in Experimental Medicine and Biology</i> , 2017, 995, 97-125.	0.8	99
5129	Primary and acquired resistance to PD-1/PD-L1 blockade in cancer treatment. <i>International Immunopharmacology</i> , 2017, 46, 210-219.	1.7	102
5130	Mechanistic and pharmacologic insights on immune checkpoint inhibitors. <i>Pharmacological Research</i> , 2017, 120, 1-9.	3.1	46
5131	Emerging and investigational therapies for neuroblastoma. <i>Expert Opinion on Orphan Drugs</i> , 2017, 5, 355-368.	0.5	27
5132	Overview of Basic Immunology for Clinical Investigators. <i>Advances in Experimental Medicine and Biology</i> , 2017, 995, 1-31.	0.8	4
5133	Systematic evaluation of immune regulation and modulation. , 2017, 5, 21.		20
5134	Skin Reactions to Immune Checkpoint Inhibitors. <i>Advances in Experimental Medicine and Biology</i> , 2017, 995, 175-184.	0.8	7
5135	Identification of an immunogenic neo-epitope encoded by mouse sarcoma using CXCR3 ligand mRNAs as sensors. <i>OncImmunology</i> , 2017, 6, e1306617.	2.1	5
5136	Immunotherapy in malignant melanoma: recent approaches and new perspectives. <i>Melanoma Management</i> , 2017, 4, 39-48.	0.1	7
5137	How many tumor indications should be initially screened in development of next generation immunotherapies?. <i>Contemporary Clinical Trials</i> , 2017, 59, 113-117.	0.8	13
5138	Beyond precision surgery: Molecularly motivated precision care for gastric cancer. <i>European Journal of Surgical Oncology</i> , 2017, 43, 856-864.	0.5	13
5139	Janus-faced Acrolein prevents allergy but accelerates tumor growth by promoting immunoregulatory Foxp3+ cells: Mouse model for passive respiratory exposure. <i>Scientific Reports</i> , 2017, 7, 45067.	1.6	13
5140	Acral lentiginous melanoma versus other melanoma: A single-center analysis in Japan. <i>Journal of Dermatology</i> , 2017, 44, 932-938.	0.6	45

#	ARTICLE	IF	CITATIONS
5141	Immunotherapy for colorectal cancer: where are we heading?. Expert Opinion on Biological Therapy, 2017, 17, 709-721.	1.4	85
5142	Strategies for Increasing Pancreatic Tumor Immunogenicity. Clinical Cancer Research, 2017, 23, 1656-1669.	3.2	131
5143	Masterful Antibodies: Checkpoint Blockade. Cancer Immunology Research, 2017, 5, 275-281.	1.6	31
5144	Cancer immunotherapies targeting the PD-1 signaling pathway. Journal of Biomedical Science, 2017, 24, 26.	2.6	501
5145	Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study. Lancet Oncology, The, 2017, 18, 792-802.	5.1	203
5146	Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions. Annals of Oncology, 2017, 28, 1484-1494.	0.6	118
5147	Emerging molecular therapeutic targets for cholangiocarcinoma. Journal of Hepatology, 2017, 67, 632-644.	1.8	150
5148	The Advantages and Challenges of Using FDG PET/CT for Response Assessment in Melanoma in the Era of Targeted Agents and Immunotherapy. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 67-77.	3.3	112
5149	Antibody-Based Cancer Therapy. International Review of Cell and Molecular Biology, 2017, 331, 289-383.	1.6	41
5150	Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. Npj Genomic Medicine, 2017, 2, .	1.7	120
5151	Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts. Drugs and Aging, 2017, 34, 331-357.	1.3	7
5152	Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncology, The, 2017, 18, 611-622.	5.1	428
5153	Talimogene Laherparepvec for Treating Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics, 2017, 35, 1035-1046.	1.7	7
5154	Optimum dosing of ipilimumab in melanoma: too little, too late?. Lancet Oncology, The, 2017, 18, 558-559.	5.1	3
5155	Molecular genetic and immunotherapeutic targets in metastatic melanoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 471, 281-293.	1.4	16
5156	Immunotherapy for gastric cancers: emerging role and future perspectives. Expert Review of Clinical Pharmacology, 2017, 10, 609-619.	1.3	33
5157	Advances in urothelial bladder cancer immunotherapy, dawn of a new age of treatment. Immunotherapy, 2017, 9, 451-460.	1.0	12
5158	Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point ¹⁸ F-FDG PET/CT Imaging in Patients with Advanced Melanoma. Journal of Nuclear Medicine, 2017, 58, 1421-1428.	2.8	209

#	ARTICLE	IF	CITATIONS
5159	Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?. <i>Angiogenesis</i> , 2017, 20, 185-204.	3.7	482
5160	Adjuvanticity of a CTLA-4 3' UTR complementary oligonucleotide for emulsion formulated recombinant subunit and inactivated vaccines. <i>Vaccine</i> , 2017, 35, 2379-2389.	1.7	7
5161	Short review of potential synergies of immune checkpoint inhibition and radiotherapy with a focus on Hodgkin lymphoma: radio-immunotherapy opens new doors. <i>Immunotherapy</i> , 2017, 9, 423-433.	1.0	9
5162	Obstacles Posed by the Tumor Microenvironment to T-Cell Activity: A Case for Synergistic Therapies. <i>Cancer Cell</i> , 2017, 31, 311-325.	7.7	502
5163	The Microenvironmental Landscape of Brain Tumors. <i>Cancer Cell</i> , 2017, 31, 326-341.	7.7	1,163
5166	Molecular Pathways: Oncologic Pathways and Their Role in T-cell Exclusion and Immune Evasion—A New Role for the AXL Receptor Tyrosine Kinase. <i>Clinical Cancer Research</i> , 2017, 23, 2928-2933.	3.2	59
5167	Immune checkpoint inhibition and its relationship with hypermutation phenotype as a potential treatment for Glioblastoma. <i>Journal of Neuro-Oncology</i> , 2017, 132, 359-372.	1.4	8
5169	BRAF plus MEK-targeted drugs: a new standard of treatment for BRAF-mutant advanced melanoma. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 35-42.	2.7	35
5170	Clinical value of monoclonal antibodies and tyrosine kinase inhibitors in the treatment of head and neck squamous cell carcinoma. <i>Medical Oncology</i> , 2017, 34, 60.	1.2	18
5171	Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines. , 2017, 178, 31-47.		89
5172	Genetics of Gastric Cancer. <i>Surgical Clinics of North America</i> , 2017, 97, 345-370.	0.5	34
5173	Neoepitopes as cancer immunotherapy targets: key challenges and opportunities. <i>Immunotherapy</i> , 2017, 9, 361-371.	1.0	58
5174	The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy. <i>European Journal of Cancer</i> , 2017, 76, 167-182.	1.3	234
5175	The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy. <i>Journal of Hepatology</i> , 2017, 67, 173-183.	1.8	165
5176	Are tumor-infiltrating lymphocytes protagonists or background actors in patient selection for cancer immunotherapy?. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 735-746.	1.4	66
5177	Recent progress in GM-CSF-based cancer immunotherapy. <i>Immunotherapy</i> , 2017, 9, 347-360.	1.0	154
5179	The Role of Targeted Therapy in the Management of Sinonasal Malignancies. <i>Otolaryngologic Clinics of North America</i> , 2017, 50, 443-455.	0.5	12
5180	Radiation and Immune Checkpoint Blockade: From Bench to Clinic. <i>Seminars in Radiation Oncology</i> , 2017, 27, 289-298.	1.0	39

#	ARTICLE	IF	CITATIONS
5181	In Situ Activation of Pituitary-Infiltrating T Lymphocytes in Autoimmune Hypophysitis. <i>Scientific Reports</i> , 2017, 7, 43492.	1.6	23
5182	Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma. <i>European Journal of Cancer</i> , 2017, 76, 152-166.	1.3	82
5183	Model-Based Characterization of the Pharmacokinetics of Pembrolizumab: A Humanized Anti-PD-1 Monoclonal Antibody in Advanced Solid Tumors. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2017, 6, 49-57.	1.3	121
5184	Improved survival and complete response rates in patients with advanced melanoma treated with concurrent ipilimumab and radiotherapy versus ipilimumab alone. <i>Cancer Biology and Therapy</i> , 2017, 18, 36-42.	1.5	123
5185	The emerging role of immune checkpoint inhibition in malignant lymphoma. <i>Haematologica</i> , 2017, 102, 30-42.	1.7	101
5187	Current progress in immunotherapy of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2017, 66, 482-484.	1.8	53
5188	Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. <i>Annals of Oncology</i> , 2017, 28, 583-589.	0.6	510
5189	A phase I/II study of cancer peptide vaccine S-288310 in patients with advanced urothelial carcinoma of the bladder. <i>Annals of Oncology</i> , 2017, 28, 798-803.	0.6	43
5190	The role of the immune system in neurofibromatosis type 1-associated nervous system tumors. <i>CNS Oncology</i> , 2017, 6, 45-60.	1.2	24
5191	Relative Efficacy of Granulocyte-Macrophage Colony-Stimulating Factor, Dacarbazine, and Glycoprotein 100 in Metastatic Melanoma: An Indirect Treatment Comparison. <i>Advances in Therapy</i> , 2017, 34, 495-512.	1.3	5
5192	Immuno-Oncology: The Third Paradigm in Early Drug Development. <i>Targeted Oncology</i> , 2017, 12, 125-138.	1.7	22
5193	Immunotherapy against cancer-related viruses. <i>Cell Research</i> , 2017, 27, 59-73.	5.7	101
5194	Mutation Profile of B-Raf Gene Analyzed by fully Automated System and Clinical Features in Japanese Melanoma Patients. <i>Pathology and Oncology Research</i> , 2017, 23, 181-188.	0.9	4
5195	Patterns and Timing of Initial Relapse in Pathologic Stage II Melanoma Patients. <i>Annals of Surgical Oncology</i> , 2017, 24, 939-946.	0.7	41
5196	The network of immunosuppressive pathways in glioblastoma. <i>Biochemical Pharmacology</i> , 2017, 130, 1-9.	2.0	76
5197	Driving gene-engineered T cell immunotherapy of cancer. <i>Cell Research</i> , 2017, 27, 38-58.	5.7	232
5198	Immune targets and neoantigens for cancer immunotherapy and precision medicine. <i>Cell Research</i> , 2017, 27, 11-37.	5.7	185
5199	Vulvar and vaginal melanoma: A unique subclass of mucosal melanoma based on a comprehensive molecular analysis of 51 cases compared with 2253 cases of nongynecologic melanoma. <i>Cancer</i> , 2017, 123, 1333-1344.	2.0	90

#	ARTICLE	IF	CITATIONS
5200	Combined treatment with ipilimumab and intratumoral interleukin-2 in pretreated patients with stage IV melanoma—safety and efficacy in a phase II study. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 441-449.	2.0	23
5201	Systemic therapy of brain metastases: non—small cell lung cancer, breast cancer, and melanoma. <i>Neuro-Oncology</i> , 2017, 19, i1-i24.	0.6	171
5202	Thyroid abnormalities following the use of cytotoxic T—lymphocyte antigen—4 and programmed death receptor protein—1 inhibitors in the treatment of melanoma. <i>Clinical Endocrinology</i> , 2017, 86, 614-620.	1.2	165
5203	Immune Toxicities Elicited by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire. <i>Cancer Research</i> , 2017, 77, 1322-1330.	0.4	188
5205	Current Trends in Cancer Therapy. , 2017, , 1-24.		7
5206	The Different T-cell Receptor Repertoires in Breast Cancer Tumors, Draining Lymph Nodes, and Adjacent Tissues. <i>Cancer Immunology Research</i> , 2017, 5, 148-156.	1.6	87
5207	Bortezomib Relieves Immune Tolerance in Nasopharyngeal Carcinoma via STAT1 Suppression and Indoleamine 2,3-Dioxygenase Downregulation. <i>Cancer Immunology Research</i> , 2017, 5, 42-51.	1.6	24
5208	Melanoma exosomes deliver a complex biological payload that upregulates PTPN 11 to suppress T lymphocyte function. <i>Pigment Cell and Melanoma Research</i> , 2017, 30, 203-218.	1.5	39
5209	Critical Issues in Head and Neck Oncology. , 2017, , .		0
5210	Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors. <i>Investigational New Drugs</i> , 2017, 35, 207-216.	1.2	70
5211	Treatment-related Death in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. <i>Clinical Oncology</i> , 2017, 29, 218-230.	0.6	49
5212	Activation induced cell death (AICD) of human melanoma antigen-specific TCR engineered CD8 T cells involves JNK, Bim and p53. <i>Expert Opinion on Therapeutic Targets</i> , 2017, 21, 117-129.	1.5	7
5213	Signaling and Immune Regulation in Melanoma Development and Responses to Therapy. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2017, 12, 75-102.	9.6	30
5214	Targeting the PD-1/PD-L1 axis in non—small cell lung cancer. <i>Current Problems in Cancer</i> , 2017, 41, 111-124.	1.0	37
5215	Dutch Melanoma Treatment Registry: Quality assurance in the care of patients with metastatic melanoma in the Netherlands. <i>European Journal of Cancer</i> , 2017, 72, 156-165.	1.3	77
5216	First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INC024360) in Patients with Advanced Solid Malignancies. <i>Clinical Cancer Research</i> , 2017, 23, 3269-3276.	3.2	244
5217	An Overview of the Changing Landscape of Treatment for—Advanced Melanoma. <i>Pharmacotherapy</i> , 2017, 37, 319-333.	1.2	33
5218	Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer. <i>Pathology</i> , 2017, 49, 141-155.	0.3	112

#	ARTICLE	IF	CITATIONS
5219	Impact of CTLA-4 blockade in conjunction with metronomic chemotherapy on preclinical breast cancer growth. <i>British Journal of Cancer</i> , 2017, 116, 324-334.	2.9	35
5220	Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity. <i>Nature Reviews Drug Discovery</i> , 2017, 16, 264-272.	21.5	204
5221	Immunological profiling of molecularly classified high-risk endometrial cancers identifies <i>POLE</i> -mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition. <i>Oncology</i> , 2017, 6, e1264565.	2.1	102
5222	Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 43-50.	0.5	317
5223	Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma. <i>American Journal of Clinical Dermatology</i> , 2017, 18, 1-15.	3.3	215
5224	The Safety of available immunotherapy for the treatment of glioblastoma. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 277-287.	1.0	19
5225	Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 785-792.	0.8	930
5226	VISTA Deficiency Accelerates the Development of Fatal Murine Lupus Nephritis. <i>Arthritis and Rheumatology</i> , 2017, 69, 814-825.	2.9	56
5227	Regulatory T cells in cancer immunotherapy. <i>Cell Research</i> , 2017, 27, 109-118.	5.7	1,212
5228	A case of vemurafenib-induced polyarthritis in a patient with melanoma: how to manage it?. <i>International Journal of Rheumatic Diseases</i> , 2017, 20, 398-401.	0.9	8
5229	Infliximab for ipilimumab-induced colitis: A series of 13 patients. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017, 13, e284-e290.	0.7	32
5230	Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature. <i>Arthritis Care and Research</i> , 2017, 69, 1751-1763.	1.5	292
5231	IL-15, TIM-3 and NK cells subsets predict responsiveness to anti-CTLA-4 treatment in melanoma patients. <i>Oncology</i> , 2017, 6, e1261242.	2.1	59
5232	Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy. <i>Cancer Immunology Research</i> , 2017, 5, 17-28.	1.6	130
5233	Cytokines and metabolic factors regulate tumoricidal T-cell function during cancer immunotherapy. <i>Immunotherapy</i> , 2017, 9, 71-82.	1.0	5
5234	Managing immune checkpoint-inhibitor-induced severe autoimmune-like hepatitis by liver-directed topical steroids. <i>Journal of Hepatology</i> , 2017, 66, 657-659.	1.8	66
5235	Therapeutic aims of drugs offering only progression-free survival are misunderstood by patients, and oncologists may be overly optimistic about likely benefits. <i>Supportive Care in Cancer</i> , 2017, 25, 237-244.	1.0	23
5236	Poly(<i>N</i> -phenylglycine)-Based Nanoparticles as Highly Effective and Targeted Near-Infrared Photothermal Therapy/Photodynamic Therapeutic Agents for Malignant Melanoma. <i>Small</i> , 2017, 13, 1602496.	5.2	88

#	ARTICLE	IF	CITATIONS
5238	Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 Blockade. <i>Cancer Immunology Research</i> , 2017, 5, 84-91.	1.6	126
5239	MHC-I Genotype Restricts the Oncogenic Mutational Landscape. <i>Cell</i> , 2017, 171, 1272-1283.e15.	13.5	307
5240	Checkpoint Inhibition in Non-Hodgkin's Lymphoma. <i>Oncology Research and Treatment</i> , 2017, 40, 662-672.	0.8	4
5241	Tests to assist in the staging of cutaneous melanoma: a generic protocol. <i>The Cochrane Library</i> , 2017, , .	1.5	1
5242	Metastatic melanoma imaging using a novel Tc-99m-labeled lactam-cyclized alpha-MSH peptide. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 4952-4955.	1.0	5
5243	Estimating Survival in Melanoma Patients With Brain Metastases: An Update of the Graded Prognostic Assessment for Melanoma Using Molecular Markers (Melanoma-molGPA). <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 812-816.	0.4	163
5244	Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy. <i>Cancer Immunology Research</i> , 2017, 5, 1133-1140.	1.6	114
5245	Activity and Functions of Tumor-associated Macrophages in Prostate Carcinogenesis. <i>European Urology Supplements</i> , 2017, 16, 301-308.	0.1	6
5246	Ipilimumab-Induced Enteritis without Colitis: A New Challenge. <i>Case Reports in Oncology</i> , 2017, 9, 705-713.	0.3	41
5247	Sepsis: Staging and Potential Future Therapies. <i>Colloquium Series on Integrated Systems Physiology From Molecule To Function</i> , 2017, 9, i-91.	0.3	0
5248	The progress and current status of immunotherapy in acute myeloid leukemia. <i>Annals of Hematology</i> , 2017, 96, 1965-1982.	0.8	37
5249	Mucosal melanoma: epidemiology, biology, management and the role of immunotherapy. <i>Expert Opinion on Orphan Drugs</i> , 2017, 5, 945-952.	0.5	0
5250	Enhancing cancer immunotherapy through nanotechnology-mediated tumor infiltration and activation of immune cells. <i>Seminars in Immunology</i> , 2017, 34, 114-122.	2.7	29
5251	Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model. <i>Nature Communications</i> , 2017, 8, 707.	5.8	123
5252	Immune-related adverse events during anticancer immunotherapy: Pathogenesis and management (Review). <i>Oncology Letters</i> , 2017, 14, 5671-5680.	0.8	54
5253	In vivo Confocal Microscopy in Differentiating Ipilimumab-Induced Anterior Uveitis from Metastatic Uveal Melanoma. <i>Case Reports in Ophthalmology</i> , 2017, 7, 404-409.	0.3	16
5255	Nonconventional patterns of benefit of solid tumors treated with PD-(L)1 inhibitors: a systematic review. <i>Immunotherapy</i> , 2017, 9, 995-1004.	1.0	14
5256	Has the melanoma information tsunami become a maelstrom?. <i>Melanoma Management</i> , 2017, 4, 179-182.	0.1	0

#	ARTICLE	IF	CITATIONS
5257	Distant intracranial failure in melanoma brain metastases treated with stereotactic radiosurgery in the era of immunotherapy and targeted agents. <i>Advances in Radiation Oncology</i> , 2017, 2, 572-580.	0.6	63
5258	001 INCOME-ASSOCIATED DISCREPANCIES IN MELANOMA SURVIVAL. <i>Journal of Investigative Dermatology Symposium Proceedings</i> , 2017, 18, S85.	0.8	0
5259	An anti-glypican 3/CD3 bispecific T cell redirecting antibody for treatment of solid tumors. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	154
5260	Stereotactic Radiotherapy Increases Functionally Suppressive Regulatory T Cells in the Tumor Microenvironment. <i>Cancer Immunology Research</i> , 2017, 5, 992-1004.	1.6	149
5261	Efficacy and safety of retreatment with nivolumab in metastatic melanoma patients previously treated with nivolumab. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 999-1004.	1.1	50
5262	New perspectives for targeting RAF kinase in human cancer. <i>Nature Reviews Cancer</i> , 2017, 17, 676-691.	12.8	285
5263	Statistical Challenges with the Advances in Cancer Therapies. , 2017, , 11-20.		0
5265	Immediate completion lymph node dissection in stage IIIA melanoma does not provide significant additional staging information beyond EORTC SN tumour burden criteria. <i>European Journal of Cancer</i> , 2017, 87, 212-215.	1.3	22
5266	Gene editing in T cell therapy. <i>Journal of Genetics and Genomics</i> , 2017, 44, 415-422.	1.7	15
5267	The changing landscape of dermatology practice: melanoma and pump-probe laser microscopy. <i>Lasers in Medical Science</i> , 2017, 32, 1935-1939.	1.0	2
5269	Urothelial Carcinoma of the Bladder and the Rise of Immunotherapy. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 1277-1284.	2.3	38
5270	Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma. <i>European Journal of Cancer</i> , 2017, 86, 115-124.	1.3	76
5271	Recent advances in malignant melanoma. <i>Internal Medicine Journal</i> , 2017, 47, 1114-1121.	0.5	40
5272	4-1BB Agonist Focuses CD8+ Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 7263-7275.	3.2	41
5274	Checkpoint inhibitors and the risk of infection. <i>Expert Review of Precision Medicine and Drug Development</i> , 2017, 2, 287-293.	0.4	3
5275	Head and Neck Squamous Cell Carcinomas Are Characterized by a Stable Immune Signature Within the Primary Tumor Over Time and Space. <i>Clinical Cancer Research</i> , 2017, 23, 7641-7649.	3.2	22
5276	Pharmacovigilance Assessment of Immune-Mediated Reactions Reported for Checkpoint Inhibitor Cancer Immunotherapies. <i>Pharmacotherapy</i> , 2017, 37, 1383-1390.	1.2	33
5278	Cutting the Brakes: Immunotherapy With PD-1 Inhibitors. <i>Clinical Skin Cancer</i> , 2017, 2, 24-31.	0.1	2

#	ARTICLE	IF	CITATIONS
5279	Not all immune-checkpoint inhibitors are created equal: Meta-analysis and systematic review of immune-related adverse events in cancer trials. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 119, 1-12.	2.0	141
5280	Acute Oncology Care: A narrative review of the acute management of neutropenic sepsis and immune-related toxicities of checkpoint inhibitors. <i>European Journal of Internal Medicine</i> , 2017, 45, 59-65.	1.0	20
5281	Long-Term Survival after Complete Surgical Resection and Adjuvant Immunotherapy for Distant Melanoma Metastases. <i>Annals of Surgical Oncology</i> , 2017, 24, 3991-4000.	0.7	102
5282	Endocrine side effects of cancer immunotherapy. <i>Endocrine-Related Cancer</i> , 2017, 24, T331-T347.	1.6	131
5283	Immunotherapy for Breast Cancer: Current and Future Strategies. <i>Current Surgery Reports</i> , 2017, 5, 1.	0.4	31
5284	Impact of immunotherapy among patients with melanoma brain metastases managed with radiotherapy. <i>Journal of Neuroimmunology</i> , 2017, 313, 118-122.	1.1	34
5285	Abscopal, immunological effects of radiotherapy: Narrowing the gap between clinical and preclinical experiences. <i>Immunological Reviews</i> , 2017, 280, 249-279.	2.8	155
5286	PD-1 Blockade Prevents the Development and Progression of Carcinogen-Induced Oral Premalignant Lesions. <i>Cancer Prevention Research</i> , 2017, 10, 684-693.	0.7	53
5287	Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. <i>Ca-A Cancer Journal for Clinicians</i> , 2017, 67, 472-492.	157.7	1,662
5288	Donor-Derived Metastatic Melanoma and Checkpoint Inhibition. <i>Transplantation Proceedings</i> , 2017, 49, 1551-1554.	0.3	24
5289	Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system. <i>Expert Review of Molecular Diagnostics</i> , 2017, 17, 1055-1069.	1.5	24
5290	Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program. <i>Journal of Immunotherapy</i> , 2017, 40, 334-340.	1.2	16
5291	High frequency of brain metastases after adjuvant therapy for high-risk melanoma. <i>Cancer Medicine</i> , 2017, 6, 2576-2585.	1.3	27
5292	A CD200R-CD28 fusion protein appropriates an inhibitory signal to enhance T-cell function and therapy of murine leukemia. <i>Blood</i> , 2017, 130, 2410-2419.	0.6	44
5293	Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers. <i>Nature Communications</i> , 2017, 8, 1050.	5.8	115
5294	Imaging spectrum of immunomodulating, chemotherapeutic and radiation therapy related intracranial effects. <i>British Journal of Radiology</i> , 2018, 91, 20170553.	1.0	3
5295	Tumor-infiltrating lymphocytes in Breast Cancer and implications for clinical practice. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2017, 1868, 527-537.	3.3	59
5296	The Antibody Repertoire of Colorectal Cancer. <i>Molecular and Cellular Proteomics</i> , 2017, 16, 2111-2124.	2.5	8

#	ARTICLE	IF	CITATIONS
5297	Malignancies in HIV-Infected and AIDS Patients. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1018, 167-179.	0.8	42
5298	Cytomegalovirus reactivation in patients with refractory checkpoint inhibitor-induced colitis. <i>European Journal of Cancer</i> , 2017, 86, 248-256.	1.3	63
5299	Mechanisms regulating T-cell infiltration and activity in solid tumors. <i>Annals of Oncology</i> , 2017, 28, xii18-xii32.	0.6	276
5300	Current chemotherapeutic regimens for brain metastases treatment. <i>Clinical and Experimental Metastasis</i> , 2017, 34, 391-399.	1.7	6
5301	Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies. <i>Annals of Oncology</i> , 2017, 28, 2860-2865.	0.6	115
5302	Avelumab and other recent advances in Merkel cell carcinoma. <i>Future Oncology</i> , 2017, 13, 2771-2783.	1.1	11
5304	The immune system prevents recurrence of transplanted but not autochthonous antigenic tumors after oncogene inactivation therapy. <i>International Journal of Cancer</i> , 2017, 141, 2551-2561.	2.3	4
5305	Checkpoint immunotherapy in head and neck cancers. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 475-489.	2.7	33
5306	Prospects and progress of immunotherapy for bladder cancer. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 1-15.	1.4	29
5307	Interleukin-6/STAT3 signaling as a promising target to improve the efficacy of cancer immunotherapy. <i>Cancer Science</i> , 2017, 108, 1947-1952.	1.7	189
5308	Using immune checkpoint inhibitors without exacerbation in a melanoma patient with pemphigus foliaceus. <i>International Journal of Dermatology</i> , 2017, 56, 1477-1479.	0.5	2
5309	Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2598-2608.	1.9	1,779
5310	Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of metastatic solid malignancies. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1477-1490.	0.9	24
5311	The safety of pembrolizumab in metastatic melanoma and rheumatoid arthritis. <i>Melanoma Research</i> , 2017, 27, 519-523.	0.6	16
5312	Local Immunotherapy of Cancer: Innovative Approaches to Harnessing Tumor-Specific Immune Responses. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	31
5314	In-depth immunophenotyping of patients with glioblastoma multiforme: Impact of steroid treatment. <i>OncImmunology</i> , 2017, 6, e1358839.	2.1	37
5315	Immunotherapy for metastatic prostate cancer. <i>Current Opinion in Urology</i> , 2017, 27, 566-571.	0.9	18
5316	The clinical value of combination of immune checkpoint inhibitors in cancer patients: A meta-analysis of efficacy and safety. <i>International Journal of Cancer</i> , 2017, 141, 2562-2570.	2.3	35

#	ARTICLE	IF	CITATIONS
5317	Nueva inmunoterapia y cáncer de pulmón. Archivos De Bronconeumologia, 2017, 53, 682-687.	0.4	8
5318	Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects. Drug Resistance Updates, 2017, 32, 1-15.	6.5	132
5319	Survival of patients with advanced metastatic melanoma: the impact of novel therapies—update 2017. European Journal of Cancer, 2017, 83, 247-257.	1.3	236
5320	The potential and promise of IL-15 in immuno-oncogenic therapies. Immunology Letters, 2017, 190, 159-168.	1.1	152
5321	Multiple treatment comparison of seven new drugs for patients with advanced malignant melanoma: a systematic review and health economic decision model in a Norwegian setting. BMJ Open, 2017, 7, e014880.	0.8	18
5322	Dendritic Cell-Based Cancer Therapies: Current Status and Future Directions. Molecular and Translational Medicine, 2017, , 99-120.	0.4	1
5323	A retrospective analysis comparing APCEDEN [®] dendritic cell immunotherapy with best supportive care in refractory cancer. Immunotherapy, 2017, 9, 889-897.	1.0	16
5324	Should we be combining local tumor therapies with immunotherapies as standard?. Future Oncology, 2017, 13, 1573-1575.	1.1	3
5325	Prognostic value of tumor PD-L1 expression combined with CD8 + tumor infiltrating lymphocytes in high grade serous ovarian cancer. International Immunopharmacology, 2017, 52, 7-14.	1.7	68
5326	Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry). Expert Opinion on Drug Safety, 2017, 16, 1255-1271.	1.0	106
5327	Lack of interleukin-6 in the tumor microenvironment augments type-1 immunity and increases the efficacy of cancer immunotherapy. Cancer Science, 2017, 108, 1959-1966.	1.7	61
5328	Photodynamic-Immune Checkpoint Therapy Eradicates Local and Distant Tumors by CD8+ T Cells. Cancer Immunology Research, 2017, 5, 832-838.	1.6	95
5329	Trial watch: Immune checkpoint blockers for cancer therapy. OncoImmunology, 2017, 6, e1373237.	2.1	62
5330	Cancer vaccines: Enhanced immunogenic modulation through therapeutic combinations. Human Vaccines and Immunotherapeutics, 2017, 13, 2561-2574.	1.4	91
5331	Programmed death-ligand 1 (PD-L1) expression in tumour cell and tumour infiltrating lymphocytes of HER2-positive breast cancer and its prognostic value. Scientific Reports, 2017, 7, 11671.	1.6	57
5332	Systemic therapy in advanced melanoma: integrating targeted therapy and immunotherapy into clinical practice. Current Opinion in Oncology, 2017, 29, 484-492.	1.1	58
5333	Immunotherapy against endocrine malignancies: immune checkpoint inhibitors lead the way. Endocrine-Related Cancer, 2017, 24, T261-T281.	1.6	33
5334	Health-related quality of life in melanoma patients: Impact of melanoma-related limb lymphoedema. European Journal of Cancer, 2017, 85, 122-132.	1.3	37

#	ARTICLE	IF	CITATIONS
5335	Pigmentary changes in patients treated with targeted anticancer agents: A systematic review and meta-analysis. <i>Journal of the American Academy of Dermatology</i> , 2017, 77, 902-910.e2.	0.6	56
5336	Stereotactic radiosurgery of early melanoma brain metastases after initiation of anti-CTLA-4 treatment is associated with improved intracranial control. <i>Radiotherapy and Oncology</i> , 2017, 125, 80-88.	0.3	58
5337	Antitumor immunity is defective in T cell-specific microRNA-155-deficient mice and is rescued by immune checkpoint blockade. <i>Journal of Biological Chemistry</i> , 2017, 292, 18530-18541.	1.6	67
5338	Clinical Pharmacology Considerations for the Development of Immune Checkpoint Inhibitors. <i>Journal of Clinical Pharmacology</i> , 2017, 57, S26-S42.	1.0	91
5339	Novel Immunologic Approaches to Melanoma Treatment. <i>Actas Dermo-sifiligráficas</i> , 2017, 108, 708-720.	0.2	0
5340	Nanomaterials for cancer immunotherapy. <i>Biomaterials</i> , 2017, 148, 16-30.	5.7	226
5341	An Update on Randomized Clinical Trials in Melanoma. <i>Surgical Oncology Clinics of North America</i> , 2017, 26, 559-586.	0.6	1
5342	Targeting Immune Checkpoints in Cancer Therapy. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 1647.	3.8	111
5343	Regulatory T Cells: Molecular and Cellular Basis for Immunoregulation. <i>Current Topics in Microbiology and Immunology</i> , 2017, 410, 3-27.	0.7	48
5344	Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. <i>New England Journal of Medicine</i> , 2017, 377, 1824-1835.	13.9	1,752
5345	Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2017, 377, 1345-1356.	13.9	3,589
5346	Immunotherapy in managing metastatic melanoma: which treatment when?. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 1523-1538.	1.4	13
5347	CTLA-4, an Essential Immune-Checkpoint for T-Cell Activation. <i>Current Topics in Microbiology and Immunology</i> , 2017, 410, 99-126.	0.7	91
5348	Tim-3, Lag-3, and TIGIT. <i>Current Topics in Microbiology and Immunology</i> , 2017, 410, 127-156.	0.7	109
5349	Immuno-oncology and Its Opportunities for Interventional Radiologists: Immune Checkpoint Inhibition and Potential Synergies with Interventional Oncology Procedures. <i>Journal of Vascular and Interventional Radiology</i> , 2017, 28, 1487-1494.	0.2	33
5350	Immunotherapies for advanced melanoma: as promising as they are expensive?. <i>Journal of the Royal Society of Medicine</i> , 2017, 110, 395-399.	1.1	2
5351	Case report: pembrolizumab-induced Type 1 diabetes in a patient with metastatic cholangiocarcinoma. <i>Immunotherapy</i> , 2017, 9, 797-804.	1.0	30
5352	CNS side effects of immune checkpoint inhibitors: preclinical models, genetics and multimodality therapy. <i>Immunotherapy</i> , 2017, 9, 929-941.	1.0	34

#	ARTICLE	IF	CITATIONS
5353	Role of PD-1 in Immunity and Diseases. <i>Current Topics in Microbiology and Immunology</i> , 2017, 410, 75-97.	0.7	136
5354	Interprofessional Collaboration with Immune Checkpoint Inhibitor Therapy: the Roles of Gastroenterology, Endocrinology and Neurology. <i>Seminars in Oncology Nursing</i> , 2017, 33, 402-414.	0.7	5
5355	Mutations in BRAF codons 594 and 596 predict good prognosis in melanoma. <i>Oncology Letters</i> , 2017, 14, 3601-3605.	0.8	25
5356	High-dose interleukin-2 (IL-2) for the treatment of melanoma: safety considerations and future directions. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 1347-1357.	1.0	60
5357	Neurological toxicities associated with immune-checkpoint inhibitors. <i>Current Opinion in Neurology</i> , 2017, 30, 659-668.	1.8	162
5358	The Challenge for Development of Valuable Immuno-oncology Biomarkers. <i>Clinical Cancer Research</i> , 2017, 23, 4970-4979.	3.2	76
5359	From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely. <i>Clinical Cancer Research</i> , 2017, 23, 4980-4991.	3.2	14
5360	Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity. <i>Clinical Cancer Research</i> , 2017, 23, 4959-4969.	3.2	115
5361	Program death-1 immune checkpoint and tumor microenvironment in malignant liver tumors. <i>Surgical Oncology</i> , 2017, 26, 423-430.	0.8	20
5362	A canine chimeric monoclonal antibody targeting PD-L1 and its clinical efficacy in canine oral malignant melanoma or undifferentiated sarcoma. <i>Scientific Reports</i> , 2017, 7, 8951.	1.6	111
5363	CXCR4 Ligands: The Next Big Hit?. <i>Journal of Nuclear Medicine</i> , 2017, 58, 77S-82S.	2.8	118
5364	Outcomes in Melanoma Patients Treated with BRAF/MEK-Directed Therapy or Immune Checkpoint Inhibition Stratified by Clinical Trial versus Standard of Care. <i>Oncology</i> , 2017, 93, 164-176.	0.9	6
5365	Neurological Complications of Immunotherapies—Beware of the Checkpoint Ahead. <i>JAMA Neurology</i> , 2017, 74, 1176.	4.5	2
5366	Pembrolizumab-induced hepatitis: diagnosis and treatment. <i>JDDG - Journal of the German Society of Dermatology</i> , 2017, 15, 933-935.	0.4	4
5367	Systemic BRAF/MEK Inhibitors as a Potential Treatment Option in Metastatic Conjunctival Melanoma. <i>Ocular Oncology and Pathology</i> , 2017, 3, 133-141.	0.5	44
5369	Modelling the Survival Outcomes of Immuno-Oncology Drugs in Economic Evaluations: A Systematic Approach to Data Analysis and Extrapolation. <i>Pharmacoeconomics</i> , 2017, 35, 1257-1270.	1.7	49
5370	HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes. <i>Nature Communications</i> , 2017, 8, 451.	5.8	107
5371	Endocrine toxicity of immune checkpoint inhibitors: essential crosstalk between endocrinologists and oncologists. <i>Cancer Medicine</i> , 2017, 6, 1923-1929.	1.3	39

#	ARTICLE	IF	CITATIONS
5372	Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. <i>Lancet Oncology</i> , The, 2017, 18, 1261-1273.	5.1	356
5373	Reduced-dose ipilimumab with standard-dose pembrolizumab: is less more?. <i>Lancet Oncology</i> , The, 2017, 18, 1144-1145.	5.1	2
5374	Risk of treatment-related mortality in cancer patients treated with ipilimumab: A systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2017, 83, 71-79.	1.3	18
5376	Immune Checkpoint Inhibitors in Organ Transplant Patients. <i>Journal of Immunotherapy</i> , 2017, 40, 277-281.	1.2	120
5377	Melanocytic lesion evolution patterns with targeted therapies and immunotherapies for advanced metastatic melanoma: An observational study. <i>Australasian Journal of Dermatology</i> , 2017, 58, 292-298.	0.4	9
5378	Artificial human antigen-presenting cells are superior to dendritic cells at inducing cytotoxic T cell responses. <i>Immunology</i> , 2017, 152, 462-471.	2.0	20
5379	Oncolytic virus-induced cell death and immunity: a match made in heaven?. <i>Journal of Leukocyte Biology</i> , 2017, 102, 631-643.	1.5	35
5381	Immune Surveillance Plays a Role in Locally Aggressive Giant Cell Lesions of Bone. <i>Clinical Orthopaedics and Related Research</i> , 2017, 475, 3071-3081.	0.7	14
5382	The anti-tumor activity of the STAT3 inhibitor STX-0119 occurs via promotion of tumor-infiltrating lymphocyte accumulation in temozolomide-resistant glioblastoma cell line. <i>Immunology Letters</i> , 2017, 190, 20-25.	1.1	26
5383	Î³ T Cells: Unexpected Regulators of Cancer Development and Progression. <i>Trends in Cancer</i> , 2017, 3, 561-570.	3.8	94
5384	Cancer Immunotherapy in Older Patients. <i>Cancer Journal (Sudbury, Mass)</i> , 2017, 23, 219-222.	1.0	18
5385	Is It Better to Use Ipilimumab Combined With a PD-1 Inhibitor or a PD-1 Inhibitor Alone as Initial Immunotherapy in Patients With Metastatic Melanoma?. <i>Clinical Skin Cancer</i> , 2017, 2, 10-17.	0.1	1
5386	TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence. <i>Cancer Discovery</i> , 2017, 7, 1088-1097.	7.7	160
5387	A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from <scp>BRAF</scp> mutation status. <i>Cancer Medicine</i> , 2017, 6, 1904-1914.	1.3	24
5388	Immunotherapy targeting immune check-point(s) in brain metastases. <i>Cytokine and Growth Factor Reviews</i> , 2017, 36, 33-38.	3.2	8
5389	Fluctuations in routine blood count might signal severe immune-related adverse events in melanoma patients treated with nivolumab. <i>Journal of Dermatological Science</i> , 2017, 88, 225-231.	1.0	67
5390	Colon Immune-Related Adverse Events: Anti-CTLA-4 and Anti-PD-1 Blockade Induce Distinct Immunopathological Entities. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 1238-1246.	0.6	116
5391	Immune checkpoint inhibitors: Navigating a new paradigm of treatment toxicities. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017, 13, 277-288.	0.7	36

#	ARTICLE	IF	CITATIONS
5392	Novedades en inmunología del melanoma. Actas Dermo-sifiliográficas, 2017, 108, 708-720.	0.2	6
5393	CASE STUDY ON AN IPILIMUMAB COST-CONTAINMENT STRATEGY IN AN ITALIAN HOSPITAL. International Journal of Technology Assessment in Health Care, 2017, 33, 199-205.	0.2	5
5394	Nivolumab and pembrolizumab: Monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable. Seminars in Oncology, 2017, 44, 132-135.	0.8	90
5395	Safety and efficacy of the antiganglioside GD3 antibody ecomeximab (KW2871) combined with high-dose interferon- γ 2b in patients with metastatic melanoma. Melanoma Research, 2017, 27, 342-350.	0.6	15
5396	Dendritic cell vaccination for metastatic melanoma: a 14-year monoinstitutional experience. Melanoma Research, 2017, 27, 351-357.	0.6	14
5397	Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. Lancet Oncology, The, 2017, 18, 1202-1210.	5.1	211
5398	Precision Medicine and PET/Computed Tomography in Melanoma. PET Clinics, 2017, 12, 449-458.	1.5	11
5399	Safety of treatment with nivolumab after ipilimumab-related meningoradiculitis and bilateral optic neuropathy. European Journal of Cancer, 2017, 83, 28-31.	1.3	33
5400	Chimiothérapies personnalisées du cancer bronchique: ce que le radiologue doit connaître. Diagnostic and Interventional Imaging, 2017, 98, 146-156.	0.0	0
5402	Cancer Immunotherapies: Are They as Effective in the Elderly?. Drugs and Aging, 2017, 34, 567-581.	1.3	31
5403	Nuevos avances de tratamiento inmunobiológico en el melanoma avanzado. Actas Dermo-sifiliográficas, 2017, 108, 721-728.	0.2	0
5404	Prediction of Response in Melanoma Therapy by Systemic Inflammatory Response "One Size Fits Not All. EBioMedicine, 2017, 18, 13-14.	2.7	2
5405	Recurrent bowel obstruction: unusual presentation of pembrolizumab-induced pancreatitis in annular pancreas. European Journal of Cancer, 2017, 82, 167-170.	1.3	11
5406	Liquid Biopsy in Cancer Patients. Current Clinical Pathology, 2017, , .	0.0	6
5407	Is Disease-Specific Immunotherapy a Potential Reality for MDS?. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S26-S30.	0.2	5
5409	Infiltrating T Cells Increase IDO1 Expression in Glioblastoma and Contribute to Decreased Patient Survival. Clinical Cancer Research, 2017, 23, 6650-6660.	3.2	141
5410	Checkpoint Inhibitors for Non-Small Cell Lung Cancer Among Older Adults. Current Oncology Reports, 2017, 19, 62.	1.8	20
5411	Short-term CTLA-4 blockade directly followed by PD-1 blockade in advanced melanoma patients: a single-center experience. Annals of Oncology, 2017, 28, 862-867.	0.6	13

#	ARTICLE	IF	CITATIONS
5412	A review of serious adverse effects under treatment with checkpoint inhibitors. <i>Current Opinion in Oncology</i> , 2017, 29, 136-144.	1.1	56
5413	PD-1 inhibitor-associated lichenoid inflammation with incidental suprabasilar acantholysis or vesiculation—Report of 4 cases. <i>Journal of Cutaneous Pathology</i> , 2017, 44, 851-856.	0.7	21
5414	Molecular and Clinical Approach to Intra-abdominal Adverse Effects of Targeted Cancer Therapies. <i>Radiographics</i> , 2017, 37, 1461-1482.	1.4	21
5415	MALT1 promotes melanoma progression through JNK/c-Jun signaling. <i>Oncogenesis</i> , 2017, 6, e365-e365.	2.1	25
5416	Intravenous dendritic cell administration enhances suppression of lung metastasis induced by carbon-ion irradiation. <i>Journal of Radiation Research</i> , 2017, 58, 446-455.	0.8	44
5418	Blockage of Core Fucosylation Reduces Cell-Surface Expression of PD-1 and Promotes Anti-tumor Immune Responses of T Cells. <i>Cell Reports</i> , 2017, 20, 1017-1028.	2.9	156
5419	Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2. <i>Structure</i> , 2017, 25, 1163-1174.	1.6	253
5420	Checkpoint inhibitors in the treatment of urological malignancies. <i>ESMO Open</i> , 2017, 2, e000165.	2.0	21
5421	Expression of monoacylglycerol lipase as a marker of tumour invasion and progression in malignant melanoma. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 2038-2045.	1.3	26
5422	Liquid Biopsies in Malignant Melanoma: From Bench to Bedside. <i>Current Clinical Pathology</i> , 2017, , 161-193.	0.0	0
5423	Immune mediated neuropathy following checkpoint immunotherapy. <i>Journal of Clinical Neuroscience</i> , 2017, 45, 14-17.	0.8	49
5424	Recombinant LCMV Vectors Induce Protective Immunity following Homologous and Heterologous Vaccinations. <i>Molecular Therapy</i> , 2017, 25, 2533-2545.	3.7	8
5425	Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study. <i>Annals of Oncology</i> , 2017, 28, 2581-2587.	0.6	201
5426	Lamtor1 Is Critically Required for CD4+ T Cell Proliferation and Regulatory T Cell Suppressive Function. <i>Journal of Immunology</i> , 2017, 199, 2008-2019.	0.4	16
5428	Angiogenesis inhibitors in early development for gastric cancer. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 1007-1017.	1.9	32
5429	An unbiased in vivo functional genomics screening approach in mice identifies novel tumor cell-based regulators of immune rejection. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 1529-1544.	2.0	12
5431	Intratatumoral Approaches for the Treatment of Melanoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2017, 23, 40-47.	1.0	45
5432	Clinical Trial Design and Endpoints for Stage IV Melanoma in the Modern Era. <i>Cancer Journal (Sudbury, Mass)</i> , 2017, 23, 63-67.	1.0	8

#	ARTICLE	IF	CITATIONS
5433	Immune checkpoint inhibitors in first-line therapy of advanced non-small cell lung cancer. <i>Current Opinion in Oncology</i> , 2017, 29, 97-104.	1.1	37
5434	Inhibitors of Cytotoxic T Lymphocyte Antigen 4 and Programmed Death 1/Programmed Death 1 Ligand for Metastatic Melanoma, Dual Versus Monotherapy – Summary of Advances and Future Directions for Studying These Drugs. <i>Cancer Journal (Sudbury, Mass)</i> , 2017, 23, 3-9.	1.0	5
5435	Targeted Therapies in Combination With Immune Therapies for the Treatment of Metastatic Melanoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2017, 23, 59-62.	1.0	9
5436	The importance for immunoregulation for long-term cancer control. <i>Future Oncology</i> , 2017, 13, 1619-1632.	1.1	9
5438	Tumour mutation status and sites of metastasis in patients with cutaneous melanoma. <i>British Journal of Cancer</i> , 2017, 117, 1026-1035.	2.9	46
5439	Immunotherapy in Non-Small Cell Lung Cancer Treatment. <i>Journal of Thoracic Imaging</i> , 2017, 32, 300-312.	0.8	47
5440	Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade. <i>Cell</i> , 2017, 170, 1120-1133.e17.	13.5	960
5441	Current status and future direction in the management of malignant melanoma. <i>Melanoma Research</i> , 2017, 27, 403-410.	0.6	50
5442	Immunomodulatory effects of current cancer treatment and the consequences for follow-up immunotherapeutics. <i>Future Oncology</i> , 2017, 13, 1649-1663.	1.1	10
5443	Trial Watch: Adoptively transferred cells for anticancer immunotherapy. <i>Oncolimmunology</i> , 2017, 6, e1363139.	2.1	60
5444	Treatment Outcomes for Metastatic Melanoma of Unknown Primary in the New Era: A Single-Institution Study and Review of the Literature. <i>Oncology</i> , 2017, 93, 249-258.	0.9	19
5445	Clinical characteristics of patient selection and imaging predictors of outcome in solid tumors treated with checkpoint-inhibitors. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 2310-2325.	3.3	46
5446	Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). <i>Lancet, The</i> , 2017, 390, 1853-1862.	6.3	1,032
5447	KEYNOTE-006: a success in melanoma, but a long way to go. <i>Lancet, The</i> , 2017, 390, 1816-1817.	6.3	1
5448	Advances in the Immunobiological Therapies for Advanced Melanoma. <i>Actas Dermo-sifiliográficas</i> , 2017, 108, 721-728.	0.2	0
5449	Insulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination Studies. <i>Targeted Oncology</i> , 2017, 12, 571-597.	1.7	135
5450	Neurological Complications of Therapeutic Monoclonal Antibodies: Trends from Oncology to Rheumatology. <i>Current Neurology and Neuroscience Reports</i> , 2017, 17, 75.	2.0	15
5451	Comparing photoporation and nucleofection for delivery of small interfering RNA to cytotoxic T cells. <i>Journal of Controlled Release</i> , 2017, 267, 154-162.	4.8	57

#	ARTICLE	IF	CITATIONS
5452	BET bromodomain inhibitors synergize with ATR inhibitors in melanoma. <i>Cell Death and Disease</i> , 2017, 8, e2982-e2982.	2.7	17
5453	Immunotherapy of cancers comes of age. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 1001-1015.	1.3	84
5454	The Immunology of Melanoma. <i>Clinics in Laboratory Medicine</i> , 2017, 37, 449-471.	0.7	34
5455	Immunotherapy based approaches in myelofibrosis. <i>Expert Review of Hematology</i> , 2017, 10, 903-914.	1.0	12
5456	Fatty Acid Uptake in T Cell Subsets Using a Quantum Dot Fatty Acid Conjugate. <i>Scientific Reports</i> , 2017, 7, 5790.	1.6	26
5457	Immunological efficacy of glypican-3 peptide vaccine in patients with advanced hepatocellular carcinoma. <i>Oncolmmunology</i> , 2017, 6, e1346764.	2.1	69
5458	Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. <i>Advances in Anatomic Pathology</i> , 2017, 24, 235-251.	2.4	469
5459	Immunotherapy for Uveal Melanoma. <i>International Ophthalmology Clinics</i> , 2017, 57, 29-39.	0.3	10
5460	Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma. <i>Current Treatment Options in Oncology</i> , 2017, 18, 51.	1.3	69
5461	Comparative immunologic characterization of autoimmune giant cell myocarditis with ipilimumab. <i>Oncolmmunology</i> , 2017, 6, e1361097.	2.1	50
5462	Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. <i>Annals of Oncology</i> , 2017, 28, 2377-2385.	0.6	631
5463	Skin Delivery of Clec4a Small Hairpin RNA Elicited an Effective Antitumor Response by Enhancing CD8 + Immunity In Vivo. <i>Molecular Therapy - Nucleic Acids</i> , 2017, 9, 419-427.	2.3	9
5464	Screening and antitumor effect of an anti-CTLA-4 nanobody. <i>Oncology Reports</i> , 2017, 39, 511-518.	1.2	19
5466	Complications rhumatologiques de l'immunothérapie anticancéreuse. <i>Revue Du Rhumatisme (Edition) Tj</i> 0.84314	0.8	0
5467	MELK Promotes Melanoma Growth by Stimulating the NF- κ B Pathway. <i>Cell Reports</i> , 2017, 21, 2829-2841.	2.9	61
5468	Antigen-specific oncolytic MV-based tumor vaccines through presentation of selected tumor-associated antigens on infected cells or virus-like particles. <i>Scientific Reports</i> , 2017, 7, 16892.	1.6	23
5469	New Immunotherapy and Lung Cancer. <i>Archivos De Bronconeumologia</i> , 2017, 53, 682-687.	0.4	8
5470	Emerging Concepts Targeting Immune Checkpoints in Cancer and Autoimmunity. <i>Current Topics in Microbiology and Immunology</i> , 2017, , .	0.7	1

#	ARTICLE	IF	CITATIONS
5471	Quality matters: immunotherapy and the evolving landscape of advanced cancer care. Expert Review of Quality of Life in Cancer Care, 2017, 2, 235-244.	0.6	2
5472	The Pancreatic Cancer Microenvironment. Cancer Journal (Sudbury, Mass), 2017, 23, 321-325.	1.0	132
5473	De-novo and acquired resistance to immune checkpoint targeting. Lancet Oncology, The, 2017, 18, e731-e741.	5.1	568
5474	The link between calcitriol and anticancer immunotherapy: vitamin D as the possible balance between inflammation and autoimmunity in the immune-checkpoint blockade. Immunotherapy, 2017, 9, 1127-1131.	1.0	13
5475	Liver immunotolerance and hepatocellular carcinoma: Patho-physiological mechanisms and therapeutic perspectives. European Journal of Cancer, 2017, 87, 101-112.	1.3	56
5476	Cure in Advanced Renal Cell Cancer: Is It an Achievable Goal?. Oncologist, 2017, 22, 1470-1477.	1.9	10
5477	Phase II study of ipilimumab in adolescents with unresectable stage III or IV malignant melanoma. European Journal of Cancer, 2017, 86, 358-363.	1.3	72
5478	Infectious Agents Associated Cancers: Epidemiology and Molecular Biology. Advances in Experimental Medicine and Biology, 2017, , .	0.8	4
5479	Surgical resection of metastatic melanoma in the era of immunotherapy and targeted therapy. Melanoma Management, 2017, 4, 61-68.	0.1	20
5480	32nd Annual Meeting and Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC) Tj ETQq1 1 0.784314 rgBT /Ove 23	0.784314	23
5481	Combining immunotherapies for the treatment of prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 694-700.	0.8	36
5482	Very early response of circulating tumour-derived DNA in plasma predicts efficacy of nivolumab treatment in patients with non-small cell lung cancer. European Journal of Cancer, 2017, 86, 349-357.	1.3	82
5483	Histopathology of pembrolizumab-induced hepatitis: a case report. Pathology, 2017, 49, 789-792.	0.3	23
5484	Using Adoptive Cell Therapy in the Modern Era of Metastatic Melanoma Treatment. Clinical Skin Cancer, 2017, 2, 32-38.	0.1	0
5485	Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives. Nature Reviews Neurology, 2017, 13, 755-763.	4.9	139
5486	CD27-Mediated Regulatory T Cell Depletion and Effector T Cell Costimulation Both Contribute to Antitumor Efficacy. Journal of Immunology, 2017, 199, 4110-4123.	0.4	37
5487	Harnessing designed nanoparticles: Current strategies and future perspectives in cancer immunotherapy. Nano Today, 2017, 17, 23-37.	6.2	69
5488	Cardiotoxicity of immune checkpoint inhibitors. ESMO Open, 2017, 2, e000247.	2.0	186

#	ARTICLE	IF	CITATIONS
5489	Matrix-binding checkpoint immunotherapies enhance antitumor efficacy and reduce adverse events. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	131
5490	Targeting Immune Checkpoint. , 2017, , 781-785.		1
5491	Fine and Predictable Tuning of TALEN Gene Editing Targeting for Improved T Cell Adoptive Immunotherapy. <i>Molecular Therapy - Nucleic Acids</i> , 2017, 9, 312-321.	2.3	36
5492	Neoantigens in the immuno-oncology space. <i>Future Oncology</i> , 2017, 13, 2209-2211.	1.1	3
5493	CD4+ T Cell and NK Cell Interplay Key to Regression of MHC Class II Tumors upon TLR7/8 Agonist Therapy. <i>Cancer Immunology Research</i> , 2017, 5, 642-653.	1.6	37
5494	Nephrotic Syndrome With Cancer Immunotherapies: A Report of 2 Cases. <i>American Journal of Kidney Diseases</i> , 2017, 70, 581-585.	2.1	76
5495	Two Cases of Sinusitis Induced by Immune Checkpoint Inhibition. <i>Journal of Immunotherapy</i> , 2017, 40, 312-314.	1.2	16
5496	A major responder to ipilimumab and nivolumab in metastatic uveal melanoma with concomitant autoimmunity. <i>Pigment Cell and Melanoma Research</i> , 2017, 30, 558-562.	1.5	31
5497	Synthesis and biological evaluation of novel N-(5-phenyl-1H-pyrazol-3-yl)benzenesulfonamide derivatives as potential BRAFV600E inhibitors. <i>Medicinal Chemistry Research</i> , 2017, 26, 2583-2591.	1.1	3
5498	Melanoma arising in an ovarian cystic teratoma: a systematic review of presentation, treatment, and outcomes. <i>Archives of Gynecology and Obstetrics</i> , 2017, 296, 397-404.	0.8	6
5499	Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy. <i>Nature Nanotechnology</i> , 2017, 12, 877-882.	15.6	541
5500	New Combination Strategies Using Programmed Cell Death 1/Programmed Cell Death Ligand 1 Checkpoint Inhibitors as a Backbone. <i>Cancer Journal (Sudbury, Mass)</i> , 2017, 23, 10-22.	1.0	45
5502	Primary oral malignant melanoma metastasis to the brain and breast: A case report and literature review. <i>Oncology Letters</i> , 2017, 14, 1275-1280.	0.8	12
5504	Immune checkpoint inhibitors and elderly people: A review. <i>European Journal of Cancer</i> , 2017, 82, 155-166.	1.3	148
5505	Chemotherapy-induced cardiotoxicity in children. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 817-832.	1.5	57
5506	Melanoma treatment guided by a panel of microRNA biomarkers. <i>Melanoma Management</i> , 2017, 4, 75-77.	0.1	1
5507	Tumor microenvironment changes leading to resistance of immune checkpoint inhibitors in metastatic melanoma and strategies to overcome resistance. <i>Pharmacological Research</i> , 2017, 123, 95-102.	3.1	52
5508	Reactivity toward <i>Bifidobacterium longum</i> and <i>Enterococcus hirae</i> demonstrate robust CD8+ T cell response and better prognosis in HBV-related hepatocellular carcinoma. <i>Experimental Cell Research</i> , 2017, 358, 352-359.	1.2	33

#	ARTICLE	IF	CITATIONS
5509	Successful Treatment of Sudden Hepatitis Induced by Long-Term Nivolumab Administration. Case Reports in Oncology, 2017, 10, 368-371.	0.3	21
5510	The new paradigm of systemic therapies for metastatic melanoma. Journal of the American Academy of Dermatology, 2017, 77, 356-368.	0.6	34
5511	Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2017, 28, iv119-iv142.	0.6	1,744
5512	The role for chemotherapy in the modern management of melanoma. Melanoma Management, 2017, 4, 125-136.	0.1	26
5513	Combining Local Immunotoxins Targeting Mesothelin with CTLA-4 Blockade Synergistically Eradicates Murine Cancer by Promoting Anticancer Immunity. Cancer Immunology Research, 2017, 5, 685-694.	1.6	37
5514	Combined immunotherapy: CTLA-4 blockade potentiates anti-tumor response induced by transcutaneous immunization. Journal of Dermatological Science, 2017, 87, 300-306.	1.0	10
5515	Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E5900-E5909.	3.3	180
5516	Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity. Cancer Immunology Research, 2017, 5, 676-684.	1.6	130
5517	A retrospective clinical analysis of 5 cases of vaginal melanoma. Molecular and Clinical Oncology, 2017, 6, 373-376.	0.4	10
5518	Circulating tumour DNA (ctDNA) as a liquid biopsy for melanoma. Cancer Letters, 2017, 404, 62-69.	3.2	98
5519	Immune checkpoints inhibitors for solid tumours after allogeneic haematopoietic stem-cell transplantation: About four clinical cases. European Journal of Cancer, 2017, 81, 138-141.	1.3	1
5520	Effect of Immunotherapy Status on Outcomes in Patients With Metastatic Melanoma to the Spine. Spine, 2017, 42, E721-E725.	1.0	11
5521	Pharmacotherapy of Glioblastoma: Established Treatments and Emerging Concepts. CNS Drugs, 2017, 31, 675-684.	2.7	24
5523	Parallel profiling of immune infiltrate subsets in uveal melanoma versus cutaneous melanoma unveils similarities and differences: A pilot study. OncoImmunology, 2017, 6, e1321187.	2.1	45
5524	The Effect of Inhibitory Signals on the Priming of Drug Hapten-Specific T Cells That Express Distinct VÎ² Receptors. Journal of Immunology, 2017, 199, 1223-1237.	0.4	41
5525	Rapid decrease of circulating tumor DNA predicted the treatment effect of nivolumab in a lung cancer patient within only 5 days. Respiratory Medicine Case Reports, 2017, 22, 31-33.	0.2	6
5526	Monitoring immune-checkpoint blockade: response evaluation and biomarker development. Nature Reviews Clinical Oncology, 2017, 14, 655-668.	12.5	787
5527	Improved infield response rates and overall survival in patients with metastatic melanoma receiving higher biological equivalent doses of radiation with ipilimumab. Journal of Radiation Oncology, 2017, 6, 215-223.	0.7	2

#	ARTICLE	IF	CITATIONS
5528	Outcomes of cervical cancer among HIV-infected and HIV-uninfected women treated at the Brazilian National Institute of Cancer. <i>Aids</i> , 2017, 31, 523-531.	1.0	36
5529	Prostate cancer immunotherapy: the path forward. <i>Current Opinion in Supportive and Palliative Care</i> , 2017, 11, 225-230.	0.5	8
5530	Addressing current challenges in cancer immunotherapy with mathematical and computational modelling. <i>Journal of the Royal Society Interface</i> , 2017, 14, 20170150.	1.5	71
5531	Targeting Adenosine in BRAF-Mutant Melanoma Reduces Tumor Growth and Metastasis. <i>Cancer Research</i> , 2017, 77, 4684-4696.	0.4	80
5532	Immunotherapy in head and neck cancer: aiming at EXTREME precision. <i>BMC Medicine</i> , 2017, 15, 110.	2.3	64
5533	State of play and clinical prospects of antibody gene transfer. <i>Journal of Translational Medicine</i> , 2017, 15, 131.	1.8	45
5534	Precision medicine in breast cancer: reality or utopia?. <i>Journal of Translational Medicine</i> , 2017, 15, 139.	1.8	56
5535	Molecular imaging biomarkers for cell-based immunotherapies. <i>Journal of Translational Medicine</i> , 2017, 15, 140.	1.8	11
5536	Ipilimumab-induced thrombotic thrombocytopenic purpura (TTP)., 2017, 5, 19.		39
5537	Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies. , 2017, 5, 35.		58
5538	The Value of Cancer Immunotherapy Summit at the 2016 Society for Immunotherapy of Cancer 31st Anniversary Annual Meeting. , 2017, 5, .		11
5539	Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. , 2017, 5, 44.		181
5540	Safe and effective administration of T-VEC in a patient with heart transplantation and recurrent locally advanced melanoma. , 2017, 5, 45.		20
5541	Health Care Resource Utilization and Associated Costs Among Metastatic Cutaneous Melanoma Patients Treated with Ipilimumab (INTUITION Study). <i>Oncologist</i> , 2017, 22, 951-962.	1.9	13
5542	The future of immune checkpoint cancer therapy after PD-1 and CTLA-4. <i>Immunotherapy</i> , 2017, 9, 681-692.	1.0	94
5543	Rationally combining immunotherapies to improve efficacy of immune checkpoint blockade in solid tumors. <i>Cytokine and Growth Factor Reviews</i> , 2017, 36, 5-15.	3.2	48
5544	Health-related quality of life results from the phase III CheckMate 067 study. <i>European Journal of Cancer</i> , 2017, 82, 80-91.	1.3	76
5545	Radiation and PD-1 inhibition: Favorable outcomes after brain-directed radiation. <i>Radiotherapy and Oncology</i> , 2017, 124, 98-103.	0.3	51

#	ARTICLE	IF	CITATIONS
5546	Critical role for Sec22b-dependent antigen cross-presentation in antitumor immunity. <i>Journal of Experimental Medicine</i> , 2017, 214, 2231-2241.	4.2	100
5547	Radiotherapy and Immune Checkpoint Blockade for Melanoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2017, 23, 32-39.	1.0	28
5548	Long-term and late treatment consequences: endocrine and metabolic effects. <i>Current Opinion in Supportive and Palliative Care</i> , 2017, 11, 205-213.	0.5	6
5549	Efficacy of Sequential Ipilimumab Monotherapy versus Best Supportive Care for Unresectable Locally Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 5671-5678.	3.2	121
5550	Immune Checkpoint Inhibitors in Lung Cancer: Imaging Considerations. <i>American Journal of Roentgenology</i> , 2017, 209, 567-575.	1.0	26
5551	Genomic profiling of colorectal cancers and the future of personalized treatment. <i>Colorectal Cancer</i> , 2017, 6, 11-22.	0.8	1
5552	Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma. <i>Medicine (United States)</i> , 2017, 96, e7325.	0.4	80
5553	Endocrine dysfunction following immune checkpoint inhibitor therapy. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2017, 24, 337-347.	1.2	18
5554	Winning the battle, but losing the war: mechanisms and morphology of cancer-therapy-associated cardiovascular toxicity. <i>Cardiovascular Pathology</i> , 2017, 30, 55-63.	0.7	31
5555	Successful immune checkpoint blockade in a patient with advanced stage microsatellite-unstable biliary tract cancer. <i>Journal of Physical Education and Sports Management</i> , 2017, 3, a001974.	0.5	54
5557	A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment 1 IMPS is an investor in and consultant for Urogen. SAP is consultant and advisor for Vaccinex. The remaining authors have nothing to disclose.. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 14-20.	0.8	67
5558	PD-1/PD-L1 immune-checkpoint blockade in B-cell lymphomas. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 203-220.	12.5	358
5559	Tumour-associated mesenchymal stem/stromal cells: emerging therapeutic targets. <i>Nature Reviews Drug Discovery</i> , 2017, 16, 35-52.	21.5	344
5560	The importance of correctly timing cancer immunotherapy. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 87-103.	1.4	26
5561	Factors associated with failure of oncology drugs in late-stage clinical development: A systematic review. <i>Cancer Treatment Reviews</i> , 2017, 52, 12-21.	3.4	87
5562	The Impact of Systemic Therapy Beyond First-line Treatment for Advanced Cervical Cancer. <i>Clinical Oncology</i> , 2017, 29, 153-160.	0.6	67
5563	Prussian blue nanoparticle-based photothermal therapy combined with checkpoint inhibition for photothermal immunotherapy of neuroblastoma. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2017, 13, 771-781.	1.7	122
5564	Functional polymorphisms in PD-L1 gene are associated with the prognosis of patients with early stage non-small cell lung cancer. <i>Gene</i> , 2017, 599, 28-35.	1.0	47

#	ARTICLE	IF	CITATIONS
5565	Combinatorial immunotherapy for melanoma. <i>Cancer Gene Therapy</i> , 2017, 24, 141-147.	2.2	24
5566	Efficacy and toxicity of rechallenge with combination immune checkpoint blockade in metastatic melanoma: a case series. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 113-117.	2.0	31
5567	Immune-Suppressing Cellular Elements of the Tumor Microenvironment. <i>Annual Review of Cancer Biology</i> , 2017, 1, 241-255.	2.3	25
5568	Distinct patterns of cytolytic T cell activation by different tumour cells revealed by Ca ²⁺ signalling and granule mobilization. <i>Immunology</i> , 2017, 150, 199-212.	2.0	3
5569	Cancer immunotherapy in patients with preexisting autoimmune disorders. <i>Seminars in Immunopathology</i> , 2017, 39, 333-337.	2.8	31
5570	The safety of anti PD-1 therapeutics for the treatment of melanoma. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 41-53.	1.0	17
5571	Deciphering Genetic Intratumor Heterogeneity and Its Impact on Cancer Evolution. <i>Annual Review of Cancer Biology</i> , 2017, 1, 223-240.	2.3	20
5572	Translational Pharmacokinetic/Pharmacodynamic Modeling of Tumor Growth Inhibition Supports Dose-Range Selection of the Anti-PD-1 Antibody Pembrolizumab. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2017, 6, 11-20.	1.3	88
5573	Preclinical Advances with Multiphoton Microscopy in Live Imaging of Skin Cancers. <i>Journal of Investigative Dermatology</i> , 2017, 137, 282-287.	0.3	22
5574	Resistance to anticancer immunity in cancer patients: potential strategies to reverse resistance. <i>Annals of Oncology</i> , 2017, 28, 457-467.	0.6	27
5575	Diverse types of dermatologic toxicities from immune checkpoint blockade therapy. <i>Journal of Cutaneous Pathology</i> , 2017, 44, 158-176.	0.7	186
5576	An update on the current management of head and neck mucosal melanoma. <i>Journal of Oral Pathology and Medicine</i> , 2017, 46, 475-479.	1.4	18
5577	Using Model-Based <i>eo</i> Learn and Confirm ^o to Reveal the Pharmacokinetics-Pharmacodynamics Relationship of Pembrolizumab in the KEYNOTE-001 Trial. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2017, 6, 21-28.	1.3	85
5578	Immunotherapy for Lung Malignancies. <i>Chest</i> , 2017, 151, 891-897.	0.4	17
5579	Next steps in immuno-oncology: enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies. <i>Annals of Oncology</i> , 2017, 28, 57-74.	0.6	45
5580	Treatment of brain metastases in the modern genomic era. , 2017, 170, 64-72.		40
5581	Chimeric antigen receptors for treatment of glioblastoma: a practical review of challenges and ways to overcome them. <i>Cancer Gene Therapy</i> , 2017, 24, 121-129.	2.2	21
5582	Immunotherapy in melanoma: Recent advances and future directions. <i>European Journal of Surgical Oncology</i> , 2017, 43, 604-611.	0.5	216

#	ARTICLE	IF	CITATIONS
5583	Targeting melanoma with front-line therapy does not abrogate Nodal-expressing tumor cells. <i>Laboratory Investigation</i> , 2017, 97, 176-186.	1.7	14
5584	Leveraging the immune system to treat advanced thyroid cancers. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 469-481.	5.5	58
5585	Systemic Therapy for Previously Untreated Advanced <i>BRAF</i> -Mutated Melanoma. <i>JAMA Oncology</i> , 2017, 3, 366.	3.4	68
5586	New Approaches to Investigate Drug-Induced Hypersensitivity. <i>Chemical Research in Toxicology</i> , 2017, 30, 239-259.	1.7	18
5587	Gammaretroviral Production and T Cell Transduction to Genetically Retarget Primary T Cells Against Cancer. <i>Methods in Molecular Biology</i> , 2017, 1514, 111-118.	0.4	13
5588	The evolving clinical management of cerebral metastases. <i>European Journal of Surgical Oncology</i> , 2017, 43, 1173-1185.	0.5	11
5589	Is there a role for therapeutic cancer vaccines in the age of checkpoint inhibitors?. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 528-532.	1.4	30
5591	Immune-mediated Disease in Ipilimumab Immunotherapy of Melanoma with FDG PET-CT. <i>Academic Radiology</i> , 2017, 24, 111-115.	1.3	58
5592	Antibody therapeutics for treating prostate cancer: where are we now and what comes next?. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 135-149.	1.4	5
5593	(Neo)adjuvant systemic therapy for melanoma. <i>European Journal of Surgical Oncology</i> , 2017, 43, 534-543.	0.5	52
5594	Immunotherapy of melanoma. <i>European Journal of Surgical Oncology</i> , 2017, 43, 594-603.	0.5	21
5595	Immunotherapy for the Treatment of Urothelial Carcinoma. <i>Journal of Urology</i> , 2017, 197, 14-22.	0.2	87
5596	Antitumor Effect of Programmed Death-1 (PD-1) Blockade in Humanized the NOG-MHC Double Knockout Mouse. <i>Clinical Cancer Research</i> , 2017, 23, 149-158.	3.2	77
5597	Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2017, 22, 81-88.	1.9	128
5598	Melanoma antigens are biomarkers for ipilimumab response. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 252-259.	1.3	9
5599	Multispectral imaging for highly accurate analysis of tumour-infiltrating lymphocytes in primary melanoma. <i>Histopathology</i> , 2017, 70, 643-649.	1.6	14
5600	Metastatic Melanoma: Insights Into the Evolution of the Treatments and Future Challenges. <i>Medicinal Research Reviews</i> , 2017, 37, 98-148.	5.0	92
5601	Radiotherapy combination opportunities leveraging immunity for the next oncology practice. <i>Ca-A Cancer Journal for Clinicians</i> , 2017, 67, 65-85.	157.7	344

#	ARTICLE	IF	CITATIONS
5602	Management Controversies in Head and Neck Melanoma. <i>JAMA Facial Plastic Surgery</i> , 2017, 19, 53-62.	2.2	19
5603	Nivolumab-induced vitiligo in a metastatic melanoma patient: A case report. <i>Journal of Oncology Pharmacy Practice</i> , 2017, 23, 629-634.	0.5	11
5604	Consequences of the Convergence of Multiple Alternate Pathways on the Estrogen Receptor in the Treatment of Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2017, 17, 79-90.	1.1	23
5605	Rationale and evidence to combine radiation therapy and immunotherapy for cancer treatment. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 281-298.	2.0	54
5606	Global chemotherapy development for gastric cancer. <i>Gastric Cancer</i> , 2017, 20, 92-101.	2.7	38
5607	Considerations for successful cancer immunotherapy in aged hosts. <i>Clinical and Experimental Immunology</i> , 2017, 187, 53-63.	1.1	56
5608	Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 40-47.	0.8	577
5609	Beyond Seed and Soil: Understanding and Targeting Metastatic Prostate Cancer; Report From the 2016 Coffeyâ€“Holden Prostate Cancer Academy Meeting. <i>Prostate</i> , 2017, 77, 123-144.	1.2	6
5610	Immune checkpoint inhibitors for nonsmall cell lung cancer treatment. <i>Journal of the Chinese Medical Association</i> , 2017, 80, 7-14.	0.6	39
5611	Expression profiles of immune-related genes are associated with neoadjuvant ipilimumab clinical benefit. <i>Oncolmmunology</i> , 2017, 6, e1231291.	2.1	29
5612	Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations. <i>Nature Reviews Urology</i> , 2017, 14, 15-25.	1.9	210
5613	Molecular Imaging and Precision Medicine. <i>PET Clinics</i> , 2017, 12, 105-118.	1.5	16
5614	Recent studies on micro-/nano-sized biomaterials for cancer immunotherapy. <i>Journal of Pharmaceutical Investigation</i> , 2017, 47, 11-18.	2.7	31
5615	Prognostic impact of the putative cancer stem cell markers ABCG 2, CD 133, ALDH 1A1 and CD 44V7/8 in metastatic melanoma. <i>British Journal of Dermatology</i> , 2017, 177, 1447-1449.	1.4	5
5616	Cytokine-Induced Killer Cells Kill Chemo-surviving Melanoma Cancer Stem Cells. <i>Clinical Cancer Research</i> , 2017, 23, 2277-2288.	3.2	34
5617	Ultrasonographic findings can identify â€“pseudoprogressionâ€™ under nivolumab therapy. <i>British Journal of Dermatology</i> , 2017, 177, 1726-1731.	1.4	11
5618	Metastatic pathways in patients with cutaneous melanoma. <i>Pigment Cell and Melanoma Research</i> , 2017, 30, 13-27.	1.5	38
5619	Ipilimumab: from preclinical development to future clinical perspectives in melanoma. <i>Future Oncology</i> , 2017, 13, 625-636.	1.1	31

#	ARTICLE	IF	CITATIONS
5621	Immunotherapy approaches in the treatment of malignant brain tumors. <i>Cancer</i> , 2017, 123, 734-750.	2.0	75
5622	Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer. <i>European Journal of Immunology</i> , 2017, 47, 385-393.	1.6	64
5624	Colon and Rectal Surgical Emergencies. , 2017, , 177-187.		0
5625	Metastasectomy in cutaneous melanoma. <i>European Journal of Surgical Oncology</i> , 2017, 43, 572-580.	0.5	18
5626	Neuroimaging of Peptide-based Vaccine Therapy in Pediatric Brain Tumors. <i>Neuroimaging Clinics of North America</i> , 2017, 27, 155-166.	0.5	8
5627	Immune-Related Adverse Effects of Cancer Immunotherapy” Implications for Rheumatology. <i>Rheumatic Disease Clinics of North America</i> , 2017, 43, 65-78.	0.8	101
5628	Metastatic Anal Cancer and Novel Agents. <i>Surgical Oncology Clinics of North America</i> , 2017, 26, 133-142.	0.6	7
5629	Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells. <i>Clinical Cancer Research</i> , 2017, 23, 1388-1396.	3.2	261
5630	Is Participation in Cancer Phase I Trials Really Therapeutic?. <i>Journal of Clinical Oncology</i> , 2017, 35, 135-138.	0.8	43
5631	Metastasectomy Following Immunotherapy with Adoptive Cell Transfer for Patients with Advanced Melanoma. <i>Annals of Surgical Oncology</i> , 2017, 24, 135-141.	0.7	24
5632	Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	139
5633	Development of Ocular Rosacea following Combined Ipilimumab and Nivolumab Treatment for Metastatic Malignant Skin Melanoma. <i>Ocular Oncology and Pathology</i> , 2017, 3, 188-192.	0.5	19
5634	Acute Angle Closure Precipitated by Hemorrhage and Necrosis of a Large Uveal Melanoma in the Setting of Systemic Immunomodulatory Therapy. <i>Ocular Oncology and Pathology</i> , 2017, 3, 254-258.	0.5	4
5635	Coexisting myasthenia gravis, myositis, and polyneuropathy induced by ipilimumab and nivolumab in a patient with non-small-cell lung cancer. <i>Medicine (United States)</i> , 2017, 96, e9262.	0.4	57
5636	Safe and Effective Standards of Care: Supporting the Administration of T-VEC for Patients With Advanced Melanoma in the Outpatient Oncology Setting. <i>Clinical Journal of Oncology Nursing</i> , 2017, 21, E260-E266.	0.3	4
5637	Risk of gastrointestinal toxicities with PD-1 inhibitors in cancer patients. <i>Medicine (United States)</i> , 2017, 96, e8931.	0.4	21
5638	Targeted therapy of brain metastases: latest evidence and clinical implications. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 781-796.	1.4	46
5639	New Approaches in CART-Cell Immunotherapy for Breast Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1026, 371-381.	0.8	31

#	ARTICLE	IF	CITATIONS
5641	Immune Checkpoint Blockade in Breast Cancer Therapy. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1026, 383-402.	0.8	24
5642	Increased infiltration and tolerised antigen-specific CD8+ TEM cells in tumor but not peripheral blood have no impact on survival of HCMV+ glioblastoma patients. <i>Onc Immunology</i> , 2017, 6, e1336272.	2.1	17
5643	Are peptide vaccines viable in combination with other cancer immunotherapies?. <i>Future Oncology</i> , 2017, 13, 1577-1580.	1.1	1
5644	Tumor Immune Microenvironment in Cancer Progression and Cancer Therapy. <i>Advances in Experimental Medicine and Biology</i> , 2017, , .	0.8	9
5645	Informatics for cancer immunotherapy. <i>Annals of Oncology</i> , 2017, 28, xii56-xii73.	0.6	19
5646	Melanoma cutané cervical. <i>EMC - Otorrinolaringologia</i> , 2017, 46, 1-9.	0.0	0
5647	Melanomi cutanei cervicofacciali. <i>EMC - Otorinolaringoiatria</i> , 2017, 16, 1-9.	0.0	0
5648	Cancer bronchique non À petites cellules de stade IV sans addiction oncogénique : traitements en 2 e ligne et au-delÀ. <i>Revue Des Maladies Respiratoires Actualites</i> , 2017, 9, 248-258.	0.0	0
5649	Toxicité pulmonaire de l'immunothérapie par les inhibiteurs de point de contrôle. <i>Revue Des Maladies Respiratoires Actualites</i> , 2017, 9, 469-474.	0.0	1
5650	Recombinant Monoclonal Antibodies, from Tumor Targeting to Cancer Immunotherapy: A Critical Overview. <i>Molecular Biology</i> , 2017, 51, 887-899.	0.4	2
5652	Preclinical and clinical development of neoantigen vaccines. <i>Annals of Oncology</i> , 2017, 28, xii11-xii17.	0.6	160
5653	Current Targeted Therapies in HER2-Positive Gastric Adenocarcinoma. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2017, 32, 351-363.	0.7	19
5655	Adaptive Resistance to Cancer Immunotherapy. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1036, 213-227.	0.8	15
5656	The Role of Tumor Microenvironment in Cancer Immunotherapy. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1036, 51-64.	0.8	124
5657	Case report on the role of radiofrequency-assisted spleen-preserving surgery for splenic metastasis in the era of check-point inhibitors. <i>Medicine (United States)</i> , 2017, 96, e9106.	0.4	7
5658	Immune checkpoint inhibitors in the treatment of advanced mucosal melanoma. <i>Melanoma Management</i> , 2017, 4, 161-167.	0.1	7
5660	An update on the relevance of vaccine research for the treatment of metastatic melanoma. <i>Melanoma Management</i> , 2017, 4, 203-215.	0.1	8
5661	Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies. <i>Japanese Journal of Clinical Immunology</i> , 2017, 40, 68-77.	0.0	22

#	ARTICLE	IF	CITATIONS
5662	Outcome Evaluation of Patients with Limited Brain Metastasis From Malignant Melanoma, Treated with Surgery, Radiation Therapy, and Targeted Therapy. <i>World Neurosurgery</i> , 2017, 105, 184-190.	0.7	13
5663	Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. <i>European Journal of Cancer</i> , 2017, 86, 37-45.	1.3	183
5665	Life expectancy difference and life expectancy ratio: two measures of treatment effects in randomised trials with non-proportional hazards. <i>BMJ: British Medical Journal</i> , 2017, 357, j2250.	2.4	67
5666	Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13. <i>BMJ: British Medical Journal</i> , 2017, 359, j4530.	2.4	423
5667	Primary adrenal malignant melanoma. <i>Medicine (United States)</i> , 2017, 96, e8956.	0.4	9
5668	MCVdb: A database for knowledge discovery in Merkel cell polyomavirus with applications in T cell immunology and vaccinology. , 2017, , .		1
5671	Concentrations of neopterin, kynurenine and tryptophan in wound secretions of patients with breast cancer and malignant melanoma: a pilot study. <i>Pteridines</i> , 2017, 28, 205-211.	0.5	1
5672	Why Did my Patient get this Kidney Problem after Receiving this New Cancer Drug?. <i>Journal of Onco-Nephrology</i> , 2017, 1, 9-17.	0.3	2
5673	PD-L1 expression as poor prognostic factor in patients with non-squamous non-small cell lung cancer. <i>Oncotarget</i> , 2017, 8, 58457-58468.	0.8	42
5674	Decreased Serum Concentration of Total IgG Is Related to Tumor Progression in Gastric Cancer Patients. <i>Yonago Acta Medica</i> , 2017, 60, 119-125.	0.3	11
5675	Transcriptional response profiles of paired tumor-normal samples offer novel perspectives in pan-cancer analysis. <i>Oncotarget</i> , 2017, 8, 41334-41347.	0.8	22
5676	Primary malignant melanoma of the cervix: Report of 14 cases and review of literature. <i>Oncotarget</i> , 2017, 8, 73162-73167.	0.8	22
5677	Rapid Evolution of Thyroid Dysfunction in Patients Treated with Nivolumab. <i>Endocrine Practice</i> , 2017, 23, 1223-1231.	1.1	23
5678	Dendritic Cell Therapy for Brain Tumors. , 2017, , 301-321.		0
5679	Introduction to Translational Immunotherapy for Brain Tumors. , 2017, , xiii-xxix.		0
5680	Operable Melanoma: Screening, Prognostication, and Adjuvant and Neoadjuvant Therapy. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 651-660.	1.8	5
5681	Aptamers as a Promising Therapeutic Tool for Cancer Immunotherapy. , 2017, , .		1
5682	Systemic Therapy Options for Patients With Unresectable Melanoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 661-672.	1.8	8

#	ARTICLE	IF	CITATIONS
5683	Uveal Melanoma: Identifying Immunological and Chemotherapeutic Targets to Treat Metastases. Asia-Pacific Journal of Ophthalmology, 2017, 6, 179-185.	1.3	13
5685	Cancer Immunotherapy in Older Patients. Cancer Journal (Sudbury, Mass), 2017, 23, 219-222.	1.0	4
5686	Clinical use of immune checkpoint inhibitors. , 2017, , .		0
5687	The future of immuno-oncology. , 2017, , .		0
5688	Improving Outcomes through Immune System Modulation in the Treatment of Gynecological Malignancies. Reproductive Immunology Open Access, 2017, 02, .	0.1	0
5689	Conditional Survival-Based "Abbreviated" Routine Cancer Surveillance for Pathologic Stage IB Melanoma. American Surgeon, 2017, 83, 1256-1262.	0.4	4
5690	Management and Supportive Care of Patients Undergoing Immunotherapy. , 2017, , .		0
5691	Immune Regulation in Breast Cancer Metastasis and Immunotherapy. , 2017, , .		0
5692	Checkpoint Inhibitor-Induced Colitis: A New Type of Inflammatory Bowel Disease?. ACG Case Reports Journal, 2017, 4, e112.	0.2	35
5693	Ipilimumab-nivolumab therapy causing STEMI in a melanoma patient: A case report. Case Reports in Internal Medicine, 2017, 4, 57.	0.0	0
5694	Novel tools to assist neoepitope targeting in personalized cancer immunotherapy. Annals of Oncology, 2017, 28, xii3-xii10.	0.6	31
5695	Checkpoint inhibitors for malignant melanoma: a systematic review and meta-analysis. Clinical, Cosmetic and Investigational Dermatology, 2017, Volume 10, 325-339.	0.8	52
5696	Inferring the Impact of Regulatory Mechanisms that Underpin CD8+ T Cell Control of B16 Tumor Growth In vivo Using Mechanistic Models and Simulation. Frontiers in Pharmacology, 2017, 7, 515.	1.6	3
5697	Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy. Frontiers in Pharmacology, 2017, 8, 49.	1.6	459
5698	Targeting immune checkpoints in malignant glioma. Oncotarget, 2017, 8, 7157-7174.	0.8	42
5699	Pneumonitis and pneumonitis-related death in cancer patients treated with programmed cell death-1 inhibitors: a systematic review and meta-analysis. Therapeutics and Clinical Risk Management, 2017, Volume 13, 1259-1271.	0.9	16
5700	Chemotherapy and Targeted Agents. , 2017, , 339-354.		3
5701	Immune Checkpoint Inhibitors in Melanoma and HIV Infection. Open AIDS Journal, 2017, 11, 91-100.	0.1	12

#	ARTICLE	IF	CITATIONS
5702	Targeting the PD-1 pathway in pediatric solid tumors and brain tumors. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 2097-2106.	1.0	45
5703	Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events. <i>ImmunoTargets and Therapy</i> , 2017, Volume 6, 51-71.	2.7	101
5704	Immune-Checkpoint Inhibitors in the Era of Precision Medicine: What Radiologists Should Know. <i>Korean Journal of Radiology</i> , 2017, 18, 42.	1.5	33
5705	Patient and oncologist preferences for attributes of treatments in advanced melanoma: a discrete choice experiment. <i>Patient Preference and Adherence</i> , 2017, Volume 11, 1389-1399.	0.8	23
5706	Immune Constitution of Patients With Brain Tumors. , 2017, , 13-32.		0
5707	Immunotherapy Clinical Trials in Neuro-Oncology. , 2017, , 181-210.		0
5708	Treatment of advanced melanoma - A changing landscape. <i>Revista Da Associação Médica Brasileira</i> , 2017, 63, 814-823.	0.3	15
5709	Cancer immunology and melanoma immunotherapy. <i>Anais Brasileiros De Dermatologia</i> , 2017, 92, 830-835.	0.5	8
5710	Profile of pembrolizumab in the treatment of head and neck squamous cell carcinoma: design development and place in therapy. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 2537-2549.	2.0	6
5711	Baseline relative eosinophil count as a predictive biomarker for ipilimumab treatment in advanced melanoma. <i>Oncotarget</i> , 2017, 8, 79809-79815.	0.8	27
5712	Immunotherapy for Prostate Cancer: Where We Are Headed. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2627.	1.8	47
5713	Newly Emerging Immune Checkpoints: Promises for Future Cancer Therapy. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2642.	1.8	72
5714	Immunotherapeutic Potential of Oncolytic H-1 Parvovirus: Hints of Glioblastoma Microenvironment Conversion towards Immunogenicity. <i>Viruses</i> , 2017, 9, 382.	1.5	36
5715	Novel immunotherapy in metastatic renal cell carcinoma. <i>Investigative and Clinical Urology</i> , 2017, 58, 220.	1.0	16
5716	New Immunotherapy Strategies in Breast Cancer. <i>International Journal of Environmental Research and Public Health</i> , 2017, 14, 68.	1.2	76
5719	PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome. <i>Frontiers in Pharmacology</i> , 2017, 8, 561.	1.6	1,276
5720	TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action. <i>International Journal of Molecular Sciences</i> , 2017, 18, 645.	1.8	193
5721	Immunoregulatory Role of NK Cells in Tissue Inflammation and Regeneration. <i>Frontiers in Immunology</i> , 2017, 8, 301.	2.2	114

#	ARTICLE	IF	CITATIONS
5722	Epigenetic Strategies to Boost Cancer Immunotherapies. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1108.	1.8	29
5723	Immunotherapeutic Concepts to Target Acute Myeloid Leukemia: Focusing on the Role of Monoclonal Antibodies, Hypomethylating Agents and the Leukemic Microenvironment. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1660.	1.8	33
5724	Bidirectional Crosstalk between Lymphatic Endothelial Cell and T Cell and Its Implications in Tumor Immunity. <i>Frontiers in Immunology</i> , 2017, 8, 83.	2.2	38
5725	Antigen Loss Variants: Catching Hold of Escaping Foes. <i>Frontiers in Immunology</i> , 2017, 8, 175.	2.2	35
5726	Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don't Forget the Fuel. <i>Frontiers in Immunology</i> , 2017, 8, 267.	2.2	61
5727	Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study. <i>Frontiers in Immunology</i> , 2017, 8, 386.	2.2	27
5728	PD-1 Blockade Promotes Emerging Checkpoint Inhibitors in Enhancing T Cell Responses to Allogeneic Dendritic Cells. <i>Frontiers in Immunology</i> , 2017, 8, 572.	2.2	59
5729	Cancer Immunotherapy: Historical Perspective of a Clinical Revolution and Emerging Preclinical Animal Models. <i>Frontiers in Immunology</i> , 2017, 8, 829.	2.2	159
5730	Immunomodulatory Monoclonal Antibodies in Combined Immunotherapy Trials for Cutaneous Melanoma. <i>Frontiers in Immunology</i> , 2017, 8, 1024.	2.2	29
5731	Coinhibitory Receptor Expression and Immune Checkpoint Blockade: Maintaining a Balance in CD8+ T Cell Responses to Chronic Viral Infections and Cancer. <i>Frontiers in Immunology</i> , 2017, 8, 1215.	2.2	80
5732	Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract. <i>Frontiers in Immunology</i> , 2017, 8, 1547.	2.2	125
5733	Recent Successes and Future Directions in Immunotherapy of Cutaneous Melanoma. <i>Frontiers in Immunology</i> , 2017, 8, 1617.	2.2	43
5734	Neoantigen Targeting—Dawn of a New Era in Cancer Immunotherapy?. <i>Frontiers in Immunology</i> , 2017, 8, 1848.	2.2	73
5735	Taming Tumor Glycolysis and Potential Implications for Immunotherapy. <i>Frontiers in Oncology</i> , 2017, 7, 36.	1.3	26
5736	Update on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2017, 7, 67.	1.3	28
5737	Genetically Engineered Vaccinia Viruses As Agents for Cancer Treatment, Imaging, and Transgene Delivery. <i>Frontiers in Oncology</i> , 2017, 7, 96.	1.3	61
5738	Gliomatosis Cerebri: Current Understanding and Controversies. <i>Frontiers in Oncology</i> , 2017, 7, 165.	1.3	26
5739	Genetic Characterization of Brain Metastases in the Era of Targeted Therapy. <i>Frontiers in Oncology</i> , 2017, 7, 230.	1.3	43

#	ARTICLE	IF	CITATIONS
5740	Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review. <i>Frontiers in Oncology</i> , 2017, 7, 233.	1.3	61
5741	Clinical Applications of Immunotherapy Combination Methods and New Opportunities for the Future. <i>BioMed Research International</i> , 2017, 2017, 1-10.	0.9	6
5742	Manipulation of Innate and Adaptive Immunity through Cancer Vaccines. <i>Journal of Immunology Research</i> , 2017, 2017, 1-7.	0.9	31
5743	Dual Roles of IL-27 in Cancer Biology and Immunotherapy. <i>Mediators of Inflammation</i> , 2017, 2017, 1-14.	1.4	90
5744	Immunotherapy as a Promising Treatment for Prostate Cancer: A Systematic Review. <i>Journal of Immunology Research</i> , 2017, 2017, 1-6.	0.9	45
5745	Genetic Mutations and Epigenetic Modifications: Driving Cancer and Informing Precision Medicine. <i>BioMed Research International</i> , 2017, 2017, 1-18.	0.9	40
5746	Are PD-1 antibodies safe for use in metastatic uveal melanoma?. <i>Melanoma Management</i> , 2017, 4, 79-82.	0.1	0
5747	Skin Cancer and Its Treatment: Novel Treatment Approaches with Emphasis on Nanotechnology. <i>Journal of Nanomaterials</i> , 2017, 2017, 1-20.	1.5	61
5748	Immunotherapy for Patients with Advanced Urothelial Cancer: Current Evidence and Future Perspectives. <i>BioMed Research International</i> , 2017, 2017, 1-13.	0.9	10
5749	Advances in Immunotherapy for Glioblastoma Multiforme. <i>Journal of Immunology Research</i> , 2017, 2017, 1-11.	0.9	73
5750	Gastric and Rectal Metastases from Malignant Melanoma Presenting with Hypochromic Anemia and Treated with Immunotherapy. <i>Case Reports in Oncological Medicine</i> , 2017, 2017, 1-4.	0.2	12
5751	Diagnostic and Therapeutic Biomarkers in Glioblastoma: Current Status and Future Perspectives. <i>BioMed Research International</i> , 2017, 2017, 1-13.	0.9	239
5752	Cost-Effectiveness of Nivolumab-Ipilimumab Combination Therapy Compared with Monotherapy for First-Line Treatment of Metastatic Melanoma in the United States. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2017, 23, 653-664.	0.5	61
5753	The current status of immunobased therapies for metastatic renal-cell carcinoma. <i>ImmunoTargets and Therapy</i> , 2017, Volume 6, 83-93.	2.7	14
5754	Melanoma: tumor microenvironment and new treatments. <i>Anais Brasileiros De Dermatologia</i> , 2017, 92, 156-166.	0.5	35
5755	Overexpression of PD-L2 is associated with shorter relapse-free survival in patients with malignant salivary gland tumors. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 2983-2992.	1.0	46
5757	The Cancer Stem Cell Niche. , 2017, , 167-184.		2
5758	Acute Hyperglycemia Associated with Anti-Cancer Medication. <i>Endocrinology and Metabolism</i> , 2017, 32, 23.	1.3	48

#	ARTICLE	IF	CITATIONS
5759	Pediatric melanoma: incidence, treatment, and prognosis. <i>Pediatric Health, Medicine and Therapeutics</i> , 2017, Volume 8, 39-45.	0.7	25
5760	Potential role of radiation therapy in augmenting the activity of immunotherapy for gynecologic cancers. <i>Cancer Management and Research</i> , 2017, Volume 9, 553-563.	0.9	14
5761	Therapy of Melanoma. , 2017, , 91-142.		0
5762	Challenging the standard of care in advanced melanoma: focus on pembrolizumab. <i>Cancer Management and Research</i> , 2017, Volume 9, 433-442.	0.9	15
5763	Effects of nivolumab in peritoneal carcinomatosis of malign melanoma in mouse model. <i>Acta Cirurgica Brasileira</i> , 2017, 32, 1006-1012.	0.3	4
5764	Checkpoint blockade in solid tumors and B-cell malignancies, with special consideration of the role of CD200. <i>Cancer Management and Research</i> , 2017, Volume 9, 601-609.	0.9	21
5766	Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis. <i>Cancer Management and Research</i> , 2017, Volume 9, 207-213.	0.9	128
5767	Spotlight on atezolizumab and its potential in the treatment of advanced urothelial bladder cancer. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 1487-1502.	1.0	12
5768	Emerging role of nivolumab in the management of patients with non-small-cell lung cancer: current data and future perspectives. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 3697-3708.	1.0	6
5769	Chimeric-antigen receptor T (CAR-T) cell therapy for solid tumors: challenges and opportunities. <i>Oncotarget</i> , 2017, 8, 90521-90531.	0.8	81
5770	Targeted therapy for soft tissue sarcomas in adolescents and young adults. <i>Adolescent Health, Medicine and Therapeutics</i> , 2017, Volume 8, 41-55.	0.7	11
5771	A natural product-like JAK2/STAT3 inhibitor induces apoptosis of malignant melanoma cells. <i>PLoS ONE</i> , 2017, 12, e0177123.	1.1	31
5772	Interleukin-like EMT inducer regulates partial phenotype switching in MITF-low melanoma cell lines. <i>PLoS ONE</i> , 2017, 12, e0177830.	1.1	17
5773	Design of short peptides to block BTLA/HVEM interactions for promoting anticancer T-cell responses. <i>PLoS ONE</i> , 2017, 12, e0179201.	1.1	28
5774	Functional differences between PD-1+ and PD-1- CD4+ effector T cells in healthy donors and patients with glioblastoma multiforme. <i>PLoS ONE</i> , 2017, 12, e0181538.	1.1	34
5775	A practical approach to pancreatic cancer immunotherapy using resected tumor lysate vaccines processed to express I \pm -gal epitopes. <i>PLoS ONE</i> , 2017, 12, e0184901.	1.1	10
5776	Utility of ipilimumab in melanoma patients who progress on anti-PD-1 therapy. <i>Melanoma Management</i> , 2017, 4, 143-145.	0.1	8
5777	Population Approach to Precision Medicine. , 2017, , 115-128.		0

#	ARTICLE	IF	CITATIONS
5778	Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: A systematic review and meta-analysis. <i>OncImmunology</i> , 2017, 6, e1344805.	2.1	142
5779	Immune profiles and clinical outcomes between sepsis patients with or without active cancer requiring admission to intensive care units. <i>PLoS ONE</i> , 2017, 12, e0179749.	1.1	18
5780	When to consider alternatives to front-line immune therapies in metastatic melanoma. <i>Melanoma Management</i> , 2017, 4, 71-74.	0.1	0
5781	Pathogenesis, Clinical Manifestations and Management of Immune Checkpoint Inhibitors Toxicity. <i>Tumori</i> , 2017, 103, 405-421.	0.6	52
5782	Anti-PD-1 monotherapy versus anti-PD1 plus anti-CTLA4 in advanced melanoma: how do we decide?. <i>Melanoma Management</i> , 2017, 4, 151-155.	0.1	2
5783	Addressing the challenges of applying precision oncology. <i>Npj Precision Oncology</i> , 2017, 1, 28.	2.3	43
5784	Presence of immune cells, low tumor proliferation and wild type BRAF mutation status is associated with a favourable clinical outcome in stage III cutaneous melanoma. <i>BMC Cancer</i> , 2017, 17, 584.	1.1	11
5785	Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma: response monitoring and resistance prediction with positron emission tomography and tumor characteristics (REPOSIT): study protocol of a phase II, open-label, multicenter study. <i>BMC Cancer</i> , 2017, 17, 649.	1.1	12
5786	Hospitalisation costs of metastatic melanoma in France; the MELISSA study (MELanoma In hoSpital) <i>Tj ETQqO O O rgBT /Overlock 10 TF 5</i>	0.9	4
5787	The biology of Hepatocellular carcinoma: implications for genomic and immune therapies. <i>Molecular Cancer</i> , 2017, 16, 149.	7.9	338
5789	Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab. <i>Journal of Translational Medicine</i> , 2017, 15, 244.	1.8	73
5790	Multifocal gastric adenocarcinoma in a patient with LRBA deficiency. <i>Orphanet Journal of Rare Diseases</i> , 2017, 12, 131.	1.2	33
5791	Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. , 2017, 5, 53.		688
5792	Regression of multifocal in transit melanoma metastases after palliative resection of dominant masses and 2 years after treatment with ipilimumab. , 2017, 5, 61.		5
5793	Whole-blood RNA transcript-based models can predict clinical response in two large independent clinical studies of patients with advanced melanoma treated with the checkpoint inhibitor, tremelimumab. , 2017, 5, 67.		28
5794	Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials. , 2017, 5, 72.		37
5795	High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute. , 2017, 5, 74.		45
5796	Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma. , 2017, 5, 83.		46

#	ARTICLE	IF	CITATIONS
5797	Safety in treatment of hepatocellular carcinoma with immune checkpoint inhibitors as compared to melanoma and non-small cell lung cancer. , 2017, 5, 93.		56
5798	Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. , 2017, 5, 95.		1,460
5800	Intestinal perforation after nivolumab immunotherapy for a malignant melanoma: a case report. Surgical Case Reports, 2017, 3, 94.	0.2	14
5802	Giant cell arteritis: pathogenic mechanisms and new potential therapeutic targets. BMC Rheumatology, 2017, 1, 2.	0.6	39
5803	Clinical safety of combined therapy of immune checkpoint inhibitors and Viscum album L. therapy in patients with advanced or metastatic cancer. BMC Complementary and Alternative Medicine, 2017, 17, 534.	3.7	31
5805	Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity. Oncotarget, 2017, 8, 90532-90544.	0.8	89
5806	Recent advances in the management of non-small cell lung cancer. F1000Research, 2017, 6, 2110.	0.8	21
5807	Checkpoint Inhibitors in Nonsmall Cell Lung Cancer. , 2017, , .		0
5808	VISTA.COMP â€” an engineered checkpoint receptor agonist that potently suppresses T cellâ€”mediated immune responses. JCI Insight, 2017, 2, .	2.3	28
5809	BRAF inhibitors: resistance and the promise of combination treatments for melanoma. Oncotarget, 2017, 8, 78174-78192.	0.8	75
5810	Preferential accumulation of regulatory T cells with highly immunosuppressive characteristics in breast tumor microenvironment. Oncotarget, 2017, 8, 33159-33171.	0.8	96
5811	Cellular immunity augmentation in mainstream oncologic therapy. Cancer Biology and Medicine, 2017, 14, 121.	1.4	8
5812	The molecular understanding of cancer: from the unspeakable illness to a curable disease. Ecancermedalscience, 2017, 11, 747.	0.6	7
5813	Cancer Immunotherapy. , 2017, , 32-65.		1
5814	Immune Checkpoint Blockade and Adaptive Immune Resistance in Cancer. , 0, , .		3
5815	PD-L1 Expression Is Associated with FOXP3+ Regulatory T-Cell Infiltration of Soft Tissue Sarcoma and Poor Patient Prognosis. Journal of Cancer, 2017, 8, 2018-2025.	1.2	80
5816	A retrospective examination of the US Food and Drug Administration’s clinical pharmacology reviews of oncology biologics for potential use of therapeutic drug monitoring. OncoTargets and Therapy, 2018, Volume 11, 113-121.	1.0	10
5817	Managing Expectations in the Transition to Proof of Concept Studies. Reviews on Recent Clinical Trials, 2017, 12, 111-123.	0.4	1

#	ARTICLE	IF	CITATIONS
5818	Advances in the Treatment of Primary Brain Tumors: The Realm of Immunotherapy. , 0, , .		0
5819	Prospect of the use of checkpoint inhibitors in hepatocellular cancer treatments. Cancer Management and Research, 2017, Volume 9, 19-27.	0.9	13
5820	Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma. Oncolytic Virotherapy, 2017, Volume 6, 11-18.	6.0	32
5821	Advances on immunotherapy in genitourinary and renal cell carcinoma. Translational Cancer Research, 2017, 6, 17-29.	0.4	10
5822	Immune checkpoints, their control by immunotherapy and ovarian cancer. Wspolczesna Onkologia, 2017, 3, 189-196.	0.7	2
5823	Severe hepatitis arising from ipilimumab administration, following melanoma treatment with nivolumab. Japanese Journal of Clinical Oncology, 2017, 47, 175-178.	0.6	52
5824	First-line treatment of metastatic melanoma: role of nivolumab. ImmunoTargets and Therapy, 2017, Volume 6, 1-10.	2.7	26
5825	Nuclear Molecular Imaging Strategies in Immune Checkpoint Inhibitor Therapy. Diagnostics, 2017, 7, 23.	1.3	13
5826	The Response of Cancer Cell Populations to Therapies. , 2017, , 137-152.		1
5827	Silencing of Foxp3 enhances the antitumor efficacy of GM-CSF genetically modified tumor cell vaccine against B16 melanoma. OncoTargets and Therapy, 2017, Volume 10, 503-514.	1.0	18
5828	Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade. Oncotarget, 2017, 8, 110693-110707.	0.8	115
5829	Management of intracranial melanomas in the era of precision medicine. Oncotarget, 2017, 8, 89326-89347.	0.8	16
5830	Aviscumine (ME-503)-Skin Reaction as significant Factor for its Efficacy Expanded Evaluation of the Results from the Phase II Trial NCT00658437. Immunotherapy (Los Angeles, Calif), 2017, 03, .	0.1	1
5831	Combined Blockade of T Cell Immunoglobulin and Mucin Domain 3 and Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1 Results in Durable Therapeutic Efficacy in Mice with Intracranial Gliomas. Medical Science Monitor, 2017, 23, 3593-3602.	0.5	20
5832	The soy-derived peptide Lunasin inhibits invasive potential of melanoma initiating cells. Oncotarget, 2017, 8, 25525-25541.	0.8	28
5833	Tumor immunotherapy: drug-induced neoantigens (xenogenization) and immune checkpoint inhibitors. Oncotarget, 2017, 8, 41641-41669.	0.8	15
5834	Immunotherapy in Gynecologic Cancers. , 2017, , .		0
5835	Case Report. Extracorporeal Membrane Oxygenation in Nivolumab Associated Pneumonitis. The Journal of Critical Care Medicine, 2017, 3, 84-88.	0.3	0

#	ARTICLE	IF	CITATIONS
5836	Comparative efficacy and safety of immune checkpoint inhibitor-related therapies for advanced melanoma: a Bayesian network analysis. <i>Oncotarget</i> , 2017, 8, 83637-83649.	0.8	7
5838	Indoleamine 2,3-dioxygenase and survivin peptide vaccine combined with temozolomide in metastatic melanoma. <i>Stem Cell Investigation</i> , 2017, 4, 77-77.	1.3	22
5839	Prognostic value of B7-H3 expression in patients with solid tumors: a meta-analysis. <i>Oncotarget</i> , 2017, 8, 93156-93167.	0.8	20
5840	Circulating Tumor DNA Analysis and Functional Imaging Provide Complementary Approaches for Comprehensive Disease Monitoring in Metastatic Melanoma. <i>JCO Precision Oncology</i> , 2017, 1, 1-14.	1.5	51
5841	Association between PD-L1 expression combined with tumor-infiltrating lymphocytes and the prognosis of patients with advanced hypopharyngeal squamous cell carcinoma. <i>Oncotarget</i> , 2017, 8, 92699-92714.	0.8	29
5842	Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3. <i>Journal of Clinical Oncology</i> , 2017, 35, 3322-3329.	0.8	204
5843	Ipilimumab in Pretreated Patients With Advanced Malignant Melanoma: Results of the South African Expanded-Access Program. <i>Journal of Global Oncology</i> , 2017, 3, 515-523.	0.5	4
5844	Fear of Cancer Recurrence in an Era of Personalized Medicine. <i>Journal of Clinical Oncology</i> , 2017, 35, 3275-3278.	0.8	39
5845	Hypermutation and microsatellite instability in gastrointestinal cancers. <i>Oncotarget</i> , 2017, 8, 112103-112115.	0.8	69
5846	Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 3449-3457.	0.8	311
5847	Exploration of the ASCO and ESMO Value Frameworks for Antineoplastic Drugs. <i>Journal of Oncology Practice</i> , 2017, 13, e653-e665.	2.5	31
5848	The concept of immune surveillance against tumors: The first theories. <i>Oncotarget</i> , 2017, 8, 7175-7180.	0.8	221
5849	Can Prostate Cancer Really Respond to Immunotherapy?. <i>Journal of Clinical Oncology</i> , 2017, 35, 4-5.	0.8	6
5850	Overcoming resistance to targeted therapy with immunotherapy and combination therapy for metastatic melanoma. <i>Oncotarget</i> , 2017, 8, 75675-75686.	0.8	42
5851	Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 3815-3822.	0.8	244
5852	Established and Novel Prognostic Biomarkers in Multiple Myeloma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 548-560.	1.8	21
5853	Safety and Efficacy Implications of Discontinuing Combination Ipilimumab and Nivolumab in Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 3792-3793.	0.8	9
5854	The role of novel immunotherapies in non-Hodgkin lymphoma. <i>Translational Cancer Research</i> , 2017, 6, 93-103.	0.4	26

#	ARTICLE	IF	CITATIONS
5855	Biomarkers for Checkpoint Inhibition. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 205-209.	1.8	11
5856	Patient-Derived Xenografting of Human Melanoma. , 2017, , 341-363.		0
5857	Immune system and melanoma biology: a balance between immunosurveillance and immune escape. Oncotarget, 2017, 8, 106132-106142.	0.8	174
5858	The MAPK hypothesis: immune-regulatory effects of MAPK-pathway genetic dysregulations and implications for breast cancer immunotherapy. Emerging Topics in Life Sciences, 2017, 1, 429-445.	1.1	45
5859	Immunotherapy for malignant pleural mesothelioma: current status and future directions. Translational Lung Cancer Research, 2017, 6, 315-324.	1.3	30
5860	Immune checkpoint blockade for hematologic malignancies: a review. Stem Cell Investigation, 2017, 4, 32-32.	1.3	59
5861	Oncogenic pathways as the basis of primary immune ignorance. Emerging Topics in Life Sciences, 2017, 1, 421-428.	1.1	0
5862	Robust detection of immune transcripts in FFPE samples using targeted RNA sequencing. Oncotarget, 2017, 8, 3197-3205.	0.8	53
5863	<i>PTEN</i> Loss-of-Function Alterations Are Associated With Intrinsic Resistance to BRAF Inhibitors in Metastatic Melanoma. JCO Precision Oncology, 2017, 1, 1-15.	1.5	275
5864	Examining the Incidence and Presentation of Melanoma in the Cardiothoracic Transplant Population. JAMA Dermatology, 2018, 154, 589.	2.0	9
5865	Cancer immunotherapy and the value of cure. Nature Reviews Clinical Oncology, 2018, 15, 268-270.	12.5	126
5866	Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice. Cell Research, 2018, 28, 433-447.	5.7	91
5867	Vaccination-induced skin-resident memory CD8 ⁺ T cells mediate strong protection against cutaneous melanoma. Oncoimmunology, 2018, 7, e1442163.	2.1	62
5868	Regulatory T cell inhibition by dasatinib is associated with natural killer cell differentiation and a favorable molecular response—The final results of the D-first study. Leukemia Research, 2018, 66, 66-72.	0.4	33
5869	Targeting the microenvironment in solid tumors. Cancer Treatment Reviews, 2018, 65, 22-32.	3.4	342
5870	Dynamics of the Intratumoral Immune Response during Progression of High-Grade Serous Ovarian Cancer. Neoplasia, 2018, 20, 280-288.	2.3	23
5871	Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGF β enhance the efficacy of cancer immunotherapy. Nature Communications, 2018, 9, 741.	5.8	238
5872	Rational design for cervical cancer therapeutics: cellular and non-cellular based strategies on the horizon for recurrent, metastatic or refractory cervical cancer. Expert Opinion on Drug Discovery, 2018, 13, 445-457.	2.5	19

#	ARTICLE	IF	CITATIONS
5873	ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5</i>	2.8	96
5874	Designing Late-Stage Randomized Clinical Trials with Cancer Immunotherapy: Can We Make It Simpler?. <i>Cancer Immunology Research</i> , 2018, 6, 250-254.	1.6	6
5875	Combined laparoscopic abdomino-endoscopic perineal total mesorectal excision for anorectal malignant melanoma: A case report. <i>International Journal of Surgery Case Reports</i> , 2018, 44, 135-138.	0.2	4
5876	Gastrointestinal toxicity of immune checkpoint inhibitors: from mechanisms to management. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018, 15, 222-234.	8.2	82
5877	Cancer-associated fibroblasts induce antigen-specific deletion of CD8 + T Cells to protect tumour cells. <i>Nature Communications</i> , 2018, 9, 948.	5.8	369
5878	Expression of <sc>MAGE</sc> and <sc>NY</sc> cancer/testis antigens is enriched in triple-negative invasive breast cancers. <i>Histopathology</i> , 2018, 73, 68-80.	1.6	34
5879	Incidence and Management of Immune-Related Adverse Events in Patients Undergoing Treatment with Immune Checkpoint Inhibitors. <i>Current Oncology Reports</i> , 2018, 20, 24.	1.8	35
5880	Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles. <i>Science Advances</i> , 2018, 4, eaar2766.	4.7	416
5881	Prognostic Significance of Platelet-Based Inflammatory Indicators in Patients with Gastric Cancer. <i>World Journal of Surgery</i> , 2018, 42, 2542-2550.	0.8	22
5882	Results and challenges of immune checkpoint inhibitors in colorectal cancer. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 561-573.	1.4	58
5883	Safety and efficacy of nivolumab in Japanese patients with malignant melanoma: An interim analysis of a postmarketing surveillance. <i>Journal of Dermatology</i> , 2018, 45, 408-415.	0.6	38
5884	Adjuvant Therapy in the Treatment of Melanoma. <i>Annals of Surgical Oncology</i> , 2018, 25, 1807-1813.	0.7	7
5885	A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy. <i>Cell Research</i> , 2018, 28, 416-432.	5.7	188
5886	Histopathological and immunophenotypic features of ipilimumab-associated colitis compared to ulcerative colitis. <i>Journal of Internal Medicine</i> , 2018, 283, 568-577.	2.7	78
5887	Tumor lysate particle loaded dendritic cell vaccine: preclinical testing of a novel personalized cancer vaccine. <i>Immunotherapy</i> , 2018, 10, 373-382.	1.0	10
5888	Mass Spectrometry Based Immuno-peptidomics for the Discovery of Cancer Neoantigens. <i>Methods in Molecular Biology</i> , 2018, 1719, 209-221.	0.4	46
5889	Late-Onset Cholecystitis with Cholangitis after Avelumab Treatment in Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, e34-e36.	0.5	28
5890	Treatment effects measured by restricted mean survival time in trials of immune checkpoint inhibitors for cancer. <i>Annals of Oncology</i> , 2018, 29, 1320-1324.	0.6	37

#	ARTICLE	IF	CITATIONS
5891	Checkpoint Inhibitors in Breast Cancer - Current Status and Future Directions. <i>Breast Care</i> , 2018, 13, 27-31.	0.8	8
5892	Large-scale database mining reveals hidden trends and future directions for cancer immunotherapy. <i>OncImmunology</i> , 2018, 7, e1444412.	2.1	11
5893	Imaging in neuro-oncology. <i>Therapeutic Advances in Neurological Disorders</i> , 2018, 11, 175628641875986.	1.5	41
5895	Optimal management of immune-related adverse events resulting from treatment with immune checkpoint inhibitors: a review and update. <i>International Journal of Clinical Oncology</i> , 2018, 23, 410-420.	1.0	50
5896	Immunotherapy in Lung Cancer and the Role of Imaging. <i>Seminars in Ultrasound, CT and MRI</i> , 2018, 39, 314-321.	0.7	4
5897	Cancer immunotherapy in patients with brain metastases. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 703-711.	2.0	15
5898	Do you know your guidelines? Diagnosis and management of cutaneous head and neck melanoma. <i>Head and Neck</i> , 2018, 40, 875-885.	0.9	5
5899	The role of interim 18F-FDG PET/CT in prediction of response to ipilimumab treatment in metastatic melanoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1289-1296.	3.3	90
5900	Subcutaneous Nanodisc Vaccination with Neoantigens for Combination Cancer Immunotherapy. <i>Bioconjugate Chemistry</i> , 2018, 29, 771-775.	1.8	68
5901	Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes. <i>Leukemia</i> , 2018, 32, 1094-1105.	3.3	164
5902	Sarcoid-like reactions in patients receiving modern melanoma treatment. <i>Melanoma Research</i> , 2018, 28, 230-236.	0.6	67
5903	Cellular Plasticity-Targeted Therapy in Head and Neck Cancers. <i>Journal of Dental Research</i> , 2018, 97, 654-664.	2.5	13
5904	Fall in thyroid stimulating hormone (TSH) may be an early marker of ipilimumab-induced hypophysitis. <i>Pituitary</i> , 2018, 21, 274-282.	1.6	25
5905	Contemporary Treatment Approaches to Sinonasal Mucosal Melanoma. <i>Current Oncology Reports</i> , 2018, 20, 10.	1.8	34
5906	Immune modulatory effects of radiotherapy as basis for well-reasoned radioimmunotherapies. <i>Strahlentherapie Und Onkologie</i> , 2018, 194, 509-519.	1.0	93
5907	Melanoma Immunotherapy in the Elderly. <i>Current Oncology Reports</i> , 2018, 20, 20.	1.8	16
5908	Dose-dependent toxicity of ipilimumab in metastatic melanoma. <i>European Journal of Cancer</i> , 2018, 95, 104-108.	1.3	6
5909	The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression. <i>Clinical Cancer Research</i> , 2018, 24, 3366-3376.	3.2	73

#	ARTICLE	IF	CITATIONS
5910	The Rationale and Emerging Use of Neoadjuvant Immune Checkpoint Blockade for Solid Malignancies. <i>Annals of Surgical Oncology</i> , 2018, 25, 1814-1827.	0.7	45
5911	Exosomes as a novel pathway for regulating development and diseases of the skin (Review). <i>Biomedical Reports</i> , 2018, 8, 207-214.	0.9	25
5912	Peptidomics. <i>Methods in Molecular Biology</i> , 2018, , .	0.4	5
5913	Efficacy and safety of concurrent immunoradiotherapy in patients with metastatic melanoma after progression on nivolumab. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 823-827.	1.1	6
5914	Hepatocellular carcinoma: Prospects for natural killer cell immunotherapy. <i>Hla</i> , 2018, 92, 3-11.	0.4	10
5915	Association between programmed cell death ligand-1 expression and extracranial metastasis in intracranial solitary fibrous tumor/hemangiopericytoma. <i>Journal of Neuro-Oncology</i> , 2018, 139, 251-259.	1.4	16
5916	Outcomes of Adoptive Cell Transfer With Tumor-infiltrating Lymphocytes for Metastatic Melanoma Patients With and Without Brain Metastases. <i>Journal of Immunotherapy</i> , 2018, 41, 241-247.	1.2	40
5917	The risk of immune-related endocrine disorders associated with anti-PD-1 inhibitors therapy for solid tumors: A systematic review and meta-analysis. <i>International Immunopharmacology</i> , 2018, 59, 328-338.	1.7	19
5918	Sequentially Responsive Therapeutic Peptide Assembling Nanoparticles for Dual-Targeted Cancer Immunotherapy. <i>Nano Letters</i> , 2018, 18, 3250-3258.	4.5	255
5919	Cost effectiveness vs. affordability in the age of immuno-oncology cancer drugs. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2018, 18, 351-357.	0.7	40
5920	Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab. <i>Clinical Cancer Research</i> , 2018, 24, 4960-4967.	3.2	222
5921	Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. <i>New England Journal of Medicine</i> , 2018, 378, 1789-1801.	13.9	1,441
5922	Real-world healthcare costs of ipilimumab in patients with advanced cutaneous melanoma in The Netherlands. <i>Anti-Cancer Drugs</i> , 2018, 29, 579-588.	0.7	11
5923	Immunotherapie in de oncologie. <i>Bijblijven (Amsterdam, Netherlands)</i> , 2018, 34, 108-116.	0.0	0
5924	An early history of T cell-mediated cytotoxicity. <i>Nature Reviews Immunology</i> , 2018, 18, 527-535.	10.6	179
5925	Immune Checkpoint Inhibitors: Game Changing Cancer Therapy With a Cardiac Cost. What Are the Mechanisms and Unresolved Questions in Cardiotoxicity?. <i>Canadian Journal of Cardiology</i> , 2018, 34, 970-971.	0.8	1
5926	Self-Delivering RNAi Targeting PD-1 Improves Tumor-Specific T Cell Functionality for Adoptive Cell Therapy of Malignant Melanoma. <i>Molecular Therapy</i> , 2018, 26, 1482-1493.	3.7	38
5927	Next generation antibody drugs: pursuit of the 'high-hanging fruit'. <i>Nature Reviews Drug Discovery</i> , 2018, 17, 197-223.	21.5	595

#	ARTICLE	IF	CITATIONS
5928	Chemokine receptor engineering of T cells with CXCR2 improves homing towards subcutaneous human melanomas in xenograft mouse model. <i>Oncolmmunology</i> , 2018, 7, e1450715.	2.1	48
5929	A flexible MHC class I multimer loading system for large-scale detection of antigen-specific T cells. <i>Journal of Experimental Medicine</i> , 2018, 215, 1493-1504.	4.2	33
5930	Top Ten Tips for Palliative Care Clinicians Caring for Cancer Patients Receiving Immunotherapies. <i>Journal of Palliative Medicine</i> , 2018, 21, 694-699.	0.6	9
5931	Real-world use, safety, and survival of ipilimumab in metastatic cutaneous melanoma in The Netherlands. <i>Anti-Cancer Drugs</i> , 2018, 29, 572-578.	0.7	11
5932	Elimination of established tumors with nanodisc-based combination chemoimmunotherapy. <i>Science Advances</i> , 2018, 4, eaao1736.	4.7	269
5933	Radiotherapy and checkpoint inhibitors: a winning new combination?. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591876824.	1.4	87
5934	Resistance of Colorectal Tumors to Anti-EGFR Antibodies. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2018, , 1-27.	0.1	1
5935	Concordance measure and discriminatory accuracy in transformation cure models. <i>Biostatistics</i> , 2018, 19, 14-26.	0.9	20
5936	Long noncoding RNAs in cancer-immunity cycle. <i>Journal of Cellular Physiology</i> , 2018, 233, 6518-6523.	2.0	119
5937	Regulatory T cells: a potential target in cancer immunotherapy. <i>Annals of the New York Academy of Sciences</i> , 2018, 1417, 104-115.	1.8	184
5938	Hepatotoxicity of immune checkpoint inhibitors: An evolving picture of risk associated with a vital class of immunotherapy agents. <i>Liver International</i> , 2018, 38, 976-987.	1.9	166
5939	Obstacles to improving outcomes in the treatment of uveal melanoma. <i>Cancer</i> , 2018, 124, 2693-2703.	2.0	15
5940	Genetic abrogation of immune checkpoints in antigen-specific cytotoxic T-lymphocyte as a potential alternative to blockade immunotherapy. <i>Scientific Reports</i> , 2018, 8, 5549.	1.6	29
5941	Clinical assessment of immune-related adverse events. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591876462.	1.4	101
5942	Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies. <i>Cancer Cell</i> , 2018, 33, 581-598.	7.7	393
5943	T Cell Dysfunction in Cancer. <i>Cancer Cell</i> , 2018, 33, 547-562.	7.7	787
5944	The impact of the intestinal microbiota in therapeutic responses against cancer. <i>Comptes Rendus - Biologies</i> , 2018, 341, 284-289.	0.1	65
5945	Metastasis-specific patterns of response and progression with anti-PD-1 treatment in metastatic melanoma. <i>Pigment Cell and Melanoma Research</i> , 2018, 31, 404-410.	1.5	34

#	ARTICLE	IF	CITATIONS
5946	Bispecific antibodies in cancer immunotherapy. , 2018, 6, 3-17.	1.4	157
5948	Immunotherapy phase I trials in patients Older than 70Âyears with advanced solid tumours. European Journal of Cancer, 2018, 95, 68-74.	1.3	24
5949	The gut microbiota influences anticancer immunosurveillance and general health. Nature Reviews Clinical Oncology, 2018, 15, 382-396.	12.5	389
5950	Structure-function analysis and therapeutic efficacy of antibodies to fungal melanin for melanoma radioimmunotherapy. Scientific Reports, 2018, 8, 5466.	1.6	19
5951	Enhanced targeting of triple-negative breast carcinoma and malignant melanoma by photochemical internalization of CSPG4-targeting immunotoxins. Photochemical and Photobiological Sciences, 2018, 17, 539-551.	1.6	25
5953	Overcoming Tumor-Induced Immune Suppression: From Relieving Inhibition to Providing Costimulation with T Cell Agonists. BioDrugs, 2018, 32, 221-231.	2.2	22
5954	Therapeutic prospects of targeting myeloidâ€derived suppressor cells and immune checkpoints in cancer. Immunology and Cell Biology, 2018, 96, 888-897.	1.0	43
5955	Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade. Cell, 2018, 173, 624-633.e8.	13.5	113
5956	PD-1/PD-L1 pathway inhibitors in advanced prostate cancer. Expert Review of Clinical Pharmacology, 2018, 11, 475-486.	1.3	83
5957	Dermatologic toxicity from immune checkpoint blockade therapy with an interstitial granulomatous pattern. Journal of Cutaneous Pathology, 2018, 45, 504-507.	0.7	25
5958	Human <sc>FOXP</sc>3⁺ T regulatory cell heterogeneity. Clinical and Translational Immunology, 2018, 7, e1005.	1.7	93
5959	CAR-T cells: the long and winding road to solid tumors. Cell Death and Disease, 2018, 9, 282.	2.7	312
5960	Isolation and characterization of circulating melanoma cells by size filtration and fluorescent in-situ hybridization. Melanoma Research, 2018, 28, 89-95.	0.6	13
5962	Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 2467-2472.	3.3	131
5963	Long-term survival with modern therapeutic agents against metastatic melanomaâ€vemurafenib and ipilimumab in a daily life setting. Medical Oncology, 2018, 35, 24.	1.2	13
5964	Cloning and expansion of antigen-specific T cells using iPS cell technology: development of â€œoff-the-shelfâ€T cells for the use in allogeneic transfusion settings. International Journal of Hematology, 2018, 107, 271-277.	0.7	21
5965	Age effects of distinct immune checkpoint blockade treatments in a mouse melanoma model. Experimental Gerontology, 2018, 105, 146-154.	1.2	26
5966	Neurological Adverse Events Associated with Immune Checkpoint Inhibitors: Diagnosis and Management. Current Neurology and Neuroscience Reports, 2018, 18, 3.	2.0	83

#	ARTICLE	IF	CITATIONS
5967	Enhanced antitumor efficacy through microwave ablation in combination with immune checkpoints blockade in breast cancer: A pre-clinical study in a murine model. <i>Diagnostic and Interventional Imaging</i> , 2018, 99, 135-142.	1.8	36
5969	Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy. <i>Oncolimmunology</i> , 2018, 7, e1433982.	2.1	38
5970	Molecular and clinical characterization of IDH associated immune signature in lower-grade gliomas. <i>Oncolimmunology</i> , 2018, 7, e1434466.	2.1	53
5971	Significant association of increased PD-L1 and PD-1 expression with nodal metastasis and a poor prognosis in oral squamous cell carcinoma. <i>International Journal of Oral and Maxillofacial Surgery</i> , 2018, 47, 836-845.	0.7	66
5972	Clinical significance of soluble programmed cell death ligand-1 (sPD-L1) in hepatocellular carcinoma patients treated with radiotherapy. <i>Radiotherapy and Oncology</i> , 2018, 129, 130-135.	0.3	69
5973	Recent developments in the treatment of advanced bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 109-114.	0.8	34
5974	Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury. <i>Modern Pathology</i> , 2018, 31, 965-973.	2.9	219
5975	CD8 T Cell Exhaustion in Chronic Infection and Cancer: Opportunities for Interventions. <i>Annual Review of Medicine</i> , 2018, 69, 301-318.	5.0	432
5976	Systemic treatments for metastatic cutaneous melanoma. <i>The Cochrane Library</i> , 2020, 2020, CD011123.	1.5	136
5978	Immuno-oncology-101: overview of major concepts and translational perspectives. <i>Seminars in Cancer Biology</i> , 2018, 52, 1-11.	4.3	39
5979	Adaptive immune cells are necessary for the enhanced therapeutic effect of sorafenib-loaded nanoparticles. <i>Biomaterials Science</i> , 2018, 6, 893-900.	2.6	19
5980	Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity. <i>Journal of Experimental Medicine</i> , 2018, 215, 859-876.	4.2	150
5981	Temozolomide-associated hypermutation in gliomas. <i>Neuro-Oncology</i> , 2018, 20, 1300-1309.	0.6	130
5982	Checkpoint-Inhibition bei Non-Hodgkin-Lymphom. <i>Karger Kompass Onkologie</i> , 2018, 5, 12-20.	0.0	0
5983	Current state and future prospects of immunotherapy for glioma. <i>Immunotherapy</i> , 2018, 10, 317-339.	1.0	60
5984	Immune Checkpoint Blockade: The New Frontier in Cancer Treatment. <i>Targeted Oncology</i> , 2018, 13, 1-20.	1.7	31
5985	Chemotherapy and immunotherapy for recurrent and metastatic head and neck cancer: a systematic review. <i>Medical Oncology</i> , 2018, 35, 37.	1.2	52
5986	Therapeutic strategies for organ-confined and non-organ-confined bladder cancer after radical cystectomy. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 377-387.	1.1	7

#	ARTICLE	IF	CITATIONS
5987	IL-2 and Beyond in Cancer Immunotherapy. <i>Journal of Interferon and Cytokine Research</i> , 2018, 38, 45-68.	0.5	83
5988	Cell death-based treatments of melanoma:conventional treatments and new therapeutic strategies. <i>Cell Death and Disease</i> , 2018, 9, 112.	2.7	94
5989	Different aberrant expression pattern of immune checkpoint receptors in patients with PTCL and NK/Tâ€œCL. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, e252-e258.	0.7	12
5990	Initiation of inflammatory tumorigenesis by CTLA4 insufficiency due to type 2 cytokines. <i>Journal of Experimental Medicine</i> , 2018, 215, 841-858.	4.2	17
5991	Unwrapping the genomic characteristics of urothelial bladder cancer and successes with immune checkpoint blockade therapy. <i>Oncogenesis</i> , 2018, 7, 2.	2.1	68
5992	Clinical Development of PD-1 in Advanced Melanoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2018, 24, 7-14.	1.0	37
5993	The structure, expression, and multifaceted role of immune-checkpoint protein VISTA as a critical regulator of anti-tumor immunity, autoimmunity, and inflammation. <i>Cellular and Molecular Immunology</i> , 2018, 15, 438-446.	4.8	88
5994	Development of an Immune-Pathology Informed Radiomics Model for Non-Small Cell Lung Cancer. <i>Scientific Reports</i> , 2018, 8, 1922.	1.6	108
5995	Complete ophthalmoplegia in Ipilmumab and Nivolumab combination treatment for metastatic melanoma. <i>Orbit</i> , 2018, 37, 381-384.	0.5	13
5996	Radiation effects on antitumor immune responses: current perspectives and challenges. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883401774257.	1.4	185
5997	Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883401774974.	1.4	200
5998	Expectedâ€œParadigm Shift in Brain Metastases Therapyâ€œImmune Checkpoint Inhibitors. <i>Molecular Neurobiology</i> , 2018, 55, 7072-7078.	1.9	18
5999	Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management. <i>ESMO Open</i> , 2018, 3, e000278.	2.0	197
6000	Role of immune-checkpoint inhibitors in lung cancer. <i>Therapeutic Advances in Respiratory Disease</i> , 2018, 12, 175346581775007.	1.0	88
6001	Cancer Systems Biology. <i>Methods in Molecular Biology</i> , 2018, , .	0.4	8
6002	Impact of genomics on the surgical management of melanoma. <i>British Journal of Surgery</i> , 2018, 105, e31-e47.	0.1	3
6003	Neuromuscular complications of immune checkpoint inhibitor therapy. <i>Muscle and Nerve</i> , 2018, 58, 10-22.	1.0	57
6005	Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors. <i>Autoimmunity Reviews</i> , 2018, 17, 284-289.	2.5	149

#	ARTICLE	IF	CITATIONS
6006	Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade. <i>Cancer Immunology Research</i> , 2018, 6, 189-200.	1.6	102
6007	The role of nivolumab in melanoma. <i>Future Oncology</i> , 2018, 14, 1241-1252.	1.1	12
6008	Targeted microbubbles with ultrasound irradiation and PD-1 inhibitor to increase antitumor activity in B-cell lymphoma. <i>Nanomedicine</i> , 2018, 13, 297-311.	1.7	4
6009	Modeling of Interactions between Cancer Stem Cells and their Microenvironment: Predicting Clinical Response. <i>Methods in Molecular Biology</i> , 2018, 1711, 333-349.	0.4	8
6010	Regulation of chitinase-3-like-1 in T cell elicits Th1 and cytotoxic responses to inhibit lung metastasis. <i>Nature Communications</i> , 2018, 9, 503.	5.8	72
6011	Safety and efficacy of anti-PD-1 therapy for metastatic melanoma and non-small-cell lung cancer in patients with viral hepatitis: a case series. <i>Melanoma Research</i> , 2018, 28, 155-158.	0.6	40
6012	Baseline neutrophil to lymphocyte ratio combined with serum lactate dehydrogenase level associated with outcome of nivolumab immunotherapy in a Japanese advanced melanoma population. <i>British Journal of Dermatology</i> , 2018, 179, 213-215.	1.4	42
6013	Correlation between sex and efficacy of immune checkpoint inhibitors (<sc>PD</sc> and Tj ETQq1 1 0.784314 rgBT /Overlock 2.3 85	2.3	85
6014	Talimogene laherparepvec: First in class oncolytic virotherapy. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 839-846.	1.4	247
6015	Current therapeutic approaches to diffuse grade II and III gliomas. <i>Therapeutic Advances in Neurological Disorders</i> , 2018, 11, 175628561775203.	1.5	35
6016	Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. <i>Journal of Hepatology</i> , 2018, 68, 1181-1190.	1.8	372
6017	Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events. <i>Cancer Immunology Research</i> , 2018, 6, 402-408.	1.6	56
6018	Nanoscale delivery systems for cancer immunotherapy. <i>Materials Horizons</i> , 2018, 5, 344-362.	6.4	57
6019	Targeting gp100 and TRP-2 with a DNA vaccine: Incorporating T cell epitopes with a human IgG1 antibody induces potent T cell responses that are associated with favourable clinical outcome in a phase I/II trial. <i>OncoImmunology</i> , 2018, 7, e1433516.	2.1	31
6020	The Risk of Diarrhea and Colitis in Patients With Advanced Melanoma Undergoing Immune Checkpoint Inhibitor Therapy: A Systematic Review and Meta-Analysis. <i>Journal of Immunotherapy</i> , 2018, 41, 101-108.	1.2	57
6021	Immune-based therapies for metastatic prostate cancer: an update. <i>Immunotherapy</i> , 2018, 10, 283-298.	1.0	9
6031	First report of overall survival for ipilimumab plus nivolumab from the phase III Checkmate 067 study in advanced melanoma. <i>Annals of Oncology</i> , 2018, 29, 542-543.	0.6	16
6032	Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. <i>Lancet Oncology</i> , The, 2018, 19, 416-426.	5.1	517

#	ARTICLE	IF	CITATIONS
6033	Increased diversity with reduced "diversity evenness" of tumor infiltrating T-cells for the successful cancer immunotherapy. <i>Scientific Reports</i> , 2018, 8, 1058.	1.6	51
6034	Challenges and Perspectives for Immunotherapy in Adenocarcinoma of the Pancreas. <i>Pancreas</i> , 2018, 47, 142-157.	0.5	19
6035	Checkpoint Inhibitors, Palliative Care, or Hospice. <i>Current Oncology Reports</i> , 2018, 20, 2.	1.8	8
6036	Pediatric patients with cutaneous melanoma: A European study. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26974.	0.8	26
6037	Treatment-related toxicities of immune checkpoint inhibitors in advanced cancers: A meta-analysis. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, 141-152.	0.7	54
6038	Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study. <i>Clinical Cancer Research</i> , 2018, 24, 1805-1815.	3.2	45
6039	Glycan-directed CAR-T cells. <i>Glycobiology</i> , 2018, 28, 656-669.	1.3	74
6040	Toxicities Associated With PD-1/PD-L1 Blockade. <i>Cancer Journal (Sudbury, Mass)</i> , 2018, 24, 36-40.	1.0	72
6041	PD-1/PD-L1 Axis in Lung Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2018, 24, 15-19.	1.0	61
6042	Combination Strategies PD-1/PD-L1 Antagonists. <i>Cancer Journal (Sudbury, Mass)</i> , 2018, 24, 54-57.	1.0	1
6043	Back from the dead: TIL apoptosis in cancer immune evasion. <i>British Journal of Cancer</i> , 2018, 118, 309-311.	2.9	8
6044	The biology and management of non-small cell lung cancer. <i>Nature</i> , 2018, 553, 446-454.	13.7	2,877
6045	Refractory thyroid carcinoma: which systemic treatment to use?. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883401775285.	1.4	18
6046	Clinicopathological characteristics, staging classification, and survival outcomes of primary malignant melanoma of the esophagus. <i>Journal of Surgical Oncology</i> , 2018, 117, 588-596.	0.8	20
6047	T cell exhaustion in cancer: Mechanisms and clinical implications. <i>Journal of Cellular Biochemistry</i> , 2018, 119, 4279-4286.	1.2	40
6048	Cytosolic high-mobility group box protein 1 (HMGB1) and/or PD-1+TILs in the tumor microenvironment may be contributing prognostic biomarkers for patients with locally advanced rectal cancer who have undergone neoadjuvant chemoradiotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 551-562.	2.0	49
6049	Expression of PD-L1 on Immune Cells Shows Better Prognosis in Laryngeal, Oropharyngeal, and Hypopharyngeal Cancer. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2018, 26, e79-e85.	0.6	32
6050	Sipuleucel-T for the treatment of prostate cancer: novel insights and future directions. <i>Future Oncology</i> , 2018, 14, 907-917.	1.1	112

#	ARTICLE	IF	CITATIONS
6051	The biology and therapeutic management of melanoma brain metastases. <i>Biochemical Pharmacology</i> , 2018, 153, 35-45.	2.0	12
6052	Unique cytologic features of thyroiditis caused by immune checkpoint inhibitor therapy for malignant melanoma. <i>Genes and Diseases</i> , 2018, 5, 46-48.	1.5	53
6053	Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 916-925.	0.4	257
6054	Increasing access to immuno-oncology therapies in Brazil. <i>Journal of Cancer Policy</i> , 2018, 16, 1-5.	0.6	7
6055	There and back again: An immunotherapy tale. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2018, 155, 1771-1774.	0.4	3
6056	Ipilimumab-induced hypophysitis involving the optic tracts and tuber cinereum evaluated using 3D fluid-attenuated inversion recovery. <i>Radiology Case Reports</i> , 2018, 13, 261-264.	0.2	7
6058	The dawn of vaccines for cancer prevention. <i>Nature Reviews Immunology</i> , 2018, 18, 183-194.	10.6	178
6059	Reprogramming immune proteins as therapeutics using molecular engineering. <i>Current Opinion in Chemical Engineering</i> , 2018, 19, 27-34.	3.8	9
6060	Case Report of Ipilimumab-Induced Diffuse, Nonnecrotizing Granulomatous Lymphadenitis and Granulomatous Vasculitis. <i>Journal of Pharmacy Practice</i> , 2018, 31, 227-229.	0.5	13
6061	Association of Immunotherapy With Durable Survival as Defined by Value Frameworks for Cancer Care. <i>JAMA Oncology</i> , 2018, 4, 326.	3.4	43
6062	Therapeutic Strategies for Breast Cancer. , 2018, , 315-330.e7.		5
6063	Therapeutic Cancer Vaccines: How Much Closer Are We?. <i>BioDrugs</i> , 2018, 32, 1-7.	2.2	15
6064	Immunologic Approaches to Breast Cancer Therapy. , 2018, , 924-933.e4.		2
6065	CTLA-4 polymorphisms are associated with treatment outcomes of patients with multiple myeloma receiving bortezomib-based regimens. <i>Annals of Hematology</i> , 2018, 97, 485-495.	0.8	14
6066	Cancer immunotherapy: A need for peripheral immunodynamic monitoring. <i>American Journal of Reproductive Immunology</i> , 2018, 79, e12793.	1.2	5
6067	A comparative study on the transdermal penetration effect of gaseous and aqueous plasma reactive species. <i>Journal Physics D: Applied Physics</i> , 2018, 51, 075401.	1.3	22
6068	Molecular Biomarkers of Primary and Acquired Resistance to T-Cell-Mediated Immunotherapy in Cancer: Landscape, Clinical Implications, and Future Directions. <i>Oncologist</i> , 2018, 23, 410-421.	1.9	23
6069	<i>Bifidobacterium</i> can mitigate intestinal immunopathology in the context of CTLA-4 blockade. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 157-161.	3.3	152

#	ARTICLE	IF	CITATIONS
6070	Genetics and Immunology: Tumor-Specific Genetic Alterations as a Target for Immune Modulating Therapies. , 2018, , 231-246.		0
6071	IDO/TDO Inhibition in Cancer. , 2018, , 289-307.		1
6072	PD1 Checkpoint Blockade in Melanoma: From Monotherapy to Combination Therapies. , 2018, , 321-331.		0
6073	Co-stimulation Agonists via CD137, OX40, GITR, and CD27 for Immunotherapy of Cancer. , 2018, , 429-446.		0
6074	The Impact of the Intestinal Microbiota in Therapeutic Responses Against Cancer. , 2018, , 447-462.		2
6075	Immune Therapies in Phase 1 Trials. , 2018, , 547-563.		0
6076	Side Effects of Cancer Immunotherapy with Checkpoint Inhibitors. , 2018, , 565-578.		1
6077	Melanoma: Immunotherapy in Advanced Melanoma and in the Adjuvant Setting. , 2018, , 579-591.		0
6078	Assessing T Cell Receptor Affinity and Avidity Against Tumor Antigens. , 2018, , 665-679.		2
6079	Checkpoint inhibitors in breast cancer – Current status. Cancer Treatment Reviews, 2018, 63, 122-134.	3.4	112
6080	Assessment of neuronal autoantibodies in patients with small cell lung cancer treated with chemotherapy with or without ipilimumab. Oncoimmunology, 2018, 7, e1395125.	2.1	26
6081	Is It Possible to Develop Cancer Vaccines to Neoantigens, What Are the Major Challenges, and How Can These Be Overcome?. Cold Spring Harbor Perspectives in Biology, 2018, 10, a028837.	2.3	7
6082	Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies. Clinical Cancer Research, 2018, 24, 1011-1018.	3.2	31
6083	Understanding preanalytical variables and their effects on clinical biomarkers of oncology and immunotherapy. Seminars in Cancer Biology, 2018, 52, 26-38.	4.3	49
6084	Update on adjuvant melanoma therapy. Current Opinion in Oncology, 2018, 30, 118-124.	1.1	12
6085	Emerging biomarkers for immunomodulatory cancer treatment of upper gastrointestinal, pancreatic and hepatic cancers. Seminars in Cancer Biology, 2018, 52, 241-252.	4.3	12
6086	Pembrolizumab Utilization and Outcomes for Advanced Melanoma in US Community Oncology Practices. Journal of Immunotherapy, 2018, 41, 86-95.	1.2	28
6087	Impact of oncogenic pathways on evasion of antitumour immune responses. Nature Reviews Cancer, 2018, 18, 139-147.	12.8	506

#	ARTICLE	IF	CITATIONS
6088	Iris pigmented lesions as a marker of cutaneous melanoma risk: an Australian case-control study. <i>British Journal of Dermatology</i> , 2018, 178, 1119-1127.	1.4	20
6089	Immune checkpoint molecules in acute myeloid leukaemia: managing the double-edged sword. <i>British Journal of Haematology</i> , 2018, 181, 38-53.	1.2	42
6090	Pattern of programmed cell death-ligand 1 expression and CD8-positive T-cell infiltration before and after chemoradiotherapy in rectal cancer. <i>European Journal of Cancer</i> , 2018, 91, 11-20.	1.3	55
6091	Thyroid dysfunctions secondary to cancer immunotherapy. <i>Journal of Endocrinological Investigation</i> , 2018, 41, 625-638.	1.8	59
6092	Improving immune-vascular crosstalk for cancer immunotherapy. <i>Nature Reviews Immunology</i> , 2018, 18, 195-203.	10.6	340
6093	Combination ipilimumab and radiosurgery for brain metastases: tumor, edema, and adverse radiation effects. <i>Journal of Neurosurgery</i> , 2018, 129, 1397-1406.	0.9	55
6094	High macrophage PD-L1 expression not responsible for T cell suppression. <i>Cellular Immunology</i> , 2018, 324, 50-58.	1.4	5
6095	Phase II trial of ipilimumab in melanoma patients with preexisting humoral immune response to NY-ESO-1. <i>European Journal of Cancer</i> , 2018, 90, 122-129.	1.3	17
6096	Beta blocker use correlates with better overall survival in metastatic melanoma patients and improves the efficacy of immunotherapies in mice. <i>Oncolimmunology</i> , 2018, 7, e1405205.	2.1	124
6097	A Believer's Overview of Cancer Immunosurveillance and Immunotherapy. <i>Journal of Immunology</i> , 2018, 200, 385-391.	0.4	103
6098	KEYNOTE-024: Unlocking a pathway to lung cancer cure?. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2018, 155, 1777-1780.	0.4	10
6099	Development of anti-drug antibodies is associated with shortened survival in patients with metastatic melanoma treated with ipilimumab. <i>Oncolimmunology</i> , 2018, 7, e1424674.	2.1	43
6100	Molecular Biomarkers in the Clinical Management of Prostate Cancer. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2018, 8, a030601.	2.9	11
6101	The clinical implications of immunogenomics in colorectal cancer: A path for precision medicine. <i>Cancer</i> , 2018, 124, 1650-1659.	2.0	32
6102	Multimodality imaging of endocrine immune related adverse events: a primer for radiologists. <i>Clinical Imaging</i> , 2018, 50, 96-103.	0.8	23
6103	Immunotherapy for cervical cancer: Can it do another lung cancer?. <i>Current Problems in Cancer</i> , 2018, 42, 148-160.	1.0	10
6104	A novel biologic platform elicits profound T cell costimulatory activity and antitumor immunity in mice. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 605-613.	2.0	4
6105	NF- κ B in the crosshairs: Rethinking an old riddle. <i>International Journal of Biochemistry and Cell Biology</i> , 2018, 95, 108-112.	1.2	43

#	ARTICLE	IF	CITATIONS
6106	The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy. <i>Journal of the National Cancer Institute</i> , 2018, 110, 777-786.	3.0	58
6108	Comprehensive analysis of the clinical immuno-oncology landscape. <i>Annals of Oncology</i> , 2018, 29, 84-91.	0.6	422
6109	Clinical response to PD-1 blockade correlates with a sub-fraction of peripheral central memory CD4+ T cells in patients with malignant melanoma. <i>International Immunology</i> , 2018, 30, 13-22.	1.8	74
6110	Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	288
6111	Integration of radiation and immunotherapy in breast cancer - Treatment implications. <i>Breast</i> , 2018, 38, 66-74.	0.9	38
6112	MHC-I genotype drives early immune selection of oncogenic mutations. <i>Molecular and Cellular Oncology</i> , 2018, 5, e1409863.	0.3	3
6113	Complimentary mechanisms of dual checkpoint blockade expand unique T-cell repertoires and activate adaptive anti-tumor immunity in triple-negative breast tumors. <i>Oncolimmunology</i> , 2018, 7, e1421891.	2.1	57
6114	The Basics of Cancer Immunotherapy. , 2018, , .		5
6115	Therapeutic Targets of FDA-Approved Immunotherapies in Oncology. , 2018, , 21-37.		3
6116	Melanoma Immunotherapy. , 2018, , 39-57.		0
6117	Management of Immune-Related Adverse Events from Immune Checkpoint Inhibitor Therapy. , 2018, , 143-152.		1
6118	Modulating Tumor Immunology by Inhibiting Indoleamine 2,3-Dioxygenase (IDO): Recent Developments and First Clinical Experiences. <i>Targeted Oncology</i> , 2018, 13, 125-140.	1.7	19
6119	Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients. , 2018, 6, 14.		118
6120	Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis. , 2018, 6, 26.		150
6121	A real world example of coverage with evidence development in Australia - ipilimumab for the treatment of metastatic melanoma. <i>Journal of Pharmaceutical Policy and Practice</i> , 2018, 11, 4.	1.1	13
6123	Nivolumab induced remitting seronegative symmetrical synovitis with pitting edema in a patient with melanoma: a case report. <i>Journal of Medical Case Reports</i> , 2018, 12, 48.	0.4	30
6124	Ipilimumab induced digital vasculitis. , 2018, 6, 12.		37
6125	Immunotherapy for Merkel cell carcinoma: a turning point in patient care. , 2018, 6, 23.		34

#	ARTICLE	IF	CITATIONS
6126	Neoadjuvant treatment for malignant and metastatic cutaneous melanoma. The Cochrane Library, 0, , .	1.5	4
6127	Temozolomide for immunomodulation in the treatment of glioblastoma. Neuro-Oncology, 2018, 20, 1566-1572.	0.6	166
6128	A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure. Clinical Cancer Research, 2018, 24, 3519-3527.	3.2	80
6129	Rationale and emerging strategies for immune checkpoint blockade in soft tissue sarcoma. Cancer, 2018, 124, 3819-3829.	2.0	39
6130	Review of diagnostic, prognostic, and predictive biomarkers in melanoma. Clinical and Experimental Metastasis, 2018, 35, 487-493.	1.7	26
6131	The importance of greater speed in drug development for advanced malignancies. Cancer Medicine, 2018, 7, 1824-1836.	1.3	23
6132	Stereotactic radiosurgery and ipilimumab for patients with melanoma brain metastases: clinical outcomes and toxicity. Journal of Neuro-Oncology, 2018, 139, 421-429.	1.4	74
6133	Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1. European Journal of Cancer, 2018, 96, 91-104.	1.3	94
6134	APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non-small cell lung cancer. Oncogene, 2018, 37, 3924-3936.	2.6	204
6135	Personal history of infections and immunotherapy: Unexpected links and possible therapeutic opportunities. OncoImmunology, 2018, 7, e1466019.	2.1	4
6136	CHECKPOINT INHIBITOR IMMUNE THERAPY. Retina, 2018, 38, 1063-1078.	1.0	252
6137	Use of ipilimumab for recurrent or metastatic malignant mucosal melanoma of the head and neck: a single institution experience. Journal of Japan Society for Head and Neck Surgery, 2018, 27, 307-311.	0.0	0
6138	The siRNA-mediated downregulation of PD-1 alone or simultaneously with CTLA-4 shows enhanced in vitro CAR-T cell functionality for further clinical development towards the potential use in immunotherapy of melanoma. Experimental Dermatology, 2018, 27, 769-778.	1.4	51
6139	Integrative Pharmacology: Advancing Development of Effective Immunotherapies. AAPS Journal, 2018, 20, 66.	2.2	10
6141	Mutation load estimation model as a predictor of the response to cancer immunotherapy. Npj Genomic Medicine, 2018, 3, 12.	1.7	55
6142	Vaccine Therapy and Immunotherapy for Pancreatic Cancer. , 2018, , 1461-1505.		0
6143	Dysregulated Response of Follicular Helper T Cells to Hepatitis B Surface Antigen Promotes HBV Persistence in Mice and Associates With Outcomes of Patients. Gastroenterology, 2018, 154, 2222-2236.	0.6	67
6144	Chronic Pruritus in the Geriatric Population. Dermatologic Clinics, 2018, 36, 199-211.	1.0	11

#	ARTICLE	IF	CITATIONS
6145	The burden of oncology promises not kept in glioblastoma. <i>Future Neurology</i> , 2018, 13, 1-4.	0.9	3
6146	PD-L1-independent Mechanisms Control the Resistance of Melanoma to CD4+ T Cell Adoptive Immunotherapy. <i>Journal of Immunology</i> , 2018, 200, 3304-3311.	0.4	6
6147	Toxicities associated with immunotherapies for hematologic malignancies. <i>Best Practice and Research in Clinical Haematology</i> , 2018, 31, 158-165.	0.7	14
6148	Cardiac Complications Associated With Checkpoint Inhibition: A Systematic Review of the Literature in an Important Emerging Area. <i>Canadian Journal of Cardiology</i> , 2018, 34, 1059-1068.	0.8	95
6149	Cutaneous melanoma: From pathogenesis to therapy (Review). <i>International Journal of Oncology</i> , 2018, 52, 1071-1080.	1.4	281
6151	Risk of Liver Toxicity with Nivolumab Immunotherapy in Cancer Patients. <i>Oncology</i> , 2018, 94, 259-273.	0.9	15
6152	Treatment Sequencing in Advanced BRAF-Mutant Melanoma Patients: Current Practice in the United States. <i>Journal of Pharmacy Technology</i> , 2018, 34, 17-23.	0.5	5
6153	Expression and Targeting of Tumor Markers in Gelfoam® Histoculture: Potential Individualized Assays for Immuno-Oncology. <i>Methods in Molecular Biology</i> , 2018, 1760, 29-37.	0.4	0
6154	Immune checkpoint blockade therapy. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 1403-1414.	1.5	79
6155	Anti-CTLA-4 therapy requires an Fc domain for efficacy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 3912-3917.	3.3	121
6156	Aplastic anemia secondary to nivolumab and ipilimumab in a patient with metastatic melanoma: a case report. <i>Experimental Hematology and Oncology</i> , 2018, 7, 6.	2.0	32
6157	The natural HLA ligandome of glioblastoma stem-like cells: antigen discovery for T cell-based immunotherapy. <i>Acta Neuropathologica</i> , 2018, 135, 923-938.	3.9	36
6158	Management of gastrointestinal adverse events induced by immune-checkpoint inhibitors. <i>Chronic Diseases and Translational Medicine</i> , 2018, 4, 1-7.	0.9	6
6159	Recent developments and obstacles in the treatment of melanoma with BRAF and MEK inhibitors. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 125, 84-88.	2.0	38
6160	Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1755-1764.	1.2	997
6161	The impact of tumor cell metabolism on T cell-mediated immune responses and immuno-metabolic biomarkers in cancer. <i>Seminars in Cancer Biology</i> , 2018, 52, 66-74.	4.3	18
6162	Biomarker-driven targeted therapies for gastric/gastro-esophageal junction malignancies. <i>Seminars in Oncology</i> , 2018, 45, 133-150.	0.8	3
6163	An overview of the toxicities of checkpoint inhibitors in older patients with cancer. <i>Journal of Geriatric Oncology</i> , 2018, 9, 451-458.	0.5	19

#	ARTICLE	IF	CITATIONS
6164	Cancer immunotherapy using checkpoint blockade. <i>Science</i> , 2018, 359, 1350-1355.	6.0	4,274
6165	Indoleamine 2,3-Dioxygenase and Its Therapeutic Inhibition in Cancer. <i>International Review of Cell and Molecular Biology</i> , 2018, 336, 175-203.	1.6	204
6166	Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies. <i>Cancer Cell</i> , 2018, 33, 649-663.e4.	7.7	448
6167	Melanoma and Immune Checkpoint Inhibitors. <i>Current Oncology Reports</i> , 2018, 20, 29.	1.8	54
6168	Abundant tumor infiltrating lymphocytes after primary systemic chemotherapy predicts poor prognosis in estrogen receptor-positive/HER2-negative breast cancers. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 135-145.	1.1	27
6169	Potential clinical and immunotherapeutic utility of talimogene laherparepvec for patients with melanoma after disease progression on immune checkpoint inhibitors and BRAF inhibitors. <i>Melanoma Research</i> , 2018, 28, 250-255.	0.6	17
6170	Comparative analysis of the effect of different radiotherapy regimes on lymphocyte and its subpopulations in breast cancer patients. <i>Clinical and Translational Oncology</i> , 2018, 20, 1219-1225.	1.2	29
6171	Primary Central Nervous System Malignant Melanoma in Children: A Case Series and Review of the Literature. <i>Journal of Pediatric Hematology/Oncology</i> , 2018, 40, 616-619.	0.3	1
6172	Enhanced expression of PD-1 and other activation markers by CD4+ T cells of young but not old patients with metastatic melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 925-933.	2.0	8
6173	Immune signatures predicting responses to immunomodulatory antibody therapy. <i>Current Opinion in Immunology</i> , 2018, 51, 91-96.	2.4	7
6174	Immune Responses to Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer. <i>Bladder Cancer</i> , 2018, 4, 1-7.	0.2	6
6175	The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England. <i>European Journal of Health Economics</i> , 2018, 19, 1163-1172.	1.4	25
6176	Single-cell technologies for profiling T cells to enable monitoring of immunotherapies. <i>Current Opinion in Chemical Engineering</i> , 2018, 19, 142-152.	3.8	11
6177	Targeting immune checkpoints in non small cell lung cancer. <i>Current Opinion in Pharmacology</i> , 2018, 40, 46-50.	1.7	49
6178	Combination immunotherapies implementing adoptive T-cell transfer for advanced-stage melanoma. <i>Melanoma Research</i> , 2018, 28, 171-184.	0.6	18
6179	Tailoring Porous Silicon for Biomedical Applications: From Drug Delivery to Cancer Immunotherapy. <i>Advanced Materials</i> , 2018, 30, e1703740.	11.1	127
6180	A cancer registry-based analysis on the non-white populations reveals a critical role of the female sex in early-onset melanoma. <i>Cancer Causes and Control</i> , 2018, 29, 405-415.	0.8	10
6181	An Overview of Immune Checkpoint Inhibitors in Gynecologic Cancers. <i>Clinical Therapeutics</i> , 2018, 40, 372-388.	1.1	17

#	ARTICLE	IF	CITATIONS
6182	Use of extracranial radiation therapy in metastatic melanoma patients receiving immunotherapy. <i>Radiotherapy and Oncology</i> , 2018, 127, 310-317.	0.3	22
6183	Primary Tumor Thickness is a Prognostic Factor in Stage IV Melanoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 90-94.	0.6	8
6184	PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux. <i>Seminars in Cancer Biology</i> , 2018, 48, 91-103.	4.3	257
6185	Current studies of immunotherapy in head and neck cancer. <i>Clinical Otolaryngology</i> , 2018, 43, 13-21.	0.6	63
6186	The expanding repertoire of targets for immune checkpoint inhibition in bladder cancer: What lies beneath the tip of the iceberg, PD-L1. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 459-468.	0.8	8
6187	A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T cell vaccine against VEGFR2, in patients with advanced pancreatic cancer. <i>Oncolmmunology</i> , 2018, 7, e1303584.	2.1	41
6188	The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC). <i>Breast Cancer</i> , 2018, 25, 34-42.	1.3	88
6189	Meta-Analysis of the Risk of Immune-Related Adverse Events With Anticytotoxic T Lymphocyte-Associated Antigen 4 and Antiprogrammed Death 1 Therapies. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 318-331.	2.3	22
6190	S100A4 blockage alleviates agonistic anti-CD137 antibody-induced liver pathology without disruption of antitumor immunity. <i>Oncolmmunology</i> , 2018, 7, e1296996.	2.1	15
6191	Targeting cancer stem cells by using chimeric antigen receptor-modified T cells: a potential and curable approach for cancer treatment. <i>Protein and Cell</i> , 2018, 9, 516-526.	4.8	46
6192	The 'Achilles' Heel' of Cancer and Its Implications for the Development of Novel Immunotherapeutic Strategies. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2018, 8, a027086.	2.9	11
6193	Rationale for immunological approaches to breast cancer therapy. <i>Breast</i> , 2018, 37, 187-195.	0.9	23
6194	The emerging role of immune checkpoint based approaches in AML and MDS. <i>Leukemia and Lymphoma</i> , 2018, 59, 790-802.	0.6	90
6195	Characteristics of adverse drug reactions in a vemurafenib early post-marketing phase vigilance study in Japan. <i>Clinical and Translational Oncology</i> , 2018, 20, 169-175.	1.2	15
6196	The avidity of tumor-specific T cells amplified by a plasmacytoid dendritic cell-based assay can predict the clinical evolution of melanoma patients. <i>Pigment Cell and Melanoma Research</i> , 2018, 31, 82-94.	1.5	3
6197	The Autophagy Receptor Adaptor p62 is Upregulated by UVA Radiation in Melanocytes and in Melanoma Cells. <i>Photochemistry and Photobiology</i> , 2018, 94, 432-437.	1.3	25
6198	Toxicity profiles of immunotherapy. , 2018, 181, 91-100.		55
6199	NCCTG N0879 (Alliance): A randomized phase 2 cooperative group trial of carboplatin, paclitaxel, and bevacizumab±everolimus for metastatic melanoma. <i>Cancer</i> , 2018, 124, 537-545.	2.0	27

#	ARTICLE	IF	CITATIONS
6200	Personalized neoantigen vaccines: A new approach to cancer immunotherapy. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 2842-2849.	1.4	85
6201	Real-world treatment patterns and outcomes among metastatic cutaneous melanoma patients treated with ipilimumab. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 962-971.	1.3	14
6202	The safety and efficacy of dabrafenib and trametinib for the treatment of melanoma. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 73-87.	1.0	32
6203	Eosinophils: The unsung heroes in cancer?. <i>Oncolmmunology</i> , 2018, 7, e1393134.	2.1	184
6204	Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage IIâ€“III Melanoma Adjuvant Therapy. <i>Journal of the National Cancer Institute</i> , 2018, 110, 87-96.	3.0	89
6205	Melanocortin-1 Receptor-Targeting Ultrasmall Silica Nanoparticles for Dual-Modality Human Melanoma Imaging. <i>ACS Applied Materials & Interfaces</i> , 2018, 10, 4379-4393.	4.0	40
6206	Dendritic cell vaccine induces antigen-specific CD8 ⁺ T cells that are metabolically distinct from those of peptide vaccine and is well-combined with PD-1 checkpoint blockade. <i>Oncolmmunology</i> , 2018, 7, e1395124.	2.1	20
6207	MicroRNAs Reprogram Tumor Immune Response. <i>Methods in Molecular Biology</i> , 2018, 1699, 67-74.	0.4	11
6208	Considerations for successful cancer immunotherapy in aged hosts. <i>Experimental Gerontology</i> , 2018, 107, 27-36.	1.2	33
6210	Drug-Induced Lung Injury. <i>Respiratory Disease Series</i> , 2018, , .	0.1	2
6211	Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy. <i>Annals of Oncology</i> , 2018, 29, 71-83.	0.6	253
6212	Prognostic role of neutrophilâ€“lymphocyte ratio in head and neck cancer: A metaâ€“analysis. <i>Head and Neck</i> , 2018, 40, 647-655.	0.9	85
6214	Retrospective study of advanced melanoma patients treated with ipilimumab after nivolumab: Analysis of 60 Japanese patients. <i>Journal of Dermatological Science</i> , 2018, 89, 60-66.	1.0	52
6215	<i>In-vitro</i> effect of pembrolizumab on different T regulatory cell subsets. <i>Clinical and Experimental Immunology</i> , 2018, 191, 189-197.	1.1	42
6216	Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens. <i>JAMA Oncology</i> , 2018, 4, 173.	3.4	753
6217	Baseline laboratory parameters predicting clinical outcome in melanoma patients treated with ipilimumab: a singleâ€“centre analysis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 972-977.	1.3	16
6218	Immunotherapy as an Option for Cancer Treatment. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2018, 66, 89-96.	1.0	19
6219	A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213.. <i>Breast Cancer Research and Treatment</i> , 2018, 167, 485-493.	1.1	71

#	ARTICLE	IF	CITATIONS
6220	Serum exosomes as predictors of clinical response to ipilimumab in metastatic melanoma. <i>Oncolmmunology</i> , 2018, 7, e1387706.	2.1	76
6221	Survival trends among patients with metastatic melanoma in the pretargeted and the post-targeted era: a US population-based study. <i>Melanoma Research</i> , 2018, 28, 56-60.	0.6	25
6222	Ipilimumab and early signs of pulmonary toxicity in patients with metastatic melanoma: a prospective observational study. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 127-134.	2.0	29
6223	DOX/IL-2/IFN- γ co-loaded thermo-sensitive polypeptide hydrogel for efficient melanoma treatment. <i>Bioactive Materials</i> , 2018, 3, 118-128.	8.6	79
6224	Immune checkpoint blockade in infectious diseases. <i>Nature Reviews Immunology</i> , 2018, 18, 91-104.	10.6	407
6225	Analysis of the immune infiltrate in undifferentiated pleomorphic sarcoma of the extremity and trunk in response to radiotherapy: Rationale for combination neoadjuvant immune checkpoint inhibition and radiotherapy. <i>Oncolmmunology</i> , 2018, 7, e1385689.	2.1	46
6226	Tumor-infiltrating immune cells as potential biomarkers predicting response to treatment and survival in patients with metastatic melanoma receiving ipilimumab therapy. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 141-151.	2.0	58
6227	Establishment of the Method for Screening Small Molecule Inhibitors Blocking the Interaction Between PD-1 and Its Ligand PD-L1. <i>Lecture Notes in Electrical Engineering</i> , 2018, , 695-703.	0.3	1
6228	Combinatorial Therapies in Melanoma: MAPK Inhibitors and Beyond. <i>American Journal of Clinical Dermatology</i> , 2018, 19, 181-193.	3.3	18
6229	PD-L1 in breast cancer: comparative analysis of 3 different antibodies. <i>Human Pathology</i> , 2018, 72, 28-34.	1.1	44
6230	BTN3A is a prognosis marker and a promising target for V β 9V α 2 T cells based-immunotherapy in pancreatic ductal adenocarcinoma (PDAC). <i>Oncolmmunology</i> , 2018, 7, e1372080.	2.1	47
6231	Microenvironment and Lung Cancer. , 2018, , 121-128.e4.		1
6232	Systemic Options for Second-Line Therapy and Beyond. , 2018, , 434-447.e5.		0
6233	Synthetic immune niches for cancer immunotherapy. <i>Nature Reviews Immunology</i> , 2018, 18, 212-219.	10.6	141
6234	Agonist OX40 immunotherapy improves survival in glioma-bearing mice and is complementary with vaccination with irradiated GM-CSF-expressing tumor cells. <i>Neuro-Oncology</i> , 2018, 20, 44-54.	0.6	51
6235	Immune Modulation Therapy and Imaging: Workshop Report. <i>Journal of Nuclear Medicine</i> , 2018, 59, 410-417.	2.8	23
6236	Cancer immunotherapy-induced endocrinopathies: Clinical behavior and therapeutic approach. <i>European Journal of Internal Medicine</i> , 2018, 47, 6-13.	1.0	52
6237	Sequential, Multiple Assignment, Randomized Trial Designs in Immuno-oncology Research. <i>Clinical Cancer Research</i> , 2018, 24, 730-736.	3.2	16

#	ARTICLE	IF	CITATIONS
6238	Development of Bell's Palsy After Treatment With Ipilimumab and Nivolumab for Metastatic Melanoma: A Case Report. <i>Journal of Immunotherapy</i> , 2018, 41, 39-41.	1.2	15
6239	AllergoOncology: Opposite outcomes of immune tolerance in allergy and cancer. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 328-340.	2.7	54
6240	Co-Delivery of Drugs and Genes Using Polymeric Nanoparticles for Synergistic Cancer Therapeutic Effects. <i>Advanced Healthcare Materials</i> , 2018, 7, 1700886.	3.9	96
6241	Immunotherapy: A New (and Old) Approach to Treatment of Soft Tissue and Bone Sarcomas. <i>Oncologist</i> , 2018, 23, 71-83.	1.9	45
6242	Therapeutic Implications of the Molecular and Immune Landscape of Triple-Negative Breast Cancer. <i>Pathology and Oncology Research</i> , 2018, 24, 701-716.	0.9	17
6243	Targeted drug delivery to melanoma. <i>Advanced Drug Delivery Reviews</i> , 2018, 127, 208-221.	6.6	99
6244	Blocking CTLA-4 while priming with a whole cell vaccine reshapes the oligoclonal T cell infiltrate and eradicates tumors in an orthotopic glioma model. <i>Oncimmunology</i> , 2018, 7, e1376154.	2.1	22
6245	Tumor infiltrating lymphocytes in lymph node metastases of stage III melanoma correspond to response and survival in nine patients treated with ipilimumab at the time of stage IV disease. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 39-45.	2.0	45
6246	Solid Tumor Immunotherapy with T Cell Engager-Armed Oncolytic Viruses. <i>Macromolecular Bioscience</i> , 2018, 18, 1700187.	2.1	56
6247	Neurological Complications of Immune-Based Therapies. , 2018, , 335-344.		0
6248	Diffuse recurrent cutaneous melanoma of the scalp and neck successfully treated with volumetric modulated arc therapy and concurrent ipilimumab. <i>Practical Radiation Oncology</i> , 2018, 8, 174-178.	1.1	3
6249	Prostate cancer immunotherapy. <i>Current Opinion in Urology</i> , 2018, 28, 15-24.	0.9	40
6250	Review of cancer treatment with immune checkpoint inhibitors. <i>Wiener Klinische Wochenschrift</i> , 2018, 130, 85-91.	1.0	102
6251	Therapeutic Implications of the Genetic Landscape of Head and Neck Cancer. <i>Seminars in Radiation Oncology</i> , 2018, 28, 2-11.	1.0	23
6252	Integrated functional and mass spectrometry-based flow cytometric phenotyping to describe the immune microenvironment in acute myeloid leukemia. <i>Journal of Immunological Methods</i> , 2018, 453, 44-52.	0.6	19
6253	Immune-related tumour response assessment criteria: a comprehensive review. <i>British Journal of Radiology</i> , 2018, 91, 20170457.	1.0	58
6254	Immunotherapy for Pediatric Malignancies. , 2018, , .		0
6255	Molecular Diagnosis and Targeting for Lung Cancer. <i>Current Human Cell Research and Applications</i> , 2018, , 1-32.	0.1	0

#	ARTICLE	IF	CITATIONS
6256	Current status of cancer immunotherapy for esophageal squamous cell carcinoma. <i>Esophagus</i> , 2018, 15, 1-9.	1.0	19
6257	Perioperative, Spatiotemporally Coordinated Activation of T and NK Cells Prevents Recurrence of Pancreatic Cancer. <i>Cancer Research</i> , 2018, 78, 475-488.	0.4	61
6258	The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma. <i>European Journal of Endocrinology</i> , 2018, 178, 173-180.	1.9	111
6259	Adverse Reactions to Biologics: Melanoma (Ipilimumab, Nivolumab, Pembrolizumab). <i>Current Problems in Dermatology</i> , 2018, 53, 82-92.	0.8	22
6261	Neutrophil-lymphocyte ratio kinetics in patients with advanced solid tumours on phase I trials of PD-1/PD-L1 inhibitors. <i>European Journal of Cancer</i> , 2018, 89, 56-63.	1.3	60
6262	Medical bioinformatics in melanoma. <i>Current Opinion in Oncology</i> , 2018, 30, 113-117.	1.1	13
6263	Positron emission tomography/computed tomography evaluation of oncolytic virus therapy efficacy in melanoma. <i>European Journal of Cancer</i> , 2018, 90, 149-152.	1.3	4
6264	Phase I Dose-Escalation Study of Anti-CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced Cancers. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 671-676.	1.9	33
6265	Synergy of Immune Checkpoint Blockade with a Novel Synthetic Consensus DNA Vaccine Targeting TERT. <i>Molecular Therapy</i> , 2018, 26, 435-445.	3.7	39
6266	Current and future immunotherapies for thyroid cancer. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 149-159.	1.1	47
6267	Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIb-IVM1c melanoma. <i>Melanoma Research</i> , 2018, 28, 44-51.	0.6	31
6268	Implications of the tumor immune microenvironment for staging and therapeutics. <i>Modern Pathology</i> , 2018, 31, 214-234.	2.9	278
6269	Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation. <i>Cancer Treatment Reviews</i> , 2018, 63, 48-60.	3.4	134
6270	Product review on the Anti-PD-L1 antibody atezolizumab. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 269-276.	1.4	41
6271	New developments in immunotherapy for pediatric solid tumors. <i>Current Opinion in Pediatrics</i> , 2018, 30, 30-39.	1.0	16
6272	Multistage Targeting Strategy Using Magnetic Composite Nanoparticles for Synergism of Photothermal Therapy and Chemotherapy. <i>Small</i> , 2018, 14, e1702994.	5.2	93
6273	Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. <i>Science</i> , 2018, 359, 582-587.	6.0	834
6274	Peptide Blocking of PD-1/PD-L1 Interaction for Cancer Immunotherapy. <i>Cancer Immunology Research</i> , 2018, 6, 178-188.	1.6	121

#	ARTICLE	IF	CITATIONS
6275	Characterization of PD-L1 expression in Chinese non-small cell lung cancer patients with PTEN expression as a means for tissue quality screening. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 471-481.	2.0	4
6276	Molecular and Genomic Determinants of Response to Immune Checkpoint Inhibition in Cancer. <i>Annual Review of Medicine</i> , 2018, 69, 333-347.	5.0	38
6277	MicroRNAs Change the Landscape of Cancer Resistance. <i>Methods in Molecular Biology</i> , 2018, 1699, 83-89.	0.4	7
6278	BRAF peptide vaccine facilitates therapy of murine BRAF-mutant melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 299-310.	2.0	48
6279	Sequential CT Findings in Patients With Non-small-cell Lung Cancer Receiving Nivolumab. <i>Clinical Lung Cancer</i> , 2018, 19, 175-180.	1.1	1
6280	Surgical and Anatomic Considerations of Malignancies Affecting the Groin: Consideration for Melanoma. , 2018, , 63-74.		0
6281	A phase I vaccination study with dendritic cells loaded with NY-ESO-1 and β -galactosylceramide: induction of polyfunctional T cells in high-risk melanoma patients. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 285-298.	2.0	49
6282	The inflammatory microenvironment and microbiome in prostate cancer development. <i>Nature Reviews Urology</i> , 2018, 15, 11-24.	1.9	311
6283	Triple negative breast cancer: Key role of Tumor-Associated Macrophages in regulating the activity of anti-PD-1/PD-L1 agents. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2018, 1869, 78-84.	3.3	150
6284	Small-Molecule Sigma1 Modulator Induces Autophagic Degradation of PD-L1. <i>Molecular Cancer Research</i> , 2018, 16, 243-255.	1.5	117
6285	CTLA-4: a moving target in immunotherapy. <i>Blood</i> , 2018, 131, 58-67.	0.6	704
6287	Melanoma Immunotherapy. <i>Current Cancer Research</i> , 2018, , 307-331.	0.2	0
6288	Liposome-based immunity-inducing systems for cancer immunotherapy. <i>Molecular Immunology</i> , 2018, 98, 8-12.	1.0	53
6289	Eight-Color Multiplex Immunohistochemistry for Simultaneous Detection of Multiple Immune Checkpoint Molecules within the Tumor Microenvironment. <i>Journal of Immunology</i> , 2018, 200, 347-354.	0.4	181
6290	Association of First-in-Class Immune Checkpoint Inhibition and Targeted Therapy With Survival in Patients With Stage IV Melanoma. <i>JAMA Oncology</i> , 2018, 4, 126.	3.4	8
6291	Recent advances in melanoma research via "omics" platforms. <i>Journal of Proteomics</i> , 2018, 188, 152-166.	1.2	13
6292	Immune checkpoint inhibitors: new strategies to checkmate cancer. <i>Clinical and Experimental Immunology</i> , 2018, 191, 133-148.	1.1	57
6293	Immune checkpoint inhibitor colitis: the flip side of the wonder drugs. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 472, 125-133.	1.4	59

#	ARTICLE	IF	CITATIONS
6294	Hepatocellular carcinoma in the era of immunotherapy. <i>Current Problems in Cancer</i> , 2018, 42, 40-48.	1.0	135
6295	PD-L1 expression with immune-infiltrate evaluation and outcome prediction in melanoma patients treated with ipilimumab. <i>Oncolimmunology</i> , 2018, 7, e1405206.	2.1	43
6296	Immune checkpoint inhibitor therapy in a liver transplant recipient with a rare subtype of melanoma: a case report and literature review. <i>Melanoma Research</i> , 2018, 28, 61-64.	0.6	55
6297	Author's reply to: Prognosis of sentinel lymph node biopsy in patients with thick melanoma by a propensity score matching prospective study. <i>International Journal of Cancer</i> , 2018, 142, 1504-1504.	2.3	0
6298	Advanced Melanoma: Current Treatment Options, Biomarkers, and Future Perspectives. <i>American Journal of Clinical Dermatology</i> , 2018, 19, 303-317.	3.3	78
6299	Immune checkpoint inhibitors in sarcomas: in quest of predictive biomarkers. <i>Laboratory Investigation</i> , 2018, 98, 41-50.	1.7	30
6300	Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience. <i>Investigational New Drugs</i> , 2018, 36, 638-646.	1.2	149
6301	Perspectives on the integration of Immuno-Oncology Biomarkers and drugs in a Health Care setting. <i>Seminars in Cancer Biology</i> , 2018, 52, 166-177.	4.3	11
6302	Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2018, 24, 1260-1270.	3.2	289
6303	Combining DNA damaging therapeutics with immunotherapy: more haste, less speed. <i>British Journal of Cancer</i> , 2018, 118, 312-324.	2.9	184
6304	Analysis of survival of patients treated with vemurafenib, ipilimumab and dabrafenib for advanced skin melanoma in daily clinical practice (Real-World Data): retrospective analysis of patients treated under drug/reimbursement programmes in Poland in 2013â€“2016. <i>Melanoma Research</i> , 2018, 28, 52-55.	0.6	6
6305	A phase 2 study of ontuxizumab, a monoclonal antibody targeting endosialin, in metastatic melanoma. <i>Investigational New Drugs</i> , 2018, 36, 103-113.	1.2	19
6306	Immunological considerations underlying heat shock protein-mediated cancer vaccine strategies. <i>Immunology Letters</i> , 2018, 193, 1-10.	1.1	13
6307	Targeted Therapies: Immunologic Effects and Potential Applications Outside of Cancer. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 7-24.	1.0	23
6308	Immunotherapy for thoracic malignancies. <i>Indian Journal of Thoracic and Cardiovascular Surgery</i> , 2018, 34, 54-64.	0.2	0
6309	New Molecular, Biological, and Immunological Agents Inducing Hypophysitis. <i>Neuroendocrinology</i> , 2018, 106, 89-100.	1.2	14
6310	Significant Clinical Response to a MEK Inhibitor Therapy in a Patient With Metastatic Melanoma Harboring an <i>RAF1</i> Fusion. <i>JCO Precision Oncology</i> , 2018, 2, 1-6.	1.5	13
6311	High CTLA-4 expression correlates with poor prognosis in thymoma patients. <i>Oncotarget</i> , 2018, 9, 16665-16677.	0.8	24

#	ARTICLE	IF	CITATIONS
6312	Immune checkpoint inhibitors of CTLA4 and PD-1 for malignant melanoma arising in ovarian cystic teratoma. <i>Medicine (United States)</i> , 2018, 97, e12937.	0.4	4
6313	Clinicopathological and prognostic significance of PD-L1 expression in sarcoma. <i>Medicine (United States)</i> , 2018, 97, e12937.	0.4	29
6314	My Patient Was Diagnosed With Nontargetable Advanced Non-Small Cell Lung Cancer. What Now? Diagnosis and Initial Treatment Options for Newly Diagnosed Patients With Advanced NSCLC. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 696-707.	1.8	5
6315	ClinicalTrials.gov for Facilitating Rapid Understanding of Potential Harms of New Drugs: The Case of Checkpoint Inhibitors. <i>Journal of Oncology Practice</i> , 2018, 14, 72-76.	2.5	8
6316	Cardiac tamponade induced by dabrafenib and trametinib combination therapy for melanoma. <i>Medicine (United States)</i> , 2018, 97, e12751.	0.4	5
6317	New Era in the Management of Melanoma Brain Metastases. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 741-750.	1.8	52
6318	Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 391-398.	0.8	156
6319	Tumor Response Assessment for Precision Cancer Therapy: Response Evaluation Criteria in Solid Tumors and Beyond. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 1019-1029.	1.8	55
6320	Lifestyle Modifications and Policy Implications for Primary and Secondary Cancer Prevention: Diet, Exercise, Sun Safety, and Alcohol Reduction. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 88-100.	1.8	34
6321	More Than 50 Subtypes of Soft Tissue Sarcoma: Paving the Path for Histology-Driven Treatments. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 925-938.	1.8	50
6322	Positive Tumor Response to Combined Checkpoint Inhibitors in a Patient With Refractory Alveolar Soft Part Sarcoma: A Case Report. <i>Journal of Global Oncology</i> , 2018, 4, 1-6.	0.5	24
6323	Practice-Changing Developments in Stage III Melanoma: Surgery, Adjuvant Targeted Therapy, and Immunotherapy. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 759-762.	1.8	13
6324	Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 383-390.	0.8	431
6325	Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2018, 36, 1714-1768.	0.8	2,691
6326	Duration of Anti-Programmed Death-1 Therapy in Advanced Melanoma: How Much of a Good Thing Is Enough?. <i>Journal of Clinical Oncology</i> , 2018, 36, 1649-1653.	0.8	4
6327	Renal Cell Carcinoma in the Era of Precision Medicine: From Molecular Pathology to Tissue-Based Biomarkers. <i>Journal of Clinical Oncology</i> , 2018, 36, 3553-3559.	0.8	49
6328	Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy. <i>Journal of Clinical Oncology</i> , 2018, 36, 850-858.	0.8	288
6329	Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037). <i>Journal of Clinical Oncology</i> , 2018, 36, 3223-3230.	0.8	267

#	ARTICLE	IF	CITATIONS
6330	Malignant melanoma: Claims and controversies. <i>Journal of Patient Safety and Risk Management</i> , 2018, 23, 243-249.	0.4	0
6331	Gastrointestinal and Hepatic Toxicities of Checkpoint Inhibitors: Algorithms for Management. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 13-19.	1.8	74
6332	Combination Immunotherapy Development in Melanoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 197-207.	1.8	39
6333	Progress in Kidney Cancer Outcomes Through Collaboration, Innovation, and Discovery. <i>Journal of Clinical Oncology</i> , 2018, 36, 3529-3532.	0.8	0
6334	Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 1658-1667.	0.8	483
6335	Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 1668-1674.	0.8	360
6337	Cardio-toxicity of checkpoint inhibitors. <i>Journal of Thoracic Disease</i> , 2018, 10, S4400-S4404.	0.6	19
6338	Experience from Turkish centers participating in the Early Access Program (EAP): Preliminary real-world safety data of nivolumab (nivo) combined with ipilimumab (ipi) in pre-treated advanced melanoma patients. <i>Journal of Oncological Science</i> , 2018, 4, 125-129.	0.1	2
6339	Mechanisms of Drug Resistance in Cancer Therapy. <i>Handbook of Experimental Pharmacology</i> , 2018, , .	0.9	1
6340	Approach and management of checkpoint inhibitor-related immune hepatitis. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 220-224.	0.6	28
6341	Immune checkpoint inhibitors in gastrointestinal malignancies. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 390-403.	0.6	6
6342	Immune-related adverse events with immune checkpoint inhibitors in thoracic malignancies: focusing on non-small cell lung cancer patients. <i>Journal of Thoracic Disease</i> , 2018, 10, S1516-S1533.	0.6	57
6343	Do immune checkpoint inhibitors need new studies methodology?. <i>Journal of Thoracic Disease</i> , 2018, 10, S1564-S1580.	0.6	58
6344	The evolving understanding of immunoediting and the clinical impact of immune escape. <i>Journal of Thoracic Disease</i> , 2018, 10, 1248-1252.	0.6	10
6345	Heart failure in cancer: role of checkpoint inhibitors. <i>Journal of Thoracic Disease</i> , 2018, 10, S4323-S4334.	0.6	15
6346	Targeting DNA damage repair in small cell lung cancer and the biomarker landscape. <i>Translational Lung Cancer Research</i> , 2018, 7, 50-68.	1.3	96
6347	Implementing tumor mutational burden (TMB) analysis in routine diagnostics—a primer for molecular pathologists and clinicians. <i>Translational Lung Cancer Research</i> , 2018, 7, 703-715.	1.3	152
6348	Autoimmune Myocarditis Caused by Immune Checkpoint Inhibitors Treated With Antithymocyte Globulin. <i>Journal of Immunotherapy</i> , 2018, 41, 332-335.	1.2	68

#	ARTICLE	IF	CITATIONS
6349	Immunotherapy in colorectal cancer: for the select few or all?. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 170-179.	0.6	51
6350	Identifying and managing the adverse effects of immune checkpoint blockade. <i>Journal of Thoracic Disease</i> , 2018, 10, S480-S489.	0.6	78
6351	Putting the brakes on CTLA-4 inhibition in lung cancer?. <i>Translational Lung Cancer Research</i> , 2018, 7, S35-S38.	1.3	7
6353	Endoscopic evaluation of immunotherapy-induced gastrointestinal toxicity. <i>World Journal of Gastrointestinal Endoscopy</i> , 2018, 10, 392-399.	0.4	20
6354	Prognostic significance of tumor immune microenvironment and immunotherapy: Novel insights and future perspectives in gastric cancer. <i>World Journal of Gastroenterology</i> , 2018, 24, 3583-3616.	1.4	118
6356	Immunohistochemistry: sole tool in diagnosing a rare case of primary vaginal amelanotic melanoma. <i>Obstetrics and Gynecology Science</i> , 2018, 61, 698.	0.6	3
6357	Pseudoprogression with subsequent complete response and severe thrombocytopenia to checkpoint inhibitor immunotherapy in a patient with advanced mucosal melanoma of the sinonasal cavity. <i>Anti-Cancer Drugs</i> , 2018, 29, 914-918.	0.7	8
6358	Vaccination with induced pluripotent stem cells confers protection against cancer. <i>Stem Cell Investigation</i> , 2018, 5, 23-23.	1.3	3
6359	Preoperative BRAF inhibition in patients with irresectable locally advanced stage III melanoma. <i>Melanoma Management</i> , 2018, 5, MMT08.	0.1	2
6360	Classification of tumor microenvironment immune types based on immune response-associated gene expression. <i>International Journal of Oncology</i> , 2019, 54, 219-228.	1.4	12
6361	Tumor Regression and Cure Depends on Sustained Th1 Responses. <i>Journal of Immunotherapy</i> , 2018, 41, 369-378.	1.2	26
6362	Cancer Stem Cell Vaccination With PD-L1 and CTLA-4 Blockades Enhances the Eradication of Melanoma Stem Cells in a Mouse Tumor Model. <i>Journal of Immunotherapy</i> , 2018, 41, 361-368.	1.2	51
6363	The growing role of precision and personalized medicine for cancer treatment. <i>Technology</i> , 2018, 06, 79-100.	1.4	237
6364	Combining immunotherapy and radiotherapy in lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, S1447-S1460.	0.6	54
6365	Tumor microenvironment classification based on Tâ€¢cell infiltration and PDâ€¢L1 in patients with mismatch repairâ€¢proficient and â€¢deficient colorectal cancer. <i>Oncology Letters</i> , 2018, 17, 2335-2343.	0.8	8
6366	Granulomatous Tumoral Melanosis Associated With Pembrolizumab Therapy: A Mimicker of Disease Progression in Metastatic Melanoma. <i>American Journal of Dermatopathology</i> , 2018, 40, 523-526.	0.3	26
6367	The Modern Approach to Targeting Melanoma. , 2018, , .		2
6368	Metastatic primary pulmonary melanoma successfully treated with checkpoint inhibitors. <i>BMJ Case Reports</i> , 2018, 2018, bcr-2017-223025.	0.2	1

#	ARTICLE	IF	CITATIONS
6370	Exosomes in melanoma: a role in tumor progression, metastasis and impaired immune system activity. <i>Oncotarget</i> , 2018, 9, 20826-20837.	0.8	97
6372	Repeated Abscopal Effect With Radiotherapy and Programmed Death 1 Blockade in Mismatch Repairâ€“Deficient Endometrial Cancer. <i>JCO Precision Oncology</i> , 2018, 2, 1-6.	1.5	4
6373	Current Perspectives on Novel Drug Carrier Systems and Therapies for Management of Pancreatic Cancer: An Updated Inclusive Review. <i>Critical Reviews in Therapeutic Drug Carrier Systems</i> , 2018, 35, 195-292.	1.2	12
6374	Multidisciplinary approach for post-liver transplant recurrence of hepatocellular carcinoma: A proposed management algorithm. <i>World Journal of Gastroenterology</i> , 2018, 24, 5081-5094.	1.4	58
6376	Case Report: Treatment Resistant Ipilimumab Related Colitis in an Elderly Metastatic Melanoma Patient. <i>Journal of Gerontology & Geriatric Research</i> , 2018, 07, .	0.1	0
6377	Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer. <i>Frontiers in Immunology</i> , 2018, 9, 3081.	2.2	116
6378	Immune Checkpoint Inhibitors in Pediatric Solid Tumors: Status in 2018. <i>Ochsner Journal</i> , 2018, 18, 370-376.	0.5	33
6379	Endocrine sequelae of immune checkpoint inhibitors. <i>Hormones</i> , 2018, 16, 341-350.	0.9	15
6383	Primary Hepatic Melanoma in a Child. <i>Chinese Medical Journal</i> , 2018, 131, 2135-2136.	0.9	1
6384	Reflectance confocal microscopy for diagnosing cutaneous melanoma in adults. <i>The Cochrane Library</i> , 2018, 12, CD013190.	1.5	41
6385	Immunotherapy in non-Hodgkin lymphoma. <i>Annals of Lymphoma</i> , 0, 2, 9-9.	4.5	0
6386	Immune Checkpoints and Innovative Therapies in Glioblastoma. <i>Frontiers in Oncology</i> , 2018, 8, 464.	1.3	70
6387	Long-term Survival of Stage IV Melanoma Patients Treated with BOLD Combination Chemotherapy and Intermediate-dose Subcutaneous Interferon-alpha. <i>Anticancer Research</i> , 2018, 38, 6393-6397.	0.5	3
6388	The Role of Melanoma Cell-Stroma Interaction in Cell Motility, Invasion, and Metastasis. <i>Frontiers in Medicine</i> , 2018, 5, 307.	1.2	27
6389	<i>BRCA1/2</i> and <i>TP53</i> mutation status associates with <i>PD-1</i> and <i>PD-L1</i> expression in ovarian cancer. <i>Oncotarget</i> , 2018, 9, 17501-17511.	0.8	70
6390	The forgotten role of adjuvant immune checkpoint inhibitors in preventing melanoma brain metastasis. <i>Immunotherapy</i> , 2018, 10, 1289-1291.	1.0	2
6391	Putting the Immunologic Brakes on Cancer. <i>Cell</i> , 2018, 175, 1452-1454.	13.5	75
6392	CAR T Cell Therapy for Neuroblastoma. <i>Frontiers in Immunology</i> , 2018, 9, 2380.	2.2	107

#	ARTICLE	IF	CITATIONS
6393	Minimally invasive isolated limb perfusion “ technical details and initial outcome of a new treatment method for limb malignancies. International Journal of Hyperthermia, 2018, 35, 667-673.	1.1	5
6394	Kaposi’s varicelliform eruption in a patient with metastatic melanoma and primary cutaneous anaplastic large cell lymphoma treated with talimogene laherparepvec and nivolumab. , 2018, 6, 122.		6
6395	Effective screening of T cells recognizing neoantigens and construction of T-cell receptor-engineered T cells. Oncotarget, 2018, 9, 11009-11019.	0.8	44
6396	The impact of immunosenescence on the efficacy of immune checkpoint inhibitors in melanoma patients: a meta-analysis. OncoTargets and Therapy, 2018, Volume 11, 7521-7527.	1.0	21
6397	Predictors of Immunotherapy-Induced Immune-Related Adverse Events. Current Oncology, 2018, 25, 403-410.	0.9	77
6398	Monoclonal antibodies for the treatment of non-hematological tumors: a safety review. Expert Opinion on Drug Safety, 2018, 17, 1197-1209.	1.0	11
6399	How Does an Anti-CTLA-4 Antibody Promote Cancer Immunity?. Trends in Immunology, 2018, 39, 953-956.	2.9	55
6400	Multifunctional Nanoparticle Approach for Targeting Melanoma. Journal of Investigative Dermatology Symposium Proceedings, 2018, 19, S89-S90.	0.8	0
6401	Reporter Genes for PET Imaging of CAR T Cells Offers Insight into Adoptive Cell Transfer. Journal of Nuclear Medicine, 2018, 59, 1892-1893.	2.8	4
6402	SS1P Immunotoxin Induces Markers of Immunogenic Cell Death and Enhances the Effect of the CTLA-4 Blockade in AE17M Mouse Mesothelioma Tumors. Toxins, 2018, 10, 470.	1.5	23
6403	Harnessing immune checkpoints for cancer therapy. Immunotherapy, 2018, 10, 1265-1284.	1.0	9
6404	Tumor Immunology, Immunotherapy and Its Application to Head and Neck Squamous Cell Carcinoma (HNSCC). , 2018, , 341-355.		2
6405	Antibodies to Costimulatory Receptor 4-1BB Enhance Anti-tumor Immunity via T Regulatory Cell Depletion and Promotion of CD8 ⁺ T Cell Effector Function. Immunity, 2018, 49, 958-970.e7.	6.6	114
6406	The Central Role of Inflammation Associated with Checkpoint Inhibitor Treatments. Journal of Immunology Research, 2018, 2018, 1-10.	0.9	26
6407	Updates on immunotherapy for colorectal cancer. Journal of Gastrointestinal Oncology, 2018, 9, 160-169.	0.6	126
6409	Tumor immunoevasion via acidosis-dependent induction of regulatory tumor-associated macrophages. Nature Immunology, 2018, 19, 1319-1329.	7.0	274
6410	Current Landscape of Immunotherapy in the Treatment of Solid Tumours, with Future Opportunities and Challenges. Current Oncology, 2018, 25, 373-384.	0.9	109
6411	⁶⁸ Ga-DOTA-GCNle-CycMSH _{hex} targets the melanocortin-1 receptor for melanoma imaging. Science Translational Medicine, 2018, 10, .	5.8	30

#	ARTICLE	IF	CITATIONS
6412	Extracellular microvesicle microRNAs as predictive biomarkers for targeted therapy in metastatic cutaneous malignant melanoma. <i>PLoS ONE</i> , 2018, 13, e0206942.	1.1	35
6413	Nation-wide survey of advanced non-melanoma skin cancers treated at dermatology departments in Japan. <i>Journal of Dermatological Science</i> , 2018, 92, 230-236.	1.0	11
6414	Inhibition of mTORC2/RICTOR Impairs Melanoma Hepatic Metastasis. <i>Neoplasia</i> , 2018, 20, 1198-1208.	2.3	21
6415	T-cell functionality testing is highly relevant to developing novel immuno-tracers monitoring T cells in the context of immunotherapies and revealed CD7 as an attractive target. <i>Theranostics</i> , 2018, 8, 6070-6087.	4.6	28
6416	A severe case of refractory esophageal stenosis induced by nivolumab and responding to tocilizumab therapy. , 2018, 6, 156.		58
6417	Cytokines, Chemokines, and Other Biomarkers of Response for Checkpoint Inhibitor Therapy in Skin Cancer. <i>Frontiers in Medicine</i> , 2018, 5, 351.	1.2	67
6418	Anticancer Therapies. , 0, , 604-616.		0
6419	The Future of Radiation Oncology in Soft Tissue Sarcoma. <i>Cancer Control</i> , 2018, 25, 107327481881550.	0.7	6
6420	Current Options and Future Directions in Immune Therapy for Glioblastoma. <i>Frontiers in Oncology</i> , 2018, 8, 578.	1.3	21
6421	Isolated adrenocorticotrophic hormone deficiency potentially induced by nivolumab following pseudoâ€ progression in clear cell renal cell carcinoma: A case report. <i>Molecular and Clinical Oncology</i> , 2018, 10, 304-308.	0.4	10
6422	A phase II trial of recombinant MAGE-A3 protein with immunostimulant AS15 in combination with high-dose Interleukin-2 (HDIL2) induction therapy in metastatic melanoma. <i>BMC Cancer</i> , 2018, 18, 1274.	1.1	31
6423	Progress of immune checkpoint therapy in the clinic (Review). <i>Oncology Reports</i> , 2019, 41, 3-14.	1.2	24
6424	Updates on Immunotherapy for the Treatment of Skin Cancer. <i>Current Dermatology Reports</i> , 2018, 7, 311-320.	1.1	2
6425	Orchestration of immune checkpoints in tumor immune contexture and their prognostic significance in esophageal squamous cell carcinoma. <i>Cancer Management and Research</i> , 2018, Volume 10, 6457-6468.	0.9	23
6426	The Era of Immune Checkpoint Therapy: From Cancer to Viral Infectionâ€ A Mini Comment on the 2018 Medicine Nobel Prize. <i>Virologica Sinica</i> , 2018, 33, 467-471.	1.2	9
6427	CCL1 is a major regulatory T cell attracting factor in human breast cancer. <i>BMC Cancer</i> , 2018, 18, 1278.	1.1	52
6428	Recent Development and Clinical Application of Cancer Vaccine: Targeting Neoantigens. <i>Journal of Immunology Research</i> , 2018, 2018, 1-9.	0.9	75
6429	Strategies of Combination Drug Delivery for Immune Checkpoint Blockades. <i>Advanced Healthcare Materials</i> , 2019, 8, e1801099.	3.9	32

#	ARTICLE	IF	CITATIONS
6430	Overview of Basic Immunology and Translational Relevance for Clinical Investigators. <i>Advances in Experimental Medicine and Biology</i> , 2018, 995, 1-41.	0.8	6
6431	Immunotherapy for Melanoma. <i>Advances in Experimental Medicine and Biology</i> , 2018, 995, 43-63.	0.8	25
6432	Immunotherapy in Lung Cancer: A New Age in Cancer Treatment. <i>Advances in Experimental Medicine and Biology</i> , 2018, 995, 65-95.	0.8	49
6433	Skin Reactions to Immune Checkpoint Inhibitors. <i>Advances in Experimental Medicine and Biology</i> , 2018, 995, 117-129.	0.8	15
6434	Immune-Related Adverse Events: Pneumonitis. <i>Advances in Experimental Medicine and Biology</i> , 2018, 995, 131-149.	0.8	19
6435	Immune checkpoint inhibitors in cancer therapy. <i>Journal of Biomedical Research</i> , 2018, 32, 317.	0.7	101
6436	Immune checkpoint inhibitors: recent progress and potential biomarkers. <i>Experimental and Molecular Medicine</i> , 2018, 50, 1-11.	3.2	1,410
6437	CTLA-4 and PD-1 Control of T-Cell Motility and Migration: Implications for Tumor Immunotherapy. <i>Frontiers in Immunology</i> , 2018, 9, 2737.	2.2	123
6438	Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials. <i>Journal of Clinical Medicine</i> , 2018, 7, 542.	1.0	64
6440	Immune checkpoint inhibitors in the onset of myasthenia gravis with hypercalcaemia. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 1421-1427.	1.7	31
6441	S5, a Withanolide Isolated from <i>Physalis Pubescens</i> L., Induces G2/M Cell Cycle Arrest via the EGFR/P38 Pathway in Human Melanoma A375 Cells. <i>Molecules</i> , 2018, 23, 3175.	1.7	15
6442	Drug-induced uveitis. <i>Current Opinion in Ophthalmology</i> , 2018, 29, 588-603.	1.3	59
6443	Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine. <i>Genome Medicine</i> , 2018, 10, 93.	3.6	121
6444	Combining PARP inhibition, radiation, and immunotherapy: A possible strategy to improve the treatment of cancer?. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3793.	1.8	54
6445	Nanoparticle-Mediated Remodeling of the Tumor Microenvironment to Enhance Immunotherapy. <i>ACS Nano</i> , 2018, 12, 11740-11755.	7.3	176
6446	Human preprocalcitonin self-antigen generates TAP-dependent and -independent epitopes triggering optimised T-cell responses toward immune-escaped tumours. <i>Nature Communications</i> , 2018, 9, 5097.	5.8	21
6448	Development of Immunity-Inducing Systems Using pH-Responsive Polysaccharides and Liposomes. <i>Kobunshi Ronbunshu</i> , 2018, 75, 433-443.	0.2	0
6449	Targeting tumor cells with antibodies enhances anti-tumor immunity. <i>Biophysics Reports</i> , 2018, 4, 243-253.	0.2	17

#	ARTICLE	IF	CITATIONS
6450	The Fast Real-time Assessment of Combination Therapies in Immuno-ONcology (FRACTION) program: innovative, high-throughput clinical screening of immunotherapies. <i>European Journal of Cancer</i> , 2018, 103, 259-266.	1.3	13
6451	Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma. <i>Journal of Translational Medicine</i> , 2018, 16, 184.	1.8	36
6452	Anti-glucocorticoid-induced Tumor Necrosis Factor-Related Protein (GITR) Therapy Overcomes Radiation-Induced Treg Immunosuppression and Drives Abscopal Effects. <i>Frontiers in Immunology</i> , 2018, 9, 2170.	2.2	48
6453	Clinical Outcomes After Pulmonary Metastasectomy for Melanoma: A Population-Based Study. <i>Annals of Thoracic Surgery</i> , 2018, 106, 1675-1681.	0.7	15
6454	Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer. <i>Chest</i> , 2018, 154, 1416-1423.	0.4	230
6455	A comparison of skin cancer screening and treatment costs at a Massachusetts cancer center, 2008 versus 2013. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 921-928.	0.6	2
6456	Genomic Characterization of Six Virus-Associated Cancers Identifies Changes in the Tumor Immune Microenvironment and Altered Genetic Programs. <i>Cancer Research</i> , 2018, 78, 6413-6423.	0.4	33
6458	Cancer Vaccine Immunotherapy with RNA-Loaded Liposomes. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2890.	1.8	44
6459	Health-related quality of life in cancer patients treated with PD-(L)1 inhibitors: a systematic review. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 1231-1239.	1.1	18
6460	Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis. , 2018, 6, 95.		146
6461	New opportunities for nanoparticles in cancer immunotherapy. <i>Biomaterials Research</i> , 2018, 22, 24.	3.2	137
6462	Defective DNA repair in hereditary ovarian cancers: Implications for therapy. <i>American Journal of Health-System Pharmacy</i> , 2018, 75, 1697-1707.	0.5	4
6463	SRS in Combination With Ipilimumab: A Promising New Dimension for Treating Melanoma Brain Metastases. <i>Technology in Cancer Research and Treatment</i> , 2018, 17, 153303381879879.	0.8	16
6464	Immunotherapy for melanoma. <i>Onkologe</i> , 2018, 24, 99-103.	0.7	1
6465	Thyroid disorders induced by checkpoint inhibitors. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2018, 19, 325-333.	2.6	87
6466	A High-Throughput Immune-Oncology Screen Identifies EGFR Inhibitors as Potent Enhancers of Antigen-Specific Cytotoxic T-lymphocyte Tumor Cell Killing. <i>Cancer Immunology Research</i> , 2018, 6, 1511-1523.	1.6	59
6467	Rapid complete remission of metastatic melanoma after first-line treatment with nivolumab plus tumor-infiltrating lymphocytes. <i>Immunotherapy</i> , 2018, 10, 1133-1136.	1.0	4
6468	Recent Progresses in Phototherapy Synergized Cancer Immunotherapy. <i>Advanced Functional Materials</i> , 2018, 28, 1804688.	7.8	234

#	ARTICLE	IF	CITATIONS
6469	The Current Status and Future Prospects of Oncolytic Viruses in Clinical Trials against Melanoma, Glioma, Pancreatic, and Breast Cancers. <i>Cancers</i> , 2018, 10, 356.	1.7	123
6470	The application of nanotechnology in immune checkpoint blockade for cancer treatment. <i>Journal of Controlled Release</i> , 2018, 290, 28-45.	4.8	67
6471	Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy. <i>Trends in Biochemical Sciences</i> , 2018, 43, 1014-1032.	3.7	151
6472	The Kinase Activity of Hematopoietic Progenitor Kinase 1 Is Essential for the Regulation of T Cell Function. <i>Cell Reports</i> , 2018, 25, 80-94.	2.9	60
6473	Predictive and on-treatment monitoring biomarkers in advanced melanoma: Moving toward personalized medicine. <i>Cancer Treatment Reviews</i> , 2018, 71, 8-18.	3.4	58
6474	Cancer immunologists scoop medicine Nobel prize. <i>Nature</i> , 2018, 562, 20-21.	13.7	121
6475	Overcoming tumor hypoxia as a barrier to radiotherapy, chemotherapy and immunotherapy in cancer treatment. <i>International Journal of Nanomedicine</i> , 2018, Volume 13, 6049-6058.	3.3	404
6476	Prognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences. <i>Frontiers in Pharmacology</i> , 2018, 9, 1050.	1.6	48
6477	A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. <i>Cell</i> , 2018, 175, 313-326.	13.5	985
6478	Vitiligo after immune checkpoint inhibitor therapy in a woman with metastatic melanoma. <i>Journal of Cancer Research and Practice</i> , 2018, 5, 161-164.	0.2	5
6479	T cell receptor richness in peripheral blood increases after cetuximab therapy and correlates with therapeutic response. <i>Oncotmunology</i> , 2018, 7, e1494112.	2.1	29
6480	Somatic Mutations and Immune Alternation in Rectal Cancer Following Neoadjuvant Chemoradiotherapy. <i>Cancer Immunology Research</i> , 2018, 6, 1401-1416.	1.6	28
6481	Financial toxicity and implications for cancer care in the era of molecular and immune therapies. <i>Annals of Translational Medicine</i> , 2018, 6, 166-166.	0.7	126
6482	Key questions about the checkpoint blockade-are microRNAs an answer?. <i>Cancer Biology and Medicine</i> , 2018, 15, 103.	1.4	36
6483	Long-term survival of patients after ipilimumab and hypofractionated brain radiotherapy for brain metastases of malignant melanoma: sequence matters. <i>Strahlentherapie Und Onkologie</i> , 2018, 194, 1144-1151.	1.0	29
6485	In situ administration of cytokine combinations induces tumor regression in mice. <i>EBioMedicine</i> , 2018, 37, 38-46.	2.7	10
6486	Expression of the Immune Checkpoint Modulator OX40 in Acute Lymphoblastic Leukemia Is Associated with BCR-ABL Positivity. <i>Neoplasia</i> , 2018, 20, 1150-1160.	2.3	14
6487	Talimogene Laherparepvec (TVEC) for the Treatment of Advanced Melanoma: A Single-Institution Experience. <i>Annals of Surgical Oncology</i> , 2018, 25, 3960-3965.	0.7	67

#	ARTICLE	IF	CITATIONS
6488	On the Road to Immunotherapy—Prospects for Treating Head and Neck Cancers With Checkpoint Inhibitor Antibodies. <i>Frontiers in Immunology</i> , 2018, 9, 2182.	2.2	15
6489	Checkpoint Blockade Reverses Anergy in IL-13R ^{hi} 2 Humanized scFv-Based CAR T Cells to Treat Murine and Canine Gliomas. <i>Molecular Therapy - Oncolytics</i> , 2018, 11, 20-38.	2.0	123
6490	Regulatory T cells in the treatment of disease. <i>Nature Reviews Drug Discovery</i> , 2018, 17, 823-844.	21.5	224
6491	Stereotactic Radiosurgery and Immune Checkpoint Inhibitors in the Management of Brain Metastases. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3054.	1.8	44
6492	Î³Î± T cell-mediated individualized immunotherapy for hepatocellular carcinoma considering clinicopathological characteristics and immunosuppressive factors. <i>Oncology Letters</i> , 2018, 15, 5433-5442.	0.8	4
6493	Potential function of CTLA-4 in the tumorigenic capacity of melanoma stem cells. <i>Oncology Letters</i> , 2018, 16, 6163-6170.	0.8	16
6494	Clinical significance of programmed death 1 ligand-1 (CD274/PD-L1) and intra-tumoral CD8+ T-cell infiltration in stage II–III colorectal cancer. <i>Scientific Reports</i> , 2018, 8, 15658.	1.6	49
6495	Liver Toxicity with Cancer Checkpoint Inhibitor Therapy. <i>Seminars in Liver Disease</i> , 2018, 38, 366-378.	1.8	31
6496	Neoadjuvant ipilimumab (3Âmg/kg or 10Âmg/kg) and high dose IFN-Î±2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire. , 2018, 6, 112.		50
6497	Checkpoint Inhibition: Will Combination with Radiotherapy and Nanoparticle-Mediated Delivery Improve Efficacy?. <i>Medicines (Basel, Switzerland)</i> , 2018, 5, 114.	0.7	17
6498	Recent advances in immunotherapies: from infection and autoimmunity, to cancer, and back again. <i>Genome Medicine</i> , 2018, 10, 79.	3.6	36
6499	Cardiac morbidity in HIV infection is associated with checkpoint inhibitor LAG-3 on CD4 T cells. <i>PLoS ONE</i> , 2018, 13, e0206256.	1.1	10
6500	Current State of Immunotherapy for HCC—Supporting Data and Toxicity Management. <i>Current Hepatology Reports</i> , 2018, 17, 434-443.	0.4	2
6501	Toxicity of radiation and immunotherapy combinations. <i>Advances in Radiation Oncology</i> , 2018, 3, 506-511.	0.6	42
6502	Role of the immunosuppressive microenvironment in immunotherapy. <i>Advances in Radiation Oncology</i> , 2018, 3, 520-526.	0.6	107
6503	Tumor-immune profiling of murine syngeneic tumor models as a framework to guide mechanistic studies and predict therapy response in distinct tumor microenvironments. <i>PLoS ONE</i> , 2018, 13, e0206223.	1.1	149
6504	Retrospective Side Effect Profiling of the Metastatic Melanoma Combination Therapy Ipilimumab-Nivolumab Using Adverse Event Data. <i>Diagnostics</i> , 2018, 8, 76.	1.3	23
6505	2018 Nobel Prize in physiology or medicine. <i>Clinical and Translational Immunology</i> , 2018, 7, e1041.	1.7	41

#	ARTICLE	IF	CITATIONS
6506	Durvalumab in NSCLC: latest evidence and clinical potential. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591880415.	1.4	22
6507	Evidence of response to pembrolizumab in a patient with Lynch syndrome-related metastatic colon cancer. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 7295-7300.	1.0	6
6508	Immune Checkpoints as Therapeutic Targets in Autoimmunity. <i>Frontiers in Immunology</i> , 2018, 9, 2306.	2.2	96
6509	Aging, immune senescence, and immunotherapy: A comprehensive review. <i>Seminars in Oncology</i> , 2018, 45, 187-200.	0.8	60
6510	How do immune checkpoint-targeted antibodies work? The need for improved pharmacokinetic evaluation in early phase studies. <i>Annals of Oncology</i> , 2018, 29, 2157-2160.	0.6	2
6511	Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment. , 2018, 6, 106.		138
6513	Novel Immunotherapies for T Cell Lymphoma and Leukemia. <i>Current Hematologic Malignancy Reports</i> , 2018, 13, 494-506.	1.2	21
6515	Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab. <i>Cancer Science</i> , 2018, 109, 3583-3590.	1.7	118
6516	Bullous pemphigoid associated with ipilimumab therapy for advanced metastatic melanoma. <i>JRSM Open</i> , 2018, 9, 205427041879302.	0.2	22
6517	Immune Checkpoint Inhibitors for the Treatment of Central Nervous System (CNS) Metastatic Disease. <i>Frontiers in Oncology</i> , 2018, 8, 414.	1.3	65
6518	Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy. <i>British Journal of Cancer</i> , 2018, 119, 950-960.	2.9	133
6519	An approved in vitro approach to preclinical safety and efficacy evaluation of engineered T cell receptor anti-CD3 bispecific (ImmTAC) molecules. <i>PLoS ONE</i> , 2018, 13, e0205491.	1.1	53
6520	Mucous Membrane Pemphigoid, Bullous Pemphigoid, and Anti-programmed Death-1/ Programmed Death-Ligand 1: A Case Report of an Elderly Woman With Mucous Membrane Pemphigoid Developing After Pembrolizumab Therapy for Metastatic Melanoma and Review of the Literature. <i>Frontiers in Medicine</i> , 2018, 5, 268.	1.2	49
6521	Immunodiagnosics and Immunotherapy Possibilities for Prostate Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1096, 185-194.	0.8	6
6522	Drug-Induced Interstitial Lung Disease: A Systematic Review. <i>Journal of Clinical Medicine</i> , 2018, 7, 356.	1.0	215
6524	Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time. <i>Frontiers in Immunology</i> , 2018, 9, 2265.	2.2	107
6525	From Cancer Immunoediting to New Strategies in Cancer Immunotherapy: The Roles of Immune Cells and Mechanics in Oncology. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1092, 113-138.	0.8	19
6526	Efficacy and safety data for checkpoint inhibitors in advanced melanoma under real-life conditions: A monocentric study conducted in Nice from 2010 to 2016. <i>Annales De Dermatologie Et De Venereologie</i> , 2018, 145, 649-658.	0.5	3

#	ARTICLE	IF	CITATIONS
6527	The 2018 Nobel Prize in Physiology or Medicine: An exemplar of bench to bedside in immunology. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 1752-1753.	1.5	24
6528	Translational control of tumor immune escape via the eIF4F-STAT1-PD-L1 axis in melanoma. <i>Nature Medicine</i> , 2018, 24, 1877-1886.	15.2	180
6529	Role of Regulatory T Cells in Tumor-Bearing Mice Treated with Allo-Hematopoietic Stem Cell Transplantation Plus Thymus Transplantation. <i>Journal of Immunology Research</i> , 2018, 2018, 1-7.	0.9	3
6530	Immune regulation of metastasis: mechanistic insights and therapeutic opportunities. <i>DMM Disease Models and Mechanisms</i> , 2018, 11, .	1.2	102
6531	Duration of adjuvant immunotherapy-“biologic, clinical and economic considerations. <i>Medical Oncology</i> , 2018, 35, 160.	1.2	9
6532	Oncolytic Viruses for Canine Cancer Treatment. <i>Cancers</i> , 2018, 10, 404.	1.7	31
6533	Nobel goes to immune checkpoint-“Innovative cancer treatment by immunotherapy. <i>Science China Life Sciences</i> , 2018, 61, 1445-1450.	2.3	3
6534	The Impact of Intratumoral and Gastrointestinal Microbiota on Systemic Cancer Therapy. <i>Trends in Immunology</i> , 2018, 39, 900-920.	2.9	56
6535	Liver toxicity in the era of immune checkpoint inhibitors: A practical approach. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 132, 125-129.	2.0	19
6536	T Cell Senescence and Tumor Immunotherapy. , 2018, , 1-24.		0
6537	Cancer immunotherapy-associated hypophysitis. <i>Seminars in Oncology</i> , 2018, 45, 181-186.	0.8	47
6538	Immune Checkpoint Inhibitor Therapy in Breast Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 1259-1268.	2.3	32
6539	LAG-3 inhibits the activation of CD4+ T cells that recognize stable pMHCII through its conformation-dependent recognition of pMHCII. <i>Nature Immunology</i> , 2018, 19, 1415-1426.	7.0	178
6540	Designing cancer immunotherapy trials with random treatment time-lag effect. <i>Statistics in Medicine</i> , 2018, 37, 4589-4609.	0.8	18
6541	Accurate quantification of T-cells expressing PD-1 in patients on anti-PD-1 immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1845-1851.	2.0	28
6542	Adjuvant and Neoadjuvant Therapy, Treatment for Advanced Disease, and Genetic Considerations for Adrenocortical Carcinoma: An Update from the SSO Endocrine and Head and Neck Disease Site Working Group. <i>Annals of Surgical Oncology</i> , 2018, 25, 3453-3459.	0.7	12
6543	Immunoengineering through cancer vaccines -“ A personalized and multi-step vaccine approach towards precise cancer immunity. <i>Journal of Controlled Release</i> , 2018, 289, 125-145.	4.8	31
6544	8 Surgical Implications of Systemic Therapy for Skin Cancer. , 2018, , .		0

#	ARTICLE	IF	CITATIONS
6545	12 High-Risk Cutaneous Malignancies. , 2018, , .		0
6546	Therapeutically Active RIG-I Agonist Induces Immunogenic Tumor Cell Killing in Breast Cancers. <i>Cancer Research</i> , 2018, 78, 6183-6195.	0.4	130
6547	Early cost-effectiveness of tumor infiltrating lymphocytes (TIL) for second line treatment in advanced melanoma: a model-based economic evaluation. <i>BMC Cancer</i> , 2018, 18, 895.	1.1	17
6548	Advances in oncological treatment: limitations of RECIST 1.1 criteria. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 62, 129-139.	0.4	29
6549	Sequential treatment approaches in the management of <i>BRAF</i> wild-type advanced melanoma: a cost-effectiveness analysis. <i>Immunotherapy</i> , 2018, 10, 1241-1252.	1.0	19
6550	The characteristics of nivolumab-induced colitis: an evaluation of three cases and a literature review. <i>BMC Gastroenterology</i> , 2018, 18, 135.	0.8	44
6551	PD-1 Expression on Mycobacterium tuberculosis-Specific CD4 T Cells Is Associated With Bacterial Load in Human Tuberculosis. <i>Frontiers in Immunology</i> , 2018, 9, 1995.	2.2	68
6552	Management of metastatic melanoma: improved survival in a national cohort following the approvals of checkpoint blockade immunotherapies and targeted therapies. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1833-1844.	2.0	52
6553	An RNA toolbox for cancer immunotherapy. <i>Nature Reviews Drug Discovery</i> , 2018, 17, 751-767.	21.5	171
6554	Management of challenging immune-related gastrointestinal adverse events associated with immune checkpoint inhibitors. <i>Future Oncology</i> , 2018, 14, 3187-3198.	1.1	9
6555	Benzylamine and Thenylamine Derived Drugs Induce Apoptosis and Reduce Proliferation, Migration and Metastasis Formation in Melanoma Cells. <i>Frontiers in Oncology</i> , 2018, 8, 328.	1.3	12
6556	Fecal microbiota transplantation: a promising strategy in preventing the progression of non-alcoholic steatohepatitis and improving the anti-cancer immune response. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 1061-1071.	1.4	27
6557	Selecting immuno-oncology-based drug combinations what should we be considering?. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 971-985.	1.3	5
6558	Trial watch: Peptide-based vaccines in anticancer therapy. <i>Oncolimmunology</i> , 2018, 7, e1511506.	2.1	121
6559	Thyroid Cancer Trials. , 2018, , 339-355.		0
6561	Tumor-specific CD8-positive T cell-mediated antitumor immunity is implicated in the antitumor effect of local hyperthermia. <i>International Journal of Hyperthermia</i> , 2018, 35, 226-231.	1.1	10
6562	UBE2N Promotes Melanoma Growth via MEK/FRA1/SOX10 Signaling. <i>Cancer Research</i> , 2018, 78, 6462-6472.	0.4	56
6563	Roles of the RANK-RANK axis in antitumour immunity implications for therapy. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 676-693.	12.5	77

#	ARTICLE	IF	CITATIONS
6564	A phase I trial of oncolytic adenovirus ICOVIR-5 administered intravenously to melanoma patients. <i>Human Gene Therapy Clinical Development</i> , 2018, , .	3.2	3
6565	A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab. , 2018, 6, 90.		32
6566	Quick efficacy seeking trial (QuEST1): a novel combination immunotherapy study designed for rapid clinical signal assessment metastatic castration-resistant prostate cancer. , 2018, 6, 91.		51
6567	Autophagosome-based strategy to monitor apparent tumor-specific CD8 T cells in patients with prostate cancer. <i>Oncolmmunology</i> , 2018, 7, e1466766.	2.1	3
6568	Stromal Fibroblasts Mediate Anti- α PD-1 Resistance via MMP-9 and Dictate TGF β 2 Inhibitor Sequencing in Melanoma. <i>Cancer Immunology Research</i> , 2018, 6, 1459-1471.	1.6	81
6569	Chemotherapy Combines Effectively with Anti- α PD-L1 Treatment and Can Augment Antitumor Responses. <i>Journal of Immunology</i> , 2018, 201, 2273-2286.	0.4	38
6570	Combined radiotherapy with nivolumab for extracranial metastatic malignant melanoma. <i>Japanese Journal of Radiology</i> , 2018, 36, 712-718.	1.0	3
6571	Melanoma. <i>Lancet, The</i> , 2018, 392, 971-984.	6.3	1,016
6572	Roles of intestinal microbiota in response to cancer immunotherapy. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2018, 37, 2235-2240.	1.3	13
6573	Recent advances in applying nanotechnologies for cancer immunotherapy. <i>Journal of Controlled Release</i> , 2018, 288, 239-263.	4.8	60
6574	Antigen-specificity and DTIC before peptide-vaccination differently shape immune-checkpoint expression pattern, anti-tumor functionality and TCR repertoire in melanoma patients. <i>Oncolmmunology</i> , 2018, 7, e1465163.	2.1	6
6575	Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer. <i>Oncolmmunology</i> , 2018, 7, e1500107.	2.1	66
6576	Somatic inactivating PTPRJ mutations and dysregulated pathways identified in canine malignant melanoma by integrated comparative genomic analysis. <i>PLoS Genetics</i> , 2018, 14, e1007589.	1.5	56
6577	Current and Future Treatment of Hepatocellular Carcinoma: An Updated Comprehensive Review. <i>Journal of Clinical and Translational Hepatology</i> , 2018, 6, 1-10.	0.7	218
6578	Costs associated with adverse events for systemic therapies in metastatic melanoma. <i>Journal of Comparative Effectiveness Research</i> , 2018, 7, 867-879.	0.6	1
6579	Immune-Related Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitors. <i>Current Rheumatology Reports</i> , 2018, 20, 65.	2.1	39
6580	An open-label, multiple ascending dose study of the anti-CTLA-4 antibody ipilimumab in viremic HIV patients. <i>PLoS ONE</i> , 2018, 13, e0198158.	1.1	20
6581	Design and conduct of early clinical studies of immunotherapy agent combinations: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies. <i>Annals of Oncology</i> , 2018, 29, 2175-2182.	0.6	20

#	ARTICLE	IF	CITATIONS
6582	Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells. <i>Frontiers in Immunology</i> , 2018, 9, 2041.	2.2	93
6583	Cutaneous Melanoma: An Updated Sign Guideline. <i>Journal of the Royal College of Physicians of Edinburgh, The</i> , 2017, 47, 214-217.	0.2	5
6584	Expert opinions on adrenal complications in immunotherapy. <i>Annales D'Endocrinologie</i> , 2018, 79, 539-544.	0.6	13
6585	Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options. <i>Frontiers in Immunology</i> , 2018, 9, 1878.	2.2	127
6586	A Practical Approach to the Use of Conventional Synthetic, Biologic and Targeted Synthetic Disease Modifying Anti-Rheumatic Drugs for the Treatment of Inflammatory Arthritis in Patients with a History of Malignancy. <i>Current Rheumatology Reports</i> , 2018, 20, 64.	2.1	6
6587	Immunological-based approaches for cancer therapy. <i>Clinics</i> , 2018, 73, e429s.	0.6	7
6588	Impact of PD-1, transforming growth factor- β expression and tumor-infiltrating CD8 ⁺ T cells on clinical outcome of patients with advanced thymic epithelial tumors. <i>Thoracic Cancer</i> , 2018, 9, 1341-1353.	0.8	20
6589	Neurologic immune-related adverse events associated with adjuvant ipilimumab: report of two cases. , 2018, 6, 83.		45
6591	Oncolytic Viruses on Drugs: Achieving Higher Therapeutic Efficacy. <i>ACS Infectious Diseases</i> , 2018, 4, 1448-1467.	1.8	27
6592	Immunotherapy in melanoma. <i>Immunotherapy</i> , 2018, 10, 987-998.	1.0	22
6593	Management of Locally and Regionally Recurrent Melanoma. , 2018, , 1-20.		0
6594	Stromal Cells in the Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1060, 99-114.	0.8	208
6596	Strategies for Predicting Response to Checkpoint Inhibitors. <i>Current Hematologic Malignancy Reports</i> , 2018, 13, 383-395.	1.2	23
6597	Multidisciplinary treatment strategies in high-risk resectable melanoma: Role of adjuvant and neoadjuvant therapy. <i>Cancer Treatment Reviews</i> , 2018, 70, 144-153.	3.4	27
6598	A comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity. <i>Journal of Autoimmunity</i> , 2018, 95, 77-99.	3.0	141
6599	Rheumatic immune-related adverse events from cancer immunotherapy. <i>Nature Reviews Rheumatology</i> , 2018, 14, 569-579.	3.5	162
6600	Insights into CD47/SIRP α axis-targeting tumor immunotherapy. <i>Antibody Therapeutics</i> , 2018, 1, 37-42.	1.2	24
6601	Emerging Role of Vedolizumab in Managing Refractory Immune Checkpoint Inhibitor-Induced Enteritis. <i>ACG Case Reports Journal</i> , 2018, 5, e17.	0.2	30

#	ARTICLE	IF	CITATIONS
6602	Epigenetics in Melanoma Development and Drug Resistance. , 2018, , .		1
6603	Immune Checkpoint Blockade and Immune Monitoring. , 0, , .		1
6604	Role of Anti-PD-1 Antibodies in Advanced Melanoma: The Era of Immunotherapy. Cureus, 2018, 10, e3700.	0.2	25
6605	Effectiveness and safety of PD-1/PD-L1 or CTLA4 inhibitors combined with chemotherapy as a first-line treatment for lung cancer: A meta-analysis. Journal of Thoracic Disease, 2018, 10, 6636-6652.	0.6	33
6606	LncRNAs as Biomarkers for Melanoma. , 2018, , .		1
6607	Clinical Trial Design in Immuno-Oncology. , 2018, , 151-173.		0
6608	Evolving Roles for Targeting CTLA-4 in Cancer Immunotherapy. Cellular Physiology and Biochemistry, 2018, 47, 721-734.	1.1	131
6609	Personalized Medicine. , 2018, , 659-673.		0
6610	Liquid Biopsy: From Basic Research to Clinical Practice. Advances in Clinical Chemistry, 2018, 83, 73-119.	1.8	49
6611	Radiotherapy and CD40 Activation Separately Augment Immunity to Checkpoint Blockade in Cancer. Cancer Research, 2018, 78, 4282-4291.	0.4	83
6612	A comprehensive analysis of clinical trials including both immunotherapy and radiation therapy. Journal of Radiation Oncology, 2018, 7, 223-232.	0.7	0
6613	Nivolumab versus ipilimumab in the treatment of advanced melanoma: a critical appraisal. British Journal of Dermatology, 2018, 179, 296-300.	1.4	39
6614	Tâ€cell tracking using Cerenkov and radioluminescence imaging. Journal of Biophotonics, 2018, 11, e201800093.	1.1	13
6615	Budding and tumorâ€infiltrating lymphocytes â€ combination of both parameters predicts survival in colorectal cancer and leads to new prognostic subgroups. Human Pathology, 2018, 79, 160-167.	1.1	32
6616	Nano delivery systems and cancer immunotherapy. Journal of Pharmaceutical Investigation, 2018, 48, 527-539.	2.7	63
6617	Mapping the HLA Ligandome of Colorectal Cancer Reveals an Imprint of Malignant Cell Transformation. Cancer Research, 2018, 78, 4627-4641.	0.4	56
6618	Primary amelanotic malignant melanoma of the male urethra with inguinal lymph node metastasis successfully controlled by nivolumab: A case report. Urology Case Reports, 2018, 18, 54-56.	0.1	11
6619	Immune Checkpoint Inhibitor Toxicity Review for the Palliative Care Clinician. Journal of Pain and Symptom Management, 2018, 56, 460-472.	0.6	14

#	ARTICLE	IF	CITATIONS
6620	Advances in the systemic treatment of melanoma brain metastases. <i>Annals of Oncology</i> , 2018, 29, 1509-1520.	0.6	31
6621	Sarcoidosis-Like Reactions Induced by Checkpoint Inhibitors. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1076-1082.	0.5	143
6622	<scp>BRAF</scp> and <scp>MEK</scp> inhibitor therapy eliminates Nestin-expressing melanoma cells in human tumors. <i>Pigment Cell and Melanoma Research</i> , 2018, 31, 708-719.	1.5	9
6623	An Update Regarding the Molecular Genetics of Melanocytic Neoplasms and the Current Applications of Molecular Genetic Technologies in Their Diagnosis and Treatment. <i>Clinics in Laboratory Medicine</i> , 2018, 38, 385-399.	0.7	1
6624	Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study. <i>Lancet Respiratory Medicine</i> , 2018, 6, 451-460.	5.2	185
6625	Immune Checkpoint Inhibitor-Associated Myocarditis. <i>Oncologist</i> , 2018, 23, 879-886.	1.9	207
6626	Immunotherapie – Die neue Ära in der Onkologie. <i>Laryngo- Rhino- Otologie</i> , 2018, 97, S3-S47.	0.2	1
6627	Regulation of innate and adaptive antitumor immunity by IAP antagonists. <i>Immunotherapy</i> , 2018, 10, 787-796.	1.0	51
6628	TP53 Mutation as Potential Negative Predictor for Response of Anti-CTLA-4 Therapy in Metastatic Melanoma. <i>EBioMedicine</i> , 2018, 32, 119-124.	2.7	61
6629	Melanoma antigen family A4 protein produced by transgenic silkworms induces antitumor immune responses. <i>Experimental and Therapeutic Medicine</i> , 2018, 15, 2512-2518.	0.8	6
6630	Combining ADCs with Immuno-Oncology Agents. <i>Cancer Drug Discovery and Development</i> , 2018, , 11-44.	0.2	5
6631	Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome. <i>Clinical Cancer Research</i> , 2018, 24, 4416-4428.	3.2	89
6632	Immune checkpoints PVR and PVRL2 are prognostic markers in AML and their blockade represents a new therapeutic option. <i>Oncogene</i> , 2018, 37, 5269-5280.	2.6	65
6636	Vemurafenib in BRAF-mutant metastatic melanoma patients in real-world clinical practice: prognostic factors associated with clinical outcomes. <i>Melanoma Research</i> , 2018, 28, 326-332.	0.6	8
6637	The Immune Landscape of Non-Small-Cell Lung Cancer. Utility of Cytologic and Histologic Samples Obtained through Minimally Invasive Pulmonary Procedures. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 24-38.	2.5	14
6638	Low expression of CD40L in tumor-free lymph node of oral cavity cancer related with poor prognosis. <i>International Journal of Clinical Oncology</i> , 2018, 23, 851-859.	1.0	6
6639	Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis. <i>Lancet Oncology</i> , 2018, 19, 737-746.	5.1	622
6640	Initial phase I/IIa trial results of an autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine in patients with solid tumors. <i>Vaccine</i> , 2018, 36, 3247-3253.	1.7	18

#	ARTICLE	IF	CITATIONS
6641	Selective Cell Capture and Release Using Antibody-Immobilized Polymer-Grafted Surface. Kobunshi Ronbunshu, 2018, 75, 155-163.	0.2	2
6642	A2A Adenosine Receptor Gene Deletion or Synthetic A2A Antagonist Liberate Tumor-Reactive CD8+ T Cells from Tumor-Induced Immunosuppression. Journal of Immunology, 2018, 201, 782-791.	0.4	101
6643	Cutaneous melanoma in adolescents and young adults. Pediatric Blood and Cancer, 2018, 65, e27292.	0.8	24
6644	Safety of combining thoracic radiation therapy with concurrent versus sequential immune checkpoint inhibition. Advances in Radiation Oncology, 2018, 3, 391-398.	0.6	33
6645	A Population-based Study of Survival Impact of New Targeted and Immune-based Therapies for Metastatic or Unresectable Melanoma. Clinical Oncology, 2018, 30, 609-617.	0.6	16
6646	Ipilimumab cystic hypophysitis mimicking metastatic melanoma. Radiology Case Reports, 2018, 13, 740-742.	0.2	6
6647	Risk of Immune-Related Pancreatitis in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors: Systematic Assessment with Meta-Analysis. Journal of Immunology Research, 2018, 2018, 1-9.	0.9	40
6648	Polysaccharides from Chinese Herbal <i>Lycium barbarum</i> Induced Systemic and Local Immune Responses in H22 Tumor-Bearing Mice. Journal of Immunology Research, 2018, 2018, 1-12.	0.9	28
6649	Development of a novel immunoproteasome digestion assay for synthetic long peptide vaccine design. PLoS ONE, 2018, 13, e0199249.	1.1	4
6650	Matrine exerts inhibitory effects in melanoma through the regulation of miR-19b-3p/PTEN. International Journal of Oncology, 2018, 53, 791-800.	1.4	15
6651	Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes in Advanced Melanoma Patients. Journal of Immunology Research, 2018, 2018, 1-10.	0.9	23
6652	PD-L1 Expression Predicts a Distinct Prognosis in Krukenberg Tumor with Corresponding Origins. Journal of Immunology Research, 2018, 2018, 1-10.	0.9	12
6653	Novel tumour antigens and the development of optimal vaccine design. , 2018, 6, 31-47.	1.4	11
6654	Generalizability of clinical trials of advanced melanoma in the real-world, population-based setting. Medical Oncology, 2018, 35, 110.	1.2	6
6655	Combining Tumor Vaccination and Oncolytic Viral Approaches with Checkpoint Inhibitors: Rationale, Pre-Clinical Experience, and Current Clinical Trials in Malignant Melanoma. American Journal of Clinical Dermatology, 2018, 19, 657-670.	3.3	14
6656	Safe Administration of Ipilimumab, Pembrolizumab, and Nivolumab in a Patient with Metastatic Melanoma, Psoriasis, and a Previous Guillain-Barré Syndrome. Case Reports in Oncological Medicine, 2018, 2018, 1-4.	0.2	6
6657	Repeated in-field radiosurgery for locally recurrent brain metastases: Feasibility, results and survival in a heavily treated patient cohort. PLoS ONE, 2018, 13, e0198692.	1.1	47
6658	Fulminant Type 1 Diabetes Mellitus Accompanied by Positive Conversion of Anti-insulin Antibody after the Administration of Anti-CTLA-4 Antibody Following the Discontinuation of Anti-PD-1 Antibody. Internal Medicine, 2018, 57, 2029-2034.	0.3	35

#	ARTICLE	IF	CITATIONS
6659	Gastrointestinal adverse events with combination of checkpoint inhibitors in advanced melanoma: a systematic review. <i>Melanoma Management</i> , 2018, 5, MMT01.	0.1	11
6660	T Lymphocyte-Based Cancer Immunotherapeutics. <i>International Review of Cell and Molecular Biology</i> , 2018, 341, 201-276.	1.6	22
6661	Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy. <i>Immunity</i> , 2018, 49, 178-193.e7.	6.6	502
6662	Graft rejection after immune checkpoint inhibitor therapy in solid organ transplant recipients. <i>Acta Oncologica</i> , 2018, 57, 1414-1418.	0.8	19
6663	Early-drug development in the era of immuno-oncology: are we ready to face the challenges?. <i>Annals of Oncology</i> , 2018, 29, 1727-1740.	0.6	20
6664	The Evolution of Radiation Therapy in Metastatic Breast Cancer: From Local Therapy to Systemic Agent. <i>International Journal of Breast Cancer</i> , 2018, 2018, 1-7.	0.6	12
6665	T cell mediated immunity after combination therapy with intralesional PV-10 and blockade of the PD-1/PD-L1 pathway in a murine melanoma model. <i>PLoS ONE</i> , 2018, 13, e0196033.	1.1	19
6666	Immunotherapy for pancreatic cancer: Barriers and breakthroughs. <i>Annals of Gastroenterological Surgery</i> , 2018, 2, 274-281.	1.2	119
6667	Phase II study of pazopanib in combination with paclitaxel in patients with metastatic melanoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 353-360.	1.1	15
6668	Seeking Convergence and Cure with New Myeloma Therapies. <i>Trends in Cancer</i> , 2018, 4, 567-582.	3.8	8
6669	Genome-Wide Analysis of Circulating Cell-Free DNA Copy Number Detects Active Melanoma and Predicts Survival. <i>Clinical Chemistry</i> , 2018, 64, 1338-1346.	1.5	9
6670	Development and validation of a functional cell-based neutralizing antibody assay for ipilimumab. <i>Bioanalysis</i> , 2018, 10, 1273-1287.	0.6	9
6671	Pediatric Cancer Immunotherapy: Opportunities and Challenges. <i>Paediatric Drugs</i> , 2018, 20, 395-408.	1.3	76
6672	Blockade of the Checkpoint Inhibitor Pathways and Activated T-Cell Therapy in Brain Tumors. , 2018, , 669-680.		0
6673	Overview of Vaccine Strategies Against Epidermal Growth Factor Receptor in Brain Tumors. , 2018, , 693-705.		0
6674	Immunotherapy Response Assessment in Neuro-Oncology (iRANO). , 2018, , 761-766.		1
6675	Emerging patents in the therapeutic areas of glioma and glioblastoma. <i>Expert Opinion on Therapeutic Patents</i> , 2018, 28, 573-590.	2.4	12
6676	Mimics of Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 2315-2321.	0.9	22

#	ARTICLE	IF	CITATIONS
6677	Immune Escape Mechanisms and Future Prospects for Immunotherapy in Neuroblastoma. <i>BioMed Research International</i> , 2018, 2018, 1-11.	0.9	60
6678	<i>Cancer Vaccines.</i> , 2018, , 161-184.e6.		2
6679	What is Cancer?. , 2018, , 307-310.		0
6680	S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies. <i>British Journal of Cancer</i> , 2018, 119, 339-346.	2.9	83
6681	Clinicopathological correlation of PD-L1 expression in primary and metastatic breast cancer and infiltrating immune cells. <i>Human Pathology</i> , 2018, 80, 170-178.	1.1	40
6682	Immunotherapies: Exploiting the Immune System for Cancer Treatment. <i>Journal of Immunology Research</i> , 2018, 2018, 1-16.	0.9	89
6683	Immune Toxicity with Checkpoint Inhibition for Metastatic Melanoma: Case Series and Clinical Management. <i>Journal of Skin Cancer</i> , 2018, 2018, 1-13.	0.5	21
6684	The Single-Cell Phenotypic Identity of Human CD8+ and CD4+ T Cells. <i>International Review of Cell and Molecular Biology</i> , 2018, 341, 63-124.	1.6	77
6685	Epigenetic Mechanisms Dictating Eradication of Cancer by Natural Killer Cells. <i>Trends in Cancer</i> , 2018, 4, 553-566.	3.8	22
6687	Endocrine, Sexual Function, and Infertility Side Effects of Immune Checkpoint Inhibitor Therapy for Genitourinary Cancers. <i>Current Urology Reports</i> , 2018, 19, 68.	1.0	12
6688	PD-1 blockade potentially enhances adoptive cytotoxic T cell potency in a human acute myeloid leukaemia animal model. <i>Hematology</i> , 2018, 23, 740-746.	0.7	10
6689	PD-L1, TIM-3, and CTLA-4 Blockade Fails To Promote Resistance to Secondary Infection with Virulent Strains of <i>Toxoplasma gondii</i> . <i>Infection and Immunity</i> , 2018, 86, .	1.0	14
6690	IFN β -induced Chemokines Are Required for CXCR3-mediated T-Cell Recruitment and Antitumor Efficacy of Anti-HER2/CD3 Bispecific Antibody. <i>Clinical Cancer Research</i> , 2018, 24, 6447-6458.	3.2	32
6691	Interferon is associated with improved survival for node-positive cutaneous melanoma: a single-institution experience. <i>Melanoma Management</i> , 2018, 5, MMT02.	0.1	4
6692	Immunobiology of Solid Cancers: Cellular and Molecular Pathways as Potential Diagnostic and Therapeutic Targets. <i>BioMed Research International</i> , 2018, 2018, 1-2.	0.9	0
6693	Interpreting the Association of First-in-Class Immune Checkpoint Inhibition and Targeted Therapy With Survival in Patients With Stage IV Melanoma—Reply. <i>JAMA Oncology</i> , 2018, 4, 1136.	3.4	1
6694	Checkpoint inhibitors as treatment for malignant gliomas: “A long way to the top”. <i>Cancer Treatment Reviews</i> , 2018, 69, 121-131.	3.4	46
6695	SOCIETY FOR ENDOCRINOLOGY ENDOCRINE EMERGENCY GUIDANCE: Acute management of the endocrine complications of checkpoint inhibitor therapy. <i>Endocrine Connections</i> , 2018, 7, G1-G7.	0.8	97

#	ARTICLE	IF	CITATIONS
6696	A Severe Case of Ipilimumab-Induced Ileocolitis Refractory to Glucocorticosteroids and Infliximab. Case Reports in Gastrointestinal Medicine, 2018, 2018, 1-3.	0.2	0
6697	Combining vaccines and immune checkpoint inhibitors to prime, expand, and facilitate effective tumor immunotherapy. Expert Review of Vaccines, 2018, 17, 697-705.	2.0	38
6698	Improved Induction of Anti-Melanoma T Cells by Adenovirus-5/3 Fiber Modification to Target Human DCs. Vaccines, 2018, 6, 42.	2.1	8
6699	Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease. Annals of Internal Medicine, 2018, 168, 121.	2.0	341
6700	The Current Understanding of the Endocrine Effects From Immune Checkpoint Inhibitors and Recommendations for Management. JNCI Cancer Spectrum, 2018, 2, pky021.	1.4	92
6701	Monitoring Immune Checkpoint Regulators as Predictive Biomarkers in Hepatocellular Carcinoma. Frontiers in Oncology, 2018, 8, 269.	1.3	106
6702	Immunotherapy for esophageal squamous cell carcinoma: a review. Fukushima Journal of Medical Sciences, 2018, 64, 46-53.	0.1	36
6703	Weighted log-rank test for time-to-event data in immunotherapy trials with random delayed treatment effect and cure rate. Pharmaceutical Statistics, 2018, 17, 541-554.	0.7	18
6704	Immune Checkpoint Inhibitor Toxicity. Current Oncology Reports, 2018, 20, 72.	1.8	91
6705	Combination immune checkpoint blockade as an effective therapy for mesothelioma. OncoImmunology, 2018, 7, e1494111.	2.1	37
6706	An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0. , 2018, 6, 44.		59
6707	Biomarkers of response to immune checkpoint blockade in cancer treatment. Critical Reviews in Oncology/Hematology, 2018, 130, 108-120.	2.0	61
6708	Estimating causal effects of time-dependent exposures on a binary endpoint in a high-dimensional setting. BMC Medical Research Methodology, 2018, 18, 67.	1.4	2
6709	A mathematical modelling tool for unravelling the antibody-mediated effects on CTLA-4 interactions. BMC Medical Informatics and Decision Making, 2018, 18, 37.	1.5	5
6710	The use of SAME in chemotherapy-induced liver injury. Critical Reviews in Oncology/Hematology, 2018, 130, 70-77.	2.0	21
6711	Treg Fragility: A Prerequisite for Effective Antitumor Immunity?. Cancer Immunology Research, 2018, 6, 882-887.	1.6	64
6712	Peptide Delivery Systems for Cancer Vaccines. Advanced Therapeutics, 2018, 1, 1800060.	1.6	30
6713	Metabolomic identification of diagnostic serum-based biomarkers for advanced stage melanoma. Metabolomics, 2018, 14, 105.	1.4	15

#	ARTICLE	IF	CITATIONS
6714	EGFR-targeted liposomal nanohybrid cerasomes: theranostic function and immune checkpoint inhibition in a mouse model of colorectal cancer. <i>Nanoscale</i> , 2018, 10, 16738-16749.	2.8	60
6715	Radiotherapy, tumor mutational burden, and immune checkpoint inhibitors: time to do the math. <i>Strahlentherapie Und Onkologie</i> , 2018, 194, 873-875.	1.0	11
6716	Creating molecules that modulate immune responses. <i>Nature Reviews Chemistry</i> , 2018, 2, 184-193.	13.8	14
6718	Reversal of Resistance in Targeted Therapy of Metastatic Melanoma: Lessons Learned from Vemurafenib (BRAFV600E-Specific Inhibitor). <i>Cancers</i> , 2018, 10, 157.	1.7	39
6719	Malignant Melanoma: Diagnostic and Management Update. <i>Plastic and Reconstructive Surgery</i> , 2018, 142, 202e-216e.	0.7	45
6720	Older melanoma patients aged 75 and above retain responsiveness to anti-PD1 therapy: results of a retrospective single-institution cohort study. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1571-1578.	2.0	35
6721	Toward Biomaterials for Enhancing Immune Checkpoint Blockade Therapy. <i>Advanced Functional Materials</i> , 2018, 28, 1802540.	7.8	92
6722	CD4+ T cell help in cancer immunology and immunotherapy. <i>Nature Reviews Immunology</i> , 2018, 18, 635-647.	10.6	1,030
6723	Deciphering mechanisms of brain metastasis in melanoma - the gist of the matter. <i>Molecular Cancer</i> , 2018, 17, 106.	7.9	46
6724	Rhabdomyolysis during high dose interleukin-2 treatment of metastatic melanoma after sequential immunotherapies: a case report. , 2018, 6, 53.		2
6725	A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma. , 2018, 6, 76.		14
6727	Immunotherapy in Glioblastoma. <i>World Neurosurgery</i> , 2018, 116, 518-528.	0.7	31
6728	Pathways in melanoma development. <i>Italian Journal of Dermatology and Venereology</i> , 2018, 153, 68-76.	0.1	4
6729	Challenges and Opportunities of Neoadjuvant Treatment in Locally Advanced Melanoma. <i>American Journal of Clinical Dermatology</i> , 2018, 19, 639-646.	3.3	1
6730	An Update on Immunotherapy for Solid Tumors: A Review. <i>Annals of Surgical Oncology</i> , 2018, 25, 3404-3412.	0.7	66
6731	The Option Value of Innovative Treatments for Metastatic Melanoma. <i>Forum for Health Economics and Policy</i> , 2018, 21, .	0.2	11
6732	Melanoma treatment in review. <i>ImmunoTargets and Therapy</i> , 2018, Volume 7, 35-49.	2.7	483
6733	Evaluation of a Rapid, Fully Automated Platform for Detection of BRAF and NRAS Mutations in Melanoma. <i>Acta Dermato-Venereologica</i> , 2018, 98, 44-49.	0.6	20

#	ARTICLE	IF	CITATIONS
6734	Immune Checkpoint Blockade in Hematologic Malignancies. , 2018, , 1583-1587.		1
6735	Reply to: "Immune-related hepatitis with immunotherapy: Are corticosteroids always needed?" Journal of Hepatology, 2018, 69, 550-551.	1.8	2
6736	Activity and Immune Correlates of a Programmed Death-1 Blockade Antibody in the treatment of Refractory Solid Tumors. Journal of Cancer, 2018, 9, 205-212.	1.2	9
6737	Treatment of Advanced Merkel Cell Carcinoma: Current Therapeutic Options and Novel Immunotherapy Approaches. Targeted Oncology, 2018, 13, 567-582.	1.7	12
6738	A new laboratory-based algorithm to predict microvascular invasion and survival in patients with hepatocellular carcinoma. International Journal of Surgery, 2018, 57, 45-53.	1.1	20
6739	Multiple Antigen Stimulating Cellular Therapy (MASCT) For Hepatocellular Carcinoma After Curative Treatment: A Retrospective Study. Journal of Cancer, 2018, 9, 1385-1393.	1.2	4
6740	Increased <i>AURKA</i> Gene Copy Number Correlates with Poor Prognosis and Predicts the Efficacy of High-dose Interferon Therapy in Acral Melanoma. Journal of Cancer, 2018, 9, 1267-1276.	1.2	7
6741	Cardiotoxicity of Anticancer Therapeutics. Frontiers in Cardiovascular Medicine, 2018, 5, 9.	1.1	68
6742	The Role of the Insulin-Like Growth Factor 1 Pathway in Immune Tumor Microenvironment and Its Clinical Ramifications in Gynecologic Malignancies. Frontiers in Endocrinology, 2018, 9, 297.	1.5	17
6743	Combining Adoptive Cell Therapy with Cytomegalovirus-Based Vaccine Is Protective against Solid Skin Tumors. Frontiers in Immunology, 2018, 8, 1993.	2.2	22
6744	Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy. Frontiers in Immunology, 2018, 9, 14.	2.2	356
6745	Tissue-Dependent Tumor Microenvironments and Their Impact on Immunotherapy Responses. Frontiers in Immunology, 2018, 9, 70.	2.2	120
6746	Checks and Balances in Autoimmune Vasculitis. Frontiers in Immunology, 2018, 9, 315.	2.2	31
6747	Targeting LAG-3 and PD-1 to Enhance T Cell Activation by Antigen-Presenting Cells. Frontiers in Immunology, 2018, 9, 385.	2.2	144
6748	Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional Bacillus Calmette-Guérin followed by Ipilimumab in Patients with Advanced Metastatic Melanoma. Frontiers in Immunology, 2018, 9, 411.	2.2	49
6749	Tumor Necrosis Factor α and Regulatory T Cells in Oncoimmunology. Frontiers in Immunology, 2018, 9, 444.	2.2	139
6750	Combination Immunotherapy: Taking Cancer Vaccines to the Next Level. Frontiers in Immunology, 2018, 9, 610.	2.2	46
6751	Predictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme. Frontiers in Immunology, 2018, 9, 727.	2.2	55

#	ARTICLE	IF	CITATIONS
6752	GMP-Grade Manufacturing of T Cells Engineered to Express a Defined α TCR. <i>Frontiers in Immunology</i> , 2018, 9, 1062.	2.2	53
6753	The Confluence of Sex Hormones and Aging on Immunity. <i>Frontiers in Immunology</i> , 2018, 9, 1269.	2.2	178
6754	Genetically Induced Tumors in the Oncopig Model Invoke an Antitumor Immune Response Dominated by Cytotoxic CD8 ⁺ T Cells and Differentiated α T Cells Alongside a Regulatory Response Mediated by FOXP3 ⁺ T Cells and Immunoregulatory Molecules. <i>Frontiers in Immunology</i> , 2018, 9, 1301.	2.2	15
6755	Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors. <i>Frontiers in Immunology</i> , 2018, 9, 1310.	2.2	404
6756	Glioblastoma Stem-Like Cells Are More Susceptible Than Differentiated Cells to Natural Killer Cell Lysis Mediated Through Killer Immunoglobulin-Like Receptors–Human Leukocyte Antigen Ligand Mismatch and Activation Receptor–Ligand Interactions. <i>Frontiers in Immunology</i> , 2018, 9, 1345.	2.2	52
6757	Combination of Ipilimumab and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma. <i>Frontiers in Oncology</i> , 2018, 8, 44.	1.3	67
6758	Therapeutic Antibodies for Myeloid Neoplasms–Current Developments and Future Directions. <i>Frontiers in Oncology</i> , 2018, 8, 152.	1.3	30
6759	Mechanisms and Therapy for Cancer Metastasis to the Brain. <i>Frontiers in Oncology</i> , 2018, 8, 161.	1.3	123
6760	Melanoma Immunotherapy: Next-Generation Biomarkers. <i>Frontiers in Oncology</i> , 2018, 8, 178.	1.3	53
6761	Expression of the Circadian Clock Gene BMAL1 Positively Correlates With Antitumor Immunity and Patient Survival in Metastatic Melanoma. <i>Frontiers in Oncology</i> , 2018, 8, 185.	1.3	60
6762	Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers. , 2018, 6, 65.		118
6763	Pelvic lymph node dissection in metastatic melanoma to the groin should not be abandoned yet. <i>European Journal of Surgical Oncology</i> , 2018, 44, 1779-1785.	0.5	5
6764	Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients. <i>BMC Cancer</i> , 2018, 18, 726.	1.1	77
6765	Immune Monitoring of Cancer Patients Prior to and During CTLA-4 or PD-1/PD-L1 Inhibitor Treatment. <i>Biomedicines</i> , 2018, 6, 26.	1.4	16
6766	Current Strategies to Enhance Anti-Tumour Immunity. <i>Biomedicines</i> , 2018, 6, 37.	1.4	11
6767	Tackling Cancer Resistance by Immunotherapy: Updated Clinical Impact and Safety of PD-1/PD-L1 Inhibitors. <i>Cancers</i> , 2018, 10, 32.	1.7	54
6768	Tune Up In Situ Autovaccination against Solid Tumors with Oncolytic Viruses. <i>Cancers</i> , 2018, 10, 171.	1.7	11
6769	The Role of Immune Checkpoint Inhibitors in Classical Hodgkin Lymphoma. <i>Cancers</i> , 2018, 10, 204.	1.7	37

#	ARTICLE	IF	CITATIONS
6770	Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors. <i>International Immunopharmacology</i> , 2018, 62, 29-39.	1.7	860
6771	Nanofluidic drug-eluting seed for sustained intratumoral immunotherapy in triple negative breast cancer. <i>Journal of Controlled Release</i> , 2018, 285, 23-34.	4.8	44
6772	A Fluorescent Probe for Early Detection of Melanoma and Its Metastasis by Specifically Imaging Tyrosinase Activity in a Mouse Model. <i>Analytical Chemistry</i> , 2018, 90, 8807-8815.	3.2	53
6773	An observational study of concomitant immunotherapies and denosumab in patients with advanced melanoma or lung cancer. <i>OncImmunology</i> , 2018, 7, e1480301.	2.1	48
6774	The Emerging Therapeutic Landscape of Advanced Melanoma. <i>Current Pharmaceutical Design</i> , 2018, 24, 549-558.	0.9	16
6775	Combinatory therapy adopting nanoparticle-based cancer vaccination with immune checkpoint blockade for treatment of post-surgical tumor recurrences. <i>Journal of Controlled Release</i> , 2018, 285, 56-66.	4.8	28
6776	Nivolumab Induces Sustained Liver Injury in a Patient with Malignant Melanoma. <i>Internal Medicine</i> , 2018, 57, 1789-1792.	0.3	26
6777	Strengths and Weaknesses of Pre-Clinical Models for Human Melanoma Treatment: Dawn of Dogsâ€™ Revolution for Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2018, 19, 799.	1.8	33
6778	Mechanisms of Intrinsic Tumor Resistance to Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1340.	1.8	61
6779	Immunotherapy in Non-Small Cell Lung Cancer: Shifting Prognostic Paradigms. <i>Journal of Clinical Medicine</i> , 2018, 7, 151.	1.0	11
6780	Validating malignant melanoma ICD-9-CM codes in Umbria, ASL Napoli 3 Sud and Friuli Venezia Giulia administrative healthcare databases: a diagnostic accuracy study. <i>BMJ Open</i> , 2018, 8, e020631.	0.8	10
6781	Cardiorenal complications of immune checkpoint inhibitors. <i>Nature Reviews Nephrology</i> , 2018, 14, 571-588.	4.1	80
6782	Dendritic cells cross-talk with tumour antigen-specific CD8+ T cells, VÎ±9Î±3Î±T cells and VÎ±24NKT cells in patients with glioblastoma multiforme and in healthy donors. <i>Clinical and Experimental Immunology</i> , 2018, 194, 54-66.	1.1	8
6783	MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	425
6784	PD-1 blockade in combination with zoledronic acid to enhance the antitumor efficacy in the breast cancer mouse model. <i>BMC Cancer</i> , 2018, 18, 669.	1.1	20
6785	Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab. , 2018, 6, 73.		46
6786	Management of adverse events related to checkpoint inhibition therapy. <i>Memo - Magazine of European Medical Oncology</i> , 2018, 11, 132-137.	0.3	22
6787	Immunotherapy for CRPC. , 2018, , 181-187.		0

#	ARTICLE	IF	CITATIONS
6788	A Robust Approach to Sample Size Calculation in Cancer Immunotherapy Trials with Delayed Treatment Effect. <i>Biometrics</i> , 2018, 74, 1292-1300.	0.8	13
6789	Hallmarks of Cancer in the Reading Room: A Guide for Radiologists. <i>American Journal of Roentgenology</i> , 2018, 211, 470-484.	1.0	6
6790	Emerging findings into molecular mechanism of brain metastasis. <i>Cancer Medicine</i> , 2018, 7, 3820-3833.	1.3	34
6791	Cancer immune checkpoint blockade therapy and its associated autoimmune cardiotoxicity. <i>Acta Pharmacologica Sinica</i> , 2018, 39, 1693-1698.	2.8	39
6792	Recent developments with immunotherapy for hepatocellular carcinoma. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 905-910.	1.4	89
6793	Immune-checkpoint inhibitors in melanoma and kidney cancer: from sequencing to rational selection. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591877742.	1.4	7
6795	Microbial biomarkers for immune checkpoint blockade therapy against cancer. <i>Journal of Gastroenterology</i> , 2018, 53, 999-1005.	2.3	15
6796	Update on systemic therapy for advanced cutaneous melanoma and recent development of novel drugs. <i>Clinical and Experimental Metastasis</i> , 2018, 35, 503-520.	1.7	9
6797	Nanotheranostics and Their Potential in the Management of Metastatic Cancer. , 2018, , 199-244.		2
6798	Cardiotoxicities associated with immune checkpoint inhibitors. <i>Current Problems in Cancer</i> , 2018, 42, 422-432.	1.0	42
6799	Comparison of glioblastoma (GBM) molecular classification methods. <i>Seminars in Cancer Biology</i> , 2018, 53, 201-211.	4.3	125
6800	Safety and efficacy of durvalumab (MEDI4736) in various solid tumors. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 2085-2096.	2.0	38
6801	Metabolic Symbiosis and Immunomodulation: How Tumor Cell-Derived Lactate May Disturb Innate and Adaptive Immune Responses. <i>Frontiers in Oncology</i> , 2018, 8, 81.	1.3	86
6802	The Potential of In Vivo Imaging for Optimization of Molecular and Cellular Anti-cancer Immunotherapies. <i>Molecular Imaging and Biology</i> , 2018, 20, 696-704.	1.3	30
6803	Principles and Developments in Cancer Immunotherapy and Approaches for Combination with Tumour Irradiation. <i>Progress in Tumor Research</i> , 2018, , 1-10.	0.1	0
6804	Wnt-signaling enhances neural crest migration of melanoma cells and induces an invasive phenotype. <i>Molecular Cancer</i> , 2018, 17, 59.	7.9	63
6805	Update on Tumor Neoantigens and Their Utility: Why It Is Good to Be Different. <i>Trends in Immunology</i> , 2018, 39, 536-548.	2.9	152
6806	Revolutionary Advances in Immunotherapy for Melanoma Are Coming into the Surgical Arena: Are We Ready?. <i>Annals of Surgical Oncology</i> , 2018, 25, 1803-1806.	0.7	1

#	ARTICLE	IF	CITATIONS
6808	Anti-PD-1 Therapy Leads to Near-Complete Remission in a Patient with Metastatic Basal Cell Carcinoma. <i>Oncology Research and Treatment</i> , 2018, 41, 391-394.	0.8	40
6809	Immune checkpoint receptors: homeostatic regulators of immunity. <i>Hepatology International</i> , 2018, 12, 223-236.	1.9	43
6810	Immune-related Adverse Events in Cancer Patients. <i>Academic Emergency Medicine</i> , 2018, 25, 819-827.	0.8	18
6811	Autoimmune comorbidities in patients with metastatic melanoma: a retrospective analysis of us claims data. <i>BMC Cancer</i> , 2018, 18, 145.	1.1	16
6812	Liquid biomarkers in melanoma: detection and discovery. <i>Molecular Cancer</i> , 2018, 17, 8.	7.9	74
6813	Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma. <i>Journal of Hematology and Oncology</i> , 2018, 11, 15.	6.9	155
6814	Concealed complete response in melanoma patients under therapy with immune checkpoint inhibitors: two case reports. , 2018, 6, 2.		11
6815	Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients. , 2018, 6, 18.		153
6816	Clinical decision making in the era of immunotherapy for high grade-glioma: report of four cases. <i>BMC Cancer</i> , 2018, 18, 239.	1.1	38
6817	Randomized phase II trial of autologous dendritic cell vaccines versus autologous tumor cell vaccines in metastatic melanoma: 5-year follow up and additional analyses. , 2018, 6, 19.		45
6818	Thoracic Imaging of Solid Tumor Patients Treated with Immune Checkpoint Inhibitors. <i>Current Radiology Reports</i> , 2018, 6, 1.	0.4	1
6819	Pharmacometric Applications and Challenges in the Development of Therapeutic Antibodies in Immuno-Oncology. <i>Current Pharmacology Reports</i> , 2018, 4, 285-291.	1.5	7
6820	Adoptive T cell therapy: points to consider. <i>Current Opinion in Immunology</i> , 2018, 51, 197-203.	2.4	41
6821	Immune-related hepatitis with immunotherapy: Are corticosteroids always needed?. <i>Journal of Hepatology</i> , 2018, 69, 548-550.	1.8	71
6822	Unmasking of intracranial metastatic melanoma during ipilimumab/nivolumab therapy: case report and literature review. <i>BMC Cancer</i> , 2018, 18, 549.	1.1	8
6823	Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden. , 2018, 6, 32.		111
6824	Anti-CTLA-4 based therapy elicits humoral immunity to galectin-3 in patients with metastatic melanoma. <i>Oncolimmunology</i> , 2018, 7, e1440930.	2.1	30
6825	Integrating oncolytic viruses in combination cancer immunotherapy. <i>Nature Reviews Immunology</i> , 2018, 18, 498-513.	10.6	448

#	ARTICLE	IF	CITATIONS
6826	CIMT 2018: Pushing frontiers in cancer immunotherapy – Report on the 16th Annual Meeting of the Association for Cancer Immunotherapy. Human Vaccines and Immunotherapeutics, 2018, 14, 2864-2873.	1.4	1
6827	Abscopal effect of radiotherapy combined with immune checkpoint inhibitors. Journal of Hematology and Oncology, 2018, 11, 104.	6.9	303
6828	Therapeutic Vaccines for Genitourinary Malignancies. Vaccines, 2018, 6, 55.	2.1	9
6829	Immune-related adverse events from combination immunotherapy in cancer patients: A comprehensive meta-analysis of randomized controlled trials. International Immunopharmacology, 2018, 63, 292-298.	1.7	83
6830	Management of Immune Checkpoint Inhibitor Toxicities: A Review and Clinical Guideline for Emergency Physicians. Journal of Emergency Medicine, 2018, 55, 489-502.	0.3	58
6831	Clinical and Molecular Characteristics Associated with Survival in Advanced Melanoma Treated with Checkpoint Inhibitors. Journal of Oncology, 2018, 2018, 1-13.	0.6	3
6832	New Directions in the Study and Treatment of Metastatic Cancer. Frontiers in Oncology, 2018, 8, 258.	1.3	14
6833	Family A and B DNA Polymerases in Cancer: Opportunities for Therapeutic Interventions. Biology, 2018, 7, 5.	1.3	3
6834	Human cancer evolution in the context of a human immune system in mice. Molecular Oncology, 2018, 12, 1797-1810.	2.1	11
6835	Management of Brain Metastases in the New Era of Checkpoint Inhibition. Current Neurology and Neuroscience Reports, 2018, 18, 70.	2.0	25
6836	Treatment of Clinically Positive Cervical Lymph Nodes by Limited Local Node Excision and Adjuvant Radiotherapy in Melanoma Patients with Major Comorbidities. Annals of Surgical Oncology, 2018, 25, 3476-3482.	0.7	6
6837	Immune Checkpoint Inhibitor-related Pneumonitis. Incidence, Risk Factors, and Clinical and Radiographic Features. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 951-953.	2.5	8
6838	CNS cancer immunity cycle and strategies to target this for glioblastoma. Oncotarget, 2018, 9, 22802-22816.	0.8	11
6839	Harnessing RIG-I and intrinsic immunity in the tumor microenvironment for therapeutic cancer treatment. Oncotarget, 2018, 9, 29007-29017.	0.8	73
6840	Metastatic Melanoma: Recent Therapeutic Progress and Future Perspectives. Drugs, 2018, 78, 1197-1209.	4.9	34
6841	Immunotherapy in aggressive B-cell lymphomas. Best Practice and Research in Clinical Haematology, 2018, 31, 299-305.	0.7	3
6842	Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nature Biotechnology, 2018, 36, 847-856.	9.4	564
6843	Focal radiation necrosis of the brain in patients with melanoma brain metastases treated with pembrolizumab. Cancer Medicine, 2018, 7, 4870-4879.	1.3	27

#	ARTICLE	IF	CITATIONS
6844	Future prospects of immune checkpoint blockade in cancer: from response prediction to overcoming resistance. <i>Experimental and Molecular Medicine</i> , 2018, 50, 1-13.	3.2	152
6845	Immune-Related Thyroiditis with Immune Checkpoint Inhibitors. <i>Thyroid</i> , 2018, 28, 1243-1251.	2.4	160
6846	Design considerations for early-phase clinical trials of immune-oncology agents. , 2018, 6, 81.		44
6847	Implementation of cell-free tumor DNA sequencing from the cerebrospinal fluid to guide treatment in a patient with primary leptomeningeal melanoma: A case report. <i>Molecular and Clinical Oncology</i> , 2018, 9, 58-61.	0.4	8
6848	Tumor-shed antigen CA125 blocks complement-mediated killing via suppression of C1q-antibody binding. <i>European Journal of Immunology</i> , 2018, 48, 1872-1882.	1.6	5
6849	The age of enlightenment in melanoma immunotherapy. , 2018, 6, 80.		25
6850	Epigenetic mechanisms of tumor resistance to immunotherapy. <i>Cellular and Molecular Life Sciences</i> , 2018, 75, 4163-4176.	2.4	27
6851	Treatment with mRNA coding for the necroptosis mediator MLKL induces antitumor immunity directed against neo-epitopes. <i>Nature Communications</i> , 2018, 9, 3417.	5.8	87
6852	Cost Estimate of Immune-Related Adverse Reactions Associated with Innovative Treatments of Metastatic Melanoma. <i>Clinical Drug Investigation</i> , 2018, 38, 967-976.	1.1	14
6853	PPAR-Induced Fatty Acid Oxidation in T Cells Increases the Number of Tumor-Reactive CD8+ T Cells and Facilitates Anti-PD-1 Therapy. <i>Cancer Immunology Research</i> , 2018, 6, 1375-1387.	1.6	226
6854	The role of automated cytometry in the new era of cancer immunotherapy (Review). <i>Molecular and Clinical Oncology</i> , 2018, 9, 355-361.	0.4	12
6855	Present and future of cancer immunotherapy: A tumor microenvironmental perspective (Review). <i>Oncology Letters</i> , 2018, 16, 4105-4113.	0.8	58
6857	Radiation and Local Anti-CD40 Generate an Effective in situ Vaccine in Preclinical Models of Pancreatic Cancer. <i>Frontiers in Immunology</i> , 2018, 9, 2030.	2.2	77
6858	Soluble PD-1 and PD-L1 as potential biomarkers for classical Hodgkin lymphoma. <i>Hematological Oncology</i> , 2018, 36, 709-712.	0.8	13
6859	High-dimensional single cell analysis identifies stem-like cytotoxic CD8+ T cells infiltrating human tumors. <i>Journal of Experimental Medicine</i> , 2018, 215, 2520-2535.	4.2	250
6860	Mouse models in the era of large human tumour sequencing studies. <i>Open Biology</i> , 2018, 8, .	1.5	7
6861	Dendritic cell vaccines for high-grade gliomas. <i>Therapeutics and Clinical Risk Management</i> , 2018, Volume 14, 1299-1313.	0.9	42
6862	Cancer stem cells as targets for DC-based immunotherapy of colorectal cancer. <i>Scientific Reports</i> , 2018, 8, 12042.	1.6	33

#	ARTICLE	IF	CITATIONS
6863	Ipilimumab for the treatment of advanced melanoma in six kidney transplant patients. <i>American Journal of Transplantation</i> , 2018, 18, 3065-3071.	2.6	41
6864	Targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with Ipilimumab. <i>International Immunopharmacology</i> , 2018, 63, 282-291.	1.7	145
6865	Expression of ILT3 predicts poor prognosis and is inversely associated with infiltration of CD45RO+ T cells in patients with colorectal cancer. <i>Pathology Research and Practice</i> , 2018, 214, 1621-1625.	1.0	9
6866	Differential diagnosis of inflammatory bowel disease: imitations and complications. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 644-653.	3.7	88
6867	Combining brachytherapy and immunotherapy to achieve in situ tumor vaccination: A review of cooperative mechanisms and clinical opportunities. <i>Brachytherapy</i> , 2018, 17, 995-1003.	0.2	23
6868	Reply to: "Mortality due to immunotherapy related hepatitis". <i>Journal of Hepatology</i> , 2018, 69, 978-979.	1.8	0
6869	Integrated Genomic Comparison of Mouse Models Reveals Their Clinical Resemblance to Human Liver Cancer. <i>Molecular Cancer Research</i> , 2018, 16, 1713-1723.	1.5	14
6870	Melanoma treatment: from conventional to nanotechnology. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 2283-2302.	1.2	128
6871	Lack of Sprouty 1 and 2 enhances survival of effector CD8 ⁺ T cells and yields more protective memory cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E8939-E8947.	3.3	22
6872	Current landscape and future directions of biomarkers for predicting responses to immune checkpoint inhibitors. <i>Cancer Management and Research</i> , 2018, Volume 10, 2475-2488.	0.9	22
6873	Interaction of PVR/PVRL2 with TIGIT/DNAM-1 as a novel immune checkpoint axis and therapeutic target in cancer. <i>Mammalian Genome</i> , 2018, 29, 694-702.	1.0	29
6874	Increased frequency of acute reactions to iodinated contrast media in cancer patients treated with anti-CTLA-4 immunomodulatory antibodies. <i>Medical Hypotheses</i> , 2018, 119, 26-28.	0.8	3
6875	CORR Insights®: External Validation and Optimization of the SPRING Model for Prediction of Survival After Surgical Treatment of Bone Metastases of the Extremities. <i>Clinical Orthopaedics and Related Research</i> , 2018, 476, 1600-1602.	0.7	2
6876	Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. <i>New England Journal of Medicine</i> , 2018, 379, 722-730.	13.9	983
6877	Enterocolitis due to immune checkpoint inhibitors: a systematic review. <i>Gut</i> , 2018, 67, 2056-2067.	6.1	179
6878	Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand-1 (PD-L1) in ovarian cancer. <i>Journal of Ovarian Research</i> , 2018, 11, 43.	1.3	60
6879	Cytosolic Processing Governs TAP-Independent Presentation of a Critical Melanoma Antigen. <i>Journal of Immunology</i> , 2018, 201, 1875-1888.	0.4	20
6880	Diagnosis and Management of Hepatitis in Patients on Checkpoint Blockade. <i>Oncologist</i> , 2018, 23, 991-997.	1.9	86

#	ARTICLE	IF	CITATIONS
6881	A novel fully human anti-CD47 antibody as a potential therapy for human neoplasms with good safety. <i>Biochimie</i> , 2018, 151, 54-66.	1.3	13
6882	Metastatic acral lentiginous melanoma in a tertiary referral center in Switzerland: a systematic analysis. <i>Melanoma Research</i> , 2018, 28, 442-450.	0.6	14
6883	An Agonistic Antibody to EPHA2 Exhibits Antitumor Effects on Human Melanoma Cells. <i>Anticancer Research</i> , 2018, 38, 3273-3282.	0.5	18
6884	Cloning and expansion of antigen-specific T cells using iPS cell technology: Possible use of regenerated T cells in personalized medicine. <i>Personalized Medicine Universe</i> , 2018, 7, 7-12.	0.1	0
6885	Safety of combining radiotherapy with immune-checkpoint inhibition. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 477-494.	12.5	208
6886	Management of Melanoma Locoregional Recurrence. , 2018, , 351-359.		1
6887	Surgery for Stage IV Metastatic Melanoma. , 2018, , 467-481.		1
6888	Adjuvant Therapy of Melanoma. , 2018, , 483-498.		0
6889	Longitudinal studies of the 18F-FDG kinetics after ipilimumab treatment in metastatic melanoma patients based on dynamic FDG PET/CT. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1261-1270.	2.0	22
6893	Monoclonal antibodies as immunomodulatory therapy against cancer and autoimmune diseases. <i>Current Opinion in Pharmacology</i> , 2018, 41, 114-121.	1.7	97
6894	Driving cars to the clinic for solid tumors. <i>Gene Therapy</i> , 2018, 25, 165-175.	2.3	67
6896	Current Immunotherapy of Melanoma. , 2018, , 567-576.		0
6897	Immune-Related Adverse Toxicities and Clinical Management. , 2018, , 577-589.		0
6898	Immunotherapy Resistance by Inflammation-Induced Dedifferentiation. <i>Cancer Discovery</i> , 2018, 8, 935-943.	7.7	130
6899	Innate Immunity in Inflammation. , 2018, , 179-190.		1
6900	Mouse models of hepatocellular carcinoma: an overview and highlights for immunotherapy research. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018, 15, 536-554.	8.2	158
6901	Immunotherapy and next-generation sequencing guided therapy for precision oncology: what have we learnt and what does the future hold?. <i>Expert Review of Precision Medicine and Drug Development</i> , 2018, 3, 205-213.	0.4	7
6902	New developments in systemic therapy for advanced biliary tract cancer. <i>Japanese Journal of Clinical Oncology</i> , 2018, 48, 703-711.	0.6	64

#	ARTICLE	IF	CITATIONS
6903	Patterns of disease control and survival in patients with melanoma brain metastases undergoing immune-checkpoint blockade. <i>European Journal of Cancer</i> , 2018, 99, 58-65.	1.3	8
6904	Adipocyte-Derived Lipids Mediate Melanoma Progression via FATP Proteins. <i>Cancer Discovery</i> , 2018, 8, 1006-1025.	7.7	248
6905	Immune checkpoint inhibition in gastric cancer: A systematic review. <i>Journal of Cellular Immunotherapy</i> , 2018, 4, 49-55.	0.6	7
6906	Breast Cancer Immunotherapy: An Update. <i>Breast Cancer: Basic and Clinical Research</i> , 2018, 12, 117822341877480.	0.6	37
6907	In vitro and in vivo characterization of pharmaceutical topical nanocarriers containing anticancer drugs for skin cancer treatment. , 2018, , 563-627.		21
6908	The Latest Cancer Agents and Their Complications. <i>Emergency Medicine Clinics of North America</i> , 2018, 36, 485-492.	0.5	8
6909	Sensitivity of different MRI sequences in the early detection of melanoma brain metastases. <i>PLoS ONE</i> , 2018, 13, e0193946.	1.1	27
6910	Pharmacologic Modulation of Human Immunity in the Era of Immuno-oncology: Something Old, Something New. <i>Mayo Clinic Proceedings</i> , 2018, 93, 917-936.	1.4	4
6911	Cancer immunotherapy: broadening the scope of targetable tumours. <i>Open Biology</i> , 2018, 8, .	1.5	162
6912	It is finally time for adjuvant therapy in melanoma. <i>Cancer Treatment Reviews</i> , 2018, 69, 101-111.	3.4	37
6913	SPIRIT: A seamless phase I/II randomized design for immunotherapy trials. <i>Pharmaceutical Statistics</i> , 2018, 17, 527-540.	0.7	10
6914	Recent progress in therapeutic antibodies for cancer immunotherapy. <i>Current Opinion in Chemical Biology</i> , 2018, 44, 56-65.	2.8	21
6915	Non-conventional Inhibitory CD4+Foxp3 ^{hi} PD-1 ^{hi} T Cells as a Biomarker of Immune Checkpoint Blockade Activity. <i>Cancer Cell</i> , 2018, 33, 1017-1032.e7.	7.7	112
6916	The immunological synapse as a pharmacological target. <i>Pharmacological Research</i> , 2018, 134, 118-133.	3.1	13
6917	Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 c259T Cells in Synovial Sarcoma. <i>Cancer Discovery</i> , 2018, 8, 944-957.	7.7	313
6918	MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 916-929.	5.1	131
6919	The reciprocal function and regulation of tumor vessels and immune cells offers new therapeutic opportunities in cancer. <i>Seminars in Cancer Biology</i> , 2018, 52, 107-116.	4.3	57
6920	Immune checkpoint inhibitors and radiosurgery for newly diagnosed melanoma brain metastases. <i>Journal of Neuro-Oncology</i> , 2018, 140, 55-62.	1.4	25

#	ARTICLE	IF	CITATIONS
6921	Immune checkpoint inhibitor PD-1 pathway is down-regulated in synovium at various stages of rheumatoid arthritis disease progression. PLoS ONE, 2018, 13, e0192704.	1.1	82
6922	Molecular Mechanisms Underlying the Action of Ipilimumab Against Metastatic Melanoma. , 2018, , 85-96.		1
6923	Immune check-point in cervical cancer. Critical Reviews in Oncology/Hematology, 2018, 129, 40-43.	2.0	38
6924	Personalized medicine in brain metastases: a plea for more translational studies. Personalized Medicine, 2018, 15, 141-143.	0.8	0
6925	Single-Cell Proteomics for Cancer Immunotherapy. Advances in Cancer Research, 2018, 139, 185-207.	1.9	21
6926	Immunotherapy of Cancer. , 2019, , 1033-1048.e1.		3
6927	Cardiac Immune-Related Adverse Events in Immune Checkpoint Inhibition Therapy. Cardiology in Review, 2019, 27, 97-107.	0.6	19
6928	Clinical Development and Initial Approval of Novel Immune Checkpoint Inhibitors in Oncology: Insights From a Global Regulatory Perspective. Clinical Pharmacology and Therapeutics, 2019, 105, 582-597.	2.3	8
6929	Adverse Effects of Immune Checkpoint Therapy in Cancer Patients Visiting the Emergency Department of a Comprehensive Cancer Center. Annals of Emergency Medicine, 2019, 73, 79-87.	0.3	68
6930	Lect2 Controls Inflammatory Monocytes to Constrain the Growth and Progression of Hepatocellular Carcinoma. Hepatology, 2019, 69, 160-178.	3.6	36
6931	Anorexia, vomiting and weight loss in a 22-year-old woman. Gut, 2019, 68, 803-927.	6.1	3
6932	Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers. Clinical Cancer Research, 2019, 25, 1233-1238.	3.2	260
6933	Myositis as an adverse event of immune checkpoint blockade for cancer therapy. Seminars in Arthritis and Rheumatism, 2019, 48, 736-740.	1.6	90
6934	Functional genomics: paving the way for more successful cancer immunotherapy. Briefings in Functional Genomics, 2019, 18, 86-98.	1.3	6
6935	Patient-reported treatment-related symptom burden for patients with advanced melanoma in Canada. Supportive Care in Cancer, 2019, 27, 219-227.	1.0	5
6936	Acquired resistance to cancer immunotherapy. Seminars in Immunopathology, 2019, 41, 31-40.	2.8	34
6937	Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma. Gut, 2019, 68, 916-927.	6.1	228
6938	Interventional therapy combined with immune checkpoint inhibitors: Emerging opportunities for cancer treatment in the era of immunotherapy. Cancer Treatment Reviews, 2019, 74, 49-60.	3.4	38

#	ARTICLE	IF	CITATIONS
6939	Impact of clinicopathological characteristics on survival in patients treated with immune checkpoint inhibitors for metastatic melanoma. <i>International Journal of Cancer</i> , 2019, 144, 169-177.	2.3	9
6940	Materials-Based Cancer Immunotherapies. , 2019, , 715-739.		2
6941	Evaluation of safety and efficacy of p53MVA vaccine combined with pembrolizumab in patients with advanced solid cancers. <i>Clinical and Translational Oncology</i> , 2019, 21, 363-372.	1.2	57
6942	Immunotherapy and targeted therapies in older patients with advanced melanoma; Young International Society of Geriatric Oncology review paper. <i>Journal of Geriatric Oncology</i> , 2019, 10, 389-397.	0.5	20
6943	Therapeutic cancer vaccine: building the future from lessons of the past. <i>Seminars in Immunopathology</i> , 2019, 41, 69-85.	2.8	56
6944	What do we know about cancer immunotherapy? Long-term survival and immune-related adverse events. <i>Allergologia Et Immunopathologia</i> , 2019, 47, 303-308.	1.0	10
6945	Emerging predictors of the response to the blockade of immune checkpoints in cancer therapy. <i>Cellular and Molecular Immunology</i> , 2019, 16, 28-39.	4.8	57
6946	Cancer immunotherapy for metastasis: past, present and future. <i>Briefings in Functional Genomics</i> , 2019, 18, 140-146.	1.3	10
6947	Does patient age influence anti-cancer immunity?. <i>Seminars in Immunopathology</i> , 2019, 41, 125-131.	2.8	60
6948	Modulating T-cell-based cancer immunotherapy via particulate systems. <i>Journal of Drug Targeting</i> , 2019, 27, 145-163.	2.1	10
6949	Oral Mucosal Injury Caused by Targeted Cancer Therapies. <i>Journal of the National Cancer Institute Monographs</i> , 2019, 2019, .	0.9	14
6950	Exercise Behaviors and Fatigue in Patients Receiving Immunotherapy for Advanced Melanoma: A Cross-Sectional Survey via Social Media. <i>Integrative Cancer Therapies</i> , 2019, 18, 153473541986443.	0.8	14
6951	Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells. <i>Journal of Autoimmunity</i> , 2019, 104, 102310.	3.0	57
6952	Review article: immune checkpoint inhibitors and the liver, from therapeutic efficacy to side effects. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 872-884.	1.9	31
6953	A Case of Immunotherapy-Induced Colitis Complicated by Perforation and Treated with Infliximab Postoperatively. <i>Case Reports in Oncological Medicine</i> , 2019, 2019, 1-6.	0.2	8
6954	On the Horizon: Targeting Next-Generation Immune Checkpoints for Cancer Treatment. <i>Chemotherapy</i> , 2019, 64, 62-80.	0.8	34
6955	Treatment patterns and outcomes for patients with unresectable stage III and metastatic melanoma in the USA. <i>Journal of Comparative Effectiveness Research</i> , 2019, 8, 461-473.	0.6	16
6956	A case of checkpoint inhibitor-induced celiac disease. , 2019, 7, 203.		25

#	ARTICLE	IF	CITATIONS
6957	Transcutaneous immunization with CD40 ligation boosts cytotoxic T lymphocyte mediated antitumor immunity independent of CD4 helper cells in mice. <i>European Journal of Immunology</i> , 2019, 49, 2083-2094.	1.6	8
6958	Management of Locally and Regionally Recurrent Melanoma. , 2019, , 515-534.		0
6959	Adjuvant Therapy. , 2019, , 717-741.		0
6960	Side Effects of Systemic Therapy and Their Clinical Management. , 2019, , 773-789.		0
6961	Melanoma Immunology and Immunotherapy. , 2019, , 651-665.		0
6962	Mucosal Melanoma. , 2019, , 439-452.		1
6963	Epigenetic Regulation in Melanoma. , 2019, , 83-98.		1
6964	Circadian Rhythms and Personalized Melanoma Therapy. <i>Europeanization and Globalization</i> , 2019, , 327-340.	0.1	0
6965	Immune microenvironment profiling of gastrointestinal stromal tumors (GIST) shows gene expression patterns associated to immune checkpoint inhibitors response. <i>Oncolimmunology</i> , 2019, 8, e1617588.	2.1	41
6966	Immune checkpoint inhibitorsâ€”induced neuromuscular toxicity: From pathogenesis to treatment. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, S74-S85.	1.4	42
6967	High Affinity of Chlorin e6 to Immunoglobulin G for Intraoperative Fluorescence Image-Guided Cancer Photodynamic and Checkpoint Blockade Therapy. <i>ACS Nano</i> , 2019, 13, 10242-10260.	7.3	78
6968	Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches. <i>Radiation Oncology</i> , 2019, 14, 141.	1.2	285
6969	Chronic Implant-Related Bone Infectionsâ€”Can Immune Modulation be a Therapeutic Strategy?. <i>Frontiers in Immunology</i> , 2019, 10, 1724.	2.2	124
6970	Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2019, 25, 2416-2429.	1.4	66
6971	The Role of the Lymphocyte Functional Crosstalk and Regulation in the Context of Checkpoint Inhibitor Treatmentâ€”Review. <i>Frontiers in Immunology</i> , 2019, 10, 2043.	2.2	7
6972	<i>Mycobacterium bovis</i> BCG in metastatic melanoma therapy. <i>Applied Microbiology and Biotechnology</i> , 2019, 103, 7903-7916.	1.7	15
6973	Tuning the Tumor Myeloid Microenvironment to Fight Cancer. <i>Frontiers in Immunology</i> , 2019, 10, 1611.	2.2	96
6974	Serious immuneâ€”related adverse events in patients with head and neck cancer after checkpoint blockade: Systematic review. <i>Head and Neck</i> , 2019, 41, 4036-4050.	0.9	3

#	ARTICLE	IF	CITATIONS
6975	Immune microenvironment modulation unmasks therapeutic benefit of radiotherapy and checkpoint inhibition. , 2019, 7, 216.		56
6976	The neurotoxic effects of immune checkpoint inhibitor therapy for melanoma. <i>Melanoma Management</i> , 2019, 6, MMT16.	0.1	2
6977	Therapeutic vaccination immunomodulation: forming the basis of all cancer immunotherapy. , 2019, 7, 251513551986223.	1.4	28
6978	Peripheral PD-1+CD56+ T-cell frequencies correlate with outcome in stage IV melanoma under PD-1 blockade. <i>PLoS ONE</i> , 2019, 14, e0221301.	1.1	16
6979	Overexpression of PDE4A Acts as Checkpoint Inhibitor Against cAMP-Mediated Immunosuppression in vitro. <i>Frontiers in Immunology</i> , 2019, 10, 1790.	2.2	12
6980	Engineering patient-specific cancer immunotherapies. <i>Nature Biomedical Engineering</i> , 2019, 3, 768-782.	11.6	123
6981	Immune checkpoint inhibitor-based combinations: is dose escalation mandatory for phase I trials?. <i>Annals of Oncology</i> , 2019, 30, 1751-1759.	0.6	13
6983	A Review of Immune-Mediated Adverse Events in Melanoma. <i>Oncology and Therapy</i> , 2019, 7, 101-120.	1.0	23
6984	Excellent Response to Nivolumab and Ipilimumab in Metastatic Gastroesophageal Junction Squamous Carcinoma. <i>Case Reports in Oncological Medicine</i> , 2019, 2019, 1-3.	0.2	1
6985	Preponderance of CTLA4 Variation Associated With Autosomal Dominant Immune Dysregulation in the MYPPPY Motif. <i>Frontiers in Immunology</i> , 2019, 10, 1544.	2.2	14
6986	HIV Infection, Cancer Treatment Regimens, and Cancer Outcomes Among Elderly Adults in the United States. <i>JAMA Oncology</i> , 2019, 5, e191742.	3.4	45
6987	Personalized Medicine in Healthcare Systems. <i>Europeanization and Globalization</i> , 2019, , .	0.1	2
6988	A tumor-targeted immune checkpoint blocker. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 15889-15894.	3.3	21
6989	Systemic Therapies for Advanced Melanoma. <i>Dermatologic Clinics</i> , 2019, 37, 409-423.	1.0	42
6990	Building on the anti-PD1/PD-L1 backbone: combination immunotherapy for cancer. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 695-708.	1.9	38
6991	Intratumorally delivered formulation, INT230-6, containing potent anticancer agents induces protective T cell immunity and memory. <i>Oncolimmunology</i> , 2019, 8, e1625687.	2.1	9
6992	Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma. , 2019, 7, 196.		62
6993	Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study. <i>Arthritis and Rheumatology</i> , 2019, 71, 2100-2111.	2.9	202

#	ARTICLE	IF	CITATIONS
6994	Immunization with mannosylated nanovaccines and inhibition of the immune-suppressing microenvironment sensitizes melanoma to immune checkpoint modulators. <i>Nature Nanotechnology</i> , 2019, 14, 891-901.	15.6	167
6995	Characterization of patients with metastatic non-small-cell lung cancer obtaining long-term benefit from immunotherapy. <i>Future Oncology</i> , 2019, 15, 2743-2757.	1.1	7
6996	Hepatocellular carcinoma: Mechanisms of progression and immunotherapy. <i>World Journal of Gastroenterology</i> , 2019, 25, 3151-3167.	1.4	80
6997	Cancer therapeutic implications of microRNAs in the regulation of immune checkpoint blockade. <i>ExRNA</i> , 2019, 1, .	1.0	6
6998	Immune recurrence score using 7 immunoregulatory protein expressions can predict recurrence in stage III breast cancer patients. <i>British Journal of Cancer</i> , 2019, 121, 230-236.	2.9	14
6999	Tumor mutational burden quantification from targeted gene panels: major advancements and challenges. , 2019, 7, 183.		231
7000	Novel Delivery Systems for Checkpoint Inhibitors. <i>Medicines (Basel, Switzerland)</i> , 2019, 6, 74.	0.7	24
7001	Immunotherapy in Dialysis-Dependent Cancer Patients: Our Experience in Patients With Metastatic Renal Cell Carcinoma and a Review of the Literature. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e903-e908.	0.9	30
7002	Photoacoustic imaging as a tool to probe the tumour microenvironment. <i>DMM Disease Models and Mechanisms</i> , 2019, 12, .	1.2	57
7003	Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	147
7004	The Role of Biomarkers for the Prediction of Response to Checkpoint Immunotherapy and the Rationale for the Use of Checkpoint Immunotherapy in Cervical Cancer. <i>Clinical Oncology</i> , 2019, 31, 834-843.	0.6	48
7005	Tumor Vasculatures: A New Target for Cancer Immunotherapy. <i>Trends in Pharmacological Sciences</i> , 2019, 40, 613-623.	4.0	79
7006	Pretreatment of Glioblastoma with Bortezomib Potentiates Natural Killer Cell Cytotoxicity through TRAIL/DR5 Mediated Apoptosis and Prolongs Animal Survival. <i>Cancers</i> , 2019, 11, 996.	1.7	28
7007	Role of tumor gene mutations in treatment response to immune checkpoint blockades. <i>Precision Clinical Medicine</i> , 2019, 2, 100-109.	1.3	11
7008	Use of Circulating Tumor DNA for Cancer Immunotherapy. <i>Clinical Cancer Research</i> , 2019, 25, 6909-6915.	3.2	34
7009	Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma. <i>Experimental Hematology and Oncology</i> , 2019, 8, 14.	2.0	10
7010	LINC0638 lncRNA is involved in the local recurrence of melanoma following surgical resection. <i>Oncology Letters</i> , 2019, 18, 101-108.	0.8	10
7011	Surgery for gastrointestinal metastases of malignant melanoma – a retrospective exploratory study. <i>World Journal of Surgical Oncology</i> , 2019, 17, 123.	0.8	8

#	ARTICLE	IF	CITATIONS
7012	Immune-Related Adverse Events: A Case-Based Approach. <i>Frontiers in Oncology</i> , 2019, 9, 530.	1.3	31
7013	Clinical update on head and neck cancer: molecular biology and ongoing challenges. <i>Cell Death and Disease</i> , 2019, 10, 540.	2.7	339
7015	Phenotypic characterisation of immune cells associated with histological regression in cutaneous melanoma. <i>Pathology</i> , 2019, 51, 487-493.	0.3	19
7016	Macroangiopathy is a positive predictive factor for response to immunotherapy. <i>Scientific Reports</i> , 2019, 9, 9728.	1.6	6
7017	Frugoside Induces Mitochondria-Mediated Apoptotic Cell Death through Inhibition of Sulfiredoxin Expression in Melanoma Cells. <i>Cancers</i> , 2019, 11, 854.	1.7	4
7018	Possible Biomarkers for Cancer Immunotherapy. <i>Cancers</i> , 2019, 11, 935.	1.7	35
7019	Uveal Melanoma: Metastases. , 2019, , 317-329.		0
7021	Hepatotoxicity of immune check point inhibitors: Approach and management. <i>Digestive and Liver Disease</i> , 2019, 51, 1074-1078.	0.4	32
7022	Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance. , 2019, 7, 165.		135
7023	The impact of targeted therapies and immunotherapy in melanoma brain metastases: A systematic review and meta-analysis. <i>Cancer</i> , 2019, 125, 3776-3789.	2.0	48
7024	Cellular Therapy for Melanoma. , 2019, , 1-33.		0
7025	Treatment of HER2-Negative Metastatic Breast Cancer: Chemotherapy. , 2019, , 449-462.		0
7026	Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity Threshold. <i>Cell</i> , 2019, 178, 585-599.e15.	13.5	162
7027	Effectiveness and safety of concurrent stereotactic radiotherapy and immunotherapy in metastatic solid tumors: a systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 142, 9-15.	2.0	13
7028	Ipilimumab-induced hypophysitis, a single academic center experience. <i>Pituitary</i> , 2019, 22, 488-496.	1.6	28
7029	Efficacy and Adverse Events of Immunotherapy with Checkpoint Inhibitors in Older Patients with Cancer. <i>Drugs and Aging</i> , 2019, 36, 927-938.	1.3	74
7030	Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. <i>Lancet Oncology</i> , The, 2019, 20, 1239-1251.	5.1	812
7031	5-year results for pembrolizumab treatment of advanced melanoma. <i>Lancet Oncology</i> , The, 2019, 20, 1187-1189.	5.1	5

#	ARTICLE	IF	CITATIONS
7032	Linking Tumor Growth Dynamics to Survival in Ipilimumab-Treated Patients With Advanced Melanoma Using Mixture Tumor Growth Dynamic Modeling. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2019, 8, 825-834.	1.3	11
7033	Macrophage-Mediated Subversion of Anti-Tumour Immunity. <i>Cells</i> , 2019, 8, 747.	1.8	68
7034	T Cell-Activating Bispecific Antibodies in Cancer Therapy. <i>Journal of Immunology</i> , 2019, 203, 585-592.	0.4	55
7035	Immunotherapy for hepatocellular carcinoma: recent advances and future perspectives. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591986269.	1.4	75
7036	Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab. <i>JAMA Oncology</i> , 2019, 5, 1411.	3.4	388
7037	PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences Are Emerging. A Literature Review. <i>Cancers</i> , 2019, 11, 1033.	1.7	160
7038	CTLA-4 antibody ipilimumab negatively affects CD4+ T-cell responses in vitro. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1359-1368.	2.0	23
7039	Immunomodulatory germline variation associated with the development of multiple primary melanoma (MPM). <i>Scientific Reports</i> , 2019, 9, 10173.	1.6	6
7040	First-in-human phase 1 study of IT1208, a defucosylated humanized anti-CD4 depleting antibody, in patients with advanced solid tumors. <i>Journal of Immunotherapy</i> , 2019, 7, 195.		32
7041	Phase I Trial of Targeted EGFR or ALK Therapy with Ipilimumab in Metastatic NSCLC with Long-Term Follow-Up. <i>Targeted Oncology</i> , 2019, 14, 417-421.	1.7	34
7042	Novel and emerging therapies for B cell lymphoma. <i>Journal of Hematology and Oncology</i> , 2019, 12, 82.	6.9	37
7043	Comparative Radioimmunotherapy of Experimental Melanoma with Novel Humanized Antibody to Melanin Labeled with ²¹³ Bismuth and ¹⁷⁷ Lutetium. <i>Pharmaceutics</i> , 2019, 11, 348.	2.0	18
7044	The Role of BRAF-Targeted Therapy for Advanced Melanoma in the Immunotherapy Era. <i>Current Oncology Reports</i> , 2019, 21, 76.	1.8	18
7045	A Pilot Study of the PD-1 Targeting Agent AMP-224 Used With Low-Dose Cyclophosphamide and Stereotactic Body Radiation Therapy in Patients With Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2019, 18, e349-e360.	1.0	31
7046	Degradation of CTLA-4 balances toxicity and efficacy. <i>Science Bulletin</i> , 2019, 64, 1388-1389.	4.3	2
7047	Sentinel lymph node biopsy in the management of conjunctival melanoma: current insights. <i>Clinical Ophthalmology</i> , 2019, Volume 13, 1297-1302.	0.9	11
7048	T Cell Dysfunction in Cancer Immunity and Immunotherapy. <i>Frontiers in Immunology</i> , 2019, 10, 1719.	2.2	219
7049	The influence of microenvironment on tumor immunotherapy. <i>FEBS Journal</i> , 2019, 286, 4160-4175.	2.2	64

#	ARTICLE	IF	CITATIONS
7050	Characterization and Comparison of GITR Expression in Solid Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 6501-6510.	3.2	37
7051	Comprehensive Clinical Trial Data Summation for BRAF-MEK Inhibition and Checkpoint Immunotherapy in Metastatic Melanoma. <i>Oncologist</i> , 2019, 24, e1197-e1211.	1.9	15
7052	DNAM-1 and the TIGIT/PVRIG/TACTILE Axis: Novel Immune Checkpoints for Natural Killer Cell-Based Cancer Immunotherapy. <i>Cancers</i> , 2019, 11, 877.	1.7	151
7053	Conjunctival Melanoma Targeted Therapy: MAPK and PI3K/mTOR Pathways Inhibition. , 2019, 60, 2764.		24
7054	Potential immune escape mechanisms underlying the distinct clinical outcome of immune checkpoint blockades in small cell lung cancer. <i>Journal of Hematology and Oncology</i> , 2019, 12, 67.	6.9	54
7055	Immune checkpoint blockade in glioma. , 2019, , 387-396.		0
7056	Immunomodulatory Methods. , 2019, , 297-334.		2
7057	Generating viable mice with heritable embryonically lethal mutations using the CRISPR-Cas9 system in two-cell embryos. <i>Nature Communications</i> , 2019, 10, 2883.	5.8	23
7058	L-Selectin Enhanced T Cells Improve the Efficacy of Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2019, 10, 1321.	2.2	50
7059	Modifiable Host Factors in Melanoma: Emerging Evidence for Obesity, Diet, Exercise, and the Microbiome. <i>Current Oncology Reports</i> , 2019, 21, 72.	1.8	29
7060	Cellular Therapies for the Treatment of Hematological Malignancies; Swine Are an Ideal Preclinical Model. <i>Frontiers in Oncology</i> , 2019, 9, 418.	1.3	7
7061	Uveal Versus Cutaneous Melanoma; Same Origin, Very Distinct Tumor Types. <i>Cancers</i> , 2019, 11, 845.	1.7	58
7062	Targeting Treg cells in cancer immunotherapy. <i>European Journal of Immunology</i> , 2019, 49, 1140-1146.	1.6	303
7063	Hijacking antibody-induced CTLA-4 lysosomal degradation for safer and more effective cancer immunotherapy. <i>Cell Research</i> , 2019, 29, 609-627.	5.7	74
7064	The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: a new independent prognostic factor?. <i>Annals of Oncology</i> , 2019, 30, 1572-1579.	0.6	153
7065	Isolated limb perfusion and infusion in the treatment of melanoma and soft tissue sarcoma in the era of modern systemic therapies. <i>Journal of Surgical Oncology</i> , 2019, 120, 540-549.	0.8	10
7066	Drug-Induced Injury, Polyps, Congenital, and Miscellaneous Disorders. , 2019, , 289-306.		0
7067	Current Immunotherapy Practices in Melanoma. <i>Surgical Oncology Clinics of North America</i> , 2019, 28, 403-418.	0.6	18

#	ARTICLE	IF	CITATIONS
7068	Vaccine Strategy in Melanoma. <i>Surgical Oncology Clinics of North America</i> , 2019, 28, 337-351.	0.6	17
7069	Future Research Goals in Immunotherapy. <i>Surgical Oncology Clinics of North America</i> , 2019, 28, 505-518.	0.6	2
7070	The Current Landscape of Immune Checkpoint Inhibition for Solid Malignancies. <i>Surgical Oncology Clinics of North America</i> , 2019, 28, 369-386.	0.6	19
7071	Role of Surgery in Combination with Immunotherapy. <i>Surgical Oncology Clinics of North America</i> , 2019, 28, 481-487.	0.6	3
7072	Expression of lymphocyte immunoregulatory biomarkers in bone and soft-tissue sarcomas. <i>Modern Pathology</i> , 2019, 32, 1772-1785.	2.9	61
7073	Immune Checkpoint Inhibitor Toxicities. <i>Mayo Clinic Proceedings</i> , 2019, 94, 1321-1329.	1.4	105
7074	Survival Outcomes of Patients with Clinical Stage III Melanoma in the Era of Novel Systemic Therapies. <i>Annals of Surgical Oncology</i> , 2019, 26, 4621-4630.	0.7	10
7075	Quantitative high-throughput screening assays for the discovery and development of SIRP±-CD47 interaction inhibitors. <i>PLoS ONE</i> , 2019, 14, e0218897.	1.1	28
7076	Immune-related adverse events following administration of anti-cytotoxic T-lymphocyte-associated protein-4 drugs: a comprehensive systematic review and meta-analysis. <i>Drug Design, Development and Therapy</i> , 2019, Volume 13, 2215-2234.	2.0	20
7077	Cell signaling and cancer: a mechanistic insight into drug resistance. <i>Molecular Biology Reports</i> , 2019, 46, 5645-5659.	1.0	63
7078	Role of immune checkpoint inhibitors in the treatment of colorectal cancer: focus on nivolumab. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 1247-1263.	1.4	29
7079	Real-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma. <i>Cancers</i> , 2019, 11, 1489.	1.7	37
7080	Monocytes reprogrammed with lentiviral vectors co-expressing GM-CSF, IFN- γ and antigens for personalized immune therapy of acute leukemia pre- or post-stem cell transplantation. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1891-1899.	2.0	10
7081	Analysis of the survival of patients receiving systemic treatment for melanoma of the skin: a retrospective population study with patients treated in Poland in 2011–2015. <i>Postepy Dermatologii i Alergologii</i> , 2019, 36, 438-441.	0.4	2
7082	Exploiting autoimmunity unleashed by low-dose immune checkpoint blockade to treat advanced cancer. <i>Scandinavian Journal of Immunology</i> , 2019, 90, e12821.	1.3	20
7083	Susceptible loci associated with autoimmune disease as potential biomarkers for checkpoint inhibitor-induced immune-related adverse events. <i>ESMO Open</i> , 2019, 4, e000472.	2.0	26
7084	Melanoma Growth Analysis in Blood Serum and Tissue Using Xenograft Model with Response to Cold Atmospheric Plasma Activated Medium. <i>Applied Sciences (Switzerland)</i> , 2019, 9, 4227.	1.3	26
7085	Preclinical rationale and clinical efficacy of antiangiogenic therapy and immune checkpoint blockade combination therapy in urogenital tumors. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 3021-3036.	1.2	20

#	ARTICLE	IF	CITATIONS
7086	Emergent Nanotechnological Strategies for Systemic Chemotherapy against Melanoma. <i>Nanomaterials</i> , 2019, 9, 1455.	1.9	34
7087	Principles of prophylactic and therapeutic management of skin toxicity during treatment with checkpoint inhibitors. <i>Postepy Dermatologii i Alergologii</i> , 2019, 36, 382-391.	0.4	24
7088	Malignancy and myositis, from molecular mimicry to tumor infiltrating lymphocytes. <i>Neuromuscular Disorders</i> , 2019, 29, 819-825.	0.3	12
7089	The mechanisms of acute interstitial nephritis in the era of immune checkpoint inhibitors in melanoma. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591987554.	1.4	21
7090	Diagnosis and Management of Immune Related Adverse Events (irAEs) in Cancer Immunotherapy. <i>Biomedicine and Pharmacotherapy</i> , 2019, 120, 109437.	2.5	45
7091	Predicting response to pembrolizumab in metastatic melanoma by a new personalization algorithm. <i>Journal of Translational Medicine</i> , 2019, 17, 338.	1.8	16
7092	Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients. <i>Genome Medicine</i> , 2019, 11, 61.	3.6	134
7093	Potential clinical application of tumor-infiltrating lymphocyte therapy for ovarian epithelial cancer prior or post-resistance to chemotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1747-1757.	2.0	16
7094	Impact of the microbiome on checkpoint inhibitor treatment in patients with non-small cell lung cancer and melanoma. <i>EBioMedicine</i> , 2019, 48, 642-647.	2.7	38
7095	Common gamma chain cytokines and CD8 T cells in cancer. <i>Seminars in Immunology</i> , 2019, 42, 101307.	2.7	25
7096	Fucosylated α 1-acid glycoprotein as a biomarker to predict prognosis following tumor immunotherapy of patients with lung cancer. <i>Scientific Reports</i> , 2019, 9, 14503.	1.6	16
7097	An innate-like $\gamma\delta$ T cell compartment in the human breast is associated with remission in triple-negative breast cancer. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	110
7098	An Integrative Approach to Inform Optimal Administration of OX40 Agonist Antibodies in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 6709-6720.	3.2	32
7099	Expression of CMV protein pp65 in cutaneous malignant melanoma. <i>PLoS ONE</i> , 2019, 14, e0223854.	1.1	1
7100	Delivery rate of patients with advanced gastric cancer to third-line chemotherapy and those patients's characteristics: an analysis in real-world setting. <i>Journal of Gastrointestinal Oncology</i> , 2019, 10, 957-964.	0.6	4
7101	Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors. <i>Frontiers in Oncology</i> , 2019, 9, 849.	1.3	117
7102	Glycogen synthase 3 (GSK-3) regulation of PD-1 expression and and its therapeutic implications. <i>Seminars in Immunology</i> , 2019, 42, 101295.	2.7	16
7103	CTLA-4 (CD152): A versatile receptor for immune-based therapy. <i>Seminars in Immunology</i> , 2019, 42, 101298.	2.7	49

#	ARTICLE	IF	CITATIONS
7104	Targeting the TIGIT-PVR immune checkpoint axis as novel therapeutic option in breast cancer. <i>Oncolmmunology</i> , 2019, 8, e1674605.	2.1	59
7105	Patient-specific dendritic cell vaccines with autologous tumor antigens in 72 patients with metastatic melanoma. <i>Melanoma Management</i> , 2019, 6, MMT20.	0.1	9
7106	The Relative Risk of Immune-Related Liver Dysfunction of PD-1/PD-L1 Inhibitors Versus Chemotherapy in Solid Tumors: A Meta-Analysis of Randomized Controlled Trials. <i>Frontiers in Pharmacology</i> , 2019, 10, 1063.	1.6	7
7107	Endocrine-related adverse events associated with immune-checkpoint inhibitors in patients with melanoma. <i>Cancer Medicine</i> , 2019, 8, 6585-6594.	1.3	31
7108	Adverse Effects of Immune Checkpoint Inhibitors (Programmed Death-1 Inhibitors and Cytotoxic) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 <i>Medicine Research</i> , 2019, 11, 225-236.	0.6	133
7109	Impact of clinicopathological features on the efficacy of immune checkpoint inhibitors plus conventional treatment in patients with advanced lung cancer. <i>Journal of Thoracic Disease</i> , 2019, 11, 3794-3807.	0.6	3
7110	The Incidence, Causes, and Risk Factors of Acute Kidney Injury in Patients Receiving Immune Checkpoint Inhibitors. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 1692-1700.	2.2	193
7111	Little Consistency In Evidence Cited By Commercial Plans For Specialty Drug Coverage. <i>Health Affairs</i> , 2019, 38, 1882-1886.	2.5	13
7112	Integrin $\alpha_3\beta_1$ -targeted radionuclide therapy combined with immune checkpoint blockade immunotherapy synergistically enhances anti-tumor efficacy. <i>Theranostics</i> , 2019, 9, 7948-7960.	4.6	64
7113	Baseline clinical and imaging predictors of treatment response and overall survival of patients with metastatic melanoma undergoing immunotherapy. <i>European Journal of Radiology</i> , 2019, 121, 108688.	1.2	20
7114	Beyond tumor mutational burden: potential and limitations in using exosomes to predict response to immunotherapy. <i>Expert Review of Molecular Diagnostics</i> , 2019, 19, 1079-1088.	1.5	15
7115	Advances in Engineering Cells for Cancer Immunotherapy. <i>Theranostics</i> , 2019, 9, 7889-7905.	4.6	44
7116	Immune checkpoint inhibitor-associated pituitary-adrenal dysfunction: A systematic review and meta-analysis. <i>Cancer Medicine</i> , 2019, 8, 7503-7515.	1.3	35
7117	Acute kidney injury from immune checkpoint inhibitor use. <i>BMJ Case Reports</i> , 2019, 12, e231211.	0.2	6
7118	A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma. <i>European Journal of Cancer</i> , 2019, 123, 58-71.	1.3	45
7119	Lesion-Level Response Dynamics to Programmed Cell Death Protein (PD-1) Blockade. <i>Journal of Clinical Oncology</i> , 2019, 37, 3546-3555.	0.8	78
7120	Oncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanoma. <i>EBioMedicine</i> , 2019, 49, 96-105.	2.7	47
7121	An inhalable nanoparticulate STING agonist synergizes with radiotherapy to confer long-term control of lung metastases. <i>Nature Communications</i> , 2019, 10, 5108.	5.8	148

#	ARTICLE	IF	CITATIONS
7122	Managing in-transit melanoma metastases in the new era of effective systemic therapies for melanoma. Expert Review of Clinical Pharmacology, 2019, 12, 1107-1119.	1.3	11
7123	Clinical efficacy and safety of anti-PD-1/PD-L1 treatments in non-small cell lung cancer (NSCLC). Artificial Cells, Nanomedicine and Biotechnology, 2019, 47, 4194-4201.	1.9	6
7124	Adoption of immunotherapy in the community for patients diagnosed with metastatic melanoma. , 2019, 7, 289.		19
7125	Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors. Cancer Cell, 2019, 36, 471-482.	7.7	280
7126	Suppressing immunotherapy by organ-specific tumor microenvironments: what is in the brain?. Cell and Bioscience, 2019, 9, 82.	2.1	6
7127	Immunotherapy in the management of squamous cell carcinoma of the head and neck. British Journal of Oral and Maxillofacial Surgery, 2019, 57, 957-966.	0.4	4
7128	Adverse Events of Concurrent Immune Checkpoint Inhibitors and Antiangiogenic Agents: A Systematic Review. Frontiers in Pharmacology, 2019, 10, 1173.	1.6	35
7129	Novel Immunotherapy Combinations. Current Oncology Reports, 2019, 21, 96.	1.8	12
7130	Melanoma-Targeting Property of Y-90-Labeled Lactam-Cyclized $\hat{\pm}$ -Melanocyte-Stimulating Hormone Peptide. Cancer Biotherapy and Radiopharmaceuticals, 2019, 34, 597-603.	0.7	11
7131	Incidence of Immune Checkpoint Inhibitor-Associated Diabetes: A Meta-Analysis of Randomized Controlled Studies. Frontiers in Pharmacology, 2019, 10, 1453.	1.6	24
7132	A Review on Curability of Cancers: More Efforts for Novel Therapeutic Options Are Needed. Cancers, 2019, 11, 1782.	1.7	53
7133	Testing Immune-Related Adverse Events in Cancer Immunotherapy. Clinics in Laboratory Medicine, 2019, 39, 669-683.	0.7	3
7134	Efficacy of immune checkpoint inhibitors in cancer patients of different ages: a meta-analysis. Future Oncology, 2019, 15, 3633-3646.	1.1	8
7135	Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma. The Cochrane Library, 2019, 7, CD012806.	1.5	22
7136	Crystallographic approaches to study the interaction modes of PD-1- and CTLA-4-blocking antibodies. Methods in Enzymology, 2019, 629, 383-399.	0.4	1
7137	Caffeine-enhanced anti-tumor activity of anti-PD1 monoclonal antibody. International Immunopharmacology, 2019, 77, 106002.	1.7	15
7138	Therapeutic Monoclonal Antibodies Targeting Immune Checkpoints for the Treatment of Solid Tumors. Antibodies, 2019, 8, 51.	1.2	32
7139	The role and therapeutic implications of T cells in cancer of the lung. Clinical and Translational Immunology, 2019, 8, e1076.	1.7	25

#	ARTICLE	IF	CITATIONS
7140	Immune checkpoint inhibitors for head and neck squamous cell carcinoma: Current landscape and future directions. <i>Head and Neck</i> , 2019, 41, 4-18.	0.9	40
7141	Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?. <i>European Journal of Cancer</i> , 2019, 122, 72-90.	1.3	97
7142	Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 22246-22251.	3.3	142
7143	Survival in Early Phase Immuno-Oncology Trials: Development and Validation of a Prognostic Index. <i>JNCI Cancer Spectrum</i> , 2019, 3, pkz071.	1.4	4
7144	Japanese real-world study of sequential nivolumab and ipilimumab treatment in melanoma. <i>Journal of Dermatology</i> , 2019, 46, 947-955.	0.6	11
7146	The Targeted Therapies Era Beyond the Surgical Point of View: What Spine Surgeons Should Know Before Approaching Spinal Metastases. <i>Cancer Control</i> , 2019, 26, 107327481987054.	0.7	16
7147	Blockade of CTLA-4 and Tim-3 pathways induces fetal loss with altered cytokine profiles by decidual CD4+T cells. <i>Cell Death and Disease</i> , 2019, 10, 15.	2.7	33
7148	Comparative efficacy and safety of combination therapies for advanced melanoma: a network meta-analysis. <i>BMC Cancer</i> , 2019, 19, 43.	1.1	31
7149	Targeting Multiple Receptors to Increase Checkpoint Blockade Efficacy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 158.	1.8	29
7150	Neurological Immune Related Adverse Events Associated with Nivolumab, Ipilimumab, and Pembrolizumab Therapy—Review of the Literature and Future Outlook. <i>Journal of Clinical Medicine</i> , 2019, 8, 1777.	1.0	87
7151	Variable indoleamine 2,3-dioxygenase expression in acral/mucosal melanoma and its possible link to immunotherapy. <i>Cancer Science</i> , 2019, 110, 3434-3441.	1.7	13
7152	Novel Biomarkers for Personalized Cancer Immunotherapy. <i>Cancers</i> , 2019, 11, 1223.	1.7	36
7153	Effects of polysaccharides on glycometabolism based on gut microbiota alteration. <i>Trends in Food Science and Technology</i> , 2019, 92, 65-70.	7.8	105
7154	Human Mesenchymal glioblastomas are characterized by an increased immune cell presence compared to Proneural and Classical tumors. <i>Oncolmmunology</i> , 2019, 8, e1655360.	2.1	76
7155	Predictive biomarkers for immune checkpoint blockade and opportunities for combination therapies. <i>Genes and Diseases</i> , 2019, 6, 232-246.	1.5	44
7156	Blood-brain barrier permeable nano immunoconjugates induce local immune responses for glioma therapy. <i>Nature Communications</i> , 2019, 10, 3850.	5.8	199
7157	Phagocytosis checkpoints as new targets for cancer immunotherapy. <i>Nature Reviews Cancer</i> , 2019, 19, 568-586.	12.8	557
7158	Targets for improving tumor response to radiotherapy. <i>International Immunopharmacology</i> , 2019, 76, 105847.	1.7	62

#	ARTICLE	IF	CITATIONS
7159	Radiation as an In Situ Auto-Vaccination: Current Perspectives and Challenges. <i>Vaccines</i> , 2019, 7, 100.	2.1	30
7161	Immune checkpoint inhibitors in esophageal squamous cell carcinoma: progress and opportunities. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 6023-6032.	1.0	25
7162	lncRNA LINC01132 is downregulated in melanoma and regulates cell proliferation by downregulating lncRNA BANCR. <i>Oncology Letters</i> , 2019, 18, 2917-2922.	0.8	12
7163	Selection of patient reported outcomes questions reflecting symptoms for patients with metastatic melanoma receiving immunotherapy. <i>Journal of Patient-Reported Outcomes</i> , 2019, 3, 19.	0.9	17
7164	Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape. , 2019, 7, 224.		154
7165	Kalantuboside B induced apoptosis and cytoprotective autophagy in human melanoma A2058 cells: An in vitro and in vivo study. <i>Free Radical Biology and Medicine</i> , 2019, 143, 397-411.	1.3	20
7166	A Novel Next-Generation Sequencing Approach to Detecting Microsatellite Instability and Pan-Tumor Characterization of 1000 Microsatellite Instability-High Cases in 67,000 Patient Samples. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 1053-1066.	1.2	147
7167	Peritumoural CCL1 and CCL22 expressing cells in hepatocellular carcinomas shape the tumour immune infiltrate. <i>Pathology</i> , 2019, 51, 586-592.	0.3	17
7169	Neoantigen vaccine: an emerging tumor immunotherapy. <i>Molecular Cancer</i> , 2019, 18, 128.	7.9	398
7170	Antibody targeting tumor-derived soluble NKG2D ligand sMIC provides dual co-stimulation of CD8 T cells and enables sMIC+ tumors respond to PD1/PD-L1 blockade therapy. , 2019, 7, 223.		23
7171	Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200. , 2019, 7, 227.		58
7172	Interleukin 4-Induced Gene 1 as an Emerging Regulator of B-Cell Biology and its Role in Cutaneous Melanoma. <i>Critical Reviews in Immunology</i> , 2019, 39, 39-57.	1.0	13
7173	Expression of Programmed Cell Death-Ligands in Hepatocellular Carcinoma: Correlation With Immune Microenvironment and Survival Outcomes. <i>Frontiers in Oncology</i> , 2019, 9, 883.	1.3	40
7174	A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1547-1559.	2.0	32
7175	Immunotherapy in Metastatic Castration-Resistant Prostate Cancer: Past and Future Strategies for Optimization. <i>Current Urology Reports</i> , 2019, 20, 64.	1.0	21
7176	Immune-checkpoint inhibitors for the treatment of metastatic melanoma: a model of cancer immunotherapy. <i>Seminars in Cancer Biology</i> , 2019, 59, 290-297.	4.3	78
7177	The Future of Immunotherapy in the Treatment of Cancer. <i>Seminars in Oncology Nursing</i> , 2019, 35, 150934.	0.7	20
7178	B7-1 drives TGF- β 2 stimulated pancreatic carcinoma cell migration and expression of EMT target genes. <i>PLoS ONE</i> , 2019, 14, e0222083.	1.1	8

#	ARTICLE	IF	CITATIONS
7179	The Evaluation of Response to Immunotherapy in Metastatic Renal Cell Carcinoma: Open Challenges in the Clinical Practice. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4263.	1.8	17
7180	Proteomics of Melanoma Response to Immunotherapy Reveals Mitochondrial Dependence. <i>Cell</i> , 2019, 179, 236-250.e18.	13.5	206
7181	The Janus Face of Tumor Microenvironment Targeted by Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4320.	1.8	43
7182	Oncodermatology of the Head and Neck. <i>Facial Plastic Surgery</i> , 2019, 35, 368-376.	0.5	2
7183	Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy. <i>Journal of Translational Medicine</i> , 2019, 17, 303.	1.8	89
7184	C-reactive protein as an early marker of immune-related adverse events. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 2625-2631.	1.2	59
7185	Looking beyond the hype: Applied AI and machine learning in translational medicine. <i>EBioMedicine</i> , 2019, 47, 607-615.	2.7	82
7186	Glycan-Modified Melanoma-Derived Apoptotic Extracellular Vesicles as Antigen Source for Anti-Tumor Vaccination. <i>Cancers</i> , 2019, 11, 1266.	1.7	47
7187	Ultrathin Metal-Organic-Layer Mediated Radiotherapy-Radiodynamic Therapy. <i>Matter</i> , 2019, 1, 1331-1353.	5.0	78
7188	Sex Differences in Cancer Immunotherapy Efficacy, Biomarkers, and Therapeutic Strategy. <i>Molecules</i> , 2019, 24, 3214.	1.7	106
7189	Principles of Cancer Treatment and Anticancer Drug Development. , 2019, , .		10
7190	Natural Killer Cells Suppress T Cell-Associated Tumor Immune Evasion. <i>Cell Reports</i> , 2019, 28, 2784-2794.e5.	2.9	77
7191	TAM Family Receptor Kinase Inhibition Reverses MDSC-Mediated Suppression and Augments Anti-“PD-1 Therapy in Melanoma. <i>Cancer Immunology Research</i> , 2019, 7, 1672-1686.	1.6	85
7192	A gut punch fights cancer and infection. <i>Nature</i> , 2019, 565, 573-574.	13.7	7
7193	Engineered triple inhibitory receptor resistance improves anti-tumor CAR-T cell performance via CD56. <i>Nature Communications</i> , 2019, 10, 4109.	5.8	72
7194	Toward T Cell-Mediated Control or Elimination of HIV Reservoirs: Lessons From Cancer Immunology. <i>Frontiers in Immunology</i> , 2019, 10, 2109.	2.2	32
7195	Autoantibody-Based Diagnostic Biomarkers: Technological Approaches to Discovery and Validation. , 0, , .		7
7197	Atmospheric reaction networks affecting climate are more complex than was thought. <i>Nature</i> , 2019, 565, 574-575.	13.7	1

#	ARTICLE	IF	CITATIONS
7198	Machine learning defined diagnostic criteria for differentiating pituitary metastasis from autoimmune hypophysitis in patients undergoing immune checkpoint blockade therapy. <i>European Journal of Cancer</i> , 2019, 119, 44-56.	1.3	26
7199	Age favoured overall survival in a large population-based Danish patient cohort treated with anti-PD1 immune checkpoint inhibitor for metastatic melanoma. <i>European Journal of Cancer</i> , 2019, 119, 122-131.	1.3	27
7200	Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985). <i>European Journal of Medicinal Chemistry</i> , 2019, 183, 111682.	2.6	102
7201	Transperineal abdominoperineal resection for anorectal melanoma: A case report. <i>International Journal of Surgery Case Reports</i> , 2019, 61, 214-217.	0.2	1
7202	Direct comparison of target-reactivity and cross-reactivity induced by CAR- and BiTE-redirected T cells for the development of antibody-based T-cell therapy. <i>Scientific Reports</i> , 2019, 9, 13293.	1.6	20
7203	Germline genetic host factors as predictive biomarkers in immuno-oncology. <i>Immuno-Oncology Technology</i> , 2019, 2, 14-21.	0.2	2
7204	RIG-I activation is critical for responsiveness to checkpoint blockade. <i>Science Immunology</i> , 2019, 4, .	5.6	80
7205	Immune checkpoint inhibitor therapy for pediatric cancers: A mini review of endocrine adverse events. <i>Clinical Pediatric Endocrinology</i> , 2019, 28, 59-68.	0.4	15
7206	LAG-3 expression on tumor-infiltrating T cells in soft tissue sarcoma correlates with poor survival. <i>Cancer Biology and Medicine</i> , 2019, 16, 331.	1.4	39
7207	Developing a score system to predict therapeutic outcomes to anti-PD-1 immunotherapy in metastatic melanoma. <i>Tumori</i> , 2019, 105, 465-473.	0.6	4
7208	Future therapeutic strategies for metastatic prostate cancer. <i>Tijdschrift Voor Urologie</i> , 2019, 9, 117-130.	0.1	5
7209	Vaccine protection against rectal acquisition of SIVmac239 in rhesus macaques. <i>PLoS Pathogens</i> , 2019, 15, e1008015.	2.1	7
7210	Safety and Efficacy of Therapeutic Cancer Vaccines Alone or in Combination With Immune Checkpoint Inhibitors in Cancer Treatment. <i>Frontiers in Pharmacology</i> , 2019, 10, 1184.	1.6	50
7211	Current Perspectives in Cancer Immunotherapy. <i>Cancers</i> , 2019, 11, 1472.	1.7	149
7212	ASO Author Reflections: Survival for Stage III Melanoma—Where Do We Stand in the Current Landscape of Melanoma Therapies?. <i>Annals of Surgical Oncology</i> , 2019, 26, 4631-4632.	0.7	0
7214	Effect of Radiotherapy Combined With Pembrolizumab on Local Tumor Control in Mucosal Melanoma Patients. <i>Frontiers in Oncology</i> , 2019, 9, 835.	1.3	32
7215	Current Possibilities of Gynecologic Cancer Treatment with the Use of Immune Checkpoint Inhibitors. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4705.	1.8	48
7216	In Vivo Administration of Recombinant Human Granulocyte Colony-Stimulating Factor Increases the Immune Effectiveness of Dendritic Cell-Based Cancer Vaccination. <i>Vaccines</i> , 2019, 7, 120.	2.1	9

#	ARTICLE	IF	CITATIONS
7217	Assessing the Effectiveness of Systemic Therapy after Stereotactic Radiosurgery on Cancer Recurrence and All-Cause Mortality. <i>World Neurosurgery</i> , 2019, 129, e572-e581.	0.7	0
7218	Past, Current, and Future of Immunotherapies for Prostate Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 884.	1.3	89
7219	Current concepts of non-coding RNA regulation of immune checkpoints in cancer. <i>Molecular Aspects of Medicine</i> , 2019, 70, 117-126.	2.7	41
7220	Radiosurgery and Immunotherapy in the Treatment of Brain Metastases. <i>World Neurosurgery</i> , 2019, 130, 615-622.	0.7	13
7221	Immune Checkpoint Inhibitor Therapyâ€related Pneumonitis: Patterns and Management. <i>Radiographics</i> , 2019, 39, 1923-1937.	1.4	109
7222	Tumor-Infiltrating Immunosuppressive Cells in Cancer-Cell Plasticity, Tumor Progression and Therapy Response. <i>Cancer Microenvironment</i> , 2019, 12, 119-132.	3.1	46
7223	Impact of combination therapy with anti-PD-1 blockade and a STAT3 inhibitor on the tumor-infiltrating lymphocyte status. <i>Immunology Letters</i> , 2019, 216, 43-50.	1.1	21
7224	Immune Checkpoint Inhibitors in Lung Cancer and Melanoma. <i>Seminars in Oncology Nursing</i> , 2019, 35, 150932.	0.7	34
7225	Melanoma plasticity and phenotypic diversity: therapeutic barriers and opportunities. <i>Genes and Development</i> , 2019, 33, 1295-1318.	2.7	203
7226	Rekombinante AntikÃ¶rper. , 2019, , .		1
7227	Sinonasal Melanoma: A Single Institutional Analysis and Future Directions. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2019, 80, 484-492.	0.4	6
7229	Effectiveness of the combination of vascular targeted photodynamic therapy and antiâ€cytotoxic Tâ€lymphocyteâ€associated antigenâ€4 in a preclinical mouse model of urothelial carcinoma. <i>International Journal of Urology</i> , 2019, 26, 414-422.	0.5	9
7230	Adverse events need for hospitalization and systemic immunosuppression in very elderly patients (over 80Âyears) treated with ipilimumab for metastatic melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 545-551.	2.0	18
7231	Tumor-Associated Antigens. , 2019, , 107-125.		3
7232	Prostate cancer and inflammation: A new molecular imaging challenge in the era of personalized medicine. <i>Nuclear Medicine and Biology</i> , 2019, 68-69, 66-79.	0.3	19
7233	Mouse PVRIG Has CD8+ T Cellâ€Specific Coinhibitory Functions and Dampens Antitumor Immunity. <i>Cancer Immunology Research</i> , 2019, 7, 244-256.	1.6	32
7234	Cutaneous adverse events of anti-programmed death 1 antibodies combined with anti-cytotoxic T-lymphocyte-associated protein 4 therapy use in patients with metastatic melanoma. <i>Melanoma Research</i> , 2019, 29, 172-177.	0.6	15
7235	The promising role of monoclonal antibodies for gastric cancer treatment. <i>Immunotherapy</i> , 2019, 11, 347-364.	1.0	10

#	ARTICLE	IF	CITATIONS
7236	Do immune-related adverse events correlate with response to immune checkpoint inhibitors?. Immunotherapy, 2019, 11, 257-259.	1.0	17
7237	High response rates for Tâ€VEEC in early metastatic melanoma (stage IIIB/Câ€VM1a). International Journal of Cancer, 2019, 145, 974-978.	2.3	67
7238	Head and Neck Cancers. , 2019, , 133-196.		0
7239	Cancer Vaccines. Hematology/Oncology Clinics of North America, 2019, 33, 199-214.	0.9	84
7240	PD-1/PD-L1 Inhibitors in Cervical Cancer. Frontiers in Pharmacology, 2019, 10, 65.	1.6	108
7241	Regulatory T cells in cancer immunosuppression â€” implications for anticancer therapy. Nature Reviews Clinical Oncology, 2019, 16, 356-371.	12.5	872
7242	Efficacy and safety of ipilimumab for treating advanced melanoma: A systematic review and metaâ€€analysis. Journal of Clinical Pharmacy and Therapeutics, 2019, 44, 420-429.	0.7	12
7243	Advancing Cancer Immunotherapies with Nanotechnology. Advanced Therapeutics, 2019, 2, 1800128.	1.6	45
7244	Immunotherapy Toxicity. Hematology/Oncology Clinics of North America, 2019, 33, 275-290.	0.9	23
7245	Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL). Leukemia, 2019, 33, 844-862.	3.3	131
7246	On the Other Side: Manipulating the Immune Checkpoint Landscape of Dendritic Cells to Enhance Cancer Immunotherapy. Frontiers in Oncology, 2019, 9, 50.	1.3	11
7247	CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment. Frontiers in Immunology, 2019, 10, 128.	2.2	568
7248	Pseudomonas Exotoxin Immunotoxins and Anti-Tumor Immunity: From Observations at the Patientâ€™s Bedside to Evaluation in Preclinical Models. Toxins, 2019, 11, 20.	1.5	37
7249	Understanding the Anti-Tumor Properties Mediated by the Synthetic Peptide GK-1. , 2019, , .		0
7251	Targeted Therapy and Immunotherapy for Melanoma in Japan. Current Treatment Options in Oncology, 2019, 20, 7.	1.3	79
7252	Hepatotoxicity induced by immune checkpoint inhibitors: a comprehensive review including current and alternative management strategies. Expert Opinion on Drug Metabolism and Toxicology, 2019, 15, 231-244.	1.5	71
7253	Recurrent vulvar melanoma in a patient with neurofibromatosis and gastrointestinal stromal tumour. BMJ Case Reports, 2019, 12, e224744.	0.2	0
7254	Chemotherapy, Biologic, and Immunotherapy Breakthroughs in Cancer Care. Obstetrics and Gynecology Clinics of North America, 2019, 46, 137-154.	0.7	3

#	ARTICLE	IF	CITATIONS
7255	Inhibition of Pannexin 1 Reduces the Tumorigenic Properties of Human Melanoma Cells. <i>Cancers</i> , 2019, 11, 102.	1.7	36
7256	Immunological Manifestations in Sarcoidosis. , 2019, , 37-54.		0
7257	Epigenetic therapy in immune-oncology. <i>Nature Reviews Cancer</i> , 2019, 19, 151-161.	12.8	345
7258	T-cell receptor mimic (TCRm) antibody therapeutics against intracellular proteins. <i>Antibody Therapeutics</i> , 2019, 2, 22-32.	1.2	12
7259	Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. <i>Annals of Oncology</i> , 2019, 30, 582-588.	0.6	641
7260	Prognostic and Predictive Immunohistochemistry-Based Biomarkers in Cancer and Immunotherapy. <i>Hematology/Oncology Clinics of North America</i> , 2019, 33, 291-299.	0.9	23
7261	Immunotherapy: enhancing the efficacy of this promising therapeutic in multiple cancers. <i>Clinical Science</i> , 2019, 133, 181-193.	1.8	51
7262	Regulatory T Cells and Their Clinical Applications in Antitumor Immunotherapy. <i>Engineering</i> , 2019, 5, 132-139.	3.2	4
7263	Immunotherapy for malignant tumors with focus on toll-like receptors. <i>Oral Science International</i> , 2019, 16, 3-7.	0.3	2
7264	Data challenges for evaluating new treatments. <i>Cancer</i> , 2019, 125, 2528-2531.	2.0	0
7265	The Tolerogenic Function of Regulatory T Cells in Pregnancy and Cancer. <i>Frontiers in Immunology</i> , 2019, 10, 911.	2.2	90
7266	Targeting Immune-Mediated Dormancy: A Promising Treatment of Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 498.	1.3	33
7267	Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma. <i>European Journal of Cancer</i> , 2019, 116, 207-215.	1.3	35
7268	Immune precision medicine for cancer: a novel insight based on the efficiency of immune effector cells. <i>Cancer Communications</i> , 2019, 39, 1-16.	3.7	49
7269	Can Immunogenic Chemotherapies Relieve Cancer Cell Resistance to Immune Checkpoint Inhibitors?. <i>Frontiers in Immunology</i> , 2019, 10, 1181.	2.2	20
7270	Precision Medicine in Cancer Therapy. <i>Cancer Treatment and Research</i> , 2019, , .	0.2	4
7271	Cardiotoxicities of Modern Treatments in Breast Cancer. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2019, 21, 34.	0.4	2
7272	Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. <i>Lancet Oncology</i> , The, 2019, 20, 1083-1097.	5.1	611

#	ARTICLE	IF	CITATIONS
7273	Learning-accelerated discovery of immune-tumour interactions. <i>Molecular Systems Design and Engineering</i> , 2019, 4, 747-760.	1.7	41
7274	Clonality of CD4+ Blood T Cells Predicts Longer Survival With CTLA4 or PD-1 Checkpoint Inhibition in Advanced Melanoma. <i>Frontiers in Immunology</i> , 2019, 10, 1336.	2.2	57
7275	Molecular Mechanisms and Countermeasures of Immunotherapy Resistance in Malignant Tumor. <i>Journal of Cancer</i> , 2019, 10, 1764-1771.	1.2	11
7276	Management of metastatic cutaneous melanoma: updates in clinical practice. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591985166.	1.4	29
7277	Aging, Cancer and Immunity. <i>Journal of Cancer</i> , 2019, 10, 3021-3027.	1.2	48
7278	Precision Medicine-Enabled Cancer Immunotherapy. <i>Cancer Treatment and Research</i> , 2019, 178, 189-205.	0.2	9
7279	Tumor-targeted IL-12 combined with tumor resection yields a survival-favorable immune profile. , 2019, 7, 154.		16
7280	Impact of Effective Systemic Therapy on Metastasectomy in Stage IV Melanoma: A Matched-Pair Analysis. <i>Annals of Surgical Oncology</i> , 2019, 26, 4610-4618.	0.7	20
7281	Probiotics <i>Lactobacillus reuteri</i> Abrogates Immune Checkpoint Blockade-Associated Colitis by Inhibiting Group 3 Innate Lymphoid Cells. <i>Frontiers in Immunology</i> , 2019, 10, 1235.	2.2	83
7282	1,2-Dihydroxyxanthone: Effect on A375-C5 Melanoma Cell Growth Associated with Interference with THP-1 Human Macrophage Activity. <i>Pharmaceuticals</i> , 2019, 12, 85.	1.7	9
7283	Cytotoxic T Cells and their Activation Status are Independent Prognostic Markers in Meningiomas. <i>Clinical Cancer Research</i> , 2019, 25, 5260-5270.	3.2	23
7284	The 6th R of Radiobiology: Reactivation of Anti-Tumor Immune Response. <i>Cancers</i> , 2019, 11, 860.	1.7	75
7285	Stability and survival analysis of elderly patients with osteolytic spinal bone metastases after palliative radiotherapy. <i>Strahlentherapie Und Onkologie</i> , 2019, 195, 1074-1085.	1.0	10
7286	In vitro assay for the development of small molecule inhibitors targeting PD-1/PD-L1. <i>Methods in Enzymology</i> , 2019, 629, 361-381.	0.4	19
7287	Translational Prospects of ultrasound-mediated tumor immunotherapy: Preclinical advances and safety considerations. <i>Cancer Letters</i> , 2019, 460, 86-95.	3.2	15
7288	m6A mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade. <i>Nature Communications</i> , 2019, 10, 2782.	5.8	468
7289	Cancer immunotherapy: the art of targeting the tumor immune microenvironment. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 227-240.	1.1	50
7290	Adjuvant Therapy for Melanoma. <i>Current Treatment Options in Oncology</i> , 2019, 20, 63.	1.3	38

#	ARTICLE	IF	CITATIONS
7291	Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients. <i>Nature Medicine</i> , 2019, 25, 929-935.	15.2	188
7292	Management of Gastrointestinal Toxicity from Immune Checkpoint Inhibitor. <i>GE Portuguese Journal of Gastroenterology</i> , 2019, 26, 268-274.	0.3	17
7293	Understanding heterogeneous tumor microenvironment in metastatic melanoma. <i>PLoS ONE</i> , 2019, 14, e0216485.	1.1	36
7294	Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma. , 2019, 7, 145.		261
7295	A Review of Efficacy and Safety of Checkpoint Inhibitor for the Treatment of Acute Myeloid Leukemia. <i>Frontiers in Pharmacology</i> , 2019, 10, 609.	1.6	60
7296	Interleukin-35 as an Emerging Player in Tumor Microenvironment. <i>Journal of Cancer</i> , 2019, 10, 2074-2082.	1.2	28
7297	Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer. <i>JAMA Oncology</i> , 2019, 5, 1310.	3.4	268
7298	Cardiotoxicity of Immune Checkpoint Inhibitors. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2019, 21, 32.	0.4	42
7299	Rheumatic immune related adverse events in patients treated with checkpoint inhibitors for immunotherapy of cancer. <i>Autoimmunity Reviews</i> , 2019, 18, 805-813.	2.5	15
7300	Application of PD-1 Blockade in Cancer Immunotherapy. <i>Computational and Structural Biotechnology Journal</i> , 2019, 17, 661-674.	1.9	333
7301	New oncologic emergencies: What is there to know about immunotherapy and its potential side effects?. <i>European Journal of Internal Medicine</i> , 2019, 66, 1-8.	1.0	19
7302	Cardiotoxicity and pro-inflammatory effects of the immune checkpoint inhibitor Pembrolizumab associated to Trastuzumab. <i>International Journal of Cardiology</i> , 2019, 292, 171-179.	0.8	44
7303	Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma. <i>Frontiers in Immunology</i> , 2019, 10, 990.	2.2	86
7304	CTLA4 Message Reflects Pathway Disruption in Monogenic Disorders and Under Therapeutic Blockade. <i>Frontiers in Immunology</i> , 2019, 10, 998.	2.2	11
7305	Molecular targeted therapy-related life-threatening toxicity in patients with malignancies. A systematic review of published cases. <i>Intensive Care Medicine</i> , 2019, 45, 988-997.	3.9	18
7306	The prognostic significance of the comprehensive complication index in patients with gastric cancer. <i>Surgery Today</i> , 2019, 49, 913-920.	0.7	10
7307	Cloxiquine, a traditional antituberculosis agent, suppresses the growth and metastasis of melanoma cells through activation of PPAR γ . <i>Cell Death and Disease</i> , 2019, 10, 404.	2.7	8
7308	Autoimmune Endocrine Dysfunctions Associated with Cancer Immunotherapies. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2560.	1.8	72

#	ARTICLE	IF	CITATIONS
7309	Comparative safety analysis of immunotherapy combined with chemotherapy versus monotherapy in solid tumors: a meta-analysis of randomized clinical trials. <i>Oncotarget</i> , 2019, 10, 3294-3301.	0.8	13
7310	Patient-Derived Non-Muscular Invasive Bladder Cancer Xenografts of Main Molecular Subtypes of the Tumor for Anti-Pd-1 Treatment Assessment. <i>Cells</i> , 2019, 8, 526.	1.8	14
7312	Real-world data on PD-1 inhibitor therapy in metastatic melanoma. <i>Acta Oncologica</i> , 2019, 58, 962-966.	0.8	26
7313	Pulling RANK on Cancer: Blocking Aire-Mediated Central Tolerance to Enhance Immunotherapy. <i>Cancer Immunology Research</i> , 2019, 7, 854-859.	1.6	8
7314	Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy. <i>Journal of Hematology and Oncology</i> , 2019, 12, 54.	6.9	416
7315	The survivorship experience for patients with metastatic melanoma on immune checkpoint and BRAF-MEK inhibitors. <i>Journal of Cancer Survivorship</i> , 2019, 13, 503-511.	1.5	31
7316	Opportunities and challenges for the development of covalent chemical immunomodulators. <i>Bioorganic and Medicinal Chemistry</i> , 2019, 27, 3421-3439.	1.4	15
7317	Recent advances in nanomaterial-based synergistic combination cancer immunotherapy. <i>Chemical Society Reviews</i> , 2019, 48, 3771-3810.	18.7	292
7318	Inhibition of the Nkp44-PCNA Immune Checkpoint Using a mAb to PCNA. <i>Cancer Immunology Research</i> , 2019, 7, 1120-1134.	1.6	26
7319	Inhibition of murine hepatoma tumor growth by cryptotanshinone involves TLR7-dependent activation of macrophages and induction of adaptive antitumor immune defenses. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1073-1085.	2.0	54
7320	Long-Term Survival, Quality of Life, and Psychosocial Outcomes in Advanced Melanoma Patients Treated with Immune Checkpoint Inhibitors. <i>Journal of Oncology</i> , 2019, 2019, 1-17.	0.6	55
7321	Cancer treatment and survivorship statistics, 2019. <i>Ca-A Cancer Journal for Clinicians</i> , 2019, 69, 363-385.	157.7	3,303
7322	Hyperprogression under Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2674.	1.8	96
7323	The Evolving Role of CD8+CD28 ^{hi} Immunosenescent T Cells in Cancer Immunology. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2810.	1.8	105
7324	Immunology and Immunotherapy in Critical Care: An Overview. <i>AACN Advanced Critical Care</i> , 2019, 30, 113-125.	0.6	6
7325	High-Plex Predictive Marker Discovery for Melanoma Immunotherapy-Treated Patients Using Digital Spatial Profiling. <i>Clinical Cancer Research</i> , 2019, 25, 5503-5512.	3.2	117
7326	Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies. <i>Journal of Hematology and Oncology</i> , 2019, 12, 59.	6.9	127
7327	Advances in Immunotherapy and Periocular Malignancy. <i>Seminars in Ophthalmology</i> , 2019, 34, 327-333.	0.8	9

#	ARTICLE	IF	CITATIONS
7328	Monitoring Patient Response to Pembrolizumab With Peripheral Blood Exhaustion Marker Profiles. <i>Frontiers in Medicine</i> , 2019, 6, 113.	1.2	25
7329	Biomarkers for Immune Checkpoint Inhibitor-Mediated Tumor Response and Adverse Events. <i>Frontiers in Medicine</i> , 2019, 6, 119.	1.2	145
7330	Combination of CTLA-4 and PD-1 blockers for treatment of cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 255.	3.5	577
7331	Immunotherapy for Colorectal Cancer: A Review of Current and Novel Therapeutic Approaches. <i>Journal of the National Cancer Institute</i> , 2019, 111, 1131-1141.	3.0	116
7332	New Insights into Molecular Oncogenesis and Therapy of Uveal Melanoma. <i>Cancers</i> , 2019, 11, 694.	1.7	23
7333	Development of immune checkpoint therapy for cancer. <i>Journal of Experimental Medicine</i> , 2019, 216, 1244-1254.	4.2	125
7334	Immune checkpoint inhibitors in malignancy. <i>Australian Prescriber</i> , 2019, 42, 62.	0.5	24
7335	Microfluidic Analysis for Separating and Measuring the Deformability of Cancer Cell Subpopulations. <i>ACS Omega</i> , 2019, 4, 8318-8323.	1.6	7
7336	Current Status of Immunotherapies for Treating Pancreatic Cancer. <i>Current Oncology Reports</i> , 2019, 21, 60.	1.8	38
7337	Immunotherapy in Nonmelanoma Skin Cancer. <i>Actas Dermo-sifiligráficas</i> , 2019, 110, 353-359.	0.2	1
7338	Immunotherapy Mythbusters in Head and Neck Cancer: The Abscopal Effect and Pseudoprogression. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 352-363.	1.8	28
7339	The promise of Immuno-oncology: implications for defining the value of cancer treatment. , 2019, 7, 129.		66
7340	Therapeutic Benefits of Ipilimumab among Japanese Patients with Nivolumab-Refractory Mucosal Melanoma: A Case Series Study. <i>Tohoku Journal of Experimental Medicine</i> , 2019, 248, 37-43.	0.5	5
7341	Recurrent Pneumonitis in Patients with Melanoma Treated with Immune Checkpoint Inhibitors. <i>Oncologist</i> , 2019, 24, 640-647.	1.9	32
7342	Regulatory B1a Cells Suppress Melanoma Tumor Immunity via IL-10 Production and Inhibiting T Helper Type 1 Cytokine Production in Tumor-Infiltrating CD8+ T Cells. <i>Journal of Investigative Dermatology</i> , 2019, 139, 1535-1544.e1.	0.3	26
7343	PD-1/PD-L1 blockade in paediatric cancers: What does the future hold?. <i>Cancer Letters</i> , 2019, 457, 74-85.	3.2	15
7344	Upper gastrointestinal symptoms and associated endoscopic and histological features in patients receiving immune checkpoint inhibitors. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 538-545.	0.6	51
7345	Research progress and clinical application of predictive biomarker for immune checkpoint inhibitors. <i>Expert Review of Molecular Diagnostics</i> , 2019, 19, 517-529.	1.5	15

#	ARTICLE	IF	CITATIONS
7346	Intratumoral regulatory T cells: markers, subsets and their impact on anti-tumor immunity. <i>Immunology</i> , 2019, 157, 232-247.	2.0	79
7347	The Impact of High-Dose Glucocorticoids on the Outcome of Immune-Checkpoint Inhibitor-Related Thyroid Disorders. <i>Cancer Immunology Research</i> , 2019, 7, 1214-1220.	1.6	44
7348	Sequential treatment failures in response to BRAF/MEK and immune checkpoint inhibitors mediated by MAP2K2 and B2M mutations in melanoma. <i>Experimental and Molecular Pathology</i> , 2019, 110, 104260.	0.9	8
7349	Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 563-580.	12.5	1,235
7350	Targeting Hypoxia-Induced Carbonic Anhydrase IX Enhances Immune-Checkpoint Blockade Locally and Systemically. <i>Cancer Immunology Research</i> , 2019, 7, 1064-1078.	1.6	104
7351	Neoplasia and intraocular inflammation: From masquerade syndromes to immunotherapy-induced uveitis. <i>Progress in Retinal and Eye Research</i> , 2019, 72, 100761.	7.3	37
7352	Prolonged overall survival following metastasectomy in stage IV melanoma. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 1719-1725.	1.3	10
7353	Immune Evasion by Head and Neck Cancer: Foundations for Combination Therapy. <i>Trends in Cancer</i> , 2019, 5, 208-232.	3.8	54
7354	TLR1/2 ligand enhances antitumor efficacy of CTLA-4 blockade by increasing intratumoral Treg depletion. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 10453-10462.	3.3	53
7355	Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity. <i>Clinical Cancer Research</i> , 2019, 25, 4808-4819.	3.2	66
7356	Treg-mediated acquired resistance to immune checkpoint inhibitors. <i>Cancer Letters</i> , 2019, 457, 168-179.	3.2	148
7357	Changes in population-level survival for advanced solid malignancies with new treatment options in the second decade of the 21st century. <i>Cancer</i> , 2019, 125, 2656-2665.	2.0	15
7358	Targeted Therapies for Brain Metastases. <i>Progress in Neurological Surgery</i> , 2019, 34, 125-137.	1.3	14
7359	How many samples are needed to infer truly clonal mutations from heterogenous tumours?. <i>BMC Cancer</i> , 2019, 19, 403.	1.1	21
7360	Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 147-164.	1.8	459
7361	Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCR β diversity. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1095-1106.	2.0	5
7362	Current concepts in advanced sinonasal mucosal melanoma: a single institution experience. <i>European Archives of Oto-Rhino-Laryngology</i> , 2019, 276, 2259-2265.	0.8	13
7363	Targeted Therapies for the Treatment of Glioblastoma in Adults. <i>Current Oncology Reports</i> , 2019, 21, 61.	1.8	15

#	ARTICLE	IF	CITATIONS
7364	PD-L1 expression in carcinoma of the esophagogastric junction is positively correlated with T-cell infiltration and overall survival. <i>Pathology Research and Practice</i> , 2019, 215, 152402.	1.0	11
7365	Efficacy and safety of combination immunotherapy for malignant solid tumors: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 138, 178-189.	2.0	31
7366	VIGLA-M: visual gene expression data analytics. <i>BMC Bioinformatics</i> , 2019, 20, 150.	1.2	8
7367	Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature. , 2019, 7, 106.		203
7368	Low CD8+ T Cell Infiltration and High PD-L1 Expression Are Associated with Level of CD44+/CD133+ Cancer Stem Cells and Predict an Unfavorable Prognosis in Pancreatic Cancer. <i>Cancers</i> , 2019, 11, 541.	1.7	77
7369	Immunometabolism: A new target for improving cancer immunotherapy. <i>Advances in Cancer Research</i> , 2019, 143, 195-253.	1.9	30
7370	Recent progress in nanomaterials for nucleic acid delivery in cancer immunotherapy. <i>Biomaterials Science</i> , 2019, 7, 2640-2651.	2.6	34
7371	Facing the future: challenges and opportunities in adoptive T cell therapy in cancer. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 811-827.	1.4	27
7372	Prophylactic and therapeutic strategies for Epstein-Barr virus-associated diseases: emerging strategies for clinical development. <i>Expert Review of Vaccines</i> , 2019, 18, 457-474.	2.0	26
7373	Advances in the Understanding of Skin Cancer: Ultraviolet Radiation, Mutations, and Antisense Oligonucleotides as Anticancer Drugs. <i>Molecules</i> , 2019, 24, 1516.	1.7	67
7375	Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy. <i>Cancer Treatment Reviews</i> , 2019, 76, 22-32.	3.4	224
7376	Checkpoint blockade and nanosensitizer-augmented noninvasive sonodynamic therapy combination reduces tumour growth and metastases in mice. <i>Nature Communications</i> , 2019, 10, 2025.	5.8	404
7378	Advanced stage at diagnosis and elevated mortality among US patients with cancer infected with HIV in the National Cancer Data Base. <i>Cancer</i> , 2019, 125, 2868-2876.	2.0	69
7379	Identification, synthesis and evaluation of CSF1R inhibitors using fragment based drug design. <i>Computational Biology and Chemistry</i> , 2019, 80, 374-383.	1.1	7
7380	Talimogene laherparepvec: review of its mechanism of action and clinical efficacy and safety. <i>Immunotherapy</i> , 2019, 11, 705-723.	1.0	77
7381	Correlation of Milestone Restricted Mean Survival Time Ratio With Overall Survival Hazard Ratio in Randomized Clinical Trials of Immune Checkpoint Inhibitors. <i>JAMA Network Open</i> , 2019, 2, e193433.	2.8	8
7382	Costimulation Induces CD4 ⁺ Cell Antitumor Immunity via an Innate-like Mechanism. <i>Cell Reports</i> , 2019, 27, 1434-1445.e3.	2.9	6
7383	The nephrotoxicity of new immunotherapies. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 513-521.	1.3	12

#	ARTICLE	IF	CITATIONS
7384	Drug development using pancreatic and lung organoid models. , 2019, , 323-342.		0
7385	Rational design of anti-GITR-based combination immunotherapy. <i>Nature Medicine</i> , 2019, 25, 759-766.	15.2	180
7386	Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities. <i>Trends in Immunology</i> , 2019, 40, 511-523.	2.9	180
7387	Expanding Therapeutic Options for Older Adults: Case-Based Updates in Breast and Lung Cancer. <i>Journal of the American Geriatrics Society</i> , 2019, 67, 1012-1019.	1.3	2
7388	New causes of hypophysitis. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2019, 33, 101276.	2.2	24
7389	Management of immune related adverse events induced by immune checkpoint inhibition. <i>Cancer Letters</i> , 2019, 456, 80-87.	3.2	36
7390	Novel approaches to promote CAR T-cell function in solid tumors. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 789-799.	1.4	5
7391	Implications of Immunotherapy in Hepatobiliary Tumors. <i>Visceral Medicine</i> , 2019, 35, 18-26.	0.5	6
7392	<p>Monoclonal antibody therapy of solid tumors: clinical limitations and novel strategies to enhance treatment efficacy</p>. <i>Biologics: Targets and Therapy</i> , 2019, Volume 13, 33-51.	3.0	115
7393	Role of immune checkpoint inhibitors in gastrointestinal cancer treatment. <i>Memo - Magazine of European Medical Oncology</i> , 2019, 12, 71-76.	0.3	2
7394	2018 International Consensus Meeting on Musculoskeletal Infection: Research Priorities from the General Assembly Questions. <i>Journal of Orthopaedic Research</i> , 2019, 37, 997-1006.	1.2	189
7395	Local Administration of GITR Agonistic Antibody Induces a Stronger Antitumor Immunity than Systemic Delivery. <i>Scientific Reports</i> , 2019, 9, 5562.	1.6	16
7396	Proposed diagnostic and treatment paradigm for high-grade neurological complications of immune checkpoint inhibitors. <i>Neuro-Oncology Practice</i> , 2019, 6, 340-345.	1.0	7
7397	The Abscopal Effect of Stereotactic Radiotherapy and Immunotherapy: Fool's Gold or El Dorado?. <i>Clinical Oncology</i> , 2019, 31, 432-443.	0.6	48
7398	Anti-colon cancer effect of matrix protein gene therapy with nanoparticles. <i>Polymer</i> , 2019, 170, 148-156.	1.8	3
7399	Early assessment with 18F-2-fluoro-2-deoxyglucose positron emission tomography/computed tomography to predict short-term outcome in clear cell renal carcinoma treated with nivolumab. <i>BMC Cancer</i> , 2019, 19, 298.	1.1	24
7400	The hop-derived prenylflavonoid isoxanthohumol inhibits the formation of lung metastasis in B16-F10 murine melanoma model. <i>Food and Chemical Toxicology</i> , 2019, 129, 257-268.	1.8	14
7401	Bibliometric analysis of global research on PD-1 and PD-L1 in the field of cancer. <i>International Immunopharmacology</i> , 2019, 72, 374-384.	1.7	109

#	ARTICLE	IF	CITATIONS
7402	Enhancing Dendritic Cell Therapy in Solid Tumors with Immunomodulating Conventional Treatment. <i>Molecular Therapy - Oncolytics</i> , 2019, 13, 67-81.	2.0	44
7403	Cancer nanomedicine for combination cancer immunotherapy. <i>Nature Reviews Materials</i> , 2019, 4, 398-414.	23.3	658
7404	Cystineâ€“glutamate antiporter xCT deficiency suppresses tumor growth while preserving antitumor immunity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 9533-9542.	3.3	108
7405	PD-1⁺regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 9999-10008.	3.3	655
7406	From immune checkpoints to vaccines: The past, present and future of cancer immunotherapy. <i>Advances in Cancer Research</i> , 2019, 143, 63-144.	1.9	52
7407	Ku80 promotes melanoma growth and regulates antitumor effect of melatonin by targeting HIF1- α dependent PDK-1 signaling pathway. <i>Redox Biology</i> , 2019, 25, 101197.	3.9	15
7408	Current and emerging systemic therapies for cutaneous metastatic melanoma. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 1135-1152.	0.9	33
7409	Sequential Blockade of PD-1 and PD-L1 Causes Fulminant Cardiotoxicityâ€“From Case Report to Mouse Model Validation. <i>Cancers</i> , 2019, 11, 580.	1.7	28
7410	The Role of the Immune System in Cutaneous Squamous Cell Carcinoma. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2009.	1.8	81
7411	T cell pathology in skin inflammation. <i>Seminars in Immunopathology</i> , 2019, 41, 359-377.	2.8	120
7412	Immune checkpoint-based therapy in myeloid malignancies: a promise yet to be fulfilled. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 393-404.	1.1	26
7413	Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers. <i>Annals of Oncology</i> , 2019, 30, 998-1004.	0.6	361
7414	Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma. <i>Frontiers in Immunology</i> , 2019, 10, 453.	2.2	177
7415	The Clinical Trial Landscape for Melanoma Therapies. <i>Journal of Clinical Medicine</i> , 2019, 8, 368.	1.0	46
7416	Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO-1) Inhibitors Based on Ortho-Naphthaquinone-Containing Natural Product. <i>Molecules</i> , 2019, 24, 1059.	1.7	14
7417	Surgical removal of the index node marked using magnetic seed localization to assess response to neoadjuvant immunotherapy in patients with stage III melanoma. <i>British Journal of Surgery</i> , 2019, 106, 519-522.	0.1	35
7418	Functional genomics in the era of cancer immunotherapy: challenges and clinical implications. <i>Briefings in Functional Genomics</i> , 2019, 18, 83-85.	1.3	0
7419	Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma. , 2019, 7, 80.		65

#	ARTICLE	IF	CITATIONS
7420	Antibody-drug therapeutic conjugates: Potential of antibody-siRNAs in cancer therapy. <i>Journal of Cellular Physiology</i> , 2019, 234, 16724-16738.	2.0	15
7421	Novel immunotherapeutic approaches for hepatocellular carcinoma treatment. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 453-470.	1.3	28
7422	T cell Co-Stimulatory molecules ICOS and CD28 stratify idiopathic pulmonary fibrosis survival. <i>Respiratory Medicine: X</i> , 2019, 1, 100002.	1.4	7
7423	Epigenetic Regulation in Melanoma. , 2019, , 1-16.		0
7424	DEPDC1B knockdown inhibits the development of malignant melanoma through suppressing cell proliferation and inducing cell apoptosis. <i>Experimental Cell Research</i> , 2019, 379, 48-54.	1.2	27
7425	Immunotherapy in colorectal cancer: rationale, challenges and potential. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 361-375.	8.2	1,039
7426	Pembrolizumab in the treatment of advanced/metastatic melanoma: a single-center institution experience. <i>Melanoma Research</i> , 2019, 29, 289-294.	0.6	5
7427	Gene expression profiling of lichenoid dermatitis immune-related adverse event from immune checkpoint inhibitors reveals increased CD14 ⁺ and CD16 ⁺ monocytes driving an innate immune response. <i>Journal of Cutaneous Pathology</i> , 2019, 46, 627-636.	0.7	27
7428	New emerging targets in cancer immunotherapy: the role of LAG3. <i>ESMO Open</i> , 2019, 4, e000482.	2.0	83
7429	Successful Treatment of Myasthenia Gravis Following PD-1/CTLA-4 Combination Checkpoint Blockade in a Patient With Metastatic Melanoma. <i>Frontiers in Oncology</i> , 2019, 9, 84.	1.3	18
7430	Assessing Long-Term Survival Benefits of Immune Checkpoint Inhibitors Using the Net Survival Benefit. <i>Journal of the National Cancer Institute</i> , 2019, 111, 1186-1191.	3.0	13
7431	Somatic Hypermutation of the <i>YAP</i> Oncogene in a Human Cutaneous Melanoma. <i>Molecular Cancer Research</i> , 2019, 17, 1435-1449.	1.5	39
7432	Use of the Response Assessment in Neuro-Oncology (RANO) criteria in clinical trials and clinical practice. <i>CNS Oncology</i> , 2019, 8, CNS28.	1.2	169
7433	Engineering Protein Delivery Depots for Cancer Immunotherapy. <i>Bioconjugate Chemistry</i> , 2019, 30, 515-524.	1.8	20
7434	Immunotherapy Associated Pulmonary Toxicity: Biology Behind Clinical and Radiological Features. <i>Cancers</i> , 2019, 11, 305.	1.7	51
7435	Glioblastoma-Derived IL6 Induces Immunosuppressive Peripheral Myeloid Cell PD-L1 and Promotes Tumor Growth. <i>Clinical Cancer Research</i> , 2019, 25, 3643-3657.	3.2	128
7436	Modulation of immune checkpoint molecule expression in mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2019, 60, 2498-2507.	0.6	21
7437	Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma. <i>Clinical and Experimental Immunology</i> , 2019, 197, 74-82.	1.1	32

#	ARTICLE	IF	CITATIONS
7438	Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-treated Patients with <i>BRAF</i> V600-mutated Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2019, 25, 3239-3246.	3.2	32
7439	<i>BRAF</i> Inhibition: Bridge or Boost to T-cell Therapy?. <i>Clinical Cancer Research</i> , 2019, 25, 2682-2684.	3.2	5
7440	PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions. <i>Oncologist</i> , 2019, 24, S31-S41.	1.9	239
7441	Turning “Cold” Into “Hot” Tumors” Opportunities and Challenges for Radio-Immunotherapy Against Primary and Metastatic Brain Cancers. <i>Frontiers in Oncology</i> , 2019, 9, 163.	1.3	85
7442	Treatment Strategies and Survival Trends for Anorectal Melanoma: Is it Time for a Change?. <i>World Journal of Surgery</i> , 2019, 43, 1809-1819.	0.8	28
7443	Leukemic B Cell CTLA-4 Suppresses Costimulation of T Cells. <i>Journal of Immunology</i> , 2019, 202, 2806-2816.	0.4	22
7444	Patient-Reported Outcomes for Cancer Patients Receiving Checkpoint Inhibitors: Opportunities for Palliative Care” A Systematic Review. <i>Journal of Pain and Symptom Management</i> , 2019, 58, 137-156.e1.	0.6	39
7445	Antibody repertoire analysis of mouse immunization protocols using microfluidics and molecular genomics. <i>MAbs</i> , 2019, 11, 870-883.	2.6	29
7446	Combining Radiation and Immune Checkpoint Blockade in the Treatment of Head and Neck Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2019, 9, 122.	1.3	63
7447	Size Matters: The Functional Role of the CEACAM1 Isoform Signature and Its Impact for NK Cell-Mediated Killing in Melanoma. <i>Cancers</i> , 2019, 11, 356.	1.7	37
7448	Targeting FER Kinase Inhibits Melanoma Growth and Metastasis. <i>Cancers</i> , 2019, 11, 419.	1.7	15
7449	An immunophenotyping of renal clear cell carcinoma with characteristics and a potential therapeutic target for patients insensitive to immune checkpoint blockade. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 13330-13341.	1.2	16
7451	Immunotherapy of Melanoma: Facts and Hopes. <i>Clinical Cancer Research</i> , 2019, 25, 5191-5201.	3.2	181
7452	Biomarkers in immune checkpoint inhibition therapy for cancer patients: what is the role of lymphocyte subsets and PD1/PD-L1?. <i>Translational Medicine Communications</i> , 2019, 4, .	0.5	3
7453	Dual functional immunostimulatory polymeric prodrug carrier with pendent indoximod for enhanced cancer immunochemotherapy. <i>Acta Biomaterialia</i> , 2019, 90, 300-313.	4.1	50
7454	A Case of Anti-“PD-L1-associated Remitting Seronegative Symmetric Synovitis With Pitting Edema. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e549-e552.	0.9	5
7455	TP53 missense mutation is associated with increased tumor-infiltrating T cells in primary prostate cancer. <i>Human Pathology</i> , 2019, 87, 95-102.	1.1	34
7456	RIG-I activating immunostimulatory RNA boosts the efficacy of anticancer vaccines and synergizes with immune checkpoint blockade. <i>EBioMedicine</i> , 2019, 41, 146-155.	2.7	31

#	ARTICLE	IF	CITATIONS
7457	Harnessing Radiation Biology to Augment Immunotherapy for Glioblastoma. <i>Frontiers in Oncology</i> , 2019, 8, 656.	1.3	32
7458	Host tissue determinants of tumour immunity. <i>Nature Reviews Cancer</i> , 2019, 19, 215-227.	12.8	150
7459	Targeting the Antibody Checkpoints to Enhance Cancer Immunotherapy—Focus on FcγRIIB. <i>Frontiers in Immunology</i> , 2019, 10, 481.	2.2	33
7460	Autoimmune genetic risk variants as germline biomarkers of response to melanoma immune-checkpoint inhibition. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 897-905.	2.0	38
7461	A novel immunogenic mouse model of melanoma for the preclinical assessment of combination targeted and immune-based therapy. <i>Scientific Reports</i> , 2019, 9, 1225.	1.6	16
7462	A Systematic Review and Meta-Analysis of Endocrine-Related Adverse Events Associated with Immune Checkpoint Inhibitors. <i>Hormone and Metabolic Research</i> , 2019, 51, 145-156.	0.7	234
7463	<p>Risk and incidence of fatal adverse events associated with immune checkpoint inhibitors: a systematic review and meta-analysis</p>. <i>Therapeutics and Clinical Risk Management</i> , 2019, Volume 15, 293-302.	0.9	27
7464	Clinical Pharmacokinetic and Pharmacodynamic Considerations in the (Modern) Treatment of Melanoma. <i>Clinical Pharmacokinetics</i> , 2019, 58, 1029-1043.	1.6	6
7465	Pathways- and epigenetic-based assessment of relative immune infiltration in various types of solid tumors. <i>Advances in Cancer Research</i> , 2019, 142, 107-143.	1.9	10
7466	Pre-existing autoimmune disease and the risk of immune-related adverse events among patients receiving checkpoint inhibitors for cancer. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 917-926.	2.0	59
7467	Immunotherapy for Head and Neck Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2019, 33, 301-321.	0.9	19
7468	The Current Status of Immunotherapies in Esophagogastric Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2019, 33, 323-338.	0.9	9
7469	Topical beclometasone dipropionate in the management of immune checkpoint inhibitor-induced microscopic colitis. <i>BMJ Case Reports</i> , 2019, 12, e226481.	0.2	9
7470	Atypical Response Patterns in Patients Treated With Nivolumab. <i>American Journal of Roentgenology</i> , 2019, 212, 1177-1181.	1.0	22
7471	Immune checkpoint modulators in cancer immunotherapy: Recent advances and combination rationales. <i>Cancer Letters</i> , 2019, 456, 23-28.	3.2	22
7472	PD-1 Tumor Suppressor Signaling in T Cell Lymphomas. <i>Trends in Immunology</i> , 2019, 40, 403-414.	2.9	24
7473	Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFNγ pathways. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 549-562.	12.5	72
7474	Improved survival prognostication of node-positive malignant melanoma patients utilizing shotgun proteomics guided by histopathological characterization and genomic data. <i>Scientific Reports</i> , 2019, 9, 5154.	1.6	12

#	ARTICLE	IF	CITATIONS
7475	The metabolic milieu in melanoma: Role of immune suppression by CD73/adenosine. <i>Tumor Biology</i> , 2019, 41, 101042831983713.	0.8	29
7476	Targeted antibody and cytokine cancer immunotherapies through collagen affinity. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	134
7477	Update on BRAF and MEK inhibition for treatment of melanoma in metastatic, unresectable, and adjuvant settings. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 381-392.	1.0	62
7478	Expansion of pharmacist clinical services to optimize the management of immune checkpoint inhibitor toxicities. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 954-960.	0.5	11
7479	A Phase Ib Study of Pembrolizumab as Second-Line Therapy for Chinese Patients With Advanced or Metastatic Melanoma (KEYNOTE-151). <i>Translational Oncology</i> , 2019, 12, 828-835.	1.7	90
7480	Clinical development of targeted and immune based anti-cancer therapies. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 156.	3.5	170
7481	Glial Cell Expression of PD-L1. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1677.	1.8	21
7482	The predictive power of tumor mutational burden in lung cancer immunotherapy response is influenced by patients' sex. <i>International Journal of Cancer</i> , 2019, 145, 2840-2849.	2.3	60
7483	Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma. <i>Annals of Oncology</i> , 2019, 30, 1154-1161.	0.6	170
7484	Development of Cancer Immunotherapy Targeting the PD-1 Pathway. <i>Journal of Nippon Medical School</i> , 2019, 86, 10-14.	0.3	15
7485	Enzalutamide therapy for advanced prostate cancer: efficacy, resistance and beyond. <i>Endocrine-Related Cancer</i> , 2019, 26, R31-R52.	1.6	49
7486	Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology. <i>Molecules</i> , 2019, 24, 1190.	1.7	163
7487	Role of the tumor microenvironment in pancreatic cancer. <i>Annals of Gastroenterological Surgery</i> , 2019, 3, 130-137.	1.2	114
7488	Tethered Signaling in Inhibitory Immune Receptors. <i>Frontiers in Physics</i> , 2019, 6, .	1.0	3
7489	Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment. <i>Molecular Cancer</i> , 2019, 18, 60.	7.9	361
7490	Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations. , 2019, 7, 91.		24
7491	Clinical and histopathological characteristics and survival analysis of 4594 Japanese patients with melanoma. <i>Cancer Medicine</i> , 2019, 8, 2146-2156.	1.3	74
7492	Rationale for Combining Radiotherapy and Immune Checkpoint Inhibition for Patients With Hypoxic Tumors. <i>Frontiers in Immunology</i> , 2019, 10, 407.	2.2	44

#	ARTICLE	IF	CITATIONS
7493	Immunology of Ocular Tumors. , 2019, , 71-78.		0
7495	Therapeutic approaches for targeting receptor tyrosine kinase like orphan receptor-1 in cancer cells. Expert Opinion on Therapeutic Targets, 2019, 23, 447-456.	1.5	21
7496	A Threshold Model for T-Cell Activation in the Era of Checkpoint Blockade Immunotherapy. Frontiers in Immunology, 2019, 10, 491.	2.2	23
7498	Could the menagerie of the gut microbiome really cure cancer? Hope or hype. , 2019, 7, 92.		16
7499	Immunological Agents Used in Cancer Treatment. Eurasian Journal of Medicine, 2019, 51, 90-94.	0.2	32
7500	Immune check-point in glioblastoma multiforme. Critical Reviews in Oncology/Hematology, 2019, 138, 60-69.	2.0	14
7501	Anti-CTLA4 synergizes with dendritic cell-targeted vaccine to promote IL-3-dependent CD4 ⁺ effector T cell infiltration into murine pancreatic tumors. Annals of the New York Academy of Sciences, 2019, 1445, 62-73.	1.8	17
7502	Chondroitin Sulfate-Based pH-Sensitive Polymer-Modified Liposomes for Intracellular Antigen Delivery and Induction of Cancer Immunity. Bioconjugate Chemistry, 2019, 30, 1518-1529.	1.8	28
7503	Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial. Journal of Clinical Oncology, 2019, 37, 52-60.	0.8	218
7504	Hypereosinophilia in a patient with metastatic non-small-cell lung cancer treated with antiprogrammed cell death 1 (anti-PD-1) therapy. Immunotherapy, 2019, 11, 577-584.	1.0	18
7505	Post-shingles granulomatous dermatosis related to anti-programmed cell death 1. Immunotherapy, 2019, 11, 591-598.	1.0	9
7506	Immunotherapy for High-Grade Gliomas: A Clinical Update and Practical Considerations for Neurosurgeons. World Neurosurgery, 2019, 124, 397-409.	0.7	19
7507	Therapeutic Cancer Vaccine and Combinations With Antiangiogenic Therapies and Immune Checkpoint Blockade. Frontiers in Immunology, 2019, 10, 467.	2.2	122
7508	Immunotherapy of Cancer: Developments and Reference Points, an Unorthodox Approach. Integrative Cancer Therapies, 2019, 18, 153473541982709.	0.8	2
7509	Perspectives on immunotherapy via oncolytic viruses. Infectious Agents and Cancer, 2019, 14, 5.	1.2	24
7510	Recent Advances in Polymeric Nanomedicines for Cancer Immunotherapy. Advanced Healthcare Materials, 2019, 8, e1801320.	3.9	43
7511	Late-onset isolated adrenocorticotrophic hormone deficiency caused by nivolumab: a case report. BMC Endocrine Disorders, 2019, 19, 25.	0.9	27
7512	Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients. , 2019, 7, 50.		44

#	ARTICLE	IF	CITATIONS
7513	Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors. , 2019, 7, 53.		59
7514	Clinical Trial Outcomes. JACC: Heart Failure, 2019, 7, 272-273.	1.9	6
7515	Emerging Nano- and Microapproaches for Cancer Immunotherapy. Advanced Science, 2019, 6, 1801847.	5.6	136
7517	Network meta-analysis of therapies for previously untreated advanced BRAF-mutated melanoma. Cancer Treatment Reviews, 2019, 74, 43-48.	3.4	38
7518	Next Generation CAR T Cells for the Immunotherapy of High-Grade Glioma. Frontiers in Oncology, 2019, 9, 69.	1.3	68
7519	Incidence of Ipilimumab-Related Serious Adverse Events in Patients with Advanced Cancer: A Meta-Analysis. Journal of Cancer, 2019, 10, 120-130.	1.2	5
7520	Clinical outcomes of advanced stage cancer patients treated with sequential immunotherapy in phase 1 clinical trials. Investigational New Drugs, 2019, 37, 1198-1206.	1.2	11
7521	Vaccine Strategies to Improve Anti-cancer Cellular Immune Responses. Frontiers in Immunology, 2019, 10, 8.	2.2	156
7522	A T-cell- α -engaging B7-H4/CD3-bispecific Fab-scFv Antibody Targets Human Breast Cancer. Clinical Cancer Research, 2019, 25, 2925-2934.	3.2	43
7523	Cardiac Complications in Immune Checkpoint Inhibition Therapy. Frontiers in Cardiovascular Medicine, 2019, 6, 3.	1.1	65
7524	Genomic Analysis of Circulating Tumor DNA Using a Melanoma-Specific UltraSEEK Oncogene Panel. Journal of Molecular Diagnostics, 2019, 21, 418-426.	1.2	18
7525	Immune-Checkpoint Blockade Opposes CD8+ T-cell Suppression in Human and Murine Cancer. Cancer Immunology Research, 2019, 7, 510-525.	1.6	47
7526	A Novel Form of 4-1BBL Prevents Cancer Development via Nonspecific Activation of CD4+ T and Natural Killer Cells. Cancer Research, 2019, 79, 783-794.	0.4	14
7527	Efficacy of PD-1 blockade in cervical cancer is related to a CD8+FoxP3+CD25+ T-cell subset with operational effector functions despite high immune checkpoint levels. , 2019, 7, 43.		42
7528	Role of Radiation Therapy in Modulation of the Tumor Stroma and Microenvironment. Frontiers in Immunology, 2019, 10, 193.	2.2	105
7529	Combinatorial Approach to Improve Cancer Immunotherapy: Rational Drug Design Strategy to Simultaneously Hit Multiple Targets to Kill Tumor Cells and to Activate the Immune System. Journal of Oncology, 2019, 2019, 1-18.	0.6	76
7530	Mediators of Inflammation in Topical Therapy of Skin Cancers. Mediators of Inflammation, 2019, 2019, 1-15.	1.4	33
7531	Combination of Baseline LDH, Performance Status and Age as Integrated Algorithm to Identify Solid Tumor Patients with Higher Probability of Response to Anti PD-1 and PD-L1 Monoclonal Antibodies. Cancers, 2019, 11, 223.	1.7	18

#	ARTICLE	IF	CITATIONS
7532	Nanoengineered Immune Niches for Reprogramming the Immunosuppressive Tumor Microenvironment and Enhancing Cancer Immunotherapy. <i>Advanced Materials</i> , 2019, 31, e1803322.	11.1	205
7533	Targeting Immune Checkpoints in Lung Cancer: Current Landscape and Future Prospects. <i>Clinical Drug Investigation</i> , 2019, 39, 341-353.	1.1	28
7534	Advances in immune checkpoint inhibitors for bone sarcoma therapy. <i>Journal of Bone Oncology</i> , 2019, 15, 100221.	1.0	122
7535	Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 990-997.	0.6	130
7536	Turning the corner on therapeutic cancer vaccines. <i>Npj Vaccines</i> , 2019, 4, 7.	2.9	490
7537	Adjuvant Ipilimumab in High-Risk Uveal Melanoma. <i>Cancers</i> , 2019, 11, 152.	1.7	27
7538	Management of intussusception in patients with melanoma. <i>Journal of Surgical Oncology</i> , 2019, 119, 897-902.	0.8	5
7539	Metastasis in the wild: investigating metastasis in non-laboratory animals. <i>Clinical and Experimental Metastasis</i> , 2019, 36, 15-28.	1.7	13
7540	GD2-Targeted Immunotherapy of Neuroblastoma. , 2019, , 63-78.		3
7541	Granulomatous Reaction in a Patient With Metastatic Melanoma Treated With Ipilimumab: First Case Reported With Isolated Cutaneous Findings. <i>Actas Dermo-sifiliográficas</i> , 2019, 110, 43-49.	0.2	4
7542	Mutational and Antigenic Landscape in Tumor Progression and Cancer Immunotherapy. <i>Trends in Cell Biology</i> , 2019, 29, 396-416.	3.6	66
7543	The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. <i>Nature Reviews Cancer</i> , 2019, 19, 133-150.	12.8	1,657
7544	Safety assessment of anticancer drugs in association with radiotherapy in metastatic malignant melanoma: a real-life report. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 881-892.	1.1	5
7545	Inhibition of the adenosinergic pathway: the indispensable part of oncological therapy in the future. <i>Purinergic Signalling</i> , 2019, 15, 53-67.	1.1	10
7546	The second genome: Effects of the mitochondrial genome on cancer progression. <i>Advances in Cancer Research</i> , 2019, 142, 63-105.	1.9	19
7547	Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor Responses in KIT-Mutant Metastatic Melanoma. <i>Journal of Investigative Dermatology</i> , 2019, 139, 728-731.	0.3	8
7549	Importance of the immune system in head and neck cancer. <i>Head and Neck</i> , 2019, 41, 2789-2800.	0.9	28
7550	Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors. <i>Clinical Pharmacokinetics</i> , 2019, 58, 835-857.	1.6	222

#	ARTICLE	IF	CITATIONS
7551	Do Not Forget About the Importance of Loco-Regional Therapy in Melanoma Management. <i>Seminars in Radiation Oncology</i> , 2019, 29, 166-170.	1.0	3
7552	Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitors. <i>Oncolmmunology</i> , 2019, 8, e1568812.	2.1	148
7553	<p>Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients<p>. <i>Therapeutics and Clinical Risk Management</i> , 2019, Volume 15, 211-221.	0.9	42
7554	Nonâ€Thermal Plasma as a Unique Delivery System of Shortâ€Lived Reactive Oxygen and Nitrogen Species for Immunogenic Cell Death in Melanoma Cells. <i>Advanced Science</i> , 2019, 6, 1802062.	5.6	177
7555	PDâ€1/PDâ€L1 pathway: Basic biology and role in cancer immunotherapy. <i>Journal of Cellular Physiology</i> , 2019, 234, 16824-16837.	2.0	279
7556	Computational Analysis of Epigenetic Modifications in Melanoma. , 2019, , 327-342.		1
7557	Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition. , 2019, 7, 49.		102
7558	Immunotherapy and radiotherapy for metastatic cancers. <i>Annals of Palliative Medicine</i> , 2019, 8, 312-325.	0.5	33
7559	Risk of Pneumonitis and Pneumonia Associated With Immune Checkpoint Inhibitors for Solid Tumors: A Systematic Review and Meta-Analysis. <i>Frontiers in Immunology</i> , 2019, 10, 108.	2.2	117
7560	Overcoming Resistance to Natural Killer Cell Based Immunotherapies for Solid Tumors. <i>Frontiers in Oncology</i> , 2019, 9, 51.	1.3	117
7561	Soluble immune checkpoint molecules: Serum markers for cancer diagnosis and prognosis. <i>Cancer Reports</i> , 2019, 2, e1160.	0.6	26
7562	Cardio-Oncology: Vascular and Metabolic Perspectives: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2019, 139, e579-e602.	1.6	142
7563	Recent success and limitations of immune checkpoint inhibitors for cancer: a lesson from melanoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 474, 421-432.	1.4	45
7564	Augmenting the synergies of chemotherapy and immunotherapy through drug delivery. <i>Acta Biomaterialia</i> , 2019, 88, 1-14.	4.1	29
7565	Advances in immunotherapy delivery from implantable and injectable biomaterials. <i>Acta Biomaterialia</i> , 2019, 88, 15-31.	4.1	127
7566	Anti-tumor immunity induced by ectopic expression of viral antigens is transient and limited by immune escape. <i>Oncolmmunology</i> , 2019, 8, e1568809.	2.1	22
7567	Immunotherapy for skin cancer. <i>International Immunology</i> , 2019, 31, 465-475.	1.8	47
7568	The Immune Checkpoint Kick Start: Optimization of Neoadjuvant Combination Therapy Using Game Theory. <i>JCO Clinical Cancer Informatics</i> , 2019, 3, 1-12.	1.0	22

#	ARTICLE	IF	CITATIONS
7569	New Strategies for Therapeutic Cancer Vaccines. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2019, 19, 213-221.	0.9	8
7570	Long-Term Survival After Brain and Spine Metastasis in Malignant Melanoma. <i>World Neurosurgery</i> , 2019, 125, 164-169.	0.7	3
7571	Evaluation of a Novel Pb-203-Labeled Lactam-Cyclized Alpha-Melanocyte-Stimulating Hormone Peptide for Melanoma Targeting. <i>Molecular Pharmaceutics</i> , 2019, 16, 1694-1702.	2.3	26
7572	T cell co-stimulation and co-inhibition in cardiovascular disease: a double-edged sword. <i>Nature Reviews Cardiology</i> , 2019, 16, 325-343.	6.1	65
7573	Biological therapies in lung cancer treatment: using our immune system as an ally to defeat the malignancy. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 457-467.	1.4	7
7574	Treatment in metastatic melanoma—time to re-think. <i>Annals of Oncology</i> , 2019, 30, 501-503.	0.6	8
7575	Improved Survival with Immunotherapy but Lack of Synergistic Effect with Radiation for Stage IV Melanoma of the Head and Neck. <i>American Surgeon</i> , 2019, 85, 1118-1124.	0.4	1
7576	Selective inhibition of low-affinity memory CD8+ T cells by corticosteroids. <i>Journal of Experimental Medicine</i> , 2019, 216, 2701-2713.	4.2	82
7577	Innovative oncology products: time to revisit the strategy development?. <i>ESMO Open</i> , 2019, 4, e000571.	2.0	2
7578	Introductory Chapter: Are We There Yet? The Long and Winding Road to Cancer Immunotherapy. , 2019, , .		0
7579	Immunotherapy for Treatment of Cancer. , 2019, , .		4
7580	Clinical Features of Liver Injury Induced by Immune Checkpoint Inhibitors in Japanese Patients. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2019, 2019, 1-12.	0.8	43
7581	Cancer immunotherapy experience in the Integral Oncology Centre “Diana Laura Riojas de Colosio”, Mdica Sur Hospital. <i>Wspolczesna Onkologia</i> , 2019, 23, 239-246.	0.7	0
7582	Complete Response and Immune-Mediated Adverse Effects With Checkpoint Blockade: Treatment of Mismatch Repair–Deficient Colorectal Neuroendocrine Carcinoma. <i>JCO Precision Oncology</i> , 2019, 3, 1-7.	1.5	4
7583	Comparative Analysis of Durable Responses on Immune Checkpoint Inhibitors Versus Other Systemic Therapies: A Pooled Analysis of Phase III Trials. <i>JCO Precision Oncology</i> , 2019, 3, 1-10.	1.5	51
7584	Upfront Surgical Resection of Melanoma Brain Metastases Provides a Bridge Toward Immunotherapy-Mediated Systemic Control. <i>Oncologist</i> , 2019, 24, 671-679.	1.9	36
7585	The Italian Society for Rheumatology clinical practice guidelines for rheumatoid arthritis. <i>Reumatismo</i> , 2019, 71, 22-49.	0.4	12
7586	Guadecitabine Plus Ipilimumab in Unresectable Melanoma: The NIBIT-M4 Clinical Trial. <i>Clinical Cancer Research</i> , 2019, 25, 7351-7362.	3.2	61

#	ARTICLE	IF	CITATIONS
7587	Patients with FLT3-mutant AML needed to enroll on FLT3-targeted therapeutic clinical trials. <i>Blood Advances</i> , 2019, 3, 4055-4064.	2.5	2
7589	Balancing the Hype with Reality: What Do Patients with Advanced Melanoma Consider When Making the Decision to Have Immunotherapy?. <i>Oncologist</i> , 2019, 24, e1190-e1196.	1.9	24
7591	Management of V600E and V600K BRAF-Mutant Melanoma. <i>Current Treatment Options in Oncology</i> , 2019, 20, 81.	1.3	28
7592	Cardiotoxicity of Immune Therapy. <i>Cardiology Clinics</i> , 2019, 37, 385-397.	0.9	54
7593	Immune checkpoint inhibitors plus chemotherapy versus chemotherapy or immune checkpoint inhibitors for first- or second-line treatment of advanced gastric and gastro-esophageal junction cancer. <i>The Cochrane Library</i> , 0, , .	1.5	0
7594	Differences in Tumor Microenvironment Dictate T Helper Lineage Polarization and Response to Immune Checkpoint Therapy. <i>Cell</i> , 2019, 179, 1177-1190.e13.	13.5	259
7595	Immunotherapy and Radiation. <i>Hematology/Oncology Clinics of North America</i> , 2019, 33, 1057-1069.	0.9	2
7596	Impaired Bâ€cell tolerance checkpoints promote the development of autoimmune diseases and pathogenic autoantibodies. <i>Immunological Reviews</i> , 2019, 292, 90-101.	2.8	86
7597	The effect of antibiotics on the clinical outcomes of patients with solid cancers undergoing immune checkpoint inhibitor treatment: a retrospective study. <i>BMC Cancer</i> , 2019, 19, 1100.	1.1	40
7598	Immune checkpoint inhibitors win the 2018 Nobel Prize. <i>Biomedical Journal</i> , 2019, 42, 299-306.	1.4	62
7599	Natural Products and Synthetic Analogs as a Source of Antitumor Drugs. <i>Biomolecules</i> , 2019, 9, 679.	1.8	117
7600	Neuroimmune interactions in Alzheimer's diseaseâ€New frontier with old challenges?. <i>Progress in Molecular Biology and Translational Science</i> , 2019, 168, 183-201.	0.9	12
7601	PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways. <i>Immunity</i> , 2019, 51, 1059-1073.e9.	6.6	229
7602	Preface: More than two decades of modern tumor immunology. <i>Methods in Enzymology</i> , 2019, 629, xxi-xl.	0.4	1
7604	20 Carcinoma of the Nasal Cavity and Anterior Skull Base. , 2019, , .		0
7605	28 Drug Development in the 21st Century: Monoclonal Antibodies and Immunotherapy. , 2019, , .		0
7606	Development of cancer immunotherapy based on PD-1/PD-L1 pathway blockade. <i>RSC Advances</i> , 2019, 9, 33903-33911.	1.7	17
7607	CAR T cell therapy: A new era for cancer treatment (Review). <i>Oncology Reports</i> , 2019, 42, 2183-2195.	1.2	103

#	ARTICLE	IF	CITATIONS
7608	Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection. , 2019, 7, 353.		91
7609	DDR1 promotes breast tumor growth by suppressing antitumor immunity. <i>Oncology Reports</i> , 2019, 42, 2844-2854.	1.2	20
7610	Autoimmune Bell's Palsy Following Immunotherapy For Metastatic Melanoma: A Report of 2 Cases. <i>Journal of Immunotherapy</i> , 2019, 42, 318-320.	1.2	9
7611	Incidence and Clinical Impact of Anti-TNF α Treatment of Severe Immune Checkpoint Inhibitor-induced Colitis in Advanced Melanoma: The Mecolit Survey. <i>Journal of Immunotherapy</i> , 2019, 42, 175-179.	1.2	57
7612	Immunoglobulin G and Subclasses as Potential Biomarkers in Metastatic Melanoma Patients Starting Checkpoint Inhibitor Treatment. <i>Journal of Immunotherapy</i> , 2019, 42, 89-93.	1.2	21
7613	Racial and Socioeconomic Disparities in the Delivery of Immunotherapy for Metastatic Melanoma in the United States. <i>Journal of Immunotherapy</i> , 2019, 42, 228-235.	1.2	53
7614	Antitumor activity of the PD-1/PD-L1 binding inhibitor BMS-202 in the humanized MHC-double knockout NOG mouse. <i>Biomedical Research</i> , 2019, 40, 243-250.	0.3	26
7615	Immune checkpoint inhibitors therapy in older patients (≥ 70 years) with metastatic melanoma: a multicentre study. <i>Postepy Dermatologii i Alergologii</i> , 2019, 36, 566-571.	0.4	13
7616	Chronic intestinal pseudo-obstruction in a patient with metastatic gastro-oesophageal junction cancer receiving treatment with pembrolizumab. <i>BMJ Case Reports</i> , 2019, 12, e232388.	0.2	3
7617	The future of radiotherapy and immunotherapy concomitantly in cancer management. <i>Medical Journal of Indonesia</i> , 2019, 28, 391-5.	0.2	1
7618	Tumor-intrinsic signaling pathways: key roles in the regulation of the immunosuppressive tumor microenvironment. <i>Journal of Hematology and Oncology</i> , 2019, 12, 125.	6.9	116
7619	Gut microbiome and CAR-T therapy. <i>Experimental Hematology and Oncology</i> , 2019, 8, 31.	2.0	33
7620	<p>Siglecs, Novel Immunotherapy Targets, Potentially Enhance The Effectiveness of Existing Immune Checkpoint Inhibitors in Glioma Immunotherapy</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 10263-10273.	1.0	25
7622	Aldo-keto reductases protect metastatic melanoma from ER stress-independent ferroptosis. <i>Cell Death and Disease</i> , 2019, 10, 902.	2.7	99
7623	Real-time prediction of patient immune cell modulation during irreversible electroporation therapy. <i>Scientific Reports</i> , 2019, 9, 17739.	1.6	25
7624	Knockdown THOC2 suppresses the proliferation and invasion of melanoma. <i>Bioengineered</i> , 2019, 10, 635-645.	1.4	17
7625	Delivery strategies of cancer immunotherapy: recent advances and future perspectives. <i>Journal of Hematology and Oncology</i> , 2019, 12, 126.	6.9	96
7626	Immune-Mediated Colitis. <i>Current Treatment Options in Gastroenterology</i> , 2019, 17, 506-523.	0.3	6

#	ARTICLE	IF	CITATIONS
7627	The Predictive Value of Tumor Mutation Burden on Efficacy of Immune Checkpoint Inhibitors in Cancers: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2019, 9, 1161.	1.3	96
7628	Co-signal Molecules in T Cell Activation. <i>Advances in Experimental Medicine and Biology</i> , 2019, , .	0.8	6
7629	Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma. <i>Nature Medicine</i> , 2019, 25, 1916-1927.	15.2	541
7630	Discovery of Small Molecules for the Reversal of T Cell Exhaustion. <i>Cell Reports</i> , 2019, 29, 3293-3302.e3.	2.9	34
7631	Evaluation of Diffusion-Weighted MRI and FDG-PET/CT to Assess Response to AdCD40L treatment in Metastatic Melanoma Patients. <i>Scientific Reports</i> , 2019, 9, 18069.	1.6	7
7632	Multiple nivolumab-induced CNS demyelination with spontaneous resolution in an asymptomatic metastatic melanoma patient. , 2019, 7, 336.		21
7633	Indirect comparison between immune checkpoint inhibitors and targeted therapies for the treatment of melanoma. <i>Journal of Cancer</i> , 2019, 10, 6114-6123.	1.2	3
7634	Analysis of key clinical features for achieving complete remission in stage III and IV non-small cell lung cancer patients. <i>Respiratory Research</i> , 2019, 20, 263.	1.4	5
7635	Current Progress in CAR-T Cell Therapy for Solid Tumors. <i>International Journal of Biological Sciences</i> , 2019, 15, 2548-2560.	2.6	252
7636	Lack of detectable neoantigen depletion signals in the untreated cancer genome. <i>Nature Genetics</i> , 2019, 51, 1741-1748.	9.4	59
7637	Neurologic Immune-Related Adverse Events Associated with Immune Checkpoint Inhibition. <i>Current Oncology Reports</i> , 2019, 21, 108.	1.8	46
7638	A Non-interventional Clinical Trial Assessing Immune Responses After Radiofrequency Ablation of Liver Metastases From Colorectal Cancer. <i>Frontiers in Immunology</i> , 2019, 10, 2526.	2.2	29
7639	Review of Drug-induced Injury in Mucosal Biopsies From the Tubular Gastrointestinal Tract. <i>Advances in Anatomic Pathology</i> , 2019, 26, 151-170.	2.4	5
7640	Precision Cancer Trials With Immunomodulatory Agents. <i>Cancer Journal (Sudbury, Mass)</i> , 2019, 25, 287-295.	1.0	3
7641	Melanoma. <i>Anti-Cancer Drugs</i> , 2019, 30, 543-553.	0.7	1
7642	Clinical Correlates of Response to Anti-PD-1-based Therapy in Patients With Metastatic Melanoma. <i>Journal of Immunotherapy</i> , 2019, 42, 221-227.	1.2	20
7643	Clinicopathologic features correlated with paradoxical outcomes in stage IIC versus IIIA melanoma patients. <i>Melanoma Research</i> , 2019, 29, 70-76.	0.6	9
7644	MiR-135b is a novel oncogenic factor in cutaneous melanoma by targeting LATS2. <i>Melanoma Research</i> , 2019, 29, 119-125.	0.6	19

#	ARTICLE	IF	CITATIONS
7645	Immunotargeted therapy in melanoma: patient, provider preferences, and willingness to pay at an academic cancer center. <i>Melanoma Research</i> , 2019, 29, 626-634.	0.6	15
7646	Adjuvant systemic therapy in high-risk melanoma. <i>Melanoma Research</i> , 2019, 29, 358-364.	0.6	16
7647	Are patients in haemodialysis good candidates for immunotherapy treatment?. <i>Melanoma Research</i> , 2019, 29, 553-555.	0.6	2
7648	Artificial Intelligence Estimates the Importance of Baseline Factors in Predicting Response to Anti-PD1 in Metastatic Melanoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 643-648.	0.6	11
7649	Immune Checkpoint Inhibitors in Uveal and Conjunctival Melanoma. <i>International Ophthalmology Clinics</i> , 2019, 59, 53-63.	0.3	29
7650	Targeted Biological Drugs and Immune Check Point Inhibitors for Locally Advanced or Metastatic Cancers of the Conjunctiva, Eyelid, and Orbit. <i>International Ophthalmology Clinics</i> , 2019, 59, 13-26.	0.3	9
7651	Immune-related adverse events in cancer patients treated with immune checkpoint inhibitors. <i>Medicine (United States)</i> , 2019, 98, e17348.	0.4	28
7652	<p>&A Case Of Ipilimumab-Induced Unusual Serous Retinal Detachment In Bilateral Eyes&/p>. <i>International Medical Case Reports Journal</i> , 2019, Volume 12, 355-361.	0.3	13
7653	Immunotherapy in metastatic melanoma: a novel scenario of new toxicities and their management. <i>Melanoma Management</i> , 2019, 6, MMT30.	0.1	19
7654	A case of sustained ventricular tachycardia due to pembrolizumab. <i>HeartRhythm Case Reports</i> , 2019, 5, 570-572.	0.2	0
7655	Combined immune checkpoint inhibitor therapy with nivolumab and ipilimumab causing acute-onset type 1 diabetes mellitus following a single administration: two case reports. <i>BMC Endocrine Disorders</i> , 2019, 19, 144.	0.9	24
7656	Scientific Rationale for Combination Immunotherapy of Hepatocellular Carcinoma with Anti-PD-1/PD-L1 and Anti-CTLA-4 Antibodies. <i>Liver Cancer</i> , 2019, 8, 413-426.	4.2	40
7657	An update on adjuvant systemic therapies in melanoma. <i>Melanoma Management</i> , 2019, 6, MMT28.	0.1	10
7658	Systemic therapies for unresectable locoregional melanoma: a significant area of need. <i>Melanoma Management</i> , 2019, 6, MMT25.	0.1	6
7660	One or Two Immune Checkpoint Inhibitors?. <i>Cancer Cell</i> , 2019, 36, 579-581.	7.7	11
7661	Hypophysitis induced by immune checkpoint inhibitors: a 10-year assessment. <i>Expert Review of Endocrinology and Metabolism</i> , 2019, 14, 381-398.	1.2	54
7662	Concurrent Radiosurgery and Immune Checkpoint Inhibition. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 253-257.	0.6	35
7663	Neurotoxicity associated with cancer immunotherapy: immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy. <i>Current Opinion in Neurology</i> , 2019, 32, 500-510.	1.8	57

#	ARTICLE	IF	CITATIONS
7664	RNA m6A methyltransferase METTL3 regulates invasiveness of melanoma cells by matrix metalloproteinase 2. <i>Melanoma Research</i> , 2019, 29, 382-389.	0.6	65
7665	Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer. <i>European Respiratory Review</i> , 2019, 28, 190058.	3.0	73
7666	A systematic analysis of immune genes and overall survival in cancer patients. <i>BMC Cancer</i> , 2019, 19, 1225.	1.1	30
7668	Prognostic Significance of Hematological Indices in Malignant Melanoma Treated With Immune Checkpoint Inhibitors. <i>Journal of Immunotherapy</i> , 2019, 42, 251-264.	1.2	13
7669	LAG3 in Solid Tumors as a Potential Novel Immunotherapy Target. <i>Journal of Immunotherapy</i> , 2019, 42, 279-283.	1.2	11
7670	Nanomaterials for Regenerative Medicine. <i>Pancreatic Islet Biology</i> , 2019, , .	0.1	1
7672	Vulvar malignancies: an interdisciplinary perspective. <i>JDDG - Journal of the German Society of Dermatology</i> , 2019, 17, 1257-1276.	0.4	28
7673	Multiplexed activation of endogenous genes by CRISPRa elicits potent antitumor immunity. <i>Nature Immunology</i> , 2019, 20, 1494-1505.	7.0	83
7674	Developing neoantigen-targeted T cell-based treatments for solid tumors. <i>Nature Medicine</i> , 2019, 25, 1488-1499.	15.2	173
7675	Hyperthermia and immunotherapy: clinical opportunities. <i>International Journal of Hyperthermia</i> , 2019, 36, 4-9.	1.1	51
7676	New Anticancer Immunotherapies: Implications for Physical Therapy. <i>Rehabilitation Oncology</i> , 2019, 37, 128-137.	0.2	0
7677	Biomarkers, measured during therapy, for response of melanoma patients to immune checkpoint inhibitors: a systematic review. <i>Melanoma Research</i> , 2019, 29, 453-464.	0.6	26
7678	Immune checkpoint inhibitors. <i>Current Opinion in Ophthalmology</i> , 2019, 30, 426-433.	1.3	8
7679	Anti-PD-1 and anti-PD-L1 drugs treatment-related adverse events for patients with cancer. <i>Medicine (United States)</i> , 2019, 98, e16324.	0.4	2
7680	Real-world treatment patterns and clinical outcomes among patients with advanced melanoma. <i>Medicine (United States)</i> , 2019, 98, e16328.	0.4	30
7681	Prediction of response to immune checkpoint inhibitor therapy using 18F-FDG PET/CT in patients with melanoma. <i>Medicine (United States)</i> , 2019, 98, e16417.	0.4	28
7682	Risk of Neurological Toxicities Following the Use of Different Immune Checkpoint Inhibitor Regimens in Solid Tumors. <i>Neurologist</i> , 2019, 24, 75-83.	0.4	31
7683	Switching to Immune Checkpoint Inhibitors upon Response to Targeted Therapy; The Road to Long-Term Survival in Advanced Melanoma Patients with Highly Elevated Serum LDH?. <i>Cancers</i> , 2019, 11, 1940.	1.7	29

#	ARTICLE	IF	CITATIONS
7684	Sunset, or dawn of a new age for ovarian cancer vaccine therapy?. <i>Gynecologic Oncology</i> , 2019, 155, 387-388.	0.6	0
7685	Enhancing the abscopal effect of radiation and immune checkpoint inhibitor therapies with magnetic nanoparticle hyperthermia in a model of metastatic breast cancer. <i>International Journal of Hyperthermia</i> , 2019, 36, 47-63.	1.1	35
7686	A population-based study of the treatment effect of first-line ipilimumab for metastatic or unresectable melanoma. <i>Melanoma Research</i> , 2019, 29, 635-642.	0.6	4
7687	Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association Canadienne Des Pathologistes (CAP-ACP). <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2019, 27, 699-714.	0.6	36
7688	Immunotherapy for cancer in people living with HIV. <i>Aids</i> , 2019, 33, F13-F19.	1.0	61
7689	Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers. <i>Cancers</i> , 2019, 11, 1926.	1.7	27
7690	BTLA blockade enhances Cancer therapy by inhibiting IL-6/IL-10-induced CD19 ^{high} B lymphocytes. , 2019, 7, 313.		67
7691	Emerging Translational Opportunities in Comparative Oncology With Companion Canine Cancers: Radiation Oncology. <i>Frontiers in Oncology</i> , 2019, 9, 1291.	1.3	17
7692	Monoclonal Antibodies: Past, Present and Future. <i>Handbook of Experimental Pharmacology</i> , 2019, 260, 81-141.	0.9	41
7693	An intra-tumoral niche maintains and differentiates stem-like CD8 T cells. <i>Nature</i> , 2019, 576, 465-470.	13.7	510
7694	Setting the scene â€” a future â€”epidemicâ€™ of immune-related adverse events in association with checkpoint inhibitor therapy. <i>Rheumatology</i> , 2019, 58, vii1-vii6.	0.9	3
7695	Understanding and Modulating Immunity With Cell Reprogramming. <i>Frontiers in Immunology</i> , 2019, 10, 2809.	2.2	13
7696	Immunotherapies for pediatric cancer: current landscape and future perspectives. <i>Cancer and Metastasis Reviews</i> , 2019, 38, 573-594.	2.7	20
7697	Arrhythmogenic Anticancer Drugs in Cardio-Oncology. <i>Cardiology Clinics</i> , 2019, 37, 459-468.	0.9	11
7698	Safe Transition to Pembrolizumab following Ipilimumab-Induced Guillain-BarrÃ© Syndrome: A Case Report and Review of the Literature. <i>Case Reports in Oncological Medicine</i> , 2019, 2019, 1-5.	0.2	6
7699	Anti-PD-1 Immunotherapy-Induced Flare of a Known Underlying Relapsing Vasculitis Mimicking Recurrent Cancer. <i>Oncologist</i> , 2019, 24, 1013-1021.	1.9	15
7700	Impact of the Gut Microbiome on Immune Checkpoint Inhibitor Efficacyâ€™ A Systematic Review. <i>Current Oncology</i> , 2019, 26, 395-403.	0.9	44
7701	Acute progressive neuropathyâ€™myositisâ€™myasthenia-like syndrome associated with immune-checkpoint inhibitor therapy in patients with metastatic melanoma. <i>Melanoma Research</i> , 2019, 29, 435-440.	0.6	23

#	ARTICLE	IF	CITATIONS
7702	Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Neurologic Toxicity: Illustrative Case and Review of the Literature. <i>Oncologist</i> , 2019, 24, 435-443.	1.9	80
7703	Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Renal Toxicity: Illustrative Case and Review. <i>Oncologist</i> , 2019, 24, 735-742.	1.9	43
7704	Effects of pharmacogenetic variants on vemurafenib-related toxicities in patients with melanoma. <i>Pharmacogenomics</i> , 2019, 20, 1283-1290.	0.6	2
7705	Predicting marker for early progression in unresectable melanoma treated with nivolumab. <i>International Journal of Clinical Oncology</i> , 2019, 24, 323-327.	1.0	17
7706	The immune checkpoint CD96 defines a distinct lymphocyte phenotype and is highly expressed on tumor-infiltrating T cells. <i>Immunology and Cell Biology</i> , 2019, 97, 152-164.	1.0	29
7707	Bad company: Microenvironmentally mediated resistance to targeted therapy in melanoma. <i>Pigment Cell and Melanoma Research</i> , 2019, 32, 237-247.	1.5	35
7708	Treatment of brain metastases with stereotactic radiosurgery and immune checkpoint inhibitors: An international meta-analysis of individual patient data. <i>Radiotherapy and Oncology</i> , 2019, 130, 104-112.	0.3	189
7709	Immunomodulators targeting the PD-1/PD-L1 protein-protein interaction: From antibodies to small molecules. <i>Medicinal Research Reviews</i> , 2019, 39, 265-301.	5.0	128
7710	Principles of adoptive T cell therapy in cancer. <i>Seminars in Immunopathology</i> , 2019, 41, 49-58.	2.8	141
7711	Stromal biology and therapy in pancreatic cancer: ready for clinical translation?. <i>Gut</i> , 2019, 68, 159-171.	6.1	246
7712	Cancer immunophenotyping by seven-colour multispectral imaging without tyramide signal amplification. <i>Journal of Pathology: Clinical Research</i> , 2019, 5, 3-11.	1.3	33
7713	Quality-adjusted survival of nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone among treatment-naïve patients with advanced melanoma: a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis. <i>Quality of Life Research</i> , 2019, 28, 109-119.	1.5	14
7714	Toxicities in Immune Checkpoint Inhibitors. , 2019, , 205-226.		2
7715	Cancer Immunotherapy: A Simple Guide for Interventional Radiologists of New Therapeutic Approaches. <i>CardioVascular and Interventional Radiology</i> , 2019, 42, 1221-1229.	0.9	5
7716	Immune Checkpoints. , 2019, , 19-43.		0
7717	Identifying hQC Inhibitors of Alzheimer's Disease by Effective Customized Pharmacophore-Based Virtual Screening, Molecular Dynamic Simulation, and Binding Free Energy Analysis. <i>Applied Biochemistry and Biotechnology</i> , 2019, 187, 1173-1192.	1.4	9
7718	Chrysin inhibit human melanoma A375.S2 cell migration and invasion via affecting MAPK signaling and NF- κ B signaling pathway in vitro. <i>Environmental Toxicology</i> , 2019, 34, 434-442.	2.1	25
7719	CTLA4 antagonists in phase I and phase II clinical trials, current status and future perspectives for cancer therapy. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 149-159.	1.9	21

#	ARTICLE	IF	CITATIONS
7720	The Emerging Role of Surgery for Patients With Advanced Melanoma Treated With Immunotherapy. <i>Journal of Surgical Research</i> , 2019, 236, 209-215.	0.8	24
7721	Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non-small-cell lung cancer: KEYNOTE-021 cohorts D and H. <i>Lung Cancer</i> , 2019, 130, 59-66.	0.9	65
7722	Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti-CTLA-4 antibody. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 609-618.	3.3	141
7723	Diet-dependent toxicity of ipilimumab in metastatic melanoma. <i>European Journal of Cancer</i> , 2019, 106, 220-224.	1.3	1
7724	Combined Nivolumab and Ipilimumab Is an Effective Treatment for Melanoma Brain Metastases. <i>Neurosurgery</i> , 2019, 84, E134-E135.	0.6	2
7725	Clinical and economic outcomes associated with treatment sequences in patients with BRAF-mutant advanced melanoma. <i>Immunotherapy</i> , 2019, 11, 283-295.	1.0	24
7726	ADAR1 Editing and its Role in Cancer. <i>Genes</i> , 2019, 10, 12.	1.0	71
7727	Association of Patient Sex With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Advanced Cancers. <i>JAMA Oncology</i> , 2019, 5, 529.	3.4	192
7728	Preparation, characterization and application of anti-human OX40 ligand (OX40L) monoclonal antibodies and establishment of a sandwich ELISA for autoimmune diseases detection. <i>International Immunopharmacology</i> , 2019, 67, 260-267.	1.7	7
7729	Dermatology today and tomorrow: from symptom control to targeted therapy. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 3-36.	1.3	31
7730	Indications for the surgical resection of stage IV disease. <i>Journal of Surgical Oncology</i> , 2019, 119, 249-261.	0.8	14
7731	Survival Extrapolation in Cancer Immunotherapy: A Validation-Based Case Study. <i>Value in Health</i> , 2019, 22, 276-283.	0.1	43
7732	Microphthalmia-Associated Transcription Factor (MITF) Regulates Immune Cell Migration into Melanoma. <i>Translational Oncology</i> , 2019, 12, 350-360.	1.7	27
7733	Actively personalized vaccination trial for newly diagnosed glioblastoma. <i>Nature</i> , 2019, 565, 240-245.	13.7	637
7734	Predicting tumour response to anti-PD-1 immunotherapy with computational modelling. <i>Physics in Medicine and Biology</i> , 2019, 64, 025017.	1.6	22
7735	A novel approach to candidemia? The potential role of checkpoint inhibition. <i>Medical Mycology</i> , 2019, 57, 151-154.	0.3	9
7736	Undo the brake of tumour immune tolerance with antibodies, peptide mimetics and small molecule compounds targeting PD-1/PD-L1 checkpoint at different locations for acceleration of cytotoxic immunity to cancer cells. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2019, 46, 105-115.	0.9	16
7737	Late-Stage Tumor Regression after PD-L1 Blockade Plus a Concurrent OX40 Agonist. <i>Cancer Immunology Research</i> , 2019, 7, 269-281.	1.6	31

#	ARTICLE	IF	CITATIONS
7738	The applications of anti-CD20 antibodies to treat various B cells disorders. <i>Biomedicine and Pharmacotherapy</i> , 2019, 109, 2415-2426.	2.5	43
7739	Immune checkpoint Ab enhances the antigen-specific anti-tumor effects by modulating both dendritic cells and regulatory T lymphocytes. <i>Cancer Letters</i> , 2019, 444, 20-34.	3.2	13
7740	Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials. <i>European Journal of Cancer</i> , 2019, 107, 1-7.	1.3	48
7741	Antimetastatic and antiangiogenic activity of trabectedin in cutaneous melanoma. <i>Carcinogenesis</i> , 2019, 40, 303-312.	1.3	28
7742	Promising immunotherapy: Highlighting cytokine-induced killer cells. <i>Journal of Cellular Biochemistry</i> , 2019, 120, 8863-8883.	1.2	11
7743	Re-examining the role of adjuvant radiation therapy. <i>Journal of Surgical Oncology</i> , 2019, 119, 242-248.	0.8	1
7744	Effective effectors: How T cells access and infiltrate the central nervous system. , 2019, 197, 52-60.		11
7745	Immune checkpoint blockade and its combination therapy with small-molecule inhibitors for cancer treatment. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2019, 1871, 199-224.	3.3	53
7746	Ipilimumab-induced severe meningoradiculitis. <i>Journal of Clinical Neuroscience</i> , 2019, 62, 246-247.	0.8	2
7747	PD-1 Expression on Circulating CD8+ T-Cells as a Prognostic Marker for Patients With Gastric Cancer. <i>Anticancer Research</i> , 2019, 39, 443-448.	0.5	18
7748	Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. <i>Nature Reviews Drug Discovery</i> , 2019, 18, 197-218.	21.5	2,005
7749	Differential effects of corticosteroids and anti-TNF on tumor-specific immune responses: implications for the management of irAEs. <i>International Journal of Cancer</i> , 2019, 145, 1408-1413.	2.3	36
7750	Immunotherapy for gastric cancer: dilemmas and prospect. <i>Briefings in Functional Genomics</i> , 2019, 18, 107-112.	1.3	90
7751	Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. <i>Annals of Oncology</i> , 2019, 30, 44-56.	0.6	1,742
7752	Immunotherapy in advanced gastric cancer, is it the future?. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 133, 25-32.	2.0	97
7753	Time to abandon single-site irradiation for inducing abscopal effects. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 123-135.	12.5	233
7754	Peptide and Protein Vaccines for Cancer. , 2019, , 101-116.		4
7755	Obstacles in the Development of Therapeutic Cancer Vaccines. , 2019, , 153-160.		2

#	ARTICLE	IF	CITATIONS
7756	Combination Therapy. , 2019, , 161-170.		0
7757	Cancer Immunotherapy: Beyond Checkpoint Blockade. Annual Review of Cancer Biology, 2019, 3, 55-75.	2.3	102
7758	<i>BRAF</i> V600 Mutational Status in Melanoma Correlates with Cytologic Features in Fine-Needle Aspirate Specimens. Acta Cytologica, 2019, 63, 10-16.	0.7	5
7759	Immune microenvironment and evasion mechanisms in adenoid cystic carcinomas of salivary glands. Oral Oncology, 2019, 88, 95-101.	0.8	54
7760	The renin angiotensin system (RAS) mediates bifunctional growth regulation in melanoma and is a novel target for therapeutic intervention. Oncogene, 2019, 38, 2320-2336.	2.6	32
7761	The multi-functionality of N-809, a novel fusion protein encompassing anti-PD-L1 and the IL-15 superagonist fusion complex. Oncolmunology, 2019, 8, e1532764.	2.1	30
7762	Updates in adjuvant systemic therapy for melanoma. Journal of Surgical Oncology, 2019, 119, 222-231.	0.8	35
7763	Can benign lymphoid tissue changes in 18F-FDG PET/CT predict response to immunotherapy in metastatic melanoma?. Cancer Immunology, Immunotherapy, 2019, 68, 297-303.	2.0	45
7764	Advanced stage melanoma therapies: Detailing the present and exploring the future. Critical Reviews in Oncology/Hematology, 2019, 133, 99-111.	2.0	48
7765	Synthetic Biology Approaches in Immunology. Biochemistry, 2019, 58, 1484-1491.	1.2	4
7766	Prognostic factors for survival in patients with metastatic malign melanoma treated with ipilimumab: Turkish Oncology Group study. Journal of Oncology Pharmacy Practice, 2019, 25, 1658-1664.	0.5	7
7767	Induced Vitiligo due to Talimogene Laherparepvec Injection for Metastatic Melanoma Associated with Long-term Complete Response. Acta Dermato-Venereologica, 2019, 99, 232-233.	0.6	7
7768	¹⁸F-FDG PET/CT for Monitoring of Ipilimumab Therapy in Patients with Metastatic Melanoma. Journal of Nuclear Medicine, 2019, 60, 335-341.	2.8	123
7769	Betulin silver nanoparticles qualify as efficient antimelanoma agents in in vitro and in vivo studies. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 134, 1-19.	2.0	22
7770	Cancer and AIDS. , 2019, , .		0
7771	From the Double Helix to Oncogenomics and Precision Cancer Medicine. , 2019, , 3-16.		0
7772	Immuno-Oncology in Lung Cancer. , 2019, , 487-497.		1
7773	Molecular Pathways in Melanomagenesis. , 2019, , 623-642.		0

#	ARTICLE	IF	CITATIONS
7774	Immunotherapies and Novel Combinations. , 2019, , 643-653.		0
7775	Immunotherapy for Glioblastoma: Adoptive T-cell Strategies. <i>Clinical Cancer Research</i> , 2019, 25, 2042-2048.	3.2	77
7776	Immunotherapy for Head and Neck Cancer. <i>Oral and Maxillofacial Surgery Clinics of North America</i> , 2019, 31, 85-100.	0.4	36
7777	Intratumoral delivery of antigen with complement C3-bound liposomes reduces tumor growth in mice. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2019, 18, 326-335.	1.7	14
7778	Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: <i>in silico</i> and real-life analysis of three larger gene panels. <i>International Journal of Cancer</i> , 2019, 144, 2303-2312.	2.3	95
7779	Altered cancer metabolism in mechanisms of immunotherapy resistance. , 2019, 195, 162-171.		97
7780	Identification of discrepancy between CTLA4 expression and CTLA4 activation in gastric cancer. <i>Immunopharmacology and Immunotoxicology</i> , 2019, 41, 386-393.	1.1	27
7781	Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial. <i>Annals of Oncology</i> , 2019, 30, 317-324.	0.6	15
7782	Whole-body magnetic resonance imaging (WB-MRI) in oncology: recommendations and key uses. <i>Radiologia Medica</i> , 2019, 124, 218-233.	4.7	52
7783	Enhancing Checkpoint Inhibitor Therapy with Ultrasound Stimulated Microbubbles. <i>Ultrasound in Medicine and Biology</i> , 2019, 45, 500-512.	0.7	42
7784	Biomimetic Nanoparticle Vaccines for Cancer Therapy. <i>Advanced Biology</i> , 2019, 3, e1800219.	3.0	84
7785	Establishment of Slice Cultures as a Tool to Study the Cancer Immune Microenvironment. <i>Methods in Molecular Biology</i> , 2019, 1884, 283-295.	0.4	28
7786	Current status of immunotherapy in metastatic colorectal cancer. <i>International Journal of Colorectal Disease</i> , 2019, 34, 13-25.	1.0	106
7787	Regulatory mechanisms of T cell activation—From basic research discoveries to a new principle of cancer therapy and the Nobel Prize. <i>Acta Physiologica</i> , 2019, 225, e13224.	1.8	2
7788	Economic Evaluation of Talimogene Laherparepvec Plus Ipilimumab Combination Therapy vs Ipilimumab Monotherapy in Patients With Advanced Unresectable Melanoma. <i>JAMA Dermatology</i> , 2019, 155, 22.	2.0	25
7789	Imaging of Cancer Immunotherapy: Current Approaches and Future Directions. <i>Radiology</i> , 2019, 290, 9-22.	3.6	147
7791	Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma. <i>Annals of Oncology</i> , 2019, 30, 57-67.	0.6	167
7792	E3611—A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High-Dose Interferon- β in Advanced Melanoma. <i>Clinical Cancer Research</i> , 2019, 25, 524-532.	3.2	8

#	ARTICLE	IF	CITATIONS
7793	Current and Emerging Targets in Immunotherapy for Osteosarcoma. <i>Journal of Oncology</i> , 2019, 2019, 1-8.	0.6	79
7794	HER2 CAR-T Cells Eradicate Uveal Melanoma and T-cell Therapy-Resistant Human Melanoma in IL2 Transgenic NOD/SCID IL2 Receptor Knockout Mice. <i>Cancer Research</i> , 2019, 79, 899-904.	0.4	84
7795	WNT/ β -catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers. <i>Clinical Cancer Research</i> , 2019, 25, 3074-3083.	3.2	435
7796	A Self-Assembled ATP Probe for Melanoma Cell Imaging. <i>Chemistry - A European Journal</i> , 2019, 25, 3501-3504.	1.7	19
7797	Treatment of Metastatic Bladder Cancer. , 2019, , 123-137.		0
7798	Cell-targeted c(AmpRCD)-sunitinib molecular conjugates impair tumor growth of melanoma. <i>Cancer Letters</i> , 2019, 446, 25-37.	3.2	28
7799	Management of immune-related adverse events resulting from immune checkpoint blockade. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 209-222.	1.1	20
7800	Gastrointestinal complications in patients treated with ipilimumab and nivolumab combination therapy or monotherapy. <i>Journal of Comparative Effectiveness Research</i> , 2019, 8, 81-90.	0.6	7
7801	Innovation in oncology clinical trial design. <i>Cancer Treatment Reviews</i> , 2019, 74, 15-20.	3.4	41
7802	Management of Urothelial Carcinoma. , 2019, , .		0
7803	Reacción granulomatosa en paciente con melanoma metastásico tratado con ipilimumab: primer caso descrito presentando clínica cutánea únicamente. <i>Actas Dermo-sifiligráficas</i> , 2019, 110, 43-49.	0.2	10
7804	Delivery technologies for cancer immunotherapy. <i>Nature Reviews Drug Discovery</i> , 2019, 18, 175-196.	21.5	1,562
7805	Complete response of metastatic melanoma in a patient with Crohn's disease simultaneously receiving anti-CTLA4 and anti-PD1 antibodies. , 2019, 7, 1.		143
7806	A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors. <i>International Journal of Cancer</i> , 2019, 145, 639-648.	2.3	151
7807	Tumor Microenvironmental pH and Enzyme Dual Responsive Polymer-Liposomes for Synergistic Treatment of Cancer Immuno-Chemotherapy. <i>Biomacromolecules</i> , 2019, 20, 882-892.	2.6	68
7808	Uterine Cervical Cancer. , 2019, , .		3
7809	Efficacy and safety of CTLA-4 inhibitors combined with PD-1 inhibitors or chemotherapy in patients with advanced melanoma. <i>International Immunopharmacology</i> , 2019, 68, 131-136.	1.7	14
7810	TCR Retrogenic Mice as a Model To Map Self-Tolerance Mechanisms to the Cancer Mucosa Antigen GUCY2C. <i>Journal of Immunology</i> , 2019, 202, 1301-1310.	0.4	6

#	ARTICLE	IF	CITATIONS
7811	Targeted Therapy against Metastatic Melanoma Based on Self-Assembled Metal-Phenolic Nanocomplexes Comprised of Green Tea Catechin. <i>Advanced Science</i> , 2019, 6, 1801688.	5.6	109
7812	Immunotherapy for Precancerous Lesions of the Uterine Cervix. , 2019, , 107-140.		0
7813	Monitoring TIGIT/DNAM-1 and PVR/PVRL2 Immune Checkpoint Expression Levels in Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 861-867.	2.0	36
7814	Immunotherapy in pancreatic cancer: New hope or mission impossible?. <i>Cancer Letters</i> , 2019, 445, 57-64.	3.2	26
7815	Revolutionizing treatment of advanced melanoma with immunotherapy. <i>Surgical Oncology</i> , 2019, , 101180.	0.8	12
7816	Low expression of CD80 predicts for poor prognosis in patients with gastric adenocarcinoma. <i>Future Oncology</i> , 2019, 15, 473-483.	1.1	19
7817	Non-Invasive Fluorescent Monitoring of Ovarian Cancer in an Immunocompetent Mouse Model. <i>Cancers</i> , 2019, 11, 32.	1.7	16
7818	PD-1 methylation regulates PD-1 expression and is associated with melanoma survival. <i>Pigment Cell and Melanoma Research</i> , 2019, 32, 435-440.	1.5	54
7819	Melanoma: Where we are and where we go. <i>Journal of Cellular Physiology</i> , 2019, 234, 3307-3320.	2.0	53
7820	Regulated LC-MS/MS bioanalysis technology for therapeutic antibodies and Fc-fusion proteins using structure-indicated approach. <i>Drug Metabolism and Pharmacokinetics</i> , 2019, 34, 19-24.	1.1	6
7821	Cancer diagnosis and immunotherapy in the age of CRISPR. <i>Genes Chromosomes and Cancer</i> , 2019, 58, 233-243.	1.5	4
7822	Efficacy and safety of BRAF inhibitors and anti-CTLA4 antibody in melanoma patientsâ€”real-world data. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 329-334.	0.8	15
7823	Concurrent versus non-concurrent immune checkpoint inhibition with stereotactic radiosurgery for metastatic brain disease: a systematic review and meta-analysis. <i>Journal of Neuro-Oncology</i> , 2019, 141, 1-12.	1.4	30
7824	Developing combination strategies using PD-1 checkpoint inhibitors to treat cancer. <i>Seminars in Immunopathology</i> , 2019, 41, 21-30.	2.8	49
7825	Immunotherapeutic Approaches in Cancer. , 2019, , 19-44.		4
7826	BRAF and MEK inhibitors differentially affect nivolumab-induced T cell activation by modulating the TCR and AKT signaling pathways. <i>Oncimmunology</i> , 2019, 8, e1512456.	2.1	15
7827	<i>miR-155</i> expression in antitumor immunity: The higher the better?. <i>Genes Chromosomes and Cancer</i> , 2019, 58, 208-218.	1.5	29
7828	Guidelines of care for the management of primary cutaneous melanoma. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 208-250.	0.6	400

#	ARTICLE	IF	CITATIONS
7829	Thyroiditis and immune check point inhibitors: the post-marketing experience using the French National Pharmacovigilance database. <i>Fundamental and Clinical Pharmacology</i> , 2019, 33, 241-249.	1.0	18
7830	Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 97-107.	2.0	61
7831	Recurrent grade 4 panuveitis with serous retinal detachment related to nivolumab treatment in a patient with metastatic renal cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 85-95.	2.0	32
7832	The Effectiveness of Checkpoint Inhibitor Combinations and Administration Timing Can Be Measured by Granzyme B PET Imaging. <i>Clinical Cancer Research</i> , 2019, 25, 1196-1205.	3.2	85
7833	The skin as a metabolic and immune-competent organ: Implications for drug-induced skin rash. <i>Journal of Immunotoxicology</i> , 2019, 16, 1-12.	0.9	20
7835	Predictive Biomarkers and Targeted Therapies in Immuno-oncology. , 2019, , 335-344.		1
7836	The Response Evaluation Criteria in Solid Tumors (RECIST). , 2019, , 501-511.		6
7837	Systemic Treatment of HER2-Negative Metastatic Breast Cancer. , 2019, , 483-508.		0
7838	The potential of BRAF-associated non-coding RNA as a therapeutic target in melanoma. <i>Expert Opinion on Therapeutic Targets</i> , 2019, 23, 53-68.	1.5	6
7839	The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy. <i>Blood</i> , 2019, 133, 550-565.	0.6	57
7840	Liver Cancers. , 2019, , .		2
7841	Nivolumab and ipilimumab: immunotherapy for treatment of malignant melanoma. <i>Future Oncology</i> , 2019, 15, 349-358.	1.1	34
7842	What's™s New in Dermatopathology: Inflammatory Dermatoses. <i>Advances in Anatomic Pathology</i> , 2019, 26, 40-55.	2.4	2
7843	Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 511-521.	1.2	153
7844	Noncoding RNA in Cholangiocarcinoma. <i>Seminars in Liver Disease</i> , 2019, 39, 013-025.	1.8	38
7845	Urothelial cancer: a narrative review of the role of novel immunotherapeutic agents with particular reference to the management of non-muscle-invasive disease. <i>BJU International</i> , 2019, 123, 947-958.	1.3	9
7846	Academic Discovery of Anticancer Drugs: Historic and Future Perspectives. <i>Annual Review of Cancer Biology</i> , 2019, 3, 385-408.	2.3	17
7847	Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma model. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 379-393.	2.0	100

#	ARTICLE	IF	CITATIONS
7848	Identification of risk in cutaneous melanoma patients: Prognostic and predictive markers. <i>Journal of Surgical Oncology</i> , 2019, 119, 175-186.	0.8	32
7849	Checkpoint-modulating immunotherapies in tumor treatment: Targets, drugs, and mechanisms. <i>International Immunopharmacology</i> , 2019, 67, 160-175.	1.7	33
7850	Rational combination immunotherapeutic approaches for effective cancer treatment. <i>Journal of Controlled Release</i> , 2019, 294, 114-130.	4.8	28
7851	Cancer Neoantigens. <i>Annual Review of Immunology</i> , 2019, 37, 173-200.	9.5	384
7852	Management of local or regional non-nodal disease. <i>Journal of Surgical Oncology</i> , 2019, 119, 187-199.	0.8	8
7854	Next-generation sequencing-based clinical sequencing: toward precision medicine in solid tumors. <i>International Journal of Clinical Oncology</i> , 2019, 24, 115-122.	1.0	35
7856	Cancer immunoediting and resistance to T cell-based immunotherapy. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 151-167.	12.5	1,093
7857	Inflammatory and Infectious Syndromes Associated With Cancer Immunotherapies. <i>Clinical Infectious Diseases</i> , 2019, 69, 909-920.	2.9	57
7858	Next generation sequencing-based gene panel tests for the management of solid tumors. <i>Cancer Science</i> , 2019, 110, 6-15.	1.7	107
7859	Inhibition of MERTK Promotes Suppression of Tumor Growth in BRAF Mutant and BRAF Wild-Type Melanoma. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 278-288.	1.9	24
7860	The distribution of T cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. <i>Cancer</i> , 2019, 125, 1470-1481.	2.0	229
7861	Regulatory T cells expressing abundant CTLA-4 on the cell surface with a proliferative gene profile are key features of human head and neck cancer. <i>International Journal of Cancer</i> , 2019, 144, 2811-2822.	2.3	35
7862	T Cell Receptors-Gene-Modified T Cells for Cancer: Methods, Data, and Challenges. <i>Advances and Controversies in Hematopoietic Transplantation and Cell Therapy</i> , 2019, , 109-133.	0.0	0
7863	Prognostic value of baseline metabolic tumor volume measured on 18F-fluorodeoxyglucose positron emission tomography/computed tomography in melanoma patients treated with ipilimumab therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 930-939.	3.3	75
7864	Case of malignant melanoma responding to dacarbazine following nivolumab. <i>Dermatologic Therapy</i> , 2019, 32, e12791.	0.8	4
7865	Clinical Development of Novel Drug-Radiotherapy Combinations. <i>Clinical Cancer Research</i> , 2019, 25, 1455-1461.	3.2	42
7866	Immune checkpoint blockade opens a new way to cancer immunotherapy. <i>Journal of Cellular Physiology</i> , 2019, 234, 8541-8549.	2.0	84
7867	Immune Checkpoint Inhibitors in Sarcoma. , 2019, , 125-137.		0

#	ARTICLE	IF	CITATIONS
7868	Body composition and sarcopenia: The next-generation of personalized oncology and pharmacology?. , 2019, 196, 135-159.		100
7869	Cancer Immunosurveillance by T Cells. International Review of Cell and Molecular Biology, 2019, 342, 149-173.	1.6	45
7870	Spinal cord astrocytomas: progresses in experimental and clinical investigations for developing recovery neurobiology-based novel therapies. Experimental Neurology, 2019, 311, 135-147.	2.0	16
7871	A Phase 1 Trial of Oncolytic Adenovirus ICOVIR-5 Administered Intravenously to Cutaneous and Uveal Melanoma Patients. Human Gene Therapy, 2019, 30, 352-364.	1.4	66
7872	Size matters: Dissecting key parameters for panelâ€­based tumor mutational burden analysis. International Journal of Cancer, 2019, 144, 848-858.	2.3	131
7873	Lost in Translation: Deciphering the Mechanism of Action of Anti-human CTLA-4. Clinical Cancer Research, 2019, 25, 1130-1132.	3.2	30
7874	Long-Term Survival in Patients Responding to Antiâ€­PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation. Clinical Cancer Research, 2019, 25, 946-956.	3.2	96
7875	Treatment patterns and outcomes for patients with advanced melanoma in US oncology clinical practices. Future Oncology, 2019, 15, 459-471.	1.1	27
7876	Identification of PD-L2, B7-H3 and CTLA-4 immune checkpoint proteins in genetic subtypes of meningioma. OncoImmunology, 2019, 8, e1512943.	2.1	31
7877	Targeting Programmed Cell Death -1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapy. , 2019, 194, 84-106.		248
7878	Addressing New Diagnostic and Treatment Challenges Associated With a New Age of Cancerâ€­Treatment. Annals of Emergency Medicine, 2019, 73, 88-90.	0.3	8
7879	Rheumatic diseases associated with immune checkpoint inhibitors in cancer immunotherapy. Modern Rheumatology, 2019, 29, 721-732.	0.9	10
7880	Efficacy of Vemurafenib Treatment in 43 Metastatic Melanoma Patients with BRAF Mutation. Single-Institute Retrospective Analysis, Early Real-Life Survival Data. Pathology and Oncology Research, 2019, 25, 45-50.	0.9	9
7881	Alternative metrics for assessing clinical benefit with immunotherapy in oncology. OncoImmunology, 2019, 8, e1343774.	2.1	3
7882	Arthritis After Cancer Immunotherapy: Symptom Duration and Treatment Response. Arthritis Care and Research, 2019, 71, 362-366.	1.5	75
7883	Beyond the vicious cycle: The role of innate osteoimmunity, automimicry and tumor-inherent changes in dictating bone metastasis. Molecular Immunology, 2019, 110, 57-68.	1.0	21
7884	Prognostic Significance of Pre- and Postoperative Lymphocyte Counts in Patients with Gastric Cancer. Digestive Surgery, 2019, 36, 137-143.	0.6	21
7885	Recent advances in therapeutic strategies for unresectable or metastatic melanoma and real-world data in Japan. International Journal of Clinical Oncology, 2019, 24, 1508-1514.	1.0	13

#	ARTICLE	IF	CITATIONS
7886	Acute autoimmune myocarditis and hepatitis due to ipilimumab monotherapy for malignant melanoma. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 966-968.	0.5	21
7887	Unresectable and Metastatic Melanoma of the Skin: Literature Review of Clinical Trials and Efficacy Endpoints Since 2000. <i>Therapeutic Innovation and Regulatory Science</i> , 2019, 53, 59-70.	0.8	9
7888	Update on advanced melanoma treatments: small molecule targeted therapy, immunotherapy, and future combination therapies. <i>Wiener Medizinische Wochenschrift</i> , 2019, 169, 314-322.	0.5	5
7889	From Molecular Mechanisms to Clinical Management of Antineoplastic Drug-Induced Cardiovascular Toxicity: A Translational Overview. <i>Antioxidants and Redox Signaling</i> , 2019, 30, 2110-2153.	2.5	96
7890	Efficacy of novel immunotherapy regimens in patients with metastatic melanoma with germline <i>CDKN2A</i> mutations. <i>Journal of Medical Genetics</i> , 2020, 57, 316-321.	1.5	33
7891	The Role of Radiolabeled Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography for the Evaluation of Renal Cancer. <i>European Urology Focus</i> , 2020, 6, 146-150.	1.6	25
7892	Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with ipilimumab. <i>Pathology and Oncology Research</i> , 2020, 26, 317-325.	0.9	20
7894	Prognostic factors for survival in patients with mucosal and ocular melanoma treated with ipilimumab: Turkish Oncology Group study. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 267-272.	0.5	8
7895	Ocular Adverse Events following Use of Immune Checkpoint Inhibitors for Metastatic Malignancies. <i>Ocular Immunology and Inflammation</i> , 2020, 28, 854-859.	1.0	52
7896	<i>Cancer Immunology</i> . , 2020, , 84-96.e5.		0
7897	<i>Therapeutic Antibodies and Immunologic Conjugates</i> . , 2020, , 486-499.e8.		2
7898	Targeting the tumor microenvironment to overcome immune checkpoint blockade therapy resistance. <i>Immunology Letters</i> , 2020, 220, 88-96.	1.1	23
7899	Uveitis in Patients Treated with CTLA-4 and PD-1 Checkpoint Blockade Inhibition. <i>Ocular Immunology and Inflammation</i> , 2020, 28, 217-227.	1.0	55
7900	The emerging role of epigenetic therapeutics in immuno-oncology. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 75-90.	12.5	260
7901	Development of an Adrenocortical Cancer Humanized Mouse Model to Characterize Anti-PD1 Effects on Tumor Microenvironment. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 26-42.	1.8	40
7902	Programmed cell death 1 protein and programmed death-ligand 1 inhibitors in the treatment of nonmelanoma skin cancer: A systematic review. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 440-459.	0.6	37
7903	Endocrine toxicity in cancer patients treated with nivolumab or pembrolizumab: results of a large multicentre study. <i>Journal of Endocrinological Investigation</i> , 2020, 43, 337-345.	1.8	33
7904	Workup and Management of Immune-Mediated Colitis in Patients Treated with Immune Checkpoint Inhibitors. <i>Oncologist</i> , 2020, 25, 197-202.	1.9	12

#	ARTICLE	IF	CITATIONS
7905	Response of patients with melanoma to immune checkpoint blockade—insights gleaned from analysis of a new mathematical mechanistic model. <i>Journal of Theoretical Biology</i> , 2020, 485, 110033.	0.8	17
7906	Adverse Events of Novel Therapies for Hematologic Malignancies: What Emergency Physicians Should Know. <i>Annals of Emergency Medicine</i> , 2020, 75, 264-286.	0.3	3
7908	The role of DNA-demethylating agents in cancer therapy. , 2020, 205, 107416.		26
7909	Advances of functional nanomaterials for cancer immunotherapeutic applications. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2020, 12, e1574.	3.3	10
7910	Site-specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti-PD-1 therapy. <i>Cancer</i> , 2020, 126, 86-97.	2.0	113
7911	Localization of PD-1 on single cancer cells by iSERS microscopy with Au/Au core/satellite nanoparticles. <i>Journal of Biophotonics</i> , 2020, 13, e201960034.	1.1	15
7912	Biomarkers Predictive of Survival and Response to Immune Checkpoint Inhibitors in Melanoma. <i>American Journal of Clinical Dermatology</i> , 2020, 21, 1-11.	3.3	13
7913	Acute tubulointerstitial nephritis and IgM deposits on glomerular capillary walls after immunotherapy with nivolumab for metastatic renal cell carcinoma. <i>CEN Case Reports</i> , 2020, 9, 48-54.	0.5	9
7914	Pathology, Biomarkers, and Molecular Diagnostics. , 2020, , 225-253.e8.		4
7916	Current Clinical Trials in the Treatment of Advanced Melanomas. <i>Surgical Clinics of North America</i> , 2020, 100, 201-208.	0.5	3
7917	The postoperative platelet distribution width is useful for predicting the prognosis in patients with esophageal squamous cell carcinoma. <i>Surgery Today</i> , 2020, 50, 123-133.	0.7	8
7918	Basics of Radiation Therapy. , 2020, , 431-460.e3.		4
7919	The antibody-based delivery of interleukin-12 to solid tumors boosts NK and CD8 ⁺ T cell activity and synergizes with immune checkpoint inhibitors. <i>International Journal of Cancer</i> , 2020, 146, 2518-2530.	2.3	39
7920	Tumor mutational burden as a predictive biomarker for checkpoint inhibitor immunotherapy. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 112-115.	1.4	47
7921	Imaging challenges of immunotherapy and targeted therapy in patients with brain metastases: response, progression, and pseudoprogression. <i>Neuro-Oncology</i> , 2020, 22, 17-30.	0.6	94
7922	At the bench: Engineering the next generation of cancer vaccines. <i>Journal of Leukocyte Biology</i> , 2020, 108, 1435-1453.	1.5	22
7923	Melanoma in older patients: declining gap in survival between younger and older patients with melanoma. <i>Acta Oncologica</i> , 2020, 59, 4-12.	0.8	9
7924	High-dimensional cytometric analysis of colorectal cancer reveals novel mediators of antitumour immunity. <i>Gut</i> , 2020, 69, 691-703.	6.1	92

#	ARTICLE	IF	CITATIONS
7925	DNA Damage Response Pathways and Cancer. , 2020, , 154-164.e4.		7
7926	Modulation of the tumor microenvironment with an oncolytic adenovirus for effective T-cell therapy and checkpoint inhibition. <i>Methods in Enzymology</i> , 2020, 635, 205-230.	0.4	9
7927	Techniques for the generation of humanized mouse models for immuno-oncology. <i>Methods in Enzymology</i> , 2020, 636, 351-368.	0.4	5
7928	Immune checkpoints in the tumor microenvironment. <i>Seminars in Cancer Biology</i> , 2020, 65, 1-12.	4.3	146
7929	Acquired resistance to cancer immunotherapy: Role of tumor-mediated immunosuppression. <i>Seminars in Cancer Biology</i> , 2020, 65, 13-27.	4.3	170
7930	Economic Evaluation of Systemic Treatments for Advanced Melanoma: A Systematic Review. <i>Value in Health</i> , 2020, 23, 52-60.	0.1	23
7931	Complex Systems in Medicine. , 2020, , .		6
7932	Current Immunotherapeutic Strategies in Cancer. <i>Recent Results in Cancer Research</i> , 2020, , .	1.8	4
7933	Current Development of Monoclonal Antibodies in Cancer Therapy. <i>Recent Results in Cancer Research</i> , 2020, 214, 1-70.	1.8	16
7934	Principles of Immunotherapy in Melanoma. <i>Surgical Clinics of North America</i> , 2020, 100, 161-173.	0.5	28
7935	Noncoding RNAs as potential mediators of resistance to cancer immunotherapy. <i>Seminars in Cancer Biology</i> , 2020, 65, 65-79.	4.3	55
7936	Management of Locoregionally Advanced Melanoma. <i>Surgical Clinics of North America</i> , 2020, 100, 109-125.	0.5	5
7937	Surgical Considerations and Systemic Therapy of Melanoma. <i>Surgical Clinics of North America</i> , 2020, 100, 141-159.	0.5	4
7938	Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor-Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors. <i>JAMA Oncology</i> , 2020, 6, 100.	3.4	68
7939	Biological regulation of diacylglycerol kinases in normal and neoplastic tissues: New opportunities for cancer immunotherapy. <i>Advances in Biological Regulation</i> , 2020, 75, 100663.	1.4	12
7940	Translational pathology, genomics and the development of systemic therapies for acral melanoma. <i>Seminars in Cancer Biology</i> , 2020, 61, 149-157.	4.3	30
7941	An evaluation of talimogene laherparepvec for the treatment of melanoma. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 9-14.	1.4	8
7942	Gut microbiome and cancer immunotherapy. <i>Journal of Cellular Physiology</i> , 2020, 235, 4082-4088.	2.0	30

#	ARTICLE	IF	CITATIONS
7943	What's new in pediatric melanoma: An update from the APSA cancer committee. <i>Journal of Pediatric Surgery</i> , 2020, 55, 1714-1721.	0.8	10
7944	Role of myeloid cells in the immunosuppressive microenvironment in gliomas. <i>Immunobiology</i> , 2020, 225, 151853.	0.8	50
7945	Image Guided Dermatologic Treatments. , 2020, , .		4
7946	Diagnosis and Management of Rare Immune-Related Adverse Events. <i>Oncologist</i> , 2020, 25, 6-14.	1.9	31
7947	Synthetic lethality as an engine for cancer drug target discovery. <i>Nature Reviews Drug Discovery</i> , 2020, 19, 23-38.	21.5	295
7948	Morphological spectrum of immune checkpoint inhibitor therapy-associated gastritis. <i>Histopathology</i> , 2020, 76, 531-539.	1.6	85
7949	Targeted therapy and immunotherapy: Emerging biomarkers in metastatic melanoma. <i>Pigment Cell and Melanoma Research</i> , 2020, 33, 390-402.	1.5	19
7952	Bioactive lipids as modulators of immune check point inhibitors. <i>Medical Hypotheses</i> , 2020, 135, 109473.	0.8	10
7953	Oral immune-related adverse events associated with PD-1 inhibitor therapy: A case series. <i>Oral Diseases</i> , 2020, 26, 325-333.	1.5	33
7954	Differential Expression of Immune Checkpoint Molecules on CD8 ⁺ T Cells Specific for Immunodominant and Subdominant Herpes Simplex Virus 1 Epitopes. <i>Journal of Virology</i> , 2020, 94, .	1.5	6
7955	The Immunoscore: Colon Cancer and Beyond. <i>Clinical Cancer Research</i> , 2020, 26, 332-339.	3.2	255
7956	Health care utilization and steroid-refractory toxicities from immune checkpoint inhibitors. <i>Cancer</i> , 2020, 126, 322-328.	2.0	13
7957	The impact of current treatment modalities on the outcomes of patients with melanoma brain metastases: A systematic review. <i>International Journal of Cancer</i> , 2020, 146, 1479-1489.	2.3	20
7958	Combined ipilimumab and nivolumab first-line and after BRAF-targeted therapy in advanced melanoma. <i>Pigment Cell and Melanoma Research</i> , 2020, 33, 358-365.	1.5	51
7959	Radiotherapy as a Backbone for Novel Concepts in Cancer Immunotherapy. <i>Cancers</i> , 2020, 12, 79.	1.7	29
7960	Dissimilar Appearances Are Deceptive—Common microRNAs and Therapeutic Strategies in Liver Cancer and Melanoma. <i>Cells</i> , 2020, 9, 114.	1.8	14
7961	<p><p>Immunotherapy for the Treatment of Breast Cancer: Emerging New Data</p><p><p>Breast Cancer: Targets and Therapy, 2019, Volume 11, 321-328.	1.0	25
7962	Development of functional liposomes by modification of stimuli-responsive materials and their biomedical applications. <i>Journal of Materials Chemistry B</i> , 2020, 8, 1093-1107.	2.9	79

#	ARTICLE	IF	CITATIONS
7964	Stereotactic body radiation therapy and minimally invasive surgery in the management of spinal metastases: A change in the paradigm. <i>NeurocirugÃa (English Edition)</i> , 2020, 31, 119-131.	0.1	2
7965	Emerging Prospects for Nanoparticle-Enabled Cancer Immunotherapy. <i>Journal of Immunology Research</i> , 2020, 2020, 1-11.	0.9	36
7966	Late-Stage Failures of Monoclonal Antibody Drugs: A Retrospective Case Study Analysis. <i>Pharmacology</i> , 2020, 105, 145-163.	0.9	32
7967	Immune Checkpoint Imaging in Oncology: A Game Changer Toward Personalized Immunotherapy?. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1137-1144.	2.8	9
7968	Assessing the efficacyâ€effectiveness gap for cancer therapies: A comparison of overall survival and toxicity between clinical trial and populationâ€based, realâ€world data for contemporary parenteral cancer therapeutics. <i>Cancer</i> , 2020, 126, 1717-1726.	2.0	35
7969	ARID1A deficiency and immune checkpoint blockade therapy: From mechanisms to clinical application. <i>Cancer Letters</i> , 2020, 473, 148-155.	3.2	31
7971	In vitro models of cancer. , 2020, , 273-325.		9
7972	The mismatch repair system is not affected in medullary thyroid carcinoma independent of stromal desmoplasia or ret proto-oncogene mutation. <i>Annals of Diagnostic Pathology</i> , 2020, 44, 151445.	0.6	5
7973	European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment â€ Update 2019. <i>European Journal of Cancer</i> , 2020, 126, 159-177.	1.3	154
7974	Oncogenic signaling pathways associated with immune evasion and resistance to immune checkpoint inhibitors in cancer. <i>Seminars in Cancer Biology</i> , 2020, 65, 51-64.	4.3	63
7975	Combining epigenetic and immune therapy to overcome cancer resistance. <i>Seminars in Cancer Biology</i> , 2020, 65, 99-113.	4.3	92
7976	Understanding genetic determinants of resistance to immune checkpoint blockers. <i>Seminars in Cancer Biology</i> , 2020, 65, 123-139.	4.3	9
7977	Precision Medicine in the Treatment of Melanoma. <i>Surgical Oncology Clinics of North America</i> , 2020, 29, 1-13.	0.6	7
7978	Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma. <i>Nature Medicine</i> , 2020, 26, 39-46.	15.2	236
7979	Immune checkpoint inhibitors and endocrine side effects, a narrative review. <i>Postgraduate Medicine</i> , 2020, 132, 206-214.	0.9	12
7980	Inverse Relationship Between Alzheimerâ€™s Disease and Cancer: How Immune Checkpoints Might Explain the Mechanisms Underlying Age-Related Diseases. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 443-454.	1.2	14
7981	Association of Insurance Status With Presentation, Treatment, and Survival in Melanoma in the Era of Immune Checkpoint Inhibitors. <i>Journal of Immunotherapy</i> , 2020, 43, 8-15.	1.2	16
7982	Absolute lymphocyte count as a prognostic biomarker for overall survival in patients with advanced melanoma treated with ipilimumab. <i>Melanoma Research</i> , 2020, 30, 71-75.	0.6	20

#	ARTICLE	IF	CITATIONS
7983	Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade. <i>Annals of Surgical Oncology</i> , 2020, 27, 1180-1188.	0.7	39
7984	Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy. <i>Cancer Letters</i> , 2020, 470, 126-133.	3.2	753
7985	Current Evidence on PET Response Assessment to Immunotherapy in Lymphomas. <i>PET Clinics</i> , 2020, 15, 23-34.	1.5	11
7986	Targeting the interleukin-17 immune axis for cancer immunotherapy. <i>Journal of Experimental Medicine</i> , 2020, 217, .	4.2	105
7987	ERâ€aminopeptidase 1 determines the processing and presentation of an immunotherapyâ€relevant melanoma epitope. <i>European Journal of Immunology</i> , 2020, 50, 270-283.	1.6	6
7988	The life-threatening eruptions of immune checkpoint inhibitor therapy. <i>Clinics in Dermatology</i> , 2020, 38, 94-104.	0.8	31
7989	Role of Radiation in the Era of Effective Systemic Therapy for Melanoma. <i>Surgical Clinics of North America</i> , 2020, 100, 189-199.	0.5	6
7990	Functionalization of Nanomaterials and Their Application in Melanoma Cancer Theranostics. <i>ACS Biomaterials Science and Engineering</i> , 2020, 6, 167-181.	2.6	28
7991	Response evaluation for immunotherapy through semi-automatic software based on RECIST 1.1, irRC, and iRECIST criteria: comparison with subjective assessment. <i>Acta Radiologica</i> , 2020, 61, 983-991.	0.5	9
7992	Neurologic Complications. , 2020, , 688-706.e7.		1
7994	Cancer of the Esophagus. , 2020, , 1174-1196.e6.		5
7995	Cancer of the Stomach. , 2020, , 1197-1210.e3.		0
7996	Identifying the optimum first-line therapy in BRAF-mutant metastatic melanoma. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 53-62.	1.1	6
7997	Transforming growth factor beta induces fibroblasts to express and release the immunomodulatory protein PDâ€1 into extracellular vesicles. <i>FASEB Journal</i> , 2020, 34, 2213-2226.	0.2	55
7998	Multifactorial Deep Learning Reveals Pan-Cancer Genomic Tumor Clusters with Distinct Immunogenomic Landscape and Response to Immunotherapy. <i>Clinical Cancer Research</i> , 2020, 26, 2908-2920.	3.2	30
7999	Impact of Viral Etiologies on the Development of Novel Immunotherapy for Hepatocellular Carcinoma. <i>Seminars in Liver Disease</i> , 2020, 40, 131-142.	1.8	3
8000	An evaluation of encorafenib for the treatment of melanoma. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 155-161.	0.9	11
8001	A highly efficient modality to block the degradation of tryptophan for cancer immunotherapy: locked nucleic acid-modified antisense oligonucleotides to inhibit human indoleamine 2,3-dioxygenase 1/tryptophan 2,3-dioxygenase expression. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 57-67.	2.0	6

#	ARTICLE	IF	CITATIONS
8002	Improved survival among patients enrolled in oncology phase 1 trials in recent decades. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 449-459.	1.1	1
8003	Renal cell cancer. , 2020, , 229-243.e4.		0
8004	Genomic profiling of a dedifferentiated mucosal melanoma following exposure to immunotherapy. <i>Melanoma Research</i> , 2020, 30, 213-218.	0.6	4
8005	CTLA4 blockade promotes vessel normalization in breast tumors <i>via</i> the accumulation of eosinophils. <i>International Journal of Cancer</i> , 2020, 146, 1730-1740.	2.3	51
8006	Preserving the CTLA-4 Checkpoint for Safer and More Effective Cancer Immunotherapy. <i>Trends in Pharmacological Sciences</i> , 2020, 41, 4-12.	4.0	82
8007	Immunogenomics: steps toward personalized medicines. , 2020, , 73-90.		0
8008	The non-responding adrenal metastasis in melanoma: The case for minimally invasive adrenalectomy in the age of modern therapies. <i>American Journal of Surgery</i> , 2020, 220, 349-353.	0.9	8
8009	PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients. <i>Thyroid</i> , 2020, 30, 177-184.	2.4	118
8010	Targeting innate sensing in the tumor microenvironment to improve immunotherapy. <i>Cellular and Molecular Immunology</i> , 2020, 17, 13-26.	4.8	76
8011	The terminal sialic acid of stage-specific embryonic antigen-4 has a crucial role in binding to a cancer-targeting antibody. <i>Journal of Biological Chemistry</i> , 2020, 295, 1009-1020.	1.6	8
8012	Regulatory T cells in breast cancer as a potent anti-cancer therapeutic target. <i>International Immunopharmacology</i> , 2020, 78, 106087.	1.7	33
8013	Immune checkpoint inhibitors and vasculitis. <i>Current Opinion in Rheumatology</i> , 2020, 32, 53-56.	2.0	24
8014	Checkpoint inhibitors in AML: are we there yet?. <i>British Journal of Haematology</i> , 2020, 188, 159-167.	1.2	31
8015	Nivolumab-induced Adrenal Insufficiency in Patients With Renal Cell Carcinoma. <i>Journal of Immunotherapy</i> , 2020, 43, 38-42.	1.2	11
8016	Sequencing Ipilimumab Immunotherapy Before or After Chemotherapy (Nab-Paclitaxel and Bevacizumab) for the Treatment of BRAFwt (BRAF Wild-Type) Metastatic Malignant Melanoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 115-121.	0.6	18
8017	Immune-related Adverse Events and Survival in Solid Tumors Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. <i>Journal of Immunotherapy</i> , 2020, 43, 1-7.	1.2	75
8018	Proliferation index and pseudoprogression as predictors of the therapeutic efficacy of suicide gene therapy for canine melanoma. <i>Melanoma Research</i> , 2020, 30, 126-135.	0.6	0
8019	CXCR4 inhibition modulates the tumor microenvironment and retards the growth of B16-OVA melanoma and Renca tumors. <i>Melanoma Research</i> , 2020, 30, 14-25.	0.6	16

#	ARTICLE	IF	CITATIONS
8020	Biomarkers for Response to Immune Checkpoint Blockade. <i>Annual Review of Cancer Biology</i> , 2020, 4, 331-351.	2.3	29
8021	An Investigation of Nine Patients with Gastrointestinal Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors. <i>Digestion</i> , 2020, 101, 60-65.	1.2	12
8022	New insight in endocrine-related adverse events associated to immune checkpoint blockade. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2020, 34, 101370.	2.2	60
8023	Challenges in assessing solid tumor responses to immunotherapy. <i>Cancer Gene Therapy</i> , 2020, 27, 528-538.	2.2	36
8024	Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma. <i>Cancer Immunology Research</i> , 2020, 8, 70-80.	1.6	47
8025	Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease. <i>Journal of Clinical Oncology</i> , 2020, 38, 576-583.	0.8	135
8026	Malignant Melanoma of the Vulva and Vagina: A US Population-Based Study of 1863 Patients. <i>American Journal of Clinical Dermatology</i> , 2020, 21, 285-295.	3.3	60
8027	Characterization of glycolysis-related gene expression in malignant melanoma. <i>Pathology Research and Practice</i> , 2020, 216, 152752.	1.0	22
8028	Regulation of PD-1/PD-L1 Pathway in Cancer by Noncoding RNAs. <i>Pathology and Oncology Research</i> , 2020, 26, 651-663.	0.9	18
8029	Malignant melanoma in HIV: Epidemiology, pathogenesis, and management. <i>Dermatologic Therapy</i> , 2020, 33, e13180.	0.8	24
8030	Is There a Clinical Future for IDO1 Inhibitors After the Failure of Epcadostat in Melanoma?. <i>Annual Review of Cancer Biology</i> , 2020, 4, 241-256.	2.3	119
8032	Antilymphocyte Globulin, Monoclonal Antibodies, and Fusion Proteins. , 2020, , 283-312.		0
8033	Influence of age on the efficacy of immune checkpoint inhibitors in advanced cancers: a systematic review and meta-analysis. <i>Acta Oncologica</i> , 2020, 59, 249-256.	0.8	28
8034	Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria. <i>Clinical Cancer Research</i> , 2020, 26, 1846-1855.	3.2	70
8035	Clinical role of serum programmed death ligand 1 in patients with hepatocellular carcinoma: Where does it come from?. <i>Surgery Today</i> , 2020, 50, 569-576.	0.7	3
8036	Intratumoral Immunotherapy Update 2019. <i>Oncologist</i> , 2020, 25, e423-e438.	1.9	92
8037	Stem, Effector, and Hybrid States of Memory CD8+ T Cells. <i>Trends in Immunology</i> , 2020, 41, 17-28.	2.9	65
8038	Organ Damage and Failure. , 2020, , 289-307.		0

#	ARTICLE	IF	CITATIONS
8039	Expanding the understanding of the heterogeneous nature of melanoma with bioinformatics and disorder-based proteomics. <i>International Journal of Biological Macromolecules</i> , 2020, 150, 1281-1293.	3.6	4
8040	Structural insights into human Arginase-1 pH dependence and its inhibition by the small molecule inhibitor CB-1158. <i>Journal of Structural Biology: X</i> , 2020, 4, 100014.	0.7	20
8041	Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609. <i>Journal of Clinical Oncology</i> , 2020, 38, 567-575.	0.8	122
8042	Immune checkpoint inhibitors in melanoma in the metastatic, neoadjuvant, and adjuvant setting. <i>Current Opinion in Oncology</i> , 2020, 32, 106-113.	1.1	52
8043	New avenues for melanoma immunotherapy: Natural Killer cells?. <i>Scandinavian Journal of Immunology</i> , 2020, 91, e12861.	1.3	13
8044	Abscopal Effect Following Immunotherapy and Combined Stereotactic Body Radiation Therapy in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma: A Report of Two Cases and Literature Review. <i>Annals of Otolaryngology, Rhinology and Laryngology</i> , 2020, 129, 517-522.	0.6	22
8045	Extracellular Vesicles and Epigenetic Modifications Are Hallmarks of Melanoma Progression. <i>International Journal of Molecular Sciences</i> , 2020, 21, 52.	1.8	38
8046	Advances of immune checkpoints in colorectal cancer treatment. <i>Biomedicine and Pharmacotherapy</i> , 2020, 123, 109745.	2.5	21
8047	Criteria of metabolic response to immunotherapy. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2020, 39, 51-56.	0.1	0
8048	Roles of microbiota in response to cancer immunotherapy. <i>Seminars in Cancer Biology</i> , 2020, 65, 164-175.	4.3	36
8049	Cytologic Evaluation of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy. <i>American Journal of Clinical Pathology</i> , 2020, 153, 513-523.	0.4	1
8050	Trends in short-term survival from distant-stage cutaneous melanoma in the United States, 2001-2013 (CONCORD-3). <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa078.	1.4	8
8051	Benign lymph node microenvironment is associated with response to immunotherapy. <i>Precision Clinical Medicine</i> , 2020, 3, 44-53.	1.3	10
8052	Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer. , 2020, 8, e000889.		29
8053	Molecular Insights and Emerging Strategies for Treatment of Metastatic Uveal Melanoma. <i>Cancers</i> , 2020, 12, 2761.	1.7	24
8054	Oncogenic Tyrosine Phosphatases: Novel Therapeutic Targets for Melanoma Treatment. <i>Cancers</i> , 2020, 12, 2799.	1.7	8
8055	Treatment Combinations with DNA Vaccines for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC). <i>Cancers</i> , 2020, 12, 2831.	1.7	12
8056	Resident Memory T Cells and Their Effect on Cancer. <i>Vaccines</i> , 2020, 8, 562.	2.1	13

#	ARTICLE	IF	CITATIONS
8057	Chemotherapy based on “Domino-effect” combined with immunotherapy amplifying the efficacy of an anti-metastatic treatment. <i>Journal of Materials Chemistry B</i> , 2020, 8, 9139-9150.	2.9	5
8058	Understanding and Overcoming the Inflammatory Toxicities of Immunotherapy. <i>Cancer Immunology Research</i> , 2020, 8, 1230-1235.	1.6	10
8059	The Immune Microenvironment in Pancreatic Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7307.	1.8	133
8061	Management of Side Effects of Systemic Therapies for Hepatocellular Carcinoma. <i>Clinics in Liver Disease</i> , 2020, 24, 755-769.	1.0	9
8062	Dysregulated NF- κ B-Dependent ICOSL Expression in Human Dendritic Cell Vaccines Impairs T-cell Responses in Patients with Melanoma. <i>Cancer Immunology Research</i> , 2020, 8, 1554-1567.	1.6	15
8063	Enhancing the efficacy of immunotherapy using radiotherapy. <i>Clinical and Translational Immunology</i> , 2020, 9, e1169.	1.7	40
8064	Immunotherapy With Radiotherapy and Chemoradiotherapy for Cervical Cancer. <i>Seminars in Radiation Oncology</i> , 2020, 30, 273-280.	1.0	39
8065	Icaritin-induced immunomodulatory efficacy in advanced hepatitis B virus-related hepatocellular carcinoma: Immunodynamic biomarkers and overall survival. <i>Cancer Science</i> , 2020, 111, 4218-4231.	1.7	40
8066	Overview of Current Progress in Immune Checkpoint Inhibitor Therapy for Advanced Hepatocellular Carcinoma. <i>Technology in Cancer Research and Treatment</i> , 2020, 19, 153303382094748.	0.8	3
8067	Targeting STAT3 in Cancer Immunotherapy. <i>Molecular Cancer</i> , 2020, 19, 145.	7.9	423
8068	Targeting Innate Immunity to Treat Cancer. <i>Cancers</i> , 2020, 12, 2723.	1.7	1
8069	Landscape of immune checkpoint inhibitor-related adverse events in Chinese population. <i>Scientific Reports</i> , 2020, 10, 15567.	1.6	20
8070	Nivolumab and Ipilimumab Immunotherapy for Hemodialysis Patients with Advanced Renal Cell Carcinoma. <i>Current Oncology</i> , 2020, 27, 225-228.	0.9	9
8071	The current state of immunotherapy for primary and secondary brain tumors: similarities and differences. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 1231-1245.	0.6	13
8072	Baseline IFN- γ and IL-10 expression in PBMCs could predict response to PD-1 checkpoint inhibitors in advanced melanoma patients. <i>Scientific Reports</i> , 2020, 10, 17626.	1.6	20
8073	Economic evaluation of nivolumab combined with ipilimumab in the first-line treatment of advanced melanoma in Japan. <i>Journal of Medical Economics</i> , 2020, 23, 1542-1552.	1.0	9
8074	<p>Management of Immune Checkpoint Inhibitor Toxicities</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 9139-9158.	0.9	18
8075	<p>Managing Ipilimumab-Induced Hypophysitis: Challenges and Current Therapeutic Strategies</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 9551-9561.	0.9	21

#	ARTICLE	IF	CITATIONS
8076	Predictive biomarkers for immunotherapy efficacy in non-small-cell lung cancer: current status and future perspectives. <i>Biomarkers in Medicine</i> , 2020, 14, 1383-1392.	0.6	16
8077	Immune checkpoint inhibitor-induced bullous pemphigoid: Towards a new class of drug-drug interaction?. <i>European Journal of Cancer</i> , 2020, 138, 122-124.	1.3	3
8078	Uncoupling Therapeutic Efficacy from Immune-Related Adverse Events in Immune Checkpoint Blockade. <i>IScience</i> , 2020, 23, 101580.	1.9	22
8079	Management of Malignant Vulval Melanoma: A Retrospective Case Series and Review of the Literature. <i>Journal of Lower Genital Tract Disease</i> , 2020, 24, 272-276.	0.9	5
8080	The Confounders of Cancer Immunotherapy: Roles of Lifestyle, Metabolic Disorders and Sociological Factors. <i>Cancers</i> , 2020, 12, 2983.	1.7	56
8081	Molecular mechanisms of breast cancer chemoresistance by immune checkpoints. <i>Life Sciences</i> , 2020, 263, 118604.	2.0	9
8082	An immune landscape based prognostic signature predicts the immune status and immunotherapeutic responses of patients with colorectal cancer. <i>Life Sciences</i> , 2020, 261, 118368.	2.0	8
8083	Advances in targeted therapy for esophageal cancer. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 229.	7.1	223
8084	Is the neutrophil-to-lymphocyte ratio a useful prognostic indicator in melanoma patients?. <i>Melanoma Management</i> , 2020, 7, MMT47.	0.1	24
8085	Senescent Tumor CD8+ T Cells: Mechanisms of Induction and Challenges to Immunotherapy. <i>Cancers</i> , 2020, 12, 2828.	1.7	10
8086	Overview of current targeted therapy in gallbladder cancer. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 230.	7.1	84
8087	Genomics-based immuno-oncology: bridging the gap between immunology and tumor biology. <i>Human Molecular Genetics</i> , 2020, 29, R214-R225.	1.4	3
8088	The Immunotherapy Revolution in Kidney Cancer Treatment. <i>Cancer Journal (Sudbury, Mass)</i> , 2020, 26, 419-431.	1.0	17
8089	Immunotherapy for Renal Cell Carcinoma. , 0, , .		0
8090	Immunotherapy in older patients with cancer. <i>Biomedical Journal</i> , 2021, 44, 260-271.	1.4	19
8091	Structural characterization of the ICOS/ICOS-L immune complex reveals high molecular mimicry by therapeutic antibodies. <i>Nature Communications</i> , 2020, 11, 5066.	5.8	23
8092	Predictive molecular markers in the era of immunotherapy. <i>Journal of Pancreatology</i> , 2020, 3, 132-138.	0.3	5
8093	Using phage-assisted continuous evolution (PACE) to evolve human PD1. <i>Experimental Cell Research</i> , 2020, 396, 112244.	1.2	3

#	ARTICLE	IF	CITATIONS
8094	A case of Schönlein-Henoch purpura induced by immune checkpoint inhibitor in a patient with metastatic melanoma. <i>European Journal of Cancer</i> , 2020, 139, 169-172.	1.3	7
8095	Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors. <i>JHEP Reports</i> , 2020, 2, 100170.	2.6	86
8096	Type I interferon signaling limits viral vector priming of CD8 + T cells during initiation of vitiligo and melanoma immunotherapy. <i>Pigment Cell and Melanoma Research</i> , 2020, 34, 683-695.	1.5	6
8097	Common phenotypic dynamics of tumor-infiltrating lymphocytes across different histologies upon checkpoint inhibition: impact on clinical outcome. <i>Cytotherapy</i> , 2020, 22, 204-213.	0.3	9
8098	Biomaterialized Bacterial Outer Membrane Vesicles Potentiate Safe and Efficient Tumor Microenvironment Reprogramming for Anticancer Therapy. <i>Advanced Materials</i> , 2020, 32, e2002085.	11.1	118
8099	Response rate and local recurrence after concurrent immune checkpoint therapy and radiotherapy for non-small cell lung cancer and melanoma brain metastases. <i>Cancer</i> , 2020, 126, 5274-5282.	2.0	19
8101	Basic research in childhood cancer: Progress and future directions in China. <i>Cancer Letters</i> , 2020, 495, 156-164.	3.2	11
8102	Emerging role of immune checkpoint inhibitors and predictive biomarkers in head and neck cancers. <i>Oral Oncology</i> , 2020, 109, 104977.	0.8	10
8103	Statistical and practical considerations in designing of immuno-oncology trials. <i>Journal of Biopharmaceutical Statistics</i> , 2020, 30, 1130-1146.	0.4	6
8104	Emergency management of immune-related toxicity. <i>Current Opinion in Oncology</i> , 2020, 32, 274-281.	1.1	5
8105	A heat-shocked melanoma cell lysate vaccine enhances tumor infiltration by prototypic effector T cells inhibiting tumor growth. , 2020, 8, e000999.		19
8106	Re-educating Tumor Associated Macrophages as a Novel Immunotherapy Strategy for Neuroblastoma. <i>Frontiers in Immunology</i> , 2020, 11, 1947.	2.2	33
8107	Analysis of tumor mutational burden: correlation of five large gene panels with whole exome sequencing. <i>Scientific Reports</i> , 2020, 10, 11387.	1.6	33
8108	Elucidation of the effect of plumbagin on the metastatic potential of B16F10 murine melanoma cells via MAPK signalling pathway. <i>Experimental Dermatology</i> , 2020, 29, 427-435.	1.4	6
8109	T cell receptor therapy against melanoma: Immunotherapy for the future?. <i>Scandinavian Journal of Immunology</i> , 2020, 92, e12927.	1.3	8
8110	The Immune Profile of Pituitary Adenomas and a Novel Immune Classification for Predicting Immunotherapy Responsiveness. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e3207-e3223.	1.8	30
8111	Immunotherapeutic strategies in pancreatic ductal adenocarcinoma (PDAC): current perspectives and future prospects. <i>Molecular Biology Reports</i> , 2020, 47, 6269-6280.	1.0	7
8112	Immune reaction and regulation in transplantation based on pluripotent stem cell technology. <i>Inflammation and Regeneration</i> , 2020, 40, 12.	1.5	20

#	ARTICLE	IF	CITATIONS
8113	Molecular Mechanisms and Potential Therapeutic Reversal of Pancreatic Cancer-Induced Immune Evasion. <i>Cancers</i> , 2020, 12, 1872.	1.7	18
8114	Rational use of 18F-FDG PET/CT in patients with advanced cutaneous melanoma: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 153, 103044.	2.0	29
8115	Real-world evidence use in assessments of cancer drugs by NICE. <i>International Journal of Technology Assessment in Health Care</i> , 2020, 36, 388-394.	0.2	23
8116	Economic evaluations of cancer immunotherapy: a systematic review and quality evaluation. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1947-1958.	2.0	7
8117	CAMK1D Triggers Immune Resistance of Human Tumor Cells Refractory to Anti-PD-L1 Treatment. <i>Cancer Immunology Research</i> , 2020, 8, 1163-1179.	1.6	17
8118	A Review of T-Cell Related Therapy for Osteosarcoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4877.	1.8	10
8119	Clinical surveillance in immunotherapy-treated patient. <i>Medicina Clínica (English Edition)</i> , 2020, 154, 493-495.	0.1	0
8120	Neuropilin-1: a checkpoint target with unique implications for cancer immunology and immunotherapy. , 2020, 8, e000967.		67
8121	A Review of the Mechanisms and Clinical Implications of Precision Cancer Therapy-Related Toxicity: A Primer for the Radiologist. <i>American Journal of Roentgenology</i> , 2020, 215, 770-780.	1.0	4
8122	Immunotherapies and Combination Strategies for Immuno-Oncology. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5009.	1.8	63
8123	Immune Checkpoint Inhibitors for Patients Aged ≥75 Years with Advanced Cancer in First- and Second-Line Settings: A Meta-Analysis. <i>Drugs and Aging</i> , 2020, 37, 747-754.	1.3	24
8124	Insights from Pharmacovigilance: Gastrointestinal-Related Immune Checkpoint Inhibitor Adverse Events. <i>Gastroenterology</i> , 2020, 159, 1195-1200.e1.	0.6	5
8125	Management of Immune Checkpoint Inhibitor-Related Rheumatological Toxicities. <i>Journal of Clinical Rheumatology and Immunology</i> , 2020, 20, 25-34.	0.4	0
8126	Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma. <i>JAMA Dermatology</i> , 2020, 156, 982.	2.0	14
8127	Association of Innovations in Radiotherapy and Systemic Treatments With Clinical Outcomes in Patients With Melanoma Brain Metastasis From 2007 to 2016. <i>JAMA Network Open</i> , 2020, 3, e208204.	2.8	10
8128	Generation of highly activated, antigen-specific tumor-infiltrating CD8 ⁺ T cells induced by a novel T cell-targeted immunotherapy. <i>Oncimmunology</i> , 2020, 9, 1782574.	2.1	2
8129	Retrospective Analysis of Treatment and Complications of Immune Checkpoint Inhibitor-Associated Colitis: Histological Ulcerations as Potential Predictor for a Steroid-Refractory Disease Course. <i>Inflammatory Intestinal Diseases</i> , 2020, 5, 109-116.	0.8	17
8130	Innovations in Metastatic Brain Tumor Treatment. , 2020, , .		1

#	ARTICLE	IF	CITATIONS
8131	Prognostic Implications of Novel Ten-Gene Signature in Uveal Melanoma. <i>Frontiers in Oncology</i> , 2020, 10, 567512.	1.3	27
8132	Chronic diarrhoea in an oncology patient – Clinical assessment and decision making. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2020, 48-49, 101708.	1.0	1
8133	Tumor MHC Expression Guides First-Line Immunotherapy Selection in Melanoma. <i>Cancers</i> , 2020, 12, 3374.	1.7	27
8134	Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets. <i>Nature Cancer</i> , 2020, 1, 1204-1217.	5.7	58
8135	Molecular imaging in immuno-oncology: current status and translational perspectives. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 1199-1211.	1.5	8
8136	Epigenetic landscape of small cell lung cancer: small image of a giant recalcitrant disease. <i>Seminars in Cancer Biology</i> , 2022, 83, 57-76.	4.3	33
8137	Mutational landscape influences immunotherapy outcomes among patients with non-small-cell lung cancer with human leukocyte antigen supertype B44. <i>Nature Cancer</i> , 2020, 1, 1167-1175.	5.7	22
8138	Baseline prognostic nutritional index and changes in pretreatment body mass index associate with immunotherapy response in patients with advanced cancer. , 2020, 8, e001674.		46
8139	Bilateral Posterior Uveitis and Retinal Detachment During Immunotherapy: A Case Report and Literature Review. <i>Frontiers in Oncology</i> , 2020, 10, 549168.	1.3	9
8140	Molecular Immunotherapy: Promising Approach to Treat Metastatic Colorectal Cancer by Targeting Resistant Cancer Cells or Cancer Stem Cells. <i>Frontiers in Oncology</i> , 2020, 10, 569017.	1.3	21
8141	Discovery Strategies to Maximize the Clinical Potential of T-Cell Engaging Antibodies for the Treatment of Solid Tumors. <i>Antibodies</i> , 2020, 9, 65.	1.2	13
8142	The Angiopoietin-2 and TIE Pathway as a Therapeutic Target for Enhancing Antiangiogenic Therapy and Immunotherapy in Patients with Advanced Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8689.	1.8	38
8143	<p>Immunotherapeutic Targets and Therapy for Renal Cell Carcinoma</p>. <i>ImmunoTargets and Therapy</i> , 2020, Volume 9, 273-288.	2.7	9
8144	Integration of the Tumor Mutational Burden and Tumor Heterogeneity Identify an Immunological Subtype of Melanoma With Favorable Survival. <i>Frontiers in Oncology</i> , 2020, 10, 571545.	1.3	12
8145	Molecular and Immune Biomarkers for Cutaneous Melanoma: Current Status and Future Prospects. <i>Cancers</i> , 2020, 12, 3456.	1.7	12
8146	HGF-Induced PD-L1 Expression in Head and Neck Cancer: Preclinical and Clinical Findings. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8770.	1.8	6
8148	ProTECT – Prediction of T-Cell Epitopes for Cancer Therapy. <i>Frontiers in Immunology</i> , 2020, 11, 483296.	2.2	14
8149	Adoptive T cell therapy: Boosting the immune system to fight cancer. <i>Seminars in Immunology</i> , 2020, 49, 101437.	2.7	22

#	ARTICLE	IF	CITATIONS
8150	Tumors establish resistance to immunotherapy by regulating T _{reg} recruitment via CCR4. , 2020, 8, e000764.		66
8151	<p>Nanomaterial-Based Tumor Photothermal Immunotherapy</p>. International Journal of Nanomedicine, 2020, Volume 15, 9159-9180.	3.3	104
8152	<p>Pretreatment CT-Based Radiomics Signature as a Potential Imaging Biomarker for Predicting the Expression of PD-L1 and CD8+TILs in ESCC</p>. OncoTargets and Therapy, 2020, Volume 13, 12003-12013.	1.0	29
8153	Immune Checkpoint Targeted Therapy in Glioma: Status and Hopes. Frontiers in Immunology, 2020, 11, 578877.	2.2	76
8154	Applications of Single-Cell Omics to Dissect Tumor Microenvironment. Frontiers in Genetics, 2020, 11, 548719.	1.1	18
8155	Current Immunotherapy Approaches in Non-Hodgkin Lymphomas. Vaccines, 2020, 8, 708.	2.1	13
8156	Enhancing Combined Immunotherapy and Radiotherapy through Nanomedicine. Bioconjugate Chemistry, 2020, 31, 2668-2678.	1.8	13
8157	Immune Checkpoint Blockade in Gynecologic Cancers: State of Affairs. Cancers, 2020, 12, 3301.	1.7	22
8158	Immune Checkpoint Blockade Enhances Immune Activity of Therapeutic Lung Cancer Vaccine. Vaccines, 2020, 8, 655.	2.1	3
8159	Cutaneous melanoma and the immunotherapy revolution (Review). International Journal of Oncology, 2020, 57, 609-618.	1.4	75
8160	Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (don't) know. Journal of Experimental and Clinical Cancer Research, 2020, 39, 236.	3.5	44
8161	Comprehensive analysis of cutaneous and uveal melanoma liver metastases. , 2020, 8, e001501.		40
8162	Overcoming Immune Evasion in Melanoma. International Journal of Molecular Sciences, 2020, 21, 8984.	1.8	88
8163	Immune Checkpoint Inhibitor-Related Pneumonitis. Respiration, 2020, 99, 932-942.	1.2	30
8164	Immunobiology of Thymic Epithelial Tumors: Implications for Immunotherapy with Immune Checkpoint Inhibitors. International Journal of Molecular Sciences, 2020, 21, 9056.	1.8	19
8165	BDCA1 ⁺ cDC2s, BDCA2 ⁺ pDCs and BDCA3 ⁺ cDC1s reveal distinct pathophysiologic features and impact on clinical outcomes in melanoma patients. Clinical and Translational Immunology, 2020, 9, e1190.	1.7	16
8166	SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery. , 2020, 8, e000705.		20
8167	Cancer Vaccines: Toward the Next Breakthrough in Cancer Immunotherapy. Journal of Immunology Research, 2020, 2020, 1-13.	0.9	76

#	ARTICLE	IF	CITATIONS
8168	Immune Checkpoints and CAR-T Cells: The Pioneers in Future Cancer Therapies?. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8305.	1.8	58
8169	Cardiotoxicity of Contemporary Anticancer Immunotherapy. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2020, 22, 62.	0.4	34
8170	Intratumoral Combinatorial Administration of CD1c (BDCA-1)+ Myeloid Dendritic Cells Plus Ipilimumab and Avelumab in Combination with Intravenous Low-Dose Nivolumab in Patients with Advanced Solid Tumors: A Phase IB Clinical Trial. <i>Vaccines</i> , 2020, 8, 670.	2.1	17
8171	<p>Thyroid Dysfunctions Due to Immune Checkpoint Inhibitors: A Review</p>. <i>International Journal of General Medicine</i> , 2020, Volume 13, 1003-1009.	0.8	21
8172	Diagnosis and Management of Hematological Adverse Events Induced by Immune Checkpoint Inhibitors: A Systematic Review. <i>Frontiers in Immunology</i> , 2020, 11, 1354.	2.2	19
8173	Immune Checkpoint Blockade in Cancer Immunotherapy: Mechanisms, Clinical Outcomes, and Safety Profiles of PD-1/PD-L1 Inhibitors. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2020, 68, 36.	1.0	26
8174	Multivalent, Soluble Nano-Self Peptides Increase Phagocytosis of Antibody-Opsonized Targets while Suppressing â€œSelfâ€•Signaling. <i>ACS Nano</i> , 2020, 14, 15083-15093.	7.3	12
8175	Impact of age on the toxicity of immune checkpoint inhibition. , 2020, 8, e000871.		37
8176	Mosaic Recombinant Adeno-associated Virus Vector rAAV/DJ/CAG for Targeted Gene Delivery to Melanoma Cells Metastasized to the Lung. <i>Anticancer Research</i> , 2020, 40, 4425-4444.	0.5	4
8177	Biological Landscape of Triple Negative Breast Cancers Expressing CTLA-4. <i>Frontiers in Oncology</i> , 2020, 10, 1206.	1.3	21
8178	Clinical Challenges of Immune Checkpoint Inhibitors. <i>Cancer Cell</i> , 2020, 38, 326-333.	7.7	286
8179	Salivary gland cancer in the era of immunotherapy: can we exploit tumor microenvironment?. <i>Expert Opinion on Therapeutic Targets</i> , 2020, 24, 1047-1059.	1.5	11
8180	Clinical characterization, genetic profiling, and immune infiltration of TOX in diffuse gliomas. <i>Journal of Translational Medicine</i> , 2020, 18, 305.	1.8	17
8181	Immune-Related Neuromuscular Complications of Checkpoint Inhibitors. <i>Current Treatment Options in Neurology</i> , 2020, 22, 1.	0.7	1
8182	A novel risk score based on a combined signature of 10 immune system genes to predict bladder cancer prognosis. <i>International Immunopharmacology</i> , 2020, 87, 106851.	1.7	12
8183	Reversal of pre-existing NGFR-driven tumor and immune therapy resistance. <i>Nature Communications</i> , 2020, 11, 3946.	5.8	71
8184	Pseudovirus for immunotherapy. <i>Nature Cancer</i> , 2020, 1, 860-861.	5.7	3
8185	Clinical Impact of PD-L1 Expression for Survival in Curatively Resected Colon Cancer. <i>Cancer Investigation</i> , 2020, 38, 406-414.	0.6	11

#	ARTICLE	IF	CITATIONS
8186	Immune checkpoint inhibitor-induced inflammatory arthritis: identification and management. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 771-785.	1.3	10
8187	<p>Past, Present, and Future of Anticancer Nanomedicine</p>. <i>International Journal of Nanomedicine</i> , 2020, Volume 15, 5719-5743.	3.3	23
8188	Immune-Checkpoint Blockade Therapy in Lymphoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5456.	1.8	24
8189	Pattern and impact of hepatic adverse events encountered during immune checkpoint inhibitors â€“ A territory-wide cohort study. <i>Cancer Medicine</i> , 2020, 9, 7052-7061.	1.3	14
8190	Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development. <i>Journal of Autoimmunity</i> , 2020, 114, 102514.	3.0	37
8191	Clinical burden of immune checkpoint inhibitor-induced pneumonitis. <i>Respiratory Investigation</i> , 2020, 58, 305-319.	0.9	11
8192	Monoclonal Antibodies in Cancer Therapy. <i>Antibodies</i> , 2020, 9, 34.	1.2	325
8193	Antitumor Immunity Augmented by Combining Radiofrequency Ablation with Anti-CTLA-4 Therapy in a Subcutaneous Murine Hepatoma Model. <i>Journal of Vascular and Interventional Radiology</i> , 2020, 31, 1178-1186.	0.2	5
8194	Immune checkpoint inhibitor induces cardiac injury through polarizing macrophages via modulating microRNA-34a/Kruppel-like factor 4 signaling. <i>Cell Death and Disease</i> , 2020, 11, 575.	2.7	41
8195	i-Move, a personalised exercise intervention for patients with advanced melanoma receiving immunotherapy: a randomised feasibility trial protocol. <i>BMJ Open</i> , 2020, 10, e036059.	0.8	8
8197	Epigenetics in modulating immune functions of stromal and immune cells in the tumor microenvironment. <i>Cellular and Molecular Immunology</i> , 2020, 17, 940-953.	4.8	41
8198	Response to Ipilimumab/Nivolumab Rechallenge and BRAF Inhibitor/MEK Inhibitor Rechallenge in a Patient with Advanced Metastatic Melanoma Previously Treated with BRAF Targeted Therapy and Immunotherapy. <i>Case Reports in Oncological Medicine</i> , 2020, 2020, 1-6.	0.2	3
8199	Mobilizing Toxins for Cancer Treatment: Historical Perspectives and Current Strategies. <i>Toxins</i> , 2020, 12, 416.	1.5	1
8200	Is it time to rethink checkpoint blockade therapy in non-Hodgkin lymphoma?. <i>British Journal of Haematology</i> , 2020, 191, 13-14.	1.2	1
8201	Pimasertib Versus Dacarbazine in Patients With Unresectable NRAS-Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with Crossover. <i>Cancers</i> , 2020, 12, 1727.	1.7	36
8202	Immunotherapy Alone or in Combination with Chemotherapy as First-Line Treatment of Non-Small Cell Lung Cancer. <i>Current Treatment Options in Oncology</i> , 2020, 21, 69.	1.3	20
8203	Progress in Neoantigen Targeted Cancer Immunotherapies. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 728.	1.8	28
8204	Sarcoidosis-like disease mimicking metastases during adjuvant ipilimumab therapy in advanced melanoma patient: CT scan and MRI help in managing difficult clinical decision. <i>BJR case Reports</i> , 2020, 6, 20190065.	0.1	5

#	ARTICLE	IF	CITATIONS
8205	Novel Approaches to the Systemic Management of Uveal Melanoma. <i>Current Oncology Reports</i> , 2020, 22, 104.	1.8	9
8206	Impact of high tumor mutational burden in solid tumors and challenges for biomarker application. <i>Cancer Treatment Reviews</i> , 2020, 89, 102084.	3.4	61
8207	Integrative bioinformatics analysis of a prognostic index and immunotherapeutic targets in renal cell carcinoma. <i>International Immunopharmacology</i> , 2020, 87, 106832.	1.7	7
8208	The immunology of renal cell carcinoma. <i>Nature Reviews Nephrology</i> , 2020, 16, 721-735.	4.1	229
8209	NKp30 a prospective target for new cancer immunotherapy strategies. <i>British Journal of Pharmacology</i> , 2020, 177, 4563-4580.	2.7	22
8210	Image-Guided Interventions in Oncology. , 2020, , .		1
8212	3D bioprinting for reconstituting the cancer microenvironment. <i>Npj Precision Oncology</i> , 2020, 4, 18.	2.3	163
8213	Changes in Immunological Status in Patients With Metastatic Colorectal Cancer Treated With First-line Chemoimmunotherapy. <i>Anticancer Research</i> , 2020, 40, 4763-4771.	0.5	0
8214	A brief review concerning Chimeric Antigen Receptors T cell therapy. <i>Journal of Cancer</i> , 2020, 11, 5424-5431.	1.2	4
8216	Novel [99mTc]-Tricarboxyl-NOTA-Conjugated Lactam-Cyclized Alpha-MSH Peptide with Enhanced Melanoma Uptake and Reduced Renal Uptake. <i>Molecular Pharmaceutics</i> , 2020, 17, 3581-3588.	2.3	14
8217	Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up. , 2020, 8, e000848.		79
8218	Current Status and Future Perspectives of Checkpoint Inhibitor Immunotherapy for Prostate Cancer: A Comprehensive Review. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5484.	1.8	36
8219	Prognostic and Clinicopathological Value of PD-L1 in Melanoma: A Meta-Analysis. <i>American Journal of the Medical Sciences</i> , 2020, 359, 339-346.	0.4	9
8220	Toxicity in combination immune checkpoint inhibitor and radiation therapy: A systematic review and meta-analysis. <i>Radiotherapy and Oncology</i> , 2020, 151, 141-148.	0.3	62
8221	Epigenetic Mechanisms of Resistance to Immune Checkpoint Inhibitors. <i>Biomolecules</i> , 2020, 10, 1061.	1.8	59
8222	The MAP kinase signal transduction pathway: promising therapeutic targets used in the treatment of melanoma. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 687-701.	1.1	6
8223	Personalized and translational approach for malignant brain tumors in the era of precision medicine: the strategic contribution of an experienced neurosurgery laboratory in a modern neurosurgery and neuro-oncology department. <i>Journal of the Neurological Sciences</i> , 2020, 417, 117083.	0.3	11
8224	Immune checkpoint inhibitor-related cutaneous adverse events. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, e149-e153.	0.7	7

#	ARTICLE	IF	CITATIONS
8225	Oxazaphosphorines combined with immune checkpoint blockers: dose-dependent tuning between immune and cytotoxic effects. , 2020, 8, e000916.		1
8226	Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy. <i>Science</i> , 2020, 369, 1481-1489.	6.0	635
8227	Targeting immune checkpoints in hematological malignancies. <i>Journal of Hematology and Oncology</i> , 2020, 13, 111.	6.9	66
8228	Injectable biodegradation-visual self-healing citrate hydrogel with high tissue penetration for microenvironment-responsive degradation and local tumor therapy. <i>Biomaterials</i> , 2020, 261, 120301.	5.7	62
8229	Isolation of Two Novel Human Anti-CTLA-4 mAbs with Intriguing Biological Properties on Tumor and NK Cells. <i>Cancers</i> , 2020, 12, 2204.	1.7	12
8230	Screening Cancer Immunotherapy: When Engineering Approaches Meet Artificial Intelligence. <i>Advanced Science</i> , 2020, 7, 2001447.	5.6	30
8231	Advances in the Systemic Treatment of Melanoma Brain Metastases. , 2020, , .		0
8232	<p>Conjunctival Melanoma: Update on Genetics, Epigenetics and Targeted Molecular and Immune-Based Therapies</p>. <i>Clinical Ophthalmology</i> , 2020, Volume 14, 3137-3152.	0.9	12
8233	The association between immune-related adverse events and survival outcomes in Asian patients with advanced melanoma receiving anti-PD-1 antibodies. <i>BMC Cancer</i> , 2020, 20, 1018.	1.1	23
8234	Clonal tracing reveals diverse patterns of response to immune checkpoint blockade. <i>Genome Biology</i> , 2020, 21, 263.	3.8	15
8235	First-Line Immune-Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Landscape and Future Progress. <i>Frontiers in Pharmacology</i> , 2020, 11, 578091.	1.6	51
8236	Organ Dysfunction in Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors. <i>Oncologist</i> , 2020, 25, e1753-e1762.	1.9	6
8237	Association of baseline systemic corticosteroid use with overall survival and time to next treatment in patients receiving immune checkpoint inhibitor therapy in real-world US oncology practice for advanced non-small cell lung cancer, melanoma, or urothelial carcinoma. <i>OncImmunology</i> , 2020, 9, 1824645.	2.1	31
8239	Targeting TIM-3 in solid tumors: innovations in the preclinical and translational realm and therapeutic potential. <i>Expert Opinion on Therapeutic Targets</i> , 2020, 24, 1251-1262.	1.5	16
8240	Leveraging Endogenous Dendritic Cells to Enhance the Therapeutic Efficacy of Adoptive T-Cell Therapy and Checkpoint Blockade. <i>Frontiers in Immunology</i> , 2020, 11, 578349.	2.2	11
8242	Novel Prognostic Model Based on Immune Signature for Head and Neck Squamous Cell Carcinoma. <i>BioMed Research International</i> , 2020, 2020, 1-9.	0.9	7
8243	Stereotactic Radiosurgery With Concurrent Immunotherapy in Melanoma Brain Metastases Is Feasible and Effective. <i>Frontiers in Oncology</i> , 2020, 10, 592796.	1.3	10
8244	Seven decades of chemotherapy clinical trials: a pan-cancer social network analysis. <i>Scientific Reports</i> , 2020, 10, 17536.	1.6	2

#	ARTICLE	IF	CITATIONS
8245	CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 28960-28970.	3.3	150
8246	Discovery of a potential biomarker for immunotherapy of melanoma: PLAC1 as an emerging target. Immunopharmacology and Immunotoxicology, 2020, 42, 604-613.	1.1	4
8247	Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities. Frontiers in Immunology, 2020, 11, 2023.	2.2	50
8248	Selecting Target Antigens for Cancer Vaccine Development. Vaccines, 2020, 8, 615.	2.1	59
8249	Association of Sociodemographic Factors With Immunotherapy Receipt for Metastatic Melanoma in the US. JAMA Network Open, 2020, 3, e2015656.	2.8	28
8250	Bias in Mean Survival From Fitting Cure Models With Limited Follow-Up. Value in Health, 2020, 23, 1034-1039.	0.1	5
8251	Preliminary analysis of distinct clinical and biologic features of bone metastases in melanoma. Melanoma Research, 2020, 30, 492-499.	0.6	3
8252	Novel platform leveraging electronic medical record (EMR) to triage patients admitted with high-grade immune-related adverse events (irAEs) to the immune-toxicity (ITOX) service. , 2020, 8, e000992.		4
8253	Transcriptional and immunohistological assessment of immune infiltration in pancreatic cancer. PLoS ONE, 2020, 15, e0238380.	1.1	16
8254	Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment. Frontiers in Immunology, 2020, 11, 1956.	2.2	143
8255	The critical role of CD4+ T cells in PD-1 blockade against MHC-II ⁺ expressing tumors such as classic Hodgkin lymphoma. Blood Advances, 2020, 4, 4069-4082.	2.5	76
8256	Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune checkpoint inhibitor endocrinopathies and the role of advanced practice providers in the management of immune-mediated toxicities. Supportive Care in Cancer, 2020, 28, 6175-6181.	1.0	15
8257	CRISPR-GEMM Pooled Mutagenic Screening Identifies KMT2D as a Major Modulator of Immune Checkpoint Blockade. Cancer Discovery, 2020, 10, 1912-1933.	7.7	71
8258	Efficacy and predictive factors of immune checkpoint inhibitors in metastatic breast cancer: a systematic review and meta-analysis. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592094092.	1.4	86
8259	Safety of pembrolizumab for resected stage III melanoma. Expert Opinion on Drug Safety, 2020, 19, 1221-1227.	1.0	3
8260	Review of the Combination Strategies Used in Anti-PD1/PD-L1 Monoclonal Antibody Treatment. E3S Web of Conferences, 2020, 185, 03009.	0.2	1
8261	Critical Analysis of Non-Thermal Plasma-Driven Modulation of Immune Cells from Clinical Perspective. International Journal of Molecular Sciences, 2020, 21, 6226.	1.8	17
8262	Immunotherapy in prostate cancer: current state and future perspectives. Therapeutic Advances in Urology, 2020, 12, 175628722095140.	0.9	24

#	ARTICLE	IF	CITATIONS
8263	The Macrophages-Microbiota Interplay in Colorectal Cancer (CRC)-Related Inflammation: Prognostic and Therapeutic Significance. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6866.	1.8	20
8264	A PD-1 peptide antagonist exhibits potent anti-tumor and immune regulatory activity. <i>Cancer Letters</i> , 2020, 493, 91-101.	3.2	9
8265	Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial. <i>Cancer Cell</i> , 2020, 38, 489-499.e3.	7.7	216
8266	Designing custom CRISPR libraries for hypothesis-driven drug target discovery. <i>Computational and Structural Biotechnology Journal</i> , 2020, 18, 2237-2246.	1.9	10
8267	Establishment of an immune microenvironment-based prognostic predictive model for gastric cancer. <i>Life Sciences</i> , 2020, 261, 118402.	2.0	10
8268	Nano-Enhanced Cancer Immunotherapy: Immunology Encounters Nanotechnology. <i>Cells</i> , 2020, 9, 2102.	1.8	56
8269	Design for immuno-oncology clinical trials enrolling both responders and nonresponders. <i>Statistics in Medicine</i> , 2020, 39, 3914-3936.	0.8	2
8270	Functional Imaging of Immunotherapy: Response Criteria, Imaging Characteristics, and Novel Immunoimaging of Advanced Malignancies. <i>Current Radiology Reports</i> , 2020, 8, 1.	0.4	0
8272	The Inhibitor of Apoptosis Protein Livin Confers Resistance to Fas-Mediated Immune Cytotoxicity in Refractory Lymphoma. <i>Cancer Research</i> , 2020, 80, 4439-4450.	0.4	7
8273	Expansion With IL-15 Increases Cytotoxicity of CD8 T Cells and Is Associated With Higher Levels of Cytotoxic Molecules and T-bet. <i>Frontiers in Immunology</i> , 2020, 11, 1868.	2.2	14
8274	Use of Immune Checkpoint Inhibitors in End Stage Kidney Disease Patients, Single Center Experience and Review of the Literature. <i>Kidney360</i> , 2020, 1, 399-402.	0.9	26
8275	Ipilimumab: an investigational immunotherapy for glioblastoma. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 1187-1193.	1.9	16
8277	Ferroptosis: a new unexpected chance to treat metastatic melanoma?. <i>Cell Cycle</i> , 2020, 19, 2411-2425.	1.3	27
8278	Safety and Effectiveness of Yttrium-90 Radioembolization around the Time of Immune Checkpoint Inhibitors for Unresectable Hepatic Metastases. <i>Journal of Vascular and Interventional Radiology</i> , 2020, 31, 1233-1241.	0.2	11
8279	Elucidating the gut microbiota composition and the bioactivity of immunostimulatory commensals for the optimization of immune checkpoint inhibitors. <i>Oncolimmunology</i> , 2020, 9, 1794423.	2.1	7
8280	Preclinical investigations and a first-in-human phase I trial of M4112, the first dual inhibitor of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase 2, in patients with advanced solid tumors. , 2020, 8, e000870.		21
8281	<p>Large-Scale Analysis Reveals the Specific Clinical and Immune Features of DGCR5 in Glioma</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 7531-7543.	1.0	11
8282	Dose escalation phase 1 study of radiotherapy in combination with anti-cytotoxic-T-lymphocyte-associated antigen 4 monoclonal antibody ipilimumab in patients with metastatic melanoma. , 2020, 8, e000627.		13

#	ARTICLE	IF	CITATIONS
8283	Non-BRAF Mutant Melanoma: Molecular Features and Therapeutical Implications. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 172.	1.6	25
8284	BILITE: A Bayesian randomized phase II design for immunotherapy by jointly modeling the longitudinal immune response and time-to-event efficacy. <i>Statistics in Medicine</i> , 2020, 39, 4439-4451.	0.8	2
8285	Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors. <i>Supportive Care in Cancer</i> , 2020, 28, 6129-6143.	1.0	28
8286	Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies. <i>Cancers</i> , 2020, 12, 2392.	1.7	171
8287	Visualization of human T lymphocyte-mediated eradication of cancer cells in vivo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 22910-22919.	3.3	32
8288	Tumor Immune Microenvironments (TIMEs): Responsive Nanoplatfoms for Antitumor Immunotherapy. <i>Frontiers in Chemistry</i> , 2020, 8, 804.	1.8	6
8289	Carbonic Anhydrase 4 serves as a Clinicopathological Biomarker for Outcomes and Immune Infiltration in Renal Cell Carcinoma, Lower Grade Glioma, Lung Adenocarcinoma and Uveal Melanoma. <i>Journal of Cancer</i> , 2020, 11, 6101-6113.	1.2	6
8290	Black phosphorus-based photothermal therapy with aCD47-mediated immune checkpoint blockade for enhanced cancer immunotherapy. <i>Light: Science and Applications</i> , 2020, 9, 161.	7.7	145
8291	Immunotherapy use in kidney transplant recipients: Immune checkpoint inhibitors and CAR-T cell therapy. <i>Journal of Onco-Nephrology</i> , 2020, 4, 165-170.	0.3	0
8292	Treatment of Metastatic Uveal Melanoma: Systematic Review. <i>Cancers</i> , 2020, 12, 2557.	1.7	43
8294	Improved Progression-Free Long-Term Survival of a Nation-Wide Patient Population with Metastatic Melanoma. <i>Cancers</i> , 2020, 12, 2591.	1.7	8
8296	Heat Shock Proteins and PD-1/PD-L1 as Potential Therapeutic Targets in Myeloproliferative Neoplasms. <i>Cancers</i> , 2020, 12, 2592.	1.7	8
8297	The Role of the Tumor Microenvironment in Developing Successful Therapeutic and Secondary Prophylactic Breast Cancer Vaccines. <i>Vaccines</i> , 2020, 8, 529.	2.1	9
8298	EZH2 inhibition: a promising strategy to prevent cancer immune editing. <i>Epigenomics</i> , 2020, 12, 1457-1476.	1.0	37
8299	Unequal Access to Newly Registered Cancer Drugs Leads to Potential Loss of Life-Years in Europe. <i>Cancers</i> , 2020, 12, 2313.	1.7	33
8300	Ipilimumab-Induced Enterocolitis: A Systematic Review and Meta-Analysis. <i>Drug Safety</i> , 2020, 43, 1255-1266.	1.4	5
8301	Concomitant myopericarditis and takotsubo syndrome following immune checkpoint inhibitor therapy. <i>BMJ Case Reports</i> , 2020, 13, e235265.	0.2	18
8302	Histological diagnosis of immune checkpoint inhibitor induced acute renal injury in patients with metastatic melanoma: a retrospective case series report. <i>BMC Nephrology</i> , 2020, 21, 391.	0.8	20

#	ARTICLE	IF	CITATIONS
8303	TCR Redirected T Cells for Cancer Treatment: Achievements, Hurdles, and Goals. <i>Frontiers in Immunology</i> , 2020, 11, 1689.	2.2	63
8304	Integrative clinical and molecular analysis of advanced biliary tract cancers on immune checkpoint blockade reveals potential markers of response. <i>Clinical and Translational Medicine</i> , 2020, 10, e118.	1.7	15
8305	Chemotherapy for the Management of Cerebral Metastases. <i>Neurosurgery Clinics of North America</i> , 2020, 31, 603-611.	0.8	5
8306	Trends in pediatric skin cancer. <i>Current Opinion in Pediatrics</i> , 2020, 32, 516-523.	1.0	6
8307	Multistage Sensitive NanoCRISPR Enable Efficient Intracellular Disruption of Immune Checkpoints for Robust Innate and Adaptive Immune Coactivation. <i>Advanced Functional Materials</i> , 2020, 30, 2004940.	7.8	27
8308	Primary Malignant Melanoma of the Cervix: A Case Report and a Review of the Literature. <i>Case Reports in Oncological Medicine</i> , 2020, 2020, 1-9.	0.2	4
8309	Oncologic Outcomes After Isolated Limb Infusion for Advanced Melanoma: An International Comparison of the Procedure and Outcomes Between the United States and Australia. <i>Annals of Surgical Oncology</i> , 2020, 27, 5107-5118.	0.7	8
8310	Diagnosis and management of immune-related adverse effects of immune checkpoint therapy in the emergency department. <i>Journal of the American College of Emergency Physicians Open</i> , 2020, 1, 1637-1659.	0.4	17
8311	Differential quantities of immune checkpoint-expressing CD8 T cells in soft tissue sarcoma subtypes. , 2020, 8, e000271.		29
8313	Association of Sex, Age, and Eastern Cooperative Oncology Group Performance Status With Survival Benefit of Cancer Immunotherapy in Randomized Clinical Trials. <i>JAMA Network Open</i> , 2020, 3, e2012534.	2.8	72
8315	<p>Encapsulated Checkpoint Blocker Before Chemotherapy: The Optimal Sequence of Anti-CTLA-4 and Doxil Combination Therapy</p>. <i>International Journal of Nanomedicine</i> , 2020, Volume 15, 5279-5288.	3.3	18
8316	<p>Combination of Immune Checkpoint Inhibitors with Chemotherapy in Lung Cancer</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 7229-7241.	1.0	12
8317	Cytoreduction and the Optimization Of Immune Checkpoint Inhibition with Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 17-26.	0.4	18
8318	T Lymphocytes Cash Their Value in Clinical Medicine. <i>Trends in Molecular Medicine</i> , 2020, 26, 800-802.	3.5	2
8319	Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial. <i>Lancet Haematology</i> , the, 2020, 7, e660-e670.	2.2	86
8320	Disparity in outcomes of melanoma adjuvant immunotherapy by demographic profile. <i>Melanoma Management</i> , 2020, 7, MMT43.	0.1	7
8321	Real World Outcomes of Ipilimumab and Nivolumab in Patients with Metastatic Melanoma. <i>Cancers</i> , 2020, 12, 2329.	1.7	45
8322	Targeted and Checkpoint Inhibitor Therapy of Metastatic Malignant Melanoma in Germany, 2000â€“2016. <i>Cancers</i> , 2020, 12, 2354.	1.7	8

#	ARTICLE	IF	CITATIONS
8323	Immune Checkpoint Inhibitors versus VEGF Targeted Therapy as Second Line Regimen in Advanced Hepatocellular Carcinoma (HCC): A Retrospective Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 2682.	1.0	4
8324	Cancer Immunotherapy and Application of Nanoparticles in Cancers Immunotherapy as the Delivery of Immunotherapeutic Agents and as the Immunomodulators. <i>Cancers</i> , 2020, 12, 3773.	1.7	33
8325	CD8+ T-cell lymphocytes infiltration predict clinical outcomes in Wilms's tumor. <i>Tumor Biology</i> , 2020, 42, 101042832097597.	0.8	19
8326	Gastrointestinal side effects of cancer treatments. <i>Therapeutic Advances in Chronic Disease</i> , 2020, 11, 204062232097035.	1.1	41
8327	Nanoparticles as Smart Carriers for Enhanced Cancer Immunotherapy. <i>Frontiers in Chemistry</i> , 2020, 8, 597806.	1.8	55
8328	Diagnosis and Differential Diagnosis of Neurological Adverse Events during Immune Checkpoint Inhibitor Therapy. <i>Journal of Oncology</i> , 2020, 2020, 1-9.	0.6	6
8329	The role and economics of immunotherapy in solid tumour management. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 2020-2024.	0.5	4
8330	PD-L1 Expression in Muscle-Invasive Urinary Bladder Urothelial Carcinoma According to Basal/Squamous-Like Phenotype. <i>Frontiers in Oncology</i> , 2020, 10, 527385.	1.3	13
8331	Current Trends in Cancer Immunotherapy. <i>Biomedicines</i> , 2020, 8, 621.	1.4	34
8332	The Prognostic Impact of Circulating Tumour DNA in Melanoma Patients Treated with Systemic Therapies—Beyond BRAF Mutant Detection. <i>Cancers</i> , 2020, 12, 3793.	1.7	12
8333	Intravenous injection of the oncolytic virus M1 awakens antitumor T cells and overcomes resistance to checkpoint blockade. <i>Cell Death and Disease</i> , 2020, 11, 1062.	2.7	32
8334	Paving the Way Towards Universal Chimeric Antigen Receptor Therapy in Cancer Treatment: Current Landscape and Progress. <i>Frontiers in Immunology</i> , 2020, 11, 604915.	2.2	9
8335	Circulating Melanoma-Derived Extracellular Vesicles: Impact on Melanoma Diagnosis, Progression Monitoring, and Treatment Response. <i>Pharmaceuticals</i> , 2020, 13, 475.	1.7	13
8337	Inflammatory Biomarkers to Detect Immune Checkpoint Inhibitor-Associated Cardiotoxicity in Lung Cancer Patients. <i>JACC: CardioOncology</i> , 2020, 2, 503-505.	1.7	2
8338	Response to PD-1 blockade in a patient with mucosal melanoma of the middle ear: Case report. <i>Clinical Case Reports (discontinued)</i> , 2020, 8, 3467-3470.	0.2	3
8339	Combining chemotherapy and autologous peptide-pulsed dendritic cells provides survival benefit in stage IV melanoma patients. <i>JDDG - Journal of the German Society of Dermatology</i> , 2020, 18, 1270-1277.	0.4	2
8341	TGF β 2-blockade uncovers stromal plasticity in tumors by revealing the existence of a subset of interferon-licensed fibroblasts. <i>Nature Communications</i> , 2020, 11, 6315.	5.8	106
8342	Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells. <i>Nature Communications</i> , 2020, 11, 6335.	5.8	46

#	ARTICLE	IF	CITATIONS
8343	Combining inhibition of galectin-3 with and before a therapeutic vaccination is critical for the prostate-tumor-free outcome. , 2020, 8, e001535.		11
8344	Immune Modulation in Lung Cancer: Current Concepts and Future Strategies. Respiration, 2020, 99, 903-929.	1.2	18
8345	Beyond chemoradiotherapy: improving treatment outcomes for patients with stage III unresectable non-small-cell lung cancer through immuno-oncology and durvalumab (Imfinzi [®] , AstraZeneca UK) Tj ETQq0 020rgBT /Overlock 10		11
8346	Structure of CTLA-4 complexed with a pH-sensitive cancer immunotherapeutic antibody. Cell Discovery, 2020, 6, 79.	3.1	6
8347	Role of Hypoxia and the Adenosine System in Immune Evasion and Prognosis of Patients with Brain Metastases of Melanoma: A Multiplex Whole Slide Immunofluorescence Study. Cancers, 2020, 12, 3753.	1.7	11
8348	SOX2 promotes resistance of melanoma with PD-L1 high expression to T-cell-mediated cytotoxicity that can be reversed by SAHA. , 2020, 8, e001037.		27
8349	Interleukin-34 Limits the Therapeutic Effects of Immune Checkpoint Blockade. IScience, 2020, 23, 101584.	1.9	15
8350	Identification of prognostic immune genes in laryngeal cancer. Journal of International Medical Research, 2020, 48, 030006052096466.	0.4	3
8351	Analysis of immune subtypes based on immunogenomic profiling identifies prognostic signature for cutaneous melanoma. International Immunopharmacology, 2020, 89, 107162.	1.7	12
8352	De novo necroptosis creates an inflammatory environment mediating tumor susceptibility to immune checkpoint inhibitors. Communications Biology, 2020, 3, 645.	2.0	30
8353	When steroids are not enough in immune-related hepatitis: current clinical challenges discussed on the basis of a case report. , 2020, 8, e001322.		26
8354	Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors. Cancer Discovery, 2020, 10, 1808-1825.	7.7	388
8355	Characteristics of TCR Repertoire Associated With Successful Immune Checkpoint Therapy Responses. Frontiers in Immunology, 2020, 11, 587014.	2.2	56
8356	Genetic Co-Administration of Soluble PD-1 Ectodomains Modifies Immune Responses against Influenza A Virus Induced by DNA Vaccination. Vaccines, 2020, 8, 570.	2.1	5
8357	Survival-Inferred Fragility Index of Phase 3 Clinical Trials Evaluating Immune Checkpoint Inhibitors. JAMA Network Open, 2020, 3, e2017675.	2.8	20
8358	Checkpoint Inhibitors in Gynecological Malignancies: Are we There Yet?. BioDrugs, 2020, 34, 749-762.	2.2	5
8359	Infectious complications in patients treated with immune checkpoint inhibitors. European Journal of Cancer, 2020, 141, 137-142.	1.3	24
8360	The Extrinsic and Intrinsic Roles of PD-L1 and Its Receptor PD-1: Implications for Immunotherapy Treatment. Frontiers in Immunology, 2020, 11, 568931.	2.2	100

#	ARTICLE	IF	CITATIONS
8361	Applications of Nanomaterials for Theranostics of Melanoma. <i>Journal of Nanotheranostics</i> , 2020, 1, 39-55.	1.7	4
8362	Current State of Combination of Locoregional Therapies with Immune Checkpoint Inhibition. <i>Journal of Vascular and Interventional Radiology</i> , 2020, 31, 1740-1744.e9.	0.2	5
8363	Immune Therapy for Central Nervous System Metastasis. <i>Neurosurgery Clinics of North America</i> , 2020, 31, 627-639.	0.8	0
8364	Clinical Update on Checkpoint Inhibitor Therapy for Conjunctival and Eyelid Melanoma. <i>International Ophthalmology Clinics</i> , 2020, 60, 77-89.	0.3	7
8365	Immune suppression caused by PD-L2 expression on tumor cells in gastric cancer. <i>Gastric Cancer</i> , 2020, 23, 961-973.	2.7	21
8366	Diverse Neoantigens and the Development of Cancer Therapies. <i>Seminars in Radiation Oncology</i> , 2020, 30, 113-128.	1.0	15
8367	Targeting PD-L1 Initiates Effective Antitumor Immunity in a Murine Model of Cushing Disease. <i>Clinical Cancer Research</i> , 2020, 26, 1141-1151.	3.2	43
8368	Imaging Intensity and Survival Outcomes in High-Risk Resected Melanoma Treated by Systemic Therapy at Recurrence. <i>Annals of Surgical Oncology</i> , 2020, 27, 3683-3691.	0.7	13
8369	Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1130-1143.	0.6	89
8370	Immune Cytolytic Activity for Comprehensive Understanding of Immune Landscape in Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 1221.	1.7	46
8371	Ectopic PD-L1 expression in JAK2 (V617F) myeloproliferative neoplasm patients is mediated via increased activation of STAT3 and STAT5. <i>Human Cell</i> , 2020, 33, 1099-1111.	1.2	9
8372	Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way?. <i>British Journal of Cancer</i> , 2020, 123, 207-215.	2.9	50
8373	Oncologic Emergencies: Immune-Based Cancer Therapies and Complications. <i>Western Journal of Emergency Medicine</i> , 2020, 21, 566-580.	0.6	13
8374	Leucocyte count predicts cardiovascular risk in heart failure with preserved ejection fraction: insights from TOPCAT Americas. <i>ESC Heart Failure</i> , 2020, 7, 1676-1687.	1.4	9
8375	A guide to cancer immunotherapy: from T cell basic science to clinical practice. <i>Nature Reviews Immunology</i> , 2020, 20, 651-668.	10.6	2,160
8376	T Cells Expressing a TCR-Like Antibody Selected Against the Heteroclitic Variant of a Shared MAGE-A Epitope Do Not Recognise the Cognate Epitope. <i>Cancers</i> , 2020, 12, 1255.	1.7	2
8377	Current Molecular Markers of Melanoma and Treatment Targets. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3535.	1.8	45
8378	Advancing the Science and Management of Renal Cell Carcinoma: Bridging the Divide between Academic and Community Practices. <i>Journal of Clinical Medicine</i> , 2020, 9, 1508.	1.0	3

#	ARTICLE	IF	CITATIONS
8379	FAM83A drives PD-L1 expression via ERK signaling and FAM83A/PD-L1 co-expression correlates with poor prognosis in lung adenocarcinoma. <i>International Journal of Clinical Oncology</i> , 2020, 25, 1612-1623.	1.0	19
8380	Surgery for Unresectable Stage IIIc and IV Melanoma in the Era of New Systemic Therapy. <i>Cancers</i> , 2020, 12, 1176.	1.7	11
8381	Scientifically based combination therapies with immunotherapy checkpoint inhibitors. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1711-1725.	1.1	6
8382	Immune-related adverse events of checkpoint inhibitors. <i>Nature Reviews Disease Primers</i> , 2020, 6, 38.	18.1	684
8383	Nine-factor-based immunohistochemistry classifier predicts recurrence for early-stage hepatocellular carcinoma after curative resection. <i>British Journal of Cancer</i> , 2020, 123, 92-100.	2.9	10
8384	Immune checkpoint blockade in solid organ tumours: Choice, dose and predictors of response. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1736-1752.	1.1	10
8385	Adult immuno-oncology: using past failures to inform the future. <i>Neuro-Oncology</i> , 2020, 22, 1249-1261.	0.6	19
8386	Opportunities for Conventional and In Situ Cancer Vaccine Strategies and Combination with Immunotherapy for Gastrointestinal Cancers, A Review. <i>Cancers</i> , 2020, 12, 1121.	1.7	31
8387	Therapeutic Targeting of Autophagy for Renal Cell Carcinoma Therapy. <i>Cancers</i> , 2020, 12, 1185.	1.7	31
8388	Pseudoprogression and Hyperprogression as New Forms of Response to Immunotherapy. <i>BioDrugs</i> , 2020, 34, 463-476.	2.2	49
8389	Trials and Tribulations of Radio-Immuno-Oncology. <i>Seminars in Radiation Oncology</i> , 2020, 30, 108-112.	1.0	3
8390	Combination immunotherapy induces distinct T-cell repertoire responses when administered to patients with different malignancies. , 2020, 8, e000368.		8
8391	Current Advances in Osteosarcoma. <i>Advances in Experimental Medicine and Biology</i> , 2020, , .	0.8	4
8392	Review of gynaecological malignant melanomas. <i>The Obstetrician and Gynaecologist</i> , 2020, 22, 199-207.	0.2	0
8393	Biomarkers for immunotherapy for treatment of glioblastoma. , 2020, 8, e000348.		33
8394	Interplay between glucocorticoids and tumor-infiltrating lymphocytes on the prognosis of adrenocortical carcinoma. , 2020, 8, e000469.		59
8395	NKTR-214 immunotherapy synergizes with radiotherapy to stimulate systemic CD8+T cell responses capable of curing multi-focal cancer. , 2020, 8, e000464.		20
8396	Efficacy of immune checkpoint inhibitors and age in cancer patients. <i>Immunotherapy</i> , 2020, 12, 587-603.	1.0	21

#	ARTICLE	IF	CITATIONS
8397	CAR T cell therapy: newer approaches to counter resistance and cost. <i>Heliyon</i> , 2020, 6, e03779.	1.4	19
8398	Exploiting immune-dependent effects of microtubule-targeting agents to improve efficacy and tolerability of cancer treatment. <i>Cell Death and Disease</i> , 2020, 11, 361.	2.7	30
8399	Metastatic melanoma: therapeutic agents in preclinical and early clinical development. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 739-753.	1.9	2
8400	Efficacy of immune checkpoint inhibitors for in-transit melanoma. , 2020, 8, e000440.		18
8401	The role of SRGN in the survival and immune infiltrates of skin cutaneous melanoma (SKCM) and SKCM-metastasis patients. <i>BMC Cancer</i> , 2020, 20, 378.	1.1	12
8402	Safety of Immune Checkpoint Inhibitors in Patients With Pre-Existing Inflammatory Bowel Disease and Microscopic Colitis. <i>JCO Oncology Practice</i> , 2020, 16, e933-e942.	1.4	33
8403	Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet, The</i> , 2020, 395, 1558-1568.	6.3	188
8404	Combining Radiation with Immunotherapy: The University of Pennsylvania Experience. <i>Seminars in Radiation Oncology</i> , 2020, 30, 173-180.	1.0	6
8405	Computational models of melanoma. <i>Theoretical Biology and Medical Modelling</i> , 2020, 17, 8.	2.1	11
8406	18F-FDG PET/CT based spleen to liver ratio associates with clinical outcome to ipilimumab in patients with metastatic melanoma. <i>Cancer Imaging</i> , 2020, 20, 36.	1.2	46
8407	The Landmark Series: Neoadjuvant Systemic Therapy (NAST) for Stage 3 Melanoma Patients – A Potential Paradigm Shift in Management. <i>Annals of Surgical Oncology</i> , 2020, 27, 2188-2200.	0.7	4
8408	Targeting Myeloid-Derived Suppressor Cell, a Promising Strategy to Overcome Resistance to Immune Checkpoint Inhibitors. <i>Frontiers in Immunology</i> , 2020, 11, 783.	2.2	78
8409	Myeloid Cell-Derived Arginase in Cancer Immune Response. <i>Frontiers in Immunology</i> , 2020, 11, 938.	2.2	249
8410	Low Expression of Programmed Death 1 (PD-1), PD-1 Ligand 1 (PD-L1), and Low CD8+ T Lymphocyte Infiltration Identify a Subgroup of Patients With Gastric and Esophageal Adenocarcinoma With Severe Prognosis. <i>Frontiers in Medicine</i> , 2020, 7, 144.	1.2	15
8411	Molecular imaging for cancer immunotherapy. <i>Immuno-Oncology Technology</i> , 2020, 5, 10-21.	0.2	15
8412	Targeting Inhibition of Foxp3 by MMP2/9 Sensitive Short Peptide Linked P60 Fusion Protein 6(P60â€MMPs) to Enhance Antitumor Immunity. <i>Macromolecular Bioscience</i> , 2020, 20, 2000098.	2.1	5
8413	Molecular Biochemical Aspects of Cancer. , 2020, , .		3
8414	The hypoxic tumour microenvironment: A safe haven for immunosuppressive cells and a therapeutic barrier to overcome. <i>Cancer Letters</i> , 2020, 487, 34-44.	3.2	32

#	ARTICLE	IF	CITATIONS
8415	Principles of Immunotherapy in Non-Small Cell Lung Cancer. <i>Thoracic Surgery Clinics</i> , 2020, 30, 187-198.	0.4	19
8416	Randomized phase II study of stereotactic body radiotherapy and interleukin-2 versus interleukin-2 in patients with metastatic melanoma. , 2020, 8, e000773.		26
8417	Neoadjuvant rituximab modulates the tumor immune environment in patients with high risk prostate cancer. <i>Journal of Translational Medicine</i> , 2020, 18, 214.	1.8	23
8418	Mixed Response to Immunotherapy in Patients with Metastatic Melanoma. <i>Annals of Surgical Oncology</i> , 2020, 27, 3488-3497.	0.7	24
8419	ASO Author Reflections: Mixed Response in Metastatic Melanoma Patients Treated with Immunotherapy. <i>Annals of Surgical Oncology</i> , 2020, 27, 3498-3499.	0.7	0
8420	Bcl6 Preserves the Suppressive Function of Regulatory T Cells During Tumorigenesis. <i>Frontiers in Immunology</i> , 2020, 11, 806.	2.2	16
8421	Diagnosis, Monitoring, and Management of Adverse Events From Immune Checkpoint Inhibitor Therapy. <i>Current Oncology</i> , 2020, 27, 43-50.	0.9	14
8423	Management of Regional Nodal Melanoma. <i>Surgical Oncology Clinics of North America</i> , 2020, 29, 415-431.	0.6	1
8424	Role of Surgery in Stage IV Melanoma. <i>Surgical Oncology Clinics of North America</i> , 2020, 29, 485-495.	0.6	8
8425	Human cancer germline antigen-specific cytotoxic T cell" what can we learn from patient. <i>Cellular and Molecular Immunology</i> , 2020, 17, 684-692.	4.8	12
8426	Safety evaluation of pembrolizumab for treating recurrent head and neck squamous cell carcinoma. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 927-934.	1.0	5
8427	Targeting immune checkpoints: Building better therapeutic puzzle in pancreatic cancer combination therapy. <i>European Journal of Cancer Care</i> , 2020, 29, e13268.	0.7	4
8428	The Pan-Omics Landscape of Renal Cell Carcinoma and Its Implication on Future Clinical Practice. <i>Kidney Cancer</i> , 2020, 4, 121-129.	0.2	2
8429	Adenovirus and Immunotherapy: Advancing Cancer Treatment by Combination. <i>Cancers</i> , 2020, 12, 1295.	1.7	28
8430	Relapse-Free Survival and PD-L1 Expression in First High- and Low-Grade Relapsed Luminal, Basal and Double-Negative P53-Mutant Non-Muscular Invasive Bladder Cancer Depending on Previous Chemo- and Immunotherapy. <i>Cancers</i> , 2020, 12, 1316.	1.7	4
8431	Interaction between lymphopenia, radiotherapy technique, dosimetry, and survival outcomes in lung cancer patients receiving combined immunotherapy and radiotherapy. <i>Radiotherapy and Oncology</i> , 2020, 150, 114-120.	0.3	66
8432	Immunotherapy for platinum-resistant ovarian cancer. <i>Gynecologic Oncology</i> , 2020, 158, 484-488.	0.6	40
8433	RAS-targeted therapies: is the undruggable drugged?. <i>Nature Reviews Drug Discovery</i> , 2020, 19, 533-552.	21.5	569

#	ARTICLE	IF	CITATIONS
8434	Cancer immunotherapy: dawn of the death of cancer?. <i>International Reviews of Immunology</i> , 2020, 39, 205-222.	1.5	5
8435	Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors. <i>Cancers</i> , 2020, 12, 1502.	1.7	145
8436	British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 679-697.	3.7	33
8437	Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities. <i>Autoimmunity Reviews</i> , 2020, 19, 102586.	2.5	80
8438	Tumor membrane-based vaccine immunotherapy in combination with anti-CTLA-4 antibody confers protection against immune checkpoint resistant murine triple-negative breast cancer. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 3184-3193.	1.4	18
8439	The Prognostic Role of High Blood Cholesterol in Advanced Cancer Patients Treated With Immune Checkpoint Inhibitors. <i>Journal of Immunotherapy</i> , 2020, 43, 196-203.	1.2	36
8440	A brief synopsis on scalp melanoma. <i>Dermatologic Therapy</i> , 2020, 33, e13795.	0.8	6
8441	A dynamic mutational landscape associated with an inter-regionally diverse immune response in malignant rhabdoid tumour. <i>Journal of Pathology</i> , 2020, 252, 22-28.	2.1	2
8442	Rational Cancer Treatment Combinations: An Urgent Clinical Need. <i>Molecular Cell</i> , 2020, 78, 1002-1018.	4.5	95
8443	Vascular effects of cancer treatments. <i>Vascular Medicine</i> , 2020, 25, 226-234.	0.8	12
8444	Immune-checkpoint inhibitors and metastatic prostate cancer therapy: Learning by making mistakes. <i>Cancer Treatment Reviews</i> , 2020, 88, 102057.	3.4	28
8445	Trial watch : the gut microbiota as a tool to boost the clinical efficacy of anticancer immunotherapy. <i>OncImmunology</i> , 2020, 9, 1774298.	2.1	22
8446	Sarcoidosis related to checkpoint and BRAF/MEK inhibitors in melanoma. <i>Autoimmunity Reviews</i> , 2020, 19, 102587.	2.5	20
8447	Immune checkpoint inhibitors-induced autoimmunity: The impact of gender. <i>Autoimmunity Reviews</i> , 2020, 19, 102590.	2.5	37
8448	Emerging combination strategies with phototherapy in cancer nanomedicine. <i>Chemical Society Reviews</i> , 2020, 49, 8065-8087.	18.7	427
8449	Correlation of novel ALK ATI with ALK immunohistochemistry and clinical outcomes in metastatic melanoma. <i>Histopathology</i> , 2020, 77, 601-610.	1.6	5
8450	Primary tumor characteristics and next-generation sequencing mutations as biomarkers for melanoma immunotherapy response. <i>Pigment Cell and Melanoma Research</i> , 2020, 33, 878-888.	1.5	5
8451	Advances in immune neoadjuvant/adjuvant therapy-related adverse events of non-small cell lung cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, , .	0.7	5

#	ARTICLE	IF	CITATIONS
8452	Innate Immune Cells and Their Contribution to T-Cell-Based Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4441.	1.8	20
8453	Prognostic impacts of tumoral expression and serum levels of PD-L1 and CTLA-4 in colorectal cancer patients. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 2533-2546.	2.0	31
8454	Clinical benefits of PD-1/PD-L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and meta-analysis. <i>Hepatology International</i> , 2020, 14, 765-775.	1.9	37
8455	Antineoplastic Agents Targeting Sphingolipid Pathways. <i>Frontiers in Oncology</i> , 2020, 10, 833.	1.3	18
8456	Intratumoral CD4+ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer. <i>Cell</i> , 2020, 181, 1612-1625.e13.	13.5	436
8457	Side effect management during immune checkpoint blockade using CTLA-4 and PD-1 antibodies for metastatic melanoma – an update. <i>JDDG - Journal of the German Society of Dermatology</i> , 2020, 18, 582-609.	0.4	24
8458	Tumor Immune Profiling-Based Neoadjuvant Immunotherapy for Locally Advanced Melanoma. <i>Annals of Surgical Oncology</i> , 2020, 27, 4122-4130.	0.7	7
8459	Integrative analysis of key candidate genes and signaling pathways in autoimmune thyroid dysfunction related to anti-CTLA-4 therapy by bioinformatics. <i>Investigational New Drugs</i> , 2020, 38, 1717-1729.	1.2	1
8460	Engineering Chimeric Antigen Receptor T Cells against Immune Checkpoint Inhibitors PD-1/PD-L1 for Treating Pancreatic Cancer. <i>Molecular Therapy - Oncolytics</i> , 2020, 17, 571-585.	2.0	42
8461	Predictive Biomarkers of Immune Checkpoint Inhibition in Gastroesophageal Cancers. <i>Frontiers in Oncology</i> , 2020, 10, 763.	1.3	32
8462	Manipulation of Metabolic Pathways and Its Consequences for Anti-Tumor Immunity: A Clinical Perspective. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4030.	1.8	7
8463	Advances in the Treatment of Non-Small Cell Lung Cancer. <i>Clinics in Chest Medicine</i> , 2020, 41, 237-247.	0.8	50
8464	Correlation Between Immune-related Adverse Event (IRAE) Occurrence and Clinical Outcome in Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Nivolumab: IRAENE Trial, an Italian Multi-institutional Retrospective Study. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 477-488.	0.9	15
8465	RNA Splicing and Cancer. <i>Trends in Cancer</i> , 2020, 6, 631-644.	3.8	140
8466	A systematic assessment of hydroxyapatite nanoparticles used in the treatment of melanoma. <i>Nano Research</i> , 2020, 13, 2106-2117.	5.8	15
8467	Case report: Neoadjuvant systemic therapy for melanoma. <i>Annals of Medicine and Surgery</i> , 2020, 55, 177-179.	0.5	2
8468	Injectable Therapies for Regional Melanoma. <i>Surgical Oncology Clinics of North America</i> , 2020, 29, 433-444.	0.6	5
8469	Targeted Therapy and Traditional Chemotherapy in Melanoma and Cutaneous Squamous Cell Carcinoma. <i>Facial Plastic Surgery</i> , 2020, 36, 186-193.	0.5	5

#	ARTICLE	IF	CITATIONS
8470	Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma. , 2020, 8, e000391.		39
8471	Real-world safety and efficacy data of ipilimumab in Japanese radically unresectable malignant melanoma patients: A postmarketing surveillance. <i>Journal of Dermatology</i> , 2020, 47, 834-848.	0.6	14
8472	Immune Checkpoint Inhibitors in Hepatocellular Cancer: Current Understanding on Mechanisms of Resistance and Biomarkers of Response to Treatment. <i>Gene Expression</i> , 2020, 20, 53-65.	0.5	65
8473	From threat to cure: understanding of virus-induced cell death leads to highly immunogenic oncolytic influenza viruses. <i>Cell Death Discovery</i> , 2020, 6, 48.	2.0	18
8474	Evolving insights into the mechanisms of toxicity associated with immune checkpoint inhibitor therapy. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1778-1789.	1.1	34
8475	Immune Checkpoint Inhibitors and Immune-Related Adverse Renal Events. <i>Kidney International Reports</i> , 2020, 5, 1139-1148.	0.4	71
8476	Efficacy of ipilimumab after anti-PD-1 therapy in sequential treatment of metastatic melanoma patients - Real world evidence. <i>Advances in Medical Sciences</i> , 2020, 65, 316-323.	0.9	12
8477	The Hippo pathway oncoprotein YAP promotes melanoma cell invasion and spontaneous metastasis. <i>Oncogene</i> , 2020, 39, 5267-5281.	2.6	53
8478	Near Infrared Light Triggered Photo/Immuno-Therapy Toward Cancers. <i>Frontiers in Bioengineering and Biotechnology</i> , 2020, 8, 488.	2.0	54
8479	Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis. , 2020, 8, e000451.		39
8480	Immunocheckpoint Inhibitor- (Nivolumab-) Associated Hypereosinophilia in Non-Small-Cell Lung Carcinoma. <i>Case Reports in Oncological Medicine</i> , 2020, 2020, 1-5.	0.2	3
8481	Nectin-2 Expression on Malignant Plasma Cells Is Associated with Better Response to TIGIT Blockade in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2020, 26, 4688-4698.	3.2	30
8482	Melanoma brain metastases: review of histopathological features and immune-molecular aspects. <i>Melanoma Management</i> , 2020, 7, MMT44.	0.1	8
8483	The Cancer-Immune Set Point in Oesophageal Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 891.	1.3	15
8484	Neurologic Toxicities of Cancer Immunotherapies: a Review. <i>Current Neurology and Neuroscience Reports</i> , 2020, 20, 27.	2.0	17
8485	Engineering Programmed Death Ligand-1/Cytotoxic T-Lymphocyte-Associated Antigen-4 Dual-Targeting Nanovesicles for Immunosuppressive Therapy in Transplantation. <i>ACS Nano</i> , 2020, 14, 7959-7969.	7.3	34
8486	Reversible suppression of T cell function in the bone marrow microenvironment of acute myeloid leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 14331-14341.	3.3	55
8487	A New Hope. <i>Current Oncology</i> , 2020, 27, 41-42.	0.9	0

#	ARTICLE	IF	CITATIONS
8488	Label-Free Infrared Spectral Histology of Skin Tissue Part II: Impact of a Lumican-Derived Peptide on Melanoma Growth. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 377.	1.8	6
8489	Lipo-Based Vaccines as an Approach to Target Dendritic Cells for Induction of T- and iNKT Cell Responses. <i>Frontiers in Immunology</i> , 2020, 11, 990.	2.2	27
8490	Targeting Autophagy Facilitates T Lymphocyte Migration by Inducing the Expression of CXCL10 in Gastric Cancer Cell Lines. <i>Frontiers in Oncology</i> , 2020, 10, 886.	1.3	4
8491	Immune Checkpoint Inhibitors for Advanced Melanoma: Experience at a Single Institution in Taiwan. <i>Frontiers in Oncology</i> , 2020, 10, 905.	1.3	14
8492	Tumor microenvironmental influences on dendritic cell and T cell function: A focus on clinically relevant immunologic and metabolic checkpoints. <i>Clinical and Translational Medicine</i> , 2020, 10, 374-411.	1.7	33
8493	Immune checkpoint inhibitors and diabetes. <i>Practical Diabetes</i> , 2020, 37, 96-100.	0.1	1
8494	Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2020, 395, 1835-1844.	6.3	423
8495	Clinicopathological and prognostic significance and molecular mechanisms governing uveal melanoma. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592091756.	1.4	9
8496	Use of Immuno-Oncology in Melanoma. <i>Current Oncology</i> , 2020, 27, 51-58.	0.9	10
8497	Melanoma brain metastases: is it time to eliminate radiotherapy?. <i>Journal of Neuro-Oncology</i> , 2020, 149, 27-33.	1.4	6
8498	Just eat it: A review of CD47 and SIRP-1± antagonism. <i>Seminars in Oncology</i> , 2020, 47, 117-124.	0.8	50
8499	Cautious Optimism—The Current Role of Immunotherapy in Gastrointestinal Cancers. <i>Current Oncology</i> , 2020, 27, 59-68.	0.9	4
8500	Integrated immune gene expression signature and molecular classification in gastric cancer: New insights. <i>Journal of Leukocyte Biology</i> , 2020, 108, 633-646.	1.5	26
8501	Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer. <i>Frontiers in Immunology</i> , 2020, 11, 369.	2.2	291
8502	Gastrointestinal and Hepatic Complications of Immunotherapy: Current Management and Future Perspectives. <i>Current Gastroenterology Reports</i> , 2020, 22, 15.	1.1	20
8503	Regulation of Cancer Immune Checkpoints. <i>Advances in Experimental Medicine and Biology</i> , 2020, , .	0.8	7
8504	ADORA1 Inhibition Promotes Tumor Immune Evasion by Regulating the ATF3-PD-L1 Axis. <i>Cancer Cell</i> , 2020, 37, 324-339.e8.	7.7	126
8505	Immunoscore: a novel prognostic tool. Association with clinical outcome, response to treatment and survival in several malignancies. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2020, 57, 432-443.	2.7	22

#	ARTICLE	IF	CITATIONS
8506	The role of T cell trafficking in CTLA-4 blockade-induced gut immunopathology. <i>BMC Biology</i> , 2020, 18, 29.	1.7	6
8507	Characteristics of Tumor-Infiltrating Lymphocytes Prior to and During Immune Checkpoint Inhibitor Therapy. <i>Frontiers in Immunology</i> , 2020, 11, 364.	2.2	50
8508	Natural Compounds with Potential to Modulate Cancer Therapies and Self-Reactive Immune Cells. <i>Cancers</i> , 2020, 12, 673.	1.7	24
8509	Advances in targeted therapy for malignant lymphoma. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 15.	7.1	66
8510	Viral Vector-Based Melanoma Gene Therapy. <i>Biomedicines</i> , 2020, 8, 60.	1.4	16
8511	Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019. <i>European Journal of Cancer</i> , 2020, 130, 126-138.	1.3	84
8512	Immunotherapy, Inflammation and Colorectal Cancer. <i>Cells</i> , 2020, 9, 618.	1.8	167
8513	Phase I study of intraventricular infusions of autologous ex vivo expanded NK cells in children with recurrent medulloblastoma and ependymoma. <i>Neuro-Oncology</i> , 2020, 22, 1214-1225.	0.6	48
8514	A case report of immune-mediated arthritis in a patient with cutaneous melanoma receiving checkpoint inhibition therapy. <i>Medicine (United States)</i> , 2020, 99, e19439.	0.4	1
8515	Discovery of Highly Potent Benzimidazole Derivatives as Indoleamine 2,3-Dioxygenase-1 (IDO1) Inhibitors: From Structure-Based Virtual Screening to <i>in Vivo</i> Pharmacodynamic Activity. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 3047-3065.	2.9	40
8516	Immune-based therapies for hepatocellular carcinoma. <i>Oncogene</i> , 2020, 39, 3620-3637.	2.6	154
8517	Molecular principles of metastasis: a hallmark of cancer revisited. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 28.	7.1	1,075
8518	Development of an Improved T-cell Assay to Assess the Intrinsic Immunogenicity of Haptenic Compounds. <i>Toxicological Sciences</i> , 2020, 175, 266-278.	1.4	13
8519	Immune Response Dysfunction in Chronic Lymphocytic Leukemia: Dissecting Molecular Mechanisms and Microenvironmental Conditions. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1825.	1.8	80
8520	Comprehensive immunohistochemical analysis of immune checkpoint molecules in adult T cell leukemia/lymphoma. <i>Annals of Hematology</i> , 2020, 99, 1093-1098.	0.8	10
8521	Addressing Recent Failures in Immuno-Oncology Trials to Guide Novel Immunotherapeutic Treatment Strategies. <i>Pharmaceutical Medicine</i> , 2020, 34, 83-91.	1.0	9
8522	Preface: More than two decades of modern tumor immunology. <i>Methods in Enzymology</i> , 2020, 635, xix-xxxviii.	0.4	0
8523	Neurologic complications of immune checkpoint inhibitors. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 479-488.	1.0	82

#	ARTICLE	IF	CITATIONS
8524	The Current Status of Immune Checkpoint Inhibitors in Neuro-Oncology: A Systematic Review. <i>Cancers</i> , 2020, 12, 586.	1.7	48
8525	Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents. <i>Journal of Clinical Medicine</i> , 2020, 9, 675.	1.0	57
8526	Analysis of DNA methylation patterns in the tumor immune microenvironment of metastatic melanoma. <i>Molecular Oncology</i> , 2020, 14, 933-950.	2.1	29
8527	Adjuvant therapies after curative treatments for hepatocellular carcinoma: Current status and prospects. <i>Genes and Diseases</i> , 2020, 7, 359-369.	1.5	40
8528	Immune checkpoint inhibitor associated neurotoxicity: Much more than meets the eye. <i>Immunology Letters</i> , 2020, 221, 72-74.	1.1	0
8529	An unexpected turn of fortune: targeting TRAIL-Rs in KRAS-driven cancer. <i>Cell Death Discovery</i> , 2020, 6, 14.	2.0	18
8530	Multiparametric MRI for early identification of therapeutic response in recurrent glioblastoma treated with immune checkpoint inhibitors. <i>Neuro-Oncology</i> , 2020, 22, 1658-1666.	0.6	27
8531	Single-Cell Approaches to Profile the Response to Immune Checkpoint Inhibitors. <i>Frontiers in Immunology</i> , 2020, 11, 490.	2.2	38
8532	How Can Immune Checkpoint Inhibitors Cause Hyperprogression in Solid Tumors?. <i>Frontiers in Immunology</i> , 2020, 11, 492.	2.2	40
8533	Correlative Monitoring of Immune Activation and Tissue Damage in Malignant Melanoma—An Algorithm for Identification of Tolerance Breakage During Immune Checkpoint Inhibitor Therapy of Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2020.	1.8	18
8534	Preface: More than two decades of modern tumor immunology. <i>Methods in Enzymology</i> , 2020, 636, xvii-xxxvi.	0.4	0
8535	Melanoma immunotherapy: strategies to overcome pharmacological resistance. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 289-304.	1.1	13
8536	Primary CNS lymphoma commonly expresses immune response biomarkers. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa018.	0.4	24
8537	Treatment Options for Advanced Melanoma After Anti-PD-1 Therapy. <i>Current Oncology Reports</i> , 2020, 22, 38.	1.8	15
8538	Comprehensive review of targeted therapy for colorectal cancer. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 22.	7.1	853
8539	Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls. <i>Current Oncology Reports</i> , 2020, 22, 39.	1.8	199
8540	<p>Contemporary Multidisciplinary Management of Sinonasal Mucosal Melanoma</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 2289-2298.	1.0	21
8541	Protein Expression in Metastatic Melanoma and the Link to Disease Presentation in a Range of Tumor Phenotypes. <i>Cancers</i> , 2020, 12, 767.	1.7	2

#	ARTICLE	IF	CITATIONS
8542	Mature Versus Registration Studies of Immuno-Oncology Agents: Does Value Improve With Time?. <i>JCO Oncology Practice</i> , 2020, 16, e779-e790.	1.4	3
8543	Tumor Microenvironment. <i>Cancer Treatment and Research</i> , 2020, , .	0.2	12
8544	T cell-engaging therapies – BiTEs and beyond. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 418-434.	12.5	296
8545	Moving towards personalized treatments of immune-related adverse events. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 504-515.	12.5	189
8546	Clinical Characteristics and Treatment of Immune-Related Adverse Events of Immune Checkpoint Inhibitors. <i>Immune Network</i> , 2020, 20, e9.	1.6	143
8547	Lymphocyte activation gene 3 (LAG3) protein expression on tumor-infiltrating lymphocytes in aggressive and TP53-mutated salivary gland carcinomas. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1363-1373.	2.0	26
8548	First referral to an integrated onco-palliative care program: a retrospective analysis of its timing. <i>BMC Palliative Care</i> , 2020, 19, 31.	0.8	11
8549	Use of immunotherapy and surgery for stage IV melanoma. <i>Cancer</i> , 2020, 126, 2614-2624.	2.0	14
8550	Understanding the immune landscape and tumor microenvironment of pancreatic cancer to improve immunotherapy. <i>Molecular Carcinogenesis</i> , 2020, 59, 775-782.	1.3	36
8551	Correlation between cutaneous adverse events and prognosis in patients with melanoma treated with nivolumab: A single institutional retrospective study. <i>Journal of Dermatology</i> , 2020, 47, 622-628.	0.6	10
8552	Sweet's syndrome under ipilimumab therapy and a brief comparison of the cases in literature. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 1762-1764.	0.5	7
8553	Gut microbiota and cancer immunotherapy: prognostic and therapeutic implications. <i>Future Oncology</i> , 2020, 16, 497-506.	1.1	16
8554	Computational Prediction and Validation of Tumor-Associated Neoantigens. <i>Frontiers in Immunology</i> , 2020, 11, 27.	2.2	86
8555	Insights Into Lung Cancer Immune-Based Biology, Prevention, and Treatment. <i>Frontiers in Immunology</i> , 2020, 11, 159.	2.2	73
8556	Tumor-Specific T Cell Activation in Malignant Brain Tumors. <i>Frontiers in Immunology</i> , 2020, 11, 205.	2.2	36
8557	Comparative Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Advanced Cancer: A Systematic Review and Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2020, 11, 40.	1.6	31
8558	Determinants of Resistance to Checkpoint Inhibitors. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1594.	1.8	39
8559	Endoplasmic Reticulum-Associated Degradation-Dependent Processing in Cross-Presentation and Its Potential for Dendritic Cell Vaccinations: A Review. <i>Pharmaceutics</i> , 2020, 12, 153.	2.0	4

#	ARTICLE	IF	CITATIONS
8560	Isolated adrenocorticotrophic hormone deficiency in a patient treated with checkpoint inhibitor therapy. <i>Baylor University Medical Center Proceedings</i> , 2020, 33, 251-253.	0.2	0
8561	Clinical and molecular insights into BCG immunotherapy for melanoma. <i>Journal of Internal Medicine</i> , 2020, 288, 625-640.	2.7	33
8562	Melanoma-Secreted Lysosomes Trigger Monocyte-Derived Dendritic Cell Apoptosis and Limit Cancer Immunotherapy. <i>Cancer Research</i> , 2020, 80, 1942-1956.	0.4	25
8563	Localized cocktail chemoimmunotherapy after in situ gelation to trigger robust systemic antitumor immune responses. <i>Science Advances</i> , 2020, 6, eaaz4204.	4.7	136
8564	MNK1 signaling induces an ANGPTL4-mediated gene signature to drive melanoma progression. <i>Oncogene</i> , 2020, 39, 3650-3665.	2.6	19
8566	Pickering emulsions with ethiodized oil and nanoparticles for slow release of intratumoral anti-CTLA4 immune checkpoint antibodies. , 2020, 8, e000579.		17
8567	Combination Therapies in Solid Tumour Oncology. , 2020, , 515-578.		0
8568	Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy. <i>Cell</i> , 2020, 182, 655-671.e22.	13.5	259
8569	FDG PET/CT for Assessment of Immune Therapy: Opportunities and Understanding Pitfalls. <i>Seminars in Nuclear Medicine</i> , 2020, 50, 518-531.	2.5	25
8570	The Role of Neoadjuvant Therapy in Melanoma. <i>Current Oncology Reports</i> , 2020, 22, 80.	1.8	8
8571	Response and survival of metastatic melanoma patients treated with immune checkpoint inhibition for recurrent disease on adjuvant dendritic cell vaccination. <i>OncolImmunology</i> , 2020, 9, 1738814.	2.1	13
8572	Ultraviolet Radiation and Melanomagenesis: From Mechanism to Immunotherapy. <i>Frontiers in Oncology</i> , 2020, 10, 951.	1.3	35
8573	Telomere Stress Potentiates STING-Dependent Anti-tumor Immunity. <i>Cancer Cell</i> , 2020, 38, 400-411.e6.	7.7	70
8574	The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. <i>Cellular and Molecular Immunology</i> , 2020, 17, 807-821.	4.8	1,136
8575	Role of DNA repair defects in predicting immunotherapy response. <i>Biomarker Research</i> , 2020, 8, 23.	2.8	47
8576	<p>Multiple Immune-Related Adverse Events and Anti-Tumor Efficacy: Real-World Data on Various Solid Tumors</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 4585-4593.	0.9	37
8577	The immunotherapy revolution in genitourinary malignancies. <i>Immunotherapy</i> , 2020, 12, 819-831.	1.0	10
8578	Fibroblast activation protein-targeted-4-1BB ligand agonist amplifies effector functions of intratumoral T cells in human cancer. , 2020, 8, e000238.		35

#	ARTICLE	IF	CITATIONS
8579	Article Commentary: Cancer Immunotherapy for the General Surgeon. <i>American Surgeon</i> , 2020, 86, 284-292.	0.4	0
8580	Nanomedicine and Onco-Immunotherapy: From the Bench to Bedside to Biomarkers. <i>Nanomaterials</i> , 2020, 10, 1274.	1.9	26
8581	Immune Checkpoint Inhibitionâ€”Does It Cause Rheumatic Diseases? Mechanisms of Cancer-Associated Loss of Tolerance and Pathogenesis of Autoimmunity. <i>Rheumatic Disease Clinics of North America</i> , 2020, 46, 587-603.	0.8	3
8582	PRMT5 control of cGAS/STING and NLRC5 pathways defines melanoma response to antitumor immunity. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	111
8583	Predicting response to immunotherapy in advanced non-small-cell lung cancer using tumor mutational burden radiomic biomarker. , 2020, 8, e000550.		101
8584	Immunotherapy discontinuation â€” how, and when? Data from melanoma as a paradigm. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 707-715.	12.5	57
8585	Harnessing NK Cell Checkpoint-Modulating Immunotherapies. <i>Cancers</i> , 2020, 12, 1807.	1.7	17
8586	Overall Survival Improved for Contemporary Patients with Melanoma: A 2004â€”2015 National Cancer Database Analysis. <i>Oncology and Therapy</i> , 2020, 8, 261-275.	1.0	9
8587	News on immune checkpoint inhibitors as immunotherapy strategies in adult and pediatric solid tumors. <i>Seminars in Cancer Biology</i> , 2022, 79, 18-43.	4.3	35
8588	PD-1 Immune Checkpoint Blockade Promotes Therapeutic Cancer Vaccine to Eradicate Lung Cancer. <i>Vaccines</i> , 2020, 8, 317.	2.1	17
8589	Dendritic Cells and Their Roles in Anti-Tumour Immunity. , 2020, , .		0
8590	Calcium-sensing receptor autoantibody-mediated hypoparathyroidism associated with immune checkpoint inhibitor therapy: diagnosis and long-term follow-up. , 2020, 8, e000687.		21
8591	Combination of Ipilimumab and Nivolumab in Cancers: From Clinical Practice to Ongoing Clinical Trials. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4427.	1.8	67
8592	Balancing Cancer Immunotherapy Efficacy and Toxicity. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 2898-2906.	2.0	28
8593	Roles for receptor tyrosine kinases in tumor progression and implications for cancer treatment. <i>Advances in Cancer Research</i> , 2020, 147, 1-57.	1.9	32
8594	Genetic Screening for Novel Regulators of Immune Checkpoint Molecules. <i>Trends in Immunology</i> , 2020, 41, 692-705.	2.9	2
8595	Metaâ€”analysis of immuneâ€”related adverse events of immune checkpoint inhibitor therapy in cancer patients. <i>Thoracic Cancer</i> , 2020, 11, 2406-2430.	0.8	40
8596	Advances in Anti-Cancer Immunotherapy: Car-T Cell, Checkpoint Inhibitors, Dendritic Cell Vaccines, and Oncolytic Viruses, and Emerging Cellular and Molecular Targets. <i>Cancers</i> , 2020, 12, 1826.	1.7	46

#	ARTICLE	IF	CITATIONS
8597	Organoid Models of Tumor Immunology. Trends in Immunology, 2020, 41, 652-664.	2.9	210
8598	Establishment of a novel gene panel as a biomarker of immune checkpoint inhibitor response. Clinical and Translational Immunology, 2020, 9, e1145.	1.7	7
8599	Rewriting History: Epigenetic Reprogramming of CD8+ T Cell Differentiation to Enhance Immunotherapy. Trends in Immunology, 2020, 41, 665-675.	2.9	42
8600	Cancer Epigenetics, Tumor Immunity, and Immunotherapy. Trends in Cancer, 2020, 6, 580-592.	3.8	166
8601	Optimal treatment strategy for metastatic melanoma patients harboring <i>BRAF-V600</i> mutations. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592092521.	1.4	31
8602	Immunotherapy combinations for the treatment of patients with solid tumors. Future Oncology, 2020, 16, 1715-1736.	1.1	6
8603	Regulatory T Cells in Tumor Microenvironment and Approach for Anticancer Immunotherapy. Immune Network, 2020, 20, e4.	1.6	75
8604	Immunotherapy in sinonasal melanoma: treatment patterns and outcomes compared to cutaneous melanoma. International Forum of Allergy and Rhinology, 2020, 10, 1087-1095.	1.5	9
8605	Immune checkpoint inhibitors: Key trials and an emerging role in breast cancer. Seminars in Cancer Biology, 2022, 79, 44-57.	4.3	104
8606	National trends in ventral hernia repairs for patients with intra-abdominal metastases. Surgery, 2020, 168, 509-517.	1.0	1
8607	Utilization and impact of immunotherapy in stage IV melanoma using the National Cancer Database. Melanoma Research, 2020, 30, 376-385.	0.6	6
8608	Virus-Specific T Cell Therapies for HIV: Lessons Learned From Hematopoietic Stem Cell Transplantation. Frontiers in Cellular and Infection Microbiology, 2020, 10, 298.	1.8	8
8609	Low-dose oncolytic adenovirus therapy overcomes tumor-induced immune suppression and sensitizes intracranial gliomas to anti-PD-1 therapy. Neuro-Oncology Advances, 2020, 2, vdaa011.	0.4	22
8610	Efficacy and tolerance of immune checkpoint inhibitors in transplant patients with cancer: A systematic review. American Journal of Transplantation, 2020, 20, 2457-2465.	2.6	86
8611	PET/CT and the Response to Immunotherapy in Lung Cancer. Current Radiopharmaceuticals, 2020, 13, 177-184.	0.3	17
8612	Response to ipilimumab therapy in metastatic melanoma patients: potential relevance of CTLA-4+ tumor infiltrating lymphocytes and their in situ localization. Cancer Immunology, Immunotherapy, 2020, 69, 653-662.	2.0	16
8613	When is it OK to Stop Anti-Programmed Death 1 Receptor (PD-1) Therapy in Metastatic Melanoma?. American Journal of Clinical Dermatology, 2020, 21, 313-321.	3.3	3
8614	Targeting cancer stem cell pathways for cancer therapy. Signal Transduction and Targeted Therapy, 2020, 5, 8.	7.1	998

#	ARTICLE	IF	CITATIONS
8615	In situ antitumor vaccination: Targeting the tumor microenvironment. <i>Journal of Cellular Physiology</i> , 2020, 235, 5490-5500.	2.0	21
8616	Clinicopathological and prognostic significance of PD-1/PD-L1 axis expression in patients with tongue squamous cell carcinoma. <i>Journal of Cellular Physiology</i> , 2020, 235, 6942-6953.	2.0	8
8617	Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2020, , .	0.8	3
8618	The expression and immunoregulation of immune checkpoint molecule VISTA in autoimmune diseases and cancers. <i>Cytokine and Growth Factor Reviews</i> , 2020, 52, 1-14.	3.2	18
8619	Reverting Immune Suppression to Enhance Cancer Immunotherapy. <i>Frontiers in Oncology</i> , 2019, 9, 1554.	1.3	49
8620	The emerging development of tumor mutational burden in patients with NSCLC. <i>Future Oncology</i> , 2020, 16, 469-481.	1.1	2
8621	Immune-mediated adverse effects of immune-checkpoint inhibitors and their management in cancer. <i>Immunology Letters</i> , 2020, 221, 61-71.	1.1	12
8622	Micro RNA Molecules as Modulators of Treatment Resistance, Immune Checkpoints Controllers and Sensitive Biomarkers in Glioblastoma Multiforme. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1507.	1.8	17
8623	The Inflammatory Milieu of Adamantinomatous Craniopharyngioma and Its Implications for Treatment. <i>Journal of Clinical Medicine</i> , 2020, 9, 519.	1.0	26
8624	Use of Magnetic Resonance Imaging to Identify Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis. <i>JAMA Network Open</i> , 2020, 3, e200032.	2.8	17
8625	An overview of binimetinib for the treatment of melanoma. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 747-754.	0.9	8
8626	Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types. <i>Cancer Medicine</i> , 2020, 9, 2643-2652.	1.3	21
8627	Nanotechnology approaches in the current therapy of skin cancer. <i>Advanced Drug Delivery Reviews</i> , 2020, 153, 109-136.	6.6	65
8628	Advanced biomaterials for cancer immunotherapy. <i>Acta Pharmacologica Sinica</i> , 2020, 41, 911-927.	2.8	62
8629	Immune checkpoint inhibitors in cancer treatment and potential effect modification by age. <i>Acta Oncologica</i> , 2020, 59, 247-248.	0.8	3
8630	Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity. <i>Onc Immunology</i> , 2020, 9, 1708065.	2.1	41
8631	Immunotherapy orchestrates radiotherapy in composing abscopal effects: A strategic review in metastatic head and neck cancer. <i>Journal of the Chinese Medical Association</i> , 2020, 83, 113-116.	0.6	3
8632	Clinicopathological Features, Staging, and Current Approaches to Treatment in High-Risk Resectable Melanoma. <i>Journal of the National Cancer Institute</i> , 2020, 112, 875-885.	3.0	20

#	ARTICLE	IF	CITATIONS
8633	Association between <i>BTLA</i> polymorphisms and susceptibility to esophageal squamous cell carcinoma in the Chinese population. <i>Journal of Clinical Laboratory Analysis</i> , 2020, 34, e23221.	0.9	19
8634	Assessing Treatment Benefit in Immuno-oncology. <i>Statistics in Biosciences</i> , 2020, 12, 83-103.	0.6	10
8635	Clinical diagnosis and treatment recommendations for ocular toxicities of targeted therapy and immune checkpoint inhibitor therapy. <i>Thoracic Cancer</i> , 2020, 11, 810-818.	0.8	19
8636	Anticancer effects of chemokine-directed antigen delivery to a cross-presenting dendritic cell subset with immune checkpoint blockade. <i>British Journal of Cancer</i> , 2020, 122, 1185-1193.	2.9	14
8637	Combination therapy with oncolytic viruses and immune checkpoint inhibitors. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 635-652.	1.4	36
8638	Revisiting Immunotherapy: A Focus on Prostate Cancer. <i>Cancer Research</i> , 2020, 80, 1615-1623.	0.4	120
8639	Macrophages/Microglia Represent the Major Source of Indolamine 2,3-Dioxygenase Expression in Melanoma Metastases of the Brain. <i>Frontiers in Immunology</i> , 2020, 11, 120.	2.2	28
8640	Immune checkpoint modulation enhances HIV-1 antibody induction. <i>Nature Communications</i> , 2020, 11, 948.	5.8	27
8641	Small Molecule Inhibition of GSK-3 Specifically Inhibits the Transcription of Inhibitory Co-receptor LAG-3 for Enhanced Anti-tumor Immunity. <i>Cell Reports</i> , 2020, 30, 2075-2082.e4.	2.9	50
8642	A novel, more reliable approach to use of progression-free survival as a predictor of gain in overall survival: The Ottawa PFS Predictive Model. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 148, 102896.	2.0	10
8643	Therapeutic efficacy of PD1/PDL1 blockade in B16 melanoma is greatly enhanced by immunization with dendritic cell-targeting lentiviral vector and protein vaccine. <i>Vaccine</i> , 2020, 38, 3369-3377.	1.7	11
8644	Harnessing cancer immunotherapy during the unexploited immediate perioperative period. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 313-326.	12.5	60
8645	Inhibition of SHP-1 Expands the Repertoire of Antitumor T Cells Available to Respond to Immune Checkpoint Blockade. <i>Cancer Immunology Research</i> , 2020, 8, 506-517.	1.6	23
8646	Reporting of Cardiovascular Events in Clinical Trials Supporting FDA Approval of Contemporary Cancer Therapies. <i>Journal of the American College of Cardiology</i> , 2020, 75, 620-628.	1.2	49
8647	Normalization Cancer Immunotherapy for Melanoma. <i>Journal of Investigative Dermatology</i> , 2020, 140, 1134-1142.	0.3	13
8648	Daratumumab for quick and sustained remission in post-transplant relapsed/refractory acute lymphoblastic leukemia. <i>Leukemia Research</i> , 2020, 91, 106332.	0.4	6
8649	Renal Toxicity of Systemic Therapy for Renal Cell Carcinoma. <i>Seminars in Nephrology</i> , 2020, 40, 49-58.	0.6	4
8650	Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis. <i>European Heart Journal</i> , 2020, 41, 1733-1743.	1.0	212

#	ARTICLE	IF	CITATIONS
8651	Gastrointestinal adverse events associated with immune checkpoint inhibitor therapy. <i>Gastroenterology Report</i> , 2020, 8, 25-30.	0.6	41
8652	Global mapping of randomised trials related articles published in high-impact-factor medical journals: a cross-sectional analysis. <i>Trials</i> , 2020, 21, 34.	0.7	19
8653	Potential Immune-Related Adverse Events Associated With Monotherapy and Combination Therapy of Ipilimumab, Nivolumab, and Pembrolizumab for Advanced Melanoma: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 91.	1.3	112
8654	Mass Spectrometry-Based Identification of MHC-Associated Peptides. <i>Cancers</i> , 2020, 12, 535.	1.7	29
8655	Mixed 20-peptide cancer vaccine in combination with docetaxel and dexamethasone for castration-resistant prostate cancer: a randomized phase II trial. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 847-857.	2.0	15
8656	Real world data of liver injury induced by immune checkpoint inhibitors in Japanese patients with advanced malignancies. <i>Journal of Gastroenterology</i> , 2020, 55, 653-661.	2.3	38
8657	A novel cyclic peptide targeting LAG-3 for cancer immunotherapy by activating antigen-specific CD8+ T cell responses. <i>Acta Pharmaceutica Sinica B</i> , 2020, 10, 1047-1060.	5.7	50
8658	Targeted melanoma radiotherapy using ultrasmall ¹⁷⁷ Lu-labeled $\hat{\pm}$ -melanocyte stimulating hormone-functionalized core-shell silica nanoparticles. <i>Biomaterials</i> , 2020, 241, 119858.	5.7	35
8659	Imaging manifestations of immune-related adverse effects in checkpoint inhibitor therapies: A primer for the radiologist. <i>Clinical Imaging</i> , 2020, 63, 35-49.	0.8	3
8660	Active targeted ligand-aza-BODIPY conjugate for near-infrared photodynamic therapy in melanoma. <i>International Journal of Pharmaceutics</i> , 2020, 579, 119189.	2.6	12
8661	Combination Therapy with Radiation and PARP Inhibition Enhances Responsiveness to Anti-PD-1 Therapy in Colorectal Tumor Models. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 81-92.	0.4	28
8663	Immunotherapy Bridge 2019 and Melanoma Bridge 2019: meeting abstracts. <i>Journal of Translational Medicine</i> , 2020, 18, 50.	1.8	4
8664	Safe Use of Nivolumab in a Patient with Epipharyngeal Carcinoma and Preexisting Ulcerative Colitis: A Histologically Proven Case Report. <i>Internal Medicine</i> , 2020, 59, 1105-1109.	0.3	6
8665	Long-Term Outcomes and Responses to Retreatment in Patients With Melanoma Treated With PD-1 Blockade. <i>Journal of Clinical Oncology</i> , 2020, 38, 1655-1663.	0.8	138
8666	Atypical Presentations and Management of Endocrine and Hepatic Immune-Related Adverse Events From Adjuvant Immune Checkpoint Inhibitor Therapy in Stage III Resected Melanoma. <i>JCO Oncology Practice</i> , 2020, 16, 10s-14s.	1.4	1
8668	Body composition is prognostic and predictive of ipilimumab activity in metastatic melanoma. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2020, 11, 748-755.	2.9	39
8669	Intratumoral injection of hemagglutinating virus of Japan-envelope vector yielded an antitumor effect for advanced melanoma: a phase I/IIa clinical study. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1131-1140.	2.0	12
8670	The Diagnostic, Prognostic, and Therapeutic Potential of Adaptive Immune Receptor Repertoire Profiling in Cancer. <i>Cancer Research</i> , 2020, 80, 643-654.	0.4	28

#	ARTICLE	IF	CITATIONS
8671	Emerging treatments for metastatic castration-resistant prostate cancer: Immunotherapy, PARP inhibitors, and PSMA-targeted approaches. <i>Cancer Treatment and Research Communications</i> , 2020, 23, 100164.	0.7	22
8672	VISTA: Coming of age as a multi-lineage immune checkpoint. <i>Clinical and Experimental Immunology</i> , 2020, 200, 120-130.	1.1	66
8673	Endocrine-Related Adverse Events Related to Immune Checkpoint Inhibitors: Proposed Algorithms for Management. <i>Oncologist</i> , 2020, 25, 290-300.	1.9	51
8674	Multicenter prospective phase II trial of nivolumab in patients with unresectable or metastatic mucosal melanoma. <i>International Journal of Clinical Oncology</i> , 2020, 25, 972-977.	1.0	20
8675	Preface: More than two decades of modern tumor immunology. <i>Methods in Enzymology</i> , 2020, 631, xxiii-xlii.	0.4	1
8676	Intratumoral expression of IL-7 and IL-12 using an oncolytic virus increases systemic sensitivity to immune checkpoint blockade. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	117
8677	A review of cancer immunotherapy toxicity. <i>Ca-A Cancer Journal for Clinicians</i> , 2020, 70, 86-104.	157.7	753
8678	Molecular stratifications, biomarker candidates and new therapeutic options in current medulloblastoma treatment approaches. <i>Cancer and Metastasis Reviews</i> , 2020, 39, 211-233.	2.7	42
8679	Conjunctival Melanoma: Current Treatments and Future Options. <i>American Journal of Clinical Dermatology</i> , 2020, 21, 371-381.	3.3	33
8680	Peptide-based targeting of immunosuppressive cells in cancer. <i>Bioactive Materials</i> , 2020, 5, 92-101.	8.6	41
8681	Tumor hypermetabolism confers resistance to immunotherapy. <i>Seminars in Cancer Biology</i> , 2020, 65, 155-163.	4.3	17
8682	The yin and yang of co-inhibitory receptors: toward anti-tumor immunity without autoimmunity. <i>Cell Research</i> , 2020, 30, 285-299.	5.7	129
8683	Directing Traffic: How to Effectively Drive T Cells into Tumors. <i>Cancer Discovery</i> , 2020, 10, 185-197.	7.7	68
8684	Safety of Combination Immune Checkpoint Inhibitors Compared to Monotherapy; A Systematic Review and Meta-Analysis. <i>Cancer Investigation</i> , 2020, 38, 150-157.	0.6	11
8685	Chemoradiation and granulocyte-colony or granulocyte macrophage-colony stimulating factors (G-CSF or GM-CSF): time to think out of the box?. <i>British Journal of Radiology</i> , 2020, 93, 20190147.	1.0	14
8686	Immunosurveillance and Immunoediting of Lung Cancer: Current Perspectives and Challenges. <i>International Journal of Molecular Sciences</i> , 2020, 21, 597.	1.8	58
8687	Health-related quality of life in cancer patients treated with immune checkpoint inhibitors: A systematic review on reporting of methods in randomized controlled trials. <i>PLoS ONE</i> , 2020, 15, e0227344.	1.1	26
8688	Criterios de respuesta metabólica a la inmunoterapia. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2020, 39, 51-56.	0.0	0

#	ARTICLE	IF	CITATIONS
8689	Novel cancer therapies for advanced cutaneous melanoma: The added value of radiomics in the decision making process—A systematic review. <i>Cancer Medicine</i> , 2020, 9, 1603-1612.	1.3	17
8690	Cancer immunotherapy through the prism of adaptation: Will Achilles catch the tortoise?. <i>Medical Hypotheses</i> , 2020, 137, 109545.	0.8	0
8691	Applications and explorations of CRISPR/Cas9 in CAR T-cell therapy. <i>Briefings in Functional Genomics</i> , 2020, 19, 175-182.	1.3	59
8692	Infiltration of CD163-positive macrophages in glioma tissues after treatment with anti-PD-L1 antibody and role of PI3K ^{Î³} inhibitor as a combination therapy with anti-PD-L1 antibody in in vivo model using temozolomide-resistant murine glioma-initiating cells. <i>Brain Tumor Pathology</i> , 2020, 37, 41-49.	1.1	37
8693	Molecular and biological rationale of hyperthermia as radio- and chemosensitizer. <i>Advanced Drug Delivery Reviews</i> , 2020, 163-164, 84-97.	6.6	81
8694	Hypofractionated radiation therapy with versus without immune checkpoint inhibitors in patients with brain metastases: A meta-analysis. <i>International Immunopharmacology</i> , 2020, 80, 106148.	1.7	9
8695	Prognostic value of the expression of chemokines and their receptors in regional lymph nodes of melanoma patients. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 3407-3418.	1.6	12
8696	Genetics and treatment of gastrointestinal stromal tumors with immune checkpoint inhibitors: what do we know?. <i>Pharmacogenomics</i> , 2020, 21, 231-234.	0.6	6
8697	Assessment of Tumor Mutational Burden in Pediatric Tumors by Real-Life Whole-Exome Sequencing and In Silico Simulation of Targeted Gene Panels: How the Choice of Method Could Affect the Clinical Decision?. <i>Cancers</i> , 2020, 12, 230.	1.7	9
8698	Therapeutic melanoma vaccine with cancer stem cell phenotype represses exhaustion and maintains antigen-specific T cell stemness by up-regulating BCL6. <i>Oncolmmunology</i> , 2020, 9, 1710063.	2.1	10
8699	Screening and Identification of Key Biomarkers for Bladder Cancer: A Study Based on TCGA and GEO Data. <i>BioMed Research International</i> , 2020, 2020, 1-20.	0.9	32
8700	The miRNAs Role in Melanoma and in Its Resistance to Therapy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 878.	1.8	50
8701	Myositis as a neuromuscular complication of immune checkpoint inhibitors. <i>Acta Neurologica Belgica</i> , 2020, 120, 355-364.	0.5	17
8702	Association of Age with Efficacy of Immunotherapy in Metastatic Melanoma. <i>Oncologist</i> , 2020, 25, e381-e385.	1.9	27
8703	Modulation of Vaccine-Induced HIV-1-Specific Immune Responses by Co-Electroporation of PD-L1 Encoding DNA. <i>Vaccines</i> , 2020, 8, 27.	2.1	11
8704	Smokers or non-smokers: who benefits more from immune checkpoint inhibitors in treatment of malignancies? An up-to-date meta-analysis. <i>World Journal of Surgical Oncology</i> , 2020, 18, 15.	0.8	58
8705	Linking Transcriptomic and Imaging Data Defines Features of a Favorable Tumor Immune Microenvironment and Identifies a Combination Biomarker for Primary Melanoma. <i>Cancer Research</i> , 2020, 80, 1078-1087.	0.4	18
8706	B Cell-Targeted Immunotherapy Limits Tumor Growth, Enhances Survival, and Prevents Lymph Node Metastasis of UV-Induced Keratinocyte Cancers in Mice. <i>Journal of Investigative Dermatology</i> , 2020, 140, 1459-1463.	0.3	7

#	ARTICLE	IF	CITATIONS
8707	GRK2 enforces androgen receptor dependence in the prostate and prostate tumors. <i>Oncogene</i> , 2020, 39, 2424-2436.	2.6	3
8708	Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response. <i>Journal of Clinical Medicine</i> , 2020, 9, 286.	1.0	50
8709	Immune gene signatures for predicting durable clinical benefit of anti-PD-1 immunotherapy in patients with non-small cell lung cancer. <i>Scientific Reports</i> , 2020, 10, 643.	1.6	124
8710	Multimodality Cardiac Imaging in the Era of Emerging Cancer Therapies. <i>Journal of the American Heart Association</i> , 2020, 9, e013755.	1.6	37
8711	Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab. <i>JAMA Oncology</i> , 2020, 6, 402.	3.4	125
8712	Myosin II Reactivation and Cytoskeletal Remodeling as a Hallmark and a Vulnerability in Melanoma Therapy Resistance. <i>Cancer Cell</i> , 2020, 37, 85-103.e9.	7.7	91
8713	Human Anti-tumor Immunity: Insights from Immunotherapy Clinical Trials. <i>Immunity</i> , 2020, 52, 36-54.	6.6	127
8714	Combined Magnetic Hyperthermia and Immune Therapy for Primary and Metastatic Tumor Treatments. <i>ACS Nano</i> , 2020, 14, 1033-1044.	7.3	161
8715	Study design of single-arm phase II immunotherapy trials with long-term survivors and random delayed treatment effect. <i>Pharmaceutical Statistics</i> , 2020, 19, 358-369.	0.7	4
8716	The potential of BRAF-targeted therapy combined with immunotherapy in melanoma. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 131-136.	1.1	9
8717	Predictive biomarkers of response to immune checkpoint inhibitors in melanoma. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 137-145.	1.1	16
8718	Expanding the Scope of Immunotherapy in Colorectal Cancer: Current Clinical Approaches and Future Directions. <i>BioMed Research International</i> , 2020, 2020, 1-24.	0.9	38
8719	Preface: More than two decades of modern tumor immunology. <i>Methods in Enzymology</i> , 2020, 632, xxiii-xlii.	0.4	0
8720	Management of Patients With Immune Checkpoint Inhibitor-Induced Enterocolitis: A Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1393-1403.e1.	2.4	47
8721	Highly efficient singlet oxygen generation, two-photon photodynamic therapy and melanoma ablation by rationally designed mitochondria-specific near-infrared AIEgens. <i>Chemical Science</i> , 2020, 11, 2494-2503.	3.7	131
8722	Therapeutic Cancer Vaccination with Ex Vivo RNA-Transfected Dendritic Cells—An Update. <i>Pharmaceutics</i> , 2020, 12, 92.	2.0	46
8723	Ribonucleic Acid Engineering of Dendritic Cells for Therapeutic Vaccination: Ready to Improve Clinical Outcome?. <i>Cancers</i> , 2020, 12, 299.	1.7	2
8724	Targeting CD47 as a Novel Immunotherapy for Multiple Myeloma. <i>Cancers</i> , 2020, 12, 305.	1.7	56

#	ARTICLE	IF	CITATIONS
8725	Regulation of immune cell metabolism by cancer cell oncogenic mutations. <i>International Journal of Cancer</i> , 2020, 147, 307-316.	2.3	3
8726	Prostate cancer cellâ€™intrinsic interferon signaling regulates dormancy and metastatic outgrowth in bone. <i>EMBO Reports</i> , 2020, 21, e50162.	2.0	58
8727	A review of the imaging manifestations of immune check point inhibitor toxicities. <i>Clinical Imaging</i> , 2020, 64, 70-79.	0.8	9
8728	New directions in chimeric antigen receptor T cell [CARâ€™T] therapy and related flow cytometry. <i>Cytometry Part B - Clinical Cytometry</i> , 2020, 98, 299-327.	0.7	28
8729	Current Treatment of Melanoma Brain Metastasis. <i>Current Treatment Options in Oncology</i> , 2020, 21, 45.	1.3	23
8730	Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer. <i>Nature Communications</i> , 2020, 11, 2168.	5.8	231
8731	Drug-Induced Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1759-1779.	2.4	20
8732	Systemic Therapy in Lung Cancer. <i>Advances in Clinical Radiology</i> , 2020, 2, 1-15.	0.1	0
8733	Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence. <i>Cancers</i> , 2020, 12, 738.	1.7	826
8734	The Role of PTEN Loss in Immune Escape, Melanoma Prognosis and Therapy Response. <i>Cancers</i> , 2020, 12, 742.	1.7	38
8735	Current Insights into Combination Therapies with MAPK Inhibitors and Immune Checkpoint Blockade. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2531.	1.8	56
8736	Increased expression of immune checkpoint programmed cell death proteinâ€™1 (<scp>PD</scp>â€™1) on T cell subsets of bone marrow aspirates in patients with <scp>Bâ€™lymphoblastic</scp> leukemia, especially in relapse and at diagnosis. <i>Cytometry Part B - Clinical Cytometry</i> , 2020, 98, 336-347.	0.7	10
8737	Integrating the immune microenvironment of prostate cancerâ€™induced bone disease. <i>Molecular Carcinogenesis</i> , 2020, 59, 822-829.	1.3	9
8739	Circulating microRNAs in oncogenic viral infections: potential diagnostic biomarkers. <i>SN Applied Sciences</i> , 2020, 2, 1.	1.5	16
8740	Microbiota-derived SSL6 enhances the sensitivity of hepatocellular carcinoma to sorafenib by down-regulating glycolysis. <i>Cancer Letters</i> , 2020, 481, 32-44.	3.2	15
8741	Emergency presentations in patients treated with immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2020, 130, 193-197.	1.3	33
8742	Thermosensitive hydrogels as sustained drug delivery system for CTLA-4 checkpoint blocking antibodies. <i>Journal of Controlled Release</i> , 2020, 323, 1-11.	4.8	47
8743	Molecular targeting of PD-1 signaling pathway as a novel therapeutic approach in HTLV-1 infection. <i>Microbial Pathogenesis</i> , 2020, 144, 104198.	1.3	7

#	ARTICLE	IF	CITATIONS
8744	Learning from clinical trials of neoadjuvant checkpoint blockade. <i>Nature Medicine</i> , 2020, 26, 475-484.	15.2	107
8745	Textural features in FDG-PET/CT can predict outcome in melanoma patients to treatment with Vemurafenib and Ipilimumab. <i>Nuklearmedizin - NuclearMedicine</i> , 2020, 59, 228-234.	0.3	20
8746	Thyroid Toxicity Following Immune Checkpoint Inhibitor Treatment in Advanced Cancer. <i>Thyroid</i> , 2020, 30, 1458-1469.	2.4	44
8747	The Anticancer Efficacy of Immune Checkpoint Inhibitors According to Patients' Age: A Systematic Review and Meta-Analysis. <i>Journal of Immunotherapy</i> , 2020, 43, 95-103.	1.2	7
8748	Simultaneous inhibition of CXCR1/2, TGF- β 2, and PD-L1 remodels the tumor and its microenvironment to drive antitumor immunity. , 2020, 8, e000326.		54
8749	Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma. , 2020, 8, e000341.		48
8750	<i>PRKDC</i>: new biomarker and drug target for checkpoint blockade immunotherapy. , 2020, 8, e000485.		32
8751	Dendritic Cells Pre-Pulsed with Wilms' Tumor 1 in Optimized Culture for Cancer Vaccination. <i>Pharmaceutics</i> , 2020, 12, 305.	2.0	7
8752	Talkin' Toxins: From Coley's to Modern Cancer Immunotherapy. <i>Toxins</i> , 2020, 12, 241.	1.5	47
8753	A _{2A} R Antagonism with DZD2269 Augments Antitumor Efficacy of Irradiation in Murine Model. <i>Journal of Cancer</i> , 2020, 11, 3685-3692.	1.2	12
8754	Donor-Transmitted Melanoma: Is It Still Bothering Us?. <i>Current Treatment Options in Oncology</i> , 2020, 21, 38.	1.3	2
8755	Public Adverse Event Data Insights into the Safety of Pembrolizumab in Melanoma Patients. <i>Cancers</i> , 2020, 12, 1008.	1.7	3
8756	Primary Resistance to PD-1-Based Immunotherapy—A Study in 319 Patients with Stage IV Melanoma. <i>Cancers</i> , 2020, 12, 1027.	1.7	17
8757	Clinical practice: chimeric antigen receptor (CAR) T cells: a major breakthrough in the battle against cancer. <i>Clinical and Experimental Medicine</i> , 2020, 20, 469-480.	1.9	8
8758	Inhibitory checkpoints in human natural killer cells: IUPHAR Review 28. <i>British Journal of Pharmacology</i> , 2020, 177, 2889-2903.	2.7	10
8759	Cytomegalovirus Enterocolitis in a Patient with Refractory Immune-Related Colitis. <i>Case Reports in Gastroenterology</i> , 2020, 14, 103-109.	0.3	14
8760	FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2776-2786.	3.3	42
8761	Therapeutic Efficacy of Immune Stimulatory Thymidine Kinase and fms-like Tyrosine Kinase 3 Ligand (TK/Flt3L) Gene Therapy in a Mouse Model of High-Grade Brainstem Glioma. <i>Clinical Cancer Research</i> , 2020, 26, 4080-4092.	3.2	18

#	ARTICLE	IF	CITATIONS
8762	Late Effects of Parasellar Lesion Treatment: Hypogonadism and Infertility. <i>Neuroendocrinology</i> , 2020, 110, 868-881.	1.2	5
8763	Anti-angiogenesis therapy overcomes the innate resistance to PD-1/PD-L1 blockade in VEGFA-overexpressed mouse tumor models. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1781-1799.	2.0	56
8764	Construction and evaluation of hyaluronic acid-based copolymers as a targeted chemotherapy drug carrier for cancer therapy. <i>Nanotechnology</i> , 2020, 31, 305702.	1.3	8
8765	Checkpoint inhibitors: Better outcomes among advanced cutaneous head and neck melanoma patients. <i>PLoS ONE</i> , 2020, 15, e0231038.	1.1	3
8766	Changing Therapeutic Landscape for Melanoma With Multiple Brain Metastases. <i>Neurosurgery</i> , 2020, 87, 498-515.	0.6	3
8767	Metastatic melanoma: can FDG-PET predict success of anti-PD-1 therapy and help determine when it can be discontinued?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2227-2232.	3.3	8
8768	An update on the safety of nivolumab for the treatment of advanced melanoma. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 409-421.	1.0	5
8769	How Non-invasive in vivo Cell Tracking Supports the Development and Translation of Cancer Immunotherapies. <i>Frontiers in Physiology</i> , 2020, 11, 154.	1.3	27
8770	Challenges to Successful Implementation of the Immune Checkpoint Inhibitors for Treatment of Glioblastoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2759.	1.8	40
8771	Association of Short-Chain Fatty Acids in the Gut Microbiome With Clinical Response to Treatment With Nivolumab or Pembrolizumab in Patients With Solid Cancer Tumors. <i>JAMA Network Open</i> , 2020, 3, e202895.	2.8	192
8773	Prognostic value of volumetric PET parameters at early response evaluation in melanoma patients treated with immunotherapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2787-2795.	3.3	21
8774	Immunotherapy in Older Patients with Advanced Melanoma: A Review of the Current Evidence. <i>Drugs and Aging</i> , 2020, 37, 411-423.	1.3	3
8775	Evolving spectrum of drug-induced uveitis at the era of immune checkpoint inhibitors results from the WHO's pharmacovigilance database. <i>Journal of Autoimmunity</i> , 2020, 111, 102454.	3.0	11
8776	Immune Checkpoint Inhibitors for Brain Metastases: A Primer for Neurosurgeons. <i>Neurosurgery</i> , 2020, 87, E281-E288.	0.6	22
8777	Mechanism-based treatment of cancer with immune checkpoint inhibitor therapies. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1690-1702.	1.1	26
8778	Development and validation of the immune signature to predict distant metastasis in patients with nasopharyngeal carcinoma. , 2020, 8, e000205.		26
8779	Immunotherapy to treat malignancy in patients with pre-existing autoimmunity. , 2020, 8, e000356.		34
8780	Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in EGFR/ALK wild-type advanced non-small cell lung cancer. , 2020, 8, e000376.		111

#	ARTICLE	IF	CITATIONS
8781	Oncolytic vaccinia virus delivering tethered IL-12 enhances antitumor effects with improved safety. , 2020, 8, e000710.		43
8782	Real-world comparative effectiveness of second-line ipilimumab for metastatic melanoma: a population-based cohort study in Ontario, Canada. BMC Cancer, 2020, 20, 304.	1.1	12
8783	Prospect of immunotherapy in neoadjuvant/adjuvant treatment for early breast cancer. Chinese Clinical Oncology, 2020, 9, 28-28.	0.4	5
8784	Radiomics, Tumor Volume, and Blood Biomarkers for Early Prediction of Pseudoprogression in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibition. Clinical Cancer Research, 2020, 26, 4414-4425.	3.2	70
8785	Systemic Therapy for Melanoma: ASCO Guideline. Journal of Clinical Oncology, 2020, 38, 3947-3970.	0.8	190
8786	Differential expression of the T-cell inhibitor TIGIT in glioblastoma and MS. Neurology: Neuroimmunology and Neuroinflammation, 2020, 7, .	3.1	22
8787	A homogeneous SIRP1±-CD47 cell-based, ligand-binding assay: Utility for small molecule drug development in immuno-oncology. PLoS ONE, 2020, 15, e0226661.	1.1	19
8788	An Organotypic Microcosm for the Pancreatic Tumor Microenvironment. Cancers, 2020, 12, 811.	1.7	7
8789	Landscape and Future Perspectives of Immunotherapy in Neuroendocrine Neoplasia. Cancers, 2020, 12, 832.	1.7	27
8790	Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells. Cancers, 2020, 12, 927.	1.7	6
8791	Molecular T-Cell Repertoire Analysis as Source of Prognostic and Predictive Biomarkers for Checkpoint Blockade Immunotherapy. International Journal of Molecular Sciences, 2020, 21, 2378.	1.8	48
8792	Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy. Annals of Oncology, 2020, 31, 724-744.	0.6	129
8793	Metastatic melanoma patients' sensitivity to ipilimumab cannot be predicted by tumor characteristics. International Journal of Surgery Oncology, 2017, 2, e43-e43.	0.2	5
8794	The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot Study. Journal of the National Cancer Institute, 2021, 113, 27-37.	3.0	17
8795	Treatment of Advanced Melanoma in 2020 and Beyond. Journal of Investigative Dermatology, 2021, 141, 23-31.	0.3	193
8796	A review of glioblastoma immunotherapy. Journal of Neuro-Oncology, 2021, 151, 41-53.	1.4	159
8797	EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. Annals of the Rheumatic Diseases, 2021, 80, 36-48.	0.5	153
8798	Dynamics of clinical biomarkers as predictors of immunotherapy benefit in metastatic melanoma patients. Clinical and Translational Oncology, 2021, 23, 311-317.	1.2	12

#	ARTICLE	IF	CITATIONS
8799	Concomitant medications and immune checkpoint inhibitor therapy for cancer: causation or association?. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 55-61.	1.4	42
8800	T-cell-based breast cancer immunotherapy. <i>Seminars in Cancer Biology</i> , 2021, 72, 90-101.	4.3	21
8801	Safety profile of immune checkpoint inhibitors: An analysis of the Italian spontaneous reporting system database. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 527-541.	1.1	5
8802	Vitamin D, autoimmunity and immune-related adverse events of immune checkpoint inhibitors. <i>Archives of Dermatological Research</i> , 2021, 313, 1-10.	1.1	14
8803	Gastroparesis Following Immune Checkpoint Inhibitor Therapy: A Case Series. <i>Digestive Diseases and Sciences</i> , 2021, 66, 1974-1980.	1.1	5
8804	A phase 1b study of dual PD-1 and CTLA-4 or KIR blockade in patients with relapsed/refractory lymphoid malignancies. <i>Leukemia</i> , 2021, 35, 777-786.	3.3	78
8805	Metabolic crosstalk in the tumor microenvironment regulates antitumor immunosuppression and immunotherapy resistance. <i>Cellular and Molecular Life Sciences</i> , 2021, 78, 173-193.	2.4	72
8806	Integration of immuno-oncology with stereotactic radiosurgery in the management of brain metastases. <i>Journal of Neuro-Oncology</i> , 2021, 151, 75-84.	1.4	19
8807	Melanoma of the External Auditory Canal: A Review of Seven Cases at a Tertiary Care Referral Center. <i>Laryngoscope</i> , 2021, 131, 165-172.	1.1	9
8808	Cancer immunotherapy in patients with new or recurrent malignancies after liver transplantation. <i>International Journal of Surgery Oncology</i> , 2021, 2, 49.	0.2	4
8809	BILATERAL CHOROIDAL DETACHMENTS SECONDARY TO IPILIMUMAB AND PEMBROLIZUMAB USE. <i>Retinal Cases and Brief Reports</i> , 2021, 15, 230-233.	0.3	6
8810	Immunomodulatory Effects of Stereotactic Body Radiation Therapy: Preclinical Insights and Clinical Opportunities. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 35-52.	0.4	54
8811	Low-dose ipilimumab plus nivolumab combined with IL-2 and hyperthermia in cancer patients with advanced disease: exploratory findings of a case series of 131 stage IV cancers – a retrospective study of a single institution. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1393-1403.	2.0	25
8812	Recent advances in nanoscale materials for antibody-based cancer theranostics. <i>Biosensors and Bioelectronics</i> , 2021, 173, 112787.	5.3	12
8813	Biomarkers for predicting the outcome of various cancer immunotherapies. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103161.	2.0	10
8814	Immune checkpoint inhibitors retain effectiveness in older patients with cutaneous metastatic melanoma. <i>Journal of Geriatric Oncology</i> , 2021, 12, 394-401.	0.5	7
8815	Ophthalmic Immune-Related Adverse Events after Anti-CTLA-4 or PD-1 Therapy Recorded in the American Academy of Ophthalmology Intelligent Research in Sight Registry. <i>Ophthalmology</i> , 2021, 128, 910-919.	2.5	29
8816	Severe immune-related hepatitis induced by immune checkpoint inhibitors: Clinical features and management proposal. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101491.	0.7	18

#	ARTICLE	IF	CITATIONS
8817	Immunotherapy for older patients with melanoma: From darkness to light?. <i>Pigment Cell and Melanoma Research</i> , 2021, 34, 550-563.	1.5	11
8818	Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management. <i>Journal of Cutaneous Medicine and Surgery</i> , 2021, 25, 59-76.	0.6	90
8819	Blocking of the PD-1/PD-L1 interaction by a novel cyclic peptide inhibitor for cancer immunotherapy. <i>Science China Life Sciences</i> , 2021, 64, 548-562.	2.3	29
8820	Knowledge gap about immune checkpoint inhibitors among rheumatologists and medical students: a survey. <i>Rheumatology International</i> , 2021, 41, 939-942.	1.5	3
8821	Artificial intelligence and the interplay between tumor and immunity. , 2021, , 211-235.		1
8822	Immune Checkpoint Inhibitor Cardiotoxicity: Understanding Basic Mechanisms and Clinical Characteristics and Finding a Cure. <i>Annual Review of Pharmacology and Toxicology</i> , 2021, 61, 113-134.	4.2	40
8824	Systemic Anticancer Agents. , 2021, , 405-418.e3.		0
8825	Efficacy of immune checkpoint inhibitors in different types of melanoma. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 4-13.	1.4	19
8826	Challenges and Opportunities in Cancer Drug Resistance. <i>Chemical Reviews</i> , 2021, 121, 3297-3351.	23.0	203
8827	Advances and trends of hydrogel therapy platform in localized tumor treatment: A review. <i>Journal of Biomedical Materials Research - Part A</i> , 2021, 109, 404-425.	2.1	42
8828	Molecular characterization of HLA class II binding to the LAG-3 T cell co-inhibitory receptor. <i>European Journal of Immunology</i> , 2021, 51, 331-341.	1.6	13
8829	Advances in the pharmacotherapeutic management of esophageal squamous cell carcinoma. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 93-107.	0.9	12
8830	Melanoma brain metastases have lower T-cell content and microvessel density compared to matched extracranial metastases. <i>Journal of Neuro-Oncology</i> , 2021, 152, 15-25.	1.4	15
8831	Neoadjuvant immunotherapy for melanoma. <i>Journal of Surgical Oncology</i> , 2021, 123, 782-788.	0.8	26
8832	Clinical Outcomes of Patients with Metastatic Cancer Receiving Immune Checkpoint Inhibitors in the Inpatient Setting. <i>Oncologist</i> , 2021, 26, 49-55.	1.9	18
8833	Current Microsatellite Instability Testing in Management of Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2021, 20, e12-e20.	1.0	32
8834	Coronary and aortic calcification are associated with cardiovascular events on immune checkpoint inhibitor therapy. <i>International Journal of Cardiology</i> , 2021, 322, 177-182.	0.8	18
8835	An Immune-Related Gene Prognostic Index for Head and Neck Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 330-341.	3.2	148

#	ARTICLE	IF	CITATIONS
8836	Co-design and development of online video resources about immunotherapy with patients and their family. <i>Patient Education and Counseling</i> , 2021, 104, 290-297.	1.0	7
8837	Patient preferences for treatment of advanced melanoma: impact of comorbidities. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 58-70.	0.4	7
8838	Current Management of Melanoma. <i>Updates in Surgery Series</i> , 2021, , .	0.0	0
8839	Acute Leukemias. <i>Hematologic Malignancies</i> , 2021, , .	0.2	2
8840	PD-1/PDL-1 Inhibitors and Cardiotoxicity; Molecular, Etiological and Management Outlines. <i>Journal of Advanced Research</i> , 2021, 29, 45-54.	4.4	31
8841	Neoadjuvant immune checkpoint inhibitors in cancer, current state of the art. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103172.	2.0	8
8842	Immune Checkpoint Therapies for Melanoma. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 99-109.	0.9	4
8843	Of immune checkpoint maladies and remedies: The throwing of jabs in the oncogenic ring of PDAC. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1875, 188483.	3.3	7
8844	Recent advances in the management of cutaneous malignant melanoma: our case cohort. <i>British Journal of Oral and Maxillofacial Surgery</i> , 2021, 59, 534-545.	0.4	5
8845	p722 ferrocifen loaded lipid nanocapsules improve survival of murine xenografted-melanoma via a potentiation of apoptosis and an activation of CD8+ T lymphocytes. <i>International Journal of Pharmaceutics</i> , 2021, 593, 120111.	2.6	10
8846	Novel human immunomodulatory T cell receptors and their double-edged potential in autoimmunity, cardiovascular disease and cancer. <i>Cellular and Molecular Immunology</i> , 2021, 18, 919-935.	4.8	11
8847	Targeting <sc>CTLA</sc> in cancer: Is it the ideal companion for <sc>PD</sc> blockade immunotherapy combinations?. <i>International Journal of Cancer</i> , 2021, 149, 31-41.	2.3	23
8848	Surgery of metastatic melanoma after systemic therapy – the SUMMIST trial: study protocol for a randomized controlled trial. <i>Acta Oncologica</i> , 2021, 60, 52-55.	0.8	5
8849	The Beneficial Role of Sunitinib in Tumor Immune Surveillance by Regulating Tumor PD-1. <i>Advanced Science</i> , 2021, 8, 2001596.	5.6	34
8850	Advances in bladder cancer biology and therapy. <i>Nature Reviews Cancer</i> , 2021, 21, 104-121.	12.8	320
8852	Adverse events reporting in phase 3 oncology clinical trials of checkpoint inhibitors: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103162.	2.0	1
8853	Checkpoint inhibitors in NSCLC for the elderly: current challenges and perspectives. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 315-323.	1.1	7
8854	The Identification and Development of a Novel Oncolytic Virus: Alphavirus M1. <i>Human Gene Therapy</i> , 2021, 32, 138-149.	1.4	11

#	ARTICLE	IF	CITATIONS
8855	IL-6 as a major regulator of MDSC activity and possible target for cancer immunotherapy. <i>Cellular Immunology</i> , 2021, 359, 104254.	1.4	141
8856	Antigen folding improves loading efficiency and antitumor efficacy of PC7A nanoparticle vaccine. <i>Journal of Controlled Release</i> , 2021, 329, 353-360.	4.8	13
8857	Toxicities Associated with Immunotherapy and Approach to Cardiotoxicity with Novel Cancer Therapies. <i>Critical Care Clinics</i> , 2021, 37, 47-67.	1.0	5
8858	State of Melanoma. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 1-27.	0.9	4
8859	Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2021, 16, 223-249.	9.6	956
8860	The application of nano-medicine to overcome the challenges related to immune checkpoint blockades in cancer immunotherapy: Recent advances and opportunities. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103160.	2.0	26
8861	High-dose per Fraction Radiotherapy Induces Both Antitumor Immunity and Immunosuppressive Responses in Prostate Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 1505-1515.	3.2	36
8862	Clinical features of immune-mediated hepatotoxicity induced by immune checkpoint inhibitors in patients with cancers. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 1747-1756.	1.2	11
8863	Ipilimumab and Radiation in Patients with High-risk Resected or Regionally Advanced Melanoma. <i>Clinical Cancer Research</i> , 2021, 27, 1287-1295.	3.2	2
8864	CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab). <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1781-1788.	2.0	22
8865	Adjuvant Therapy of Melanoma. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 73-84.	0.9	2
8866	Using Machine Learning Algorithms to Predict Immunotherapy Response in Patients with Advanced Melanoma. <i>Clinical Cancer Research</i> , 2021, 27, 131-140.	3.2	93
8867	microRNA expression patterns in tumor infiltrating lymphocytes are strongly associated with response to adoptive cell transfer therapy. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1541-1555.	2.0	4
8868	The Lipogenic Regulator SREBP2 Induces Transferrin in Circulating Melanoma Cells and Suppresses Ferroptosis. <i>Cancer Discovery</i> , 2021, 11, 678-695.	7.7	114
8869	Role, function and regulation of the thymocyte selection-associated high mobility group box protein in CD8+ T cell exhaustion. <i>Immunology Letters</i> , 2021, 229, 1-7.	1.1	9
8870	Radiotherapy and Immunotherapy Combinations for Lung Cancer. <i>Current Oncology Reports</i> , 2021, 23, 4.	1.8	11
8871	Immunostimulatory nanoparticle incorporating two immune agonists for the treatment of pancreatic tumors. <i>Journal of Controlled Release</i> , 2021, 330, 1095-1105.	4.8	34
8872	A Functional Chemiluminescent Probe for in Vivo Imaging of Natural Killer Cell Activity Against Tumours. <i>Angewandte Chemie - International Edition</i> , 2021, 60, 5699-5703.	7.2	81

#	ARTICLE	IF	CITATIONS
8874	Hyperprogressive disease in patients receiving immune checkpoint inhibitors. <i>Current Problems in Cancer</i> , 2021, 45, 100688.	1.0	5
8875	Nano-immunotherapy: Unique mechanisms of nanomaterials in synergizing cancer immunotherapy. <i>Nano Today</i> , 2021, 36, 101023.	6.2	45
8876	The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study. <i>European Heart Journal</i> , 2021, 42, 1621-1631.	1.0	102
8877	Oxidized Lipoproteins Promote Resistance to Cancer Immunotherapy Independent of Patient Obesity. <i>Cancer Immunology Research</i> , 2021, 9, 214-226.	1.6	18
8878	Self-Adjuvanted Molecular Activator (SeaMac) Nanovaccines Promote Cancer Immunotherapy. <i>Advanced Healthcare Materials</i> , 2021, 10, e2002080.	3.9	20
8879	Considerations when treating high-grade pediatric glioma patients with immunotherapy. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 205-219.	1.4	5
8880	Exploring the relationship between Overall Survival (OS), Progression Free Survival (PFS) and Objective Response Rate (ORR) in patients with advanced melanoma. <i>Cancer Treatment and Research Communications</i> , 2021, 26, 100272.	0.7	3
8881	Current status of PD-1/PD-L1 blockade immunotherapy in breast cancer. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 321-332.	0.6	22
8882	Current status of cancer immunotherapy for gynecologic malignancies. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 167-172.	0.6	16
8883	Discordance of immunotherapy response predictive biomarkers between primary lesions and paired metastases in tumours: A systematic review and meta-analysis. <i>EBioMedicine</i> , 2021, 63, 103137.	2.7	44
8884	A Functional Chemiluminescent Probe for in Vivo Imaging of Natural Killer Cell Activity Against Tumours. <i>Angewandte Chemie</i> , 2021, 133, 5763-5767.	1.6	8
8885	A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study. <i>Clinical Cancer Research</i> , 2021, 27, 1631-1640.	3.2	70
8886	A group sequential design and sample size estimation for an immunotherapy trial with a delayed treatment effect. <i>Statistical Methods in Medical Research</i> , 2021, 30, 904-915.	0.7	5
8887	Endocrine Adverse Events Caused by Different Types and Different Doses of Immune Checkpoint Inhibitors in the Treatment of Solid Tumors: A Meta-Analysis and Systematic Review. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 282-297.	1.0	6
8888	Predictive Biomarkers for Immune Checkpoint Inhibitors in Metastatic Breast Cancer. <i>Cancer Medicine</i> , 2021, 10, 53-61.	1.3	39
8889	New-generation anticancer drugs and medication-related osteonecrosis of the jaw (MRONJ): Late onset 3 years after ipilimumab endovenous administration with a possible role of target therapy. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, 61-66.	0.2	7
8890	Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial. <i>Targeted Oncology</i> , 2021, 16, 47-57.	1.7	8
8891	Real-world, population-based cohort study of toxicity and resource utilization of second-line ipilimumab for metastatic melanoma in Ontario, Canada. <i>International Journal of Cancer</i> , 2021, 148, 1910-1918.	2.3	4

#	ARTICLE	IF	CITATIONS
8892	The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker. <i>Cancer Cell</i> , 2021, 39, 154-173.	7.7	491
8893	Studying Immunotherapy Resistance in a Melanoma Autologous Humanized Mouse Xenograft. <i>Molecular Cancer Research</i> , 2021, 19, 346-357.	1.5	6
8894	Emerging Immunotherapies in the Treatment of Brain Metastases. <i>Oncologist</i> , 2021, 26, 231-241.	1.9	29
8895	Human CXCR5 ⁺ PD-1 ⁺ CD8 T cells in healthy individuals and patients with hematologic malignancies. <i>European Journal of Immunology</i> , 2021, 51, 703-713.	1.6	11
8896	Effect of adoptive T-cell immunotherapy on immunological parameters and prognosis in patients with advanced pancreatic cancer. <i>Cytotherapy</i> , 2021, 23, 137-145.	0.3	10
8897	Combinatorial Approaches to the Treatment of Advanced Melanoma. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 145-158.	0.9	5
8898	CT, MRI and PET/CT features of abdominal manifestations of cutaneous melanoma: a review of current concepts in the era of tumor-specific therapies. <i>Abdominal Radiology</i> , 2021, 46, 2219-2235.	1.0	14
8899	Abdominal immune-related adverse events: detection on ultrasonography, CT, MRI and 18F-Fluorodeoxyglucose positron emission tomography. <i>British Journal of Radiology</i> , 2021, 94, 20200663.	1.0	13
8900	The role of the microbiome in drug resistance in gastrointestinal cancers. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 165-176.	1.1	22
8901	Expression profile of immune checkpoint genes and their roles in predicting immunotherapy response. <i>Briefings in Bioinformatics</i> , 2021, 22, .	3.2	147
8902	Radiation therapy and molecular-targeted agents in preclinical testing for immunotherapy, brain tumors, and sarcomas: Opportunities and challenges. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28439.	0.8	1
8903	Network-based survival analysis to discover target genes for developing cancer immunotherapies and predicting patient survival. <i>Journal of Applied Statistics</i> , 2021, 48, 1352-1373.	0.6	3
8904	Health-related quality of life of long-term advanced melanoma survivors treated with anti-CTLA-4 immune checkpoint inhibition compared to matched controls. <i>Acta Oncologica</i> , 2021, 60, 69-77.	0.8	19
8905	Liver biopsy findings in patients on immune checkpoint inhibitors. <i>Modern Pathology</i> , 2021, 34, 426-437.	2.9	48
8906	Clinical Pharmacology and Interplay of Immune Checkpoint Agents: A Yin-Yang Balance. <i>Annual Review of Pharmacology and Toxicology</i> , 2021, 61, 85-112.	4.2	50
8907	Emerging cancer therapies and cardiovascular risk. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 837-845.	1.0	0
8908	Novel Clinical Trial Designs and Statistical Methods in the Era of Precision Medicine. <i>Statistics in Biopharmaceutical Research</i> , 2021, 13, 133-146.	0.6	3
8909	Current status and future perspectives of immunotherapy in bladder cancer treatment. <i>Science China Life Sciences</i> , 2021, 64, 512-533.	2.3	21

#	ARTICLE	IF	CITATIONS
8910	Hyperprogressive disease rarely occurs during checkpoint inhibitor treatment for advanced melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1491-1496.	2.0	15
8911	Pre-treatment high-sensitivity troponin T for the short-term prediction of cardiac outcomes in patients on immune checkpoint inhibitors. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13400.	1.7	17
8912	Reinvigorating exhausted CD8 ⁺ cytotoxic T lymphocytes in the tumor microenvironment and current strategies in cancer immunotherapy. <i>Medicinal Research Reviews</i> , 2021, 41, 156-201.	5.0	56
8913	Efficacy and safety of immune checkpoint inhibitors (ICIs) in extensive-stage small cell lung cancer (SCLC). <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 593-606.	1.2	10
8914	Evaluation of emergency departments visits in patients treated with immune checkpoint inhibitors. <i>Supportive Care in Cancer</i> , 2021, 29, 2029-2035.	1.0	7
8915	Nanomedicines as Multifunctional Modulators of Melanoma Immune Microenvironment. <i>Advanced Therapeutics</i> , 2021, 4, 2000147.	1.6	2
8916	Is single versus combination therapy problematic in the treatment of cutaneous melanoma?. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 9-23.	1.3	5
8917	Immune checkpoint: The novel target for antitumor therapy. <i>Genes and Diseases</i> , 2021, 8, 25-37.	1.5	27
8918	Chimeric antigen receptor T-cell therapy for melanoma. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 209-223.	1.3	12
8919	PD-1 and LAG-3 blockade improve anti-tumor vaccine efficacy. <i>Oncolmmunology</i> , 2021, 10, 1912892.	2.1	25
8920	Practical Management of Melanoma. , 2021, , 241-256.		0
8921	Introduction on Treatment for Infectious Diseases and Immunological Disorders. , 2021, ,		0
8922	Targeted Therapies in Cancer Treatment. , 2021, , 57-78.		1
8923	Metastatic cancer: How one can address the therapeutic challenge. , 2021, , 485-514.		0
8924	Leukemia: Trends in treatment and how close we have achieved eradication. , 2021, , 547-587.		0
8925	Adding Adjuvants to Fluoropyrimidine-based Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: An Option Worthy of Serious Consideration. <i>Journal of Cancer</i> , 2021, 12, 417-427.	1.2	2
8926	Immune cell infiltrates as prognostic biomarkers in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis. <i>Journal of Pathology: Clinical Research</i> , 2021, 7, 99-112.	1.3	14
8927	CTLA-4 expression by B-1a B cells is essential for immune tolerance. <i>Nature Communications</i> , 2021, 12, 525.	5.8	43

#	ARTICLE	IF	CITATIONS
8928	The Immune System and Responses to Cancer: Coordinated Evolution. <i>F1000Research</i> , 2015, 4, 552.	0.8	6
8929	Biomedical Engineering in Cancer Diagnosis and Therapy. , 2021, , 173-191.		0
8930	Penile Lymphoepithelioma-Like Carcinoma: A Rare Case With PD-L1 Expression. <i>International Journal of Surgical Pathology</i> , 2021, 29, 690-692.	0.4	2
8931	Modulation of Signaling Pathways by Immunotherapeutics in Lung Cancer. , 2021, , 241-261.		0
8932	Construction of an immune-related lncRNA pairs model to predict prognosis and immune landscape of lung adenocarcinoma patients. <i>Bioengineered</i> , 2021, 12, 4123-4135.	1.4	3
8933	Immune checkpoint inhibitors-associated risk of immune-related hypothyroidism in older patients with advanced melanoma: a real-world analysis of US SEER-Medicare data. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 489-497.	1.0	1
8934	Nivolumab-induced Vogt-Koyanagi-Harada-like Syndrome and Adrenocortical Insufficiency with Long-term Survival in a Patient with Non-small-cell Lung Cancer. <i>Internal Medicine</i> , 2021, 60, 3593-3598.	0.3	8
8936	Toxicities of Novel Antineoplastic Therapies. , 2021, , 711-738.		1
8937	Health Economic Studies Are Important for Patients With Irritable Bowel Syndrome and Their Gastroenterologists. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 43-45.	2.4	7
8938	Review of immune checkpoint inhibitors in immuno-oncology. <i>Advances in Pharmacology</i> , 2021, 91, 111-139.	1.2	43
8939	Next Generation Imaging Techniques to Define Immune Topographies in Solid Tumors. <i>Frontiers in Immunology</i> , 2020, 11, 604967.	2.2	12
8940	miRNA-Based Therapeutics in the Era of Immune-Checkpoint Inhibitors. <i>Pharmaceuticals</i> , 2021, 14, 89.	1.7	9
8941	Cancer Biology, Epidemiology, and Treatment in the 21st Century: Current Status and Future Challenges From a Biomedical Perspective. <i>Cancer Control</i> , 2021, 28, 107327482110387.	0.7	8
8942	Development of a prognostic model based on an immunogenomic landscape analysis of medulloblastoma. <i>Bioscience Reports</i> , 2021, 41, .	1.1	3
8943	Immuno-modulating Mediators of Colon Cancer as Immuno-therapeutic: Mechanism and Potential. , 2021, , 271-308.		0
8944	Development of a Non-IgG PD-1/PD-L1 Inhibitor by <i>in Silico</i> Mutagenesis and an In-Cell Protein-Protein Interaction Assay. <i>ACS Chemical Biology</i> , 2021, 16, 316-323.	1.6	7
8945	Narrative review of cytokines and cell surface markers in the tumor microenvironment of stage I lung cancer. <i>AME Medical Journal</i> , 0, 6, 39-39.	0.4	0
8946	Malignant Melanoma: From Molecular Characterization to Targeted Therapies. , 2021, , .		0

#	ARTICLE	IF	CITATIONS
8947	Immunotherapy for Pancreatic Cancer and Cholangiocarcinoma. , 2021, , 185-194.		0
8948	Therapeutic options for the management of cervical cancer. , 2021, , 193-212.		0
8949	Critical Analysis of Immune Checkpoint Inhibitor Immunotoxicity Management. SN Comprehensive Clinical Medicine, 2021, 3, 84-94.	0.3	0
8950	Interactions between Biomedical Microâ€¦Nanoâ€¦Motors and the Immune Molecules, Immune Cells, and the Immune System: Challenges and Opportunities. Advanced Healthcare Materials, 2021, 10, e2001788.	3.9	32
8951	Imaging of Response to Radiosurgery and Immunotherapy in Brain Metastases: Quo Vadis?. Current Treatment Options in Neurology, 2021, 23, 1.	0.7	0
8952	Human gut microbial communities dictate efficacy of anti-PD-1 therapy in a humanized microbiome mouse model of glioma. Neuro-Oncology Advances, 2021, 3, vtab023.	0.4	10
8953	Ipilimumab in Melanoma: An Evergreen Drug. , 2021, , 217-235.		0
8954	Melanin Chemistry. , 2021, , 1-31.		0
8955	Targeting MDSC for Immune-Checkpoint Blockade in Cancer Immunotherapy: Current Progress and New Prospects. Clinical Medicine Insights: Oncology, 2021, 15, 117955492110355.	0.6	45
8956	Tumor-intrinsic determinants of immunogenic cell death modalities. OncoImmunology, 2021, 10, 1893466.	2.1	30
8957	Assessing immune organs on 18F-FDG PET/CT imaging for therapy monitoring of immune checkpoint inhibitors: inter-observer variability, prognostic value and evolution during the treatment course of melanoma patients. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2573-2585.	3.3	35
8958	Immunotherapy-Associated Cardiotoxicity of Immune Checkpoint Inhibitors and Chimeric Antigen Receptor T Cell Therapy: Diagnostic and Management Challenges and Strategies. Current Cardiology Reports, 2021, 23, 11.	1.3	35
8962	YY1 expression and PD-1 regulation in CD8 T lymphocytes. , 2021, , 289-309.		1
8963	Immune Checkpoint Inhibitor with or without Radiotherapy in Melanoma Patients with Brain Metastases: A Systematic Review and Meta-Analysis. Korean Journal of Radiology, 2021, 22, 584.	1.5	12
8964	Cancer Immunotherapy: Overview of Immune Checkpoint Inhibitors. , 2021, , 31-47.		0
8965	Colon cancer and immunotherapyâ€”can we go beyond microsatellite instability?. Translational Gastroenterology and Hepatology, 2021, 6, 12-12.	1.5	19
8966	Antibody-mediated delivery of LIGHT to the tumor boosts natural killer cells and delays tumor progression. MAbs, 2021, 13, 1868066.	2.6	2
8967	Breast Cancer Metastasis. Advances in Experimental Medicine and Biology, 2021, 1187, 183-204.	0.8	30

#	ARTICLE	IF	CITATIONS
8968	A Case of Guillain-Barré Syndrome and Stevens-Johnson Syndrome/Toxic Epidermal Necrosis Overlap After Pembrolizumab Treatment. <i>Journal of Investigative Medicine High Impact Case Reports</i> , 2021, 9, 232470962110374.	0.3	5
8969	Prognostic Value of PLXND1 and TGF- β 21 Coexpression and Its Correlation With Immune Infiltrates in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 604131.	1.3	13
8970	The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial. <i>Investigational New Drugs</i> , 2021, 39, 829-835.	1.2	8
8971	A narrative review of immune checkpoint mechanisms and current immune checkpoint therapy. <i>Annals of Blood</i> , 0, 7, 33-33.	0.4	3
8972	Understanding the Role of Plasticity in Glioblastoma. , 2021, , .		0
8973	Prevalence, therapy and tumour response in patients with rheumatic immune-related adverse events following immune checkpoint inhibitor therapy: a single-centre analysis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110069.	1.2	13
8974	Transcriptional Profiling of Macrophages <i>in situ</i> in Metastatic Melanoma Reveals Localization-Dependent Phenotypes and Function. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
8975	Potentiality of multiple modalities for single-cell analyses to evaluate the tumor microenvironment in clinical specimens. <i>Scientific Reports</i> , 2021, 11, 341.	1.6	17
8976	Next-Generation Immunotherapies to Improve Anticancer Immunity. <i>Frontiers in Pharmacology</i> , 2020, 11, 566401.	1.6	8
8977	Melanoom en andere huidtumoren. , 2021, , 515-526.		0
8978	Cutaneous Malignant Melanoma: A Review of Early Diagnosis and Management. <i>World Journal of Oncology</i> , 2021, 12, 7-19.	0.6	53
8979	Clinical Proteomics of Metastatic Melanoma Reveals Profiles of Organ Specificity and Treatment Resistance. <i>Clinical Cancer Research</i> , 2021, 27, 2074-2086.	3.2	12
8980	Concomitant Proton Pump Inhibitors and Immune Checkpoint Inhibitors Increase Nephritis Frequency. <i>In Vivo</i> , 2021, 35, 2831-2840.	0.6	12
8981	Auswirkungen von Chemotherapeutika auf zirkulierende Leukozytenpopulationen: Mögliche Implikationen für den Erfolg von CAR-T-Zell-Therapien. <i>Karger Kompass Onkologie</i> , 2021, 8, 116-127.	0.0	0
8982	Acute pancreatitis induced by drugs used in the treatment of solid malignant neoplasms. <i>Onkologiya Zhurnal Imeni P A Gertsena</i> , 2021, 10, 46.	0.0	0
8983	Diseases of the Vulva. , 2021, , 1-34.		0
8984	Immune System Efficiency in Cancer and the Microbiota Influence. <i>Pathobiology</i> , 2021, 88, 170-186.	1.9	14
8985	Overcoming therapeutic resistance in glioblastoma: Moving beyond the sole targeting of the glioma cells. , 2021, , 91-118.		0

#	ARTICLE	IF	CITATIONS
8986	Industrial Perspective on Immunotherapy. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1295, 327-347.	0.8	0
8988	Fine-Tuning the Tumour Microenvironment: Current Perspectives on the Mechanisms of Tumour Immunosuppression. <i>Cells</i> , 2021, 10, 56.	1.8	14
8989	Skin Cancer: Molecular Biomarker for Diagnosis, Prognosis, Prevention, and Targeted Therapy. , 2021, , 101-130.		0
8990	Overcoming Therapeutic Challenges for Pancreatic Ductal with xCT Inhibitors. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1301, 7-24.	0.8	1
8991	Gold digging: Searching for gut microbiota that enhances Antitumor immunity. <i>Journal of Cellular Physiology</i> , 2021, 236, 5495-5511.	2.0	2
8992	Association of acute interstitial nephritis with nivolumab in renal cell carcinoma: A case report. <i>Indian Journal of Nephrology</i> , 2021, 31, 303.	0.2	1
8993	Conventional Radiological Techniques and PET-CT in Treatment Response Evaluation in Immunotherapy Settings. , 2021, , 83-99.		0
8994	No Impact of NRAS Mutation on Features of Primary and Metastatic Melanoma or on Outcomes of Checkpoint Inhibitor Immunotherapy: An Italian Melanoma Intergroup (IMI) Study. <i>Cancers</i> , 2021, 13, 475.	1.7	20
8995	Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy. , 2021, 9, e001642.		28
8996	Tumor infiltrating lymphocyte clusters are associated with response to immune checkpoint inhibition in BRAF V600E/K mutated malignant melanomas. <i>Scientific Reports</i> , 2021, 11, 1834.	1.6	27
8997	Mechanisms and Management of Immune Checkpoint Inhibitor-Related Cardiac Adverse Events. <i>JMA Journal</i> , 2021, 4, 91-98.	0.6	13
8998	Efficacy and safety of anti-PD-1/PD-L1 combinations versus standard of care in cancer: a systematic review and meta-analysis.. <i>Oncology</i> , 2021, 10, 1878599.	2.1	11
8999	The Current Landscape of Antibody-based Therapies in Solid Malignancies. <i>Theranostics</i> , 2021, 11, 1493-1512.	4.6	20
9000	Generation of triacyl lipopeptide-modified glycoproteins by metabolic glycoengineering as the neoantigen to boost anti-tumor immune response. <i>Theranostics</i> , 2021, 11, 7425-7438.	4.6	7
9001	Immunotherapy in colorectal cancer. <i>Advances in Cancer Research</i> , 2021, 151, 137-196.	1.9	18
9002	Research Interest and Public Interest in Melanoma: A Bibliometric and Google Trends Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 629687.	1.3	15
9003	A 4 Gene-based Immune Signature Predicts Dedifferentiation and Immune Exhaustion in Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e3208-e3220.	1.8	5
9004	Clinical Practice Guideline on Melanoma From the Spanish Academy of Dermatology and Venereology (AEDV). <i>Actas Dermo-sifiliográficas</i> , 2021, 112, 142-152.	0.2	2

#	ARTICLE	IF	CITATIONS
9005	Are radiologists ready to evaluate true response to immunotherapy?. <i>Insights Into Imaging</i> , 2021, 12, 29.	1.6	5
9006	Introduction: Immuno-oncology seminar. <i>Journal of Surgical Oncology</i> , 2021, 123, 708-709.	0.8	0
9007	Monoclonal Antibodies: A Prospective and Retrospective View. <i>Current Medicinal Chemistry</i> , 2021, 28, 435-471.	1.2	8
9008	Efficacy and safety of Infliximab for steroid-resistant immune-related adverse events: A retrospective study. <i>Molecular and Clinical Oncology</i> , 2021, 14, 65.	0.4	14
9009	Vaccine Increases the Diversity and Activation of Intratumoral T Cells in the Context of Combination Immunotherapy. <i>Cancers</i> , 2021, 13, 968.	1.7	9
9010	Neoantigen-based vaccines as a promising strategy in cancer immunotherapeutics. <i>Immunomedicine</i> , 2021, 1, e1021.	0.7	1
9011	Epitope spreading toward wild-type melanocyte-lineage antigens rescues suboptimal immune checkpoint blockade responses. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	54
9012	Ratio of the interferon- γ signature to the immunosuppression signature predicts anti-PD-1 therapy response in melanoma. <i>Npj Genomic Medicine</i> , 2021, 6, 7.	1.7	41
9013	Lights and Shadows in Immuno-Oncology Drug Development. <i>Cancers</i> , 2021, 13, 691.	1.7	0
9014	From antibodies to living drugs: Quo vadis cancer immunotherapy?. <i>Biologia Futura</i> , 2021, 72, 85-99.	0.6	2
9016	Tumor immunogenomic signatures improve a prognostic model of melanoma survival. <i>Journal of Translational Medicine</i> , 2021, 19, 78.	1.8	4
9017	Synthetic TILs: Engineered Tumor-Infiltrating Lymphocytes With Improved Therapeutic Potential. <i>Frontiers in Oncology</i> , 2020, 10, 593848.	1.3	12
9018	The evolving landscape of immunotherapy in solid tumors. <i>Journal of Surgical Oncology</i> , 2021, 123, 798-806.	0.8	17
9019	Impact of cancer evolution on immune surveillance and checkpoint inhibitor response. <i>Seminars in Cancer Biology</i> , 2022, 84, 89-102.	4.3	21
9020	Targeting tumor-associated macrophages to synergize tumor immunotherapy. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 75.	7.1	323
9021	Immunotherapy for the treatment of colorectal cancer. <i>Journal of Surgical Oncology</i> , 2021, 123, 760-774.	0.8	18
9022	Immune cell engagers in solid tumors: promises and challenges of the next generation immunotherapy. <i>ESMO Open</i> , 2021, 6, 100046.	2.0	25
9023	Adjuvant immunotherapy for melanoma. <i>Journal of Surgical Oncology</i> , 2021, 123, 789-797.	0.8	20

#	ARTICLE	IF	CITATIONS
9024	Immune Checkpoint Inhibitor-Induced Diabetes Mellitus: Potential Role of T Cells in the Underlying Mechanism. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2093.	1.8	17
9025	Pituitary enlargement following ipilimumab without long term endocrine dysfunction. <i>Current Problems in Cancer</i> , 2021, 45, 100710.	1.0	1
9026	Enhancing the Generation of Eomeshi CD8+ T Cells Augments the Efficacy of OX40- and CTLA-4 ^{hi} Targeted Immunotherapy. <i>Cancer Immunology Research</i> , 2021, 9, 430-440.	1.6	8
9027	Examining the Relationship between Circulating CD4 ^{hi} CD8 ^{hi} Double-Negative T Cells and Outcomes of Immuno-Checkpoint Inhibitor Therapy ^{hi} Looking for Biomarkers and Therapeutic Targets in Metastatic Melanoma. <i>Cells</i> , 2021, 10, 406.	1.8	7
9028	Integrase-Defective Lentiviral Vector Is an Efficient Vaccine Platform for Cancer Immunotherapy. <i>Viruses</i> , 2021, 13, 355.	1.5	17
9029	The efficacy of immunotherapy for in-transit metastases of melanoma: an analysis of randomized controlled trials. <i>Melanoma Research</i> , 2021, 31, 181-185.	0.6	14
9030	Cancer cell heterogeneity & plasticity in glioblastoma and brain tumors. <i>Seminars in Cancer Biology</i> , 2022, 82, 162-175.	4.3	58
9031	Oxidation of Innate Immune Checkpoint CD47 on Cancer Cells with Non-Thermal Plasma. <i>Cancers</i> , 2021, 13, 579.	1.7	26
9032	Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 435-453.	12.5	31
9033	Re-evaluation of Sentinel Lymph Node Biopsy for Melanoma. <i>Current Treatment Options in Oncology</i> , 2021, 22, 22.	1.3	16
9034	Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade. <i>Cancer Discovery</i> , 2021, 11, 1524-1541.	7.7	103
9035	Molecular and Clinicopathological Characterization of a Prognostic Immune Gene Signature Associated With MGMT Methylation in Glioblastoma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 600506.	1.8	5
9036	Immune checkpoint inhibition in COVID-19: risks and benefits. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 1173-1179.	1.4	27
9037	Prognosticating role of serum eosinophils on immunotherapy efficacy in patients with advanced melanoma. <i>Immunotherapy</i> , 2021, 13, 217-225.	1.0	6
9038	The Tumor Microenvironment in SCC: Mechanisms and Therapeutic Opportunities. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 636544.	1.8	10
9039	T cell immune regulator 1 is a prognostic marker associated with immune infiltration in glioblastoma multiforme. <i>Oncology Letters</i> , 2021, 21, 252.	0.8	8
9040	Defining and Targeting BRAF Mutations in Solid Tumors. <i>Current Treatment Options in Oncology</i> , 2021, 22, 30.	1.3	25
9041	Proteomic profile of melanoma cell ^{hi} derived small extracellular vesicles in patients ^{hi} plasma: a potential correlate of melanoma progression. <i>Journal of Extracellular Vesicles</i> , 2021, 10, e12063.	5.5	38

#	ARTICLE	IF	CITATIONS
9042	Effectiveness and safety of nivolumab in patients with advanced melanoma: A multicenter, observational study. <i>International Journal of Cancer</i> , 2021, 148, 2789-2798.	2.3	5
9043	Tackling cancer cell dormancy: Insights from immune models, and transplantation. <i>Seminars in Cancer Biology</i> , 2022, 78, 5-16.	4.3	9
9044	Local Depletion of Immune Checkpoint Ligand CTLA4 Expressing Cells in Tumor Beds Enhances Antitumor Host Immunity. <i>Advanced Therapeutics</i> , 2021, 4, 2000269.	1.6	27
9045	Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects. <i>Frontiers in Oncology</i> , 2020, 10, 600573.	1.3	100
9046	Correlations Between Tumor Mutation Burden and Immunocyte Infiltration and Their Prognostic Value in Colon Cancer. <i>Frontiers in Genetics</i> , 2021, 12, 623424.	1.1	20
9047	The association between immune checkpoint or BRAF/MEK inhibitor therapy and uveitis in patients with advanced cutaneous melanoma. <i>European Journal of Cancer</i> , 2021, 144, 215-223.	1.3	9
9048	Low immunogenicity of common cancer hot spot mutations resulting in false immunogenic selection signals. <i>PLoS Genetics</i> , 2021, 17, e1009368.	1.5	19
9049	Characterizing tumor shrinkage as a measure of clinical benefit for immune checkpoint inhibitors. , 2021, 9, e001177.		0
9050	Imaging of Oncologic Treatment-Related Pneumonitis: A Focused Review on Emerging Issues of Immune-Checkpoint Inhibitor Pneumonitis, From the AJR Special Series on Inflammation. <i>American Journal of Roentgenology</i> , 2021, , 1-9.	1.0	7
9051	Management of COVID-19 in cancer patients receiving cardiotoxic anti-cancer therapy. Future recommendations for cardio-oncology. <i>Oncology Reviews</i> , 2021, 15, 510.	0.8	2
9052	Murine cancer cachexia models replicate elevated catabolic pembrolizumab clearance in humans. <i>JCSM Rapid Communications</i> , 2021, 4, 232-244.	0.6	6
9053	Molecular profiling of Asian patients with advanced melanoma receiving check-point inhibitor treatment. <i>ESMO Open</i> , 2021, 6, 100002.	2.0	12
9054	Immunotherapy Targeting Myeloid-Derived Suppressor Cells (MDSCs) in Tumor Microenvironment. <i>Frontiers in Immunology</i> , 2020, 11, 585214.	2.2	30
9055	Harnessing Tumor Necrosis Factor Alpha to Achieve Effective Cancer Immunotherapy. <i>Cancers</i> , 2021, 13, 564.	1.7	46
9056	Immune checkpoint inhibitors. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	27
9057	Radiotherapy and Immunotherapy for Head and Neck Cancer: Current Evidence and Challenges. <i>Frontiers in Oncology</i> , 2020, 10, 608772.	1.3	30
9058	Tumor Burden and Immunotherapy: Impact on Immune Infiltration and Therapeutic Outcomes. <i>Frontiers in Immunology</i> , 2020, 11, 629722.	2.2	75
9059	Immunotherapy with 4-1BBL-Expressing iPS Cell-Derived Myeloid Lines Amplifies Antigen-Specific T Cell Infiltration in Advanced Melanoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1958.	1.8	5

#	ARTICLE	IF	CITATIONS
9060	Decoding Melanoma Development and Progression: Identification of Therapeutic Vulnerabilities. <i>Frontiers in Oncology</i> , 2020, 10, 626129.	1.3	48
9061	Maintenance Therapy in AML. <i>Frontiers in Oncology</i> , 2020, 10, 619085.	1.3	14
9062	Automated digital TIL analysis (ADTA) adds prognostic value to standard assessment of depth and ulceration in primary melanoma. <i>Scientific Reports</i> , 2021, 11, 2809.	1.6	20
9063	Long-Term Progression-Free Survival of Patients with Metastatic Melanoma or Renal Cell Carcinoma following High-Dose Interleukin-2. <i>Journal of Investigative Medicine</i> , 2021, 69, 888-892.	0.7	10
9064	Combination of radiation therapy for brain metastasis and anti-PD-1/PD-L1 treatment in non-small cell lung cancer: two cases and review of the literature. <i>Anti-Cancer Drugs</i> , 2021, 32, 460-464.	0.7	1
9065	Cancer Vaccines: Adjuvant Potency, Importance of Age, Lifestyle, and Treatments. <i>Frontiers in Immunology</i> , 2020, 11, 615240.	2.2	59
9066	Involvement of Cellular Prion Protein in Invasion and Metastasis of Lung Cancer by Inducing Treg Cell Development. <i>Biomolecules</i> , 2021, 11, 285.	1.8	9
9067	Nanomedicine-based cancer immunotherapy: recent trends and future perspectives. <i>Cancer Gene Therapy</i> , 2021, 28, 911-923.	2.2	44
9068	Role of gut microbiome in the outcome of cancer immunotherapy. <i>International Journal of Cancer</i> , 2021, 149, 760-768.	2.3	3
9069	Checkpoint inhibitor-induced autoimmune central nervous system disorder in patients with metastatic melanoma and Hodgkin's lymphoma. <i>Clinical and Experimental Neuroimmunology</i> , 2021, 12, 127-134.	0.5	1
9070	Recent Progress in Nanomedicine for Melanoma Theranostics With Emphasis on Combination Therapy. <i>Frontiers in Bioengineering and Biotechnology</i> , 2021, 9, 661214.	2.0	7
9071	The Entire Intestinal Tract Surveillance Using Capsule Endoscopy after Immune Checkpoint Inhibitor Administration: A Prospective Observational Study. <i>Diagnostics</i> , 2021, 11, 543.	1.3	3
9072	New immunological potential markers for triple negative breast cancer: IL18R1, CD53, TRIM, Jaw1, LTB, PTPRCAP. <i>Discover Oncology</i> , 2021, 12, 6.	0.8	10
9073	Emerging Trends for Radio-Immunotherapy in Rectal Cancer. <i>Cancers</i> , 2021, 13, 1374.	1.7	18
9074	Alternative Splicing of the Inhibitory Immune Checkpoint Receptor SLAMF6 Generates a Dominant Positive Form, Boosting T-cell Effector Functions. <i>Cancer Immunology Research</i> , 2021, 9, 637-650.	1.6	6
9075	Therapeutic Targeting of Checkpoint Receptors within the DNAM1 Axis. <i>Cancer Discovery</i> , 2021, 11, 1040-1051.	7.7	24
9076	Multimarker scores of Th1 and Th2 immune cellular profiles in peripheral blood predict response and immune related toxicity with CTLA4 blockade and IFN± in melanoma. <i>Translational Oncology</i> , 2021, 14, 101014.	1.7	13
9077	Immune checkpoint inhibitors and cellular treatment for lymphoma immunotherapy. <i>Clinical and Experimental Immunology</i> , 2021, 205, 1-11.	1.1	11

#	ARTICLE	IF	CITATIONS
9078	Immune-related adverse events and immune checkpoint inhibitor tolerance on rechallenge in patients with irAEs: a single-center experience. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 2789-2800.	1.2	11
9079	Immuno-oncology: a narrative review of gastrointestinal and hepatic toxicities. <i>Annals of Translational Medicine</i> , 2021, 9, 423-423.	0.7	6
9080	Checkpoint blockade toxicities: Insights into autoimmunity and treatment. <i>Seminars in Immunology</i> , 2021, 52, 101473.	2.7	11
9081	Quantitative Dynamic 18F-FDG PET/CT in Survival Prediction of Metastatic Melanoma under PD-1 Inhibitors. <i>Cancers</i> , 2021, 13, 1019.	1.7	12
9082	An Update on the Role of Ubiquitination in Melanoma Development and Therapies. <i>Journal of Clinical Medicine</i> , 2021, 10, 1133.	1.0	7
9083	Oncolytic vaccinia virus induces a novel phenotype of CD8+ effector T cells characterized by high ICOS expression. <i>Molecular Therapy - Oncolytics</i> , 2021, 20, 422-432.	2.0	5
9084	Melanoma cutáneo. <i>Medicine</i> , 2021, 13, 1493-1505.	0.0	1
9085	Multimodal Non-Surgical Treatments of Aggressive Pituitary Tumors. <i>Frontiers in Endocrinology</i> , 2021, 12, 624686.	1.5	13
9086	Pharmacological Interventions for the Prevention and Treatment of Immune Checkpoint Inhibitor-Associated Enterocolitis: A Systematic Review. <i>Digestive Diseases and Sciences</i> , 2022, 67, 1128-1155.	1.1	4
9087	Host response to immune checkpoint inhibitors contributes to tumor aggressiveness. , 2021, 9, e001996.		9
9088	Immunotherapy and predictive immunologic profile: the tip of the iceberg. <i>Medical Oncology</i> , 2021, 38, 51.	1.2	4
9089	Melanoma primario de cuello uterino: Reporte de caso. <i>Revista Colombiana De Cancerología</i> , 2021, 25, .	0.0	0
9090	Hypophysitis due to Immune Checkpoint Inhibitors. <i>Endocrinology and Disorders</i> , 2021, 5, 01-07.	0.1	0
9091	Immunotherapy in Advanced Biliary Tract Cancers. <i>Cancers</i> , 2021, 13, 1569.	1.7	19
9092	Radiotherapy as an immune checkpoint blockade combination strategy for hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2021, 27, 919-927.	1.4	14
9093	Temporal Trends and Outcomes Among Patients Admitted for Immune-Related Adverse Events: A Single-Center Retrospective Cohort Study from 2011 to 2018. <i>Oncologist</i> , 2021, 26, 514-522.	1.9	18
9094	Expression and immunogenicity assessment of a plant-made immunogen targeting the cytotoxic T-lymphocyte associated antigen-4: a possible approach for cancer immunotherapy. <i>Journal of Biotechnology</i> , 2021, 329, 29-37.	1.9	9
9095	Characterization of genetics in patients with mucosal melanoma treated with immune checkpoint blockade. <i>Cancer Medicine</i> , 2021, 10, 2627-2635.	1.3	5

#	ARTICLE	IF	CITATIONS
9096	Validation of the American Joint Committee on Cancer Eighth Edition Staging of Patients With Metastatic Cutaneous Melanoma Treated With Immune Checkpoint Inhibitors. <i>JAMA Network Open</i> , 2021, 4, e210980.	2.8	16
9098	Development of a poor-prognostic-mutations derived immune prognostic model for acute myeloid leukemia. <i>Scientific Reports</i> , 2021, 11, 4856.	1.6	7
9099	Discovery of Diaminopyrimidine Carboxamide HPK1 Inhibitors as Preclinical Immunotherapy Tool Compounds. <i>ACS Medicinal Chemistry Letters</i> , 2021, 12, 653-661.	1.3	18
9100	National early access programs and clinical trials: What opportunities for early access to therapeutic innovations for patients with malignant melanoma?. <i>Cancer</i> , 2021, 127, 2181-2183.	2.0	2
9101	Targeting the Tumor Microenvironment for Improving Therapeutic Effectiveness in Cancer Immunotherapy: Focusing on Immune Checkpoint Inhibitors and Combination Therapies. <i>Cancers</i> , 2021, 13, 1188.	1.7	27
9102	Chest CT Diagnosis and Clinical Management of Drug-related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper from the Fleischner Society. <i>Radiology</i> , 2021, 298, 550-566.	3.6	53
9103	Cancer Cell Membrane Camouflaged Mesoporous Silica Nanoparticles Combined with Immune Checkpoint Blockade for Regulating Tumor Microenvironment and Enhancing Antitumor Therapy. <i>International Journal of Nanomedicine</i> , 2021, Volume 16, 2107-2121.	3.3	30
9104	Cancer Vaccines, Adjuvants, and Delivery Systems. <i>Frontiers in Immunology</i> , 2021, 12, 627932.	2.2	78
9105	Promises and challenges of adoptive T-cell therapies for solid tumours. <i>British Journal of Cancer</i> , 2021, 124, 1759-1776.	2.9	113
9106	Rational nanocarrier design towards clinical translation of cancer nanotherapy. <i>Biomedical Materials (Bristol)</i> , 2021, 16, 032005.	1.7	14
9107	The Evolving Immunotherapy Landscape and the Epidemiology, Diagnosis, and Management of Cardiototoxicity. <i>JACC: CardioOncology</i> , 2021, 3, 35-47.	1.7	80
9108	Integrative Analysis of the Expression of SIGLEC Family Members in Lung Adenocarcinoma via Data Mining. <i>Frontiers in Oncology</i> , 2021, 11, 608113.	1.3	7
9109	Targeting Genome Stability in Melanoma—A New Approach to an Old Field. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3485.	1.8	4
9110	Immune Checkpoint Inhibitor-Based Strategies for Synergistic Cancer Therapy. <i>Advanced Healthcare Materials</i> , 2021, 10, e2002104.	3.9	47
9111	Advanced Nanotechnology for Enhancing Immune Checkpoint Blockade Therapy. <i>Nanomaterials</i> , 2021, 11, 661.	1.9	23
9112	Mitochondrial Inhibition: a Treatment Strategy in Cancer?. <i>Current Oncology Reports</i> , 2021, 23, 49.	1.8	11
9113	A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies. <i>Clinical Cancer Research</i> , 2021, 27, 3050-3060.	3.2	24
9114	Cutaneous melanoma: cost of illness under Brazilian health system perspectives. <i>BMC Health Services Research</i> , 2021, 21, 284.	0.9	6

#	ARTICLE	IF	CITATIONS
9115	Immunotherapy for Hepatocellular Carcinoma: Current Limits and Prospects. <i>Frontiers in Oncology</i> , 2021, 11, 589680.	1.3	23
9116	Immune Cell Profiling of Peripheral Blood as Signature for Response During Checkpoint Inhibition Across Cancer Types. <i>Frontiers in Oncology</i> , 2021, 11, 558248.	1.3	17
9117	Sex- and Gender-Based Pharmacological Response to Drugs. <i>Pharmacological Reviews</i> , 2021, 73, 730-762.	7.1	80
9118	Peptide-based therapeutic cancer vaccine: Current trends in clinical application. <i>Cell Proliferation</i> , 2021, 54, e13025.	2.4	68
9119	Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	84
9120	TIGIT-related transcriptome profile and its association with tumor immune microenvironment in breast cancer. <i>Bioscience Reports</i> , 2021, 41, .	1.1	9
9121	Drug-Related Pneumonitis in Cancer Treatment during the COVID-19 Era. <i>Cancers</i> , 2021, 13, 1052.	1.7	5
9122	Pembrolizumab-Induced Lichenoid Dermatitis in a Patient With Metastatic Cancer of Unknown Primary. <i>Cureus</i> , 2021, 13, e13768.	0.2	3
9123	The Role of Immune Checkpoint Therapy in Propagating Neurologic Immune-Related Adverse Events. <i>Neurology</i> , 2021, 96, 733-734.	1.5	6
9124	Use of checkpoint inhibitors in patients with lymphoid malignancies receiving allogeneic cell transplantation: a review. <i>Bone Marrow Transplantation</i> , 2021, 56, 1784-1793.	1.3	5
9125	Cutaneous Squamous Cell Carcinoma in the Age of Immunotherapy. <i>Cancers</i> , 2021, 13, 1148.	1.7	19
9126	A signature of estimate-stromal-immune score-based genes associated with the prognosis of lung adenocarcinoma. <i>Translational Lung Cancer Research</i> , 2021, 10, 1484-1500.	1.3	22
9127	Thinking Small: Small Molecules as Potential Synergistic Adjuncts to Checkpoint Inhibition in Melanoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3228.	1.8	5
9128	Detect it so you can treat it: A case series and proposed checklist to detect neurotoxicity in checkpoint therapy. <i>ENeurologicalSci</i> , 2021, 22, 100324.	0.5	9
9129	Neurologic Adverse Events of Immune Checkpoint Inhibitors. <i>Neurology</i> , 2021, 96, 754-766.	1.5	109
9130	Ageing, cancer, and antitumor immunity. <i>International Journal of Clinical Oncology</i> , 2022, 27, 316-322.	1.0	29
9131	Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti-PD-1 Refractory Melanoma. <i>Cancer Discovery</i> , 2021, 11, 1996-2013.	7.7	32
9132	Adverse Events Following Administration of Anti-CTLA4 Antibody Ipilimumab. <i>Frontiers in Oncology</i> , 2021, 11, 624780.	1.3	14

#	ARTICLE	IF	CITATIONS
9133	T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitors. <i>Nature Communications</i> , 2021, 12, 1402.	5.8	85
9134	Chest CT Diagnosis and Clinical Management of Drug-Related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors. <i>Chest</i> , 2021, 159, 1107-1125.	0.4	53
9135	Ligand Bound Fatty Acid Binding Protein 7 (FABP7) Drives Melanoma Cell Proliferation Via Modulation of Wnt/ β 2-Catenin Signaling. <i>Pharmaceutical Research</i> , 2021, 38, 479-490.	1.7	13
9136	Pyroptosis: mechanisms and diseases. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 128.	7.1	821
9137	Systemic Therapy of Metastatic Melanoma: On the Road to Cure. <i>Cancers</i> , 2021, 13, 1430.	1.7	50
9138	Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics. <i>AAPS Journal</i> , 2021, 23, 39.	2.2	356
9139	Clinical outcome of patients with metastatic melanoma of unknown primary in the era of novel therapy. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3123-3135.	2.0	6
9140	Specific Patterns of Blood ILCs in Metastatic Melanoma Patients and Their Modulations in Response to Immunotherapy. <i>Cancers</i> , 2021, 13, 1446.	1.7	12
9141	Evaluation of a Multidisciplinary Immunotherapy Toxicity Monitoring Program for Patients Receiving Ipilimumab for Metastatic Melanoma. <i>JCO Oncology Practice</i> , 2021, 17, e1631-e1638.	1.4	5
9142	Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab. <i>Gastric Cancer</i> , 2021, 24, 946-958.	2.7	61
9143	Recent advancements in melanoma management. <i>Internal Medicine Journal</i> , 2021, 51, 327-333.	0.5	4
9144	Therapeutic applications of the cancer immunoediting hypothesis. <i>Seminars in Cancer Biology</i> , 2022, 78, 63-77.	4.3	29
9145	Immune Checkpoint Inhibitors in the Treatment of Cancer. <i>Current Clinical Pharmacology</i> , 2022, 17, 103-113.	0.2	18
9146	Progress and Challenges of Predictive Biomarkers for Immune Checkpoint Blockade. <i>Frontiers in Oncology</i> , 2021, 11, 617335.	1.3	49
9147	The Role of Immune Checkpoint Molecules for Relapse After Allogeneic Hematopoietic Cell Transplantation. <i>Frontiers in Immunology</i> , 2021, 12, 634435.	2.2	27
9148	Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma. <i>American Journal of Clinical Dermatology</i> , 2021, 22, 301-314.	3.3	18
9149	CTLA-4 in Regulatory T Cells for Cancer Immunotherapy. <i>Cancers</i> , 2021, 13, 1440.	1.7	88
9150	Association of blood biomarkers and autoimmunity with immune related adverse events in patients with cancer treated with immune checkpoint inhibitors. <i>Scientific Reports</i> , 2021, 11, 9029.	1.6	39

#	ARTICLE	IF	CITATIONS
9151	pH-Responsive Lipid Nanocapsules: A Promising Strategy for Improved Resistant Melanoma Cell Internalization. <i>Cancers</i> , 2021, 13, 2028.	1.7	11
9152	Chemotherapy agents stimulate dendritic cells against human colon cancer cells through upregulation of the transporter associated with antigen processing. <i>Scientific Reports</i> , 2021, 11, 9080.	1.6	6
9153	Sinonasal mucosal melanoma: treatment strategies and survival rates for a rare disease entity. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 1137-1147.	1.0	8
9155	IDO1-mediated Trp-kynurenine-AhR signal activation induces stemness and tumor dormancy in oral squamous cell carcinomas. <i>Oral Science International</i> , 2022, 19, 31-43.	0.3	6
9156	Insights Gained from Single-Cell Analysis of Immune Cells in the Tumor Microenvironment. <i>Annual Review of Immunology</i> , 2021, 39, 583-609.	9.5	153
9157	Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis. <i>Clinical and Translational Oncology</i> , 2021, 23, 1885-1904.	1.2	11
9158	Aliphatic Polyester-Based Materials for Enhanced Cancer Immunotherapy. <i>Macromolecular Bioscience</i> , 2021, 21, e2100087.	2.1	7
9159	Epidemiology of brain metastases and leptomeningeal disease. <i>Neuro-Oncology</i> , 2021, 23, 1447-1456.	0.6	123
9160	Interfaces between cellular responses to DNA damage and cancer immunotherapy. <i>Genes and Development</i> , 2021, 35, 602-618.	2.7	61
9161	The Future of Cancer Diagnosis, Treatment and Surveillance: A Systemic Review on Immunotherapy and Immuno-PET Radiotracers. <i>Molecules</i> , 2021, 26, 2201.	1.7	23
9162	Cervical Cancer Immunotherapy: Facts and Hopes. <i>Clinical Cancer Research</i> , 2021, 27, 4953-4973.	3.2	129
9163	Inhibiting the MNK1/2-eIF4E axis impairs melanoma phenotype switching and potentiates antitumor immune responses. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	35
9164	Immune checkpoint inhibitor associated vitiligo and its impact on survival in patients with metastatic melanoma: an Italian Melanoma Intergroup study. <i>ESMO Open</i> , 2021, 6, 100064.	2.0	21
9165	The safety and efficacy of immune-checkpoint inhibitors in patients with cancer and pre-existing autoimmune diseases. <i>Immunotherapy</i> , 2021, 13, 527-539.	1.0	12
9166	Neoadjuvant Cytoreductive Treatment With BRAF/MEK Inhibition of Prior Unresectable Regionally Advanced Melanoma to Allow Complete Surgical Resection, REDUCTOR. <i>Annals of Surgery</i> , 2021, 274, 383-389.	2.1	28
9167	Advances in Lipid-Based Nanoparticles for Cancer Chemoimmunotherapy. <i>Pharmaceutics</i> , 2021, 13, 520.	2.0	25
9168	Clinical efficacy of immune checkpoint inhibitors in patients with brain metastases. <i>Immunotherapy</i> , 2021, 13, 419-432.	1.0	9
9169	TAP 1.0: A robust immunoinformatic tool for the prediction of tumor T-cell antigens based on AAindex properties. <i>Computational Biology and Chemistry</i> , 2021, 91, 107452.	1.1	13

#	ARTICLE	IF	CITATIONS
9170	Latest therapeutic target for gastric cancer: Anthrax toxin receptor 1. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 216-222.	0.8	6
9171	Sarcoma IL-12 overexpression facilitates NK cell immunomodulation. <i>Scientific Reports</i> , 2021, 11, 8321.	1.6	9
9172	The Ratio of IP10 to IL-8 in Plasma Reflects and Predicts the Response of Patients With Lung Cancer to Anti-PD-1 Immunotherapy Combined With Chemotherapy. <i>Frontiers in Immunology</i> , 2021, 12, 665147.	2.2	11
9173	Development and validation of a web-based patient decision aid for immunotherapy for patients with metastatic melanoma: study protocol for a multicenter randomized trial. <i>Trials</i> , 2021, 22, 294.	0.7	1
9174	The Role of Systemic Therapy in Advanced Cutaneous Melanoma of the Head and Neck. <i>Otolaryngologic Clinics of North America</i> , 2021, 54, 329-342.	0.5	1
9175	Inflammatory Markers in Cancer Immunotherapy. <i>Biology</i> , 2021, 10, 325.	1.3	28
9176	Trials and tribulations of pancreatic cancer immunotherapy. <i>Cancer Letters</i> , 2021, 504, 1-14.	3.2	37
9177	Anti-angiogenic agents "overcoming tumour endothelial cell energy and improving immunotherapy outcomes. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 527-540.	12.5	162
9178	Emerging antibody therapies for pancreatic adenocarcinoma: a review of recent phase 2 trials. <i>Expert Opinion on Emerging Drugs</i> , 2021, 26, 103-129.	1.0	2
9179	Human KIT+ myeloid cells facilitate visceral metastasis by melanoma. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	5
9180	The synergistic strategies for the immunotherapy with photothermal nanoagents. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2021, 13, e1717.	3.3	9
9181	Imaging spectrum of adverse events of immune checkpoint inhibitors. <i>Clinical Radiology</i> , 2021, 76, 262-272.	0.5	9
9182	High sensitivity sanger sequencing detection of BRAF mutations in metastatic melanoma FFPE tissue specimens. <i>Scientific Reports</i> , 2021, 11, 9043.	1.6	13
9183	Impact of novel systemic therapies on the first-year costs of care for melanoma among Medicare beneficiaries. <i>Cancer</i> , 2021, 127, 2926-2933.	2.0	7
9184	Contemporary Neoadjuvant Therapies for High-Risk Melanoma: A Systematic Review. <i>Cancers</i> , 2021, 13, 1905.	1.7	7
9185	Nanobodies for Medical Imaging: About Ready for Prime Time?. <i>Biomolecules</i> , 2021, 11, 637.	1.8	21
9186	A Review of Cancer Immunotherapy Toxicity: Immune Checkpoint Inhibitors. <i>Journal of Medical Toxicology</i> , 2021, 17, 411-424.	0.8	54
9187	Advances in Targeting Cutaneous Melanoma. <i>Cancers</i> , 2021, 13, 2090.	1.7	19

#	ARTICLE	IF	CITATIONS
9188	Ipilimumab and Stereotactic Radiosurgery with CyberKnife® System in Melanoma Brain Metastases: A Retrospective Monoinstitutional Experience. <i>Cancers</i> , 2021, 13, 1857.	1.7	5
9189	Comparison of EQ-5D-3L with QLU-C10D in Metastatic Melanoma Using Cost-Utility Analysis. <i>Pharmacoeconomics - Open</i> , 2021, 5, 459-467.	0.9	5
9190	Pediatric Melanoma—Diagnosis, Management, and Anticipated Outcomes. <i>Surgical Oncology Clinics of North America</i> , 2021, 30, 373-388.	0.6	2
9191	Therapeutic Application of Monoclonal Antibodies in Pancreatic Cancer: Advances, Challenges and Future Opportunities. <i>Cancers</i> , 2021, 13, 1781.	1.7	17
9192	Brain-invasive meningiomas: molecular mechanisms and potential therapeutic options. <i>Brain Tumor Pathology</i> , 2021, 38, 156-172.	1.1	8
9193	CD8+ T cells inhibit metastasis and CXCL4 regulates its function. <i>British Journal of Cancer</i> , 2021, 125, 176-189.	2.9	21
9194	Immunotherapy for the Breast Cancer treatment: Current Evidence and Therapeutic Options. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2021, 21, .	0.6	2
9195	Integrated Analysis Reveals Prognostic Value and Immune Correlates of CD86 Expression in Lower Grade Glioma. <i>Frontiers in Oncology</i> , 2021, 11, 654350.	1.3	14
9196	Recent progress in cancer immunotherapy approaches based on nanoparticle delivery devices. <i>Journal of Pharmaceutical Investigation</i> , 2021, 51, 399-412.	2.7	26
9197	Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor. , 2021, 9, e002371.		44
9198	Metabolic barriers to cancer immunotherapy. <i>Nature Reviews Immunology</i> , 2021, 21, 785-797.	10.6	245
9199	Graves™ Disease during Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review). <i>Cancers</i> , 2021, 13, 1944.	1.7	21
9200	Protein-Based Nanomedicine for Therapeutic Benefits of Cancer. <i>ACS Nano</i> , 2021, 15, 8001-8038.	7.3	59
9201	Immunotherapy Is Associated with a Survival Benefit in Patients Receiving Chemotherapy for Metastatic Pancreatic Cancer. <i>Journal of Pancreatic Cancer</i> , 2021, 7, 31-38.	1.6	2
9202	Systemic effect of radiotherapy before or after nivolumab in lung cancer: an observational, retrospective, multicenter study. <i>Tumori</i> , 2022, 108, 250-257.	0.6	9
9203	Emerging Trends in Immunomodulatory Nanomaterials Toward Cancer Therapy. <i>Synthesis Lectures on Biomedical Engineering</i> , 2021, 16, i-84.	0.1	0
9204	IL-7 coupled with IL-12 increases intratumoral T cell clonality, leading to complete regression of non-immunogenic tumors. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3557-3571.	2.0	11
9205	Controversies on the possible role of immune checkpoint inhibitors in pediatric cancers: balancing irAEs and efficacy. <i>Tumori</i> , 2021, 107, 276-281.	0.6	6

#	ARTICLE	IF	CITATIONS
9206	Radiological assessment of response and adverse events associated with novel systemic oncological therapies. <i>Clinical Radiology</i> , 2021, 76, 247-261.	0.5	0
9207	Hematological immune related adverse events after treatment with immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2021, 147, 170-181.	1.3	40
9208	Enhance anti-lung tumor efficacy of chimeric antigen receptor-T cells by ectopic expression of Cx36 motif chemokine receptor 6. <i>Science Bulletin</i> , 2021, 66, 803-812.	4.3	17
9209	The Pattern of Time to Onset and Resolution of Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors in Cancer: A Pooled Analysis of 23 Clinical Trials and 8,436 Patients. <i>Cancer Research and Treatment</i> , 2021, 53, 339-354.	1.3	63
9210	The Next Decade of Immune Checkpoint Therapy. <i>Cancer Discovery</i> , 2021, 11, 838-857.	7.7	363
9211	Emerging principles of brain immunology and immune checkpoint blockade in brain metastases. <i>Brain</i> , 2021, 144, 1046-1066.	3.7	24
9212	Endocrine toxicities of immune checkpoint inhibitors. <i>Nature Reviews Endocrinology</i> , 2021, 17, 389-399.	4.3	162
9213	Development of Antihuman Killer Cell Lectin-Like Receptor Subfamily G Member 1 Monoclonal Antibodies for Flow Cytometry. <i>Monoclonal Antibodies in Immunodiagnosis and Immunotherapy</i> , 2021, 40, 76-80.	0.8	8
9215	Malignant Melanoma in Children and Adolescents Treated in Pediatric Oncology Centers: An Australian and New Zealand Children's Oncology Group (ANZCHOG) Study. <i>Frontiers in Oncology</i> , 2021, 11, 660172.	1.3	1
9217	Population-Based Frequency of Ophthalmic Adverse Events in Melanoma, Other Cancers, and After Immune Checkpoint Inhibitor Treatment. <i>American Journal of Ophthalmology</i> , 2021, 224, 282-291.	1.7	10
9218	The Current Landscape of Immune Checkpoint Blockade in Glioblastoma. <i>Neurosurgery Clinics of North America</i> , 2021, 32, 235-248.	0.8	8
9219	Immunotherapy and fatigue: what we know and what we don't know. <i>Oncotarget</i> , 2021, 12, 719-720.	0.8	3
9220	Envisioning the immune system to determine its role in pancreatic ductal adenocarcinoma: Culprit or victim?. <i>Immunology Letters</i> , 2021, 232, 48-59.	1.1	2
9221	Combination of MAPK inhibition with photothermal therapy synergistically augments the anti-tumor efficacy of immune checkpoint blockade. <i>Journal of Controlled Release</i> , 2021, 332, 194-209.	4.8	25
9222	Vitiligo induced by immune checkpoint inhibitors in melanoma patients: an expert opinion. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 883-888.	1.0	27
9223	Panels and models for accurate prediction of tumor mutation burden in tumor samples. <i>Npj Precision Oncology</i> , 2021, 5, 31.	2.3	7
9224	Immune Checkpoints, Inhibitors and Radionuclides in Prostate Cancer: Promising Combinatorial Therapy Approach. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4109.	1.8	15
9225	Therapeutic Targeting of the Tumor Microenvironment. <i>Cancer Discovery</i> , 2021, 11, 933-959.	7.7	646

#	ARTICLE	IF	CITATIONS
9226	Therapies of Hematological Malignancies: An Overview of the Potential Targets and Their Inhibitors. <i>Current Chemical Biology</i> , 2021, 15, 19-49.	0.2	2
9227	Armored CAR T-Cells: The Next Chapter in T-Cell Cancer Immunotherapy. <i>Biologics: Targets and Therapy</i> , 2021, Volume 15, 95-105.	3.0	33
9228	Radionecrosis (RN) in patients with brain metastases treated with stereotactic radiosurgery (SRS) and immunotherapy. <i>International Journal of Neuroscience</i> , 2023, 133, 186-193.	0.8	6
9229	Precision Oncology Beyond Genomics: The Future Is Here—It Is Just Not Evenly Distributed. <i>Cells</i> , 2021, 10, 928.	1.8	13
9230	Evaluation of practical experiences of German speaking radiation oncologists in combining radiation therapy with checkpoint blockade. <i>Scientific Reports</i> , 2021, 11, 7624.	1.6	5
9231	Different Apples, Same Tree: Visualizing Current Biological and Clinical Insights into CTLA-4 Insufficiency and LRBA and DEF6 Deficiencies. <i>Frontiers in Pediatrics</i> , 2021, 9, 662645.	0.9	15
9232	Emerging drugs for the treatment of triple-negative breast cancer: a focus on phase II immunotherapy trials. <i>Expert Opinion on Emerging Drugs</i> , 2021, 26, 131-147.	1.0	5
9233	Injectables in Head and Neck Cutaneous Melanoma Treatment. <i>Otolaryngologic Clinics of North America</i> , 2021, 54, 425-438.	0.5	1
9234	Pulmonary metastasectomy in the era of targeted therapy and immunotherapy. <i>Journal of Thoracic Disease</i> , 2021, 13, 2618-2627.	0.6	12
9235	Functional Impairments and Rehabilitation Outcomes of Patients With Immunotherapy-Induced Acute Inflammatory Demyelinating Polyradiculoneuropathy, Myasthenia Gravis, and Myositis. <i>American Journal of Physical Medicine and Rehabilitation</i> , 2021, 100, 1015-1019.	0.7	1
9236	Biomarkers, Clinical Features, and Rechallenge for Immune Checkpoint Inhibitor Renal Immune-Related Adverse Events. <i>Kidney International Reports</i> , 2021, 6, 1022-1031.	0.4	54
9237	Primary vaginal malignant melanoma. <i>Medicine (United States)</i> , 2021, 100, e25691.	0.4	8
9238	Tumour Hypoxia-Mediated Immunosuppression: Mechanisms and Therapeutic Approaches to Improve Cancer Immunotherapy. <i>Cells</i> , 2021, 10, 1006.	1.8	45
9239	TIM3 expression on TILs is associated with poor response to neoadjuvant chemotherapy in patients with locally advanced triple-negative breast cancer. <i>BMC Cancer</i> , 2021, 21, 357.	1.1	14
9241	Tumor Immune Microenvironment Characterization Identifies Prognosis and Immunotherapy-Related Gene Signatures in Melanoma. <i>Frontiers in Immunology</i> , 2021, 12, 663495.	2.2	30
9242	Effects of Chemotherapy Agents on Circulating Leukocyte Populations: Potential Implications for the Success of CAR-T Cell Therapies. <i>Cancers</i> , 2021, 13, 2225.	1.7	21
9243	Safety and Efficacy of Personalized Cancer Vaccines in Combination With Immune Checkpoint Inhibitors in Cancer Treatment. <i>Frontiers in Oncology</i> , 2021, 11, 663264.	1.3	19
9244	Lymph Node Immune Profiles as Predictive Biomarkers for Immune Checkpoint Inhibitor Response. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 674558.	1.6	10

#	ARTICLE	IF	CITATIONS
9245	Involvement of TRPM8 Channel in Radiation-Induced DNA Damage Repair Mechanism Contributing to Radioresistance of B16 Melanoma. <i>Biological and Pharmaceutical Bulletin</i> , 2021, 44, 642-652.	0.6	6
9246	CRISPR/Cas9 Gene-Editing in Cancer Immunotherapy: Promoting the Present Revolution in Cancer Therapy and Exploring More. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 674467.	1.8	22
9247	Surgery of small bowel melanoma metastases in the era of efficient medical therapies. <i>Melanoma Research</i> , 2021, Publish Ahead of Print, 358-365.	0.6	2
9248	Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study. <i>BMC Cancer</i> , 2021, 21, 642.	1.1	9
9249	Challenges and Opportunities for Immunotherapy in Gynecologic Cancer. <i>Advances in Oncology</i> , 2021, 1, 113-123.	0.1	0
9250	Role of cardiovascular magnetic resonance in early detection and treatment of cardiac dysfunction in oncology patients. <i>International Journal of Cardiovascular Imaging</i> , 2021, 37, 3003-3017.	0.7	4
9251	Targeting therapy for prostate cancer by pharmaceutical and clinical pharmaceutical strategies. <i>Journal of Controlled Release</i> , 2021, 333, 41-64.	4.8	22
9252	T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments. <i>Leukemia</i> , 2021, 35, 1843-1863.	3.3	123
9253	Serum alanine aminotransferase as an early marker of outcomes in patients receiving anti-PD-1 or anti-CTLA-4 antibody. <i>Scientific Reports</i> , 2021, 11, 10264.	1.6	0
9254	Combination Strategies to Augment Immune Check Point Inhibitors Efficacy - Implications for Translational Research. <i>Frontiers in Oncology</i> , 2021, 11, 559161.	1.3	34
9255	Soluble cytotoxic T-lymphocyte-associated antigen 4 (sCTLA-4) as a potential biomarker for diagnosis and evaluation of the prognosis in Glioma. <i>BMC Immunology</i> , 2021, 22, 33.	0.9	9
9256	Impact of Circulating and Tissue Biomarkers in Adjuvant and Neoadjuvant Therapy for High-Risk Melanoma: Ready for Prime Time?. <i>American Journal of Clinical Dermatology</i> , 2021, 22, 511-522.	3.3	6
9257	Structure-Based Design of Highly Potent Toll-like Receptor 7/8 Dual Agonists for Cancer Immunotherapy. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 7507-7532.	2.9	18
9258	Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma. <i>Frontiers in Immunology</i> , 2021, 12, 661737.	2.2	29
9259	Importance of lymph node immune responses in MSI-H/dMMR colorectal cancer. <i>JCI Insight</i> , 2021, 6, .	2.3	17
9260	Emerging biological therapies for the treatment of malignant pleural mesothelioma. <i>Expert Opinion on Emerging Drugs</i> , 2021, 26, 179-192.	1.0	3
9261	Immune checkpoints in targeted-immunotherapy of pancreatic cancer: New hope for clinical development. <i>Acta Pharmaceutica Sinica B</i> , 2021, 11, 1083-1097.	5.7	23
9262	Immunotherapy and radiation for high-grade glioma: a narrative review. <i>Translational Cancer Research</i> , 2021, 10, 2537-2570.	0.4	6

#	ARTICLE	IF	CITATIONS
9263	MiRNA-based model for predicting the TMB level in colon adenocarcinoma based on a LASSO logistic regression method. <i>Medicine (United States)</i> , 2021, 100, e26068.	0.4	1
9264	Cancer Therapeuticsâ€“related Cardiac Dysfunction in Patients Treated With Immune Checkpoint Inhibitors: An Understudied Manifestation. <i>Journal of Immunotherapy</i> , 2021, 44, 179-184.	1.2	5
9265	Current status of medical treatment for gastroenteropancreatic neuroendocrine neoplasms and future perspectives. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 1185-1196.	0.6	8
9266	Narrative review of immunotherapy and radiation therapy in elderly patients. <i>Translational Cancer Research</i> , 2021, 10, 2620-2631.	0.4	1
9267	Narrative review of immune checkpoint inhibitors and radiation therapy for brain metastases. <i>Translational Cancer Research</i> , 2021, 10, 2527-2536.	0.4	1
9268	Association Between First-Line Immune Checkpoint Inhibition and Survival for Medicare-Insured Patients With Advanced Nonâ€“Small Cell Lung Cancer. <i>JAMA Network Open</i> , 2021, 4, e2111113.	2.8	17
9269	Leptomeningeal disease from melanomaâ€“Poor prognosis despite new therapeutic modalities. <i>European Journal of Cancer</i> , 2021, 148, 395-404.	1.3	16
9270	Case Report: Circulating Myeloid-Derived Suppressive-Like Cells and Exhausted Immune Cells in Non-Small Cell Lung Cancer Patients Treated With Three Immune Checkpoint Inhibitors. <i>Frontiers in Immunology</i> , 2021, 12, 672219.	2.2	2
9271	Correlation of Peripheral Blood Parameters and Immune-Related Adverse Events with the Efficacy of Immune Checkpoint Inhibitors. <i>Journal of Oncology</i> , 2021, 2021, 1-15.	0.6	8
9272	The efficacy and safety of Nivolumab combined with Ipilimumab in the immunotherapy of cancer: a meta-analysis. <i>Immunopharmacology and Immunotoxicology</i> , 2021, 43, 386-394.	1.1	6
9273	Approaches for refining and furthering the development of CAR-based T cell therapies for solid malignancies. <i>Expert Opinion on Drug Discovery</i> , 2021, 16, 1105-1117.	2.5	3
9274	Programmed death ligandâ€“1 regulates angiogenesis and metastasis by participating in the câ€“JUN/VEGFR2 signaling axis in ovarian cancer. <i>Cancer Communications</i> , 2021, 41, 511-527.	3.7	31
9275	Recent Advances in Engineered Materials for Immunotherapyâ€“Involved Combination Cancer Therapy. <i>Advanced Materials</i> , 2021, 33, e2007630.	11.1	112
9276	Evolution of the Randomized Clinical Trial in the Era of Precision Oncology. <i>JAMA Oncology</i> , 2021, 7, 728.	3.4	94
9277	Sequential immunotherapy in melanoma. <i>Melanoma Research</i> , 2021, Publish Ahead of Print, 366-370.	0.6	3
9278	Combinatorial Therapies to Overcome BRAF/MEK Inhibitors Resistance in Melanoma Cells: An in vitro Study. <i>Journal of Experimental Pharmacology</i> , 2021, Volume 13, 521-535.	1.5	5
9279	Safety and discontinuation rate of immune checkpoint inhibitors used in patients with solid and hematological malignancies. A population based retrospective analysis. <i>Journal of Oncology Pharmacy Practice</i> , 2022, 28, 771-776.	0.5	2
9280	Decreased survival in patients treated by chemotherapy after targeted therapy compared to immunotherapy in metastatic melanoma. <i>Cancer Medicine</i> , 2021, 10, 3155-3164.	1.3	5

#	ARTICLE	IF	CITATIONS
9281	Resistance to Targeted Therapy and RASSF1A Loss in Melanoma: What Are We Missing?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5115.	1.8	8
9282	Mechanisms of Cardiovascular Toxicities Associated With Immunotherapies. <i>Circulation Research</i> , 2021, 128, 1780-1801.	2.0	48
9283	Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5801.	1.8	182
9284	Therapeutic Induction of Tertiary Lymphoid Structures in Cancer Through Stromal Remodeling. <i>Frontiers in Immunology</i> , 2021, 12, 674375.	2.2	23
9285	Melanoma models for the next generation of therapies. <i>Cancer Cell</i> , 2021, 39, 610-631.	7.7	90
9286	Expanding the Role of Checkpoint Inhibitors in Immune Cold Tumors. <i>Advances in Oncology</i> , 2021, 1, 85-95.	0.1	0
9287	Endocrine-related adverse events in a large series of cancer patients treated with anti-PD1 therapy. <i>Endocrine</i> , 2021, 74, 172-179.	1.1	19
9288	Inhibition of CDK4/6 Promotes CD8 T-cell Memory Formation. <i>Cancer Discovery</i> , 2021, 11, 2564-2581.	7.7	58
9289	Chromatin accessibility governs the differential response of cancer and T ^H 1 cells to arginine starvation. <i>Cell Reports</i> , 2021, 35, 109101.	2.9	20
9290	Combining a Universal Telomerase Based Cancer Vaccine With Ipilimumab in Patients With Metastatic Melanoma - Five-Year Follow Up of a Phase I/IIa Trial. <i>Frontiers in Immunology</i> , 2021, 12, 663865.	2.2	17
9291	Recent Progress in Dendritic Cell-Based Cancer Immunotherapy. <i>Cancers</i> , 2021, 13, 2495.	1.7	26
9292	EIF3H knockdown inhibits malignant melanoma through regulating cell proliferation, apoptosis and cell cycle. <i>Experimental Cell Research</i> , 2021, 402, 112488.	1.2	4
9293	Integrated microenvironment-associated genomic profiles identify LRRC15 mediating recurrent glioblastoma-associated macrophages infiltration. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 5534-5546.	1.6	7
9294	The Immunotherapy Landscape in Adrenocortical Cancer. <i>Cancers</i> , 2021, 13, 2660.	1.7	8
9295	Management of adverse events in cancer treatment with immune checkpoint inhibitors. <i>Journal of the Korean Medical Association</i> , 2021, 64, 358-365.	0.1	0
9296	CAR T Cell-Based Immunotherapy for the Treatment of Glioblastoma. <i>Frontiers in Neuroscience</i> , 2021, 15, 662064.	1.4	80
9297	Chemotherapy in focus: A meta-analysis confronts immunotherapy in the treatment of advanced melanoma. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 161, 103304.	2.0	3
9298	Conjunctival melanoma: New insights in tumour genetics and immunology, leading to new therapeutic options. <i>Progress in Retinal and Eye Research</i> , 2022, 86, 100971.	7.3	35

#	ARTICLE	IF	CITATIONS
9299	Systemic Therapy for Head and Neck Skin Cancers. <i>Face</i> , 2021, 2, 121-130.	0.1	0
9300	LILRB4 suppresses immunity in solid tumors and is a potential target for immunotherapy. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	53
9301	Near Infrared Photoimmunotherapy; A Review of Targets for Cancer Therapy. <i>Cancers</i> , 2021, 13, 2535.	1.7	47
9302	Evolution of Cancer Vaccines—Challenges, Achievements, and Future Directions. <i>Vaccines</i> , 2021, 9, 535.	2.1	38
9303	Mechanistic basis for Cancer Immune Evasion and role of immune checkpoint blockades in Immuno-Oncology. <i>Global Journal of Cancer Therapy</i> , 2021, , 035-042.	0.4	1
9304	Histopathology of Gastrointestinal Immune-related Adverse Events. <i>American Journal of Surgical Pathology</i> , 2021, Publish Ahead of Print, e15-e26.	2.1	7
9305	Epigenetic dysregulation of immune-related pathways in cancer: bioinformatics tools and visualization. <i>Experimental and Molecular Medicine</i> , 2021, 53, 761-771.	3.2	8
9306	Current management of melanoma patients with nodal metastases. <i>Clinical and Experimental Metastasis</i> , 2022, 39, 181-199.	1.7	8
9307	Bacillus Calmette—Guérin Immunotherapy for Cancer. <i>Vaccines</i> , 2021, 9, 439.	2.1	27
9308	Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition. <i>European Journal of Cancer</i> , 2021, 148, 61-75.	1.3	15
9309	uPAR ⁺ extracellular vesicles: a robust biomarker of resistance to checkpoint inhibitor immunotherapy in metastatic melanoma patients. , 2021, 9, e002372.		23
9310	Risk of Ophthalmic Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis. <i>Ocular Immunology and Inflammation</i> , 2022, 30, 1449-1459.	1.0	7
9311	Serum levels of soluble B and T lymphocyte attenuator predict overall survival in patients undergoing immune checkpoint inhibitor therapy for solid malignancies. <i>International Journal of Cancer</i> , 2021, 149, 1189-1198.	2.3	17
9312	Genome profiling of mismatch repair genes in eight types of tumors. <i>Cell Cycle</i> , 2021, 20, 1-16.	1.3	0
9313	Metabolic Interplay between the Immune System and Melanoma Cells: Therapeutic Implications. <i>Biomedicines</i> , 2021, 9, 607.	1.4	12
9314	Hypoxia-dependent drivers of melanoma progression. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 159.	3.5	45
9315	The immunotherapeutic role of indoleamine 2,3-dioxygenase in head and neck squamous cell carcinoma: A systematic review. <i>Clinical Otolaryngology</i> , 2021, 46, 919-934.	0.6	17
9316	Drug and molecular radiotherapy combinations for metastatic castration resistant prostate cancer. <i>Nuclear Medicine and Biology</i> , 2021, 96-97, 101-111.	0.3	10

#	ARTICLE	IF	CITATIONS
9317	Risk of Cardiac Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 645245.	1.3	9
9318	Prediction of Immune-Checkpoint Blockade Monotherapy Response in Patients With Melanoma Based on Easily Accessible Clinical Indicators. <i>Frontiers in Oncology</i> , 2021, 11, 659754.	1.3	6
9319	Imaging of Neurologic Injury following Oncologic Therapy. <i>Radiologic Clinics of North America</i> , 2021, 59, 425-440.	0.9	2
9320	Signature based on metabolic-related gene pairs can predict overall survival of osteosarcoma patients. <i>Cancer Medicine</i> , 2021, 10, 4493-4509.	1.3	9
9321	Endogenous retroviruses in the origins and treatment of cancer. <i>Genome Biology</i> , 2021, 22, 147.	3.8	73
9322	Oncolytic virotherapy reverses the immunosuppressive tumor microenvironment and its potential in combination with immunotherapy. <i>Cancer Cell International</i> , 2021, 21, 262.	1.8	31
9323	Anti-HER3 monoclonal antibody exerts antitumor activity in a mouse model of colorectal adenocarcinoma. <i>Oncology Reports</i> , 2021, 46, .	1.2	22
9324	Predictive and Prognostic Value of BRAF and NRAS Mutation of 159 Sentinel Lymph Node Cases in Melanoma—A Retrospective Single-Institute Study. <i>Cancers</i> , 2021, 13, 3302.	1.7	3
9325	Integration of Salmonella into Combination Cancer Therapy. <i>Cancers</i> , 2021, 13, 3228.	1.7	15
9326	Multi-detector computed tomography (MDCT)-based severity score as a prognostic tool in patients with suspected immune checkpoint inhibitor therapy associated colitis. <i>European Radiology</i> , 2021, 31, 8868-8878.	2.3	2
9327	Potential experimental immune checkpoint inhibitors for the treatment of cancer of the liver. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 827-835.	1.9	3
9328	Durability of CNS disease control in NSCLC patients with brain metastases treated with immune checkpoint inhibitors plus cranial radiotherapy. <i>Lung Cancer</i> , 2021, 156, 76-81.	0.9	7
9329	MHC Class I Deficiency in Solid Tumors and Therapeutic Strategies to Overcome It. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6741.	1.8	28
9330	Perspectives on Immunotherapy of Metastatic Colorectal Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 659964.	1.3	23
9331	New Targeted Therapies and Immunotherapies for Locally Advanced Periocular Malignant Tumours: Towards a New "Eye-Sparing" Paradigm?. <i>Cancers</i> , 2021, 13, 2822.	1.7	7
9332	Intracranial response after extracranial radiation in a patient with rapidly progressing metastatic melanoma. <i>BMJ Case Reports</i> , 2021, 14, e240921.	0.2	4
9333	Modelling the interplay between the CD4 ⁺ /CD8 ⁺ T-cell ratio and the expression of MHC-I in tumours. <i>Journal of Mathematical Biology</i> , 2021, 83, 2.	0.8	0
9334	Checkpoint blockade accelerates a novel switch from an NKT-driven TNF response toward a T cell driven IFN- γ response within the tumor microenvironment. , 2021, 9, e002269.		2

#	ARTICLE	IF	CITATIONS
9335	Immunotherapy combined with high- and low-dose radiation to all sites leads to complete clearance of disease in a patient with metastatic vaginal melanoma. <i>Gynecologic Oncology</i> , 2021, 161, 645-652.	0.6	15
9337	The Research on the Treatment of Metastatic Skin Cutaneous Melanoma by Huanglian Jiedu Decoction Based on the Analysis of Immune Infiltration Analysis. <i>Evidence-based Complementary and Alternative Medicine</i> , 2021, 2021, 1-22.	0.5	0
9338	Immune checkpoint inhibitor-associated acute kidney injury and mortality: An observational study. <i>PLoS ONE</i> , 2021, 16, e0252978.	1.1	23
9339	Interactions between Cancer-Associated Fibroblasts and T Cells in the Pancreatic Tumor Microenvironment and the Role of Chemokines. <i>Cancers</i> , 2021, 13, 2995.	1.7	29
9340	Hepatectomy and immune checkpoint inhibitor treatment for liver metastasis originating from non-cutaneous melanoma: a report of three cases. <i>International Cancer Conference Journal</i> , 2021, 10, 274-279.	0.2	2
9341	Recent Advances in the Treatment of Melanoma. <i>New England Journal of Medicine</i> , 2021, 384, 2229-2240.	13.9	201
9342	Current clinical trials and patent update on lung cancer: a retrospective review. <i>Lung Cancer Management</i> , 2021, 10, LMT45.	1.5	0
9343	Managing side effects of immune checkpoint inhibitors in breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 162, 103354.	2.0	15
9344	Precision medicine in pediatric solid cancers. <i>Seminars in Cancer Biology</i> , 2022, 84, 214-227.	4.3	10
9345	Metabolomics Monitoring of Treatment Response to Brain Tumor Immunotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 691246.	1.3	13
9346	Vulvar and Vaginal Melanomasâ€”The Darker Shades of Gynecological Cancers. <i>Biomedicines</i> , 2021, 9, 758.	1.4	10
9347	A Case of Symptomatic Cerebral Radiation Necrosis for an Extra-Cranial Neoplasm from Conventional Radiotherapy With Concurrent Immunotherapy. <i>Cureus</i> , 2021, 13, e15712.	0.2	0
9348	Role of the intestinal microbiome and microbial-derived metabolites in immune checkpoint blockade immunotherapy of cancer. <i>Genome Medicine</i> , 2021, 13, 107.	3.6	74
9349	Advances in siRNA delivery strategies for the treatment of MDR cancer. <i>Life Sciences</i> , 2021, 274, 119337.	2.0	21
9350	Palmitoylated antigens for the induction of anti-tumor CD8+ TÂ€cells and enhanced tumor recognition. <i>Molecular Therapy - Oncolytics</i> , 2021, 21, 315-328.	2.0	3
9351	Reâ€thinking therapeutic development for CNS metastatic disease. <i>Experimental Dermatology</i> , 2021, , .	1.4	1
9352	Incidence of immune checkpoint inhibitorâ€mediated diarrhea and colitis (imDC) in patients with cancer and preexisting inflammatory bowel disease: a propensity scoreâ€matched retrospective study. , 2021, 9, e002567.		10
9353	Immunotherapy Discontinuation in Metastatic Melanoma: Lessons from Real-Life Clinical Experience. <i>Cancers</i> , 2021, 13, 3074.	1.7	20

#	ARTICLE	IF	CITATIONS
9354	Vulvar Melanoma: Molecular Characteristics, Diagnosis, Surgical Management, and Medical Treatment. <i>American Journal of Clinical Dermatology</i> , 2021, 22, 639-651.	3.3	15
9355	Current Perspectives and Novel Strategies of NRAS-Mutant Melanoma. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 3709-3719.	1.0	24
9357	A systematic study of novel drug delivery mechanisms and treatment strategies for pancreatic cancer. <i>Journal of Drug Delivery Science and Technology</i> , 2021, 63, 102539.	1.4	9
9358	The Tumor Microenvironment Factors That Promote Resistance to Immune Checkpoint Blockade Therapy. <i>Frontiers in Oncology</i> , 2021, 11, 641428.	1.3	32
9359	Current and Future Scenario of Immunotherapy for the Treatment of Hepatocellular Carcinoma. <i>Current Cancer Therapy Reviews</i> , 2021, 17, 148-158.	0.2	0
9360	Prognostic impact of thyroid dysfunctions on progression-free survival in patients with metastatic melanoma treated with anti-PD-1 antibodies. <i>Melanoma Research</i> , 2021, 31, 208-217.	0.6	8
9361	Catenin Alpha-2 Mutation Changes the Immune Microenvironment in Lung Adenocarcinoma Patients Receiving Immune Checkpoint Inhibitors. <i>Frontiers in Pharmacology</i> , 2021, 12, 645862.	1.6	7
9362	Cutaneous Toxicities in the Setting of Immune Checkpoint Blockade. <i>Surgical Pathology Clinics</i> , 2021, 14, 209-224.	0.7	3
9363	Identification and validation of expressed HLA-binding breast cancer neoepitopes for potential use in individualized cancer therapy. , 2021, 9, e002605.		7
9364	Symphony of nanomaterials and immunotherapy based on the cancer-immunity cycle. <i>Acta Pharmaceutica Sinica B</i> , 2022, 12, 107-134.	5.7	70
9365	Sex-related differences in the efficacy of immune checkpoint inhibitors in malignancy: a systematic review and meta-analysis. <i>Aging</i> , 2021, 13, 15413-15432.	1.4	9
9366	Generation of a safe and efficacious llama single-domain antibody fragment (vHH) targeting the membrane-proximal region of 4-1BB for engineering therapeutic bispecific antibodies for cancer. , 2021, 9, e002131.		27
9367	A Signaling View into the Inflammatory Tumor Microenvironment. <i>Immuno</i> , 2021, 1, 91-118.	0.6	4
9368	The role of immunotherapy and molecular-targeted therapy in the treatment of melanoma (Review). <i>Oncology Reports</i> , 2021, 46, .	1.2	14
9369	Cutaneous melanoma in children and adolescents: The EXPeRT/PARTNER diagnostic and therapeutic recommendations. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28992.	0.8	9
9370	Risk of Immune-related Adverse Events in Melanoma Patients With Preexisting Autoimmune Disease Treated With Immune Checkpoint Inhibitors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021, 44, 413-418.	0.6	8
9371	Guidelines for clinical evaluation of anti-cancer drugs. <i>Cancer Science</i> , 2021, 112, 2563-2577.	1.7	17
9372	The knowns & unknowns of pulmonary toxicity following immune checkpoint inhibitor therapies: a narrative review. <i>Translational Lung Cancer Research</i> , 2021, 10, 2752-2765.	1.3	5

#	ARTICLE	IF	CITATIONS
9373	Safety of immune checkpoint inhibitors in patients with cancer and pre-existing autoimmune disease. <i>Annals of Translational Medicine</i> , 2021, 9, 1033-1033.	0.7	23
9374	Circulating Tumor DNA as a Marker for Treatment Response in Metastatic Melanoma Patients Using Next-Generation Sequencing—A Prospective Feasibility Study. <i>Cancers</i> , 2021, 13, 3101.	1.7	5
9375	Reprogramming the anti-tumor immune response via CRISPR genetic and epigenetic editing. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021, 21, 592-606.	1.8	11
9376	Bleeding complications in patients with squamous cell carcinoma of the head and neck. <i>Head and Neck</i> , 2021, 43, 2844-2858.	0.9	12
9377	Optic Perineuritis Associated with Nivolumab Treatment for Non-Small Cell Lung Cancer. <i>Case Reports in Oncology</i> , 2021, 14, 792-796.	0.3	4
9378	Recombinant Newcastle Disease Virus Immunotherapy Drives Oncolytic Effects and Durable Systemic Antitumor Immunity. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1723-1734.	1.9	5
9379	Tim β /CTLA β pathways regulate decidual immune cells—extravillous trophoblasts interaction by IL β and IL α . <i>FASEB Journal</i> , 2021, 35, e21754.	0.2	15
9380	Acquired Resistance to Immune Checkpoint Blockades: The Underlying Mechanisms and Potential Strategies. <i>Frontiers in Immunology</i> , 2021, 12, 693609.	2.2	21
9381	Syntheses, Biological Evaluations, and Mechanistic Studies of Benzo[<i>c</i>][1,2,5]oxadiazole Derivatives as Potent PD-L1 Inhibitors with <i>In Vivo</i> Antitumor Activity. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 8391-8409.	2.9	29
9382	Tumor innervation: peripheral nerves take control of the tumor microenvironment. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	79
9383	Combined with interventional therapy, immunotherapy can create a new outlook for tumor treatment. <i>Quantitative Imaging in Medicine and Surgery</i> , 2021, 11, 2837-2860.	1.1	4
9384	Thermal ablation in non-small cell lung cancer: a review of treatment modalities and the evidence for combination with immune checkpoint inhibitors. <i>Translational Lung Cancer Research</i> , 2021, 10, 2842-2857.	1.3	28
9385	Cancer immunotherapy: it's time to better predict patients' response. <i>British Journal of Cancer</i> , 2021, 125, 927-938.	2.9	63
9386	Kidney injury associated with antitumor therapy: focus on the adverse events of modern immuno-oncological drugs. <i>Terapevticheskii Arkhiv</i> , 2021, 93, 649-660.	0.2	0
9387	Regulatory T-Cells as an Emerging Barrier to Immune Checkpoint Inhibition in Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 684098.	1.3	41
9388	Evaluating the impacts of emerging cancer therapies on ovarian function. <i>Current Opinion in Endocrine and Metabolic Research</i> , 2021, 18, 15-28.	0.6	6
9389	Immunomodulatory mAbs as Tools to Investigate on Cis-Interaction of PD-1/PD-L1 on Tumor Cells and to Set Up Methods for Early Screening of Safe and Potent Combinatorial Treatments. <i>Cancers</i> , 2021, 13, 2858.	1.7	12
9390	Emerging nanomaterials for cancer immunotherapy. <i>Exploration of Medicine</i> , 2021, 2, 208-231.	1.5	1

#	ARTICLE	IF	CITATIONS
9391	Expression of NKG2D ligands is downregulated by β -catenin signalling and associates with HCC aggressiveness. <i>Journal of Hepatology</i> , 2021, 74, 1386-1397.	1.8	37
9392	Advancing to the era of cancer immunotherapy. <i>Cancer Communications</i> , 2021, 41, 803-829.	3.7	90
9393	Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 184.	3.5	204
9394	Recent Advances and Future Perspective of DC-Based Therapy in NSCLC. <i>Frontiers in Immunology</i> , 2021, 12, 704776.	2.2	13
9395	Efficacy and safety of anti-PD-1 inhibitor combined with nab-paclitaxel in Chinese patients with refractory melanoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 1159-1169.	1.2	13
9397	The Mechanism of Stimulating and Mobilizing the Immune System Enhancing the Anti-Tumor Immunity. <i>Frontiers in Immunology</i> , 2021, 12, 682435.	2.2	27
9398	Our current understanding of checkpoint inhibitor therapy in cancer immunotherapy. <i>Annals of Allergy, Asthma and Immunology</i> , 2021, 126, 630-638.	0.5	23
9400	USP22 deficiency in melanoma mediates resistance to T _H 1 cells through IFN γ -JAK1-STAT1 signal axis. <i>Molecular Therapy</i> , 2021, 29, 2108-2120.	3.7	11
9401	Checkpoint inhibitor immunotherapy toxicity and overall survival among older adults with advanced cancer. <i>Journal of Geriatric Oncology</i> , 2021, 12, 813-819.	0.5	23
9402	Therapeutic Advancements Across Clinical Stages in Melanoma, With a Focus on Targeted Immunotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 670726.	1.3	26
9403	Application of Immune Checkpoint Inhibitors in Solid Organ Transplantation Recipients: A Systematic Review. <i>Interdisciplinary Sciences, Computational Life Sciences</i> , 2021, 13, 801-814.	2.2	7
9404	Impact of the development of immune related adverse events in metastatic melanoma treated with PD-1 inhibitors. <i>Melanoma Research</i> , 2021, 31, 258-263.	0.6	9
9405	Immunotherapy and Vaccination in Surgically Resectable Non-Small Cell Lung Cancer (NSCLC). <i>Vaccines</i> , 2021, 9, 689.	2.1	9
9406	A Comparative Retrospective Study of Immunotherapy RANO Versus Standard RANO Criteria in Glioblastoma Patients Receiving Immune Checkpoint Inhibitor Therapy. <i>Frontiers in Oncology</i> , 2021, 11, 679331.	1.3	4
9407	Immunocompetent cancer-on-chip models to assess immuno-oncology therapy. <i>Advanced Drug Delivery Reviews</i> , 2021, 173, 281-305.	6.6	38
9408	Novel induction of CD40 expression by tumor cells with RAS/RAF/PI3K pathway inhibition augments response to checkpoint blockade. <i>Molecular Cancer</i> , 2021, 20, 85.	7.9	23
9409	Emerging roles of activating transcription factor (ATF) family members in tumourigenesis and immunity: Implications in cancer immunotherapy. <i>Genes and Diseases</i> , 2022, 9, 981-999.	1.5	22
9410	The Prognostic Potential of Human Prostate Cancer-Associated Macrophage Subtypes as Revealed by Single-Cell Transcriptomics. <i>Molecular Cancer Research</i> , 2021, 19, 1778-1791.	1.5	20

#	ARTICLE	IF	CITATIONS
9411	Adrenocortical Carcinoma Steroid Profiles: In Silico Pan-Cancer Analysis of TCGA Data Uncovers Immunotherapy Targets for Potential Improved Outcomes. <i>Frontiers in Endocrinology</i> , 2021, 12, 672319.	1.5	6
9412	Early Tumor Size Reduction of at least 10% at the First Follow-Up Computed Tomography Can Predict Survival in the Setting of Advanced Melanoma and Immunotherapy. <i>Academic Radiology</i> , 2021, , .	1.3	2
9413	Long non-coding RNAs XIST and MALAT1 hijack the PD-L1 regulatory signaling pathway in breast cancer subtypes. <i>Oncology Letters</i> , 2021, 22, 593.	0.8	11
9414	Cancer Vaccines: Promising Therapeutics or an Unattainable Dream. <i>Vaccines</i> , 2021, 9, 668.	2.1	32
9415	Higher TLR7 Gene Expression Predicts Poor Clinical Outcome in Advanced NSCLC Patients Treated with Immunotherapy. <i>Genes</i> , 2021, 12, 992.	1.0	5
9416	Impact of Endoscopic Ultrasound-Guided Tissue Acquisition on Decision-Making in Precision Medicine for Pancreatic Cancer: Beyond Diagnosis. <i>Diagnostics</i> , 2021, 11, 1195.	1.3	9
9417	Prospects and Challenges for T Cell-Based Therapies of HCC. <i>Cells</i> , 2021, 10, 1651.	1.8	13
9418	Peptide-based assemblies as immune checkpoint inhibitor delivery systems for enhanced immunotherapy. <i>Applied Materials Today</i> , 2021, 23, 101063.	2.3	2
9419	Cancer-Mediated Muscle Cachexia: Etiology and Clinical Management. <i>Trends in Endocrinology and Metabolism</i> , 2021, 32, 382-402.	3.1	22
9420	A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 240.	3.5	3
9421	Advances in immunotherapeutic targets for childhood cancers: A focus on glypican-2 and B7-H3. , 2021, 223, 107892.		11
9422	Retrospective Analysis of Rechallenge with Ipilimumab in Patients with Metastatic Melanoma. <i>Journal of Skin Cancer</i> , 2021, 2021, 1-3.	0.5	2
9423	Clinical course of patients with renal cell carcinoma or urothelial carcinoma who had stable disease as an initial response to a PD-1 or PD-L1 inhibitor. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, , .	0.7	2
9424	Toxicity and time lapse between immunotherapy and stereotactic radiotherapy of brain metastases. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2021, 25, 432-440.	0.6	7
9425	Intersection of Two Checkpoints: Could Inhibiting the DNA Damage Response Checkpoint Rescue Immune Checkpoint-Refractory Cancer?. <i>Cancers</i> , 2021, 13, 3415.	1.7	15
9426	Predictive factors of neoadjuvant immune checkpoint blockade in melanoma. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-9.	1.4	3
9427	Clinical efficacy of T-cell therapy after short-term BRAF-inhibitor priming in patients with checkpoint inhibitor-resistant metastatic melanoma. , 2021, 9, e002703.		9
9428	Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors. , 2021, 9, e002890.		87

#	ARTICLE	IF	CITATIONS
9429	Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 495-508.	21.5	120
9430	Research status on immunotherapy trials of gastric cancer. <i>World Journal of Clinical Cases</i> , 2021, 9, 5782-5793.	0.3	5
9431	Comprehensive Characterization of Immune Landscape Based on Epithelial-Mesenchymal Transition Signature in OSCC: Implication for Prognosis and Immunotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 587862.	1.3	6
9432	Predictive biomarkers of inhibitors immune checkpoints therapy in malignant tumors. <i>Russian Journal of Pediatric Hematology and Oncology</i> , 2021, 8, 73-83.	0.1	2
9433	Myeloid-Derived Suppressor Cells: Implications in the Resistance of Malignant Tumors to T Cell-Based Immunotherapy. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 707198.	1.8	17
9434	TGF- β Alters the Proportion of Infiltrating Immune Cells in a Pancreatic Ductal Adenocarcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2022, 26, 113-121.	0.9	9
9435	The social meanings of choice in living-with advanced breast cancer. <i>Social Science and Medicine</i> , 2021, 280, 114047.	1.8	8
9436	Synergies between therapeutic ultrasound, gene therapy and immunotherapy in cancer treatment. <i>Advanced Drug Delivery Reviews</i> , 2021, 178, 113906.	6.6	20
9437	Oncolytic Adenovirus: Prospects for Cancer Immunotherapy. <i>Frontiers in Microbiology</i> , 2021, 12, 707290.	1.5	29
9438	Immune and Cell Cycle Checkpoint Inhibitors for Cancer Immunotherapy. , 0, , .		0
9439	Regional Delivery of Anti-PD-1 Agent for Colorectal Liver Metastases Improves Therapeutic Index and Anti-Tumor Activity. <i>Vaccines</i> , 2021, 9, 807.	2.1	2
9440	Personalized Neoantigen-Pulsed DC Vaccines: Advances in Clinical Applications. <i>Frontiers in Oncology</i> , 2021, 11, 701777.	1.3	21
9441	Cutaneous adverse events associated with immune checkpoint blockade: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 163, 103376.	2.0	9
9442	Targeting the spectrum of immune checkpoints in prostate cancer. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 1253-1266.	1.3	13
9443	Targeting galectins in T cell-based immunotherapy within tumor microenvironment. <i>Life Sciences</i> , 2021, 277, 119426.	2.0	6
9444	Inhibition of lung tumorigenesis by a small molecule CA170 targeting the immune checkpoint protein VISTA. <i>Communications Biology</i> , 2021, 4, 906.	2.0	12
9445	A Rare Presentation of Checkpoint Inhibitor Induced Distal RTA. <i>Case Reports in Oncological Medicine</i> , 2021, 2021, 1-5.	0.2	2
9446	Immunotherapy in Older Adults With Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 2115-2127.	0.8	33

#	ARTICLE	IF	CITATIONS
9447	Blocking Fc γ RIIB in Smooth Muscle Cells Reduces Hypertension. <i>Circulation Research</i> , 2021, 129, 308-325.	2.0	6
9448	B7-H3/CD276: An Emerging Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2021, 12, 701006.	2.2	100
9449	Evaluation of the reporting quality of clinical practice guidelines on melanoma using the RIGHT checklist. <i>Annals of Translational Medicine</i> , 2021, 9, 1172-1172.	0.7	0
9450	Disruptor of telomeric silencing 1-like promotes ovarian cancer tumor growth by stimulating pro-tumorigenic metabolic pathways and blocking apoptosis. <i>Oncogenesis</i> , 2021, 10, 48.	2.1	10
9451	Tumor Mutation Burden Prediction Model in Egyptian Breast Cancer patients based on Next Generation Sequencing. <i>Asian Pacific Journal of Cancer Prevention</i> , 2021, 22, 2053-2059.	0.5	5
9452	The Abscopal Effect in the Era of Checkpoint Inhibitors. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7204.	1.8	22
9453	Immune Checkpoint Inhibitor Therapy Toxicities. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 87.	3.8	2
9454	Correlation between vascular endothelial growth factor pathway and immune microenvironment in head and neck squamous cell carcinoma. <i>BMC Cancer</i> , 2021, 21, 836.	1.1	5
9455	Advances in Adoptive Cellular Therapy (ACT). , 0, , .		0
9456	Hyperprogressive Disease in Cancers Treated With Immune Checkpoint Inhibitors. <i>Frontiers in Pharmacology</i> , 2021, 12, 678409.	1.6	15
9457	Immunotherapy: New insights in breast cancer treatment. <i>Human Antibodies</i> , 2021, 29, 193-202.	0.6	3
9458	Potential Therapeutic Approaches through Modulating the Autophagy Process for Skin Barrier Dysfunction. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7869.	1.8	11
9459	Analysis of risk factors for immune-related adverse events in various solid tumors using real-world data. <i>Future Oncology</i> , 2021, 17, 2593-2603.	1.1	14
9460	Intestinal microbiota: A potential target for enhancing the antitumor efficacy and reducing the toxicity of immune checkpoint inhibitors. <i>Cancer Letters</i> , 2021, 509, 53-62.	3.2	13
9461	Analyzing the impact of ATF3 in tumorigenesis and immune cell infiltration of ovarian tumor: a bioinformatics study. <i>Medical Oncology</i> , 2021, 38, 91.	1.2	6
9462	Recognition, Staging, and Management of Melanoma. <i>Medical Clinics of North America</i> , 2021, 105, 643-661.	1.1	4
9463	Mechanisms Driving Immune-Related Adverse Events in Cancer Patients Treated with Immune Checkpoint Inhibitors. <i>Current Cardiology Reports</i> , 2021, 23, 98.	1.3	34
9464	Telomerase as a Target for Therapeutic Cancer Vaccines and Considerations for Optimizing Their Clinical Potential. <i>Frontiers in Immunology</i> , 2021, 12, 682492.	2.2	18

#	ARTICLE	IF	CITATIONS
9465	Design and Encapsulation of Immunomodulators onto Gold Nanoparticles in Cancer Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8037.	1.8	17
9466	Health Care Utilization and Costs Associated With Systemic First-Line Metastatic Melanoma Therapies in the United States. <i>JCO Oncology Practice</i> , 2021, , OP.21.00140.	1.4	6
9467	Preoperative Immunotherapy in the Multidisciplinary Management of Oral Cavity Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 682075.	1.3	6
9468	Use of immune checkpoint inhibitors in patients with solid tumors and pre-existing autoimmune or inflammatory disease: real-world data. <i>Lung Cancer Management</i> , 2021, 10, LMT51.	1.5	10
9469	Evolution of systemic treatment for advanced hepatocellular carcinoma. <i>Kaohsiung Journal of Medical Sciences</i> , 2021, 37, 643-653.	0.8	11
9470	The DANTE trial protocol: a randomised phase III trial to evaluate the Duration of ANti-PD-1 monoclonal antibody Treatment in patients with metastatic mElanoma. <i>BMC Cancer</i> , 2021, 21, 761.	1.1	12
9471	Cancer-Associated Fibroblasts: Implications for Cancer Therapy. <i>Cancers</i> , 2021, 13, 3526.	1.7	22
9473	Immune checkpoints and cancer development: Therapeutic implications and future directions. <i>Pathology Research and Practice</i> , 2021, 223, 153485.	1.0	29
9474	Low-dose ipilimumab combined with anti-PD-1 immunotherapy in patients with metastatic melanoma following anti-PD-1 treatment failure. <i>Melanoma Research</i> , 2021, 31, 464-471.	0.6	2
9475	Nivolumab and Ipilimumab Combination Immunotherapy for Patients with Metastatic Collecting Duct Carcinoma. <i>Case Reports in Urology</i> , 2021, 2021, 1-4.	0.1	4
9476	Pharmacological inhibitors of anaplastic lymphoma kinase (ALK) induce immunogenic cell death through on-target effects. <i>Cell Death and Disease</i> , 2021, 12, 713.	2.7	29
9477	New systemic therapies for cutaneous melanoma: why, who and what. <i>Italian Journal of Dermatology and Venereology</i> , 2021, 156, 344-355.	0.1	2
9478	Intratumour microbiome associated with the infiltration of cytotoxic CD8+ T cells and patient survival in cutaneous melanoma. <i>European Journal of Cancer</i> , 2021, 151, 25-34.	1.3	59
9479	Identification of a class of non-conventional ER-stress-response-derived immunogenic peptides. <i>Cell Reports</i> , 2021, 36, 109312.	2.9	13
9480	Molecular Mechanisms of Resistance to Immune Checkpoint Inhibitors in Melanoma Treatment: An Update. <i>Biomedicines</i> , 2021, 9, 835.	1.4	20
9481	Endocrine adverse effects of immune checkpoint inhibitors. <i>Internal Medicine Journal</i> , 2021, 51, 1016-1020.	0.5	2
9482	Treatment of Advanced Metastatic Melanoma. <i>Dermatology Practical and Conceptual</i> , 2021, 11, 2021164S.	0.5	10
9483	Genomic, Microbial and Immunological Microenvironment of Colorectal Polyps. <i>Cancers</i> , 2021, 13, 3382.	1.7	7

#	ARTICLE	IF	CITATIONS
9484	Recruitment, outcomes, and toxicity trends in phase I oncology trials: Six-year experience in a large institution. <i>Cancer Reports</i> , 2021, , e1465.	0.6	1
9485	Epigenetic Mechanisms in DNA Double Strand Break Repair: A Clinical Review. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 685440.	1.6	17
9486	Cytokines: Signalling Improved Immunotherapy?. <i>Current Oncology Reports</i> , 2021, 23, 103.	1.8	0
9487	Malignant melanoma: evolving practice management in an era of increasingly effective systemic therapies. <i>Current Problems in Surgery</i> , 2022, 59, 101030.	0.6	4
9488	Systemic immune-inflammation index is a stage-dependent prognostic factor in patients with operable non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 3144-3154.	1.3	15
9489	Multitumor Case Series of Germline BRCA1, BRCA2 and CHEK2-Mutated Patients Responding Favorably on Immune Checkpoint Inhibitors. <i>Current Oncology</i> , 2021, 28, 3227-3239.	0.9	2
9490	Palliative care physicians'™ recognition of patients after immune checkpoint inhibitors and immune-related adverse events. <i>Supportive Care in Cancer</i> , 2022, 30, 775-784.	1.0	0
9491	Cancer immunotherapy from biology to nanomedicine. <i>Journal of Controlled Release</i> , 2021, 336, 410-432.	4.8	12
9492	First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas. , 2021, 9, e002863.		20
9493	Immune checkpoint inhibitors for advanced or metastatic basal cell carcinoma: how much evidence do we need?. <i>Immunotherapy</i> , 2021, 13, 1293-1304.	1.0	3
9494	Identification of Immune-Related Subtypes and Characterization of Tumor Microenvironment Infiltration in Bladder Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 723817.	1.8	9
9495	Tumor-on-chip modeling of organ-specific cancer and metastasis. <i>Advanced Drug Delivery Reviews</i> , 2021, 175, 113798.	6.6	57
9496	Hypothalamicâ€Pituitary Autoimmunity in Patients Treated with Anti-PD-1 and Anti-PD-L1 Antibodies. <i>Cancers</i> , 2021, 13, 4036.	1.7	3
9497	Finite Mixture Models, a Flexible Alternative to Standard Modeling Techniques for Extrapolated Mean Survival Times Needed for Cost-Effectiveness Analyses. <i>Value in Health</i> , 2021, 24, 1643-1650.	0.1	2
9498	sCD28, sCD80, sCTLA-4, and sBTLA Are Promising Markers in Diagnostic and Therapeutic Approaches for Aseptic Loosening and Periprosthetic Joint Infection. <i>Frontiers in Immunology</i> , 2021, 12, 687065.	2.2	5
9499	Deciphering the Dynamic Complexities of the Liver Microenvironment â€” Toward a Better Understanding of Immune-Mediated liver Injury Caused by Immune Checkpoint Inhibitors (ILICI). <i>AAPS Journal</i> , 2021, 23, 99.	2.2	1
9500	Electroretinographic Findings in Melanoma-Associated Retinopathy Treated by Intravitreal Dexamethasone Implant. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2021, 52, 454-456.	0.4	5
9501	The role of the bacterial microbiome in the treatment of cancer. <i>BMC Cancer</i> , 2021, 21, 934.	1.1	22

#	ARTICLE	IF	CITATIONS
9502	Systemic Treatment of Cutaneous Adverse Events After Immune Checkpoint Inhibitor Therapy: A Review. <i>Dermatitis</i> , 2023, 34, 201-208.	0.8	4
9503	The State of Immunotherapy in Hepatobiliary Cancers. <i>Cells</i> , 2021, 10, 2096.	1.8	18
9504	The establishment of a prognostic scoring model based on the new tumor immune microenvironment classification in acute myeloid leukemia. <i>BMC Medicine</i> , 2021, 19, 176.	2.3	10
9505	Advances in immune therapies for the treatment of microsatellite instabilityâ€‘high/deficient mismatch repair metastatic colorectal cancer (Review). <i>International Journal of Oncology</i> , 2021, 59, .	1.4	4
9506	Trinity immune enhancing nanoparticles for boosting antitumor immune responses of immunogenic chemotherapy. <i>Nano Research</i> , 2022, 15, 1183-1192.	5.8	7
9507	Systemic administration of polymersomal oncolytic peptide LTX-315 combining with CpG adjuvant and anti-PD-1 antibody boosts immunotherapy of melanoma. <i>Journal of Controlled Release</i> , 2021, 336, 262-273.	4.8	23
9508	Multifunctional Nanocarriersâ€‘Mediated Synergistic Combination of Immune Checkpoint Inhibitor Cancer Immunotherapy and Interventional Oncology Therapy. <i>Advanced NanoBiomed Research</i> , 2021, 1, 2100010.	1.7	5
9509	Advances in the <i>in vitro</i> digestion and fermentation of polysaccharides. <i>International Journal of Food Science and Technology</i> , 2021, 56, 4970-4982.	1.3	23
9510	Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 2656-2666.	0.8	145
9511	The Microenvironment of Small Intestinal Neuroendocrine Tumours Contains Lymphocytes Capable of Recognition and Activation after Expansion. <i>Cancers</i> , 2021, 13, 4305.	1.7	7
9512	Analysis of cytokines in serum and bronchoalveolar lavage fluid in patients with immune-checkpoint inhibitor-associated pneumonitis: a cross-sectional caseâ€‘control study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 1711-1720.	1.2	22
9513	Incidence and characteristics of metastatic intracranial lesions in stage III and IV melanoma: a single institute retrospective analysis. <i>Journal of Neuro-Oncology</i> , 2021, 154, 197-203.	1.4	10
9514	Prediction of Immunotherapy Response in Melanoma through Combined Modeling of Neoantigen Burden and Immune-Related Resistance Mechanisms. <i>Clinical Cancer Research</i> , 2021, 27, 4265-4276.	3.2	23
9515	Immunomodulation by durvalumab and pomalidomide in patients with relapsed/refractory multiple myeloma. <i>Scientific Reports</i> , 2021, 11, 16460.	1.6	3
9516	Faecal microbiota transplantation enhances efficacy of immune checkpoint inhibitors therapy against cancer. <i>World Journal of Gastroenterology</i> , 2021, 27, 5362-5375.	1.4	17
9517	Identification of a robust signature for clinical outcomes and immunotherapy response in gastric cancer: based on N6-methyladenosine related long noncoding RNAs. <i>Cancer Cell International</i> , 2021, 21, 432.	1.8	16
9518	Characterizing Trends in Cancer Patients' Survival Using the JPSurv Software. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 2001-2009.	1.1	9
9519	Case Report: A Case Report and Literature Review on Severe Bullous Skin Reaction Induced by anti-PD-1 Immunotherapy in a Cervical Cancer Patient. <i>Frontiers in Pharmacology</i> , 2021, 12, 707967.	1.6	4

#	ARTICLE	IF	CITATIONS
9521	Lung Cancer Surgery after Neoadjuvant Immunotherapy. <i>Cancers</i> , 2021, 13, 4033.	1.7	12
9522	Human immunocompetent Organ-on-Chip platforms allow safety profiling of tumor-targeted T-cell bispecific antibodies. <i>ELife</i> , 2021, 10, .	2.8	33
9523	Benzamide derivative radiotracers targeting melanin for melanoma imaging and therapy: Preclinical/clinical development and combination with other treatments. , 2021, 224, 107829.		12
9524	Epitranscriptomic Approach: To Improve the Efficacy of ICB Therapy by Co-Targeting Intracellular Checkpoint CISH. <i>Cells</i> , 2021, 10, 2250.	1.8	6
9525	Clinical Categorization Algorithm (CLICAL) and Machine Learning Approach (SRF-CLICAL) to Predict Clinical Benefit to Immunotherapy in Metastatic Melanoma Patients: Real-World Evidence from the Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy. <i>Cancers</i> , 2021, 13, 4164.	1.7	5
9526	Inhibition of MEK pathway enhances the antitumor efficacy of chimeric antigen receptor T cells against neuroblastoma. <i>Cancer Science</i> , 2021, 112, 4026-4036.	1.7	12
9527	Comparing syngeneic and autochthonous models of breast cancer to identify tumor immune components that correlate with response to immunotherapy in breast cancer. <i>Breast Cancer Research</i> , 2021, 23, 83.	2.2	13
9528	Implantable optical fibers for immunotherapeutics delivery and tumor impedance measurement. <i>Nature Communications</i> , 2021, 12, 5138.	5.8	28
9529	The Effect of Ferroptosis-Related Genes on Prognosis and Tumor Mutational Burden in Hepatocellular Carcinoma. <i>Journal of Oncology</i> , 2021, 2021, 1-12.	0.6	10
9530	Magnetic systems for cancer immunotherapy. <i>Acta Pharmaceutica Sinica B</i> , 2021, 11, 2172-2196.	5.7	40
9531	Multidimensional Analyses of Tumor Immune Microenvironment Reveal the Possible Rationality of Immunotherapy and Identify High Immunotherapy Response Subtypes for Renal Papillary Cell Carcinoma. <i>Frontiers in Immunology</i> , 2021, 12, 657951.	2.2	2
9532	Toxicidades cutáneas de las terapias dirigidas, inmunoterapias y citocinas contra el cáncer. <i>EMC - Dermatología</i> , 2021, 55, 1-19.	0.1	0
9533	Transfer learning between preclinical models and human tumors identifies a conserved NK cell activation signature in anti-CTLA-4 responsive tumors. <i>Genome Medicine</i> , 2021, 13, 129.	3.6	17
9534	Cell-based electrochemical cytosensor for rapid and sensitive evaluation of the anticancer effects of saponin on human malignant melanoma cells. <i>Bioelectrochemistry</i> , 2021, 140, 107813.	2.4	9
9535	Sargramostim and immune checkpoint inhibitors: combinatorial therapeutic studies in metastatic melanoma. <i>Immunotherapy</i> , 2021, 13, 1011-1029.	1.0	8
9536	Current understanding of nonsurgical interventions for refractory differentiated thyroid cancer: a systematic review. <i>Future Science OA</i> , 2021, 7, FSO738.	0.9	3
9537	Systemic and liver-directed therapies in metastatic uveal melanoma: state-of-the-art and novel perspectives. <i>Future Oncology</i> , 2021, 17, 4583-4606.	1.1	2
9538	Advances in Engineered Polymer Nanoparticle Tracking Platforms towards Cancer Immunotherapy—Current Status and Future Perspectives. <i>Vaccines</i> , 2021, 9, 935.	2.1	18

#	ARTICLE	IF	CITATIONS
9539	The Emerging Role of T-Cell Immunoglobulin Mucin-3 in Breast Cancer: A Promising Target For Immunotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 723238.	1.3	5
9540	MERTK on mononuclear phagocytes regulates T cell antigen recognition at autoimmune and tumor sites. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	15
9541	Extramammary Paget's Disease: Diagnosis, Pathogenesis, and Treatment with Focus on Recent Developments. <i>Current Oncology</i> , 2021, 28, 2969-2986.	0.9	43
9542	Next-Generation Immunotherapy Approaches in Melanoma. <i>Current Oncology Reports</i> , 2021, 23, 116.	1.8	3
9543	Sex Differences in Cancer Genomes: Much Learned, More Unknown. <i>Endocrinology</i> , 2021, 162, .	1.4	5
9544	Immune Checkpoint Inhibitors and Neurotoxicity. <i>Current Neuropharmacology</i> , 2021, 19, 1246-1263.	1.4	10
9545	Strategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K- $\hat{\gamma}$ and $\hat{\beta}$. <i>Frontiers in Immunology</i> , 2021, 12, 718621.	2.2	16
9546	Novel oncolytic adenovirus expressing enhanced cross-hybrid IgG A Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids. , 2021, 9, e003000.		27
9548	Biomarkers in metastatic melanoma of the skin: can we more accurately choose the tactics of treating our patients?. <i>Meditsinskiy Sovet</i> , 2021, , 48-63.	0.1	2
9549	Dual targeting of CTLA-4 and CD47 on T _{reg} cells promotes immunity against solid tumors. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	39
9550	Immune checkpoint inhibitor-related hepatotoxicity: A review. <i>World Journal of Gastroenterology</i> , 2021, 27, 5376-5391.	1.4	52
9551	Dendrimers for cancer immunotherapy: Avidity-based drug delivery vehicles for effective anti-tumor immune response. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2022, 14, e1752.	3.3	13
9552	Nanomedicines modulating myeloid-derived suppressor cells for improving cancer immunotherapy. <i>Nano Today</i> , 2021, 39, 101163.	6.2	18
9553	Immune-mediated adverse events in immune checkpoint inhibitors therapy: literature review. <i>Journal of Modern Oncology</i> , 2021, 23, 319-326.	0.1	4
9554	Feasibility of Monitoring Tumor Response by Tracking Nanoparticle-Labelled T Cells Using X-ray Fluorescence Imaging—A Numerical Study. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8736.	1.8	8
9555	Cancer immunotherapy with PI3K and PD-1 dual-blockade via optimal modulation of T cell activation signal. , 2021, 9, e002279.		19
9556	Immunotherapy in Hepatocellular Carcinoma. <i>Current Treatment Options in Oncology</i> , 2021, 22, 87.	1.3	25
9557	The Danish metastatic melanoma database (DAMMED): A nation-wide platform for quality assurance and research in real-world data on medical therapy in Danish melanoma patients. <i>Cancer Epidemiology</i> , 2021, 73, 101943.	0.8	21

#	ARTICLE	IF	CITATIONS
9558	Current Trends of Immunotherapy in the Treatment of Cutaneous Melanoma: A Review. <i>Dermatology and Therapy</i> , 2021, 11, 1481-1496.	1.4	12
9559	Overcoming Immune Resistance in Prostate Cancer: Challenges and Advances. <i>Cancers</i> , 2021, 13, 4757.	1.7	10
9560	Clinical characterization and treatment of head and neck mucosal melanoma: a Chilean experience. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2021, 132, 273-280.	0.2	1
9561	Tumor-Derived Exosomes: Hidden Players in PD-1/PD-L1 Resistance. <i>Cancers</i> , 2021, 13, 4537.	1.7	20
9562	Prior Exposure to Coxsackievirus A21 Does Not Mitigate Oncolytic Therapeutic Efficacy. <i>Cancers</i> , 2021, 13, 4462.	1.7	2
9563	Profiling the inhibitory receptors LAG-3, TIM-3, and TIGIT in renal cell carcinoma reveals malignancy. <i>Nature Communications</i> , 2021, 12, 5547.	5.8	31
9564	Outcomes for systemic therapy in older patients with metastatic melanoma: Results from the Dutch Melanoma Treatment Registry. <i>Journal of Geriatric Oncology</i> , 2021, 12, 1031-1038.	0.5	2
9565	Extracellular acidity in tumor tissue upregulates programmed cell death ligand 1 expression on tumor cells via proton-sensing G protein-coupled receptors. <i>International Journal of Cancer</i> , 2021, 149, 2116-2124.	2.3	12
9566	Immune Checkpoint Inhibitor-Associated Tumor Lysis Syndrome: A Real-World Pharmacovigilance Study. <i>Frontiers in Pharmacology</i> , 2021, 12, 679207.	1.6	3
9567	The Status of Adjuvant and Neoadjuvant Melanoma Therapy, New Developments and Upcoming Challenges. <i>Targeted Oncology</i> , 2021, 16, 537-552.	1.7	20
9568	The augment of regulatory T cells undermines the efficacy of anti-PD-L1 treatment in cervical cancer. <i>BMC Immunology</i> , 2021, 22, 60.	0.9	9
9569	PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy. <i>Frontiers in Pharmacology</i> , 2021, 12, 731798.	1.6	134
9570	Macrophage-Based Combination Therapies as a New Strategy for Cancer Immunotherapy. <i>Kidney Diseases (Basel, Switzerland)</i> , 2022, 8, 26-43.	1.2	16
9571	Engineered Bifunctional Proteins for Targeted Cancer Therapy: Prospects and Challenges. <i>Advanced Materials</i> , 2021, 33, e2103114.	11.1	6
9572	The Stromal and Immune Landscape of Nasopharyngeal Carcinoma and Its Implications for Precision Medicine Targeting the Tumor Microenvironment. <i>Frontiers in Oncology</i> , 2021, 11, 744889.	1.3	19
9573	Characterization of m6A-Related Genes Landscape in Skin Cutaneous Melanoma to Aid Immunotherapy and Assess Prognosis. <i>International Journal of General Medicine</i> , 2021, Volume 14, 5345-5361.	0.8	7
9574	A CLDN18.2-Targeting Bispecific T Cell Co-Stimulatory Activator for Cancer Immunotherapy. <i>Cancer Management and Research</i> , 2021, Volume 13, 6977-6987.	0.9	8
9575	Biologic therapies for checkpoint inhibitor-induced cutaneous toxicities: a single-institution study of 17 consecutively treated patients. <i>Supportive Care in Cancer</i> , 2022, 30, 989-994.	1.0	4

#	ARTICLE	IF	CITATIONS
9576	The prevalence of homologous recombination deficiency (HRD) in various solid tumors and the role of HRD as a single biomarker to immune checkpoint inhibitors. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 2427-2435.	1.2	5
9577	A Novel Immunomodulator Delivery Platform Based on Bacterial Biomimetic Vesicles for Enhanced Antitumor Immunity. <i>Advanced Materials</i> , 2021, 33, e2103923.	11.1	19
9578	Current Landscape of Non-Small Cell Lung Cancer: Epidemiology, Histological Classification, Targeted Therapies, and Immunotherapy. <i>Cancers</i> , 2021, 13, 4705.	1.7	86
9579	Trends in Diagnosis and Treatment of Metastatic Cancer in the United States. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021, 44, 572-579.	0.6	15
9580	Prognostic and Predictive Biomarkers in Gliomas. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10373.	1.8	110
9581	Development of preclinical and clinical models for immune-related adverse events following checkpoint immunotherapy: a perspective from SITC and AACR. , 2021, 9, e002627.		15
9582	Clinical Efficacy and Future Prospects of Immunotherapy in Lung Cancer. <i>Life</i> , 2021, 11, 1029.	1.1	8
9583	Microbiota and Colorectal Cancer: From Gut to Bedside. <i>Frontiers in Pharmacology</i> , 2021, 12, 760280.	1.6	22
9584	Immune PET Imaging. <i>Radiologic Clinics of North America</i> , 2021, 59, 875-886.	0.9	2
9585	Diagnosis, treatment and predictors of prognosis of myocarditis. A narrative review. <i>Cardiovascular Pathology</i> , 2021, 54, 107362.	0.7	10
9586	The role of interferons in melanoma resistance to immune checkpoint blockade: mechanisms of escape and therapeutic implications. <i>British Journal of Dermatology</i> , 2021, , .	1.4	9
9587	Pharmacologically induced uveitis. <i>Survey of Ophthalmology</i> , 2021, 66, 781-801.	1.7	6
9588	Combination of immunotherapy-radiotherapy in non-small cell lung cancer: Reality and perspective. <i>Radiation Medicine and Protection</i> , 2021, 2, 160-164.	0.4	3
9589	Oncolytic Virotherapy for Melanoma Brain Metastases, a Potential New Treatment Paradigm?. <i>Brain Sciences</i> , 2021, 11, 1260.	1.1	4
9590	Gastrointestinal Adverse Events Induced by Immune-Checkpoint Inhibitors. <i>Digestion</i> , 2021, 102, 965-973.	1.2	2
9591	Recent Advances in Pediatric Cancer Research. <i>Cancer Research</i> , 2021, 81, 5783-5799.	0.4	8
9592	The Challenges and Future of Immunotherapy for Gliomas. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 371-378.	1.0	3
9593	Leveraging the Treg-intrinsic CTLA4-“PKC” signaling pathway for cancer immunotherapy. , 2021, 9, e002792.		2

#	ARTICLE	IF	CITATIONS
9594	Management of Immune-Related Adverse Events in Patients With Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 720759.	1.3	3
9595	Cardiac Toxicity Associated with Cancer Immunotherapy and Biological Drugs. <i>Cancers</i> , 2021, 13, 4797.	1.7	12
9596	Shifting Gears in Precision Oncology—Challenges and Opportunities of Integrative Data Analysis. <i>Biomolecules</i> , 2021, 11, 1310.	1.8	3
9597	PD-L1 Expression Is Significantly Associated with Tumor Mutation Burden and Microsatellite Instability Score. <i>Cancers</i> , 2021, 13, 4659.	1.7	20
9598	Identification of a Gene Prognostic Model of Gastric Cancer Based on Analysis of Tumor Mutation Burden. <i>Pathology and Oncology Research</i> , 2021, 27, 1609852.	0.9	10
9599	Immunotherapy in Patients With Poor Performance Status: The Jury Is Still Out on This Special Population. <i>JCO Oncology Practice</i> , 2021, 17, 583-586.	1.4	7
9600	Hyperprogression: A Unique Phenomenon of Progression of Existing Tumor Secondary to Immunotherapy. <i>Cureus</i> , 2021, 13, e17992.	0.2	1
9601	PD-1 and PD-L1 expression in cardiac transplantation. <i>Cardiovascular Pathology</i> , 2021, 54, 107331.	0.7	9
9602	Case Report: Ipilimumab-induced Multisystem Autoimmune-like Toxicities Suggestive of Vogt-Koyanagi-Harada—like Syndrome. <i>Optometry and Vision Science</i> , 2021, 98, 1309-1316.	0.6	6
9603	Remodeling the Tumor Myeloid Landscape to Enhance Antitumor Antibody Immunotherapies. <i>Cancers</i> , 2021, 13, 4904.	1.7	8
9604	Electrochemotherapy as a Trigger to Overcome Primary Resistance to Anti-PD-1 Treatment: A Case Report of Melanoma of the Scalp. <i>Frontiers in Oncology</i> , 2021, 11, 742666.	1.3	5
9605	PARP Inhibitors in Melanoma—An Expanding Therapeutic Option?. <i>Cancers</i> , 2021, 13, 4520.	1.7	8
9606	Molecular Markers and Targets in Melanoma. <i>Cells</i> , 2021, 10, 2320.	1.8	72
9607	Which adjuvant treatment for patients with BRAFV600-mutant cutaneous melanoma?. <i>Annales De Dermatologie Et De Venereologie</i> , 2021, 148, 145-155.	0.5	4
9608	Results of isolated limb perfusion for metastasized malignant melanoma. <i>Surgical Oncology</i> , 2021, 38, 101603.	0.8	1
9610	Characterization and modulation of anti- \hat{I}^2 TCR antibodies and their respective binding sites at the \hat{I}^2 TCR chain to enrich engineered T \hat{A} cells. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021, 22, 388-400.	1.8	4
9611	Clinical translation of immunomodulatory therapeutics. <i>Advanced Drug Delivery Reviews</i> , 2021, 176, 113896.	6.6	8
9612	Ipilimumab in a real—world population: A prospective Phase IV trial with long—term follow—up. <i>International Journal of Cancer</i> , 2022, 150, 100-111.	2.3	11

#	ARTICLE	IF	CITATIONS
9613	Combination strategies to maximize the benefits of cancer immunotherapy. <i>Journal of Hematology and Oncology</i> , 2021, 14, 156.	6.9	202
9614	Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 37-50.	12.5	350
9615	The CD112R/CD112 axis: a breakthrough in cancer immunotherapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 285.	3.5	24
9616	The promise and perils of immunotherapy. <i>Blood Advances</i> , 2021, 5, 3709-3725.	2.5	23
9617	Simultaneously Combined Cancer Cell- and CTLA4-Targeted NIR-PIT Causes a Synergistic Treatment Effect in Syngeneic Mouse Models. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 2262-2273.	1.9	20
9618	Therapeutic cancer vaccines revamping: technology advancements and pitfalls. <i>Annals of Oncology</i> , 2021, 32, 1537-1551.	0.6	36
9619	Beyond Nicotinamide Metabolism: Potential Role of Nicotinamide N-Methyltransferase as a Biomarker in Skin Cancers. <i>Cancers</i> , 2021, 13, 4943.	1.7	37
9620	Diagnosis and management of adrenocorticotrophic hormone-secreting pituitary carcinoma: a case report and review of the literature. <i>Future Rare Diseases</i> , 2021, 1, .	0.1	1
9621	Immune checkpoint inhibitors for triple-negative breast cancer: From immunological mechanisms to clinical evidence. <i>International Immunopharmacology</i> , 2021, 98, 107876.	1.7	15
9622	The impact of sarcopenia on the efficacy and safety of immune checkpoint inhibitors in patients with solid tumours. <i>Acta Oncologica</i> , 2021, 60, 1597-1603.	0.8	13
9623	Clonal dynamics of circulating tumor DNA during immune checkpoint blockade therapy for melanoma. <i>Cancer Science</i> , 2021, 112, 4748-4757.	1.7	9
9624	A fatal affair: Circulating tumor cell relationships that shape metastasis. <i>IScience</i> , 2021, 24, 103073.	1.9	8
9625	Immune checkpoint inhibitors in melanoma. <i>Lancet, The</i> , 2021, 398, 1002-1014.	6.3	462
9626	mRNA-Based Cancer Vaccines: A Therapeutic Strategy for the Treatment of Melanoma Patients. <i>Vaccines</i> , 2021, 9, 1060.	2.1	39
9627	Melanoma of glans penis and urethra: A case report and systematic review of the literature of a rare and complex neoplasm. <i>Urologia</i> , 2021, , 039156032110464.	0.3	4
9628	Combined targeted therapy and immunotherapy for cancer treatment. <i>World Journal of Clinical Cases</i> , 2021, 9, 7643-7652.	0.3	5
9629	Recombinant adenovirus expressing the fusion protein PD1PVR improves CD8+ T cell-mediated antitumor efficacy with long-term tumor-specific immune surveillance in hepatocellular carcinoma. <i>Cellular Oncology (Dordrecht)</i> , 2021, 44, 1243-1255.	2.1	7
9630	Epigenetic mechanisms of liver tumor resistance to immunotherapy. <i>World Journal of Hepatology</i> , 2021, 13, 979-1002.	0.8	5

#	ARTICLE	IF	CITATIONS
9631	Non-coding RNAs in melanoma: Biological functions and potential clinical applications. <i>Molecular Therapy - Oncolytics</i> , 2021, 22, 219-231.	2.0	11
9632	Critically ill patients with severe immune checkpoint inhibitor related neurotoxicity: A multi-center case series. <i>Journal of Critical Care</i> , 2021, 65, 126-132.	1.0	6
9633	Adjuvant and Neoadjuvant Therapeutics for the Treatment of Cutaneous Melanoma. <i>Clinics in Plastic Surgery</i> , 2021, 48, 651-658.	0.7	5
9634	Short Review on Advances in Hydrogel-Based Drug Delivery Strategies for Cancer Immunotherapy. <i>Tissue Engineering and Regenerative Medicine</i> , 2022, 19, 263-280.	1.6	11
9635	A Phase I/II Study to Assess the Safety and Efficacy of Pazopanib and Pembrolizumab Combination Therapy in Patients with Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 434-446.	0.9	16
9636	Strategic enhancement of immune checkpoint inhibition in refractory Colorectal Cancer: Trends and future prospective. <i>International Immunopharmacology</i> , 2021, 99, 108017.	1.7	5
9637	Expression of programmed death ligand 1 in drug-resistant osteosarcoma: An exploratory study. <i>Surgery Open Science</i> , 2021, 6, 10-14.	0.5	4
9638	TIM-3: An update on immunotherapy. <i>International Immunopharmacology</i> , 2021, 99, 107933.	1.7	71
9639	Emerging Therapies in the Treatment of Advanced Melanoma. <i>Clinics in Plastic Surgery</i> , 2021, 48, 713-733.	0.7	3
9640	An update on immunotherapy with PD-1 and PD-L1 blockade. <i>Yeungnam University Journal of Medicine</i> , 2021, 38, 308-317.	0.7	1
9641	Advance investigation on synthetic small-molecule inhibitors targeting PD-1/PD-L1 signaling pathway. <i>Life Sciences</i> , 2021, 282, 119813.	2.0	21
9642	Non-Operative Options for Loco-regional Melanoma. <i>Clinics in Plastic Surgery</i> , 2021, 48, 631-642.	0.7	1
9643	Recent advances in immune checkpoint therapy in non-small cell lung cancer and opportunities for nanoparticle-based therapy. <i>European Journal of Pharmacology</i> , 2021, 909, 174404.	1.7	18
9644	Cancer cell immune mimicry delineates onco-immunologic modulation. <i>IScience</i> , 2021, 24, 103133.	1.9	9
9645	The Landscape of the Tumor Microenvironment in Skin Cutaneous Melanoma Reveals a Prognostic and Immunotherapeutically Relevant Gene Signature. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 739594.	1.8	4
9646	The role of regulatory T cells in the pathogenesis and treatment of prostate cancer. <i>Life Sciences</i> , 2021, 284, 119132.	2.0	26
9647	Intra- and inter-reader agreement of iRECIST and RECIST 1.1 criteria for the assessment of tumor response in patients receiving checkpoint inhibitor immunotherapy for lung cancer. <i>Lung Cancer</i> , 2021, 161, 60-67.	0.9	2
9648	Impact of intratumoural CD73 expression on prognosis and therapeutic response in patients with gastric cancer. <i>European Journal of Cancer</i> , 2021, 157, 114-123.	1.3	15

#	ARTICLE	IF	CITATIONS
9649	Ocular side effects of checkpoint inhibitors. Survey of Ophthalmology, 2021, 66, 951-959.	1.7	16
9650	Progress and challenges of immunotherapy in triple-negative breast cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1876, 188593.	3.3	106
9651	Intracranial malignant melanoma: An egyptian institute experience. Interdisciplinary Neurosurgery: Advanced Techniques and Case Management, 2021, 26, 101370.	0.2	1
9652	Metabolic reprogramming and immunity in cancer. , 2022, , 137-196.		1
9653	Delivery strategies for ex vivo and in vivo T-cell reprogramming. , 2022, , 31-62.		0
9654	Indoleamine 2,3-dioxygenase 1 (IDO): A mediator of immunoresistance in adults with brain cancer treated with immunomodulatory therapy. , 2022, , 127-151.		0
9655	The effects of anticancer therapies on bone metastases in breast cancer. , 2022, , 987-1002.		0
9656	Delivery strategies to overcome tumor immunotherapy resistance. , 2022, , 529-547.		0
9657	Intrinsic and acquired cancer immunotherapy resistance. , 2022, , 463-497.		0
9658	Magnetic lipid nanovehicles synergize the controlled thermal release of chemotherapeutics with magnetic ablation while enabling non-invasive monitoring by MRI for melanoma theranostics. Bioactive Materials, 2022, 8, 153-164.	8.6	20
9660	Endocrinopathies Associated With Immune Checkpoint Inhibitors. , 2022, , 301-314.		0
9661	Delivery strategies for immune checkpoint blockade. , 2022, , 1-29.		0
9662	Immune checkpoint blockade therapy in high-grade glioma. , 2022, , 91-108.		0
9663	Current Role of Immunotherapy. , 2022, , 905-911.		0
9664	Development of Skin Rash Predicts Outcome of Anti-PD-1- and Anti-CTLA4-Based Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer or Squamous Cell Carcinoma of the Head and Neck: A Single-Center Analysis. Oncology Research and Treatment, 2021, 44, 538-546.	0.8	5
9665	Granzyme family acts as a predict biomarker in cutaneous melanoma and indicates more benefit from anti-PD-1 immunotherapy. International Journal of Medical Sciences, 2021, 18, 1657-1669.	1.1	12
9666	The Tumor Infiltrating Lymphocytes (TILs): Did We Find the Missed Piece of the Huge Puzzle?. Open Journal of Obstetrics and Gynecology, 2021, 11, 146-161.	0.1	2
9667	Bispecific antibodies: A promising entrant in cancer immunotherapy. , 2021, , 233-266.		2

#	ARTICLE	IF	CITATIONS
9668	Laser nanobubbles induce immunogenic cell death in breast cancer. <i>Nanoscale</i> , 2021, 13, 3644-3653.	2.8	7
9669	Identification of Immune-Related lncRNA Signature to Predict Prognosis and Immunotherapeutic Efficiency in Bladder Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 542140.	1.3	21
9670	Hypoxia and the phenomenon of immune exclusion. <i>Journal of Translational Medicine</i> , 2021, 19, 9.	1.8	63
9671	Immune classification of osteosarcoma. <i>Mathematical Biosciences and Engineering</i> , 2021, 18, 1879-1897.	1.0	20
9672	Characterization of immune landscape in papillary thyroid cancer reveals distinct tumor immunogenicity and implications for immunotherapy. <i>Oncolimmunology</i> , 2021, 10, e1964189.	2.1	24
9673	Immune profiling of pituitary tumors reveals variations in immune infiltration and checkpoint molecule expression. <i>Pituitary</i> , 2021, 24, 359-373.	1.6	12
9674	A stratified phase I dose escalation trial of hypofractionated radiotherapy followed by ipilimumab in metastatic melanoma: long-term follow-up and final outcomes. <i>Oncolimmunology</i> , 2021, 10, 1863631.	2.1	16
9675	Immune-checkpoint blockade of CTLA-4 (CD152) in antigen-specific human T-cell responses differs profoundly between neonates, children, and adults. <i>Oncolimmunology</i> , 2021, 10, 1938475.	2.1	3
9676	CAR-NK cell immunotherapy: Development and challenges toward an off-the-shelf product. , 2021, , 213-230.		2
9677	Macrophage contributes to radiation-induced anti-tumor abscopal effect on transplanted breast cancer by HMGB1/TNF- α signaling factors. <i>International Journal of Biological Sciences</i> , 2021, 17, 926-941.	2.6	17
9678	Assessing the Educational and Supportive Care Needs of Canadian Metastatic Melanoma Patients and Survivors Attending an Outpatient Clinic. <i>Journal of Patient Experience</i> , 2021, 8, 237437352110331.	0.4	1
9679	Immunotherapy-Related Imaging Findings in Patients with Gynecological Malignancies: What Radiologists Need to Know. <i>Korean Journal of Radiology</i> , 2021, 22, 1310.	1.5	4
9680	Clinical sequencing to assess tumor mutational burden as a useful biomarker to immunotherapy in various solid tumors. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592199299.	1.4	20
9681	Novel SIRP α Antibodies That Induce Single-Agent Phagocytosis of Tumor Cells while Preserving T Cells. <i>Journal of Immunology</i> , 2021, 206, 712-721.	0.4	37
9682	Targeting the ubiquitination/deubiquitination process to regulate immune checkpoint pathways. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 28.	7.1	28
9683	Emerging immune checkpoint inhibitors for the treatment of hepatocellular carcinoma. <i>Expert Opinion on Emerging Drugs</i> , 2021, 26, 39-52.	1.0	9
9684	Full Spectrum Flow Cytometry as a Powerful Technology for Cancer Immunotherapy Research. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 612801.	1.6	52
9685	Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination. <i>Nature Medicine</i> , 2021, 27, 152-164.	15.2	451

#	ARTICLE	IF	CITATIONS
9686	An Instance-Specific Causal Framework for Learning Intercellular Communication Networks that Define Microenvironments Of Individual Tumors. SSRN Electronic Journal, 0, , .	0.4	0
9687	Tumor Microenvironment: Immune Effector and Suppressor Imbalance. Current Cancer Research, 2021, , 1-25.	0.2	0
9688	Development of a mechanism of action-reflective, dual target cell-based reporter bioassay for a bispecific monoclonal antibody targeting human CTLA-4 and PD-1. MAbs, 2021, 13, 1914359.	2.6	2
9689	Tumorvaccine. Springer Reference Medizin, 2021, , 1-5.	0.0	0
9690	Current Advancements and Novel Strategies in the Treatment of Metastatic Melanoma. Integrative Cancer Therapies, 2021, 20, 153473542199007.	0.8	25
9691	A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma. Oncoimmunology, 2021, 10, 1898105.	2.1	11
9693	Anorectal Mucosal Melanoma in the Era of Immune Checkpoint Inhibition: Should We Change Our Surgical Management Paradigm?. Diseases of the Colon and Rectum, 2021, 64, 555-562.	0.7	8
9694	Immunotherapy for head and neck cancer – The current scenario. IP International Journal of Comprehensive and Advanced Pharmacology, 2021, 5, 146-150.	0.1	0
9695	Real world outcomes of combination and timing of immunotherapy with radiotherapy for melanoma with brain metastases. Cancer Medicine, 2021, 10, 1201-1211.	1.3	14
9696	Perspectives of Immunotherapy in Advanced Melanoma: Combinations and Sequencing. , 2021, , 281-310.		0
9698	Hematopoietic versus Solid Cancers and T Cell Dysfunction: Looking for Similarities and Distinctions. Cancers, 2021, 13, 284.	1.7	15
9699	Treatment with therapeutic anticoagulation is not associated with immunotherapy response in advanced cancer patients. Journal of Translational Medicine, 2021, 19, 47.	1.8	10
9700	Testosterone for Managing Treatment-related Fatigue in Patients With Metastatic Renal Cell Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2021, 44, 137-142.	0.6	3
9701	The combination of encorafenib and binimetinib for the treatment of patients with BRAF-mutated advanced, unresectable, or metastatic melanoma: an update. Expert Review of Precision Medicine and Drug Development, 2021, 6, 19-29.	0.4	3
9702	Immune determinants of Barrett's progression to esophageal adenocarcinoma. JCI Insight, 2021, 6, .	2.3	25
9703	An Overview of Liver Directed Locoregional Therapies. Surgical Oncology Clinics of North America, 2021, 30, 103-123.	0.6	8
9704	Targeting cancer metastasis with antibody therapeutics. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2021, 13, e1698.	3.3	17
9706	Immune Checkpoint Inhibitory Therapy in Sarcomas: Is There Light at the End of the Tunnel?. Cancers, 2021, 13, 360.	1.7	25

#	ARTICLE	IF	CITATIONS
9707	Immune checkpoint inhibitor-induced aseptic meningitis and encephalitis: a case-series and narrative review. <i>Therapeutic Advances in Drug Safety</i> , 2021, 12, 204209862110047.	1.0	20
9708	Noninvasive Imaging of Cancer Immunotherapy. <i>Nanotheranostics</i> , 2021, 5, 90-112.	2.7	22
9709	Optimal combination treatment regimens of vaccine and radiotherapy augment tumor-bearing host immunity. <i>Communications Biology</i> , 2021, 4, 78.	2.0	10
9710	Utilizing Xenogeneic Cells As a Therapeutic Agent for Treating Diseases. <i>Cell Transplantation</i> , 2021, 30, 096368972110119.	1.2	11
9711	Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 25-31.	1.0	12
9713	Human Ferritin Platform and Its Optimized Structures to Enhance Anti-Cancer Immunity. <i>Advanced Therapeutics</i> , 2021, 4, 2000208.	1.6	6
9714	Metastasectomy for melanoma is associated with improved overall survival in responders to targeted molecular or immunotherapy. <i>Journal of Surgical Oncology</i> , 2020, 122, 555-561.	0.8	8
9715	Advances in drug development for targeted therapies for glioblastoma. <i>Medicinal Research Reviews</i> , 2020, 40, 1950-1972.	5.0	7
9716	Peptide and Protein-Based Cancer Vaccines. , 2013, , 111-146.		2
9718	Systemic Therapy in Melanoma. , 2014, , 461-474.		1
9719	Overcoming Resistance of Melanoma to Immunotherapy with Monoclonal Antibodies Against Checkpoints Inhibitors. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2013, , 143-155.	0.1	1
9720	Treatment of Brain Tumors. <i>Advances in Delivery Science and Technology</i> , 2014, , 169-194.	0.4	1
9722	Targeted Therapies in Melanoma. <i>Current Clinical Pathology</i> , 2015, , 211-227.	0.0	4
9723	Engineered Cell-Based Therapies: A Vanguard of Design-Driven Medicine. <i>Advances in Experimental Medicine and Biology</i> , 2014, 844, 369-391.	0.8	4
9724	The PI3K-AKT Pathway in Melanoma. , 2016, , 165-180.		3
9725	Immunological Targets for Immunotherapy: Inhibitory T Cell Receptors. <i>Methods in Molecular Biology</i> , 2020, 2055, 23-60.	0.4	12
9726	Germline Genetics in Immuno-oncology: From Genome-Wide to Targeted Biomarker Strategies. <i>Methods in Molecular Biology</i> , 2020, 2055, 93-117.	0.4	4
9727	Introduction to Diagnostic and Prognostic Biomarkers and Therapeutic Targets in Melanoma. , 2012, , 1-7.		1

#	ARTICLE	IF	CITATIONS
9728	Targeted Inhibition of B-Raf. , 2012, , 63-76.		1
9729	Integrating Molecular Biomarkers into Current Clinical Management in Melanoma. Methods in Molecular Biology, 2014, 1102, 27-42.	0.4	7
9730	Immune System Functional Pathway Analysis Using Single Cell Network Profiling (SCNP): A Novel Tool in Cancer Immunotherapy. Methods in Molecular Biology, 2014, 1102, 583-599.	0.4	4
9731	Markers for Anti-cytotoxic T-lymphocyte Antigen 4 (CTLA-4) Therapy in Melanoma. Methods in Molecular Biology, 2014, 1102, 83-95.	0.4	7
9732	Managing Checkpoint Inhibitor Symptoms and Toxicity for Metastatic Melanoma. , 2020, , 1187-1214.		2
9733	Systemic Therapy for Mucosal, Acral, and Uveal Melanoma. , 2020, , 1301-1335.		2
9734	Current Perspectives on Nasopharyngeal Carcinoma. Advances in Experimental Medicine and Biology, 2019, 1164, 11-34.	0.8	135
9735	Neurological Complications of Immune-Based Therapies. , 2020, , 365-372.		2
9736	Targeting Cancer with Genetically Engineered TCR T Cells. Recent Results in Cancer Research, 2020, 214, 129-151.	1.8	6
9737	Personalized Neo-Epitope Vaccines for Cancer Treatment. Recent Results in Cancer Research, 2020, 214, 153-167.	1.8	9
9738	The Era of Checkpoint Inhibition: Lessons Learned from Melanoma. Recent Results in Cancer Research, 2020, 214, 169-187.	1.8	7
9740	Molecular and Functional Imaging in Oncology Therapy Response. Medical Radiology, 2020, , 255-272.	0.0	2
9742	Cytotoxic CD8+ Lymphocytes in the Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2020, 1224, 53-62.	0.8	56
9743	CCL22 Signaling in the Tumor Environment. Advances in Experimental Medicine and Biology, 2020, 1231, 79-96.	0.8	30
9744	The Role of the Immune Infiltrate in Distinct Cancer Types and Its Clinical Implications. Cancer Treatment and Research, 2020, 180, 197-211.	0.2	4
9745	Overview of Basic Immunology and Clinical Application. Advances in Experimental Medicine and Biology, 2020, 1244, 1-36.	0.8	8
9746	Skin Reactions to Immune Checkpoint Inhibitors. Advances in Experimental Medicine and Biology, 2020, 1244, 235-246.	0.8	7
9747	Immunotherapy for Melanoma. Advances in Experimental Medicine and Biology, 2020, 1244, 51-68.	0.8	41

#	ARTICLE	IF	CITATIONS
9748	Immuno-oncology for Gynecologic Malignancies. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1244, 149-182.	0.8	1
9749	Non-FDG PET/CT. <i>Recent Results in Cancer Research</i> , 2020, 216, 669-718.	1.8	9
9750	Genetically Modified T-Cell Therapy for Osteosarcoma: Into the Roaring 2020s. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1257, 109-131.	0.8	7
9751	The Immune System and Pathogenesis of Melanoma and Non-melanoma Skin Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1268, 211-226.	0.8	11
9752	Regulatory T Cells in the Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1273, 105-134.	0.8	14
9753	Genetically Modified T-Cell Therapy for Osteosarcoma. <i>Advances in Experimental Medicine and Biology</i> , 2014, 804, 323-340.	0.8	16
9754	Fc γ RIIB as a Key Determinant of Agonistic Antibody Efficacy. <i>Current Topics in Microbiology and Immunology</i> , 2014, 382, 355-372.	0.7	19
9755	Recent Advances in Skin Cancer Treatment in Older Adults. , 2015, , 97-103.		1
9756	Title is missing!. , 2017, , .		82
9757	Sequencing and Combinations of Molecularly Targeted and Immunotherapy for BRAF-Mutant Melanoma. , 2019, , 1-27.		1
9758	Systemic Therapy for Mucosal, Acral and Uveal Melanoma. , 2019, , 1-37.		1
9760	Challenges of Immunotherapy. , 2016, , 419-434.		1
9761	Medikamentöse Tumorthherapie in der Dermato-Onkologie. , 2014, , .		2
9762	Neue Arzneimittel 2011. , 2012, , 43-126.		1
9764	Melanoma: From Tumor-Specific Mutations to a New Molecular Taxonomy and Innovative Therapeutics. , 2015, , 7-27.		2
9765	Melanom. , 2018, , 1869-1885.		1
9766	TRICOM Poxviral-Based Vaccines for the Treatment of Cancer. , 2014, , 291-327.		1
9767	Immunotherapy for Osteosarcoma. , 2016, , 31-41.		2

#	ARTICLE	IF	CITATIONS
9768	Understanding Melanoma Progression by Gene Expression Signatures. , 2013, , 47-78.		2
9769	Antibody Therapies in Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2016, 909, 1-67.	0.8	8
9771	Novel Inflammatory and Immunomodulatory Mediators in Sepsis. , 2017, , 211-234.		1
9772	Immunology and Immunotherapy in Ovarian Cancer. <i>Comprehensive Gynecology and Obstetrics</i> , 2017, , 225-242.	0.0	2
9773	Application of Fluorescence in Studying Therapeutic Enzymes. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1148, 105-114.	0.8	3
9774	Membrane Proteins as Targets for Biological Drugs. , 2019, , 49-65.		2
9775	Structures of Immune Checkpoints: An Overview on the CD28-B7 Family. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1172, 63-78.	0.8	15
9776	Molecular and Cellular Functions of CTLA-4. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1248, 7-32.	0.8	91
9777	Therapeutic Development of Immune Checkpoint Inhibitors. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1248, 619-649.	0.8	15
9778	Mechanisms of Resistance to Checkpoint Blockade Therapy. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1248, 83-117.	0.8	22
9779	Rational Discovery of Response Biomarkers: Candidate Prognostic Factors and Biomarkers for Checkpoint Inhibitor-Based Immunotherapy. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1248, 143-166.	0.8	3
9780	Cancer Immunotherapy Targeting Co-signal Molecules. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1189, 313-326.	0.8	4
9781	Stimulatory and Inhibitory Co-signals in Autoimmunity. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1189, 213-232.	0.8	10
9782	Co-signaling Molecules in Neurological Diseases. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1189, 233-265.	0.8	4
9783	Interim [18F]FDG PET/CT can predict response to anti-PD-1 treatment in metastatic melanoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1932-1943.	3.3	17
9784	SEOM clinical guideline for the management of immune-related adverse events in patients treated with immune checkpoint inhibitors (2019). <i>Clinical and Translational Oncology</i> , 2020, 22, 213-222.	1.2	14
9785	The Role of Anti-PD-1/PD-L1 in the Treatment of Skin Cancer. <i>BioDrugs</i> , 2020, 34, 495-503.	2.2	15
9786	Drug-Induced Liver Injury. , 2018, , 844-890.e17.		2

#	ARTICLE	IF	CITATIONS
9787	Biologics and Their Interactions with Radiation. , 2012, , 83-94.		1
9788	Cancer Immunology. , 2014, , 78-97.e5.		3
9790	Inmunoterapia en c�ncer cut�neo no melanoma. Actas Dermo-sifiligr�ficas, 2019, 110, 353-359.	0.2	4
9791	Single-Cell RNA Sequencing Reveals a Dynamic Stromal Niche That Supports Tumor Growth. Cell Reports, 2020, 31, 107628.	2.9	186
9792	Current Therapy for Basal Cell Carcinoma and the Potential Role for Immunotherapy With Checkpoint Inhibitors. Clinical Skin Cancer, 2017, 2, 59-65.	0.1	3
9793	Phase 1 Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma Patients With Brain Metastases. International Journal of Radiation Oncology Biology Physics, 2017, 99, 22-30.	0.4	103
9794	Immune checkpoint inhibitors to treat cutaneous malignancies. Journal of the American Academy of Dermatology, 2020, 83, 1239-1253.	0.6	56
9795	Radioterapia estereot�pica corporal y cirug�a m�nimamente invasiva en el manejo de las met�stasis espinales: un cambio de paradigma. Neurocirug�a, 2020, 31, 119-131.	0.2	5
9796	Age and Melanocytic Lesions. Surgical Oncology Clinics of North America, 2020, 29, 369-386.	0.6	1
9797	M�lanome � Th�rapeutique par les m�dications : anticorps anti-CTLA-4 et anti-PD1. Bulletin De L'Academie Nationale De Medecine, 2014, 198, 297-308.	0.0	4
9800	ALDH1A3 is epigenetically regulated during melanocyte transformation and is a target for melanoma treatment. Oncogene, 2017, 36, 5695-5708.	2.6	40
9801	Expression patterns of programmed death ligand 1 correlate with different microenvironments and patient prognosis in hepatocellular carcinoma. British Journal of Cancer, 2018, 119, 80-88.	2.9	74
9802	Comprehensive T cell repertoire characterization of non-small cell lung cancer. Nature Communications, 2020, 11, 603.	5.8	140
9803	CD8+ T cell states in human cancer: insights from single-cell analysis. Nature Reviews Cancer, 2020, 20, 218-232.	12.8	766
9804	Prognostic relevance of programmed cell death 1 ligand 2 (PDCD1LG2/PD-L2) in patients with advanced stage colon carcinoma treated with chemotherapy. Scientific Reports, 2020, 10, 22330.	1.6	13
9805	Auristatin Payloads for Antibody�Drug Conjugates (ADCs). RSC Drug Discovery Series, 2019, , 73-99.	0.2	3
9806	Engineering anti-cancer nanovaccine based on antigen cross-presentation. Bioscience Reports, 2019, 39, .	1.1	47
9807	<i>In situ</i> vaccination with nanoparticles for cancer immunotherapy: understanding the immunology. International Journal of Hyperthermia, 2020, 37, 4-17.	1.1	12

#	ARTICLE	IF	CITATIONS
9808	Limited-duration anti-PD-1 therapy for patients with metastatic melanoma. <i>Acta Oncologica</i> , 2020, 59, 438-443.	0.8	7
9809	The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 775-784.	1.1	268
9810	Radiation therapy and immunotherapy in breast cancer treatment: preliminary data and perspectives. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 501-510.	1.1	10
9811	Economic evaluation of adverse events of dabrafenib plus trametinib versus nivolumab in patients with advanced BRAF-mutant cutaneous melanoma for adjuvant therapy in Germany. <i>Journal of Market Access & Health Policy</i> , 2021, 9, 1861804.	0.8	5
9812	Induction of liver-specific intrahepatic myeloid cells aggregation expands CD8 T cell and inhibits growth of murine hepatoma. <i>Oncolmmunology</i> , 2018, 7, e1502129.	2.1	7
9813	Correlation between patients' age and cancer immunotherapy efficacy. <i>Oncolmmunology</i> , 2019, 8, e1568810.	2.1	44
9814	Adult precision medicine: learning from the past to enhance the future. <i>Neuro-Oncology Advances</i> , 2021, 3, vdaa145.	0.4	11
9815	Complete Recovery of Immune Checkpoint Inhibitor-induced Colitis by Diverting Loop Ileostomy. <i>Journal of Immunotherapy</i> , 2020, 43, 145-148.	1.2	4
9816	Carpal Tunnel Syndrome: A New Adverse Effect of Immune Checkpoint Inhibitors, 11 Cases. <i>Journal of Immunotherapy</i> , 2021, 44, 122-126.	1.2	5
9817	Checkpoint Blockade in Melanoma Patients With Underlying Chronic Lymphocytic Leukemia. <i>Journal of Immunotherapy</i> , 2021, 44, 9-15.	1.2	10
9818	Development of a biconal cutaneous T-cell lymphoproliferative process during treatment with immune checkpoint inhibitors for metastatic melanoma. <i>Melanoma Research</i> , 2017, 27, 383-386.	0.6	5
9819	Nationwide Outcomes of Advanced Melanoma According to BRAFV600 Status. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021, 44, 82-89.	0.6	2
9820	Clinical Characteristics and Treatment Response With Checkpoint Inhibitors in Malignant Melanoma of the Vulva and Vagina. <i>Journal of Lower Genital Tract Disease</i> , 2021, 25, 146-151.	0.9	12
9821	Risk of Toxicity After Initiating Immune Checkpoint Inhibitor Treatment in Patients With Rheumatoid Arthritis. <i>Journal of Clinical Rheumatology</i> , 2021, 27, 267-271.	0.5	23
9822	Ipilimumab-Induced Organizing Pneumonia on 18F-FDG PET/CT in a Patient With Malignant Melanoma. <i>Clinical Nuclear Medicine</i> , 2017, 42, e345-e346.	0.7	21
9840	Uptake of positron emission tomography tracers reflects the tumor immune status in esophageal squamous cell carcinoma. <i>Cancer Science</i> , 2020, 111, 1969-1978.	1.7	13
9841	Regressed melanocytic nevi secondary to pembrolizumab therapy: an emerging melanocytic dermatologic effect from immune checkpoint antibody blockade. <i>International Journal of Dermatology</i> , 2019, 58, 1045-1052.	0.5	11
9842	Label-free counting of circulating cells by in vivo photoacoustic flow cytometry. , 2018, , .		2

#	ARTICLE	IF	CITATIONS
9843	Non-invasive monitoring of circulating melanoma cells by in vivo photoacoustic flow cytometry. , 2019, , .		1
9844	Resolution of ipilimumab induced severe hepatotoxicity with triple immunosuppressants therapy. BMJ Case Reports, 2015, 2015, bcr2014208102.	0.2	38
9845	Ipilimumab-associated colitis or refractory <i>Clostridium difficile</i> infection?. BMJ Case Reports, 2015, 2015, bcr2015211160.	0.2	10
9846	Rare side effect of adjuvant ipilimumab after surgical resection of melanoma: Guillain-Barré syndrome. BMJ Case Reports, 2017, 2017, bcr-2017-221318.	0.2	6
9847	Non-thermal histotripsy tumor ablation promotes abscopal immune responses that enhance cancer immunotherapy. , 2020, 8, e000200.		99
9848	Immune Checkpoint Inhibitor Cancer Therapy: Spectrum of Imaging Findings. Radiographics, 2017, 37, 2132-2144.	1.4	87
9849	Cancer-Associated Fibroblasts Affect Intratumoral CD8+ and FoxP3+ T Cells Via IL6 in the Tumor Microenvironment. Clinical Cancer Research, 2018, 24, 4820-4833.	3.2	225
9850	Effectiveness of Immunotherapies from Oyster Mushroom (<i>Pleurotus</i> species) in the Management of Immunocompromised Patients. International Journal of Immunology, 2015, 3, 8.	0.2	17
9851	Modeling Immune-Mediated Activations and Interactions in Breast Cancer Progression. International Journal of Systems Science and Applied Mathematics, 2019, 4, 1.	0.2	1
9852	Phosphoinositide 3-kinase $\hat{\imath}$ inhibition promotes antitumor responses but antagonizes checkpoint inhibitors. JCI Insight, 2018, 3, .	2.3	38
9853	MicroRNA-146a regulates immune-related adverse events caused by immune checkpoint inhibitors. JCI Insight, 2020, 5, .	2.3	49
9854	Combination of host immune metabolic biomarkers for the PD-1 blockade cancer immunotherapy. JCI Insight, 2020, 5, .	2.3	58
9855	CX3CR1 $\hat{\imath}$ CD8+ T cells are critical in antitumor efficacy but functionally suppressed in the tumor microenvironment. JCI Insight, 2020, 5, .	2.3	48
9856	Akt and SHP-1 are DC-intrinsic checkpoints for tumor immunity. JCI Insight, 2016, 1, e89020.	2.3	17
9857	Transcriptional dissection of melanoma identifies a high-risk subtype underlying TP53 family genes and epigenome deregulation. JCI Insight, 2017, 2, .	2.3	48
9858	Combination central tolerance and peripheral checkpoint blockade unleashes antimelanoma immunity. JCI Insight, 2017, 2, .	2.3	34
9859	Requirement of Treg-intrinsic CTLA4/PKC $\hat{\imath}$ signaling pathway for suppressing tumor immunity. JCI Insight, 2017, 2, .	2.3	24
9860	Emerging strategies for combination checkpoint modulators in cancer immunotherapy. Journal of Clinical Investigation, 2018, 128, 3209-3218.	3.9	170

#	ARTICLE	IF	CITATIONS
9861	Tumor-conditional anti-CTLA4 uncouples antitumor efficacy from immunotherapy-related toxicity. <i>Journal of Clinical Investigation</i> , 2018, 129, 349-363.	3.9	99
9862	An adapted anti-CTLA4 therapeutic aimed at mitigating the toxicities of checkpoint inhibition. <i>Journal of Clinical Investigation</i> , 2018, 129, 75-77.	3.9	1
9863	Immunotherapy transforms cancer treatment. <i>Journal of Clinical Investigation</i> , 2018, 129, 46-47.	3.9	34
9864	Personal tumor antigens in blood malignancies: genomics-directed identification and targeting. <i>Journal of Clinical Investigation</i> , 2020, 130, 1595-1607.	3.9	10
9865	Killers 2.0: NK cell therapies at the forefront of cancer control. <i>Journal of Clinical Investigation</i> , 2019, 129, 3499-3510.	3.9	166
9866	Time to dissect the autoimmune etiology of cancer antibody immunotherapy. <i>Journal of Clinical Investigation</i> , 2020, 130, 51-61.	3.9	66
9867	Haploinsufficiency of immune checkpoint receptor CTLA4 induces a distinct neuroinflammatory disorder. <i>Journal of Clinical Investigation</i> , 2020, 130, 5551-5561.	3.9	18
9868	Autoimmune melanocyte destruction is required for robust CD8+ memory T cell responses to mouse melanoma. <i>Journal of Clinical Investigation</i> , 2011, 121, 1797-1809.	3.9	65
9869	CD40 ligation reverses T cell tolerance in acute myeloid leukemia. <i>Journal of Clinical Investigation</i> , 2013, 123, 1999-2010.	3.9	60
9870	Amazing IL-9: revealing a new function for an "old" cytokine. <i>Journal of Clinical Investigation</i> , 2012, 122, 3857-3859.	3.9	23
9871	Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. <i>Journal of Clinical Investigation</i> , 2013, 123, 1371-1381.	3.9	256
9872	Lung tumor NF- κ B signaling promotes T cell-mediated immune surveillance. <i>Journal of Clinical Investigation</i> , 2013, 123, 2509-2522.	3.9	102
9873	Radiation and immunotherapy: a synergistic combination. <i>Journal of Clinical Investigation</i> , 2013, 123, 2756-2763.	3.9	226
9874	Immune response to RB1-regulated senescence limits radiation-induced osteosarcoma formation. <i>Journal of Clinical Investigation</i> , 2013, 123, 5351-5360.	3.9	54
9875	Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. <i>Journal of Clinical Investigation</i> , 2013, 123, 4980-4980.	3.9	123
9876	Lymphatic vessels regulate immune microenvironments in human and murine melanoma. <i>Journal of Clinical Investigation</i> , 2016, 126, 3389-3402.	3.9	157
9877	Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade. <i>Journal of Clinical Investigation</i> , 2015, 125, 3377-3383.	3.9	146
9878	Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma. <i>Journal of Clinical Investigation</i> , 2016, 126, 921-937.	3.9	71

#	ARTICLE	IF	CITATIONS
9879	Metabolic regulation of immune responses: therapeutic opportunities. <i>Journal of Clinical Investigation</i> , 2016, 126, 2031-2039.	3.9	78
9880	Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. <i>Journal of Clinical Investigation</i> , 2016, 126, 3130-3144.	3.9	773
9881	TAP-independent self-peptides enhance T cell recognition of immune-escaped tumors. <i>Journal of Clinical Investigation</i> , 2016, 126, 784-794.	3.9	60
9882	Cancer immunotherapy innovator James Allison receives the 2015 Lasker-DeBaakey Clinical Medical Research Award. <i>Journal of Clinical Investigation</i> , 2015, 125, 3732-3736.	3.9	19
9883	Antitumor adaptive immunity remains intact following inhibition of autophagy and antimalarial treatment. <i>Journal of Clinical Investigation</i> , 2016, 126, 4417-4429.	3.9	67
9884	NLRC4 suppresses melanoma tumor progression independently of inflammasome activation. <i>Journal of Clinical Investigation</i> , 2016, 126, 3917-3928.	3.9	65
9885	Overcoming therapeutic resistance in glioblastoma: the way forward. <i>Journal of Clinical Investigation</i> , 2017, 127, 415-426.	3.9	354
9886	Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy. <i>Journal of Clinical Investigation</i> , 2018, 128, 1338-1354.	3.9	64
9887	Resisting fatal attraction: a glioma oncometabolite prevents CD8+ T cell recruitment. <i>Journal of Clinical Investigation</i> , 2017, 127, 1218-1220.	3.9	15
9888	Î2-Catenin-mediated immune evasion pathway frequently operates in primary cutaneous melanomas. <i>Journal of Clinical Investigation</i> , 2018, 128, 2048-2063.	3.9	71
9889	Increased vessel perfusion predicts the efficacy of immune checkpoint blockade. <i>Journal of Clinical Investigation</i> , 2018, 128, 2104-2115.	3.9	152
9890	Beyond the Standard of Care: A Review of Novel Immunotherapy Trials for the Treatment of Lung Cancer. <i>Cancer Control</i> , 2013, 20, 22-31.	0.7	53
9891	The use of patient-reported outcomes to detect adverse events in metastatic melanoma patients receiving immunotherapy: a randomized controlled pilot trial. <i>Journal of Patient-Reported Outcomes</i> , 2020, 4, 88.	0.9	19
9892	Therapeutic Vaccines and Immunotherapy in Castration-Resistant Prostate Cancer: Current Progress and Clinical Applications. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, 33, e166-e170.	1.8	13
9893	A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, 9079-9079.	0.8	7
9894	Adjuvant Therapy Failure Patterns in the Modern Era of Melanoma Management. <i>Annals of Surgical Oncology</i> , 2020, 27, 5128-5136.	0.7	13
9895	Cancer Genomics. <i>F1000Research</i> , 2015, 4, 1162.	0.8	2
9896	The Immune System and Responses to Cancer: Coordinated Evolution. <i>F1000Research</i> , 2015, 4, 552.	0.8	5

#	ARTICLE	IF	CITATIONS
9897	Current clinical immunotherapeutic approaches for head and neck cancer. <i>F1000Research</i> , 2016, 5, 803.	0.8	5
9898	Virotherapy: cancer gene therapy at last?. <i>F1000Research</i> , 2016, 5, 2105.	0.8	14
9899	Recent advances in molecular genetics of melanoma progression: implications for diagnosis and treatment. <i>F1000Research</i> , 2016, 5, 1529.	0.8	4
9900	Recent advances in understanding antitumor immunity. <i>F1000Research</i> , 2016, 5, 2545.	0.8	29
9901	Advances in treating glioblastoma. <i>F1000prime Reports</i> , 2014, 6, 46.	5.9	42
9902	Synergistic Enhancement of Paclitaxel-induced Inhibition of Cell Growth by Metformin in Melanoma Cells. <i>Development & Reproduction</i> , 2019, 23, 119-128.	0.1	10
9903	Prospects for personalized targeted therapies for cutaneous squamous cell carcinoma. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2014, 33, 72-75.	1.6	11
9904	Merkel cell carcinoma: current status of targeted and future potential for immunotherapies. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2014, 33, 76-82.	1.6	14
9905	Current options and future directions in the systemic treatment of metastatic melanoma. <i>Journal of Community and Supportive Oncology</i> , 2014, 12, 20-26.	0.1	5
9906	Effectiveness and safety of ipilimumab therapy in advanced melanoma: evidence from clinical practice sites in the US. <i>Journal of Community and Supportive Oncology</i> , 2015, 13, 131-138.	0.1	5
9907	Immunotherapy-induced Colitis: An Emerging Problem for the Hospitalist. <i>Journal of Hospital Medicine</i> , 2018, 13, 413-418.	0.7	25
9908	Immune checkpoint inhibitor-induced colitis: A comprehensive review. <i>World Journal of Clinical Cases</i> , 2019, 7, 405-418.	0.3	171
9909	Immunotherapy in the Precision Medicine Era: Melanoma and Beyond. <i>PLoS Medicine</i> , 2016, 13, e1002196.	3.9	21
9910	Monitoring of Regulatory T Cell Frequencies and Expression of CTLA-4 on T Cells, before and after DC Vaccination, Can Predict Survival in GBM Patients. <i>PLoS ONE</i> , 2012, 7, e32614.	1.1	83
9911	Clinical Efficacy and Safety of Bevacizumab Monotherapy in Patients with Metastatic Melanoma: Predictive Importance of Induced Early Hypertension. <i>PLoS ONE</i> , 2012, 7, e38364.	1.1	46
9912	Mitochondrial Respiration - An Important Therapeutic Target in Melanoma. <i>PLoS ONE</i> , 2012, 7, e40690.	1.1	93
9913	Melanoma-Associated Cancer-Testis Antigen 16 (CT16) Regulates the Expression of Apoptotic and Antiapoptotic Genes and Promotes Cell Survival. <i>PLoS ONE</i> , 2012, 7, e45382.	1.1	18
9914	Characterization of Human $\gamma\delta$ T Lymphocytes Infiltrating Primary Malignant Melanomas. <i>PLoS ONE</i> , 2012, 7, e49878.	1.1	137

#	ARTICLE	IF	CITATIONS
9915	The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network. PLoS ONE, 2013, 8, e53745.	1.1	414
9916	Pancreatic Tumors and Immature Immunosuppressive Myeloid Cells in Blood and Spleen: Role of Inhibitory Co-Stimulatory Molecules PDL1 and CTLA4. An In Vivo and In Vitro Study. PLoS ONE, 2013, 8, e54824.	1.1	44
9917	Coordinate Autophagy and mTOR Pathway Inhibition Enhances Cell Death in Melanoma. PLoS ONE, 2013, 8, e55096.	1.1	131
9918	Imatinib Reverses Doxorubicin Resistance by Affecting Activation of STAT3-Dependent NF- κ B and HSP27/p38/AKT Pathways and by Inhibiting ABCB1. PLoS ONE, 2013, 8, e55509.	1.1	95
9919	Expression of Drug Targets in Patients Treated with Sorafenib, Carboplatin and Paclitaxel. PLoS ONE, 2013, 8, e69748.	1.1	3
9920	Immune Monitoring of the Circulation and the Tumor Microenvironment in Patients with Regionally Advanced Melanoma Receiving Neoadjuvant Ipilimumab. PLoS ONE, 2014, 9, e87705.	1.1	261
9921	Novel Small Molecule XPO1/CRM1 Inhibitors Induce Nuclear Accumulation of TP53, Phosphorylated MAPK and Apoptosis in Human Melanoma Cells. PLoS ONE, 2014, 9, e102983.	1.1	41
9922	Immune Suppressive Effect of Cinnamaldehyde Due to Inhibition of Proliferation and Induction of Apoptosis in Immune Cells: Implications in Cancer. PLoS ONE, 2014, 9, e108402.	1.1	38
9923	Corticosteroids Augment BRAF Inhibitor Vemurafenib Induced Lymphopenia and Risk of Infection. PLoS ONE, 2015, 10, e0124590.	1.1	9
9924	Brucella spp. Lumazine Synthase Induces a TLR4-Mediated Protective Response against B16 Melanoma in Mice. PLoS ONE, 2015, 10, e0126827.	1.1	18
9925	Combination of Id2 Knockdown Whole Tumor Cells and Checkpoint Blockade: A Potent Vaccine Strategy in a Mouse Neuroblastoma Model. PLoS ONE, 2015, 10, e0129237.	1.1	17
9926	Tumor-Targeted Human T Cells Expressing CD28-Based Chimeric Antigen Receptors Circumvent CTLA-4 Inhibition. PLoS ONE, 2015, 10, e0130518.	1.1	53
9927	Discovery of a Good Responder Subtype of Esophageal Squamous Cell Carcinoma with Cytotoxic T-Lymphocyte Signatures Activated by Chemoradiotherapy. PLoS ONE, 2015, 10, e0143804.	1.1	13
9928	Investigation of FOXM1 as a Potential New Target for Melanoma. PLoS ONE, 2015, 10, e0144241.	1.1	35
9929	An Immunocompetent Mouse Model for MLL/AF9 Leukemia Reveals the Potential of Spontaneous Cytotoxic T-Cell Response to an Antigen Expressed in Leukemia Cells. PLoS ONE, 2015, 10, e0144594.	1.1	13
9930	The Predicted Impact of Ipilimumab Usage on Survival in Previously Treated Advanced or Metastatic Melanoma in the UK. PLoS ONE, 2015, 10, e0145524.	1.1	16
9931	More Accurate Prediction of Metastatic Pancreatic Cancer Patients' Survival with Prognostic Model Using Both Host Immunity and Tumor Metabolic Activity. PLoS ONE, 2016, 11, e0145692.	1.1	14
9932	Annual Hospital Volume of High Dose Interleukin-2 and Inpatient Mortality in Melanoma and Renal Cell Carcinoma Patients. PLoS ONE, 2016, 11, e0147153.	1.1	13

#	ARTICLE	IF	CITATIONS
9933	Optimizing Timing of Immunotherapy Improves Control of Tumors by Hypofractionated Radiation Therapy. PLoS ONE, 2016, 11, e0157164.	1.1	247
9934	Correlation of histopathologic characteristics to protein expression and function in malignant melanoma. PLoS ONE, 2017, 12, e0176167.	1.1	27
9935	Passage of Humanized Monoclonal Antibodies Across the Blood- Brain Barrier: Relevance in the Treatment of Cancer Brain Metastases?. Journal of Applied Biopharmaceutics and Pharmacokinetics, 2015, 2, 50-58.	0.1	3
9936	Blockade of programmed cell death protein-1 pathway for the treatment of melanoma. Journal of Antioxidant Activity, 2017, 1, 1-11.	1.0	12
9937	Flexible Sigmoidoscopy Rather than Colonoscopy Is Adequate for the Diagnosis of Ipilimumab-Associated Colitis. Southern Medical Journal, 2019, 112, 154-158.	0.3	14
9938	Detection of clinically relevant immune checkpoint markers by multicolor flow cytometry. Journal of Biological Methods, 2019, 6, e114.	1.0	14
9939	Operable Melanoma: Screening, Prognostication, and Adjuvant and Neoadjuvant Therapy. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 651-660.	1.8	7
9940	Biomarkers for Checkpoint Inhibition. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 205-209.	1.8	12
9941	New Options and New Questions: How to Select and Sequence Therapies for Patients with Metastatic Melanoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 524-530.	1.8	3
9942	Combination Therapies Building on the Efficacy of CTLA4 and BRAF Inhibitors for Metastatic Melanoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 675-678.	1.8	5
9943	Multidisciplinary Approach to Brain Metastasis from Melanoma: The Emerging Role of Systemic Therapies. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , 393-398.	1.8	24
9944	Exploring Novel Immune-Related Toxicities and Endpoints with Immune-Checkpoint Inhibitors in Non-Small Cell Lung Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , e280-e285.	1.8	27
9945	Progress in the Treatment of Advanced Prostate Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , 117-131.	1.8	31
9946	Infectious Colitis Associated With Ipilimumab Therapy. Gastroenterology Research, 2014, 7, 28-31.	0.4	14
9947	Novel Drugs and Combination Therapies for the Treatment of Metastatic Melanoma. Journal of Clinical Medicine Research, 2016, 8, 63-75.	0.6	49
9948	Current Immune-Related Molecular Approach in Combating Nasopharyngeal Cancer. World Journal of Oncology, 2019, 10, 157-161.	0.6	6
9949	Potential utilization of neopterin measurements in the assessment of pyrexia in metastatic melanoma treated with combined targeted therapy: a case report. Pteridines, 2020, 31, 151-157.	0.5	1
9950	Effectiveness of electrochemotherapy after IFN- γ adjuvant therapy of melanoma patients. Radiology and Oncology, 2016, 50, 21-27.	0.6	19

#	ARTICLE	IF	CITATIONS
9951	Two distinct clinical patterns of checkpoint inhibitor-induced thyroid dysfunction. <i>Endocrine Connections</i> , 2020, 9, 318-325.	0.8	23
9952	A novel melanoma therapy stirs up a storm: ipilimumab-induced thyrotoxicosis. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2015, 2015, 140092.	0.2	27
9953	Hyponatraemia secondary to nivolumab-induced primary adrenal failure. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2016, 2016, .	0.2	60
9954	Combination immune checkpoint inhibitor therapy nivolumab and ipilimumab associated with multiple endocrinopathies. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2018, 2018, .	0.2	26
9955	French Endocrine Society Guidance on endocrine side effects of immunotherapy. <i>Endocrine-Related Cancer</i> , 2019, 26, G1-G18.	1.6	95
9956	Novel cancer therapies and their association with diabetes. <i>Journal of Molecular Endocrinology</i> , 2019, 62, R187-R199.	1.1	20
9957	CTLA-4 Antibodies in Cancer Immunotherapy. <i>MOJ Immunology</i> , 2016, 3, .	11.0	3
9958	Radiation Therapy for Melanoma. , 0, , 101-120.		5
9959	Immune Checkpoint Inhibitors in the Treatment of Melanoma: From Basic Science to Clinical Application. , 0, , 121-142.		31
9960	Dendritic Cell-Based Cancer Immunotherapy Targeting Wilmsâ€™ Tumor 1 for Pediatric Cancer. , 0, , 113-130.		2
9961	T lymphocytes against solid malignancies: winning ways to defeat tumours. <i>Cell Stress</i> , 2018, 2, 200-212.	1.4	22
9962	The prognostic significance of BRAF mutation status in stage III B&C melanoma. <i>Expert Review of Dermatology</i> , 2013, 8, 127-129.	0.3	2
9963	Liquid Biopsies for Assessing Metastatic Melanoma Progression. <i>Critical Reviews in Oncogenesis</i> , 2016, 21, 141-154.	0.2	15
9964	Ipilimumab and Gemcitabine for Advanced Pancreatic Cancer: A Phase Ib Study. <i>Oncologist</i> , 2020, 25, e808-e815.	1.9	114
9965	Nivolumab for recurrent cutaneous squamous cell carcinoma: three cases. <i>European Journal of Dermatology</i> , 2018, 28, 78-81.	0.3	42
9966	Practical clinical guide on the use of talimogene laherparepvec monotherapy in patients with unresectable melanoma in Europe. <i>European Journal of Dermatology</i> , 2018, 28, 736-749.	0.3	6
9967	Ipilimumab in the treatment of metastatic melanoma: a summary of recent studies. <i>Tumori</i> , 2013, 99, 302e-5e.	0.6	2
9968	Metastatic melanoma with spontaneous regression, psoriasis and HLA-Cw6: case report and a hypothesis to explore. <i>Tumori</i> , 2014, 100, 144e-7e.	0.6	2

#	ARTICLE	IF	CITATIONS
9969	Targeted Therapy for Cutaneous Melanoma: Beyond BRAF.... Journal of Patient-centered Research and Reviews, 2014, 1, 12-20.	0.6	3
9970	An Update on Immune Checkpoint Inhibitor-related Hypophysitis. US Endocrinology, 2020, 16, 117.	0.3	3
9971	New landscapes and horizons in hepatocellular carcinoma therapy. Aging, 2020, 12, 3053-3094.	1.4	37
9972	Development of a prognostic index and screening of potential biomarkers based on immunogenomic landscape analysis of colorectal cancer. Aging, 2020, 12, 5832-5857.	1.4	34
9973	High mutation load, immune-activated microenvironment, favorable outcome, and better immunotherapeutic efficacy in melanoma patients harboring MUC16/CA125 mutations. Aging, 2020, 12, 10827-10843.	1.4	16
9974	Construction of immune-related gene pairs signature to predict the overall survival of osteosarcoma patients. Aging, 2020, 12, 22906-22926.	1.4	15
9975	Fatal gastrointestinal toxicity with ipilimumab after BRAF/MEK inhibitor combination in a melanoma patient achieving pathological complete response. Oncotarget, 2016, 7, 56619-56627.	0.8	16
9976	Samarium-153-EDTMP (Quadramet®) with or without vaccine in metastatic castration-resistant prostate cancer: A randomized Phase 2 trial. Oncotarget, 2016, 7, 69014-69023.	0.8	38
9977	Phenotypic screening reveals TNFR2 as a promising target for cancer immunotherapy. Oncotarget, 2016, 7, 68278-68291.	0.8	48
9978	Pharmacological interventions for melanoma: Comparative analysis using bayesian meta-analysis. Oncotarget, 2016, 7, 80855-80871.	0.8	2
9979	The evaluation of immunotherapy and chemotherapy treatment on melanoma: a network meta-analysis. Oncotarget, 2016, 7, 81493-81511.	0.8	14
9980	Potent CD4+ T cell-associated antitumor memory responses induced by trifunctional bispecific antibodies in combination with immune checkpoint inhibition. Oncotarget, 2017, 8, 4520-4529.	0.8	9
9981	Autologous reconstitution of human cancer and immune system <i>in vivo</i>. Oncotarget, 2017, 8, 2053-2068.	0.8	20
9982	Therapeutic potential of the metabolic modulator phenformin in targeting the stem cell compartment in melanoma. Oncotarget, 2017, 8, 6914-6928.	0.8	38
9983	Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma. Oncotarget, 2017, 8, 21539-21553.	0.8	103
9984	Clinicopathologic implications of immune classification by PD-L1 expression and CD8-positive tumor-infiltrating lymphocytes in stage II and III gastric cancer patients. Oncotarget, 2017, 8, 26356-26367.	0.8	54
9985	Synergistic effects of the immune checkpoint inhibitor CTLA-4 combined with the growth inhibitor lycorine in a mouse model of renal cell carcinoma. Oncotarget, 2017, 8, 21177-21186.	0.8	20
9986	Prognostic significance of tumor-infiltrating immune cells and PD-L1 expression in esophageal squamous cell carcinoma. Oncotarget, 2017, 8, 30175-30189.	0.8	69

#	ARTICLE	IF	CITATIONS
9987	TIM-3 is a potential prognostic marker for patients with solid tumors: A systematic review and meta-analysis. <i>Oncotarget</i> , 2017, 8, 31705-31713.	0.8	72
9988	Combination GITR targeting/PD-1 blockade with vaccination drives robust antigen-specific antitumor immunity. <i>Oncotarget</i> , 2017, 8, 39117-39130.	0.8	21
9989	Breaking the crosstalk of the cellular tumorigenic network: Hypothesis for addressing resistances to targeted therapies in advanced NSCLC. <i>Oncotarget</i> , 2017, 8, 43555-43570.	0.8	10
9990	Radiation improves antitumor effect of immune checkpoint inhibitor in murine hepatocellular carcinoma model. <i>Oncotarget</i> , 2017, 8, 41242-41255.	0.8	89
9991	Epigenetic modifiers upregulate MHC II and impede ovarian cancer tumor growth. <i>Oncotarget</i> , 2017, 8, 44159-44170.	0.8	41
9992	Driving better and safer HER2-specific CARs for cancer therapy. <i>Oncotarget</i> , 2017, 8, 62730-62741.	0.8	46
9993	A cellular platform for the evaluation of immune checkpoint molecules. <i>Oncotarget</i> , 2017, 8, 64892-64906.	0.8	48
9994	Accumulation of prohibitin is a common cellular response to different stressing stimuli and protects melanoma cells from ER stress and chemotherapy-induced cell death. <i>Oncotarget</i> , 2017, 8, 43114-43129.	0.8	19
9995	Cblb-deficient T cells are less susceptible to PD-L1-mediated inhibition. <i>Oncotarget</i> , 2017, 8, 41841-41853.	0.8	19
9996	Chemosensitivity-directed therapy compared to dacarbazine in chemo-naive advanced metastatic melanoma: a multicenter randomized phase-3 DeCOG trial. <i>Oncotarget</i> , 2017, 8, 76029-76043.	0.8	7
9997	MiR-34a modulates ionizing radiation-induced senescence in lung cancer cells. <i>Oncotarget</i> , 2017, 8, 69797-69807.	0.8	45
9998	The immune checkpoint molecule V-set Ig domain-containing 4 is an independent prognostic factor for multiple myeloma. <i>Oncotarget</i> , 2017, 8, 58122-58132.	0.8	13
9999	Effective antitumor peptide vaccines can induce severe autoimmune pathology. <i>Oncotarget</i> , 2017, 8, 70317-70331.	0.8	12
10000	Unfolded protein response signaling impacts macrophage polarity to modulate breast cancer cell clearance and melanoma immune checkpoint therapy responsiveness. <i>Oncotarget</i> , 2017, 8, 80545-80559.	0.8	33
10001	Failure of anti tumor-derived endothelial cell immunotherapy depends on augmentation of tumor hypoxia. <i>Oncotarget</i> , 2014, 5, 10368-10381.	0.8	18
10002	PAX3d mRNA over 2.76 copies/ μ L in the bloodstream predicts cutaneous malignant melanoma relapse. <i>Oncotarget</i> , 2017, 8, 85479-85491.	0.8	3
10003	Analyses of functions of an anti-PD-L1/TGF β 2R2 bispecific fusion protein (M7824). <i>Oncotarget</i> , 2017, 8, 75217-75231.	0.8	44
10004	PD-L1 expression and CD8+ tumor-infiltrating lymphocytes are associated with ALK rearrangement and clinicopathological features in inflammatory myofibroblastic tumors. <i>Oncotarget</i> , 2017, 8, 89465-89474.	0.8	13

#	ARTICLE	IF	CITATIONS
10005	Clinical significance of YAP1 activation in head and neck squamous cell carcinoma. <i>Oncotarget</i> , 2017, 8, 111130-111143.	0.8	34
10006	The anti-rheumatic drug, leflunomide, synergizes with MEK inhibition to suppress melanoma growth. <i>Oncotarget</i> , 2018, 9, 3815-3829.	0.8	17
10007	Current status and perspectives in immunotherapy for metastatic melanoma. <i>Oncotarget</i> , 2018, 9, 12452-12470.	0.8	73
10008	Microsatellite instability is a biomarker for immune checkpoint inhibitors in endometrial cancer. <i>Oncotarget</i> , 2018, 9, 5652-5664.	0.8	105
10009	Dynamic changes during the treatment of pancreatic cancer. <i>Oncotarget</i> , 2018, 9, 14764-14790.	0.8	21
10010	Intratumoral administration of mRNA encoding a fusokine consisting of IFN- γ and the ectodomain of the TGF- β receptor II potentiates antitumor immunity. <i>Oncotarget</i> , 2014, 5, 10100-10113.	0.8	66
10011	Immunotherapy in mucosal melanoma: a case report and review of the literature. <i>Oncotarget</i> , 2018, 9, 17971-17977.	0.8	19
10012	A pilot study of peptide vaccines for VEGF receptor 1 and 2 in patients with recurrent/progressive high grade glioma. <i>Oncotarget</i> , 2018, 9, 21569-21579.	0.8	20
10013	Concurrent, but not sequential, PD-1 blockade with a DNA vaccine elicits anti-tumor responses in patients with metastatic, castration-resistant prostate cancer. <i>Oncotarget</i> , 2018, 9, 25586-25596.	0.8	66
10014	Real world experience in low-dose ipilimumab in combination with PD-1 blockade in advanced melanoma patients. <i>Oncotarget</i> , 2018, 9, 28903-28909.	0.8	37
10015	Simplifying checkpoint inhibitor delivery through <i>in vivo</i> generation of synthetic DNA-encoded monoclonal antibodies (DMAbs). <i>Oncotarget</i> , 2019, 10, 13-16.	0.8	15
10016	Clinical validation of the tempus xT next-generation targeted oncology sequencing assay. <i>Oncotarget</i> , 2019, 10, 2384-2396.	0.8	119
10017	IgG based immunome analyses of breast cancer patients reveal underlying signaling pathways. <i>Oncotarget</i> , 2019, 10, 3491-3505.	0.8	7
10018	The landscape of novel and complementary targets for immunotherapy: an analysis of gene expression in the tumor microenvironment. <i>Oncotarget</i> , 2019, 10, 4532-4545.	0.8	8
10019	The impact of systemic precision medicine and immunotherapy treatments on brain metastases. <i>Oncotarget</i> , 2019, 10, 6739-6753.	0.8	13
10020	Checkpoint blockade inhibitors enhances the effectiveness of a <i>Listeria monocytogenes</i> -based melanoma vaccine. <i>Oncotarget</i> , 2020, 11, 740-754.	0.8	8
10021	A comprehensive analysis of clinical trials in pancreatic cancer: what is coming down the pike?. <i>Oncotarget</i> , 2020, 11, 3489-3501.	0.8	30
10022	Deconstructing tumor heterogeneity: the stromal perspective. <i>Oncotarget</i> , 2020, 11, 3621-3632.	0.8	29

#	ARTICLE	IF	CITATIONS
10023	PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma. <i>Oncotarget</i> , 2015, 6, 3479-3492.	0.8	146
10024	Targeting the tumor microenvironment to enhance antitumor immune responses. <i>Oncotarget</i> , 2015, 6, 1359-1381.	0.8	59
10025	New Perspectives on the Role of Vitiligo in Immune Responses to Melanoma. <i>Oncotarget</i> , 2011, 2, 684-694.	0.8	88
10026	Molecular stratification of metastatic melanoma using gene expression profiling : Prediction of survival outcome and benefit from molecular targeted therapy. <i>Oncotarget</i> , 2015, 6, 12297-12309.	0.8	148
10027	ERBB activation modulates sensitivity to MEK1/2 inhibition in a subset of driver-negative melanoma. <i>Oncotarget</i> , 2015, 6, 22348-22360.	0.8	12
10028	Molecular characterization of a selected cohort of patients affected by pulmonary metastases of malignant melanoma: Hints from BRAF, NRAS and EGFR evaluation. <i>Oncotarget</i> , 2015, 6, 19868-19879.	0.8	8
10029	Loss of tumor suppressors KAI1 and p27 identifies a unique subgroup of primary melanoma patients with poor prognosis. <i>Oncotarget</i> , 2015, 6, 23026-23035.	0.8	12
10030	A novel immune resistance mechanism of melanoma cells controlled by the ADAR1 enzyme. <i>Oncotarget</i> , 2015, 6, 28999-29015.	0.8	53
10031	Phase 1b study of lenvatinib (E7080) in combination with temozolomide for treatment of advanced melanoma. <i>Oncotarget</i> , 2015, 6, 43127-43134.	0.8	19
10032	Effects of a novel Nodal-targeting monoclonal antibody in melanoma. <i>Oncotarget</i> , 2015, 6, 34071-34086.	0.8	24
10033	Antibiotic drug tigecycline inhibits melanoma progression and metastasis in a p21CIP1/Waf1-dependent manner. <i>Oncotarget</i> , 2016, 7, 3171-3185.	0.8	41
10034	Identification of TIM3 2-Fluoro oligonucleotide aptamer by HT-SELEX for cancer immunotherapy. <i>Oncotarget</i> , 2016, 7, 4522-4530.	0.8	44
10035	Tumor CTLA-4 overexpression predicts poor survival in patients with nasopharyngeal carcinoma. <i>Oncotarget</i> , 2016, 7, 13060-13068.	0.8	80
10036	CD40-activated B cells induce anti-tumor immunity <i>in vivo</i> . <i>Oncotarget</i> , 2017, 8, 27740-27753.	0.8	43
10037	Emerging therapeutic targets in esophageal adenocarcinoma. <i>Oncotarget</i> , 2016, 7, 48644-48655.	0.8	13
10038	Dynamic contrast-enhanced MRI coupled with a subtraction technique is useful for treatment response evaluation of malignant melanoma hepatic metastasis. <i>Oncotarget</i> , 2016, 7, 38513-38522.	0.8	9
10039	Medical management of malignant melanoma. <i>Australian Prescriber</i> , 2015, 38, 74-78.	0.5	24
10040	Resistance mechanisms in melanoma to immuneoncologic therapy with checkpoint inhibitors. , 2019, 2, 744-761.		3

#	ARTICLE	IF	CITATIONS
10041	Drug resistance in cancer immunotherapy: new strategies to improve checkpoint inhibitor therapies. , 2019, 2, 980-993.		9
10042	The dark side of immunotherapy: pancreatic cancer. , 2020, 3, 491-520.		15
10043	Decoding cancer's camouflage: epithelial-mesenchymal plasticity in resistance to immune checkpoint blockade. , 2020, 3, 832-853.		7
10044	Gastrointestinal toxicities of immune checkpoint inhibitors: a multicenter retrospective analysis. Annals of Gastroenterology, 2020, 34, 46-52.	0.4	2
10045	Current applications and future prospects of nanotechnology in cancer immunotherapy. Cancer Biology and Medicine, 2019, 16, 487-497.	1.4	40
10046	The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy. Cancer Biology and Medicine, 2019, 16, 655-670.	1.4	95
10047	T Cell Metabolism in Cancer Immunotherapy. Immunometabolism, 2020, 2, .	0.7	16
10048	Alterations of DNA damage repair in cancer: from mechanisms to applications. Annals of Translational Medicine, 2020, 8, 1685-1685.	0.7	44
10049	What does the future hold for immunotherapy in cancer?. Annals of Translational Medicine, 2016, 4, 177-177.	0.7	9
10050	Revisiting of cancer vaccine's specific immunotherapy comes to field with the biomarker. Annals of Translational Medicine, 2016, 4, 179-179.	0.7	1
10051	Uveal melanoma as a target for immune-therapy. Annals of Translational Medicine, 2016, 4, 172-172.	0.7	63
10052	The European Organization for Research and Treatment of Cancer perspective on designing clinical trials with immune therapeutics. Annals of Translational Medicine, 2016, 4, 267-267.	0.7	17
10053	Melanoma immunotherapy dominates the field. Annals of Translational Medicine, 2016, 4, 269-269.	0.7	19
10054	DNA damage, tumor mutational load and their impact on immune responses against cancer. Annals of Translational Medicine, 2016, 4, 264-264.	0.7	35
10055	Acquired resistance mechanisms to immunotherapy. Annals of Translational Medicine, 2016, 4, 547-547.	0.7	2
10056	Breakthroughs in the treatment of advanced squamous-cell NSCLC: not the neglected sibling anymore?. Annals of Translational Medicine, 2018, 6, 143-143.	0.7	13
10057	The use of baseline tumor size to prognosticate overall survival in stage IV melanoma patients treated with the PD-1 inhibitor pembrolizumab. Annals of Translational Medicine, 2019, 7, S24-S24.	0.7	8
10058	Immunotherapy and targeted therapy's the new roadmap in cancer treatment. Annals of Translational Medicine, 2019, 7, 595-595.	0.7	25

#	ARTICLE	IF	CITATIONS
10059	Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition). Chinese Clinical Oncology, 2016, 5, 57-57.	0.4	46
10060	Immunotherapy in patients with autoimmune disease. Journal of Thoracic Disease, 2020, 12, 7032-7038.	0.6	13
10061	A consensus on immunotherapy from the 2017 Chinese Lung Cancer Summit expert panel. Translational Lung Cancer Research, 2018, 7, 428-436.	1.3	7
10062	The Prognostic Role of the Surgical Approach and Adjuvant Therapy in Operable Mucosal Melanoma of the Head and Neck. Clinical and Experimental Otorhinolaryngology, 2017, 10, 97-103.	1.1	14
10063	Development of red blood cell autoantibodies following treatment with checkpoint inhibitors: a new class of anti-neoplastic, immunotherapeutic agents associated with immune dysregulation. Immunohematology, 2017, 33, 15-21.	0.2	29
10064	Treatment of cutaneous melanoma: current approaches and future prospects. Cancer Management and Research, 2010, 2, 197.	0.9	38
10065	Immune Checkpoint Inhibitor Can Reduce HCV-RNA without Liver Damage. Internal Medicine, 2020, 59, 2245-2248.	0.3	6
10066	Nanoparticles in Melanoma. Current Medicinal Chemistry, 2014, 21, 3701-3716.	1.2	7
10067	Immune Checkpoint Inhibitors: Basics and Challenges. Current Medicinal Chemistry, 2019, 26, 3009-3025.	1.2	286
10068	Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy. Current Medicinal Chemistry, 2019, 26, 3026-3041.	1.2	142
10069	Biological Therapy of Hematologic Malignancies: Toward a Chemotherapy-free Era. Current Medicinal Chemistry, 2019, 26, 1002-1018.	1.2	11
10070	Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules. Current Medicinal Chemistry, 2020, 27, 2402-2448.	1.2	12
10071	Immunosuppression and Immunotargeted Therapy in Acute Myeloid Leukemia - The Potential Use of Checkpoint Inhibitors in Combination with Other Treatments. Current Medicinal Chemistry, 2019, 26, 5244-5261.	1.2	8
10072	The Next Generation of Pattern Recognition Receptor Agonists: Improving Response Rates in Cancer Immunotherapy. Current Medicinal Chemistry, 2020, 27, 5654-5674.	1.2	13
10073	Molecular Markers of Regulatory T Cells in Cancer Immunotherapy with Special Focus on Acute Myeloid Leukemia (AML) - A Systematic Review. Current Medicinal Chemistry, 2020, 27, 4673-4698.	1.2	18
10074	Nanoparticles: Properties and Applications in Cancer Immunotherapy. Current Pharmaceutical Design, 2019, 25, 1962-1979.	0.9	12
10075	Evolution of Molecular Targets in Melanoma Treatment. Current Pharmaceutical Design, 2020, 26, 396-414.	0.9	10
10076	Integrating Bioinformatics Strategies in Cancer Immunotherapy: Current and Future Perspectives. Combinatorial Chemistry and High Throughput Screening, 2020, 23, 687-698.	0.6	7

#	ARTICLE	IF	CITATIONS
10077	Immunomodulatory Drugs: Immune Checkpoint Agents in Acute Leukemia. <i>Current Drug Targets</i> , 2017, 18, 315-331.	1.0	39
10078	Anti-tumor Drug Targets Analysis: Current Insight and Future Prospect. <i>Current Drug Targets</i> , 2019, 20, 1180-1202.	1.0	13
10079	Lentiviral Vectors: A Versatile Tool to Fight Cancer. <i>Current Molecular Medicine</i> , 2013, 13, 602-625.	0.6	27
10080	Past, Present and Future Strategies of Immunotherapy in Gynecological Malignancies. <i>Current Molecular Medicine</i> , 2013, 13, 648-669.	0.6	13
10081	Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer. <i>Current Cancer Drug Targets</i> , 2019, 19, 595-630.	0.8	61
10082	Translational Peptide-associated Nanosystems: Promising Role as Cancer Vaccines. <i>Current Topics in Medicinal Chemistry</i> , 2015, 16, 291-313.	1.0	2
10083	Towards Breast Cancer Vaccines, Progress and Challenges. <i>Current Drug Discovery Technologies</i> , 2019, 16, 251-258.	0.6	21
10084	Immune Checkpoint Inhibitors-related Rheumatic Diseases: What Rheumatologist Should Know?. <i>Current Rheumatology Reviews</i> , 2019, 15, 201-208.	0.4	10
10085	Can Combined Therapy Benefit Immune Checkpoint Blockade Response in Hepatocellular Carcinoma?. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2019, 19, 222-228.	0.9	4
10086	Synergies of Targeting Angiogenesis and Immune Checkpoints in Cancer: From Mechanism to Clinical Applications. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2020, 20, 768-776.	0.9	6
10087	Promising Strategies for Overcoming BRAF Inhibitor Resistance Based on Known Resistance Mechanisms. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2020, 20, 1415-1430.	0.9	3
10088	Insights into the Role of PAX-3 in the Development of Melanocytes and Melanoma. <i>The Open Cancer Journal</i> , 2011, 4, 1-6.	0.2	5
10089	Monoclonal Antibodies: Application in Radiopharmacy. <i>Current Radiopharmaceuticals</i> , 2014, 6, 231-248.	0.3	7
10090	The Role of PET/CT in the Era of Immune Checkpoint Inhibitors: State of Art. <i>Current Radiopharmaceuticals</i> , 2020, 13, 24-31.	0.3	6
10091	Immune checkpoint-targeted therapy: cancer and autoimmune diseases represent two sides of the same coin. <i>Journal of Autoimmune Disorders</i> , 2016, 2, .	0.2	6
10092	Cancer Immunology and Immunotherapy. <i>Anticancer Research</i> , 2016, 36, 5593-5606.	0.5	69
10093	Immune Blockade Inhibition in Breast Cancer. <i>Anticancer Research</i> , 2016, 36, 5607-5622.	0.5	37
10094	Immune-based Therapies for Non-small Cell Lung Cancer. <i>Anticancer Research</i> , 2017, 37, 377-388.	0.5	66

#	ARTICLE	IF	CITATIONS
10095	Multi-omics Profiling of Patients with Melanoma Treated with Nivolumab in Project HOPE. <i>Anticancer Research</i> , 2017, 37, 1321-1328.	0.5	6
10096	Clinical Study on the Medical Value of Combination Therapy Involving Adoptive Immunotherapy and Chemotherapy for Stage IV Colorectal Cancer (COMVI Study). <i>Anticancer Research</i> , 2017, 37, 3941-3946.	0.5	18
10097	Comparison of the Serum Tumor Markers S100 and Melanoma-inhibitory Activity (MIA) in the Monitoring of Patients with Metastatic Melanoma Receiving Vaccination Immunotherapy with Dendritic Cells. <i>Anticancer Research</i> , 2017, 37, 5033-5037.	0.5	6
10098	New Drug Combination Strategies in Melanoma: Current Status and Future Directions New Drug Combination Strategies in Melanoma: Current Status and Future Directions. <i>Anticancer Research</i> , 2017, 37, 5941-5953.	0.5	27
10099	Immune Checkpoint Inhibitors in Gynecological Cancers: Update of Literature and Perspectives of Clinical Research. <i>Anticancer Research</i> , 2017, 37, 5955-5965.	0.5	45
10100	Complete Lymph Node Dissection in Melanoma: A Systematic Review and Meta-Analysis. <i>Anticancer Research</i> , 2017, 37, 6825-6829.	0.5	17
10101	Highly Activated PD-1/PD-L1 Pathway in Gastric Cancer with PD-L1 Expression. <i>Anticancer Research</i> , 2018, 38, 107-112.	0.5	31
10102	The Positive Relationship Between γ H2AX and PD-L1 Expression in Lung Squamous Cell Carcinoma. <i>In Vivo</i> , 2018, 32, 171-177.	0.6	10
10103	Thyrototoxicosis and Adrenocortical Hormone Deficiency During Immune-checkpoint Inhibitor Treatment for Malignant Melanoma. <i>In Vivo</i> , 2018, 32, 345-351.	0.6	19
10104	Patient-Reported Outcomes During Immunotherapy for Metastatic Melanoma: Mixed Methods Study of Patients' and Clinicians' Experiences. <i>Journal of Medical Internet Research</i> , 2020, 22, e14896.	2.1	24
10106	Endocrine adverse events related with immune checkpoint inhibitors: an update for clinicians. <i>Immunotherapy</i> , 2020, 12, 481-510.	1.0	7
10107	Cytokine therapy for renal cell cancer: the evolving role of immunomodulation. <i>Therapy: Open Access in Clinical Medicine</i> , 2011, 8, 347-358.	0.2	4
10108	Precipitation of Autoimmune Diabetes With Anti-PD-1 Immunotherapy. <i>Diabetes Care</i> , 2015, 38, e55-e57.	4.3	278
10109	Patient Preferences in Adjuvant and Palliative Treatment of Advanced Melanoma: A Discrete Choice Experiment. <i>Acta Dermato-Venereologica</i> , 2020, 100, adv00083-9.	0.6	17
10110	Increasing Costs of Skin Cancer due to Increasing Incidence and Introduction of Pharmaceuticals, 2007-2017. <i>Acta Dermato-Venereologica</i> , 2020, 100, adv00147.	0.6	15
10111	Management of cutaneous melanoma: comparison of the leading international guidelines updated to the 8th American Joint Committee on Cancer staging system and workup proposal by the Italian Society of Dermatology. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2020, 155, 126-145.	0.8	5
10112	Immunoscore and its introduction in clinical practice. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 64, 152-161.	0.4	48
10113	Endocrine dysfunctions during treatment of immune-checkpoint inhibitors. <i>Trends in Immunotherapy</i> , 2018, 2, .	0.2	6

#	ARTICLE	IF	CITATIONS
10114	Updates to Clinical Information on Anticancer Immunotherapy. Korean Journal of Clinical Pharmacy, 2018, 28, 65-75.	0.0	3
10115	Cloning and expansion of antigen-specific T cells using iPSC technology: A novel strategy for cancer immunotherapy. Inflammation and Regeneration, 2015, 35, 220-225.	1.5	1
10116	Treatment of skin reaction induced by nivolumab combined with radiotherapy in non-small cell lung cancer: a case report. Chinese Medical Sciences Journal, 2018, 00, 0-0.	0.2	9
10117	NF- κ B Inhibition Suppresses Experimental Melanoma Lung Metastasis. Journal of Cancer Science and Clinical Therapeutics, 2020, 04, 256-265.	0.2	8
10118	Enhancing graft-versus-leukemia after transplant: the rise of anti-cancer vaccines. Frontiers in Bioscience - Landmark, 2012, 17, 635.	3.0	6
10119	The role of bacteria in the treatment of cancer: A comprehensive review. Plant Biotechnology Persa, 2020, 2, 26-34.	0.2	1
10120	A case of non-comatose acute hepatic failure: An immune-related adverse event due to sequential administration of nivolumab and ipilimumab. Acta Hepatologica Japonica, 2019, 60, 83-90.	0.0	5
10121	Immune Response Checkpoint Inhibitors: New Risks of a New Class of Antitumor Agents. Safety and Risk of Pharmacotherapy, 2020, 8, 9-22.	0.1	10
10122	The evolution of surgical management for vertebral column tumors. Journal of Neurosurgery: Spine, 2019, 30, 417-423.	0.9	15
10123	The Systemic Treatment of Melanoma: The Place of Immune Checkpoint Inhibitors and the Suppression of Intracellular Signal Transduction. Deutsches \times 0308;rzteblatt International, 2019, 116, 497-504.	0.6	15
10124	Challenges and shifting paradigms in clinical trials in oncology: the case for immunological and targeted therapies. Ecancermedicalsecience, 2019, 13, 936.	0.6	3
10125	The Safety of Therapeutic Monoclonal Antibodies: Implications for Cancer Therapy Including Immuno-Checkpoint Inhibitors. Physiological Research, 2016, 65, S455-S462.	0.4	24
10126	PD-L1 and PD-L2 Expression in Cervical Cancer: Regulation and Biomarker Potential. Frontiers in Immunology, 2020, 11, 596825.	2.2	53
10127	Overexpression of B7-H3 in \pm -SMA-Positive Fibroblasts Is Associated With Cancer Progression and Survival in Gastric Adenocarcinomas. Frontiers in Oncology, 2019, 9, 1466.	1.3	39
10128	High-Dose Ipilimumab and High-Dose Interleukin-2 for Patients With Advanced Melanoma. Frontiers in Oncology, 2019, 9, 1483.	1.3	10
10130	Combined Anti-Cancer Strategies Based on Anti-Checkpoint Inhibitor Antibodies. Antibodies, 2020, 9, 17.	1.2	14
10131	Novel Nuclear Medicine Imaging Applications in Immuno-Oncology. Cancers, 2020, 12, 1303.	1.7	6
10132	The Role of Regional Therapies for in-Transit Melanoma in the Era of Improved Systemic Options. Cancers, 2015, 7, 1154-1177.	1.7	20

#	ARTICLE	IF	CITATIONS
10133	The Role of Immune Checkpoint Blockade in Uveal Melanoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 879.	1.8	57
10134	Preparation of Biphenyl-Conjugated Bromotyrosine for Inhibition of PD-1/PD-L1 Immune Checkpoint Interactions. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3639.	1.8	8
10135	Efficient Delivery and Replication of Oncolytic Virus for Successful Treatment of Head and Neck Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7073.	1.8	22
10136	Spatial and Temporal Changes in PD-L1 Expression in Cancer: The Role of Genetic Drivers, Tumor Microenvironment and Resistance to Therapy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7139.	1.8	33
10137	LAG-3, TIM-3 and VISTA Expression on Tumor-Infiltrating Lymphocytes in Oropharyngeal Squamous Cell Carcinoma—Potential Biomarkers for Targeted Therapy Concepts. <i>International Journal of Molecular Sciences</i> , 2021, 22, 379.	1.8	24
10138	Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: An Overview. <i>Pharmaceuticals</i> , 2021, 14, 3.	1.7	16
10139	Kidney Biopsy Should Be Performed to Document the Cause of Immune Checkpoint Inhibitor—Associated Acute Kidney Injury: CON. <i>Kidney360</i> , 2020, 1, 162-165.	0.9	10
10140	Next generation therapies change the landscape in melanoma. <i>F1000 Medicine Reports</i> , 2011, 3, 8.	2.9	7
10141	An analysis of early morning acth levels in the first case of pembrolizumab-induced adrenalitis as a delayed immune-related event (dire) — case study. <i>Wiadomości Lekarskie</i> , 2020, 73, 396-400.	0.1	2
10142	Combined Inhibition of NF- κ B and Bcl-2 Triggers Synergistic Reduction of Viability and Induces Apoptosis in Melanoma Cells. <i>Oncology Research</i> , 2014, 21, 173-180.	0.6	5
10143	Combination of chemotherapy and immunotherapy for colon cancer in China: A meta-analysis. <i>World Journal of Gastroenterology</i> , 2014, 20, 1095.	1.4	42
10144	Ipilimumab associated colitis: An IpiColitis case series at MedStar Georgetown University Hospital. <i>World Journal of Gastroenterology</i> , 2015, 21, 4373.	1.4	24
10145	Viro-immune therapy: A new strategy for treatment of pancreatic cancer. <i>World Journal of Gastroenterology</i> , 2016, 22, 748.	1.4	16
10146	Specific CD8 ⁺ T cell response immunotherapy for hepatocellular carcinoma and viral hepatitis. <i>World Journal of Gastroenterology</i> , 2016, 22, 6469.	1.4	53
10147	Progress in systemic therapy of advanced hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2016, 22, 6582.	1.4	43
10148	Personalized medicine in gastric cancer: Where are we and where are we going?. <i>World Journal of Gastroenterology</i> , 2016, 22, 1160.	1.4	37
10149	Immune checkpoint and inflammation as therapeutic targets in pancreatic carcinoma. <i>World Journal of Gastroenterology</i> , 2016, 22, 7440.	1.4	15
10150	Colonic ulcerations may predict steroid-refractory course in patients with ipilimumab-mediated enterocolitis. <i>World Journal of Gastroenterology</i> , 2017, 23, 2023.	1.4	68

#	ARTICLE	IF	CITATIONS
10151	Multiparametric analysis of colorectal cancer immune responses. <i>World Journal of Gastroenterology</i> , 2018, 24, 2995-3005.	1.4	16
10152	Checkpoint inhibitors: What gastroenterologists need to know. <i>World Journal of Gastroenterology</i> , 2018, 24, 5433-5438.	1.4	14
10153	Secondary causes of inflammatory bowel diseases. <i>World Journal of Gastroenterology</i> , 2020, 26, 3998-4017.	1.4	38
10154	Immunotherapy and Complexity: Overcoming Barriers to Control of Advanced Cancer. <i>MEDICC Review</i> , 2014, 16, 65.	0.5	7
10155	Investigating the role of immunotherapy in advanced/recurrent female genital tract melanoma: a preliminary experience. <i>Journal of Gynecologic Oncology</i> , 2019, 30, e94.	1.0	29
10156	Radiotherapy and immune checkpoint blockades: a snapshot in 2016. <i>Radiation Oncology Journal</i> , 2016, 34, 250-259.	0.7	26
10157	The evolution in melanoma treatment as a reflection of precision-oriented medicine. <i>Oncology Letters</i> , 2013, 5, 424-426.	0.8	7
10158	Use of immunotherapy in the treatment of gastric cancer (Review). <i>Oncology Letters</i> , 2019, 18, 5681-5690.	0.8	31
10159	Analysis of immune-related signatures of colorectal cancer identifying two different immune phenotypes: Evidence for immune checkpoint inhibitor therapy. <i>Oncology Letters</i> , 2020, 20, 517-524.	0.8	12
10160	New Systemic Treatment for Malignant Melanoma. <i>Korean Journal of Medicine</i> , 2013, 85, 357.	0.1	3
10161	Immunotherapy a New Hope for Cancer Treatment: A Review. <i>Pakistan Journal of Biological Sciences</i> , 2018, 21, 135-150.	0.2	21
10162	Ipilimumab-Associated Retinopathy. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2015, 46, 658-660.	0.4	41
10163	Treatment of Ipilimumab-Induced Vogt-Koyanagi-Harada Syndrome With Oral Dexamethasone. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2017, 48, 928-931.	0.4	22
10164	Novel Approaches to Pediatric Cancer: Immunotherapy. <i>AIMS Medical Science</i> , 2015, 2, 104-117.	0.2	1
10165	Monoclonal Antibodies as Treatment Modalities in Head and Neck Cancers. <i>AIMS Medical Science</i> , 2015, 2, 347-359.	0.2	1
10166	Immunotherapy for synovial sarcoma. <i>AIMS Medical Science</i> , 2019, 6, 191-200.	0.2	1
10167	How should we diagnose and manage checkpoint inhibitor-associated colitis?. <i>Cleveland Clinic Journal of Medicine</i> , 2018, 85, 679-683.	0.6	5
10168	Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancer. <i>Journal of Thoracic Disease</i> , 2013, 5 Suppl 5, S579-92.	0.6	37

#	ARTICLE	IF	CITATIONS
10169	Impact of the immune system and immunotherapy in colorectal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2015, 6, 208-23.	0.6	142
10170	Immunotherapy for advanced gastric and esophageal cancer: preclinical rationale and ongoing clinical investigations. <i>Journal of Gastrointestinal Oncology</i> , 2015, 6, 561-9.	0.6	61
10171	Immunotherapy in lung cancer. <i>Translational Lung Cancer Research</i> , 2014, 3, 2-14.	1.3	53
10172	Immunotherapy prospects in the treatment of lung cancer and mesothelioma. <i>Translational Lung Cancer Research</i> , 2014, 3, 34-45.	1.3	22
10173	Immunotherapy in lung cancer. <i>Translational Lung Cancer Research</i> , 2014, 3, 53-63.	1.3	50
10174	A phase I study of MEDI4736, NNT-PD-L1 antibody in patients with advanced solid tumors. <i>Translational Lung Cancer Research</i> , 2014, 3, 406-7.	1.3	19
10175	The past, present and future of immunotherapy against tumor. <i>Translational Lung Cancer Research</i> , 2015, 4, 253-64.	1.3	34
10176	New strategies in immunotherapy for non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2015, 4, 553-9.	1.3	35
10177	Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. <i>Translational Lung Cancer Research</i> , 2015, 4, 560-75.	1.3	303
10178	Chemotherapy for advanced cancers. <i>Annals of Palliative Medicine</i> , 2014, 3, 203-28.	0.5	11
10179	Genotyping of cutaneous melanoma. <i>Chinese Clinical Oncology</i> , 2014, 3, 27.	0.4	17
10180	Checkpoint inhibitors in the treatment of cutaneous malignant melanoma. <i>Chinese Clinical Oncology</i> , 2014, 3, 30.	0.4	6
10181	Chemotherapy, biochemotherapy and anti-VEGF therapy in metastatic mucosal melanoma. <i>Chinese Clinical Oncology</i> , 2014, 3, 36.	0.4	11
10182	Adjuvant therapy of mucosal melanoma. <i>Chinese Clinical Oncology</i> , 2014, 3, 33.	0.4	2
10183	Treatment algorithm of metastatic mucosal melanoma. <i>Chinese Clinical Oncology</i> , 2014, 3, 38.	0.4	16
10184	The inflammatory microenvironment in brain metastases: potential treatment target?. <i>Chinese Clinical Oncology</i> , 2015, 4, 21.	0.4	51
10185	Genomic profiling of brain metastases: current knowledge and new frontiers. <i>Chinese Clinical Oncology</i> , 2015, 4, 22.	0.4	16
10186	Systemic therapies for melanoma brain metastases: which drug for whom and when?. <i>Chinese Clinical Oncology</i> , 2015, 4, 25.	0.4	20

#	ARTICLE	IF	CITATIONS
10187	Upcoming innovations in lung cancer immunotherapy: focus on immune checkpoint inhibitors. Chinese Clinical Oncology, 2015, 4, 48.	0.4	5
10188	Predictive factors for immunotherapy in melanoma. Annals of Translational Medicine, 2015, 3, 208.	0.7	27
10189	Melanoma: oncogenic drivers and the immune system. Annals of Translational Medicine, 2015, 3, 265.	0.7	19
10190	Immune checkpoint inhibitors: therapeutic advances in melanoma. Annals of Translational Medicine, 2015, 3, 267.	0.7	47
10191	Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition). Annals of Translational Medicine, 2015, 3, 322.	0.7	32
10192	Geografía histórica de los espacios reales: Aláridiga, Aceca y Barciles, despoblados del rey en la vega del Tajo. Estudios Geográficos, 2018, 79, 209.	0.4	3
10193	Combination of Poly-Gamma-Glutamate and Cyclophosphamide Enhanced Antitumor Efficacy Against Tumor Growth and Metastasis in a Murine Melanoma Model. Journal of Microbiology and Biotechnology, 2013, 23, 1339-1346.	0.9	7
10194	Malignt melanom "diagnostikk, behandling og oppfølging i Norge. Tidsskrift for Den Norske Laegeforening, 2013, 133, 2154-2158.	0.2	10
10195	Immune-related Adverse Events: Overview and Management Strategies for the Use of Immune Checkpoint Inhibitors. Journal of Rheumatic Diseases, 2019, 26, 221.	0.4	3
10196	Immunotherapy in metastatic prostate cancer. Indian Journal of Urology, 2016, 32, 271.	0.2	6
10197	Immune based therapy for melanoma. Indian Journal of Medical Research, 2016, 143, 135.	0.4	19
10198	Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implications. Asian Journal of Andrology, 2014, 16, 364.	0.8	15
10199	Immune checkpoint blockade therapy: The 2014 Tang prize in biopharmaceutical science. Biomedical Journal, 2015, 38, 5.	1.4	22
10200	Perspectives on the clinical development of immunotherapy in prostate cancer. Asian Journal of Andrology, 2018, 20, 253.	0.8	13
10201	Immunotherapy and its advances in the management of head-and-neck cancer. CHRISMED Journal of Health and Research, 2019, 6, 199.	0.1	4
10202	Low doses in immunotherapy: Are they effective?. Cancer Research Statistics and Treatment, 2019, 2, 54.	0.1	12
10203	The hallmarks of cancer and their therapeutic targeting in current use and clinical trials. Iraqi Journal of Hematology, 2020, 9, 1.	0.0	6
10204	Immune Checkpoint Blockers and Ovarian Cancer. Indian Journal of Medical and Paediatric Oncology, 2017, 38, 182-189.	0.1	4

#	ARTICLE	IF	CITATIONS
10205	Immunotherapy in breast cancer. <i>Journal of Carcinogenesis</i> , 2019, 18, 2.	2.5	56
10206	Programmed death-ligand 1 signaling pathway involves in bladder cancer growth and progression. <i>Journal of Carcinogenesis</i> , 2019, 18, 3.	2.5	2
10207	Checkpoint immunotherapy by nivolumab for treatment of metastatic melanoma. <i>Journal of Cancer Research and Therapeutics</i> , 2018, 14, 1167-1175.	0.3	51
10208	Safety of Immune Checkpoint Blockade in Patients with Cancer and Preexisting Autoimmune Diseases and/or Chronic Inflammatory Disorders. <i>Journal of Immunotherapy and Precision Oncology</i> , 2019, 2, 59-64.	0.6	8
10209	The Impact of Immune Checkpoint Inhibitor-Related Adverse Events and Their Immunosuppressive Treatment on Patients's™ Outcomes. <i>Journal of Immunotherapy and Precision Oncology</i> , 2018, 1, 7-18.	0.6	40
10210	Should We Design Clinical Trials Differently in the Era of Cancer Immunotherapy?. <i>Journal of Immunotherapy and Precision Oncology</i> , 2019, 2, 36-39.	0.6	3
10211	Immunotherapy in oral cancer. <i>Journal of Pharmacy and Bioallied Sciences</i> , 2019, 11, 107.	0.2	37
10212	Immune checkpoint inhibitors: Advances and impact in neuro-oncology. , 2019, 10, 9.		18
10213	NK Cell-Based Immunotherapies in Cancer. <i>Immune Network</i> , 2020, 20, e14.	1.6	79
10214	Immune landscape and biomarkers for immuno-oncology in colorectal cancers. <i>Journal of Pathology and Translational Medicine</i> , 2020, 54, 351-360.	0.4	9
10215	Present Status and Problems on Molecular Targeted Therapy of Cancer. <i>Cancer Research and Treatment</i> , 2012, 44, 1-10.	1.3	24
10216	Ipilimumab Real-World Efficacy and Safety in Korean Melanoma Patients from the Korean Named-Patient Program Cohort. <i>Cancer Research and Treatment</i> , 2017, 49, 44-53.	1.3	27
10217	High-Throughput Multiplex Immunohistochemical Imaging of the Tumor and Its Microenvironment. <i>Cancer Research and Treatment</i> , 2020, 52, 98-108.	1.3	18
10218	Primary Adrenal Insufficiency from Immune Checkpoint Inhibitors. <i>AACE Clinical Case Reports</i> , 2018, 4, 232-234.	0.4	5
10219	Ipilimumab Induced Encephalitis: A Case Report. <i>Immunome Research</i> , 2015, 11, .	0.1	4
10220	Active (Patient Specific) Immunotherapy of Colon Cancer: A Transition from Preclinical Studies to Successful Clinical Trials. <i>Journal of Clinical & Cellular Immunology</i> , 2014, 05, .	1.5	2
10221	The Future of Melanoma Therapy is the Combination Approach. <i>Journal of Molecular Biomarkers & Diagnosis</i> , 2011, 02, .	0.4	2
10222	Pharmacovigilance of Oncology Biosimilars. <i>Journal of Pharmacovigilance</i> , 2016, 04, .	0.2	3

#	ARTICLE	IF	CITATIONS
10223	Dynamic Duo: Synergy between Cancer Radiation Therapy and Immunotherapy. Immunotherapy (Los Tj ETQq0 0 0,rgBT /Overlock 10 Tf	0.9	1
10224	Ritalin Use Modifies Alcohol Effects in Rats. Journal of Behavioral and Brain Science, 2014, 04, 453-464.	0.2	1
10225	Conjugation of Magnetite Nanoparticles with Melanogenesis Substrate, NPrCAP Provides Melanoma Targeted, <i>in Situ</i> Peptide Vaccine Immunotherapy through HSP Production by Chemo-Thermotherapy. Journal of Biomaterials and Nanobiotechnology, 2012, 03, 140-153.	1.0	12
10226	Combined Effects of Capsaicin and HA14-1 in Inducing Apoptosis in Melanoma Cells. Journal of Cosmetics Dermatological Sciences and Applications, 2013, 03, 175-189.	0.1	5
10227	A Study of Zoledronic Acid as Neo-Adjuvant, Perioperative Therapy in Patients with Resectable Pancreatic Ductal Adenocarcinoma. Journal of Cancer Therapy, 2013, 04, 797-803.	0.1	26
10228	Anti-Cancer Activities and Interaction of Imiquimod and Flex-Het, SHetA2, in Melanoma and Ovarian Cancer. Journal of Cancer Therapy, 2013, 04, 7-19.	0.1	3
10229	A Real-World Observational Study of Patients with Advanced Melanoma Receiving First-Line Ipilimumab in a Community Practice Setting. Journal of Cancer Therapy, 2014, 05, 1049-1058.	0.1	4
10230	Healthcare Resource Utilization and Associated Costs in Patients with Advanced Melanoma Receiving First-Line Ipilimumab. Journal of Cancer Therapy, 2015, 06, 833-840.	0.1	10
10231	Is Use of Radiation Hormesis the Missing Link to a Better Cancer Treatment?. Journal of Cancer Therapy, 2015, 06, 601-605.	0.1	12
10232	Novel therapy for advanced gastric cancer. World Journal of Gastrointestinal Oncology, 2015, 7, 263.	0.8	6
10233	Anti program death-1/anti program death-ligand 1 in digestive cancers. World Journal of Gastrointestinal Oncology, 2015, 7, 95.	0.8	53
10234	Is metastatic pancreatic cancer an untargetable malignancy?. World Journal of Gastrointestinal Oncology, 2016, 8, 297.	0.8	8
10235	Immune checkpoint inhibitor-induced diarrhea/colitis: Endoscopic and pathologic findings. World Journal of Gastrointestinal Pathophysiology, 2019, 10, 17-28.	0.5	26
10236	Immunobiology of hepatocarcinogenesis: Ways to go or almost there?. World Journal of Gastrointestinal Pathophysiology, 2016, 7, 242.	0.5	12
10237	Diarrhoea in a patient with metastatic melanoma: Ipilimumab ileocolitis treated with infliximab. World Journal of Gastrointestinal Pharmacology and Therapeutics, 2013, 4, 80.	0.6	14
10238	Evaluation of response to immune checkpoint inhibitors: Is there a role for positron emission tomography?. World Journal of Radiology, 2017, 9, 27.	0.5	17
10239	From "magic bullets" to specific cancer immunotherapy. Swiss Medical Weekly, 2013, 143, w13734.	0.8	10
10240	Cancer immunology – development of novel anti-cancer therapies. Swiss Medical Weekly, 2015, 145, w14066.	0.8	18

#	ARTICLE	IF	CITATIONS
10241	The updated Swiss guidelines 2016 for the treatment and follow-up of cutaneous melanoma. Swiss Medical Weekly, 2016, 146, w14279.	0.8	35
10242	Current status of cancer immunotherapy. Journal of Stem Cells and Regenerative Medicine, 2014, 10, 8-13.	2.2	17
10243	New Oncological Drugs: Analysis of Survival Gain. Global & Regional Health Technology Assessment, 2014, 1, GRHTA.2014.1235.	0.2	4
10244	Immunotherapy – new perspective in lung cancer. World Journal of Clinical Oncology, 2020, 11, 250-259.	0.9	10
10245	Targeted immunotherapy for non-small cell lung cancer. World Journal of Clinical Oncology, 2014, 5, 39.	0.9	7
10246	Immunotherapy in pancreatic cancer: Unleash its potential through novel combinations. World Journal of Clinical Oncology, 2017, 8, 230.	0.9	52
10247	Role of senescence induction in cancer treatment. World Journal of Clinical Oncology, 2018, 9, 180-187.	0.9	30
10248	Present and future of immune checkpoint blockade: Monotherapy to adjuvant approaches. World Journal of Immunology, 2015, 5, 1.	0.5	4
10249	Ipilimumab-induced hypophysitis: early Australian experience. Medical Journal of Australia, 2014, 201, 198-199.	0.8	8
10250	Standards of care and novel approaches in the management of glioblastoma multiforme. Chinese Journal of Cancer, 2014, 33, 32-39.	4.9	121
10251	Novel anti-melanoma treatment: focus on immunotherapy. Chinese Journal of Cancer, 2014, 33, 458-465.	4.9	11
10252	Cancer immunotherapy in clinical practice: the past, present, and future. Chinese Journal of Cancer, 2014, 33, 445-457.	4.9	38
10253	Immunotargeting of Melanoma. , 0, , .		1
10254	Harnessing the Immune System to Fight Cancer: The Promise of Genetic Cancer Vaccines. , 0, , .		4
10255	Adoptive Cell Therapy of Melanoma: The Challenges of Targeting the Beating Heart. , 0, , .		2
10256	Surgery and the Staging of Melanoma. , 0, , .		2
10257	Immune Checkpoint Blockade: A New Paradigm in Treating Advanced Cancer. Journal of the Advanced Practitioner in Oncology, 2014, 5, 418-31.	0.2	48
10258	Pembrolizumab: First in Class for Treatment of Metastatic Melanoma. Journal of the Advanced Practitioner in Oncology, 2015, 6, 234-8.	0.2	3

#	ARTICLE	IF	CITATIONS
10259	Understanding and Managing Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Patients With Advanced Melanoma. <i>Journal of the Advanced Practitioner in Oncology</i> , 2017, 8, 58-72.	0.2	7
10260	Full Spectrum: Efficacy and Toxicity of Immunotherapy in Metastatic Melanoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, S-1-S-5.	2.3	5
10261	Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 255-289.	2.3	393
10262	Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 367-402.	2.3	326
10263	Quantifying the Survival Benefits of Oncology Drugs With a Focus on Immunotherapy Using Restricted Mean Survival Time. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 278-285.	2.3	12
10264	The Italian Network for Tumor Biotherapy (NIBIT): past, present and future goals. <i>Reviews in Health Care</i> , 2014, 5, 3-6.	0.1	2
10265	Enhanced Antitumor Efficacy with Combined Administration of Astragalus and Pterostilbene for Melanoma. <i>Asian Pacific Journal of Cancer Prevention</i> , 2014, 15, 1163-1169.	0.5	7
10266	Immune Checkpoint Inhibitors: Therapeutic Tools for Breast Cancer. <i>Asian Pacific Journal of Cancer Prevention</i> , 2016, 17, 905-910.	0.5	23
10267	Mechanistic considerations for the use of monoclonal antibodies for cancer therapy. <i>Cancer Biology and Medicine</i> , 2014, 11, 20-33.	1.4	109
10268	Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma. <i>Cancer Biology and Medicine</i> , 2014, 11, 237-46.	1.4	64
10269	Understanding the function and dysfunction of the immune system in lung cancer: the role of immune checkpoints. <i>Cancer Biology and Medicine</i> , 2015, 12, 79-86.	1.4	28
10270	Fueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitors. <i>Cancer Biology and Medicine</i> , 2015, 12, 201-8.	1.4	67
10271	Explosive mutation accumulation triggered by heterozygous human Pol μ proofreading-deficiency is driven by suppression of mismatch repair. <i>ELife</i> , 2018, 7, .	2.8	33
10272	Tumors attenuating the mitochondrial activity in T cells escape from PD-1 blockade therapy. <i>ELife</i> , 2020, 9, .	2.8	40
10273	Cancer systems immunology. <i>ELife</i> , 2020, 9, .	2.8	14
10274	Metastatic melanoma – a review of current and future drugs. <i>Drugs in Context</i> , 2012, 2012, 1-17.	1.0	25
10275	Evaluating cost benefits of combination therapies for advanced melanoma. <i>Drugs in Context</i> , 2016, 5, 1-14.	1.0	19
10276	Anti-Programmed Cell Death Protein 1 (PD-1) Immunotherapy for Metastatic Hepatocellular Carcinoma After Liver Transplantation: A Report of Three Cases. <i>Cureus</i> , 2020, 12, e11150.	0.2	16

#	ARTICLE	IF	CITATIONS
10277	Ipilimumab as a Cause of Severe Pan-Colitis and Colonic Perforation. <i>Cureus</i> , 2017, 9, e1182.	0.2	16
10278	Stereotactic Radiosurgery and Ipilimumab Versus Stereotactic Radiosurgery Alone in Melanoma Brain Metastases. <i>Cureus</i> , 2017, 9, e1511.	0.2	15
10279	The Most Recent Oncologic Emergency: What Emergency Physicians Need to Know About the Potential Complications of Immune Checkpoint Inhibitors. <i>Cureus</i> , 2017, 9, e1774.	0.2	17
10280	Complete Response of Metastatic Melanoma to Local Radiation and Immunotherapy: 6.5 Year Follow-Up. <i>Cureus</i> , 2018, 10, e3723.	0.2	7
10281	A Rare Case of Ipilimumab-induced Reversible Hypophysitis and Permanent Primary Hypothyroidism. <i>Cureus</i> , 2019, 11, e5001.	0.2	3
10282	Concurrent Radiosurgery and Systemic Therapies for Melanoma Brain Metastases: A Systematic Review. <i>Cureus</i> , 2019, 11, e6147.	0.2	7
10283	Immune-mediated Colitis from Dual Checkpoint Inhibitors. <i>Cureus</i> , 2019, 11, e6233.	0.2	2
10284	A Rare Case of Immune-Mediated Primary Adrenal Insufficiency With Cytotoxic T-Lymphocyte Antigen-4 Inhibitor Ipilimumab in Metastatic Melanoma of Lung and Neck of Unknown Primary. <i>Cureus</i> , 2020, 12, e8602.	0.2	6
10285	The Association of Radiation Dose-Fractionation and Immunotherapy Use With Overall Survival in Metastatic Melanoma Patients. <i>Cureus</i> , 2020, 12, e8767.	0.2	7
10286	Current Treatment Modalities Targeting Tumor Microenvironment in Castration-Resistant Prostate Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1329, 295-323.	0.8	5
10287	Identification of Immune Subtypes for Predicting the Prognosis of Patients in Head and Neck Squamous Cell Carcinoma. <i>Technology in Cancer Research and Treatment</i> , 2021, 20, 153303382110458.	0.8	2
10288	CCL21-DC tumor antigen vaccine augments anti-PD-1 therapy in lung cancer. <i>AIMS Medical Science</i> , 2021, 8, 269-275.	0.2	0
10289	Analysis of the efficacy and prognostic factors of PD-1 inhibitors in advanced gallbladder cancer. <i>Annals of Translational Medicine</i> , 2021, 9, 1568-1568.	0.7	5
10290	Therapeutic Potential. , 2021, , 465-518.		0
10292	Cutaneous Melanoma and Other Skin Cancers. <i>UNIPA Springer Series</i> , 2021, , 979-1007.	0.1	0
10293	An Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin-2) and Ipilimumab (Yervoy) in Patients with Metastatic Melanoma. <i>Oncolimmunology</i> , 2021, 10, 1984059.	2.1	2
10294	Cancer Immunotherapy Strategies: Basic Principles. <i>Bioanalysis</i> , 2021, , 29-49.	0.1	0
10295	Clinical Characteristics and Outcomes of Oral Mucositis Associated With Immune Checkpoint Inhibitors in Patients With Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 1415-1424.	2.3	10

#	ARTICLE	IF	CITATIONS
10296	Therapeutic melanoma inhibition by local micelle-mediated cyclic nucleotide repression. <i>Nature Communications</i> , 2021, 12, 5981.	5.8	13
10297	NK Cells in the Tumor Microenvironment as New Potential Players Mediating Chemotherapy Effects in Metastatic Melanoma. <i>Frontiers in Oncology</i> , 2021, 11, 754541.	1.3	16
10298	Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy. , 2021, 9, e003066.		34
10299	Low expression of endoplasmic reticulum stress-related gene SERP1 is associated with poor prognosis and immune infiltration in skin cutaneous melanoma. <i>Aging</i> , 2021, 13, 23036-23071.	1.4	3
10300	Bioinspired and Biomimetic Delivery Platforms for Cancer Vaccines. <i>Advanced Materials</i> , 2022, 34, e2103790.	11.1	81
10301	Real-World Incidence of Immune-Related Adverse Events Associated with Nivolumab Plus Ipilimumab in Patients with Advanced Renal Cell Carcinoma: A Retrospective Observational Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 4767.	1.0	3
10302	Fractal and Multifractal Analysis of PET-CT Images for Therapy Assessment of Metastatic Melanoma Patients under PD-1 Inhibitors: A Feasibility Study. <i>Cancers</i> , 2021, 13, 5170.	1.7	1
10303	Real World Outcomes in Patients with Advanced Melanoma Treated in Alberta, Canada: A Time-Era Based Analysis. <i>Current Oncology</i> , 2021, 28, 3978-3986.	0.9	7
10304	Vaccines for Non-Viral Cancer Prevention. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10900.	1.8	4
10305	Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types. , 2021, 9, e003499.		23
10306	RAC1 Activation as a Potential Therapeutic Option in Metastatic Cutaneous Melanoma. <i>Biomolecules</i> , 2021, 11, 1554.	1.8	12
10307	Preclinical Evaluation of LVR01 Attenuated Salmonella as Neoadjuvant Intralesional Therapy in Combination with Chemotherapy for Melanoma Treatment. <i>Journal of Investigative Dermatology</i> , 2022, 142, 1435-1443.e2.	0.3	2
10308	Impact of Antibiotics and Proton Pump Inhibitors on Efficacy and Tolerance of Anti-PD-1 Immune Checkpoint Inhibitors. <i>Frontiers in Immunology</i> , 2021, 12, 716317.	2.2	39
10309	Is there still a role for talimogene laherparepvec (T-VEC) in advanced melanoma? An indirect efficacy comparison of T-VEC plus ipilimumab combination therapy versus T-VEC alone as salvage therapy in unresectable metastatic melanoma. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 1647-1653.	1.4	1
10310	The Current Application and Future Prospects of Astragalus Polysaccharide Combined With Cancer Immunotherapy: A Review. <i>Frontiers in Pharmacology</i> , 2021, 12, 737674.	1.6	7
10311	A Combinatorial CRISPR-Cas9 Screen Identifies Ifenprodil as an Adjunct to Sorafenib for Liver Cancer Treatment. <i>Cancer Research</i> , 2021, 81, 6219-6232.	0.4	13
10312	Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy. <i>Nature Communications</i> , 2021, 12, 6071.	5.8	44
10313	Landscape of Myeloid-derived Suppressor Cell in Tumor Immunotherapy. <i>Biomarker Research</i> , 2021, 9, 77.	2.8	41

#	ARTICLE	IF	CITATIONS
10314	Review article: drug-induced small bowel injury. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 1370-1388.	1.9	12
10315	Immunotherapy in non-small cell lung cancer: who are the long-responders?. <i>Anti-Cancer Drugs</i> , 2021, 32, 1150-1152.	0.7	0
10316	Review of the recent clinical trials for PD-1/PD-L1 based lung cancer immunotherapy. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 1355-1370.	1.1	6
10317	Antitumor Activity of Ipilimumab or BRAF ± MEK Inhibition After Pembrolizumab in Patients With Advanced Melanoma: Analysis from KEYNOTE-006. <i>Annals of Oncology</i> , 2021, , .	0.6	5
10318	Central Nervous System Metastases. <i>Hematology/Oncology Clinics of North America</i> , 2022, 36, 161-188.	0.9	10
10319	Effect of Immune Checkpoint Blockade on Myeloid-Derived Suppressor Cell Populations in Patients With Melanoma. <i>Frontiers in Immunology</i> , 2021, 12, 740890.	2.2	15
10320	CD137 agonist potentiates the abscopal efficacy of nanoparticle-based photothermal therapy for melanoma. <i>Nano Research</i> , 2022, 15, 2300-2314.	5.8	12
10321	Raman Spectroscopy and Machine Learning Reveals Early Tumor Microenvironmental Changes Induced by Immunotherapy. <i>Cancer Research</i> , 2021, 81, 5745-5755.	0.4	13
10322	Pan-cancer analysis reveals homologous recombination deficiency score as a predictive marker for immunotherapy responders. <i>Human Cell</i> , 2022, 35, 199-213.	1.2	20
10323	Inhibition of estrogen signaling in myeloid cells increases tumor immunity in melanoma. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	40
10324	Archetypes of checkpoint-responsive immunity. <i>Trends in Immunology</i> , 2021, 42, 960-974.	2.9	5
10325	Pulmonary Toxicities Associated With the Use of Immune Checkpoint Inhibitors: An Update From the Immuno-Oncology Subgroup of the Neutropenia, Infection & Myelosuppression Study Group of the Multinational Association for Supportive Care in Cancer. <i>Frontiers in Pharmacology</i> , 2021, 12, 743582.	1.6	14
10326	Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. <i>Cell</i> , 2021, 184, 5309-5337.	13.5	588
10327	Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Progresses and Challenges. <i>Frontiers in Oncology</i> , 2021, 11, 737497.	1.3	22
10328	Novel Immunological Approaches in the Treatment of Locally Advanced Rectal Cancer. <i>Clinical Colorectal Cancer</i> , 2022, 21, 3-9.	1.0	11
10329	Anticoagulation with Factor Xa Inhibitors Is Associated with Improved Overall Response and Progression-Free Survival in Patients with Metastatic Malignant Melanoma Receiving Immune Checkpoint Inhibitors—A Retrospective, Real-World Cohort Study. <i>Cancers</i> , 2021, 13, 5103.	1.7	25
10330	Crosstalk Between the Tumor Microenvironment and Cancer Cells: A Promising Predictive Biomarker for Immune Checkpoint Inhibitors. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 738373.	1.8	15
10331	Combination of immunotherapy and other targeted therapies in advanced cutaneous melanoma. <i>Human Vaccines and Immunotherapeutics</i> , 2021, , 1-9.	1.4	5

#	ARTICLE	IF	CITATIONS
10332	High-Dimensional Single-Cell Transcriptomics in Melanoma and Cancer Immunotherapy. <i>Genes</i> , 2021, 12, 1629.	1.0	8
10333	Editorial: Genetic and Epigenetic Control of Immune Responses. <i>Frontiers in Immunology</i> , 2021, 12, 775101.	2.2	2
10334	Niraparib exhibits a synergistic anti-tumor effect with PD-L1 blockade by inducing an immune response in ovarian cancer. <i>Journal of Translational Medicine</i> , 2021, 19, 415.	1.8	25
10335	Understanding the immune response and the current landscape of immunotherapy in pancreatic cancer. <i>World Journal of Gastroenterology</i> , 2021, 27, 6775-6793.	1.4	12
10336	Role of PRKDC in cancer initiation, progression, and treatment. <i>Cancer Cell International</i> , 2021, 21, 563.	1.8	17
10337	An Immune-Related Gene Prognostic Index for Triple-Negative Breast Cancer Integrates Multiple Aspects of Tumor-Immune Microenvironment. <i>Cancers</i> , 2021, 13, 5342.	1.7	15
10338	Insights into Potential Pathogenesis and Treatment Options for Immune-Checkpoint Inhibitor-Related Pneumonitis. <i>Biomedicines</i> , 2021, 9, 1484.	1.4	10
10339	Hospital Variation in Cancer Treatments and Survival Outcomes of Advanced Melanoma Patients: Nationwide Quality Assurance in The Netherlands. <i>Cancers</i> , 2021, 13, 5077.	1.7	1
10340	Is there a role for neoadjuvant anti-PD-1 therapies in glioma?. <i>Current Opinion in Neurology</i> , 2021, Publish Ahead of Print, 834-839.	1.8	0
10341	Identification of Novel Modalities Through Bibliometric Analysis for Timely Development of Regulatory Guidance: A Case Study of T Cell Immunity. <i>Frontiers in Medicine</i> , 2021, 8, 756870.	1.2	2
10342	Intestinal Microbiota and Gene Expression Reveal Similarity and Dissimilarity Between Immune-Mediated Colitis and Ulcerative Colitis. <i>Frontiers in Oncology</i> , 2021, 11, 763468.	1.3	10
10343	Non-small cell lung cancer: Emerging molecular targeted and immunotherapeutic agents. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1876, 188636.	3.3	27
10344	Wrapping <i>Porphyromonas gingivalis</i> for tumor microenvironment immunomodulation and photothermal immunotherapy. <i>Nano Today</i> , 2021, 41, 101311.	6.2	19
10345	Novel Strategies in the Treatment of Multiple Myeloma: From Proteasome Inhibitors to Immunotherapy. <i>Journal of Cell Science & Therapy</i> , 2010, 01, .	0.3	0
10346	Immunit� et nouvelles voies th�rapeutiques dans le m�lanome. <i>Bulletin De L'Academie Nationale De Medecine</i> , 2010, 194, 1373-1381.	0.0	0
10347	Les m�lanomes : facteurs pronostiques et traitements adjuvants. <i>Traitement M�dical du m�lanome malin M�tastatique</i> . , 2011, , 673-683.		0
10348	Immunotherapy of Melanoma: A New Era. , 2011, , 359-372.		0
10349	Melanoma Stem Cells. , 2011, , 255-279.		0

#	ARTICLE	IF	CITATIONS
10350	Neueste Erkenntnisse und Blick in die Zukunft. Fortschritte Der Praktischen Dermatologie Und Venerologie, 2011, , 1-48.	0.0	0
10351	Melanocytic Nevi and Neoplasms. , 2011, , 675-693.		1
10352	Treatment of Disseminated Melanoma. , 2011, , 629-633.		0
10353	Dermatoonkologie. Fortschritte Der Praktischen Dermatologie Und Venerologie, 2011, , 69-102.	0.0	0
10354	New Therapeutic Approaches in Signaling. , 2011, , 337-357.		0
10355	Tumor Microenvironment for Melanoma Cells. , 2011, , 297-307.		0
10356	Vaccine Therapy for Melanoma. , 2011, , 606-612.		0
10357	Management of the Patient with Melanoma. , 2011, , 318-326.		2
10358	A case of advanced malignant melanoma responding to single-dose dacarbazine. Skin Cancer, 2011, 26, 139-142.	0.1	0
10360	The Role of the Microenvironment " Models for the Study of Melanoma. , 0, , .		0
10362	Recombinant protein vaccination for antigen-specific cancer immunotherapy. , 2011, , 87-102.		0
10363	Targeting regulatory T cells and other strategies to enable cancer vaccines. , 2011, , 182-201.		0
10364	Update on Current Phase III Clinical Trials in Melanoma. , 0, , .		1
10365	Immunomodulatory Functions of Cancer Stem Cells. , 2012, , 301-332.		0
10366	Update on Clinical Trials for Malignant Melanoma. , 0, , .		0
10367	Rare Tumors of the Skin and Subcutaneous Tissues. Pediatric Oncology, 2012, , 455-482.	0.5	0
10369	Diagnostic and Prognostic Biomarkers and Therapeutic Targets in Melanoma: An Overview. , 2012, , 305-317.		1
10370	Emerging Agents in Renal Cell Carcinoma. , 2012, , 285-301.		0

#	ARTICLE	IF	CITATIONS
10371	Modulating the Tumor Microenvironment. , 2012, , 353-369.		0
10372	Entering a New Era â€“ Prostate Cancer Immuno-Therapy After the FDA Approval for Sipuleucel-T. , 0, , .		0
10374	Anti-CTLA-4 Monoclonal Antibodies. , 2012, , 273-289.		0
10377	Updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma. Swiss Medical Weekly, 2011, 141, w13320.	0.8	41
10378	Exploring the Therapeutic Efficacy of Glioma Vaccines Based on Allo- and Syngeneic Antigens and Distinct Immunological Costimulation Activators. Journal of Clinical & Cellular Immunology, 2012, 01, 004.	1.5	2
10379	Melanom. , 2012, , 1710-1726.		0
10380	A Review of Novel Systemic Therapies and Brain Radiosurgery for Metastatic Melanoma. World Journal of Oncology, 2012, 3, 93-96.	0.6	1
10385	Possibilities of Targeted Therapies for Brain Metastasis. , 2012, , 87-107.		0
10386	Developing Cancer Immunotherapies by the manipulation of Immune Checkpoints. IOSR Journal of Pharmacy, 2012, 2, 01-08.	0.1	0
10387	Treatment of Occupational Skin Cancer. , 2012, , 1079-1085.		0
10388	Recent Advances in Cancer Immunotherapy. Practica Otologica, 2012, 105, 87-94.	0.0	0
10389	A Case of Malignant Melanoma in the Temporal Muscle. Practica Otologica, 2012, 105, 863-868.	0.0	0
10391	Is There a Role for Systemic Chemotherapy in the Treatment of Brain Metastases?. , 2012, , 133-151.		0
10392	Targeted Therapies and Vaccination. , 2012, , 261-275.		0
10396	Characterizing and Modulating the Tumor Microenvironment in Renal Cell Carcinoma: Potential Therapeutic Strategies. , 2012, , 239-252.		0
10397	45 Melanoom en andere huidtumoren. , 2012, , 541-550.		0
10398	Current Trends and Future Directions in Clinical Trials for Malignant Melanoma Treatment Using Anti-Angiogenic Strategies. Journal of Cancer Therapy, 2012, 03, 312-320.	0.1	0
10402	Cytokines, Chemokines, and ?Marshalling for War?. Journal of Cell Science & Therapy, 0, s5, .	0.3	0

#	ARTICLE	IF	CITATIONS
10406	Update in Hematology and Medical Oncology: Evidence Published in 2011. <i>Annals of Internal Medicine</i> , 2012, 157, 276.	2.0	0
10407	Monitoring Antigen-Specific Responses in Clinical Trials of Cancer Immunotherapy. , 2013, , 425-453.		0
10408	Issues in Pre-clinical Models, Clinical Trial Design and Analytical Considerations in Developing and Evaluating Novel Cancer Immunotherapies. , 2013, , 455-474.		0
10409	Augmenting the Skin Immune System. , 2013, , 151-164.		0
10411	Les nouveaut�s physiopathologiques � la base de la r�volution th�rapeutique des bioth�rapies dans les rhumatismes inflammatoires. <i>Bulletin De L'Academie Nationale De Medecine</i> , 2012, 196, 1261-1278.	0.0	0
10413	Drug treatment for melanoma: progress, but who pays?. <i>Medical Journal of Australia</i> , 2012, 197, 491-492.	0.8	0
10415	Immunomodulation. , 0, , .		0
10416	The 2-Series Eicosanoids in Cancer: Future Targets for Glioma Therapy?. <i>Journal of Cancer Therapy</i> , 2013, 04, 338-352.	0.1	0
10417	Glucocorticoid-Induced TNF Receptor (GITR). , 2013, , 1-8.		0
10418	Interleukin 2. , 2013, , 1-12.		0
10419	Recent Advances in Cancer Treatment. , 2013, , 25-35.		0
10420	Tumortherapie. <i>Fortschritte Der Praktischen Dermatologie Und Venerologie</i> , 2013, , 422-433.	0.0	0
10421	A Case of Primary Malignant Melanoma of the Esophagus with Submucosal Invasion. <i>Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association)</i> , 2013, 74, 1473-1478.	0.0	0
10422	Cancer immunotherapy with blocking of immune checkpoints. <i>Okayama Igakkai Zasshi</i> , 2013, 125, 13-18.	0.0	0
10423	Monoclonal Antibodies in Cancer. , 2013, , 337-359.		1
10424	gp100. , 2013, , 1-7.		0
10425	Development of Antitumor Cellular Immunity. , 2013, , 107-133.		0
10426	Treatment of Distant and Irresectable Metastatic Disease. , 2013, , 79-104.		0

#	ARTICLE	IF	CITATIONS
10427	Primary Malignant Vaginal Melanoma: A Case Report. Journal of Clinical Case Reports, 2013, 04, .	0.0	0
10428	Elastography as a New Screening Tool for Metastatic Lymph Nodes in Melanoma Patients. Journal of Clinical & Experimental Oncology, 2013, 02, .	0.1	2
10429	Cellular immunotherapy for leukemia. Drug Delivery System, 2013, 28, 10-16.	0.0	0
10431	Combination Therapy for Liver Metastases: Chemotherapy and Radiologic Interventions. , 2013, , 469-480.		0
10432	Malignant Melanoma of Unknown Primary Origin. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.0	0
10434	Tumor-Produced Immune Regulating Factors. , 2013, , 287-306.		0
10436	CTLA-4. , 2013, , 1-14.		0
10437	38 Years of Hybridoma Technology as a Source of Analytical Tools for Immunodiagnosics of Infectious Diseases. Some Contributions Developed in Cuba to Improve the Original Procedures and Future Prospects. Journal of Immunological Techniques in Infectious Diseases, 2013, 02, .	0.1	0
10438	Treatment-Induced Acute Leukaemia after Major Response to Cyclophosphamide-Based Metronomic Chemotherapy in Refractory Heavily Pre-Treated Prostate Cancer. Journal of Cancer Therapy, 2013, 04, 165-169.	0.1	2
10439	Management of In-Transit Malignant Melanoma. , 0, , .		1
10440	Recent New Drug Approvals, Part 2: Drugs Undergoing Active Clinical Studies in Children. Journal of Pediatric Pharmacology and Therapeutics, 2013, 18, 14-38.	0.3	7
10441	Hypophysitis als Folge einer Ipilimumab-Therapie bei metastasiertem Melanom. Fortschritte Der Praktischen Dermatologie Und Venerologie, 2013, , 611-613.	0.0	0
10442	Personalized Peptide Vaccine as a Novel Immunotherapy Against Advanced Cancer. , 2013, , 361-369.		0
10443	Cancer Vaccines and the Potential Benefit of Combination with Standard Cancer Therapies. , 2013, , 347-359.		0
10444	Nivolumab with Vaccine in Ipilimumab-Refractory or -Naive Melanoma. Journal of Vaccines & Vaccination, 2013, 04, .	0.3	0
10445	Cancer Biotherapy: The Best is Yet to Come. Journal of Cancer Science & Therapy, 2013, 05, .	1.7	0
10446	The Role of Chemotherapy for Metastatic Disease. , 2013, , 299-318.		0
10447	Tumor immunotherapy. , 2013, , 935-945.		0

#	ARTICLE	IF	CITATIONS
10448	The Efficacy and Cost of Biological Targeted Agents in Oncology. SSRN Electronic Journal, 0, , .	0.4	0
10449	Zielgerichtete und Immuntherapien beim fernmetastasierten Melanom. Fortschritte Der Praktischen Dermatologie Und Venerologie, 2013, , 17-29.	0.0	0
10450	Early Clinical Outcomes of Chimeric Antigen Receptor Modified T Cells and the Generation of "Armored" CAR T Cells for Future Applications to Cancer Immunotherapy. AACR Education Book, 2013, 2013, 71-76.	0.0	0
10451	Therapeutic Vaccines and Immunotherapy in Castration-Resistant Prostate Cancer: Current Progress and Clinical Applications. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , e166-e170.	1.8	4
10452	Melanoma: Molecular Classification and Therapy. , 2014, , 461-471.		0
10454	BRAF-Targeted Therapy in Metastatic Melanoma. , 2013, , 473-490.		0
10456	Colon, Rectum, and Anus. , 2014, , 415-454.		0
10457	Pacientų sergančių plitusia ar metastazuojančia melanoma, gydymas ipilimumabu. sukeliamų pažeidimų reikšmės vertinimas. Health Sciences, 2013, 23, 53-56.	0.0	0
10459	Marker Utility for Combination Therapy. Methods in Molecular Biology, 2014, 1102, 97-115.	0.4	0
10460	Monoclonal Antibodies to CTLA-4 with Focus on Ipilimumab. , 2014, , 233-258.		0
10461	Induction of Tumor Immunity by Targeted Inhibition of Nonsense-Mediated mRNA Decay. , 2014, , 67-82.		0
10462	T Cell Co-regulatory Signals and Their Role in Cancer Therapy. , 2014, , 323-341.		0
10463	Emerging Clinical Issues in Melanoma in the Molecularly Targeted Era. Methods in Molecular Biology, 2014, 1102, 11-26.	0.4	0
10464	Nanotechnology Applications in Dermatology. , 2013, , 85-194.		0
10465	The Cancer Super-Chaperone Hsp90: Its Posttranslational Regulation and Drug Targeting. , 2013, , 253-270.		0
10466	Heat-Shock Protein-Based Cancer Immunotherapy. , 2014, , 37-56.		0
10467	Immunotherapy in Renal Cell Carcinoma. , 2014, , 125-147.		0
10468	Novel Insights/Translational Implication from the Emerging Biology of Melanoma. Methods in Molecular Biology, 2014, 1102, 3-9.	0.4	3

#	ARTICLE	IF	CITATIONS
10469	Targeted therapieÅ«n. , 2014, , 55-66.		1
10470	Melanom. , 2014, , 31-97.		0
10471	Melanoom: systemische behandeling. , 2014, , 189-197.		0
10474	Unexpectedly good results, and no chemotherapy required. Journal of Community and Supportive Oncology, 2013, 11, 377-380.	0.1	0
10476	Engineering DNA Vaccines for Cancer Therapy. , 2014, , 449-471.		0
10477	Engineering T Cells to Target Tumor Cells. , 2014, , 71-101.		0
10480	Metastatic Uveal Melanoma. , 2014, , 275-285.		0
10481	SA-4-1BBL: A Novel Form of the 4-1BB Costimulatory Ligand as an Adjuvant Platform for the Development of Subunit Cancer Vaccines. , 2014, , 347-386.		0
10482	Cancer Immune Modulation and Immunosuppressive Cells: Current and Future Therapeutic Approaches. Advances in Delivery Science and Technology, 2014, , 187-214.	0.4	1
10483	Cancer Vaccines: Fundamentals and Strategies. Advances in Delivery Science and Technology, 2014, , 163-185.	0.4	0
10484	Politikk eller kvasivitenskap?. Tidsskrift for Den Norske Laegeforening, 2014, 134, 320-322.	0.2	3
10485	Non-small Cell Lung Cancer, NSCLC. , 2014, , 193-201.		2
10486	Tim-3 Regulation of Cancer Immunity. , 2014, , 239-261.		0
10487	Overcoming Immune Suppression: Therapeutic Strategies Targeting T-Cell Function in Cancer. , 2014, , 435-462.		0
10488	Immunotherapy of Malignant Melanoma. , 2014, , 139-154.		0
10489	Cancer Immunotherapy: The Dawn of the Renaissance after the Medieval Dark Ages. Korean Journal of Medicine, 2014, 87, 284.	0.1	1
10490	BO-110, a dsRNA-Based Anticancer Agent. Advances in Delivery Science and Technology, 2014, , 453-470.	0.4	0
10491	Metastatic Melanoma. , 2014, , 529-567.		0

#	ARTICLE	IF	CITATIONS
10492	Immunotherapy and Hepatocellular Carcinoma. <i>Journal of Liver</i> , 2014, 3, .	0.3	0
10494	How T Cells Single Out Tumor Cells: "And That Has Made All the Difference", 2014, , 13-20.		0
10495	Prostate Cancer Vaccines Generated with the Disruptive RNAi® Technology Follow the Path Paved by Sipuleucel-T and ProstateVAC-VF. , 2014, , 155-169.		0
10496	Developing Cancer Immunotherapies as Drugs: Setting the Stage Through Methodological Progress. , 2014, , 53-62.		0
10497	Reflections on Cancer Vaccines. , 2014, , 65-68.		0
10498	The Present Status of Therapeutic Cancer Vaccines. <i>Juntendo Medical Journal</i> , 2014, 60, s48-s52.	0.1	0
10499	An update on current management of advanced renal cell cancer, biomarkers, and future directions. <i>Journal of Cancer Therapeutics & Research</i> , 2014, 3, 8.	1.2	4
10500	Melanoma. Part II. Personalized Medicine: Using Molecular Tools to Guide Targeted Therapy. , 2014, , 97-131.		1
10501	Cancer Stem Cells in Melanoma. , 2014, , 203-228.		0
10503	A Case of Metastatic Gastric Malignant Melanoma Diagnosed by Tarry Stool 8 Years after the Resection of the Primary Skin Lesion. <i>Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association)</i> , 2014, 75, 1577-1582.	0.0	2
10504	Endocrine Complications. , 2014, , 885-893.		0
10505	Neurologic Complications. , 2014, , 822-844.e6.		0
10506	Current Status of Immunotherapy in Gastroesophageal Cancer. , 2014, , 179-191.		0
10507	Dendritic Cell-Based Cancer Vaccines. , 2014, , 69-87.		0
10508	Metastatic Melanoma with Spontaneous Regression, Psoriasis and HLA-Cw6: Case Report and a Hypothesis to Explore. <i>Tumori</i> , 2014, 100, e144-e147.	0.6	1
10509	p53 in Head and Neck Cancer. , 2014, , 227-258.		0
10510	Neue Medikamente bei Melanom und Mammakarzinom. <i>Pharma-Kritik (discontinued)</i> , 2014, 36, .	0.0	0
10512	An Uncommon Presentation for Cardiac Melanoma. <i>Journal of Patient-centered Research and Reviews</i> , 2014, 1, 128-132.	0.6	1

#	ARTICLE	IF	CITATIONS
10514	Adjuvant radiotherapy for melanoma metastatic to axillary and inguinal nodes: Regional tumor control and late effects. <i>Journal of Cancer Research & Therapy</i> , 2014, 2, 144-152.	0.1	1
10515	How to Personalize Perioperative Chemotherapy in Early Non-small Cell Lung Cancer?. , 2015, , 49-66.		0
10516	Liver Metastases from Melanoma Cancer. , 2015, , 69-77.		0
10518	Advances in Management of Merkel Cell Carcinoma in Organ Transplant Recipients: Role of Polyoma Virus and Immunosuppression. , 2015, , 99-110.		0
10520	Overcoming Cancer Tolerance with Immune Checkpoint Blockade. , 2015, , 87-129.		0
10522	Less Common Rectal Tumors. , 2015, , 323-347.		0
10524	Emerging Biomarkers During Clinical Development of Anti-CTLA4 Antibody Therapy. , 2015, , 427-439.		0
10525	T Cell Immunotherapy: From Synthetic Biology to Clinical Practice. , 2015, , 217-230.		0
10526	Management of Metastatic Bladder Tumours. , 2015, , 627-646.		0
10527	Immune Checkpoint Inhibitors (Anti-CTLA4, Anti-PD-1) in RCC. , 2015, , 469-481.		0
10528	Curable Resection in Gastric and Lymph Node Metastases From Melanoma. <i>CRSLS MIS Case Reports From SLS</i> , 2014, 18, .	0.2	0
10529	Combination BRAF-Directed Therapy and Immunotherapy. <i>Cancer Drug Discovery and Development</i> , 2015, , 163-182.	0.2	0
10530	Melanoma: Historical Context. <i>Cancer Drug Discovery and Development</i> , 2015, , 1-23.	0.2	0
10532	Lungenmetastasen beim Melanom. , 2015, , 139-149.		0
10533	Melanoma of the Head and Neck. , 2014, , 831-856.		0
10534	A Case of Melanoma Metastasis to the Parotid Lymph Node from an Unknown Primary Site. <i>Practica Otologica</i> , 2015, 108, 633-638.	0.0	0
10535	Challenges for the Clinical Implementation of Precision Medicine Trials. , 2015, , 133-144.		0
10536	Inflammatory Mechanisms of Infection-Associated Cancer. , 2015, , 151-167.		0

#	ARTICLE	IF	CITATIONS
10537	Inflammation and Lung Cancer: Addressing Inflammation with Immunotherapy. , 2015, , 191-209.		0
10538	Immunotherapy in Melanoma, Gastrointestinal (GI), and Pulmonary Malignancies. AIMS Public Health, 2015, 2, 86-114.	1.1	1
10539	The Actual State and Potential of Immunotherapy for Lung Cancer. Japanese Journal of Lung Cancer, 2015, 55, 991-994.	0.0	0
10540	Targeted Therapies For Intestinal Tumorigenesis. , 2015, , 391-440.		0
10541	Fighting Fire with Fire in Cancer. , 2015, , 39-49.		1
10542	T Cell Blockade Immunotherapy Against Cancer and Abscopal Effect in Combination Therapy. Cancer Drug Discovery and Development, 2015, , 211-229.	0.2	0
10543	Integrins: Friends or Foes of Antitumor Cytotoxic T Lymphocyte Response. Resistance To Targeted Anti-cancer Therapeutics, 2015, , 73-89.	0.1	0
10544	Cancer Induced Immunosuppression and Its Modulation by Signal Inhibitors. Resistance To Targeted Anti-cancer Therapeutics, 2015, , 287-301.	0.1	0
10545	Fc Gamma R. , 2015, , 1-20.		0
10546	Recent Updates in Cancer Immunotherapy. Korean Journal of Otorhinolaryngology-Head and Neck Surgery, 2015, 58, 449.	0.0	1
10548	Cancer Immunotherapy: Targeting Checkpoint Blockade. Advancements in Genetic Engineering, 2015, 04, .	0.1	0
10549	Patient Selection and Monitoring for Immunotherapies: Challenges for Immune Checkpoint Antibody and Cell Therapies. , 2015, , 85-101.		0
10550	A Case of Ipilimumab Induced Hypophysitis. The Medicine Forum, 2015, 16, .	0.0	0
10551	The Role of Vaccines for HPV-Related Head and Neck Cancers. Head and Neck Cancer Clinics, 2015, , 99-110.	0.0	1
10552	Diarrhea and generalized weakness in a patient with metastatic melanoma and a lumbosacral mass, after initiation of therapy with a checkpoint inhibitor: A case report. International Journal of Case Reports and Images, 2015, 6, 682.	0.0	0
10553	T Cell Modulation: Anti-PD-1 Antibodies for the Treatment of Cancer. Cancer Drug Discovery and Development, 2015, , 231-244.	0.2	0
10554	Selection and Monitoring of Patients for Immunotherapy (Peptide Vaccines). , 2015, , 63-84.		0
10555	Therapy for Late Stage Melanoma. Journal of Carcinogenesis & Mutagenesis, 2015, 06, .	0.3	0

#	ARTICLE	IF	CITATIONS
10556	Progress in Clinical Use of CC Chemokine Receptor 4 Antibody for Regulatory T Cell Suppression. , 2015, , 207-227.		1
10557	Immunopathology of Hepatobiliary Tumors and Immunotherapy of Liver Cancers. , 2015, , 199-215.		0
10558	Clinical Approach to Advanced Melanoma for Today and Tomorrow. , 2015, , 637-662.		0
10559	Peptide Vaccine: Overview. , 2015, , 1-13.		0
10560	Ewolucja systemowego leczenia przeciwnowotworowego. Nowotwory, 2015, 65, 1-6.	0.1	0
10561	T Cell Tuning for Tumour Therapy: Enhancing Effector Function and Memory Potential of Therapeutic T cells. Current Gene Therapy, 2015, 15, 289-299.	0.9	0
10562	Managing Advanced Melanoma: Targeting the PD-1 Pathway with Pembrolizumab. Cancer Research Frontiers, 2015, 1, 127-137.	0.2	0
10563	Melanoma and immunotherapy. , 2015, , 199-212.		0
10564	NEW PHARMACOLOGICAL APPROACHES IN THE TREATMENT OF ONCOLOGICAL DISEASES. Journal of IMAB, 2015, 21, 818-822.	0.1	0
10565	Advanced skin melanoma – systemic treatment. OnCOReview, 2015, 5, 133-138.	0.1	0
10566	Tyrosine Kinase Inhibitors for the Treatment of Thyroid Cancer: Present and Future. Endocrinology&Metabolism International Journal, 2015, 2, .	0.1	0
10567	CANCER IMMUNOLOGY AND IMMUNOTHERAPY – UNDERSTANDING AND ADAPTATION THE CURRENT EVIDENCE TO OPTIMIZE PATIENT THERAPY OUTCOMES. Journal of IMAB, 2015, 21, 926-940.	0.1	0
10568	An Overview of Promising Immunotherapeutic Strategies in Oncology. Journal of Cancer Prevention & Current Research, 2015, 3, .	0.1	0
10569	Improving of Antitumor Immunity and Therapeutic Efficacy of Cancer Vaccines and Adoptive Immunotherapies Using Monoclonal Antibodies. MOJ Immunology, 2015, 2, .	11.0	0
10571	The Management and Biology of Metastatic Cancers to the Brain. , 2016, , 21-35.		0
10572	Therapie des malignen Melanoms. , 2016, , 169-178.		0
10573	Dermatologic Toxicities to Melanoma Targeted Therapies. , 2016, , 267-277.		1
10574	Immunotherapy in Melanoma. , 2016, , 207-236.		0

#	ARTICLE	IF	CITATIONS
10575	Diagnostic Applications of Nuclear Medicine: Malignant Melanoma. , 2016, , 1-39.		0
10576	The Long-Term Endocrine Sequelae of Multimodality Cancer Therapy. , 2016, , 1799-1832.		0
10577	Melanom. , 2016, , 1-17.		0
10578	Tumor Immunology and Immunotherapy in Cancer Patients. , 2016, , 425-442.		2
10579	Therapeutic Potential. , 2016, , 437-488.		0
10580	A Case of Melanoma Metastasis to the Parotid Lymph Node from an Unknown Primary Site. Practica Otologica, Supplement, 2016, 145, 68-69.	0.0	0
10581	Kutane Nebenwirkungen neuer Krebsmedikamente. , 2016, , 305-312.		0
10582	Targeted Cancer Therapy. Nishinon Journal of Dermatology, 2016, 78, 221-228.	0.0	0
10583	Immunotherapeutic Anticancer Drugs and Other Miscellaneous Anticancer Drugs. , 2016, , 135-153.		0
10584	Molecular Basis for Tumor Immunity. , 2016, , .		0
10585	Treatment Patterns and Healthcare Costs among U.S. Patients with Advanced Melanoma Initiating Subsequent Systemic Therapy Following Use of Ipilimumab (IPI). Journal of Cancer Therapy, 2016, 07, 335-343.	0.1	0
10586	New Treatments for Advanced Melanoma. Nishinon Journal of Dermatology, 2016, 78, 5-12.	0.0	0
10587	Cancer Vaccines in Castration Resistant Prostate Cancer—An Evolution in Design. , 2016, , 107-124.		0
10588	Better Together: Immunotherapy as Future Combination Strategy for Breast Cancer. Immunotherapy (Los Angeles, Calif), 2016, 02, .	0.1	0
10589	Melanoma—Treatment. , 2016, , 79-109.		0
10590	Cancer Vaccines. , 2016, , 295-333.		0
10591	Targeted Therapy in Melanoma. , 2016, , 237-265.		0
10592	CD8 T Cells. , 2016, , 1-12.		0

#	ARTICLE	IF	CITATIONS
10593	Progress in Immunotherapy for Hematological Malignancies. The Journal of the Japanese Society of Internal Medicine, 2016, 105, 1061-1068.	0.0	0
10594	Controversies in the Surgical Management of Melanoma. , 2016, , 159-184.		0
10595	Immunotherapy and Hypophysitis in the Clinical Practice: A Case Report. Journal of Clinical Case Reports, 2016, 06, .	0.0	1
10596	Primary Urethral Melanoma. , 2016, , 173-189.		1
10597	Aiming the Immune System to Improve the Antitumor Efficacy of Radiation Therapy. , 2016, , 159-181.		0
10598	Head and Neck Cutaneous Melanoma. , 2016, , 657-663.		0
10599	Perianal melanoma with a BRAF gene mutation in a young Portuguese Roma native. BMJ Case Reports, 2016, 2016, bcr2015212772.	0.2	3
10601	Evolving Paradigms in Melanoma Therapy. Journal of the Advanced Practitioner in Oncology, 2016, 7, 291-294.	0.2	1
10602	How Checkpoint Inhibitors Are Changing the Treatment Paradigm in Solid Tumors: What Advanced Practitioners in Oncology Need to Know. Journal of the Advanced Practitioner in Oncology, 2016, 7, .	0.2	3
10603	New Frontiers in Treatment. , 2017, , 209-221.		0
10605	Malignant Melanoma in the Adolescent and Young Adult (AYA) Population. Pediatric Oncology, 2017, , 231-267.	0.5	0
10606	Surgical Considerations and Emergencies in the Cancer Patient Receiving Immunotherapy. , 2017, , 31-44.		0
10609	T-Cell Mediated Immunomodulation and Transplant Optimization. , 2017, , 223-235.		0
10610	SBRT and the Treatment of Oligometastatic Disease. Cancer Treatment and Research, 2017, , 21-39.	0.2	0
10612	Principles of Cancer Targeted Therapy in Older Adults. , 2017, , 1-15.		0
10613	Therapeutische Grundlagen in der gynÄkologischen Onkologie. , 2017, , 183-253.		0
10615	Scalp Melanoma Treated with Ipilimumab in Elderly Patient: A Complete Response to Treatmentâ€”Case Report. Journal of Pharmacy and Pharmacology, 2017, 5, .	0.1	0
10616	Immunotherapy for Renal Cell Cancer (RCC). , 2017, , 295-317.		0

#	ARTICLE	IF	CITATIONS
10617	Melanoma Stem Cells. , 2017, , 311-337.		0
10618	Development of Cancer Vaccine and Targeted Immune Checkpoint Therapies. , 2017, , 225-241.		0
10619	T Cell Immune Responses in Skin. , 2017, , 121-135.		0
10620	Anti-VEGFR Therapy as a Partner for Immune-Based Therapy Approaches in HCC. , 2017, , 85-101.		0
10621	Malignes Melanom beim alten und geriatrischen Patienten. , 2017, , 1-8.		0
10622	Vaccine Therapy and Immunotherapy for Pancreatic Cancer. , 2017, , 1-45.		0
10623	Modulating Immune Responses to Overcome Resistance in Hepatocellular Carcinoma. Resistance To Targeted Anti-cancer Therapeutics, 2017, , 25-43.	0.1	0
10624	Altered Signal Transduction Pathways in Melanoma. , 2017, , 177-207.		0
10625	[¹⁸ F]Fluorodeoxyglucose positron emission tomography reveals a complete remission of refractory metastatic melanoma after therapy with ipilimumab. Indian Journal of Nuclear Medicine, 2017, 32, 66.	0.1	1
10627	Immunotherapy for Gynecologic Cancer. Comprehensive Gynecology and Obstetrics, 2017, , 69-85.	0.0	0
10628	Novel Therapies and Future Directions in Treatment of Musculoskeletal Sarcomas. , 2017, , 439-457.		0
10629	Immune Checkpoint Inhibitors in Melanoma Define a New Era in Immunotherapy Aiming for Cure. , 2017, , 427-436.		0
10630	Management of Melanoma. , 2017, , 15-23.		0
10631	The Tumor Microenvironment in Cutaneous Melanoma: Friend or Foe. , 2017, , 481-506.		0
10632	Myometrium and Sigmoid Colon Metastatic Melanoma Simulating a Ewing Tumor: A Case Report. Open Journal of Obstetrics and Gynecology, 2017, 07, 897-906.	0.1	0
10634	Immunotherapy and Targeted Therapies in Advanced Castration Resistant Prostate Cancer. , 2017, , 357-377.		1
10635	Diagnostic Applications of Nuclear Medicine: Malignant Melanoma. , 2017, , 1065-1102.		0
10636	Immunotherapie van kanker. , 2017, , 181-190.		0

#	ARTICLE	IF	CITATIONS
10637	æ—Ÿæœ-ã•ã,%ã,-ç•CEã«ç™ºã¿jã™ã,«çš®è†šæ,³æ€Sèè...«ç~ãf^ãf ©ãf³ã,¹ãf-ãf¼ã,ãfSãfŠãf«ãfªã,µãf¼ãf• Skin Cancer, 2017, 32, 14		
10638	Re-Thinking the Interplay between Tumorigenesis and Immunity. Journal of Cell Signaling, 2017, 01, .	0.3	0
10639	Advanced Care Provider and Nursing Approach to Assessment and Management of Immunotherapy-Related Dermatologic Adverse Events. Journal of the Advanced Practitioner in Oncology, 2017, 8, 138-145.	0.2	3
10640	Problems of Cancer Treatment. Part 2. Treatment Based on Modification of Anticancer Immunological Responses in Therapy. Advances in Cell Biology, 2017, 5, 96-112.	1.5	1
10641	Immune Checkpoint Blockade: Subjugation of the Masses. , 0, , .		0
10642	DLI Induced by Molecular Target Antineoplastic Drug: What Are the Characteristics of DLI in Molecular Target Antineoplastic Drugs?. Respiratory Disease Series, 2018, , 139-164.	0.1	0
10646	REVIEW OF APPROACHES TO IMMUNOTHERAPY IN ONCOLOGY. Issledovaniã I Praktika V Medicine, 2017, 4, 51-65.	0.1	4
10647	Immunothã©rapie par anticorps monoclonaux : ingã©nierie, indications et perspectives. Bulletin De L'Academie Nationale De Medecine, 2017, 201, 1023-1035.	0.0	0
10648	Adjuvant Therapy. , 2018, , 1-25.		0
10649	Side Effects of Systemic Therapy and Their Clinical Management. , 2018, , 1-17.		0
10650	Mucosal Melanoma. , 2018, , 1-14.		0
10651	Immune Biomarkers in Paediatric Malignancies. , 2018, , 259-273.		0
10652	Ipilimumab Activity in Advanced Uveal Melanoma: A Pooled Analysis. International Journal of Cancer and Clinical Research, 2017, 4, .	0.1	0
10653	Heterogeneity and Plasticity of Melanoma: Challenges of Current Therapies. , 0, , 57-65.		2
10654	Concurrent ipilimumab and CMV colitis refractory to oral steroids. Journal of Community and Supportive Oncology, 2017, 15, .	0.1	1
10655	æ”¾ãº,,ç-šã«ã,ã,«æš-èè...«ç~ã...ç-«ã®æ»æ€SãCE-ãã...ç-«æ”¾ãº,,ç-šç™,æ³•¼ã^Immuno¼Radiotherapy¼%ã®ã¼f¼æ€S. Skin Can		
10656	Pericardial Effusion with Tamponade, an Immune-Related Adverse Event Associated with Nivolumab Therapy: A Case Report and Review of the Literature. Journal of Cancer Therapy, 2018, 09, 1039-1047.	0.1	2
10657	Immune check point inhibitors for head and neck cancer and its proper management on utilizing head and neck cancer collaborative program. Journal of Japanese Society of Oral Oncology, 2018, 30, 144-150.	0.0	0

#	ARTICLE	IF	CITATIONS
10681	Ipilimumab: A tale of twists and turns. South Asian Journal of Cancer, 2018, 07, 193-194.	0.2	3
10682	Design of Cell-Specific Liposomal DDS by Surface Modification of Functional Polymers. Journal of the Society of Powder Technology, Japan, 2018, 55, 389-396.	0.0	0
10685	New tricks for old targets: Anti-CTLA-4 antibodies re-envisioned for cancer immunotherapy. Oncotarget, 2018, 9, 31171-31172.	0.8	0
10686	Immune Checkpoint Inhibitors in the Treatment of Lymphomas. Klinicheskaya Onkogematologiya/Clinical Oncohematology, 2018, 11, 303-312.	0.1	10
10687	The role of prophylactic radiotherapy in prevention of brain metastasis. The Egyptian Journal of Hospital Medicine, 2018, 73, 5976-5981.	0.0	0
10689	Where Weâ€™ve Been and Where Weâ€™re Going. , 2018, , 2-23.		0
10690	Cytokines (IL-2, IFN GM-CSF etc) Melanoma. , 2019, , 1-31.		0
10693	Radiation and Immunotherapy for Sarcoma. , 2019, , 47-65.		0
10694	Personalized Cancer Immunotherapy: Todayâ€™s Challenge and Tomorrowâ€™s Promise. Journal of Immunotherapy and Precision Oncology, 2018, 1, 56-67.	0.6	4
10695	Melanoma Vaccines. , 2019, , 1-23.		0
10696	NIVOLUMAB EXPERIENCE IN THE TREATMENT OF PRE-TREATED PATIENTS WITH METASTATIC SKIN MELANOMA. Malignant Tumours, 2018, 8, 78-85.	0.1	1
10697	Genomic Applications in Melanoma. , 2019, , 509-540.		0
10698	Management of immune-related adverse events in patients treated with immune checkpoint inhibitorsâ€™ Rheumatology point of view. Hong Kong Bulletin on Rheumatic Diseases, 2018, 18, 56-60.	0.1	0
10699	Oncotherapies for HCC. , 2019, , 153-165.		0
10700	Evolution of Cancer, Adaptive Immunity, and Immunotherapy. Journal of Analytical Oncology, 0, 8, 18-34.	0.1	0
10701	Cancer Immunotherapy Related Endocrine Adverse Effects. International Journal of Thyroidology, 2019, 12, 97.	0.1	0
10702	Managing Checkpoint Inhibitor Symptoms and Toxicity. , 2019, , 1-28.		0
10703	Gastrointestinal side effects of immune checkpoint inhibitors: new topic for gastrooncologists. Hematology & Medical Oncology, 2019, 4, .	0.1	0

#	ARTICLE	IF	CITATIONS
10704	Innate and Adaptive Immune Responses to Cancer. , 2019, , 111-159.		3
10705	T Cell Senescence and Tumor Immunotherapy. , 2019, , 2091-2114.		0
10706	Adjuvant Systemic Therapy for High-Risk Melanoma Patients. , 2019, , 1-20.		0
10707	Local and Recurrent Regional Metastases of Melanoma. , 2019, , 1-33.		1
10708	Introduction to Melanoma Immunology. , 2019, , 1-15.		0
10709	Immunotherapy with mRNA vaccination and immunomodulation nanomedicine for cancer therapy. , 2019, , 551-600.		0
10710	Programmed Death-1 and Programmed Death Ligand-1 Blockade for Advanced Urothelial Carcinoma. Urological Science, 2019, 30, 2-7.	0.2	2
10711	Melanoma Immunology and Immunotherapy. , 2019, , 1-15.		0
10712	Novel Immunotherapies and Novel Combinations of Immunotherapy. , 2019, , 1-22.		0
10713	Immunotherapy in Breast Cancer. , 2019, , 541-552.		1
10714	Dermatological Complications of Systemic Therapies for Melanoma. , 2019, , 1-22.		0
10715	Melanom. , 2019, , 45-134.		0
10716	Checkpoint Inhibitors in the Treatment of Metastatic Melanoma. , 2019, , 1-24.		0
10717	Harnessing the Immune System to Target Cancer Cells. Resistance To Targeted Anti-cancer Therapeutics, 2019, , 137-151.	0.1	0
10718	Targeted and Immune Therapy for Periocular and Orbital Malignancies. Current Practices in Ophthalmology, 2019, , 83-97.	0.1	0
10720	Sentinel Lymph Node Biopsy for Eyelid and Conjunctival Malignancies. , 2019, , 261-277.		0
10721	Anticancer Immunotherapy: Prospects and Challenges. , 2019, , 189-228.		0
10722	Immunomodulatory Nanomaterials. Pancreatic Islet Biology, 2019, , 119-142.	0.1	2

#	ARTICLE	IF	CITATIONS
10723	Search for drug discovery targets focusing on cancer stroma. Translational and Regulatory Sciences, 2019, 1, 58-65.	0.2	0
10724	Resistance to Checkpoint Blockade Inhibitors and Immunomodulatory Drugs. Resistance To Targeted Anti-cancer Therapeutics, 2019, , 155-179.	0.1	0
10725	Cancer Therapy. , 2019, , 7-76.		0
10726	Emerging Novel Therapies in Overcoming Resistance to Targeted Therapy. Resistance To Targeted Anti-cancer Therapeutics, 2019, , 223-258.	0.1	0
10727	A Case of Multiple Small Bowel Metastases from Cutaneous Malignant Melanoma with Gastrointestinal Bleeding. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association), 2019, 80, 2213-2220.	0.0	0
10728	The Expression of CD155 on Renal Cell Carcinoma Cells. Advances in Clinical Medicine, 2019, 09, 373-381.	0.0	0
10729	Melanoma Prognosis and Staging. , 2019, , 1-27.		0
10730	Mechanism of resistance to immune checkpoint inhibitors. Cancer Drug Resistance (Alhambra, Calif), 2019, 2, 178-188.	0.9	3
10732	Prospects for immunotherapy as a novel therapeutic strategy against hepatocellular carcinoma. World Journal of Meta-analysis, 2019, 7, 80-95.	0.1	2
10734	The future is now: beyond first line systemic therapy in hepatocellular carcinoma. Translational Cancer Research, 2019, 8, S261-S274.	0.4	5
10737	Toxicidad cutánea de los fármacos anti-PD-1/anti-PD-L1. Piel, 2019, 34, 221-227.	0.0	0
10738	Experiencia clínica con ipilimumab en el tratamiento de melanoma metastásico o irresecable en el Instituto Nacional de Cancerología, Bogotá, Colombia : serie de casos.. Revista Colombiana De Hematología Y Oncología, 2019, 6, 10-17.	0.0	0
10739	The Advanced Practice Provider Perspective: Treating Patients With Immuno-Oncology Combination Therapy Across Tumor Types. Journal of the Advanced Practitioner in Oncology, 2019, 10, 367-386.	0.2	0
10740	Tackling Immunotherapy Resistance: Developing Rational Combinations of Immunotherapy and Targeted Drugs. Journal of Immunotherapy and Precision Oncology, 2019, 2, 23-35.	0.6	1
10743	Immunotherapy in head and neck cancer. Pomeranian Journal of Life Sciences, 2019, 65, 15-19.	0.1	2
10745	Beyond PD-1/PD-L1 Axis Blockade: New Combination Strategies in Metastatic Melanoma Treatment. Current Cancer Therapy Reviews, 2019, 15, 110-119.	0.2	0
10746	PROGRESS IN DNA VACCINE APPROACHES FOR CANCER IMMUNOTHERAPY. , 2019, , 347-375.		0
10748	Precision Medicine and Complexity. , 2020, , 149-173.		0

#	ARTICLE	IF	CITATIONS
10749	Immuno-Oncology Medicines: Policy Implications and Economic Considerations. <i>Innovations in Pharmacy</i> , 2019, 10, 9.	0.2	4
10750	RECIST 1.1 AND irRC FOR RESPONSE ASSESMENT IN PATIENTS WITH DISSEMINATED CUTANEOUS MELANOMA TREATED WITH IPILIMUMAB OR DENDRITIC CELL VACCINE. <i>Siberian Journal of Oncology</i> , 2019, 18, 13-20.	0.1	0
10752	Immunotherapy Landscape in Prostate Cancer: Successes, Failures and Promises. <i>Annals of Urologic Oncology</i> , 2019, 1-18.	0.0	0
10753	Cancer immunotherapy: Role of the immune system in malignant transformation. <i>Revista Médica Del Hospital General De México</i> , 2019, 82, .	0.0	0
10755	Malignancy, Staging and Surgical Management. , 2020, , 77-104.		0
10756	Trends in the Abscopal Effect After Radiation to Spinal Metastases: A Systematic Review. <i>Cureus</i> , 2019, 11, e5844.	0.2	4
10758	Malignant melanoma types and treatment. <i>Demiroğlu Bilim Üniversitesi Florence Nightingale Tıp Derisi</i> , 2019, 5, 155-165.	0.0	0
10759	Safety, Tolerability, and Use of Steroids. , 2020, , 127-137.		0
10760	Brain Metastases from Lung Tumors. , 2020, , 259-266.		0
10762	Immunotherapy in Oral Cancer: A Fourth Dimension of Cancer Treatment. , 2020, , 129-154.		1
10763	Combining Radiosurgery and Systemic Therapies for Treatment of Brain Metastases. , 2020, , 247-258.		0
10764	Management of Melanoma Brain Metastasis. , 2020, , 281-287.		0
10765	Melanoma: 18F-FDG PET/CT for Response Assessment of Melanoma Following Immunotherapy. , 2020, , 55-65.		3
10766	Assessment of Efficacy of Systemic Therapy in Patients with Metastatic Melanoma. , 2020, , 57-71.		0
10767	Proteínas de checkpoint imunológico como novo alvo da imunoterapia contra o câncer: revisão da literatura. <i>HU Revista</i> , 2019, 45, 325-333.	0.3	3
10768	Genomic Characterization of Brain Metastases: Implications for Precision Medicine. , 2020, , 43-58.		0
10769	Photoacoustic signal classification for in vivo photoacoustic flow cytometry based on support vector machine. , 2019, , .		1
10770	Immunotherapy in Oncology. , 2020, , 3-6.		0

#	ARTICLE	IF	CITATIONS
10771	Safety Profiles and Pharmacovigilance Considerations for Recently Patented Anticancer Drugs: Cutaneous Melanoma. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2019, 14, 203-225.	0.8	1
10773	Hematologic Malignancies: PET/CT for Response Assessment of Hematologic Malignancies Following Immunotherapy. , 2020, , 81-90.		0
10774	Regional Gene Therapy for Cancer. , 2020, , 55-71.		0
10775	Isolated Limb Perfusion and Infusion in the Management of In-Transit Melanoma of the Extremities: Modern Data Affecting Practice. , 2020, , 379-394.		0
10776	Immunotherapy in Esophageal Cancer. , 2020, , 289-310.		0
10779	Immune-related adverse events associated with cancer immunotherapy. <i>Practical Oncology</i> , 2019, 2, 24-44.	0.1	0
10780	Immunosenescence and Cancer Immunotherapy at Old Age: Basics. , 2020, , 71-90.		1
10781	Role of Precision Medicine in Patients with CNS Metastasis. , 2020, , 69-82.		0
10782	Particle Therapy: Protons and Heavy Ions. <i>Advances in Oto-Rhino-Laryngology</i> , 2020, 84, 87-105.	1.6	4
10784	Tumors: Melanoma. , 2020, , 1-11.		0
10785	Cancer in Older Adults. , 2020, , 189-209.		0
10786	Paradigms in Cancer Drug Development: A Universe with Many Galaxies. , 2020, , 17-44.		0
10788	Gastrointestinal Toxicities of Immunotherapy. , 2020, , 201-222.		0
10789	The Roles of CD4+ T-Cells in Tumor Immunity. , 2020, , 63-90.		0
10790	Adjuvant Systemic Therapy for High-Risk Melanoma Patients. , 2020, , 747-766.		0
10791	Genome Medicine for Brain Tumors: Current Status and Future Perspectives. <i>Neurologia Medico-Chirurgica</i> , 2020, 60, 531-542.	1.0	5
10792	Checkpoint Inhibitors in the Treatment of Metastatic Melanoma. , 2020, , 1141-1164.		0
10793	Dermatological Complications of Systemic Therapies for Melanoma. , 2020, , 1337-1358.		0

#	ARTICLE	IF	CITATIONS
10794	Timing of changing therapy from gemcitabine and cisplatin chemotherapy based on real-world data of advanced urothelial carcinoma. <i>Oncology Letters</i> , 2020, 19, 2943-2949.	0.8	4
10796	BILATERAL SEROUS RETINAL DETACHMENT AND UVEITIS ASSOCIATED WITH PEMBROLIZUMAB TREATMENT IN METASTATIC MELANOMA. <i>Retinal Cases and Brief Reports</i> , 2022, 16, 430-434.	0.3	7
10798	Durvalumab-Associated Granulomatous Reaction Mimicking Recurrence of Lung Cancer. <i>American Journal of Therapeutics</i> , 2022, 29, e757-e759.	0.5	0
10800	Regional Melanoma Therapy: Positive Sentinel Lymph Node. , 2021, , 149-160.		0
10803	Vigilancia clínica de los pacientes que reciben inmunoterapia. <i>Medicina Clínica</i> , 2020, 154, 493-495.	0.3	0
10805	Immunotherapy for cancer of the oral cavity and oropharynx. The use of monoclonal antibodies. <i>Bukovinian Medical Herald</i> , 2020, 24, 178-186.	0.1	0
10808	Side effects and management in immunotherapy based on immune checkpoint inhibitors. <i>World Chinese Journal of Digestology</i> , 2020, 28, 755-764.	0.0	1
10809	Tratamiento adyuvante de melanoma cutáneo : indicaciones y alternativas.. <i>Revista Colombiana De Hematología Y Oncología</i> , 2020, 7, 56-63.	0.0	0
10811	Overcoming Cancer Tolerance with Immune Checkpoint Blockade. , 2021, , 85-128.		0
10813	Adoptive T-Cell Therapy: Optimizing Chemokine Receptor-Mediated Homing of T-Cells in Cancer Immunotherapy. , 2021, , 251-271.		0
10814	Biomarkers for Immune Checkpoint Inhibitors. , 2021, , 449-463.		0
10815	Development of a novel humanized mouse model for improved evaluation of in vivo anti-cancer effects of anti-PD-1 antibody. <i>Scientific Reports</i> , 2021, 11, 21087.	1.6	7
10816	Factors Associated with Thyroid-Related Adverse Events in Patients Receiving PD-1 or PD-L1 Inhibitors Using Machine Learning Models. <i>Cancers</i> , 2021, 13, 5465.	1.7	4
10817	The (re)discovery of tumor-intrinsic determinants of immune sensitivity by functional genetic screens. <i>Immuno-Oncology Technology</i> , 2021, 11, 100043.	0.2	9
10818	Complete Response After Stereotactic Body Radiation Therapy With Concurrent Immunotherapy for Vaginal Melanoma. <i>Advances in Radiation Oncology</i> , 2022, 7, 100839.	0.6	3
10819	Prognostic Value of Lymph Node Ratio in Cutaneous Melanoma: A Systematic Review. <i>Cureus</i> , 2021, 13, e19117.	0.2	3
10820	The role of PI3'lipid signalling in melanoma initiation, progression and maintenance. <i>Experimental Dermatology</i> , 2022, 31, 43-56.	1.4	7
10821	IL-10 Signaling Elicited by Nivolumab-Induced Activation of the MAP Kinase Pathway Does Not Fully Contribute to Nivolumab-Modulated Heterogeneous T Cell Responses. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11848.	1.8	4

#	ARTICLE	IF	CITATIONS
10822	Individualized Proteogenomics Reveals the Mutational Landscape of Melanoma Patients in Response to Immunotherapy. <i>Cancers</i> , 2021, 13, 5411.	1.7	1
10823	Evaluation Expression of miR-146a and miR-155 in Non-Small-Cell Lung Cancer Patients. <i>Frontiers in Oncology</i> , 2021, 11, 715677.	1.3	7
10824	Immune checkpoint inhibition for the treatment of cancers: An update and critical review of ongoing clinical trials. <i>Clinical Immunology</i> , 2021, 232, 108873.	1.4	19
10825	Elimination of acquired resistance to PD-1 blockade via the concurrent depletion of tumour cells and immunosuppressive cells. <i>Nature Biomedical Engineering</i> , 2021, 5, 1306-1319.	11.6	21
10826	Biological Bases of Immune-Related Adverse Events and Potential Crosslinks With Immunogenic Effects of Radiation. <i>Frontiers in Pharmacology</i> , 2021, 12, 746853.	1.6	14
10827	CHI3L1 regulates PD-L1 and anti-CHI3L1 PD-1 antibody elicits synergistic antitumor responses. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	25
10828	Role of purinergic system and vitamin D in the anti-cancer immune response. <i>Life Sciences</i> , 2021, 287, 120110.	2.0	5
10829	Immunotherapeutic treatments in hepatocellular carcinoma; achievements, challenges and future prospects. <i>International Immunopharmacology</i> , 2021, 101, 108322.	1.7	18
10830	Cytokines (IL-2, IFN, GM-CSF, etc.) Melanoma. , 2020, , 1109-1140.		0
10831	Macromolecules and Antibody-Based Drugs. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1248, 485-530.	0.8	3
10832	Anti-cancer Effects of Silibinin: The Current Status in Cancer Chemoprevention. , 2020, , 161-208.		0
10833	Immunometabolism and Its Potential to Improve the Current Limitations of Immunotherapy. <i>Methods in Molecular Biology</i> , 2020, 2184, 233-263.	0.4	1
10835	Antibody-Based Targeted Interventions for the Diagnosis and Treatment of Skin Cancers. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2020, 21, 162-186.	0.9	2
10836	Current and future aspects of TIM-3 as biomarker or as potential targeted in non-small cell lung cancer scope: is there a role in clinical practice?. <i>Translational Lung Cancer Research</i> , 2020, 9, 2311-2314.	1.3	6
10837	Tumors of the Conjunctiva and Ocular Surface. , 2021, , 175-208.		0
10838	Pharmaceutical Care Contributes to the Advanced Management of Patients Receiving Immune Checkpoint Inhibitors. <i>Biological and Pharmaceutical Bulletin</i> , 2020, 43, 1969-1974.	0.6	7
10840	Genetic Variants in Immune Related Genes as Predictors of Responsiveness to BCG Immunotherapy in Metastatic Melanoma Patients. <i>Cancers</i> , 2021, 13, 91.	1.7	1
10841	The Role of PET/CT in Melanoma Patients: A Surgeon's Perspective. , 2021, , 151-166.		0

#	ARTICLE	IF	CITATIONS
10842	Immune checkpoint inhibitor myocarditis: a systematic case study. Russian Journal of Cardiology, 2020, 25, 3910.	0.4	6
10843	Multidimensional indicators of scholarly impact in the skin oncology literature: is there a correlation between bibliometric and altmetric profiles?. Journal of Plastic Surgery and Hand Surgery, 2021, 55, 232-241.	0.4	3
10845	What is the Impact of the Analysis Method Used for Health State Utility Values on QALYs in Oncology? A Simulation Study Comparing Progression-Based and Time-to-Death Approaches. Applied Health Economics and Health Policy, 2021, 19, 389-401.	1.0	3
10846	Vaccines as Immunotherapy. , 2021, , 31-61.		1
10847	Nonclinical drug development. , 2022, , 573-588.		0
10848	How do we approach to the difficult to treat Japanese case. Combination therapy of Immunotherapy and Radiotherapy in Immunoradiotherapy%. Skin Cancer, 2020, 35, 98-104.	0.1	0
10849	Response Evaluations for Precision Cancer Therapy and Immunotherapy. Medical Radiology, 2020, , 15-27.	0.0	0
10850	Rheumatological Toxicities of Immunotherapy. , 2020, , 277-286.		0
10851	Synergy of Immunotherapy and Radiosurgery. , 2020, , 355-369.		0
10852	Sequencing and Combinations of Molecularly Targeted and Immunotherapy for BRAF-Mutant Melanoma. , 2020, , 1215-1241.		0
10853	Melanoma Vaccines. , 2020, , 1243-1265.		0
10854	Local and Recurrent Regional Metastases of Melanoma. , 2020, , 705-737.		5
10855	Novel Immunotherapies and Novel Combinations of Immunotherapy for Metastatic Melanoma. , 2020, , 1165-1186.		0
10856	BET mechanisms in cancer. , 2020, , 101-142.		0
10857	Exciting progress of cancer immunotherapy focusing on immune checkpoints. E3S Web of Conferences, 2020, 185, 03007.	0.2	0
10858	CHAPTER 14. Cell and Immune Therapy. RSC Detection Science, 2020, , 303-344.	0.0	0
10859	Phytochemicals Plus Checkpoint Inhibitors in GI Cancers. , 2020, , 83-107.		0
10860	Long-Term Response in PD-L1-Negative Advanced Non-Small Cell Lung Carcinoma With Discontinued and Restarted Nivolumab Therapy Due to Immune-Related Adverse Event. Journal of the Japanese Association of Rural Medicine, 2020, 68, 797.	0.0	0

#	ARTICLE	IF	CITATIONS
10861	elearning for cancer immunotherapy. Ecancermedalscience, 2020, 14, ed94.	0.6	0
10862	Principles of Cancer Targeted Therapy in Older Adults. , 2020, , 881-894.		0
10863	Current Perspectives on Cancer Immunotherapy in Bone. , 2020, , 421-437.		0
10864	The terminal sialic acid of stage-specific embryonic antigen-4 has a crucial role in binding to a cancer-targeting antibody. Journal of Biological Chemistry, 2020, 295, 1009-1020.	1.6	8
10865	ERKRANKUNGEN DES BLUTES UND DES GERINNINGSSYSTEMS, SOLIDE TUMOREN UND PRINZIPIEN DER INTERNISTISCHEN ONKOLOGIE. , 2020, , B-1-B30-3.		0
10866	Bioactive Lipid (BAL)-Based Therapeutic Approach to Cancer That Enhances Antitumor Action and Ameliorates Cytokine Release Syndrome of Immune Checkpoint Inhibitors. , 2020, , 207-235.		0
10867	Future Therapies for Malignant Brainstem Tumors. , 2020, , 347-392.		0
10868	Metabolische und endokrine Toxizität antineoplastischer Substanzen. Springer Reference Medizin, 2020, , 1-9.	0.0	0
10869	Cellular Therapy for Melanoma. , 2020, , 1267-1299.		0
10870	A Case of Emergency Laparoscopic Surgery for Intestinal Intussusception and Obstruction due to Jejunal Metastasis of Malignant Melanoma. Nihon Daicho Komonbyo Gakkai Zasshi, 2020, 73, 121-126.	0.1	1
10871	Immunotherapy in Gastrointestinal Malignancies. Diagnostics and Therapeutic Advances in GI Malignancies, 2020, , 15-29.	0.2	0
10872	Immunotherapy and Radiosurgery. , 2020, , 423-436.		0
10873	The Role of Interventional Oncology in the Treatment of Metastatic Melanoma. , 2020, , 273-285.		0
10874	Immunopathology and Immunotherapy for Breast Cancer. , 2020, , 541-555.		1
10875	Melanoma Prognosis and Staging. , 2020, , 271-297.		2
10877	Genome Engineering Tools in Immunotherapy. , 2020, , 73-102.		0
10878	Targeting the Immune System in Pancreatic Cancer. Molecular and Translational Medicine, 2020, , 203-218.	0.4	0
10879	Cancer Immunotherapy Confers a Global Benefit. , 2020, , 1-48.		0

#	ARTICLE	IF	CITATIONS
10880	Immunotherapy for Pediatric Solid Tumors. , 2020, , 49-73.		1
10881	Non-melanoma Skin Cancer and Cutaneous Melanoma from the Oncological Point of View. , 2020, , 41-68.		0
10884	A Canadian cancer trials group phase IB study of durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) given concurrently or sequentially in patients with advanced, incurable solid malignancies. Investigational New Drugs, 2020, 38, 1442-1447.	1.2	0
10885	VitÃ­igo asociado a tratamiento inmunomodulador del melanoma metastÃ­ico. Piel, 2020, 35, 237-240.	0.0	0
10886	Prognostic and predictive factors associated with ipilimumab-related adverse events: a retrospective analysis of 11 NCI-sponsored phase I clinical trials. Oncotarget, 2020, 11, 1427-1434.	0.8	0
10888	Tumor-Specific and Tumor-Agnostic Molecular Signatures Associated With Response to Immune Checkpoint Inhibitors. JCO Precision Oncology, 2021, 5, 1625-1638.	1.5	10
10889	Aberrant Methylation and Immune Microenvironment Are Associated With Overexpressed Fibronectin 1: A Diagnostic and Prognostic Target in Head and Neck Squamous Cell Carcinoma. Frontiers in Molecular Biosciences, 2021, 8, 753563.	1.6	10
10890	Evaluation of single domain antibodies as nuclear tracers for imaging of the immune checkpoint receptor human lymphocyte activation gene-3 in cancer. EJNMMI Research, 2021, 11, 115.	1.1	5
10891	Safety Profile of Immunotherapy Combined With Antiangiogenic Therapy in Patients With Melanoma: Analysis of Three Clinical Studies. Frontiers in Pharmacology, 2021, 12, 747416.	1.6	0
10892	Unleashing TNF cytotoxicity to enhance cancer immunotherapy. Trends in Immunology, 2021, 42, 1128-1142.	2.9	28
10893	Immune-checkpoint inhibitors in renal transplanted patients affected by melanoma: a systematic review. Immunotherapy, 2022, 14, 65-75.	1.0	6
10894	Immune Modulating AntibodyâDrug Conjugate (IM-ADC) for Cancer Immunotherapy. Journal of Medicinal Chemistry, 2021, 64, 15716-15726.	2.9	35
10895	Immune Cell Infiltration Landscape of Ovarian Cancer to Identify Prognosis and Immunotherapy-Related Genes to Aid Immunotherapy. Frontiers in Cell and Developmental Biology, 2021, 9, 749157.	1.8	6
10896	miRNA as a Modulator of Immunotherapy and Immune Response in Melanoma. Biomolecules, 2021, 11, 1648.	1.8	15
10897	Checkpoint Inhibitors in Melanoma Patients with Underlying Autoimmune Disease. Cancer Management and Research, 2021, Volume 13, 8199-8208.	0.9	9
10898	Unravelling Checkpoint Inhibitor Associated Autoimmune Diabetes: From Bench to Bedside. Frontiers in Endocrinology, 2021, 12, 764138.	1.5	22
10899	Immunotherapy Monitoring with Immune Checkpoint Inhibitors Based on [18F]FDG PET/CT in Metastatic Melanomas and Lung Cancer. Journal of Clinical Medicine, 2021, 10, 5160.	1.0	20
10900	Effectiveness and safety of immune checkpoint inhibitors in combination with palliative radiotherapy in advanced melanoma: A systematic review. Critical Reviews in Oncology/Hematology, 2021, 167, 103499.	2.0	0

#	ARTICLE	IF	CITATIONS
10901	AMPD1 Is Associated With the Immune Response and Serves as a Prognostic Marker in HER2-Positive Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 749135.	1.3	6
10902	Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma. <i>Nature Communications</i> , 2021, 12, 6375.	5.8	22
10903	Engineering T cells to survive and thrive in the hostile tumor microenvironment. <i>Current Opinion in Biomedical Engineering</i> , 2022, 21, 100360.	1.8	5
10904	¹⁸ F- β -FDG positron emission tomography-computed tomography has a low positive predictive value for detecting occult recurrence in asymptomatic patients with high-risk Stages IIB, IIC, and IIIA melanoma. <i>Journal of Surgical Oncology</i> , 2022, 125, 525-534.	0.8	0
10905	First-line immune-based combination therapies for advanced non-small cell lung cancer: A Bayesian network meta-analysis. <i>Cancer Medicine</i> , 2021, 10, 9139.	1.3	4
10907	Combinatorial Analysis of AT-Rich Interaction Domain 1A and CD47 in Gastric Cancer Patients Reveals Markers of Prognosis. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 745120.	1.8	2
10908	Comparative Review of Malignant Melanoma and Histologically Well-Differentiated Melanocytic Neoplasm in the Oral Cavity of Dogs. <i>Veterinary Sciences</i> , 2021, 8, 261.	0.6	4
10909	NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2021, 159, 113-124.	1.3	13
10915	Combination of Chemotherapy and Cytokine Therapy in Treatment of Cancers. , 2021, , 169-182.		0
10916	T-Cell Immunotherapy: From Synthetic Biology to Clinical Practice. , 2021, , 199-218.		0
10921	Systemic Treatment in Advanced Melanoma. <i>Updates in Surgery Series</i> , 2021, , 167-174.	0.0	0
10922	Targeting an engineered cytokine with interleukin-2 and interleukin-15 activity to the neovasculature of solid tumors. <i>Oncotarget</i> , 2020, 11, 3972-3983.	0.8	2
10923	Imaging and Radiomics of Immuno-oncology of Primary and Secondary Gastrointestinal Malignancies. <i>Digestive Disease Interventions</i> , 2020, 04, 373-381.	0.3	0
10924	Combination Therapies with Y90: Immunoradiation. <i>Digestive Disease Interventions</i> , 2020, 04, 382-388.	0.3	2
10926	Introducing, OncoTarget. <i>Oncotarget</i> , 2010, 1, 2-2.	0.8	0
10927	Immune profiling of the bone marrow microenvironment in patients with high-risk localized prostate cancer. <i>Oncotarget</i> , 2020, 11, 4253-4265.	0.8	1
10928	Acute liver injury associated with rechallenge with a different type of immune checkpoint inhibitor in a patient with a history of severe immune-related adverse events. <i>Acta Hepatologica Japonica</i> , 2020, 61, 572-581.	0.0	2
10929	Vacunas basadas en neoantígenos y control del cáncer: perspectivas. <i>Revista Colombiana De Cancerología</i> , 2020, 24, 178-88.	0.0	0

#	ARTICLE	IF	CITATIONS
10930	Real-accessible novelties in immunotherapy from the perspective of a medical oncologist working in the Czech Republic. <i>Onkologie (Czech Republic)</i> , 2020, 14, 199-204.	0.0	0
10931	Immunotherapy induced enterocolitis and gastritis – What to do and when?. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2020, 48-49, 101703.	1.0	8
10932	Strategizing Screening for Melanoma in an Era of Novel Treatments: A Model-Based Approach. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 2599-2607.	1.1	2
10933	Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitor Therapy. <i>Anesthesia and Analgesia</i> , 2021, 132, 374-383.	1.1	8
10934	Regulatory T Cells Play an Important Role in the Prevention of Murine Melanocytic Nevi and Melanomas. <i>Cancer Prevention Research</i> , 2021, 14, 165-174.	0.7	1
10937	Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials. <i>Cancer Immunity</i> , 2010, 10, 9.	3.2	89
10938	Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. <i>Cancer Immunity</i> , 2010, 10, 11.	3.2	165
10939	Angiogenesis and melanoma - from basic science to clinical trials. <i>American Journal of Cancer Research</i> , 2011, 1, 852-68.	1.4	21
10940	Ipilimumab and cancer immunotherapy: a new hope for advanced stage melanoma. <i>Yale Journal of Biology and Medicine</i> , 2011, 84, 381-9.	0.2	36
10941	Cancer immunotherapy takes a multi-faceted approach to kick the immune system into gear. <i>Yale Journal of Biology and Medicine</i> , 2011, 84, 371-80.	0.2	47
10942	Current status of immunotherapy for the treatment of lung cancer. <i>Journal of Thoracic Disease</i> , 2010, 2, 237-44.	0.6	21
10943	Two cases of partial hepatectomy for malignant melanoma. <i>Hawai'i Journal of Medicine & Public Health: A Journal of Asia Pacific Medicine & Public Health</i> , 2012, 71, 92-6.	0.4	1
10944	Monoclonal antibodies in cancer therapy. <i>Cancer Immunity</i> , 2012, 12, 14.	3.2	206
10945	Introduction to monoclonal antibodies. <i>Cancer Immunity</i> , 2012, 12, 11.	3.2	4
10946	Ipilimumab (yervoy) prolongs survival in advanced melanoma: serious side effects and a hefty price tag may limit its use. <i>P and T</i> , 2012, 37, 503-30.	1.0	76
10947	Downregulation of Noxa by RAF/MEK inhibition counteracts cell death response in mutant B-RAF melanoma cells. <i>American Journal of Cancer Research</i> , 2012, 2, 726-35.	1.4	10
10948	CTLA-4 blockade in tumor models: an overview of preclinical and translational research. <i>Cancer Immunity</i> , 2013, 13, 5.	3.2	220
10950	The MAPK (ERK) Pathway: Investigational Combinations for the Treatment Of BRAF-Mutated Metastatic Melanoma. <i>P and T</i> , 2013, 38, 96-108.	1.0	69

#	ARTICLE	IF	CITATIONS
10951	Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma. <i>Cancer Immunity</i> , 2013, 13, 7.	3.2	51
10953	Preclinical evaluation of the mTOR inhibitor, temsirolimus, in combination with the epothilone B analog, ixabepilone in renal cell carcinoma. <i>American Journal of Cancer Research</i> , 2013, 3, 390-401.	1.4	3
10954	Targeting immune checkpoints: releasing the restraints on anti-tumor immunity for patients with melanoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2012, 18, 153-9.	1.0	25
10955	New approaches to the development of adenoviral dendritic cell vaccines in melanoma. <i>Current Opinion in Investigational Drugs</i> , 2010, 11, 1399-408.	2.3	12
10956	Adenosine limits the therapeutic effectiveness of anti-CTLA4 mAb in a mouse melanoma model. <i>American Journal of Cancer Research</i> , 2014, 4, 172-81.	1.4	58
10957	Metastatic amelanotic melanoma of the jejunum diagnosed on capsule endoscopy. <i>Gastroenterology and Hepatology</i> , 2012, 8, 691-3.	0.2	2
10960	Combination immunotherapy for high-risk resected and metastatic melanoma patients. <i>Ochsner Journal</i> , 2014, 14, 164-74.	0.5	7
10961	Advances in cancer immunotherapy. <i>Discovery Medicine</i> , 2013, 15, 120-5.	0.5	10
10963	Stereotactic Ablative Radiotherapy (SABR): Impact on the Immune System and Potential for Future Therapeutic Modulation. <i>Molecular and Cellular Pharmacology</i> , 2013, 5, 19-25.	1.7	13
10966	An update on current management of advanced renal cell cancer, biomarkers, and future directions. , 2014, 1, 1-10.		4
10967	In vivo efficacy of nano hyaluronan-conjugated cisplatin for treatment of murine melanoma. <i>Journal of Drugs in Dermatology</i> , 2014, 13, 283-7.	0.4	12
10968	Melanoma: Molecular Pathogenesis and Therapeutic Management. <i>Molecular and Cellular Pharmacology</i> , 2014, 6, 228.	1.7	72
10969	Anti-tumor immune response in early stage non small cell lung cancer (NSCLC): implications for adjuvant therapy. <i>Translational Lung Cancer Research</i> , 2013, 2, 415-22.	1.3	2
10972	Changes in tumor-antigen expression profile as human small-cell lung cancers progress. <i>Cancer Biology and Medicine</i> , 2015, 12, 96-105.	1.4	1
10973	Upregulation of Immune Checkpoint Molecules, PD-1 and LAG-3, on CD4+ and CD8+ T Cells after Gastric Cancer Surgery. <i>Yonago Acta Medica</i> , 2015, 58, 39-44.	0.3	42
10976	Increased expression of immunosuppressive molecules on intratumoral and circulating regulatory T cells in non-small-cell lung cancer patients. <i>American Journal of Cancer Research</i> , 2015, 5, 2190-201.	1.4	31
10977	State of the art management of metastatic gastroesophageal cancer. <i>Annals of Translational Medicine</i> , 2015, 3, 236.	0.7	4
10979	Raising the bar: optimizing combinations of targeted therapy and immunotherapy. <i>Annals of Translational Medicine</i> , 2015, 3, 272.	0.7	0

#	ARTICLE	IF	CITATIONS
10980	Tailoring the Treatment of Melanoma: Implications for Personalized Medicine. <i>Yale Journal of Biology and Medicine</i> , 2015, 88, 389-95.	0.2	3
10981	Combined BRAF and MEK inhibition in BRAF(V600E) mutant melanoma: a synergistic and potentially safe combination partner with immunotherapy. <i>Annals of Translational Medicine</i> , 2015, 3, 313.	0.7	3
10982	Immunotherapy meets targeted therapy: will this team end the war against cancer?. <i>Translational Lung Cancer Research</i> , 2015, 4, 752-5.	1.3	1
10983	PD-1, PD-L1 and PD-L2 expression in mouse prostate cancer. <i>American Journal of Clinical and Experimental Urology</i> , 2016, 4, 1-8.	0.4	22
10984	The Checkpoint Immunotherapy Revolution: What Started as a Trickle Has Become a Flood, Despite Some Daunting Adverse Effects; New Drugs, Indications, and Combinations Continue to Emerge. <i>P and T</i> , 2016, 41, 185-91.	1.0	49
10985	Novel Therapies in Development for Metastatic Colorectal Cancer. <i>Gastrointestinal Cancer Research: GCR</i> , 2014, 7, S2-7.	0.8	2
10986	Stereotactic radiation therapy combined with immunotherapy: augmenting the role of radiation in local and systemic treatment. <i>Oncology</i> , 2015, 29, 331-40.	0.4	45
10987	Visceral metastases and prostate cancer treatment: 'die hard,' 'tough neighborhoods,' or 'evil humors'?. <i>Oncology</i> , 2014, 28, 974-80.	0.4	13
10988	Exercise in Regulation of Inflammation-Immune Axis Function in Cancer Initiation and Progression. <i>Oncology</i> , 2015, 29, 908-20, 922.	0.4	50
10989	Prediction of positron emission tomography/computed tomography (PET/CT) positivity in patients with high-risk primary melanoma. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 6, 277-285.	1.0	9
10990	Systemic Therapies for Late-stage Melanoma. <i>Journal of Clinical and Aesthetic Dermatology</i> , 2016, 9, 36-40.	0.1	1
10991	Combined VEGFR and CTLA-4 blockade increases the antigen-presenting function of intratumoral DCs and reduces the suppressive capacity of intratumoral MDSCs. <i>American Journal of Cancer Research</i> , 2016, 6, 2514-2531.	1.4	35
10992	Breast Cancer Immunotherapy. <i>Mã dica</i> , 2015, 10, 185-191.	0.4	5
10993	Decreased Serum Concentration of Total IgG Is Related to Tumor Progression in Gastric Cancer Patients. <i>Yonago Acta Medica</i> , 2017, 60, 119-125.	0.3	8
10994	Advances and Future Directions in the Treatment of Hepatocellular Carcinoma. <i>Gastroenterology and Hepatology</i> , 2017, 13, 398-410.	0.2	10
10995	A contemporary dose selection algorithm for stereotactic radiosurgery in the treatment of brain metastases - An initial report. <i>Journal of Radiosurgery and SBRT</i> , 2016, 4, 43-52.	0.2	7
10997	The Role of Checkpoint Inhibition in Non-Small Cell Lung Cancer. <i>Ochsner Journal</i> , 2017, 17, 379-387.	0.5	6
10998	How Checkpoint Inhibitors Are Changing the Treatment Paradigm in Solid Tumors: What Advanced Practitioners in Oncology Need to Know. <i>Journal of the Advanced Practitioner in Oncology</i> , 2016, 7, 498-509.	0.2	6

#	ARTICLE	IF	CITATIONS
10999	Triggers of inflammatory myopathy: insights into pathogenesis. <i>Discovery Medicine</i> , 2018, 25, 75-83.	0.5	22
11005	Advances in the systemic treatment of metastatic melanoma. <i>Oncology</i> , 2013, 27, 374-81.	0.4	3
11007	Deglycosylation of PD-L1 by 2-deoxyglucose reverses PARP inhibitor-induced immunosuppression in triple-negative breast cancer. <i>American Journal of Cancer Research</i> , 2018, 8, 1837-1846.	1.4	26
11008	Promising clinical application of ctDNA in evaluating immunotherapy efficacy. <i>American Journal of Cancer Research</i> , 2018, 8, 1947-1956.	1.4	6
11009	Economic Burden of Adverse Events Associated with Immunotherapy and Targeted Therapy for Metastatic Melanoma in the Elderly. <i>American Health and Drug Benefits</i> , 2018, 11, 334-343.	0.5	6
11011	Systemic Therapy in Metastatic Melanoma. <i>Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS</i> , 2015, 32, 57S-65S.	0.6	1
11012	Therapeutic targeting of immune checkpoints with small molecule inhibitors. <i>American Journal of Translational Research (discontinued)</i> , 2019, 11, 529-541.	0.0	9
11013	Editors' Choice Meddling with meddlers: curbing regulatory T cells and augmenting antitumor immunity. <i>Nagoya Journal of Medical Science</i> , 2019, 81, 1-18.	0.6	18
11014	The role of the immune system in brain metastasis. <i>Current Neurobiology</i> , 2019, 10, 33-48.	1.0	21
11016	Overexpression of B7-H3 as an opportunity for targeted therapy in head and neck cancers. <i>American Journal of Translational Research (discontinued)</i> , 2019, 11, 5183-5196.	0.0	6
11018	Combined signature of nine immune-related genes: a novel risk score for predicting prognosis in hepatocellular carcinoma. <i>American Journal of Translational Research (discontinued)</i> , 2020, 12, 1184-1202.	0.0	7
11020	Trend and socioeconomic disparities in survival outcome of metastatic melanoma after approval of immune checkpoint inhibitors: a population-based study. <i>American Journal of Translational Research (discontinued)</i> , 2020, 12, 3767-3779.	0.0	3
11021	Ultrathin metal-organic layer-mediated radiotherapy-radiodynamic therapy enhances immunotherapy of metastatic cancers. <i>Matter</i> , 2019, 1, 1331-1353.	5.0	20
11023	Immunotherapy in urothelial cancer, part 1: T-cell checkpoint inhibition in advanced or metastatic disease. <i>Clinical Advances in Hematology and Oncology</i> , 2017, 15, 466-477.	0.3	3
11024	Immunotherapy in urothelial cancer, part 2: adjuvant, neoadjuvant, and adjunctive treatment. <i>Clinical Advances in Hematology and Oncology</i> , 2017, 15, 543-551.	0.3	6
11025	Effect of carboplatin when administered after dacarbazine failure: Clinical benefit of sequential therapy. <i>Molecular and Clinical Oncology</i> , 2020, 13, 73.	0.4	2
11026	Fundamentals to clinical application of nanoparticles in cancer immunotherapy and radiotherapy. <i>Ecancermedicalscience</i> , 2020, 14, 1095.	0.6	2
11027	Construction of a prognostic model based on nine immune-related genes and identification of small molecule drugs for hepatocellular carcinoma (HCC). <i>American Journal of Translational Research (discontinued)</i> , 2020, 12, 5108-5130.	0.0	5

#	ARTICLE	IF	CITATIONS
11028	4-1BB co-stimulation further enhances anti-PD-1-mediated reinvigoration of exhausted CD39 CD8 T cells from primary and metastatic sites of epithelial ovarian cancers. , 2020, 8, .		7
11029	Comprehensive characterization of the tumor microenvironment for assessing immunotherapy outcome in patients with head and neck squamous cell carcinoma. <i>Aging</i> , 2020, 12, 22509-22526.	1.4	4
11030	Gastrointestinal and liver adverse effects of anti-tumoral immune therapy: from recognition to treatment. <i>Gastroenterology and Hepatology From Bed To Bench</i> , 2021, 14, 195-199.	0.6	0
11032	Real Life Clinical Management and Survival in Advanced Cutaneous Melanoma: The Italian Clinical National Melanoma Registry Experience. <i>Frontiers in Oncology</i> , 2021, 11, 672797.	1.3	2
11033	SAEgnal: A Predictive Assessment Framework for Optimizing Safety Profiles in Immuno-Oncology Combination Trials. <i>AMIA Summits on Translational Science Proceedings</i> , 2021, 2021, 535-544.	0.4	0
11034	Development of a fully canine anti-canine CTLA4 monoclonal antibody for comparative translational research in dogs with spontaneous tumors. <i>MAbs</i> , 2021, 13, 2004638.	2.6	15
11035	Tumors: Melanoma. , 2021, , 5260-5270.		0
11036	Gastrointestinal adverse events of immunotherapy. <i>BJR Open</i> , 2021, 3, .	0.4	0
11037	Systemic Therapy of Advanced Melanoma. , 2021, , 219-237.		0
11038	Simultaneous silencing of the A2aR and PD-1 immune checkpoints by siRNA-loaded nanoparticles enhances the immunotherapeutic potential of dendritic cell vaccine in tumor experimental models. <i>Life Sciences</i> , 2022, 288, 120166.	2.0	10
11039	The combination therapy of oncolytic HSV-1 armed with anti-PD-1 antibody and IL-12 enhances anti-tumor efficacy. <i>Translational Oncology</i> , 2022, 15, 101287.	1.7	9
11040	Is There a Role for Immunotherapy in Central Nervous System Cancers?. <i>Hematology/Oncology Clinics of North America</i> , 2022, 36, 237-252.	0.9	5
11041	The Effect of Albumin-Binding Moiety on Tumor Targeting and Biodistribution Properties of ⁶⁷ Ga-Labeled Albumin Binder-Conjugated Alpha-Melanocyte-Stimulating Hormone Peptides. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2022, 37, 47-55.	0.7	1
11042	Characterization of the CpG Island Hypermethylated Phenotype Subclass in Primary Melanomas. <i>Journal of Investigative Dermatology</i> , 2022, 142, 1869-1881.e10.	0.3	5
11043	The role of myeloid-derived suppressor cells in lung cancer and targeted immunotherapies. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 65-81.	1.1	9
11044	Modulation of the blood-tumor barrier to enhance drug delivery and efficacy for brain metastases. <i>Neuro-Oncology Advances</i> , 2021, 3, v133-v143.	0.4	11
11045	Targeting tumor microenvironment and metastasis in children with solid tumors. <i>Current Opinion in Pediatrics</i> , 2022, 34, 53-60.	1.0	7
11046	Chemokine level predicts the therapeutic effect of anti-PD-1 antibody (nivolumab) therapy for malignant melanoma. <i>Archives of Dermatological Research</i> , 2021, , 1.	1.1	1

#	ARTICLE	IF	CITATIONS
11048	The Potential of Induced Pluripotent Stem Cells to Advance the Treatment of Pancreatic Ductal Adenocarcinoma. <i>Cancers</i> , 2021, 13, 5789.	1.7	2
11049	External validation of the American Joint Committee on Cancer melanoma staging system eighth edition using the surveillance, epidemiology, and end results program. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, , .	0.7	1
11050	The Role of the Innate Immune System in Cancer Dormancy and Relapse. <i>Cancers</i> , 2021, 13, 5621.	1.7	15
11051	Neurosurgery at the crossroads of immunology and nanotechnology. New reality in the COVID-19 pandemic. <i>Advanced Drug Delivery Reviews</i> , 2022, 181, 114033.	6.6	5
11052	A review of neurotoxicities associated with immunotherapy and a framework for evaluation. <i>Neuro-Oncology Advances</i> , 2021, 3, v108-v120.	0.4	6
11053	Successful Conversion Surgery Following Bullous Pemphigoid after Nivolumab for Advanced Gastric Cancer. <i>Japanese Journal of Gastroenterological Surgery</i> , 2021, 54, 802-812.	0.0	0
11054	Current Progress and Future Perspectives of Immune Checkpoint in Cancer and Infectious Diseases. <i>Frontiers in Genetics</i> , 2021, 12, 785153.	1.1	28
11055	BIPSE: A biomarker-based phase I/II design for immunotherapy trials with progression-free survival endpoint. <i>Statistics in Medicine</i> , 2022, 41, 1205-1224.	0.8	4
11056	IL-34, the rationale for its expression in physiological and pathological conditions. <i>Seminars in Immunology</i> , 2021, 54, 101517.	2.7	12
11057	Combination of pembrolizumab plus temozolomide therapy in unresectable and advanced melanoma: a multicenter retrospective analysis in China. <i>Annals of Translational Medicine</i> , 2021, 9, 1625-1625.	0.7	10
11058	Clinical Significance of Distant Metastasis-Free Survival (DMFS) in Melanoma: A Narrative Review from Adjuvant Clinical Trials. <i>Journal of Clinical Medicine</i> , 2021, 10, 5475.	1.0	8
11059	Vaccination against Cancer or Infectious Agents during Checkpoint Inhibitor Therapy. <i>Vaccines</i> , 2021, 9, 1396.	2.1	5
11060	Management of Acute Myeloid Leukemia: Current Treatment Options and Future Perspectives. <i>Cancers</i> , 2021, 13, 5722.	1.7	17
11061	Refractory Immune Checkpoint Inhibitor-induced Colitis Improved by Fecal Microbiota Transplantation: A Case Report. <i>Inflammatory Bowel Diseases</i> , 2022, 28, e43-e44.	0.9	12
11062	The Prognostic Significance of PD1 and PDL1 Gene Expression in Lung Cancer: A Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 759497.	1.3	4
11063	TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment. , 2022, 9, e003134.		32
11064	Anticancer natural products targeting immune checkpoint protein network. <i>Seminars in Cancer Biology</i> , 2022, 86, 1008-1032.	4.3	8
11065	Immune checkpoint inhibition for pancreatic ductal adenocarcinoma: limitations and prospects: a systematic review. <i>Cell Communication and Signaling</i> , 2021, 19, 117.	2.7	25

#	ARTICLE	IF	CITATIONS
11066	Clinical experience with CTLA-4 blockade for cancer immunotherapy: From the monospecific monoclonal antibody ipilimumab to probodies and bispecific molecules targeting the tumor microenvironment. <i>Pharmacological Research</i> , 2022, 175, 105997.	3.1	43
11067	Overexpression of PD-1 on T cells promotes tolerance in cardiac transplantation via ICOS-dependent mechanisms. <i>JCI Insight</i> , 2021, 6, .	2.3	11
11068	Metabolic Reprogramming in the Tumor Microenvironment With Immunocytes and Immune Checkpoints. <i>Frontiers in Oncology</i> , 2021, 11, 759015.	1.3	13
11069	M&M: A maximum duration design with the Maxcombo test for a group sequential trial of an immunotherapy with a random delayed treatment effect. <i>Statistics in Medicine</i> , 2022, 41, 815-830.	0.8	3
11070	Age-Based Disparities in Metastatic Melanoma Patients Treated in the Immune Checkpoint Inhibitors (ICI) Versus Non-ICI Era: A Population-Based Study. <i>Frontiers in Immunology</i> , 2021, 12, 609728.	2.2	9
11071	Chemogenetic modulation of sensory neurons reveals their regulating role in melanoma progression. <i>Acta Neuropathologica Communications</i> , 2021, 9, 183.	2.4	21
11072	The Evolution and Future of Targeted Cancer Therapy: From Nanoparticles, Oncolytic Viruses, and Oncolytic Bacteria to the Treatment of Solid Tumors. <i>Nanomaterials</i> , 2021, 11, 3018.	1.9	8
11073	T Cell Bispecific Antibodies: An Antibody-Based Delivery System for Inducing Antitumor Immunity. <i>Pharmaceuticals</i> , 2021, 14, 1172.	1.7	13
11074	Vaccines as Priming Tools for T Cell Therapy for Epithelial Cancers. <i>Cancers</i> , 2021, 13, 5819.	1.7	4
11075	Nuclear Imaging of Endogenous Markers of Lymphocyte Response. , 2022, , 15-59.		1
11076	Cancer Immunotherapy: Current and Future Perspectives on a Therapeutic Revolution. <i>Journal of Clinical Medicine</i> , 2021, 10, 5246.	1.0	2
11077	Adjuvant Pembrolizumab versus IFN±2b or Ipilimumab in Resected High-Risk Melanoma. <i>Cancer Discovery</i> , 2022, 12, 644-653.	7.7	32
11078	The Half-Life-Extended IL21 can Be Combined With Multiple Checkpoint Inhibitors for Tumor Immunotherapy. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 779865.	1.8	11
11079	Reprogramming NK cells and macrophages via combined antibody and cytokine therapy primes tumors for elimination by checkpoint blockade. <i>Cell Reports</i> , 2021, 37, 110021.	2.9	21
11080	Thymic Function and T-Cell Receptor Repertoire Diversity: Implications for Patient Response to Checkpoint Blockade Immunotherapy. <i>Frontiers in Immunology</i> , 2021, 12, 752042.	2.2	11
11081	Immune Checkpoint Inhibitor Therapy for Bone Metastases: Specific Microenvironment and Current Situation. <i>Journal of Immunology Research</i> , 2021, 2021, 1-18.	0.9	21
11082	Tumour-infiltrating bystander CD8 ⁺ T cells activated by IL-15 contribute to tumour control in non-small cell lung cancer. <i>Thorax</i> , 2022, 77, 769-780.	2.7	9
11083	The Role of the Tumor Microenvironment and Treatment Strategies in Colorectal Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 792691.	2.2	39

#	ARTICLE	IF	CITATIONS
11084	Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer. <i>Nature Communications</i> , 2021, 12, 7005.	5.8	66
11085	Neoantigen-Reactive T Cells: The Driving Force behind Successful Melanoma Immunotherapy. <i>Cancers</i> , 2021, 13, 6061.	1.7	5
11086	T Cell Immune Profiles of Blood and Tumor in Dogs Diagnosed With Malignant Melanoma. <i>Frontiers in Veterinary Science</i> , 2021, 8, 772932.	0.9	4
11088	Nonproportional Hazardsâ€™ An Evaluation of the MaxCombo Test in Cancer Clinical Trials. <i>Statistics in Biopharmaceutical Research</i> , 2023, 15, 300-309.	0.6	5
11089	Near-infrared photoimmunotherapy for the treatment of skin disorders. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 509-517.	1.4	0
11090	Cost-effectiveness of adjuvant systemic therapies for patients with high-risk melanoma in Europe: a model-based economic evaluation. <i>ESMO Open</i> , 2021, 6, 100303.	2.0	7
11091	Immuntherapien bei soliden Tumoren: Auf dem Weg zum Standard beim Melanom. , 0, , .		0
11092	Neurologic Toxicities of Immunotherapy. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 417-429.	0.8	2
11093	Skin Reactions to Immune Checkpoint Inhibitors. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 319-330.	0.8	3
11094	Immunotherapy for Melanoma. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 81-111.	0.8	7
11095	Immune System in Action. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 1-43.	0.8	0
11096	A Status Quo Review of Immunotherapy for Advanced Hepatocellular Carcinoma. <i>Advances in Clinical Medicine</i> , 2021, 11, 5740-5746.	0.0	1
11097	Construction and validation of a novel pyroptosis-related signature to predict prognosis in patients with cutaneous melanoma. <i>Mathematical Biosciences and Engineering</i> , 2021, 19, 688-706.	1.0	9
11098	Colitis Induced by Immune-checkpoint Inhibitors. <i>Nihon Daicho Komonbyo Gakkai Zasshi</i> , 2021, 74, 599-605.	0.1	0
11099	External stimuli-responsive nanomedicine for cancer immunotherapy. , 2021, , .		0
11100	Pulmonary Toxicities of Immunotherapy. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 357-375.	0.8	4
11101	Resistance to Immunotherapy: Mechanisms and Means for Overcoming. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 45-80.	0.8	2
11102	Immuno-Oncology for Gynecologic Malignancies. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 193-232.	0.8	1

#	ARTICLE	IF	CITATIONS
11103	Interacting Genetic Lesions of Melanoma in the Tumor Microenvironment: Defining a Viable Therapy. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1350, 123-143.	0.8	0
11104	Acral Lentiginous Melanoma: A United States Multi-Center Substage Survival Analysis. <i>Cancer Control</i> , 2021, 28, 107327482110535.	0.7	7
11105	BDNF expression in GISTs predicts poor prognosis when associated with PD-L1 positive tumor-infiltrating lymphocytes. <i>Oncoimmunology</i> , 2021, 10, 2003956.	2.1	3
11106	Efficacy and Safety of Apatinib in Patients with Recurrent or Refractory Melanoma. <i>Oncologist</i> , 2022, 27, e463-e470.	1.9	7
11107	Tertiary lymphoid structures in cancer. <i>Science</i> , 2022, 375, eabf9419.	6.0	303
11108	Micellar paclitaxel boosts ICD and chemo-immunotherapy of metastatic triple negative breast cancer. <i>Journal of Controlled Release</i> , 2022, 341, 498-510.	4.8	46
11109	Subclonal landscape of cancer drives resistance to immune therapy. <i>Cancer Treatment and Research Communications</i> , 2022, 30, 100507.	0.7	8
11110	Immunotherapy in skin cancers - A narrative review. <i>Journal of Skin and Sexually Transmitted Diseases</i> , 0, .	0.0	0
11111	TGF β 2 Induces the Soluble Isoform of CTLA-4 – Implications for CTLA-4 Based Checkpoint Inhibitor Antibodies in Malignant Melanoma. <i>Frontiers in Immunology</i> , 2021, 12, 763877.	2.2	5
11112	Immune Landscape and Role of Immunotherapy in Treatment of HPV-Associated Head and Neck Squamous Cell Carcinoma (HNSCC). <i>Current Otorhinolaryngology Reports</i> , 2022, 10, 96-107.	0.2	0
11113	Atezolizumab, cobimetinib, and vemurafenib as first-line treatment for unresectable metastatic BRAF V600 mutated melanoma. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 17-25.	1.1	7
11114	Targets and Strategies for Cancer. <i>Methods in Molecular Biology</i> , 2022, 2435, 7-17.	0.4	0
11115	Integrative analysis of CRISPR screening data uncovers new opportunities for optimizing cancer immunotherapy. <i>Molecular Cancer</i> , 2022, 21, 2.	7.9	14
11116	Immune Checkpoint Inhibitor-Induced Cerebral Pseudoprogression: Patterns and Categorization. <i>Frontiers in Immunology</i> , 2021, 12, 798811.	2.2	9
11117	Durvalumab-Induced Demyelinating Lesions in a Patient With Extensive-Stage Small-Cell Lung Cancer: A Case Report. <i>Frontiers in Pharmacology</i> , 2021, 12, 799728.	1.6	2
11118	New Approaches to Dendritic Cell-Based Therapeutic Vaccines Against HIV-1 Infection. <i>Frontiers in Immunology</i> , 2021, 12, 719664.	2.2	8
11119	Factors Determining Long-Term Antitumor Responses to Immune Checkpoint Blockade Therapy in Melanoma. <i>Frontiers in Immunology</i> , 2021, 12, 810388.	2.2	9
11120	Prediction performance of twelve tumor mutation burden panels in melanoma and non-small cell lung cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 169, 103573.	2.0	2

#	ARTICLE	IF	CITATIONS
11121	Immunotherapy in older patients with hepatocellular carcinoma. <i>European Journal of Cancer</i> , 2022, 162, 76-98.	1.3	8
11122	Discovery and development of a novel N-(3-bromophenyl)-{[(phenylcarbamoyl)amino]methyl}-N-hydroxythiophene-2-carboximidamide indoleamine 2,3-dioxygenase inhibitor using knowledge-based drug design. <i>European Journal of Medicinal Chemistry</i> , 2022, 229, 114043.	2.6	1
11123	Nanomaterials with changeable physicochemical property for boosting cancer immunotherapy. <i>Journal of Controlled Release</i> , 2022, 342, 210-227.	4.8	16
11124	Efficacy of ipilimumab and nivolumab in patients with high-grade neuroendocrine neoplasms. <i>ESMO Open</i> , 2022, 7, 100364.	2.0	25
11125	Ultrasensitive detection of BRAF mutations in circulating tumor DNA of non-metastatic melanoma. <i>ESMO Open</i> , 2022, 7, 100357.	2.0	10
11126	Up-converted nano-gasholder with precise nitric oxide release remodels immunosuppressive microenvironment and potentiates tumor immunotherapy. <i>Nano Today</i> , 2022, 42, 101381.	6.2	10
11127	The changing clinical spectrum of endocrine adverse events in cancer immunotherapy. <i>Trends in Endocrinology and Metabolism</i> , 2022, 33, 87-104.	3.1	11
11128	Antigen Receptor T Cells (CAR-T) Effectively Control Tumor Growth in a Colorectal Liver Metastasis Model. <i>Journal of Surgical Research</i> , 2022, 272, 37-50.	0.8	4
11129	Inhibiting VEGF in cancer immunotherapy. <i>Clinical Immunology Communications</i> , 2022, 2, 12-16.	0.5	3
11130	Fundamentals to clinical application of nanoparticles in cancer immunotherapy and radiotherapy. <i>Ecancermedalscience</i> , 2020, 14, 1095.	0.6	5
11131	Effect of carboplatin when administered after dacarbazine failure: Clinical benefit of sequential therapy. <i>Molecular and Clinical Oncology</i> , 2020, 13, 1-1.	0.4	0
11132	649â€¦Incidence of thromboembolism (TE) in patients with melanoma receiving immune checkpoint inhibitor (ICI) therapy and its adverse impact on survival. , 2020, , .		0
11133	648â€¦Cytokine changes during immune-related adverse events and steroid treatment in melanoma patients receiving immune checkpoint inhibitors. , 2020, , .		2
11134	Comprehensive characterization of the tumor microenvironment for assessing immunotherapy outcome in patients with head and neck squamous cell carcinoma. <i>Ageing</i> , 2020, 12, 22509-22526.	1.4	7
11135	Immunotherapy for cancer. <i>South African General Practitioner</i> , 2021, 2, 89-91.	0.0	0
11136	Anlotinib in Combination with TQB2450 in Patients with Platinum-Resistant or Platinum-Refractory Ovarian Cancer (ACTION): A Multicenter, Single-Arm, Open-Label, Phase 1b Trial. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
11137	Clinical Evaluation of Patients with Suspected Reproductive Endocrine Disorders. , 2022, , 1267-1277.		0
11138	Endocrine Complications of Biological Cancer Therapies. , 2022, , 1775-1778.		0

#	ARTICLE	IF	CITATIONS
11139	An Observational Study on the Molecular Profiling of Primary Melanomas Reveals a Progression Dependence on Mitochondrial Activation. <i>Cancers</i> , 2021, 13, 6066.	1.7	4
11140	Signal pathways of melanoma and targeted therapy. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 424.	7.1	115
11141	Advances in Diagnosis and Treatment for Leptomeningeal Disease in Melanoma. <i>Current Oncology Reports</i> , 2022, 24, 43-54.	1.8	3
11142	Role of CTLA Inhibition in Management of Non-Small Cell Lung Cancer. <i>Current Oncology Reports</i> , 2022, 24, 113-123.	1.8	4
11144	Low-Dose Nivolumab with or without Ipilimumab as Adjuvant Therapy Following the Resection of Melanoma Metastases: A Sequential Dual Cohort Phase II Clinical Trial. <i>Cancers</i> , 2022, 14, 682.	1.7	6
11145	Tumor-Infiltrating Lymphocytes in Colorectal Cancer: The Fundamental Indication and Application on Immunotherapy. <i>Frontiers in Immunology</i> , 2021, 12, 808964.	2.2	53
11146	Prostate cancer immunotherapy. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 577-590.	1.4	17
11147	Adjuvant treatment of high-risk melanoma – cost-effectiveness analysis of treatment options for BRAF 600 mutated tumors. <i>Health Economics Review</i> , 2022, 12, 8.	0.8	1
11148	Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses. , 2022, 10, e003853.		16
11149	Immunotherapeutic Strategies in Cancer and Atherosclerosis – Two Sides of the Same Coin. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 812702.	1.1	2
11151	XP-524 is a dual-BET/EP300 inhibitor that represses oncogenic KRAS and potentiates immune checkpoint inhibition in pancreatic cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	16
11152	In vitro characterization of a small molecule PD-1 inhibitor that targets the PD-I/PD-L1 interaction. <i>Scientific Reports</i> , 2022, 12, 303.	1.6	6
11153	Stereotactic radiosurgery with immune checkpoint inhibitors for brain metastases: a meta-analysis study. <i>British Journal of Neurosurgery</i> , 2023, 37, 1533-1543.	0.4	8
11154	Management of metastatic melanoma with new immunotherapy approaches beyond PD-1/CTLA-4 inhibitors. <i>Current Opinion in Oncology</i> , 2022, 34, 123-130.	1.1	3
11155	Use of CRISPR/Cas9 gene editing to improve chimeric antigen-receptor T cell therapy: A systematic review and meta-analysis of preclinical studies. <i>Cytotherapy</i> , 2022, 24, 405-412.	0.3	6
11156	TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapy. <i>European Journal of Cancer</i> , 2022, 161, 99-107.	1.3	10
11157	Identification of an at-risk subpopulation with high immune infiltration based on the peroxisome pathway and TIM3 in colorectal cancer. <i>BMC Cancer</i> , 2022, 22, 44.	1.1	8
11158	Comprehensive analysis of a TNF family based-signature in diffuse gliomas with regard to prognosis and immune significance. <i>Cell Communication and Signaling</i> , 2022, 20, 6.	2.7	15

#	ARTICLE	IF	CITATIONS
11159	International Center-Level Variation in Utilization of Completion Lymph Node Dissection and Adjuvant Systemic Therapy for Sentinel Lymph Node-Positive Melanoma at Major Referral Centers. <i>Annals of Surgery</i> , 2023, 277, e1106-e1115.	2.1	7
11160	Cutaneous Stevens Johnson â€“ Toxic Epidermal Necrolysis Immunotherapy related Toxicities in Lung Cancer Patients. <i>Journal of Oncology Pharmacy Practice</i> , 2022, 28, 1276-1282.	0.5	1
11161	Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC). <i>Annals of Surgical Oncology</i> , 2022, 29, 3694-3708.	0.7	21
11162	Preoperative Immune Checkpoint Inhibition and Cryoablation in Early-Stage Breast Cancer. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
11163	Nanovesicleâ€“Mediated Targeted Delivery of Immune Checkpoint Blockades to Potentiate Therapeutic Efficacy and Prevent Side Effects. <i>Advanced Materials</i> , 2022, 34, e2106516.	11.1	26
11164	Radiation necrosis in renal cell carcinoma brain metastases treated with checkpoint inhibitors and radiosurgery: An international multicenter study. <i>Cancer</i> , 2022, 128, 1429-1438.	2.0	21
11165	Loss of SMAD4 Is Associated With Poor Tumor Immunogenicity and Reduced PD-L1 Expression in Pancreatic Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 806963.	1.3	14
11166	Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier. <i>Cancer Cell International</i> , 2022, 22, 2.	1.8	83
11167	Risk assessment, diagnosis, and treatment of cancer treatment-related adrenal insufficiency. <i>Expert Review of Endocrinology and Metabolism</i> , 2022, 17, 21-33.	1.2	3
11168	Real-world frequency of BRAF testing and utilization of therapies in patients with advanced melanoma. <i>Melanoma Research</i> , 2022, Publish Ahead of Print, 79-87.	0.6	3
11169	Overall survival in the real-world and clinical trials: a case study validating external controls in advanced melanoma. <i>Future Oncology</i> , 2022, 18, 1321-1331.	1.1	2
11170	Complications following novel therapies for nonâ€“small cell lung cancer. <i>Journal of Internal Medicine</i> , 2022, 291, 732-754.	2.7	6
11171	The Predictive Value of MAP2K1/2 Mutations on Efficiency of Immunotherapy in Melanoma. <i>Frontiers in Immunology</i> , 2021, 12, 785526.	2.2	6
11173	Myeloid-Derived Suppressor Cells in Solid Tumors. <i>Cells</i> , 2022, 11, 310.	1.8	39
11175	Expression of Immunomodulatory Checkpoint Molecules in Drug-Resistant Neuroblastoma: An Exploratory Study. <i>Cancers</i> , 2022, 14, 751.	1.7	5
11176	Innate Immunity and Cancer Pathophysiology. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2022, 17, 425-457.	9.6	41
11177	Combination of genetically engineered T cells and immune checkpoint blockade for the treatment of cancer. <i>Immunotherapy Advances</i> , 2022, 2, .	1.2	8
11178	mTOR Pathway Gene Mutations Predict Response to Immune Checkpoint Inhibitors in Multiple Cancers. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0

#	ARTICLE	IF	CITATIONS
11179	CNS and PNS manifestation in immune checkpoint inhibitors: A systematic review. <i>Journal of the Neurological Sciences</i> , 2022, 432, 120089.	0.3	10
11180	Advances in management of locally advanced cervical cancer. <i>Indian Journal of Medical Research</i> , 2022, .	0.4	7
11181	Emerging strategies for biomaterial-assisted cancer immunotherapy. <i>Korean Journal of Chemical Engineering</i> , 2022, 39, 227-240.	1.2	1
11183	Single-Cell Immune Mapping of Melanoma Sentinel Lymph Nodes Reveals an Actionable Immunotolerant Microenvironment. <i>Clinical Cancer Research</i> , 2022, 28, 2069-2081.	3.2	9
11185	Immunotherapy and Gene Therapy: New Challenges in the Diagnosis and Management of Drug-Induced Liver Injury. <i>Frontiers in Pharmacology</i> , 2021, 12, 786174.	1.6	8
11186	Differential expression of inhibitory receptor NKG2A distinguishes disease-specific exhausted CD8 + T cells. <i>MedComm</i> , 2022, 3, e111.	3.1	2
11188	TCR-T Immunotherapy: The Challenges and Solutions. <i>Frontiers in Oncology</i> , 2021, 11, 794183.	1.3	36
11189	Perspectives on the role of breast cancer susceptibility gene in breast cancer. <i>International Journal of Clinical Oncology</i> , 2022, 27, 495-511.	1.0	1
11190	Immunotherapy for glioblastoma: the promise of combination strategies. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 35.	3.5	85
11191	Metabolic and Nutritional Disorders Following the Administration of Immune Checkpoint Inhibitors: A Pharmacovigilance Study. <i>Frontiers in Endocrinology</i> , 2021, 12, 809063.	1.5	0
11192	PET Imaging of Melanoma. , 2022, , .		0
11193	The Impact of Esophageal Oncological Surgery on Perioperative Immune Function; Implications for Adjuvant Immune Checkpoint Inhibition. <i>Frontiers in Immunology</i> , 2022, 13, 823225.	2.2	6
11194	Comparison of Laboratory Methods for the Clinical Follow Up of Checkpoint Blockade Therapies in Leukemia: Current Status and Challenges Ahead. <i>Frontiers in Oncology</i> , 2022, 12, 789728.	1.3	2
11195	Immune-checkpoint inhibitors: long-term implications of toxicity. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 254-267.	12.5	360
11196	New Therapeutic Approaches for Conjunctival Melanoma—What We Know So Far and Where Therapy Is Potentially Heading: Focus on Lymphatic Vessels and Dendritic Cells. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1478.	1.8	4
11197	Immune-Related Toxicity Among Adolescent and Young Adult with Melanoma as Compared with the Elderly. <i>Journal of Adolescent and Young Adult Oncology</i> , 2022, , .	0.7	2
11198	Tumors resurrect an embryonic vascular program to escape immunity. <i>Science Immunology</i> , 2022, 7, eabm6388.	5.6	27
11199	Electrical Stimulation for Immune Modulation in Cancer Treatments. <i>Frontiers in Bioengineering and Biotechnology</i> , 2021, 9, 795300.	2.0	15

#	ARTICLE	IF	CITATIONS
11200	Immune checkpoint inhibitors, endocrine adverse events, and outcomes of melanoma. <i>Endocrine Connections</i> , 2022, 11, .	0.8	4
11201	Metabolic Implications of Immune Checkpoint Proteins in Cancer. <i>Cells</i> , 2022, 11, 179.	1.8	15
11202	Systemic lupus erythematosus reactivation after chemoimmunotherapy in preexisting autoimmune disease. <i>Tumori</i> , 2022, 108, 609-614.	0.6	3
11203	Solid Tumor TIL Therapy Is Infiltrating Multiple Centers With Lympho-â€œsightsâ€œSet on Becoming Standard of Care. , 2022, 19, .		0
11204	The Pellino1â€œPKCÎ, Signaling Axis Is an Essential Target for Improving Antitumor CD8+ T-lymphocyte Function. <i>Cancer Immunology Research</i> , 2022, 10, 327-342.	1.6	8
11205	Inborn Errors of Immunity and Their Phenocopies: CTLA4 and PD-1. <i>Frontiers in Immunology</i> , 2021, 12, 806043.	2.2	7
11206	Phase I Trial of Cetuximab, Radiotherapy, and Ipilimumab in Locally Advanced Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 1335-1344.	3.2	14
11207	Selfâ€œBlockade of PDâ€œL1 with Bacteriaâ€œDerived Outerâ€œMembrane Vesicle for Enhanced Cancer Immunotherapy. <i>Advanced Materials</i> , 2022, 34, e2106307.	11.1	51
11208	Vectorized Treg-depleting Î±CTLA-4 elicits antigen cross-presentation and CD8⁺ T cell immunity to reject â€œcoldâ€œ™ tumors. , 2022, 10, e003488.		14
11209	Preoperative Chemoradiotherapy plus Nivolumab before Surgery in Patients with Microsatellite Stable and Microsatellite Instabilityâ€œHigh Locally Advanced Rectal Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 1136-1146.	3.2	62
11210	Pro-BNP in the differential diagnosis of dyspnea in patients treated with immune-checkpoint inhibitors: Case Report. <i>Journal of Oncology Pharmacy Practice</i> , 2022, 28, 1239-1243.	0.5	1
11211	Gastroenteropancreatic Neuroendocrine Neoplasms (GEP NENs) : The Role of Checkpoint Inhibitors. <i>Current Cancer Drug Targets</i> , 2022, 22, .	0.8	0
11212	The â€œotherâ€œ™ big complication: how chronic kidney disease impacts on cancer risks and outcomes. <i>Nephrology Dialysis Transplantation</i> , 2023, 38, 1071-1079.	0.4	16
11213	Altered Frequencies and Functions of Innate Lymphoid Cells in Melanoma Patients Are Modulated by Immune Checkpoints Inhibitors. <i>Frontiers in Immunology</i> , 2022, 13, 811131.	2.2	6
11214	Squamous cell carcinoma of the lung: improving the detection and management of immune-related adverse events. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 203-213.	1.1	4
11215	Plasma Thymidine Kinase Activity as a Novel Biomarker in Metastatic Melanoma Patients Treated with Immune Checkpoint Inhibitors. <i>Cancers</i> , 2022, 14, 702.	1.7	3
11216	Presence of <sc>Tim</sc>3⁺ and <sc>PD</sc>â€œ1⁺<sc>CD8</sc>⁺<sc>T</sc> cells identifies microsatellite stable colorectal carcinomas with immune exhaustion and distinct clinicopathological features. <i>Journal of Pathology</i> , 2022, 257, 186-197.	2.1	13
11217	The Prognostic Value of Albumin-Globulin Ratio and Eosinophil-Neutrophil Ratio in Patients with Advanced Tumors Undergoing Treatment with PD-1/PD-L1 Inhibitors. <i>Nutrition and Cancer</i> , 2022, 74, 2815-2828.	0.9	4

#	ARTICLE	IF	CITATIONS
11218	Tebentafusp in advanced uveal melanoma: proof of principle for the efficacy of T-cell receptor therapeutics and bispecifics in solid tumors. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 997-1004.	1.4	7
11219	PD-1 blockade therapy promotes infiltration of tumor-attacking exhausted T cell clonotypes. <i>Cell Reports</i> , 2022, 38, 110331.	2.9	45
11220	Influence of DNA Mismatch Repair (MMR) System in Survival and Response to Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC): Retrospective Analysis. <i>Biomedicines</i> , 2022, 10, 360.	1.4	17
11221	The immune modifying effects of chemotherapy and advances in chemo-immunotherapy. , 2022, 236, 108111.		25
11222	Adverse events induced by nivolumab and ipilimumab combination regimens. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592110583.	1.4	11
11223	Neoantigens and their potential applications in tumor immunotherapy (Review). <i>Oncology Letters</i> , 2022, 23, 88.	0.8	10
11224	Identification of SCN7A as the key gene associated with tumor mutation burden in gastric cancer. <i>BMC Gastroenterology</i> , 2022, 22, 45.	0.8	3
11225	CCR8-targeted specific depletion of clonally expanded Treg cells in tumor tissues evokes potent tumor immunity with long-lasting memory. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	68
11226	Disrupting cancer angiogenesis and immune checkpoint networks for improved tumor immunity. <i>Seminars in Cancer Biology</i> , 2022, 86, 981-996.	4.3	15
11227	Combining Hepatic Percutaneous Perfusion with Ipilimumab plus Nivolumab in advanced uveal melanoma (CHOPIN): study protocol for a phase Ib/randomized phase II trial. <i>Trials</i> , 2022, 23, 137.	0.7	10
11228	Histological Features of Celiac-Disease-like Conditions Related to Immune Checkpoint Inhibitors Therapy: A Signal to Keep in Mind for Pathologists. <i>Diagnostics</i> , 2022, 12, 395.	1.3	2
11229	Emerging new therapeutic antibody derivatives for cancer treatment. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 39.	7.1	158
11230	Outcomes After Curative Metastasectomy for Patients with Malignant Melanoma: A Systematic Review and Meta-analysis. <i>Annals of Surgical Oncology</i> , 2022, 29, 3709-3723.	0.7	13
11231	Biomarkers of treatment benefit with atezolizumab plus vemurafenib plus cobimetinib in BRAFV600 mutationâ€“positive melanoma. <i>Annals of Oncology</i> , 2022, 33, 544-555.	0.6	12
11232	Immune checkpoint inhibitors for the treatment of melanoma. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 563-576.	1.4	10
11233	Bibliometric analysis of the 100 top-cited articles on immunotherapy of urological cancer. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-8.	1.4	11
11234	Oral Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors: Salivary Gland Dysfunction and Mucosal Diseases. <i>Cancers</i> , 2022, 14, 792.	1.7	8
11235	Cilengitide, an Î±vÎ²3-integrin inhibitor, enhances the efficacy of anti-programmed cell death-1 therapy in a murine melanoma model. <i>Bioengineered</i> , 2022, 13, 4557-4572.	1.4	6

#	ARTICLE	IF	CITATIONS
11236	The Predictive Potential of the Baseline C-Reactive Protein Levels for the Efficiency of Immune Checkpoint Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis. <i>Frontiers in Immunology</i> , 2022, 13, 827788.	2.2	15
11237	Checkpoint: Inspecting the barriers in glioblastoma immunotherapies. <i>Seminars in Cancer Biology</i> , 2022, 86, 473-481.	4.3	9
11238	Managing Metastatic Melanoma in 2022: A Clinical Review. <i>JCO Oncology Practice</i> , 2022, 18, 335-351.	1.4	91
11239	A comprehensive evaluation of the safety of ipilimumab, nivolumab and their combination therapy: A systematic review and network meta-analysis. <i>Journal of Oncology Pharmacy Practice</i> , 2023, 29, 557-576.	0.5	0
11240	Retrospective analysis of clinical trial safety data for pembrolizumab reveals the effect of co-occurring infections on immune-related adverse events. <i>PLoS ONE</i> , 2022, 17, e0263402.	1.1	7
11241	Predictive Efficacy of Blood-Based Tumor Mutation Burden Assay for Immune Checkpoint Inhibitors Therapy in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2022, 12, 795933.	1.3	4
11242	Efficacy of radiotherapy combined with immune checkpoint inhibitors in patients with melanoma: a systemic review and meta-analysis. <i>Melanoma Research</i> , 2022, 32, 71-78.	0.6	7
11243	In situ vaccination using unique TLR9 ligand K3-SPG induces long-lasting systemic immune response and synergizes with systemic and local immunotherapy. <i>Scientific Reports</i> , 2022, 12, 2132.	1.6	8
11244	Recent insights into the use of immune checkpoint inhibitors in gastric cancer. <i>Porto Biomedical Journal</i> , 2022, 7, e162.	0.4	3
11245	Leveraging self-assembled nanobiomaterials for improved cancer immunotherapy. <i>Cancer Cell</i> , 2022, 40, 255-276.	7.7	45
11246	FOXP3/HAT1 Axis Controls Treg Infiltration in the Tumor Microenvironment by Inducing CCR4 Expression in Breast Cancer. <i>Frontiers in Immunology</i> , 2022, 13, 740588.	2.2	23
11247	Immune Checkpoint Therapies and Atherosclerosis: Mechanisms and Clinical Implications. <i>Journal of the American College of Cardiology</i> , 2022, 79, 577-593.	1.2	34
11248	Recent advance in nanomaterials for cancer immunotherapy. <i>Chemical Engineering Journal</i> , 2022, 435, 134145.	6.6	16
11249	Mesenchymal-epithelial transition factor (MET) immunoreactivity in positive sentinel nodes from patients with melanoma. <i>Annals of Diagnostic Pathology</i> , 2022, 58, 151909.	0.6	1
11250	Predictive Biomarkers for Outcomes of Immune Checkpoint Inhibitors (ICIs) in Melanoma: A Systematic Review. <i>Cancers</i> , 2021, 13, 6366.	1.7	10
11251	4-1BB co-stimulation further enhances anti-PD-1-mediated reinvigoration of exhausted CD39 ⁺ CD8 T cells from primary and metastatic sites of epithelial ovarian cancers. , 2020, 8, e001650.		35
11252	Adaptive Dosing of Nivolumab + Ipilimumab Immunotherapy Based Upon Early, Interim Radiographic Assessment in Advanced Melanoma (The ADAPT-IT Study). <i>Journal of Clinical Oncology</i> , 2022, 40, 1059-1067.	0.8	26
11255	Expression of immune checkpoint regulators, cytotoxic T lymphocyte antigen 4 (CTLA-4), and CD137 in cervical carcinoma. <i>International Journal of Clinical and Experimental Pathology</i> , 2021, 14, 1038-1047.	0.5	0

#	ARTICLE	IF	CITATIONS
11256	Therapeutische Grundlagen in der gynÄkologischen Onkologie. , 2021, , 179-254.		0
11257	Grading of lymphocyte infiltrating tumor can be used as a prognosis factor compared to T Pathology and N Pathology on recurrency of colon cancer. Indonesia Journal of Biomedical Science, 2020, 15, 39-42.	0.1	0
11258	Importance of immune cell infiltration in tumor microenvironment of head and neck cancer. Onkologie (Czech Republic), 2021, 15, 67-72.	0.0	0
11259	Regulatory landscape in the approval of cancer vaccine. , 2022, , 325-348.		0
11260	Immune Checkpoint Inhibitors in 10 Years: Contribution of Basic Research and Clinical Application in Cancer Immunotherapy. Immune Network, 2022, 22, e2.	1.6	53
11261	Strategies to mitigate the toxicity of cancer therapeutics. Advances in Cancer Research, 2022, , 215-244.	1.9	5
11262	Neoadjuvant therapy for melanoma: rationale for neoadjuvant therapy and pivotal clinical trials. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592210830.	1.4	13
11263	Functional nanomaterials and nanocomposite in cancer vaccines. , 2022, , 241-258.		0
11264	Monoclonal Antibodies to CTLA-4 with Focus on Ipilimumab. Experientia Supplementum (2012), 2022, 113, 295-350.	0.5	3
11266	Melanoma therapeutics: a literature review. Journal of Biomedical Research, 2022, 36, 77.	0.7	16
11267	Nanotechnology-based manipulation of dendritic cells for enhanced immunotherapy strategies. , 2022, , 129-148.		0
11268	Novel dendritic cell vaccine strategies. , 2022, , 109-135.		1
11269	Hepatocellular carcinoma stem cells, progression and therapy. , 2022, , 97-107.		1
11270	Recent developments in cancer vaccines. , 2022, , 29-75.		1
11272	Tumor mutational burden and somatic mutation status to predict disease recurrence in advanced melanoma. Melanoma Research, 2022, 32, 112-119.	0.6	4
11273	Vedolizumab Attenuates Immune-Checkpoint-Therapy-Induced Infliximab-Refractory Colitis. Diagnostics, 2022, 12, 480.	1.3	3
11274	Management of In-Transit Metastases. Current Oncology Reports, 2022, 24, 573.	1.8	0
11275	Novel Immune-Related Ferroptosis Signature in Esophageal Cancer: An Informatics Exploration of Biological Processes Related to the TMEM161B-AS1/hsa-miR-27a-3p/GCH1 Regulatory Network. Frontiers in Genetics, 2022, 13, 829384.	1.1	14

#	ARTICLE	IF	CITATIONS
11276	Superinduction of immunosuppressive glioblastoma extracellular vesicles by IFN- β through PD-L1 and IDO1. <i>Neuro-Oncology Advances</i> , 2022, 4, .	0.4	8
11277	D-mannose facilitates immunotherapy and radiotherapy of triple-negative breast cancer via degradation of PD-L1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	66
11278	The role of the CRISPR-Cas system in cancer drug development: Mechanisms of action and therapy. <i>Biotechnology Journal</i> , 2022, 17, e2100468.	1.8	6
11279	Ligand-mediated PAI-1 inhibition in a mouse model of peritoneal carcinomatosis. <i>Cell Reports Medicine</i> , 2022, 3, 100526.	3.3	7
11280	Identification of Neoantigens in Cancer Cells as Targets for Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2594.	1.8	14
11281	Histone deacetylase inhibitor-based oncolytic virotherapy: A promising strategy for cancer treatment. <i>Drug Discovery Today</i> , 2022, 27, 1689-1697.	3.2	5
11282	Immune Checkpoint Inhibitors-Associated Cardiotoxicity. <i>Cancers</i> , 2022, 14, 1145.	1.7	25
11283	Oncologic Outcome and Immune Responses of Radiotherapy with Anti-PD-1 Treatment for Brain Metastases Regarding Timing and Benefiting Subgroups. <i>Cancers</i> , 2022, 14, 1240.	1.7	12
11284	Synergistic checkpoint-blockade and radiotherapy-radiodynamic therapy via an immunomodulatory nanoscale metal-organic framework. <i>Nature Biomedical Engineering</i> , 2022, 6, 144-156.	11.6	47
11285	A Bayesian phase I/II biomarker-based design for identifying subgroup-specific optimal dose for immunotherapy. <i>Statistical Methods in Medical Research</i> , 2022, 31, 1104-1119.	0.7	5
11286	Adverse effects of combination immunotherapy in renal cancer, lung cancer, and melanoma. <i>Onkologie (Czech Republic)</i> , 2022, 16, 10-15.	0.0	0
11287	Tumor associated macrophages reprogrammed by targeted bifunctional bioorthogonal nanozymes for enhanced tumor immunotherapy. <i>Materials Today</i> , 2022, 56, 16-28.	8.3	25
11288	Cardiotoxicity of Systemic Melanoma Treatments. <i>Current Treatment Options in Oncology</i> , 2022, 23, 240-253.	1.3	2
11291	Cancer pharmacomicrobiomics: targeting microbiota to optimise cancer therapy outcomes. <i>Gut</i> , 2022, 71, 1412-1425.	6.1	79
11292	Human Leukocyte Antigen Class I Antigen-Processing Machinery Upregulation by Anticancer Therapies in the Era of Checkpoint Inhibitors. <i>JAMA Oncology</i> , 2022, 8, 462.	3.4	22
11293	Treatment of Metastatic Melanoma in the Elderly. <i>Current Oncology Reports</i> , 2022, 24, 825-833.	1.8	5
11294	Sex dimorphism in the tumor microenvironment - From bench to bedside and back. <i>Seminars in Cancer Biology</i> , 2022, 86, 166-179.	4.3	8
11295	The relative contribution of the decreasing trend in tumour thickness to the 2010s increase in net survival from cutaneous malignant melanoma in Italy: a population-based investigation*. <i>British Journal of Dermatology</i> , 2022, 187, 52-63.	1.4	11

#	ARTICLE	IF	CITATIONS
11297	Immunomodulatory Properties of Immune Checkpoint Inhibitorsâ€”More than Boosting T-Cell Responses?. <i>Cancers</i> , 2022, 14, 1710.	1.7	13
11298	Entinostat Decreases Immune Suppression to Promote Antitumor Responses in a HER2+ Breast Tumor Microenvironment. <i>Cancer Immunology Research</i> , 2022, 10, 656-669.	1.6	26
11299	Role of CD155/TIGIT in Digestive Cancers: Promising Cancer Target for Immunotherapy. <i>Frontiers in Oncology</i> , 2022, 12, 844260.	1.3	7
11300	Review of Immune-Related Adverse Events (irAEs) in Non-Small-Cell Lung Cancer (NSCLC)â€”Their Incidence, Management, Multiorgan irAEs, and Rechallenge. <i>Biomedicines</i> , 2022, 10, 790.	1.4	17
11301	Hypersensitivity Reactions and Immune-Related Adverse Events to Immune Checkpoint Inhibitors: Approaches, Mechanisms, and Models. <i>Immunology and Allergy Clinics of North America</i> , 2022, 42, 285-305.	0.7	4
11302	Strategies for Manipulating T Cells in Cancer Immunotherapy. <i>Biomolecules and Therapeutics</i> , 2022, , .	1.1	0
11303	PDL1 positivity rate between triple negative and non-luminal Her2+ cases. <i>Current Cancer Therapy Reviews</i> , 2022, 18, .	0.2	0
11304	Camrelizumab combined with apatinib and S-1 as second-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2597-2608.	2.0	25
11305	TIGIT Blockade Exerts Synergistic Effects on Microwave Ablation Against Cancer. <i>Frontiers in Immunology</i> , 2022, 13, 832230.	2.2	13
11306	Prognostic value of CD155/TIGIT expression in patients with colorectal cancer. <i>PLoS ONE</i> , 2022, 17, e0265908.	1.1	11
11307	The Current State of Treatment and Future Directions in Cutaneous Malignant Melanoma. <i>Biomedicines</i> , 2022, 10, 822.	1.4	18
11308	Targeting the PSGL-1 Immune Checkpoint Promotes Immunity to PD-1â€”Resistant Melanoma. <i>Cancer Immunology Research</i> , 2022, 10, 612-625.	1.6	12
11309	Preclinical characterization of the novel anti-SIRPÎ± antibody BR105 that targets the myeloid immune checkpoint. , 2022, 10, e004054.		7
11310	Immunotherapy in Combination with Well-Established Treatment Strategies in Pancreatic Cancer: Current Insights. <i>Cancer Management and Research</i> , 2022, Volume 14, 1043-1061.	0.9	6
11311	Agonistic CD27 antibody potency is determined by epitope-dependent receptor clustering augmented through Fc-engineering. <i>Communications Biology</i> , 2022, 5, 229.	2.0	8
11313	Primary Small Bowel Melanoma: A Case Report and Review of Literature. <i>Frontiers in Surgery</i> , 2022, 9, 792243.	0.6	0
11314	Outcomes of Patients with Metastatic Melanomaâ€”A Single-Institution Retrospective Analysis. <i>Cancers</i> , 2022, 14, 1672.	1.7	1
11315	Frequency of Immune Checkpoint Inhibitor-Induced Vasculitides: An Observational Study Using Data From the Japanese Adverse Drug Event Report Database. <i>Frontiers in Pharmacology</i> , 2022, 13, 803706.	1.6	6

#	ARTICLE	IF	CITATIONS
11316	Anti-PD-1: When to Stop Treatment. <i>Current Oncology Reports</i> , 2022, 24, 905-915.	1.8	5
11317	Basic cancer immunology for radiation oncologists. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2022, 66, 508-518.	0.9	2
11318	Toll-like receptor agonist combinations augment mouse T-cell anti-tumor immunity via IL-12- and interferon γ -mediated suppression of immune checkpoint receptor expression. <i>Oncolimmunology</i> , 2022, 11, 2054758.	2.1	7
11319	Is Timing of Steroid Exposure Prior to Immune Checkpoint Inhibitor Initiation Associated with Treatment Outcomes in Melanoma? A Population-Based Study. <i>Cancers</i> , 2022, 14, 1296.	1.7	8
11320	The evolutionary legacy of immune checkpoint inhibitors. <i>Seminars in Cancer Biology</i> , 2022, 86, 491-498.	4.3	37
11322	A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance. <i>Nature Immunology</i> , 2022, 23, 660-670.	7.0	191
11323	Emerging Strategies in TCR-Engineered T Cells. <i>Frontiers in Immunology</i> , 2022, 13, 850358.	2.2	20
11324	QUAD SHOT Radiotherapy and Doublet Immunotherapy in the Management of Anal Mucosal Melanoma: A Case Series of Efficacy and Toxicity of a Novel Treatment Approach and a Review of the Literature. <i>Clinical Colorectal Cancer</i> , 2022, , .	1.0	3
11325	Betulin Attenuates TGF- β 1- and PGE $_2$ -Mediated Inhibition of NK Cell Activity to Suppress Tumor Progression and Metastasis in Mice. <i>Biological and Pharmaceutical Bulletin</i> , 2022, 45, 339-353.	0.6	1
11326	Current Clinical Trial Landscape of OX40 Agonists. <i>Current Oncology Reports</i> , 2022, 24, 951-960.	1.8	15
11327	A single-cell transcriptomic landscape of innate and adaptive intratumoral immunity in triple negative breast cancer during chemo- and immunotherapies. <i>Cell Death Discovery</i> , 2022, 8, 106.	2.0	10
11328	A compact and simple method of achieving differential transgene expression by exploiting translational readthrough. <i>BioTechniques</i> , 2022, 72, 143-154.	0.8	2
11329	Medical Affairs and Innovative Medicinal Product Strategy Development. <i>Pharmaceutical Medicine</i> , 2022, 36, 71.	1.0	1
11330	Evolution of Molecular Targeted Cancer Therapy: Mechanisms of Drug Resistance and Novel Opportunities Identified by CRISPR-Cas9 Screening. <i>Frontiers in Oncology</i> , 2022, 12, 755053.	1.3	12
11331	Systematic review and meta-analysis of genomic alterations in acral melanoma. <i>Pigment Cell and Melanoma Research</i> , 2022, 35, 369-386.	1.5	6
11332	The Prognostic Relevance of PMCA4 Expression in Melanoma: Gender Specificity and Implications for Immune Checkpoint Inhibition. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3324.	1.8	4
11333	Spectrum of DNA mismatch repair failures viewed through the lens of cancer genomics and implications for therapy. <i>Clinical Science</i> , 2022, 136, 383-404.	1.8	8
11334	Pan-cancer analysis of necroptosis-related gene signature for the identification of prognosis and immune significance. <i>Discover Oncology</i> , 2022, 13, 17.	0.8	12

#	ARTICLE	IF	CITATIONS
11335	Advances in Nanotechnology Development to Overcome Current Roadblocks in CAR-T Therapy for Solid Tumors. <i>Frontiers in Immunology</i> , 2022, 13, 849759.	2.2	4
11336	A novel stimuli-responsive magnetic hydrogel based on nature-inspired tragacanth gum for chemo/hyperthermia treatment of cancerous cells. <i>Journal of Polymer Research</i> , 2022, 29, 1.	1.2	14
11337	Association of Blood Biochemical Indexes and Antibiotic Exposure With Severe Immune-related Adverse Events in Patients With Advanced Cancers Receiving PD-1 Inhibitors. <i>Journal of Immunotherapy</i> , 2022, 45, 210-216.	1.2	15
11338	Tumor-Draining Lymph Node Reconstruction Promotes B Cell Activation During E0771 Mouse Breast Cancer Growth. <i>Frontiers in Pharmacology</i> , 2022, 13, 825287.	1.6	3
11339	Advanced Biomaterials for Cell-Specific Modulation and Restore of Cancer Immunotherapy. <i>Advanced Science</i> , 2022, 9, e2200027.	5.6	26
11340	AXL inhibition improves BRAF-targeted treatment in melanoma. <i>Scientific Reports</i> , 2022, 12, 5076.	1.6	14
11341	Fc-independent functions of anti-CTLA-4 antibodies contribute to anti-tumor efficacy. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2421-2431.	2.0	9
11342	Discovery of efficacy biomarkers for non-small cell lung cancer with first-line anti-PD-1 immunotherapy by data-independent acquisition mass spectrometry. <i>Clinical and Experimental Immunology</i> , 2022, , .	1.1	1
11343	Bidirectional crosstalk between therapeutic cancer vaccines and the tumor microenvironment: Beyond tumor antigens. <i>Fundamental Research</i> , 2023, 3, 1005-1024.	1.6	4
11344	Immune-Related Adverse Events After Immune Checkpoint Inhibitors for Melanoma Among Older Adults. <i>JAMA Network Open</i> , 2022, 5, e223461.	2.8	16
11345	Hallmarks of Resistance to Immune-Checkpoint Inhibitors. <i>Cancer Immunology Research</i> , 2022, 10, 372-383.	1.6	36
11346	Development of Peptide-Based Vaccines for Cancer. <i>Journal of Oncology</i> , 2022, 2022, 1-17.	0.6	32
11347	Addressing the Elephant in the Immunotherapy Room: Effector T-Cell Priming versus Depletion of Regulatory T-Cells by Anti-CTLA-4 Therapy. <i>Cancers</i> , 2022, 14, 1580.	1.7	17
11348	Frontline Dual Checkpoint Inhibition in Metastatic Melanoma Over Anti-PD-1 Monotherapy: The Case for a Comparative Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 1596-1597.	0.8	4
11349	Immune Checkpoint Inhibitor-Induced Hypophysitis and Patterns of Loss of Pituitary Function. <i>Frontiers in Oncology</i> , 2022, 12, 836859.	1.3	25
11350	Immune Landscape and an RBM38-Associated Immune Prognostic Model with Laboratory Verification in Malignant Melanoma. <i>Cancers</i> , 2022, 14, 1590.	1.7	2
11351	Identification of New Vulnerabilities in Conjunctival Melanoma Using Image-Based High Content Drug Screening. <i>Cancers</i> , 2022, 14, 1575.	1.7	0
11352	First-line <sc>PD</sc>-1</sc> inhibitors plus chemotherapy versus bevacizumab plus chemotherapy for advanced non-squamous non-small cell lung cancer: A Bayesian network meta-analysis of randomized controlled trials. <i>Cancer Medicine</i> , 2022, 11, 2043-2055.	1.3	5

#	ARTICLE	IF	CITATIONS
11353	Evaluation of the TCR Repertoire as a Predictive and Prognostic Biomarker in Cancer: Diversity or Clonality?. <i>Cancers</i> , 2022, 14, 1771.	1.7	15
11354	Optimizing therapeutic outcomes of immune checkpoint blockade by a microbial tryptophan metabolite. , 2022, 10, e003725.		39
11355	AllergoOncology: Role of immune cells and immune proteins. <i>Clinical and Translational Allergy</i> , 2022, 12, e12133.	1.4	7
11356	Checkpoint Inhibitors and Induction of Celiac Disease-like Condition. <i>Biomedicines</i> , 2022, 10, 609.	1.4	5
11357	Clinic, Endoscopic and Histological Features in Patients Treated with ICI Developing GI Toxicity: Some News and Reappraisal from a Mono-Institutional Experience. <i>Diagnostics</i> , 2022, 12, 685.	1.3	1
11358	Association of the Microbiota and Pancreatic Cancer: Opportunities and Limitations. <i>Frontiers in Immunology</i> , 2022, 13, 844401.	2.2	15
11359	The influence of transarterial chemoembolization on serum levels of soluble programmed cell death ligand-1 in advanced hepatocellular carcinoma patients. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2022, , .	0.7	3
11360	Immunotherapy-based combination strategies for treatment of EGFR-TKI-resistant non-small-cell lung cancer. <i>Future Oncology</i> , 2022, 18, 1757-1775.	1.1	14
11361	“Know thyself” – host factors influencing cancer response to immune checkpoint inhibitors. <i>Journal of Pathology</i> , 2022, 257, 513-525.	2.1	8
11362	Tyrosinase suppresses vasculogenic mimicry in human melanoma cells. <i>Oncology Letters</i> , 2022, 23, 169.	0.8	6
11363	Basal and one-month differed neutrophil, lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild-type melanoma. <i>Journal of Translational Medicine</i> , 2022, 20, 159.	1.8	12
11364	Dual Relationship Between Stromal Cells and Immune Cells in the Tumor Microenvironment. <i>Frontiers in Immunology</i> , 2022, 13, 864739.	2.2	40
11365	Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [18F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 2323-2341.	3.3	48
11366	Prediction of tumor mutation burden from H&E whole-slide images: a comparison of training strategies with convolutional neural networks. , 2022, , .		0
11367	Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons. <i>Cell Communication and Signaling</i> , 2022, 20, 44.	2.7	109
11368	The microbial metabolite trimethylamine N-oxide promotes antitumor immunity in triple-negative breast cancer. <i>Cell Metabolism</i> , 2022, 34, 581-594.e8.	7.2	105
11369	Multifunctional nanomedicines for synergistic photodynamic immunotherapy based on tumor immune microenvironment. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2022, 173, 103-120.	2.0	1
11370	International society of oncology pharmacy practitioners (ISOPP) position statement: The role of oncology pharmacy practitioners in immunotherapy treatment with immune checkpoint inhibitors for malignant conditions. <i>Journal of Oncology Pharmacy Practice</i> , 2022, , 107815522210901.	0.5	0

#	ARTICLE	IF	CITATIONS
11371	The Role and Potential of 18F-FDG PET/CT in Malignant Melanoma: Prognostication, Monitoring Response to Targeted and Immunotherapy, and Radiomics. <i>Diagnostics</i> , 2022, 12, 929.	1.3	11
11372	Dietary <i>Lactobacillus</i> -Derived Exopolysaccharide Enhances Immune-Checkpoint Blockade Therapy. <i>Cancer Discovery</i> , 2022, 12, 1336-1355.	7.7	56
11373	Neoadjuvant Immune Checkpoint Inhibitor Therapy in Melanoma: Efficacy, Safety and Timing. <i>BioDrugs</i> , 2022, 36, 373-380.	2.2	2
11374	Management of Regional Lymph Nodes in Head and Neck Melanoma. <i>Oral and Maxillofacial Surgery Clinics of North America</i> , 2022, , .	0.4	0
11375	A Serendipitous Preoperative Trial of Combined Ipilimumab Plus Nivolumab for Localized Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2022, 20, e173-e179.	0.9	1
11376	Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. <i>Lancet, The</i> , 2022, 399, 1718-1729.	6.3	236
11377	Inhibition of renalase drives tumour rejection by promoting T cell activation. <i>European Journal of Cancer</i> , 2022, 165, 81-96.	1.3	2
11378	Checkpoint Inhibitor Immune-Related Adverse Events: A Multimodality Pictorial Review. <i>Academic Radiology</i> , 2022, 29, 1869-1884.	1.3	3
11379	Discovery of 4-phenylindolines containing a (5-cyanopyridin-3-yl)methoxy moiety as potent inhibitors of the PD-1/PD-L1 interaction. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2022, 63, 128647.	1.0	4
11380	Coagulation and inflammation in cancer: Limitations and prospects for treatment. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2022, 1877, 188727.	3.3	9
11381	Systemic nano-delivery of low-dose STING agonist targeted to CD103+ dendritic cells for cancer immunotherapy. <i>Journal of Controlled Release</i> , 2022, 345, 721-733.	4.8	25
11382	Nanotechnology-based multifunctional vaccines for cancer immunotherapy. <i>Chemical Engineering Journal</i> , 2022, 437, 135505.	6.6	13
11383	Ag nanoparticles enhance immune checkpoint blockade efficacy by promoting of immune surveillance in melanoma. <i>Journal of Colloid and Interface Science</i> , 2022, 616, 189-200.	5.0	14
11384	Anti-CTLA-4 and anti-PD-1 immunotherapies repress tumor progression in preclinical breast and colon model with independent regulatory T cells response. <i>Translational Oncology</i> , 2022, 20, 101405.	1.7	25
11385	Revisiting metallodrugs for the treatment of skin cancers. <i>Coordination Chemistry Reviews</i> , 2022, 462, 214506.	9.5	11
11386	Polymersome-mediated cytosolic delivery of cyclic dinucleotide STING agonist enhances tumor immunotherapy. <i>Bioactive Materials</i> , 2022, 16, 1-11.	8.6	26
11387	Research Trends in Immune Checkpoint Blockade for Melanoma: Visualization and Bibliometric Analysis. <i>Journal of Medical Internet Research</i> , 2022, 24, e32728.	2.1	7
11388	A Model-Based Framework to Identify Optimal Administration Protocols for Immunotherapies in Castration-Resistance Prostate Cancer. <i>Cancers</i> , 2022, 14, 135.	1.7	2

#	ARTICLE	IF	CITATIONS
11389	Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy. , 2021, 9, e003439.		10
11390	Combination of Immune Checkpoint Inhibitors and Liver-Specific Therapies in Liver-Metastatic Uveal Melanoma: Can We Thus Overcome Its High Resistance?. <i>Cancers</i> , 2021, 13, 6390.	1.7	10
11391	Immune Checkpoint Inhibitor Treatment and Ophthalmologist Consultations in Patients with Malignant Melanoma or Lung Cancer—A Nationwide Cohort Study. <i>Cancers</i> , 2022, 14, 49.	1.7	2
11392	Glucocorticoid receptor regulates PD-L1 and MHC-I in pancreatic cancer cells to promote immune evasion and immunotherapy resistance. <i>Nature Communications</i> , 2021, 12, 7041.	5.8	43
11393	Current Immunotherapeutic Strategies Targeting the PD-1/PD-L1 Axis in Non-Small Cell Lung Cancer with Oncogenic Driver Mutations. <i>International Journal of Molecular Sciences</i> , 2022, 23, 245.	1.8	6
11394	Melanoma trials that defined surgical management: Brief overview of current/upcoming adjuvant/neoadjuvant trials. <i>Journal of Surgical Oncology</i> , 2022, 125, 38-45.	0.8	1
11395	Patients'™ Experience of Systemic Treatment of Hepatocellular Carcinoma: A Review of the Impact on Quality of Life. <i>Cancers</i> , 2022, 14, 179.	1.7	5
11396	A Case of Metastatic Sinonasal Mucosal Melanoma Treated with Immunotherapy. <i>Journal of Clinical Otolaryngology</i> , 2021, 32, 265-269.	0.1	0
11397	Phase Ib Study of Atezolizumab Plus Interferon- γ with or without Bevacizumab in Patients with Metastatic Renal Cell Carcinoma and Other Solid Tumors. <i>Current Oncology</i> , 2021, 28, 5466-5479.	0.9	2
11398	Improvement of PD-1 Blockade Efficacy and Elimination of Immune-Related Gastrointestinal Adverse Effect by mTOR Inhibitor. <i>Frontiers in Immunology</i> , 2021, 12, 793831.	2.2	16
11399	Therapeutic advances in non-small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy. <i>MedComm</i> , 2021, 2, 692-729.	3.1	38
11400	Bladder-Sparing Chemoradiotherapy Combined with Immune Checkpoint Inhibition for Locally Advanced Urothelial Bladder Cancer—A Review. <i>Cancers</i> , 2022, 14, 38.	1.7	16
11401	A class of two-sample nonparametric statistics for binary and time-to-event outcomes. <i>Statistical Methods in Medical Research</i> , 2022, 31, 225-239.	0.7	0
11402	Targeting Cross-Presentation as a Route to Improve the Efficiency of Peptide-Based Cancer Vaccines. <i>Cancers</i> , 2021, 13, 6189.	1.7	9
11403	Management of acute kidney injury in gastrointestinal tumor: An overview. <i>World Journal of Clinical Cases</i> , 2021, 9, 10746-10764.	0.3	0
11404	LAG-3 and PD-1 blockade raises the bar for melanoma. <i>Nature Cancer</i> , 2021, 2, 1251-1253.	5.7	20
11405	The importance of establishing genetic phase in clinical medicine. <i>International Journal of Immunogenetics</i> , 2022, 49, 1-7.	0.8	4
11406	The foundations of immune checkpoint blockade and the ipilimumab approval decennial. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 509-528.	21.5	201

#	ARTICLE	IF	CITATIONS
11407	The value of anticancer drugs – a regulatory view. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 207-215.	12.5	14
11408	Treatment patterns and clinical outcomes for patients with melanoma and central nervous system metastases: A real-world study. <i>Cancer Medicine</i> , 2022, 11, 139-150.	1.3	6
11409	Prognostic significance of natural killer cell-associated markers in gastric cancer: quantitative analysis using multiplex immunohistochemistry. <i>Journal of Translational Medicine</i> , 2021, 19, 529.	1.8	8
11410	Neoadjuvant immune checkpoint inhibitors in high-risk stage III melanoma. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-11.	1.4	3
11411	Magnetic nanoparticles in theranostics of malignant melanoma. <i>EJNMMI Research</i> , 2021, 11, 127.	1.1	9
11412	Mucinous adenocarcinoma: A unique clinicopathological subtype in colorectal cancer. <i>World Journal of Gastrointestinal Surgery</i> , 2021, 13, 1567-1583.	0.8	17
11413	Pan-cancer analysis reveals molecular patterns associated with age. <i>Cell Reports</i> , 2021, 37, 110100.	2.9	26
11414	Quantitative imaging biomarkers of immune-related adverse events in immune-checkpoint blockade-treated metastatic melanoma patients: a pilot study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 1857-1869.	3.3	9
11415	Immunotherapy Resistance in Glioblastoma. <i>Frontiers in Genetics</i> , 2021, 12, 750675.	1.1	13
11416	Lymphocyte-activating gene-3 expression is associated with tumor-infiltrating lymphocyte levels in HER2-positive breast cancers. <i>Medicine (United States)</i> , 2021, 100, e28057.	0.4	4
11418	A Promising Treatment Strategy for Lung Cancer: A Combination of Radiotherapy and Immunotherapy. <i>Cancers</i> , 2022, 14, 203.	1.7	7
11419	CRISPR Screens to Identify Regulators of Tumor Immunity. <i>Annual Review of Cancer Biology</i> , 2022, 6, 103-122.	2.3	5
11420	Myocarditis and diaphragmatic rhabdomyolysis with respiratory failure in a patient with metastatic melanoma treated with Nivolumab. <i>Journal of Oncology Pharmacy Practice</i> , 2022, 28, 750-753.	0.5	2
11421	Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review. <i>Frontiers in Immunology</i> , 2021, 12, 775761.	2.2	45
11422	Prognostic Value of an Immune-Related Gene Signature in Oral Squamous Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 776979.	1.3	2
11424	Immunotherapy for Gynaecological Cancers. , 2021, , 503-512.		0
11425	Biological therapies in patients with liver disease: are they really lifesavers?. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 473-490.	1.4	0
11426	Triple negative breast cancer: any closer to cracking the code?. <i>Current Opinion in Obstetrics and Gynecology</i> , 2022, 34, 52-55.	0.9	4

#	ARTICLE	IF	CITATIONS
11427	The Transmembrane Receptor TIRC7 Identifies a Distinct Subset of Immune Cells with Prognostic Implications in Cholangiocarcinoma. <i>Cancers</i> , 2021, 13, 6272.	1.7	1
11428	Assessment of Treatment Effects and Long-term Benefits in Immune Checkpoint Inhibitor Trials Using the Flexible Parametric Cure Model. <i>JAMA Network Open</i> , 2021, 4, e2139573.	2.8	8
11429	Foxp3+ CD4+ regulatory T cells control dendritic cells in inducing antigen-specific immunity to emerging SARS-CoV-2 antigens. <i>PLoS Pathogens</i> , 2021, 17, e1010085.	2.1	13
11430	The spectrum of clinical trials aiming at personalizing medicine. <i>Chinese Clinical Oncology</i> , 2014, 3, 13.	0.4	15
11431	Cross talks between autoimmunity and cancer. , 2022, , 15-49.		0
11432	Cardiac complications of cancer therapies. <i>Advances in Cancer Research</i> , 2022, , 167-214.	1.9	5
11433	Utilization of Immunotherapy in Patients with Cancer Treated in Routine Care Settings: A Population-Based Study Using Health Administrative Data. <i>Oncologist</i> , 2022, 27, 675-684.	1.9	4
11434	Anchoring a Xenogeneic Antigen-Guided Immune Activation System to Tumor Cell Membrane for Solid Tumor Treatment. <i>Advanced Functional Materials</i> , 0, , 2111499.	7.8	5
11435	Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 2657-2668.	3.2	4
11436	Recent developments in cancer therapy: A brief journey during the last 12 years. <i>Indian Journal of Pharmacy and Pharmacology</i> , 2022, 9, 1-2.	0.1	0
11437	The interferon-stimulated gene RIPK1 regulates cancer cell intrinsic and extrinsic resistance to immune checkpoint blockade. <i>Immunity</i> , 2022, 55, 671-685.e10.	6.6	35
11438	The Role of Myeloid Cells in Hepatotoxicity Related to Cancer Immunotherapy. <i>Cancers</i> , 2022, 14, 1913.	1.7	7
11439	A clinical study of genetic testing to guide the dosing of warfarin after heart valve replacement. <i>BMC Cardiovascular Disorders</i> , 2022, 22, 183.	0.7	0
11440	Lymph node-targeted neoantigen nanovaccines potentiate anti-tumor immune responses of post-surgical melanoma. <i>Journal of Nanobiotechnology</i> , 2022, 20, 190.	4.2	25
11441	Mechanisms of Immunotherapy Resistance in Cutaneous Melanoma: Recognizing a Shapeshifter. <i>Frontiers in Oncology</i> , 2022, 12, 880876.	1.3	21
11442	Emerging therapies for glioblastoma: current state and future directions. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 142.	3.5	103
11443	The soluble form of CD160 acts as a tumor mediator of immune escape in melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2731-2742.	2.0	6
11444	Skin Cancer Management: Current Scenario And Future Perspectives. <i>Current Drug Safety</i> , 2023, 18, 143-158.	0.3	1

#	ARTICLE	IF	CITATIONS
11445	Immune Checkpoint Inhibitors as Therapy to Down-Stage Hepatocellular Carcinoma Prior to Liver Transplantation. <i>Cancers</i> , 2022, 14, 2056.	1.7	24
11446	Unleashing Cell-Intrinsic Inflammation as a Strategy to Kill AML Blasts. <i>Cancer Discovery</i> , 2022, 12, 1760-1781.	7.7	15
11448	The impact of an immuno-oncology service at a regional cancer centre based in the north west of the UK. <i>British Journal of Nursing</i> , 2022, 31, 414-420.	0.3	0
11449	Phase I study of [131I] ICF01012, a targeted radionuclide therapy, in metastatic melanoma: MELRIV-1 protocol. <i>BMC Cancer</i> , 2022, 22, 417.	1.1	5
11450	Neurological Toxic Effects Associated With Treatment With Immune Checkpoint Inhibitors—Are We Really Safer Now?. <i>JAMA Network Open</i> , 2022, 5, e227731.	2.8	0
11451	Emerging role of RNA sensors in tumor microenvironment and immunotherapy. <i>Journal of Hematology and Oncology</i> , 2022, 15, 43.	6.9	11
11452	Association of Immune Checkpoint Inhibitors With Neurologic Adverse Events. <i>JAMA Network Open</i> , 2022, 5, e227722.	2.8	25
11453	Immune-Related Adverse Events (irAEs) in Cancer, with Inputs from a Nursing Expert: A Review. <i>Indian Journal of Medical and Paediatric Oncology</i> , 0, 43, .	0.1	0
11454	Brain radiotherapy, tremelimumab-mediated CTLA-4-directed blockade +/and~ trastuzumab in patients with breast cancer brain metastases. <i>Npj Breast Cancer</i> , 2022, 8, 50.	2.3	17
11455	High Levels of Circulating Monocytic Myeloid-Derived Suppressive-Like Cells Are Associated With the Primary Resistance to Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: An Exploratory Analysis. <i>Frontiers in Immunology</i> , 2022, 13, 866561.	2.2	15
11456	A Review of the Effects of Cervical Cancer Standard Treatment on Immune Parameters in Peripheral Blood, Tumor Draining Lymph Nodes, and Local Tumor Microenvironment. <i>Journal of Clinical Medicine</i> , 2022, 11, 2277.	1.0	5
11458	Spoiled for Choice: Do We Finally Have Clarity on Optimal Treatment Sequencing for Patients with Metastatic Melanoma Harboring an Actionable BRAF Mutation?. <i>Annals of Surgical Oncology</i> , 2022, , .	0.7	0
11559	Direct and indirect regulation of the tumor immune microenvironment by VEGF. <i>Journal of Leukocyte Biology</i> , 2022, 111, 1269-1286.	1.5	28
11560	Incidence of hepatotoxicity associated with addition of immune checkpoint blockade to systemic solid tumor therapy: a meta-analysis of phase 3 randomized controlled trials. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2837-2848.	2.0	5
11561	Transcriptional and post-transcriptional regulation of checkpoint genes on the tumour side of the immunological synapse. <i>Heredity</i> , 2022, 129, 64-74.	1.2	4
11562	Characterization of anticancer drug resistance by reverse-phase protein array: new targets and strategies. <i>Expert Review of Proteomics</i> , 2022, 19, 115-129.	1.3	3
11563	Promoting antibody-dependent cellular phagocytosis for effective macrophage-based cancer immunotherapy. <i>Science Advances</i> , 2022, 8, eabl9171.	4.7	30
11564	Neoantigen Identification and Response to Adoptive Cell Transfer in Anti-“PD-1 Na~ve and Experienced Patients with Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2022, 28, 3042-3052.	3.2	18

#	ARTICLE	IF	CITATIONS
11566	Effects of tumor derived exosomes on T cells markers expression. Brazilian Journal of Biology, 2022, 84, e250556.	0.4	1
11567	Efficacy and safety of nivolumab in metastatic melanoma: real-world practice. European Journal of Dermatology, 2019, 29, 315-321.	0.3	14
11568	Adjuvant therapy for resected stage III melanoma patients: high-dose interferon-alpha versus ipilimumab combined with kinases inhibitors. Tumori, 2012, 98, 185-90.	0.6	5
11569	The economic crisis and cancer chemotherapy: the role of the oncologist. Tumori, 2012, 98, 532-3.	0.6	2
11570	Metastatic melanoma: a regional review and future directions. Tumori, 2012, 98, 575-80.	0.6	12
11573	Phase Ib study on the humanized anti-CCR4 antibody, KW-0761, in advanced solid tumors.. Nagoya Journal of Medical Science, 2021, 83, 827-840.	0.6	6
11574	Developing and characterizing a single-domain antibody (nanobody) against human cytotoxic T-lymphocyte-associated protein 4 (hCTLA-4).. Iranian Journal of Basic Medical Sciences, 2021, 24, 1264-1271.	1.0	0
11575	Real Life Clinical Management and Survival in Advanced Cutaneous Melanoma: The Italian Clinical National Melanoma Registry Experience. Frontiers in Oncology, 2021, 11, 672797.	1.3	8
11586	Algorithm for the management of metastatic cutaneous melanoma. Chinese Clinical Oncology, 2014, 3, 32.	0.4	1
11587	Checkpoint inhibitors in treatment of metastatic mucosal melanoma. Chinese Clinical Oncology, 2014, 3, 37.	0.4	6
11588	Toxicity of checkpoint inhibitors. Chinese Clinical Oncology, 2014, 3, 31.	0.4	12
11592	Increased psychomotor retardation and tension as short-term neuropsychiatric adverse events of immune checkpoint inhibitors. Journal of Cancer Research and Therapeutics, 2022, 18, 140-146.	0.3	2
11594	Case Report: Primary Duodenal Melanoma with Brain Metastasis. , 2021, 25, 1-5.		2
11596	Melanoma: An immunotherapy journey from bench to bedside. Cancer Treatment and Research, 2022, 183, 49-89.	0.2	0
11597	A Biomathematical Model of Tumor Response to Radioimmunotherapy With $\hat{I}\pm$ PDL1 and $\hat{I}\pm$ CTLA4. IEEE/ACM Transactions on Computational Biology and Bioinformatics, 2023, 20, 808-821.	1.9	3
11598	Immune-Based Therapeutic Interventions for Acute Myeloid Leukemia. Cancer Treatment and Research, 2022, 183, 225-254.	0.2	6
11600	Immune escape mechanisms and therapeutic approaches in cancer: the cancer-immunity cycle. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592210962.	1.4	21
11601	HLA Class I Downregulation in Progressing Metastases of Melanoma Patients Treated With Ipilimumab. Pathology and Oncology Research, 2022, 28, 1610297.	0.9	5

#	ARTICLE	IF	CITATIONS
11602	Gastrointestinal Toxicities of Immune Checkpoint Inhibitors Are Associated With Enhanced Tumor Responsiveness and Improved Survival. <i>Gastroenterology Research</i> , 2022, 15, 56-66.	0.4	2
11603	Translating Molecules into Imaging—The Development of New PET Tracers for Patients with Melanoma. <i>Diagnostics</i> , 2022, 12, 1116.	1.3	7
11604	Tumour burden score and immune-related hepatotoxicity in patients with hepatocellular carcinoma or liver metastases treated with immune checkpoint inhibitors. <i>Liver Cancer International</i> , 0, , .	0.2	0
11605	Transcriptional profiling of macrophages in situ in metastatic melanoma reveals localization-dependent phenotypes and function. <i>Cell Reports Medicine</i> , 2022, 3, 100621.	3.3	15
11606	Retreatment With Immune Checkpoint Inhibitors After a Severe Immune-Related Hepatitis: Results From a Prospective Multicenter Study. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 732-740.	2.4	19
11607	Functionalization of Nanomaterials for Skin Cancer Theranostics. <i>Frontiers in Bioengineering and Biotechnology</i> , 2022, 10, 887548.	2.0	1
11608	Clinical Combinatorial Treatments Based on Cancer Vaccines: Combination with Checkpoint Inhibitors and Beyond. <i>Current Drug Targets</i> , 2022, 23, .	1.0	1
11609	Hematological and Extra-Hematological Autoimmune Complications after Checkpoint Inhibitors. <i>Pharmaceuticals</i> , 2022, 15, 557.	1.7	3
11610	In vivo labeling reveals continuous trafficking of TCF-1+ T cells between tumor and lymphoid tissue. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	42
11611	Immune Checkpoint Inhibitors in Cancer Therapy. <i>Current Oncology</i> , 2022, 29, 3044-3060.	0.9	239
11612	HLA-DR Presentation of the Tumor Antigen MSLN Associates with Clinical Outcome of Ovarian Cancer Patients. <i>Cancers</i> , 2022, 14, 2260.	1.7	5
11613	The cure from within? a review of the microbiome and diet in melanoma. <i>Cancer and Metastasis Reviews</i> , 2022, 41, 261-280.	2.7	8
11614	Novel Al ¹⁸ F-NOTA-Conjugated Lactam-Cyclized \pm -Melanocyte-Stimulating Hormone Peptides with Enhanced Melanoma Uptake. <i>Bioconjugate Chemistry</i> , 2022, 33, 982-990.	1.8	1
11615	Novel ⁶⁴ Cu-Labeled NOTA-Conjugated Lactam-Cyclized Alpha-Melanocyte-Stimulating Hormone Peptides with Enhanced Tumor to Kidney Uptake Ratios. <i>Molecular Pharmaceutics</i> , 2022, 19, 2535-2541.	2.3	6
11616	What Zebrafish and Nanotechnology Can Offer for Cancer Treatments in the Age of Personalized Medicine. <i>Cancers</i> , 2022, 14, 2238.	1.7	6
11617	Resistance Mechanisms to Anti-PD Cancer Immunotherapy. <i>Annual Review of Immunology</i> , 2022, 40, 45-74.	9.5	122
11618	CSF2RB Is a Unique Biomarker and Correlated With Immune Infiltrates in Lung Adenocarcinoma. <i>Frontiers in Oncology</i> , 2022, 12, 822849.	1.3	7
11619	NeoSplice: a bioinformatics method for prediction of splice variant neoantigens. <i>Bioinformatics Advances</i> , 2022, 2, .	0.9	13

#	ARTICLE	IF	CITATIONS
11620	Advanced materials for management of immune-related adverse events induced by immune checkpoint inhibitors. <i>Materials and Design</i> , 2022, 219, 110738.	3.3	0
11621	A Conceptual Framework for Inducing T Cell-Mediated Immunity Against Glioblastoma. <i>Seminars in Immunopathology</i> , 2022, 44, 697-707.	2.8	5
11622	Immune checkpoint inhibition in patients with inactive pre-existing neuromuscular autoimmune diseases. <i>Journal of the Neurological Sciences</i> , 2022, 438, 120275.	0.3	5
11623	Adjuvant and Neoadjuvant Therapies in Cutaneous Melanoma. <i>Oral and Maxillofacial Surgery Clinics of North America</i> , 2022, 34, 315-324.	0.4	2
11624	MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer. <i>Future Oncology</i> , 2022, 18, 2465-2473.	1.1	40
11625	CAR-T Therapy for Pediatric High-Grade Gliomas: Peculiarities, Current Investigations and Future Strategies. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	9
11626	Comparative Efficacy and Safety of Anti-PD-1/PD-L1 for the Treatment of Non-Small Cell Lung Cancer: A Network Meta-Analysis of 13 Randomized Controlled Studies. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	2
11627	Hematological Prognostic Scoring System Can Predict Overall Survival and Can Indicate Response to Immunotherapy in Patients With Osteosarcoma. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	3
11628	Tumor-Associated Macrophages Regulate PD-1/PD-L1 Immunosuppression. <i>Frontiers in Immunology</i> , 2022, 13, 874589.	2.2	71
11629	Therapeutic Effects of Cold Atmospheric Plasma on Solid Tumor. <i>Frontiers in Medicine</i> , 2022, 9, .	1.2	13
11630	Can Natural Products be Used to Overcome the Limitations of Colorectal Cancer Immunotherapy?. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	1
11631	Neoadjuvant chemoradiation alters the immune microenvironment in pancreatic ductal adenocarcinoma. <i>Oncolmmunology</i> , 2022, 11, 2066767.	2.1	9
11632	CAD v1.0: Cancer Antigens Database Platform for Cancer Antigen Algorithm Development and Information Exploration. <i>Frontiers in Bioengineering and Biotechnology</i> , 2022, 10, .	2.0	2
11633	Nanomaterials in cancer: Reviewing the combination of hyperthermia and triggered chemotherapy. <i>Journal of Controlled Release</i> , 2022, 347, 89-103.	4.8	20
11634	Engineered bacterial membrane vesicles are promising carriers for vaccine design and tumor immunotherapy. <i>Advanced Drug Delivery Reviews</i> , 2022, 186, 114321.	6.6	36
11635	CD39 â€“ A bright target for cancer immunotherapy. <i>Biomedicine and Pharmacotherapy</i> , 2022, 151, 113066.	2.5	20
11636	The Role of Surgery in the Treatment of Melanoma Pulmonary Metastases in the Modern Era. <i>Journal of Surgical Research</i> , 2022, 277, 125-130.	0.8	1
11637	The future of targeted kinase inhibitors in melanoma. , 2022, 239, 108200.		17

#	ARTICLE	IF	CITATIONS
11638	New opportunities of immunocorrection in complex treatment of cervical cancer patients. Russian Journal of Immunology: RJl: Official Journal of Russian Society of Immunology, 2021, 24, 115-122.	0.2	1
11639	Meta-Analysis of Efficacy From CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients. Frontiers in Oncology, 2022, 12, 876098.	1.3	2
11640	Adoptive Cell Transfer and Vaccines in Melanoma: The Horizon Comes Into View. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, 42, 730-737.	1.8	1
11641	Single agent Talimogene Laherparepvec for stage IIIB-IVM1c melanoma patients: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2022, 175, 103705.	2.0	3
11642	Association of the gut microbiome with cancer immunotherapy. International Journal of Clinical Oncology, 2022, , 1.	1.0	0
11644	FLG Is a Potential Biomarker of Prognosis and Immunotherapy in Skin Cutaneous Melanoma. Applied Bionics and Biomechanics, 2022, 2022, 1-11.	0.5	3
11645	Incidence of fatigue associated with immune checkpoint inhibitors in patients with cancer: a meta-analysis. ESMO Open, 2022, 7, 100474.	2.0	3
11647	Systemic anticancer agents. , 2013, , 397-407.e2.		1
11648	Crosstalk of Immuno-Oncology and Metabolism: Influence of Akkermansia muciniphila and Personalized Therapy Approach. , 2022, , 91-115.		1
11650	Fueling Cancer Vaccines to Improve T Cell-Mediated Antitumor Immunity. Frontiers in Oncology, 2022, 12, .	1.3	4
11651	Cancer vaccines: past, present and future; a review article. Discover Oncology, 2022, 13, 31.	0.8	24
11652	Evolution of Medical Approaches and Prominent Therapies in Breast Cancer. Cancers, 2022, 14, 2450.	1.7	4
11653	Risk factors for pneumonitis in advanced extrapulmonary cancer patients treated with immune checkpoint inhibitors. BMC Cancer, 2022, 22, 551.	1.1	4
11654	Re-introduction of T-VEC Monotherapy in Recurrent Melanoma is Effective. Journal of Immunotherapy, 2022, Publish Ahead of Print, .	1.2	1
11655	Artificial intelligence for the prevention and clinical management of hepatocellular carcinoma. Journal of Hepatology, 2022, 76, 1348-1361.	1.8	75
11656	Role of radiomics in predicting immunotherapy response. Journal of Medical Imaging and Radiation Oncology, 2022, 66, 575-591.	0.9	10
11657	CD4 ⁺ T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy. , 2022, 10, e004022.		7
11658	Paired primary and metastatic lesions of patients with ipilimumab-treated melanoma: high variation in lymphocyte infiltration and HLA-ABC expression whereas tumor mutational load is similar and correlates with clinical outcome. , 2022, 10, e004329.		15

#	ARTICLE	IF	CITATIONS
11659	Cancer Immunoediting in the Era of Immuno-oncology. <i>Clinical Cancer Research</i> , 2022, 28, 3917-3928.	3.2	31
11660	Checkpoint Immunotherapy in Pediatrics: Here, Gone, and Back Again. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, 42, 781-794.	1.8	10
11661	An analysis report on the application of immune checkpoint inhibitors after liver transplantation. <i>Therapeutic Advances in Chronic Disease</i> , 2022, 13, 204062232210993.	1.1	3
11663	Changing the Drug Development and Therapeutic Paradigm with Biologic Drug Combinations and Bispecifics: How to Choose Between These Two Approaches?. <i>Clinical and Translational Science</i> , 0, , .	1.5	2
11665	A single local delivery of paclitaxel and nucleic acids via an immunoreactive polymer eliminates tumors and induces antitumor immunity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	10
11666	Management of immune-related hepatitis in patients being treated with checkpoint inhibitors for metastatic melanoma, a review and case series. <i>Journal of Oncology Pharmacy Practice</i> , 2023, 29, 1163-1171.	0.5	3
11667	Tumor-induced erythroid precursor-differentiated myeloid cells mediate immunosuppression and curtail anti-PD-1/PD-L1 treatment efficacy. <i>Cancer Cell</i> , 2022, 40, 674-693.e7.	7.7	41
11668	Durable and dynamic hTERT immune responses following vaccination with the long-peptide cancer vaccine UVI: long-term follow-up of three phase I clinical trials. , 2022, 10, e004345.		15
11669	The efficacy of immune checkpoint blockade for melanoma in-transit with or without nodal metastases – A multicenter cohort study. <i>European Journal of Cancer</i> , 2022, 169, 210-222.	1.3	12
11670	Oncolytic virus delivery modulated immune responses toward cancer therapy: Challenges and perspectives. <i>International Immunopharmacology</i> , 2022, 108, 108882.	1.7	12
11671	Managing antibody stability: Effects of stressors on Ipilimumab from the commercial formulation to diluted solutions. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2022, 176, 54-74.	2.0	3
11672	Anticalin®-based therapeutics: Expanding new frontiers in drug development. <i>International Review of Cell and Molecular Biology</i> , 2022, , 89-106.	1.6	3
11673	Transcriptomic datasets of cancer patients treated with immune-checkpoint inhibitors: a systematic review. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	27
11674	Comprehensive Evaluation of Anti-PD-1, Anti-PD-L1, Anti-CTLA-4 and Their Combined Immunotherapy in Clinical Trials: A Systematic Review and Meta-analysis. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	12
11675	Cancer Vaccination against Extracellular Vimentin Efficiently Adjuvanted with Montanide ISA 720/CpG. <i>Cancers</i> , 2022, 14, 2593.	1.7	5
11676	mTOR pathway gene mutations predict response to immune checkpoint inhibitors in multiple cancers. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	9
11677	Adverse effects under immune checkpoint inhibitors on [18F]FDG PET/CT imaging. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 66, .	0.4	7
11679	Tissue-Resident Innate Immune Cell-Based Therapy: A Cornerstone of Immunotherapy Strategies for Cancer Treatment. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, .	1.8	5

#	ARTICLE	IF	CITATIONS
11680	Overview of Checkpoint Inhibitors Mechanism of Action: Role of Immune-Related Adverse Events and Their Treatment on Progression of Underlying Cancer. <i>Frontiers in Medicine</i> , 2022, 9, .	1.2	19
11681	Immunotherapy toxicities: An SGO clinical practice statement. <i>Gynecologic Oncology</i> , 2022, , .	0.6	1
11682	Impact of acetaminophen on the efficacy of immunotherapy in cancer patients. <i>Annals of Oncology</i> , 2022, 33, 909-915.	0.6	21
11683	European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022. <i>European Journal of Cancer</i> , 2022, 170, 256-284.	1.3	92
11684	Versatile tests for window mean survival time. <i>Statistics in Medicine</i> , 0, , .	0.8	2
11685	Immune checkpoint inhibitor toxicity and associated outcomes in older patients with cancer. <i>Journal of Geriatric Oncology</i> , 2022, 13, 1011-1016.	0.5	1
11686	Advanced biomaterials for cancer theranostic. <i>International Journal of Health Sciences</i> , 0, , 8670-8677.	0.0	0
11687	Peptide vaccine-treated, long-term surviving cancer patients harbor self-renewing tumor-specific CD8+ T cells. <i>Nature Communications</i> , 2022, 13, .	5.8	8
11688	Immune-related adverse events in older adults: Data mining of the FDA Adverse Event Reporting System. <i>Journal of Geriatric Oncology</i> , 2022, , .	0.5	2
11689	Association of age with survival in older patients with cutaneous melanoma treated with immune checkpoint inhibitors. <i>Journal of Geriatric Oncology</i> , 2022, 13, 1003-1010.	0.5	2
11690	Immunotherapy and Antivascular Targeted Therapy in Patientsâ€™ Treatment with Concurrent Malignant Tumors after Organ Transplantation: Opportunity or Challenge. <i>Journal of Immunology Research</i> , 2022, 2022, 1-13.	0.9	0
11691	Neoadjuvant immunotherapy in gastrointestinal cancers â€“ The new standard of care?. <i>Seminars in Cancer Biology</i> , 2022, 86, 834-850.	4.3	12
11692	Cancer therapeutic drug guide. , 2023, , 451-506.		0
11695	Progress in the Treatment of Advanced Melanoma. <i>Advances in Clinical Medicine</i> , 2022, 12, 5256-5262.	0.0	0
11697	A Brief Introduction to Current Cancer Gene Therapy. <i>Methods in Molecular Biology</i> , 2022, , 1-21.	0.4	3
11698	Rheumatoid Arthritis Symptoms Diagnosed by Rheumatic Immune-related Adverse Events Caused by Nivolumab in a Patient with Esophageal Cancer: A Case Report. <i>Internal Medicine</i> , 2022, , .	0.3	1
11699	Generation of molecular-targeting helix-loop-helix peptides for inhibition of the interaction between cytotoxic T-lymphocyte-associated protein 4 and B7 in the dog. <i>Journal of Veterinary Medical Science</i> , 2022, 84, 1101-1107.	0.3	0
11701	Safety, activity, and pharmacokinetics of camrelizumab in advanced Asian melanoma patients: a phase I study. <i>BMC Cancer</i> , 2022, 22, .	1.1	4

#	ARTICLE	IF	CITATIONS
11702	Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with CTLA-4 or TIM-3 blockade. , 2022, 10, e004762.		19
11703	Ultrasensitive Fibroblast Activation Protein-Î±-Activated Fluorogenic Probe Enables Selective Imaging and Killing of Melanoma <i>In Vivo</i>. ACS Sensors, 2022, 7, 1837-1846.	4.0	4
11704	Diabetes and cancer: Optimising glycaemic control. Journal of Human Nutrition and Dietetics, 2023, 36, 504-513.	1.3	3
11705	Recent Advances and Challenges in Uveal Melanoma Immunotherapy. Cancers, 2022, 14, 3094.	1.7	23
11706	Tumor metabolite lactate promotes tumorigenesis by modulating MOESIN lactylation and enhancing TGF-Î² signaling in regulatory T cells. Cell Reports, 2022, 39, 110986.	2.9	82
11707	The advanced development of molecular targeted therapy for hepatocellular carcinoma. Cancer Biology and Medicine, 2022, 19, 1-16.	1.4	18
11708	Exonuclease 1 is a Potential Diagnostic and Prognostic Biomarker in Hepatocellular Carcinoma. Frontiers in Molecular Biosciences, 0, 9, .	1.6	5
11709	Review of the Clinical Pharmacokinetics, Efficacy and Safety of Pembrolizumab. Current Drug Metabolism, 2022, 23, 460-472.	0.7	6
11710	Current Status and Future Directions of Bacteria-Based Immunotherapy. Frontiers in Immunology, 0, 13, .	2.2	7
11711	Radiopharmaceuticals as Novel Immune System Tracers. Advances in Radiation Oncology, 2022, , 100936.	0.6	1
11712	Emerging Management Approach for the Adverse Events of Immunotherapy of Cancer. Molecules, 2022, 27, 3798.	1.7	29
11714	Virus-Based Immuno-Oncology Models. Biomedicines, 2022, 10, 1441.	1.4	4
11715	Immunological Responses to Cancer Therapy. International Journal of Molecular Sciences, 2022, 23, 6989.	1.8	0
11716	A Safety Analysis of Programmed Death 1 Pathway Inhibitors in Patients With Solid Tumor Malignancies and Preexisting Autoimmune Disease. Journal of Clinical Rheumatology, 2022, 28, 338-345.	0.5	2
11717	Immune Checkpoint Inhibitor-Associated Myositis. Journal of Clinical Rheumatology, 2022, 28, 367-373.	0.5	8
11718	Value of a Signature of Immune-Related Genes in Predicting the Prognosis of Melanoma and Its Responses to Immune Checkpoint Blocker Therapies. Computational and Mathematical Methods in Medicine, 2022, 2022, 1-13.	0.7	3
11719	Role of Adenoviruses in Cancer Therapy. Frontiers in Oncology, 0, 12, .	1.3	6
11720	First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2022, 28, 3452-3463.	3.2	21

#	ARTICLE	IF	CITATIONS
11722	Obesity and adipose tissue impact on T-cell response and cancer immune checkpoint blockade therapy. <i>Immunotherapy Advances</i> , 2022, 2, .	1.2	5
11723	Clinical Manifestations, Monitoring, and Prognosis: A Review of Cardiotoxicity After Antitumor Strategy. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	7
11724	Challenging Dermatologic Considerations Associated with Immune Checkpoint Inhibitors. <i>American Journal of Clinical Dermatology</i> , 0, , .	3.3	3
11725	CD8+ α Lymphocyte Infiltration Is a Specific Feature of Colitis Induced by Immune Checkpoint Inhibitors. <i>Digestive Diseases and Sciences</i> , 2023, 68, 451-459.	1.1	5
11726	Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 529-540.	21.5	134
11727	Distinguishable Prognostic Signatures and Tumor Immunogenicity Between Pancreatic Head Cancer and Pancreatic Body/Tail Cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
11728	Intratumoural administration of an NKT cell agonist with CpG promotes NKT cell infiltration associated with an enhanced antitumour response and abscopal effect. <i>Oncolmunology</i> , 2022, 11, .	2.1	7
11729	Narrative Review of Synergistics Effects of Combining Immunotherapy and Stereotactic Radiation Therapy. <i>Biomedicines</i> , 2022, 10, 1414.	1.4	4
11730	Clinical evidence for synergy between immunotherapy and radiotherapy (<scp>SITAR</scp>). <i>Journal of Medical Imaging and Radiation Oncology</i> , 2022, 66, 881-895.	0.9	9
11731	Adjuvant Treatments of Adult Melanoma: A Systematic Review and Network Meta-Analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
11732	Molecular and Clinical Characterization of CD80 Expression via Large-Scale Analysis in Breast Cancer. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	0
11733	Immunotherapy for advanced hepatocellular carcinoma: From clinical trials to real-world data and future advances. <i>World Journal of Clinical Oncology</i> , 2022, 13, 448-472.	0.9	6
11734	Cancer treatment and survivorship statistics, 2022. <i>Ca-A Cancer Journal for Clinicians</i> , 2022, 72, 409-436.	157.7	897
11736	Immune Cell Networks Uncover Candidate Biomarkers of Melanoma Immunotherapy Response. <i>Journal of Personalized Medicine</i> , 2022, 12, 958.	1.1	0
11737	Turning a Targeting \hat{I}^2 -Catenin/Bcl9 Peptide Inhibitor into a GdOF@Au Core/Shell Nanoflower for Enhancing Immune Response to Cancer Therapy in Combination with Immune Checkpoint Inhibitors. <i>Pharmaceutics</i> , 2022, 14, 1306.	2.0	1
11738	CTLA-4: As an Immunosuppressive Immune Checkpoint in Breast Cancer. <i>Current Molecular Medicine</i> , 2023, 23, 521-526.	0.6	3
11739	Ursodeoxycholic acid reduces antitumor immunosuppression by inducing CHIP-mediated TGF- \hat{I}^2 degradation. <i>Nature Communications</i> , 2022, 13, .	5.8	26
11740	Early-stage Breast Cancer: Tailored External Beam Fractionation Approaches for Treatment of the Whole or Partial Breast. <i>Seminars in Radiation Oncology</i> , 2022, 32, 245-253.	1.0	1

#	ARTICLE	IF	CITATIONS
11741	Tumour-draining lymph nodes in head and neck cancer are characterized by accumulation of CTLA-4 and PD-1 expressing Treg cells. <i>Translational Oncology</i> , 2022, 23, 101469.	1.7	6
11744	Vaginal Malignant Melanoma: Case Report and Review of the Literature. <i>European Journal of Case Reports in Internal Medicine</i> , 0, , .	0.2	2
11745	Lack of Efficacy of Immune Checkpoint Inhibitors in Cancer Patients Older Than 75?. <i>Journal of Immunotherapy</i> , 0, Publish Ahead of Print, .	1.2	0
11746	Immunotherapy of Metastatic Melanoma. , 0, , .		0
11747	Immune-Mediated Hepatitis During Immune Checkpoint Inhibitor cancer Immunotherapy: Lessons From Autoimmune Hepatitis and Liver Immunology. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	16
11748	Bacterial Cellulose as Drug Delivery System for Optimizing Release of Immune Checkpoint Blocking Antibodies. <i>Pharmaceutics</i> , 2022, 14, 1351.	2.0	8
11749	Clinical outcomes of PD-1/PD-L1 inhibitors in patients with advanced hepatocellular carcinoma: a systematic review and meta-analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 969-978.	1.2	9
11750	Comparison of the Effectiveness of IgG Antibody versus F(ab ϵ ²) Antibody Fragment in CTLA4-Targeted Near-Infrared Photoimmunotherapy. <i>Molecular Pharmaceutics</i> , 2022, 19, 3600-3611.	2.3	1
11752	Therapeutic targeting of regulatory T cells in cancer. <i>Trends in Cancer</i> , 2022, 8, 944-961.	3.8	44
11753	Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Psoriasis: A Systematic Review and Meta-Analysis of Observational Studies. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
11754	Aggressive Stereotactic Radiosurgery Coupled With Immune and Targeted Therapy for Recurrent Melanoma Brain Metastases: A Case Report and Literature Review. <i>Cureus</i> , 2022, , .	0.2	0
11755	Preclinical development of a vaccine-based immunotherapy regimen (VBIR) that induces potent and durable T cell responses to tumor-associated self-antigens. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 287-300.	2.0	3
11756	Multi-modal molecular programs regulate melanoma cell state. <i>Nature Communications</i> , 2022, 13, .	5.8	9
11757	Insights Into the Host Contribution of Endocrine Associated Immune-Related Adverse Events to Immune Checkpoint Inhibition Therapy. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	9
11758	The Value of Histopathological Characteristics and BRAF and NRAS Mutations for the Diagnosis, Risk Stratification, and Prognosis of Malignant Invasive Melanoma. , 0, , .		0
11759	Deciphering Prognostic Value of TTN and Its Correlation With Immune Infiltration in Lung Adenocarcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
11760	Systematic evaluation of the predictive gene expression signatures of immune checkpoint inhibitors in metastatic melanoma. <i>Molecular Carcinogenesis</i> , 0, , .	1.3	8
11761	CCDC69 is a prognostic marker of breast cancer and correlates with tumor immune cell infiltration. <i>Frontiers in Surgery</i> , 0, 9, .	0.6	6

#	ARTICLE	IF	CITATIONS
11762	Identification of Endoplasmic Reticulum Stress-Related Subtypes, Infiltration Analysis of Tumor Microenvironment, and Construction of a Prognostic Model in Colorectal Cancer. <i>Cancers</i> , 2022, 14, 3326.	1.7	2
11763	Immune Checkpoint Inhibitors: The Unexplored Landscape of Geriatric Oncology. <i>Oncologist</i> , 2022, 27, 778-789.	1.9	2
11764	Clinical activity of checkpoint inhibitors in angiosarcoma: A retrospective cohort study. <i>Cancer</i> , 2022, 128, 3383-3391.	2.0	9
11765	Risk factors and predictors of immune-related adverse events: implications for patients with non-small cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 861-874.	1.1	6
11766	Dynamics of Melanoma-Associated Epitope-Specific CD8+ T Cells in the Blood Correlate With Clinical Outcome Under PD-1 Blockade. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
11767	Changes of Immune Cell Fractions in Patients Treated with Immune Checkpoint Inhibitors. <i>Cancers</i> , 2022, 14, 3440.	1.7	1
11768	DOCK4 as a Potential Biomarker Associated with Immune Infiltration in Stomach Adenocarcinoma: A Database Analysis. <i>International Journal of General Medicine</i> , 0, Volume 15, 6127-6143.	0.8	1
11769	The increasing role of abdominal metastasectomy for malignant melanoma in the era of modern therapeutics. <i>Surgical Oncology</i> , 2022, 44, 101808.	0.8	1
11770	Intratumoral administration of pro-inflammatory allogeneic dendritic cells improved the anti-tumor response of systemic anti-CTLA-4 treatment via unleashing a T cell-dependent response. <i>Oncolimmunology</i> , 2022, 11, .	2.1	5
11771	Immune checkpoint inhibitor therapy for malignant tumors in liver transplantation recipients: A systematic review of the literature. <i>Transplantation Reviews</i> , 2022, 36, 100712.	1.2	5
11772	Interaction of immune checkpoint PD-1 and chemokine receptor 4 (CXCR4) promotes a malignant phenotype in pancreatic cancer cells. <i>PLoS ONE</i> , 2022, 17, e0270832.	1.1	4
11773	Precision cancer sono-immunotherapy using deep-tissue activatable semiconducting polymer immunomodulatory nanoparticles. <i>Nature Communications</i> , 2022, 13, .	5.8	70
11774	Validation of the Optimum Timing of Assessment of Tumor Infiltrating Lymphocytes During Preoperative Chemotherapy for Breast Cancer. <i>Cancer Diagnosis & Prognosis</i> , 2022, 2, 443-451.	0.3	0
11775	International Multicenter Study of Clinical Outcomes of Sinonasal Melanoma Shows Survival Benefit for Patients Treated with Immune Checkpoint Inhibitors and Potential Improvements to the Current TNM Staging System. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2023, 84, 307-319.	0.4	10
11776	Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trial. <i>Lancet Oncology</i> , The, 2022, 23, 1009-1020.	5.1	44
11777	Improving the efficacy of immunotherapy in small cell lung cancer: Leveraging recent scientific discoveries and tumor-specific antigens. <i>Seminars in Oncology</i> , 2022, , .	0.8	0
11778	Mixed Response to Cancer Immunotherapy is Driven by Intratumor Heterogeneity and Differential Interlesion Immune Infiltration. <i>Cancer Research Communications</i> , 2022, 2, 739-753.	0.7	2
11779	Patients deriving long-term benefit from immune checkpoint inhibitors demonstrate conserved patterns of site-specific mutations. <i>Scientific Reports</i> , 2022, 12, .	1.6	2

#	ARTICLE	IF	CITATIONS
11780	Local delivery of low-dose anti-CTLA-4 to the melanoma lymphatic basin leads to systemic T cell reduction and effector T cell activation. <i>Science Immunology</i> , 2022, 7, .	5.6	18
11781	Normalization of tumor vasculature: A potential strategy to increase the efficiency of immune checkpoint blockades in cancers. <i>International Immunopharmacology</i> , 2022, 110, 108968.	1.7	2
11782	Primary anorectal malignant melanoma: rare but highly lethal malignancy. <i>Turkish Journal of Medical Sciences</i> , 0, , .	0.4	0
11783	The Challenges of Novel Therapies in the Care of the Critically Ill Cancer Patient. , 2023, , 448-458.		0
11785	The gut microbiome, immune check point inhibition and immune-related adverse events in non-small cell lung cancer. <i>Cancer and Metastasis Reviews</i> , 2022, 41, 347-366.	2.7	11
11786	Comprehensive Analysis of HMCN1 Somatic Mutation in Clear Cell Renal Cell Carcinoma. <i>Genes</i> , 2022, 13, 1282.	1.0	2
11787	The Role of Tumor Microenvironment and Immune Response in Colorectal Cancer Development and Prognosis. <i>Pathology and Oncology Research</i> , 0, 28, .	0.9	9
11788	Immunotherapy-induced Hepatotoxicity: A Review. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 000, 000-000.	0.7	3
11789	Small Molecules and Immunotherapy Agents for Enhancing Radiotherapy in Glioblastoma. <i>Biomedicines</i> , 2022, 10, 1763.	1.4	4
11790	Hemidesmosomal Reactivity and Treatment Recommendations in Immune Checkpoint Inhibitor-Induced Bullous Pemphigoid—A Retrospective, Monocentric Study. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
11791	Predicting cancer immunotherapy response from gut microbiomes using machine learning models. <i>Oncotarget</i> , 2022, 13, 876-889.	0.8	12
11792	Potential association factors for developing effective peptide-based cancer vaccines. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
11793	Recent Advances in Immunotherapy for the Treatment of Malignant Melanoma. <i>Current Pharmaceutical Design</i> , 2022, 28, 2363-2374.	0.9	3
11794	The expression pattern of Immune checkpoints after chemo/radiotherapy in the tumor microenvironment. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
11795	Tumor-promoting properties of karyopherin β 1 in melanoma by stabilizing Ras-GTPase-activating protein SH3 domain-binding protein 1. <i>Cancer Gene Therapy</i> , 2022, 29, 1939-1950.	2.2	2
11796	A pan-tumor-siRNA aptamer chimera to block nonsense-mediated mRNA decay inflames and suppresses tumor progression. <i>Molecular Therapy - Nucleic Acids</i> , 2022, 29, 413-425.	2.3	9
11797	Development and therapeutic manipulation of the head and neck cancer tumor environment to improve clinical outcomes. <i>Frontiers in Oral Health</i> , 0, 3, .	1.2	3
11798	Anlotinib combined with TQB2450 in patients with platinum-resistant or -refractory ovarian cancer: A multi-center, single-arm, phase 1b trial. <i>Cell Reports Medicine</i> , 2022, 3, 100689.	3.3	12

#	ARTICLE	IF	CITATIONS
11799	Real-world safety and effectiveness of pembrolizumab in Japanese patients with radically unresectable melanoma: An all-case postmarketing surveillance in Japan. <i>Journal of Dermatology</i> , 2022, 49, 1096-1105.	0.6	4
11800	Targeting the antigen processing and presentation pathway to overcome resistance to immune checkpoint therapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	9
11801	Immune Checkpoint Inhibitors in Cancer Therapy—How to Overcome Drug Resistance?. <i>Cancers</i> , 2022, 14, 3575.	1.7	18
11802	Chokeberry (<i>Aronia melanocarpa</i>) fruit extract abrogates melanoma progression through boosting up IFN- γ -producing cells. <i>Journal of Functional Foods</i> , 2022, 95, 105185.	1.6	1
11803	Immune Response Regulation has Therapeutic Potential in the Treatment of Cancer. <i>McGill Science Undergraduate Research Journal</i> , 2015, 10, 37-44.	0.1	0
11804	Evaluation of Thyroid Dysfunction Associated with the Use of Molecular Targeted Antineoplastic Drugs Using the Japanese Adverse Drug Event Report Database. <i>Iryo Yakugaku (Japanese Journal of)</i> Tj ETQq1 1 0.764314 rgBT /Overlock 10 T	0.764314	1
11805	Imaging features of toxicities associated with immune checkpoint inhibitors. <i>European Journal of Radiology Open</i> , 2022, 9, 100434.	0.7	6
11806	Salmonella-induced immune response reduces recurrence and tumor dissemination in preclinical melanoma model. <i>Current Research in Immunology</i> , 2022, 3, 159-166.	1.2	0
11807	Immune Checkpoint Inhibitors Induced Hepatotoxicity; Gastroenterologists—Perspectives. <i>Middle East Journal of Digestive Diseases</i> , 2022, 14, 244-253.	0.2	1
11808	Current Understanding of Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) Signaling in T-Cell Biology and Disease Therapy. <i>Molecules and Cells</i> , 2022, 45, 513-521.	1.0	13
11809	Molecular and clinical features of a potential immunotherapy target ELK3 in glioma. <i>Medicine (United)</i> Tj ETQq0 0 0.4 rgBT /Overlock 10 T	0.4	2
11810	Anti-PD-1 Monotherapy in Advanced Melanoma—Real-World Data from a 77-Month-Long Retrospective Observational Study. <i>Biomedicines</i> , 2022, 10, 1737.	1.4	8
11811	Immature tertiary lymphoid structure formation was increased in the melanoma tumor microenvironment of IKZF1 transgenic mice. <i>Translational Cancer Research</i> , 2022, 11, 2388-2397.	0.4	1
11813	Inhibition of stearoyl-CoA desaturase 1 (SCD1) enhances the antitumor T cell response through regulating β -catenin signaling in cancer cells and ER stress in T cells and synergizes with anti-PD-1 antibody. , 2022, 10, e004616.		25
11814	Safety and efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients with preexisting antinuclear antibodies: a retrospective cohort study. <i>Translational Lung Cancer Research</i> , 2022, 11, 1420-1433.	1.3	7
11815	Immunology Meets Bioengineering: Improving the Effectiveness of Glioblastoma Immunotherapy. <i>Cancers</i> , 2022, 14, 3698.	1.7	8
11816	Therapeutic Strategies to Enhance Tumor Antigenicity: Making the Tumor Detectable by the Immune System. <i>Biomedicines</i> , 2022, 10, 1842.	1.4	5
11817	Characteristics and usefulness of transabdominal ultrasonography in immune-mediated colitis. <i>Intestinal Research</i> , 2023, 21, 126-136.	1.0	1

#	ARTICLE	IF	CITATIONS
11818	Immunotherapy: Reshape the Tumor Immune Microenvironment. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	77
11819	The promising immune checkpoint LAG-3 in cancer immunotherapy: from basic research to clinical application. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	44
11820	Radiotherapy combined with immunotherapy: the dawn of cancer treatment. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	142
11821	Proton Therapy Outcomes for Head and Neck Cutaneous Melanoma: Proton Collaborative Group Analysis. <i>International Journal of Particle Therapy</i> , 2022, 9, 40-48.	0.9	0
11822	Progress of immunotherapy in the treatment of pancreatic cancer. , 0, 6, 182-191.		0
11823	Current clinical landscape of oncolytic viruses as novel cancer immunotherapeutic and recent preclinical advancements. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	16
11824	Use of First-Line Immune Checkpoint Inhibitors and Association With Overall Survival Among Patients With Metastatic Melanoma in the Anti-“PD-1 Era. <i>JAMA Network Open</i> , 2022, 5, e2225459.	2.8	14
11825	Synergistic effects of radiotherapy and targeted immunotherapy in improving tumor treatment efficacy: a review. <i>Clinical and Translational Oncology</i> , 2022, 24, 2255-2271.	1.2	6
11826	Immunotherapy in non-small cell lung cancer: Past, present, and future directions. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	32
11827	Pharmacological ascorbate as a novel therapeutic strategy to enhance cancer immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
11829	Cancer: Immunology and Immunotherapy. <i>Research Journal of Pharmacology and Pharmacodynamics</i> , 2022, , 159-164.	0.1	2
11830	Dermatological adverse events under programmed cell death-1 inhibitors as a prognostic marker in metastatic melanoma. <i>Dermatologic Therapy</i> , 2022, 35, .	0.8	3
11831	Metabolic profiles of regulatory T cells and their adaptations to the tumor microenvironment: implications for antitumor immunity. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	50
11832	Whole transcriptome and proteome analyses identify potential targets and mechanisms underlying tumor treating fields against glioblastoma. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	5
11833	Targeting Melanin in Melanoma with Radionuclide Therapy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9520.	1.8	5
11834	Patient-reported tolerability of adjuvant ipilimumab (3 or 10Âmg/kg) versus high-dose interferon alfa-2b for resected high-risk stage III-“IV melanoma in phase III trial E1609. <i>Quality of Life Research</i> , 0, , .	1.5	0
11835	Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	89
11836	Immunotherapy in Ovarian Cancer. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2022, 70, .	1.0	8

#	ARTICLE	IF	CITATIONS
11837	Treatment of Metastatic Melanoma with a Combination of Immunotherapies and Molecularly Targeted Therapies. <i>Cancers</i> , 2022, 14, 3779.	1.7	18
11838	Whole-body tumor burden in PET/CT expert review. <i>Clinical and Translational Imaging</i> , 0, , .	1.1	2
11839	Emerging Immune-Monitoring System for Immune Checkpoint Inhibitors. <i>Life</i> , 2022, 12, 1229.	1.1	4
11840	Using the canine microbiome to bridge translation of cancer immunotherapy from pre-clinical murine models to human clinical trials. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
11842	Current Opportunities for Targeting Dysregulated Neurodevelopmental Signaling Pathways in Glioblastoma. <i>Cells</i> , 2022, 11, 2530.	1.8	8
11843	EMT-Related Gene Signature Predicts the Prognosis in Uveal Melanoma Patients. <i>Journal of Oncology</i> , 2022, 2022, 1-19.	0.6	5
11844	Insomnia in patients treated with checkpoint inhibitors for cancer: A meta-analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
11845	Homologous recombination repair gene mutations as a predictive biomarker for immunotherapy in patients with advanced melanoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
11846	Selective suppression of melanoma lacking IFN- γ pathway by JAK inhibition depends on T cells and host TNF signaling. <i>Nature Communications</i> , 2022, 13, .	5.8	11
11847	Cancer vaccines: the next immunotherapy frontier. <i>Nature Cancer</i> , 2022, 3, 911-926.	5.7	207
11848	Ocular Inflammatory Complications of Treatment for Metastatic Melanoma. <i>Ocular Immunology and Inflammation</i> , 2023, 31, 1669-1673.	1.0	0
11849	Microbiome in cancer: An exploration of carcinogenesis, immune responses and immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
11850	Role of BTLA/HVEM network in development of gastric cancer. <i>Human Immunology</i> , 2022, 83, 637-644.	1.2	6
11851	Intracranial Metastatic Melanoma. , 0, , .		0
11852	Randomized Versus Real-World Evidence on the Efficacy and Toxicity of Checkpoint Inhibitors in Cancer in Patients with Advanced Non-small Cell Lung Cancer or Melanoma: A Meta-analysis. <i>Targeted Oncology</i> , 2022, 17, 507-515.	1.7	1
11853	The epiphany derived from T-cell "inflamed" profiles: Pan-cancer characterization of CD8A as a biomarker spanning clinical relevance, cancer prognosis, immunosuppressive environment, and treatment responses. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	4
11854	The role of kidney biopsy in immune checkpoint inhibitor nephrotoxicity. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	2
11855	Clinical factors associated with outcome in solid tumor patients treated with immune-checkpoint inhibitors: a single institution retrospective analysis. <i>Discover Oncology</i> , 2022, 13, .	0.8	5

#	ARTICLE	IF	CITATIONS
11856	Immune checkpoints in osteosarcoma: Recent advances and therapeutic potential. <i>Cancer Letters</i> , 2022, 547, 215887.	3.2	24
11857	Update on Immune Checkpoint Inhibitors for Conjunctival Melanoma. <i>Journal of Ophthalmic and Vision Research</i> , 0, , .	0.7	0
11858	End-of-Life Use of Systemic Therapy in Patients With Advanced Melanoma: A Nationwide Cohort Study. <i>JCO Oncology Practice</i> , 2022, 18, e1611-e1620.	1.4	1
11859	The evolving role of checkpoint inhibitors in the treatment of urothelial carcinoma. <i>British Journal of Clinical Pharmacology</i> , 0, , .	1.1	1
11860	Impact of intratumoural <sc>CD96</sc> expression on clinical outcome and therapeutic benefit in gastric cancer. <i>Cancer Science</i> , 2022, 113, 4070-4081.	1.7	7
11861	Interventional radiology meets immuno-oncology for hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2022, , .	1.8	5
11862	Immunotherapeutic targets in nonâ€small cell lung cancer. <i>Immunology</i> , 2023, 168, 256-272.	2.0	5
11863	Loss of MHC-I antigen presentation correlated with immune checkpoint blockade tolerance in MAPK inhibitor-resistant melanoma. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	5
11864	Pituitary hormone Î±-MSH promotes tumor-induced myelopoiesis and immunosuppression. <i>Science</i> , 2022, 377, 1085-1091.	6.0	22
11865	Clinical utility of tumour mutational burden on efficacy of immune checkpoint inhibitors in malignant solid tumours: protocol for a systematic review and meta-analysis. <i>BMJ Open</i> , 2022, 12, e058692.	0.8	3
11866	An anti-CTLA-4 heavy chainâ€only antibody with enhanced T _{reg} depletion shows excellent preclinical efficacy and safety profile. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	13
11867	Successful treatment of advanced muscle-invasive bladder cancer with the combined therapy of toripalimab and chemotherapy: a case report. <i>Anti-Cancer Drugs</i> , 0, Publish Ahead of Print, .	0.7	0
11868	Neobavaisoflavone inhibits antitumor immunosuppression via myeloid-derived suppressor cells. <i>International Immunopharmacology</i> , 2022, 111, 109103.	1.7	5
11869	Differential RNA expression of immune-related genes and tumor cell proximity from intratumoral M1 macrophages in acral lentiginous melanomas treated with PD-1 blockade. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2022, 1868, 166516.	1.8	0
11870	Cabozantinib after prior checkpoint inhibitor therapy in patients with solid tumors: A systematic literature review. <i>Cancer Treatment Reviews</i> , 2022, 110, 102453.	3.4	2
11871	Vulvovaginal melanoma. , 2023, , 279-304.		0
11872	Tebentafusp for the treatment of HLA-A*02:01â€positive adult patients with unresectable or metastatic uveal melanoma. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 1017-1027.	1.1	11
11873	Eight gene mutation-based polygenic hazard score as a potential predictor for immune checkpoint inhibitor therapy outcome in metastatic melanoma. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	1

#	ARTICLE	IF	CITATIONS
11874	Dynamics of plasma thymidine kinase activity in metastatic melanoma reflects immune checkpoint inhibitor efficacy. <i>Acta Oncologica</i> , 2022, 61, 1116-1120.	0.8	2
11875	Fifty years of progress in surgical oncology: Melanoma. <i>Journal of Surgical Oncology</i> , 2022, 126, 888-895.	0.8	0
11876	Health-related quality of life in patients with advanced melanoma treated with ipilimumab: prognostic implications and changes during treatment. <i>ESMO Open</i> , 2022, 7, 100588.	2.0	1
11877	The efficacy of immune checkpoint inhibitors in elderly patients: a meta-analysis and meta-regression. <i>ESMO Open</i> , 2022, 7, 100577.	2.0	11
11878	Biphenyl-based small molecule inhibitors: Novel cancer immunotherapeutic agents targeting PD-1/PD-L1 interaction. <i>Bioorganic and Medicinal Chemistry</i> , 2022, 73, 117001.	1.4	9
11879	Biologicals as theranostic vehicles in paediatric oncology. <i>Nuclear Medicine and Biology</i> , 2022, 114-115, 58-64.	0.3	0
11880	Changes in the survival of adult patients with metastasized melanoma with the approval of immune checkpoint inhibitors: A retrospective study from the United States database. <i>Cancer Epidemiology</i> , 2022, 81, 102254.	0.8	1
11881	<i>Dermatology (Skin)</i> , 2022, , 29-58.		0
11882	Present Status of the Therapeutic Approaches to Treat Uveal Melanoma. , 2022, , 3773-3792.		0
11883	Tumor-infiltrating Lymphocytes as Markers of the Antitumor Therapy Efficacy: Myth or Reality?. , 2023, , 91-115.		0
11884	<i>Cardiology (Heart)</i> , 2022, , 7-27.		0
11885	Light-Based Treatment Modalities and Anticancer Immunity. , 2022, , 1-27.		0
11886	Efficacy and Safety of Immune Checkpoint Inhibitors for Advanced Malignant Melanoma: A Meta-Analysis on Monotherapy Vs Combination Therapy. <i>Journal of Cancer</i> , 2022, 13, 3091-3102.	1.2	4
11887	Diagnostic Applications of Nuclear Medicine: Malignant Melanoma. , 2022, , 1235-1269.		0
11888	Radiotherapy and Immunotherapy for Head and Neck Cancer. , 2022, , 91-113.		0
11889	Nervous System Related Adverse Reactions and Management Strategies of Tumor Immune Checkpoint Inhibitors. <i>Advances in Clinical Medicine</i> , 2022, 12, 7964-7971.	0.0	0
11890	Principles of Checkpoint Inhibition in Malignant Lymphoma. , 2022, , .		0
11891	Advances in Tumor Microenvironment Immune Profiling. , 2022, , 1-24.		0

#	ARTICLE	IF	CITATIONS
11892	Targeting Metastatic Disease: Challenges and New Opportunities. , 2022, , 51-68.		0
11893	Programmed death ligand 1 gene silencing in murine glioma models reveals cell line-specific modulation of tumor growth in vivo. <i>Neuro-Oncology Advances</i> , 2022, 4, .	0.4	0
11894	The Identification and Clinical Applications of Mutated Antigens in the Era of Immunotherapy. <i>Cancers</i> , 2022, 14, 4255.	1.7	3
11895	Immune-Related Uncommon Adverse Events in Patients with Cancer Treated with Immunotherapy. <i>Diagnostics</i> , 2022, 12, 2091.	1.3	5
11896	Cardiovascular complications of immune checkpoint inhibitors for cancer. <i>European Heart Journal</i> , 2022, 43, 4458-4468.	1.0	30
11897	Safety and Efficacy of Allogeneic Natural Killer Cells in Combination with Pembrolizumab in Patients with Chemotherapy-Refractory Biliary Tract Cancer: A Multicenter Open-Label Phase 1/2a Trial. <i>Cancers</i> , 2022, 14, 4229.	1.7	4
11898	Immune Checkpoint Inhibitors for Gastrointestinal Malignancies: An Update. <i>Cancers</i> , 2022, 14, 4201.	1.7	1
11899	Immune checkpoint inhibitor-induced arthralgia is tightly associated with improved overall survival in cancer patients. <i>Rheumatology</i> , 2023, 62, 1451-1459.	0.9	1
11900	LS-007 inhibits melanoma growth via inducing apoptosis and cell cycle arrest and regulating macrophage polarization. <i>Melanoma Research</i> , 0, Publish Ahead of Print, .	0.6	0
11901	Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	8
11902	Transient cell-in-cell formation underlies tumor relapse and resistance to immunotherapy. <i>ELife</i> , 0, 11, .	2.8	23
11903	Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	97
11904	Immune status for monitoring and treatment of bladder cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
11905	Overcoming the cardiac toxicities of cancer therapy immune checkpoint inhibitors. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
11906	Recent advances in immune checkpoint inhibitors for non-small lung cancer treatment. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
11907	Biofabrication of 3D breast cancer models for dissecting the cytotoxic response of human T cells expressing engineered MAIT cell receptors. <i>Biofabrication</i> , 2022, 14, 044105.	3.7	14
11908	Immune Checkpoint Inhibitor-Induced Myositis/Myocarditis with Myasthenia Gravis-like Misleading Presentation: A Case Series in Intensive Care Unit. <i>Journal of Clinical Medicine</i> , 2022, 11, 5611.	1.0	5
11909	Evaluating Antibody Pharmacokinetics as Prerequisite for Determining True Efficacy as Shown by Dual Targeting of PD-1 and CD96. <i>Biomedicines</i> , 2022, 10, 2146.	1.4	0

#	ARTICLE	IF	CITATIONS
11910	Alpha radionuclide-chelated radioimmunotherapy promoters enable local radiotherapy/chemodynamic therapy to discourage cancer progression. <i>Biomaterials Research</i> , 2022, 26, .	3.2	18
11911	Boosting the Immune Response—Combining Local and Immune Therapy for Prostate Cancer Treatment. <i>Cells</i> , 2022, 11, 2793.	1.8	3
11912	Inpatient utilization of immune checkpoint inhibitors and clinical outcomes. <i>Journal of Oncology Pharmacy Practice</i> , 0, , 107815522211239.	0.5	1
11913	Durable disease control and refractory bullous pemphigoid after immune checkpoint inhibitor discontinuation in metastatic renal cell carcinoma: A case report. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
11914	Tissue engineered cancer metastases as cancer vaccine to improve cancer immunotherapy. <i>Acta Biomaterialia</i> , 2022, 153, 299-307.	4.1	1
11915	Intratumoral CD73: An immune checkpoint shaping an inhibitory tumor microenvironment and implicating poor prognosis in Chinese melanoma cohorts. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
11916	Safety and efficacy of nivolumab compared with other regimens in patients with melanoma: A network meta-analysis. <i>Medicine (United States)</i> , 2022, 101, e29390.	0.4	0
11917	Mutated processes predict immune checkpoint inhibitor therapy benefit in metastatic melanoma. <i>Nature Communications</i> , 2022, 13, .	5.8	16
11918	Thyroid-related adverse events induced by immune checkpoint inhibitors. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	9
11919	Functional Downregulation of PD-L1 and PD-L2 by CpG and non-CpG Oligonucleotides in Melanoma Cells. <i>Cancers</i> , 2022, 14, 4698.	1.7	0
11920	Carbon ion irradiation plus CTLA4 blockade elicits therapeutic immune responses in a murine tumor model. <i>Cancer Letters</i> , 2022, 550, 215928.	3.2	8
11921	Efficacy of long-term extended nursing services combined with atezolizumab in patients with bladder cancer after endoscopic bladder resection. <i>Medicine (United States)</i> , 2022, 101, e30690.	0.4	0
11922	Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC)., 2022, 10, e005413.		6
11923	Pancreatic involvement due to immune checkpoint inhibitors: a proposed classification. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 895-901.	2.0	2
11924	Design Strategies and Precautions for Using Vaccinia Virus in Tumor Virotherapy. <i>Vaccines</i> , 2022, 10, 1552.	2.1	2
11925	Evaluating the Combined Anticancer Response of Checkpoint Inhibitor Immunotherapy and FAP-Targeted Molecular Radiotherapy in Murine Models of Melanoma and Lung Cancer. <i>Cancers</i> , 2022, 14, 4575.	1.7	5
11926	Development of immunotherapy for high-grade gliomas: Overcoming the immunosuppressive tumor microenvironment. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	10
11927	Deep learning reveals predictive sequence concepts within immune repertoires to immunotherapy. <i>Science Advances</i> , 2022, 8, .	4.7	23

#	ARTICLE	IF	CITATIONS
11928	Changes in the Epidemiology of Hepatocellular Carcinoma in Asia. <i>Cancers</i> , 2022, 14, 4473.	1.7	20
11929	Associating resistance to immune checkpoint inhibitors with immunological escape in colorectal cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
11930	The role of polyamine metabolism in remodeling immune responses and blocking therapy within the tumor immune microenvironment. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	15
11931	Tipping the scales: Immunotherapeutic strategies that disrupt immunosuppression and promote immune activation. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
11932	Immune checkpoint inhibitor-induced hepatitis injury: risk factors, outcomes, and impact on survival. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 2235-2242.	1.2	4
11933	Beyond <scp>PD&L1</scp>: Assessment of <scp>LAG</scp> and other predictive biomarkers in non"small cell lung carcinoma. <i>Cancer Cytopathology</i> , 2023, 131, 151-153.	1.4	0
11934	V-Set and immunoglobulin domain containing (VSIG) proteins as emerging immune checkpoint targets for cancer immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
11936	Evaluating the role of IDO1 macrophages in immunotherapy using scRNA-seq and bulk-seq in colorectal cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
11938	Adoptive Cellular Therapy for Metastatic Melanoma: The Road to Commercialization and Treatment Guidelines for Clinicians. <i>Annals of Surgical Oncology</i> , 2023, 30, 589-601.	0.7	2
11939	NAD/NAMPT and mTOR Pathways in Melanoma: Drivers of Drug Resistance and Prospective Therapeutic Targets. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9985.	1.8	11
11940	Diagnosis and management of immune checkpoint inhibitor-associated acute kidney injury. <i>Nature Reviews Nephrology</i> , 2022, 18, 794-805.	4.1	20
11941	Hospitalized cancer patients with comorbidities and low lymphocyte counts had poor clinical outcomes to immune checkpoint inhibitors. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
11942	ADCC enhancement: A conundrum or a boon to mAb therapy?. <i>Biologicals</i> , 2022, 79, 10-18.	0.5	1
11943	Harnessing the immune system by targeting immune checkpoints: Providing new hope for Oncotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
11944	Toxicity and response to ipilimumab and nivolumab in older patients with metastatic melanoma: A multicentre retrospective analysis. <i>Pigment Cell and Melanoma Research</i> , 2022, 35, 587-594.	1.5	3
11945	Intratumoral administration of CD1c (BDCA-1) and CD141 (BDCA-3) myeloid dendritic cells in combination with talimogene laherparepvec in immune checkpoint blockade refractory advanced melanoma patients: a phase I clinical trial. , 2022, 10, e005141.		11
11946	Combination treatment of radiofrequency ablation and peptide neoantigen vaccination: Promising modality for future cancer immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
11949	Analysis of combination therapy of immune checkpoint inhibitors in osteosarcoma. <i>Frontiers in Chemistry</i> , 0, 10, .	1.8	5

#	ARTICLE	IF	CITATIONS
11951	Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	33
11952	Monoclonal antibodies in cervical malignancy-related HPV. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	7
11953	Giant penile melanoma. <i>Urology Herald</i> , 2022, 10, 145-150.	0.1	0
11954	Circulating biomarkers of response to immunotherapy and immune-related adverse events. <i>Expert Review of Molecular Diagnostics</i> , 2022, 22, 855-865.	1.5	2
11955	Immune checkpoint inhibitors as mediators for immunosuppression by cancer-associated fibroblasts: A comprehensive review. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	11
11956	Clinical utility of CAR T cell therapy in brain tumors: Lessons learned from the past, current evidence and the future stakes. <i>International Reviews of Immunology</i> , 0, , 1-19.	1.5	2
11957	Immunotherapy improves disease prognosis by affecting the tumor microenvironment: A bibliometric study. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
11958	Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases. <i>Nature Reviews Rheumatology</i> , 2022, 18, 641-656.	3.5	37
11959	A newly discovered PD-L1 B-cell epitope peptide vaccine (PDL1-Vaxx) exhibits potent immune responses and effective anti-tumor immunity in multiple syngeneic mice models and (synergizes) in combination with a dual HER-2 B-cell vaccine (B-Vaxx). <i>Oncolmmunology</i> , 2022, 11, .	2.1	10
11960	From simplicity to complexity in current melanoma models. <i>Experimental Dermatology</i> , 2022, 31, 1818-1836.	1.4	3
11961	Chemotherapeutics and CAR-T Cell-Based Immunotherapeutics Screening on a 3D Bioprinted Vascularized Breast Tumor Model. <i>Advanced Functional Materials</i> , 2022, 32, .	7.8	12
11962	The multiple roles of LDH in cancer. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 749-762.	12.5	53
11963	Fueling immune checkpoint blockade with oncolytic viruses: Current paradigms and challenges ahead. <i>Cancer Letters</i> , 2022, 550, 215937.	3.2	6
11965	Systemic adjuvant therapy for high-risk cutaneous melanoma. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211340.	1.4	7
11966	Cutaneous Reactions to Oncologic Immunotherapy. <i>Updates in Clinical Dermatology</i> , 2022, , 317-330.	0.1	0
11967	AKT Isoforms in the Immune Response in Cancer. <i>Current Topics in Microbiology and Immunology</i> , 2022, , 349-366.	0.7	0
11968	Thyroid Dland Disorders Associated with Combination of Antiangiogenic Agents and Immune Checkpoint Inhibitors: A Pharmacovigilance Study. , 2022, , .		0
11969	Advances in the Application of Nanomaterials to the Treatment of Melanoma. <i>Pharmaceutics</i> , 2022, 14, 2090.	2.0	2

#	ARTICLE	IF	CITATIONS
11970	Epitope Mapping of Therapeutic Antibodies Targeting Human LAG3. <i>Journal of Immunology</i> , 2022, 209, 1586-1594.	0.4	4
11971	Differences and Similarities in the Pattern of Early Metabolic and Morphologic Response after Induction Chemo-Immunotherapy versus Induction Chemotherapy Alone in Locally Advanced Squamous Cell Head and Neck Cancer. <i>Cancers</i> , 2022, 14, 4811.	1.7	1
11972	Multiplexed imaging mass cytometry reveals distinct tumor-immune microenvironments linked to immunotherapy responses in melanoma. <i>Communications Medicine</i> , 2022, 2, .	1.9	6
11973	Targeted Therapy and Immunotherapy in Melanoma. <i>Dermatologic Clinics</i> , 2023, 41, 65-77.	1.0	14
11974	Tumor Microenvironment in Hepatocellular Carcinoma: Key Players for Immunotherapy. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 9, 1109-1125.	1.8	11
11975	From Cold to Hot: Changing Perceptions and Future Opportunities for Quantitative Systems Pharmacology Modeling in Cancer Immunotherapy. <i>Clinical Pharmacology and Therapeutics</i> , 2023, 113, 963-972.	2.3	6
11976	Tumor response assessment on imaging following immunotherapy. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	12
11977	Focus on PD-1/PD-L1 as a Therapeutic Target in Ovarian Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12067.	1.8	15
11978	Why do tumor-infiltrating lymphocytes have variable efficacy in the treatment of solid tumors?. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
11979	Targeting Both Autophagy and Immunotherapy in Breast Cancer Treatment. <i>Metabolites</i> , 2022, 12, 966.	1.3	2
11982	Targeting FGL2 in glioma immunosuppression and malignant progression. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
11983	Update on Immune Checkpoint Inhibitor Enterocolitis. <i>Current Gastroenterology Reports</i> , 2022, 24, 171-181.	1.1	5
11984	Update on immune checkpoint therapy for melanoma. <i>Dermatological Reviews</i> , 0, , .	0.3	0
11985	Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	59
11986	Signaling pathways and therapeutic interventions in gastric cancer. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	54
11987	Expert Clinical Management of Severe Immune-Related Adverse Events: Results from a Multicenter Survey on Hot Topics for Management. <i>Journal of Clinical Medicine</i> , 2022, 11, 5977.	1.0	2
11988	Computational Approaches and Challenges in Spatial Transcriptomics. <i>Genomics, Proteomics and Bioinformatics</i> , 2023, 21, 24-47.	3.0	28
11989	Immune Checkpoint Inhibitors and RAS-ERK Pathway-Targeted Drugs as Combined Therapy for the Treatment of Melanoma. <i>Biomolecules</i> , 2022, 12, 1562.	1.8	5

#	ARTICLE	IF	CITATIONS
11990	Metastatic pancreatic neuroendocrine tumors feature elevated T cell infiltration. <i>JCI Insight</i> , 2022, 7, .	2.3	2
11991	Editorial commentary: Immune checkpoint inhibitors and the cardiovascular system: Reflecting on the past and looking towards the future. <i>Trends in Cardiovascular Medicine</i> , 2024, 34, 78-79.	2.3	0
11992	Novel Biomarkers and Therapeutic Targets for Melanoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11656.	1.8	3
11993	Chimeric immune checkpoint protein vaccines inhibit the tumorigenesis and growth of rat cholangiocarcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
11994	Systemic CD4 Immunity and PD-L1/PD-1 Blockade Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13241.	1.8	9
11995	Clinical Factors Associated with Long-Term Survival in Metastatic Melanoma Treated with Anti-PD1 Alone or in Combination with Ipilimumab. <i>Current Oncology</i> , 2022, 29, 7695-7704.	0.9	0
11996	Development of the Novel Bifunctional Fusion Protein BR102 That Simultaneously Targets PD-L1 and TGF- β 2 for Anticancer Immunotherapy. <i>Cancers</i> , 2022, 14, 4964.	1.7	8
11997	Systematic comparison with autoimmune liver disease identifies specific histological features of immune checkpoint inhibitor-related adverse events. , 2022, 10, e005635.		11
11998	Immune checkpoint inhibitor-mediated colitis is associated with cancer overall survival. <i>World Journal of Gastroenterology</i> , 0, 28, 5750-5763.	1.4	1
11999	PD-1 and CTLA-4 inhibitors in combination vs. alone for the treatment of advanced melanoma: A systematic review and meta-analysis. <i>Medicine (United States)</i> , 2022, 101, e30561.	0.4	4
12000	Genomic instability, origin and evolution of cancer, and personalized immunotherapy. <i>Vacunas (English Edition)</i> , 2022, 23, 222-233.	0.3	0
12001	Tertiary lymphoid structures as unique constructions associated with the organization, education, and function of tumor-infiltrating immunocytes. <i>Journal of Zhejiang University: Science B</i> , 2022, 23, 812-822.	1.3	3
12002	Melanoma classification and management in the era of molecular medicine. <i>Dermatologic Clinics</i> , 2023, 41, 49-63.	1.0	15
12003	Knowledge mapping and current trends of immunotherapy for prostate cancer: A bibliometric study. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	10
12004	Clustering using unsupervised machine learning can stratify the risk of immune-related liver injury. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 0, , .	1.4	2
12005	Clinical implications of T cell exhaustion for cancer immunotherapy. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 775-790.	12.5	182
12006	LAG3-PD1 or CTLA4-PD1 Inhibition in Advanced Melanoma: Indirect Cross Comparisons of the CheckMate-067 and RELATIVITY-047 Trials. <i>Cancers</i> , 2022, 14, 4975.	1.7	9
12007	Long-Term Toxicities of Immune Checkpoint Inhibitor (ICI) in Melanoma Patients. <i>Current Oncology</i> , 2022, 29, 7953-7963.	0.9	10

#	ARTICLE	IF	CITATIONS
12009	Changes in the Immune Cell Repertoire for the Treatment of Malignant Melanoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12991.	1.8	3
12010	An update on the use of cryoablation and immunotherapy for breast cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	9
12011	Targeting the epigenome in malignant melanoma: Facts, challenges and therapeutic promises. , 2022, 240, 108301.		9
12012	Immunoregulatory signal networks and tumor immune evasion mechanisms: insights into therapeutic targets and agents in clinical development. <i>Biochemical Journal</i> , 2022, 479, 2219-2260.	1.7	6
12013	The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma. <i>Nature Communications</i> , 2022, 13, .	5.8	15
12014	Trends in Melanoma Phase 3 Clinical Trials since 2010: Is there Hope for Advanced Melanoma Therapies beyond Approved Treatment Mechanisms?. <i>Cancers</i> , 2022, 14, 5184.	1.7	7
12015	Novel IKZF3 transcriptomic signature correlates with positive outcomes of skin cutaneous melanoma: A pan-cancer analysis. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	1
12016	Cancer Immunotherapy: Harnessing the Immune System to Fight Cancer. <i>Journal of Clinical Medicine</i> , 2022, 11, 6356.	1.0	2
12017	The genetics of myelodysplastic syndromes and the opportunities for tailored treatments. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
12019	Immune-Checkpoint Inhibitors (ICIs) in Metastatic Colorectal Cancer (mCRC) Patients beyond Microsatellite Instability. <i>Cancers</i> , 2022, 14, 4974.	1.7	15
12020	Immune Checkpoint Inhibitors Do Not Increase Short-Term Risk of Hypertension in Cancer Patients: a Systematic Literature Review and Meta-Analysis. <i>Hypertension</i> , 2022, 79, 2611-2621.	1.3	16
12021	Virtual clinical trials of anti-PD-1 and anti-CTLA-4 immunotherapy in advanced hepatocellular carcinoma using a quantitative systems pharmacology model. , 2022, 10, e005414.		18
12022	Expression profile of immunoregulatory factors in canine tumors. <i>Veterinary Immunology and Immunopathology</i> , 2022, 253, 110505.	0.5	0
12023	A promising research direction for colorectal cancer immunotherapy: The regulatory mechanism of CCL5 in colorectal cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
12024	OncoTherad® is an immunomodulator of biological response that downregulate RANK/RANKL signaling pathway and PD-1/PD-L1 immune checkpoint in non-muscle invasive bladder cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 5025-5036.	1.2	3
12025	Immunotherapy targeting inhibitory checkpoints: The role of NK and other innate lymphoid cells. <i>Seminars in Immunology</i> , 2022, 61-64, 101660.	2.7	4
12026	Interdependence of sequential cytotoxic T lymphocyte and natural killer cell cytotoxicity against melanoma cells. <i>Journal of Physiology</i> , 2022, 600, 5027-5054.	1.3	5
12027	The end of wide local excision (WLE) margins for melanoma ?. <i>European Journal of Cancer</i> , 2023, 178, 82-87.	1.3	3

#	ARTICLE	IF	CITATIONS
12028	A photodynamically sensitized dendritic cell vaccine that promotes the anti-tumor effects of anti-PD-L1 monoclonal antibody in a murine model of head and neck squamous cell carcinoma. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	4
12029	Retrospective analysis: checkpoint inhibitor accessibility for thoracic and head and neck cancers and factors influencing it in a tertiary centre in India. <i>Ecancermedicalsecience</i> , 0, 16, .	0.6	3
12030	Tumor-intrinsic SIRPA promotes sensitivity to checkpoint inhibition immunotherapy in melanoma. <i>Cancer Cell</i> , 2022, 40, 1324-1340.e8.	7.7	11
12031	Dostarlimab an Inhibitor of PD-1/PD-L1: A New Paradigm for the Treatment of Cancer. <i>Medicina (Lithuania)</i> , 2022, 58, 1572.	0.8	5
12032	VSTM5 is a novel immune checkpoint that promotes oral tolerance of cell-mediated and antibody responses. <i>Biochemical and Biophysical Research Communications</i> , 2022, 635, 283-290.	1.0	1
12033	Immune checkpoint blockade in melanoma: Advantages, shortcomings and emerging roles of the nanoparticles. <i>International Immunopharmacology</i> , 2022, 113, 109300.	1.7	4
12034	RAS: Circuitry and therapeutic targeting. <i>Cellular Signalling</i> , 2023, 101, 110505.	1.7	1
12035	A Review of Immune Checkpoint Blockade for the General Surgeon. <i>Journal of Surgical Research</i> , 2023, 281, 289-298.	0.8	3
12036	Immunotherapy-based Combination Therapies for Malignant Melanomas. , 2022, , .		0
12037	Harnessing the Tumor Microenvironment for Cancer Immunotherapy. , 2022, , 1-25.		1
12038	Immune Checkpoint Inhibitors in Hodgkin Lymphoma and Non-Hodgkin Lymphoma. , 0, , .		0
12039	Perspective Chapter: Liposome Mediated Delivery of Immunotherapeutics for Cancer. , 0, , .		0
12040	Nanoparticle Enhancement of Natural Killer (NK) Cell-Based Immunotherapy. <i>Cancers</i> , 2022, 14, 5438.	1.7	8
12042	PD-L1 expression and association with genetic background in pheochromocytoma and paraganglioma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
12043	Re-purposing the pro-senescence properties of doxorubicin to introduce immunotherapy in breast cancer brain metastasis. <i>Cell Reports Medicine</i> , 2022, 3, 100821.	3.3	8
12044	Translating the evolving molecular landscape of tumors to biomarkers of response for cancer immunotherapy. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	14
12045	Targeted Therapies for Hepatocellular Carcinoma Treatment: A New Era Ahead—A Systematic Review. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14117.	1.8	7
12046	Efficacy and toxicity of Ipilimumab-Nivolumab combination therapy in elderly metastatic melanoma patients. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3

#	ARTICLE	IF	CITATIONS
12047	A Novel Glycolysis-Related Long Noncoding RNA Signature for Predicting Overall Survival in Gastric Cancer. <i>Pathology and Oncology Research</i> , 0, 28, .	0.9	3
12048	Tissue-resident memory T cells in the era of (Neo) adjuvant melanoma management. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
12049	Granulomatous interstitial nephritis with CTLA-4 haploinsufficiency: a case report. <i>BMC Nephrology</i> , 2022, 23, .	0.8	2
12050	Landscape of immune-related signatures induced by targeting of different epigenetic regulators in melanoma: implications for immunotherapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	3.5	9
12051	Retrospective study of the incidence of sarcoidosis-like reaction in patients treated with immunotherapy. <i>Clinical Radiology</i> , 2022, , .	0.5	0
12052	Immune checkpoint gene <i>VSIR</i> predicts patient prognosis in acute myeloid leukemia and myelodysplastic syndromes. <i>Cancer Medicine</i> , 2023, 12, 5590-5602.	1.3	3
12053	Transcriptomic characterization and construction of M2 macrophage-related prognostic and immunotherapeutic signature in ovarian metastasis of gastric cancer. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 1121-1138.	2.0	6
12054	The past, present, and future of chemotherapy with a focus on individualization of drug dosing. <i>Journal of Controlled Release</i> , 2022, 352, 840-860.	4.8	9
12055	Tumor Immune Microenvironment and Immunotherapy in Non-Small Cell Lung Cancer: Update and New Challenges. , 2022, 13, 1615.		21
12056	Gut microbiota diversity and composition in predicting immunotherapy response and immunotherapy-related colitis in melanoma patients: A systematic review. <i>World Journal of Clinical Oncology</i> , 0, 13, 929-942.	0.9	6
12057	Identification of CD73 as a Novel Biomarker Encompassing the Tumor Microenvironment, Prognosis, and Therapeutic Responses in Various Cancers. <i>Cancers</i> , 2022, 14, 5663.	1.7	5
12058	Two cases of nivolumab plus ipilimumab therapy for dialysis patients with advanced bone metastasis from renal cell carcinoma. <i>CEN Case Reports</i> , 2023, 12, 237-241.	0.5	3
12059	Folate Receptor-Mediated Delivery of Cas9 RNP for Enhanced Immune Checkpoint Disruption in Cancer Cells. <i>Small</i> , 2023, 19, .	5.2	12
12060	Advances of Electroporation-Related Therapies and the Synergy with Immunotherapy in Cancer Treatment. <i>Vaccines</i> , 2022, 10, 1942.	2.1	7
12061	Analysis of top-cited articles on melanoma. <i>Acta Dermatovenerologica Alpina, Panonica Et Adriatica</i> , 2022, 31, .	0.1	0
12062	Eosinophilia in cancer and its regulation by sex hormones. <i>Trends in Endocrinology and Metabolism</i> , 2023, 34, 5-20.	3.1	6
12063	“Trojan horse” nanoparticle-delivered cancer cell membrane vaccines to enhance cancer immunotherapy by overcoming immune-escape. <i>Biomaterials Science</i> , 2023, 11, 2020-2032.	2.6	8
12064	Synergistic potential of immune checkpoint inhibitors and therapeutic cancer vaccines. <i>Seminars in Cancer Biology</i> , 2023, 88, 81-95.	4.3	11

#	ARTICLE	IF	CITATIONS
12065	Tumor microenvironment-modulated multiple nanotherapeutic system for potent cancer immunotherapy and metastasis inhibition. <i>Nano Today</i> , 2023, 48, 101702.	6.2	3
12066	Manejo de toxicidades por inmunoterapias. , 2022, 22, .		0
12067	Endocrine Toxicities Related to Immunotherapy. , 2022, , 1-40.		0
12068	An Updated Focus on Immune Checkpoint Inhibitors and Tubulointerstitial Nephritis. , 2023, , 157-184.		0
12069	The Use of Immunotherapy in Cancer Patients with Autoimmune Diseases. , 2023, , 267-286.		0
12071	A Review of Neurotoxicities Associated with Immune Checkpoint Inhibitors. , 2022, , 1-16.		0
12072	Identification of immune subtypes of melanoma based on single-cell and bulk RNA sequencing data. <i>Mathematical Biosciences and Engineering</i> , 2022, 20, 2920-2936.	1.0	0
12073	Immunotherapy for Cancer: Common Gastrointestinal, Liver, and Pancreatic Side Effects and Their Management. <i>American Journal of Gastroenterology</i> , 2022, 117, 1917-1932.	0.2	4
12074	Short-course pembrolizumab and continuous afatinib therapy for recurrent or metastatic head and neck squamous cell carcinoma: a real-world data analysis. <i>BMC Cancer</i> , 2022, 22, .	1.1	3
12075	Recent advances in the progress of immune checkpoint inhibitors in the treatment of advanced gastric cancer: A review. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
12076	Immune landscape and immunotherapy for penile cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
12077	Designing Cancer Immunotherapies That Engage T Cells and NK Cells. <i>Annual Review of Immunology</i> , 2023, 41, 17-38.	9.5	30
12078	Characterization and dynamics of the soluble immunological microenvironment in melanoma patients undergoing radiotherapy. <i>Radiation Oncology</i> , 2022, 17, .	1.2	0
12079	The Flip of the Coin of Personalized Cancer Immunotherapy: A Focused Review on Rare Immune Checkpoint Related Adverse Effects. , 0, , .		0
12080	Epigenetic Mechanisms Underlying Melanoma Resistance to Immune and Targeted Therapies. <i>Cancers</i> , 2022, 14, 5858.	1.7	2
12081	Utility of ctDNA Liquid Biopsies from Cancer Patients: An Institutional Study of 285 ctDNA Samples. <i>Cancers</i> , 2022, 14, 5859.	1.7	0
12082	Molecular subtypes and a prognostic model for hepatocellular carcinoma based on immune- and immunogenic cell death-related lncRNAs. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
12083	Incidence rate and treatment strategy of immune checkpoint inhibitor mediated hepatotoxicity: A systematic review. , 2023, 1, 46-55.		1

#	ARTICLE	IF	CITATIONS
12084	Successful Targeting of CTLA-4 in a Melanoma Clinical Case: A Long-Term "One Stop Therapeutic Shop" OncoTargets and Therapy, 0, Volume 15, 1409-1415.	1.0	2
12085	Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity. , 2022, 10, e005517.		5
12086	Emerging Sonodynamic Therapy-Based Nanomedicines for Cancer Immunotherapy. Advanced Science, 2023, 10, .	5.6	50
12087	Chemo-Immunotherapy in First Line Extensive Stage Small Cell Lung Cancer (ES-SCLC): A Systematic Review and Meta-Analysis. Current Oncology, 2022, 29, 9046-9065.	0.9	6
12088	Targeting PIM Kinases to Improve the Efficacy of Immunotherapy. Cells, 2022, 11, 3700.	1.8	4
12089	Prognostic Hematologic Biomarkers Following Immune Checkpoint Inhibition in Metastatic Uveal Melanoma. Cancers, 2022, 14, 5789.	1.7	3
12090	KIAA1429 regulates alternative splicing events of cancer-related genes in hepatocellular carcinoma. Frontiers in Oncology, 0, 12, .	1.3	2
12091	Immunotherapeutic strategies to induce inflection in the immune response: therapy for cancer and COVID-19. Biotechnology and Genetic Engineering Reviews, 0, , 1-40.	2.4	5
12092	Dynamic Changes in the Extracellular Matrix in Primary, Metastatic, and Recurrent Ovarian Cancers. Cells, 2022, 11, 3769.	1.8	2
12093	Systemic Therapy in Advanced Nodular Melanoma versus Superficial Spreading Melanoma: A Nation-Wide Study of the Dutch Melanoma Treatment Registry. Cancers, 2022, 14, 5694.	1.7	3
12094	PET/CT radiomics for prediction of hyperprogression in metastatic melanoma patients treated with immune checkpoint inhibitors. Frontiers in Oncology, 0, 12, .	1.3	3
12095	ARID1A loss induces polymorphonuclear myeloid-derived suppressor cell chemotaxis and promotes prostate cancer progression. Nature Communications, 2022, 13, .	5.8	20
12096	Pituitary Gland. , 2022, , 1-50.		0
12097	Hypothyroidism After Use of Immune Checkpoint Inhibitor Therapy in Patient With Graves' Disease: Cure?. , 2022, 1, .		1
12098	Effects of BRAF V600E and NRAS mutational status on the progression-free survival and clinicopathological characteristics of patients with melanoma. Oncology Letters, 2022, 25, .	0.8	9
12099	Reprogramming immune cells activity by furin-like enzymes as emerging strategy for enhanced immunotherapy in cancer. British Journal of Cancer, 0, , .	2.9	0
12100	3-Bromopyruvate Suppresses the Malignant Phenotype of Vemurafenib-Resistant Melanoma Cells. International Journal of Molecular Sciences, 2022, 23, 15650.	1.8	4
12101	Immunotherapy for Melanoma: The Significance of Immune Checkpoint Inhibitors for the Treatment of Advanced Melanoma. International Journal of Molecular Sciences, 2022, 23, 15720.	1.8	13

#	ARTICLE	IF	CITATIONS
12102	Advanced diagnostic and therapeutic strategies in nanotechnology for lung cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
12103	Checkpoint inhibitors are a basic science-based, transformative new treatment for lung cancer. <i>Respirology</i> , 2023, 28, 101-106.	1.3	2
12104	Discovery and Chemical Development of Uvelostinag (MK-1454): A Therapeutic Cyclic Dinucleotide Agonist of the Stimulator of Interferon Gene. <i>ACS Symposium Series</i> , 0, , 1-94.	0.5	0
12105	DNA Vaccines to Improve Immunogenicity and Effectiveness in Cancer Vaccinations: Advancement and Developments. <i>Current Gene Therapy</i> , 2022, 23, .	0.9	0
12106	An individualized causal framework for learning intercellular communication networks that define microenvironments of individual tumors. <i>PLoS Computational Biology</i> , 2022, 18, e1010761.	1.5	3
12107	Current status and novel insights into the role of metastasectomy in the era of immunotherapy. <i>Expert Review of Anticancer Therapy</i> , 2023, 23, 57-66.	1.1	1
12108	Novel Therapeutic Approaches in Neoplastic Meningitis. <i>Cancers</i> , 2023, 15, 119.	1.7	3
12110	Extracellular vesicle DNA from human melanoma tissues contains cancer-specific mutations. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	1
12111	Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2022, 387, 2113-2125.	13.9	120
12112	Insights and Strategies of Melanoma Immunotherapy: Predictive Biomarkers of Response and Resistance and Strategies to Improve Response Rates. <i>International Journal of Molecular Sciences</i> , 2023, 24, 41.	1.8	6
12113	Bioactive Glasses as Carriers of Cancer-Targeted Drugs: Challenges and Opportunities in Bone Cancer Treatment. <i>Materials</i> , 2022, 15, 9082.	1.3	5
12114	Immune Checkpoint Inhibitor Therapy in Oncology. <i>JACC: CardioOncology</i> , 2022, 4, 579-597.	1.7	25
12115	Tumor-derived extracellular vesicles in the colorectal cancer immune environment and immunotherapy. , 2023, 241, 108332.		4
12117	Assessing the risk of cardiovascular events in patients receiving immune checkpoint inhibitors. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	2
12118	Whole protein or long peptides in therapeutic vaccination strategies, does it make a difference?. <i>Expert Opinion on Biological Therapy</i> , 0, , 1-3.	1.4	0
12119	Treatment of rheumatic adverse events of cancer immunotherapy. <i>Best Practice and Research in Clinical Rheumatology</i> , 2022, 36, 101805.	1.4	9
12120	The association between albumin levels and survival in patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	4
12121	A survival analysis of cutaneous metastases in lung cancer: A 25-year experience. <i>Pneumon</i> , 2022, 35, 1-5.	0.6	0

#	ARTICLE	IF	CITATIONS
12123	Biomaterials for enhanced immunotherapy. <i>APL Bioengineering</i> , 2022, 6, .	3.3	7
12124	Metabolism heterogeneity in melanoma fuels deactivation of immunotherapy: Predict before protect. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
12125	Immune-related adverse events: A bibliometric analysis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	10
12126	Recent advances in the liposomal nanovesicles based immunotherapy in the treatment of cancer: A review. <i>Saudi Pharmaceutical Journal</i> , 2023, 31, 279-294.	1.2	3
12127	MOVIE: a phase I, open-label, multicenter study to evaluate the safety and tolerability of metronomic vinorelbine combined with durvalumab plus tremelimumab in patients with advanced solid tumors. <i>ESMO Open</i> , 2022, 7, 100646.	2.0	7
12128	Single-cell RNA sequencing reveals distinct T cell populations in immune-related adverse events of checkpoint inhibitors. <i>Cell Reports Medicine</i> , 2023, 4, 100868.	3.3	16
12129	Dynamized ultra-low dilution of <i>Ruta graveolens</i> disrupts plasma membrane organization and decreases migration of melanoma cancer cell. <i>Cell Adhesion and Migration</i> , 2023, 17, 1-13.	1.1	1
12130	Age-associated remodeling of T cell immunity and metabolism. <i>Cell Metabolism</i> , 2023, 35, 36-55.	7.2	19
12131	Where Do We Stand with Immunotherapy for Advanced Pancreatic Ductal Adenocarcinoma: A Synopsis of Clinical Outcomes. <i>Biomedicines</i> , 2022, 10, 3196.	1.4	6
12133	Characterization of the high-affinity anti-CTLA-4 monoclonal antibody JS007 for immune checkpoint therapy of cancer. <i>MAbs</i> , 2023, 15, .	2.6	0
12134	Atherosclerosis With Immune Checkpoint Inhibitor Therapy. <i>JACC: CardioOncology</i> , 2022, 4, 598-615.	1.7	22
12135	A New Risk Factor for Cardiovascular Events in Patients Receiving Immune Checkpoint Inhibitor Therapy?. <i>JACC: CardioOncology</i> , 2022, 4, 670-672.	1.7	1
12136	Melanoma Treatments and Mortality Rate Trends in the US, 1975 to 2019. <i>JAMA Network Open</i> , 2022, 5, e2245269.	2.8	19
12137	Cancer immunotherapies transition endothelial cells into HEVs that generate TCF1+ T lymphocyte niches through a feed-forward loop. <i>Cancer Cell</i> , 2022, 40, 1600-1618.e10.	7.7	40
12138	Melanogenesis and the Targeted Therapy of Melanoma. <i>Biomolecules</i> , 2022, 12, 1874.	1.8	9
12139	Regression in cutaneous melanoma: histological assessment, immune mechanisms and clinical implications. <i>Pathology</i> , 2023, 55, 227-235.	0.3	3
12140	ALKBH5 promotes PD-L1-mediated immune escape through m6A modification of ZDHHC3 in glioma. <i>Cell Death Discovery</i> , 2022, 8, .	2.0	15
12141	Anti-4-1BB immunotherapy enhances systemic immune effects of radiotherapy to induce B and T cell-dependent anti-tumor immune activation and improve tumor control at unirradiated sites. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 1445-1460.	2.0	5

#	ARTICLE	IF	CITATIONS
12142	Safety Profiling of Tumor-targeted T Cell-Targeted Bispecific Antibodies with Alveolus Lung- and Colon-on-Chip. <i>Bio-protocol</i> , 2023, 13, .	0.2	1
12143	Radiopharmaceuticals heat anti-tumor immunity. <i>Theranostics</i> , 2023, 13, 767-786.	4.6	4
12144	Aptamer-Based Immunotherapeutic Strategies. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2023, 38, 246-255.	0.7	1
12145	Like Plasmonic Au-Pd Heterostructures Boost Near-Infrared Photoimmunotherapy. <i>Advanced Science</i> , 2023, 10, .	5.6	15
12146	Population mortality in advanced melanoma patients with and without response and progression; data from the Dutch Melanoma Treatment Registry. <i>European Journal of Cancer</i> , 2023, , .	1.3	0
12147	CAR T-Cell Immunotherapy Treating T-ALL: Challenges and Opportunities. <i>Vaccines</i> , 2023, 11, 165.	2.1	9
12148	Thyroid-Stimulating Hormone. , 2022, , 173-207.		1
12149	Immunotherapy Assessment: A New Paradigm for Radiologists. <i>Diagnostics</i> , 2023, 13, 302.	1.3	1
12150	Prolactin receptor signaling: A novel target for cancer treatment - Exploring anti-PRLR signaling strategies. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	6
12151	Targeting RNA Exonuclease XRN1 Potentiates Efficacy of Cancer Immunotherapy. <i>Cancer Research</i> , 2023, 83, 922-938.	0.4	4
12152	Immune Checkpoint Therapy: A New Opportunity for Cancer Treatment. , 2023, , 1-20.		0
12153	Hijacking Immunotherapy-Resistant Melanoma for a Cure. <i>Oncologist</i> , 0, , .	1.9	0
12154	Therapeutic antibodies for precise cancer immunotherapy: current and future perspectives. <i>Medical Review</i> , 2023, 2, 555-569.	0.3	6
12155	IGF2: A Role in Metastasis and Tumor Evasion from Immune Surveillance?. <i>Biomedicines</i> , 2023, 11, 229.	1.4	10
12156	Neoadjuvant treatment for stage III and IV cutaneous melanoma. <i>The Cochrane Library</i> , 2023, 2023, .	1.5	1
12157	Immune-mediated hepatitis induced by immune checkpoint inhibitors: Current updates and future perspectives. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	13
12158	Immune Pathways with Aging Characteristics Improve Immunotherapy Benefits and Drug Prediction in Human Cancer. <i>Cancers</i> , 2023, 15, 342.	1.7	0
12159	Progress in the application of hydrogels in immunotherapy of gastrointestinal tumors. <i>Drug Delivery</i> , 2023, 30, .	2.5	5

#	ARTICLE	IF	CITATIONS
12160	Predictive Biomarkers for Immune-Related Endocrinopathies following Immune Checkpoint Inhibitors Treatment. <i>Cancers</i> , 2023, 15, 375.	1.7	10
12161	Combination therapy with oncolytic viruses and immune checkpoint inhibitors in head and neck squamous cell carcinomas: an approach of complementary advantages. <i>Cancer Cell International</i> , 2023, 23, .	1.8	5
12162	Increasing cure rates of solid tumors by immune checkpoint inhibitors. <i>Experimental Hematology and Oncology</i> , 2023, 12, .	2.0	17
12163	Potential dual synergy between electrochemotherapy and sequence of immunotherapies in metastatic melanoma: A case report. <i>Molecular and Clinical Oncology</i> , 2023, 18, .	0.4	4
12164	Research landscape and trends of melanoma immunotherapy: A bibliometric analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
12165	Cost-effectiveness of immune checkpoint inhibition and targeted treatment in combination as adjuvant treatment of patient with BRAF-mutant advanced melanoma. <i>BMC Health Services Research</i> , 2023, 23, .	0.9	3
12166	Pancreatic Cancer Resistance to Treatment: The Role of Microbiota. <i>Biomedicines</i> , 2023, 11, 157.	1.4	5
12167	The other immuno-PET: Metabolic tracers in evaluation of immune responses to immune checkpoint inhibitor therapy for solid tumors. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
12168	A comprehensive single-cell map of T cell exhaustion-associated immune environments in human breast cancer. <i>Nature Communications</i> , 2023, 14, .	5.8	39
12169	Checkpoint inhibitor hepatotoxicity: pathogenesis and management. <i>Hepatology</i> , 2024, 79, 198-212.	3.6	2
12170	Melanoma antigens recognized by T cells and their use for immunotherapy. <i>Experimental Dermatology</i> , 0, , .	1.4	3
12172	Exploring Mast Cellâ€“CD8 T Cell Interactions in Inflammatory Skin Diseases. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1564.	1.8	5
12173	Therapy with oncolytic viruses: progress and challenges. <i>Nature Reviews Clinical Oncology</i> , 2023, 20, 160-177.	12.5	86
12175	Association of Sialic Acidâ€“Binding Immunoglobulin-Like Lectin 15 With Phenotypes in Esophageal Squamous Cell Carcinoma in the Setting of Neoadjuvant Chemoradiotherapy. <i>JAMA Network Open</i> , 2023, 6, e2250965.	2.8	3
12176	Patterns of Failure Outcomes for Combination of Stereotactic Radiosurgery and Immunotherapy for Melanoma Brain Metastases. , 2023, 4, .		0
12177	CTLAâ€“4 inhibition facilitates follicular Tâ€“B cell interaction and the production of tumorâ€“specific antibodies. <i>International Journal of Cancer</i> , 0, , .	2.3	1
12178	Strahlentherapie und Immuntherapie. <i>Springer Reference Medizin</i> , 2023, , 1-20.	0.0	0
12179	The imbalance betweenÂ“NKG2A and NKG2D expression is involved in NK cell immunosuppression and tumor progression of patients with hepatitis B virusâ€“related hepatocellular carcinoma. <i>Hepatology Research</i> , 2023, 53, 417-431.	1.8	3

#	ARTICLE	IF	CITATIONS
12180	Corticosteroids and Cancer Immunotherapy. <i>Clinical Cancer Research</i> , 2023, 29, 2580-2587.	3.2	8
12181	The Role of Cellular Immunity and Adaptive Immunity in Pathophysiology of Brain and Spinal Cord Tumors. <i>Advances in Experimental Medicine and Biology</i> , 2023, , 51-72.	0.8	0
12182	Microbiota in Cancer Immunotherapy: The Next Milestone of Immuno-oncology?. , 2023, , 269-287.		1
12183	Immunopathogenesis of Immune Checkpoint Inhibitor Induced Myocarditis: Insights from Experimental Models and Treatment Implications. <i>Biomedicines</i> , 2023, 11, 107.	1.4	4
12184	Final efficacy and safety results and biomarker analysis of a phase 2 study of cabozantinib in Japanese patients with advanced renal cell carcinoma. <i>International Journal of Clinical Oncology</i> , 2023, 28, 416-426.	1.0	1
12185	Targeting regulatory T cells in gastric cancer: Pathogenesis, immunotherapy, and prognosis. <i>Biomedicine and Pharmacotherapy</i> , 2023, 158, 114180.	2.5	5
12186	Comparative efficacy and safety of immune checkpoint inhibitors for unresectable advanced melanoma: A systematic review and network meta-analysis. <i>International Immunopharmacology</i> , 2023, 115, 109657.	1.7	7
12187	Second near-infrared nanomaterials for cancer photothermal immunotherapy. <i>Materials Today Advances</i> , 2023, 17, 100339.	2.5	1
12188	Stereotactic radiosurgery and combined immune checkpoint therapy with ipilimumab and nivolumab in patients with melanoma brain metastases: A retrospective monocentric toxicity analysis. <i>Clinical and Translational Radiation Oncology</i> , 2023, 39, 100573.	0.9	1
12189	PPP2R2D Suppresses Effector T Cell Exhaustion and Regulatory T Cell Expansion and Inhibits Tumor Growth in Melanoma. <i>Journal of Immunology</i> , 2022, 209, 621-628.	0.4	1
12191	Targeting Notch-Driven Cytokine Secretion: Novel Therapies for Triple Negative Breast Cancer. <i>DNA and Cell Biology</i> , 2023, 42, 73-81.	0.9	2
12192	Shedding Light on Immunological Research in Lyon, France. IRCI2022 Brings the Scientific World to Lyon and Bridges the Latest Immunological Findings in Cancer and Infection. <i>Journal of Immunology</i> , 2022, 209, 2251-2259.	0.4	1
12193	Advancements in Cancer Immunotherapies. <i>Vaccines</i> , 2023, 11, 59.	2.1	8
12194	The Role of Immune Checkpoint Inhibitors in Cancer Therapy. <i>Clinics and Practice</i> , 2023, 13, 22-40.	0.6	14
12195	Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors: The Past and the Future. <i>Journal of Immunotherapy and Precision Oncology</i> , 2023, 6, 19-30.	0.6	1
12196	Alternatives and reduced need for sentinel lymph node biopsy (SLNB) staging for melanoma. <i>European Journal of Cancer</i> , 2023, 182, 163-169.	1.3	6
12197	Novel immune directed therapies in myelodysplastic syndromes and acute myeloid leukemia. <i>Current Opinion in Hematology</i> , 2023, 30, 38-44.	1.2	3
12199	Heat Shock Proteins in Cancer Immunotherapy. , 2023, , 1-15.		0

#	ARTICLE	IF	CITATIONS
12200	Impact of Precision Medicine in Oncology. Cancer Journal (Sudbury, Mass), 2023, 29, 15-19.	1.0	1
12201	Immune checkpoint inhibitor-related pneumonitis and COVID-19: a case-matched comparison of CT findings. Radiologia Medica, 2023, 128, 212-221.	4.7	2
12202	Clinical significance of immune checkpoint proteins in HPV-infected cervical cancer. Journal of Infection and Public Health, 2023, 16, 542-550.	1.9	4
12203	Gallbladder Cancer: Epigenetic Landscape, Targeted Therapy, and Prospect of Epitherapy. , 2023, , 201-235.		1
12204	Cancer immunotherapy via nucleic acid aptamers. , 2023, , 317-346.		0
12205	Efficacy of immune checkpoint inhibitor monotherapy or combined with other small molecule-targeted agents in ovarian cancer. Expert Reviews in Molecular Medicine, 2023, 25, .	1.6	1
12206	Immunomodulatory Therapy in Head and Neck Squamous Cell Carcinoma: Recent Advances and Clinical Prospects. Technology in Cancer Research and Treatment, 2023, 22, 153303382211505.	0.8	7
12207	ImmunoPET Imaging of Immune Checkpoints to Assess Their Cancer Therapeutic Potential. , 2023, , 1-34.		0
12208	Tumor immunology. , 2023, , 245-452.		0
12209	Combining targeted DNA repair inhibition and immune-oncology approaches for enhanced tumor control. Molecular Cell, 2023, 83, 660-680.	4.5	10
12210	Impact of Immune-Related Adverse Events on Immune Checkpoint Inhibitors Treated Cancer Patientsâ€™™ Survival: Single Center Experience and Literature Review. Cancers, 2023, 15, 888.	1.7	5
12211	Immune Microenvironment and Immunotherapies for Diffuse Intrinsic Pontine Glioma. Cancers, 2023, 15, 602.	1.7	10
12212	[18F]FDG PET/CT Imaging in Cancer Treatment with Checkpoint Inhibitors. , 2023, , 1-40.		0
12213	Treatment with Anti-HER2 Chimeric Antigen Receptor Tumor-Infiltrating Lymphocytes (CAR-TILs) Is Safe and Associated with Antitumor Efficacy in Mice and Companion Dogs. Cancers, 2023, 15, 648.	1.7	6
12215	Pulmonary Side Effects of Immunotherapy. , 2023, , 1-13.		0
12216	The Impact of Facility Type and Volume on Outcomes in Head and Neck Mucosal Melanoma. Otolaryngology - Head and Neck Surgery, 2023, 168, 1079-1088.	1.1	5
12217	Phytochemicals as Immunomodulatory Agents in Melanoma. International Journal of Molecular Sciences, 2023, 24, 2657.	1.8	4
12218	Current â€œstate of the artâ€œ on dendritic cell-based cancer vaccines in melanoma. Current Opinion in Oncology, 0, Publish Ahead of Print, .	1.1	2

#	ARTICLE	IF	CITATIONS
12219	Immunomodulatory effect of locoregional therapy in the tumor microenvironment. <i>Molecular Therapy</i> , 2023, 31, 951-969.	3.7	8
12220	Clinical adoptive regulatory T Cell therapy: State of the art, challenges, and prospective. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	3
12221	Assessing the impact of open-label designs in patient-reported outcomes: investigation in oncology clinical trials. <i>JNCI Cancer Spectrum</i> , 2023, 7, .	1.4	3
12222	Introduction on Cancer Immunotherapy. , 2023, , 1-27.		0
12223	An <i>in silico</i> model to study the impact of carbonic anhydrase IX expression on tumour growth and anti-PD-1 therapy. <i>Journal of the Royal Society Interface</i> , 2023, 20, .	1.5	2
12224	Getting personal in metastatic melanoma: neoantigen-based vaccines as a new therapeutic strategy. <i>Current Opinion in Oncology</i> , 2023, 35, 94-99.	1.1	4
12225	Current progress and challenges of immunotherapy in gastric cancer: A focus on CAR-T cells therapeutic approach. <i>Life Sciences</i> , 2023, 318, 121459.	2.0	6
12226	Bibliometric Analysis of Hotspots and Frontiers of Immunotherapy in Pancreatic Cancer. <i>Healthcare (Switzerland)</i> , 2023, 11, 304.	1.0	5
12227	Imaging the immune cell in immunotherapy. , 2023, , 197-238.		1
12229	Immune-Related Adverse Events of the Gastrointestinal System. <i>Cancers</i> , 2023, 15, 691.	1.7	1
12230	Peptide Vaccines in Melanoma: Chemical Approaches towards Improved Immunotherapeutic Efficacy. <i>Pharmaceutics</i> , 2023, 15, 452.	2.0	3
12231	Treatment and outcome trends and predictors of overall survival of rectal melanoma: Analysis of the National Cancer Database. <i>European Journal of Surgical Oncology</i> , 2023, 49, 1275-1282.	0.5	1
12232	Immunotherapies in rare cancers. <i>Molecular Cancer</i> , 2023, 22, .	7.9	15
12233	Developments of PROTACs technology in immune-related diseases. <i>European Journal of Medicinal Chemistry</i> , 2023, 249, 115127.	2.6	4
12234	Checkpoint Blockade in Cancer Immunotherapy: Squaring the Circle. <i>European Medical Journal Oncology</i> , 0, , 70-76.	0.0	1
12235	Optimizing Patient Pathways in Advanced Biliary Tract Cancers: Recent Advances and a French Perspective. <i>Targeted Oncology</i> , 2023, 18, 51-76.	1.7	2
12236	Immunotherapy: Targeting Cancer Cells. <i>Biological and Medical Physics Series</i> , 2023, , 179-217.	0.3	0
12237	A pathway-based mutation signature to predict the clinical outcomes and response to CTLA-4 inhibitors in melanoma. <i>Computational and Structural Biotechnology Journal</i> , 2023, 21, 2536-2546.	1.9	4

#	ARTICLE	IF	CITATIONS
12238	Migration of stem-like CD8 T cells between tissue microenvironments underpins successful anti-tumour immune responses. , 2023, 2, .		3
12239	Combining radiotherapy and NK cell-based therapies: The time has come. International Review of Cell and Molecular Biology, 2023, , .	1.6	1
12240	Whole-Exome Sequencing and cfDNA Analysis Uncover Genetic Determinants of Melanoma Therapy Response in a Real-World Setting. International Journal of Molecular Sciences, 2023, 24, 4302.	1.8	0
12241	Checkpoint blockade and <scp>BRAF</scp>/<scp>MEK</scp> therapy in the therapeutic setting improved the overall survival after sentinel node biopsy: A retrospective study comparing patients with primary care between 1998–2009 and 2010–2017. International Journal of Cancer, 2023, 153, 380-388.	2.3	0
12242	PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma. Journal of Biomedical Science, 2023, 30, .	2.6	4
12243	Improvement strategy for immune checkpoint blockade: A focus on the combination with immunogenic cell death inducers. Cancer Letters, 2023, 562, 216167.	3.2	5
12244	Immune Checkpoint Inhibitors in pMMR/MSS Colorectal Cancer. Journal of Gastrointestinal Cancer, 2023, 54, 1017-1030.	0.6	3
12245	Live-attenuated Japanese encephalitis virus inhibits glioblastoma growth and elicits potent antitumor immunity. Frontiers in Immunology, 0, 14, .	2.2	1
12246	Accelerating the Evolution of Immune-Related Enterocolitis Management. Journal of Clinical Oncology, 2023, 41, 3110-3115.	0.8	2
12247	Combination of immune-checkpoint inhibitors and targeted therapies for melanoma therapy: The more, the better?. Cancer and Metastasis Reviews, 2023, 42, 481-505.	2.7	2
12248	Engineered skin bacteria induce antitumor T cell responses against melanoma. Science, 2023, 380, 203-210.	6.0	37
12249	Oncogenic drivers dictate immune control of acute myeloid leukemia. Nature Communications, 2023, 14, .	5.8	2
12250	SMG7-AS1 as a prognostic biomarker and predictor of immunotherapy responses for skin cutaneous melanoma. Genomics, 2023, 115, 110614.	1.3	2
12251	The evolving landscape of PCSK9 inhibition in cancer. European Journal of Pharmacology, 2023, 949, 175721.	1.7	7
12252	Mechano-modulation of T cells for cancer immunotherapy. Biomaterials, 2023, 297, 122101.	5.7	5
12253	Ionizable polymeric nanocarriers for the codelivery of bi-adjuvant and neoantigens in combination tumor immunotherapy. Bioactive Materials, 2023, 26, 169-180.	8.6	3
12254	Elaborating on anti CTLA-4 mechanisms of action using an agent-based modeling approach. Frontiers in Applied Mathematics and Statistics, 0, 8, .	0.7	1
12255	Organoids as an Enabler of Precision Immuno-Oncology. Cells, 2023, 12, 1165.	1.8	2

#	ARTICLE	IF	CITATIONS
12256	Dynamic changes of circulating soluble PD-1/PD-L1 and its association with patient survival in immune checkpoint blockade-treated melanoma. <i>International Immunopharmacology</i> , 2023, 118, 110092.	1.7	5
12258	Recent Developments in the Management of Orbital and Periocular Neoplasms. , 2022, , 311-325.		0
12259	Evaluation of the Effect of CD70 Co-Expression on CD8 T Cell Response in Protein-Prime MVA-Boost Vaccination in Mice. <i>Vaccines</i> , 2023, 11, 245.	2.1	0
12260	Immune-related adverse events in checkpoint blockade: Observations from human tissue and therapeutic considerations. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	8
12261	Melanome der Haut und Schleimhaut. , 2022, , 205-236.		0
12262	Metabolic dialogs between B cells and the tumor microenvironment: Implications for anticancer immunity. <i>Cancer Letters</i> , 2023, 556, 216076.	3.2	1
12263	TSC2 regulates tumor susceptibility to TRAIL-mediated T cell killing by orchestrating mTOR signaling. <i>EMBO Journal</i> , 2023, 42, .	3.5	2
12264	First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817. , 2023, 11, e006127.		14
12265	Real-world efficacy of the first line therapy with prolgolimab in patients with metastatic melanoma: interim results of the FORA (FORteca Real practice Assessment) observational study. <i>Journal of Modern Oncology</i> , 2023, 24, 413-425.	0.1	5
12266	Common toxicities associated with immune checkpoint inhibitors and targeted therapy in the treatment of melanoma: A systematic scoping review. <i>Critical Reviews in Oncology/Hematology</i> , 2023, 183, 103919.	2.0	3
12267	Interim result of phase II, prospective, single-arm trial of long-course chemoradiotherapy combined with concurrent tislelizumab in locally advanced rectal cancer. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	5
12268	Helper Innate Lymphoid Cells"Unappreciated Players in Melanoma Therapy. <i>Cancers</i> , 2023, 15, 933.	1.7	1
12269	Immunotherapy for Cutaneous Melanoma. , 2023, , 1-35.		0
12270	Immunotherapeutic Approaches in Ovarian Cancer. <i>Current Issues in Molecular Biology</i> , 2023, 45, 1233-1249.	1.0	5
12271	Targeted Therapy of Interleukin-34 as a Promising Approach to Overcome Cancer Therapy Resistance. <i>Cancers</i> , 2023, 15, 971.	1.7	3
12272	Recent advancement in breast cancer treatment using CAR T cell therapy:- A review. <i>Advances in Cancer Biology Metastasis</i> , 2023, 7, 100090.	1.1	2
12273	Using temporal heatmaps to identify worthwhile articles on immune checkpoint blockade for melanoma (ICBM) in Mainland China, Hong Kong, and Taiwan since 2000: A bibliometric analysis. <i>Medicine (United States)</i> , 2023, 102, e32797.	0.4	6
12274	Immunotherapy plus stereotactic body radiation therapy or whole-brain radiation therapy in brain metastases. <i>Immunotherapy</i> , 2023, 15, 163-174.	1.0	1

#	ARTICLE	IF	CITATIONS
12275	Immune checkpoint inhibition: a future guided by radiology. <i>British Journal of Radiology</i> , 0, , .	1.0	1
12276	Identifying a wide range of mutations in the <i>BRAF</i> gene for prescribing targeted drugs for melanoma treatment. <i>Vestnik Medicinskogo Instituta REAVIZ Reabilitaci, VraĀi ZdorovĒe</i> , 2023, 13, 71-76.	0.1	0
12277	Inhibitor of Apoptosis Proteins Antagonist Induces T-cell Proliferation after Cross-Presentation by Dendritic Cells. <i>Cancer Immunology Research</i> , 2023, 11, 450-465.	1.6	2
12278	Radiotherapy, PARP Inhibition, and Immune-Checkpoint Blockade: A Triad to Overcome the Double-Edged Effects of Each Single Player. <i>Cancers</i> , 2023, 15, 1093.	1.7	4
12280	Immunotherapy in Melanoma: Recent Advances and Future Directions. <i>Cancers</i> , 2023, 15, 1106.	1.7	39
12281	Subclinical Celiac Disease Unmasked by Immune Checkpoint Inhibitor Therapy. <i>Journal of Immunotherapy</i> , 2023, 46, 152-153.	1.2	1
12283	<i>Salmonella typhimurium</i> may support cancer treatment: a review. <i>Acta Biochimica Et Biophysica Sinica</i> , 2023, 55, 331-342.	0.9	2
12284	Evaluation and management of acute high-grade immunotherapy-related neurotoxicity. <i>Heliyon</i> , 2023, 9, e13725.	1.4	0
12285	Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers. <i>Current Oncology</i> , 2023, 30, 2366-2387.	0.9	5
12286	Objective response to immune checkpoint inhibitor therapy in NRAS-mutant melanoma: A systematic review and meta-analysis. <i>Frontiers in Medicine</i> , 0, 10, .	1.2	2
12287	Immunotherapy associated central nervous system complications in primary brain tumors. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	2
12289	Exosomal microRNAs in cancer: Potential biomarkers and immunotherapeutic targets for immune checkpoint molecules. <i>Frontiers in Genetics</i> , 0, 14, .	1.1	6
12291	The past, present, and future of immunotherapy for colorectal cancer. , 2023, 40, .		3
12292	Cancer immunotherapies: A hope for the incurable?. <i>Frontiers in Molecular Medicine</i> , 0, 3, .	0.6	3
12293	The role of immune checkpoint inhibitors in patients with intracranial metastatic disease. <i>Journal of Neuro-Oncology</i> , 2023, 161, 469-478.	1.4	0
12294	New Approaches in Early-Stage NSCL Management: Potential Use of PARP Inhibitors and Immunotherapy Combination. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4044.	1.8	0
12295	Neoadjuvant immune checkpoint inhibition in the management of glioblastoma: Exploring a new frontier. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	4
12296	The prognostic value of tumor mutation burden (TMB) and its relationship with immune infiltration in breast cancer patients. <i>European Journal of Medical Research</i> , 2023, 28, .	0.9	1

#	ARTICLE	IF	CITATIONS
12297	The Changing Landscape of Immunotherapy for Advanced Renal Cancer. <i>Urologic Clinics of North America</i> , 2023, 50, 335-349.	0.8	2
12298	Investigational drugs for recurrent or primary advanced metastatic cervical cancer: what is in the clinical development pipeline?. <i>Expert Opinion on Investigational Drugs</i> , 2023, 32, 201-211.	1.9	1
12299	Immunotherapy of Cancer: Towards a New Era. <i>European Medical Journal Oncology</i> , 0, , 76-82.	0.0	0
12300	Ocular adverse events associated with immune checkpoint inhibitors, a scoping review. <i>Journal of Ophthalmic Inflammation and Infection</i> , 2023, 13, .	1.2	8
12301	Acquired radioresistance in EMT6 mouse mammary carcinoma cell line is mediated by CTLA-4 and PD-1 through JAK/STAT/PI3K pathway. <i>Scientific Reports</i> , 2023, 13, .	1.6	1
12302	Killer to cure: Expression and production costs calculation of tobacco plantâ€made cancerâ€immune checkpoint inhibitors. <i>Plant Biotechnology Journal</i> , 2023, 21, 1254-1269.	4.1	4
12303	Developing an m5C regulatorâ€mediated RNA methylation modification signature to predict prognosis and immunotherapy efficacy in rectal cancer. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	0
12304	Safety of Immune Checkpoint Inhibitors in Patients With Advanced Chronic Kidney Disease: A Retrospective Cohort Study. <i>Oncologist</i> , 2023, 28, e379-e390.	1.9	4
12305	Advances in immune checkpoint inhibitors induced-cardiotoxicity. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
12306	Blockade of neutrophil recruitment to tumor sites based on sialic acid-modified nanoplateforms enhances the efficacy of checkpoint blockade immunotherapy. <i>Asian Journal of Pharmaceutical Sciences</i> , 2023, 18, 100784.	4.3	0
12307	RAGA prevents tumor immune evasion of LUAD by promoting CD47 lysosome degradation. <i>Communications Biology</i> , 2023, 6, .	2.0	3
12308	Endocrine Consequences Following Immune Checkpoint Inhibitors Therapy. , 2023, , 1-32.		0
12309	Study of Immunotherapy and Intestinal Flora Changes in Patients with Liver Cancer. <i>Journal of Biosciences and Medicines</i> , 2023, 11, 287-293.	0.1	0
12310	Harnessing epithelial-mesenchymal plasticity to boost cancer immunotherapy. , 2023, 20, 318-340.		13
12311	Identification of tumor mutation burden-associated molecular and clinical features in cancer by analyzing multi-omics data. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	9
12312	N6-methyladenosine RNA Methylation Correlates with Immune Microenvironment and Immunotherapy Response of Melanoma. <i>Journal of Investigative Dermatology</i> , 2023, 143, 1579-1590.e5.	0.3	1
12314	Immune-related adverse events as potential surrogates of immune checkpoint inhibitorsâ€™ efficacy: a systematic review and meta-analysis of randomized studies. <i>ESMO Open</i> , 2023, 8, 100787.	2.0	13
12315	Immunotherapy of Osteosarcoma. , 2023, , 1-39.		0

#	ARTICLE	IF	CITATIONS
12316	Molecular and functional imaging in cancer-targeted therapy: current applications and future directions. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	25
12317	Harnessing imaging tools to guide immunotherapy trials: summary from the National Cancer Institute Cancer Imaging Steering Committee workshop. <i>Lancet Oncology</i> , The, 2023, 24, e133-e143.	5.1	6
12318	Pharmacodynamic activity of BMS-986156, a glucocorticoid-induced TNF receptor-related protein agonist, alone or in combination with nivolumab in patients with advanced solid tumors. <i>ESMO Open</i> , 2023, 8, 100784.	2.0	1
12319	Imaging-calculated splenic volume is associated with response in melanoma patients treated with immunotherapy. <i>Immunotherapy</i> , 2023, 15, 343-351.	1.0	0
12320	3D Spheroid Configurations Are Possible Indicators for Evaluating the Pathophysiology of Melanoma Cell Lines. <i>Cells</i> , 2023, 12, 759.	1.8	8
12321	Immunotherapy in Melanoma: Highlights for the General Practitioner. <i>Praxis</i> , 2023, 112, 135-142.	0.2	1
12322	An Immunological Perspective on the Mechanism of Drug Induced Liver Injury: Focused on Drugs for Treatment of Hepatocellular Carcinoma and Liver Transplantation. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5002.	1.8	6
12324	Immune checkpoint inhibitors related respiratory disorders in patients with lung cancer: A meta-analysis of randomized controlled trials. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	0
12325	Progression in immunotherapy for advanced prostate cancer. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	3
12326	Current landscape and tailored management of immune-related adverse events. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	1
12327	Phase 1 pilot study of RRx-001 + nivolumab in patients with advanced metastatic cancer (PRIMETIME). <i>Frontiers in Immunology</i> , 0, 14, .	2.2	3
12328	Diversity of immune checkpoints in cancer immunotherapy. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	11
12329	Clinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohort. <i>JHEP Reports</i> , 2023, 5, 100719.	2.6	10
12330	Status and prognostic value of immunological biomarkers of breast cancer. <i>Oncology Letters</i> , 2023, 25, .	0.8	1
12331	Human small intestine contains 2 functionally distinct regulatory T-cell subsets. <i>Journal of Allergy and Clinical Immunology</i> , 2023, 152, 278-289.e6.	1.5	2
12332	Causal relationships between gut microbiota and programmed cell death protein 1/programmed cell death-ligand 1: A bidirectional Mendelian randomization study. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	3
12333	Current Advances in Immune Checkpoint Therapy. , 0, , .		0
12334	Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy. <i>Cancer Cell</i> , 2023, 41, 450-465.	7.7	60

#	ARTICLE	IF	CITATIONS
12335	The Melanoma-Associated Antigen Family A (MAGE-A): A Promising Target for Cancer Immunotherapy?. <i>Cancers</i> , 2023, 15, 1779.	1.7	7
12336	Rheumatic Immune-Related Adverse Events due to Immune Checkpoint Inhibitorsâ€™ A 2023 Update. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5643.	1.8	7
12337	Anti-TIGIT therapies for solid tumors: a systematic review. <i>ESMO Open</i> , 2023, 8, 101184.	2.0	25
12338	Imaging Features of Immunotherapy. <i>IDKD Springer Series</i> , 2023, , 169-176.	0.8	0
12339	Targeting myeloid-derived suppressor cells in tumor immunotherapy: Current, future and beyond. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	3
12340	Irreconcilable Differences: The Divorce Between Response Rates, Progression-Free Survival, and Overall Survival. <i>Journal of Clinical Oncology</i> , 2023, 41, 2706-2712.	0.8	22
12341	Peripheral lymphocyte fluctuation as an indicator of severe immune-related adverse events in patients treated with immune checkpoint inhibitors. <i>Cancer Medicine</i> , 2023, 12, 10636-10646.	1.3	3
12342	Neoadjuvant immunotherapy in colorectal cancer beyond immune checkpoint inhibitors: emerging from bench to bedside. <i>Minerva Surgery</i> , 2023, 78, .	0.1	2
12343	Melanoma Brain Metastases: A Systematic Review of Opportunities for Earlier Detection, Diagnosis, and Treatment. <i>Life</i> , 2023, 13, 828.	1.1	3
12344	Immune Checkpoint Inhibitor Associated Myocarditis and Cardiomyopathy: A Translational Review. <i>Biology</i> , 2023, 12, 472.	1.3	2
12346	Immunotherapies for advanced hepatocellular carcinoma. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	4
12347	Interactive process mining of cancer treatment sequences with melanoma real-world data. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
12348	Immune profiling and prognostic model of pancreatic cancer using quantitative pathology and single-cell RNA sequencing. <i>Journal of Translational Medicine</i> , 2023, 21, .	1.8	7
12349	Epigenetic state determines the in vivo efficacy of STING agonist therapy. <i>Nature Communications</i> , 2023, 14, .	5.8	12
12350	Systemic LRG1 Expression in Melanoma is Associated with Disease Progression and Recurrence. <i>Cancer Research Communications</i> , 2023, 3, 672-683.	0.7	4
12351	A Therapeutic Vaccine in Combination with Cyclic GMPâ€™AMP Cures More Differentiated Melanomas in Mice. <i>Journal of Immunology</i> , 2023, 210, 1428-1436.	0.4	3
12352	Towards a consensus definition of immune exclusion in cancer. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	6
12353	Immune Checkpoint Inhibitors and the Kidney: A Focus on Diagnosis and Management for Personalised Medicine. <i>Cancers</i> , 2023, 15, 1891.	1.7	2

#	ARTICLE	IF	CITATIONS
12354	Pembrolizumab plus lenvatinib combination therapy for advanced endometrial carcinoma. Expert Review of Anticancer Therapy, 2023, 23, 361-368.	1.1	1
12355	Pituitary and adrenal disorders induced by immune checkpoint inhibitors. Annales D'Endocrinologie, 2023, 84, 339-345.	0.6	2
12356	Mimicry of Tumour-Associated Carbohydrates: Is It a Promising Option for Cancer Treatment?. Immuno, 2023, 3, 122-147.	0.6	0
12357	Novel nanotherapeutics for cancer immunotherapy by CTLA-4 aptamer-functionalized albumin nanoparticle loaded with antihistamine. Journal of Cancer Research and Clinical Oncology, 2023, 149, 7515-7527.	1.2	3
12358	Unleashing the potential of combining FGFR inhibitor and immune checkpoint blockade for FGF/FGFR signaling in tumor microenvironment. Molecular Cancer, 2023, 22, .	7.9	18
12359	Infectious Complications of Targeted Therapies for Solid Cancers or Leukemias/Lymphomas. Cancers, 2023, 15, 1989.	1.7	2
12361	Bispecific antibodies targeting immunomodulatory checkpoints for cancer therapy. Cancer Biology and Medicine, 2023, 20, 181-195.	1.4	10
12363	Vascular endothelial growth factor inhibitors promote antitumor responses via tumor microenvironment immunosuppression in advanced colorectal cancer. Scandinavian Journal of Gastroenterology, 2023, 58, 1009-1020.	0.6	4
12364	Overcoming the Limitations of Therapeutic Strategies to Combat Pancreatic Cancer Using Nanotechnology. Current Cancer Drug Targets, 2023, 23, .	0.8	1
12365	T cell immunotherapies engage neutrophils to eliminate tumor antigen escape variants. Cell, 2023, 186, 1432-1447.e17.	13.5	49
12366	Kidney Adverse Events Associated with Immune Checkpoint Inhibitor Therapy. Clinical Journal of the American Society of Nephrology: CJASN, 2023, 18, 843-849.	2.2	3
12368	Crosstalk between triple negative breast cancer and microenvironment. Oncotarget, 2023, 14, 284-293.	0.8	2
12369	Cost-effectiveness of second-line ipilimumab for metastatic melanoma: A real-world population-based cohort study of resource utilization. Cancer Medicine, 2023, 12, 11451-11461.	1.3	1
12370	Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial. Nature Medicine, 2023, 29, 888-897.	15.2	16
12371	Ubiquitin-Specific Protease 43 Impacts Pancreatic Ductal Adenocarcinoma Prognosis by Altering Its Proliferation and Infiltration of Surrounding Immune Cells. Journal of Immunology Research, 2023, 2023, 1-13.	0.9	1
12372	Kidney function while on immune checkpoint inhibitors: Trends in incidence of acute kidney injury, and its causes and outcomes. Journal of Onco-Nephrology, 2023, 7, 57-65.	0.3	2
12373	How have immune checkpoint inhibitors transformed melanoma treatment?. Trends in Urology & Men's Health, 2023, 14, 26-30.	0.2	0
12374	Immune-related pulmonary toxicities of checkpoint inhibitors in non-small cell lung cancer: Diagnosis, mechanism, and treatment strategies. Frontiers in Immunology, 0, 14, .	2.2	3

#	ARTICLE	IF	CITATIONS
12375	Patient-derived xenografts or organoids in the discovery of traditional and self-assembled drug for tumor immunotherapy. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	4
12376	From Co-Stimulation to Co-Inhibition: A Continuum of Immunotherapy Care Toward Long-Term Survival in Melanoma. <i>OncoTargets and Therapy</i> , 0, Volume 16, 227-232.	1.0	2
12377	Immunotherapy in Prostate Cancer: Recent Advances and Future Directions. <i>European Medical Journal Urology</i> , 0, , 51-61.	0.0	5
12378	Evolution-Informed Strategies for Combating Drug Resistance in Cancer. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6738.	1.8	5
12379	Machine learning-based construction of immunogenic cell death-related score for improving prognosis and response to immunotherapy in melanoma. <i>Aging</i> , 2023, 15, 2667-2688.	1.4	2
12380	Dietary tryptophan metabolite released by intratumoral <i>Lactobacillus reuteri</i> facilitates immune checkpoint inhibitor treatment. <i>Cell</i> , 2023, 186, 1846-1862.e26.	13.5	92
12381	Epidemiology of Melanoma. , 0, , .		0
12382	Evidence of Association between CTLA-4 Gene Polymorphisms and Colorectal Cancers in Saudi Patients. <i>Genes</i> , 2023, 14, 874.	1.0	2
12383	Mechanisms of resistance to melanoma immunotherapy. <i>Onkologie (Czech Republic)</i> , 2023, 17, 51-56.	0.0	0
12384	Immunotherapeutic and their immunological aspects: Current treatment strategies and agents. <i>National Journal of Maxillofacial Surgery</i> , 2022, 13, 322.	0.1	1
12385	Administration of immune checkpoint inhibitors at rural towns using the Teleoncology model of care—A North Queensland perspective. <i>Australian Journal of Rural Health</i> , 0, , .	0.7	0
12386	Prior anti-CTLA-4 therapy impacts molecular characteristics associated with anti-PD-1 response in advanced melanoma. <i>Cancer Cell</i> , 2023, 41, 791-806.e4.	7.7	5
12387	Mechanism of inert inflammation in an immune checkpoint blockade-resistant tumor subtype bearing transcription elongation defects. <i>Cell Reports</i> , 2023, 42, 112364.	2.9	0
12388	Promising Therapeutic Impact of Immune Checkpoint Inhibitors in Type II Endometrial Cancer Patients with Deficient Mismatch Repair Status. <i>Healthcare (Switzerland)</i> , 2023, 11, 1073.	1.0	0
12389	Pan-cancer analysis and experimental validation of DTL as a potential diagnosis, prognosis and immunotherapy biomarker. <i>BMC Cancer</i> , 2023, 23, .	1.1	3
12390	Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired. <i>Cancer Cell International</i> , 2023, 23, .	1.8	24
12391	Involvement of the kynurenine pathway in breast cancer: updates on clinical research and trials. <i>British Journal of Cancer</i> , 2023, 129, 185-203.	2.9	6
12393	Monoclonal antibodies for the treatment of squamous cell carcinoma: A literature review. <i>Cancer Reports</i> , 2023, 6, .	0.6	4

#	ARTICLE	IF	CITATIONS
12394	Immune checkpoint therapyâ€”current perspectives and future directions. <i>Cell</i> , 2023, 186, 1652-1669.	13.5	114
12396	Predictive biomarkers of immunotherapy response with pharmacological applications in solid tumors. <i>Acta Pharmacologica Sinica</i> , 2023, 44, 1879-1889.	2.8	15
12397	Relationship between the tumor microenvironment and the efficacy of the combination of radiotherapy and immunotherapy. <i>International Review of Cell and Molecular Biology</i> , 2023, , .	1.6	1
12398	Clinical Relevance of Targeted Therapy and Immune-Checkpoint Inhibition in Lung Cancer. <i>Pharmaceutics</i> , 2023, 15, 1252.	2.0	7
12400	A perspective of immunotherapy for acute myeloid leukemia: Current advances and challenges. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	0
12401	Implications of the Organ-Specific Immune Environment for Immune Priming Effect of Radiotherapy in Metastatic Setting. <i>Biomolecules</i> , 2023, 13, 689.	1.8	0
12402	Immunotherapy for Peritoneal Carcinomatosis: Challenges and Prospective Outcomes. <i>Cancers</i> , 2023, 15, 2383.	1.7	5
12403	A bibliometric and visualized research on global trends of immune checkpoint inhibitors related complications in melanoma, 2011â€”2021. <i>Frontiers in Endocrinology</i> , 0, 14, .	1.5	0
12404	Clinical and molecular overview of immunotherapeutic approaches for malignant skin melanoma: Past, present and future. <i>Critical Reviews in Oncology/Hematology</i> , 2023, 186, 103988.	2.0	2
12405	Immunotherapy and Cancer Stem Cells. , 2023, , 165-235.		0
12406	Health-state utilities in long-term advanced melanoma survivors comparable with the general population. <i>Quality of Life Research</i> , 0, , .	1.5	0
12407	Exome-Based Genomic Markers Could Improve Prediction of Checkpoint Inhibitor Efficacy Independently of Tumor Type. <i>International Journal of Molecular Sciences</i> , 2023, 24, 7592.	1.8	1
12409	Preâ€”treatment comorbidities, Câ€”reactive protein and eosinophil count, and immuneâ€”related adverse events as predictors of survival with checkpoint inhibition for multiple tumour entities. <i>Cancer Medicine</i> , 2023, 12, 12253-12262.	1.3	2
12410	Cerium End-Deposited Gold Nanorods-Based Photoimmunotherapy for Boosting Tumor Immunogenicity. <i>Pharmaceutics</i> , 2023, 15, 1309.	2.0	0
12420	General aspects of cancer therapy. , 2023, , 1-35.		0
12439	Immunotherapy and Cancer: The Pharmacistsâ€™ Perspective. , 2023, , 1-34.		0
12444	Cancer immunotherapy. , 2023, , 681-741.		0
12459	The clinical application of immuno-therapeutics. , 2024, , 237-288.e7.		0

#	ARTICLE	IF	CITATIONS
12461	Repurposing drugs in glioblastoma. , 2023, , 285-317.		0
12462	The major clinical components of cancer immunotherapy (modulating cell-mediated immune) Tj ETQq1 1 0.784314 rgBT /Overlock 10		0
12463	Rational Design of Chemically Controlled Antibodies and Protein Therapeutics. ACS Chemical Biology, 2023, 18, 1259-1265.	1.6	3
12490	Local $\hat{1}^3\hat{1}$ T cells: translating promise to practice in cancer immunotherapy. British Journal of Cancer, 2023, 129, 393-405.	2.9	4
12492	iatrogenic Conditions. , 2023, , 871-905.		0
12494	Immune Checkpoint Inhibitors and Anti-Angiogenic Therapy for Cancer. , 2023, , 1-21.		0
12506	Principles of Monoclonal and Small Molecular Targeting Agents for Pediatric Cancer Management. , 2023, , 1-19.		0
12562	Effect of posttranslational modifications and subclass on IgG activity: from immunity to immunotherapy. Nature Immunology, 2023, 24, 1244-1255.	7.0	10
12567	Crosstalk between immune checkpoint and DNA damage response inhibitors for radiosensitization of tumors. Strahlentherapie Und Onkologie, 2023, 199, 1152-1163.	1.0	2
12568	Palliative Chemotherapy in Advanced or Metastatic Gastric Cancer. IX-2. Target Agents and Immunotherapy. , 2023, , 63-67.		0
12572	Immunotherapy for Meningiomas. Advances in Experimental Medicine and Biology, 2023, , 225-234.	0.8	0
12581	The contribution of automated cytometry in immuno-oncology. Methods in Cell Biology, 2023, , .	0.5	0
12587	Malignant Melanocytic Tumors: Melanoma. , 2023, , 351-392.		0
12603	Akkermansia muciniphila: a potential booster to improve the effectiveness of cancer immunotherapy. Journal of Cancer Research and Clinical Oncology, 2023, 149, 13477-13494.	1.2	2
12604	Preconditioning with immunogenic cell death-inducing treatments for subsequent immunotherapy. International Review of Cell and Molecular Biology, 2023, , .	1.6	0
12606	TIGIT, a novel immune checkpoint therapy for melanoma. Cell Death and Disease, 2023, 14, .	2.7	8
12618	Immunotherapy for Ocular Tumors. , 2023, , 1-61.		0
12629	Oncolytic intralesional therapy for metastatic melanoma. Clinical and Experimental Metastasis, 0, , .	1.7	0

#	ARTICLE	IF	CITATIONS
12646	Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	34
12659	Turning up the heat: CTLA4 blockade in urothelial cancer. <i>Nature Reviews Urology</i> , 0, , .	1.9	1
12666	Heterogeneity of the tumor immune microenvironment and clinical interventions. <i>Frontiers of Medicine</i> , 2023, 17, 617-648.	1.5	0
12678	Recent Advancements in the Inhibition of Metastasis of Colorectal Cancer Using Anticancer Compounds. , 2023, , 1-32.		0
12684	Green synthesis of nano-based drug delivery systems developed for hepatocellular carcinoma treatment: a review. <i>Molecular Biology Reports</i> , 0, , .	1.0	0
12717	Biomarkers of Prediction of Immunotherapy and Updates on CTLA-4 Therapy. , 2023, , 1-35.		0
12725	Systemic Treatment of Small Cell Lung Cancer. , 2023, , 1-21.		0
12738	Immunotherapy for Melanoma. , 2023, , 1693-1712.		0
12760	Vaccines and sera. , 2024, , 15-62.		0
12768	The need for ambulatory emergency oncology: exemplified by the management of immune checkpoint inhibitor toxicity. <i>Supportive Care in Cancer</i> , 2023, 31, .	1.0	0
12771	T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome. <i>Nature Reviews Drug Discovery</i> , 2023, 22, 996-1017.	21.5	7
12773	CD8 T-cell subsets: heterogeneity, functions, and therapeutic potential. <i>Experimental and Molecular Medicine</i> , 2023, 55, 2287-2299.	3.2	7
12778	Pulmonary Toxicity Associated with Immune Checkpoint Inhibitors-Based Therapy: Current Perspectives and Future Directions. <i>Drug Safety</i> , 2023, 46, 1313-1322.	1.4	1
12789	Recent advances in immunopeptidomic-based tumor neoantigen discovery. <i>Advances in Immunology</i> , 2023, , 1-36.	1.1	0
12795	Fc γ receptors and immunomodulatory antibodies in cancer. <i>Nature Reviews Cancer</i> , 2024, 24, 51-71.	12.8	3
12799	Immune Effects of Ablation. , 2023, , 1-17.		0
12843	Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations. <i>Nature Reviews Immunology</i> , 0, , .	10.6	2
12859	ROS, Redox Regulation, and Anticancer Therapy. , 2023, , 311-409.		0

#	ARTICLE	IF	CITATIONS
12862	Perspectives in ROS/Redox Regulation Cancer Therapy. , 2023, , 411-431.		0
12863	Immune Checkpoint Inhibitors and Systemic Side Effects: Overview for the Inpatient Dermatologist. Current Dermatology Reports, 2023, 12, 225-232.	1.1	0
12883	Immune checkpoint inhibitor-related myositis and myocarditis: diagnostic pitfalls and imaging contribution in a real-world, institutional case series. Journal of Neurology, 0, , .	1.8	0
12888	Immune Checkpoint Inhibition. , 2024, , 1-91.		0
12895	Mechanisms of immune checkpoint inhibitors: insights into the regulation of circular RNAs involved in cancer hallmarks. Cell Death and Disease, 2024, 15, .	2.7	0
12898	The efficacy of immune checkpoint inhibitors therapy versus chemotherapy in the treatment of advanced and metastatic urothelial carcinoma: a meta-analysis. Journal of Cancer Research and Clinical Oncology, 2024, 150, .	1.2	0
12900	Associations between HIFs and tumor immune checkpoints: mechanism and therapy. Discover Oncology, 2024, 15, .	0.8	1
12904	Anti-CTLA-4 nanobody as a promising approach in cancer immunotherapy. Cell Death and Disease, 2024, 15, .	2.7	0
12910	CAR-T cell therapy: a game-changer in cancer treatment and beyond. Clinical and Translational Oncology, 0, , .	1.2	0
12911	Current drug therapy for colorectal cancer. , 2024, , 115-148.		0
12920	Neuroimmune Interactions. , 2024, , 59-71.		0
12953	Cancer immunotherapy-associated endocrine complications and treatment strategies. , 2024, , 199-221.		0
12954	How does time speak about cancer, its diagnosis, treatments, and challenges?. , 2024, , 55-81.		0
12968	Recent advances in light-triggered cancer immunotherapy. Journal of Materials Chemistry B, 2024, 12, 2650-2669.	2.9	0
12971	Dendrimer-based nanomedicines for cancer immunotherapy. , 2024, , 317-347.		0
12982	Therapeutic Strategies in BRAF V600 Wild-Type Cutaneous Melanoma. American Journal of Clinical Dermatology, 0, , .	3.3	0
13022	Unleashing the power of antibodies: Engineering for tomorrow's therapy. Advances in Protein Chemistry and Structural Biology, 2024, , .	1.0	0
13035	PD-1/PD-L1 Inhibitors for the Treatment of Lung Cancer. , 2024, , 65-86.		0

#	ARTICLE	IF	CITATIONS
13036	Editorial: Radiotherapy strategies for precise treatment on brain metastases. <i>Frontiers in Oncology</i> , 0, 14, .	1.3	0
13056	LAG-3 Inhibitors for the Treatment of Lung Cancer. , 2024, , 131-152.		0
13059	New Therapeutic Strategies for Cervical Cancer with Special Reference to Immunotherapy. <i>Comprehensive Gynecology and Obstetrics</i> , 2024, , 205-216.	0.0	0